PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nakkazi, E				Nakkazi, Esther			A dose of reality about fakes	NATURE MEDICINE			English	News Item																			0	0	0	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					358	358		10.1038/nm0410-358b	http://dx.doi.org/10.1038/nm0410-358b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376020	Bronze			2022-12-27	WOS:000276446800013
J	Boulenguez, P; Liabeuf, S; Bos, R; Bras, H; Jean-Xavier, C; Brocard, C; Stil, A; Darbon, P; Cattaert, D; Delpire, E; Marsala, M; Vinay, L				Boulenguez, Pascale; Liabeuf, Sylvie; Bos, Remi; Bras, Helene; Jean-Xavier, Celine; Brocard, Cecile; Stil, Aurelie; Darbon, Pascal; Cattaert, Daniel; Delpire, Eric; Marsala, Martin; Vinay, Laurent			Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury	NATURE MEDICINE			English	Article							K-CL COTRANSPORTER; POST-ACTIVATION DEPRESSION; RECIPROCAL INHIBITION; NEUROPATHIC PAIN; ANION GRADIENT; ADULT-RATS; IN-VITRO; EXPRESSION; MOTONEURONS; MECHANISM	Hyperexcitability of spinal reflexes and reduced synaptic inhibition are commonly associated with spasticity after spinal cord injury (SCI). In adults, the activation of gamma-aminobutyric acid(A) (GABA(A)) and glycine receptors inhibits neurons as a result of low intracellular chloride (Cl-) concentration, which is maintained by the potassium-chloride cotransporter KCC2 (encoded by Slc12a5). We show that KCC2 is downregulated after SCI in rats, particularly in motoneuron membranes, thereby depolarizing the Cl-equilibrium potential and reducing the strength of postsynaptic inhibition. Blocking KCC2 in intact rats reduces the rate-dependent depression (RDD) of the Hoffmann reflex, as is observed in spasticity. RDD is also decreased in KCC2-deficient mice and in intact rats after intrathecal brain-derived neurotrophic factor (BDNF) injection, which downregulates KCC2. The early decrease in KCC2 after SCI is prevented by sequestering BDNF at the time of SCI. Conversely, after SCI, BDNF upregulates KCC2 and restores RDD. Our results open new perspectives for the development of therapeutic strategies to alleviate spasticity.	[Boulenguez, Pascale; Liabeuf, Sylvie; Bos, Remi; Bras, Helene; Jean-Xavier, Celine; Brocard, Cecile; Stil, Aurelie; Darbon, Pascal; Vinay, Laurent] CNRS, Lab Plast & Physiopathol Motricite UMR6196, Marseille, France; [Boulenguez, Pascale; Liabeuf, Sylvie; Bos, Remi; Bras, Helene; Jean-Xavier, Celine; Brocard, Cecile; Stil, Aurelie; Darbon, Pascal; Vinay, Laurent] Aix Marseille Univ, Marseille, France; [Cattaert, Daniel] CNRS, Ctr Neurosci Integrat & Cognit, Talence, France; [Cattaert, Daniel] Univ Bordeaux, Talence, France; [Delpire, Eric] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA; [Marsala, Martin] Univ Calif San Diego, Dept Anesthesiol, Anesthesiol Res Lab, La Jolla, CA 92093 USA; [Marsala, Martin] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University; University of California System; University of California San Diego; Slovak Academy of Sciences	Vinay, L (corresponding author), CNRS, Lab Plast & Physiopathol Motricite UMR6196, Marseille, France.	vinay@dpm.cnrs-mrs.fr	Bras, Helene/L-8915-2018; Cattaert, Daniel/D-8630-2014; Darbon, Pascal/A-4903-2012	Darbon, Pascal/0000-0002-7772-9604; Jean-Xavier, Celine/0000-0003-0500-1099; Bos, Remi/0000-0003-2639-3271	Christopher and Dana Reeve Foundation [VB1-0502-2, VB2-0801-2]; French Agence Nationale pour la Recherche; French Institut pour la Recherche sur la Moelle epiniere et l'Encephale; US National Institutes of Health [GM074771, NS051644]; Slovak Research and Development Agency [APVV-0314-06]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051644] Funding Source: NIH RePORTER	Christopher and Dana Reeve Foundation; French Agence Nationale pour la Recherche(French National Research Agency (ANR)); French Institut pour la Recherche sur la Moelle epiniere et l'Encephale; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Slovak Research and Development Agency(Slovak Research and Development Agency); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grants from the Christopher and Dana Reeve Foundation (VB1-0502-2 and VB2-0801-2 to L. V.), the French Agence Nationale pour la Recherche (to L. V.), the French Institut pour la Recherche sur la Moelle epiniere et l'Encephale (to L. V.), the US National Institutes of Health (GM074771 to E. D. and NS051644 to M. M.) and the Slovak Research and Development Agency (APVV-0314-06 to M. M.). We thank the company Pharmaxon for their help and expertise concerning SCI in rats. We also thank all team members, particularly F. Brocard, P. Coulon, K. Sadlaoud and S. Tazerart, for their assistance throughout the experiments, and F. Clarac for his support.	Alvarez FJ, 1997, J COMP NEUROL, V379, P150; Biering-Sorensen F, 2006, SPINAL CORD, V44, P708, DOI 10.1038/sj.sc.3101928; Blaesse P, 2006, J NEUROSCI, V26, P10407, DOI 10.1523/JNEUROSCI.3257-06.2006; Boorman GI, 1996, ELECTROMYOGR MOTOR C, V101, P84, DOI 10.1016/0924-980X(95)00262-J; Boulenguez P, 2009, CURR OPIN NEUROBIOL, V19, P587, DOI 10.1016/j.conb.2009.10.005; Boyce VS, 2007, J NEUROPHYSIOL, V98, P1988, DOI 10.1152/jn.00391.2007; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868; Crone C, 2007, EXP BRAIN RES, V181, P193, DOI 10.1007/s00221-007-0993-1; Crone C, 2003, BRAIN, V126, P495, DOI 10.1093/brain/awg036; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359, DOI 10.1152/jn.1999.82.1.359; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Edgerton V R, 1997, Adv Neurol, V72, P233; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; Edgley SA, 2006, EXP BRAIN RES, V171, P541, DOI 10.1007/s00221-005-0302-9; Gomez-Pinilla F, 2007, NEUROSCIENCE, V148, P893, DOI 10.1016/j.neuroscience.2007.05.051; Grey MJ, 2008, EXP BRAIN RES, V185, P189, DOI 10.1007/s00221-007-1142-6; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hultborn H, 1996, EXP BRAIN RES, V108, P450; Jean-Xavier C, 2007, P NATL ACAD SCI USA, V104, P11477, DOI 10.1073/pnas.0704832104; Jean-Xavier C, 2006, J NEUROPHYSIOL, V96, P2274, DOI 10.1152/jn.00328.2006; Jiang ZY, 1999, BRAIN RES, V816, P493, DOI 10.1016/S0006-8993(98)01199-8; Katz R, 1999, J PHYSIOLOGY-PARIS, V93, P379, DOI 10.1016/S0928-4257(00)80065-0; Li XL, 2007, NEUROPEPTIDES, V41, P135, DOI 10.1016/j.npep.2007.02.001; Li YR, 2004, J NEUROPHYSIOL, V91, P767, DOI 10.1152/jn.00788.2003; Lu J, 1999, J NEUROBIOL, V39, P558, DOI 10.1002/(SICI)1097-4695(19990615)39:4<558::AID-NEU9>3.0.CO;2-5; Mazzocchio R, 1997, BRAIN, V120, P991, DOI 10.1093/brain/120.6.991; Miletic G, 2008, PAIN, V137, P532, DOI 10.1016/j.pain.2007.10.016; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Norton JA, 2008, BRAIN, V131, P1478, DOI 10.1093/brain/awn050; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Remy-Neris O, 1999, EXP BRAIN RES, V129, P433, DOI 10.1007/s002210050910; Riekki R, 2008, J NEUROPHYSIOL, V99, P3075, DOI 10.1152/jn.00606.2007; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rivera C, 2002, J CELL BIOL, V159, P747, DOI 10.1083/jcb.200209011; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Stil A, 2009, NEUROSCIENCE, V164, P809, DOI 10.1016/j.neuroscience.2009.08.035; SYKOVA E, 1992, CAN J PHYSIOL PHARM, V70, pS301, DOI 10.1139/y92-276; THOMPSON FJ, 1992, J NEUROPHYSIOL, V68, P1473, DOI 10.1152/jn.1992.68.5.1473; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; WALLIS DI, 1992, GEN PHARMACOL-VASC S, V23, P1035, DOI 10.1016/0306-3623(92)90283-P; Williams JR, 1999, J BIOL CHEM, V274, P12656, DOI 10.1074/jbc.274.18.12656; Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014; Yates C, 2008, SPINAL CORD, V46, P798, DOI 10.1038/sc.2008.49; Ziskind-Conhaim L, 1998, PERSPECT DEV NEUROBI, V5, P279	49	376	394	1	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					302	U97		10.1038/nm.2107	http://dx.doi.org/10.1038/nm.2107			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20190766	Green Published			2022-12-27	WOS:000275289500035
J	Min, J; Zaslavsky, A; Fedele, G; McLaughlin, SK; Reczek, EE; De Raedt, T; Guney, I; Strochlic, DE; MacConaill, LE; Beroukhim, R; Bronson, RT; Ryeom, S; Hahn, WC; Loda, M; Cichowski, K				Min, Junxia; Zaslavsky, Alexander; Fedele, Giuseppe; McLaughlin, Sara K.; Reczek, Elizabeth E.; De Raedt, Thomas; Guney, Isil; Strochlic, David E.; MacConaill, Laura E.; Beroukhim, Rameen; Bronson, Roderick T.; Ryeom, Sandra; Hahn, William C.; Loda, Massimo; Cichowski, Karen			An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappa B	NATURE MEDICINE			English	Article							ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; EZH2; MUTATIONS; INACTIVATION; SIGNATURE; REVEALS; BRAF	Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappa B (NF-kappa B). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappa B through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappa B and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.	[Min, Junxia; McLaughlin, Sara K.; Reczek, Elizabeth E.; De Raedt, Thomas; Cichowski, Karen] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; [Min, Junxia; Fedele, Giuseppe; McLaughlin, Sara K.; Reczek, Elizabeth E.; De Raedt, Thomas; Guney, Isil; Strochlic, David E.; Beroukhim, Rameen; Bronson, Roderick T.; Hahn, William C.; Loda, Massimo; Cichowski, Karen] Harvard Univ, Sch Med, Boston, MA USA; [Zaslavsky, Alexander; Ryeom, Sandra] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Fedele, Giuseppe; Guney, Isil; Strochlic, David E.; Beroukhim, Rameen; Hahn, William C.; Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [MacConaill, Laura E.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA; [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Beroukhim, Rameen; Hahn, William C.; Loda, Massimo] Broad Inst Harvard, Cambridge, MA USA; [Beroukhim, Rameen; Hahn, William C.] MIT, Cambridge, MA 02139 USA; [Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Loda, Massimo] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Cichowski, Karen] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Cichowski, K (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.	kcichowski@rics.bwh.harvard.edu	De Raedt, Thomas/AAC-3172-2021; Min, Junxia/E-7622-2016	Min, Junxia/0000-0001-8099-6327	US Department of Defense [PC074048]; Ludwig Center at Dana-Farber/Harvard Cancer Center; NATIONAL CANCER INSTITUTE [K08CA122833] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); Ludwig Center at Dana-Farber/Harvard Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The PMMP-luc-neo retroviral luciferase construct was generously provided by A. L. Kung and M. Chheda (Dana-Farber Cancer Institute (DFCI)). pRL-TK was a gift from J. Boehm (Broad Institute). We thank D. Barbie (DFCI), J. Boehm for NF-kappa B target primers and R. Chen (DFCI) for I kappa B alpha SR and G. Evan for helpful discussions. This grant was supported by in part by the US Department of Defense (PC074048) and the Ludwig Center at Dana-Farber/Harvard Cancer Center.	Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; Arai Y, 1996, Int J Urol, V3, P373, DOI 10.1111/j.1442-2042.1996.tb00556.x; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Bernards A, 2007, GROWTH FACTORS, V25, P355, DOI 10.1080/08977190701830375; CARTER BS, 1990, CANCER RES, V50, P6830; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho NY, 2006, INT J CANCER, V119, P1858, DOI 10.1002/ijc.22071; Daskivich TJ, 2006, CURR OPIN UROL, V16, P173, DOI 10.1097/01.mou.0000193392.77469.e2; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Gioeli D, 1999, CANCER RES, V59, P279; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeong JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003949; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; RICCARDI VM, 1992, NEUROFIBROMATOSIS PH, pCH3; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomlins SA, 2006, ANNU REV PATHOL-MECH, V1, P243, DOI 10.1146/annurev.pathol.1.110304.100047; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von Bergh ARM, 2004, GENE CHROMOSOME CANC, V39, P324, DOI 10.1002/gcc.20004; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Weinberg RA, 2007, BIOL CANC; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200	50	293	336	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					286	U82		10.1038/nm.2100	http://dx.doi.org/10.1038/nm.2100			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20154697	Green Accepted			2022-12-27	WOS:000275289500033
J	Verdeguer, F; Le Corre, S; Fischer, E; Callens, C; Garbay, S; Doyen, A; Igarashi, P; Terzi, F; Pontoglio, M				Verdeguer, Francisco; Le Corre, Stephanie; Fischer, Evelyne; Callens, Celine; Garbay, Serge; Doyen, Antonia; Igarashi, Peter; Terzi, Fabiola; Pontoglio, Marco			A mitotic transcriptional switch in polycystic kidney disease	NATURE MEDICINE			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-BETA; PLANAR CELL POLARITY; CYST FORMATION; RENAL INJURY; SLOW-ONSET; ADULT MICE; GENE; INACTIVATION; PKD1; DYSFUNCTION	Hepatocyte nuclear factor-1 beta (HNF-1 beta) is a transcription factor required for the expression of several renal cystic genes and whose prenatal deletion leads to polycystic kidney disease (PKD)(1). We show here that inactivation of Hnf1b from postnatal day 10 onward does not elicit cystic dilations in tubules after their proliferative morphogenetic elongation is over. Cystogenic resistance is intrinsically linked to the quiescent state of cells. In fact, when Hnf1b deficient quiescent cells are forced to proliferate by an ischemia-reperfusion injury, they give rise to cysts, owing to loss of oriented cell division. Remarkably, in quiescent cells, the transcription of crucial cystogenic target genes is maintained even in the absence of HNF-1 beta. However, their expression is lost as soon as cells proliferate and the chromatin of target genes acquires heterochromatin marks. These results unveil a previously undescribed aspect of gene regulation. It is well established that transcription is shut off during the mitotic condensation of chromatin(2,3). We propose that transcription factors such as HNF-1 beta might be involved in reprogramming gene expression after transcriptional silencing is induced by mitotic chromatin condensation. Notably, HNF-1 beta remains associated with the mitotically condensed chromosomal barrels. This association suggests that HNF-1 beta is a bookmarking factor that is necessary for reopening the chromatin of target genes after mitotic silencing. (C) 2010 Nature America, Inc. All rights reserved.	[Le Corre, Stephanie; Terzi, Fabiola] Univ Paris 05, Hop Necker Enfants Malad, INSERM, Ctr Rech Croissance & Signalisat,U845, Paris, France; [Igarashi, Peter] Univ Texas SW Med Ctr Dallas, Dept Internal Med & Pediat, Dallas, TX 75390 USA; [Verdeguer, Francisco; Fischer, Evelyne; Callens, Celine; Garbay, Serge; Doyen, Antonia; Pontoglio, Marco] Inst Pasteur, Gene Express Dev & Dis Lab, Dept Dev Biol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Texas System; University of Texas Southwestern Medical Center Dallas; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pontoglio, M (corresponding author), Univ Paris 05, CNRS, INSERM, Inst Cochin,Team 26,U567,UMR 8104, Paris, France.	marco.pontoglio@inserm.fr	fischer, evelyne/GLT-9457-2022; Verdeguer, Francisco/O-5486-2016; Terzi, Fabiola/N-5482-2018	Verdeguer, Francisco/0000-0002-5798-1503; Igarashi, Peter/0000-0001-8698-1185; fischer, evelyne/0000-0001-5054-1444	Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Universite Paris Descartes; Polycystic Kidney Disease Foundation; Societe de Nephrologie; Agence Nationale Recherche; Fondation de la Recherche Medicale; Fundacion La Caixa; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042921, R01DK042921] Funding Source: NIH RePORTER	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Paris Descartes; Polycystic Kidney Disease Foundation; Societe de Nephrologie; Agence Nationale Recherche(French National Research Agency (ANR)); Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); Fundacion La Caixa(La Caixa Foundation); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to S. Bettiol, J. B. Weitzman and M. Yaniv for critical advice. We are grateful to R. Sandford (Cambridge Institute of Medical Research) for Pkd2-specific antibodies and to B. Viollet, (Institut Cochin, Paris) for the GFP-HNF-4 alpha fusion construct. MxCre mice were kindly provided by K. Rajewsky (Harvard Medical School, Boston), and the ROSA26R strain was provided by P. Soriano (Fred Hutchinson Cancer Research Center, Seattle). We thank E. Perret and P. Roux from the "Plate-Forme d'Imagerie Dynamique," Institut Pasteur, Paris) for assistance and advice. This work was supported by Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite Paris Descartes, Polycystic Kidney Disease Foundation, Societe de Nephrologie, Agence Nationale Recherche, Fondation de la Recherche Medicale. F. V. was a recipient of a fellowship from Societe de Nephrologie and from Fundacion La Caixa.	Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Bukanov NO, 2006, NATURE, V444, P949, DOI 10.1038/nature05348; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; Coffinier C, 2002, DEVELOPMENT, V129, P1829; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Fischer E, 2006, NAT GENET, V38, P21, DOI 10.1038/ng1701; Fischer E, 2004, NEPHROL DIAL TRANSPL, V19, P2700, DOI 10.1093/ndt/gfh533; Gong YM, 2009, J AM SOC NEPHROL, V20, P41, DOI 10.1681/ASN.2008020238; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Guay-Woodford LM, 2003, AM J PHYSIOL-RENAL, V285, pF1034, DOI 10.1152/ajprenal.00195.2003; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Komura JI, 2007, P NATL ACAD SCI USA, V104, P15741, DOI 10.1073/pnas.0702363104; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lantinga-van Leeuwen IS, 2007, HUM MOL GENET, V16, P3188, DOI 10.1093/hmg/ddm299; Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326; Lindner TH, 1999, HUM MOL GENET, V8, P2001, DOI 10.1093/hmg/8.11.2001; Ma ZD, 2007, P NATL ACAD SCI USA, V104, P20386, DOI 10.1073/pnas.0705957104; Marquez MG, 2002, ANAT EMBRYOL, V205, P431, DOI 10.1007/s00429-002-0262-9; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; Park KM, 2004, J BIOL CHEM, V279, P52282, DOI 10.1074/jbc.M407629200; Patel V, 2008, HUM MOL GENET, V17, P1578, DOI 10.1093/hmg/ddn045; Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; Runembert I, 2004, AM J PHYSIOL-RENAL, V287, pF960, DOI 10.1152/ajprenal.00064.2004; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Takakura A, 2009, HUM MOL GENET, V18, P2523, DOI 10.1093/hmg/ddp147; Takakura A, 2008, J AM SOC NEPHROL, V19, P2351, DOI 10.1681/ASN.2007101139; Torres VE, 2007, LANCET, V369, P1287, DOI 10.1016/S0140-6736(07)60601-1; Ulinski T, 2006, J AM SOC NEPHROL, V17, P497, DOI 10.1681/ASN.2005101040	32	107	110	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2010	16	1					106	U143		10.1038/nm.2068	http://dx.doi.org/10.1038/nm.2068			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	19966811	Green Accepted			2022-12-27	WOS:000273395500043
J	Lydon, N				Lydon, Nicholas			Attacking cancer at its foundation	NATURE MEDICINE			English	Article							GROWTH-FACTOR-RECEPTOR; PROTEIN-TYROSINE KINASE; CELL LUNG-CANCER; GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; PHENYLAMINO-PYRIMIDINE PAP; SIMIAN SARCOMA-VIRUS; SIGNAL-TRANSDUCTION; BCR-ABL		Grant Biopharma, Jackson, WY USA		Lydon, N (corresponding author), Grant Biopharma, Jackson, WY USA.	nick.lydon@me.com						Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Arteaga CL, 2004, NAT MED, V10, P577, DOI 10.1038/nm0604-577; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; FARLEY K, 1992, ANAL BIOCHEM, V203, P151, DOI 10.1016/0003-2697(92)90056-D; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GEISSLER JF, 1996, CANCER RES, V56, P100; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Goldstein DM, 2008, NAT REV DRUG DISCOV, V7, P391, DOI 10.1038/nrd2541; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GRAZIANI Y, 1982, BIOCHIM BIOPHYS ACTA, V714, P415, DOI 10.1016/0304-4165(82)90148-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; Herbst RS, 2004, NAT REV CANCER, V4, P956, DOI 10.1038/nrc1506; Heymach JV, 2005, BRIT J CANCER, V92, pS14, DOI 10.1038/sj.bjc.6602604; HUNTER T, 1984, SCI AM, V251, P70, DOI 10.1038/scientificamerican0884-70; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; LYDON NB, 1990, ONCOGENE RES, V5, P161; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Magnusson MK, 2002, BLOOD, V100, P1088, DOI 10.1182/blood-2002-01-0165; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; MCGLYNN E, 1992, BACULOVIRUS RECOMBIN, P209; NOWELL PC, 1960, SCIENCE, V132, P1497; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Siddiqui MAA, 2007, DRUGS, V67, P805, DOI 10.2165/00003495-200767050-00012; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Traxler PM, 1997, EXPERT OPIN THER PAT, V7, P571, DOI 10.1517/13543776.7.6.571; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Wedge SR, 2002, CANCER RES, V62, P4645; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; Zimmermann J, 1996, ARCH PHARM, V329, P371, DOI 10.1002/ardp.19963290707; Zimmermann J, 1996, BIOORG MED CHEM LETT, V6, P1221, DOI 10.1016/0960-894X(96)00197-7	64	16	16	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2009	15	10					1153	1157		10.1038/nm1009-1153	http://dx.doi.org/10.1038/nm1009-1153			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812577				2022-12-27	WOS:000270596400026
J	Albani, S; Prakken, B				Albani, Salvatore; Prakken, Berent			The advancement of translational medicine-from regional challenges to global solutions	NATURE MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; OBSTACLES		[Albani, Salvatore] Univ Arizona, Arizona Arthrit Ctr, Tucson, AZ 85721 USA; [Prakken, Berent] Univ Med Ctr Utrecht, Ctr Mol & Cellular Intervent, Dept Pediat Immunol, Utrecht, Netherlands; [Albani, Salvatore; Prakken, Berent] Eureka Inst Translat Med, Siracusa, Italy	University of Arizona; Utrecht University; Utrecht University Medical Center	Albani, S (corresponding author), Univ Arizona, Arizona Arthrit Ctr, Tucson, AZ 85721 USA.	salbani@arthritis.arizona.edu			NIAID NIH HHS [R01 AI084551] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084551] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2008, ANN INTERN MED, V148, P55, DOI 10.7326/0003-4819-148-1-200801010-00196; Barrett JS, 2008, AAPS J, V10, P9, DOI 10.1208/s12248-007-9002-7; *BATT MEM I, 2008, TECHN TAL CAP STAT B; Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038/nrd1382; FitzGerald GA, 2005, NAT REV DRUG DISCOV, V4, P815, DOI 10.1038/nrd1849; Goldsmith ZG, 2004, INT J MOL MED, V13, P483; Hayday AC, 2008, NAT IMMUNOL, V9, P575, DOI 10.1038/ni0608-575; Horig H, 2005, NAT MED, V11, P705, DOI 10.1038/nm0705-705; Horton R, 2004, LANCET, V364, P1995, DOI 10.1016/S0140-6736(04)17523-5; Jawaheer D, 2003, ARTHRITIS RHEUM-US, V48, P906, DOI 10.1002/art.10989; Lesko LJ, 2004, NAT REV DRUG DISCOV, V3, P763, DOI 10.1038/nrd1499; Mankoff Stacey P, 2004, J Transl Med, V2, P14, DOI 10.1186/1479-5876-2-14; Moses H, 2005, JAMA-J AM MED ASSOC, V294, P1333, DOI 10.1001/jama.294.11.1333; *ORG EC COOP DEV, 2008, OECD HLTH DAT 2008 S; Persidis A, 2000, NAT BIOTECHNOL, V18, P570, DOI 10.1038/75476; Pober JS, 2001, FASEB J, V15, P2303, DOI 10.1096/fj.01-0540lsf; Rothaermel FT, 2005, RES POLICY, V34, P305, DOI 10.1016/j.respol.2004.11.006; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306; Shuchman M, 2007, NEW ENGL J MED, V357, P1365, DOI 10.1056/NEJMp078176; van den Broek T, 2008, EXPERT OPIN BIOL TH, V8, P1773, DOI 10.1517/14712598.8.11.1773 ; Waldman SA, 2007, CLIN PHARMACOL THER, V82, P343, DOI 10.1038/sj.clpt.6100360; Woodcock J, 2008, ANNU REV MED, V59, P1, DOI 10.1146/annurev.med.59.090506.155819; Yetley E. A., 2007, NOVART FDN SYMP, V282, P69; Yetley E. A., 2007, NOVART FDN SYMP, V282, P212; Yetley Elizabeth A, 2007, Novartis Found Symp, V282, P59; Zerhouni EA, 2006, TRANSL RES, V148, P4, DOI 10.1016/j.lab.2006.05.001; 2008, VENTURE INSIGHTS Q, V4, P15	28	32	35	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1006	1009		10.1038/nm0909-1006	http://dx.doi.org/10.1038/nm0909-1006			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19734876				2022-12-27	WOS:000269979200018
J	Hammad, H; Chieppa, M; Perros, F; Willart, MA; Germain, RN; Lambrecht, BN				Hammad, Hamida; Chieppa, Marcello; Perros, Frederic; Willart, Monique A.; Germain, Ronald N.; Lambrecht, Bart N.			House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells	NATURE MEDICINE			English	Article							THYMIC STROMAL LYMPHOPOIETIN; DENDRITIC CELLS; EPITHELIAL-CELLS; ALVEOLAR MACROPHAGES; TH2 RESPONSES; INFLAMMATION; LIPOPOLYSACCHARIDE; ACTIVATION; INDUCTION; TOLL-LIKE-RECEPTOR-4	Barrier epithelial cells and airway dendritic cells (DCs) make up the first line of defense against inhaled substances such as house dust mite (HDM) allergen and endotoxin (lipopolysaccharide, LPS). We hypothesized that these cells need to communicate with each other to cause allergic disease. We show in irradiated chimeric mice that Toll-like receptor 4 (TLR4) expression on radioresistant lung structural cells, but not on DCs, is necessary and sufficient for DC activation in the lung and for priming of effector T helper responses to HDM. TLR4 triggering on structural cells caused production of the innate proallergic cytokines thymic stromal lymphopoietin, granulocyte-macrophage colony-stimulating factor, interleukin-25 and interleukin-33. The absence of TLR4 on structural cells, but not on hematopoietic cells, abolished HDM-driven allergic airway inflammation. Finally, inhalation of a TLR4 antagonist to target exposed epithelial cells suppressed the salient features of asthma, including bronchial hyperreactivity. Our data identify an innate immune function of airway epithelial cells that drives allergic inflammation via activation of mucosal DCs.	[Hammad, Hamida; Perros, Frederic; Willart, Monique A.; Lambrecht, Bart N.] Univ Ghent, Dept Resp Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Chieppa, Marcello; Germain, Ronald N.] NIAID, Immunol Lab, Sect Lymphocyte Biol, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, Rotterdam, Netherlands	Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Erasmus University Rotterdam; Erasmus MC	Lambrecht, BN (corresponding author), Univ Ghent, Dept Resp Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Germain, Ronald N./Z-1945-2019; Hammad, Hamida/J-9391-2015; Chieppa, Marcello/K-4846-2012; Chieppa, Marcello/AAG-9835-2019; Lambrecht, Bart N/K-2484-2014; Perros, Frédéric/N-6921-2017; Chieppa, Marcello/I-8447-2018; Germain, Ronald/ABE-7090-2020	Hammad, Hamida/0000-0003-3762-8603; Chieppa, Marcello/0000-0001-9819-0823; Lambrecht, Bart N/0000-0003-4376-6834; Perros, Frédéric/0000-0001-7730-2427; Chieppa, Marcello/0000-0001-9819-0823; 	Intramural NIH HHS [ZIA AI000545-21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000545] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Berndt A, 2007, AM J PHYSIOL-LUNG C, V292, pL936, DOI 10.1152/ajplung.00394.2006; Beutler B, 2001, DRUG METAB DISPOS, V29, P474; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; IROMPETTE A, 2009, NATURE, V457, P585; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106, DOI 10.1152/ajplung.2001.281.5.L1106; Matute-Bello G, 2004, J IMMUNOL METHODS, V292, P25, DOI 10.1016/j.jim.2004.05.010; NATHAN AI, 2009, J ALLERGY CLIN  0127, DOI DOI 10.1016/J.JACI.2008.12; Nolte MA, 2007, J EXP MED, V204, P1487, DOI 10.1084/jem.20070325; Noulin N, 2005, J IMMUNOL, V175, P6861, DOI 10.4049/jimmunol.175.10.6861; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Robays LJ, 2007, J IMMUNOL, V178, P5305, DOI 10.4049/jimmunol.178.8.5305; Saito T, 2005, CELL TISSUE RES, V321, P75, DOI 10.1007/s00441-005-1113-9; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Skerrett SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL143, DOI 10.1152/ajplung.00030.2004; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Veres TZ, 2007, AM J RESP CELL MOL, V37, P553, DOI 10.1165/rcmb.2007-0087OC; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	45	814	844	3	103	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					410	416		10.1038/nm.1946	http://dx.doi.org/10.1038/nm.1946			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19330007	Green Accepted			2022-12-27	WOS:000264937200028
J	Hidalgo, A; Chang, JS; Jang, JE; Peired, AJ; Chiang, EY; Frenette, PS				Hidalgo, Andres; Chang, Jungshan; Jang, Jung-Eun; Peired, Anna J.; Chiang, Elaine Y.; Frenette, Paul S.			Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury	NATURE MEDICINE			English	Article							SICKLE-CELL-DISEASE; ACUTE LUNG INJURY; E-SELECTIN; P-SELECTIN; IN-VIVO; ADHESION MOLECULE-1; LEUKOCYTE ADHESION; MAC-1 CD11B/CD18; INTEGRIN; MICE	Selectins and their ligands mediate leukocyte rolling, allowing interactions with chemokines that lead to integrin activation and arrest. Here we show that E-selectin is crucial for generating a secondary wave of activating signals, transduced specifically by E-selectin ligand-1, that induces polarized, activated alpha(M)beta(2) integrin clusters at the leading edge of crawling neutrophils, allowing capture of circulating erythrocytes or platelets. In a humanized mouse model of sickle cell disease, the capture of erythrocytes by alpha(M)beta(2) microdomains leads to acute lethal vascular occlusions. In a model of transfusion-related acute lung injury, polarized neutrophils capture circulating platelets, resulting in the generation of oxidative species that produce vascular damage and lung injury. Inactivation of E-selectin or alpha(M)beta(2) prevents tissue injury in both inflammatory models, suggesting broad implications of this paradigm in thromboinflammatory diseases. These results indicate that endothelial selectins can influence neutrophil behavior beyond its canonical rolling step through delayed, organ-damaging, polarized activation.	[Hidalgo, Andres; Chang, Jungshan; Jang, Jung-Eun; Peired, Anna J.; Chiang, Elaine Y.; Frenette, Paul S.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Hidalgo, Andres; Chang, Jungshan; Jang, Jung-Eun; Peired, Anna J.; Chiang, Elaine Y.; Frenette, Paul S.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY USA; [Frenette, Paul S.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA; [Frenette, Paul S.] Mt Sinai Sch Med, Inst Immunol, New York, NY USA; [Frenette, Paul S.] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Frenette, PS (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY USA.	andres.hidalgo@mssm.edu; paul.frenette@mssm.edu	Hidalgo, Andrés/L-5643-2014; Frenette, Paul S/J-8272-2012; Peired, Anna Julie/J-9952-2019	Hidalgo, Andrés/0000-0001-5513-555X; Frenette, Paul S/0000-0003-0862-9922; Peired, Anna Julie/0000-0001-9732-1369	US National Institutes of Health [R01 HL69438, T32 HL07824]; American Heart Association [0735165N]; Spanish Ministry of Science and Innovation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007824, R01HL069438] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank C. Jakubzick for help establishing the lung injury model and B. Wolitzky (Immune Tolerance Network) for the 9A9 antibody to E-selectin. This work was supported by US National Institutes of Health grants R01 HL69438 to P.S.F. and T32 HL07824 to J.C. and by a Scientist Development Grant from the American Heart Association to A.H.(0735165N). P.S.F. is supported by an Established Investigator Award from the American Heart Association. A.H. is the recipient of a Ramon y Cajal fellowship from the Spanish Ministry of Science and Innovation.	Abboud M, 1998, LANCET, V351, P959; Arimura Kosei, 2005, Haematologica, V90, pECR10; Barreiro O, 2007, IMMUNOL REV, V218, P147, DOI 10.1111/j.1600-065X.2007.00529.x; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chang JS, 2008, BLOOD, V111, P915, DOI 10.1182/blood-2007-04-084061; Chiang EY, 2007, NAT METHODS, V4, P219, DOI 10.1038/nmeth1018; Coller BS, 2005, ARTERIOSCL THROM VAS, V25, P658, DOI 10.1161/01.ATV.0000156877.94472.a5; Dagia NM, 2006, NAT MED, V12, P1185, DOI 10.1038/nm1470; Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; Evangelista V, 1999, BLOOD, V93, P876, DOI 10.1182/blood.V93.3.876.403k25_876_885; Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782; Frenette PS, 2007, J CLIN INVEST, V117, P850, DOI 10.1172/JCI30920; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GAARDER A., 1961, NATURE, V192, P531, DOI 10.1038/192531a0; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Goel MS, 2002, BLOOD, V100, P3797, DOI 10.1182/blood-2002-03-0712; Hidalgo A, 2007, IMMUNITY, V26, P477, DOI 10.1016/j.immuni.2007.03.011; Hirahashi J, 2006, IMMUNITY, V25, P271, DOI 10.1016/j.immuni.2006.05.014; Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004; Husemann J, 2001, ARTERIOSCL THROM VAS, V21, P1301, DOI 10.1161/hq0801.095150; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Simon SI, 2000, J IMMUNOL, V164, P4348, DOI 10.4049/jimmunol.164.8.4348; SIMON SI, 1995, J IMMUNOL, V155, P1502; Smith ML, 2004, J EXP MED, V200, P935, DOI 10.1084/jem.20040424; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Stuart MJ, 2004, LANCET, V364, P1343, DOI 10.1016/S0140-6736(04)17192-4; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Totani L, 2006, BIOCHEM J, V396, P89, DOI 10.1042/BJ20051924; Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799; Wakefield TW, 2008, ARTERIOSCL THROM VAS, V28, P387, DOI 10.1161/ATVBAHA.108.162289; Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491; WANG RH, 1993, J CLIN INVEST, V92, P1326, DOI 10.1172/JCI116706; Zarbock A, 2007, IMMUNITY, V26, P773, DOI 10.1016/j.immuni.2007.04.011; Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499; Zennadi R, 2008, TRANSFUS CLIN BIOL, V15, P23, DOI 10.1016/j.tracli.2008.04.009	49	248	256	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					384	391		10.1038/nm.1939	http://dx.doi.org/10.1038/nm.1939			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19305412	Green Accepted			2022-12-27	WOS:000264937200025
J	Katsuno, M; Adachi, H; Sobue, G				Katsuno, Masahisa; Adachi, Hiroaki; Sobue, Gen			The case for cholesterol	NATURE MEDICINE			English	Editorial Material							HUNTINGTONS-DISEASE; BETA; MICE; PATHWAY		[Katsuno, Masahisa; Adachi, Hiroaki; Sobue, Gen] Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Katsuno, Masahisa] Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Katsuno, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ka2no@med.nagoya-u.ac.jp; sobueg@med.nagoya-u.ac.jp	Adachi, Hiroaki/AAM-7812-2020; KATSUNO, MASAHISA/I-7502-2014	Adachi, Hiroaki/0000-0002-9302-4663; KATSUNO, MASAHISA/0000-0001-9453-9311				Andersson S, 2005, P NATL ACAD SCI USA, V102, P3857, DOI 10.1073/pnas.0500634102; Butler R, 2006, NAT REV NEUROSCI, V7, P784, DOI 10.1038/nrn1989; Dupuis L, 2008, NEUROLOGY, V70, P1004, DOI 10.1212/01.wnl.0000285080.70324.27; Huntington G., 1872, MED SURG REP, V26, P320; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Leoni V, 2008, BRAIN, V131, P2851, DOI 10.1093/brain/awn212; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Valenza M, 2005, J NEUROSCI, V25, P9932, DOI 10.1523/JNEUROSCI.3355-05.2005; Valenza M, 2007, HUM MOL GENET, V16, P2187, DOI 10.1093/hmg/ddm170	12	17	18	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					253	254		10.1038/nm0309-253	http://dx.doi.org/10.1038/nm0309-253			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19265827				2022-12-27	WOS:000263914000024
J	Santos, EB; Yeh, R; Lee, J; Nikhamin, Y; Punzalan, B; Punzalan, B; La Perle, K; Larson, SM; Sadelain, M; Brentjens, RJ				Santos, Elmer B.; Yeh, Raymond; Lee, James; Nikhamin, Yan; Punzalan, Blesida; Punzalan, Blesserene; La Perle, Krista; Larson, Steven M.; Sadelain, Michel; Brentjens, Renier J.			Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; LYMPHOCYTE TRAFFICKING; ADOPTIVE IMMUNOTHERAPY; PROSTATE-CANCER; GENE-TRANSFER; EXPRESSION; BIOLUMINESCENCE; TUMORS; VISUALIZATION; REJECTION	We developed a new approach to bioluminescent T cell imaging using a membrane-anchored form of the Gaussia luciferase (GLuc) enzyme, termed extGLuc, which we could stably express in both mouse and human primary T cells. In vitro, extGLuc(+) cells emitted significantly higher bioluminescent signal when compared to cells expressing GLuc, Renilla luciferase (RLuc) or membrane-anchored RLuc (extRLuc). In vivo, mouse extGLuc(+) T cells showed higher bioluminescent signal when compared to GLuc(+) and RLuc(+) T cells. Application of this imaging approach to human T cells genetically modified to express tumor-specific chimeric antigen receptors (CARs) enabled us to show in vivo CAR-mediated T cell accumulation in tumor, T cell persistence over time and concomitant imaging of T cells and tumor cells modified to express firefly luciferase. This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models.	[Yeh, Raymond; Lee, James; Nikhamin, Yan; Sadelain, Michel; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; [Santos, Elmer B.; Punzalan, Blesida; Punzalan, Blesserene; Larson, Steven M.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA; [Santos, Elmer B.; Punzalan, Blesida; Punzalan, Blesserene; Larson, Steven M.; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA; [Santos, Elmer B.; Larson, Steven M.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10021 USA; [La Perle, Krista] Mem Sloan Kettering Canc Ctr, Res Anim Resource Ctr, New York, NY 10021 USA; [Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Gene Transfer & Somat Cell Engn Lab, New York, NY 10021 USA; [Sadelain, Michel; Brentjens, Renier J.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Brentjens, RJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	brentjer@mskcc.org	La Perle, Krista Marie DuBray/B-3099-2015		US National Institutes of Health [CA95152, CA059350, CA08748, CA086438, CA096945, CA094060, CA083084]; Alliance for Cancer Gene Therapy; Damon Runyon Clinical Investigator Award; Canada Club of New York, Kate's Team; Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC; Geoffrey Beene Cancer Foundation; Chronic Lymphocytic Leukemia Foundation; Ludwig Center for Cancer Immunotherapy; Bocina Cancer Research Fund; NATIONAL CANCER INSTITUTE [P01CA059350, P30CA008748, K08CA095152, P50CA086438, R25CA096945, P01CA094060] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Cancer Gene Therapy; Damon Runyon Clinical Investigator Award; Canada Club of New York, Kate's Team; Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC; Geoffrey Beene Cancer Foundation; Chronic Lymphocytic Leukemia Foundation; Ludwig Center for Cancer Immunotherapy; Bocina Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by US National Institutes of Health grants CA95152, CA059350, CA08748, CA086438, CA096945, CA094060 and CA083084, The Alliance for Cancer Gene Therapy, the Damon Runyon Clinical Investigator Award (R.J.B.), The Annual Terry Fox Run for Cancer Research organized by the Canada Club of New York, Kate's Team, W. H. Goodwin and A. Goodwin and the Commonwealth Cancer Foundation for Research and the Experimental Therapeutics Center of MSKCC, the Geoffrey Beene Cancer Foundation, the Chronic Lymphocytic Leukemia Foundation, the Ludwig Center for Cancer Immunotherapy and the Bocina Cancer Research Fund.	Badr CE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000571; Beilhack A, 2005, BLOOD, V106, P1113, DOI 10.1182/blood-2005-02-0509; Billotey C, 2005, RADIOLOGY, V236, P579, DOI 10.1148/radiol.2362040603; Brentjens RJ, 2007, CLIN CANCER RES, V13, P5426, DOI 10.1158/1078-0432.CCR-07-0674; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Cao YA, 2005, TRANSPLANTATION, V80, P134, DOI 10.1097/01.TP.0000164347.50559.A3; Cao YA, 2004, P NATL ACAD SCI USA, V101, P221, DOI 10.1073/pnas.2637010100; Cheng GF, 2007, MOL BIOCHEM PARASIT, V155, P167, DOI 10.1016/j.molbiopara.2007.06.013; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Edinger M, 2003, BLOOD, V101, P640, DOI 10.1182/blood-2002-06-1751; Gade TPF, 2005, CANCER RES, V65, P9080, DOI 10.1158/0008-5472.CAN-05-0436; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Greer LF, 2002, LUMINESCENCE, V17, P43, DOI 10.1002/bio.676; Hinrichs CS, 2006, CURR OPIN IMMUNOL, V18, P363, DOI 10.1016/j.coi.2006.03.009; Hu DE, 2005, MAGN RESON MED, V54, P1473, DOI 10.1002/mrm.20717; Huang X, 2006, BLOOD, V107, P483, DOI 10.1182/blood-2005-05-2133; Kalikin LM, 2003, CANCER BIOL THER, V2, P656; Kim YJ, 2004, MOL IMAGING BIOL, V6, P331, DOI 10.1016/j.mibio.2004.06.009; Kircher MF, 2003, CANCER RES, V63, P6838; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Koehne G, 2003, NAT BIOTECHNOL, V21, P405, DOI 10.1038/nbt805; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Nakajima A, 2001, J CLIN INVEST, V107, P1293, DOI 10.1172/JCI12037; Pichler A, 2004, P NATL ACAD SCI USA, V101, P1702, DOI 10.1073/pnas.0304326101; Quintas-Cardama A, 2007, HUM GENE THER, V18, P1253, DOI 10.1089/hum.2007.088; Remy I, 2006, NAT METHODS, V3, P977, DOI 10.1038/nmeth979; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Scheffold C, 2002, CANCER RES, V62, P5785; Serrano LM, 2006, BLOOD, V107, P2643, DOI 10.1182/blood-2005-09-3904; Suzuki T, 2007, FEBS LETT, V581, P4551, DOI 10.1016/j.febslet.2007.08.036; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Tarner IH, 2002, CLIN IMMUNOL, V105, P304, DOI 10.1006/clim.2002.5299; Thorne SH, 2006, SCIENCE, V311, P1780, DOI 10.1126/science.1121411; Venisnik KM, 2007, MOL IMAGING BIOL, V9, P267, DOI 10.1007/s11307-007-0101-8; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329	36	100	114	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					338	344		10.1038/nm.1930	http://dx.doi.org/10.1038/nm.1930			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19219023	Green Accepted			2022-12-27	WOS:000263914000036
J	Van Gool, F; Galli, M; Gueydan, C; Kruys, V; Prevot, PP; Bedalov, A; Mostoslavsky, R; Alt, FW; De Smedt, T; Leo, O				Van Gool, Frederic; Galli, Mara; Gueydan, Cyril; Kruys, Veronique; Prevot, Pierre-Paul; Bedalov, Antonio; Mostoslavsky, Raul; Alt, Frederick W.; De Smedt, Thibaut; Leo, Oberdan			Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner	NATURE MEDICINE			English	Article							COLONY-ENHANCING FACTOR; NF-KAPPA-B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; DEFICIENT MICE; INFLAMMATION; MOLECULE; INHIBITOR; APOPTOSIS; POLY(ADP-RIBOSE); LETHALITY	Tumor necrosis factor (TNF) synthesis is known to play a major part in numerous inflammatory disorders, and multiple transcriptional and post-transcriptional regulatory mechanisms have therefore evolved to dampen the production of this key proinflammatory cytokine(1,2). The high expression of nicotinamide phosphoribosyltransferase (Nampt), an enzyme involved in the nicotinamide-dependent NAD biosynthetic pathway, in cells of the immune system(3) has led us to examine the potential relationship between NAD metabolism and inflammation. We show here that intracellular NAD concentration promotes TNF synthesis by activated immune cells. Using a positive screen, we have identified Sirt6, a member of the sirtuin family(4), as the NAD-dependent enzyme able to regulate TNF production by acting at a post-transcriptional step. These studies reveal a previously undescribed relationship between metabolism and the inflammatory response and identify Sirt6 and the nicotinamide-dependent NAD biosynthetic pathway as novel candidates for immunointervention in an inflammatory setting.	[Van Gool, Frederic; Galli, Mara; Leo, Oberdan] Univ Libre Bruxelles, Inst Biol & Med Mol, Physiol Anim Lab, B-6041 Gosselies, Belgium; [Gueydan, Cyril; Kruys, Veronique] Univ Libre Bruxelles, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; [Prevot, Pierre-Paul] Univ Libre Bruxelles, Inst Biol & Med Mol, Lab Mol Biol Ectoparasites, B-6041 Gosselies, Belgium; [Bedalov, Antonio] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Mostoslavsky, Raul; Alt, Frederick W.] Childrens Hosp, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA; [Mostoslavsky, Raul; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [De Smedt, Thibaut] TopoTarget Switzerland SA, CH-1004 Lausanne, Switzerland	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Fred Hutchinson Cancer Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Leo, O (corresponding author), Univ Libre Bruxelles, Inst Biol & Med Mol, Physiol Anim Lab, 12 Rue Prof Jeneer & Brachet, B-6041 Gosselies, Belgium.	oleo@ulb.ac.be	Kruys, Veronique I/N-6613-2018; Van Gool, Frederic/V-4638-2019	Kruys, Veronique/0000-0002-3144-5403; Gueydan, Cyril/0000-0003-3097-7667	The Belgian Program in Interuniversity Poles of Attraction initiated by the Belgian state, the Prime Minister's office; Research Concerted Action of the Communaute francaise de Belgique; Direction Generale des Technologies de la Recherche et de l'Energie, Region Wallonne ( Belgium); Fonds Jean Brachet and by TopoTarget Switzerland; Fonds national de la recherche scientifique (FRS-FNRS); French community of Belgium; NATIONAL CANCER INSTITUTE [R01CA129132] Funding Source: NIH RePORTER	The Belgian Program in Interuniversity Poles of Attraction initiated by the Belgian state, the Prime Minister's office; Research Concerted Action of the Communaute francaise de Belgique; Direction Generale des Technologies de la Recherche et de l'Energie, Region Wallonne ( Belgium); Fonds Jean Brachet and by TopoTarget Switzerland; Fonds national de la recherche scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); French community of Belgium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	APO866 was synthesized and kindly provided by Astellas Pharma. We wish to thank G. de Murcia ( formerly at the Ecole Superieure de Biotechnologie de Strasbourg, Illkirch Cedex) for providing the Parp1-knockout mouse strain and V. Sartorelli ( US National Institutes of Health) for providing the pHan-SIRT1 vector ( wild-type and mutant forms). This work was supported by The Belgian Program in Interuniversity Poles of Attraction initiated by the Belgian state, the Prime Minister's office, Science Policy Programming, by a Research Concerted Action of the Communaute francaise de Belgique, by grants from the Direction Generale des Technologies de la Recherche et de l'Energie, Region Wallonne ( Belgium), by a grant from the Fonds Jean Brachet and by TopoTarget Switzerland SA. F. V. G. and M. G. have been supported by research grants from the Fonds national de la recherche scientifique (FRS-FNRS), French community of Belgium. The scientific responsibility is assumed by the authors.	Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Cuzzocrea S, 2005, PHARMACOL RES, V52, P72, DOI 10.1016/j.phrs.2005.02.016; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Fukuzawa M, 1997, IMMUNOL LETT, V59, P7, DOI 10.1016/S0165-2478(97)00088-6; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Hasmann M, 2003, CANCER RES, V63, P7436; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Henson PM, 2005, NAT IMMUNOL, V6, P1179, DOI 10.1038/ni1205-1179; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI [10.1172/JCI19930, 10.1172/JCI200419930]; Kuhnle S, 1999, BIOCHEM BIOPH RES CO, V263, P433, DOI 10.1006/bbrc.1999.1393; Luk T, 2008, J LEUKOCYTE BIOL, V83, P804, DOI 10.1189/jlb.0807581; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Szabo C, 2003, INTENS CARE MED, V29, P863, DOI 10.1007/s00134-003-1737-8; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Ungerstedt JS, 2003, CLIN EXP IMMUNOL, V131, P48, DOI 10.1046/j.1365-2249.2003.02031.x; Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	26	214	218	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					206	210		10.1038/nm.1906	http://dx.doi.org/10.1038/nm.1906			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19151729	Green Accepted			2022-12-27	WOS:000263119400024
J	Nickoloff, BJ				Nickoloff, Brian J.			Saving the skin from drug-induced detachment	NATURE MEDICINE			English	Editorial Material							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; CYTOTOXIC T-CELLS; RISK		Loyola Univ, Chicago Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Chicago Med Ctr, Bldg 112,Room 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu						Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Benyo Z, 2006, MOL PHARMACOL, V70, P1844, DOI 10.1124/mol.106.030833; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; MIYAUCHI H, 1991, ARCH DERMATOL, V127, P851, DOI 10.1001/archderm.127.6.851; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Quinn AM, 2005, ARCH DERMATOL, V141, P683, DOI 10.1001/archderm.141.6.683; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Watanabe H, 2008, J IMMUNOL, V180, P5826, DOI 10.4049/jimmunol.180.9.5826; WOLKENSTEIN P, 1995, ARCH DERMATOL, V131, P544, DOI 10.1001/archderm.131.5.544	14	12	12	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1311	1313		10.1038/nm1208-1311	http://dx.doi.org/10.1038/nm1208-1311			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057552				2022-12-27	WOS:000261393600011
J	Obermeier, B; Mentele, R; Malotka, J; Kellermann, J; Kumpfel, T; Wekerle, H; Lottspeich, F; Hohlfeld, R; Dornmair, K				Obermeier, Birgit; Mentele, Reinhard; Malotka, Joachim; Kellermann, Josef; Kuempfel, Tania; Wekerle, Hartmut; Lottspeich, Friedrich; Hohlfeld, Reinhard; Dornmair, Klaus			Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; CLONAL EXPANSION; SOMATIC HYPERMUTATION; B-CELLS; IDENTIFICATION; SEGMENTS; GENES; BRAIN; ANTIBODIES; COMPONENTS	We describe a method for correlating the immunoglobulin (Ig) proteomes with the B cell transcriptomes in human fluid and tissue samples, using multiple sclerosis as a paradigm. Oligoclonal Ig bands and elevated numbers of clonally expanded B cells in the cerebrospinal fluid (CSF) are diagnostic hallmarks of multiple sclerosis. Here we compared the Ig transcriptomes of B cells with the corresponding Ig proteomes in CSF samples from four subjects with multiple sclerosis. We created individual Ig transcriptome databases that contained the subject-specific mutations introduced by V(D) J recombination and somatic hypermutation and then searched the CSF for corresponding characteristic peptides by mass spectrometry. In each sample, the Ig transcriptomes and proteomes strongly overlapped, showing that CSF B cells indeed produce the oligoclonal Ig bands. This approach can be applied to other organ-specific diagnostic fluid or tissue samples to compare the Ig transcripts of local B cells with the corresponding antibody proteomes of individual subjects.	[Obermeier, Birgit; Mentele, Reinhard; Kuempfel, Tania; Hohlfeld, Reinhard; Dornmair, Klaus] Univ Munich, Univ Hosp Grosshadern, Inst Clin Neuroimmunol, D-81377 Munich, Germany; [Obermeier, Birgit; Malotka, Joachim; Wekerle, Hartmut; Hohlfeld, Reinhard; Dornmair, Klaus] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany; [Mentele, Reinhard; Kellermann, Josef; Lottspeich, Friedrich] Max Planck Inst Biochem, Dept Prot Analyt, D-82152 Martinsried, Germany	University of Munich; Max Planck Society; Max Planck Society	Dornmair, K (corresponding author), Univ Munich, Univ Hosp Grosshadern, Inst Clin Neuroimmunol, Marchioninistr 15, D-81377 Munich, Germany.	dornmair@neuro.mpg.de	Kümpfel, Tania/ABH-1780-2021					Baranzini SE, 1999, J IMMUNOL, V163, P5133; Colombo M, 2000, J IMMUNOL, V164, P2782, DOI 10.4049/jimmunol.164.5.2782; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1942, J CLIN INVEST, V21, P571, DOI 10.1172/JCI101335; KASCHKA WP, 1979, INFECT IMMUN, V26, P933, DOI 10.1128/IAI.26.3.933-941.1979; LINK H, 1970, CLIN EXP IMMUNOL, V6, P435; LOSY J, 1990, ACTA NEUROL SCAND, V82, P4; Meinl E, 2006, ANN NEUROL, V59, P880, DOI 10.1002/ana.20890; Monson NL, 2005, J NEUROIMMUNOL, V158, P170, DOI 10.1016/j.jneuroim.2004.04.022; O'Connor KC, 2005, J IMMUNOL, V175, P1974, DOI 10.4049/jimmunol.175.3.1974; OBERMEIER B, 2008, NAT PROTOC      0518; Odegard VH, 2006, NAT REV IMMUNOL, V6, P573, DOI 10.1038/nri1896; Owens GP, 1998, ANN NEUROL, V43, P236, DOI 10.1002/ana.410430214; Owens GP, 2003, J IMMUNOL, V171, P2725, DOI 10.4049/jimmunol.171.5.2725; Owens GP, 2007, J IMMUNOL, V179, P6343, DOI 10.4049/jimmunol.179.9.6343; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Qian WJ, 2006, MOL CELL PROTEOMICS, V5, P1727, DOI 10.1074/mcp.M600162-MCP200; Qin YF, 1998, J CLIN INVEST, V102, P1045, DOI 10.1172/JCI3568; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; VANDVIK B, 1976, SCAND J IMMUNOL, V5, P427, DOI 10.1111/j.1365-3083.1976.tb00297.x; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; Zverlov VV, 2005, PROTEOMICS, V5, P3646, DOI 10.1002/pmic.200401199	25	192	204	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					688	693		10.1038/nm1714	http://dx.doi.org/10.1038/nm1714			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18488038				2022-12-27	WOS:000256468700036
J	Jones, CA; London, NR; Chen, H; Park, KW; Sauvaget, D; Stockton, RA; Wythe, JD; Suh, W; Larrieu-Lahargue, F; Mukouyama, YS; Lindblom, P; Seth, P; Frias, A; Nishiya, N; Ginsberg, MH; Gerhardt, H; Zhang, K; Li, DY				Jones, Christopher A.; London, Nyall R.; Chen, Haoyu; Park, Kye Won; Sauvaget, Dominique; Stockton, Rebecca A.; Wythe, Joshua D.; Suh, Wonhee; Larrieu-Lahargue, Frederic; Mukouyama, Yoh-Suke; Lindblom, Per; Seth, Pankaj; Frias, Antonio; Nishiya, Naoyuki; Ginsberg, Mark H.; Gerhardt, Holger; Zhang, Kang; Li, Dean Y.			Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability	NATURE MEDICINE			English	Article							OXYGEN-INDUCED RETINOPATHY; MACULAR DEGENERATION; AXON GUIDANCE; SLIT; MOUSE; RECEPTOR; MIDLINE; GROWTH; NEOVASCULARIZATION; MORPHOGENESIS	The angiogenic sprout has been compared to the growing axon, and indeed, many proteins direct pathfinding by both structures(1). The Roundabout ( Robo) proteins are guidance receptors with well- established functions in the nervous system(2,3); however, their role in the mammalian vasculature remains ill defined(4-8). Here we show that an endothelial-specific Robo, Robo4, maintains vascular integrity. Activation of Robo4 by Slit2 inhibits vascular endothelial growth factor ( VEGF)- 165 - induced migration, tube formation and permeability in vitro and VEGF- 165 - stimulated vascular leak in vivo by blocking Src family kinase activation. In mouse models of retinal and choroidal vascular disease, Slit2 inhibited angiogenesis and vascular leak, whereas deletion of Robo4 enhanced these pathologic processes. Our results define a previously unknown function for Robo receptors in stabilizing the vasculature and suggest that activating Robo4 may have broad therapeutic application in diseases characterized by excessive angiogenesis and/ or vascular leak.	Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Jones, Christopher A.; London, Nyall R.; Park, Kye Won; Wythe, Joshua D.; Suh, Wonhee; Larrieu-Lahargue, Frederic; Frias, Antonio; Zhang, Kang; Li, Dean Y.] Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; [Chen, Haoyu; Stockton, Rebecca A.; Zhang, Kang] Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA; [Sauvaget, Dominique; Lindblom, Per; Gerhardt, Holger] London Res Inst Canc Res, Vasc Biol Lab, London WC2A 3PX, England; [Nishiya, Naoyuki; Ginsberg, Mark H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Mukouyama, Yoh-Suke] NHLBI, Stem Cell & Neuro Vasc Dev & Patterning Sect, Dev Biol Lab, Genet & Dev Biol Ctr,NIH, Bethesda, MD 20892 USA; [Seth, Pankaj] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA; [Seth, Pankaj] Harvard Univ, Sch Med, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of London; Institute of Cancer Research - UK; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Li, DY (corresponding author), Univ Utah, Dept Oncol Sci, 15 North 2030 East, Salt Lake City, UT 84112 USA.	Kang.Zhang@hmbg.utah.edu; Dean.Li@hmbg.utah.edu	Gerhardt, Holger/G-4610-2011; Xiao, Yang/B-5668-2012; Chen, Haoyu/A-7432-2013; Chu, Kai On/E-2325-2016; Zhang, Kang/Y-2740-2019; Gerhardt, Holger/G-4610-2011	Gerhardt, Holger/0000-0002-3030-0384; Chen, Haoyu/0000-0003-0676-4610; Zhang, Kang/0000-0002-4549-1697; Mukouyama, Yoh-suke/0000-0002-9084-4922; Wythe, Joshua/0000-0002-3225-2937; Park, Kye Won/0000-0003-2771-249X; Gerhardt, Holger/0000-0001-9228-7472; Nishiya, Naoyuki/0000-0003-1575-9944	Cancer Research UK Funding Source: Medline; Intramural NIH HHS [Z01 HL005702-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL068873, R01 HL077671, R01 HL068873-05, R01 HL077671-03, R01 HL084516-02, R01 HL065648, R01 HL077671-04, R01 HL084516-01A1, R01 HL084516, R01 HL068873-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084516, Z01HL005702, R01HL065648, R01HL077671, R01HL068873] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battye R, 2001, J NEUROSCI, V21, P4290, DOI 10.1523/JNEUROSCI.21-12-04290.2001; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Kaus S, 2006, J BIOL CHEM, V281, P11347, DOI 10.1074/jbc.M508853200; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Long H, 2004, NEURON, V42, P213, DOI 10.1016/S0896-6273(04)00179-5; Morlot C, 2007, P NATL ACAD SCI USA, V104, P14923, DOI 10.1073/pnas.0705310104; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Patel K, 2001, DEVELOPMENT, V128, P5031; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Silva RLE, 2005, INVEST OPHTH VIS SCI, V46, P3323, DOI 10.1167/iovs.04-1210; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Uemura AK, 2006, EXP CELL RES, V312, P676, DOI 10.1016/j.yexcr.2005.10.030; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Werdich XQ, 2004, EXP EYE RES, V79, P623, DOI 10.1016/j.exer.2004.07.006; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371	29	293	330	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					448	453		10.1038/nm1742	http://dx.doi.org/10.1038/nm1742			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18345009	Green Accepted			2022-12-27	WOS:000254674100033
J	Jones, KS; Petrow-Sadowski, C; Huang, YK; Bertolette, DC; Ruscetti, FW				Jones, Kathryn S.; Petrow-Sadowski, Cari; Huang, Ying K.; Bertolette, Daniel C.; Ruscetti, Francis W.			Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells	NATURE MEDICINE			English	Article							LYMPHOTROPIC VIRUS TYPE-1; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; HEPARAN-SULFATE PROTEOGLYCANS; BLOOD MONONUCLEAR-CELLS; I TAX; ASYMPTOMATIC CARRIERS; IMMUNE SUPPRESSION; VIRAL REPLICATION; MESSENGER-RNA; LEUKEMIA	Cell- free human T- lymphotropic virus type 1 ( HTLV- 1) virions are poorly infectious in vitro for their primary target cells, CD4(+) T cells. Here, we show that HTLV- 1 can efficiently infect myeloid and plasmacytoid dendritic cells ( DCs). Moreover, DCs exposed to HTLV- 1, both before and after being productively infected, can rapidly, efficiently and reproducibly transfer virus to autologous primary CD4(+) T cells. This DC- mediated transfer of HTLV-1 involves heparan sulfate proteoglycans and neuropilin-1 and results in long- term productive infection and interleukin-2- independent transformation of the CD4(+) T cells. These studies, along with observations of HTLV-1- infected DCs in the peripheral blood of infected individuals, indicate that DCs have a central role in HTLV-1 transmission, dissemination and persistence in vivo. In addition to altering the current paradigm concerning how HTLV-1 transmission occurs, these studies suggest that impairment of DC function after HTLV- 1 infection plays a part in pathogenesis.	[Jones, Kathryn S.; Petrow-Sadowski, Cari] Sci Applicat Int Corp, Basic Res Program, Frederick, MD USA; [Huang, Ying K.; Bertolette, Daniel C.; Ruscetti, Francis W.] NCI, Ctr Canc Res, Canc & Inflammat Program, Expt Immunol Lab, Frederick, MD 21702 USA	Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jones, KS (corresponding author), Sci Applicat Int Corp, Basic Res Program, Frederick, MD USA.	joneska@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010252] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Dahoodi ZM, 2003, J CLIN EXP HEMATOPAT, V43, P43; Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Ceccaldi PE, 2006, J VIROL, V80, P4771, DOI 10.1128/JVI.80.10.4771-4780.2006; Courreges MC, 2007, J VIROL, V81, P3769, DOI 10.1128/JVI.02728-06; Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; EHRLICH GD, 1989, BLOOD, V74, P1066; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; Feuer G, 2005, ONCOGENE, V24, P5996, DOI 10.1038/sj.onc.1208971; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Ghez D, 2006, J VIROL, V80, P6844, DOI 10.1128/JVI.02719-05; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; Gummuluru S, 2002, J VIROL, V76, P10692, DOI 10.1128/JVI.76.21.10692-10701.2002; Hague BF, 2003, VIRUS RES, V93, P31, DOI 10.1016/S0168-1702(03)00048-0; Hishizawa M, 2004, BRIT J HAEMATOL, V125, P568, DOI 10.1111/j.1365-2141.2004.04956.x; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jones KS, 2006, J VIROL, V80, P8291, DOI 10.1128/JVI.00389-06; Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; Kampani K, 2007, J VIROL METHODS, V141, P125, DOI 10.1016/j.jviromet.2006.11.043; KATSUKI T, 1987, JPN J CANCER RES, V78, P639; Kubota R, 2003, BLOOD, V101, P3074, DOI 10.1182/blood-2002-08-2477; Li M, 2007, J VIROL METHODS, V142, P159, DOI 10.1016/j.jviromet.2007.01.023; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699; Makino M, 2001, SCAND J IMMUNOL, V54, P574, DOI 10.1046/j.1365-3083.2001.01003.x; Makino M, 1999, J VIROL, V73, P4575, DOI 10.1128/JVI.73.6.4575-4581.1999; Makino M, 2000, VIROLOGY, V274, P140, DOI 10.1006/viro.2000.0445; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; Mascarenhas RE, 2006, CLIN VACCINE IMMUNOL, V13, P547, DOI 10.1128/CVI.13.5.547-552.2006; Nath MD, 2003, BLOOD, V101, P3085, DOI 10.1182/blood-2002-07-2277; Overbaugh J, 2004, NAT MED, V10, P20, DOI 10.1038/nm0104-20; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812; Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003; Pohl C, 2007, CELL MICROBIOL, V9, P279, DOI 10.1111/j.1462-5822.2006.00863.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SHINZATO O, 1991, BLOOD, V78, P2082; Silva MTT, 2007, CLIN INFECT DIS, V44, P689, DOI 10.1086/510679; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; TAGUCHI H, 1989, ACTA MED OKAYAMA, V43, P317; Thomas JA, 2007, J VIROL, V81, P4367, DOI 10.1128/JVI.02357-06; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129; Ureta-Vidal A, 2001, J INFECT DIS, V183, P857, DOI 10.1086/319264; Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960; Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88; Zhang L, 2006, J VIROL, V80, P7459, DOI 10.1128/JVI.00130-06; ZUCKERMAN AJ, 1995, HAEMOPHILIA, V1, P2, DOI 10.1111/j.1365-2516.1995.tb00122.x	50	198	203	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					429	436		10.1038/nm1745	http://dx.doi.org/10.1038/nm1745			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376405				2022-12-27	WOS:000254674100030
J	Coury, F; Annels, N; Rivollier, A; Olsson, S; Santoro, A; Speziani, C; Azocar, O; Flacher, M; Djebali, S; Tebib, J; Brytting, M; Egeler, RM; Rabourdin-Combe, C; Henter, JI; Arico, M; Delprat, C				Coury, Fabienne; Annels, Nicola; Rivollier, Aymeric; Olsson, Selma; Santoro, Alessandra; Speziani, Carole; Azocar, Olga; Flacher, Monique; Djebali, Sophia; Tebib, Jacques; Brytting, Maria; Egeler, R. Maarten; Rabourdin-Combe, Chantal; Henter, Jan-Inge; Arico, Maurizio; Delprat, Christine			Langerhans cell histiocytosis reveals a new IL-17A dependent pathway of dendritic cell fusion	NATURE MEDICINE			English	Article							CD4 T-CELLS; RHEUMATOID-ARTHRITIS; EXPRESSION; RECEPTOR; DISEASE; INTERLEUKIN-17; INFECTION; CYTOKINE; IL-23; DIFFERENTIATION	IL-17A is a T cell-specific cytokine(1) that is involved in chronic inflammations, such as Mycobacterium infection(2), Crohn's disease(3), rheumatoid arthritis(4) and multiple sclerosis(5). Mouse models have explained the molecular basis of IL-17A production(6,7) and have shown that IL-17A has a positive effect not only on granuloma formation(8) and neurodegeneration(9) through unknown mechanisms, but also on bone resorption through Receptor activator of NF-kappa B ligand (RANKL) induction in osteoblasts(4,10). Langerhans cell histiocytosis (LCH) is a rare disease of unknown etiology, lacking an animal model, that cumulates symptoms that are found separately in various IL-17A-related diseases, such as aggressive chronic granuloma formation, bone resorption and soft tissue lesions with occasional neurodegeneration(11,12). We examined IL-17A in the context of LCH and found that there were high serum levels of IL-17A during active LCH and unexpected IL-17A synthesis by dendritic cells (DCs), the major cell type in LCH lesions. We also found an IL-17A-dependent pathway for DC fusion, which was highly potentiated by IFN-gamma and led to giant cells expressing three major tissue-destructive enzymes: tartrate resistant acidic phosphatase and matrix metalloproteinases 9 and 12. IFN-gamma expression has been previously documented in LCH13 and observed in IL-17A-related diseases(14-17). Notably, serum IL-17A-dependent fusion activity correlates with LCH activity. Thus, IL-17A and IL-17A-stimulated DCs represent targets that may have clinical value in the treatment of LCH and other IL-17A-related inflammatory disorders.	[Coury, Fabienne; Rivollier, Aymeric; Speziani, Carole; Azocar, Olga; Flacher, Monique; Djebali, Sophia; Rabourdin-Combe, Chantal; Delprat, Christine] INSERM, U851, F-69007 Lyon, France; [Tebib, Jacques] Univ Lyon, F-69007 Lyon, France; Univ Lyon 1, F-69622 Villeurbanne, France; [Rivollier, Aymeric; Speziani, Carole; Azocar, Olga; Flacher, Monique; Djebali, Sophia; Rabourdin-Combe, Chantal; Delprat, Christine] IFR128, F-69007 Lyon, France; [Coury, Fabienne; Tebib, Jacques] Ctr Hosp Lyon Sud, Hosp Civils Lyon, F-69310 Pierre Benite, France; [Annels, Nicola; Egeler, R. Maarten] Leiden Univ, Med Ctr, Dept Pediat Immunol, NL-2300 RC Leiden, Netherlands; [Annels, Nicola; Egeler, R. Maarten] Leiden Univ, Med Ctr, Dept Hematol, NL-2300 RC Leiden, Netherlands; [Annels, Nicola; Egeler, R. Maarten] Leiden Univ, Med Ctr, Dept Oncol, NL-2300 RC Leiden, Netherlands; [Coury, Fabienne; Egeler, R. Maarten] Leiden Univ, Med Ctr, Dept Bone Marrow Transplantat & Autoimmune Dis, NL-2300 RC Leiden, Netherlands; [Olsson, Selma; Henter, Jan-Inge] Karolinska Univ Hosp, Karolinska Inst, Dept Woman & Child Hlth, Child Canc Res Unit, S-17176 Stockholm, Sweden; [Santoro, Alessandra; Arico, Maurizio] Ospedale Bambini G Di Cristina, I-90134 Palermo, Italy; [Santoro, Alessandra] AO Cervello, I-90134 Palermo, Italy; [Brytting, Maria] Swedish Inst Infect Dis Control, Dept Virol, S-17182 Solna, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Karolinska Institutet; Karolinska University Hospital; Swedish Institute for Infectious Disease Control	Delprat, C (corresponding author), INSERM, U851, 21 Ave Tony Garnier, F-69007 Lyon, France.	cdelprat@free.fr	Arico, Maurizio/S-3039-2019; DJEBALI, SOPHIA/A-1798-2017	Arico, Maurizio/0000-0002-1908-6671; DJEBALI, SOPHIA/0000-0002-0567-5387; Rivollier, Aymeric Marie Christian/0000-0001-8734-2916; coury, fabienne/0000-0002-9175-8620; Henter, Jan-Inge/0000-0002-0629-2126				Aarvak T, 1999, J IMMUNOL, V162, P1246; Annels NE, 2003, J EXP MED, V197, P1385, DOI 10.1084/jem.20030137; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Beverley PCL, 2005, NAT REV CANCER, V5, P488, DOI 10.1038/nrc1632; Cruz A, 2006, J IMMUNOL, V177, P1416, DOI 10.4049/jimmunol.177.3.1416; da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785; Edgar JDM, 2001, J PEDIATR-US, V139, P600, DOI 10.1067/mpd.2001.117068; Egeler RM, 1999, BLOOD, V94, P4195; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Grois N, 2005, BRAIN, V128, P829, DOI 10.1093/brain/awh403; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Laman JD, 2003, TRENDS IMMUNOL, V24, P190, DOI 10.1016/S1471-4906(03)00063-2; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Patel DN, 2007, J BIOL CHEM, V282, P27229, DOI 10.1074/jbc.M703250200; Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood-2004-01-0041; Rust R, 2006, J PATHOL, V209, P474, DOI 10.1002/path.2003; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; SATO NE, 2003, J EXP MED, V197, P1385; Suryani S, 2007, J NEUROIMMUNOL, V183, P96, DOI 10.1016/j.jneuroim.2006.11.023; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; Vaknin-Dembinsky A, 2006, J IMMUNOL, V176, P7768, DOI 10.4049/jimmunol.176.12.7768; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolk K, 2007, J IMMUNOL, V178, P5973, DOI 10.4049/jimmunol.178.9.5973; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	30	144	156	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					81	87		10.1038/nm1694	http://dx.doi.org/10.1038/nm1694			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157139				2022-12-27	WOS:000252222400026
J	Qiao, J; Kottke, T; Willmon, C; Galivo, F; Wongthida, P; Diaz, RM; Thompson, J; Ryno, P; Barber, GN; Chester, J; Selby, P; Harrington, K; Melcher, A; Vile, RG				Qiao, Jian; Kottke, Timothy; Willmon, Candice; Galivo, Feorillo; Wongthida, Phonphimon; Diaz, Rosa Maria; Thompson, Jill; Ryno, Pamela; Barber, Glen N.; Chester, John; Selby, Peter; Harrington, Kevin; Melcher, Alan; Vile, Richard G.			Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; BREAST-CANCER; MALIGNANT-MELANOMA; GENE-THERAPY; DELIVERY; VECTORS; INDUCTION; RESPONSES; EFFICACY; IMMUNITY	In many common cancers, dissemination of secondary tumors via the lymph nodes poses the most significant threat to the affected individual. Metastatic cells often reach the lymph nodes by mimicking the molecular mechanisms used by hematopoietic cells to traffic to peripheral lymphoid organs. Therefore, we exploited naive T cell trafficking in order to chaperone an oncolytic virus to lymphoid organs harboring metastatic cells. Metastatic burden was initially reduced by viral oncolysis and was then eradicated, as tumor cell killing in the lymph node and spleen generated protective antitumor immunity. Lymph node purging of tumor cells was possible even in virus-immune mice. Adoptive transfer of normal T cells loaded with oncolytic virus into individuals with cancer would be technically easy to implement both to reduce the distribution of metastases and to vaccinate the affected individual in situ against micrometastatic disease. As such, this adoptive transfer could have a great therapeutic impact, in the adjuvant setting, on many different cancer types.	[Qiao, Jian; Kottke, Timothy; Willmon, Candice; Galivo, Feorillo; Wongthida, Phonphimon; Diaz, Rosa Maria; Thompson, Jill; Ryno, Pamela; Vile, Richard G.] Mayo Clin, Program Mol Med, Rochester, MN 55905 USA; [Barber, Glen N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Chester, John; Selby, Peter; Melcher, Alan; Vile, Richard G.] Univ Leeds, Leeds Teaching Hosp UK Natl Hlth Serv Trust, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; [Chester, John; Selby, Peter; Melcher, Alan; Vile, Richard G.] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; [Vile, Richard G.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Harrington, Kevin] Inst Canc Res, London SW7 3RP, England	Mayo Clinic; University of Miami; Cancer Research UK; University of Leeds; University of Leeds; Mayo Clinic; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Vile, RG (corresponding author), Mayo Clin, Program Mol Med, Rochester, MN 55905 USA.	vile.richard@mayo.edu		Willmon, Candice/0000-0002-9103-7364; Melcher, Alan/0000-0002-2042-3380; Harrington, Kevin/0000-0002-6014-348X; Galivo, Feorillo/0000-0002-0553-922X	NCI NIH HHS [CA RO1107082-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P365; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Benson JR, 2007, LANCET ONCOL, V8, P331, DOI 10.1016/S1470-2045(07)70103-1; Beri A, 2006, NAT CLIN PRACT UROL, V3, P602, DOI 10.1038/ncpuro0625; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Chester J, 2002, NAT BIOTECHNOL, V20, P256, DOI 10.1038/nbt0302-256; Cole C, 2005, NAT MED, V11, P1073, DOI 10.1038/nm1297; Crittenden M, 2003, CANCER RES, V63, P3173; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Dyall R, 1998, J EXP MED, V188, P1553, DOI 10.1084/jem.188.9.1553; Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794; Engelhorn ME, 2006, NAT MED, V12, P198, DOI 10.1038/nm1363; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Harrington K, 2002, HUM GENE THER, V13, P1263, DOI 10.1089/104303402760128504; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Kelly PF, 2007, MOL THER, V15, P211, DOI 10.1038/sj.mt.6300033; Kottke T, 2006, GENE THER, V13, P1166, DOI 10.1038/sj.gt.3302722; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Linardakis E, 2002, CANCER RES, V62, P5495; Lun X, 2006, JNCI-J NATL CANCER I, V98, P1546, DOI 10.1093/jnci/djj413; Markovic SN, 2007, MAYO CLIN PROC, V82, P490, DOI 10.4065/82.4.490; Matsuura K, 2006, CANCER-AM CANCER SOC, V106, P1227, DOI 10.1002/cncr.21729; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Murta EFC, 2000, TUMORI J, V86, P403, DOI 10.1177/030089160008600507; Ong HT, 2007, GENE THER, V14, P324, DOI 10.1038/sj.gt.3302880; Peters AM, 1998, BRIT J RADIOL, V71, P252, DOI 10.1259/bjr.71.843.9616233; Power AT, 2007, MOL THER, V15, P123, DOI 10.1038/sj.mt.6300039; Shields JD, 2007, ONCOGENE, V26, P2997, DOI 10.1038/sj.onc.1210114; Shinozaki K, 2005, HEPATOLOGY, V41, P196, DOI 10.1002/hep.20536; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195; Thanarajasingam U, 2007, CANCER RES, V67, P300, DOI 10.1158/0008-5472.CAN-06-1017; Thirukkumaran CM, 2007, BONE MARROW TRANSPL, V40, P1, DOI 10.1038/sj.bmt.1705668; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thorne SH, 2005, CURR GENE THER, V5, P429, DOI 10.2174/1566523054546215; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Weninger W, 2003, SEMIN IMMUNOL, V15, P257, DOI 10.1016/j.smim.2003.08.007; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yokoyama WM, 2006, IMMUNOL REV, V214, P143, DOI 10.1111/j.1600-065X.2006.00458.x; Yotnda P, 2004, BLOOD, V104, P2272, DOI 10.1182/blood-2003-11-3803	43	118	130	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					37	44		10.1038/nm1681	http://dx.doi.org/10.1038/nm1681			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18066076				2022-12-27	WOS:000252222400020
J	Lam, TKT				Lam, Tony K. T.			Neuronal regulation of homeostasis by nutrient sensing	NATURE MEDICINE			English	Article							HEPATIC GLUCOSE-PRODUCTION; CENTRAL INSULIN ACTION; CHAIN FATTY-ACIDS; FOOD-INTAKE; PROTEIN-KINASE; NERVOUS-SYSTEM; LOCOMOTOR-ACTIVITY; LIPID-METABOLISM; SKELETAL-MUSCLE; GASTRIC BYPASS	In type 2 diabetes and obesity, the homeostatic control of glucose and energy balance is impaired, leading to hyperglycemia and hyperphagia. Recent studies indicate that nutrient-sensing mechanisms in the body activate negative-feedback systems to regulate energy and glucose homeostasis through a neuronal network. Direct metabolic signaling within the intestine activates gut-brain and gut-brain-liver axes to regulate energy and glucose homeostasis, respectively. In parallel, direct metabolism of nutrients within the hypothalamus regulates food intake and blood glucose levels. These findings highlight the importance of the central nervous system in mediating the ability of nutrient sensing to maintain homeostasis. Futhermore, they provide a physiological and neuronal framework by which enhancing or restoring nutrient sensing in the intestine and the brain could normalize energy and glucose homeostasis in diabetes and obesity.	[Lam, Tony K. T.] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada; [Lam, Tony K. T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Lam, Tony K. T.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto	Lam, TKT (corresponding author), Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada.	tony.lam@uhnres.utoronto.ca			Canadian Institutes of Health Research [MOP-82701, 86554] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; Benoit SC, 2009, J CLIN INVEST, V119, P2577, DOI 10.1172/JCI36714; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Buettner C, 2006, CELL METAB, V4, P49, DOI 10.1016/j.cmet.2006.04.014; Caspi L, 2007, CELL METAB, V6, P99, DOI 10.1016/j.cmet.2007.07.005; Cha SH, 2009, BIOCHEM BIOPH RES CO, V386, P212, DOI 10.1016/j.bbrc.2009.06.017; Chakravarthy MV, 2009, J LIPID RES, V50, P630, DOI 10.1194/jlr.M800379-JLR200; Chari M, 2008, DIABETES, V57, P836, DOI 10.2337/db07-1464; Cheung GWC, 2009, CELL METAB, V10, P99, DOI 10.1016/j.cmet.2009.07.005; Coll AP, 2007, CELL, V129, P251, DOI 10.1016/j.cell.2007.04.001; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Cota D, 2007, GASTROENTEROLOGY, V132, P2158, DOI 10.1053/j.gastro.2007.03.049; Cummings DE, 2009, INT J OBESITY, V33, pS33, DOI 10.1038/ijo.2009.15; Cummings DE, 2007, J CLIN INVEST, V117, P13, DOI 10.1172/JCI30227; Edgerton DS, 2006, J CLIN INVEST, V116, P521, DOI 10.1172/JCI27073; Gillum MP, 2008, CELL, V135, P813, DOI 10.1016/j.cell.2008.10.043; GREENBERG D, 1990, AM J PHYSIOL, V259, pR110, DOI 10.1152/ajpregu.1990.259.1.R110; He W, 2006, NAT NEUROSCI, V9, P227, DOI 10.1038/nn1626; Hu ZY, 2005, J BIOL CHEM, V280, P39681, DOI 10.1074/jbc.C500398200; Huo L, 2009, CELL METAB, V9, P537, DOI 10.1016/j.cmet.2009.05.003; Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Khamzina L, 2005, ENDOCRINOLOGY, V146, P1473, DOI 10.1210/en.2004-0921; Kievit P, 2006, CELL METAB, V4, P123, DOI 10.1016/j.cmet.2006.06.010; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Knauf C, 2008, DIABETES, V57, P2603, DOI 10.2337/db07-1788; Koch L, 2008, J CLIN INVEST, V118, P2132, DOI 10.1172/JCI31073; Konner AC, 2007, CELL METAB, V5, P438, DOI 10.1016/j.cmet.2007.05.004; Kondo H, 2006, AM J PHYSIOL-ENDOC M, V291, pE1092, DOI 10.1152/ajpendo.00583.2005; Lam CKL, 2008, AM J PHYSIOL-ENDOC M, V295, pE491, DOI 10.1152/ajpendo.90481.2008; Lam CKL, 2009, PHYSIOLOGY, V24, P159, DOI 10.1152/physiol.00003.2009; Lam TKT, 2005, SCIENCE, V309, P943, DOI 10.1126/science.1112085; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lam TKT, 2007, NAT MED, V13, P171, DOI 10.1038/nm1540; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; Lopez M, 2008, CELL METAB, V7, P389, DOI 10.1016/j.cmet.2008.03.006; Matzinger D, 2000, GUT, V46, P688, DOI 10.1136/gut.46.5.689; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Morgan K, 2004, J BIOL CHEM, V279, P31139, DOI 10.1074/jbc.M400458200; Morton GJ, 2005, CELL METAB, V2, P411, DOI 10.1016/j.cmet.2005.10.009; Murphy KG, 2006, NATURE, V444, P854, DOI 10.1038/nature05484; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098; Plum L, 2006, J CLIN INVEST, V116, P1761, DOI 10.1172/JCI29063; Pocai A, 2006, J CLIN INVEST, V116, P1081, DOI 10.1172/JCI26640; Pocai A, 2005, DIABETES, V54, P3182, DOI 10.2337/diabetes.54.11.3182; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Reed JA, 2008, AM J PHYSIOL-ENDOC M, V294, pE752, DOI 10.1152/ajpendo.00463.2007; Ross R, 2008, DIABETES, V57, P2061, DOI 10.2337/db08-0206; Rubino F, 2008, DIABETES CARE, V31, pS290, DOI 10.2337/dc08-s271; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Sandoval DA, 2009, NAT REV DRUG DISCOV, V8, P386, DOI 10.1038/nrd2874; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Shiuchi T, 2009, CELL METAB, V10, P466, DOI 10.1016/j.cmet.2009.09.013; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sindelar DK, 1996, DIABETES, V45, P1594, DOI 10.2337/diabetes.45.11.1594; Stafford JM, 2008, DIABETES, V57, P1482, DOI 10.2337/db07-1702; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Troy S, 2008, CELL METAB, V8, P201, DOI 10.1016/j.cmet.2008.08.008; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; van den Hoek AM, 2004, DIABETES, V53, P2529, DOI 10.2337/diabetes.53.10.2529; Wang PYT, 2008, NATURE, V452, P1012, DOI 10.1038/nature06852; Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051; Yen CLE, 2009, NAT MED, V15, P442, DOI 10.1038/nm.1937	71	95	96	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					392	395		10.1038/nm0410-392	http://dx.doi.org/10.1038/nm0410-392			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376051				2022-12-27	WOS:000276446800040
J	Seeman, E				Seeman, Ego			Rebuilding Humpty Dumpty with a serotonin inhibitor	NATURE MEDICINE			English	Editorial Material								Serotonin produced in the gut reduces the formation of bone. This biology is now harnessed with an orally available inhibitor of gut serotonin synthesis (pages 308-312). The inhibitor promotes bone formation in rodents and points the way to the development of much-needed bone-building drugs.	Univ Melbourne, Dept Endocrinol & Med, Melbourne, Vic, Australia	University of Melbourne	Seeman, E (corresponding author), Univ Melbourne, Dept Endocrinol & Med, Melbourne, Vic, Australia.	egos@unimelb.edu.au	Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X				PARFITT AM, 1996, OSTEOPOROSIS	1	4	4	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					264	265		10.1038/nm0310-264	http://dx.doi.org/10.1038/nm0310-264			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208508				2022-12-27	WOS:000275289500025
J	Doi, M; Takahashi, Y; Komatsu, R; Yamazaki, F; Yamada, H; Haraguchi, S; Emoto, N; Okuno, Y; Tsujimoto, G; Kanematsu, A; Ogawa, O; Todo, T; Tsutsui, K; van der Horst, GTJ; Okamura, H				Doi, Masao; Takahashi, Yukari; Komatsu, Rie; Yamazaki, Fumiyoshi; Yamada, Hiroyuki; Haraguchi, Shogo; Emoto, Noriaki; Okuno, Yasushi; Tsujimoto, Gozoh; Kanematsu, Akihiro; Ogawa, Osamu; Todo, Takeshi; Tsutsui, Kazuyoshi; van der Horst, Gijsbertus T. J.; Okamura, Hitoshi			Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6	NATURE MEDICINE			English	Article							PRIMARY ALDOSTERONISM; EXPRESSION; GENE; TRILOSTANE; MOUSE; RAT; 11-BETA-HYDROXYLASE; MUTATIONS; PRESSURE; WEB	Malfunction of the circadian clock has been linked to the pathogenesis of a variety of diseases. We show that mice lacking the core clock components Cryptochrome-1 (Cry1) and Cryptochrome-2 (Cry2) (Cry-null mice) show salt-sensitive hypertension due to abnormally high synthesis of the mineralocorticoid aldosterone by the adrenal gland. An extensive search for the underlying cause led us to identify type VI 3 beta-hydroxyl-steroid dehydrogenase (Hsd3b6) as a new hypertension risk factor in mice. Hsd3b6 is expressed exclusively in aldosterone-producing cells and is under transcriptional control of the circadian clock. In Cry-null mice, Hsd3b6 messenger RNA and protein levels are constitutively high, leading to a marked increase in 3 beta-hydroxysteroid dehydrogenase-isomerase (3 beta-HSD) enzymatic activity and, as a consequence, enhanced aldosterone production. These data place Hsd3b6 in a pivotal position through which circadian clock malfunction is coupled to the development of hypertension. Translation of these findings to humans will require clinical examination of human HSD3B1 gene, which we found to be functionally similar to mouse Hsd3b6.	[Doi, Masao; Takahashi, Yukari; Komatsu, Rie; Yamazaki, Fumiyoshi; Yamada, Hiroyuki; Okamura, Hitoshi] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Syst Biol, Sakyo Ku, Kyoto, Japan; [Haraguchi, Shogo; Tsutsui, Kazuyoshi] Waseda Univ, Fac Educ & Integrated Arts & Sci, Dept Biol, Lab Integrat Brain Sci,Shinjuku Ku, Tokyo, Japan; [Emoto, Noriaki] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med,Chuo Ku, Kobe, Hyogo 657, Japan; [Okuno, Yasushi] Kyoto Univ, Dept Syst Biosci Drug Discovery, Sakyo Ku, Kyoto, Japan; [Tsujimoto, Gozoh] Kyoto Univ, Dept Genom Drug Discovery Sci, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto, Japan; [Kanematsu, Akihiro; Ogawa, Osamu] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Kyoto, Japan; [Todo, Takeshi] Osaka Univ, Grad Sch Med, Dept Radiat Biol & Med Genet, Suita, Osaka, Japan; [van der Horst, Gijsbertus T. J.] Erasmus Univ, Med Ctr, Ctr Biomed Genet, Dept Genet, Rotterdam, Netherlands	Kyoto University; Waseda University; Kobe University; Kyoto University; Kyoto University; Kyoto University; Osaka University; Erasmus University Rotterdam; Erasmus MC	Okamura, H (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Syst Biol, Sakyo Ku, Kyoto, Japan.	okamurah@pharm.kyoto-u.ac.jp	van der Horst, Gijsbertus TJ/E-3661-2015; Doi, Masao/J-9267-2019	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Doi, Masao/0000-0001-6264-9217; Haraguchi, Shogo/0000-0002-8731-3311; Okamura, Hitoshi/0000-0002-3013-4881; Emoto, Noriaki/0000-0001-6673-2616	Ministry of Education, Culture, Sports, Science and Technology of Japan; Nakatomi Foundation, SRF; Senri Life Science Foundation; Takeda Science Foundation; Netherlands Organization of Scientific research [ZonMW Vici 918.36.619]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Nakatomi Foundation, SRF; Senri Life Science Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Netherlands Organization of Scientific research(Netherlands Organization for Scientific Research (NWO))	We thank T. Ono, A. Hirasawa, T. Koshimizu, K. Terasawa, H. Nishinaga, M. Sato, Y. Yamaguchi, M. Matsuo, J. M. Fustin, K. Toida, H. Sei and K. Ishimura for technical support and valuable discussion. We also thank T. Michel for critical reading of the manuscript. This work was supported in part by the Specially Promoted Research (to H. O.) and Grant-in-Aid for Young Scientists (to M. D.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and grants from Nakatomi Foundation, SRF (to H. O.), Senri Life Science Foundation, Takeda Science Foundation (to M. D.) and the Netherlands Organization of Scientific research, ZonMW Vici 918.36.619 (to G.T.J.v.d.H.). Trilostane was a generous gift from Mochida Pharmaceutical. Eplerenone was a generous gift from Pfizer.	Abbaszade IG, 1997, ENDOCRINOLOGY, V138, P1392, DOI 10.1210/en.138.4.1392; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Bradley TD, 2003, CIRCULATION, V107, P1822, DOI 10.1161/01.CIR.0000061758.05044.64; Brown NJ, 2003, CIRCULATION, V107, P2512, DOI 10.1161/01.CIR.0000071081.35693.9A; Brown R, 2003, NAT REV DRUG DISCOV, V2, P177, DOI 10.1038/nrd1039; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Furlan R, 2000, CIRCULATION, V102, P1912, DOI 10.1161/01.CIR.102.16.1912; GIROUD CJP, 1956, P SOC EXP BIOL MED, V92, P154; GOMEZSANCHEZ C, 1976, ENDOCRINOLOGY, V99, P567, DOI 10.1210/endo-99-2-567; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Ishida A, 2005, CELL METAB, V2, P297, DOI 10.1016/j.cmet.2005.09.009; JUNGMANN E, 1982, RES EXP MED, V180, P193, DOI 10.1007/BF01851059; Kaplan N.M., 2006, KAPLANS CLIN HYPERTE, P410; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Maeda A, 2006, INVEST OPHTH VIS SCI, V47, P4050, DOI 10.1167/iovs.06-0183; Makhanova N, 2008, HYPERTENSION, V51, P134, DOI 10.1161/HYPERTENSIONAHA.107.098897; Mason JI, 1997, STEROIDS, V62, P164, DOI 10.1016/S0039-128X(96)00176-6; Matsunaga M, 2004, P NATL ACAD SCI USA, V101, P17282, DOI 10.1073/pnas.0407176101; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mitsui S, 2001, GENE DEV, V15, P995, DOI 10.1101/gad.873501; Moisan AM, 1999, J CLIN ENDOCR METAB, V84, P4410, DOI 10.1210/jc.84.12.4410; NAKADA T, 1985, UROLOGY, V25, P207, DOI 10.1016/0090-4295(85)90548-5; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; Peng LH, 2002, MOL CELL ENDOCRINOL, V187, P213, DOI 10.1016/S0303-7207(01)00689-X; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; Rainey WE, 1999, MOL CELL ENDOCRINOL, V151, P151, DOI 10.1016/S0303-7207(99)00051-9; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; RHEAUME E, 1992, NAT GENET, V1, P239, DOI 10.1038/ng0792-239; Scheer FAJL, 2009, P NATL ACAD SCI USA, V106, P4453, DOI 10.1073/pnas.0808180106; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wijnen H, 2006, ANNU REV GENET, V40, P409, DOI 10.1146/annurev.genet.40.110405.090603; WINTERBERG B, 1985, CARDIOLOGY, V72, P117, DOI 10.1159/000173956; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Young WF, 2007, CLIN ENDOCRINOL, V66, P607, DOI 10.1111/j.1365-2265.2007.02775.x	47	298	309	1	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					67	U102		10.1038/nm.2061	http://dx.doi.org/10.1038/nm.2061			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20023637	Green Submitted			2022-12-27	WOS:000273395500038
J	Echtler, K; Stark, K; Lorenz, M; Kerstan, S; Walch, A; Jennen, L; Rudelius, M; Seidl, S; Kremmer, E; Emambokus, NR; von Bruehl, ML; Frampton, J; Isermann, B; Genzel-Boroviczeny, O; Schreiber, C; Mehilli, J; Kastrati, A; Schwaiger, M; Shivdasani, RA; Massberg, S				Echtler, Katrin; Stark, Konstantin; Lorenz, Michael; Kerstan, Sandra; Walch, Axel; Jennen, Luise; Rudelius, Martina; Seidl, Stefan; Kremmer, Elisabeth; Emambokus, Nikla R.; von Bruehl, Marie-Luise; Frampton, Jon; Isermann, Berend; Genzel-Boroviczeny, Orsolya; Schreiber, Christian; Mehilli, Julinda; Kastrati, Adnan; Schwaiger, Markus; Shivdasani, Ramesh A.; Massberg, Steffen			Platelets contribute to postnatal occlusion of the ductus arteriosus	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PERMANENT ANATOMIC CLOSURE; TRANSCRIPTION FACTOR NF-E2; IN-VIVO; NITRIC-OXIDE; PREMATURE-INFANTS; GLYCOPROTEIN IIB; ADHESION; PROSTAGLANDIN; ACTIVATION	The ductus arteriosus (DA) is a fetal shunt vessel between the pulmonary artery and the aorta that closes promptly after birth. Failure of postnatal DA closure is a major cause of morbidity and mortality particularly in preterm neonates. The events leading to DA closure are incompletely understood. Here we show that platelets have an essential role in DA closure. Using intravital microscopy of neonatal mice, we observed that platelets are recruited to the luminal aspect of the DA during closure. DA closure is impaired in neonates with malfunctioning platelet adhesion or aggregation or with defective platelet biogenesis. Defective DA closure resulted in a left-to-right shunt with increased pulmonary perfusion, pulmonary vascular remodeling and right ventricular hypertrophy. Our findings indicate that platelets are crucial for DA closure by promoting thrombotic sealing of the constricted DA and by supporting luminal remodeling. A retrospective clinical study revealed that thrombocytopenia is an independent predictor for failure of DA closure in preterm human newborns, indicating that platelets are likely to contribute to DA closure in humans.	[Echtler, Katrin; Stark, Konstantin; Lorenz, Michael; Kerstan, Sandra; von Bruehl, Marie-Luise; Mehilli, Julinda; Kastrati, Adnan; Massberg, Steffen] Tech Univ Munich, Klin Herz & Kreislauferkrankungen, Deutsch Herzzentrum, Munich, Germany; [Walch, Axel; Jennen, Luise] Gesell Strahlen & Umweltforsch MbH, Inst Pathol, Helmholtz Zentrum Munchen, Deutsch Forschungszentrum Umwelt & Gesundheit, D-8042 Neuherberg, Germany; [Rudelius, Martina; Seidl, Stefan] Tech Univ Munich, Inst Allgemeine Pathol & Pathol Anat, Munich, Germany; [Kremmer, Elisabeth] Inst Mol Immunol, Deutsch Forschungszentrum Umwelt & Gesundheit, Helmholtz Zentrum Munchen, Munich, Germany; [Emambokus, Nikla R.] Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; [Frampton, Jon] Univ Birmingham, Inst Biomed Res, Birmingham, W Midlands, England; [Isermann, Berend] Univ Klinikum Heidelberg, Med Klin, Heidelberg, Germany; [Genzel-Boroviczeny, Orsolya] Univ Munich, Perinatalzentrum, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany; [Schreiber, Christian] Tech Univ Munich, Klin Herz & Gefasschirurg, Deutsch Herzzentrum, Munich, Germany; [Schwaiger, Markus] Tech Univ Munich, Nukl Med Klin Klinikums Rechts Isar, Munich, Germany; [Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol & Canc Biol, Boston, MA 02115 USA; [Massberg, Steffen] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Massberg, Steffen] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Birmingham; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Massberg, S (corresponding author), Tech Univ Munich, Klin Herz & Kreislauferkrankungen, Deutsch Herzzentrum, Munich, Germany.	massberg@dhm.mhn.de	Mehilli, Julinda/F-2629-2016; Massberg, Steffen/AAN-6054-2021; , Kastrati/Y-2389-2019; Stark, Konstantin/AAJ-2815-2020; Walch, Axel/B-4554-2012	Stark, Konstantin/0000-0002-5369-8399; Walch, Axel/0000-0001-5578-4023; schwaiger, markus/0000-0002-2305-7144	Deutsche Forschungsgemeinschaft; Ernst und Berta-Grimmke Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ernst und Berta-Grimmke Foundation	We thank M. Shakibaei, S. Reder and J. Schwarz for their support. This work was supported by the Deutsche Forschungsgemeinschaft and the Ernst und Berta-Grimmke Foundation.	Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424; Bancalari E, 2005, BIOL NEONATE, V88, P192, DOI 10.1159/000087582; Boo N. Y., 2006, SMJ Singapore Medical Journal, V47, P763; Clyman RI, 1999, PEDIATR RES, V45, P19, DOI 10.1203/00006450-199901000-00005; Clyman RI, 2002, AM J PHYSIOL-REG I, V282, pR199, DOI 10.1152/ajpregu.00298.2001; CLYMAN RI, 1980, J PEDIATR-US, V97, P455, DOI 10.1016/S0022-3476(80)80205-8; Clyman RI, 2006, BIOL NEONATE, V89, P330, DOI 10.1159/000092870; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Emambokus NR, 2003, IMMUNITY, V19, P33, DOI 10.1016/S1074-7613(03)00173-0; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Fischer LM, 2005, PHARMACOTHERAPY, V25, P503, DOI 10.1592/phco.25.4.503.61021; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FRIEDMAN WF, 1976, NEW ENGL J MED, V295, P526, DOI 10.1056/NEJM197609022951003; Gislason GH, 2006, CIRCULATION, V113, P2906, DOI 10.1161/CIRCULATIONAHA.106.616219; Gordon PV, 2007, J PEDIATR GASTR NUTR, V45, P509, DOI 10.1097/MPG.0b013e3181558591; Hammerman C, 2001, DRUG SAFETY, V24, P537, DOI 10.2165/00002018-200124070-00005; Hermes-DeSantis ER, 2006, J PERINATOL, V26, pS14, DOI 10.1038/sj.jp.7211465; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; Higgs EA, 1997, BRIT J PHARMACOL, V120, P439, DOI 10.1111/j.1476-5381.1997.tb06831.x; Hippisley-Cox J, 2005, BMJ-BRIT MED J, V330, P1366, DOI 10.1136/bmj.330.7504.1366; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; KAAPA P, 1993, J PEDIATR-US, V123, P115, DOI 10.1016/S0022-3476(05)81553-7; Kajino H, 2000, AM J PHYSIOL-REG I, V279, pR278, DOI 10.1152/ajpregu.2000.279.1.R278; Kasirer-Friede A, 2007, IMMUNOL REV, V218, P247, DOI 10.1111/j.1600-065X.2007.00532.x; LLOYD TR, 1994, AM HEART J, V127, P1664, DOI 10.1016/0002-8703(94)90415-4; MACINTYRE DE, 1975, NATURE, V258, P337, DOI 10.1038/258337a0; Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Massberg S, 2005, CIRCULATION, V112, P1180, DOI 10.1161/CIRCULATIONAHA.105.539221; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; MEYERS KM, 1979, NATURE, V282, P331, DOI 10.1038/282331a0; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; Noori S, 2009, PEDIATRICS, V123, pE138, DOI 10.1542/peds.2008-2418; Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16; Olley P M, 1978, Adv Prostaglandin Thromboxane Res, V4, P345; RADOMSKI MW, 1993, ADV EXP MED BIOL, V344, P251; RELLER MD, 1991, AM J DIS CHILD, V145, P1017, DOI 10.1001/archpedi.1991.02160090069025; Roberts I, 2008, BLOOD REV, V22, P173, DOI 10.1016/j.blre.2008.03.004; Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Seidner SR, 2001, PEDIATR RES, V50, P365, DOI 10.1203/00006450-200109000-00012; Sheffield MJ, 2009, J PERINATOL, V29, P39, DOI 10.1038/jp.2008.122; SHIMADA S, 1989, PEDIATR RES, V26, P565, DOI 10.1203/00006450-198912000-00010; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SILVER MM, 1981, HUM PATHOL, V12, P1123, DOI 10.1016/S0046-8177(81)80333-4; Slomp J, 1997, ARTERIOSCL THROM VAS, V17, P1003, DOI 10.1161/01.ATV.17.5.1003; SLOMP J, 1992, ATHEROSCLEROSIS, V93, P25, DOI 10.1016/0021-9150(92)90197-O; Smith GCS, 1998, PHARMACOL REV, V50, P35; Struthmann L, 2009, J THROMB HAEMOST, V7, P1727, DOI 10.1111/j.1538-7836.2009.03582.x; TADA T, 1990, ACTA ANAT, V139, P326; Theilmeier G, 2002, BLOOD, V99, P4486, DOI 10.1182/blood.V99.12.4486; Thomas DW, 1998, J CLIN INVEST, V102, P1994, DOI 10.1172/JCI5116; Van Overmeire B, 2004, LANCET, V364, P1945, DOI 10.1016/S0140-6736(04)17477-1; Waleh N, 2005, PEDIATR RES, V57, P254, DOI 10.1203/01.PDR.0000148278.64777.EF; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623	60	110	119	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					75	U111		10.1038/nm.2060	http://dx.doi.org/10.1038/nm.2060			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	19966813				2022-12-27	WOS:000273395500039
J	Cope, DW; Di Giovanni, G; Fyson, SJ; Orban, G; Errington, AC; Lorincz, ML; Gould, TM; Carter, DA; Crunelli, V				Cope, David W.; Di Giovanni, Giuseppe; Fyson, Sarah J.; Orban, Gergely; Errington, Adam C.; Lorincz, Magor L.; Gould, Timothy M.; Carter, David A.; Crunelli, Vincenzo			Enhanced tonic GABA(A) inhibition in typical absence epilepsy	NATURE MEDICINE			English	Article							GAMMA-HYDROXYBUTYRIC ACID; RAT-BRAIN; SYNAPTIC-TRANSMISSION; MOUSE MODEL; RECEPTORS; MECHANISMS; SPIKE; WAVE; THALAMUS; SEIZURES	The cellular mechanisms underlying typical absence seizures, which characterize various idiopathic generalized epilepsies, are not fully understood, but impaired gamma-aminobutyric acid (GABA)-ergic inhibition remains an attractive hypothesis. In contrast, we show here that extrasynaptic GABA(A) receptor-dependent 'tonic' inhibition is increased in thalamocortical neurons from diverse genetic and pharmacological models of absence seizures. Increased tonic inhibition is due to compromised GABA uptake by the GABA transporter GAT-1 in the genetic models tested, and GAT-1 is crucial in governing seizure genesis. Extrasynaptic GABA(A) receptors are a requirement for seizures in two of the best characterized models of absence epilepsy, and the selective activation of thalamic extrasynaptic GABA(A) receptors is sufficient to elicit both electrographic and behavioral correlates of seizures in normal rats. These results identify an apparently common cellular pathology in typical absence seizures that may have epileptogenic importance and highlight potential therapeutic targets for the treatment of absence epilepsy.	[Cope, David W.; Di Giovanni, Giuseppe; Fyson, Sarah J.; Orban, Gergely; Errington, Adam C.; Lorincz, Magor L.; Gould, Timothy M.; Carter, David A.; Crunelli, Vincenzo] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales	Cardiff University	Cope, DW (corresponding author), Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales.	copedw@cf.ac.uk; crunelli@cf.ac.uk	Carter, David/A-4479-2010; Orban, Gergely/J-8561-2016; Errington, Adam/D-1678-2011; Lőrincz, Magor L/C-7746-2012; Di Giovanni, Giuseppe/N-3047-2013; Crunelli, Vincenzo/A-7258-2010	Carter, David/0000-0002-8419-3975; Orban, Gergely/0000-0003-4222-9391; Errington, Adam/0000-0002-2171-389X; Lőrincz, Magor L/0000-0001-5240-1904; Di Giovanni, Giuseppe/0000-0003-2006-563X; Crunelli, Vincenzo/0000-0001-7154-9752	Epilepsy Research UK [P0802]; Italian Ministry for University and Scientific Research; Wellcome Trust [71436]; European Union [HEALTH F2-2007-202167]	Epilepsy Research UK; Italian Ministry for University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); Wellcome Trust(Wellcome TrustEuropean Commission); European Union(European Commission)	We thank P. Blanning for his help in genotyping mice, D. Belelli who kindly provided the genotyping protocol for the delta subunit-knockout mice and K. Thomas for initial discussions on the antisense oligodeoxynucleotide experiments. H. Parri, S. Hughes and N. Leresche commented on a previous version of the manuscript. D. W. C. is a research Fellow of Epilepsy Research UK (grant P0802), and G.O. was supported by a Fellowship of the Italian Ministry for University and Scientific Research. This work was also supported by the Wellcome Trust (grant 71436) and the European Union (grant HEALTH F2-2007-202167).	Aizawa M, 1997, NEUROSCI RES, V29, P17, DOI 10.1016/S0168-0102(97)00066-7; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BANERJEE PK, 1993, NEUROSCIENCE, V56, P11, DOI 10.1016/0306-4522(93)90557-V; Beckman ML, 1999, J NEUROSCI, V19; Belelli D, 2005, J NEUROSCI, V25, P11513, DOI 10.1523/JNEUROSCI.2679-05.2005; Bessaih T, 2006, J NEUROPHYSIOL, V96, P3074, DOI 10.1152/jn.00682.2006; Blumenfeld H, 2005, EPILEPSIA, V46, P21, DOI 10.1111/j.1528-1167.2005.00311.x; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Bragina L, 2008, J NEUROCHEM, V105, P1781, DOI 10.1111/j.1471-4159.2008.05273.x; Bright DP, 2007, J NEUROSCI, V27, P2560, DOI 10.1523/JNEUROSCI.5100-06.2007; Caddick SJ, 1999, J NEUROPHYSIOL, V81, P2066, DOI 10.1152/jn.1999.81.5.2066; Chiu CS, 2005, J NEUROSCI, V25, P3234, DOI 10.1523/JNEUROSCI.3364-04.2005; Cope DW, 2005, J NEUROSCI, V25, P11553, DOI 10.1523/JNEUROSCI.3362-05.2005; Crunelli V, 2002, NAT REV NEUROSCI, V3, P371, DOI 10.1038/nrn811; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; De Biasi S, 1998, NEUROSCIENCE, V83, P815, DOI 10.1016/S0306-4522(97)00414-4; Ettinger AB, 1999, EPILEPSIA, V40, P1159, DOI 10.1111/j.1528-1157.1999.tb00835.x; FARIELLO RG, 1987, NEUROPHARMACOLOGY, V26, P161, DOI 10.1016/0028-3908(87)90204-8; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Fletcher CF, 1999, HUM MOL GENET, V8, P1907, DOI 10.1093/hmg/8.10.1907; Glykys J, 2007, NEURON, V56, P763, DOI 10.1016/j.neuron.2007.11.002; Herd MB, 2009, EUR J NEUROSCI, V29, P1177, DOI 10.1111/j.1460-9568.2009.06680.x; Hosford DA, 1997, EPILEPSIA, V38, P408, DOI 10.1111/j.1528-1157.1997.tb01729.x; Hosford DA, 1997, EPILEPSY RES, V27, P55, DOI 10.1016/S0920-1211(97)01023-1; Hu J, 2008, NEUROPHARMACOLOGY, V54, P309, DOI 10.1016/j.neuropharm.2007.09.013; Huntsman MM, 1999, SCIENCE, V283, P541, DOI 10.1126/science.283.5401.541; Jia F, 2005, J NEUROPHYSIOL, V94, P4491, DOI 10.1152/jn.00421.2005; JUHASZ G, 1990, NEUROSCI LETT, V114, P333, DOI 10.1016/0304-3940(90)90586-X; Kananura C, 2002, ARCH NEUROL-CHICAGO, V59, P1137, DOI 10.1001/archneur.59.7.1137; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LeFeuvre Y, 1997, J PHYSIOL-LONDON, V502, P91, DOI 10.1111/j.1469-7793.1997.091bl.x; Macdonald RL, 2004, BIOCHEM PHARMACOL, V68, P1497, DOI 10.1016/j.bcp.2004.07.029; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; Maljevic S, 2006, ANN NEUROL, V59, P983, DOI 10.1002/ana.20874; McCormick DA, 2001, ANNU REV PHYSIOL, V63, P815, DOI 10.1146/annurev.physiol.63.1.815; Perucca E, 1998, EPILEPSIA, V39, P5, DOI 10.1111/j.1528-1157.1998.tb01268.x; Pow DV, 2005, CELL TISSUE RES, V320, P379, DOI 10.1007/s00441-004-0928-0; Quick MW, 1997, J NEUROSCI, V17, P2967; RICHARDS DA, 1995, J NEUROCHEM, V65, P1674; SNEAD OC, 1991, NEUROPHARMACOLOGY, V30, P161, DOI 10.1016/0028-3908(91)90199-L; Storustovu SI, 2006, J PHARMACOL EXP THER, V316, P1351, DOI 10.1124/jpet.105.092403; Sutch RJ, 1999, NEUROCHEM INT, V34, P415, DOI 10.1016/S0197-0186(99)00046-7; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tan HO, 2007, P NATL ACAD SCI USA, V104, P17536, DOI 10.1073/pnas.0708440104; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wang D, 2003, MOL PHARMACOL, V64, P905, DOI 10.1124/mol.64.4.905; Wu YM, 2007, NEURON, V56, P851, DOI 10.1016/j.neuron.2007.10.021	48	304	312	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1392	U6		10.1038/nm.2058	http://dx.doi.org/10.1038/nm.2058			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966779	Green Submitted, Green Published, Green Accepted			2022-12-27	WOS:000272407800019
J	Wiseman, RW; Karl, JA; Bimber, BN; O'Leary, CE; Lank, SM; Tuscher, JJ; Detmer, AM; Bouffard, P; Levenkova, N; Turcotte, CL; Szekeres, E; Wright, C; Harkins, T; O'Connor, DH				Wiseman, Roger W.; Karl, Julie A.; Bimber, Benjamin N.; O'Leary, Claire E.; Lank, Simon M.; Tuscher, Jennifer J.; Detmer, Ann M.; Bouffard, Pascal; Levenkova, Natalya; Turcotte, Cynthia L.; Szekeres, Edward, Jr.; Wright, Chris; Harkins, Timothy; O'Connor, David H.			Major histocompatibility complex genotyping with massively parallel pyrosequencing	NATURE MEDICINE			English	Article							CLASS-I SEQUENCES; IMMUNODEFICIENCY VIRUS-REPLICATION; RHESUS MACAQUE; CYNOMOLGUS MACAQUES; CHINESE-ORIGIN; PRIMATE MODELS; REGION; IDENTIFICATION; POLYMORPHISM; DIVERSITY	Major histocompatibility complex (MHC) genetics dictate adaptive cellular immune responses, making robust MHC genotyping methods essential for studies of infectious disease, vaccine development and transplantation. Nonhuman primates provide essential preclinical models for these areas of biomedical research. Unfortunately, given the unparalleled complexity of macaque MHCs, existing methodologies are inadequate for MHC typing of these key model animals. Here we use pyrosequencing of complementary DNA-PCR amplicons as a general approach to determine comprehensive MHC class I genotypes in nonhuman primates. More than 500 unique MHC class I sequences were resolved by sequence-based typing of rhesus, cynomolgus and pig-tailed macaques, nearly half of which have not been reported previously. The remarkable sensitivity of this approach in macaques demonstrates that pyrosequencing is viable for ultra-high-throughput MHC genotyping of primates, including humans.	[Wiseman, Roger W.; Karl, Julie A.; O'Leary, Claire E.; Lank, Simon M.; Tuscher, Jennifer J.; Detmer, Ann M.; O'Connor, David H.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA; [Bimber, Benjamin N.; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; [Wright, Chris] Univ Illinois, High Throughput Sequencing & Genotyping Unit, Urbana, IL 61801 USA; [Harkins, Timothy] Roche Appl Sci, Indianapolis, IN USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign; Roche Holding	O'Connor, DH (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53706 USA.	doconnor@primate.wisc.edu		Bimber, Benjamin/0000-0001-8092-3080; o'connor, david/0000-0003-2139-470X; Tuscher, Jennifer/0000-0002-8798-4545; O'Leary, Claire/0000-0001-9052-4593	US National Institute of Allergy and Infectious Diseases [HHSN266200400088C/N01-AI-40088]; Battelle Biomedical Research Center under US National Institute of Allergy and Infectious Diseases [N01-A1-30061]; US National Center for Research Resources [P51 RR000167, P40 RR019995]; US National Institutes of Health;  [RR15459-01];  [RR020141-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR020141, C06RR015459, P51RR000167, P40RR019995] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096789] Funding Source: NIH RePORTER	US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Battelle Biomedical Research Center under US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Fresh blood or frozen peripheral blood mononuclear cell samples from various macaques were graciously provided by L. Picker (Oregon National Primate Research Center), P. Johnson (New England Primate Research Center), D. Read (Battelle Biomedical Research Center), N. Miller (US National Institute of Allergy and Infectious Diseases), J. Hoxie (University of Pennsylvania), J. Mankowski (Johns Hopkins University), T. Andrus (Charles River Biomedical Research Foundation, Inc.) and I. Lussier (Alpha Genesis, Inc.). L. Hetrick, A. Lane, E. Vlach and J. Thimmapuram provided outstanding emulsion PCR, pyrosequencing and informatics support at the University of Illinois at Urbana-Champaign. We thank D. Watkins and R. DeMars for insightful comments on this manuscript. This work was supported by US National Institute of Allergy and Infectious Diseases contract number HHSN266200400088C/N01-AI-40088. Some support was also provided by a subcontract from the Battelle Biomedical Research Center under US National Institute of Allergy and Infectious Diseases contract N01-A1-30061. This publication was made possible in part by grant numbers P51 RR000167 and P40 RR019995 from the US National Center for Research Resources, a component of the US National Institutes of Health to the Wisconsin National Primate Research Center, University of Wisconsin-Madison. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01.	Bontrop RE, 2006, HUM IMMUNOL, V67, P388, DOI 10.1016/j.humimm.2006.03.007; Campbell KJ, 2009, IMMUNOGENETICS, V61, P177, DOI 10.1007/s00251-008-0351-x; Daza-Vamenta R, 2004, GENOME RES, V14, P1501, DOI 10.1101/gr.2134504; Gardner MB, 2008, ILAR J, V49, P220, DOI 10.1093/ilar.49.2.220; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Haigwood NL, 2004, AIDS REV, V6, P187; Hale DA, 2005, PHILOS T R SOC B, V360, P1723, DOI 10.1098/rstb.2005.1703; Horton R, 2008, IMMUNOGENETICS, V60, P1, DOI 10.1007/s00251-007-0262-2; Kaizu M, 2007, IMMUNOGENETICS, V59, P693, DOI 10.1007/s00251-007-0233-7; Karl JA, 2008, IMMUNOGENETICS, V60, P37, DOI 10.1007/s00251-007-0267-x; Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746; Krebs KC, 2005, J IMMUNOL, V175, P5230, DOI 10.4049/jimmunol.175.8.5230; Kulski JK, 2004, MOL BIOL EVOL, V21, P2079, DOI 10.1093/molbev/msh216; Loffredo JT, 2007, J VIROL, V81, P8827, DOI 10.1128/JVI.00895-07; Loffredo JT, 2007, HIV MOL IMMUNOLOGY 2, P29; MARSH SGE, 2000, HLA FACTS BOOK, P3; O'Leary CE, 2009, IMMUNOGENETICS, V61, P689, DOI 10.1007/s00251-009-0397-4; Otting N, 2005, P NATL ACAD SCI USA, V102, P1626, DOI 10.1073/pnas.0409084102; Otting N, 2008, IMMUNOGENETICS, V60, P507, DOI 10.1007/s00251-008-0311-5; Otting N, 2007, IMMUNOGENETICS, V59, P367, DOI 10.1007/s00251-007-0201-2; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Patterson JL, 2005, ILAR J, V46, P15, DOI 10.1093/ilar.46.1.15; Robinson J, 2005, NUCLEIC ACIDS RES, V33, pD523, DOI 10.1093/nar/gki032; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Watanabe A, 2007, GENOMICS, V89, P402, DOI 10.1016/j.ygeno.2006.11.002; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Wiseman RW, 2007, J VIROL, V81, P349, DOI 10.1128/JVI.01841-06	29	115	158	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1322	U123		10.1038/nm.2038	http://dx.doi.org/10.1038/nm.2038			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19820716	Green Accepted			2022-12-27	WOS:000271543700022
J	Ghiringhelli, F; Apetoh, L; Tesniere, A; Aymeric, L; Ma, YT; Ortiz, C; Vermaelen, K; Panaretakis, T; Mignot, G; Ullrich, E; Perfettini, JL; Schlemmer, F; Tasdemir, E; Uhl, M; Genin, P; Civas, A; Ryffel, B; Kanellopoulos, J; Tschopp, J; Andre, F; Lidereau, R; McLaughlin, NM; Haynes, NM; Smyth, MJ; Kroemer, G; Zitvogel, L				Ghiringhelli, Francois; Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Mignot, Gregoire; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Uhl, Martin; Genin, Pierre; Civas, Ahmet; Ryffel, Bernhard; Kanellopoulos, Jean; Tschopp, Juerg; Andre, Fabrice; Lidereau, Rosette; McLaughlin, Nicole M.; Haynes, Nicole M.; Smyth, Mark J.; Kroemer, Guido; Zitvogel, Laurence			Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors	NATURE MEDICINE			English	Article							CALRETICULIN EXPOSURE; ALA POLYMORPHISM; P2X(7) RECEPTOR; B-CELLS; INNATE; CANCER; IDENTIFICATION; CASPASE-1; RELEASE; IL-1	The therapeutic efficacy of anticancer chemotherapies may depend on dendritic cells (DCs), which present antigens from dying cancer cells to prime tumor-specific interferon-gamma (IFN-gamma)-producing T lymphocytes. Here we show that dying tumor cells release ATP, which then acts on P2X(7) purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1 beta (IL-1 beta). The priming of IFN-gamma-producing CD8(+) T cells by dying tumor cells fails in the absence of a functional IL-1 receptor 1 and in Nlpr3-deficient (Nlrp3(-/-)) or caspase-1-deficient (Casp-1(-/-)) mice unless exogenous IL-1 beta is provided. Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7(-/-) or Nlrp3(-/-) or Casp1(-/-) hosts. Anthracycline-treated individuals with breast cancer carrying a loss-of-function allele of P2RX7 developed metastatic disease more rapidly than individuals bearing the normal allele. These results indicate that the NLRP3 inflammasome links the innate and adaptive immune responses against dying tumor cells.	[Ghiringhelli, Francois; Apetoh, Lionel; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Mignot, Gregoire; Ullrich, Evelyn; Andre, Fabrice; Zitvogel, Laurence] INSERM, U805, Villejuif, France; [Ghiringhelli, Francois; Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Mignot, Gregoire; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Andre, Fabrice; Kroemer, Guido; Zitvogel, Laurence] Inst Gustave Roussy, Villejuif, France; [Ghiringhelli, Francois; Mignot, Gregoire] INSERM, AVENIR Team, CRI 866, Dijon, France; [Ghiringhelli, Francois; Mignot, Gregoire] Ctr Georges Francois Leclerc, Dijon, France; [Apetoh, Lionel; Tesniere, Antoine; Aymeric, Laetitia; Ma, Yuting; Ortiz, Carla; Vermaelen, Karim; Panaretakis, Theocharis; Ullrich, Evelyn; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Andre, Fabrice; Kroemer, Guido; Zitvogel, Laurence] Univ Paris Sud, Villejuif, France; [Apetoh, Lionel] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; [Tesniere, Antoine; Panaretakis, Theocharis; Perfettini, Jean-Luc; Schlemmer, Frederic; Tasdemir, Ezgi; Kroemer, Guido] INSERM, U848, Villejuif, France; [Ortiz, Carla] Univ Chile, Fac Ciencias Quim Farmaceut, Ctr FONDAP Estudios Mol Celula, Santiago, Chile; [Vermaelen, Karim] Ghent Univ Hosp, Dept Resp Med, Immunoregulat Lab, Ghent, Belgium; [Uhl, Martin] Inst Pasteur, INSERM, U818, F-75724 Paris, France; [Genin, Pierre; Civas, Ahmet] Univ Paris 05, CNRS, Lab Regulat Transcript & Malad Genet, UPR 2228, Paris 06, France; [Ryffel, Bernhard] CNRS, Transgenose Inst, IEM, UMR6218, F-45071 Orleans, France; [Kanellopoulos, Jean] Univ Paris, CNRS, UMR8619, Orsay, France; [Tschopp, Juerg] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; [Lidereau, Rosette] Ctr Rene Huguenin, INSERM, U735, St Cloud, France; [McLaughlin, Nicole M.; Haynes, Nicole M.; Smyth, Mark J.] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia; [Zitvogel, Laurence] CICBT507, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidad de Chile; Ghent University; Ghent University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Peter Maccallum Cancer Center	Zitvogel, L (corresponding author), INSERM, U805, Villejuif, France.	kroemer@orange.fr; zitvogel@igr.fr	KROEMER, Guido/B-4263-2013; Apetoh, Lionel/G-3310-2014; Kroemer, Guido/AAY-9859-2020; ANDRE, Fabrice/AAL-2683-2020; Mignot, Grégoire/R-4976-2017; Apetoh, Lionel/AIC-2384-2022; PERFETTINI, Jean-Luc/N-4699-2017; Smyth, Mark J/H-8709-2014	KROEMER, Guido/0000-0002-9334-4405; Apetoh, Lionel/0000-0002-2774-438X; ANDRE, Fabrice/0000-0001-5795-8357; Mignot, Grégoire/0000-0002-0682-0152; Apetoh, Lionel/0000-0002-2774-438X; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Smyth, Mark J/0000-0001-7098-7240; Ullrich, Evelyn/0000-0001-8530-1192; ghiringhelli, francois/0000-0002-5465-8305; Panaretakis, Theocharis/0000-0001-5754-6950; Schlemmer, Frederic/0000-0003-2113-7113; ZITVOGEL, laurence/0000-0003-1596-0998; Genin, Pierre/0000-0002-7502-3851; Aymeric, Laetitia/0000-0001-7459-7231	Ligue Nationale contre le Cancer; Fondation pour la Recherche Medicale; European Union; association for International cancer research; Canceropole Ile-de-France; Institut National du Cancer; Agence Nationale pour la Recherche; European Molecular Biology Organization; National Health; Association pour la recherche sur le cancer RC; National Health and Medical Research Council of Australia; Cancer Council of Victoria; China Scholarship Council; Leukemia Foundation; European Respiratory Society Fellowship [605]	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Union(European Commission); association for International cancer research; Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale pour la Recherche(French National Research Agency (ANR)); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); National Health; Association pour la recherche sur le cancer RC; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); China Scholarship Council(China Scholarship Council); Leukemia Foundation; European Respiratory Society Fellowship	We thank I. Couillin (CNRS) and A. Mignon (Cochin Hospital) for helpful discussion and for providing IL-1RA, R. Schreiber (Washington University School of Medicine) for monoclonal antibodies to IL-1 alpha, IL-1 beta and IL-1R, H. Yang (Feinstein Institute for Medical Research) for antibody to HMGB1, H. Yagita (School of Medicine, Juntendo University) for the N2B2 antibody to mouse TRAIL, J.-C. Guery (INSERM) for IL12rb2<SUP>-/-</SUP> mice, V. Dixit (Pennington Biomedical Research Center) for Pycard<SUP>-/-</SUP> mice, M. Albert (Pasteur Institute) for membrane-bound OVA-transfected mouse embryonic fibroblast cells, S. Forget and J. Bombled for access to the genomics platform, V. Vasseur and the Institut Gustave Roussy animal facility for breeding of transgenic mice, I. Martins for help in ATP release screening and A. Boissonnas (INSERM, Curie Institute) for providing OT1-GFP mice. We are deeply indebted to P. Arveux and S. Dabakuyo for useful help with the statistical analyses. The authors are supported by grants from the Ligue Nationale contre le Cancer (to L. Aymeric., G.K. and L.Z.), the Fondation pour la Recherche Medicale (to L. Apetoh., G.K., E.U., F.S. and L.Z.), the European Union (INFLACARE grant), the association for International cancer research (to G.K.) Canceropole Ile-de-France, Institut National du Cancer (L.Z., G.K.), Agence Nationale pour la Recherche (to G.K.), the European Molecular Biology Organization (L. Apetoh.), INSERM (A.T.), the National Health, Association pour la recherche sur le cancer RC (to G.M.), National Health and Medical Research Council of Australia, Cancer Council of Victoria, the China Scholarship Council (Y.M.) and the Leukemia Foundation (M.J.S., N.M.M. and N.M.H.). K.V. is the recipient of a European Respiratory Society Fellowship (number 605).	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Brydges S, 2006, CURR TOP MICROBIOL, V305, P127, DOI 10.1007/3-540-29714-6_7; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Hagemann T, 2007, CANCER CELL, V12, P300, DOI 10.1016/j.ccr.2007.10.005; Hinrichs CS, 2006, CURR OPIN IMMUNOL, V18, P363, DOI 10.1016/j.coi.2006.03.009; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Reginato AM, 2007, CURR OPIN RHEUMATOL, V19, P134, DOI 10.1097/BOR.0b013e328040c00b; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Selzner N, 2004, CELL DEATH DIFFER, V11, pS172, DOI 10.1038/sj.cdd.4401505; Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	52	1290	1336	3	191	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1170	U99		10.1038/nm.2028	http://dx.doi.org/10.1038/nm.2028			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19767732				2022-12-27	WOS:000270596400029
J	Iadecola, C				Iadecola, Costantino			Bleeding in the brain Killer waves of depolarization in subarachnoid bleed	NATURE MEDICINE			English	Editorial Material							DELAYED CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; HEMORRHAGE; MANAGEMENT; PERFUSION; GLUCOSE		Weill Cornell Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY USA	Cornell University	Iadecola, C (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY USA.	coi2001@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X	NHLBI NIH HHS [P01 HL096571] Funding Source: Medline; NINDS NIH HHS [R37 NS034179] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL096571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034179] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Busija DW, 2008, PROG NEUROBIOL, V86, P379, DOI 10.1016/j.pneurobio.2008.09.008; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; HIJDRA A, 1986, NEUROLOGY, V36, P329, DOI 10.1212/WNL.36.3.329; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; Minhas PS, 2003, NEUROSURGERY, V52, P1017, DOI 10.1227/01.NEU.0000058231.08870.1F; Nozari A, 2010, ANN NEUROL, V67, P221, DOI 10.1002/ana.21871; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Shin HK, 2007, BRAIN, V130, P1631, DOI 10.1093/brain/awm071; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Stein SC, 2006, NEUROSURGERY, V59, P781, DOI 10.1227/01.NEU.0000227519.27569.45; Strong AJ, 2008, INTENS CARE MED, V34, P1169, DOI 10.1007/s00134-008-1045-4; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Takano T, 2009, J CLIN INVEST, V119, P16, DOI 10.1172/JCI38051	15	23	24	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1131	1132		10.1038/nm1009-1131	http://dx.doi.org/10.1038/nm1009-1131			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812570				2022-12-27	WOS:000270596400020
J	Hecker, L; Vittal, R; Jones, T; Jagirdar, R; Luckhardt, TR; Horowitz, JC; Pennathur, S; Martinez, FJ; Thannickal, VJ				Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Pennathur, Subramaniam; Martinez, Fernando J.; Thannickal, Victor J.			NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury	NATURE MEDICINE			English	Article							INDUCED PULMONARY FIBROSIS; NOX-FAMILY; TRANSFORMING GROWTH-FACTOR-BETA-1; REACTIVE OXYGEN; GROWTH-FACTOR; NULL MICE; FIBROBLASTS; DISEASE; DIFFERENTIATION; INDUCTION	Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the reduction of O-2 to reactive oxygen species, have increased in number during eukaryotic evolution(1,2). Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiology and pathophysiology have not been fully elucidated(3,4). The best established physiological role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants(5,6). The prototypical member of this family, NOX-2 (gp91(phox)), is expressed in phagocytic cells and mediates microbicidal activities(7,8). Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis. Transforming growth factor. beta 1 (TGF-beta 1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription. NOX-4-dependent generation of hydrogen peroxide (H2O2) is required for TGF-beta 1-induced myofibroblast differentiation, extracellular matrix (ECM) production and contractility. NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF). Genetic or pharmacologic targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury. These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.	[Pennathur, Subramaniam] Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI USA; [Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Martinez, Fernando J.; Thannickal, Victor J.] Univ Michigan, Sch Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Thannickal, VJ (corresponding author), Univ Alabama, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.	vjthan@uab.edu	VITTAL, RAGINI/AAE-9052-2020; Jagirdar, Rajesh/AAO-2327-2021	Jagirdar, Rajesh/0000-0001-7005-7772; Horowitz, Jeffrey/0000-0002-1505-2837	US National Institutes of Health [R01 HL067967, K08 HL081059]; National Institutes of Health-sponsored Lung Tissue Research Consortium [N01 HR046162]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067967, K08HL081059] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health-sponsored Lung Tissue Research Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank D. Lambeth, Department of Biochemistry, Emory University, for providing the rabbit polyclonal antibody to NOX-4 and A. Jesaitis, Department of Microbiology, Montana State University, for the mouse monoclonal antibody to NOX-2. We thank D. Arenberg, Department of Internal Medicine, University of Michigan, for providing primary lung mesenchymal cells from human subjects with IPF (IPF-MCs). This work was supported by grants from the US National Institutes of Health R01 HL067967 ( to V. J. T.) and K08 HL081059 ( to J. C. H.) and by a National Institutes of Health-sponsored Lung Tissue Research Consortium grant, N01 HR046162 ( to F. J. M.).	Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; Bedard K, 2007, BIOCHIMIE, V89, P1107, DOI 10.1016/j.biochi.2007.01.012; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Kawahara T, 2007, BMC EVOL BIOL, V7, DOI 10.1186/147-2148-7-109; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; Raghu G, 2006, AM J RESP CRIT CARE, V174, P810, DOI 10.1164/rccm.200602-163OC; ROBERTS SN, 1995, J PATHOL, V176, P309, DOI 10.1002/path.1711760313; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Sumimoto H, 2008, FEBS J, V275, P3249, DOI 10.1111/j.1742-4658.2008.06488.x; Thannickal VJ, 2009, AM J RESP CELL MOL, V40, P507, DOI 10.1165/rcmb.2008-0360PS; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; THRALL RS, 1982, AM REV RESPIR DIS, V126, P488; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vittal R, 2005, AM J PATHOL, V166, P367, DOI 10.1016/S0002-9440(10)62260-2; Waghray M, 2005, FASEB J, V19, P854, DOI 10.1096/fj.04-2882fje; ZHANG K, 1994, AM J PATHOL, V145, P114	29	604	634	1	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1077	U133		10.1038/nm.2005	http://dx.doi.org/10.1038/nm.2005			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19701206	Green Accepted			2022-12-27	WOS:000269979200030
J	Yemisci, M; Gursoy-Ozdemir, Y; Vural, A; Can, A; Topalkara, K; Dalkara, T				Yemisci, Muge; Gursoy-Ozdemir, Yasemin; Vural, Atay; Can, Alp; Topalkara, Kamil; Dalkara, Turgay			Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; BLOOD-BRAIN-BARRIER; FOCAL ISCHEMIA; MICROCIRCULATORY OBSTRUCTION; LEUKOCYTE ACCUMULATION; HYDROGEN-PEROXIDE; EARLY REPERFUSION; IN-VIVO; STROKE; THERAPY	Here we show that ischemia induces sustained contraction of pericytes on microvessels in the intact mouse brain. Pericytes remain contracted despite successful reopening of the middle cerebral artery after 2 h of ischemia. Pericyte contraction causes capillary constriction and obstructs erythrocyte flow. Suppression of oxidative-nitrative stress relieves pericyte contraction, reduces erythrocyte entrapment and restores microvascular patency; hence, tissue survival improves. In contrast, peroxynitrite application causes pericyte contraction. We also show that the microvessel wall is the major source of oxygen and nitrogen radicals causing ischemia and reperfusion-induced microvascular dysfunction. These findings point to a major but previously not recognized pathophysiological mechanism; ischemia and reperfusion-induced injury to pericytes may impair microcirculatory reflow and negatively affect survival by limiting substrate and drug delivery to tissue already under metabolic stress, despite recanalization of an occluded artery. Agents that can restore pericyte dysfunction and microvascular patency may increase the success of thrombolytic and neuroprotective treatments.	[Yemisci, Muge; Gursoy-Ozdemir, Yasemin; Vural, Atay; Topalkara, Kamil; Dalkara, Turgay] Hacettepe Univ, Fac Med, Dept Neurol, TR-06100 Ankara, Turkey; [Yemisci, Muge; Gursoy-Ozdemir, Yasemin; Vural, Atay; Topalkara, Kamil; Dalkara, Turgay] Hacettepe Univ, Inst Neurol Sci & Psychiat, TR-06100 Ankara, Turkey; [Can, Alp] Ankara Univ, Sch Med, Dept Histol & Embryol, TR-06100 Ankara, Turkey	Hacettepe University; Hacettepe University; Ankara University	Dalkara, T (corresponding author), Hacettepe Univ, Fac Med, Dept Neurol, TR-06100 Ankara, Turkey.	tdalkara@hacettepe.edu.tr	Vural, Atay/K-7388-2012; Gursoy-Ozdemir, Yasemin/X-2778-2019; Yemisci, Muge/I-9928-2013; Can, Alp/AAO-5734-2020	Vural, Atay/0000-0003-3222-874X; Gursoy-Ozdemir, Yasemin/0000-0002-0860-8964; Yemisci, Muge/0000-0002-1528-1998; Dalkara, Turgay/0000-0003-3943-7819	The Turkish Academy of Sciences; Hacettepe University Research Fund [0401105001]; Scientific and Technical Research Council of Turkey [104S254]; Ankara University Biotechnology Institute [2001K120240]; Brain Research Association	The Turkish Academy of Sciences(Turkish Academy of Sciences); Hacettepe University Research Fund(Hacettepe University); Scientific and Technical Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Ankara University Biotechnology Institute(Ankara University); Brain Research Association	This work was supported by The Turkish Academy of Sciences (T. D. and Y.G.-O.), Hacettepe University Research Fund 0401105001 (T. D.), Scientific and Technical Research Council of Turkey 104S254 (Y.G.-O.), Ankara University Biotechnology Institute 2001K120240 (A. C.) and Brain Research Association (M.Y.). We are grateful to M. A. Moskowitz for his support and comments. Part of this study was presented at the Society For Neuroscience 37th Annual Meeting in San Diego, California, 2007.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Allt G, 2001, CELLS TISSUES ORGANS, V169, P1, DOI 10.1159/000047855; AMES A, 1968, AM J PATHOL, V52, P437; ANWAR M, 1988, CIRC RES, V63, P27, DOI 10.1161/01.RES.63.1.27; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; Bandopadhyay R, 2001, J NEUROCYTOL, V30, P35, DOI 10.1023/A:1011965307612; Belayev L, 2002, STROKE, V33, P1077, DOI 10.1161/hs0402.105555; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Chrissobolis S, 2006, STROKE, V37, P2174, DOI 10.1161/01.STR.0000231647.41578.df; CROWELL RM, 1972, NEUROLOGY, V22, P500, DOI 10.1212/WNL.22.5.500; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; Faraci FM, 2006, J APPL PHYSIOL, V100, P739, DOI 10.1152/japplphysiol.01044.2005; FISCHER EG, 1973, ARCH NEUROL-CHICAGO, V29, P361, DOI 10.1001/archneur.1973.00490300023002; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; GARCIA JH, 1994, AM J PATHOL, V145, P728; Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143; Gursoy-Ozdemir Y, 2000, STROKE, V31, P1974, DOI 10.1161/01.STR.31.8.1974; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Hudetz AG, 1997, MICROCIRCULATION, V4, P233, DOI 10.3109/10739689709146787; Iadecola C, 1997, J NEUROSCI, V17, P9157; Juttler E, 2006, NAT CLIN PRACT CARD, V3, P656, DOI 10.1038/ncpcardio0721; Kamouchi M, 2007, NEUROSCI LETT, V416, P12, DOI 10.1016/j.neulet.2007.01.039; Li PA, 1998, NEUROSCI LETT, V253, P191, DOI 10.1016/S0304-3940(98)00643-0; LITTLE JR, 1976, STROKE, V7, P25, DOI 10.1161/01.STR.7.1.25; LITTLE JR, 1975, MAYO CLIN PROC, V50, P264; Liu SM, 2002, J CEREBR BLOOD F MET, V22, P1222, DOI 10.1097/01.wcb.0000037998.34930.83; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Molina CA, 2005, STROKE, V36, P2311, DOI 10.1161/01.STR.0000182100.65262.46; NEWELL DW, 1995, J NEUROSCI, V15, P7702; Ohtake M, 2004, NEUROPATHOLOGY, V24, P219, DOI 10.1111/j.1440-1789.2004.00560.x; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; Ritter LS, 2000, STROKE, V31, P1153, DOI 10.1161/01.STR.31.5.1153; VERDOUW PD, 1984, EUR J PHARMACOL, V102, P499, DOI 10.1016/0014-2999(84)90571-5; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262, DOI 10.1152/ajpheart.1996.271.3.H1262; Wu DM, 2003, AM J PHYSIOL-HEART C, V284, pH2083, DOI 10.1152/ajpheart.01007.2002	44	459	473	4	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1031	U82		10.1038/nm.2022	http://dx.doi.org/10.1038/nm.2022			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19718040				2022-12-27	WOS:000269979200023
J	Koehn, BH; Schoenberger, SP				Koehn, Brent H.; Schoenberger, Stephen P.			Tumor immunotherapy: making an immortal army	NATURE MEDICINE			English	Editorial Material							CELLS		[Koehn, Brent H.; Schoenberger, Stephen P.] La Jolla Inst Allergy & Immunol, Cellular Immunol Lab, La Jolla, CA USA	La Jolla Institute for Immunology	Koehn, BH (corresponding author), La Jolla Inst Allergy & Immunol, Cellular Immunol Lab, La Jolla, CA USA.	sps@liai.org			NATIONAL CANCER INSTITUTE [R01CA081261] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081261-10, R01 CA081261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Croce Jenifer C., 2008, V469, P3, DOI 10.1007/978-1-60327-469-2_1; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Herodotus, 1972, HISTORIES; Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Stemberger C, 2009, SEMIN IMMUNOL, V21, P62, DOI 10.1016/j.smim.2009.02.004; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002	8	11	12	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					731	732		10.1038/nm0709-731	http://dx.doi.org/10.1038/nm0709-731			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584859	Green Accepted			2022-12-27	WOS:000267806900021
J	Weaver, TA; Charafeddine, AH; Agarwal, A; Turner, AP; Russell, M; Leopardi, FV; Kampen, RL; Stempora, L; Song, MQ; Larsen, CP; Kirk, AD				Weaver, Tim A.; Charafeddine, Ali H.; Agarwal, Avinash; Turner, Alexandra P.; Russell, Maria; Leopardi, Frank V.; Kampen, Robert L.; Stempora, Linda; Song, Mingqing; Larsen, Christian P.; Kirk, Allan D.			Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates	NATURE MEDICINE			English	Article							DONOR-SPECIFIC TRANSFUSION; CHRONIC PLAQUE PSORIASIS; T-CELL MEMORY; TRANSPLANTATION TOLERANCE; BARRIER; IMMUNITY	Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA-3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.	[Weaver, Tim A.; Charafeddine, Ali H.; Agarwal, Avinash; Turner, Alexandra P.; Russell, Maria; Leopardi, Frank V.; Kampen, Robert L.; Stempora, Linda; Song, Mingqing; Kirk, Allan D.] NIDDK, Transplantat Branch, US NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Weaver, Tim A.; Charafeddine, Ali H.; Leopardi, Frank V.; Kampen, Robert L.; Larsen, Christian P.; Kirk, Allan D.] Emory Univ, Emory Transplant Ctr, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Emory University	Kirk, AD (corresponding author), NIDDK, Transplantat Branch, US NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	adkirk@emory.edu	Larsen, Christian P./B-6906-2012; Kirk, Allan D./B-6905-2012	Larsen, Christian P./0000-0001-6573-2649; Kirk, Allan/0000-0003-2004-5962	Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Disease, NIH [Z01 DK062007-06]; National Institutes of Health [1U01AI079223-01A1]; Georgia Research Alliance; McKelvey Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI079223, U19AI043900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK062007] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Disease, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Research Alliance; McKelvey Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded in part by the Division of Intramural Research, National Institute of Diabetes, Digestive and Kidney Disease, NIH (Z01 DK062007-06). Salary support for T. A. W. was provided by the Howard Hughes Medical Institute through the NIH Research Scholars Program. A. D. K. is supported by the National Institutes of Health (1U01AI079223-01A1), the Georgia Research Alliance and the McKelvey Foundation. We gratefully acknowledge the expert assistance of J. Bacher and the staff of the NIH Veterinary Pathology Department.	Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Chamian F, 2005, P NATL ACAD SCI USA, V102, P2075, DOI 10.1073/pnas.0409569102; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Girlanda R, 2008, AM J TRANSPLANT, V8, P600, DOI 10.1111/j.1600-6143.2007.02109.x; Harari A, 2006, IMMUNOL REV, V211, P236, DOI 10.1111/j.0105-2896.2006.00395.x; Kirk AD, 2003, IMMUNOL REV, V196, P176, DOI 10.1046/j.1600-065X.2003.00081.x; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Meier-Kriesche HU, 2006, AM J TRANSPLANT, V6, P1111, DOI 10.1111/j.1600-6143.2006.01270.x; Ortonne JP, 2003, EUR J DERMATOL, V13, P117; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Preston EH, 2005, AM J TRANSPLANT, V5, P1032, DOI 10.1111/j.1600-6143.2005.00796.x; Valujskikh A, 2007, J AM SOC NEPHROL, V18, P2252, DOI 10.1681/ASN.2007020151; Wu ZH, 2004, NAT MED, V10, P87, DOI 10.1038/nm965	14	148	155	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					746	749		10.1038/nm.1993	http://dx.doi.org/10.1038/nm.1993			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584865	Green Accepted			2022-12-27	WOS:000267806900026
J	Malicdan, MCV; Noguchi, S; Hayashi, YK; Nonaka, I; Nishino, I				Malicdan, May Christine V.; Noguchi, Satoru; Hayashi, Yukiko K.; Nonaka, Ikuya; Nishino, Ichizo			Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model	NATURE MEDICINE			English	Article							INCLUSION-BODY MYOPATHY; N-ACETYLNEURAMINIC ACID; RIMMED VACUOLES; DISTAL MYOPATHY; SKELETAL-MUSCLE; KINASE GNE; EXPRESSION; ACETYLMANNOSAMINE; BIOSYNTHESIS; SIALYLATION	Distal myopathy with rimmed vacuoles (DMRV)-hereditary inclusion body myopathy (hIBM) is an adult-onset, moderately progressive autosomal recessive myopathy; eventually, affected individuals become wheelchair bound(1). It is characterized clinically by skeletal muscle atrophy and weakness, and pathologically by rimmed vacuoles, which are actually accumulations of autophagic vacuoles(2-4), scattered angular fibers and intracellular accumulation of amyloid and other proteins(5). To date, no therapy is available for this debilitating myopathy, primarily because the disease pathomechanism has been enigmatic. It is known that the disease gene underlying DMRV-hIBM is GNE, encoding glucosamine (UDP-N-acetyl)-2-epimerase and N-acetylmannosamine kinase(6-8)-two essential enzymes in sialic acid biosynthesis(9). It is still unclear, however, whether decreased sialic acid production causes muscle degeneration, as GNE has been proposed to have roles other than for sialic acid biosynthesis(10-12). By showing that muscle atrophy and weakness are completely prevented in a mouse model of DMRV-hIBM after treatment with sialic acid metabolites orally, we provide evidence that hyposialylation is indeed one of the key factors in the pathomechanism of DMRV-hIBM. These results support the notion that DMRV-hIBM can potentially be treated simply by giving sialic acids, a strategy that could be applied in clinical trials in the near future.	[Malicdan, May Christine V.; Noguchi, Satoru; Hayashi, Yukiko K.; Nonaka, Ikuya; Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan; [Malicdan, May Christine V.] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto, Japan	National Center for Neurology & Psychiatry - Japan; Kyoto University	Noguchi, S (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan.	noguchi@ncnp.go.jp	Malicdan, May Christine/F-2806-2013; Nishino, Ichizo/G-2676-2010; Malicdan, May Christine/AAK-7422-2021	Nishino, Ichizo/0000-0001-9452-112X; 	Japanese Health Sciences Foundation; Japanese National Institute of Biomedical Innovation [19A-7]; Ministry of Health Labour and Welfare in Japan; Kato Memorial Trust for Nambyo Research; Neuromuscular Disease Foundation	Japanese Health Sciences Foundation; Japanese National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Ministry of Health Labour and Welfare in Japan(Ministry of Health, Labour and Welfare, Japan); Kato Memorial Trust for Nambyo Research(Kato Memorial Trust for Nambyo Research); Neuromuscular Disease Foundation	The authors acknowledge the valuable assistance offered by F. Funato and R. Hoshi in motor performance evaluation of mice, toxicology assays and sialic acid measurement. This study is supported partly by the Research on Psychiatric and Neurological Diseases and Mental Health grant from the Japanese Health Sciences Foundation; the Program for Promotion of Fundamental Studies in Health Sciences of the Japanese National Institute of Biomedical Innovation the Research Grant (19A-7) for Nervous and Mental Disorders from the Ministry of Health Labour and Welfare in Japan, the Kato Memorial Trust for Nambyo Research and the Neuromuscular Disease Foundation.	Amsili S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002477; Askanas V, 2006, NEUROLOGY, V66, pS39, DOI 10.1212/01.wnl.0000192128.13875.1e; ASKANAS V, 2003, MOL GENETIC BASIS NE, P501; Broccolini A, 2008, J NEUROCHEM, V105, P971, DOI 10.1111/j.1471-4159.2007.05208.x; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; COMB DG, 1958, J AM CHEM SOC, V80, P497, DOI 10.1021/ja01535a062; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Gagiannis D, 2007, BBA-GEN SUBJECTS, V1770, P297, DOI 10.1016/j.bbagen.2006.09.023; Galeano B, 2007, J CLIN INVEST, V117, P1585, DOI 10.1172/JCI30954; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Iijima R, 2004, FEBS LETT, V561, P163, DOI 10.1016/S0014-5793(04)00164-4; Ikeuchi T, 1997, ANN NEUROL, V41, P432, DOI 10.1002/ana.410410405; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kotani K, 1994, Nihon Shokakibyo Gakkai Zasshi, V91, P154; Krause S, 2005, EXP CELL RES, V304, P365, DOI 10.1016/j.yexcr.2004.11.010; Kumamoto T, 1998, INTERNAL MED, V37, P746, DOI 10.2169/internalmedicine.37.746; Lynch GS, 2001, J PHYSIOL-LONDON, V535, P591, DOI 10.1111/j.1469-7793.2001.00591.x; Malicdan MCV, 2007, HUM MOL GENET, V16, P2669, DOI 10.1093/hmg/ddm220; Malicdan MCV, 2007, AUTOPHAGY, V3, P396, DOI 10.4161/auto.4270; Malicdan MCV, 2008, PHYSIOL GENOMICS, V35, P106, DOI 10.1152/physiolgenomics.90219.2008; Malicdan MCV, 2009, METHOD ENZYMOL, V453, P379, DOI 10.1016/S0076-6879(08)04019-6; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Nishino I, 2005, Acta Myol, V24, P80; Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6; Noguchi S, 2004, J BIOL CHEM, V279, P11402, DOI 10.1074/jbc.M313171200; Nonaka Ikuya, 2005, Curr Neurol Neurosci Rep, V5, P61, DOI 10.1007/s11910-005-0025-0; ROBITAILLE G, 1991, J DAIRY SCI, V74, P3314, DOI 10.3168/jds.S0022-0302(91)78518-4; SCHMIDT S, 2004, METHOD MOL BIOL, V299, P408; Spuler S, 2008, ANN NEUROL, V63, P323, DOI 10.1002/ana.21309; THOMAS GH, 1985, BIOCHIM BIOPHYS ACTA, V846, P37, DOI 10.1016/0167-4889(85)90107-7; Tsuruta Y, 2001, ACTA NEUROPATHOL, V101, P579; Wang ZY, 2006, J BIOL CHEM, V281, P27016, DOI 10.1074/jbc.M604903200	35	115	129	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					690	U127		10.1038/nm.1956	http://dx.doi.org/10.1038/nm.1956			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19448634	Green Submitted			2022-12-27	WOS:000266731600029
J	Watanabe, H; Chopra, N; Laver, D; Hwang, HS; Davies, SS; Roach, DE; Duff, HJ; Roden, DM; Wilde, AAM; Knollmann, BC				Watanabe, Hiroshi; Chopra, Nagesh; Laver, Derek; Hwang, Hyun Seok; Davies, Sean S.; Roach, Daniel E.; Duff, Henry J.; Roden, Dan M.; Wilde, Arthur A. M.; Knollmann, Bjoern C.			Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans	NATURE MEDICINE			English	Article							RYANODINE RECEPTOR; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; MUTATIONS; CASQ2; MECHANISMS; MYOCYTES; INCREASE; DEATH	Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca2+ release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.	[Watanabe, Hiroshi; Chopra, Nagesh; Hwang, Hyun Seok; Davies, Sean S.; Roden, Dan M.; Knollmann, Bjoern C.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Watanabe, Hiroshi; Chopra, Nagesh; Hwang, Hyun Seok; Davies, Sean S.; Roden, Dan M.; Knollmann, Bjoern C.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; [Laver, Derek] Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia; [Laver, Derek] Hunter Med Res Inst, Callaghan, NSW, Australia; [Roach, Daniel E.; Duff, Henry J.] Univ Calgary, Libin Cardiovasc Inst, Calgary, AB, Canada; [Wilde, Arthur A. M.] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands	Vanderbilt University; Vanderbilt University; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Amsterdam; Academic Medical Center Amsterdam	Knollmann, BC (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.	bjorn.knollmann@vanderbilt.edu	Roden, Dan/ABD-5412-2021	Davies, Sean/0000-0001-9879-8062; Knollmann, Bjorn/0000-0003-4956-9735; Duff, Henry/0000-0001-9292-5411	US National Institutes of Health [HL88635, HL71670, HL49989]; American Heart Association Established Investigator Award [0840071N]; Australian Research Council [DP0557780]; New South Wales Health through Hunter Medical Research Institute; Leducq Foundation [05CVD01]; Alberta Heart and Stroke Foundation Chair; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071670, R01HL049989, R01HL088635] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Established Investigator Award(American Heart Association); Australian Research Council(Australian Research Council); New South Wales Health through Hunter Medical Research Institute; Leducq Foundation(Leducq Foundation); Alberta Heart and Stroke Foundation Chair; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank S. Huke and S. Kim for their assistance with the data analysis and the preparation of figures, P. Johnson for his assistance with the single-channel recording and N. Masalha and S.A. Clur for their assistance in patient care and management. This work was supported in part by the US National Institutes of Health grants HL88635 and HL71670 (to B.C.K.) and HL49989 (to D.M.R.), by the American Heart Association Established Investigator Award 0840071N (to B.C.K.), by the Australian Research Council grant DP0557780 (to D.R.L.), by an infrastructure grant from New South Wales Health through Hunter Medical Research Institute (to D.R.L.), by the Leducq Foundation grant 05CVD01 (to A.A.M.W. and D.M.R.) and by the Alberta Heart and Stroke Foundation Chair in Cardiovascular Medicine (to H.J.D.).	Cerrone M, 2007, CIRC RES, V101, P1039, DOI 10.1161/CIRCRESAHA.107.148064; De Rosa G, 2004, PEDIATR EMERG CARE, V20, P175, DOI 10.1097/01.pec.0000117927.65522.7a; di Barletta MR, 2006, CIRCULATION, V114, P1012, DOI 10.1161/CIRCULATIONAHA.106.623793; Gyorke S, 1997, J PHYSIOL-LONDON, V500, P297; Jiang DW, 2004, P NATL ACAD SCI USA, V101, P13062, DOI 10.1073/pnas.0402388101; Knollmann BC, 2006, J CLIN INVEST, V116, P2510, DOI 10.1172/JCI29128; Lahat H, 2001, AM J HUM GENET, V69, P1378, DOI 10.1086/324565; LEENHARDT A, 1995, CIRCULATION, V91, P1512, DOI 10.1161/01.CIR.91.5.1512; MARBAN E, 1986, J CLIN INVEST, V78, P1185, DOI 10.1172/JCI112701; Mohamed U, 2006, HEART RHYTHM, V3, P1486, DOI 10.1016/j.hrthm.2006.08.018; PIZZAIE S, 2008, J CARDIOVASC ELECTR, V9, P1319; Postma AV, 2002, CIRC RES, V91, pE21, DOI 10.1161/01.RES.0000038886.18992.6B; Priori SG, 2001, CIRCULATION, V103, P196; ROBINSON M, 2007, HEART RHYTHM S, V4, pS100; ROSEN MR, 1980, CIRC RES, V46, P117, DOI 10.1161/01.RES.46.1.117; SHOSHANBARMATZ V, 1993, J MEMBRANE BIOL, V133, P171; Venetucci LA, 2006, CIRC RES, V98, P1299, DOI 10.1161/01.RES.0000222000.35500.65; Wilde AAM, 2008, NEW ENGL J MED, V358, P2024, DOI 10.1056/NEJMoa0708006	18	398	411	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					380	383		10.1038/nm.1942	http://dx.doi.org/10.1038/nm.1942			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19330009	Green Accepted			2022-12-27	WOS:000264937200024
J	Koenen, RR; von Hundelshausen, P; Nesmelova, IV; Zernecke, A; Liehn, EA; Sarabi, A; Kramp, BK; Piccinini, AM; Paludan, SR; Kowalska, MA; Kungl, AJ; Hackeng, TM; Mayo, KH; Weber, C				Koenen, Rory R.; von Hundelshausen, Philipp; Nesmelova, Irina V.; Zernecke, Alma; Liehn, Elisa A.; Sarabi, Alisina; Kramp, Birgit K.; Piccinini, Anna M.; Paludan, Soren R.; Kowalska, M. Anna; Kungl, Andreas J.; Hackeng, Tilman M.; Mayo, Kevin H.; Weber, Christian			Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice	NATURE MEDICINE			English	Article							MONOCYTE ARREST; RANTES; PLATELET-FACTOR-4; DEFICIENT; CCR5; CXC; OLIGOMERIZATION; RECRUITMENT; DEPOSITION; RECEPTORS	Atherosclerosis is characterized by chronic inflammation of the arterial wall due to chemokine-driven mononuclear cell recruitment(1-4). Activated platelets can synergize with chemokines to exacerbate atherogenesis; for example, by deposition of the chemokines platelet factor-4 (PF4, also known as CXCL4) and RANTES (CCL5), triggering monocyte arrest on inflamed endothelium(5-9). Homo-oligomerization is required for the recruitment functions of CCL5, and chemokine heteromerization has more recently emerged as an additional regulatory mechanism, as evidenced by a mutual modulation of CXCL8 and CXCL4 activities and by enhanced monocyte arrest resulting from CCL5-CXCL4 interactions(10-13). The CCL5 antagonist Met-RANTES reduces diet-induced atherosclerosis(9,14); however, CCL5 antagonism may not be therapeutically feasible, as suggested by studies using Ccl5-deficient mice which imply that direct CCL5 blockade would severely compromise systemic immune responses, delay macrophage-mediated viral clearance and impair normal T cell functions(15,16). Here we determined structural features of CCL5-CXCL4 heteromers and designed stable peptide inhibitors that specifically disrupt proinflammatory CCL5-CXCL4 interactions, thereby attenuating monocyte recruitment and reducing atherosclerosis without the aforementioned side effects. These results establish the in vivo relevance of chemokine heteromers and show the potential of targeting heteromer formation to achieve therapeutic effects.	[Koenen, Rory R.; von Hundelshausen, Philipp; Zernecke, Alma; Liehn, Elisa A.; Sarabi, Alisina; Kramp, Birgit K.; Weber, Christian] Univ Aachen, Rhein Westfal TH Aachen, Fac Med, Inst Cardiovasc Mol Res, D-52074 Aachen, Germany; [Nesmelova, Irina V.; Mayo, Kevin H.] Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; [Piccinini, Anna M.; Kungl, Andreas J.] Graz Univ, Dept Pharmaceut Chem, A-8010 Graz, Austria; [Paludan, Soren R.] Univ Aarhus, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark; [Kowalska, M. Anna] Childrens Hosp Philadelphia, Dept Hematol, Philadelphia, PA 19104 USA; [Hackeng, Tilman M.; Weber, Christian] Univ Maastricht, Cardiovasc Res Inst Maastricht, NL-6229 ER Maastricht, Netherlands	RWTH Aachen University; University of Minnesota System; University of Minnesota Twin Cities; University of Graz; Aarhus University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Maastricht University	Weber, C (corresponding author), Univ Aachen, Rhein Westfal TH Aachen, Fac Med, Inst Cardiovasc Mol Res, Pauwelsstr 30, D-52074 Aachen, Germany.	cweber@ukaachen.de	Koenen, Rory/H-4172-2012; Liehn, Elisa Anamaria/D-9623-2011; Nesmelova, Irina/D-6033-2015; Weber, Christian/AAW-2153-2020; von Hundelshausen, Philipp/F-7435-2014	Koenen, Rory/0000-0002-9955-9730; Liehn, Elisa Anamaria/0000-0002-1253-3272; Nesmelova, Irina/0000-0002-1835-1533; Weber, Christian/0000-0003-4610-8714; von Hundelshausen, Philipp/0000-0001-7474-9370; Hackeng, Tilman/0000-0003-0142-0843; Piccinini, Anna Maria/0000-0002-7588-0415; Kungl, Andreas/0000-0003-3362-797X	Deutsche Forschungsgemeinschaft [WE1913/5-2, WE1913/7-1, KO2948/1-1, HU1618/1-1, ZE827/1-1, FOR809]; Interdisciplinary Center for Clinical Research "Biomat'' within the Medical Faculty of RWTH Aachen University [TV-B112, TV-B113]; Nederlandse Organisatie voor Wetenschappelijk Onderzoek [917.36.372]; US National Institutes of Health [HL07062]; US National Science Foundation [BIR-961477]; University of Minnesota Medical School and the Minnesota Medical Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research "Biomat'' within the Medical Faculty of RWTH Aachen University; Nederlandse Organisatie voor Wetenschappelijk Onderzoek(Netherlands Organization for Scientific Research (NWO)European Commission); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Science Foundation(National Science Foundation (NSF)); University of Minnesota Medical School and the Minnesota Medical Foundation	This study was supported by grants from the Deutsche Forschungsgemeinschaft (WE1913/5-2, WE1913/7-1 to C. W., KO2948/1-1 to R. R. K., HU1618/1-1 to P. v. H., ZE827/1-1 to A. Z. and FOR809 to R. R. K., P. v. H., A. Z. and C. W.), the Interdisciplinary Center for Clinical Research "Biomat'' within the Medical Faculty of RWTH Aachen University (TV-B112 and TV-B113 to R. R. K. and C. W.), Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VIDI 917.36.372 to T. M. H.) and the US National Institutes of Health (National Research Service Award training grant HL07062 to I. V. N.). We thank S. Meiler, S. Winkler, J. Tupiec, S. Knarren, M. Garbe, S. Wilbertz, D. Suylen and W. Adriaens for technical assistance. Computer resources were provided by the Minnesota Supercomputing Institute ( University of Minnesota). NMR instrumentation was provided with funds from the US National Science Foundation (BIR-961477), the University of Minnesota Medical School and the Minnesota Medical Foundation. Met-RANTES was provided by P. Nelson ( University of Munich). NMR chemical-shift assignments for the CCL5 monomer state were provided by S. Grzesiek ( University of Basel).	Anders HJ, 2003, J IMMUNOL, V170, P5658, DOI 10.4049/jimmunol.170.11.5658; Baltus T, 2003, BLOOD, V102, P1985, DOI 10.1182/blood-2003-04-1175; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Braunersreuther V, 2007, ARTERIOSCL THROM VAS, V27, P373, DOI 10.1161/01.ATV.0000253886.44609.ae; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Crown SE, 2006, J BIOL CHEM, V281, P25438, DOI 10.1074/jbc.M601518200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Duma L, 2007, J MOL BIOL, V365, P1063, DOI 10.1016/j.jmb.2006.10.040; Hackeng TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/pnas.96.18.10068; Halden Y, 2004, BIOCHEM J, V377, P533, DOI 10.1042/BJ20030729; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; ILYINA E, 1994, BIOCHEMISTRY-US, V33, P13436, DOI 10.1021/bi00249a032; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; Nesmelova IV, 2008, J BIOL CHEM, V283, P24155, DOI 10.1074/jbc.M803308200; Nesmelova IV, 2005, J BIOL CHEM, V280, P4948, DOI 10.1074/jbc.M405364200; Nesmelova IV, 2004, J MAGN RESON, V166, P129, DOI 10.1016/j.jmr.2003.09.004; Paoletti S, 2005, BLOOD, V105, P3405, DOI 10.1182/blood-2004-04-1648; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Rajagopal P, 1997, PROTEIN SCI, V6, P2624; Sachais BS, 2007, THROMB HAEMOSTASIS, V98, P1108, DOI 10.1160/TH07-04-0271; Schober A, 2002, CIRCULATION, V106, P1523, DOI 10.1161/01.CIR.0000028590.02477.6F; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Sorensen LN, 2004, SCAND J IMMUNOL, V59, P321, DOI 10.1111/j.0300-9475.2004.01399.x; Sticht H, 1999, BIOCHEMISTRY-US, V38, P5995, DOI 10.1021/bi990065i; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; Veillard NR, 2004, CIRC RES, V94, P253, DOI 10.1161/01.RES.0000109793.17591.4E; von Hundelshausen P, 2005, BLOOD, V105, P924, DOI 10.1182/blood-2004-06-2475; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; Weber C, 2006, TRENDS IMMUNOL, V27, P268, DOI 10.1016/j.it.2006.04.002; Weber C, 2005, CIRC RES, V96, P612, DOI 10.1161/01.RES.0000160077.17427.57; Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415; Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38; Zernecke A, 2008, ARTERIOSCL THROM VAS, V28, P1897, DOI 10.1161/ATVBAHA.107.161174	42	336	350	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					97	103		10.1038/nm.1898	http://dx.doi.org/10.1038/nm.1898			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19122657				2022-12-27	WOS:000262425100024
J	Downward, J				Downward, Julian			Targeting RAS and PI3K in lung cancer	NATURE MEDICINE			English	Editorial Material							PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; INHIBITOR; THERAPY		Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502	9	56	57	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2008	14	12					1315	1316		10.1038/nm1208-1315	http://dx.doi.org/10.1038/nm1208-1315			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057554				2022-12-27	WOS:000261393600013
J	Ambros, V				Ambros, Victor			The evolution of our thinking about microRNAs	NATURE MEDICINE			English	Editorial Material							HETEROCHRONIC GENE LIN-14; SMALL TEMPORAL RNAS; C-ELEGANS; CAENORHABDITIS-ELEGANS; REGULATORY RNA; INTERFERENCE; PROTEIN; EXPRESSION; ENCODES; SWITCH		Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Ambros, V (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Med, 373 Plantat St,B2-306, Worcester, MA 01605 USA.	victor.ambros@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066826, R01GM034028] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM34028, GM066826] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Bashirullah A, 2003, DEV BIOL, V259, P1, DOI 10.1016/S0012-1606(03)00063-0; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Chen K, 2006, COLD SPRING HARB SYM, V71, P149, DOI 10.1101/sqb.2006.71.039; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grosshans H, 2005, DEV CELL, V8, P321, DOI 10.1016/j.devcel.2004.12.019; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Heimberg AM, 2008, P NATL ACAD SCI USA, V105, P2946, DOI 10.1073/pnas.0712259105; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Rosalind, 2004, Cell, VS116, pS89, DOI 10.1016/S0092-8674(04)00035-2; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Prochnik SE, 2007, DEV GENES EVOL, V217, P73, DOI 10.1007/s00427-006-0116-1; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Sernpere LF, 2003, DEV BIOL, V259, P9, DOI 10.1016/S0012-1606(03)00208-2; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Sokol NS, 2008, GENE DEV, V22, P1591, DOI 10.1101/gad.1671708; WICKENS M, 1994, NATURE, V367, P17, DOI 10.1038/367017a0; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813	31	142	154	2	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1036	1040		10.1038/nm1008-1036	http://dx.doi.org/10.1038/nm1008-1036			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841144				2022-12-27	WOS:000259892300031
J	Stephan, MT; Ponomarev, V; Brentjens, RJ; Chang, AH; Dobrenkov, KV; Heller, G; Sadelain, M				Stephan, Matthias T.; Ponomarev, Vladimir; Brentjens, Renier J.; Chang, Alex H.; Dobrenkov, Konstantin V.; Heller, Glenn; Sadelain, Michel			T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; EX-VIVO EXPANSION; IMMUNOLOGICAL SYNAPSE; IN-VIVO; ESTABLISHED TUMORS; PROSTATE-CANCER; CROSS-LINKING; GENE-TRANSFER; LYMPHOCYTES; CD28	To reject tumors, T cells must overcome poor tumor immunogenicity and an adverse tumor microenvironment. Providing agonistic costimulatory signals to tumor-infiltrating T cells to augment T cell function remains a challenge for the implementation of safe and effective immunotherapy. We hypothesized that T cells overexpressing selected costimulatory ligands could serve as cellular vehicles mediating powerful, yet constrained, anatomically targeted costimulation. Here, we show that primary human T cells expressing CD80 and 4-1BB ligand (4-1BBL) vigorously respond to tumor cells lacking costimulatory ligands and provoke potent rejection of large, systemic tumors in immunodeficient mice. In addition to showing costimulation of bystander T cells (transcostimulation), we show the effect of CD80 and 4-1BBL binding to their respective receptors in the immunological synapse of isolated single cells (autocostimulation). This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy.	Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, Mol Pharmacol & Chem Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Immunol Grad Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	CHANG, ALEX/A-8284-2011	Ponomarev, Vladimir/0000-0002-9119-9128; Stephan, Matthias/0000-0001-8310-0100	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA059350, R24CA083084] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748, P30CA08748, CA59350, R24 CA83084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andarini S, 2004, CANCER RES, V64, P3281, DOI 10.1158/0008-5472.CAN-03-3911; Arlen PM, 2006, CLIN CANCER RES, V12, P1260, DOI 10.1158/1078-0432.CCR-05-2059; Blansfield JA, 2005, J IMMUNOTHER, V28, P593, DOI 10.1097/01.cji.0000178913.41256.06; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Copier J, 2006, INT REV IMMUNOL, V25, P297, DOI 10.1080/08830180600992472; Daugherty AL, 2006, ADV DRUG DELIVER REV, V58, P686, DOI 10.1016/j.addr.2006.03.011; DING L, 1994, EUR J IMMUNOL, V24, P859, DOI 10.1002/eji.1830240413; Drake CG, 2006, ADV IMMUNOL, V90, P51, DOI 10.1016/S0065-2776(06)90002-9; Dustin Michael L., 2006, V43, P175, DOI 10.1007/019; Finger EB, 2002, NAT IMMUNOL, V3, P1056, DOI 10.1038/ni1102-1056; Gade TPF, 2005, CANCER RES, V65, P9080, DOI 10.1158/0008-5472.CAN-05-0436; Gallardo HF, 1997, GENE THER, V4, P1115, DOI 10.1038/sj.gt.3300506; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Guinn B, 1999, J IMMUNOL, V162, P5003; Holdorf AD, 2002, NAT IMMUNOL, V3, P259, DOI 10.1038/ni761; Jang IK, 1998, BIOCHEM BIOPH RES CO, V242, P613, DOI 10.1006/bbrc.1997.8016; Keller AM, 2007, P NATL ACAD SCI USA, V104, P5989, DOI 10.1073/pnas.0700946104; Kershaw MH, 2005, NAT REV IMMUNOL, V5, P928, DOI 10.1038/nri1729; Lamers CHJ, 2007, CANCER IMMUNOL IMMUN, V56, P1875, DOI 10.1007/s00262-007-0330-3; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Leen AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI 10.1146/annurev.immunol.25.022106.141527; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; Micklethwaite K, 2007, BIOL BLOOD MARROW TR, V13, P707, DOI 10.1016/j.bbmt.2007.02.004; Milowsky MI, 2007, J CLIN ONCOL, V25, P540, DOI 10.1200/JCO.2006.07.8097; Nam KO, 2005, J IMMUNOL, V174, P1898, DOI 10.4049/jimmunol.174.4.1898; Papanicolaou GA, 2003, BLOOD, V102, P2498, DOI 10.1182/blood-2003-02-0345; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; Pentcheva-Hoang T, 2004, IMMUNITY, V21, P401, DOI 10.1016/j.immuni.2004.06.017; Rabu C, 2005, J BIOL CHEM, V280, P41472, DOI 10.1074/jbc.M506881200; Radoja S, 2001, J IMMUNOL, V167, P5042, DOI 10.4049/jimmunol.167.9.5042; Riley JL, 2005, BLOOD, V105, P13, DOI 10.1182/blood-2004-04-1596; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Sanchez-Lockhart M, 2006, J IMMUNOL, V176, P4778, DOI 10.4049/jimmunol.176.8.4778; Smythe JA, 1999, J IMMUNOL, V163, P3239; Somersalo K, 2004, J CLIN INVEST, V113, P49, DOI 10.1172/JCI200419337; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Tseng SY, 2005, J IMMUNOL, V175, P7829, DOI 10.4049/jimmunol.175.12.7829; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	50	220	255	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1440	1449		10.1038/nm1676	http://dx.doi.org/10.1038/nm1676			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18026115				2022-12-27	WOS:000251445400018
J	Carter, CC; Onafuwa-Nuga, A; McNamara, LA; Riddell, J; Bixby, D; Savona, MR; Collins, KL				Carter, Christoph C.; Onafuwa-Nuga, Adewunmi; McNamara, Lucy A.; Riddell, James; Bixby, Dale; Savona, Michael R.; Collins, Kathleen L.			HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEMATOPOIETIC STEM-CELLS	HIV causes a chronic infection characterized by depletion of CD4(+) T lymphocytes and the development of opportunistic infections. Despite drugs that inhibit viral spread, HIV infection has been difficult to cure because of uncharacterized reservoirs of infected cells that are resistant to highly active antiretroviral therapy (HAART) and the immune response. Here we used CD34(+) cells from infected people as well as in vitro studies of wild-type HIV to show infection and killing of CD34(+) multipotent hematopoietic progenitor cells (HPCs). In some HPCs, we detected latent infection that stably persisted in cell culture until viral gene expression was activated by differentiation factors. A unique reporter HIV that directly detects latently infected cells in vitro confirmed the presence of distinct populations of active and latently infected HPCs. These findings have major implications for understanding HIV bone marrow pathology and the mechanisms by which HIV causes persistent infection.	[Carter, Christoph C.; Collins, Kathleen L.] Univ Michigan, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; [Carter, Christoph C.; Collins, Kathleen L.] Univ Michigan, Med Sci Testing Program, Ann Arbor, MI 48109 USA; [Onafuwa-Nuga, Adewunmi; Riddell, James; Bixby, Dale; Savona, Michael R.; Collins, Kathleen L.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [McNamara, Lucy A.; Collins, Kathleen L.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [McNamara, Lucy A.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Collins, KL (corresponding author), Univ Michigan, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA.	klcollin@umich.edu		McNamara, Lucy/0000-0001-8240-7493	US National Institutes of Health [RO1 AI051192, MO1-RR000042]; Burroughs Wellcome Foundation; University of Michigan; Rackham Predoctoral Fellowship; US National Science Foundation; Bernard Maas Fellowship; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051192] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Foundation(Burroughs Wellcome Fund); University of Michigan(University of Michigan System); Rackham Predoctoral Fellowship; US National Science Foundation(National Science Foundation (NSF)); Bernard Maas Fellowship; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by US National Institutes of Health grant RO1 AI051192, MO1-RR000042, the Burroughs Wellcome Foundation, the University of Michigan Molecular Mechanisms in Microbial Pathogenesis Training Grant (C. C. C.), the Rackham Predoctoral Fellowship (C. C. C.), a US National Science Foundation predoctoral fellowship (L. A. M.) and a Bernard Maas Fellowship (L. A. M.). We thank C. van de Ven (University of Michigan) for umbilical cord blood and C. McIntyre-Ramm for assistance with human studies. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health: p89.6 from R. G. Collman (University of Pennsylvania), pNL4-3 from M. Martin (Viral Pathogenesis and Vaccine Section at the US National Institute of Allergy and Infectious Diseases), p94UG-114.1 and pYU-2 from B. Hahn (University of Alabama at Birmingham) and pMJ4 from T. Ndung'u (Nelson Mandela School of Medicine), B. Renjifo (Harvard School of Public Health) and M. Essex (Harvard School of Public Health). pCMV-G was from N. Hopkins, (Massachusetts Institute of Technology), pCMV-HIV-1 and pHIV-7/SF-GFP were from S.-J.-K. Yee (City of Hope National Medical Center) and pEGFP-N2-LAMP1 was from N. Andrews (Yale University).	Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; CLOUSE KA, 1989, J IMMUNOL, V142, P431; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Davis TA, 1998, J IMMUNOL, V160, P3689; Gasmi M, 1999, J VIROL, V73, P1828, DOI 10.1128/JVI.73.3.1828-1834.1999; Kohno T, 2002, J VIROL METHODS, V106, P167, DOI 10.1016/S0166-0934(02)00162-3; Kuroda H, 2009, J VIROL METHODS, V157, P113, DOI 10.1016/j.jviromet.2008.11.021; Majka M, 1999, J CLIN INVEST, V104, P1739, DOI 10.1172/JCI7779; NEAL TF, 1995, BLOOD, V86, P1749, DOI 10.1182/blood.V86.5.1749.bloodjournal8651749; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Weichold FF, 1998, BLOOD, V91, P907, DOI 10.1182/blood.V91.3.907.907_907_915; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Yamamoto N, 2006, VIRUS GENES, V32, P105, DOI 10.1007/s11262-005-5851-2; Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood-2007-11-122119; Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	20	231	238	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					446	U127		10.1038/nm.2109	http://dx.doi.org/10.1038/nm.2109			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20208541	Green Accepted			2022-12-27	WOS:000276446800049
J	McMillin, DW; Delmore, J; Weisberg, E; Negri, JM; Geer, DC; Klippel, S; Mitsiades, N; Schlossman, RL; Munshi, NC; Kung, AL; Griffin, JD; Richardson, PG; Anderson, KC; Mitsiades, CS				McMillin, Douglas W.; Delmore, Jake; Weisberg, Ellen; Negri, Joseph M.; Geer, D. Corey; Klippel, Steffen; Mitsiades, Nicholas; Schlossman, Robert L.; Munshi, Nikhil C.; Kung, Andrew L.; Griffin, James D.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.			Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity	NATURE MEDICINE			English	Article							MULTIPLE-MYELOMA CELLS; LENALIDOMIDE PLUS DEXAMETHASONE; HISTONE DEACETYLASE INHIBITION; BONE-MARROW STROMA; GENE-EXPRESSION; CLINICAL-IMPLICATIONS; MOLECULAR SEQUELAE; RESISTANCE; BORTEZOMIB; IDENTIFICATION	Conventional anticancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, we developed the tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay. Tumor cells (for example, myeloma, leukemia and solid tumors) stably expressing luciferase are cultured with nonmalignant accessory cells (for example, stromal cells) for selective quantification of tumor cell viability, in presence versus absence of stromal cells or drug treatment. CS-BLI is high-throughput scalable and identifies stroma-induced chemoresistance in diverse malignancies, including imatinib resistance in leukemic cells. A stroma-induced signature in tumor cells correlates with adverse clinical prognosis and includes signatures for activated Akt, Ras, NF-kappa B, HIF-1 alpha, myc, hTERT and IRF4; for biological aggressiveness; and for self-renewal. Unlike conventional screening, CS-BLI can also identify agents with increased activity against tumor cells interacting with stroma. One such compound, reversine, shows more potent activity in an orthotopic model of diffuse myeloma bone lesions than in conventional subcutaneous xenografts. Use of CS-BLI, therefore, enables refined screening of candidate anticancer agents to enrich preclinical pipelines with potential therapeutics that overcome stroma-mediated drug resistance and can act in a synthetic lethal manner in the context of tumor-stroma interactions.	[McMillin, Douglas W.; Delmore, Jake; Negri, Joseph M.; Geer, D. Corey; Klippel, Steffen; Mitsiades, Nicholas; Schlossman, Robert L.; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; [McMillin, Douglas W.; Delmore, Jake; Weisberg, Ellen; Negri, Joseph M.; Geer, D. Corey; Klippel, Steffen; Mitsiades, Nicholas; Schlossman, Robert L.; Munshi, Nikhil C.; Griffin, James D.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA; [McMillin, Douglas W.; Delmore, Jake; Weisberg, Ellen; Negri, Joseph M.; Geer, D. Corey; Klippel, Steffen; Schlossman, Robert L.; Munshi, Nikhil C.; Griffin, James D.; Richardson, Paul G.; Anderson, Kenneth C.; Mitsiades, Constantine S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Munshi, Nikhil C.] Boston VA Healthcare Syst, Boston, MA USA; [Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Dana-Farber Cancer Institute	Mitsiades, CS (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.	constantine_mitsiades@dfci.harvard.edu	Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022; Munshi, Nikhil/ABE-2338-2021	Kung, Andrew L/0000-0002-9091-488X; 	Dunkin Donuts Rising Stars program at the Dana-Farber Cancer Institute; Chambers Medical Foundation; Steven Cobb Foundation; US National Institutes of Health [R01CA050947]; NATIONAL CANCER INSTITUTE [R01CA124929, R01CA050947, P50CA100707, P01CA155258, P01CA078378] Funding Source: NIH RePORTER	Dunkin Donuts Rising Stars program at the Dana-Farber Cancer Institute; Chambers Medical Foundation; Steven Cobb Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by the Dunkin Donuts Rising Stars program at the Dana-Farber Cancer Institute (C. S. M.), the Chambers Medical Foundation (C. S. M. and P. G. R.), the Steven Cobb Foundation (D. W. M., C. S. M.) and US National Institutes of Health grant R01CA050947 (C. S. M. and K. C. A.). We wish to thank T. Libermann and M. Joseph-Bruno (Harvard Institutes of Medicine Genomics Core) for generation of gene expression data and L. Buon for help with bioinformatic analyses.	Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Grigorieva I, 1998, EXP HEMATOL, V26, P597; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lindvall C, 2003, CANCER RES, V63, P1743; Lust JA, 1999, HEMATOL ONCOL CLIN N, V13, P1117, DOI 10.1016/S0889-8588(05)70115-5; Mitsiades CS, 2004, CANCER CELL, V6, P439, DOI 10.1016/j.ccr.2004.10.020; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Mitsiades CS, 2003, CANCER RES, V63, P6689; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood-2006-04-015909; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; Roodman GD, 2002, J BONE MINER RES, V17, P1921, DOI 10.1359/jbmr.2002.17.11.1921; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood-2006-07-038430; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	38	240	251	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					483	U171		10.1038/nm.2112	http://dx.doi.org/10.1038/nm.2112			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20228816	Green Accepted			2022-12-27	WOS:000276446800055
J	Mooney, P				Mooney, Paul			In search of little blue pills	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					360	360		10.1038/nm0410-360b	http://dx.doi.org/10.1038/nm0410-360b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376024	Bronze			2022-12-27	WOS:000276446800017
J	Myers, MG; Kahn, CR; Accili, D				Myers, Martin G., Jr.; Kahn, C. Ronald; Accili, Domenico			Leptin therapy for type 1 diabetes gains traction	NATURE MEDICINE			English	Editorial Material									[Myers, Martin G., Jr.] Univ Michigan Med Sch, Dept Med, Ann Arbor, MI USA; [Kahn, C. Ronald] Joslin Diabet Ctr, Boston, MA USA; [Kahn, C. Ronald] Harvard Med Sch, Boston, MA USA; [Accili, Domenico] Columbia Univ, Dept Med, New York, NY USA	University of Michigan System; University of Michigan; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Columbia University	Myers, MG (corresponding author), Univ Michigan Med Sch, Dept Med, Ann Arbor, MI USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [R01 DK082659] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082659] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Wang MY, 2010, P NATL ACAD SCI USA, V107, P4813, DOI 10.1073/pnas.0909422107	1	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					380	380		10.1038/nm0410-380	http://dx.doi.org/10.1038/nm0410-380			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376045	Bronze			2022-12-27	WOS:000276446800056
J	Johnson, PL; Truitt, W; Fitz, SD; Minick, PE; Dietrich, A; Sanghani, S; Traskman-Bendz, L; Goddard, AW; Brundin, L; Shekhar, A				Johnson, Philip L.; Truitt, William; Fitz, Stephanie D.; Minick, Pamela E.; Dietrich, Amy; Sanghani, Sonal; Traskman-Bendz, Lil; Goddard, Andrew W.; Brundin, Lena; Shekhar, Anantha			A key role for orexin in panic anxiety	NATURE MEDICINE			English	Article							CEREBROSPINAL-FLUID; GABA DYSFUNCTION; DISORDER; RATS; HYPOTHALAMUS; INHIBITION; ALPRAZOLAM; HYPOCRETIN; SYSTEM; SLEEP	Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks. In individuals with panic disorder there is evidence of decreased central gamma-aminobutyric acid (GABA) activity as well as marked increases in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate(1-3). In a rat model of panic disorder, chronic inhibition of GABA synthesis in the dorsomedial-perifornical hypothalamus of rats produces anxiety-like states and a similar vulnerability to sodium lactate-induced cardioexcitatory responses(4-9). The dorsomedial-perifornical hypothalamus is enriched in neurons containing orexin (ORX, also known as hypocretin)(10), which have a crucial role in arousal(10,11), vigilance(10) and central autonomic mobilization(12), all of which are key components of panic. Here we show that activation of ORX-synthesizing neurons is necessary for developing a panic-prone state in the rat panic model, and either silencing of the hypothalamic gene encoding ORX (Hcrt) with RNAi or systemic ORX-1 receptor antagonists blocks the panic responses. Moreover, we show that human subjects with panic anxiety have elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety. Taken together, our results suggest that the ORX system may be involved in the pathophysiology of panic anxiety and that ORX antagonists constitute a potential new treatment strategy for panic disorder. (C) 2010 Nature America, Inc. All rights reserved.	[Johnson, Philip L.; Truitt, William; Fitz, Stephanie D.; Minick, Pamela E.; Dietrich, Amy; Goddard, Andrew W.; Shekhar, Anantha] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Truitt, William] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; [Sanghani, Sonal] Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA; [Traskman-Bendz, Lil; Brundin, Lena] Univ Lund Hosp, Dept Clin Sci, Sect Psychiat, S-22185 Lund, Sweden; [Shekhar, Anantha] Indiana Clin & Translat Sci Inst, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Lund University; Skane University Hospital	Shekhar, A (corresponding author), Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.	ashekhar@iupui.edu	Johnson, Philip/K-8574-2019	Johnson, Philip/0000-0002-5398-8214; Brundin, Lena/0000-0002-8327-6242	NCATS NIH HHS [UL1 TR001108] Funding Source: Medline; NCRR NIH HHS [UL1 RR025761-015988, UL1 RR025761, UL1RR025761] Funding Source: Medline; NIMH NIH HHS [R01 MH052619-11, R01 MH052619, R01 MH065702-06, R01 MH52619, R01 MH065702] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002529, UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052619, R01MH065702] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM PSYCH ASS, 2005, DIAGN STAT MAN MENT, P429; Andreatini R, 2001, BRAZ J MED BIOL RES, V34, P145, DOI 10.1590/S0100-879X2001000200001; Boshuisen ML, 2002, BIOL PSYCHIAT, V52, P126, DOI 10.1016/S0006-3223(02)01355-0; Brisbare-Roch C, 2007, NAT MED, V13, P150, DOI 10.1038/nm1544; Brundin L, 2007, EUR NEUROPSYCHOPHARM, V17, P573, DOI 10.1016/j.euroneuro.2007.01.005; Chou TC, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-19-j0003.2001; COWLEY DS, 1991, BIOL PSYCHIAT, V30, P49, DOI 10.1016/0006-3223(91)90069-X; De Boer SF, 2003, EUR J PHARMACOL, V463, P145, DOI 10.1016/S0014-2999(03)01278-0; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Ferguson AV, 2003, FRONT NEUROENDOCRIN, V24, P141, DOI 10.1016/S0091-3022(03)00028-1; Goddard AW, 2004, AM J PSYCHIAT, V161, P2186, DOI 10.1176/appi.ajp.161.12.2186; Goddard AW, 2001, ARCH GEN PSYCHIAT, V58, P556, DOI 10.1001/archpsyc.58.6.556; GORMAN JM, 1994, AM J PSYCHIAT, V151, P547; GRILLON C, 1994, BIOL PSYCHIAT, V35, P431, DOI 10.1016/0006-3223(94)90040-X; Ishii Y, 2005, BEHAV BRAIN RES, V157, P331, DOI 10.1016/j.bbr.2004.07.012; Johnson PL, 2008, NEUROPSYCHOPHARMACOL, V33, P2093, DOI 10.1038/sj.npp.1301621; Johnson PL, 2006, J NEUROSCI, V26, P7093, DOI 10.1523/JNEUROSCI.0408-06.2006; Kayaba Y, 2003, AM J PHYSIOL-REG I, V285, pR581, DOI 10.1152/ajpregu.00671.2002; LIEBOWITZ MR, 1986, J CLIN PSYCHOPHARM, V6, P13; LIEBOWITZ MR, 1986, AM J PSYCHIAT, V143, P495; Ludewig S, 2002, DEPRESS ANXIETY, V15, P55, DOI 10.1002/da.10026; Roy-Byrne PP, 2006, LANCET, V368, P1023, DOI 10.1016/S0140-6736(06)69418-X; Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055; Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092; Salomon RM, 2003, BIOL PSYCHIAT, V54, P96, DOI 10.1016/S0006-3223(02)01740-7; Samuels BC, 2004, AM J PHYSIOL-REG I, V287, pR472, DOI 10.1152/ajpregu.00667.2003; Shekhar A, 2003, ANN NY ACAD SCI, V985, P308; Shekhar A, 1997, J NEUROSCI, V17, P9726; Shekhar A, 1996, PHARMACOL BIOCHEM BE, V55, P249, DOI 10.1016/S0091-3057(96)00077-9; Shekhar A, 2000, NEUROPHARMACOLOGY, V39, P1139, DOI 10.1016/S0028-3908(99)00215-4; Shekhar A, 2006, J NEUROSCI, V26, P9205, DOI 10.1523/JNEUROSCI.2491-06.2006	31	263	284	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					111	U149		10.1038/nm.2075	http://dx.doi.org/10.1038/nm.2075			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20037593	Green Submitted, Green Accepted			2022-12-27	WOS:000273395500044
J	Nistal-Villan, E; Garcia-Sastre, A				Nistal-Villan, Estanislao; Garcia-Sastre, Adolfo			New prospects for the rational design of antivirals	NATURE MEDICINE			English	Editorial Material							AVIAN INFLUENZA; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; POLYMERASE; VIRUS; SUBUNIT; ENDONUCLEASE; MORTALITY; PB2		[Nistal-Villan, Estanislao; Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY USA; [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Global Hlth & Emerging Pathogens Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Nistal-Villan, E (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	adolfo.garcia-sastre@mssm.edu	Nistal-Villán, Estanislao/AAM-8029-2020; Nistal-Villan, Estanislao/GWM-7994-2022	Nistal-Villán, Estanislao/0000-0003-2458-8833; Garcia-Sastre, Adolfo/0000-0002-6551-1827	NIAAA NIH HHS [HHNSN266200700010C] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Beigel J, 2008, ANTIVIR RES, V78, P91, DOI 10.1016/j.antiviral.2008.01.003; Dias A, 2009, NATURE, V458, P914, DOI 10.1038/nature07745; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; Guilligay D, 2008, NAT STRUCT MOL BIOL, V15, P500, DOI 10.1038/nsmb.1421; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; He XJ, 2008, NATURE, V454, P1123, DOI 10.1038/nature07120; Itoh Y, 2009, NATURE, V460, P1021, DOI 10.1038/nature08260; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648; Obayashi E, 2008, NATURE, V454, P1127, DOI [10.1038/nature07225, 10.5940/jcrsj.50.329]; Sugiyama K, 2009, EMBO J, V28, P1803, DOI 10.1038/emboj.2009.138; Tarendeau F, 2007, NAT STRUCT MOL BIOL, V14, P229, DOI 10.1038/nsmb1212; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Yuan PW, 2009, NATURE, V458, P909, DOI 10.1038/nature07720; Zhao C, 2009, J VIROL, V83, P9024, DOI 10.1128/JVI.00911-09	15	21	23	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2009	15	11					1253	1254		10.1038/nm1109-1253	http://dx.doi.org/10.1038/nm1109-1253			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19893557	Green Accepted, Bronze			2022-12-27	WOS:000271543700012
J	Goldstein, JL				Goldstein, Joseph L.			Lasker Awards and papal portraiture: turning fields upside down	NATURE MEDICINE			English	Article												joe.goldstein@utsouthwestern.edu							0	3	3	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2009	15	10					1137	1140		10.1038/nm1009-1137	http://dx.doi.org/10.1038/nm1009-1137			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812573				2022-12-27	WOS:000270596400022
J	Meier, A; Chang, JJ; Chan, ES; Pollard, RB; Sidhu, HK; Kulkarni, S; Wen, TF; Lindsay, RJ; Orellana, L; Mildvan, D; Bazner, S; Streeck, H; Alter, G; Lifson, JD; Carrington, M; Bosch, RJ; Robbins, GK; Altfeld, M				Meier, Angela; Chang, J. Judy; Chan, Ellen S.; Pollard, Richard B.; Sidhu, Harlyn K.; Kulkarni, Smita; Wen, Tom Fang; Lindsay, Robert J.; Orellana, Liliana; Mildvan, Donna; Bazner, Suzane; Streeck, Hendrik; Alter, Galit; Lifson, Jeffrey D.; Carrington, Mary; Bosch, Ronald J.; Robbins, Gregory K.; Altfeld, Marcus			Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; IFN-ALPHA PRODUCTION; IMMUNE ACTIVATION; VIRAL LOAD; PROGNOSTIC VALUE; SIV INFECTION; RNA LEVELS; T-CELLS; I INTERFERON; SERUM-LEVELS	Manifestations of viral infections can differ between women and men(1), and marked sex differences have been described in the course of HIV-1 disease. HIV-1-infected women tend to have lower viral loads early in HIV-1 infection but progress faster to AIDS for a given viral load than men(2-7). Here we show substantial sex differences in the response of plasmacytoid dendritic cells (pDCs) to HIV-1. pDCs derived from women produce markedly more interferon-alpha (IFN-alpha) in response to HIV-1-encoded Toll-like receptor 7 (TLR7) ligands than pDCs derived from men, resulting in stronger secondary activation of CD8(+) T cells. In line with these in vitro studies, treatment-naive women chronically infected with HIV-1 had considerably higher levels of CD8(+) T cell activation than men after adjusting for viral load. These data show that sex differences in TLR-mediated activation of pDCs may account for higher immune activation in women compared to men at a given HIV-1 viral load and provide a mechanism by which the same level of viral replication might result in faster HIV-1 disease progression in women compared to men. Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HIV-1-associated pathology.	[Meier, Angela; Chang, J. Judy; Sidhu, Harlyn K.; Wen, Tom Fang; Lindsay, Robert J.; Bazner, Suzane; Streeck, Hendrik; Alter, Galit; Altfeld, Marcus] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA; [Chan, Ellen S.; Orellana, Liliana; Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Pollard, Richard B.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; [Kulkarni, Smita; Carrington, Mary] NCI, Canc & Inflammat Program, Expt Immunol Lab, Frederick, MD 21701 USA; [Lifson, Jeffrey D.] NCI, Sci Applicat Int Corp Frederick, AIDS & Canc Virus Program, Frederick, MD 21701 USA; [Mildvan, Donna] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA; [Bazner, Suzane; Robbins, Gregory K.; Altfeld, Marcus] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Altfeld, M (corresponding author), MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.	maltfeld@partners.org	Altfeld, Marcus/AAE-7306-2019; Robbins, Gregory/F-7988-2011; Orellana, Liliana/I-5249-2013	Altfeld, Marcus/0000-0001-5972-2997; Robbins, Gregory/0000-0001-7545-5817; Orellana, Liliana/0000-0003-3736-4337	US National Institutes of Health (NIH)-National Institute of Allergy Infectious Diseases [R21 AI071806, PO1 AI074415, K01AI062435]; Harvard University Center for AIDS Research; Bill & Melinda Gates Foundation; Doris Duke Charitable Foundation; German Research Society (Deutsche Forschungsgemeinschaft); National Health and Medical Research Council of Australia [519578]; National Institute of Allergy and Infectious Diseases [AI38855, AI27659, AI38858, AI25879, AI27666]; Agouron/Pfizer, Bristol Myers Squibb and GlaxoSmithKline; US National Cancer Institute (NCI), NIH [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC010791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI062435, U01AI038855, U01AI025879, U01AI027666, U01AI027659, R21AI071806, P01AI074415, U01AI038858] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)-National Institute of Allergy Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Harvard University Center for AIDS Research; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); German Research Society (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Agouron/Pfizer, Bristol Myers Squibb and GlaxoSmithKline(Pfizer); US National Cancer Institute (NCI), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank S. Deeks, P. Hunt, B. Walker and J. Spritzler for valuable intellectual input and discussions and the ACTG 384 main study and immunology A5007 substudy teams. These studies were supported by US National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases grants to M. A. (R21 AI071806, PO1 AI074415) and G. K. R. (K01AI062435), the Harvard University Center for AIDS Research, the Bill & Melinda Gates Foundation and the Doris Duke Charitable Foundation. A. M. was supported by a fellowship from the German Research Society (Deutsche Forschungsgemeinschaft), and J. J. C. was supported by a Fellowship awarded from the National Health and Medical Research Council of Australia (519578). ACTG 384 was supported in part by National Institute of Allergy and Infectious Diseases grants AI38855, AI27659, AI38858, AI25879 and AI27666 and by Agouron/Pfizer, Bristol Myers Squibb and GlaxoSmithKline. This project has been funded in whole or in part with federal funds from the US National Cancer Institute (NCI), NIH, under Contract number HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Support Program of the NIH, NCI, Center for Cancer Research. M. A. is a Distinguished Clinical Scientist of the Doris Duke Charitable Foundation. We thank the Mark and Lisa Schwartz Foundation and the Phillip T. and Susan M. Ragon Foundation for their support.	Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Boasso A, 2008, CLIN IMMUNOL, V126, P235, DOI 10.1016/j.clim.2007.08.015; Boasso A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002961; Chang JJ, 2009, BLOOD, V113, P269, DOI 10.1182/blood-2008-10-184598; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Deeks SG, 2004, J CLIN INVEST, V113, P808, DOI 10.1172/JCI200421318; Evans JS, 1997, J INFECT DIS, V175, P795, DOI 10.1086/513973; EYSTER ME, 1983, NEW ENGL J MED, V309, P583, DOI 10.1056/NEJM198309083091003; Fahey JL, 1998, AIDS, V12, P1581, DOI 10.1097/00002030-199813000-00004; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249; Gandhi RT, 2006, JAIDS-J ACQ IMM DEF, V42, P426, DOI 10.1097/01.qai.0000226789.51992.3f; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Guiducci C, 2009, J INTERN MED, V265, P43, DOI 10.1111/j.1365-2796.2008.02050.x; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Herbeuval JP, 2007, CLIN IMMUNOL, V123, P121, DOI 10.1016/j.clim.2006.09.016; Herbeuval JP, 2006, P NATL ACAD SCI USA, V103, P7000, DOI 10.1073/pnas.0600363103; Hughes GC, 2008, J IMMUNOL, V180, P2029, DOI 10.4049/jimmunol.180.4.2029; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Khatissian E, 1996, RES VIROLOGY, V147, P181, DOI 10.1016/0923-2516(96)80233-0; KROWN SE, 1991, J ACQ IMMUN DEF SYND, V4, P871; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Lyles CM, 1999, J INFECT DIS, V180, P1018, DOI 10.1086/314980; Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; MILDVAN D, 1992, LANCET, V339, P453, DOI 10.1016/0140-6736(92)91058-G; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Rodriguez B, 2006, AIDS, V20, P1379, DOI 10.1097/01.aids.0000233571.51899.ab; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034; Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400; Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967	39	394	399	2	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					955	U161		10.1038/nm.2004	http://dx.doi.org/10.1038/nm.2004			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19597505	Green Accepted			2022-12-27	WOS:000268770400042
J	Chang, J; Wang, Z; Tang, E; Fan, ZP; McCauley, L; Franceschi, R; Guan, KL; Krebsbach, PH; Wang, CY				Chang, Jia; Wang, Zhuo; Tang, Eric; Fan, Zhipeng; McCauley, Laurie; Franceschi, Renny; Guan, Kunliang; Krebsbach, Paul H.; Wang, Cun-Yu			Inhibition of osteoblastic bone formation by nuclear factor-kappa B	NATURE MEDICINE			English	Article							NEMO/IKK-GAMMA; ACTIVATION; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; DIFFERENTIATION; OSTEOPOROSIS; PATHWAY	An imbalance in bone formation relative to bone resorption results in the net bone loss that occurs in osteoporosis and inflammatory bone diseases. Although it is well known how bone resorption is stimulated, the molecular mechanisms that mediate impaired bone formation are poorly understood. Here we show that the time- and stage-specific inhibition of endogenous inhibitor of kappa B kinase (IKK)-nuclear factor-kappa B (NF-kappa B) in differentiated osteoblasts substantially increases trabecular bone mass and bone mineral density without affecting osteoclast activities in young mice. Moreover, inhibition of IKK-NF-kappa B in differentiated osteoblasts maintains bone formation, thereby preventing osteoporotic bone loss induced by ovariectomy in adult mice. Inhibition of IKK-NF-kappa B enhances the expression of Fos-related antigen-1 (Fra-1), an essential transcription factor involved in bone matrix formation in vitro and in vivo. Taken together, our results suggest that targeting IKK-NF-kappa B may help to promote bone formation in the treatment of osteoporosis and other bone diseases.	[Chang, Jia; Tang, Eric; Fan, Zhipeng; Wang, Cun-Yu] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Mol Signalling Lab, Los Angeles, CA 90024 USA; [Chang, Jia; Tang, Eric; Fan, Zhipeng; Wang, Cun-Yu] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Wang, Zhuo; Krebsbach, Paul H.] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; [McCauley, Laurie; Franceschi, Renny] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [McCauley, Laurie] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Guan, Kunliang] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; [Guan, Kunliang] Univ Calif San Diego, Ctr Comprehens Canc, San Diego, CA 92103 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, CY (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Mol Signalling Lab, Los Angeles, CA 90024 USA.	cwang@dentistry.ucla.edu	Guan, Kun-Liang/ADK-7088-2022; Krebsbach, Paul H./AAC-4765-2021; McCauley, Laurie/G-4041-2012		US National Institute of Dental and Craniofacial Research [DE17684, DE019412, DE1016513, DE13848, DE018890]; US National Institute of Diabetes and Kidney Disease [DK053904]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013848, R01DE016513, R01DE019412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017684, R01DE013848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053904] Funding Source: NIH RePORTER	US National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); US National Institute of Diabetes and Kidney Disease; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank J. Adams for valuable advice and G. Karsenty (Columbia University) for Col1a1 promoter and T. Gilmore (Boston University) for c-Rel vector. This work was supported by US National Institute of Dental and Craniofacial Research grants (DE17684, DE019412, DE1016513, DE13848 and DE018890) and US National Institute of Diabetes and Kidney Disease grants (DK053904).	Bilic-Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105-2896.2005.00334.x; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Harnish DC, 2006, CURR OPIN INVESTIG D, V7, P997; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009; Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Pearse RN, 2006, CLIN CANCER RES, V12, p6274S, DOI 10.1158/1078-0432.CCR-06-0648; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yang F, 2004, J IMMUNOL, V172, P2446, DOI 10.4049/jimmunol.172.4.2446; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593	35	344	376	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					682	U120		10.1038/nm.1954	http://dx.doi.org/10.1038/nm.1954			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19448637	Green Accepted			2022-12-27	WOS:000266731600028
J	Kessenbrock, K; Krumbholz, M; Schonermarck, U; Back, W; Gross, WL; Werb, Z; Grone, HJ; Brinkmann, V; Jenne, DE				Kessenbrock, Kai; Krumbholz, Markus; Schoenermarck, Ulf; Back, Walter; Gross, Wolfgang L.; Werb, Zena; Groene, Hermann-Josef; Brinkmann, Volker; Jenne, Dieter E.			Netting neutrophils in autoimmune small-vessel vasculitis	NATURE MEDICINE			English	Article							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; EXTRACELLULAR TRAPS; DNA; MYELOPEROXIDASE; CELLS	Small-vessel vasculitis (SVV) is a chronic autoinflammatory condition linked to antineutrophil cytoplasm autoantibodies (ANCAs). Here we show that chromatin fibers, so-called neutrophil extracellular traps (NETs), are released by ANCA-stimulated neutrophils and contain the targeted autoantigens proteinase-3 (PR3) and myeloperoxidase (MPO). Deposition of NETs in inflamed kidneys and circulating MPO-DNA complexes suggest that NET formation triggers vasculitis and promotes the autoimmune response against neutrophil components in individuals with SVV.	[Kessenbrock, Kai; Krumbholz, Markus; Jenne, Dieter E.] Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany; [Kessenbrock, Kai; Werb, Zena] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Krumbholz, Markus] Univ Munich, Inst Clin Neuroimmunol, Munich, Germany; [Schoenermarck, Ulf] Univ Hosp Grosshadern, Med Clin 1, Div Nephrol, Munich, Germany; [Back, Walter] Univ Heidelberg, Mannheim Clin, Dept Pathol, D-6800 Mannheim, Germany; [Gross, Wolfgang L.] Med Univ Lubeck, Univ Klinikum Schleswig Holstein, Vasculitis Ctr, Dept Rheumatol, D-23538 Lubeck, Germany; [Gross, Wolfgang L.] Rheumaklin Bad Bramstedt, Lubeck, Germany; [Groene, Hermann-Josef] German Canc Res Ctr, Dept Cellular & Mol Pathol, D-6900 Heidelberg, Germany; [Brinkmann, Volker] Max Planck Inst Infect Biol, Microscopy Core Facil, Berlin, Germany	Max Planck Society; University of California System; University of California San Francisco; University of Munich; University of Munich; Ruprecht Karls University Heidelberg; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society	Kessenbrock, K (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany.	kai.kessenbrock@ucsf.edu; djenne@neuro.mpg.de	Schönermarck, Ulf/AAE-6590-2020; Jenne, Dieter Erich/AAP-1414-2020; Gross, Wolfgang Ludwig WG/C-8733-2011; Brinkmann, Volker/A-6015-2009; Kessenbrock, Kai/B-6936-2011	Schonermarck, Ulf/0000-0002-3266-9791	Deutsche Forschungsgemeinschaft [SFB 571]; US National Institutes of Health [AI053194]; Susan G. Komen for the Cure Foundation; Alexander von Humboldt Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank W. Samtleben for providing serum samples, R. Bittner for technical assistance and E. Csernok and A. Kniepert for help with serum samples. Moreover, we are grateful to M. Sixt and E. Meinl for helpful suggestions and H. Wekerle for his constant interest and support of this work. We also thank M. Monestier (Temple University) for providing us with histone-specific monoclonal antibody and G. Koch (University of Freiburg) for the kind gift of the antibody specific for MxA. This work was funded by the Deutsche Forschungsgemeinschaft (SFB 571). It was further supported by the US National Institutes of Health (AI053194) and by fellowships from the Susan G. Komen for the Cure Foundation and the Alexander von Humboldt Foundation.	Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Harper L, 2000, AM J PATHOL, V157, P211, DOI 10.1016/S0002-9440(10)64532-4; Holdenrieder S, 2006, ANN NY ACAD SCI, V1075, P318, DOI 10.1196/annals.1368.043; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; Kallenberg CGM, 2006, NAT CLIN PRACT RHEUM, V2, P661, DOI 10.1038/ncprheum0355; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; MURAO S, 1988, P NATL ACAD SCI USA, V85, P1232, DOI 10.1073/pnas.85.4.1232; Pfister H, 2004, BLOOD, V104, P1411, DOI 10.1182/blood-2004-01-0267; Wenzel J, 2005, J PATHOL, V205, P435, DOI 10.1002/path.1721; Woltman AM, 2007, KIDNEY INT, V71, P1001, DOI 10.1038/sj.ki.5002187; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	16	1079	1149	2	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2009	15	6					623	625		10.1038/nm.1959	http://dx.doi.org/10.1038/nm.1959			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19448636	Green Accepted			2022-12-27	WOS:000266731600020
J	Strauss, JF; De Paolo, LV				Strauss, Jerome F., III; De Paolo, Louis V.			Funding for the reproductive sciences in the US	NATURE MEDICINE			English	Editorial Material							ANIMAL REPRODUCTION; AGRICULTURE; TECHNOLOGY; PRIORITIES; BIOLOGY		[Strauss, Jerome F., III] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23298 USA; [De Paolo, Louis V.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strauss, JF (corresponding author), Virginia Commonwealth Univ, Sch Med, 1101 E Marshall St, Richmond, VA 23298 USA.	jfstrauss@vcu.edu						[Anonymous], 1996, CONTRACEPTIVE RES DE; Behrman RE, 2007, PRETERM BIRTH CAUSES; Clarke Adele, 1998, DISCIPLINING REPRODU; Ireland JJ, 2008, J ANIM SCI, V86, P2797, DOI 10.2527/jas.2008-1088; Longo LD, 2008, AM J OBSTET GYNECOL, V198, P489, DOI 10.1016/j.ajog.2008.02.032; Makinson C, 1999, INT J GYNECOL OBSTET, V67, pS101, DOI 10.1016/S0020-7292(99)00153-8; Mirando MA, 2007, J ANIM SCI, V85, pE11, DOI 10.2527/jas.2006-506; Mirando MA, 2006, BIOL REPROD, V74, P459, DOI 10.1095/biolreprod.105.048686; NASS S, 2004, NEW FRONTIERS CONTRA; Pion GA, 2006, BIOL REPROD, V74, P230, DOI 10.1095/biolreprod.105.045427; Population Reference Bureau, 2008, WORLD POP DAT SHEET; Romundstad LB, 2008, LANCET, V372, P737, DOI 10.1016/S0140-6736(08)61041-7; Strauss JF, 2007, FERTIL STERIL, V87, P717, DOI 10.1016/j.fertnstert.2006.11.003; Strauss JF, 2004, NATURE, V432, P43, DOI 10.1038/432043a; Townsend J, 1992, STRENGTHENING RES AC	15	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11		S			1214	1217		10.1038/nm1108-1214	http://dx.doi.org/10.1038/nm1108-1214			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	397FU	18989308				2022-12-27	WOS:000262649100032
J	Banaszynski, LA; Sellmyer, MA; Contag, CH; Wandless, TJ; Thorne, SH				Banaszynski, Laura A.; Sellmyer, Mark A.; Contag, Christopher H.; Wandless, Thomas J.; Thorne, Steve H.			Chemical control of protein stability and function in living mice	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; MAMMALIAN PROTEIN; GENE-EXPRESSION; SMALL MOLECULES; STEM-CELLS; MUTATION; DEFECTS	Conditional control of protein function in vivo offers great potential for deconvoluting the roles of individual proteins in complicated systems. We recently developed a method in which a small protein domain, termed a destabilizing domain, confers instability to fusion protein partners in cultured cells. Instability is reversed when a cell-permeable small molecule binds this domain. Here we describe the use of this system to regulate protein function in living mammals. We show regulation of secreted proteins and their biological activity with conditional secretion of an immunomodulatory cytokine, resulting in tumor burden reduction in mouse models. Additionally, we use this approach to control the function of a specific protein after systemic delivery of the gene that encodes it to a tumor, suggesting uses for enhancing the specificity and efficacy of targeted gene-based therapies. This method represents a new strategy to regulate protein function in living organisms with a high level of control.	[Sellmyer, Mark A.; Contag, Christopher H.; Thorne, Steve H.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Sellmyer, Mark A.; Contag, Christopher H.; Thorne, Steve H.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; [Sellmyer, Mark A.; Contag, Christopher H.; Thorne, Steve H.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Banaszynski, Laura A.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA; [Sellmyer, Mark A.; Wandless, Thomas J.] Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Contag, CH (corresponding author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.	ccontag@stanford.edu; wandless@stanford.edu	Banaszynski, Laura/B-9612-2009	Contag, Christopher/0000-0002-1011-8278; Sellmyer, Mark/0000-0002-1407-1905	US National Institutes of Health; In vivo Cellular and Molecular Imaging Center [R24 CA92862, P50 CA114747, GM073046]; joint A. and Cynthia Fry Gunn Research Fund; US National Institutes of Health [pSC-65, VSC20]; NATIONAL CANCER INSTITUTE [P50CA114747, R24CA092862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073046] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); In vivo Cellular and Molecular Imaging Center; joint A. and Cynthia Fry Gunn Research Fund; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was Supported by the US National Institutes of Health, through the Small Animal Imaging Resource Program, the In vivo Cellular and Molecular Imaging Center (grant numbers R24 CA92862 and P50 CA114747) and GM073046, and the joint A. and Cynthia Fry Gunn Research Fund. We thank T. Clackson for the Shield-1 formulation protocol and B. Moss (US National Institutes of Health) for pSC-65 and VSC20.	Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006; Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu KJ, 2007, NATURE, V446, P79, DOI 10.1038/nature05557; Lode HN, 2000, IMMUNOL RES, V21, P279, DOI 10.1385/IR:21:2-3:279; Lucas R, 2005, CURR CANCER DRUG TAR, V5, P381, DOI 10.2174/1568009054863627; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Maynard-Smith LA, 2007, J BIOL CHEM, V282, P24866, DOI 10.1074/jbc.M703902200; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; POIRIER F, 1993, DEVELOPMENT, V119, P1229; Ryding ADS, 2001, J ENDOCRINOL, V171, P1, DOI 10.1677/joe.0.1710001; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schreiber SL, 2003, CHEM ENG NEWS, V81, P51, DOI 10.1021/cen-v081n009.p051; Stankunas K, 2003, MOL CELL, V12, P1615, DOI 10.1016/S1097-2765(03)00491-X; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Thorne SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JCI32727; Tisi LC, 2002, ANAL CHIM ACTA, V457, P115, DOI 10.1016/S0003-2670(01)01496-9; YAMADA G, 1995, DEVELOPMENT, V121, P2917	30	102	126	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1123	1127		10.1038/nm.1754	http://dx.doi.org/10.1038/nm.1754			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18836461	Green Accepted			2022-12-27	WOS:000259892300044
J	Honma, K; Iwao-Koizumi, K; Takeshita, F; Yamamoto, Y; Yoshida, T; Nishio, K; Nagahara, S; Kato, K; Ochiya, T				Honma, Kimi; Iwao-Koizumi, Kyoko; Takeshita, Fumitaka; Yamamoto, Yusuke; Yoshida, Teruhiko; Nishio, Kazuto; Nagahara, Shunji; Kato, Kikuya; Ochiya, Takahiro			RPN2 gene confers docetaxel resistance in breast cancer	NATURE MEDICINE			English	Article							SMALL INTERFERING RNA; MDR1 P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; IN-VIVO; BCL-XL; CELL-DEATH; KAPPA-B; EXPRESSION; APOPTOSIS	Drug resistance acquired by cancer cells has led to treatment failure. To understand the regulatory network underlying docetaxel resistance in breast cancer cells and to identify molecular targets for therapy, we tested small interfering RNAs (siRNAs) against 36 genes whose expression was elevated in human nonresponders to docetaxel for the ability to promote apoptosis of docetaxel-resistant human breast cancer cells (MCF7-ADR cells). The results indicate that the downregulation of the gene encoding ribopholin II (RPN2), which is part of an N-oligosaccharyl transferase complex, most efficiently induces apoptosis of MCF7-ADR cells in the presence of docetaxel. RPN2 silencing induced reduced glycosylation of the P-glycoprotein, as well as decreased membrane localization, thereby sensitizing MCF7-ADR cells to docetaxel. Moreover, in vivo delivery of siRNA specific for RPN2 markedly reduced tumor growth in two types of models for drug resistance. Thus, RPN2 silencing makes cancer cells hypersensitive response to docetaxel, and RPN2 might be a new target for RNA interference-based therapeutics against drug resistance.	[Honma, Kimi; Takeshita, Fumitaka; Yamamoto, Yusuke; Ochiya, Takahiro] Japanese Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, Tokyo 1040045, Japan; [Honma, Kimi] KOKEN, Koken Biosci Inst, Kita Ku, Tokyo 1150051, Japan; [Iwao-Koizumi, Kyoko; Kato, Kikuya] Osaka Med Ctr Canc & Cardiovasc Dis, Res Inst, Higashinari Ku, Osaka 5378511, Japan; [Yoshida, Teruhiko] Japanese Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; [Nishio, Kazuto] Japanese Natl Canc Ctr, Res Inst, Div Pharmaceut, Tokyo 1040045, Japan; [Nagahara, Shunji] Dainippon Sumitomo Pharma, Osaka 5670878, Japan	National Cancer Center - Japan; Osaka Medical Center for Cancer & Cardiovascular Diseases; National Cancer Center - Japan; National Cancer Center - Japan	Ochiya, T (corresponding author), Japanese Natl Canc Ctr, Res Inst, Sect Studies Metastasis, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.	tochiya@ncc.go.jp	Ochiya, Takahiro/AAH-7585-2019; Masumi, Kyoko/M-7025-2016	Masumi, Kyoko/0000-0002-0184-9853	Japanese Ministry of Education, Culture, Sports, Science and Technology; National Institute of Biomedical Innovation of Japan	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation of Japan(National Institute of Biomedical Innovation)	Human mammary carcinoma cell lines, MCF7 cells and multidrug-resistant MCF7-ADR cells were provided by Shien-Lab, Medical Oncology, National Cancer Center Hospital of Japan. We gratefully thank S. Noguchi for the initiation of the whole project and for helpful discussion. We also thank H. Inaji, K. Yoshioka and K. Itoh for their kind assistance; J. Miyazaki (Osaka University) for the kind gift of CAG promoter; and A. Inoue and M. Wada for their excellent technical work. This work was supported in part by a grant-in-aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control of Japan; a grant-in-aid for Scientific Research on Priority Areas Cancer from the Japanese Ministry of Education, Culture, Sports, Science and Technology; and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan.	Bentley J, 1997, CANCER LETT, V115, P221, DOI 10.1016/S0304-3835(97)04739-3; Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4; Burg D, 2006, BIOCHEM PHARMACOL, V71, P268, DOI 10.1016/j.bcp.2005.11.003; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; Crown J, 2004, ONCOLOGIST, V9, P24, DOI 10.1634/theoncologist.9-suppl_2-24; Duan ZF, 2004, MOL CANCER THER, V3, P833; Engels FK, 2005, BRIT J CANCER, V93, P173, DOI 10.1038/sj.bjc.6602698; Formenti SC, 2003, J CLIN ONCOL, V21, P864, DOI 10.1200/JCO.2003.06.132; Galimberti S, 2003, J CHEMOTHERAPY, V15, P374, DOI 10.1179/joc.2003.15.4.374; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Gradishar WJ, 2005, ANN ONCOL, V16, P1297, DOI 10.1093/annonc/mdi254; Guensberg P, 2002, CHEMOTHERAPY, V48, P189, DOI 10.1159/000063873; Honma K, 2001, BIOCHEM BIOPH RES CO, V289, P1075, DOI 10.1006/bbrc.2001.6133; Honma Kimi, 2004, Curr Drug Discov Technol, V1, P287, DOI 10.2174/1570163043334839; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; Jones SE, 2005, J CLIN ONCOL, V23, P5542, DOI 10.1200/JCO.2005.02.027; Kato K, 1997, NUCLEIC ACIDS RES, V25, P4694, DOI 10.1093/nar/25.22.4694; Kaufmann M, 2003, J CLIN ONCOL, V21, P2600, DOI 10.1200/JCO.2003.01.136; Kelleher DJ, 2006, GLYCOBIOLOGY, V16, p47R, DOI 10.1093/glycob/cwj066; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; KRAMER R, 1995, BRIT J CANCER, V71, P670, DOI 10.1038/bjc.1995.133; Leonessa F, 2003, ENDOCR-RELAT CANCER, V10, P43, DOI 10.1677/erc.0.0100043; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604; Lin JC, 2005, ONCOL REP, V13, P983; Loo TW, 2005, J BIOL CHEM, V280, P2522, DOI 10.1074/jbc.M411483200; Lytle RA, 2004, J NEURO-ONCOL, V68, P233, DOI 10.1023/B:NEON.0000033382.40601.5a; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; MULLER C, 1995, J CELL PHYSIOL, V163, P538, DOI 10.1002/jcp.1041630314; Nieth C, 2003, FEBS LETT, V545, P144, DOI 10.1016/S0014-5793(03)00523-4; O'Brian CA, 2001, CANCER METAST REV, V20, P95, DOI 10.1023/A:1013186430906; Ochiya T, 1999, NAT MED, V5, P707, DOI 10.1038/9560; Ochiya T, 2007, EXPERT OPIN DRUG DIS, V2, P159, DOI 10.1517/17460441.2.2.159; Ochiya Takahiro, 2001, Current Gene Therapy, V1, P31, DOI 10.2174/1566523013348887; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; VERGNIOL JC, 1992, J CHROMATOGR-BIOMED, V582, P273, DOI 10.1016/0378-4347(92)80333-L; Walczak H, 2000, CANCER RES, V60, P3051; Wu H, 2003, CANCER RES, V63, P1515; Zhan MC, 2005, J BIOL CHEM, V280, P4825, DOI 10.1074/jbc.M407450200; Zhang ZG, 2004, MOL PHARMACOL, V66, P395, DOI 10.1124/mol.104.001966	50	120	126	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2008	14	9					939	948		10.1038/nm.1858	http://dx.doi.org/10.1038/nm.1858			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18724378				2022-12-27	WOS:000258988600026
J	Vandal, OH; Pierini, LM; Schnappinger, D; Nathan, CF; Ehrt, S				Vandal, Omar H.; Pierini, Lynda M.; Schnappinger, Dirk; Nathan, Carl F.; Ehrt, Sabine			A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; INTERFERON-GAMMA; PHAGOSOME MATURATION; CULTURED MACROPHAGES; MURINE MACROPHAGES; MOUSE MACROPHAGES; GENE-EXPRESSION; IDENTIFICATION; ACIDIFICATION; MUTANTS	Acidification of the phagosome is considered to be a major mechanism used by macrophages against bacteria, including Mycobacterium tuberculosis (Mtb). Mtb blocks phagosome acidification(1), but interferon-g (IFN-g) restores acidification and confers antimycobacterial activity2,3. Nonetheless, it remains unclear whether acid kills Mtb, whether the intrabacterial pH of any pathogen falls when it is in the phagosome and whether acid resistance is required for mycobacterial virulence. In vitro at pH 4.5, Mtb survived in a simple buffer and maintained intrabacterial pH. Therefore, Mtb resists phagolysosomal concentrations of acid. Mtb also maintained its intrabacterial pH and survived when phagocytosed by IFN-gamma-activated macrophages. We used transposon mutagenesis to identify genes responsible for Mtb's acid resistance. A strain disrupted in Rv3671c, a previously uncharacterized gene encoding a membrane-associated protein, was sensitive to acid and failed to maintain intrabacterial pH in acid in vitro and in activated macrophages. Growth of the mutant was also severely attenuated in mice. Thus, Mtb is able to resist acid, owing in large part to Rv3671c, and this resistance is essential for virulence. Disruption of Mtb's acid resistance and intrabacterial pH maintenance systems is an attractive target for chemotherapy.	[Vandal, Omar H.; Pierini, Lynda M.; Schnappinger, Dirk; Nathan, Carl F.; Ehrt, Sabine] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA; [Pierini, Lynda M.] Weill Cornell Med Coll, Dept Biochem, New York, NY 10065 USA	Cornell University; Cornell University	Nathan, CF (corresponding author), Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA.	cnathan@med.cornell.edu; sae2004@med.cornell.edu	Ehrt, Sabine/AAU-6449-2020		NIAID NIH HHS [P01 AI056293-04, P01 AI056293, P01 AI056293-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056293] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; DUBOS RJ, 1947, J EXP MED, V85, P9, DOI 10.1084/jem.85.1.9; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Gomes MS, 1999, INFECT IMMUN, V67, P3199, DOI 10.1128/IAI.67.7.3199-3206.1999; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Huynh KK, 2007, MICROBIOL MOL BIOL R, V71, P452, DOI 10.1128/MMBR.00003-07; KANAI K, 1979, JPN J MED SCI BIOL, V32, P135, DOI 10.7883/yoken1952.32.135; MacGurn JA, 2007, INFECT IMMUN, V75, P2668, DOI 10.1128/IAI.01872-06; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Metchnikoff E., 1905, IMMUNITY INFECT DIS; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MohamedMohaideen NN, 2008, BIOCHEMISTRY-US, V47, P6092, DOI 10.1021/bi701929m; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; NATHAN CF, 1986, NEW ENGL J MED, V315, P6, DOI 10.1056/NEJM198607033150102; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Pethe K, 2004, P NATL ACAD SCI USA, V101, P13642, DOI 10.1073/pnas.0401657101; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Rohde KH, 2007, CELL HOST MICROBE, V2, P352, DOI 10.1016/j.chom.2007.09.006; Rose L, 2004, MICROBES INFECT, V6, P965, DOI 10.1016/j.micinf.2004.05.011; Schaible UE, 1998, J IMMUNOL, V160, P1290; SIBLEY LD, 1987, INFECT IMMUN, V55, P680, DOI 10.1128/IAI.55.3.680-685.1987; Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Vandal OH, 2006, INFECT IMMUN, V74, P1751, DOI 10.1128/IAI.74.3.1751-1756.2006; Via LE, 1998, J CELL SCI, V111, P897; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	40	231	237	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					849	854		10.1038/nm.1795	http://dx.doi.org/10.1038/nm.1795			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18641659	Green Accepted			2022-12-27	WOS:000258237500032
J	Faghihi, MA; Modarresi, F; Khalil, AM; Wood, DE; Sahagan, BG; Morgan, TE; Finch, CE; Laurent, GS; Kenny, PJ; Wahlestedt, C				Faghihi, Mohammad Ali; Modarresi, Farzaneh; Khalil, Ahmad M.; Wood, Douglas E.; Sahagan, Barbara G.; Morgan, Todd E.; Finch, Caleb E.; Laurent, Georges St., III; Kenny, Paul J.; Wahlestedt, Claes			Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase	NATURE MEDICINE			English	Article							AMYLOID PRECURSOR PROTEIN; BACE1 GENE-EXPRESSION; A-BETA; OXIDATIVE STRESS; TRANSGENIC MICE; MITOCHONDRIAL DYSFUNCTION; NEUROLOGICAL DISORDERS; SYNAPTIC PLASTICITY; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM	Recent efforts have revealed that numerous protein-coding messenger RNAs have natural antisense transcript partners, most of which seem to be noncoding RNAs. Here we identify a conserved noncoding antisense transcript for beta-secretase-1 (BACE1), a crucial enzyme in Alzheimer's disease pathophysiology. The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo. Upon exposure to various cell stressors including amyloid-beta 1-42 (A beta 1-42), expression of BACE1-AS becomes elevated, increasing BACE1 mRNA stability and generating additional A beta 1-42 through a post-transcriptional feed-forward mechanism. BACE1-AS concentrations were elevated in subjects with Alzheimer's disease and in amyloid precursor protein transgenic mice. These data show that BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease-associated pathophysiology. In summary, we report that a long noncoding RNA is directly implicated in the increased abundance of A beta 1-42 in Alzheimer's disease.	[Faghihi, Mohammad Ali; Modarresi, Farzaneh; Khalil, Ahmad M.; Wahlestedt, Claes] Scripps Res Inst, Mol & Integrat Neurosci Dept, Jupiter, FL 33458 USA; [Faghihi, Mohammad Ali] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden; [Wood, Douglas E.; Sahagan, Barbara G.] Pfizer Inc, Global Res & Dev, Cent Nervous Syst Discovery, Groton, CT 06340 USA; [Morgan, Todd E.; Finch, Caleb E.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA; [Laurent, Georges St., III] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Laurent, Georges St., III] Univ Antiquia, Immunovirol Biogenesis Grp, Medellin 1226, Colombia; [Kenny, Paul J.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL 33458 USA	Scripps Research Institute; Karolinska Institutet; Pfizer; University of Southern California; George Washington University; Universidad de Antioquia; Scripps Research Institute	Wahlestedt, C (corresponding author), Scripps Res Inst, Mol & Integrat Neurosci Dept, 5353 Parkside Dr, Jupiter, FL 33458 USA.	clawah@scripps.edu	Finch, Caleb/AAA-7250-2022; Wahlestedt, Claes/A-7039-2009; Faghihi, Mohammad Ali/AAH-3139-2019; Faghihi, Mohammad Ali/AAD-7159-2020	Faghihi, Mohammad Ali/0000-0002-8330-9067	NIA NIH HHS [R21 AG029290-02, R21 AG029290, AG 029290] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R21AG029290] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Borghi R, 2007, NEUROBIOL AGING, V28, P1009, DOI 10.1016/j.neurobiolaging.2006.05.004; Brooks WM, 2007, BRAIN RES, V1127, P127, DOI 10.1016/j.brainres.2006.09.106; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Emilsson L, 2006, NEUROBIOL DIS, V21, P618, DOI 10.1016/j.nbd.2005.09.004; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Esposito G, 2006, NEUROSCI LETT, V404, P342, DOI 10.1016/j.neulet.2006.06.012; Faghihi MA, 2004, EXPERT REV MOL DIAGN, V4, P317, DOI 10.1586/14737159.4.3.317; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Harkany T, 2000, REV NEUROSCIENCE, V11, P329; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Holsinger RMD, 2004, ANN NEUROL, V55, P898, DOI 10.1002/ana.20144; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Johnston JA, 2005, BIOCHEM SOC T, V33, P1096, DOI 10.1042/BST0331096; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Laurent GS, 2007, TRENDS NEUROSCI, V30, P612, DOI 10.1016/j.tins.2007.10.002; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Li Y, 2006, FASEB J, V20, P285, DOI 10.1096/fj.05-4986com; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Ma HF, 2007, P NATL ACAD SCI USA, V104, P8167, DOI 10.1073/pnas.0609521104; Matsuyama S, 2007, NEUROREPORT, V18, P1083, DOI 10.1097/WNR.0b013e3281e72b18; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Monaco S, 2006, CURR MED CHEM, V13, P1903, DOI 10.2174/092986706777585022; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653; Rossner S, 2006, PROG NEUROBIOL, V79, P95, DOI 10.1016/j.pneurobio.2006.06.001; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Su Y, 2003, FEBS LETT, V546, P407, DOI 10.1016/S0014-5793(03)00645-8; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Tamagno E, 2006, FREE RADICAL BIO MED, V41, P202, DOI 10.1016/j.freeradbiomed.2006.01.021; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Thakker DR, 2006, PHARMACOL THERAPEUT, V109, P413, DOI 10.1016/j.pharmthera.2005.08.006; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Walsh DM, 2005, BIOCHEM SOC T, V33, P1087, DOI 10.1042/BST0331087; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Yatin SM, 1998, J MOL NEUROSCI, V11, P183, DOI 10.1385/JMN:11:3:183; Zhao J, 2007, J NEUROSCI, V27, P3639, DOI 10.1523/JNEUROSCI.4396-06.2007; Zhong ZY, 2007, ARCH GEN PSYCHIAT, V64, P718, DOI 10.1001/archpsyc.64.6.718; Zhu DH, 2006, J NEUROSCI, V26, P11111, DOI 10.1523/JNEUROSCI.3505-06.2006	50	1027	1107	3	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2008	14	7					723	730		10.1038/nm1784	http://dx.doi.org/10.1038/nm1784			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18587408	Green Accepted			2022-12-27	WOS:000257452700019
J	Town, T; Laouar, Y; Pittenger, C; Mori, T; Szekely, CA; Tan, J; Duman, RS; Flavell, RA				Town, Terrence; Laouar, Yasmina; Pittenger, Christopher; Mori, Takashi; Szekely, Christine A.; Tan, Jun; Duman, Ronald S.; Flavell, Richard A.			Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology	NATURE MEDICINE			English	Article							AMYLOID-PRECURSOR-PROTEIN; TRANSGENIC MOUSE MODEL; A-BETA; DISEASE; MICE; BRAIN; MICROGLIA; BURDEN; PROGRESSION; DEFICIENCY	Alzheimer's disease is the most common dementia and is pathologically characterized by deposition of amyloid-beta peptide (A beta) into beta-amyloid plaques, neuronal injury and low-level, chronic activation of brain immunity(1). Transforming growth factor-beta s (TGF-beta s) are pleiotropic cytokines that have key roles in immune cell activation, inflammation and repair after injury(2). We genetically interrupted TGF-beta and downstream Smad2/3 signaling (TGF-beta-Smad2/3) in innate immune cells by inducing expression of CD11c promoter-driven dominant-negative TGF-beta receptor type II in C57BL/6 mice (CD11c-DNR)(3), crossed these mice with mice overexpressing mutant human amyloid precursor protein, the Tg2576 Alzheimer's disease mouse model(4), and evaluated Alzheimer's disease-like pathology. Aged double-transgenic mice showed complete mitigation of Tg2576-associated hyperactivity and partial mitigation of defective spatial working memory. Brain parenchymal and cerebrovascular beta-amyloid deposits and A beta abundance were markedly (up to 90%) attenuated in Tg2576-CD11c-DNR mice. This was associated with increased infiltration of A beta-containing peripheral macrophages around cerebral vessels and beta-amyloid plaques. In vitro, cultures of peripheral macrophages, but not microglia, from CD11c-DNR mice showed blockade of classical TGF-beta activated Smad2/3 but also showed hyperactivation of alternative bone morphogenic protein-activated Smad1/5/8 signaling and increased A beta phagocytosis. Similar effects were noted after pharmacological inhibition of activin-like kinase-5, a type I TGF-beta receptor. Taken together, our results suggest that blockade of TGF-beta-Smad2/3 signaling in peripheral macrophages represents a new therapeutic target for Alzheimer's disease.	[Town, Terrence; Laouar, Yasmina; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Town, Terrence] Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Dept Biomed Sci & Neurosurg, Los Angeles, CA 90048 USA; [Pittenger, Christopher; Duman, Ronald S.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; [Mori, Takashi] Saitama Med Univ, Saitama Med Ctr, Inst Med Sci, Kawagoe, Saitama 3508550, Japan; [Szekely, Christine A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Szekely, Christine A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Tan, Jun] Univ S Florida, Coll Med, Dept Psychiat & Behav Med, Silver Child Dev Ctr,Rashid Lab Dev Neurobiol, Tampa, FL 33612 USA; [Duman, Ronald S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06508 USA; [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Cedars Sinai Medical Center; Yale University; Saitama Medical University; Cedars Sinai Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; State University System of Florida; University of South Florida; Yale University; Howard Hughes Medical Institute; Yale University	Town, T (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 300 Cedar St, New Haven, CT 06520 USA.	terrence.town@cshs.org; richard.flavell@yale.edu	Pittenger, Christopher/G-8402-2012; Tan, Jun/I-5339-2012	Pittenger, Christopher/0000-0003-2117-9321	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K99AG029726, R00AG029726] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIA NIH HHS [K99 AG029726-01, R00 AG029726, 4R00AG029726, R00 AG029726-02, K99 AG029726, 1K99AG029726] Funding Source: Medline; NINDS NIH HHS [R01 NS048335] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Ellis RJ, 1996, NEUROLOGY, V46, P1592, DOI 10.1212/WNL.46.6.1592; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; King DL, 1999, BEHAV BRAIN RES, V103, P145, DOI 10.1016/S0166-4328(99)00037-6; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Lemere CA, 2000, ANN NY ACAD SCI, V920, P328; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Robbins EM, 2006, J NEUROSCI, V26, P365, DOI 10.1523/JNEUROSCI.3854-05.2006; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Stalder AK, 2005, J NEUROSCI, V25, P11125, DOI 10.1523/JNEUROSCI.2545-05.2005; Tan J, 2002, NAT NEUROSCI, V5, P1288, DOI 10.1038/nn968; Tesseur I, 2006, J CLIN INVEST, V116, P3060, DOI 10.1172/JCI27341; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; WISNIEWSKI HM, 1989, CAN J NEUROL SCI, V16, P535, DOI 10.1017/S0317167100029887; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321	30	353	363	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					681	687		10.1038/nm1781	http://dx.doi.org/10.1038/nm1781			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18516051	Green Accepted			2022-12-27	WOS:000256468700035
J	Lasaro, MO; Tatsis, N; Hensley, SE; Whitbeck, JC; Lin, SW; Rux, JJ; Wherry, EJ; Cohen, GH; Eisenberg, RJ; Ertl, HC				Lasaro, Marcio O.; Tatsis, Nia; Hensley, Scott E.; Whitbeck, J. Charles; Lin, Shih-Wen; Rux, John J.; Wherry, E. John; Cohen, Gary H.; Eisenberg, Roselyn J.; Ertl, Hildegund C.			Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses	NATURE MEDICINE			English	Article							VIRUS GLYCOPROTEIN-D; T-CELL-ACTIVATION; SIMPLEX VIRUS-1; B-LYMPHOCYTE; CRYSTAL-STRUCTURE; RECEPTOR; EXPRESSION; HVEM; GD; SUPERFAMILY	Interactions between the herpesvirus entry mediator (HVEM) and the B- and T-lymphocyte attenuator (BTLA) inhibit B and T cell activation. HVEM-BTLA interactions are blocked by herpes simplex virus (HSV) glycoprotein D (gD) through binding of its N-terminal domain to the BTLA binding site of HVEM. In this study, we inserted viral antigens into the C-terminal domain of gD and expressed these antigens with plasmid or E1-deleted (replication-defective) adenovirus vectors. Viral antigens fused to gD induced T and B cell responses to the antigen that were far more potent than those elicited by the same antigen expressed without gD. The immunopotentiating effect required binding of the gD chimeric protein to HVEM. Overall, the studies demonstrate that targeting of antigen to the BTLA binding site of HVEM augments the immunogenicity of vaccines.	[Lasaro, Marcio O.; Tatsis, Nia; Hensley, Scott E.; Lin, Shih-Wen; Rux, John J.; Wherry, E. John; Ertl, Hildegund C.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Lin, Shih-Wen] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Whitbeck, J. Charles; Eisenberg, Roselyn J.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; [Whitbeck, J. Charles; Cohen, Gary H.; Eisenberg, Roselyn J.] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ertl, HC (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	ertl@wistar.org	Wherry, John/ABI-1280-2020		NCI NIH HHS [R01 CA077523, CA10815, P30 CA010815] Funding Source: Medline; NIAID NIH HHS [R37 AI018289, P01 AI052271, AI-18289, R01 AI018289, AI-052271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA077523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018289, R37AI018289, P01AI052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bender FC, 2003, J VIROL, V77, P9542, DOI 10.1128/JVI.77.17.9542-9552.2003; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Cheung TC, 2005, P NATL ACAD SCI USA, V102, P13218, DOI 10.1073/pnas.0506172102; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; Compaan DM, 2005, J BIOL CHEM, V280, P39553, DOI 10.1074/jbc.M507629200; Connolly SA, 2003, J VIROL, V77, P8127, DOI 10.1128/JVI.77.14.8127-8140.2003; Fitzgerald JC, 2003, J IMMUNOL, V170, P1416, DOI 10.4049/jimmunol.170.3.1416; FRIEDMAN HM, 1984, NATURE, V309, P633, DOI 10.1038/309633a0; Granger SW, 2003, CYTOKINE GROWTH F R, V14, P289, DOI 10.1016/S1359-6101(03)00031-5; Han P, 2004, J IMMUNOL, V172, P5931, DOI 10.4049/jimmunol.172.10.5931; He Z, 2000, VIROLOGY, V270, P146, DOI 10.1006/viro.2000.0271; Hensley SE, 2005, J IMMUNOL, V175, P6032, DOI 10.4049/jimmunol.175.9.6032; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; Howard BR, 2003, NAT STRUCT BIOL, V10, P475, DOI 10.1038/nsb927; Hurchla MA, 2005, J IMMUNOL, V174, P3377, DOI 10.4049/jimmunol.174.6.3377; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Kresge Kristen Jill, 2005, IAVI Rep, V9, P18; Krieg C, 2007, NAT IMMUNOL, V8, P162, DOI 10.1038/ni1418; Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875; Lasaro MO, 2005, MICROBES INFECT, V7, P1541, DOI 10.1016/j.micinf.2005.05.024; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lin KY, 1996, CANCER RES, V56, P21; Monaco-Malbet S, 2000, STRUCTURE, V8, P1069, DOI 10.1016/S0969-2126(00)00507-4; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; Sarrias MR, 2000, MOL IMMUNOL, V37, P665, DOI 10.1016/S0161-5890(00)00089-4; Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997	30	50	55	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					205	212		10.1038/nm1704	http://dx.doi.org/10.1038/nm1704			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18193057	Green Accepted			2022-12-27	WOS:000252946700031
J	Katsnelson, A				Katsnelson, Alla			Substandard drugs overshadowed by focus on fakes	NATURE MEDICINE			English	News Item																			0	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					364	364		10.1038/nm0410-364b	http://dx.doi.org/10.1038/nm0410-364b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376033	Bronze			2022-12-27	WOS:000276446800026
J	Desgrosellier, JS; Barnes, LA; Shields, DJ; Huang, M; Lau, SK; Prevost, N; Tarin, D; Shattil, SJ; Cheresh, DA				Desgrosellier, Jay S.; Barnes, Leo A.; Shields, David J.; Huang, Miller; Lau, Steven K.; Prevost, Nicolas; Tarin, David; Shattil, Sanford J.; Cheresh, David A.			An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression	NATURE MEDICINE			English	Article							FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION SITES; HUMAN BREAST-CANCER; CELL-MIGRATION; EXTRACELLULAR-MATRIX; HUMAN-MELANOMA; C-SRC; METASTASIS; SURVIVAL; ALPHA-V-BETA-3	Integrins regulate adhesion-dependent growth, survival and invasion of tumor cells. In particular, expression of integrin alpha(v)beta(3) is associated with progression of a variety of human tumors. Here we reveal a previously undescribed adhesion-independent role for integrin alpha(v)beta(3) in pancreatic cancer and other carcinomas. Specifically, alpha(v)beta(3) expressed in carcinoma cells enhanced anchorage-independent tumor growth in vitro and increased lymph node metastases in vivo. These effects required recruitment of c-Src to the beta(3) integrin cytoplasmic tail, leading to c-Src activation, Crk-associated substrate (CAS) phosphorylation and tumor cell survival that, unexpectedly, was independent of cell adhesion or focal adhesion kinase (FAK) activation. Pharmacological blockade of c-Src kinase activity or decreased expression of endogenous alpha(v)beta(3) integrin or c-Src not only inhibited anchorage-independent growth but also suppressed metastasis in vivo, yet these manipulations did not affect tumor cell migration or invasion. These data define an unexpected role for an integrin as a mediator of anchorage independence, suggesting that an alpha(v)beta(3)-c-Src signaling module may account for the aggressive behavior of integrin alpha(v)beta(3)-expressing tumors in humans.	[Desgrosellier, Jay S.; Barnes, Leo A.; Shields, David J.; Huang, Miller; Lau, Steven K.; Tarin, David; Cheresh, David A.] Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA USA; [Prevost, Nicolas; Shattil, Sanford J.] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA USA.	dcheresh@ucsd.edu	Desgrosellier, Jay S/A-8756-2008	Huang, Miller/0000-0002-3371-0100; Lau, Steven/0000-0002-6433-8735	US National Institutes of Health [CA123774, CA78045, CA45726, CA95262, CA129660, HL57900]; NATIONAL CANCER INSTITUTE [R01CA095262, R37CA050286, P01CA078045, R01CA045726, R21CA129660, F32CA123774, T32CA121938] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We wish to thank D. Stupack, L. Acevedo and S. Anand for critical reading of the manuscript. We also want to express our gratitude to M. Bouvet and A. Lowy for their help in obtaining human pancreatic tumor sections. J.S.D. was supported by a US National Institutes of Health Ruth L. Kirschstein National Research Service Award Post-doctoral Fellowship (grant CA123774). This work was supported by funding from the US National Institutes of Health grant numbers CA78045, CA45726, CA95262, CA129660 and HL57900 (to D.A.C.).	ALBELDA SM, 1990, CANCER RES, V50, P6757; Allan AL, 2006, AM J PATHOL, V169, P233, DOI 10.2353/ajpath.2006.051152; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gruber G, 2005, BRIT J CANCER, V92, P41, DOI 10.1038/sj.bjc.6602278; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Huveneers S, 2008, J BIOL CHEM, V283, P13243, DOI 10.1074/jbc.M800927200; Huveneers S, 2007, CANCER RES, V67, P2693, DOI 10.1158/0008-5472.CAN-06-3654; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Takayama S, 2005, ANTICANCER RES, V25, P79; Tsatsanis C, 2004, ANN NY ACAD SCI, V1028, P168, DOI 10.1196/annals.1322.019; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004	49	206	217	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2009	15	10					1163	U89		10.1038/nm.2009	http://dx.doi.org/10.1038/nm.2009			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19734908	Green Accepted			2022-12-27	WOS:000270596400028
J	Beaumier, CM; Harris, LD; Goldstein, S; Klatt, NR; Whitted, S; McGinty, J; Apetrei, C; Pandrea, I; Hirsch, VM; Brenchley, JM				Beaumier, Coreen M.; Harris, Levelle D.; Goldstein, Simoy; Klatt, Nichole R.; Whitted, Sonya; McGinty, John; Apetrei, Cristian; Pandrea, Ivona; Hirsch, Vanessa M.; Brenchley, Jason M.			CD4 downregulation by memory CD4(+) T cells in vivo renders African green monkeys resistant to progressive SIVagm infection	NATURE MEDICINE			English	Article							SIMIAN-IMMUNODEFICIENCY-VIRUS; NONHUMAN PRIMATE HOSTS; SOOTY MANGABEYS; MICROBIAL TRANSLOCATION; PLASMA LIPOPOLYSACCHARIDE; AIDS PATHOGENESIS; IMMUNE ACTIVATION; CORECEPTOR USAGE; HIV-INFECTION; NATURAL HOSTS	African green monkeys (genus Chlorocebus) can be infected with species-specific simian immunodeficiency virus (SIVagm) but do not develop AIDS. These natural hosts of SIV, like sooty mangabeys, maintain high levels of SIV replication but have evolved to avoid immunodeficiency. Elucidating the mechanisms that allow natural hosts to coexist with SIV without overt disease may provide crucial information for understanding AIDS pathogenesis. Here we show that many CD4(+) T cells from African green monkeys downregulate CD4 in vivo as they enter the memory pool; that downregulation of CD4 by memory T cells is independent of SIV infection; that the CD4(-) memory T cells maintain functions that are normally attributed to CD4(+) T cells, including production of interleukin-2 (IL-2), production of IL-17, expression of forkhead box P3 and expression of CD40 ligand; that loss of CD4 expression protects these T cells from infection by SIVagm in vivo; and that these CD4(-) T cells can maintain major histocompatibility complex class II restriction. These data show that the absence of SIV-induced disease progression in natural host species may be partially explained by preservation of a subset of T cells that maintain CD4(+) T cell function while being resistant to SIV infection in vivo. (C) 2009 Nature America, Inc. All rights reserved.	[Beaumier, Coreen M.; Harris, Levelle D.; Goldstein, Simoy; Klatt, Nichole R.; Whitted, Sonya; McGinty, John; Hirsch, Vanessa M.; Brenchley, Jason M.] NIAID, Mol Microbiol Lab, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Apetrei, Cristian; Pandrea, Ivona] Tulane Natl Primate Ctr, Div Comparat Pathol, New Orleans, LA USA; [Apetrei, Cristian; Pandrea, Ivona] Tulane Natl Primate Ctr, Div Microbiol, New Orleans, LA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tulane University; Tulane University	Brenchley, JM (corresponding author), NIAID, Mol Microbiol Lab, US Natl Inst Hlth, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jbrenchl@mail.nih.gov	Apetrei, Cristian/AAG-9032-2021; Brenchley, Jason/AAC-5085-2019	Apetrei, Cristian/0000-0002-0322-7185; Brenchley, Jason/0000-0001-8357-2984	intramural National Institute of Allergy and Infectious Diseases; US National Institutes of Health program; Tulane National Primate Center [R01 AI064066, R01 AI065325, RR-00168]; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR000168, P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064066, R01AI065325, ZIAAI000370] Funding Source: NIH RePORTER	intramural National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US National Institutes of Health program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tulane National Primate Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	These studies were supported by the intramural National Institute of Allergy and Infectious Diseases, US National Institutes of Health program and by R01 AI064066 (I. P.), R01 AI065325 (C. A.) and RR-00168 (Tulane National Primate Center). We would like to thank the Bad Boys of Cleveland, D. Douek (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health) and D. Price (Cardiff University) for helpful discussions. We are grateful to J. E. Schmitz and R. Zahn (Harvard University) for the kind donation of microbeads coated with antibody to CD3 and CD28 for stimulation of T cells from nonhuman primates. We also appreciate the technical advice of B. Lafont and G. Mettler.	Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516; Balagopal A, 2008, GASTROENTEROLOGY, V135, P226, DOI 10.1053/j.gastro.2008.03.022; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Barry AP, 2007, J IMMUNOL, V178, P8002, DOI 10.4049/jimmunol.178.12.8002; Beer BE, 2001, J VIROL, V75, P12014, DOI 10.1128/JVI.75.24.12014-12027.2001; Bilic I, 2006, NAT IMMUNOL, V7, P392, DOI 10.1038/ni1311; Boulassel MR, 2007, CLIN IMMUNOL, V124, P149, DOI 10.1016/j.clim.2007.05.005; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Chakrabarti LA, 2000, J VIROL, V74, P1209, DOI 10.1128/JVI.74.3.1209-1223.2000; Dunham R, 2006, BLOOD, V108, P209, DOI 10.1182/blood-2005-12-4897; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Goldstein S, 2005, J VIROL, V79, P5153, DOI 10.1128/JVI.79.8.5153-5162.2005; Goldstein S, 2000, J VIROL, V74, P11744, DOI 10.1128/JVI.74.24.11744-11753.2000; Goldstein S, 2006, J VIROL, V80, P4868, DOI 10.1128/JVI.80.10.4868-4877.2006; Gordon SN, 2008, J VIROL, V82, P3725, DOI 10.1128/JVI.02408-07; Gordon SN, 2007, J IMMUNOL, V179, P3026, DOI 10.4049/jimmunol.179.5.3026; Gregson JNS, 2009, AIDS, V23, P29, DOI 10.1097/QAD.0b013e3283199780; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hirsch V, 1997, J VIROL, V71, P1608, DOI 10.1128/JVI.71.2.1608-1620.1997; Hirsch VM, 2004, AIDS REV, V6, P40; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kioussis D, 2002, NAT REV IMMUNOL, V2, P909, DOI 10.1038/nri952; Klatt NR, 2008, J CLIN INVEST, V118, P2039, DOI 10.1172/JCI33814; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Ling BH, 2008, VIROLOGY, V379, P38, DOI 10.1016/j.virol.2008.06.012; Marchetti G, 2008, AIDS, V22, P2035, DOI 10.1097/QAD.0b013e3283112d29; Matsunaga S, 2000, IMMUNOL LETT, V75, P47, DOI 10.1016/S0165-2478(00)00273-X; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Milush JM, 2007, J IMMUNOL, V179, P3047, DOI 10.4049/jimmunol.179.5.3047; Murayama Y, 1999, CLIN EXP IMMUNOL, V117, P504; Murayama Y, 1997, INT IMMUNOL, V9, P843, DOI 10.1093/intimm/9.6.843; Pandrea I, 2003, VIROLOGY, V317, P119, DOI 10.1016/j.virol.2003.08.015; Pandrea I, 2008, TRENDS IMMUNOL, V29, P419, DOI 10.1016/j.it.2008.05.004; Pandrea I, 2008, J VIROL, V82, P5501, DOI 10.1128/JVI.02555-07; Pandrea I, 2007, BLOOD, V109, P1069, DOI 10.1182/blood-2006-05-024364; Pandrea I, 2006, J MED PRIMATOL, V35, P194, DOI 10.1111/j.1600-0684.2006.00168.x; Pandrea I, 2006, J VIROL, V80, P4858, DOI 10.1128/JVI.80.10.4858-4867.2006; Pandrea IV, 2007, J IMMUNOL, V179, P3035, DOI 10.4049/jimmunol.179.5.3035; Papasavvas E, 2009, AIDS, V23, P369, DOI 10.1097/QAD.0b013e32831e9c76; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; RAHEMTULLA A, 1994, EUR J IMMUNOL, V24, P2213, DOI 10.1002/eji.1830240942; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Roelke ME, 2006, J WILDLIFE DIS, V42, P234, DOI 10.7589/0090-3558-42.2.234; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034; Sumpter B, 2007, J IMMUNOL, V178, P1680, DOI 10.4049/jimmunol.178.3.1680; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; Zhang YJ, 2000, J VIROL, V74, P6893, DOI 10.1128/JVI.74.15.6893-6910.2000	55	110	110	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					879	U75		10.1038/nm.1970	http://dx.doi.org/10.1038/nm.1970			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19525963	Green Accepted			2022-12-27	WOS:000268770400031
J	Zhu, J; Hladik, F; Woodward, A; Klock, A; Peng, T; Johnston, C; Remington, M; Magaret, A; Koelle, DM; Wald, A; Corey, L				Zhu, Jia; Hladik, Florian; Woodward, Amanda; Klock, Alexis; Peng, Tao; Johnston, Christine; Remington, Michael; Magaret, Amalia; Koelle, David M.; Wald, Anna; Corey, Lawrence			Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition	NATURE MEDICINE			English	Article							HERPES-SIMPLEX-VIRUS; GENITAL HERPES; DENDRITIC CELLS; MALE CIRCUMCISION; CONTROLLED-TRIAL; T-LYMPHOCYTES; INFECTION; WOMEN; RISK; SKIN	To explore the mechanism by which herpes simplex virus (HSV)-2 infection is related to HIV-1 acquisition, we conducted in situ analysis of the cellular infiltrate from sequential biopsies of HSV-2 lesions from patients on and off antiviral therapy. CD4(+) and CD8(+) T cells and a mixed population of plasmacytoid and myeloid dendritic cells (DCs), including cells expressing the C-type lectin receptor DC-SIGN, persisted at sites of HSV-2 reactivation for months after healing, even with daily antiviral therapy. The CD4(+) T cells that persisted reacted to HSV-2 antigen, were enriched for expression of the chemokine receptor CCR5, and were contiguous to DCs expressing the interleukin-3 receptor CD123 or DC-SIGN. Ex vivo infection with a CCR5-tropic strain of HIV-1 revealed greater concentrations of integrated HIV-1 DNA in cells derived from healed genital lesion biopsies than in cells from control skin biopsies. The persistence and enrichment of HIV receptor-positive inflammatory cells in the genitalia help explain the inability of anti-HSV-2 therapy to reduce HIV acquisition. (C) 2009 Nature America, Inc. All rights reserved.	[Zhu, Jia; Hladik, Florian; Woodward, Amanda; Klock, Alexis; Peng, Tao; Johnston, Christine; Magaret, Amalia; Koelle, David M.; Wald, Anna; Corey, Lawrence] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA; [Zhu, Jia; Klock, Alexis; Peng, Tao; Remington, Michael; Magaret, Amalia; Koelle, David M.; Wald, Anna; Corey, Lawrence] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Hladik, Florian; Woodward, Amanda; Johnston, Christine; Koelle, David M.; Wald, Anna; Corey, Lawrence] Univ Washington, Dept Med, Seattle, WA USA; [Hladik, Florian] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA; [Wald, Anna; Corey, Lawrence] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, 1124 Columbia St, Seattle, WA 98104 USA.	lcorey@fhcrc.org	Hladik, Florian/G-1041-2012; Hladik, Florian/AAR-8852-2021; Corey, Lawrence/AAE-1796-2020; Koelle, David/Q-6529-2016; Wald, Anna/B-6272-2012	Hladik, Florian/0000-0002-0375-2764; Hladik, Florian/0000-0002-0375-2764; Corey, Lawrence/0000-0002-2179-2436; Koelle, David/0000-0003-1255-9023; Wald, Anna/0000-0003-3486-6438; Johnston, Christine/0000-0002-3073-0843; Zhu, Jia/0000-0002-8676-5105	National Institutes of Health [R37AI042528, P01AI030731, AI50132, HD51455]; Tietze Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD051455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050132, R21AI050132, K23AI079394, R37AI042528, P01AI030731] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tietze Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank M. Mack (University Hospital Regensburg, Germany) for the antibody to CCR5 and C. McClurkan, L. Ballweber and H. Xie for technical assistance. We also thank our dedicated study participants. This work was supported by the National Institutes of Health (R37AI042528, P01AI030731, AI50132 and HD51455) and the Tietze Foundation.	Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Barcy S, 2005, J INFECT DIS, V191, P2012, DOI 10.1086/430389; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; Donaghy H, 2009, J VIROL, V83, P1952, DOI 10.1128/JVI.01578-08; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Granelli-Piperno A, 2006, J IMMUNOL, V176, P991, DOI 10.4049/jimmunol.176.2.991; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Gupta R, 2004, J INFECT DIS, V190, P1374, DOI 10.1086/424519; Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007; HOOK EW, 1992, J INFECT DIS, V165, P251, DOI 10.1093/infdis/165.2.251; Johnston C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004222; KOELLE DM, 1994, J INFECT DIS, V169, P956, DOI 10.1093/infdis/169.5.956; Koelle DM, 2006, J VIROL, V80, P2863, DOI 10.1128/JVI.80.6.2863-2872.2006; Koelle DM, 1998, J CLIN INVEST, V101, P1500, DOI 10.1172/JCI1758; KOELLE DM, 1994, J VIROL, V68, P2803, DOI 10.1128/JVI.68.5.2803-2810.1994; Magaret AS, 2007, J CLIN MICROBIOL, V45, P1618, DOI 10.1128/JCM.01405-06; Mark KE, 2008, J INFECT DIS, V198, P1141, DOI 10.1086/591913; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Ochoa MT, 2008, J INVEST DERMATOL, V128, P2225, DOI 10.1038/jid.2008.56; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Posavad CM, 1998, NAT MED, V4, P381, DOI 10.1038/nm0498-381; Rebbapragada A, 2007, AIDS, V21, P589, DOI 10.1097/QAD.0b013e328012b896; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Wakim LM, 2008, SCIENCE, V319, P198, DOI 10.1126/science.1151869; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Watson-Jones D, 2008, NEW ENGL J MED, V358, P1560, DOI 10.1056/NEJMoa0800260; Weiler AM, 2008, J VIROL, V82, P4154, DOI 10.1128/JVI.01947-07; Zhu J, 2007, J EXP MED, V204, P595, DOI 10.1084/jem.20061792	40	272	281	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					886	U83		10.1038/nm.2006	http://dx.doi.org/10.1038/nm.2006			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19648930	Green Accepted			2022-12-27	WOS:000268770400032
J	Gattinoni, L; Zhong, XS; Palmer, DC; Ji, Y; Hinrichs, CS; Yu, ZY; Wrzesinski, C; Boni, A; Cassard, L; Garvin, LM; Paulos, CM; Muranski, P; Restifo, NP				Gattinoni, Luca; Zhong, Xiao-Song; Palmer, Douglas C.; Ji, Yun; Hinrichs, Christian S.; Yu, Zhiya; Wrzesinski, Claudia; Boni, Andrea; Cassard, Lydie; Garvin, Lindsay M.; Paulos, Chrystal M.; Muranski, Pawel; Restifo, Nicholas P.			Wnt signaling arrests effector T cell differentiation and generates CD8(+) memory stem cells	NATURE MEDICINE			English	Article							BETA-CATENIN; IN-VIVO; ADOPTIVE IMMUNOTHERAPY; TRANSCRIPTION FACTORS; SELF-RENEWAL; LONG-TERM; IMMUNITY; CANCER; PROLIFERATION; MAINTENANCE	Self-renewing cell populations such as hematopoietic stem cells and memory B and T lymphocytes might be regulated by shared signaling pathways(1). The Wnt-beta-catenin pathway is an evolutionarily conserved pathway that promotes hematopoietic stem cell self-renewal and multipotency by limiting stem cell proliferation and differentiation(2,3), but its role in the generation and maintenance of memory T cells is unknown. We found that induction of Wnt-beta-catenin signaling by inhibitors of glycogen sythase kinase-3 beta or the Wnt protein family member Wnt3a arrested CD8(+) T cell development into effector cells. By blocking T cell differentiation, Wnt signaling promoted the generation of CD44(low)CD62L(high)Sca-1(high)CD122(high)Bcl-2(high) self-renewing multipotent CD8(+) memory stem cells with proliferative and antitumor capacities exceeding those of central and effector memory T cell subsets. These findings reveal a key role for Wnt signaling in the maintenance of 'stemness' in mature memory CD8(+) T cells and have major implications for the design of new vaccination strategies and adoptive immunotherapies.	[Gattinoni, Luca; Zhong, Xiao-Song; Palmer, Douglas C.; Ji, Yun; Hinrichs, Christian S.; Yu, Zhiya; Wrzesinski, Claudia; Boni, Andrea; Cassard, Lydie; Garvin, Lindsay M.; Paulos, Chrystal M.; Muranski, Pawel; Restifo, Nicholas P.] NCI, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gattinoni, L (corresponding author), NCI, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA.	gattinol@mail.nih.gov; restifo@nih.gov	Gattinoni, Luca/A-2281-2008; Restifo, Nicholas Phillip/M-6549-2019; Ji, Yun/B-7245-2009; Waldmann, Thomas/AAT-5972-2021; Palmer, Douglas/B-9454-2008; Muranski, Pawel/E-5572-2010; Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/Z-1614-2019; Hinrichs, Christian/V-9851-2019	Gattinoni, Luca/0000-0003-2239-3282; Ji, Yun/0000-0001-6340-7009; Waldmann, Thomas/0000-0003-4500-6660; Palmer, Douglas/0000-0001-5018-5734; Hinrichs, Christian/0000-0001-5597-2841; Restifo, Nicholas P./0000-0003-4229-4580	US National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010763] Funding Source: NIH RePORTER	US National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research. We would like to thank S. A. Rosenberg, C. A. Klebanoff and S. Kerkar for critical review of the manuscript and A. Mixon and S. Farid of the Flow Cytometry Unit for Flow Cytometry analyses and sorting. This study was done in partial fulfillment of a PhD in Biochemistry (to D.C.P.) at the George Washington University, Washington, DC.	Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100; Ding Y, 2008, NAT MED, V14, P162, DOI 10.1038/nm1707; Fearon DT, 2001, SCIENCE, V293, P248, DOI 10.1126/science.1062589; Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Hinrichs CS, 2008, BLOOD, V111, P5326, DOI 10.1182/blood-2007-09-113050; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Jeannet G, 2008, BLOOD, V111, P142, DOI 10.1182/blood-2007-07-102558; Kaech SM, 2007, IMMUNITY, V27, P393, DOI 10.1016/j.immuni.2007.08.007; Katoh M, 2007, INT J MOL MED, V19, P529; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Klebanoff CA, 2006, IMMUNOL REV, V211, P214, DOI 10.1111/j.0105-2896.2006.00391.x; Luckey CJ, 2006, P NATL ACAD SCI USA, V103, P3304, DOI 10.1073/pnas.0511137103; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Mizumoto K, 2007, TRENDS CELL BIOL, V17, P465, DOI 10.1016/j.tcb.2007.08.004; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pantaleo G, 2006, NAT REV IMMUNOL, V6, P417, DOI 10.1038/nri1840; Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schilham MW, 1998, J IMMUNOL, V161, P3984; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Williams MA, 2008, IMMUNITY, V28, P533, DOI 10.1016/j.immuni.2008.02.014; Willinger T, 2006, J IMMUNOL, V176, P1439, DOI 10.4049/jimmunol.176.3.1439; Wrzesinski C, 2007, J CLIN INVEST, V117, P492, DOI 10.1172/JCI30414; Zeng YA, 2004, DEVELOPMENT, V131, P2911, DOI 10.1242/dev.01177; Zhang Y, 2005, NAT MED, V11, P1299, DOI 10.1038/nm1326	40	672	698	4	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2009	15	7					808	U129		10.1038/nm.1982	http://dx.doi.org/10.1038/nm.1982			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19525962	Green Accepted			2022-12-27	WOS:000267806900036
J	La Spada, AR				La Spada, Albert R.			Silencing neurodegeneration	NATURE MEDICINE			English	Editorial Material							POLYGLUTAMINE-INDUCED NEURODEGENERATION; HUNTINGTONS-DISEASE; RNAI; THERAPY; MODEL		[La Spada, Albert R.] Univ Washington, UWMC, Dept Lab Med, Seattle, WA 98195 USA; [La Spada, Albert R.] Univ Washington, UWMC, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [La Spada, Albert R.] Univ Washington, UWMC, Div Neurogenet, Dept Neurol, Seattle, WA 98195 USA; [La Spada, Albert R.] Univ Washington, UWMC, Ctr Neurogenet & Neurotherapeut, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	La Spada, AR (corresponding author), Univ Washington, UWMC, Dept Lab Med, Room NW120,1959 NE Pacific St, Seattle, WA 98195 USA.	laspada@u.washington.edu	La Spada, Albert/AAG-8809-2020					Bonini NM, 2005, NEURON, V48, P715, DOI 10.1016/j.neuron.2005.11.008; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Lee JA, 2006, NEURON, V52, P103, DOI 10.1016/j.neuron.2006.09.027; McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105; Shao J, 2007, HUM MOL GENET, V16, pR115, DOI 10.1093/hmg/ddm213; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zu T, 2004, J NEUROSCI, V24, P8853, DOI 10.1523/JNEUROSCI.2978-04.2004	13	3	4	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2009	15	3					252	253		10.1038/nm0309-252	http://dx.doi.org/10.1038/nm0309-252			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19265826				2022-12-27	WOS:000263914000023
J	Biddinger, SB; Haas, JT; Yu, BB; Bezy, O; Jing, EX; Zhang, WW; Unterman, TG; Carey, MC; Kahn, CR				Biddinger, Sudha B.; Haas, Joel T.; Yu, Bian B.; Bezy, Olivier; Jing, Enxuan; Zhang, Wenwei; Unterman, Terry G.; Carey, Martin C.; Kahn, C. Ronald			Hepatic insulin resistance directly promotes formation of cholesterol gallstones	NATURE MEDICINE			English	Article							ABCG8; LIVER; DISEASE; MICE; EXPRESSION; GENES; ALPHA; FOXO1	Despite the well-documented association between gallstones and the metabolic syndrome(1,2), the mechanistic links between these two disorders remain unknown. Here we show that mice solely with hepatic insulin resistance, created by liver-specific disruption of the insulin receptor (LIRKO mice)(3) are markedly predisposed toward cholesterol gallstone formation due to at least two distinct mechanisms. Disinhibition of the forkhead transcription factor FoxO1, increases expression of the biliary cholesterol transporters Abcg5 and Abcg8, resulting in an increase in biliary cholesterol secretion. Hepatic insulin resistance also decreases expression of the bile acid synthetic enzymes, particularly Cyp7b1, and produces partial resistance to the farnesoid X receptor, leading to a lithogenic bile salt profile. As a result, after twelve weeks on a lithogenic diet, all of the LIRKO mice develop gallstones. Thus, hepatic insulin resistance provides a crucial link between the metabolic syndrome and increased cholesterol gallstone susceptibility.	[Biddinger, Sudha B.; Haas, Joel T.; Bezy, Olivier; Jing, Enxuan; Kahn, C. Ronald] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; [Biddinger, Sudha B.] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; [Yu, Bian B.; Carey, Martin C.; Kahn, C. Ronald] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; [Zhang, Wenwei; Unterman, Terry G.] Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; [Zhang, Wenwei; Unterman, Terry G.] Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; [Zhang, Wenwei; Unterman, Terry G.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Carey, Martin C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Harvard University; Harvard Medical School	Biddinger, SB (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	sudha.biddinger@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021; Haas, Joel/R-6379-2018	Kahn, Ronald/0000-0002-7583-9228; Haas, Joel/0000-0002-0028-5988; Bezy, Olivier/0000-0003-4367-5043	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031036, R01DK073687, R01DK045935, K08DK073358, R37DK036588, P30DK036836, R01DK031036, K12DK063696, R01DK036588] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK073687, R01 DK045935, R01 DK073687, DK063695-05, K08 DK073358, K12 DK063696, R37 DK036588, DK45935, R01 DK036588, R37 DK036588-22, DK036588, DK036836-20, R01 DK073687-01, DK031036, P30 DK036836, R37 DK031036, R01 DK031036, K08 DK073358-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYOSHI T, 1986, J LIPID RES, V27, P915; Attili AF, 1997, HEPATOLOGY, V26, P809, DOI 10.1002/hep.510260401; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Biddinger SB, 2005, DIABETES, V54, P1314, DOI 10.2337/diabetes.54.5.1314; Biddinger SB, 2008, CELL METAB, V7, P125, DOI 10.1016/j.cmet.2007.11.013; CAREY MC, 1961, FUTURE PERSP IN PRES, V161, P77; Chen Q, 1999, GASTROENTEROLOGY, V116, P678, DOI 10.1016/S0016-5085(99)70190-3; Diehl AK, 2000, HEPATOLOGY, V31, P528, DOI 10.1002/hep.510310238; Everhart JE, 1999, GASTROENTEROLOGY, V117, P632, DOI 10.1016/S0016-5085(99)70456-7; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; GRUNDY SM, 1984, J CLIN INVEST, V73, P1156, DOI 10.1172/JCI111301; HEUMAN DM, 1989, J LIPID RES, V30, P719; Ishida H, 2000, J BIOCHEM, V127, P57, DOI 10.1093/oxfordjournals.jbchem.a022584; Jiang ZY, 2008, J LIPID RES, V49, P464, DOI 10.1194/jlr.M700295-JLR200; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Moschetta A, 2004, NAT MED, V10, P1352, DOI 10.1038/nm1138; OSLER W, 1992, PRINCIPLES PRACTICE, V432; Remaley AT, 2002, BIOCHEM BIOPH RES CO, V295, P276, DOI 10.1016/S0006-291X(02)00652-6; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; SHAFFER EA, 1977, J CLIN INVEST, V59, P828, DOI 10.1172/JCI108705; Uppal H, 2008, HEPATOLOGY, V47, P1331, DOI 10.1002/hep.22175; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2005, J BIOL CHEM, V280, P8742, DOI 10.1074/jbc.M411080200; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200	30	200	218	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2008	14	7					778	782		10.1038/nm1785	http://dx.doi.org/10.1038/nm1785			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18587407	Green Accepted			2022-12-27	WOS:000257452700027
J	Li, J; Wang, LL; Mamon, H; Kulke, MH; Berbeco, R; Makrigiorgos, GM				Li, Jin; Wang, Lilin; Mamon, Harvey; Kulke, Matthew H.; Berbeco, Ross; Makrigiorgos, G. Mike			Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; SINGLE-NUCLEOTIDE POLYMORPHISMS; GROWTH-FACTOR RECEPTOR; MUTATION DETECTION; PROGNOSTIC-FACTORS; PLASMA DNA; P53; RESISTANCE; GEFITINIB; CARCINOMA	PCR is widely employed as the initial DNA amplification step for genetic testing. However, a key limitation of PCR-based methods is the inability to selectively amplify low levels of mutations in a wild-type background. As a result, downstream assays are limited in their ability to identify subtle genetic changes that can have a profound impact in clinical decision-making and outcome. Here we describe co-amplification at lower denaturation temperature PCR ( COLD-PCR), a novel form of PCR that amplifies minority alleles selectively from mixtures of wild-type and mutation-containing sequences irrespective of the mutation type or position on the sequence. We replaced regular PCR with COLD-PCR before sequencing or genotyping assays to improve mutation detection sensitivity by up to 100-fold and identified new mutations in the genes encoding p53, KRAS and epidermal growth factor in heterogeneous cancer samples that had been missed by the currently used methods. For clinically relevant microdeletions, COLD-PCR enabled exclusive amplification and isolation of the mutants. COLD-PCR will transform the capabilities of PCR-based genetic testing, including applications in cancer, infectious diseases and prenatal identification of fetal alleles in maternal blood.	[Li, Jin; Wang, Lilin; Mamon, Harvey; Berbeco, Ross; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Boston, MA 02115 USA; [Li, Jin; Wang, Lilin; Mamon, Harvey; Berbeco, Ross; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Div Phys, Dept Radiat Oncol, Boston, MA 02115 USA; [Li, Jin; Wang, Lilin; Mamon, Harvey; Berbeco, Ross; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Div Radiat Therapy, Dept Radiat Oncol, Boston, MA 02115 USA; [Kulke, Matthew H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Makrigiorgos, GM (corresponding author), Harvard Univ, Sch Med, Div Genom Stabil & DNA Repair, Dept Radiat Oncol, Room JF514,44 Binney St, Boston, MA 02115 USA.	mmakrigiorgos@partners.org	Makrigiorgos, Mike/AFC-4575-2022; Lin, Xin/L-9950-2013; Mamon, Harvey J/B-2335-2009	Lin, Xin/0000-0002-7491-8928; Mamon, Harvey J/0000-0002-6060-9059	NATIONAL CANCER INSTITUTE [R33CA111994, T32CA009078, R21CA111994, R21CA115439] Funding Source: NIH RePORTER; NCI NIH HHS [CA115439-01, 5 T32 CA09078, CA111994-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Fuery CJ, 2000, CLIN CHEM, V46, P620; Gonzalez R, 2000, ANN ONCOL, V11, P1097, DOI 10.1023/A:1008305412635; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hoffmann C, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm435; Huang C, 1998, ONCOGENE, V16, P2469, DOI 10.1038/sj.onc.1201776; Huang CL, 1998, INT J ONCOL, V12, P553; Jackson PE, 2001, CANCER RES, V61, P33; Janne PA, 2006, CLIN CANCER RES, V12, P751, DOI 10.1158/1078-0432.CCR-05-2047; Kimura T, 2004, ANN NY ACAD SCI, V1022, P55, DOI 10.1196/annals.1318.010; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Li J, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm403; Liew M, 2004, CLIN CHEM, V50, P1156, DOI 10.1373/clinchem.2004.032136; Lipsky RH, 2001, CLIN CHEM, V47, P635; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Mayall F, 1998, J CLIN PATHOL, V51, P611, DOI 10.1136/jcp.51.8.611; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Shao ZM, 2001, CLIN CANCER RES, V7, P2222; Silva JM, 2002, CLIN CANCER RES, V8, P3761; Sun XY, 2002, NAT BIOTECHNOL, V20, P186, DOI 10.1038/nbt0202-186; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Yeung A, 2005, BIOTECHNIQUES, V38, P749, DOI 10.2144/05385RV01	27	297	365	2	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					579	584		10.1038/nm1708	http://dx.doi.org/10.1038/nm1708			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18408729				2022-12-27	WOS:000255681800040
J	Han, Z; Fu, A; Wang, H; Diaz, R; Geng, L; Onishko, H; Hallahan, DE				Han, Zhaozhong; Fu, Allie; Wang, Hailun; Diaz, Roberto; Geng, Ling; Onishko, Halina; Hallahan, Dennis E.			Noninvasive assessment of cancer response to therapy	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; RENAL-CELL CARCINOMA; FACTOR-RECEPTOR; PHAGE DISPLAY; ANNEXIN-V; COLORECTAL-CANCER; TUMOR-GROWTH; SU11248; PTK787/ZK-222584	Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration	[Han, Zhaozhong; Fu, Allie; Wang, Hailun; Diaz, Roberto; Geng, Ling; Onishko, Halina; Hallahan, Dennis E.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; [Wang, Hailun; Hallahan, Dennis E.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Hallahan, Dennis E.] Vanderbilt Univ, Sch Med, Dept Biomed Engn, Nashville, TN 37232 USA; [Hallahan, Dennis E.] Vanderbilt Ingram Can Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Hallahan, DE (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 1301 22nd Ave S,B902 TVC, Nashville, TN 37232 USA.	dennis.hallahan@vanderbilt.edu	Wang, Hailun/T-5696-2019	Wang, Hailun/0000-0001-8651-2856	NATIONAL CANCER INSTITUTE [R01CA112385, R01CA125757, R01CA089674] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA112385, R01-CA125757, R01-CA89674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Belhocine T, 2002, CLIN CANCER RES, V8, P2766; Drevs J, 2002, CANCER RES, V62, P4015; Hallahan D, 2003, CANCER CELL, V3, P63, DOI 10.1016/S1535-6108(02)00238-6; HALLAHAN DE, NAT PROTOC; Han ZZ, 2002, BIOCHEM BIOPH RES CO, V292, P1036, DOI 10.1006/bbrc.2002.6741; Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Ladner RC, 1999, Q J NUCL MED, V43, P119; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574; Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516; Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Prenen H, 2006, CLIN CANCER RES, V12, P2622, DOI 10.1158/1078-0432.CCR-05-2275; Ruoslahti E, 2004, BIOCHEM SOC T, V32, P397, DOI 10.1042/BST0320397; Rusckowski M, 2000, J NUCL MED, V41, P363; Schueneman AJ, 2003, CANCER RES, V63, P4009; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sun L, 2003, J MED CHEM, V46, P1116, DOI 10.1021/jm0204183; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Vand de Wiele C, 2003, J CLIN ONCOL, V21, P3483, DOI 10.1200/JCO.2003.12.096; Wood JM, 2000, CANCER RES, V60, P2178; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yazici S, 2005, PROSTATE, V65, P203, DOI 10.1002/pros.20283	26	59	66	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					343	349		10.1038/nm1691	http://dx.doi.org/10.1038/nm1691			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18297085				2022-12-27	WOS:000253815700042
J	Said, EA; Dupuy, FP; Trautmann, L; Zhang, YW; Shi, Y; El-Far, M; Hill, BJ; Noto, A; Ancuta, P; Peretz, Y; Fonseca, SG; Van Grevenynghe, J; Boulassel, MR; Bruneau, J; Shoukry, NH; Routy, JP; Douek, DC; Haddad, EK; Sekaly, RP				Said, Elias A.; Dupuy, Franck P.; Trautmann, Lydie; Zhang, Yuwei; Shi, Yu; El-Far, Mohamed; Hill, Brenna J.; Noto, Alessandra; Ancuta, Petronela; Peretz, Yoav; Fonseca, Simone G.; Van Grevenynghe, Julien; Boulassel, Mohamed R.; Bruneau, Julie; Shoukry, Naglaa H.; Routy, Jean-Pierre; Douek, Daniel C.; Haddad, Elias K.; Sekaly, Rafick-Pierre			Programmed death-1-induced interleukin-10 production by monocytes impairs CD4(+) T cell activation during HIV infection	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC VIRAL-INFECTION; SERUM IL-10 LEVELS; DISEASE PROGRESSION; PD-1 EXPRESSION; DENDRITIC CELLS; ANTIRETROVIRAL THERAPY; CYTOKINE SIGNALING-3; IMMUNE ACTIVATION; HUMAN MACROPHAGES	Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4(+) T cell numbers during HIV infection. Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection. Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections. Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10. Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4(+) T cell dysfunction. We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.	[Said, Elias A.; Dupuy, Franck P.; Trautmann, Lydie; Zhang, Yuwei; Shi, Yu; El-Far, Mohamed; Noto, Alessandra; Ancuta, Petronela; Peretz, Yoav; Fonseca, Simone G.; Van Grevenynghe, Julien; Bruneau, Julie; Shoukry, Naglaa H.; Haddad, Elias K.; Sekaly, Rafick-Pierre] CRCHUM, Hop St Luc, Montreal, PQ, Canada; [Said, Elias A.; Dupuy, Franck P.; Trautmann, Lydie; Zhang, Yuwei; Shi, Yu; El-Far, Mohamed; Noto, Alessandra; Ancuta, Petronela; Peretz, Yoav; Fonseca, Simone G.; Van Grevenynghe, Julien; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, Dept Microbiol & Immunol, Immunol Lab, Montreal, PQ H3C 3J7, Canada; [Said, Elias A.; Dupuy, Franck P.; Trautmann, Lydie; Zhang, Yuwei; Shi, Yu; El-Far, Mohamed; Noto, Alessandra; Ancuta, Petronela; Peretz, Yoav; Fonseca, Simone G.; Van Grevenynghe, Julien; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, CRCHUM, Inst Nat Sante & Rech Med, U743, Montreal, PQ H3C 3J7, Canada; [Trautmann, Lydie; Sekaly, Rafick-Pierre] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA; [Hill, Brenna J.; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Boulassel, Mohamed R.; Routy, Jean-Pierre] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Immunodeficiency Serv & Div Hematol, Montreal, PQ, Canada; [Bruneau, Julie] Univ Montreal, Dept Med Familiale, Montreal, PQ, Canada; [Shoukry, Naglaa H.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Haddad, Elias K.; Sekaly, Rafick-Pierre] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Vaccine & Gene Therapy Institute of Florida; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McGill University; Royal Victoria Hospital; Universite de Montreal; Universite de Montreal; McGill University	Sekaly, RP (corresponding author), CRCHUM, Hop St Luc, Montreal, PQ, Canada.	Rafick-pierre.sekaly@umontreal.ca	Said, Elias/AAY-5557-2020; FONSECA, SIMONE GONÇALVES/U-9278-2019; Zhang, Yuwei/H-3287-2018	Ancuta, Petronela/0000-0003-1922-5640; El-Far, Mohamed/0000-0002-6458-4207; Trautmann, Lydie/0000-0002-3012-0009; Said, Elias/0000-0003-4224-6351	Canadian Institutes of Health Research (CIHR); Canadian Foundation for Infectious Diseases; Fonds de la recherche en sante du Quebec; US National Institutes of Health; Canadian Foundation for AIDS Research; Canadian Network for Vaccines and Immunotherapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076174, ZIAAI005066, ZIAAI005033, ZIAAI005034, ZIAAI005031] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Infectious Diseases; Fonds de la recherche en sante du Quebec(Fonds de la Recherche en Sante du Quebec); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Foundation for AIDS Research; Canadian Network for Vaccines and Immunotherapeutics; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the subjects for their participation in this study. We also thank M. Legault and C. Grignon for their clinical assistance with the recruitment of study subjects. We are grateful to V. A. Evans and J. D. Schatzle for help in manuscript revision. E. A. S., L. T., M. E.-F. and J. V. G. are funded by the Canadian Institutes of Health Research (CIHR). N. H. S. holds a joint New Investigator Award from the Canadian Foundation for Infectious Diseases and CIHR. J. B. and J.-P. R. are clinician-scientists supported by Fonds de la recherche en sante du Quebec. R.-P. S. is the Canada Research Chair in Human Immunology. This study was supported by funds from the US National Institutes of Health, the CIHR, the Canadian Foundation for AIDS Research, the Fonds de la recherche en sante du Quebec AIDS and Infectious Disease Network (SIDA-MI) and the Canadian Network for Vaccines and Immunotherapeutics. This study was funded in part by the Intramural Program of the US National Institutes of Health. Vectors were generously provided by E. Cohen at the Institut de Recherches Cliniques de Montreal. The lentiviral vector pWPI (empty vector), packaging plasmid psPAX2 and envelope plasmid pMD2G were generously provided by D. Trono (University of Geneva).	Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420415, 10.1172/JCI200420515]; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Boasso A, 2008, CLIN IMMUNOL, V129, P132, DOI 10.1016/j.clim.2008.05.009; BREEN EC, 1990, J IMMUNOL, V144, P480; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Bright JJ, 1998, J IMMUNOL, V161, P1772; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; CHOLLETMARTIN S, 1994, AIDS, V8, P879, DOI 10.1097/00002030-199407000-00003; Clerici M, 1996, BLOOD, V88, P574, DOI 10.1182/blood.V88.2.574.bloodjournal882574; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Ejrnaes M, 2006, J EXP MED, V203, P2461, DOI 10.1084/jem.20061462; El Kasmi KC, 2006, J IMMUNOL, V177, P7880, DOI 10.4049/jimmunol.177.11.7880; El-Far Mohamed, 2008, Curr HIV/AIDS Rep, V5, P13, DOI 10.1007/s11904-008-0003-7; Frankenberger M, 1996, BLOOD, V87, P373; Geng L, 2006, J VIRAL HEPATITIS, V13, P725, DOI 10.1111/j.1365-2893.2006.00746.x; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Groschel S, 2008, J MOL MED, V86, P443, DOI 10.1007/s00109-008-0310-x; Hagiwara E, 1996, AIDS RES HUM RETROV, V12, P127, DOI 10.1089/aid.1996.12.127; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Huber M, 2008, P NATL ACAD SCI USA, V105, P20846, DOI 10.1073/pnas.0809077106; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; KETLINSKY SA, 1992, VESTN ROS AKAD MED+, P36; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Kumar A, 1998, CLIN EXP IMMUNOL, V114, P78; Lin DYW, 2008, P NATL ACAD SCI USA, V105, P3011, DOI 10.1073/pnas.0712278105; MALEFYT RD, 1991, J EXP MED, V174, P915; Meier A, 2008, AIDS, V22, P655, DOI 10.1097/QAD.0b013e3282f4de23; Nelson DR, 2003, HEPATOLOGY, V38, P859, DOI 10.1053/jhep.2003.50427; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; Norris PJ, 2006, AIDS RES HUM RETROV, V22, P757, DOI 10.1089/aid.2006.22.757; Orsilles MA, 2006, APMIS, V114, P55, DOI 10.1111/j.1600-0463.2006.apm_108.x; Pandrea I, 2007, BLOOD, V109, P1069, DOI 10.1182/blood-2006-05-024364; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; SalazarGonzalez JF, 1997, CLIN IMMUNOL IMMUNOP, V84, P36, DOI 10.1006/clin.1997.4364; Shrestha S, 2007, CANCER EPIDEM BIOMAR, V16, P1626, DOI 10.1158/1055-9965.EPI-06-0881; Stylianou E, 1999, CLIN EXP IMMUNOL, V116, P115; Swaminathan S, 2003, SEMIN HEMATOL, V40, P107, DOI 10.1016/S0037-1963(03)70002-X; Than S, 1997, J INFECT DIS, V175, P47, DOI 10.1093/infdis/175.1.47; Trabattoni D, 2003, BLOOD, V101, P2514, DOI 10.1182/blood-2002-10-3065; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06; Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Xiao Y, 2008, VIROLOGY, V372, P384, DOI 10.1016/j.virol.2007.10.036; Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	320	350	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					452	U136		10.1038/nm.2106	http://dx.doi.org/10.1038/nm.2106			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20208540	Green Accepted			2022-12-27	WOS:000276446800050
J	Liang, Y; Vogel, JL; Narayanan, A; Peng, H; Kristie, TM				Liang, Yu; Vogel, Jodi L.; Narayanan, Aarthi; Peng, Hua; Kristie, Thomas M.			Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency	NATURE MEDICINE			English	Article							IMMEDIATE-EARLY PROMOTERS; HOST-CELL FACTOR; SIMPLEX-VIRUS; ANDROGEN-RECEPTOR; COACTIVATOR HCF-1; GENE-EXPRESSION; H3 LYSINE-4; EARLY TIMES; IN-VIVO; METHYLATION	Reversible methylation of histone tails serves as either a positive signal recognized by transcriptional assemblies or a negative signal that result in repression(1-4). Invading viral pathogens that depend upon the host cell's transcriptional apparatus are also subject to the regulatory impact of chromatin assembly and modifications(5-8). Here we show that infection by the alpha-herpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accumulation of chromatin bearing repressive histone H3 Lys9 methylation. To enable expression of viral immediate early (IE) genes, both viruses use the cellular transcriptional coactivator host cell factor-1 (HCF-1) to recruit the lysine-specific demethylase-1 (LSD1) to the viral immediate early promoters. Depletion of LSD1 or inhibition of its activity with monoamine oxidase inhibitors (MAOIs) results in the accumulation of repressive chromatin and a block to viral gene expression. As HCF-1 is a component of the Set1 and MLL1 histone H3 Lys4 methyltransferase complexes(9,10), it thus coordinates modulation of repressive H3 Lys9 methylation levels with addition of activating H3 Lys4 trimethylation marks. Strikingly, MAOIs also block the reactivation of HSV from latency in sensory neurons, indicating that the HCF-1 complex is a crucial component of the reactivation mechanism. The results support pharmaceutical control of histone modifying enzymes as a strategy for controlling herpesvirus infections.	[Liang, Yu; Vogel, Jodi L.; Narayanan, Aarthi; Peng, Hua; Kristie, Thomas M.] NIAID, Mol Genet Sect, Viral Dis Lab, US Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kristie, TM (corresponding author), NIAID, Mol Genet Sect, Viral Dis Lab, US Natl Inst Hlth, 9000 Rockville Pike, Bethesda, MD 20892 USA.	thomas_kristie@nih.gov			Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000712] Funding Source: NIH RePORTER	Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank J. Skinner for expert statistical analysis of the experimental data; B. Moss, J. Yewdell, T. Pierson, J. Bennink and A. McBride for critical discussions and comments on this manuscript; members of the Molecular Genetics Section of the Laboratory of Viral Diseases for discussion, advice and technical assistance; the US National Institute of Allergy and Infectious Diseases Bld33 Animal Care Facility staff; N. Fraser (University of Pennsylvania School of Medicine) for HSV-1 strain 17, W. Ruyechan (University at Buffalo, State University of New York) for ICP8-specific sera and X. Chen (University of California at Davis) for MCF7 inducible LSD shRNA cells. These studies were supported by the Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health.	Amelio AL, 2006, J VIROL, V80, P2063, DOI 10.1128/JVI.80.4.2063-2068.2006; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang J, 2006, J VIROL, V80, P5740, DOI 10.1128/JVI.00169-06; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Knipe DM, 2008, NAT REV MICROBIOL, V6, P211, DOI 10.1038/nrmicro1794; Kolb G, 2008, J VIROL, V82, P9555, DOI 10.1128/JVI.01174-08; Kouzarides T, 2007, EPIGENETICS, P191; Kristie TM, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P112; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; Kubat NJ, 2004, J VIROL, V78, P1139, DOI 10.1128/JVI.78.3.1139-1149.2004; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Lieberman PM, 2008, J CELL PHYSIOL, V216, P295, DOI 10.1002/jcp.21421; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mok HP, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-228; Narayanan A, 2007, P NATL ACAD SCI USA, V104, P10835, DOI 10.1073/pnas.0704351104; Neumann DM, 2007, J VIROL, V81, P13248, DOI 10.1128/JVI.01569-07; Oh J, 2008, J VIROL, V82, P3530, DOI 10.1128/JVI.00586-07; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Pesola JA, 2005, J VIROL, V79, P14516, DOI 10.1128/JVI.79.23.14516-14525.2005; Placek BJ, 2009, J VIROL, V83, P1416, DOI 10.1128/JVI.01276-08; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sawtell NM, 2006, J VIROL, V80, P38, DOI 10.1128/JVI.80.1.38-50.2006; Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Sinclair J, 2010, BBA-GENE REGUL MECH, V1799, P286, DOI 10.1016/j.bbagrm.2009.08.001; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang QY, 2005, P NATL ACAD SCI USA, V102, P16055, DOI 10.1073/pnas.0505850102; Whitlow Z, 2009, J VIROL, V83, P9591, DOI 10.1128/JVI.01115-09; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	40	202	245	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1312	U112		10.1038/nm.2051	http://dx.doi.org/10.1038/nm.2051			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19855399	Green Accepted			2022-12-27	WOS:000271543700020
J	St John, AL; Abraham, SN				St John, Ashley L.; Abraham, Soman N.			Salmonella disrupts lymph node architecture by TLR4-mediated suppression of homeostatic chemokines	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; TYPHIMURIUM INFECTION; LYMPHOCYTES; MACROPHAGES; EXPRESSION; CELLS; LIPOPOLYSACCHARIDE; FOLLICLES; VIRULENCE; PROMOTES	We report that infection of draining lymph nodes (DLNs) by Salmonella typhimurium results in the specific downregulation of the homeostatic chemokines CCL21 and CXCL13, which are essential for normal DLN organization and function. Our data reveal that the mechanism of this suppression is dependent on S. typhimurium LPS (sLPS). The decrease in CCL21 expression involves interaction between sLPS and CCL21-producing cells within DLNs, triggering a distinct Toll-like receptor 4 (TLR4)-mediated host signaling response. In this response, suppressor of cytokine signaling-3 (Socs3) is upregulated, which negatively regulates mothers against decapentaplegic homolog-3 (Smad3)-initiated production of CCL21. Disruption of lymph node architecture and cellular trafficking enhances S. typhimurium virulence and could represent a mechanism of immune suppression used by pathogens that primarily target lymphoid tissue.	[St John, Ashley L.; Abraham, Soman N.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; [Abraham, Soman N.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Abraham, Soman N.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Abraham, Soman N.] Duke Natl Univ Singapore, Grad Sch Med, Program Emerging Infect Dis, Singapore, Singapore	Duke University; Duke University; Duke University; National University of Singapore	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.	soman.abraham@duke.edu	StJohn, Ashley/AAE-4378-2021	StJohn, Ashley/0000-0001-5098-1044	US National Institutes of Health [R01 AI35678, R01 DK077159, R01 AI50021, R37 DK50814, R21 AI056101]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI074751, R01AI050021, R21AI056101, R01AI035678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077159, R21DK077307, R37DK050814] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank M. Krangel, M. Gunn, M. Kuehn, Y. He and W. Zhang for their discussions and J. Wright for the use of equipment. Salmonella strains chi 3761 and chi 8573 were a gift from R. Curtiss (Arizona State University) and M. Kuehn (Duke University). S. typhimurium SL1344 was a gift from A. Aballay (Duke University), and E. coli J96 was a gift from S. Normark (Umea University). G. Li provided technical advice. Z. Swan, C. Kunder, G. Li and A. Bickell provided critical manuscript review. This work was supported by US National Institutes of Health grants R01 AI35678, R01 DK077159, R01 AI50021, R37 DK50814 and R21 AI056101.	Ansel KM, 2002, IMMUNITY, V16, P67, DOI 10.1016/S1074-7613(01)00257-6; Bonneau M, 2006, J LEUKOCYTE BIOL, V79, P268, DOI 10.1189/jlb.0605288; Cyster JG, 2000, IMMUNOL REV, V176, P181; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; KUMAR A, 1984, INDIAN J MED RES, V80, P270; KUMAR A, 1984, INDIAN J MED RES, V80, P557; Liu X, 2008, MOL IMMUNOL, V45, P1405, DOI 10.1016/j.molimm.2007.08.018; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mittrucker HW, 2000, J IMMUNOL, V164, P1648, DOI 10.4049/jimmunol.164.4.1648; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; Mueller SN, 2007, SCIENCE, V317, P670, DOI 10.1126/science.1144830; NAUCIEL C, 1990, J IMMUNOL, V145, P1265; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Oyston PCF, 2004, NAT REV MICROBIOL, V2, P967, DOI 10.1038/nrmicro1045; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Stoiber D, 1999, J IMMUNOL, V163, P2640; Uchiya K, 2005, INFECT IMMUN, V73, P5587, DOI 10.1128/IAI.73.9.5587-5594.2005; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222	24	46	47	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1259	U51		10.1038/nm.2036	http://dx.doi.org/10.1038/nm.2036			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19855398	Green Accepted			2022-12-27	WOS:000271543700013
J	Feuerer, M; Herrero, L; Cipolletta, D; Naaz, A; Wong, J; Nayer, A; Lee, J; Goldfine, AB; Benoist, C; Shoelson, S; Mathis, D				Feuerer, Markus; Herrero, Laura; Cipolletta, Daniela; Naaz, Afia; Wong, Jamie; Nayer, Ali; Lee, Jongsoon; Goldfine, Allison B.; Benoist, Christophe; Shoelson, Steven; Mathis, Diane			Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters	NATURE MEDICINE			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; DENDRITIC CELLS; MACROPHAGES; ACTIVATION; EXPRESSION; ABLATION; BETA; MICE; GENE	Obesity is accompanied by chronic, low-grade inflammation of adipose tissue, which promotes insulin resistance and type-2 diabetes. These findings raise the question of how fat inflammation can escape the powerful armamentarium of cells and molecules normally responsible for guarding against a runaway immune response. CD4(+) Foxp3(+) T regulatory (T-reg) cells with a unique phenotype were highly enriched in the abdominal fat of normal mice, but their numbers were strikingly and specifically reduced at this site in insulin-resistant models of obesity. Loss-of-function and gain-of-function experiments revealed that these T-reg cells influenced the inflammatory state of adipose tissue and, thus, insulin resistance. Cytokines differentially synthesized by fat-resident regulatory and conventional T cells directly affected the synthesis of inflammatory mediators and glucose uptake by cultured adipocytes. These observations suggest that harnessing the anti-inflammatory properties of T-reg cells to inhibit elements of the metabolic syndrome may have therapeutic potential. (C) 2009 Nature America, Inc. All rights reserved.	[Cipolletta, Daniela] European Sch Mol Med, Naples, Italy; [Feuerer, Markus; Herrero, Laura; Cipolletta, Daniela; Naaz, Afia; Wong, Jamie; Nayer, Ali; Lee, Jongsoon; Goldfine, Allison B.; Benoist, Christophe; Shoelson, Steven; Mathis, Diane] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Joslin Diabetes Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.	Mathis, D (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	dm@hms.harvard.edu	Lee, Jongsoon/AAG-1674-2020; Eckhardt, Erik/G-1567-2010; Herrero, Laura/D-4011-2014	Herrero, Laura/0000-0003-4244-4673; Lee, Jongsoon/0000-0002-0891-5059	Young Chair funds; US National Institutes of Health [DK51729, DK73547, T32 DK7260]; Adler Chair funds; Joslin's National Institutes of Diabetes and Digestive and Kidney Diseases-funded Diabetes and Endocrinology Research Center core facilities; German Research Foundation [FE 801/1-1]; Charles A. King Trust Postdoctoral Fellowship; Ministry of Science of Spain; European School of Molecular Medicine, respectively; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051729, T32DK007260, R01DK051729, R01DK073547] Funding Source: NIH RePORTER	Young Chair funds; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Adler Chair funds; Joslin's National Institutes of Diabetes and Digestive and Kidney Diseases-funded Diabetes and Endocrinology Research Center core facilities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); German Research Foundation(German Research Foundation (DFG)); Charles A. King Trust Postdoctoral Fellowship; Ministry of Science of Spain(Spanish Government); European School of Molecular Medicine, respectively; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank D. Littman (New York University) for the DTR construct, L. Roser and K. Hattori for assistance with mice, S. Rudensky (Memorial Sloan Kettering Cancer Center) for providing us with Foxp3<SUP>DTR</SUP> mice, J. LaVecchio and G. Buruzala for flow cytometry and J. Hill, J. Perez and R. Melamed for help with the microarray analysis. This work was supported by Young Chair funds to D. M. and C. B., by the US National Institutes of Health (DK51729 and DK73547) and Adler Chair funds to S. S. and by Joslin's National Institutes of Diabetes and Digestive and Kidney Diseases-funded Diabetes and Endocrinology Research Center core facilities. Postdoctoral fellowship support for M. F. was from the German Research Foundation (Emmy-Noether Fellowship, FE 801/1-1) and the Charles A. King Trust Postdoctoral Fellowship, and for L. H. from the Ministry of Science of Spain. J. W. and D. C. were supported by predoctoral fellowships from the US National Institutes of Health (T32 DK7260) and the European School of Molecular Medicine, respectively.	Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Bluher M, 2005, EXP CLIN ENDOCR DIAB, V113, P534, DOI 10.1055/s-2005-872851; Bosello O, 2000, Obes Rev, V1, P47, DOI 10.1046/j.1467-789x.2000.00008.x; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Caspar-Bauguil S, 2005, FEBS LETT, V579, P3487, DOI 10.1016/j.febslet.2005.05.031; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Correia-Neves M, 2001, IMMUNITY, V14, P21, DOI 10.1016/S1074-7613(01)00086-3; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Duffield JS, 2005, AM J PATHOL, V167, P1207, DOI 10.1016/S0002-9440(10)61209-6; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kumada M, 2004, CIRCULATION, V109, P2046, DOI 10.1161/01.CIR.0000127953.98131.ED; Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Miyake Y, 2007, J IMMUNOL, V178, P5001, DOI 10.4049/jimmunol.178.8.5001; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Nguyen LT, 2007, ARTHRITIS RHEUM-US, V56, P509, DOI 10.1002/art.22272; Nolan KF, 2004, J IMMUNOL, V172, P2201, DOI 10.4049/jimmunol.172.4.2201; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Pacholczyk R, 2006, IMMUNITY, V25, P249, DOI 10.1016/j.immuni.2006.05.016; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Scarpelli D, 2006, DIABETES, V55, P1529, DOI 10.2337/db06-0047; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Tang Q, 2008, IMMUNITY, V28, P687, DOI 10.1016/j.immuni.2008.03.016; Thorburn J, 2003, CLIN CANCER RES, V9, P861; Tran TT, 2008, CELL METAB, V7, P410, DOI 10.1016/j.cmet.2008.04.004; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Wan SG, 2007, J IMMUNOL, V178, P271, DOI 10.4049/jimmunol.178.1.271; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145; Wong J, 2007, J IMMUNOL, V178, P7032, DOI 10.4049/jimmunol.178.11.7032; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	58	1445	1500	0	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					930	U137		10.1038/nm.2002	http://dx.doi.org/10.1038/nm.2002			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19633656	Green Accepted			2022-12-27	WOS:000268770400038
J	Thomas, C				Thomas, Clare			Roadblocks in HIV research: five questions	NATURE MEDICINE			English	Article							VACCINE	What are the most important questions that the HIV field needs to answer to make progress? Nature Medicine asked this question to a group of HIV researchers to identify some of the key roadblocks in HIV research.										Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; *COORD COMM GLOB H, 2004, PLOS MED, V2, pE25; Enquist LW, 2009, J VIROL, V83, P5296, DOI 10.1128/JVI.00151-09; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Willyard C, 2009, NAT MED, V15, P126, DOI 10.1038/nm0209-126	10	30	30	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					855	859		10.1038/nm0809-855	http://dx.doi.org/10.1038/nm0809-855			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19661992				2022-12-27	WOS:000268770400025
J	Muchamuel, T; Basler, M; Aujay, MA; Suzuki, E; Kalim, KW; Lauer, C; Sylvain, C; Ring, ER; Shields, J; Jiang, J; Shwonek, P; Parlati, F; Demo, SD; Bennett, MK; Kirk, CJ; Groettrup, M				Muchamuel, Tony; Basler, Michael; Aujay, Monette A.; Suzuki, Erika; Kalim, Khalid W.; Lauer, Christoph; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.; Groettrup, Marcus			A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis	NATURE MEDICINE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; T-CELL REPERTOIRE; IRREVERSIBLE INHIBITOR; VIRUS-INFECTION; TNF-ALPHA; INDUCTION; EXPRESSION; BORTEZOMIB; TOLERANCE; RESPONSES	The immunoproteasome, a distinct class of proteasome found predominantly in monocytes and lymphocytes, is known to shape the antigenic repertoire presented on class I major histocompatibility complexes (MHC-I). However, a specific role for the immunoproteasome in regulating other facets of immune responses has not been established. We describe here the characterization of PR-957, a selective inhibitor of low-molecular mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome. PR-957 blocked presentation of LMP7-specific, MHC-I-restricted antigens in vitro and in vivo. Selective inhibition of LMP7 by PR-957 blocked production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells. In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in reductions in cellular infiltration, cytokine production and autoantibody levels. These studies reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for targeting LMP7 in autoimmune disorders.	[Muchamuel, Tony; Aujay, Monette A.; Suzuki, Erika; Sylvain, Catherine; Ring, Eileen R.; Shields, Jamie; Jiang, Jing; Shwonek, Peter; Parlati, Francesco; Demo, Susan D.; Bennett, Mark K.; Kirk, Christopher J.] Proteolix Inc, San Francisco, CA USA; [Basler, Michael; Groettrup, Marcus] Univ Constance, Biotechnol Inst Thurgau, Kreuzlingen, Switzerland; [Basler, Michael; Kalim, Khalid W.; Lauer, Christoph; Groettrup, Marcus] Univ Constance, Div Immunol, Dept Biol, D-7750 Constance, Germany	University of Konstanz	Kirk, CJ (corresponding author), Proteolix Inc, San Francisco, CA USA.	ckirk@proteolix.com; Marcus.Groettrup@uni-konstanz.de	Groettrup, Marcus/AAT-2623-2020	Basler, Michael/0000-0002-9428-2349; Muchamuel, Tony/0000-0002-4143-3086	German National Science Foundation [GR 1517/4-2]; Swiss National Science Foundation [31003A_ 119699]; Graduate School Chemical Biology	German National Science Foundation(German Research Foundation (DFG)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Graduate School Chemical Biology	We thank R. Deshaies for discussion and comments. We thank N. Shastri (University of California-Berkeley) for providing T cell hybridomas and V. Cerundulo (University of Oxford) for the contribution of recombinant vaccinia viruses. We acquired P14 (transgenic line 318) and RIP-GP mice from M. van den Broek, University Hospital Zurich. Psmb8<SUP>-/-</SUP> gene-targeted mice were obtained from J. Monaco, University of Cincinnati. We thank J. Mattar (Rheumatology, Ueberlingen-Nussdorf) for the collection of blood from individuals with rheumatoid arthritis and L. Klotz and P. Knolle for instructions on the TH17 differentiation assay. U. Beck is achnowledged for excellent technical assistance. This work was funded by the German National Science Foundation grant GR 1517/4-2 and the Swiss National Science Foundation grant 31003A_ 119699. K. W. K. holds a fellowship of the Graduate School Chemical Biology at University of Constance (KoRS-CB).	Basler M, 2004, J IMMUNOL, V173, P3925, DOI 10.4049/jimmunol.173.6.3925; Basler M, 2007, EUR J IMMUNOL, V37, P896, DOI 10.1002/eji.200636372; Basler M, 2006, J IMMUNOL, V176, P6665, DOI 10.4049/jimmunol.176.11.6665; Berkers CR, 2005, NAT METHODS, V2, P357, DOI 10.1038/nmeth759; Borissenko L, 2007, CHEM REV, V107, P687, DOI 10.1021/cr0502504; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; Caudill CM, 2006, J IMMUNOL, V176, P4075, DOI 10.4049/jimmunol.176.7.4075; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chen WS, 2001, J EXP MED, V193, P1319, DOI 10.1084/jem.193.11.1319; De M, 2003, J BIOL CHEM, V278, P6153, DOI 10.1074/jbc.M209292200; Demo SD, 2007, CANCER RES, V67, P6383, DOI 10.1158/0008-5472.CAN-06-4086; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Frausto RF, 2007, J NEUROIMMUNOL, V192, P124, DOI 10.1016/j.jneuroim.2007.09.024; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Ho YK, 2007, CHEM BIOL, V14, P419, DOI 10.1016/j.chembiol.2007.03.008; Kagari T, 2002, J IMMUNOL, V169, P1459, DOI 10.4049/jimmunol.169.3.1459; Khan S, 2001, J IMMUNOL, V167, P6859, DOI 10.4049/jimmunol.167.12.6859; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Klare N, 2007, J MOL BIOL, V373, P1, DOI 10.1016/j.jmb.2007.07.038; Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888; Naujokat C, 2007, IMMUNOLOGY, V120, P120, DOI 10.1111/j.1365-2567.2006.02487.x; Nussbaum AK, 2005, J IMMUNOL, V175, P1153, DOI 10.4049/jimmunol.175.2.1153; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Palmowski MJ, 2006, J IMMUNOL, V177, P983, DOI 10.4049/jimmunol.177.2.983; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Qureshi N, 2005, IMMUNOL RES, V31, P243, DOI 10.1385/IR:31:3:243; Qureshi N, 2003, J IMMUNOL, V171, P1515, DOI 10.4049/jimmunol.171.3.1515; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Schwartz AL, 1999, ANNU REV MED, V50, P57; SHENK KD, 2008, Patent No. 20070293465; Strehl B, 2006, J IMMUNOL, V177, P6238, DOI 10.4049/jimmunol.177.9.6238; VAN KL, 1994, IMMUNITY, V1, P533; Williams RO, 2000, J IMMUNOL, V165, P7240, DOI 10.4049/jimmunol.165.12.7240; ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520	40	436	473	2	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					781	U12		10.1038/nm.1978	http://dx.doi.org/10.1038/nm.1978			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19525961	Green Submitted			2022-12-27	WOS:000267806900031
J	Hong, HS; Lee, J; Lee, E; Kwon, YS; Lee, E; Ahn, W; Jiang, MH; Kim, JC; Son, Y				Hong, Hyun Sook; Lee, Jungsun; Lee, EunAh; Kwon, Young Sam; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Kim, Jae Chan; Son, Youngsook			A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells	NATURE MEDICINE			English	Article							MESENCHYMAL STEM-CELLS; GROWTH-FACTOR RECEPTOR; BONE-MARROW STROMA; MYOCARDIAL-INFARCTION; PROTEIN-KINASE; WOUND REPAIR; DIFFERENTIATION; ACTIVATION; PROLIFERATION; EXPRESSION	Tissue injury may create a specific microenvironment for inducing the systemic participation of stromal-like cells in the repair process. Here we show that substance P is an injury-inducible factor that acts early in the wound healing process to induce CD29(+) stromal-like cell mobilization. Likewise, mobilization of such cells also occurs in uninjured mice, rats and rabbits if substance P is intravenously injected. Upon further characterization these substance P-mobilized CD29(+) cells were found to be similar to stromal cells from a number of connective tissues, including bone marrow (that is, bone marrow stromal cells, or BMSCs). Both substance P injection and transfusion of autologously derived substance P-mobilized CD29(+) cells from uninjured rabbits accelerated wound healing in an alkali burn model. Also, epithelial engraftment of the transfused cells into the injured tissue occurred during the wound healing. Finally, using human BMSCs as a test population, we show that substance P stimulates transmigration, cell proliferation, activation of the extracellular signal-related kinases (Erk) 1 and 2 and nuclear translocation of beta-catenin in vitro. This finding highlights a previously undescribed function of substance P as a systemically acting messenger of injury and a mobilizer of CD29(+) stromal-like cells to participate in wound healing.	[Kwon, Young Sam; Kim, Jae Chan] Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 140757, South Korea; [Hong, Hyun Sook; Lee, EunAh; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Son, Youngsook] Kyung Hee Univ, Grad Sch Biotechnol, Yongin 441706, South Korea; [Hong, Hyun Sook; Lee, EunAh; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Son, Youngsook] Kyung Hee Univ, Coll Life Sci, Dept Genet Engn, Yongin 441706, South Korea; [Hong, Hyun Sook; Lee, Jungsun] Seoul Natl Univ Technol, MCTT, Inst Res & Dev, Seoul 139743, South Korea	Chung Ang University; Chung Ang University Hospital; Kyung Hee University; Kyung Hee University	Kim, JC (corresponding author), Chung Ang Univ, Coll Med, Dept Ophthalmol, Hangangro 3,65-207, Seoul 140757, South Korea.	jck50ey@kornet.net; ysson@khu.ac.kr	Ahn, Woosung/GXG-2482-2022; HONG, HYUN SOOK/AAI-3017-2020	Ahn, Woosung/0000-0001-6933-4947; HONG, HYUN SOOK/0000-0003-3659-1386				Al-Sarraj A, 2002, NEUROSCI LETT, V332, P111, DOI 10.1016/S0304-3940(02)00939-4; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; GALLAR J, 1990, INVEST OPHTH VIS SCI, V31, P1968; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Ho WZ, 1997, J IMMUNOL, V159, P5654; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kidd BL, 2003, NEUROREPORT, V14, P2189, DOI 10.1097/00001756-200312020-00011; Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133; Kuznetsov SA, 2007, STEM CELLS, V25, P1830, DOI 10.1634/stemcells.2007-0140; Lai XN, 1998, PEPTIDES, V19, P1209, DOI 10.1016/S0196-9781(98)00068-0; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lim Mira, 2003, Ocul Surf, V1, P53; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MILLER A, 1981, NEUROSCI LETT, V23, P243, DOI 10.1016/0304-3940(81)90005-7; Nakamura M, 2003, DIABETOLOGIA, V46, P839, DOI 10.1007/s00125-003-1105-9; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737; Opalenik SR, 2005, FASEB J, V19, P1561, DOI 10.1096/fj.04-2978fje; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; PAYAN DG, 1983, J IMMUNOL, V131, P1613; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; RAMESHWAR P, 1993, BLOOD, V81, P391; Rameshwar P, 2001, J NEUROIMMUNOL, V121, P22, DOI 10.1016/S0165-5728(01)00443-X; RAMESHWAR P, 1995, BLOOD, V86, P482, DOI 10.1182/blood.V86.2.482.bloodjournal862482; Rameshwar P, 2001, BLOOD, V97, P3025, DOI 10.1182/blood.V97.10.3025; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rochefort GY, 2006, STEM CELLS, V24, P2202, DOI 10.1634/stemcells.2006-0164; Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004-0330OC; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Sato Y, 2005, BLOOD, V106, P756, DOI 10.1182/blood-2005-02-0572; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Watanabe M, 2002, JPN J OPHTHALMOL, V46, P616, DOI 10.1016/S0021-5155(02)00617-2; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamada N, 2004, INVEST OPHTH VIS SCI, V45, P1125, DOI 10.1167/iovs.03-0626; Yang CM, 2002, CELL SIGNAL, V14, P913, DOI 10.1016/S0898-6568(02)00039-6; Ye J, 2004, EYE, V18, P839, DOI 10.1038/sj.eye.6701346; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Zhong J, 2006, J CELL PHYSIOL, V207, P540, DOI 10.1002/jcp.20605	46	279	288	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					425	435		10.1038/nm.1909	http://dx.doi.org/10.1038/nm.1909			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19270709				2022-12-27	WOS:000264937200030
J	Wang, Y; Roche, O; Yan, MS; Finak, G; Evans, AJ; Metcalf, JL; Hast, BE; Hanna, SC; Wondergem, B; Furge, KA; Irwin, MS; Kim, WY; Teh, BT; Grinstein, S; Park, M; Marsden, PA; Ohh, M				Wang, Yi; Roche, Olga; Yan, Mathew S.; Finak, Greg; Evans, Andrew J.; Metcalf, Julie L.; Hast, Bridgid E.; Hanna, Sara C.; Wondergem, Bill; Furge, Kyle A.; Irwin, Meredith S.; Kim, William Y.; Teh, Bin T.; Grinstein, Sergio; Park, Morag; Marsden, Philip A.; Ohh, Michael			Regulation of endocytosis via the oxygen-sensing pathway	NATURE MEDICINE			English	Article							VON-HIPPEL-LINDAU; HYPOXIA-INDUCIBLE FACTOR; SMALL GTPASE RAB5; MEMBRANE-FUSION; PROTEIN; RABAPTIN-5; EFFECTOR; BINDING; GROWTH; CANCER	Tumor hypoxia is associated with disease progression, resistance to conventional cancer therapies and poor prognosis(1,2). Hypoxia, by largely unknown mechanisms, leads to deregulated accumulation of and signaling via receptor tyrosine kinases (RTKs) that are critical for driving oncogenesis. Here, we show that hypoxia or loss of von Hippel-Lindau protein-the principal negative regulator of hypoxia-inducible factor (HIF)(3)-prolongs the activation of epidermal growth factor receptor that is attributable to lengthened receptor half-life and retention in the endocytic pathway. The deceleration in endocytosis is due to the attenuation of Rab5-mediated early endosome fusion via HIF-dependent downregulation of a critical Rab5 effector, rabaptin-5, at the level of transcription. Primary kidney and breast tumors with strong hypoxic signatures show significantly lower expression of rabaptin-5 RNA and protein. These findings reveal a general role of the oxygen-sensing pathway in endocytosis and support a model in which tumor hypoxia or oncogenic activation of HIF prolongs RTK-mediated signaling by delaying endocytosis-mediated deactivation of receptors.	[Wang, Yi; Evans, Andrew J.; Metcalf, Julie L.; Irwin, Meredith S.; Marsden, Philip A.; Ohh, Michael] Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; [Yan, Mathew S.; Marsden, Philip A.] Univ Toronto, St Michaels Hosp, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; [Yan, Mathew S.] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada; [Finak, Greg; Park, Morag] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; [Evans, Andrew J.] Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada; [Hast, Bridgid E.; Hanna, Sara C.; Kim, William Y.] Univ N Carolina, Dept Haematol Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Wondergem, Bill; Furge, Kyle A.] Van Andel Res Inst, Grand Rapids, MI 49503 USA; [Irwin, Meredith S.] Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Grinstein, Sergio] Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; [Grinstein, Sergio] Hosp Sick Children, Dept Biochem, Toronto, ON M5G 1X8, Canada; [Grinstein, Sergio] Univ Toronto, Toronto, ON M5G 1X8, Canada; [Park, Morag] McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; [Park, Morag] McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McGill University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of North Carolina; University of North Carolina Chapel Hill; Van Andel Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University; McGill University	Ohh, M (corresponding author), Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca	Roche, Olga/K-9342-2014; Marsden, Philip A/B-1441-2012; Roche, UCLM/F-5697-2019	Roche, UCLM/0000-0003-1884-8256; Teh, Bin Tean/0000-0003-1514-1124; Finak, Greg/0000-0003-4341-9090	Canadian Institutes of Health Research [MOP77718, MOP37778]; CIHR; Canada Research Chairs	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs(Canada Research ChairsCGIAR)	This work was supported by grants from the Canadian Institutes of Health Research (CIHR MOP77718 to M.O., MOP37778 to P.A.M. and CIHR team grant to M. P.). Y.W. and O.R. are recipients of CIHR postdoctoral fellowships. M.S.I. and M.O. are Canada Research Chairs.	Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hsu T, 2006, J BIOL CHEM, V281, P12069, DOI 10.1074/jbc.M511621200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Koeman JM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000176; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Korobko EV, 2006, CELL CYCLE, V5, P1854, DOI 10.4161/cc.5.16.3092; Lippe R, 2001, METHOD ENZYMOL, V329, P132; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE145, DOI 10.1038/14097; Roberts AM, 2008, CURR OPIN ONCOL, V20, P83, DOI 10.1097/CCO.0b013e3282f310de; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Walmsley SR, 2006, BLOOD, V108, P3176, DOI 10.1182/blood-2006-04-018796; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Zhong H, 1999, CANCER RES, V59, P5830	36	150	151	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					319	324		10.1038/nm.1922	http://dx.doi.org/10.1038/nm.1922			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19252501				2022-12-27	WOS:000263914000033
J	Jinnin, M; Medici, D; Park, L; Limaye, N; Liu, YQ; Boscolo, E; Bischoff, J; Vikkula, M; Boye, E; Olsen, BR				Jinnin, Masatoshi; Medici, Damian; Park, Lucy; Limaye, Nisha; Liu, Yanqiu; Boscolo, Elisa; Bischoff, Joyce; Vikkula, Miikka; Boye, Eileen; Olsen, Bjorn R.			Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DOMAIN-CONTAINING RECEPTOR; FOCAL ADHESION KINASE; TYROSINE KINASE; TRANSCRIPTIONAL REGULATION; JUVENILE HEMANGIOMAS; CELL-ADHESION; ANTHRAX TOXIN; GENE; TRANSDUCTION	Infantile hemangiomas are localized and rapidly growing regions of disorganized angiogenesis. We show that expression of vascular endothelial growth factor receptor-1 (VEGFR1) in hemangioma endothelial cells (hemECs) and hemangioma tissue is markedly reduced compared to controls. Low VEGFR1 expression in hemECs results in VEGF-dependent activation of VEGFR2 and downstream signaling pathways. In hemECs, transcription of the gene encoding VEGFR1 (FLT1) is dependent on nuclear factor of activated T cells ( NFAT). Low VEGFR1 expression in hemECs is caused by reduced activity of a pathway involving beta 1 integrin, the integrin-like receptor tumor endothelial marker-8 (TEM8), VEGFR2 and NFAT. In a subset of individuals with hemangioma, we found missense mutations in the genes encoding VEGFR2 (KDR) and TEM8 (ANTXR1). These mutations result in increased interactions among VEGFR2, TEM8 and b1 integrin proteins and in inhibition of integrin activity. Normalization of the constitutive VEGFR2 signaling in hemECs with soluble VEGFR1 or antibodies that neutralize VEGF or stimulate b1 integrin suggests that local administration of these or similar agents may be effective in hemangioma treatment.	[Boscolo, Elisa; Bischoff, Joyce] Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; [Jinnin, Masatoshi; Medici, Damian; Park, Lucy; Liu, Yanqiu; Boye, Eileen; Olsen, Bjorn R.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; [Limaye, Nisha; Vikkula, Miikka] Univ Catholique Louvain, Duve Inst, B-1200 Brussels, Belgium	Harvard University; Boston Children's Hospital; Harvard University; Harvard School of Dental Medicine; Universite Catholique Louvain	Boye, E (corresponding author), Childrens Hosp, Dept Surg, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	eileen_boye@hms.harvard.edu; bjorn_olsen@hms.harvard.edu	Boscolo, Elisa/F-9483-2019; Vikkula, Miikka/Q-1038-2018; BISCHOFF, JOYCE/K-3354-2019	Boscolo, Elisa/0000-0002-6996-0419; Vikkula, Miikka/0000-0002-6236-338X; BISCHOFF, JOYCE/0000-0002-6367-1974	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, P01AR048564, R37AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR048564-03, P01 AR048564-02S1, AR48564, P01 AR048564-04, P01 AR048564, P01 AR048564-01A10001, P01 AR048564-01A1, AR36820, P01 AR048564-050003, P01 AR048564-05, P01 AR048564-050004, R01 AR036820, P01 AR048564-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Akuzawa N, 2000, ARTERIOSCL THROM VAS, V20, P377, DOI 10.1161/01.ATV.20.2.377; Aplin AE, 1998, PHARMACOL REV, V50, P197; Barnes CM, 2005, P NATL ACAD SCI USA, V102, P19097, DOI 10.1073/pnas.0509579102; Blei F, 1998, ARCH DERMATOL, V134, P718, DOI 10.1001/archderm.134.6.718; Boye E, 2001, J CLIN INVEST, V107, P745, DOI 10.1172/JCI11432; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brouillard P, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.024174; Chiller KG, 2002, ARCH DERMATOL, V138, P1567, DOI 10.1001/archderm.138.12.1567; Claesson-Welsh L, 2003, BIOCHEM SOC T, V31, P20, DOI 10.1042/bst0310020; Ferrara N, 2005, EXP SUPPL, V94, P209; Fragoso R, 2006, BLOOD, V107, P1608, DOI 10.1182/blood-2005-06-2530; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Haggstrom AN, 2007, J PEDIATR-US, V150, P291, DOI 10.1016/j.jpeds.2006.12.003; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Inoue T, 2000, FEBS LETT, V469, P14, DOI 10.1016/S0014-5793(00)01246-1; Ito N, 2001, CELL SIGNAL, V13, P849, DOI 10.1016/S0898-6568(01)00209-1; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Khan ZA, 2006, BLOOD, V108, P915, DOI 10.1182/blood-2006-03-006478; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kuriyama M, 2004, BIOCHEM BIOPH RES CO, V325, P843, DOI 10.1016/j.bbrc.2004.10.102; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Li Q, 2003, J PATHOL, V201, P296, DOI 10.1002/path.1443; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mulliken J B, 1993, Semin Vasc Surg, V6, P204; North PE, 2006, CARDIOVASC PATHOL, V15, P303, DOI 10.1016/j.carpath.2006.03.001; North PE, 2000, HUM PATHOL, V31, P11, DOI 10.1016/S0046-8177(00)80192-6; North PE, 2001, ARCH DERMATOL, V137, P559; Picard A, 2008, PEDIATR RES, V63, P263, DOI 10.1203/PDR.0b013e318163a243; Razon MJ, 1998, MICROCIRCULATION-LON, V5, P189, DOI 10.1038/sj.mn.7300009; Ritter MR, 2006, AM J PATHOL, V168, P621, DOI 10.2353/ajpath.2006.050618; Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X; Satonaka H, 2004, CIRC RES, V94, P693, DOI 10.1161/01.RES.0000118250.67032.5E; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; Shenoy PS, 2001, BIOCHEM CELL BIOL, V79, P399, DOI 10.1139/bcb-79-4-399; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Sun YS, 2006, BLOOD, V107, P1476, DOI 10.1182/blood-2005-05-1912; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Walter JW, 2002, GENE CHROMOSOME CANC, V33, P295, DOI 10.1002/gcc.10028; Werner E, 2006, J BIOL CHEM, V281, P23227, DOI 10.1074/jbc.M603676200; Young AE, 1988, VASCULAR BIRTHMARKS, P24	48	247	267	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1236	1246		10.1038/nm.1877	http://dx.doi.org/10.1038/nm.1877			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18931684	Green Accepted			2022-12-27	WOS:000260751200043
J	Yousefi, S; Gold, JA; Andina, N; Lee, JJ; Kelly, AM; Kozlowski, E; Schmid, I; Straumann, A; Reichenbach, J; Gleich, GJ; Simon, HU				Yousefi, Shida; Gold, Jeffrey A.; Andina, Nicola; Lee, James J.; Kelly, Ann M.; Kozlowski, Evelyne; Schmid, Ines; Straumann, Alex; Reichenbach, Janine; Gleich, Gerald J.; Simon, Hans-Uwe			Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense	NATURE MEDICINE			English	Article							NEUTROPHIL EXTRACELLULAR TRAPS; CROHNS-DISEASE; T-CELLS; APOPTOSIS; INFLAMMATION; EXPRESSION; MECHANISMS; CYTOKINES; SURVIVIN; PROTEINS	Although eosinophils are considered useful in defense mechanisms against parasites, their exact function in innate immunity remains unclear. The aim of this study is to better understand the role of eosinophils within the gastrointestinal immune system. We show here that lipopolysaccharide from Gram-negative bacteria activates interleukin-5 (IL-5)- or interferon-gamma-primed eosinophils to release mitochondrial DNA in a reactive oxygen species - dependent manner, but independent of eosinophil death. Notably, the process of DNA release occurs rapidly in a catapult-like manner - in less than one second. In the extracellular space, the mitochondrial DNA and the granule proteins form extracellular structures able to bind and kill bacteria both in vitro and under inflammatory conditions in vivo. Moreover, after cecal ligation and puncture, II5-transgenic but not wild-type mice show intestinal eosinophil infiltration and extracellular DNA deposition in association with protection against microbial sepsis. These data suggest a previously undescribed mechanism of eosinophil-mediated innate immune responses that might be crucial for maintaining the intestinal barrier function after inflammation-associated epithelial cell damage, preventing the host from uncontrolled invasion of bacteria.	[Yousefi, Shida; Andina, Nicola; Kozlowski, Evelyne; Schmid, Ines; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland; [Gold, Jeffrey A.; Kelly, Ann M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care, Portland, OR 97239 USA; [Lee, James J.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA; [Straumann, Alex] Kantonsspital Olten, Dept Gastroenterol, CH-4600 Olten, Switzerland; [Reichenbach, Janine] Univ Childrens Hosp, CH-8032 Zurich, Switzerland; [Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT 84132 USA	University of Bern; Oregon Health & Science University; Mayo Clinic; Mayo Clinic Phoenix; Kantonsspital Olten; University Children's Hospital Zurich; Utah System of Higher Education; University of Utah	Yousefi, S (corresponding author), Univ Bern, Inst Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	shida.yousefi@pki.unibe.ch; hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020; Reichenbach, Janine/U-2171-2018; Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-5079-2020	Simon, Hans-Uwe/0000-0002-9404-7736; Reichenbach, Janine/0000-0002-9008-1312; Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; gold, jeffrey/0000-0001-6683-9907	Swiss National Science Foundation [310000-112078, 310000-107526]; Stanley Thomas Johnson Foundation, Bern, Switzerland; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067522] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Stanley Thomas Johnson Foundation, Bern, Switzerland; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank M. Kohler for critical review of the confocal microscopy and imaging data. We also thank D. Simon for histological examination of the mouse tissue sections. This work was supported by the Swiss National Science Foundation (grants 310000-112078 and 310000-107526) and Stanley Thomas Johnson Foundation, Bern, Switzerland.	Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Conus S, 2008, J EXP MED, V205, P685, DOI 10.1084/jem.20072152; Davis MDP, 2003, J ALLERGY CLIN IMMUN, V112, P988, DOI 10.1016/j.jaci.2003.08.028; DUBUCQUOI S, 1995, GUT, V37, P242, DOI 10.1136/gut.37.2.242; Edwards J, 2005, NATURE, V435, P164, DOI 10.1038/435164a; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Hankard GF, 1997, J PEDIATR GASTR NUTR, V24, P568, DOI 10.1097/00005176-199705000-00015; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Kostylina G, 2008, CELL DEATH DIFFER, V15, P134, DOI 10.1038/sj.cdd.4402238; Lee NA, 1997, J IMMUNOL, V158, P1332; MandicMulec I, 1997, INFECT IMMUN, V65, P110, DOI 10.1128/IAI.65.1.110-115.1997; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; Melo RCN, 2008, J LEUKOCYTE BIOL, V83, P229, DOI 10.1189/jlb.0707503; Nolan A, 2008, AM J RESP CRIT CARE, V177, P301, DOI 10.1164/rccm.200703-515OC; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Straumann A, 2004, ALLERGY, V59, P15, DOI 10.1046/j.1398-9995.2003.00382.x; Takedatsu H, 2004, EUR J IMMUNOL, V34, P1561, DOI 10.1002/eji.200324680; Vassina EM, 2006, EUR J IMMUNOL, V36, P1975, DOI 10.1002/eji.200635943; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	31	652	674	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					949	953		10.1038/nm.1855	http://dx.doi.org/10.1038/nm.1855			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18690244				2022-12-27	WOS:000258988600027
J	Krishnamoorthy, N; Oriss, TB; Paglia, M; Fei, MJ; Yarlagadda, M; Vanhaesebroeck, B; Ray, A; Ray, P				Krishnamoorthy, Nandini; Oriss, Timothy B.; Paglia, Melissa; Fei, Mingjian; Yarlagadda, Manohar; Vanhaesebroeck, Bart; Ray, Anuradha; Ray, Prabir			Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR GATA-3; BOUND TGF-BETA; AIRWAY INFLAMMATION; MAST-CELLS; PROTO-ONCOGENE; CHOLERA-TOXIN; GROWTH-FACTOR; W-LOCUS; EXPRESSION; RESPONSES	Dendritic cells ( DCs) are integral to the differentiation of T helper cells into T helper type 1 T(H)1, T(H)2 and T(H)17 subsets. Interleukin-6 ( IL-6) plays an important part in regulating these three arms of the immune response by limiting the T(H)1 response and promoting the T(H)2 and T(H)17 responses. In this study, we investigated pathways in DCs that promote IL-6 production. We show that the allergen house dust mite ( HDM) or the mucosal adjuvant cholera toxin promotes cell surface expression of c-Kit and its ligand, stem cell factor ( SCF), on DCs. This dual upregulation of c-Kit and SCF results in sustained signaling downstream of c-Kit, promoting IL-6 secretion. Intranasal administration of antigen into c-Kit-mutant mice or neutralization of IL-6 in cultures established from the lung-draining lymph nodes of immunized wild-type mice blunted the T(H)2 and T(H)17 responses. DCs lacking functional c-Kit or those unable to express membrane-bound SCF secreted lower amounts of IL- 6 in response to HDM or cholera toxin. DCs expressing nonfunctional c-Kit were unable to induce a robust T(H)2 or T(H)17 response and elicited diminished allergic airway inflammation when adoptively transferred into mice. Expression of the Notch ligand Jagged-2, which has been associated with T(H)2 differentiation, was blunted in DCs from c-Kit-mutant mice. c-Kit upregulation was specifically induced by T(H)2- and T(H)17-skewing stimuli, as the T(H)1-inducing adjuvant, CpG oligodeoxynucleotide, did not promote either c-Kit or Jagged-2 expression. DCs generated from mice expressing a catalytically inactive form of the p110 delta subunit of phosphatidylinositol-3 ( PI3) kinase ( p110(D910A)) secreted lower amounts of IL-6 upon stimulation with cholera toxin. Collectively, these results highlight the importance of the c-Kit-PI3 kinase-IL-6 signaling axis in DCs in regulating T cell responses.	[Krishnamoorthy, Nandini; Oriss, Timothy B.; Paglia, Melissa; Fei, Mingjian; Yarlagadda, Manohar; Ray, Anuradha; Ray, Prabir] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA; [Krishnamoorthy, Nandini; Ray, Anuradha; Ray, Prabir] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA; [Vanhaesebroeck, Bart] Queen Mary Univ London, Ctr Cell Signalling, Inst Canc, Barts & London Queen Marys Sch Med & Dent, London EC1M 6BQ, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; Queen Mary University London	Ray, A (corresponding author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, 3459 5th Ave, Pittsburgh, PA 15213 USA.	raya@pitt.edu; rayp@pitt.edu			NHLBI NIH HHS [HL 077430, R01 HL060207, P50 HL084932, R01 HL069810, HL 069810, R01 HL077430, HL 084932, HL 060207] Funding Source: Medline; NIAID NIH HHS [R01 AI048927, AI 048927] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060207, R01HL069810, P50HL084932, R01HL077430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048927] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103; Bagley KC, 2002, INFECT IMMUN, V70, P5533, DOI 10.1128/IAI.70.10.5533-5539.2002; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Cates EC, 2004, J IMMUNOL, V173, P6384, DOI 10.4049/jimmunol.173.10.6384; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chatterjea D, 2005, IMMUNOL LETT, V99, P122, DOI 10.1016/j.imlet.2005.02.015; Chen L, 2006, J IMMUNOL, V177, P2373, DOI 10.4049/jimmunol.177.4.2373; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dodge IL, 2003, J IMMUNOL, V170, P4457, DOI 10.4049/jimmunol.170.9.4457; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood-2003-12-4114; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kalesnikoff J, 2006, P NATL ACAD SCI USA, V103, P2659, DOI 10.1073/pnas.0511191103; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Lukacs NW, 1996, J IMMUNOL, V156, P3945; Luty WH, 2007, J IMMUNOL, V179, P819, DOI 10.4049/jimmunol.179.2.819; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Okkenhaug K, 2002, SCIENCE, V297, P1031; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Ostroukhova M, 2006, J CLIN INVEST, V116, P996, DOI 10.1172/JCI26490; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	49	158	164	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					565	573		10.1038/nm1766	http://dx.doi.org/10.1038/nm1766			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18454155	Green Accepted			2022-12-27	WOS:000255681800038
J	Mendez, I; Vinuela, A; Astradsson, A; Mukhida, K; Hallett, P; Robertson, H; Tierney, T; Holness, R; Dagher, A; Trojanowski, JQ; Isacson, O				Mendez, Ivar; Vinuela, Angel; Astradsson, Arnar; Mukhida, Karim; Hallett, Penelope; Robertson, Harold; Tierney, Travis; Holness, Renn; Dagher, Alain; Trojanowski, John Q.; Isacson, Ole			Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years	NATURE MEDICINE			English	Article							ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; LEWY BODIES; STEM-CELLS; TRANSPLANTATION	Postmortem analysis of five subjects with Parkinson's disease 9-14 years after transplantation of fetal midbrain cell suspensions revealed surviving grafts that included dopamine and serotonin neurons without pathology. These findings are important for the understanding of the etiopathogenesis of midbrain dopamine neuron degeneration and future use of cell replacement therapies.	[Vinuela, Angel; Astradsson, Arnar; Hallett, Penelope; Tierney, Travis; Isacson, Ole] Harvard Univ, Belmont, MA 02478 USA; [Vinuela, Angel; Astradsson, Arnar; Hallett, Penelope; Tierney, Travis; Isacson, Ole] McLean Hosp, US Natl Inst Neurol Disorders & Stroke, Udall Parkinsons Dis Res Ctr Excellence, Belmont, MA 02478 USA; [Mendez, Ivar; Mukhida, Karim; Robertson, Harold; Holness, Renn] Dalhousie Univ, Halifax, NS B3H 3A7, Canada; [Mendez, Ivar; Mukhida, Karim; Robertson, Harold; Holness, Renn] Queen Elizabeth 2 Hlth Sci Ctr, Div Neurosurg, Halifax, NS B3H 3A7, Canada; [Mendez, Ivar; Mukhida, Karim; Robertson, Harold; Holness, Renn] Queen Elizabeth 2 Hlth Sci Ctr, Dept Anat & Neurobiol, Halifax, NS B3H 3A7, Canada; [Mendez, Ivar; Mukhida, Karim; Robertson, Harold; Holness, Renn] Queen Elizabeth 2 Hlth Sci Ctr, Dept Pharmacol, Halifax, NS B3H 3A7, Canada; [Tierney, Travis] Massachusetts Gen Hosp, Neurosci Serv, Boston, MA 02114 USA; [Dagher, Alain] McGill Univ, Montreal, PQ H3A 2B4, Canada; [Dagher, Alain] Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada; [Trojanowski, John Q.] Univ Penn, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Inst Aging,NINDS Udall Parkinsons Dis Res Ctr Exc, Philadelphia, PA 19104 USA	Harvard University; Harvard University; McLean Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); NIH National Library of Medicine (NLM); Dalhousie University; Queen Elizabeth II Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Harvard University; Massachusetts General Hospital; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Pennsylvania; Pennsylvania Medicine	Isacson, O (corresponding author), Harvard Univ, 115 Mill St, Belmont, MA 02478 USA.	isacson@hms.harvard.edu		Hallett, Penelope/0000-0002-8858-9096; Isacson, Ole/0000-0001-8091-8302	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS039793, P50NS053488] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS039793, P50 NS039793-08, P50 NS053488, NS 053488, P50 NS 39793] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; Carlsson T, 2007, J NEUROSCI, V27, P8011, DOI 10.1523/JNEUROSCI.2079-07.2007; Carta M, 2007, BRAIN, V130, P1819, DOI 10.1093/brain/awm082; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Galvin JE, 2001, EXP NEUROL, V168, P347, DOI 10.1006/exnr.2000.7615; Isacson O, 2003, ANN NEUROL, V53, pS135, DOI 10.1002/ana.10482; Kuusisto E, 2003, J NEUROPATH EXP NEUR, V62, P1241, DOI 10.1093/jnen/62.12.1241; Lewy F., 1914, DEUT Z NERVENHEILKD, V50, P50; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Pruszak J, 2007, STEM CELLS, V25, P2257, DOI 10.1634/stemcells.2006-0744; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Takahashi H, 2001, NEUROPATHOLOGY, V21, P315, DOI 10.1046/j.1440-1789.2001.00403.x	15	319	334	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					507	509		10.1038/nm1752	http://dx.doi.org/10.1038/nm1752			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18391961	Green Accepted			2022-12-27	WOS:000255681800030
J	Judenhofer, MS; Wehrl, HF; Newport, DF; Catana, C; Siegel, SB; Becker, M; Thielscher, A; Kneilling, M; Lichy, MP; Eichner, M; Klingel, K; Reischl, G; Widmaier, S; Rocken, M; Nutt, RE; Machulla, HJ; Uludag, K; Cherry, SR; Claussen, CD; Pichler, BJ				Judenhofer, Martin S.; Wehrl, Hans F.; Newport, Danny F.; Catana, Ciprian; Siegel, Stefan B.; Becker, Markus; Thielscher, Axel; Kneilling, Manfred; Lichy, Matthias P.; Eichner, Martin; Klingel, Karin; Reischl, Gerald; Widmaier, Stefan; Roecken, Martin; Nutt, Robert E.; Machulla, Hans-Juergen; Uludag, Kamil; Cherry, Simon R.; Claussen, Claus D.; Pichler, Bernd J.			Simultaneous PET-MRI: a new approach for functional and morphological imaging	NATURE MEDICINE			English	Article							IN-VIVO; SIMULTANEOUS ACQUISITION; PERFORMANCE EVALUATION; ATTENUATION CORRECTION; SCANNER; DETECTOR; IMAGES; SPECTROSCOPY; FMRI	Noninvasive imaging at the molecular level is an emerging field in biomedical research. This paper introduces a new technology synergizing two leading imaging methodologies: positron emission tomography ( PET) and magnetic resonance imaging ( MRI). Although the value of PET lies in its high- sensitivity tracking of biomarkers in vivo, it lacks resolving morphology. MRI has lower sensitivity, but produces high soft- tissue contrast and provides spectroscopic information and functional MRI ( fMRI). We have developed a three- dimensional animal PET scanner that is built into a 7- T MRI. Our evaluations show that both modalities preserve their functionality, even when operated isochronously. With this combined imaging system, we simultaneously acquired functional and morphological PET- MRI data from living mice. PET- MRI provides a powerful tool for studying biology and pathology in preclinical research and has great potential for clinical applications. Combining fMRI and spectroscopy with PET paves the way for a new perspective in molecular imaging.	[Judenhofer, Martin S.; Wehrl, Hans F.; Lichy, Matthias P.; Claussen, Claus D.; Pichler, Bernd J.] Univ Tubingen, Dept Radiol, Lab Preclin Imaging & Imaging Tech Werner Siemens, D-72076 Tubingen, Germany; [Newport, Danny F.; Siegel, Stefan B.; Nutt, Robert E.] Siemens Preclin Solut, Knoxville, TN 37932 USA; [Catana, Ciprian; Cherry, Simon R.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Becker, Markus; Widmaier, Stefan] Bruker BioSpin MRI GmbH, D-76275 Ettingen, Germany; [Thielscher, Axel; Uludag, Kamil] Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; [Kneilling, Manfred; Roecken, Martin] Univ Tubingen, Dermatol Clin, D-72076 Tubingen, Germany; [Eichner, Martin] Univ Tubingen, Dept Med Biometry, D-72070 Tubingen, Germany; [Klingel, Karin] Univ Tubingen, Inst Pathol, Dept Mol Pathol, D-72076 Tubingen, Germany; [Reischl, Gerald; Machulla, Hans-Juergen] Univ Tubingen, PET Ctr, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Siemens AG; University of California System; University of California Davis; Bruker Corporation; Bruker BioSpin GmbH; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Pichler, BJ (corresponding author), Univ Tubingen, Dept Radiol, Lab Preclin Imaging & Imaging Tech Werner Siemens, Rontgenweg 13, D-72076 Tubingen, Germany.	Bernd.Pichler@med.uni-tuebingen.de	Siegel, Stefan/AGS-2464-2022; Siegel, Stefan/I-4782-2019; Pichler, Bernd J/B-4483-2012; Cherry, Simon/AAH-1000-2019; Catana, Ciprian/A-1246-2013	Cherry, Simon/0000-0002-0155-5644; Rocken, Martin/0000-0003-3795-7001; Uludag, Kamil/0000-0002-2813-5930; Thielscher, Axel/0000-0002-4752-5854	NIBIB NIH HHS [R21 EB004483-01] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB004483] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Catana C, 2006, J NUCL MED, V47, P1968; Cherry SR, 2004, PHYS MED BIOL, V49, pR13, DOI 10.1088/0031-9155/49/3/R01; DING YS, 1994, J LABELLED COMPD RAD, V34, P989, DOI 10.1002/jlcr.2580341012; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; Garlick PB, 1997, NMR BIOMED, V10, P138, DOI 10.1002/(SICI)1099-1492(199705)10:3<138::AID-NBM474>3.0.CO;2-H; Gilbert KM, 2006, PHYS MED BIOL, V51, P2825, DOI 10.1088/0031-9155/51/11/010; Judenhofer MS, 2007, RADIOLOGY, V244, P807, DOI 10.1148/radiol.2443061756; Lucas AJ, 2006, TECHNOL CANCER RES T, V5, P337, DOI 10.1177/153303460600500405; Marsden PK, 2002, BRIT J RADIOL, V75, pS53, DOI 10.1259/bjr.75.suppl_9.750053; Marzola P, 2003, EUR J RADIOL, V48, P165, DOI 10.1016/j.ejrad.2003.08.007; Montandon ML, 2005, NEUROIMAGE, V25, P278, DOI 10.1016/j.neuroimage.2004.11.021; Pichler B, 1998, IEEE T NUCL SCI, V45, P1298, DOI 10.1109/23.682020; Pichler BJ, 2006, J NUCL MED, V47, P639; Raylman RR, 2007, J MAGN RESON, V186, P305, DOI 10.1016/j.jmr.2007.03.012; Raylman RR, 2006, PHYS MED BIOL, V51, P6371, DOI 10.1088/0031-9155/51/24/006; Reischl G, 2006, RADIOCHIM ACTA, V94, P447, DOI 10.1524/ract.2006.94.8.447; SCHLEMMER HP, 2007, J NUCL MED S, V48; SCHLYER D, 2007, J NUCL MED S, V48; Shao Y, 1997, IEEE T NUCL SCI, V44, P1167, DOI 10.1109/23.596982; Shao YP, 1997, PHYS MED BIOL, V42, P1965, DOI 10.1088/0031-9155/42/10/010; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; SIEGEL S, 1992, IEEE T NUCL SCI, V39, P1117, DOI 10.1109/23.159770; Slates RB, 1999, PHYS MED BIOL, V44, P2015, DOI 10.1088/0031-9155/44/8/312; Tai YC, 2001, PHYS MED BIOL, V46, P1845, DOI 10.1088/0031-9155/46/7/308; Tai YC, 2005, J NUCL MED, V46, P455; Tkac I, 2004, MAGN RESON MED, V52, P478, DOI 10.1002/mrm.20184; Townsend DW, 2003, SEMIN NUCL MED, V33, P193, DOI 10.1053/snuc.2003.127314; Weber R, 2006, NEUROIMAGE, V29, P1303, DOI 10.1016/j.neuroimage.2005.08.028; Yamamoto S, 2007, J NUCL MED S, V48; Yang YF, 2004, PHYS MED BIOL, V49, P2527, DOI 10.1088/0031-9155/49/12/005	30	713	742	7	181	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					459	465		10.1038/nm1700	http://dx.doi.org/10.1038/nm1700			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376410				2022-12-27	WOS:000254674100035
J	Raffatellu, M; Santos, RL; Verhoeven, DE; George, MD; Wilson, RP; Winter, SE; Godinez, I; Sankaran, S; Paixao, TA; Gordon, MA; Kolls, JK; Dandekar, S; Baumler, AJ				Raffatellu, Manuela; Santos, Renato L.; Verhoeven, David E.; George, Michael D.; Wilson, R. Paul; Winter, Sebastian E.; Godinez, Ivan; Sankaran, Sumathi; Paixao, Tatiane A.; Gordon, Melita A.; Kolls, Jay K.; Dandekar, Satya; Baumler, Andreas J.			Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut	NATURE MEDICINE			English	Article							ENTERICA SEROVAR TYPHIMURIUM; HUMAN AIRWAY EPITHELIUM; HIV-INFECTED PATIENTS; T-CELL DEPLETION; NEUTROPHIL RECRUITMENT; GASTROINTESTINAL-TRACT; KLEBSIELLA-PNEUMONIAE; IMMUNE-RESPONSE; GENE-EXPRESSION; SIV INFECTION	Salmonella typhimurium causes a localized enteric infection in immunocompetent individuals, whereas HIV- infected individuals develop a life- threatening bacteremia. Here we show that simian immunodeficiency virus (SIV) infection results in depletion of T helper type 17 (T(H)17) cells in the ileal mucosa of rhesus macaques, thereby impairing mucosal barrier functions to S. typhimurium dissemination. In SIV- negative macaques, the gene expression profile induced by S. typhimurium in ligated ileal loops was dominated by T(H)17 responses, including the expression of interleukin- 17 (IL- 17) and IL- 22. T(H)17 cells were markedly depleted in SIV- infected rhesus macaques, resulting in blunted T(H)17 responses to S. typhimurium infection and increased bacterial dissemination. IL- 17 receptor - deficient mice showed increased systemic dissemination of S. typhimurium from the gut, suggesting that IL- 17 deficiency causes defects in mucosal barrier function. We conclude that SIV infection impairs the IL- 17 axis, an arm of the mucosal immune response preventing systemic microbial dissemination from the gastrointestinal tract.	[Raffatellu, Manuela; Santos, Renato L.; Verhoeven, David E.; George, Michael D.; Wilson, R. Paul; Winter, Sebastian E.; Godinez, Ivan; Sankaran, Sumathi; Paixao, Tatiane A.; Dandekar, Satya; Baumler, Andreas J.] Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; [Gordon, Melita A.] Univ Liverpool, Fac Med, Div Gastroenterol, Liverpool L69 3BX, Merseyside, England; [Kolls, Jay K.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	University of California System; University of California Davis; University of Liverpool; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Baumler, AJ (corresponding author), Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, 1 Shields Ave, Davis, CA 95616 USA.	ajbaumler@ucdavis.edu	Baumler, Andreas J/H-2301-2011; Gordon, Melita/F-5563-2012; Kolls, Jay/AAH-1829-2019; Winter, Sebastian E/A-4118-2009; de Lima Santos, Renato/A-1134-2008; Paixão, Tatiane/A-2871-2013; brasileira, Inct Pecuaria/J-9542-2013	Baumler, Andreas J/0000-0001-9152-7809; Gordon, Melita/0000-0002-0629-0884; Kolls, Jay/0000-0001-5151-6304; Winter, Sebastian E/0000-0003-1532-9178; de Lima Santos, Renato/0000-0002-4830-0470; Paixão, Tatiane/0000-0001-8284-9902; Verhoeven, David/0000-0002-0766-4606; Raffatellu, Manuela/0000-0001-6487-4215	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061271, R37HL079142, R01HL079142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044170, R01AI040124, R29AI040124, R21AI065534, R01AI043274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061297, R01DK043183] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061271, R37 HL079142, R01 HL079142-04, R01 HL061271-08, R01 HL079142] Funding Source: Medline; NIAID NIH HHS [AI040124, AI065534, R29 AI040124, AI044170, R01 AI043274, AI06055, AI43274, R21 AI065534, R01 AI044170, R01 AI040124] Funding Source: Medline; NIDDK NIH HHS [DK43183, R01 DK043183, DK61297, R01 DK061297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAUSA KO, 1977, SCAND J INFECT DIS, V9, P181, DOI 10.3109/inf.1977.9.issue-3.05; Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071; Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Coffey MJ, 1998, J CLIN INVEST, V102, P663, DOI 10.1172/JCI2117; Daniel M D, 1987, Cancer Detect Prev Suppl, V1, P501; ENG RHK, 1986, AM J CLIN PATHOL, V86, P105, DOI 10.1093/ajcp/86.1.105; George MD, 2003, VIROLOGY, V312, P84, DOI 10.1016/S0042-6822(03)00207-1; George S, 1998, J INFECT DIS, V178, P1530, DOI 10.1086/314460; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779; Gordon MA, 2002, AIDS, V16, P1633, DOI 10.1097/00002030-200208160-00009; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; HEISE C, 1994, J INFECT DIS, V169, P1116, DOI 10.1093/infdis/169.5.1116; Hohmann EL, 2001, CLIN INFECT DIS, V32, P263, DOI 10.1086/318457; Kankwatira AM, 2004, TROP DOCT, V34, P198, DOI 10.1177/004947550403400404; Kao CY, 2005, J IMMUNOL, V175, P6676, DOI 10.4049/jimmunol.175.10.6676; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Karim M, 1991, J Pak Med Assoc, V41, P35; KENT TH, 1966, ARCH PATHOL, V82, P272; Laan M, 1999, J IMMUNOL, V162, P2347; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Nau GJ, 2003, J IMMUNOL, V170, P5203, DOI 10.4049/jimmunol.170.10.5203; Ogawa A, 2004, CLIN IMMUNOL, V110, P55, DOI 10.1016/j.clim.2003.09.013; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pitrak DL, 1999, AIDS, V13, pS25; Pitrak DL, 1999, AM J HEALTH-SYST PH, V56, pS9, DOI 10.1093/ajhp/56.suppl_5.S9; Raffatellu M, 2007, INFECT IMMUN, V75, P4342, DOI 10.1128/IAI.01571-06; Reis BP, 2003, VET MICROBIOL, V97, P269, DOI 10.1016/j.vetmic.2003.09.019; Sankaran S, 2008, J VIROL, V82, P538, DOI 10.1128/JVI.01449-07; Santos RL, 2002, VET PATHOL, V39, P200, DOI 10.1354/vp.39-2-200; Schwartz S, 2005, BIOCHEM BIOPH RES CO, V337, P505, DOI 10.1016/j.bbrc.2005.09.075; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Smit-McBride Z, 1998, J VIROL, V72, P6646, DOI 10.1128/JVI.72.8.6646-6656.1998; Thamlikitkul V, 1996, TROP MED INT HEALTH, V1, P443, DOI 10.1046/j.1365-3156.1996.d01-92.x; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668; Zhang SP, 2003, INFECT IMMUN, V71, P1, DOI 10.1128/IAI.71.1.1-12.2003; Zhang SP, 2002, INFECT IMMUN, V70, P3843, DOI 10.1128/IAI.70.7.3843-3855.2002; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Ziesche E, 2007, J BIOL CHEM, V282, P16006, DOI 10.1074/jbc.M611040200	49	440	449	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					421	428		10.1038/nm1743	http://dx.doi.org/10.1038/nm1743			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376406	Green Accepted			2022-12-27	WOS:000254674100029
J	Tammela, T; Saaristo, A; Holopainen, T; Lyytikkae, J; Kotronen, A; Pitkonen, M; Abo-Ramadan, U; Ylae-Herttuala, S; Petrova, TV; Alitalo, K				Tammela, Tuomas; Saaristo, Anne; Holopainen, Tanja; Lyytikkae, Johannes; Kotronen, Anna; Pitkonen, Miia; Abo-Ramadan, Usama; Ylae-Herttuala, Seppo; Petrova, Tatiana V.; Alitalo, Kari			Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation	NATURE MEDICINE			English	Article							GROWTH-FACTOR-C; EDEMA FOLLOWING TREATMENT; GENE-THERAPY; VEGF-C; HEREDITARY LYMPHEDEMA; ENDOTHELIAL-CELLS; BREAST-CANCER; TRANSGENIC MICE; LYMPHANGIOGENESIS; METASTASIS	Surgery or radiation therapy of metastatic cancer often damages lymph nodes, leading to secondary lymphedema. Here we show, using a newly established mouse model, that collecting lymphatic vessels can be regenerated and fused to lymph node transplants after lymph node removal. Treatment of lymph node-excised mice with adenovirally delivered vascular endothelial growth factor-C (VEGF-C) or VEGF-D induced robust growth of the lymphatic capillaries, which gradually underwent intrinsic remodeling, differentiation and maturation into functional collecting lymphatic vessels, including the formation of uniform endothelial cell-cell junctions and intraluminal valves. The vessels also reacquired pericyte contacts, which downregulated lymphatic capillary markers during vessel maturation. Growth factor therapy improved the outcome of lymph node transplantation, including functional reconstitution of the immunological barrier against tumor metastasis. These results show that growth factor-induced maturation of lymphatic vessels is possible in adult mice and provide a basis for future therapy of lymphedema.	Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, Biomedicum,Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Turku Univ, Cent Hosp, Dept Neurol, Expt MRI Lab, FIN-20521 Turku, Finland; Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, FIN-70211 Kuopio, Finland; Univ Helsinki, Biomedicum, Dev & Differentiat Lab, FIN-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; University of Helsinki; University of Turku; University of Eastern Finland; University of Helsinki	Alitalo, K (corresponding author), Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, Biomedicum,Mol Canc Biol Lab, PO Box 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	kari.alitalo@helsinki.fi	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Yla-Herttuala, Seppo/0000-0001-7593-2708; /0000-0003-3675-6961	NHLBI NIH HHS [5 R01 HL075183-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Baluk P, 2007, J EXP MED, V204, P2349, DOI 10.1084/jem.20062596; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BAUMEISTER RG, 1981, LANCET, V1, P147; Becker C, 2006, ANN SURG, V243, P313, DOI 10.1097/01.sla.0000201258.10304.16; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Clark B, 2005, QJM-INT J MED, V98, P343, DOI 10.1093/qjmed/hci053; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Enholm B, 2001, CIRC RES, V88, P623, DOI 10.1161/01.RES.88.6.623; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; Ikomi F, 2006, MICROCIRCULATION, V13, P365, DOI 10.1080/10739680600745810; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Ito WD, 1997, CIRC RES, V80, P829; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; Kozaki K, 2000, CANCER RES, V60, P2535; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Makinen T, 2005, GENE DEV, V19, P397, DOI 10.1101/gad.330105; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; Mellor RH, 2007, CIRCULATION, V115, P1912, DOI 10.1161/CIRCULATIONAHA.106.675348; Mortimer PS, 1996, QJM-MON J ASSOC PHYS, V89, P377; Ng CP, 2004, MICROVASC RES, V68, P258, DOI 10.1016/j.mvr.2004.08.002; Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804; Petrova TV, 2004, NAT MED, V10, P974, DOI 10.1038/nm1094; Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72; RABSON JA, 1982, ANN SURG, V196, P92, DOI 10.1097/00000658-198207000-00019; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rockson SG, 2001, AM J MED, V110, P288, DOI 10.1016/S0002-9343(00)00727-0; Saaristo A, 2004, FASEB J, V18, P1707, DOI 10.1096/fj.04-1592fje; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Saaristo A, 2006, AM J PATHOL, V169, P1080, DOI 10.2353/ajpath.2006.051251; Schaper W, 2003, ARTERIOSCL THROM VAS, V23, P1143, DOI 10.1161/01.ATV.0000069625.11230.96; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Tabibiazar R, 2006, PLOS MED, V3, P1114, DOI 10.1371/journal.pmed.0030254; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Vintersten K, 2004, GENESIS, V40, P241, DOI 10.1002/gene.20095; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830	50	269	283	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1458	1466		10.1038/nm1689	http://dx.doi.org/10.1038/nm1689			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18059280				2022-12-27	WOS:000251445400020
J	Bendle, GM; Linnemann, C; Hooijkaas, AI; Bies, L; de Witte, MA; Jorritsma, A; Kaiser, ADM; Pouw, N; Debets, R; Kieback, E; Uckert, W; Song, JY; Haanen, JBAG; Schumacher, TNM				Bendle, Gavin M.; Linnemann, Carsten; Hooijkaas, Anna I.; Bies, Laura; de Witte, Moniek A.; Jorritsma, Annelies; Kaiser, Andrew D. M.; Pouw, Nadine; Debets, Reno; Kieback, Elisa; Uckert, Wolfgang; Song, Ji-Ying; Haanen, John B. A. G.; Schumacher, Ton N. M.			Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy	NATURE MEDICINE			English	Article							ENHANCED ANTITUMOR-ACTIVITY; BONE-MARROW FAILURE; CANCER REGRESSION; TUMOR-REGRESSION; TCR-ALPHA; LYMPHOCYTES; IMMUNOTHERAPY; BETA; MELANOMA; ANTIGEN	The transfer of T cell receptor (TCR) genes can be used to induce immune reactivity toward defined antigens to which endogenous T cells are insufficiently reactive. This approach, which is called TCR gene therapy, is being developed to target tumors and pathogens, and its clinical testing has commenced in patients with cancer. In this study we show that lethal cytokine-driven autoimmune pathology can occur in mouse models of TCR gene therapy under conditions that closely mimic the clinical setting. We show that the pairing of introduced and endogenous TCR chains in TCR gene-modified T cells leads to the formation of self-reactive TCRs that are responsible for the observed autoimmunity. Furthermore, we demonstrate that adjustments in the design of gene therapy vectors and target T cell populations can be used to reduce the risk of TCR gene therapy-induced autoimmune pathology.	[Bendle, Gavin M.; Linnemann, Carsten; Hooijkaas, Anna I.; Bies, Laura; de Witte, Moniek A.; Jorritsma, Annelies; Kaiser, Andrew D. M.; Haanen, John B. A. G.; Schumacher, Ton N. M.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Pouw, Nadine; Debets, Reno] Erasmus MC Daniel den Hoed Canc Ctr, Lab Expt Tumor Immunol, Dept Med Oncol, Rotterdam, Netherlands; [Kieback, Elisa; Uckert, Wolfgang] Max Delbruck Ctr Mol Med, Berlin, Germany; [Song, Ji-Ying] Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; [Haanen, John B. A. G.] Netherlands Canc Inst, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Netherlands Cancer Institute; Netherlands Cancer Institute	Bendle, GM (corresponding author), Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands.	g.bendle@nki.nl; t.schumacher@nki.nl	Haanen, John/AAD-8578-2022; Kaiser, Andrew D/C-2617-2012; Haanen, John/AAD-8534-2022; Schumacher, Ton/Y-2432-2019	Haanen, John/0000-0001-5884-7704; Schumacher, Ton/0000-0003-0517-8804; Pouw, Nadine/0000-0002-6470-3720	Leukaemia and Lymphoma Research Travel Fellowship [06037]; Netherlands Organization for Scientific Research [431-00-005]; Dutch Cancer Society [NKI 2009-4282, 2003-2860]	Leukaemia and Lymphoma Research Travel Fellowship; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding)	We thank the Experimental Animal Department for animal husbandry, H. van Tinteren for advice on statistical analysis and R. Gomez for experimental assistance. We are grateful to A. Pfauth and F. van Diepen for assistance with flow cytometry. G. M. B. is supported by a Leukaemia and Lymphoma Research Travel Fellowship (06037). C. L. is a fellow in the PhD Fellowship Program of Boehringer Ingelheim Fonds-Foundation for Basic Research in Biomedicine. T.N.M.S. and J.B.A.G.H. are supported by grants from The Netherlands Organization for Scientific Research (431-00-005), the Dutch Cancer Society (NKI 2009-4282 and 2003-2860), The Landsteiner Foundation for Blood Transfusion Research (04-08) and FP6 Integrated Project Adoptive T cell Targeting to Activate Cancer Killing (ATTACK). Cytotoxic T lymphocyte clone LP9 was kindly provided by G. Adema (Radboud University).	Agbaht K, 2007, TRANSFUSION, V47, P1405, DOI 10.1111/j.1537-2995.2007.01282.x; Bendle GM, 2009, CURR OPIN IMMUNOL, V21, P209, DOI 10.1016/j.coi.2009.02.007; Bloom ML, 2004, EXP HEMATOL, V32, P1163, DOI 10.1016/j.exphem.2004.08.006; Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986; Cohen CJ, 2006, CANCER RES, V66, P8878, DOI 10.1158/0008-5472.CAN-06-1450; de Witte MA, 2008, J IMMUNOL, V181, P5128, DOI 10.4049/jimmunol.181.7.5128; de Witte MA, 2008, J IMMUNOL, V181, P2563, DOI 10.4049/jimmunol.181.4.2563; de Witte MA, 2006, BLOOD, V108, P870, DOI 10.1182/blood-2005-08-009357; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; Heemskerk MHM, 2004, J EXP MED, V199, P885, DOI 10.1084/jem.20031110; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Jorritsma A, 2007, BLOOD, V110, P3564, DOI 10.1182/blood-2007-02-075010; Kaneko S, 2009, BLOOD, V113, P1006, DOI 10.1182/blood-2008-05-156059; Kessels HWHG, 2006, J IMMUNOL, V177, P976, DOI 10.4049/jimmunol.177.2.976; Kessels HWHG, 2001, NAT IMMUNOL, V2, P957, DOI 10.1038/ni1001-957; Kieback E, 2008, P NATL ACAD SCI USA, V105, P623, DOI 10.1073/pnas.0710198105; Kolen S, 2002, J IMMUNOTHER, V25, P385, DOI 10.1097/00002371-200209000-00002; Kuball J, 2007, BLOOD, V109, P2331, DOI 10.1182/blood-2006-05-023069; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morris EC, 2005, P NATL ACAD SCI USA, V102, P7934, DOI 10.1073/pnas.0500357102; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Romieu R, 1998, J IMMUNOL, V161, P5133; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Schreurs MWJ, 2000, CANCER RES, V60, P6995; Schroeder ML, 2002, BRIT J HAEMATOL, V117, P275, DOI 10.1046/j.1365-2141.2002.03450.x; Schumacher TNM, 2002, NAT REV IMMUNOL, V2, P512, DOI 10.1038/nri841; Sebestyen Z, 2008, J IMMUNOL, V180, P7736, DOI 10.4049/jimmunol.180.11.7736; Shrikant P, 2002, J IMMUNOL, V169, P1753, DOI 10.4049/jimmunol.169.4.1753; Tang Y, 2010, BLOOD, V115, P541, DOI 10.1182/blood-2009-03-211383; Theobald M, 1997, J EXP MED, V185, P833, DOI 10.1084/jem.185.5.833; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thomas S, 2007, J IMMUNOL, V179, P5803, DOI 10.4049/jimmunol.179.9.5803; Uckert W, 2009, CANCER IMMUNOL IMMUN, V58, P809, DOI 10.1007/s00262-008-0649-4; Varela-Rohena A, 2008, NAT MED, V14, P1390, DOI 10.1038/nm.1779; Voss RH, 2008, J IMMUNOL, V180, P391, DOI 10.4049/jimmunol.180.1.391; Weinhold M, 2007, J IMMUNOL, V179, P5534, DOI 10.4049/jimmunol.179.8.5534; Willemsen RA, 2000, GENE THER, V7, P1369, DOI 10.1038/sj.gt.3301253; Zhou JH, 2005, J IMMUNOL, V175, P7046, DOI 10.4049/jimmunol.175.10.7046	41	300	316	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2010	16	5					565	U98		10.1038/nm.2128	http://dx.doi.org/10.1038/nm.2128			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20400962				2022-12-27	WOS:000277394700035
J	Dolgin, E				Dolgin, Elie			Anticounterfeit campaigners go back to school	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					362	362		10.1038/nm0410-362c	http://dx.doi.org/10.1038/nm0410-362c			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376028	Bronze			2022-12-27	WOS:000276446800021
J	Gupta, R; Lavollay, M; Mainardi, JL; Arthur, M; Bishai, WR; Lamichhane, G				Gupta, Radhika; Lavollay, Marie; Mainardi, Jean-Luc; Arthur, Michel; Bishai, William R.; Lamichhane, Gyanu			The Mycobacterium tuberculosis protein Ldt(Mt2) is a nonclassical transpeptidase required for virulence and resistance to amoxicillin	NATURE MEDICINE			English	Article							CLAVULANIC ACID; PEPTIDOGLYCAN; PERSISTENCE; INHIBITION; MECHANISM; PHASE	The peptidoglycan layer is a vital component of the bacterial cell wall. The existing paradigm describes the peptidoglycan network as a static structure that is cross-linked predominantly by 4 -> 3 transpeptide linkages. However, the nonclassical 3 -> 3 linkages predominate the transpeptide networking of the peptidoglycan layer of nonreplicating Mycobacterium tuberculosis(1,2). The molecular basis of these linkages and their role in the physiology of the peptidoglycan layer, virulence and susceptibility of M. tuberculosis to drugs remain undefined. Here we identify MT2594 as an L,D-transpeptidase that generates 3 -> 3 linkages in M. tuberculosis. We show that the loss of this protein leads to altered colony morphology, loss of virulence and increased susceptibility to amoxicillin-clavulanate during the chronic phase of infection. This suggests that 3 -> 3 cross-linking is vital to the physiology of the peptidoglycan layer. Although a functional homolog exists, expression of ldt(Mt2) is dominant throughout the growth phases of M. tuberculosis. 4 -> 3 transpeptide linkages are targeted by one of the most widely used classes of antibacterial drugs in human clinical use today, beta-lactams. Recently, meropenem-clavulanate was shown to be effective against drug-resistant M. tuberculosis(3). Our study suggests that a combination of L,D-transpeptidase and beta-lactamase inhibitors could effectively target persisting bacilli during the chronic phase of tuberculosis.	[Gupta, Radhika; Bishai, William R.; Lamichhane, Gyanu] Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA; [Lavollay, Marie; Mainardi, Jean-Luc; Arthur, Michel] Univ Paris 06, Ctr Rech Cordeliers, Lab Rech Mol Antibiot, Paris, France; [Lavollay, Marie; Mainardi, Jean-Luc; Arthur, Michel] Univ Paris 05, Paris, France; [Lavollay, Marie; Mainardi, Jean-Luc; Arthur, Michel] INSERM, Paris, France; [Mainardi, Jean-Luc] Hop Europeen Georges Pompidou, Paris, France	Johns Hopkins University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Lamichhane, G (corresponding author), Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA.	lamichhane@jhu.edu	Arthur, Michel/G-3680-2013; LAVOLLAY, Marie/G-6824-2015; MAINARDI, Jean-Luc/E-2714-2014	Arthur, Michel/0000-0003-1007-636X; LAVOLLAY, Marie/0000-0003-1464-6913; MAINARDI, Jean-Luc/0000-0002-4159-0129; Gupta, Radhika/0000-0002-0445-0194; Lamichhane, Gyanu/0000-0002-2214-0114	US National Institutes of Health [AI30036]; Foundation pour la Recherche Medicale [200661107918]; Institut National de la Sante et de la Recherche Medicale; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030036] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We gratefully acknowledge the support of US National Institutes of Health award AI30036. This work was also supported by the Foundation pour la Recherche Medicale (Equipe FRM 2006 (Dequation 200661107918)). M. Lavollay is the recipient of an Institut National de la Sante et de la Recherche Medicale PhD fellowship (Poste d'Accueil pour Pharmacien, Medecin, et Veterinaire).	AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; Auger G, 2003, FEMS MICROBIOL LETT, V219, P115, DOI 10.1016/S0378-1097(02)01203-X; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Boneca IG, 2007, P NATL ACAD SCI USA, V104, P997, DOI 10.1073/pnas.0609672104; Crick DC, 2008, MYCOBACTERIAL CELL ENVELOPE, P25; Donald PR, 2001, SCAND J INFECT DIS, V33, P466, DOI 10.1080/00365540152029954; Fauci AS, 2008, J INFECT DIS, V197, P1493, DOI 10.1086/587904; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Goren M. B., 1979, TUBERCULOSIS, P63; Hugonnet JE, 2007, BIOCHEMISTRY-US, V46, P11998, DOI 10.1021/bi701506h; Hugonnet JE, 2009, SCIENCE, V323, P1215, DOI 10.1126/science.1167498; Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC; Keren I, 2004, J BACTERIOL, V186, P8172, DOI 10.1128/JB.186.24.8172-8180.2004; Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100; LAVOLLAY M, 2009, MOL MICROBI IN PRESS; Lavollay M, 2008, J BACTERIOL, V190, P4360, DOI 10.1128/JB.00239-08; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Matsuhashi M, 1966, Tanpakushitsu Kakusan Koso, V11, P875; NADLER JP, 1991, CHEST, V99, P1025, DOI 10.1378/chest.99.4.1025; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; Vollmer W, 2004, J BACTERIOL, V186, P5978, DOI 10.1128/jb.186.18.5978-5987.2004; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; WIETZERBIN J, 1974, BIOCHEMISTRY-US, V13, P3471, DOI 10.1021/bi00714a008	29	198	205	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					466	U22		10.1038/nm.2120	http://dx.doi.org/10.1038/nm.2120			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20305661	Green Accepted			2022-12-27	WOS:000276446800052
J	Liu, LZ; Zhong, Q; Tian, T; Dubin, K; Athale, SK; Kupper, TS				Liu, Luzheng; Zhong, Qiong; Tian, Tian; Dubin, Krista; Athale, Shruti K.; Kupper, Thomas S.			Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity	NATURE MEDICINE			English	Article							VACCINIA ANKARA MVA; SMALLPOX VACCINATION; SKIN; COMPLICATIONS; EFFICACY; ANTIGEN	Variola major (smallpox) infection claimed hundreds of millions lives before it was eradicated by a simple vaccination strategy: epicutaneous application of the related orthopoxvirus vaccinia virus (VACV) to superficially injured skin (skin scarification, s.s.)(1). However, the remarkable success of this strategy was attributed to the immunogenicity of VACV rather than to the unique mode of vaccine delivery. We now show that VACV immunization via s.s., but not conventional injection routes, is essential for the generation of superior T cell-mediated immune responses that provide complete protection against subsequent challenges, independent of neutralizing antibodies. Skin-resident effector memory T cells (T-EM cells) provide complete protection against cutaneous challenge, whereas protection against lethal respiratory challenge requires both respiratory mucosal TEM cells and central memory T cells (T-CM cells). Vaccination with recombinant VACV (rVACV) expressing a tumor antigen was protective against tumor challenge only if delivered via the s.s. route; it was ineffective if delivered by hypodermic injection. The clinically safer nonreplicative modified vaccinia Ankara virus (MVA) also generated far superior protective immunity when delivered via the s.s. route compared to intramuscular (i.m.) injection as used in MVA clinical trials. Thus, delivery of rVACV-based vaccines, including MVA vaccines, through physically disrupted epidermis has clear-cut advantages over conventional vaccination via hypodermic injection.	[Liu, Luzheng; Zhong, Qiong; Tian, Tian; Dubin, Krista; Athale, Shruti K.; Kupper, Thomas S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Harvard Skin Dis Res Ctr,Dept Dermatol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kupper, TS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Harvard Skin Dis Res Ctr,Dept Dermatol, Boston, MA 02115 USA.	lzliu@rics.bwh.harvard.edu; tkupper@partners.org	Kupper, Thomas/O-4962-2019		NIH-US National Institute of Allergy and Infectious Diseases [R01 AI042124, R37 AI025082, U19AI57330, AI057159]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025082, U19AI057330, U54AI057159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR065807] Funding Source: NIH RePORTER	NIH-US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank B. Moss ( US National Institute of Health (NIH)) for providing rVACV expressing EGFP and OT-IT cell epitope OVA<INF>257-264</INF>, as well as WR-VACV. We thank K. Rock ( University of Massachusetts Medical School) for providing the MO5 cell line and M. Seaman ( Beth Israel Hospital) for providing the MVA stocks. FTY720 was provided by V. Brinkmann at Novartis Pharmaceuticals. This work was supported by NIH-US National Institute of Allergy and Infectious Diseases grants R01 AI042124 and R37 AI025082 to T. S. K. and NIH grant U19AI57330 subcontracted to T. S. K., a Dermatology Foundation Research Career Development Award to L. L. and a Career Development Award and a New Opportunities Grant to L. L. from US National Institute of Allergy and Infectious Diseases-New England Regional Center of Excellence/Biodefense and Emerging Infectious Disease (AI057159).	Bray M, 2003, ANTIVIR RES, V58, P101, DOI 10.1016/S0166-3542(03)00008-1; Bray M, 2003, CLIN INFECT DIS, V36, P766, DOI 10.1086/374244; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Drexler I, 2004, CURR OPIN BIOTECH, V15, P506, DOI 10.1016/j.copbio.2004.09.001; EARL PL, 1998, CURRENT PROTOCOLS MO, V2, pCH16; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Kennedy JS, 2009, EXPERT REV VACCINES, V8, P13, DOI 10.1586/14760584.8.1.13; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; Liu LZ, 2006, IMMUNITY, V25, P511, DOI 10.1016/j.immuni.2006.06.019; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; NEFF JM, 1967, NEW ENGL J MED, V276, P125, DOI 10.1056/NEJM196701192760301; NEFF JM, 1967, PEDIATRICS, V39, P916; NEFF JM, 1970, J AMER MED ASSOC, V213, P123, DOI 10.1001/jama.213.1.123; Norbury CC, 2002, NAT IMMUNOL, V3, P265, DOI 10.1038/ni762; Parrino J, 2007, VACCINE, V25, P1513, DOI 10.1016/j.vaccine.2006.10.047; Partidos CD, 2005, CELL MOL LIFE SCI, V62, P1418, DOI 10.1007/s00018-005-4529-1; Phelps AL, 2007, VACCINE, V25, P34, DOI 10.1016/j.vaccine.2006.07.022; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Stewart AJ, 2006, J INFECTION, V52, P329, DOI 10.1016/j.jinf.2005.07.021; Tian T, 2009, J INVEST DERMATOL, V129, P70, DOI 10.1038/jid.2008.191; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Woodland DL, 2009, NAT REV IMMUNOL, V9, P153, DOI 10.1038/nri2496	26	177	180	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					224	U132		10.1038/nm.2078	http://dx.doi.org/10.1038/nm.2078			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20081864	Green Accepted			2022-12-27	WOS:000274297000045
J	Kienast, Y; von Baumgarten, L; Fuhrmann, M; Klinkert, WEF; Goldbrunner, R; Herms, J; Winkler, F				Kienast, Yvonne; von Baumgarten, Louisa; Fuhrmann, Martin; Klinkert, Wolfgang E. F.; Goldbrunner, Roland; Herms, Jochen; Winkler, Frank			Real-time imaging reveals the single steps of brain metastasis formation	NATURE MEDICINE			English	Article							MELANOMA METASTASES; MDA-MB-435 CELLS; BREAST-CANCER; TUMOR-CELL; GROWTH; ANGIOGENESIS; EXPRESSION; DORMANCY; VEGF; MICROMETASTASES	Brain metastasis frequently occurs in individuals with cancer and is often fatal. We used multiphoton laser scanning microscopy to image the single steps of metastasis formation in real time. Thus, it was possible to track the fate of individual metastasizing cancer cells in vivo in relation to blood vessels deep in the mouse brain over minutes to months. The essential steps in this model were arrest at vascular branch points, early extravasation, persistent close contacts to microvessels and perivascular growth by vessel cooption (melanoma) or early angiogenesis (lung cancer). Inefficient steps differed between the tumor types. Long-term dormancy was only observed for single perivascular cancer cells, some of which moved continuously. Vascular endothelial growth factor-A (VEGF-A) inhibition induced long-term dormancy of lung cancer micrometastases by preventing angiogenic growth to macrometastases. The ability to image the establishment of brain metastases in vivo provides new insights into their evolution and response to therapies.	[Kienast, Yvonne; von Baumgarten, Louisa; Winkler, Frank] Univ Munich, Dept Neurol, D-8000 Munich, Germany; [Kienast, Yvonne; Fuhrmann, Martin; Herms, Jochen] Univ Munich, Dept Neuropathol, D-8000 Munich, Germany; [Goldbrunner, Roland] Univ Munich, Dept Neurosurg, D-8000 Munich, Germany; [Klinkert, Wolfgang E. F.] Max Planck Inst Neurobiol, Martinsried, Germany	University of Munich; University of Munich; University of Munich; Max Planck Society	Winkler, F (corresponding author), Univ Munich, Dept Neurol, D-8000 Munich, Germany.	frank.winkler@med.uni-muenchen.de	Fuhrmann, Martin/J-2707-2018; Fuhrmann, Martin/E-4565-2011; Herms, Jochen/D-3518-2011; von Baumgarten, Louisa/A-4636-2016	Fuhrmann, Martin/0000-0001-7672-2913; Winkler, Frank/0000-0003-4892-6104	German Cancer Foundation (Deutsche Kebshilfe); German Research Foundation (Deutsche Forschungsgemeinschaft) [WI1930/4-1]; German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung); German Federal Ministry of Economics and Technology (Bundesministerium fur Wirtschaft und Technologie) [16IN0675, 13N10171, 13N9268]; Hypatia Foundation	German Cancer Foundation (Deutsche Kebshilfe); German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung)(Federal Ministry of Education & Research (BMBF)); German Federal Ministry of Economics and Technology (Bundesministerium fur Wirtschaft und Technologie)(Federal Ministry for Economic Affairs and Energy (BMWi)); Hypatia Foundation	W. and J.H. received funding for this work from the German Cancer Foundation (Deutsche Kebshilfe), and F. W. received a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft; WI1930/4-1). J.H. received additional funding from the German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung) and German Federal Ministry of Economics and Technology (Bundesministerium fur Wirtschaft und Technologie) (16IN0675; 13N10171; 13N9268). Y.K. received a research grant from the Hypatia Foundation. We wish to thank C. Eggert for her excellent technical assistance, A. Ullrich, W. Hiddemann, R. Jain and U. Koedel for helpful discussions, K. Ogston for editing the manuscript and G. Mitteregger for her supervision of the animal facility. The PC14-PE6 human lung cancer cell line was kindly provided by I.J. Fidler, MD Anderson Cancer Center.	Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Bouvet M, 2006, CANCER RES, V66, P11293, DOI 10.1158/0008-5472.CAN-06-2662; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chambers AF, 2000, ADV CANCER RES, V79, P91, DOI 10.1016/S0065-230X(00)79003-8; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Dome B, 2003, J NEUROPATH EXP NEUR, V62, P655; Fidler IJ, 2002, LANCET ONCOL, V3, P53, DOI 10.1016/S1470-2045(01)00622-2; FIDLER IJ, 1986, CANCER RES, V46, P5167; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Hoffman RM, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1992485; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ito S, 2001, INT J CANCER, V93, P212, DOI 10.1002/ijc.1318; KAWAGUCHI T, 1982, Invasion and Metastasis, V2, P40; KAYE AH, 2001, BRAIN TUMORS ENCY AP, P999; Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269; KOOP S, 1995, CANCER RES, V55, P2520; Kusters B, 2007, ONCOGENE, V26, P5808, DOI 10.1038/sj.onc.1210360; Kusters B, 2002, CANCER RES, V62, P341; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Palmieri D, 2007, CLIN CANCER RES, V13, P1656, DOI 10.1158/1078-0432.CCR-06-2659; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; SCHACKERT G, 1989, INT J CANCER, V44, P892, DOI 10.1002/ijc.2910440524; Scherbarth S, 1997, CANCER RES, V57, P4105; Seitz G, 2008, CELL PROLIFERAT, V41, P365, DOI 10.1111/j.1365-2184.2008.00520.x; Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Townson JL, 2006, CELL CYCLE, V5, P1744, DOI 10.4161/cc.5.16.2864; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8; WOOD S, 1958, ARCH PATHOL, V66, P550; Wyckoff JB, 2000, CANCER RES, V60, P2504; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Yano S, 2000, CANCER RES, V60, P4959	37	712	723	1	106	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					116	U157		10.1038/nm.2072	http://dx.doi.org/10.1038/nm.2072			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20023634				2022-12-27	WOS:000273395500045
J	Starczynowski, DT; Kuchenbauer, F; Argiropoulos, B; Sung, S; Morin, R; Muranyi, A; Hirst, M; Hogge, D; Marra, M; Wells, RA; Buckstein, R; Lam, W; Humphries, RK; Karsan, A				Starczynowski, Daniel T.; Kuchenbauer, Florian; Argiropoulos, Bob; Sung, Sandy; Morin, Ryan; Muranyi, Andrew; Hirst, Martin; Hogge, Donna; Marra, Marco; Wells, Richard A.; Buckstein, Rena; Lam, Wan; Humphries, R. Keith; Karsan, Aly			Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC PROGENITOR CELLS; MICRORNA EXPRESSION PROFILES; MYELODYSPLASTIC SYNDROMES; KAPPA-B; BONE-MARROW; CHROMOSOME 5Q; CD34(+) CELLS; INTERLEUKIN-6; ACTIVATION	5q-syndrome is a subtype of myelodysplastic syndrome characterized by severe anemia and variable neutropenia but normal or high platelet counts with dysplastic megakaryocytes. We examined expression of microRNAs (miRNAs) encoded on chromosome 5q as a possible cause of haploinsufficiency. We show that deletion of chromosome 5q correlates with loss of two miRNAs that are abundant in hematopoietic stem/progenitor cells (HSPCs), miR-145 and miR-146a, and we identify Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP) and tumor necrosis factor receptor-associated factor-6 (TRAF6) as respective targets of these miRNAs. TIRAP is known to lie upstream of TRAF6 in innate immune signaling. Knockdown of miR-145 and miR-146a together or enforced expression of TRAF6 in mouse HSPCs resulted in thrombocytosis, mild neutropenia and megakaryocytic dysplasia. A subset of mice transplanted with TRAF6-expressing marrow progressed either to marrow failure or acute myeloid leukemia. Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q-syndrome.	[Starczynowski, Daniel T.; Kuchenbauer, Florian; Argiropoulos, Bob; Sung, Sandy; Morin, Ryan; Muranyi, Andrew; Hirst, Martin; Hogge, Donna; Marra, Marco; Lam, Wan; Humphries, R. Keith; Karsan, Aly] British Columbia Canc Agcy, Res Ctr, Vancouver, BC V5Z 4E6, Canada; [Starczynowski, Daniel T.; Lam, Wan; Karsan, Aly] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Wells, Richard A.; Buckstein, Rena] Sunnybrook Res Inst, JD Crashley Myelodysplast Syndrome Lab, Toronto, ON, Canada; [Humphries, R. Keith] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of British Columbia	Karsan, A (corresponding author), British Columbia Canc Agcy, Res Ctr, Vancouver, BC V5Z 4E6, Canada.	akarsan@bccrc.ca	Marra, Marco A/B-5987-2008; Morin, Ryan/AAE-7824-2019; Hirst, Martin/B-7684-2016; Karsan, Aly/K-2067-2015	Marra, Marco A/0000-0001-7146-7175; Morin, Ryan/0000-0003-2932-7800; Humphries, Richard/0000-0003-0540-7005; Hogge, Donna/0000-0002-5205-9982	Canadian Institutes of Health Research (CIHR) [MOP 89976]; Leukemia and Lymphoma Society of Canada; Canadian Cancer Society; Terry Fox Foundation; Stem Cell Network; Michael Smith Foundation for Health Research (MSFHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Leukemia and Lymphoma Society of Canada; Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox Foundation; Stem Cell Network; Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research)	We thank R. Deleeuw, R. Chari, W. Lockwood, S. Watson and E. Vucic for technical assistance and helpful discussions and M. Abbott for animal husbandry. K. Tohyama (Kawasaki Medical School) provided the MDS-L cell line. The NF-kappa B site-containing luciferase reporter plasmid was a gift from F. Jirik (University of Calgary). This work was supported by the Canadian Institutes of Health Research (CIHR; MOP 89976), Leukemia and Lymphoma Society of Canada and Canadian Cancer Society grants to A. K., a CIHR grant and a Terry Fox Foundation Program Project award to R. K. H., and a Stem Cell Network grant to M. M. D. T. S. is supported in part by CIHR and Michael Smith Foundation for Health Research (MSFHR) fellowships. M. M. and A. K. are Senior Scholars of the MSFHR.	Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bigoni R, 2001, HAEMATOLOGICA, V86, P375; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; Chen H, 2006, ONCOGENE, V25, P6520, DOI 10.1038/sj.onc.1209653; Corey SJ, 2007, NAT REV CANCER, V7, P118, DOI 10.1038/nrc2047; Corral LG, 1999, J IMMUNOL, V163, P380; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Gentner B, 2009, NAT METHODS, V6, P63, DOI [10.1038/NMETH.1277, 10.1038/nmeth.1277]; Giagounidis AAN, 2006, CLIN CANCER RES, V12, P5, DOI 10.1158/1078-0432.CCR-05-1437; Gondek LP, 2008, BLOOD, V111, P1534, DOI 10.1182/blood-2007-05-092304; Hast R, 1999, LEUKEMIA RES, V23, P579, DOI 10.1016/S0145-2126(99)00042-9; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HEROLD M, 1992, LEUKEMIA RES, V16, P585, DOI 10.1016/0145-2126(92)90006-S; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Hsu HC, 2002, ONCOLOGY-BASEL, V63, P64, DOI 10.1159/000065722; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Kroef MJPL, 1997, LEUKEMIA, V11, P519, DOI 10.1038/sj.leu.2400597; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Larrivee B, 2005, J IMMUNOL, V175, P3015, DOI 10.4049/jimmunol.175.5.3015; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li X, 2004, INT J HEMATOL, V80, P140, DOI 10.1532/IJH97.NA0402; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Mansell A, 2004, J BIOL CHEM, V279, P37227, DOI 10.1074/jbc.C400289200; Maratheftis CI, 2007, CLIN CANCER RES, V13, P1154, DOI 10.1158/1078-0432.CCR-06-2108; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Martinez-Ramirez A, 2005, GENE CHROMOSOME CANC, V42, P287, DOI 10.1002/gcc.20154; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nimer SD, 2006, J CLIN ONCOL, V24, P2576, DOI 10.1200/JCO.2005.03.6715; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Starczynowski DT, 2008, BLOOD, V112, P3412, DOI 10.1182/blood-2007-11-122028; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takada S, 2008, LEUKEMIA, V22, P1274, DOI 10.1038/sj.leu.2405031; Tang MH, 2008, J EXP MED, V205, P1611, DOI 10.1084/jem.20080297; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; VERHOEF GEG, 1992, LEUKEMIA, V6, P1268; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang L, 2008, HAEMATOL-HEMATOL J, V93, P994, DOI 10.3324/haematol.12603	47	486	516	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					49	U84		10.1038/nm.2054	http://dx.doi.org/10.1038/nm.2054			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	19898489				2022-12-27	WOS:000273395500036
J	Villablanca, EJ; Raccosta, L; Zhou, D; Fontana, R; Maggioni, D; Negro, A; Sanvito, F; Ponzoni, M; Valentinis, B; Bregni, M; Prinetti, A; Steffensen, KR; Sonnino, S; Gustafsson, JA; Doglioni, C; Bordignon, C; Traversari, C; Russo, V				Villablanca, Eduardo J.; Raccosta, Laura; Zhou, Dan; Fontana, Raffaella; Maggioni, Daniela; Negro, Aurora; Sanvito, Francesca; Ponzoni, Maurilio; Valentinis, Barbara; Bregni, Marco; Prinetti, Alessandro; Steffensen, Knut R.; Sonnino, Sandro; Gustafsson, Jan-Ake; Doglioni, Claudio; Bordignon, Claudio; Traversari, Catia; Russo, Vincenzo			Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses	NATURE MEDICINE			English	Article							NUCLEAR RECEPTORS; T-CELLS; MIGRATION; METABOLISM; CHOLESTEROL; IMMUNOGENICITY; INFLAMMATION; OXYSTEROLS; DEPLETION; THERAPY	Sterol metabolism has recently been linked to innate and adaptive immune responses through liver X receptor (LXR) signaling. Whether products of sterol metabolism interfere with antitumor responses is currently unknown. Dendritic cells (DCs) initiate immune responses, including antitumor activity after their CC chemokine receptor-7 (CCR7)-dependent migration to lymphoid organs. Here we report that human and mouse tumors produce LXR ligands that inhibit CCR7 expression on maturing DCs and, therefore, their migration to lymphoid organs. In agreement with this observation, we detected CD83(+)CCR7(-) DCs within human tumors. Mice injected with tumors expressing the LXR ligand-inactivating enzyme sulfotransferase 2B1b (SULT2B1b) successfully controlled tumor growth by regaining DC migration to tumor-draining lymph nodes and by developing overt inflammation within tumors. The control of tumor growth was also observed in chimeric mice transplanted with bone marrow from mice lacking the gene encoding LXR-alpha (Nr1h3(-/-) mice) Thus, we show a new mechanism of tumor immunoescape involving products of cholesterol metabolism. The manipulation of this pathway could restore antitumor immunity in individuals with cancer.	[Villablanca, Eduardo J.; Raccosta, Laura; Fontana, Raffaella; Maggioni, Daniela; Negro, Aurora; Bordignon, Claudio; Russo, Vincenzo] Ist Sci San Raffaele, Div Mol Oncol, Program Immunol & Bio Immuno Gene Therapy Canc, Canc Gene Therapy Unit, I-20132 Milan, Italy; [Villablanca, Eduardo J.] Univ Vita Salute San Raffaele, Milan, Italy; [Zhou, Dan; Valentinis, Barbara; Bordignon, Claudio; Traversari, Catia] MolMed SpA, Milan, Italy; [Sanvito, Francesca; Ponzoni, Maurilio; Doglioni, Claudio] Ist Sci San Raffaele, Dept Pathol, I-20132 Milan, Italy; [Bregni, Marco] Ist Sci San Raffaele, Strateg Program Oncol, I-20132 Milan, Italy; [Prinetti, Alessandro; Sonnino, Sandro] Univ Milan, Dept Med Chem Biochem & Biotechnol, Ctr Excellence Neurodegenerat Dis, Segrate, Italy; [Steffensen, Knut R.; Gustafsson, Jan-Ake] Karolinska Inst, Novum, Dept Biosci & Nutr, Huddinge, Sweden; [Gustafsson, Jan-Ake] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Karolinska Institutet; University of Houston System; University of Houston	Russo, V (corresponding author), Ist Sci San Raffaele, Div Mol Oncol, Program Immunol & Bio Immuno Gene Therapy Canc, Canc Gene Therapy Unit, I-20132 Milan, Italy.	catia.traversari@molmed.com; v.russo@hsr.it	Villablanca, Eduardo/E-1380-2016; raccosta, laura/K-3101-2016; Sonnino, Sandro/R-4154-2017; Russo, Vincenzo/K-5650-2016; Prinetti, Alessandro/R-4206-2017; Daniela, Maggioni/AAN-6553-2020	Villablanca, Eduardo/0000-0001-9522-9729; raccosta, laura/0000-0002-1625-9573; Sonnino, Sandro/0000-0001-8180-5908; Russo, Vincenzo/0000-0003-1592-5041; Prinetti, Alessandro/0000-0003-0252-2593; Daniela, Maggioni/0000-0001-9894-6387; bregni, marco/0000-0002-3789-1199; DOGLIONI, Claudio/0000-0002-4969-5216; Steffensen, Knut/0000-0001-6093-2801	Fondazione Cariplo, Italian Association for Cancer Research, European Community [LSHC-CT-2006-518334]; Italian Ministry of Health	Fondazione Cariplo, Italian Association for Cancer Research, European Community(European CommissionFondazione Cariplo); Italian Ministry of Health(Ministry of Health, Italy)	We thank M. E. Bianchi and G. Parmiani for helpful discussions and for the critical review of this manuscript. Additionally, we thank D. Mangelsdorf, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, for providing us with GAL4-LXRs plasmids; M. Liden, Ludwig Institute for Cancer Research, Stockholm, for GAL4-RXR and TK-MHC100-luc plasmids; F. Nystrom, Linkoping University, for GAL4-PPAR-gamma plasmid; C. Strott, National Institutes of Health, for the mouse SULT2B1b-encoding plasmid; L. Naldini, Scientific Institute S. Raffaele, for the lentiviral vector hPGK.GFP.wPRE.mhCMV.Delta NGFr.SV40PA; and M. Rocchi and C. Lanterna for technical help. This work was supported by Fondazione Cariplo, Italian Association for Cancer Research, European Community Project 'Cancer Immunotherapy' LSHC-CT-2006-518334 and the Italian Ministry of Health.	Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Allavena P, 2000, IMMUNOL REV, V177, P141, DOI 10.1034/j.1600-065X.2000.17714.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012; Degl'Innocenti E, 2008, CANCER RES, V68, P292, DOI 10.1158/0008-5472.CAN-07-2429; Fuda H, 2007, J LIPID RES, V48, P1343, DOI 10.1194/jlr.M700018-JLR200; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Geyeregger R, 2007, BLOOD, V109, P4288, DOI 10.1182/blood-2006-08-043422; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; He DN, 2006, DRUG METAB DISPOS, V34, P1749, DOI 10.1124/dmd.106.011114; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; LE NF, 2001, J BIOL CHEM, V276, P17920; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; MAVILIO F, 1994, BLOOD, V83, P1988; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Nencioni A, 2002, J IMMUNOL, V169, P1228, DOI 10.4049/jimmunol.169.3.1228; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Randolph GJ, 2008, CURR OPIN LIPIDOL, V19, P462, DOI 10.1097/MOL.0b013e32830d5f09; Randolph GJ, 2008, ANNU REV IMMUNOL, V26, P293, DOI 10.1146/annurev.immunol.26.021607.090254; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Shimizu C, 2003, ENDOCRINOLOGY, V144, P1186, DOI 10.1210/en.2002-221011; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Villablanca EJ, 2008, J LEUKOCYTE BIOL, V84, P871, DOI 10.1189/jlb.0108047; Yang X, 2007, COLD SPRING HARB SYM, V72, P387, DOI 10.1101/sqb.2007.72.058	35	211	219	0	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					98	U137		10.1038/nm.2074	http://dx.doi.org/10.1038/nm.2074			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20037595				2022-12-27	WOS:000273395500042
J	Han, YG; Kim, HJ; Dlugosz, AA; Ellison, DW; Gilbertson, RJ; Alvarez-Buylla, A				Han, Young-Goo; Kim, Hong Joo; Dlugosz, Andrzej A.; Ellison, David W.; Gilbertson, Richard J.; Alvarez-Buylla, Arturo			Dual and opposing roles of primary cilia in medulloblastoma development	NATURE MEDICINE			English	Article							INTRAFLAGELLAR TRANSPORT; CEREBELLAR DEVELOPMENT; REPRESSOR FUNCTIONS; MOUSE MODEL; HEDGEHOG; PROLIFERATION; MORPHOGENESIS; DISRUPTION; EXPRESSION; EXPANSION	Recent work has shown that primary cilia are essential for Hedgehog (Hh) signaling during mammalian development(1-9). It is also known that aberrant Hh signaling can lead to cancer(10), but the role of primary cilia in oncogenesis is not known. Cerebellar granule neuron precursors (GNPs) can give rise to medulloblastomas, the most common malignant brain tumor in children(11). The primary cilium and Hh signaling are required for GNP proliferation(8,12-15). We asked whether primary cilia in GNPs have a role in medulloblastoma growth in mice. Genetic ablation of primary cilia blocked medulloblastoma formation when this tumor was driven by a constitutively active Smoothened protein (Smo), an upstream activator of Hh signaling. In contrast, removal of cilia was required for medulloblastoma growth by a constitutively active glioma-associated oncogene family zinc finger-2 (GLI2), a downstream transcription factor. Thus, primary cilia are either required for or inhibit medulloblastoma formation, depending on the initiating oncogenic event. Remarkably, the presence or absence of cilia was associated with specific variants of human medulloblastomas; primary cilia were found in medulloblastomas with activation in HH or WNT signaling but not in most medulloblastomas in other distinct molecular subgroups. Primary cilia could serve as a diagnostic tool and provide new insights into the mechanism of tumorigenesis.	[Han, Young-Goo; Alvarez-Buylla, Arturo] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Han, Young-Goo; Alvarez-Buylla, Arturo] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Kim, Hong Joo] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA; [Dlugosz, Andrzej A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Dlugosz, Andrzej A.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Ellison, David W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; St Jude Children's Research Hospital	Alvarez-Buylla, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	abuylla@stemcell.ucsf.edu	Ellison, David/N-4806-2018; Han, Young-Goo/N-2664-2018; Gilbertson, Richard James/ABE-1346-2021	Han, Young-Goo/0000-0002-4008-294X; Gilbertson, Richard James/0000-0001-7539-9472; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Kim, Hong Joo/0000-0002-9157-1612	Mark Linder/American Brain Tumor Association Fellowship; US National Institutes of Health [NS28478, HD32116, P30 DK063720]; Goldhirsh Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD032116] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA087837, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028478, R01NS028478, R29NS028478] Funding Source: NIH RePORTER	Mark Linder/American Brain Tumor Association Fellowship; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Goldhirsh Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank L. S. Goldstein at the University of California-San Diego for providing us with Kif3a<SUP>fl/fl</SUP> mice; D. Rowitch at UCSF for SmoM2<SUP>fl/+</SUP> mice; B. Yoder at the University of Alabama-Birmingham for Ift88<SUP>fl/fl</SUP> mice; C. Cowdrey and the Neurological Surgery Tissue Bank at UCSF for human medulloblastoma samples; R. Segal and C. Stiles at Harvard University for Zic-specific and Olig2- specific antibodies; and A. Ruiz i Altaba at University of Geneva Medical School for Gli1 cDNA. We thank S. Wong, J. Reiter, D. Cano and S. Cervantes-Roldan for sharing unpublished data. We thank S. Vandenberg for helping with assessing the tumor types; J. Morris, K. Blaschke and M. Sachs for helping with quantitative RT-PCR; R. Romero for technical assistance; and D. Rowitch, J. Reiter, S Wong, R. Ihrie, S. Nader and T. Nguyen for comments on the manuscript. Y.-G.H. was, in part, supported by Mark Linder/American Brain Tumor Association Fellowship. The work was supported by grants from the US National Institutes of Health (NS28478 and HD32116), John G Bowes Research Fund and a grant from the Goldhirsh Foundation to A.A.-B. Confocal microscopy at Diabetes & Endocrinology Research Center. Microscopy and Imaging Core was supported by an US National Institutes of Health grant P30 DK063720.	Chizhikov VV, 2007, J NEUROSCI, V27, P9780, DOI 10.1523/JNEUROSCI.5586-06.2007; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Dahmane N, 1999, DEVELOPMENT, V126, P3089; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Han YG, 2008, NAT NEUROSCI, V11, P277, DOI 10.1038/nn2059; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Martinelli DC, 2007, GENE DEV, V21, P1231, DOI 10.1101/gad.1546307; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Spassky N, 2008, DEV BIOL, V317, P246, DOI 10.1016/j.ydbio.2008.02.026; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	40	278	287	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1062	U114		10.1038/nm.2020	http://dx.doi.org/10.1038/nm.2020			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19701203	Green Accepted, Green Submitted			2022-12-27	WOS:000269979200027
J	Pellegrini, M; Calzascia, T; Elford, AR; Shahinian, A; Lin, AE; Dissanayake, D; Dhanji, S; Nguyen, LT; Gronski, MA; Morre, M; Assouline, B; Lahl, K; Sparwasser, T; Ohashi, PS; Mak, TW				Pellegrini, Marc; Calzascia, Thomas; Elford, Alisha R.; Shahinian, Arda; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Gronski, Matthew A.; Morre, Michel; Assouline, Brigitte; Lahl, Katharina; Sparwasser, Tim; Ohashi, Pamela S.; Mak, Tak W.			Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies	NATURE MEDICINE			English	Article							REGULATORY T-CELLS; E3 UBIQUITIN LIGASE; TGF-BETA; CBL-B; TRANSGENIC MICE; NEGATIVE REGULATION; IMMUNE-RESPONSE; CUTTING EDGE; IN-VITRO; INTERLEUKIN-7	Identifying key factors that enhance immune responses is crucial for manipulating immunity to tumors. We show that after a vaccine-induced immune response, adjuvant interleukin-7 (IL-7) improves antitumor responses and survival in an animal model. The improved immune response is associated with increased IL-6 production and augmented T helper type 17 cell differentiation. Furthermore, IL-7 modulates the expression of two ubiquitin ligases: Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of T cell activation, is repressed, and SMAD-specific E3 ubiquitin protein ligase-2 (Smurf2) is enhanced, which antagonizes transforming growth factor-beta signaling. Notably, we show that although short term IL-7 therapy potently enhances vaccine-mediated immunity, in the absence of vaccination it is inefficient in promoting antitumor immune responses, despite inducing homeostatic proliferation of T cells. The ability of adjuvant IL-7 to antagonize inhibitory networks at the cellular and molecular level has major implications for immunotherapy in the treatment of tumors.	[Pellegrini, Marc; Calzascia, Thomas; Elford, Alisha R.; Shahinian, Arda; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Ohashi, Pamela S.; Mak, Tak W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Pellegrini, Marc; Calzascia, Thomas; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Ohashi, Pamela S.; Mak, Tak W.] Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON, Canada; [Gronski, Matthew A.] Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA USA; [Morre, Michel; Assouline, Brigitte] Cytheris Inc, Issy Les Moulineaux, France; [Lahl, Katharina] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Sparwasser, Tim] Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hanover, NH USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Virginia; Technical University of Munich	Ohashi, PS (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada.	pohashi@uhnres.utoronto.ca	Sparwasser, Tim D/AAA-4306-2022; Pellegrini, Marc/F-7670-2014; Lahl, Katharina/AAA-1909-2021; Sparwasser, Tim/AAF-7085-2019; Lin, Amy Erica/ABG-4745-2020	Lahl, Katharina/0000-0003-4919-331X; Sparwasser, Tim/0000-0001-5645-902X; Lin, Amy Erica/0000-0002-0554-2832; Pellegrini, Marc/0000-0003-3627-3126; Calzascia, Thomas/0000-0001-8225-6744; Gronski, Matthew/0000-0003-4779-5720; Ohashi, Pamela S./0000-0003-2915-9317; Dissanayake, Dilan/0000-0003-4270-7015	Canadian Institute for Health; Ontario Institute for Cancer Research; Terry Fox Cancer Foundation National Cancer Institute of Canada; Boninchi Foundation (Geneva, Switzerland); National Cancer Institute of Canada; Cancer Research Institute (New York)	Canadian Institute for Health(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research; Terry Fox Cancer Foundation National Cancer Institute of Canada; Boninchi Foundation (Geneva, Switzerland); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Cancer Research Institute (New York)	E. Deenick and R. Kalaf assisted with the injection of mice. M. Nikpour assisted with statistical analyses. This work was supported by a Canadian Institute for Health Research grant and funding from the Ontario Institute for Cancer Research to P. S. O. and a Terry Fox Cancer Foundation National Cancer Institute of Canada grant to T. W. M. T. C. was supported by the Boninchi Foundation (Geneva, Switzerland) and is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada. M. P. holds an Irvington Institute Fellowship with the Cancer Research Institute (New York). P. S. O. holds a Canada Research Chair in autoimmunity and tumor immunity.	AOKI T, 1992, P NATL ACAD SCI USA, V89, P3850, DOI 10.1073/pnas.89.9.3850; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Bellone M, 2008, TRENDS IMMUNOL, V29, P235, DOI 10.1016/j.it.2008.02.003; Calzascia T, 2007, J CLIN INVEST, V117, P3833, DOI 10.1172/JCI32567; CAYEUX S, 1995, EUR J IMMUNOL, V25, P2325, DOI 10.1002/eji.1830250831; Chiang JY, 2007, J CLIN INVEST, V117, P1029, DOI 10.1172/JCI29472; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; Fry TJ, 2001, BLOOD, V97, P1525, DOI 10.1182/blood.V97.6.1525; Gajewski TF, 2006, IMMUNOL REV, V213, P131, DOI 10.1111/j.1600-065X.2006.00442.x; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gronski MA, 2004, NAT MED, V10, P1234, DOI 10.1038/nm1114; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; King CG, 2006, NAT MED, V12, P1088, DOI 10.1038/nm1449; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Li LQ, 2006, NAT IMMUNOL, V7, P1157, DOI 10.1038/ni1398; Lin AE, 2007, CURR OPIN IMMUNOL, V19, P665, DOI 10.1016/j.coi.2007.10.002; Liu SJ, 2007, INT IMMUNOL, V19, P1213, DOI 10.1093/intimm/dxm093; Loeser S, 2007, J EXP MED, V204, P879, DOI 10.1084/jem.20061699; LYNCH DH, 1994, J EXP MED, V179, P31, DOI 10.1084/jem.179.1.31; Martin-Orozco N, 2006, J EXP MED, V203, P817, DOI 10.1084/jem.20060219; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Miller PW, 2000, HUM GENE THER, V11, P53, DOI 10.1089/10430340050016157; Mueller DL, 2004, NAT IMMUNOL, V5, P883, DOI 10.1038/ni1106; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Nanjappa SG, 2008, J CLIN INVEST, V118, P1027, DOI 10.1172/JCI32020; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Prendergast GC, 2007, CANCER RES, V67, P3500, DOI 10.1158/0008-5472.CAN-06-4626; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Strasser A, 2004, TRENDS IMMUNOL, V25, P610, DOI 10.1016/j.it.2004.08.012; Tripathi P, 2007, J IMMUNOL, V178, P4027, DOI 10.4049/jimmunol.178.7.4027; Wohlfert EA, 2006, J IMMUNOL, V176, P1316, DOI 10.4049/jimmunol.176.3.1316; Wohlfert EA, 2004, J IMMUNOL, V173, P1059, DOI 10.4049/jimmunol.173.2.1059; Yang BL, 2008, NAT IMMUNOL, V9, P1356, DOI 10.1038/ni.1670; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	55	158	168	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					528	536		10.1038/nm.1953	http://dx.doi.org/10.1038/nm.1953			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19396174				2022-12-27	WOS:000265889300031
J	Razani, B; Semenkovich, CF				Razani, Babak; Semenkovich, Clay F.			Getting away from glucose: stop sugarcoating diabetes	NATURE MEDICINE			English	Editorial Material							AUTOPHAGY; DISEASE; STRESS; ROLES	Type 2 diabetes is often viewed as a disorder of glucose metabolism. But many factors come into play in this condition, with obesity a prime risk factor and cardiovascular disease a major result. In Bedside to Bench, Babak Razani and Clay Semenkovich examine the linkages between diabetes and cardiovascular disease. They call for new research approaches in the wake of clinical trials showing that lowering glucose levels does not decrease cardiovascular events in people with type 2 diabetes. In Bench to Bedside, Steven Shoelson and Allison Goldfine examine how type 2 diabetes and other disorders can stem from obesity-and its effect on inflammation. These authors take a look at two recent studies showing how obesity perturbs inflammatory gene networks.	[Razani, Babak; Semenkovich, Clay F.] Washington Univ, Dept Med, St Louis, MO 63130 USA; [Semenkovich, Clay F.] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL)	Razani, B (corresponding author), Washington Univ, Dept Med, St Louis, MO 63130 USA.	csemenko@wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Razani, Babak/0000-0002-7172-9240				[Anonymous], 1982, Diabetes, V31 Suppl 5, P1; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Doria A, 2008, JAMA-J AM MED ASSOC, V300, P2389, DOI 10.1001/jama.2008.649; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	15	6	6	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					372	373		10.1038/nm0409-372	http://dx.doi.org/10.1038/nm0409-372			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19350008				2022-12-27	WOS:000264937200018
J	Jaworski, K; Ahmadian, M; Duncan, RE; Sarkadi-Nagy, E; Varady, KA; Hellerstein, MK; Lee, HY; Samuel, VT; Shulman, GI; Kim, KH; de Val, S; Kang, C; Sul, HS				Jaworski, Kathy; Ahmadian, Maryam; Duncan, Robin E.; Sarkadi-Nagy, Eszter; Varady, Krista A.; Hellerstein, Marc K.; Lee, Hui-Young; Samuel, Varman T.; Shulman, Gerald I.; Kim, Kee-Hong; de Val, Sarah; Kang, Chulho; Sul, Hei Sook			AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency	NATURE MEDICINE			English	Article							INHIBITS ADIPOCYTE DIFFERENTIATION; ADIPOSE-TISSUE; ARACHIDONIC-ACID; TRANSGENIC MICE; LIPID-METABOLISM; PROTEIN-KINASE; PPAR-GAMMA; EXPRESSION; RECEPTOR; CELLS	A main function of white adipose tissue is to release fatty acids from stored triacylglycerol for other tissues to use as an energy source. Whereas endocrine regulation of lipolysis has been extensively studied, autocrine and paracrine regulation is not well understood. Here we describe the role of the newly identified major adipocyte phospholipase A(2), AdPLA (encoded by Pla2g16, also called HREV107), in the regulation of lipolysis and adiposity. AdPLA-null mice have a markedly higher rate of lipolysis owing to increased cyclic AMP levels arising from the marked reduction in the amount of adipose prostaglandin E-2 that binds the Gai-coupled receptor, EP3. AdPLA-null mice have markedly reduced adipose tissue mass and triglyceride content but normal adipogenesis. They also have higher energy expenditure with increased fatty acid oxidation within adipocytes. AdPLA-deficient ob/ob mice remain hyperphagic but lean, with increased energy expenditure, yet have ectopic triglyceride storage and insulin resistance. AdPLA is a major regulator of adipocyte lipolysis and is crucial for the development of obesity.	[Jaworski, Kathy; Ahmadian, Maryam; Duncan, Robin E.; Sarkadi-Nagy, Eszter; Varady, Krista A.; Hellerstein, Marc K.; de Val, Sarah; Sul, Hei Sook] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Lee, Hui-Young; Samuel, Varman T.; Shulman, Gerald I.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Kim, Kee-Hong; Kang, Chulho] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Yale University; University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 220 Morgan Hall, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Duncan, Robin/AAH-7465-2021; Han, Zaiqi/AAI-2233-2019; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668; Lee, Hui-Young/0000-0002-3464-6382; Jaworski, Kathy/0000-0001-6014-5066	US National Institutes of Health [DK75682]; Natural Sciences and Engineering Research Council of Canada [DK59635]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093928, T32DK061918, U2CDK059635, U24DK059635, R01DK040936, R01DK075682] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by DK75682 from the US National Institutes of Health to H. S. S. and DK59635 to G. I. S. R. E. D. and K. A. V. are recipients of postdoctoral fellowships from the Natural Sciences and Engineering Research Council of Canada. R. E. D. is a recipient of a postdoctoral fellowship from the Canadian Institutes of Health Research. The authors would like to thank O. Barauskas for technical help; D. Frasson for fatty acid oxidation measurement; Y. Wang for performing WR1339 injections; J. Lu, J. Chen, R. Mantara and N. Nag for assistance with animal maintenance; A. Birkenfled and D. Frederick for assistance with clamping studies; C. Lange and J. Chithalen for assistance with graphics; and Merck Frosst Canada for the kind gift of L826266.	Aubert J, 2000, MOL CELL ENDOCRINOL, V160, P149, DOI 10.1016/S0303-7207(99)00210-5; Bansode RR, 2008, J BIOL CHEM, V283, P231, DOI 10.1074/jbc.M707268200; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen JL, 2005, J BIOL CHEM, V280, P25396, DOI 10.1074/jbc.M413948200; COHENLURIA R, 1992, CELL SIGNAL, V4, P331, DOI 10.1016/0898-6568(92)90073-H; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; Duncan RE, 2008, J BIOL CHEM, V283, P25428, DOI 10.1074/jbc.M804146200; Duncan RE, 2007, ANNU REV NUTR, V27, P79, DOI 10.1146/annurev.nutr.27.061406.093734; Fain JN, 2000, J LIPID RES, V41, P1689; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Fajas L, 2003, J LIPID RES, V44, P1652, DOI 10.1194/jlr.M300248-JLR200; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; Girouard H, 1998, PROSTAG OTH LIPID M, V56, P43, DOI 10.1016/S0090-6980(98)00035-5; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hertzel AV, 2006, AM J PHYSIOL-ENDOC M, V290, pE814, DOI 10.1152/ajpendo.00465.2005; Jaworski K, 2007, AM J PHYSIOL-GASTR L, V293, pG1, DOI 10.1152/ajpgi.00554.2006; Johansson SM, 2007, ACTA PHYSIOL, V190, P87, DOI 10.1111/j.1365-201X.2007.01692.x; KATHER H, 1979, J CLIN INVEST, V64, P609, DOI 10.1172/JCI109500; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Latasa MJ, 2003, MOL CELL BIOL, V23, P5896, DOI 10.1128/MCB.23.16.5896-5907.2003; Lucas KK, 2005, PROSTAG OTH LIPID M, V77, P235, DOI 10.1016/j.prostaglandins.2005.02.004; Lucas S, 2003, J LIPID RES, V44, P154, DOI 10.1194/jlr.M200250-JLR200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Massiera F, 2003, J LIPID RES, V44, P271, DOI 10.1194/jlr.M200346-JLR200; Petersen RK, 2003, J LIPID RES, V44, P2320, DOI 10.1194/jlr.M300192-JLR200; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; RICHELSEN B, 1992, PROSTAG LEUKOTR ESS, V47, P171, DOI 10.1016/0952-3278(92)90235-B; Samuel VT, 2006, DIABETES, V55, P2042, DOI 10.2337/db05-0705; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; SCHALOSKE RH, 2006, BIOCH BIOPHYS ACTA; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Turner SM, 2003, AM J PHYSIOL-ENDOC M, V285, pE790, DOI 10.1152/ajpendo.00402.2002; VANCE DE, 2008, BIOCH LIPIDS LIPOPRO, P277; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; Viswanadha S, 2006, J LIPID RES, V47, P1859, DOI 10.1194/jlr.D600005-JLR200; Yan HY, 2003, J LIPID RES, V44, P424, DOI 10.1194/jlr.M200357-JLR200; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; YOUN JH, 1993, DIABETES, V42, P757, DOI 10.2337/diabetes.42.5.757; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103	45	186	194	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					159	168		10.1038/nm.1904	http://dx.doi.org/10.1038/nm.1904			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19136964	Green Accepted			2022-12-27	WOS:000263119400018
J	Sadelain, M; Kwak, LW; Haining, N				Sadelain, Michel; Kwak, Larry W.; Haining, Nick			Turning T cells against tumors	NATURE MEDICINE			English	Editorial Material									[Sadelain, Michel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Kwak, Larry W.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Haining, Nick] Dana Farber Canc Inst, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1022	1022						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841138	Bronze			2022-12-27	WOS:000259892300026
J	Diehl, F; Schmidt, K; Choti, MA; Romans, K; Goodman, S; Li, M; Thornton, K; Agrawal, N; Sokoll, L; Szabo, SA; Kinzler, KW; Vogelstein, B; Diaz, LA				Diehl, Frank; Schmidt, Kerstin; Choti, Michael A.; Romans, Katharine; Goodman, Steven; Li, Meng; Thornton, Katherine; Agrawal, Nishant; Sokoll, Lori; Szabo, Steve A.; Kinzler, Kenneth W.; Vogelstein, Bert; Diaz, Luis A., Jr.			Circulating mutant DNA to assess tumor dynamics	NATURE MEDICINE			English	Article							NUCLEIC-ACIDS; CANCER; PLASMA; QUANTIFICATION; MARKERS; BREAST; CELLS; SERUM	The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers for individuals with cancer could similarly enhance the management of their disease. DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. In this study, we applied a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in 162 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer. We found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy. We suggest that this personalized genetic approach could be generally applied to individuals with other types of cancer.	[Diehl, Frank; Schmidt, Kerstin; Romans, Katharine; Li, Meng; Thornton, Katherine; Agrawal, Nishant; Szabo, Steve A.; Kinzler, Kenneth W.; Vogelstein, Bert; Diaz, Luis A., Jr.] Johns Hopkins Med Inst, Howard Hughes Med Inst, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA; [Diehl, Frank; Schmidt, Kerstin; Romans, Katharine; Li, Meng; Thornton, Katherine; Agrawal, Nishant; Szabo, Steve A.; Kinzler, Kenneth W.; Vogelstein, Bert; Diaz, Luis A., Jr.] Johns Hopkins Med Inst, Sidney Kimmel Canc Ctr, Baltimore, MD 21231 USA; [Choti, Michael A.] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; [Goodman, Steven] Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA; [Sokoll, Lori] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Med Inst, Howard Hughes Med Inst, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.	vogelbe@jhmi.edu; ldiaz1@jhmi.edu		Diaz, Luis/0000-0002-7079-8914; Goodman, Steven/0000-0002-3872-5723	Miracle Foundation; US National Colorectal Cancer Research Alliance; US National Institutes of Health [CA43460, CA57345, CA62924, CA129825]; NATIONAL CANCER INSTITUTE [R37CA043460, R01CA057345, R37CA057345, P50CA062924, R01CA129825, R01CA043460] Funding Source: NIH RePORTER	Miracle Foundation; US National Colorectal Cancer Research Alliance; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G. Traverso for useful discussions; D. Heslop, C. Vaughn and D. Edelstein for their help with plasma collection; and L. Fayad for help with the interpretation of imaging studies. This work was supported by the Virginia and D. K. Ludwig Fund for Cancer Research, the Miracle Foundation, the US National Colorectal Cancer Research Alliance and US National Institutes of Health grants CA43460, CA57345, CA62924 and CA129825.	Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Diehl F, 2006, NAT METHODS, V3, P551, DOI 10.1038/NMETH898; Dressman D, 2003, P NATL ACAD SCI USA, V100, P8817, DOI 10.1073/pnas.1133470100; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Goebel G, 2005, DIS MARKERS, V21, P105, DOI 10.1155/2005/218759; Goldstein MJ, 2005, CANCER INVEST, V23, P338, DOI 10.1081/CNV-200058878; Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002; Hacia JG, 1999, J MED GENET, V36, P730, DOI 10.1136/jmg.36.10.730; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Rago C, 2007, CANCER RES, V67, P9364, DOI 10.1158/0008-5472.CAN-07-0605; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	16	1717	1880	10	323	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					985	990		10.1038/nm.1789	http://dx.doi.org/10.1038/nm.1789			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18670422	Green Accepted			2022-12-27	WOS:000258988600033
J	Burton, JB; Johnson, M; Sato, M; Koh, SBS; Mulholland, DJ; Stout, D; Chatziioannou, AF; Phelps, ME; Wu, H; Wu, L				Burton, Jeremy B.; Johnson, Mai; Sato, Makoto; Koh, Sok Boon S.; Mulholland, David J.; Stout, David; Chatziioannou, Arion F.; Phelps, Michael E.; Wu, Hong; Wu, Lily			Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer	NATURE MEDICINE			English	Article							RADICAL PROSTATECTOMY; PELVIC LYMPHADENECTOMY; IN-VIVO; VECTOR; PROGRESSION; SURVIVAL; CELLS; LEADS; MICE	The accurate assessment of nodal involvement in prostate cancer is crucial to planning treatment, yet there is a shortage of noninvasive imaging techniques capable of visualizing nodal lesions directly. This study demonstrates the feasibility of using recombinant human adenoviral vectors to detect nodal metastases in a human prostate cancer model. This was achieved by the prostate-restricted expression of optical and positron emission tomography (PET) imaging reporter genes by the viral vector coupled with the innate lymphotropic properties of adenovirus. We show that peritumoral administration of these vectors results in the direct detection of reporter gene expression in metastatic lesions within sentinel lymph nodes. Notably, this approach parallels the current lymphoscintigraphy method but enables the direct PET visualization of sentinel lymph node metastases, eliminating the need for invasive lymphadenectomy. These findings may lead to more effective diagnostic and therapeutic strategies for individuals with advanced-stage prostate cancer.	[Burton, Jeremy B.; Mulholland, David J.; Stout, David; Chatziioannou, Arion F.; Phelps, Michael E.; Wu, Hong; Wu, Lily] Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Johnson, Mai; Sato, Makoto; Wu, Lily] Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Urol, Los Angeles, CA 90095 USA; [Koh, Sok Boon S.; Wu, Lily] Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Bioengn, Los Angeles, CA 90095 USA; [Koh, Sok Boon S.; Wu, Lily] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wu, L (corresponding author), Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	lwu@mednet.ucla.edu			NCI NIH HHS [2U24 CA092865, R01 CA101904-06, R01 CA101904, R21 CA122693, R01 CA101904-01, U24 CA092865, R21 CA122693-02, P50 CA092131, P50 CA092131-070003] Funding Source: Medline; NIGMS NIH HHS [T32 GM008652, T32-GM008652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U24CA092865, R01CA101904, R21CA122693, P50CA092131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Bader P, 2003, J UROLOGY, V169, P849, DOI 10.1097/01.ju.0000049032.38743.c7; Brakenhielm E, 2007, INT J CANCER, V121, P2153, DOI 10.1002/ijc.22900; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chow PL, 2006, PHYS MED BIOL, V51, P379, DOI 10.1088/0031-9155/51/2/013; Daneshmand S, 2004, J UROLOGY, V172, P2252, DOI 10.1097/01.ju.0000143448.04161.cc; Epstein JI, 2000, UROLOGY, V56, P283, DOI 10.1016/S0090-4295(00)00640-3; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749; Heidenreich A, 2007, EUR UROL, V52, P29, DOI 10.1016/j.eururo.2007.04.020; Ikomi F, 1999, LYMPHOLOGY, V32, P90; Iyer M, 2001, P NATL ACAD SCI USA, V98, P14595, DOI 10.1073/pnas.251551098; Johnson M, 2006, HUM GENE THER, V17, P1262, DOI 10.1089/hum.2006.17.1262; Johnson Mai, 2005, Mol Imaging, V4, P463; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Labow D, 2000, HUM GENE THER, V11, P759, DOI 10.1089/10430340050015653; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Link RE, 2001, UROL CLIN N AM, V28, P491, DOI 10.1016/S0094-0143(05)70157-9; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Roehl KA, 2004, J UROLOGY, V172, P910, DOI 10.1097/01.ju.0000134888.22332.bb; Rorvik J, 2001, Curr Opin Urol, V11, P181; Rosenfeld ME, 1995, CLIN CANCER RES, V1, P1571; Sadeghi H, 2005, CURR GENE THER, V5, P411, DOI 10.2174/1566523054546189; Szuba A, 2003, J NUCL MED, V44, P43; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; TILNEY NL, 1970, IMMUNOLOGY, V19, P181; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WOLF JS, 1995, J UROLOGY, V153, P993, DOI 10.1016/S0022-5347(01)67620-1; Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549	32	71	76	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					882	888		10.1038/nm.1727	http://dx.doi.org/10.1038/nm.1727			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18622403	Green Accepted			2022-12-27	WOS:000258237500037
J	Zhou, CC; Zhang, YJ; Irani, RA; Zhang, H; Mi, TJ; Popek, EJ; Hicks, MJ; Ramin, SM; Kellems, RE; Xia, Y				Zhou, Cissy C.; Zhang, Yujin; Irani, Roxanna A.; Zhang, Hong; Mi, Tiejuan; Popek, Edwina J.; Hicks, M. John; Ramin, Susan M.; Kellems, Rodney E.; Xia, Yang			Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice	NATURE MEDICINE			English	Article							REDUCED UTERINE PERFUSION; MATERNAL AUTOANTIBODIES; SOLUBLE ENDOGLIN; HYPERTENSION; RENIN; CELLS; PATHOPHYSIOLOGY; PATHOGENESIS; ENDOTHELIN; ANTIBODIES	Pre-eclampsia affects approximately 5% of pregnancies and remains a leading cause of maternal and neonatal mortality and morbidity in the United States and the world(1,2). The clinical hallmarks of this maternal disorder include hypertension, proteinuria, endothelial dysfunction and placental defects. Advanced-stage clinical symptoms include cerebral hemorrhage, renal failure and the HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. An effective treatment of pre-eclampsia is unavailable owing to the poor understanding of the pathogenesis of the disease. Numerous recent studies(3-5) have shown that women with pre-eclampsia possess autoantibodies, termed AT(1)-AAs, that bind and activate the angiotensin II receptor type 1a (AT(1) receptor). We show here that key features of pre-eclampsia, including hypertension, proteinuria, glomerular endotheliosis (a classical renal lesion of pre-eclampsia), placental abnormalities and small fetus size appeared in pregnant mice after injection with either total IgG or affinity-purified AT(1)-AAs from women with pre-eclampsia. These features were prevented by co-injection with losartan, an AT(1) receptor antagonist, or by an antibody neutralizing seven-amino-acid epitope peptide. Thus, our studies indicate that pre-eclampsia may be a pregnancy-induced autoimmune disease in which key features of the disease result from autoantibody-induced angiotensin receptor activation. This hypothesis has obvious implications regarding pre-eclampsia screening, diagnosis and therapy.	[Zhou, Cissy C.; Zhang, Yujin; Irani, Roxanna A.; Mi, Tiejuan; Kellems, Rodney E.; Xia, Yang] Univ Texas Houston, Sch Med, Dept Biochem, Houston, TX 77030 USA; [Zhou, Cissy C.; Zhang, Yujin; Irani, Roxanna A.; Mi, Tiejuan; Kellems, Rodney E.; Xia, Yang] Univ Texas Houston, Sch Med, Dept Mol Biol, Houston, TX 77030 USA; [Zhang, Hong] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Popek, Edwina J.; Hicks, M. John] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; [Ramin, Susan M.] Univ Texas Houston, Sch Med, Dept Obstet Gynecol & Reprod Sci, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston	Xia, Y (corresponding author), Univ Texas Houston, Sch Med, Dept Biochem, 6431 Fannin, Houston, TX 77030 USA.	yang.xia@uth.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076558] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL076558, HL076558] Funding Source: Medline; NICHD NIH HHS [HD34130, R56 HD034130, R01 HD034130-11A2, R01 HD034130] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexander BT, 2001, HYPERTENSION, V37, P485, DOI 10.1161/01.HYP.37.2.485; Alexander BT, 2001, HYPERTENSION, V37, P1191, DOI 10.1161/01.HYP.37.4.1191; Barron LA, 2001, HYPERTENSION, V38, P730, DOI 10.1161/01.HYP.38.3.730; Bobst SM, 2005, AM J HYPERTENS, V18, P330, DOI 10.1016/j.amjhyper.2004.10.002; Borzychowski AM, 2006, SEMIN FETAL NEONAT M, V11, P309, DOI 10.1016/j.siny.2006.04.001; CAMPBELL DM, 1985, BRIT J OBSTET GYNAEC, V92, P131, DOI 10.1111/j.1471-0528.1985.tb01064.x; Dechend R, 2000, CIRCULATION, V101, P2382, DOI 10.1161/01.CIR.101.20.2382; Dechend R, 2005, HYPERTENSION, V45, P742, DOI 10.1161/01.HYP.0000154785.50570.63; Dechend R, 2003, CIRCULATION, V107, P1632, DOI 10.1161/01.CIR.0000058200.90059.B1; DECHEND R, 2006, HYPERTENS PREGNANCY, V25; DEJONG CLD, 1991, CLIN PERINATOL, V18, P683, DOI 10.1016/S0095-5108(18)30491-3; ESKENAZI B, 1993, AM J OBSTET GYNECOL, V169, P1112, DOI 10.1016/0002-9378(93)90265-K; Gilbert JS, 2007, HYPERTENSION, V50, P1142, DOI 10.1161/HYPERTENSIONAHA.107.096594; Granger JP, 2002, MICROCIRCULATION, V9, P147, DOI 10.1038/sj.mn.7800137; Granger JP, 2001, HYPERTENSION, V38, P718, DOI 10.1161/01.HYP.38.3.718; Herse F, 2007, HYPERTENSION, V49, P604, DOI 10.1161/01.HYP.0000257797.49289.71; LaMarca BBD, 2005, HYPERTENSION, V46, P1022, DOI 10.1161/01.HYP.0000175476.26719.36; LaMarca BBD, 2005, HYPERTENSION, V46, P82, DOI 10.1161/01.HYP.0000169152.59854.36; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Levine RJ, 2005, JAMA-J AM MED ASSOC, V293, P77, DOI 10.1001/jama.293.1.77; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Llinas M, 2005, HYPERTENSION, V46, P884; Luft FC, 2000, J MOL MED-JMM, V78, P63, DOI 10.1007/s001090000087; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Roberts JM, 2002, PLACENTA, V23, P359, DOI 10.1053/plac.2002.0819; Roberts L, 2006, HYPERTENSION, V47, P615, DOI 10.1161/01.HYP.0000197950.42301.dd; Takimoto E, 1996, SCIENCE, V274, P995, DOI 10.1126/science.274.5289.995; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Wallukat G, 1999, J CLIN INVEST, V103, P945, DOI 10.1172/JCI4106; Wallukat G, 2003, CAN J PHYSIOL PHARM, V81, P79, DOI 10.1139/Y02-160; Walther T, 2005, HYPERTENSION, V46, P1275, DOI 10.1161/01.HYP.0000190040.66563.04; Xia Y, 2003, J SOC GYNECOL INVEST, V10, P82, DOI 10.1016/S1071-5576(02)00259-9; Xia Y, 2007, J IMMUNOL, V179, P3391, DOI 10.4049/jimmunol.179.6.3391; Xia Y, 2007, HYPERTENSION, V50, P269, DOI 10.1161/HYPERTENSIONAHA.107.091322; Zhou CCY, 2008, HYPERTENSION, V51, P1010, DOI 10.1161/HYPERTENSIONAHA.107.097790; Zhou CC, 2007, CIRC RES, V100, P88, DOI 10.1161/01.RES.0000254703.11154.18	40	331	353	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					855	862		10.1038/nm.1856	http://dx.doi.org/10.1038/nm.1856			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18660815	Green Accepted			2022-12-27	WOS:000258237500033
J	Lo, EH				Lo, Eng H.			A new penumbra: transitioning from injury into repair after stroke	NATURE MEDICINE			English	Article							ACUTE ISCHEMIC-STROKE; NITRIC-OXIDE SYNTHASE; TISSUE-PLASMINOGEN ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; N-TERMINAL KINASE; BRAIN-INJURY; MATRIX-METALLOPROTEINASE; FUNCTIONAL RECOVERY; CLINICAL-TRIALS; MICE DEFICIENT	The penumbra is an area of brain tissue that is damaged but not yet dead after focal ischemia. The existence of a penumbra implies that therapeutic salvage is theoretically possible after stroke. The first decade of penumbral science investigated the ischemic regulation of electrophysiology, cerebral blood flow and metabolism. The second decade advanced our understanding of molecular mechanisms that mediate penumbral cell death. And the third decade saw the rapid development of clinical neuroimaging tools that are now increasingly applied in stroke patients. But how can we look ahead as we move into the fourth decade of penumbra research? This author speculates that a paradigm shift is needed. Most molecular targets for therapy have biphasic roles in stroke pathophysiology. During the acute phase, these targets mediate injury. During the recovery phase, the same mediators contribute to neurovascular remodeling. It is this boundary zone that comprises the new penumbra, and future investigations should dissect where, when and how damaged brain makes the transition from injury into repair.	[Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Program Neurosci, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Lo, EH (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab, Massachusetts Gen Hosp E 149-2401, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu						Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Baron JC, 2001, BRAIN, V124, P2, DOI 10.1093/brain/124.1.2; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Chen JL, 2007, ANN NEUROL, V62, P49, DOI 10.1002/ana.21160; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; Ginsberg MD, 2007, STROKE, V38, P1967, DOI 10.1161/STROKEAHA.106.479170; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; HEISS WD, 1983, STROKE, V14, P329, DOI 10.1161/01.STR.14.3.329; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Hoyte L, 2004, EXP NEUROL, V188, P200, DOI 10.1016/j.expneurol.2004.05.008; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lo EH, 2008, BRIT J PHARMACOL, V153, pS396, DOI 10.1038/sj.bjp.0707626; Lo EH, 2005, STROKE, V36, P189, DOI 10.1161/01.STR.0000153069.96296.fd; Lo EH, 1996, STROKE, V27, P1381, DOI 10.1161/01.STR.27.8.1381; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Moustafa RR, 2008, BRIT J PHARMACOL, V153, pS44, DOI 10.1038/sj.bjp.0707530; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; POWERS WJ, 1984, ANN NEUROL, V16, P546, DOI 10.1002/ana.410160504; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; SUN F, 2007, ACUTE ISCHEMIC INJUR, P65; Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015; Waetzig V, 2006, PROG NEUROBIOL, V80, P84, DOI 10.1016/j.pneurobio.2006.08.002; Wahlgren NG, 2004, CEREBROVASC DIS, V17, P153, DOI 10.1159/000074808; Wang XY, 2004, STROKE, V35, P2726, DOI 10.1161/01.STR.0000143219.16695.af; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Warach S, 2003, STROKE, V34, P2533, DOI 10.1161/01.STR.0000092395.19554.9A; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	50	436	456	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					497	500		10.1038/nm1735	http://dx.doi.org/10.1038/nm1735			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18463660				2022-12-27	WOS:000255681800027
J	Frenette, PS; Mohandas, N				Frenette, Paul S.; Mohandas, Narla			A trigger for TRALI	NATURE MEDICINE			English	Editorial Material							TRANSPORTER-LIKE PROTEIN-2; ACUTE LUNG INJURY; CHOLINE		[Frenette, Paul S.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Mohandas, Narla] New York Blood Ctr, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; New York Blood Center	Frenette, PS (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY USA.	paul.frenette@mssm.edu	Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NHLBI NIH HHS [R01 HL069438] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bux J, 2008, VOX SANG, V94, P277, DOI 10.1111/j.1423-0410.2007.01031.x; Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x; Curtis BR, 2010, BLOOD, V115, P2073, DOI 10.1182/blood-2009-11-248336; Greinacher A, 2010, NAT MED, V16, P45, DOI 10.1038/nm.2070; Hidalgo A, 2009, NAT MED, V15, P384, DOI 10.1038/nm.1939; HILLYER CD, 2006, BLOOD BANKING TRANSF, P95; Kelher MR, 2009, BLOOD, V113, P2079, DOI 10.1182/blood-2008-09-177857; Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432; Nair TS, 2004, J NEUROSCI, V24, P1772, DOI 10.1523/JNEUROSCI.5063-03.2004; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005; Traiffort E, 2005, J NEUROCHEM, V92, P1116, DOI 10.1111/j.1471-4159.2004.02962.x; VANLEEUWEN A, 1964, VOX SANG, V9, P431	14	7	10	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					382	383		10.1038/nm0410-382	http://dx.doi.org/10.1038/nm0410-382			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376047				2022-12-27	WOS:000276446800037
J	Edgerton, VR; Roy, RR				Edgerton, V. Reggie; Roy, Roland R.			Spasticity: a switch from inhibition to excitation	NATURE MEDICINE			English	Editorial Material							SPINAL-CORD-INJURY	The involuntary muscle spasms that occur as a result of neuromotor disorders and spinal cord injury can have dangerous consequences for affected individuals. New findings shed light on one mechanism contributing to spasticity: limited chloride transport in motoneurons (pages 302-307).	[Edgerton, V. Reggie; Roy, Roland R.] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Edgerton, V. Reggie; Roy, Roland R.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; [Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Edgerton, VR (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA.	vre@ucla.edu						Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359, DOI 10.1152/jn.1999.82.1.359; Elbasiouny SM, 2010, NEUROREHAB NEURAL RE, V24, P23, DOI 10.1177/1545968309343213; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Heckman CJ, 2005, MUSCLE NERVE, V31, P135, DOI 10.1002/mus.20261; Lu Y, 2008, J PHYSIOL-LONDON, V586, P5701, DOI 10.1113/jphysiol.2008.152348; Malhotra S, 2009, CLIN REHABIL, V23, P651, DOI 10.1177/0269215508101747; Norton JA, 2008, BRAIN, V131, P1478, DOI 10.1093/brain/awn050	8	12	17	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					270	271		10.1038/nm0310-270	http://dx.doi.org/10.1038/nm0310-270			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208512				2022-12-27	WOS:000275289500029
J	Edgington, LE; Berger, AB; Blum, G; Albrow, VE; Paulick, MG; Lineberry, N; Bogyo, M				Edgington, Laura E.; Berger, Alicia B.; Blum, Galia; Albrow, Victoria E.; Paulick, Margot G.; Lineberry, Neil; Bogyo, Matthew			Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes	NATURE MEDICINE			English	Article							FLUOROCHROME-LABELED INHIBITORS; DEATH IN-VIVO; CELL-DEATH; ANNEXIN-V; DNA FRAGMENTATION; TUMOR RESPONSE; ACTIVATION; CHEMOTHERAPY; PEPTIDE; VISUALIZATION	Imaging agents that enable direct visualization and quantification of apoptosis in vivo have great potential value for monitoring chemotherapeutic response as well as for early diagnosis and disease monitoring. We describe here the development of fluorescently labeled activity-based probes (ABPs) that covalently label active caspases in vivo. We used these probes to monitor apoptosis in the thymi of mice treated with dexamethasone as well as in tumor-bearing mice treated with the apoptosis-inducing monoclonal antibody Apomab (Genentech). Caspase ABPs provided direct readouts of the kinetics of apoptosis in live mice, whole organs and tissue extracts. The probes produced a maximum fluorescent signal that could be monitored noninvasively and that coincided with the peak in caspase activity, as measured by gel analysis. Overall, these studies demonstrate that caspase-specific ABPs have the potential to be used for noninvasive imaging of apoptosis in both preclinical and clinical settings.	[Edgington, Laura E.; Berger, Alicia B.; Bogyo, Matthew] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Blum, Galia; Albrow, Victoria E.; Paulick, Margot G.; Bogyo, Matthew] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Lineberry, Neil] Stanford Univ, Sch Med, Dept Immunol, Stanford, CA 94305 USA; [Bogyo, Matthew] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Bogyo, M (corresponding author), Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA.	mbogyo@stanford.edu		Bogyo, Matthew/0000-0003-3753-4412; Edgington-Mitchell, Laura/0000-0002-6810-6149	US National Institutes of Health [U54 RR020843, R01 EB005011]; Public Health Services [CA09302]; US National Cancer Institute; Department of Health and Human Services.; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005011] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health and Human Services.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We would like to thank G. Salvesen from the Burnham Institute for Medical Research for the kind gift of recombinant caspases and for creative input on the project. We thank B. Sloane, Wayne State University, for the kind gift of cathepsin antibodies and C. Watts of the University of Dundee for the kind gift of legumain antibodies. We thank R. Weimer for critical discussion of the data and help with protocols for the use of Apomab. We thank A. Fan and D. Felsher for assistance with the MYC mouse model. We thank the Molecular Imaging Program at Stanford and the Stanford Small Animal Imaging Facility for assistance with noninvasive imaging studies. This work was funded by US National Institutes of Health grants U54 RR020843 and R01 EB005011 (to M. B.). M. G. P. was supported by Public Health Services grant CA09302, awarded by the US National Cancer Institute, Department of Health and Human Services.	Adams C, 2008, CELL DEATH DIFFER, V15, P751, DOI 10.1038/sj.cdd.4402306; Aloya R, 2006, APOPTOSIS, V11, P2089, DOI 10.1007/s10495-006-0282-7; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Bauer C, 2005, J NUCL MED, V46, P1066; Bedner E, 2000, EXP CELL RES, V259, P308, DOI 10.1006/excr.2000.4955; Belhocine T, 2002, CLIN CANCER RES, V8, P2766; Berger AB, 2006, MOL CELL, V23, P509, DOI 10.1016/j.molcel.2006.06.021; Blankenberg FG, 2006, NAT PROTOC, V1, P108, DOI 10.1038/nprot.2006.17; Blum G, 2007, NAT CHEM BIOL, V3, P668, DOI 10.1038/nchembio.2007.26; Brewer JA, 2002, J IMMUNOL, V169, P1837, DOI 10.4049/jimmunol.169.4.1837; Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p; Cohen A, 2009, CELL RES, V19, P625, DOI 10.1038/cr.2009.17; Cohen J J, 1992, Semin Immunol, V4, P363; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Hofstra L, 2000, LANCET, V356, P209, DOI 10.1016/S0140-6736(00)02482-X; Kato D, 2005, NAT CHEM BIOL, V1, P33, DOI 10.1038/nchembio707; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Lee A, 2001, ORG LETT, V3, P3707, DOI 10.1021/ol0166496; Methot N, 2004, J BIOL CHEM, V279, P27905, DOI 10.1074/jbc.M400247200; Ntziachristos V, 2004, P NATL ACAD SCI USA, V101, P12294, DOI 10.1073/pnas.0401137101; Odaka C, 2002, CELL DEATH DIFFER, V9, P104, DOI 10.1038/sj/cdd/4400941; Petrovsky A, 2003, CANCER RES, V63, P1936; Pozarowski P, 2003, CYTOM PART A, V55A, P50, DOI 10.1002/cyto.a.10074; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Rottey S, 2006, J NUCL MED, V47, P1813; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Schellenberger EA, 2003, NEOPLASIA, V5, P187, DOI 10.1016/S1476-5586(03)80050-7; Sexton KB, 2007, CELL DEATH DIFFER, V14, P727, DOI 10.1038/sj.cdd.4402074; Sexton KB, 2007, BIOORG MED CHEM LETT, V17, P649, DOI 10.1016/j.bmcl.2006.10.100; Smolewski P, 2001, CYTOMETRY, V44, P73, DOI 10.1002/1097-0320(20010501)44:1<73::AID-CYTO1084>3.0.CO;2-S; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vermeersch H, 2004, NUCL MED COMMUN, V25, P259, DOI 10.1097/00006231-200403000-00008; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Zavitsanou K, 2007, J MOL HISTOL, V38, P313, DOI 10.1007/s10735-007-9104-7; Zhou D, 2006, BIOORG MED CHEM LETT, V16, P5041, DOI 10.1016/j.bmcl.2006.07.045	35	225	232	7	100	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					967	U177		10.1038/nm.1938	http://dx.doi.org/10.1038/nm.1938			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19597506	Green Accepted			2022-12-27	WOS:000268770400044
J	Hessell, AJ; Poignard, P; Hunter, M; Hangartner, L; Tehrani, DM; Bleeker, WK; Parren, PWHI; Marx, PA; Burton, DR				Hessell, Ann J.; Poignard, Pascal; Hunter, Meredith; Hangartner, Lars; Tehrani, David M.; Bleeker, Wim K.; Parren, Paul W. H. I.; Marx, Preston A.; Burton, Dennis R.			Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV PRECLINICAL INTERVENTIONS; HIV-1/SIV CHIMERIC VIRUS; NEUTRALIZING ANTIBODY; SEXUAL TRANSMISSION; PASSIVE TRANSFER; EXPOSURES; INFECTION; EFFICIENT; STRATEGY	Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required(1). This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infection in control animals in single-challenge experiments. In contrast, most human infection via sexual encounter probably involves repeated exposures to much lower doses of virus(2-4). Therefore, animal studies may have provided an overestimate of the levels of antibodies required for protection in humans. We investigated whether plasma concentrations of antibody corresponding to relatively modest neutralization titers in vitro could protect macaques from repeated intravaginal exposure to low doses of a simian immunodeficiency virus-HIV chimera (SHIV) that uses the CC chemokine receptor 5 (CCR5) co-receptor. An effector function-deficient variant of the neutralizing antibody was also included. The results show that a substantially larger number of challenges is required to infect macaques treated with neutralizing antibody than control antibody-treated macaques, and support the notion that effector function may contribute to antibody protection. Overall, the results imply that lower amounts of antibody than previously considered protective may provide benefit in the context of typical human exposure to HIV-1.	[Hessell, Ann J.; Poignard, Pascal; Tehrani, David M.; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Hessell, Ann J.; Poignard, Pascal; Tehrani, David M.; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA; [Hunter, Meredith; Marx, Preston A.] Tulane Univ, Tulane Natl Primate Res Ctr, Covington, LA USA; [Hangartner, Lars] Univ Zurich, Inst Med Virol, Zurich, Switzerland; [Bleeker, Wim K.; Parren, Paul W. H. I.] Genmab, Utrecht, Netherlands	Scripps Research Institute; International AIDS Vaccine Initiative; Scripps Research Institute; Tulane University; University of Zurich; Genmab	Hessell, AJ (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.		poignard, pascal/N-6678-2013; Hangartner, Lars/H-3503-2011; poignard, pascal/AAB-4613-2020; Hangartner, Lars/AAS-1320-2021	Hangartner, Lars/0000-0002-3165-2058; Poignard, Pascal/0000-0002-0021-7192; Hessell, Ann/0000-0001-7471-9366; Parren, Paul/0000-0002-4365-3859	US National Institutes of Health (NIH) [AI55332]; Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative; Swiss National Foundation [PA00A-109033]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055332, R37AI055332] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative; Swiss National Foundation(Swiss National Science Foundation (SNSF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	ELISA for recombinant monomeric HIV-1 gp120<INF>JR-FL</INF> was provided by Progenics. We thank K. Saye-Francisco for antibody production and quality control assistance at The Scripps Research Institute and S. Hoffenberg at the IAVI AIDS Vaccine Design Laboratory. We thank A. Haahr Andreasen for statistical advice and analysis. We are grateful for the assistance provided by E. Rakasz, G. Borchardt, and C. McNair with genotyping and viral load assessments at the Wisconsin National Primate Research Center. We also thank M. Huber and R. Astronomo for reviewing the manuscript. Support for this work was provided by US National Institutes of Health (NIH) grant AI55332 to D. R. B., by the Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative and by the Swiss National Foundation, Fellowship PA00A-109033.	Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Chakraborty H, 2001, AIDS, V15, P621, DOI 10.1097/00002030-200103300-00012; Cline AN, 2005, J MED PRIMATOL, V34, P303; Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06; Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Hezareh M, 2001, J VIROL, V75, P12161, DOI 10.1128/JVI.75.24.12161-12168.2001; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Kaizu M, 2007, IMMUNOGENETICS, V59, P693, DOI 10.1007/s00251-007-0233-7; Kim CN, 2006, J MED PRIMATOL, V35, P210, DOI 10.1111/j.1600-0684.2006.00169.x; Klasse PJ, 2006, PLOS MED, V3, P1501, DOI 10.1371/journal.pmed.0030351; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Li YX, 2009, J VIROL, V83, P1045, DOI 10.1128/JVI.01992-08; Mascola JR, 2003, CURR MOL MED, V3, P209, DOI 10.2174/1566524033479799; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Nishimura Y, 2002, J VIROL, V76, P2123, DOI 10.1128/jvi.76.5.2123-2130.2002; Otten RA, 2005, J INFECT DIS, V191, P164, DOI 10.1086/426452; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Regoes RR, 2005, PLOS MED, V2, P798, DOI 10.1371/journal.pmed.0020249; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Subbarao S, 2007, J MED PRIMATOL, V36, P238, DOI 10.1111/j.1600-0684.2007.00241.x; Tan RCH, 1999, J MED PRIMATOL, V28, P164, DOI 10.1111/j.1600-0684.1999.tb00265.x; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Yant LJ, 2006, J VIROL, V80, P5074, DOI 10.1128/JVI.80.10.5074-5077.2006; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580	35	447	465	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					951	U155		10.1038/nm.1974	http://dx.doi.org/10.1038/nm.1974			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19525965	Green Accepted			2022-12-27	WOS:000268770400041
J	Liesz, A; Suri-Payer, E; Veltkamp, C; Doerr, H; Sommer, C; Rivest, S; Giese, T; Veltkamp, R				Liesz, Arthur; Suri-Payer, Elisabeth; Veltkamp, Claudia; Doerr, Henrike; Sommer, Clemens; Rivest, Serge; Giese, Thomas; Veltkamp, Roland			Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; FOCAL CEREBRAL-ISCHEMIA; INTERFERON-GAMMA; BRAIN; INFLAMMATION; INJURY; ACTIVATION; INTERLEUKIN-10; LYMPHOCYTES; MECHANISMS	Systemic and local inflammatory processes have a key, mainly detrimental role in the pathophysiology of ischemic stroke. Currently, little is known about endogenous counterregulatory immune mechanisms. We examined the role of the key immunomodulators CD4(+)CD25(+) forkhead box P3 (Foxp3)(+) regulatory T lymphocytes (T-reg cells), after experimental brain ischemia. Depletion of T-reg cells profoundly increased delayed brain damage and deteriorated functional outcome. Absence of T-reg cells augmented postischemic activation of resident and invading inflammatory cells including microglia and T cells, the main sources of deleterious cerebral tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), respectively. Early antagonization of TNF-alpha and delayed neutralization of IFN-gamma prevented infarct growth in T-reg cell-depleted mice. Intracerebral interleukin-10 (IL-10) substitution abrogated the cytokine overexpression after T-reg cell depletion and prevented secondary infarct growth, whereas transfer of IL-10 deficient T-reg cells in an adoptive transfer model was ineffective. In conclusion, T-reg cells are major cerebroprotective modulators of postischemic inflammatory brain damage targeting multiple inflammatory pathways. IL-10 signaling is essential for their immunomodulatory effect.	[Liesz, Arthur; Veltkamp, Roland] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Suri-Payer, Elisabeth] German Canc Res Ctr, Dept Immunogenet, D-69120 Heidelberg, Germany; [Veltkamp, Claudia] German Canc Res Ctr, Dept Internal Med 4, D-69120 Heidelberg, Germany; [Doerr, Henrike; Sommer, Clemens] Johannes Gutenberg Univ Mainz, Dept Neuropathol, D-55131 Mainz, Germany; [Rivest, Serge] Univ Laval, Res Ctr, CHU Laval, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; [Giese, Thomas] Heidelberg Univ, Dept Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz; Laval University; Ruprecht Karls University Heidelberg	Veltkamp, R (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Roland.Veltkamp@med.uni-heidelberg.de	Suri-Payer, Elisabeth/ABC-2448-2021; Liesz, Arthur/AAT-7147-2021	Liesz, Arthur/0000-0002-9069-2594; Rivest, Serge/0000-0002-6082-770X	Else-Krorner Fresenius Stiftung; Ministerium fur Wissenschaftund Kultur Baden-Wurttemberg	Else-Krorner Fresenius Stiftung; Ministerium fur Wissenschaftund Kultur Baden-Wurttemberg	This study was supported by grants from the Else-Krorner Fresenius Stiftung and the Ministerium fur Wissenschaftund Kultur Baden-Wurttemberg to R. V. We would like to thank H. Burgers and D. Stefan for excellent technical assistance and I. Galani ( German Cancer Research Center, Heidelberg) for providing the Rag2<SUP>-/-</SUP> mice.	Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Baird AE, 2006, CIRCULATION, V113, P2035, DOI 10.1161/CIRCULATIONAHA.105.620732; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Blais V, 2004, J IMMUNOL, V172, P7043, DOI 10.4049/jimmunol.172.11.7043; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Dirnagl U, 2004, E SCHERING RES FDN W, V47, P87; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Frenkel D, 2005, J NEUROL SCI, V233, P125, DOI 10.1016/j.jns.2005.03.022; Gee JM, 2008, STROKE, V39, P1575, DOI 10.1161/STROKEAHA.107.501486; Gee JM, 2007, STROKE, V38, P783, DOI 10.1161/01.STR.0000248425.59176.7b; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025; McNeill A, 2007, SCAND J IMMUNOL, V65, P63, DOI 10.1111/j.1365-3083.2006.01870.x; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; O'Connor RA, 2008, J NEUROIMMUNOL, V193, P1, DOI 10.1016/j.jneuroim.2007.11.016; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Perera MN, 2006, J CLIN NEUROSCI, V13, P1, DOI 10.1016/j.jocn.2005.07.005; Planas AM, 2006, BIOCHEM SOC T, V34, P1267, DOI 10.1042/BST0341267; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Steiner GE, 2000, J IMMUNOL METHODS, V237, P39, DOI 10.1016/S0022-1759(99)00240-9; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Suri-Payer E, 2006, SPRINGER SEMIN IMMUN, V28, P3, DOI 10.1007/s00281-006-0021-8; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vogel J, 1999, STROKE, V30, P1134, DOI 10.1161/01.STR.30.5.1134; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	50	735	776	3	67	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					192	199		10.1038/nm.1927	http://dx.doi.org/10.1038/nm.1927			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19169263				2022-12-27	WOS:000263119400022
J	Anderson, ME; Mohler, PJ				Anderson, Mark E.; Mohler, Peter J.			Rescuing a failing heart: think globally, treat locally	NATURE MEDICINE			English	Editorial Material							CALMODULIN; FAILURE; MORTALITY; CHANNEL		[Anderson, Mark E.; Mohler, Peter J.] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; [Anderson, Mark E.; Mohler, Peter J.] Univ Iowa, Carver Coll Med, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Anderson, ME (corresponding author), Univ Iowa, Carver Coll Med, Dept Internal Med, 200 Hawkins Dr,315GH, Iowa City, IA 52242 USA.	mark-e-anderson@uiowa.edu						Anderson ME, 2006, NAT CLIN PRACT CARD, V3, P437, DOI 10.1038/ncpcardio0585; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Dick IE, 2008, NATURE, V451, P830, DOI 10.1038/nature06529; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Hjalmarson A, 1999, LANCET, V353, P2001; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Tadross MR, 2008, CELL, V133, P1228, DOI 10.1016/j.cell.2008.05.025; Xie FG, 2004, J CLIN INVEST, V113, P686, DOI 10.1172/JCI200417341	9	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2009	15	1					25	26		10.1038/nm0109-25	http://dx.doi.org/10.1038/nm0109-25			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19129780				2022-12-27	WOS:000262425100014
J	Pallen, CJ				Pallen, Catherine J.			Breaking the pain connection	NATURE MEDICINE			English	Editorial Material							NEUROPATHIC PAIN; SENSITIZATION; MICE; SRC		[Pallen, Catherine J.] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; [Pallen, Catherine J.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada	University of British Columbia; Child & Family Research Institute; University of British Columbia	Pallen, CJ (corresponding author), Univ British Columbia, Dept Pediat, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	cpallen@interchange.ubc.ca		Pallen, Catherine/0000-0002-3576-5295				Abe T, 2005, EUR J NEUROSCI, V22, P1445, DOI 10.1111/j.1460-9568.2005.04340.x; Childers WE, 2007, J MED CHEM, V50, P2557, DOI 10.1021/jm060728b; Garry EM, 2003, CURR BIOL, V13, P321, DOI 10.1016/S0960-9822(03)00084-8; Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Liu XJ, 2008, NAT MED, V14, P1325, DOI 10.1038/nm.1883; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Tao F, 2008, MOL THER, V16, P1776, DOI 10.1038/mt.2008.192; Vadalouca A, 2006, ANN NY ACAD SCI, V1088, P164, DOI 10.1196/annals.1366.016; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	12	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2008	14	12					1313	1315		10.1038/nm1208-1313	http://dx.doi.org/10.1038/nm1208-1313			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057553				2022-12-27	WOS:000261393600012
J	Yu, PB; Deng, DY; Lai, CS; Hong, CC; Cuny, GD; Bouxsein, ML; Hong, DW; McManus, PM; Katagiri, T; Sachidanandan, C; Kamiya, N; Fukuda, T; Mishina, Y; Peterson, RT; Bloch, KD				Yu, Paul B.; Deng, Donna Y.; Lai, Carol S.; Hong, Charles C.; Cuny, Gregory D.; Bouxsein, Mary L.; Hong, Deborah W.; McManus, Patrick M.; Katagiri, Takenobu; Sachidanandan, Chetana; Kamiya, Nobuhiro; Fukuda, Tomokazu; Mishina, Yuji; Peterson, Randall T.; Bloch, Kenneth D.			BMP type I receptor inhibition reduces heterotopic ossification	NATURE MEDICINE			English	Article							BONE-FORMATION; SMAD PROTEINS; PROGRESSIVA; DIFFERENTIATION; IDENTIFICATION; ELEMENTS; ARREST; CELLS; ACVR1	Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread postnatal ossification of soft tissues(1-4) and is without known effective treatments. Affected individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2 (ALK2)(5). Here we show that intramuscular expression in the mouse of an inducible transgene encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional impairment, thus phenocopying key aspects of human FOP. A selective inhibitor of BMP type I receptor kinases, LDN-193189 (ref. 6), inhibits activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in tissues expressing caALK2 induced by adenovirus specifying Cre (Ad. Cre). This treatment resulted in a reduction in ectopic ossification and functional impairment. In contrast to localized induction of caALK2 by Ad. Cre (which entails inflammation), global postnatal expression of caALK2 (induced without the use of Ad. Cre and thus without inflammation) does not lead to ectopic ossification. However, if in this context an inflammatory stimulus was provided with a control adenovirus, ectopic bone formation was induced. Like LDN-193189, corticosteroid treatment inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and an inflammatory milieu are both required for the development of ectopic ossification in this model. These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small molecule inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes associated with excessive BMP signaling.	[Yu, Paul B.; Deng, Donna Y.; Lai, Carol S.; Hong, Deborah W.; McManus, Patrick M.; Sachidanandan, Chetana; Peterson, Randall T.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA; [Yu, Paul B.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA; [Yu, Paul B.; Bloch, Kenneth D.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Hong, Charles C.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37232 USA; [Hong, Charles C.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; [Cuny, Gregory D.] Brigham & Womens Hosp, Lab Drug Discovery Neurodegenerat, Harvard NeuroDiscovery Ctr, Cambridge, MA 02139 USA; [Cuny, Gregory D.] Harvard Univ, Sch Med, Cambridge, MA 02139 USA; [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Orthopaed Biomech Lab, Boston, MA 02215 USA; [Bouxsein, Mary L.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Katagiri, Takenobu] Saitama Med Univ, Div Pathophysiol, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; [Kamiya, Nobuhiro; Fukuda, Tomokazu; Mishina, Yuji] NIEHS, Mol Dev Biol Sect, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Vanderbilt University; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Saitama Medical University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Yu, PB (corresponding author), Massachusetts Gen Hosp, Div Cardiol, Dept Med, Thier 505,50 Blossom St, Boston, MA 02114 USA.	pbyu@partners.org	Hong, Charles/C-9989-2010; Yu, Paul B./J-7540-2019; Fukuda, Tomokazu/O-1257-2018	Yu, Paul B./0000-0003-2145-4944; Fukuda, Tomokazu/0000-0001-8456-0483; Peterson, Randall/0000-0003-0727-3469; Cuny, Gregory/0000-0002-3188-4748	US National Institutes of Health [HL079943, HL074352]; US National Institute of Environmental Health Sciences Intramural Research Program [ES071003-10]; Howard Hughes Medical Institute Early Career Award; GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease; Center for Research in Fibrodysplasia Ossificans Progressiva and Related Disorders at the University of Pennsylvania; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL079943, K08HL081535, R01HL074352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS067497] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institute of Environmental Health Sciences Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Howard Hughes Medical Institute Early Career Award(Howard Hughes Medical Institute); GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease(GlaxoSmithKline); Center for Research in Fibrodysplasia Ossificans Progressiva and Related Disorders at the University of Pennsylvania; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank P. ten Dijke (Leiden University Medical Center) for providing BRE-Luc and CAGA-Luc and K. Miyazono (University of Tokyo) for providing caALK2, caALK3, caALK4, caALK5, caALK6 and caALK7. We are grateful to H. Beppu, E. Schipani, H. Kronenberg, A. Wagers, J. Groppe, W. Zapol and F. Kaplan for insightful discussions and technical expertise, A. Graveline and D. Panus for technical assistance and E. Buys for technical expertise. This work was supported by US National Institutes of Health grants HL079943 (P.B.Y.) and HL074352 (K. D. B.), the US National Institute of Environmental Health Sciences Intramural Research Program grant ES071003-10 (Y.M.) and Partners Healthcare. This work was also supported by a Howard Hughes Medical Institute Early Career Award (P.B.Y.), a Pulmonary Hypertension Association Mentored Clinical Scientist Award (P.B.Y.), a grant from the GlaxoSmithKline Research & Education Foundation for Cardiovascular Disease (P.B.Y.) and a Developmental Grant from the Center for Research in Fibrodysplasia Ossificans Progressiva and Related Disorders at the University of Pennsylvania (C. C. H.).	Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030; BUYSE G, 1995, EUR J PEDIATR, V154, P694, DOI 10.1007/BF02276711; Corriere MA, 2008, J SURG RES, V145, P142, DOI 10.1016/j.jss.2007.03.077; Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Fukuda T, 2006, GENESIS, V44, P159, DOI 10.1002/dvg.20201; Fukuda T, 2009, J BIOL CHEM, V284, P7149, DOI 10.1074/jbc.M801681200; Groppe JC, 2007, CLIN ORTHOP RELAT R, P87, DOI 10.1097/BLO.0b013e318126c049; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hegyi L, 2003, J PATHOL, V201, P141, DOI 10.1002/path.1413; Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007; Kaplan FS, 2007, EXPERT OPIN BIOL TH, V7, P705, DOI 10.1517/14712598.7.5.705; Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472; Koefoed M, 2005, MOL THER, V12, P212, DOI 10.1016/j.ymthe.2005.02.026; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Pignolo RJ, 2005, CLIN REV BONE MINER, V3, P195, DOI 10.1385/BMM:3:3-4:195; Scarlett RF, 2004, CLIN ORTHOP RELAT R, P275, DOI 10.1097/01.blo.0000129557.38803.26; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Shore EM, 2006, J BONE MINER RES, V21, pS75; Shore EM, 2008, BONE, V43, P427, DOI 10.1016/j.bone.2008.05.013; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916; Waheed I, 2005, HUM GENE THER, V16, P489, DOI 10.1089/hum.2005.16.489; Yu PB, 2008, J BIOL CHEM, V283, P3877, DOI 10.1074/jbc.M706797200; Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang DH, 2003, J BONE MINER RES, V18, P1593, DOI 10.1359/jbmr.2003.18.9.1593; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	33	487	535	3	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1363	1369		10.1038/nm.1888	http://dx.doi.org/10.1038/nm.1888			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029982	Green Accepted			2022-12-27	WOS:000261393600021
J	Chaouat, G				Chaouat, Gerard			Funding for research in reproduction in the European union	NATURE MEDICINE			English	Editorial Material									Univ Paris Sud Orsay & Assistance Publ, INSERM, U782, Equipe Implantat & Dialogue Cytokin Mere Conceptu, F-92141 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Chaouat, G (corresponding author), Univ Paris Sud Orsay & Assistance Publ, INSERM, U782, Equipe Implantat & Dialogue Cytokin Mere Conceptu, 3 Rue Carnets, F-92141 Clamart, France.	gerard_chaouat@wanadoo.fr						Bischof P, 2006, GYNECOL OBSTET INVES, V62, P206, DOI 10.1159/000094005; MARIOMON R, 2004, EVALUATION EFFECTIVE; REDMAN CWE, 1992, PREECLAMPSIA FACTS H; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; Zondervan K, 2000, BEST PRACT RES CL OB, V14, P403, DOI 10.1053/beog.1999.0083; 2007, J REPROD IMMUNOL, V76, P1	6	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11		S			1218	1220		10.1038/nm1108-1218	http://dx.doi.org/10.1038/nm1108-1218			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	397FU	18989309				2022-12-27	WOS:000262649100033
J	Oishi, Y; Manabe, I; Tobe, K; Ohsugi, M; Kubota, T; Fujiu, K; Maemura, K; Kubota, N; Kadowaki, T; Nagai, R				Oishi, Yumiko; Manabe, Ichiro; Tobe, Kazuyuki; Ohsugi, Mitsuru; Kubota, Tetsuya; Fujiu, Katsuhito; Maemura, Koji; Kubota, Naoto; Kadowaki, Takashi; Nagai, Ryozo			SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta	NATURE MEDICINE			English	Article							ACTIVATED-RECEPTOR-DELTA; CARNITINE PALMITOYLTRANSFERASE-I; SKELETAL-MUSCLE; UNCOUPLING PROTEIN-2; INSULIN-RESISTANCE; FAT OXIDATION; GENE; SUMO; EXPRESSION; BINDING	Obesity and metabolic syndrome are increasingly recognized as major risk factors for cardiovascular disease. Herein we show that Kruppel-like transcription factor 5 (KLF5) is a crucial regulator of energy metabolism. Klf5(+/-) mice were resistant to high fat-induced obesity, hypercholesterolemia and glucose intolerance, despite consuming more food than wild-type mice. This may in part reflect their enhanced energy expenditure. Expression of the genes involved in lipid oxidation and energy uncoupling, including those encoding carnitine-palmitoyl transferase-1b (Cpt1b) and uncoupling proteins 2 and 3 (Ucp2 and Ucp3), was upregulated in the soleus muscles of Klf5(+/-) m ice. Under basal conditions, KLF5 modified with small ubiquitin-related modifier (SUMO) proteins was associated with transcriptionally repressive regulatory complexes containing unliganded peroxisome proliferator-activated receptor-delta (PPAR-delta) and co-repressors and thus inhibited Cpt1b, Ucp2 and Ucp3 expression. Upon agonist stimulation of PPAR-delta, KLF5 was deSUMOylated, and became associated with transcriptional activation complexes containing both the liganded PPAR-delta and CREB binding protein (CBP). This activation complex increased the expression of Cpt1b, Ucp2 and Ucp3. Thus, SUMOylation seems to be a molecular switch affecting function of KLF5 and the transcriptional regulatory programs governing lipid metabolism.	[Oishi, Yumiko; Manabe, Ichiro; Fujiu, Katsuhito; Maemura, Koji; Nagai, Ryozo] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; [Oishi, Yumiko; Kubota, Tetsuya; Kubota, Naoto; Kadowaki, Takashi] Natl Inst Hlth & Nutr, Clin Nutr Program, Shinjuku Ku, Tokyo 1628636, Japan; [Manabe, Ichiro] Univ Tokyo, Nano Bioengn Educ Program, Bunkyo Ku, Tokyo 1138655, Japan; [Tobe, Kazuyuki; Ohsugi, Mitsuru; Kubota, Tetsuya; Kubota, Naoto; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; [Tobe, Kazuyuki] Toyama Univ, Dept Internal Med 1, Toyama 9300194, Japan	University of Tokyo; National Institute of Health & Nutrition - Japan; University of Tokyo; University of Tokyo; University of Toyama	Manabe, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	manabe-tky@umin.ac.jp; nagai-tky@umin.ac.jp	Manabe, Ichiro/AAE-5105-2021; Kubota, Naoto/N-7892-2015; Manabe, Ichiro/E-1529-2014					Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Bezaire V, 2007, FASEB J, V21, P312, DOI 10.1096/fj.06-6966rev; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Chou CC, 2007, J BIOL CHEM, V282, P27239, DOI 10.1074/jbc.M700351200; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fujiu K, 2005, CIRC RES, V97, P1132, DOI 10.1161/01.RES.0000190613.22565.13; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Haldar SM, 2007, J MOL CELL CARDIOL, V43, P1, DOI 10.1016/j.yjmcc.2007.04.005; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Kelley DE, 2005, J CLIN INVEST, V115, P1699, DOI 10.1172/JCI25758; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Lee CH, 2006, P NATL ACAD SCI USA, V103, P2434, DOI 10.1073/pnas.0510815103; Lee CH, 2006, P NATL ACAD SCI USA, V103, P3444, DOI 10.1073/pnas.0511253103; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Sebastian D, 2007, AM J PHYSIOL-ENDOC M, V292, pE677, DOI 10.1152/ajpendo.00360.2006; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Smith AG, 2005, INT J BIOCHEM CELL B, V37, P2047, DOI 10.1016/j.biocel.2005.03.002; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Ukropcova B, 2005, J CLIN INVEST, V115, P1934, DOI 10.1172/JCI24332; van der Leij FR, 2002, J BIOL CHEM, V277, P26994, DOI 10.1074/jbc.M203189200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047	48	118	128	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					656	666		10.1038/nm1756	http://dx.doi.org/10.1038/nm1756			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18500350				2022-12-27	WOS:000256468700032
J	van Grevenynghe, J; Procopio, FA; He, Z; Chomont, N; Riou, C; Zhang, YW; Gimmig, S; Boucher, G; Wilkinson, P; Shi, Y; Yassine-Diab, B; Said, EA; Trautmann, L; El Far, M; Balderas, RS; Boulassel, MR; Routy, JP; Haddad, EK; Sekaly, RP				van Grevenynghe, Julien; Procopio, Francesco A.; He, Zhong; Chomont, Nicolas; Riou, Catherine; Zhang, Yuwei; Gimmig, Sylvain; Boucher, Genevieve; Wilkinson, Peter; Shi, Yu; Yassine-Diab, Bader; Said, Elias A.; Trautmann, Lydie; El Far, Mohamed; Balderas, Robert S.; Boulassel, Mohamed-Rachid; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre			Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection	NATURE MEDICINE			English	Article							KAPPA-B; SURVIVAL; GENE; EFFECTOR; DISEASE; POLYMORPHISMS; LYMPHOCYTES; SPECIFICITY; PROGRESSION; ACTIVATION	The persistence of central memory CD4(+) T cells (T-CM cells) is a major correlate of immunological protection in HIV/AIDS, as the rate of T-CM cell decline predicts HIV disease progression. In this study, we show that T-CM cells and effector memory CD4(+) T cells (T-EM cells) from HIV+ elite controller (EC) subjects are less susceptible to Fas-mediated apoptosis and persist longer after multiple rounds of T cell receptor triggering when compared to T-CM and T-EM cells from aviremic successfully treated (ST) subjects or from HIV- donors. We show that persistence of T-CM cells from EC subjects is a direct consequence of inactivation of the FOXO3a pathway. Silencing the transcriptionally active form of FOXO3a by small interfering RNA or by introducing a FOXO3a dominant-negative form (FOXO3a Nt) extended the long-term survival of T-CM cells from ST subjects to a length of time similar to that of T-CM cells from EC subjects. The crucial role of FOXO3a in the survival of memory cells will help shed light on the underlying immunological mechanisms that control viral replication in EC subjects.	[van Grevenynghe, Julien; Procopio, Francesco A.; He, Zhong; Chomont, Nicolas; Riou, Catherine; Zhang, Yuwei; Gimmig, Sylvain; Boucher, Genevieve; Wilkinson, Peter; Shi, Yu; Yassine-Diab, Bader; Said, Elias A.; Trautmann, Lydie; El Far, Mohamed; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, Immunol Lab, Ctr Rech, Hop St Luc, Montreal, PQ H2X 1P1, Canada; [van Grevenynghe, Julien; Procopio, Francesco A.; He, Zhong; Chomont, Nicolas; Zhang, Yuwei; Shi, Yu; Yassine-Diab, Bader; Said, Elias A.; Trautmann, Lydie; El Far, Mohamed; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, Immunol Lab, Dept Microbiol & Immunol, Montreal, PQ H3T 1J4, Canada; [van Grevenynghe, Julien; Procopio, Francesco A.; He, Zhong; Chomont, Nicolas; Zhang, Yuwei; Shi, Yu; Yassine-Diab, Bader; Said, Elias A.; Trautmann, Lydie; El Far, Mohamed; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, Ctr Hosp, Inst Natl Sante Rech Med U743, Ctr Rech, Montreal, PQ H2X 1P1, Canada; [Balderas, Robert S.] BD Biosci, San Diego, CA 92121 USA; [Boulassel, Mohamed-Rachid; Routy, Jean-Pierre] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Immunodeficiency Serv, Montreal, PQ H3A 1A1, Canada; [Boulassel, Mohamed-Rachid; Routy, Jean-Pierre] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Haematol, Montreal, PQ H3A 1A1, Canada; [Haddad, Elias K.; Sekaly, Rafick-Pierre] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	Haddad, EK (corresponding author), Univ Montreal, Immunol Lab, Ctr Rech, Hop St Luc, 264 Rene Levesque Blvd E, Montreal, PQ H2X 1P1, Canada.	elias.haddad@umontreal.ca; rafick-pierre.sekaly@umontreal.ca	Wilkinson, Peter/AAK-6426-2020; Chomont, Nicolas/ABG-2545-2020; Procopio, Francesco/ABD-8065-2021; Zhang, Yuwei/H-3287-2018; Said, Elias/AAY-5557-2020	Wilkinson, Peter/0000-0002-1365-0470; Chomont, Nicolas/0000-0001-9747-5018; Boucher, Genevieve/0000-0001-6389-9007; Said, Elias/0000-0003-4224-6351; Trautmann, Lydie/0000-0002-3012-0009				Biancotto A, 2007, BLOOD, V109, P4272, DOI 10.1182/blood-2006-11-055764; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bostik P, 2006, AIDS, V20, P181, DOI 10.1097/01.aids.0000198092.77948.8a; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; Harari A, 2002, BLOOD, V100, P1381, DOI 10.1182/blood-2001-11-0080; Harrer T, 1996, J IMMUNOL, V156, P2616; Hendel H, 1999, J IMMUNOL, V162, P6942; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kim JR, 2006, OBESITY, V14, P188, DOI 10.1038/oby.2006.24; KNIGHT S C, 1990, International Reviews of Immunology, V6, P163, DOI 10.3109/08830189009056627; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Lavoie PM, 2005, INT IMMUNOL, V17, P931, DOI 10.1093/intimm/dxh273; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Okoye A, 2007, J EXP MED, V204, P2171, DOI 10.1084/jem.20070567; Philp AJ, 2001, CANCER RES, V61, P7426; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Riou C, 2007, J EXP MED, V204, P79, DOI 10.1084/jem.20061681; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shamim Z, 2006, BONE MARROW TRANSPL, V37, P485, DOI 10.1038/sj.bmt.1705277; Sun Y, 2005, J IMMUNOL, V174, P4753, DOI 10.4049/jimmunol.174.8.4753; Urbich C, 2005, FASEB J, V19, P974, DOI 10.1096/fj.04-2727fje; Wilson JDK, 2000, J INFECT DIS, V182, P792, DOI 10.1086/315764; Wu HC, 2006, J CLIN LAB ANAL, V20, P245, DOI 10.1002/jcla.20149; Zanetti M, 2006, TRENDS IMMUNOL, V27, P511, DOI 10.1016/j.it.2006.09.004	32	125	126	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					266	274		10.1038/nm1728	http://dx.doi.org/10.1038/nm1728			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18311149				2022-12-27	WOS:000253815700032
J	Hosooka, T; Noguchi, T; Kotani, K; Nakamura, T; Sakaue, H; Inoue, H; Ogawa, W; Tobimatsu, K; Takazawa, K; Sakai, M; Matsuki, Y; Hiramatsu, R; Yasuda, T; Lazar, MA; Yamanashi, Y; Kasuga, M				Hosooka, Tetsuya; Noguchi, Tetsuya; Kotani, Ko; Nakamura, Takehiro; Sakaue, Hiroshi; Inoue, Hiroshi; Ogawa, Wataru; Tobimatsu, Kazutoshi; Takazawa, Kazuo; Sakai, Mashito; Matsuki, Yasushi; Hiramatsu, Ryuji; Yasuda, Tomoharu; Lazar, Mitchell A.; Yamanashi, Yuji; Kasuga, Masato			Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation	NATURE MEDICINE			English	Article							ACTIVATED-RECEPTOR-GAMMA; INSULIN-RESISTANCE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; GLUCOSE-INTOLERANCE; P62(DOK); MICE; SENSITIVITY; ADIPOGENESIS; INHIBITION	Insulin receptor substrate (IRS)-1 and IRS-2 have dominant roles in the action of insulin(1), but other substrates of the insulin receptor kinase, such as Gab1, c-Cbl, SH2-B and APS, are also of physiological relevance(2-5). Although the protein downstream of tyrosine kinases-1 (Dok1) is known to function as a multisite adapter molecule in insulin signaling(6-8), its role in energy homeostasis has remained unclear. Here we show that Dok1 regulates adiposity. Expression of Dok1 in white adipose tissue was markedly increased in mice fed a high-fat diet, whereas adipocytes lacking this adapter were smaller and showed a reduced hypertrophic response to this dietary manipulation. Dok1-deficient mice were leaner and showed improved glucose tolerance and insulin sensitivity compared with wild-type mice. Embryonic fibroblasts from Dok1-deficient mice were impaired in adipogenic differentiation, and this defect was accompanied by an increased activity of the protein kinase ERK and a consequent increase in the phosphorylation of peroxisome proliferator-activated receptor (PPAR)-gamma on Ser112. Mutation of this negative regulatory site for the transactivation activity of PPAR-gamma blocked development of the lean phenotype caused by Dok1 ablation. These results indicate that Dok1 promotes adipocyte hypertrophy by counteracting the inhibitory effect of ERK on PPAR-gamma and may thus confer predisposition to diet-induced obesity.	[Hosooka, Tetsuya; Noguchi, Tetsuya; Kotani, Ko; Nakamura, Takehiro; Sakaue, Hiroshi; Inoue, Hiroshi; Ogawa, Wataru; Tobimatsu, Kazutoshi; Takazawa, Kazuo; Sakai, Mashito; Kasuga, Masato] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Matsuki, Yasushi; Hiramatsu, Ryuji] Dainippon Sumitomo Pharma, Genom Sci Labs, Takarazuka, Hyogo 6658555, Japan; [Inoue, Hiroshi; Yasuda, Tomoharu; Yamanashi, Yuji] Tokyo Med & Dent Univ, Med Res Inst, Bunkyo Ku, Dept Cell Regulat, Tokyo 1138510, Japan; [Lazar, Mitchell A.] Univ Penn, Div Endocrinol Diabet & Metab, Dept Med Genet & Pharmacol, Philadelphia, PA 19104 USA; [Lazar, Mitchell A.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA	Kobe University; Tokyo Medical & Dental University (TMDU); University of Pennsylvania; University of Pennsylvania	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	Sakaue, Hiroshi/ABE-2337-2021; OGAWA, Wataru/AAQ-9586-2020; Yasuda, Tomoharu/J-5102-2019; Lazar, Mitchell A/AAF-3738-2019	Sakaue, Hiroshi/0000-0002-2468-2363; Yasuda, Tomoharu/0000-0001-9997-6852; Sakai, Mashito/0000-0002-4908-2727; Inoue, Hiroshi/0000-0002-7724-6637				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Bard-Chapeau EA, 2005, NAT MED, V11, P567, DOI 10.1038/nm1227; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cock TA, 2004, EMBO REP, V5, P142, DOI 10.1038/sj.embor.7400082; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Duan CJ, 2004, MOL CELL BIOL, V24, P7435, DOI 10.1128/MCB.24.17.7435-7443.2004; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jones JR, 2005, P NATL ACAD SCI USA, V102, P6207, DOI 10.1073/pnas.0306743102; Koutnikova H, 2003, P NATL ACAD SCI USA, V100, P14457, DOI 10.1073/pnas.2336090100; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Minami A, 2003, DIABETES, V52, P2657, DOI 10.2337/diabetes.52.11.2657; Molero JC, 2004, J CLIN INVEST, V114, P1326, DOI [10.1172/JCI200421480, 10.1172/JCI21480]; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sakai T, 2007, J BIOL CHEM, V282, P2038, DOI 10.1074/jbc.M608144200; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shinohara H, 2005, J EXP MED, V201, P333, DOI 10.1084/jem.20041817; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Yamanashi Y, 2000, GENE DEV, V14, P11; YAMANASHI Y, 1997, DOK CELL, V88, P205	30	82	89	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					188	193		10.1038/nm1706	http://dx.doi.org/10.1038/nm1706			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18204460				2022-12-27	WOS:000252946700028
J	Bauer, TR; Allen, JM; Hai, M; Tuschong, LM; Khan, IF; Olson, EM; Adler, RL; Burkholder, TH; Gu, YC; Russell, DW; Hickstein, DD				Bauer, Thomas R., Jr.; Allen, James M.; Hai, Mehreen; Tuschong, Laura M.; Khan, Iram F.; Olson, Erik M.; Adler, Rima L.; Burkholder, Tanya H.; Gu, Yu-chen; Russell, David W.; Hickstein, Dennis D.			Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors	NATURE MEDICINE			English	Article							DISEASE PHENOTYPE; GENE-THERAPY; COMBINED IMMUNODEFICIENCY; REPOPULATING CELLS; HUMAN GENOME; TRANSDUCTION; TRANSCRIPTION; REPLICATION; REVERSE; ANTIGEN	Recent successes in treating genetic immunodeficiencies have demonstrated the therapeutic potential of stem cell gene therapy(1-4). However, the use of gammaretroviral vectors in these trials led to insertional activation of nearby oncogenes and leukemias in some study subjects, prompting studies of modified or alternative vector systems(5). Here we describe the use of foamy virus vectors to treat canine leukocyte adhesion deficiency ( CLAD). Four of five dogs with CLAD that received nonmyeloablative conditioning and infusion of autologous, CD34(+) hematopoietic stem cells transduced by a foamy virus vector expressing canine CD18 had complete reversal of the CLAD phenotype, which was sustained more than 2 years after infusion. In vitro assays showed correction of the lymphocyte proliferation and neutrophil adhesion defects that characterize CLAD. There were no genotoxic complications, and integration site analysis showed polyclonality of transduced cells and a decreased risk of integration near oncogenes as compared to gammaretroviral vectors. These results represent the first successful use of a foamy virus vector to treat a genetic disease, to our knowledge, and suggest that foamy virus vectors will be effective in treating human hematopoietic diseases.	[Allen, James M.; Khan, Iram F.; Olson, Erik M.; Russell, David W.] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; [Bauer, Thomas R., Jr.; Hai, Mehreen; Tuschong, Laura M.; Adler, Rima L.; Gu, Yu-chen; Hickstein, Dennis D.] NCI, Ctr Canc Res, Natl Inst Hlth, Bethesda, MD 20892 USA; [Burkholder, Tanya H.] NIH, Off Res Serv, Div Vet Resources, Bethesda, MD 20892 USA; [Russell, David W.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; University of Washington; University of Washington Seattle	Russell, DW (corresponding author), Univ Washington, Dept Med, Div Hematol, 1959 NE Pacific St,Box 357720, Seattle, WA 98195 USA.	drussell@u.washington.edu; hicksted@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [P01 HL053750, R01 HL085107, HL53750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC010384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085107, P01HL053750] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Anderson D.C., 2001, METABOLIC MOL BASES, P4829; Bauer TR, 2006, BLOOD, V108, P3313, DOI 10.1182/blood-2006-03-006908; Bauer TR, 2005, EXP HEMATOL, V33, P706, DOI 10.1016/j.exphem.2005.03.010; Bauer TR, 2004, BLOOD, V103, P3582, DOI 10.1182/blood-2003-11-4008; BEATTY PG, 1983, J IMMUNOL, V131, P2913; Creevy KE, 2003, VET IMMUNOL IMMUNOP, V94, P11, DOI 10.1016/S0165-2427(03)00057-6; Derse D, 2007, J VIROL, V81, P6731, DOI 10.1128/JVI.02752-06; Falcone V, 2003, CURR TOP MICROBIOL, V277, P161; Gaspar HB, 2006, MOL THER, V14, P505, DOI 10.1016/j.ymthe.2006.06.007; Gu YC, 2006, BONE MARROW TRANSPL, V37, P607, DOI 10.1038/sj.bmt.1705291; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; HAWLEY RG, 1994, GENE THER, V1, P136; Horn PA, 2004, BLOOD, V103, P3710, DOI 10.1182/blood-2003-07-2414; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Josephson NC, 2002, P NATL ACAD SCI USA, V99, P8295, DOI 10.1073/pnas.122131099; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Moebes A, 1997, J VIROL, V71, P7305, DOI 10.1128/JVI.71.10.7305-7311.1997; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Russell DW, 1996, J VIROL, V70, P217, DOI 10.1128/JVI.70.1.217-222.1996; Storb R, 1999, BLOOD, V94, P2523, DOI 10.1182/blood.V94.7.2523.419k18_2523_2529; Tone Y, 2007, BLOOD, V109, P1182, DOI 10.1182/blood-2006-08-039057; Trobridge G, 2004, J VIROL, V78, P2327, DOI 10.1128/JVI.78.5.2327-2335.2004; Trobridge G, 2002, MOL THER, V6, P321, DOI 10.1006/mthe.2002.0672; Trobridge GD, 1998, HUM GENE THER, V9, P2517, DOI 10.1089/10430349850019355; Trowald-Wigh G, 2000, J SMALL ANIM PRACT, V41, P211, DOI 10.1111/j.1748-5827.2000.tb03198.x; Vassilopoulos G, 2001, BLOOD, V98, P604, DOI 10.1182/blood.V98.3.604; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yu SF, 1999, J VIROL, V73, P1565, DOI 10.1128/JVI.73.2.1565-1572.1999	30	113	115	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					93	97		10.1038/nm1695	http://dx.doi.org/10.1038/nm1695			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157138	Green Accepted			2022-12-27	WOS:000252222400028
J	Jayaraman, K				Jayaraman, Killugudi			Failure of Indian whistleblower scheme points to deeper woes	NATURE MEDICINE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					364	364		10.1038/nm0410-364a	http://dx.doi.org/10.1038/nm0410-364a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376034	Bronze			2022-12-27	WOS:000276446800025
J	Lebrin, F; Srun, S; Raymond, K; Martin, S; van den Brink, S; Freitas, C; Breant, C; Mathivet, T; Larrivee, B; Thomas, JL; Arthur, HM; Westermann, CJJ; Disch, F; Mager, JJ; Snijder, RJ; Eichmann, A; Mummery, CL				Lebrin, Franck; Srun, Samly; Raymond, Karine; Martin, Sabrina; van den Brink, Stieneke; Freitas, Catarina; Breant, Christiane; Mathivet, Thomas; Larrivee, Bruno; Thomas, Jean-Leon; Arthur, Helen M.; Westermann, Cornelis J. J.; Disch, Frans; Mager, Johannes J.; Snijder, Repke J.; Eichmann, Anne; Mummery, Christine L.			Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; TGF-BETA RECEPTOR; PDGF-B; VASCULAR DEVELOPMENT; ANGIOGENESIS; PERICYTES; ENDOGLIN; GROWTH; MOUSE; MICE	Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder characterized by vascular malformations. Many affected individuals develop recurrent nosebleeds, which can severely affect their quality of life and are clinically difficult to treat. We report here that treatment with thalidomide reduced the severity and frequency of nosebleeds (epistaxis) in the majority of a small group of subjects with HHT tested. The blood hemoglobin levels of the treated individuals rose as a result of reduced hemorrhage and enhanced blood vessel stabilization. In mice heterozygous for a null mutation in the Eng gene (encoding endoglin), an experimental model of HHT, thalidomide treatment stimulated mural cell coverage and thus rescued vessel wall defects. Thalidomide treatment increased platelet-derived growth factor-B (PDGF-B) expression in endothelial cells and stimulated mural cell activation. The effects of thalidomide treatment were partially reversed by pharmacological or genetic interference with PDGF signaling from endothelial cells to pericytes. Biopsies of nasal epithelium from individuals with HHT treated or not with thalidomide showed that similar mechanisms may explain the effects of thalidomide treatment in humans. Our findings demonstrate the ability of thalidomide to induce vessel maturation, which may be useful as a therapeutic strategy for the treatment of vascular malformations.	[Lebrin, Franck; Srun, Samly; Martin, Sabrina; Freitas, Catarina; Breant, Christiane; Mathivet, Thomas; Larrivee, Bruno; Eichmann, Anne] Coll France, Inst Nat Sante & Rech Med, U833, F-75231 Paris, France; [Raymond, Karine] Inst Curie, CNRS, Ctr Rech, UMR144, F-75231 Paris, France; [van den Brink, Stieneke] Hubrecht Inst, Dev Biol & Stem Cell Res, Utrecht, Netherlands; [Thomas, Jean-Leon] Inst Nat Sante & Rech Med, U711, Paris, France; [Westermann, Cornelis J. J.; Disch, Frans; Mager, Johannes J.; Snijder, Repke J.] St Antonius Hosp, Nieuwegein, Netherlands; [Mummery, Christine L.] Leiden Univ, Med Ctr, Dept Anat & Embryol, Leiden, Netherlands; [Arthur, Helen M.] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); St. Antonius Hospital Utrecht; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK	Lebrin, F (corresponding author), Coll France, Inst Nat Sante & Rech Med, U833, F-75231 Paris, France.	franck.lebrin@college-de-france.fr; c.l.mummery@lumc.nl	Thomas, Jean-Leon/F-1151-2016; Mathivet, Thomas/L-2663-2016; Freitas, Catarina M/A-2555-2017; Raymond, Karine/E-2693-2017; Arthur, Helen/C-7808-2009	Freitas, Catarina M/0000-0002-3393-5326; Raymond, Karine/0000-0001-5892-8117; Mummery, Christine/0000-0002-4549-6535; Larrivee, Bruno/0000-0003-1388-3108; Arthur, Helen/0000-0001-6522-1363; lebrin, franck/0000-0002-1650-6757; Mathivet, Thomas/0000-0001-7761-1684	Institut National de la Sante et de la Recherche Medicale; Agence Nationale de la Recherche (Agence Nationale de la Recherche blanc, Neuroscience); Fondation pour la Recherche Medicale; Fondation Bettencourt; Association pour la Recherche sur le Cancer [3980]; Netherlands Heart Foundation [2008B106]; British Heart Foundation; EU [QLG1-CT-2001-01032]; Stichting Wetenschappelijk Onderzoek Rendu Osler; Besluit subsidies investeringen kennisinfrastructuur; HHT Foundation International	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche (Agence Nationale de la Recherche blanc, Neuroscience)(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation Bettencourt; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Netherlands Heart Foundation(Netherlands Heart Foundation); British Heart Foundation(British Heart Foundation); EU(European Commission); Stichting Wetenschappelijk Onderzoek Rendu Osler; Besluit subsidies investeringen kennisinfrastructuur; HHT Foundation International	We thank A. Nishiyama (University of Connecticut Stem Cell Institute) for providing NG2DsRedBAC mice. This work was supported by grants from Institut National de la Sante et de la Recherche Medicale, Agence Nationale de la Recherche (Agence Nationale de la Recherche blanc, Neuroscience), Fondation pour la Recherche Medicale, Fondation Bettencourt, Association pour la Recherche sur le Cancer (3980), the Netherlands Heart Foundation (2008B106), the British Heart Foundation, the EU (QLG1-CT-2001-01032), Stichting Wetenschappelijk Onderzoek Rendu Osler and the Besluit subsidies investeringen kennisinfrastructuur program 'Dutch Platform for Tissue Engineering' and HHT Foundation International.	Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Bajanca F, 2004, DEV DYNAM, V231, P402, DOI 10.1002/dvdy.20136; Bauditz J, 2004, GUT, V53, P609, DOI 10.1136/gut.2003.029710; Bauditz J, 2007, WORLD J GASTROENTERO, V13, P5979, DOI 10.3748/wjg.13.5979; Bose P, 2009, NEW ENGL J MED, V360, P2143, DOI 10.1056/NEJMc0901421; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Carvalho RLC, 2004, DEVELOPMENT, V131, P6237, DOI 10.1242/dev.01529; Cirulli A, 2003, ACTA HAEMATOL-BASEL, V110, P29, DOI 10.1159/000072411; Dabak V, 2008, DIGEST DIS SCI, V53, P1632, DOI 10.1007/s10620-007-0067-z; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dudley A, 2003, BIOCHEM BIOPH RES CO, V310, P135, DOI 10.1016/j.bbrc.2003.08.129; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1; Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Govani FS, 2009, EUR J HUM GENET, V17, P860, DOI 10.1038/ejhg.2009.35; Hamzah J, 2008, NATURE, V453, P410, DOI 10.1038/nature06868; Hasumi Y, 2007, INT J CANCER, V121, P2606, DOI 10.1002/ijc.22999; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Jakobsson L, 2007, J CELL BIOL, V177, P751, DOI 10.1083/jcb.200701146; JOHNSON WE, 1996, CARNIVORE BEHAV ECOL, V2, P189; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kamalaporn P, 2009, EUR J GASTROEN HEPAT, V21, P1347, DOI 10.1097/MEG.0b013e32832c9346; Kurstin R, 2002, ONCOLOGY-NY, V16, P21; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lebrin F, 2008, TRENDS CARDIOVAS MED, V18, P25, DOI 10.1016/j.tcm.2007.11.003; Letarte M, 2005, CARDIOVASC RES, V68, P155, DOI 10.1016/j.cardiores.2005.04.028; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PREZENCINAS M, 2002, HAEMATOLOGICA, V87, pELT34; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Therapontos C, 2009, P NATL ACAD SCI USA, V106, P8573, DOI 10.1073/pnas.0901505106; Torsney E, 2003, CIRCULATION, V107, P1653, DOI 10.1161/01.CIR.0000058170.92267.00; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; Vollmar B, 2000, AM J PHYSIOL-HEART C, V279, pH1591, DOI 10.1152/ajpheart.2000.279.4.H1591; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895	42	235	250	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					420	U101		10.1038/nm.2131	http://dx.doi.org/10.1038/nm.2131			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20364125				2022-12-27	WOS:000276446800046
J	Janes, MR; Limon, JJ; So, LM; Chen, J; Lim, RJ; Chavez, MA; Vu, C; Lilly, MB; Mallya, S; Ong, ST; Konopleva, M; Martin, MB; Ren, PD; Liu, Y; Rommel, C; Fruman, DA				Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Vu, Collin; Lilly, Michael B.; Mallya, Sharmila; Ong, S. Tiong; Konopleva, Marina; Martin, Michael B.; Ren, Pingda; Liu, Yi; Rommel, Christian; Fruman, David A.			Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor	NATURE MEDICINE			English	Article							MAMMALIAN TARGET; PHILADELPHIA-CHROMOSOME; RAPAMYCIN; MTOR; ACTIVATION; TYROSINE; 3-KINASE; PATHWAY; COMPLEX; PI3K	Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation. We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells. In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin. Unexpectedly, PP242 has much weaker effects than rapamycin on the proliferation and function of normal lymphocytes. PI-103, a less selective TORC1/2 inhibitor that also targets phosphoinositide 3-kinase (PI3K), is more immunosuppressive than PP242. These findings establish that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.	[Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Fruman, David A.] Univ Calif Irvine, Inst Immunol, Irvine, CA 92717 USA; [Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Fruman, David A.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; [Vu, Collin; Lilly, Michael B.; Mallya, Sharmila] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA; [Ong, S. Tiong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Stem Cell Transplantat, Houston, TX 77030 USA; [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Dept Cellular Therapy, Houston, TX 77030 USA; [Martin, Michael B.; Ren, Pingda; Liu, Yi; Rommel, Christian] Intellikine Inc, La Jolla, CA USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; National University of Singapore; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fruman, DA (corresponding author), Univ Calif Irvine, Inst Immunol, Irvine, CA 92717 USA.	dfruman@uci.edu		Ong, S. Tiong/0000-0001-9460-3483	University of California Irvine [CA-62203, GM-076516]; US National Institutes of Health [T32-CA009054, T34GM069337]; University of California Industry-University Cooperative Research Program; Chao Family Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA062203, T32CA009054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055246, P50GM076516, T34GM069337] Funding Source: NIH RePORTER	University of California Irvine(University of California System); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California Industry-University Cooperative Research Program(University of California System); Chao Family Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Shokat, T. Wilson, and M. Kharas for support and helpful discussions and R. Nguyen for constructing BCR-ABL mutants. For access to the LSM710 Zeiss confocal microscope we thank E. Gratton's laboratory in the Department of Biomedical Engineering, University of California-Irvine. The SUP-B15 cells stably expressing firefly luciferase (SUP-B15<SUP>ffLuc</SUP>) were a kind gift from M. Jensen ( City of Hope). Technical assistance was provided through the Optical Biology Core facility of the Developmental Biology Center, a shared resource supported in part by the Cancer Center Support Grant (CA-62203) and the Center for Complex Biological Systems Support Grant (GM-076516) at the University of California Irvine. The Lumina IVIS bioluminescent imager was supported by a grant to the University of California-Irvine from the California Institute of Regenerative Medicine. This work was supported by US National Institutes of Health training grant T32-CA009054 ( to M.R.J.), National Institutes of Health Minority Access to Research Careers grant T34GM069337 ( to M. A. C.), a Research Scholar Grant from the American Cancer Society ( to D. A. F.), a Discovery Grant from the University of California Industry-University Cooperative Research Program ( to D. A. F.), a sponsored research agreement from Intellikine, Inc. ( to D. A. F.) and a Bridge award from the Chao Family Comprehensive Cancer Center. M.R.J. is an awardee of the Jackie Murphy and Carol Malouf Scholar Achievement Rewards for College Scientists.	Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]; Abraham Robert T, 2009, F1000 Biol Rep, V1, P8, DOI 10.3410/B1-8; Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Burgess MR, 2006, THESCIENTIFICWORLDJO, V6, P918, DOI 10.1100/tsw.2006.184; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Durand CA, 2009, J IMMUNOL, V183, P5673, DOI 10.4049/jimmunol.0900432; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Foa R, 2008, BLOOD, V112, P119; Fruman DA, 2009, IMMUNOL REV, V228, P253, DOI 10.1111/j.1600-065X.2008.00750.x; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gruber F, 2009, BRIT J HAEMATOL, V145, P581, DOI 10.1111/j.1365-2141.2009.07666.x; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hedrick SM, 2009, NAT IMMUNOL, V10, P1057, DOI 10.1038/ni.1784; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Janes MR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe25; Kennedy JA, 2008, LEUKEMIA, V22, P2029, DOI 10.1038/leu.2008.206; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kojima K, 2008, LEUKEMIA, V22, P1728, DOI 10.1038/leu.2008.158; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LOPEZFAUQUED M, INT J CANCER, DOI DOI 10.1002/IJC.24926; Luo FR, 2006, CLIN CANCER RES, V12, P7180, DOI 10.1158/1078-0432.CCR-06-1112; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martelli AM, 2005, HISTOL HISTOPATHOL, V20, P239, DOI 10.14670/HH-20.239; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Park S, 2008, LEUKEMIA, V22, P1698, DOI 10.1038/leu.2008.144; Prabhu S, 2007, ONCOGENE, V26, P1188, DOI 10.1038/sj.onc.1209901; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Sankhala K, 2009, TARGET ONCOL, V4, P135, DOI 10.1007/s11523-009-0107-z; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Shor B, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-28; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zhang M, 2008, MOL CELL BIOL, V28, P6496, DOI 10.1128/MCB.00477-08	49	289	344	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					205	U115		10.1038/nm.2091	http://dx.doi.org/10.1038/nm.2091			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20072130	Green Accepted			2022-12-27	WOS:000274297000042
J	Chen, YH; Chang, M; Davidson, BL				Chen, Yong Hong; Chang, Michael; Davidson, Beverly L.			Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy	NATURE MEDICINE			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; ADENOASSOCIATED VIRUS; MOUSE MODEL; GENE; EVOLUTION; VECTORS; PHENOTYPES; LIBRARIES; TROPISM	The brain vasculature forms an immense network such that most neural cells are in contact with a microvessel. Here we tested the hypothesis that endothelia lining these vessels can be harnessed to create a cellular reservoir of enzyme replacement therapy to diseased brain. As a model system, we used mice with central nervous system (CNS) deficits due to lysosomal storage disease (LSD mice). The basic premise of this work is that recombinant enzyme expressed in, and secreted from, the vascular endothelia will be endocytosed by underlying neurons and glia, decreasing neuropathology. We screened a phage library in vivo by panning to identify peptides that bound the vascular endothelia in diseased and wild-type mice. Epitopes binding diseased brain were distinct from those panned from normal brain. Moreover, different epitopes were identified in two distinct LSD disease models, implying a unique vascular signature imparted by the disease state. Presentation of these epitopes on the capsid of adeno-associated virus (AAV) expanded the biodistribution of intravenously injected AAV from predominantly liver to include the CNS. Peripheral injection of the epitope-modified AAVs expressing the enzymes lacking in LSD mice reconstituted enzyme activity throughout the brain and improved disease phenotypes in two distinct disease models.	[Chen, Yong Hong; Davidson, Beverly L.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Chang, Michael; Davidson, Beverly L.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA; [Davidson, Beverly L.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Davidson, BL (corresponding author), Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.	beverly-davidson@uiowa.edu		Davidson, Beverly/0000-0002-3715-6290	US National Institutes of Health [HD33531, NS34568, DK54759]; Batten Disease Research and Support Association; Roy J. Carver Trust; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034568] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Batten Disease Research and Support Association; Roy J. Carver Trust; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank G. Liu and J. Wilson for technical assistance and the Central Microscopy Research Facility at the University of Iowa. We thank C. Stein and P. Staber for reading of the manuscript. We thank W. Sly, St. Louis University, for goat antibody to beta-glucuronidase. This work was supported by the US National Institutes of Health (grants HD33531, NS34568 and DK54759), the Batten Disease Research and Support Association and the Roy J. Carver Trust.	Chang M, 2008, MOL THER, V16, P649, DOI 10.1038/mt.2008.9; Grifman M, 2001, MOL THER, V3, P964, DOI 10.1006/mthe.2001.0345; Grimm D, 2008, J VIROL, V82, P5887, DOI 10.1128/JVI.00254-08; Koerber JT, 2006, NAT PROTOC, V1, P701, DOI 10.1038/nprot.2006.93; Liu GM, 2005, J NEUROSCI, V25, P9321, DOI 10.1523/JNEUROSCI.2936-05.2005; Maheshri N, 2006, NAT BIOTECHNOL, V24, P198, DOI 10.1038/nbt1182; Muller OJ, 2003, NAT BIOTECHNOL, V21, P1040, DOI 10.1038/nbt856; Perabo L, 2006, J VIROL, V80, P7265, DOI 10.1128/JVI.00076-06; Sleat DE, 2004, J NEUROSCI, V24, P9117, DOI 10.1523/JNEUROSCI.2729-04.2004; Song L, 2003, IN VITRO CELL DEV-AN, V39, P313; Vogler C, 2001, PEDIATR RES, V49, P342, DOI 10.1203/00006450-200103000-00007; Work LM, 2006, MOL THER, V13, P683, DOI 10.1016/j.ymthe.2005.11.013	12	131	155	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1215	U145		10.1038/nm.2025	http://dx.doi.org/10.1038/nm.2025			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19749771	Green Accepted			2022-12-27	WOS:000270596400035
J	Nishimura, S; Manabe, I; Nagasaki, M; Eto, K; Yamashita, H; Ohsugi, M; Otsu, M; Hara, K; Ueki, K; Sugiura, S; Yoshimura, K; Kadowaki, T; Nagai, R				Nishimura, Satoshi; Manabe, Ichiro; Nagasaki, Mika; Eto, Koji; Yamashita, Hiroshi; Ohsugi, Mitsuru; Otsu, Makoto; Hara, Kazuo; Ueki, Kohjiro; Sugiura, Seiryo; Yoshimura, Kotaro; Kadowaki, Takashi; Nagai, Ryozo			CD8(+) effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; AUTOIMMUNE-DISEASE; MICE; ACCUMULATION; INFILTRATION; ADIPOCYTES; ACTIVATION	Inflammation is increasingly regarded as a key process underlying metabolic diseases in obese individuals. In particular, obese adipose tissue shows features characteristic of active local inflammation. At present, however, little is known about the sequence of events that comprises the inflammatory cascade or the mechanism by which inflammation develops. We found that large numbers of CD8(+) effector T cells infiltrated obese epididymal adipose tissue in mice fed a high-fat diet, whereas the numbers of CD4(+) helper and regulatory T cells were diminished. The infiltration by CD8(+) T cells preceded the accumulation of macrophages, and immunological and genetic depletion of CD8(+) T cells lowered macrophage infiltration and adipose tissue inflammation and ameliorated systemic insulin resistance. Conversely, adoptive transfer of CD8(+) T cells to CD8-deficient mice aggravated adipose inflammation. Coculture and other in vitro experiments revealed a vicious cycle of interactions between CD8(+) T cells, macrophages and adipose tissue. Our findings suggest that obese adipose tissue activates CD8(+) T cells, which, in turn, promote the recruitment and activation of macrophages in this tissue. These results support the notion that CD8(+) T cells have an essential role in the initiation and propagation of adipose inflammation.	[Nishimura, Satoshi; Manabe, Ichiro; Nagasaki, Mika; Yamashita, Hiroshi; Nagai, Ryozo] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; [Nishimura, Satoshi; Manabe, Ichiro] Univ Tokyo, Grad Sch Med, Nanobioengn Educ Program, Tokyo, Japan; [Nishimura, Satoshi; Manabe, Ichiro] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; [Manabe, Ichiro; Ueki, Kohjiro; Kadowaki, Takashi; Nagai, Ryozo] Univ Tokyo, Comprehens Ctr Educ & Res Chem Biol Dis, Tokyo, Japan; [Nagasaki, Mika] Univ Tokyo, Computat Diagnost Radiol & Prevent Med, Tokyo, Japan; [Eto, Koji; Otsu, Makoto] Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Div Stem Cell Therapy, Tokyo, Japan; [Ohsugi, Mitsuru; Hara, Kazuo; Ueki, Kohjiro; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; [Sugiura, Seiryo] Univ Tokyo, Grad Sch Frontier Sci, Dept Human & Engineered Environm Studies, Tokyo, Japan; [Yoshimura, Kotaro] Univ Tokyo, Grad Sch Med, Dept Plast Surg, Tokyo, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Nishimura, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.	snishi-tky@umin.ac.jp; manabe-tky@umin.ac.jp	Manabe, Ichiro/AAE-5105-2021; Manabe, Ichiro/E-1529-2014; Eckhardt, Erik/G-1567-2010; Yoshimura, Kotaro/C-8524-2009	Otsu, Makoto/0000-0002-9769-0217; Yoshimura, Kotaro/0000-0002-7152-5475	Japan Society for the Promotion of Science for Young Scientists; Grants-in-Aid for Scientific Research; Translational Systems Biology and Medicine Initiative; Global Centers of Excellence program; Ministry of Education, Culture, Sports, Science and Technology of Japan; National Institute of Biomedical Innovation; Grants-in-Aid for Scientific Research [21390321] Funding Source: KAKEN	Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Translational Systems Biology and Medicine Initiative; Global Centers of Excellence program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We gratefully acknowledge A. Matsuoka, X. Yingda, E. Magoshi, M. Hayashi, K. Wakabayashi, M. Tajima and Y. Yamazaki for excellent technical assistance. This study was supported by Research Fellowships from the Japan Society for the Promotion of Science for Young Scientists (S. N.), Grants-in-Aid for Scientific Research (I. M., R. N.) and grants for Translational Systems Biology and Medicine Initiative (R. N., T. K.) and Global Centers of Excellence program (R. N., T. K.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a research grant from the National Institute of Biomedical Innovation (R.N.)	Brake DK, 2006, AM J PHYSIOL-CELL PH, V291, pC1232, DOI 10.1152/ajpcell.00008.2006; Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Kintscher U, 2008, ARTERIOSCL THROM VAS, V28, P1304, DOI 10.1161/ATVBAHA.108.165100; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Mahajan D, 2006, J AM SOC NEPHROL, V17, P2731, DOI 10.1681/ASN.2005080842; Miller R, 2006, J INTERF CYTOK RES, V26, P787, DOI 10.1089/jir.2006.26.787; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nishimura S, 2008, J CLIN INVEST, V118, P710, DOI 10.1172/JCI33328; Nishimura S, 2007, DIABETES, V56, P1517, DOI 10.2337/db06-1749; Rausch ME, 2008, INT J OBESITY, V32, P451, DOI 10.1038/sj.ijo.0803744; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.humimm.2004.12.006; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451	22	1528	1573	5	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					914	U116		10.1038/nm.1964	http://dx.doi.org/10.1038/nm.1964			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19633658				2022-12-27	WOS:000268770400036
J	Nishimura, Y; Shimojima, M; Tano, Y; Miyamura, T; Wakita, T; Shimizu, H				Nishimura, Yorihiro; Shimojima, Masayuki; Tano, Yoshio; Miyamura, Tatsuo; Wakita, Takaji; Shimizu, Hiroyuki			Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71	NATURE MEDICINE			English	Article							CYNOMOLGUS MONKEYS; MOLECULAR-BASIS; INFECTION; EXPRESSION; EVOLUTION; MOUSE; ENCEPHALOMYELITIS; ENCEPHALITIS; OUTBREAK	Enterovirus 71 (EV71) is a major causative agent of hand, foot and mouth disease (HFMD), a common febrile disease occurring mainly in young children. Although clinical manifestations of HFMD are usually mild and self limiting, a severe EV71 outbreak can lead to a diverse array of neurological diseases. Identification of the specific cellular receptors is crucial for elucidating the mechanism of early virus-host interactions and the pathogenesis of enteroviruses(1). Here we identify human P-selectin glycoprotein ligand-1 (PSGL-1; CD162), a sialomucin membrane protein expressed on leukocytes that has a major role in early stages of inflammation(2-4), as a functional receptor for EV71 using an expression cloning method by panning(5). The N-terminal region of PSGL-1 binds specifically to EV71. Stable PSGL-1 expression allowed EV71 entry and replication, and development of cytopathic effects in nonsusceptible mouse L929 cells. Five out of eight EV71 strains bound soluble PSGL-1 and used intact PSGL-1 as the primary receptor for infection of Jurkat T cells. Three other EV71 strains did not use PSGL-1, suggesting the presence of strain-specific replication of EV71 in leukocytes. EV71 replicated in nonleukocyte cell lines in a PSGL-1-independent manner, indicating the presence of alternative receptor(s) for EV71. The identification of PSGL-1 as a receptor for EV71 sheds new light on a role for PSGL-1-positive leukocytes in cell tropism and pathogenesis during the course of HFMD and other EV71-mediated diseases.	[Nishimura, Yorihiro; Tano, Yoshio; Miyamura, Tatsuo; Wakita, Takaji; Shimizu, Hiroyuki] Natl Inst Infect Dis, Dept Virol 2, Musashimurayama, Tokyo, Japan; [Shimojima, Masayuki] Univ Tokyo, Div Virol, Dept Microbiol & Immunol, Inst Med Sci,Minato Ku, Tokyo, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo	Shimizu, H (corresponding author), Natl Inst Infect Dis, Dept Virol 2, Musashimurayama, Tokyo, Japan.	hshimizu@nih.go.jp	Shimizu, Hiroyuki/AAU-9621-2020	Shimizu, Hiroyuki/0000-0002-2987-2377				[Anonymous], 2008, Wkly Epidemiol Rec, V83, P169; Arita M, 2008, J VIROL, V82, P1787, DOI 10.1128/JVI.01798-07; Brown BA, 1999, J VIROL, V73, P9969, DOI 10.1128/JVI.73.12.9969-9975.1999; Chan LG, 2000, CLIN INFECT DIS, V31, P678, DOI 10.1086/314032; Chang SC, 2004, J NEUROVIROL, V10, P338, DOI 10.1080/13550280490521032; Chen CS, 2007, J VIROL, V81, P8996, DOI 10.1128/JVI.00236-07; Chen LC, 2006, J MED VIROL, V78, P780, DOI 10.1002/jmv.20623; Chua BH, 2008, J GEN VIROL, V89, P1622, DOI 10.1099/vir.0.83676-0; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; Hsueh C, 2000, MODERN PATHOL, V13, P1200, DOI 10.1038/modpathol.3880222; Kitamura T, 2000, METH MOL B, V134, P143; Kung CM, 2007, J MED VIROL, V79, P60, DOI 10.1002/jmv.20761; Kuo RL, 2002, J GEN VIROL, V83, P1367, DOI 10.1099/0022-1317-83-6-1367; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Lin TY, 2003, CLIN INFECT DIS, V36, P269, DOI 10.1086/345905; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x; Nagata N, 2004, J GEN VIROL, V85, P2981, DOI 10.1099/vir.0.79883-0; Nagata N, 2002, J MED VIROL, V67, P207, DOI 10.1002/jmv.2209; Oberste MS, 1999, J VIROL, V73, P1941, DOI 10.1128/JVI.73.3.1941-1948.1999; Ong KC, 2008, J NEUROPATH EXP NEUR, V67, P532, DOI 10.1097/NEN.0b013e31817713e7; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Shimojimaa M, 2003, ANAL BIOCHEM, V315, P138, DOI 10.1016/S0003-2697(02)00708-X; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Thatte A, 2002, J LEUKOCYTE BIOL, V72, P470; Wang SM, 2003, J INFECT DIS, V188, P564, DOI 10.1086/376998; Wong KT, 2008, J NEUROPATH EXP NEUR, V67, P162, DOI 10.1097/nen.0b013e318163a990	29	297	354	2	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					794	U14		10.1038/nm.1961	http://dx.doi.org/10.1038/nm.1961			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19543284				2022-12-27	WOS:000267806900033
J	Kilarski, WW; Samolov, B; Petersson, L; Kvanta, A; Gerwins, P				Kilarski, Witold W.; Samolov, Branka; Petersson, Ludvig; Kvanta, Anders; Gerwins, Par			Biomechanical regulation of blood vessel growth during tissue vascularization	NATURE MEDICINE			English	Article							GRANULATION-TISSUE; INTUSSUSCEPTIVE ANGIOGENESIS; ENDOTHELIAL-CELLS; CROSS-LINKING; IN-VIVO; PROLIFERATION; MYOFIBROBLASTS; CONTRACTION; MECHANISMS; PHENOTYPE	Formation of new vessels in granulation tissue during wound healing has been assumed to occur solely through sprouting angiogenesis. In contrast, we show here that neovascularization can be accomplished by nonangiogenic expansion of preexisting vessels. Using neovascularization models based on the chick chorioallantoic membrane and the healing mouse cornea, we found that tissue tension generated by activated fibroblasts or myofibroblasts during wound contraction mediated and directed translocation of the vasculature. These mechanical forces pulled vessels from the preexisting vascular bed as vascular loops with functional circulation that expanded as an integral part of the growing granulation tissue through vessel enlargement and elongation. Blockade of vascular endothelial growth factor receptor-2 confirmed that biomechanical forces were sufficient to mediate the initial vascular growth independently of endothelial sprouting or proliferation. The neovascular network was further remodeled by splitting, sprouting and regression of individual vessels. This model explains the rapid appearance of large functional vessels in granulation tissue during wound healing.	[Kilarski, Witold W.; Petersson, Ludvig; Gerwins, Par] Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; [Samolov, Branka; Kvanta, Anders] Karolinska Inst, Dept Clin Neurosci, Sect Ophthalmol & Vis, Stockholm, Sweden; [Gerwins, Par] Univ Uppsala Hosp, Dept Oncol Radiol & Clin Immunol, Sect Radiol, Uppsala, Sweden	Uppsala University; Karolinska Institutet; Uppsala University; Uppsala University Hospital	Kilarski, WW (corresponding author), Swiss Fed Inst Technol, Lab Mechanobiol & Morphogenesis, CH-1015 Lausanne, Switzerland.	witold.kilarski@epfl.ch; par.gerwins@imbim.uu.se	Kilarski, Witold W./G-8673-2012; Kilarski, Witold/AAA-1843-2019	Kilarski, Witold W./0000-0003-0734-4749; 	Goran Gustafsson Foundation; Swedish Cancer Foundation [4422-B04O5XAB]; Swedish Research Council [K2005-31X-15348-01A, 2006-13828-37891-37]; Children's Cancer Foundation of Sweden [04/037]; Lions Cancer Research Foundation in Uppsala; Magnus Bergvall Foundation; King Gustaf V's 80-Year Foundation; Uppsala Foundation for Medical Research; Crown Princess Margareta Foundation; Edwin Jordan Foundation; Karolinska Institute research grants; Stiftelsen Synframjandets Forskningsfond; St. Erik Eye Hospital Research Foundation; Sigvard and Marianne Bernadotte Research Foundation for Children's Eye Care	Goran Gustafsson Foundation; Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Children's Cancer Foundation of Sweden(Swedish Cancer Society); Lions Cancer Research Foundation in Uppsala; Magnus Bergvall Foundation; King Gustaf V's 80-Year Foundation; Uppsala Foundation for Medical Research; Crown Princess Margareta Foundation; Edwin Jordan Foundation; Karolinska Institute research grants(Karolinska Institutet); Stiftelsen Synframjandets Forskningsfond; St. Erik Eye Hospital Research Foundation; Sigvard and Marianne Bernadotte Research Foundation for Children's Eye Care	We thank M. Aronsson for help with cornea experiments, J. Kilarska for help with image processing and analysis and K. Kullander and N. Rabe for help with microscopy of whole-mount corneas. We also thank M. Swartz for allowing us to use her laboratory to perform gel contraction and image analysis and A. Bikfalvi for comments. This study was supported by grants to P. G. from the Goran Gustafsson Foundation, the Swedish Cancer Foundation (project 4422-B04O5XAB), the Swedish Research Council (project K2005-31X-15348-01A), the Children's Cancer Foundation of Sweden (project 04/037), Lions Cancer Research Foundation in Uppsala, the Magnus Bergvall Foundation, King Gustaf V's 80-Year Foundation and Uppsala Foundation for Medical Research, by grants to A. K. from the Crown Princess Margareta Foundation (KMA), the Edwin Jordan Foundation, Karolinska Institute research grants, Stiftelsen Synframjandets Forskningsfond, and Swedish Research Council (project 2006-13828-37891-37) and by grants to B. S. from St. Erik Eye Hospital Research Foundation, Sigvard and Marianne Bernadotte Research Foundation for Children's Eye Care and Stiftelsen Synframjandets Forskningsfond.	Augustin HG, 1998, TRENDS PHARMACOL SCI, V19, P216, DOI 10.1016/S0165-6147(98)01211-5; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BARNHILL R, 1982, MICROVASC RES, V23, P129; Burri PH, 2002, MOL ASPECTS MED, V23, pS1; Clark ER, 1939, AM J ANAT, V64, P251, DOI 10.1002/aja.1000640203; Clark ER, 1918, AM J ANAT, V23, P37, DOI 10.1002/aja.1000230103; Djonov V, 2003, CELL TISSUE RES, V314, P107, DOI 10.1007/s00441-003-0784-3; Dor Y, 2003, TRENDS CELL BIOL, V13, P131, DOI 10.1016/S0962-8924(03)00022-9; DUDAR TE, 1983, MICROVASC RES, V25, P1, DOI 10.1016/0026-2862(83)90040-7; Dvorak HF, 2003, AM J PATHOL, V162, P1747, DOI 10.1016/S0002-9440(10)64309-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eastwood M, 1998, CELL MOTIL CYTOSKEL, V40, P13, DOI 10.1002/(SICI)1097-0169(1998)40:1<13::AID-CM2>3.0.CO;2-G; Fukumura D, 2003, CIRC RES, V93, pE88, DOI 10.1161/01.RES.0000099243.20096.FA; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gschwandtner ME, 2001, MICROVASC RES, V62, P226, DOI 10.1006/mvre.2001.2330; Hlushchuk R, 2008, AM J PATHOL, V173, P1173, DOI 10.2353/ajpath.2008.071131; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; JUNGHANS BM, 1989, CORNEA, V8, P141; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kilarski WW, 2005, LAB INVEST, V85, P643, DOI 10.1038/labinvest.3700255; Kilarski WW, 2003, EXP CELL RES, V291, P70, DOI 10.1016/S0014-4827(03)00374-4; Korff T, 1999, J CELL SCI, V112, P3249; Kumar V., 2004, ROBBINS COTRAN PATHO; Lee CR, 2001, BIOMATERIALS, V22, P3145, DOI 10.1016/S0142-9612(01)00067-9; Lockhart AC, 2003, WOUND REPAIR REGEN, V11, P306, DOI 10.1046/j.1524-475X.2003.11411.x; Lorena D, 2002, WOUND REPAIR REGEN, V10, P86, DOI 10.1046/j.1524-475X.2002.00201.x; Lusimbo WS, 2000, ANAT REC, V259, P25, DOI 10.1002/(SICI)1097-0185(20000501)259:1<25::AID-AR3>3.0.CO;2-Y; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; McClain SA, 1996, AM J PATHOL, V149, P1257; MORRISON JC, 1995, INVEST OPHTH VIS SCI, V36, P751; MUTHUKKARUPPAN V, 1979, SCIENCE, V205, P1416, DOI 10.1126/science.472760; Patan S, 2001, CIRC RES, V89, P723, DOI 10.1161/hh2001.097870; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Rendell MS, 1998, J SURG RES, V80, P373, DOI 10.1006/jsre.1998.5463; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rogers P A, 1998, Angiogenesis, V2, P287, DOI 10.1023/A:1009222030539; Samolov B, 2005, EXP EYE RES, V80, P159, DOI 10.1016/j.exer.2004.08.023; Scherer SS, 2008, PLAST RECONSTR SURG, V122, P786, DOI 10.1097/PRS.0b013e31818237ac; Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; SHOLLEY MM, 1984, LAB INVEST, V51, P624; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Thurston G, 2000, MICROCIRCULATION, V7, P67, DOI 10.1038/sj.mn.7300155; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Vosseler S, 2005, CANCER RES, V65, P1294, DOI 10.1158/0008-5472.CAN-03-3986; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920	54	164	171	1	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2009	15	6					657	U145		10.1038/nm.1985	http://dx.doi.org/10.1038/nm.1985			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19483693				2022-12-27	WOS:000266731600025
J	Krishnamoorthy, G; Saxena, A; Mars, LT; Domingues, HS; Mentele, R; Ben-Nun, A; Lassmann, H; Dornmair, K; Kurschus, FC; Liblau, RS; Wekerle, H				Krishnamoorthy, Gurumoorthy; Saxena, Amit; Mars, Lennart T.; Domingues, Helena S.; Mentele, Reinhard; Ben-Nun, Avraham; Lassmann, Hans; Dornmair, Klaus; Kurschus, Florian C.; Liblau, Roland S.; Wekerle, Hartmut			Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN; MICE; INDUCTION; BINDING; BRAIN; RAT; MOG	We describe here the paradoxical development of spontaneous experimental autoimmune encephalomyelitis (EAE) in transgenic mice expressing a myelin oligodendrocyte glycoprotein (MOG)-specific T cell antigen receptor (TCR) in the absence of MOG. We report that in Mog-deficient mice (Mog(-/-)), the autoimmune response by transgenic T cells is redirected to a neuronal cytoskeletal self antigen, neurofilament-M (NF-M). Although components of radically different protein classes, the cross-reacting major histocompatibility complex I-A(b)-restricted epitope sequences of MOG(35-55) and NF-M18-30 share essential TCR contact positions. This pattern of cross-reaction is not specific to the transgenic TCR but is also commonly seen in MOG(35-55)-I-A(b)-reactive T cells. We propose that in the C57BL/6 mouse, MOG and NF-M response components add up to overcome the general resistance of this strain to experimental induction of autoimmunity. Similar cumulative responses against more than one autoantigen may have a role in spontaneously developing human autoimmune diseases.	[Krishnamoorthy, Gurumoorthy; Domingues, Helena S.; Dornmair, Klaus; Kurschus, Florian C.; Wekerle, Hartmut] Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany; [Saxena, Amit; Mars, Lennart T.; Liblau, Roland S.] Univ Toulouse 3, INSERM, U563, F-31062 Toulouse, France; [Domingues, Helena S.] Univ Coimbra, Ctr Neurosci & Cell Biol, Program Expt Biol & Biomed, Coimbra, Portugal; [Mentele, Reinhard; Dornmair, Klaus] Univ Munich, Univ Hosp Grosshadern, Inst Clin Neuroimmunol, Munich, Germany; [Mentele, Reinhard] Max Planck Inst Biochem, Dept Prot Analyt, D-82152 Martinsried, Germany; [Ben-Nun, Avraham] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Lassmann, Hans] Med Univ Vienna, Ctr Brain Res, Vienna, Austria	Max Planck Society; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade de Coimbra; University of Munich; Max Planck Society; Weizmann Institute of Science; Medical University of Vienna	Wekerle, H (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany.	hwekerle@neuro.mpg.de	Lassmann, Hans/Z-2269-2019; Domingues, Sofia/A-9842-2011; Kurschus, Florian/B-2838-2014; Mars, Lennart T/K-7593-2014; Krishnamoorthy, Gurumoorthy/O-1650-2013; Liblau, Roland/J-3530-2014; Kurschus, Florian C./AAP-9777-2020; Saxena, Amit/J-4119-2012	Lassmann, Hans/0000-0001-8617-5052; Domingues, Sofia/0000-0003-1230-2682; Mars, Lennart T/0000-0001-7997-1974; Krishnamoorthy, Gurumoorthy/0000-0002-7798-6707; Kurschus, Florian C./0000-0001-7550-0681; LIBLAU, Roland/0000-0001-5477-5475	Deutsche Forschungsgemeinschaft (Sonderforschungsbereiche (SFB) 571; Max Planck Society; Portuguese Fundacao para a Ciencia ea Tecnologia (FCT) [SFRH/BD/15885/2005]; EU Project Neuropromise [PL 018637]; Israel Science Foundation; National Multiple Sclerosis Society of New York [RG3195B8/2]; Alexander von Humboldt Prize Awardee	Deutsche Forschungsgemeinschaft (Sonderforschungsbereiche (SFB) 571(German Research Foundation (DFG)); Max Planck Society(Max Planck SocietyFoundation CELLEX); Portuguese Fundacao para a Ciencia ea Tecnologia (FCT)(Portuguese Foundation for Science and Technology); EU Project Neuropromise; Israel Science Foundation(Israel Science Foundation); National Multiple Sclerosis Society of New York(National Multiple Sclerosis Society); Alexander von Humboldt Prize Awardee(Alexander von Humboldt Foundation)	Mog<SUP>Cre/Cre</SUP>, Nefm<SUP>-/-</SUP>, 2D2 and Mog<SUP>-/-</SUP> mice were generously provided by A. Waisman (Johannes Gutenberg University of Mainz), J.-P. Julien (Laval University), V. K. Kuchroo (Harvard Medical School) and D. Pham-Dinh (INSERM UMR 546). We thank F. Lottspeich for granting us permission to use his mass spectrometer. We thank L. Penner and I. Arnold-Ammer for technical support. This project was supported by the Deutsche Forschungsgemeinschaft (Sonderforschungsbereiche (SFB) 571, Projects A1 and B6) and the Max Planck Society. H. S. D. is supported by a PhD fellowship (Portuguese Fundacao para a Ciencia ea Tecnologia (FCT) program SFRH/BD/15885/2005). Part of the study (conducted by H. W., R. L. and H. L.) was funded by the EU Project Neuropromise (PL 018637), and A. B.-N. was supported by the Israel Science Foundation and the National Multiple Sclerosis Society of New York (RG3195B8/2). A. B.-N. is an Alexander von Humboldt Prize Awardee.	ABROMSONLEEMAN S, 1993, J NEUROIMMUNOL, V45, P89, DOI 10.1016/0165-5728(93)90168-X; AMOR S, 1994, J IMMUNOL, V153, P4349; Bartos A, 2007, J NEUROL, V254, P20, DOI 10.1007/s00415-006-0185-0; Ben-Nun A, 2006, EUR J IMMUNOL, V36, P478, DOI 10.1002/eji.200535363; Berger T, 1997, LAB INVEST, V76, P355; Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603; Bettelli E, 2006, J CLIN INVEST, V116, P2393, DOI 10.1172/JCI28334; CHANTRY A, 1989, J BIOL CHEM, V264, P21603; Delarasse C, 2003, J CLIN INVEST, V112, P544, DOI 10.1172/JCI200315861; Goebels N, 2000, BRAIN, V123, P508, DOI 10.1093/brain/123.3.508; Hovelmeyer N, 2005, J IMMUNOL, V175, P5875, DOI 10.4049/jimmunol.175.9.5875; Huizinga R, 2007, J NEUROPATH EXP NEUR, V66, P295, DOI 10.1097/nen.0b013e318040ad5c; Jacomy H, 1999, J NEUROCHEM, V73, P972, DOI 10.1046/j.1471-4159.1999.0730972.x; KELLY BM, 1992, J CELL BIOL, V118, P397, DOI 10.1083/jcb.118.2.397; KOJIMA K, 1994, J EXP MED, V180, P817, DOI 10.1084/jem.180.3.817; Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330; Litzenburger T, 1998, J EXP MED, V188, P169, DOI 10.1084/jem.188.1.169; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; Petersen TR, 2004, EUR J IMMUNOL, V34, P165, DOI 10.1002/eji.200324669; Stefferl A, 2000, J IMMUNOL, V165, P2859, DOI 10.4049/jimmunol.165.5.2859; Wekerle H, 2006, CURR TOP MICROBIOL, V305, P25, DOI 10.1007/3-540-29714-6_2; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	23	114	120	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					626	U142		10.1038/nm.1975	http://dx.doi.org/10.1038/nm.1975			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19483694				2022-12-27	WOS:000266731600021
J	Ootani, A; Li, XN; Sangiorgi, E; Ho, QT; Ueno, H; Toda, S; Sugihara, H; Fujimoto, K; Weissman, IL; Capecchi, MR; Kuo, CJ				Ootani, Akifumi; Li, Xingnan; Sangiorgi, Eugenio; Ho, Quoc T.; Ueno, Hiroo; Toda, Shuji; Sugihara, Hajime; Fujimoto, Kazuma; Weissman, Irving L.; Capecchi, Mario R.; Kuo, Calvin J.			Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche	NATURE MEDICINE			English	Article							MOUSE SMALL-INTESTINE; PROGENITOR CELLS; TISSUE; DIFFERENTIATION; RENEWAL; SIGNALS; NEUROGENIN-3; MAINTENANCE; HOMEOSTASIS; DISRUPTION	The in vitro analysis of intestinal epithelium has been hampered by a lack of suitable culture systems. Here we describe robust long-term methodology for small and large intestinal culture, incorporating an air-liquid interface and underlying stromal elements. These cultures showed prolonged intestinal epithelial expansion as sphere-like organoids with proliferation and multilineage differentiation. The Wnt growth factor family positively regulates proliferation of the intestinal epithelium in vivo. Accordingly, culture growth was inhibited by the Wnt antagonist Dickkopf-1 (Dkk1) and markedly stimulated by a fusion protein between the Wnt agonist R-spondin-1 and immunoglobulin Fc (RSpo1-Fc). Furthermore, treatment with the gamma-secretase inhibitor dibenzazepine and neurogenin-3 overexpression induced goblet cell and enteroendocrine cell differentiation, respectively, consistent with endogenous Notch signaling and lineage plasticity. Epithelial cells derived from both leucine-rich repeat-containing G protein-coupled receptor-5-positive (Lgr5(+)) and B lymphoma moloney murine leukemia virus insertion region homolog-1-positive (Bmi1(+)) lineages, representing putative intestinal stem cell (ISC) populations, were present in vitro and were expanded by treatment with RSpo1-Fc; this increased number of Lgr5(+) cells upon RSpo1-Fc treatment was subsequently confirmed in vivo. Our results indicate successful long-term intestinal culture within a microenvironment accurately recapitulating the Wnt- and Notch-dependent ISC niche.	[Ootani, Akifumi; Li, Xingnan; Ho, Quoc T.; Kuo, Calvin J.] Stanford Univ, Dept Med, Sch Med, Div Hematol, Stanford, CA 94305 USA; [Sangiorgi, Eugenio; Capecchi, Mario R.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA; [Sangiorgi, Eugenio; Capecchi, Mario R.] Univ Utah, Sch Med, Howard Hughes Med Inst, Salt Lake City, UT USA; [Ueno, Hiroo; Weissman, Irving L.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Toda, Shuji; Sugihara, Hajime] Saga Med Sch, Dept Pathol, Saga, Japan; [Fujimoto, Kazuma] Saga Med Sch, Dept Internal Med, Saga, Japan	Stanford University; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Stanford University; Saga University; Saga University	Ootani, A (corresponding author), Stanford Univ, Dept Med, Sch Med, Div Hematol, Stanford, CA 94305 USA.	aootani@stanford.edu; cjkuo@stanford.edu	Sangiorgi, Eugenio/AAP-9836-2020	Sangiorgi, Eugenio/0000-0001-9079-9175; Kuo, Calvin/0000-0002-7427-5985	NATIONAL CANCER INSTITUTE [R01CA086065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085527, R01DK085720, R01DK069989, P30DK056339] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA086065, R01 CA86065-06] Funding Source: Medline; NIDDK NIH HHS [P30 DK056339, R01 DK069989-01, R01 DK069989, U01 DK085527-02, R01 DK085720, R01 DK069989-05, P30 DK56339, U01 DK085527, R01 DK085720-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abud HE, 2005, EXP CELL RES, V303, P252, DOI 10.1016/j.yexcr.2004.10.006; Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; BINGMANN D, 1982, EXP BRAIN RES, V48, P89; Bjerknes M, 2006, METHOD ENZYMOL, V419, P337, DOI 10.1016/S0076-6879(06)19014-X; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Booth C, 1999, EXP CELL RES, V249, P359, DOI 10.1006/excr.1999.4483; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Kaeffer B, 2002, IN VITRO CELL DEV-AN, V38, P123; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Lopez-Diaz L, 2007, DEV BIOL, V309, P298, DOI 10.1016/j.ydbio.2007.07.015; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Ootani A, 2003, AM J PATHOL, V162, P1905, DOI 10.1016/S0002-9440(10)64324-6; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Schonhoff SE, 2004, DEV BIOL, V270, P443, DOI 10.1016/j.ydbio.2004.03.013; Scoville DH, 2008, GASTROENTEROLOGY, V134, P849, DOI 10.1053/j.gastro.2008.01.079; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; Toda S, 2002, BIOCHEM BIOPH RES CO, V294, P906, DOI 10.1016/S0006-291X(02)00561-2; Ueno H, 2006, DEV CELL, V11, P519, DOI 10.1016/j.devcel.2006.08.001; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang JF, 2006, NEW ENGL J MED, V355, P270, DOI 10.1056/NEJMoa054288; WILLIAMS ED, 1992, AM J PATHOL, V141, P773; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	40	567	600	3	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					1	U140		10.1038/nm.1951	http://dx.doi.org/10.1038/nm.1951			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19398967	Green Accepted, Green Submitted			2022-12-27	WOS:000266731600031
J	Machnik, A; Neuhofer, W; Jantsch, J; Dahlmann, A; Tammela, T; Machura, K; Park, JK; Beck, FX; Muller, DN; Derer, W; Goss, J; Ziomber, A; Dietsch, P; Wagner, H; van Rooijen, N; Kurtz, A; Hilgers, KF; Alitalo, K; Eckardt, KU; Luft, FC; Kerjaschki, D; Titze, J				Machnik, Agnes; Neuhofer, Wolfgang; Jantsch, Jonathan; Dahlmann, Anke; Tammela, Tuomas; Machura, Katharina; Park, Joon-Keun; Beck, Franz-Xaver; Mueller, Dominik N.; Derer, Wolfgang; Goss, Jennifer; Ziomber, Agata; Dietsch, Peter; Wagner, Hubertus; van Rooijen, Nico; Kurtz, Armin; Hilgers, Karl F.; Alitalo, Kari; Eckardt, Kai-Uwe; Luft, Friedrich C.; Kerjaschki, Dontscho; Titze, Jens			Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; OSMOTICALLY INACTIVE NA+; TUMOR LYMPHANGIOGENESIS; INTERSTITIAL FLOW; SODIUM-BALANCE; DOCA-SALT; VEGF-C; RATS; HYPERTENSION; MICE	In salt-sensitive hypertension, the accumulation of Na(+) in tissue has been presumed to be accompanied by a commensurate retention of water to maintain the isotonicity of body fluids. We show here that a high-salt diet (HSD) in rats leads to interstitial hypertonic Na(+) accumulation in skin, resulting in increased density and hyperplasia of the lymphcapillary network. The mechanisms underlying these effects on lymphatics involve activation of tonicity-responsive enhancer binding protein (TonEBP) in mononuclear phagocyte system (MPS) cells infiltrating the interstitium of the skin. TonEBP binds the promoter of the gene encoding vascular endothelial growth factor-C (VEGF-C, encoded by Vegfc) and causes VEGF-C secretion by macrophages. MPS cell depletion or VEGF-C trapping by soluble VEGF receptor-3 blocks VEGF-C signaling, augments interstitial hypertonic volume retention, decreases endothelial nitric oxide synthase expression and elevates blood pressure in response to HSD. Our data show that TonEBP-VEGF-C signaling in MPS cells is a major determinant of extracellular volume and blood pressure homeostasis and identify VEGFC as an osmosensitive, hypertonicity-driven gene intimately involved in salt-induced hypertension.	[Machnik, Agnes; Jantsch, Jonathan; Dahlmann, Anke; Goss, Jennifer; Ziomber, Agata; Hilgers, Karl F.; Eckardt, Kai-Uwe; Titze, Jens] Univ Erlangen Nurnberg, D-8520 Erlangen, Germany; [Neuhofer, Wolfgang; Beck, Franz-Xaver] Univ Munich, Dept Physiol, D-8000 Munich, Germany; [Jantsch, Jonathan] Univ Clin Erlangen, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany; [Tammela, Tuomas; Alitalo, Kari] Biomedicum Helsinki, Lab Mol Canc Biol, Helsinki, Finland; [Machura, Katharina; Kurtz, Armin] Univ Regensburg, Inst Physiol, Regensburg, Germany; [Park, Joon-Keun] Hannover Med Sch, Dept Med, Div Nephrol, Hannover, Germany; [Mueller, Dominik N.; Luft, Friedrich C.] Max Delbruck Ctr Mol Med, Berlin, Germany; [Mueller, Dominik N.; Luft, Friedrich C.] Fac Med Charite, Expt & Clin Res Ctr, Berlin, Germany; [Derer, Wolfgang; Luft, Friedrich C.] HELIOS Klinikum Berlin Brandenburg, Berlin, Germany; [Dietsch, Peter] Inst Biochem, Berlin, Germany; [Wagner, Hubertus] Max Rubner Inst, Dept Safety & Qual Meat, Kulmbach, Germany; [van Rooijen, Nico] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Kerjaschki, Dontscho] Med Univ Vienna, Dept Pathol, Vienna, Austria	University of Erlangen Nuremberg; University of Munich; University of Erlangen Nuremberg; University of Helsinki; University of Regensburg; Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Vrije Universiteit Amsterdam; Medical University of Vienna		jtitze@molmed.uni-erlangen.de	Alitalo, Kari K/J-5013-2014; Van Rooijen, Nico/Z-1578-2019; Titze, Jens/GXV-1636-2022; Schröder, Agnes/AHC-9286-2022	Alitalo, Kari K/0000-0002-7331-0902; Luft, Friedrich/0000-0002-8635-1199; Titze, Jens/0000-0001-8463-8404; Muller, Dominik N/0000-0003-3650-5644; /0000-0003-3675-6961	Interdisziplinares Zentrum fur klinische Forschung Erlangen [TP B13]; Bundesministerium fur Bildung und Forschung - Forschung unter Weltraumbedingungen [50WB0620]; Deutsche Forschungsgemeinschaft [Ti345/2]; sixth Framework Integrated Project Lymphangiogenomics [LSGH-2004-503573]; EuReGene	Interdisziplinares Zentrum fur klinische Forschung Erlangen; Bundesministerium fur Bildung und Forschung - Forschung unter Weltraumbedingungen(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); sixth Framework Integrated Project Lymphangiogenomics(European Commission); EuReGene	This work was supported in part by grants from the Interdisziplinares Zentrum fur klinische Forschung Erlangen (TP B13), from the Bundesministerium fur Bildung und Forschung - Forschung unter Weltraumbedingungen (50WB0620), and from the Deutsche Forschungsgemeinschaft (Ti345/2) to J. T., from the sixth Framework Integrated Project Lymphangiogenomics (LSGH-2004-503573) to D. K., and from a Fresenius Nephro-Core Stipend to A. Z. F. C. L. and D. N. M. were supported by EuReGene; D. N. M. is a Helmholtz fellow. We thank N. Rakova for translating Russian articles and E. Prell, M. Klewer and B. Hausknecht for their technical assistance. We thank P. Uhrin (Department of Vascular Biology and Thrombosis Research, Medical University of Vienna) for the Swiss-129Sv mice and H. M. Kwon (Department of Medicine, University of Maryland) for pCMV-Tag2-TonEBP.	Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486; Ahmad S, 2006, CIRC RES, V99, P715, DOI 10.1161/01.RES.0000243989.46006.b9; Boardman KC, 2003, CIRC RES, V92, P801, DOI 10.1161/01.RES.0000065621.69843.49; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fukuda S, 2004, CIRC RES, V95, P100, DOI 10.1161/01.RES.0000133677.77465.38; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Goldman J, 2007, AM J PHYSIOL-HEART C, V292, pH2176, DOI 10.1152/ajpheart.01011.2006; GUYTON AC, 1972, ANN BIOMED ENG, V1, P254, DOI 10.1007/BF02584211; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Heer M, 2000, AM J PHYSIOL-RENAL, V278, pF585, DOI 10.1152/ajprenal.2000.278.4.F585; Jantsch J, 2008, J IMMUNOL METHODS, V337, P71, DOI 10.1016/j.jim.2008.04.004; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kang KT, 2007, HYPERTENSION, V49, P893, DOI 10.1161/01.HYP.0000259669.40991.1e; Karpanen T, 2001, CANCER RES, V61, P1786; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Konovchuk V. N., 1992, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V78, P42; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Leonard AM, 2006, AM J HYPERTENS, V19, P1264, DOI 10.1016/j.amjhyper.2006.05.025; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lohela M, 2008, AM J PATHOL, V173, P1891, DOI 10.2353/ajpath.2008.080378; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Neuhofer W, 2005, ANNU REV PHYSIOL, V67, P531, DOI 10.1146/annurev.physiol.67.031103.154456; Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104; Obst M, 2004, KIDNEY INT, V65, P2268, DOI 10.1111/j.1523-1755.2004.00646.x; Pitts RF, 1974, PHYSL KIDNEY BODY FL, P11; Rutkowski JM, 2006, AM J PHYSIOL-HEART C, V291, pH1402, DOI 10.1152/ajpheart.00038.2006; Schafflhuber M, 2007, AM J PHYSIOL-RENAL, V292, pF1490, DOI 10.1152/ajprenal.00300.2006; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Titze J, 2005, AM J PHYSIOL-RENAL, V289, pF793, DOI 10.1152/ajprenal.00096.2005; Titze J, 2004, AM J PHYSIOL-HEART C, V287, pH203, DOI 10.1152/ajpheart.01237.2003; Titze J, 2003, AM J PHYSIOL-RENAL, V285, pF1108, DOI 10.1152/ajprenal.00200.2003; Titze J, 2002, AM J KIDNEY DIS, V40, P508, DOI 10.1053/ajkd.2002.34908; TOLINS JP, 1994, KIDNEY INT, V46, P230, DOI 10.1038/ki.1994.264; Trzewik J, 2001, FASEB J, V15, P1711, DOI 10.1096/fj.01-0067com; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Ziomber A, 2008, AM J PHYSIOL-RENAL, V295, pF1752, DOI 10.1152/ajprenal.00531.2007	40	666	682	1	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2009	15	5					545	552		10.1038/nm.1960	http://dx.doi.org/10.1038/nm.1960			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19412173				2022-12-27	WOS:000265889300033
J	Binder, NB; Niederreiter, B; Hoffmann, O; Stange, R; Pap, T; Stulnig, TM; Mack, M; Erben, RG; Smolen, JS; Redlich, K				Binder, Nikolaus B.; Niederreiter, Birgit; Hoffmann, Oskar; Stange, Richard; Pap, Thomas; Stulnig, Thomas M.; Mack, Matthias; Erben, Reinhold G.; Smolen, Josef S.; Redlich, Kurt			Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis	NATURE MEDICINE			English	Article							KAPPA-B LIGAND; BONE LOSS; RECEPTOR ACTIVATOR; NECROSIS-FACTOR; EXPRESSION; CELLS; CYTOKINE; HORMONE; MCP-1; DIFFERENTIATION	Understanding the mechanisms of osteoclastogenesis is crucial for developing new drugs to treat diseases associated with bone loss, such as osteoporosis. Here we report that the C-C chemokine receptor-2 (CCR2) is crucially involved in balancing bone mass. CCR2-knockout mice have high bone mass owing to a decrease in number, size and function of osteoclasts. In normal mice, activation of CCR2 in osteoclast progenitor cells results in both nuclear factor-kappa B (NF-kappa B) and extracellular signal-related kinase 1 and 2 (ERK1/2) signaling but not that of p38 mitogen-activated protein kinase or c-Jun N-terminal kinase. The induction of NF-kappa B and ERK1/2 signaling in turn leads to increased surface expression of receptor activator of NF-kappa B (RANK, encoded by Tnfrsf11a), making the progenitor cells more susceptible to RANK ligand-induced osteoclastogenesis. In ovariectomized mice, a model of postmenopausal osteoporosis, CCR2 is upregulated on wild-type preosteoclasts, thus increasing the surface expression of RANK on these cells and their osteoclastogenic potential, whereas CCR2-knockout mice are resistant to ovariectomy-induced bone loss. These data reveal a previously undescribed pathway by which RANK, osteoclasts and bone homeostasis are regulated in health and disease.	[Binder, Nikolaus B.; Niederreiter, Birgit; Smolen, Josef S.; Redlich, Kurt] Med Univ Vienna, Div Rheumatol, Vienna, Austria; [Hoffmann, Oskar] Univ Vienna, Inst Pharmacol & Toxicol, Vienna, Austria; [Stange, Richard; Pap, Thomas] Univ Munster, Inst Expt Musculoskeletal Med, Munster, Germany; [Stange, Richard] Univ Munster, Dept Trauma Hand & Reconstruct Surg, Munster, Germany; [Stulnig, Thomas M.] Med Univ Vienna, Div Endocrinol & Metab, Vienna, Austria; [Mack, Matthias] Univ Regensburg, Div Nephrol, Regensburg, Germany; [Erben, Reinhold G.] Univ Vet Med Vienna, Inst Pathophysiol, Vienna, Austria	Medical University of Vienna; University of Vienna; University of Munster; University of Munster; Medical University of Vienna; University of Regensburg; University of Veterinary Medicine Vienna	Redlich, K (corresponding author), Med Univ Vienna, Div Rheumatol, Vienna, Austria.	kurt.redlich@meduniwien.ac.at	Erben, Reinhold/AAG-8007-2020	Erben, Reinhold/0000-0003-0801-6958; Stange, Richard/0000-0003-0807-3151; Stulnig, Thomas/0000-0003-3300-6161				Arici A, 1999, BIOL REPROD, V61, P85, DOI 10.1095/biolreprod61.1.85; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Breitkreutz I, 2007, BRIT J HAEMATOL, V139, P55, DOI 10.1111/j.1365-2141.2007.06747.x; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choi SJ, 2000, BLOOD, V96, P671; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Hayer S, 2005, J EXP MED, V201, P903, DOI 10.1084/jem.20040852; Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Janis K, 2004, AM J REPROD IMMUNOL, V51, P22, DOI 10.1046/j.8755-8920.2003.00117.x; Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846; Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649; Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200; Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200; Koh KK, 2001, INT J CARDIOL, V81, P43, DOI 10.1016/S0167-5273(01)00527-7; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KRUSE K, 1986, EUR J PEDIATR, V145, P27, DOI 10.1007/BF00441848; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; MANOLAGAS SC, 1992, CALCIFIED TISSUE INT, V50, P199, DOI 10.1007/BF00296282; McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459; Miyamoto Takeshi, 2003, Keio J Med, V52, P1; Owen JL, 2005, CELL IMMUNOL, V235, P122, DOI 10.1016/j.cellimm.2005.08.032; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002-9440(10)63144-6; RUSSELL RGG, 1981, METAB BONE DIS RELAT, V3, P255, DOI 10.1016/0221-8747(81)90041-2; Stepan J J, 2003, Endocr Regul, V37, P225; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; Viedt C, 2002, ARTERIOSCL THROM VAS, V22, P914, DOI 10.1161/01.ATV.0000019009.73586.7F; Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394; Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550; Yamada Y, 2002, GENOMICS, V80, P8, DOI 10.1006/geno.2002.6793; Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019	44	136	144	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					417	424		10.1038/nm.1945	http://dx.doi.org/10.1038/nm.1945			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19330010				2022-12-27	WOS:000264937200029
J	Ishii, K; Fumoto, T; Iwai, K; Takeshita, S; Ito, M; Shimohata, N; Aburatani, H; Taketani, S; Lelliott, CJ; Vidal-Puig, A; Ikeda, K				Ishii, Kiyo-aki; Fumoto, Toshio; Iwai, Kazuhiro; Takeshita, Sunao; Ito, Masako; Shimohata, Nobuyuki; Aburatani, Hiroyuki; Taketani, Shigeru; Lelliott, Christopher J.; Vidal-Puig, Antonio; Ikeda, Kyoji			Coordination of PGC-1 beta and iron uptake in mitochondrial biogenesis and osteoclast activation	NATURE MEDICINE			English	Article							RESPONSIVE ELEMENT; BONE-RESORPTION; CRUCIAL ROLE; TRANSCRIPTION; OSTEOPOROSIS; COACTIVATOR; INSIGHTS; RANKL; PATHOPHYSIOLOGY; DIFFERENTIATION	Osteoclasts are acid-secreting polykaryons that have high energy demands and contain abundant mitochondria. How mitochondrial biogenesis is integrated with osteoclast differentiation is unknown. We found that the transcription of Ppargc1b, which encodes peroxisome proliferator-activated receptor-gamma coactivator 1 beta (PGC-1 beta), was induced during osteoclast differentiation by cAMP response element-binding protein (CREB) as a result of reactive oxygen species. Knockdown of Ppargc1b in vitro inhibited osteoclast differentiation and mitochondria biogenesis, whereas deletion of the Ppargc1b gene in mice resulted in increased bone mass due to impaired osteoclast function. We also observed defects in PGC-1 beta-deficient osteoblasts. Owing to the heightened iron demand in osteoclast development, transferrin receptor 1 (TfR1) expression was induced post-transcriptionally via iron regulatory protein 2. TfR1-mediated iron uptake promoted osteoclast differentiation and bone-resorbing activity, associated with the induction of mitochondrial respiration, production of reactive oxygen species and accelerated Ppargc1b transcription. Iron chelation inhibited osteoclastic bone resorption and protected against bone loss following estrogen deficiency resulting from ovariectomy. These data establish mitochondrial biogenesis orchestrated by PGC-1 beta, coupled with iron uptake through TfR1 and iron supply to mitochondrial respiratory proteins, as a fundamental pathway linked to osteoclast activation and bone metabolism.	[Ishii, Kiyo-aki; Fumoto, Toshio; Takeshita, Sunao; Ikeda, Kyoji] NCGG, Dept Bone & Joint Dis, Aichi 4748522, Japan; [Iwai, Kazuhiro] Osaka Univ, Dept Biochem & Biophys, Grad Sch Med, Suita, Osaka 5650871, Japan; [Iwai, Kazuhiro] Osaka Univ, Cell Biol & Metab Grp, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Iwai, Kazuhiro; Shimohata, Nobuyuki] Osaka City Univ, Dept Mol Cell Biol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; [Iwai, Kazuhiro] Japan Sci Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; [Ito, Masako] Nagasaki Univ, Sch Med, Dept Radiol, Nagasaki 8528501, Japan; [Aburatani, Hiroyuki] Univ Tokyo, RCAST, Genomesci Div, Meguro Ku, Tokyo 1538904, Japan; [Taketani, Shigeru] Kyoto Inst Technol, Dept Biotechnol, Sakyo Ku, Kyoto 6068585, Japan; [Lelliott, Christopher J.] AstraZeneca R&D, Dept Biosci, SE-43183 Molndal, Sweden; [Vidal-Puig, Antonio] Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 0QQ, England	Osaka University; Osaka University; Osaka Metropolitan University; Japan Science & Technology Agency (JST); Nagasaki University; University of Tokyo; Kyoto Institute of Technology; AstraZeneca; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Ikeda, K (corresponding author), NCGG, Dept Bone & Joint Dis, 36-3 Gengo, Aichi 4748522, Japan.	kikeda@nils.go.jp	Lelliott, Christopher J/G-4620-2011; fumoto, toshio/F-6345-2015; IWAI, KAZUHIRO/GSN-7385-2022	Lelliott, Christopher J/0000-0001-8087-4530; fumoto, toshio/0000-0002-9273-8939; Iwai, Kazuhiro/0000-0001-5620-5951; Ishii, Kiyo-aki/0000-0001-9846-5575; Vidal-Puig, Antonio/0000-0003-4220-9577	British Heart Foundation Funding Source: Medline; Medical Research Council [G0600717, G0802051] Funding Source: Medline; MRC [G0600717, G0802051] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Allerson CR, 1999, J BIOL CHEM, V274, P26439, DOI 10.1074/jbc.274.37.26439; Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Ashizuka M, 2002, MOL CELL BIOL, V22, P6375, DOI 10.1128/MCB.22.18.6375-6383.2002; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; Borgna-Pignatti C, 2006, HAEMATOLOGICA, V91, P1159; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brown D, 1996, J EXP BIOL, V199, P2345; Dunn LL, 2007, TRENDS CELL BIOL, V17, P93, DOI 10.1016/j.tcb.2006.12.003; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; Ito M, 2005, J BONE MINER RES, V20, P1828, DOI 10.1359/JBMR.050610; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859; Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood-2004-09-3662; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Morabito N, 2004, J BONE MINER RES, V19, P722, DOI 10.1359/JBMR.040113; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; SASSA S, 1977, J BIOL CHEM, V252, P2428; Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515; Sonoda J, 2007, P NATL ACAD SCI USA, V104, P5223, DOI 10.1073/pnas.0611623104; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200; Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365-2141.2004.05143.x; Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593	39	241	260	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					259	266		10.1038/nm.1910	http://dx.doi.org/10.1038/nm.1910			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19252502				2022-12-27	WOS:000263914000025
J	Jagannath, C; Lindsey, DR; Dhandayuthapani, S; Xu, Y; Hunter, RL; Eissa, NT				Jagannath, Chinnaswamy; Lindsey, Devin R.; Dhandayuthapani, Subramanian; Xu, Yi; Hunter, Robert L., Jr.; Eissa, N. Tony			Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells	NATURE MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS H37RV; CLASS-II MOLECULES; ANTIGEN PRESENTATION; PHAGOSOME MATURATION; PROTEIN-DEGRADATION; ADAPTIVE IMMUNITY; HUMAN MACROPHAGES; INNATE IMMUNITY; EXPRESSION; INFECTION	The variable efficacy of Bacille Calmette Guerin ( BCG) vaccination against tuberculosis has prompted efforts to improve the vaccine. In this study, we used autophagy to enhance vaccine efficacy against tuberculosis in a mouse model. We examined the effect of autophagy on the processing of the immunodominant mycobacterial antigen Ag85B by antigen presenting cells (APCs), macrophages and dendritic cells (DCs). We found that rapamycin-induced autophagy enhanced Ag85B presentation by APCs infected with wild-type Mycobacterium tuberculosis H37Rv, H37Rv-derived Delta fbpA attenuated candidate vaccine or BCG. Furthermore, rapamycin enhanced localization of mycobacteria with autophagosomes and lysosomes. Rapamycin-enhanced antigen presentation was attenuated when autophagy was suppressed by 3-methyladenine or by small interfering RNA against beclin-1. Notably, mice immunized with rapamycin-treated DCs infected with either DfbpA or BCG showed enhanced T helper type 1-mediated protection when challenged with virulent Mycobacterium tuberculosis. Finally, overexpression of Ag85B in BCG induced autophagy in APCs and enhanced immunogenicity in mice, suggesting that vaccine efficacy can be enhanced by augmenting autophagy-mediated antigen presentation.	[Jagannath, Chinnaswamy; Lindsey, Devin R.; Hunter, Robert L., Jr.] Univ Texas Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Dhandayuthapani, Subramanian] Univ Texas Hlth Sci Ctr San Antonio, Reg Acad Hlth Ctr, Edinburg, TX 78541 USA; [Dhandayuthapani, Subramanian] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, Edinburg, TX 78541 USA; [Xu, Yi; Eissa, N. Tony] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Jagannath, C (corresponding author), Univ Texas Hlth Sci Ctr, Dept Pathol & Lab Med, 6431 Fannin, Houston, TX 77030 USA.	Chinnaswamy.Jagannath@uth.tmc.edu			US National Institutes of Health National Institute of Allergy and Infectious Diseases [AI49534]; National Heart, Lung, and Blood Institute [HL080205]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, R01AI049534] Funding Source: NIH RePORTER	US National Institutes of Health National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by US National Institutes of Health National Institute of Allergy and Infectious Diseases grant AI49534 (C.J.) and National Heart, Lung, and Blood Institute grant HL080205 (N.T.E.). We are grateful to L.Y. Armitige (University of Texas Health Sciences Center-Houston) for the fbpA and fbpB mutant strains, K. Rock (University of Massachusetts-Worcester) for the BMA.A3 cell line and C. Harding and H. Boom (Case Western Reserve University) for BB7 T cells. Recombinant ESAT-6 was kindly provided by A. Arora (Central Drug Research Institute, India), and TD17 mAb was a gift from K. Huygen (Pasteur Institute). Mycobacterial vector pMV206 was kindly provided by W. Jacobs (Albert Einstein Medical College).	AM AO, 2005, AUTOPHAGY, V1, P53; Amano A, 2006, J BIOCHEM, V140, P161, DOI 10.1093/jb/mvj162; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; Copenhaver RH, 2004, INFECT IMMUN, V72, P7084, DOI 10.1128/IAI.72.12.7084-7095.2004; DEAN RT, 1977, ACTA BIOL MED GER, V36, P1815; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; GRIFFIN JP, 1994, INFECT IMMUN, V62, P1683, DOI 10.1128/IAI.62.5.1683-1690.1994; Gupta UD, 2007, VACCINE, V25, P3742, DOI 10.1016/j.vaccine.2007.01.112; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Harth G, 1996, INFECT IMMUN, V64, P3038, DOI 10.1128/IAI.64.8.3038-3047.1996; Hmama Z, 1998, J IMMUNOL, V161, P4882; Horwitz MA, 2006, VACCINE, V24, P1593, DOI 10.1016/j.vaccine.2005.10.002; Katti MK, 2008, CELL MICROBIOL, V10, P1286, DOI 10.1111/j.1462-5822.2008.01126.x; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; LEVINE TP, 1991, CRIT REV BIOCHEM MOL, V26, P439, DOI 10.3109/10409239109086790; Mazzaccaro RJ, 1998, ADV EXP MED BIOL, V452, P85; Medd PG, 2000, SEMIN CELL DEV BIOL, V11, P203, DOI 10.1006/scdb.2000.0162; Miller BH, 2004, INFECT IMMUN, V72, P2872, DOI 10.1128/IAI.72.5.2872-2878.2004; Moulton RA, 2007, J LEUKOCYTE BIOL, V82, P956, DOI 10.1189/jlb.0206119; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Noss EH, 2000, CELL IMMUNOL, V201, P63, DOI 10.1006/cimm.2000.1633; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; PANCHOLI P, 1993, SCIENCE, V260, P984, DOI 10.1126/science.8098550; Ramachandra L, 2001, J EXP MED, V194, P1421, DOI 10.1084/jem.194.10.1421; Rohde K, 2007, IMMUNOL REV, V219, P37, DOI 10.1111/j.1600-065X.2007.00547.x; Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004; Schmid D, 2007, AUTOPHAGY, V3, P133, DOI 10.4161/auto.3591; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Singh CR, 2006, J IMMUNOL, V177, P3250, DOI 10.4049/jimmunol.177.5.3250; Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419; Soualhine H, 2007, J IMMUNOL, V179, P5137, DOI 10.4049/jimmunol.179.8.5137; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Ullrich HJ, 2000, J IMMUNOL, V165, P6073, DOI 10.4049/jimmunol.165.11.6073; Vergne I, 2003, TRAFFIC, V4, P600, DOI 10.1034/j.1600-0854.2003.00120.x; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022	36	362	385	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2009	15	3					267	276		10.1038/nm.1928	http://dx.doi.org/10.1038/nm.1928			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19252503				2022-12-27	WOS:000263914000026
J	Goldstein, JL				Goldstein, Joseph L.			Exuberant unpredictability: sine qua non for priceless and prizeworthy biomedical research FOREWORD	NATURE MEDICINE			English	Editorial Material																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1029	1032		10.1038/nm1008-1029	http://dx.doi.org/10.1038/nm1008-1029			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841142				2022-12-27	WOS:000259892300029
J	Varela, I; Pereira, S; Ugalde, AP; Navarro, CL; Suarez, MF; Cau, P; Cadinanos, J; Osorio, FG; Foray, N; Cobo, J; de Carlos, F; Levy, N; Freije, JMP; Lopez-Otin, C				Varela, Ignacio; Pereira, Sandrine; Ugalde, Alejandro P.; Navarro, Claire L.; Suarez, Maria F.; Cau, Pierre; Cadinanos, Juan; Osorio, Fernando G.; Foray, Nicolas; Cobo, Juan; de Carlos, Felix; Levy, Nicolas; Freije, Jose M. P.; Lopez-Otin, Carlos			Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging	NATURE MEDICINE			English	Article							GILFORD-PROGERIA-SYNDROME; PRELAMIN-A; INHIBITING FARNESYLATION; TRANSFERASE INHIBITORS; PROTEIN-PRENYLATION; LAMIN-A; MICE; DISEASE; DEFICIENT; DEFECTS	Several human progerias, including Hutchinson-Gilford progeria syndrome (HGPS), are caused by the accumulation at the nuclear envelope of farnesylated forms of truncated prelamin A, a protein that is also altered during normal aging(1,2). Previous studies in cells from individuals with HGPS have shown that farnesyltransferase inhibitors (FTIs) improve nuclear abnormalities associated with prelamin A accumulation, suggesting that these compounds could represent a therapeutic approach for this devastating progeroid syndrome(3). We show herein that both prelamin A and its truncated form progerin/LA Delta 50 undergo alternative prenylation by geranylgeranyltransferase in the setting of farnesyltransferase inhibition, which could explain the low efficiency of FTIs in ameliorating the phenotypes of progeroid mouse models. We also show that a combination of statins and aminobisphosphonates efficiently inhibits both farnesylation and geranylgeranylation of progerin and prelamin A and markedly improves the aging-like phenotypes of mice deficient in the metalloproteinase Zmpste24, including growth retardation, loss of weight, lipodystrophy, hair loss and bone defects. Likewise, the longevity of these mice is substantially extended. These findings open a new therapeutic approach for human progeroid syndromes associated with nuclear-envelope abnormalities.	[Varela, Ignacio; Ugalde, Alejandro P.; Suarez, Maria F.; Cadinanos, Juan; Osorio, Fernando G.; Freije, Jose M. P.; Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; [Pereira, Sandrine; Navarro, Claire L.; Cau, Pierre; Levy, Nicolas] Univ Aix Marseille 2, Fac Med, INSERM, UMR S Genet Med & Geom Fonctionnelle 910, F-13385 Marseille 05, France; [Foray, Nicolas] INSERM, ID17, European Synchrotron Res Facil, U647, F-38043 Grenoble, France; [Cobo, Juan; de Carlos, Felix] Univ Oviedo, Inst Asturiano Odontol, E-33006 Oviedo, Spain; [Cobo, Juan; de Carlos, Felix] Univ Oviedo, Dept Cirugia & Especialidades Med Quirurg, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oviedo; University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, Calle Fernando Bongera S-N, E-33006 Oviedo, Spain.	clo@uniovi.es	LEVY, Nicolas/J-1632-2014; Navarro, Claire/V-8774-2017; Foray, Nicolas/Q-2363-2019; Cau, Pierre/M-3541-2016; Varela, Ignacio/G-1699-2016; Freije, José M.P./A-6535-2008; Pineiro-Ugalde, Alejandro/AAB-5229-2020; Varela, Ignacio/AAA-7680-2021; López-Otín, Carlos/AAB-2106-2020; Suárez, María Fernanda Valencia/F-8200-2019; Foray, Nicolas/I-4755-2018	LEVY, Nicolas/0000-0001-5171-6365; Navarro, Claire/0000-0001-9490-2643; Foray, Nicolas/0000-0002-1282-1303; Varela, Ignacio/0000-0002-0969-506X; Freije, José M.P./0000-0002-4688-8266; Pineiro-Ugalde, Alejandro/0000-0003-2522-0627; Varela, Ignacio/0000-0002-0969-506X; López-Otín, Carlos/0000-0001-6964-1904; Suárez, María Fernanda Valencia/0000-0001-8987-8431; Foray, Nicolas/0000-0002-1282-1303; Cadinanos, Juan/0000-0001-7561-7759				BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; Cadinanos J, 2005, CELL CYCLE, V4, P1732, DOI 10.4161/cc.4.12.2202; Capell BC, 2005, P NATL ACAD SCI USA, V102, P12879, DOI 10.1073/pnas.0506001102; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Espada J, 2008, J CELL BIOL, V181, P27, DOI 10.1083/jcb.200801096; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Glynn MW, 2005, HUM MOL GENET, V14, P2959, DOI 10.1093/hmg/ddi326; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hennekam RCM, 2006, AM J MED GENET A, V140A, P2603, DOI 10.1002/ajmg.a.31346; Issat T, 2007, INT J ONCOL, V30, P1413; Kipling D, 2004, SCIENCE, V305, P1426, DOI 10.1126/science.1102587; Konstantinopoulos PA, 2007, TRENDS PHARMACOL SCI, V28, P6, DOI 10.1016/j.tips.2006.11.005; Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266; Liu YY, 2006, J CELL SCI, V119, P4644, DOI 10.1242/jcs.03263; Mallampalli MP, 2005, P NATL ACAD SCI USA, V102, P14416, DOI 10.1073/pnas.0503712102; Navarro CL, 2006, HUM MOL GENET, V15, pR151, DOI 10.1093/hmg/ddl214; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; Ramirez CL, 2007, CELL MOL LIFE SCI, V64, P155, DOI 10.1007/s00018-006-6349-3; Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078-0432.CCR-06-0843; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Scaffidi P, 2006, SCIENCE, V312, P1059, DOI 10.1126/science.1127168; Schmidmaier R, 2006, ANTI-CANCER DRUG, V17, P621, DOI 10.1097/01.cad.0000215058.85813.02; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Toth JI, 2005, P NATL ACAD SCI USA, V102, P12873, DOI 10.1073/pnas.0505767102; Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yamagata T, 2007, RHEUMATOL INT, V27, P631, DOI 10.1007/s00296-006-0270-9; Yang SH, 2006, J CLIN INVEST, V116, P2115, DOI 10.1172/JCI28968; Young SG, 2006, J BIOL CHEM, V281, P39741, DOI 10.1074/jbc.R600033200	30	290	309	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2008	14	7					767	772		10.1038/nm1786	http://dx.doi.org/10.1038/nm1786			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18587406				2022-12-27	WOS:000257452700025
J	Rittirsch, D; Flierl, MA; Nadeau, BA; Day, DE; Huber-Lang, M; Mackay, CR; Zetoune, FS; Gerard, NP; Cianflone, K; Kohl, J; Gerard, C; Sarma, JV; Award, P				Rittirsch, Daniel; Flierl, Michael A.; Nadeau, Brian A.; Day, Danielle E.; Huber-Lang, Markus; Mackay, Charles R.; Zetoune, Firas S.; Gerard, Norma P.; Cianflone, Katherine; Koehl, Joerg; Gerard, Craig; Sarma, J. Vidya; Award, Peter			Functional roles for C5a receptors in sepsis	NATURE MEDICINE			English	Article							ACYLATION-STIMULATING PROTEIN; MOBILITY GROUP BOX-1; IN-VIVO; CHEMOATTRACTANT RECEPTOR; CHROMATIN PROTEIN; IMMUNE-RESPONSES; IMPROVE SURVIVAL; TNF-ALPHA; C5L2; ANAPHYLATOXIN	The function of the C5a receptors, C5ar ( encoded by C5ar) and C512 ( encoded by Gpr77), especially of C512, which was originally termed a 'default receptor', remains a controversial topic. Here we investigated the role of each receptor in the setting of cecal ligation and puncture-induced sepsis by using antibody-induced blockade of C5a receptors and knockout mice. In 'mid-grade' sepsis ( 30-40% survival), blockade or absence of either C5ar or C512 greatly improved survival and attenuated the buildup of proinflammatory mediators in plasma. In vivo appearance or in vitro release of high mobility group box 1 protein ( HMGB1) required C512 but not C5ar. In 'high-grade' sepsis ( 100% lethality), the only protective condition was the combined blockade of C512 and C5ar. These data suggest that C5ar and C512 contribute synergistically to the harmful consequences in sepsis and that C512 is required for the release of HMGB1. Thus, contrary to earlier speculation, C512 is a functional receptor rather than merely a default receptor.	[Rittirsch, Daniel; Flierl, Michael A.; Nadeau, Brian A.; Day, Danielle E.; Zetoune, Firas S.; Sarma, J. Vidya; Award, Peter] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Huber-Lang, Markus] Univ Hosp, Dept Traumatol Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Mackay, Charles R.] St Vincents Hosp, Garvan Inst Med Res, Immunol & Inflammat Dept, Darlinghurst, NSW 2010, Australia; [Gerard, Norma P.; Gerard, Craig] Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat,Pulm Div, Boston, MA 02115 USA; [Gerard, Norma P.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Cianflone, Katherine] Univ Laval, Hop Laval, Ctr Rech, Ste Foy, PQ G1V 4G5, Canada; [Koehl, Joerg] Cincinnati Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA; [Koehl, Joerg] Med Univ Lubeck, Inst Systemat Inflammat Res, D-23538 Lubeck, Germany	University of Michigan System; University of Michigan; Ulm University; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Laval University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Lubeck	Award, P (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	ward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020; Koehl, Joerg/C-8531-2011; Mackay, Charles R/A-9673-2008	Koehl, Joerg/0000-0003-1121-3178; Mackay, Charles R/0000-0002-6338-7340; Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069511, P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R01GM029507, R37GM029507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31963, R01 HL069511, P01 HL031963-250001, HL-69511, P01 HL031963] Funding Source: Medline; NIAID NIH HHS [AI-057839, R01 AI057839] Funding Source: Medline; NIGMS NIH HHS [R01 GM061656, R01 GM061656-07, R01 GM029507, R37 GM029507, GM-61656, R01 GM029507-27, GM-29507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baelder R, 2005, J IMMUNOL, V174, P783, DOI 10.4049/jimmunol.174.2.783; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; Chen NJ, 2007, NATURE, V446, P203, DOI 10.1038/nature05559; Czermak BJ, 1999, J IMMUNOL, V162, P2321; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gavrilyuk V, 2005, J NEUROCHEM, V92, P1140, DOI 10.1111/j.1471-4159.2004.02942.x; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Godau J, 2004, J IMMUNOL, V173, P3437, DOI 10.4049/jimmunol.173.5.3437; Hawlisch H, 2006, MOL IMMUNOL, V43, P13, DOI 10.1016/j.molimm.2005.06.028; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Johswich K, 2007, ADV EXP MED BIOL, V598, P159; Johswich K, 2006, J BIOL CHEM, V281, P39088, DOI 10.1074/jbc.M609734200; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Kim JY, 2005, AM J PHYSIOL-LUNG C, V288, pL958, DOI 10.1152/ajplung.00359.2004; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Koleva M, 2002, GASTROENTEROLOGY, V122, P697, DOI 10.1053/gast.2002.31883; Lee H, 2006, NAT BIOTECHNOL, V24, P1279, DOI 10.1038/nbt1248; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Suda K, 2006, WORLD J SURG, V30, P1755, DOI 10.1007/s00268-005-0369-2; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yamada S, 2003, CLIN CHEM, V49, P1535, DOI 10.1373/49.9.1535; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636	38	290	317	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2008	14	5					551	557		10.1038/nm1753	http://dx.doi.org/10.1038/nm1753			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18454156	Green Accepted			2022-12-27	WOS:000255681800036
J	Niranjan, T; Bielesz, B; Gruenwald, A; Ponda, MP; Kopp, JB; Thomas, DB; Susztak, K				Niranjan, Thiruvur; Bielesz, Bernhard; Gruenwald, Antje; Ponda, Manish P.; Kopp, Jeffrey B.; Thomas, David B.; Susztak, Katalin			The Notch pathway in podocytes plays a role in the development of glomerular disease	NATURE MEDICINE			English	Article							DIABETIC-NEPHROPATHY; TGF-BETA; GROWTH ARREST; TRANSGENIC MICE; RENAL-DISEASE; RBP-J; EXPRESSION; APOPTOSIS; INHIBITION; PROTEIN	Albuminuria associated with sclerosis of the glomerulus leads to a progressive decline in renal function affecting millions of people. Here we report that activation of the Notch pathway, which is critical in glomerular patterning, contributes to the development of glomerular disease. Expression of the intracellular domain of Notch1 (ICN1) was increased in glomerular epithelial cells in diabetic nephropathy and in focal segmental glomerulosclerosis. Conditional re-expression of ICN1 in vivo exclusively in podocytes caused proteinuria and glomerulosclerosis. In vitro and in vivo studies showed that ICN1 induced apoptosis of podocytes through the activation of p53. Genetic deletion of a Notch transcriptional partner (Rbpj) specifically in podocytes or pharmacological inhibition of the Notch pathway (with a gamma-secretase inhibitor) protected rats with proteinuric kidney diseases. Collectively, our observations suggest that Notch activation in mature podocytes is a new mechanism in the pathogenesis of glomerular disease and thus could represent a new therapeutic target.	[Niranjan, Thiruvur; Bielesz, Bernhard; Gruenwald, Antje; Ponda, Manish P.; Susztak, Katalin] Albert Einstein Coll Med, Dept Med, Div Nephrol, Bronx, NY 10461 USA; [Kopp, Jeffrey B.] NIDDK, Kidney Dis Sect, NIH, Bethesda, MD 20892 USA; [Thomas, David B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yeshiva University; Albert Einstein College of Medicine	Susztak, K (corresponding author), Albert Einstein Coll Med, Dept Med, Div Nephrol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ksusztak@aecom.yu.edu	Susztak, Katalin/ABE-7474-2021; Bielesz, Bernhard/AAQ-2683-2021; Kopp, Jeffrey B/O-2681-2015	Susztak, Katalin/0000-0002-1005-3726; Bielesz, Bernhard/0000-0002-4491-0562; Kopp, Jeffrey B/0000-0001-9052-186X	NIDDK NIH HHS [1R01DK076077, R01 DK076077-02, R01 DK076077-01A1, R01 DK076077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043308, R01DK076077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2003, Am J Kidney Dis, V42, P1; Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2009070721, 10.1681/ASN.2004080648]; Chen LH, 2005, AM J PHYSIOL-RENAL, V288, pF939, DOI 10.1152/ajprenal.00369.2004; Cheng HT, 2005, KIDNEY INT, V68, P1951, DOI 10.1111/j.1523-1755.2005.00627.x; Cheng HT, 2007, DEVELOPMENT, V134, P801, DOI 10.1242/dev.02773; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Hostetter TH, 2001, NEW ENGL J MED, V345, P910, DOI 10.1056/NEJM200109203451209; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kato H, 1997, DEVELOPMENT, V124, P4133; Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083; Langham RG, 2002, DIABETOLOGIA, V45, P1572, DOI 10.1007/s00125-002-0946-y; Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164; Morrissey J, 2002, J AM SOC NEPHROL, V13, pS14; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Mundel P, 2001, Adv Nephrol Necker Hosp, V31, P235; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; OKA C, 1995, DEVELOPMENT, V121, P3291; Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163; Piscione TD, 2004, GENE EXPR PATTERNS, V4, P707, DOI 10.1016/j.modgep.2004.04.007; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shigehara T, 2003, J AM SOC NEPHROL, V14, P1998, DOI 10.1681/ASN.V1481998; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Stanger BZ, 2005, P NATL ACAD SCI USA, V102, P12443, DOI 10.1073/pnas.0505690102; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894; Susztak K, 2003, J AM SOC NEPHROL, V14, pS271, DOI 10.1097/01.ASN.0000078035.81397.8A; Szabo C, 2006, DIABETES, V55, P3004, DOI 10.2337/db06-0147; Takemoto M, 2006, EMBO J, V25, P1160, DOI 10.1038/sj.emboj.7601014; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vooijs M, 2007, DEVELOPMENT, V134, P535, DOI 10.1242/dev.02733; Wada T, 2005, J AM SOC NEPHROL, V16, P2615, DOI 10.1681/ASN.2005020142; Walsh DW, 2008, BBA-MOL BASIS DIS, V1782, P10, DOI 10.1016/j.bbadis.2007.09.005; Wang P, 2003, DEVELOPMENT, V130, P5019, DOI 10.1242/dev.00682; Wolf G, 2005, DIABETES, V54, P1626, DOI 10.2337/diabetes.54.6.1626; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	46	303	348	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2008	14	3					290	298		10.1038/nm1731	http://dx.doi.org/10.1038/nm1731			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18311147				2022-12-27	WOS:000253815700035
J	Stromnes, IM; Cerretti, LM; Liggitt, D; Harris, RA; Goverman, JM				Stromnes, Ingunn M.; Cerretti, Lauren M.; Liggitt, Denny; Harris, Robert A.; Goverman, Joan M.			Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells	NATURE MEDICINE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CD4 T-CELLS; MULTIPLE-SCLEROSIS; IFN-GAMMA; INTERFERON-GAMMA; MOUSE STRAINS; FAS LIGAND; INDUCTION; EXPRESSION	Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous system (CNS) characterized by a wide range of clinical signs(1). The location of lesions in the CNS is variable and is a crucial determinant of clinical outcome. Multiple sclerosis is believed to be mediated by myelin-specific T cells, but the mechanisms that determine where T cells initiate inflammation are unknown. Differences in lesion distribution have been linked to the HLA complex, suggesting that T cell specificity influences sites of inflammation(2). We demonstrate that T cells that are specific for different myelin epitopes generate populations characterized by different T helper type 17 (T(H)17) to T helper type 1 (T(H)1) ratios depending on the functional avidity of interactions between TCR and peptide-MHC complexes. Notably, the T(H)17: T(H)1 ratio of infiltrating T cells determines where inflammation occurs in the CNS. Myelin-specific T cells infiltrate the meninges throughout the CNS, regardless of the T(H)17: T(H)1 ratio. However, T cell infiltration and inflammation in the brain parenchyma occurs only when T(H)17 cells outnumber T(H)1 cells and trigger a disproportionate increase in interleukin-17 expression in the brain. In contrast, T cells showing a wide range of T(H)17: T(H)1 ratios induce spinal cord parenchymal inflammation. These findings reveal critical differences in the regulation of inflammation in the brain and spinal cord.	[Stromnes, Ingunn M.; Cerretti, Lauren M.; Goverman, Joan M.] Dept Immunol, Seattle, WA 98195 USA; [Liggitt, Denny] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; [Harris, Robert A.] Karolinska Inst, Dept Clin Neurosci, Appl Immunol Grp, S-17176 Stockholm, Sweden	University of Washington; University of Washington Seattle; Karolinska Institutet	Goverman, JM (corresponding author), Dept Immunol, Box 357650,HSC H474B,1959 NE Pacific St, Seattle, WA 98195 USA.	goverman@u.washington.edu	Harris, Robert A./I-6234-2019	Harris, Robert A./0000-0003-4990-509X; Goverman, Joan/0000-0002-7361-9424	NCI NIH HHS [T32-CA009537, T32 CA009537] Funding Source: Medline; NIAID NIH HHS [R01 AI072737-11, AI072737, R01 AI072737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdul-Majid KB, 2000, J NEUROIMMUNOL, V111, P23, DOI 10.1016/S0165-5728(00)00360-X; Abromson-Leeman S, 2004, AM J PATHOL, V165, P1519, DOI 10.1016/S0002-9440(10)63410-4; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Badie B, 2000, EXP NEUROL, V162, P290, DOI 10.1006/exnr.1999.7345; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; Brabb T, 2000, J EXP MED, V192, P871, DOI 10.1084/jem.192.6.871; Cheng XD, 2007, J NEUROIMMUNOL, V185, P75, DOI 10.1016/j.jneuroim.2007.01.012; Cruz A, 2006, J IMMUNOL, V177, P1416, DOI 10.4049/jimmunol.177.3.1416; Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268; Fukazawa T, 2000, TISSUE ANTIGENS, V55, P199, DOI 10.1034/j.1399-0039.2000.550302.x; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Kjellen P, 2001, J NEUROIMMUNOL, V120, P25, DOI 10.1016/S0165-5728(01)00407-6; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Muhl H, 2003, INT IMMUNOPHARMACOL, V3, P1247, DOI 10.1016/S1567-5769(03)00131-0; Muller DM, 2000, ACTA NEUROPATHOL, V100, P174, DOI 10.1007/s004019900163; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Raine C.S., 1997, MULTIPLE SCLEROSIS C, P243; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; Stromnes IM, 2006, NAT PROTOC, V1, P1810, DOI 10.1038/nprot.2006.285; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Toft-Hansen H, 2004, J IMMUNOL, V173, P5209, DOI 10.4049/jimmunol.173.8.5209; Tsunoda I, 2000, BRAIN PATHOL, V10, P402; van der Veen RC, 2001, INT IMMUNOPHARMACOL, V1, P1491, DOI 10.1016/S1567-5769(01)00093-5; Weissert R, 2001, J IMMUNOL, V166, P7588, DOI 10.4049/jimmunol.166.12.7588; Wensky AK, 2005, J IMMUNOL, V174, P1416, DOI 10.4049/jimmunol.174.3.1416; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	30	458	466	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					337	342		10.1038/nm1715	http://dx.doi.org/10.1038/nm1715			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18278054	Green Accepted			2022-12-27	WOS:000253815700041
J	Buckanovich, RJ; Facciabene, A; Kim, S; Benencia, F; Sasaroli, D; Balint, K; Katsaros, D; O'Brien-Jenkins, A; Gimotty, PA; Coukos, G				Buckanovich, Ronald J.; Facciabene, Andrea; Kim, Sarah; Benencia, Fabian; Sasaroli, Dimitra; Balint, Klara; Katsaros, Dionysios; O'Brien-Jenkins, Anne; Gimotty, Phyllis A.; Coukos, George			Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; EPITHELIAL OVARIAN-CANCER; NF-KAPPA-B; LYMPHOCYTE ACCUMULATION; LEUKOCYTE ADHESION; VASCULAR FUNCTION; EMERGING ROLE; EXPRESSION; ANTAGONISTS; IMMUNOTHERAPY	In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ETBR) was associated with the absence of TILs and short patient survival time. The ETBR inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ETBR neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans.	[Buckanovich, Ronald J.; Facciabene, Andrea; Kim, Sarah; Benencia, Fabian; Sasaroli, Dimitra; Balint, Klara; O'Brien-Jenkins, Anne; Gimotty, Phyllis A.; Coukos, George] Univ Penn, Ctr Res Ovarian Canc Early Detect & Cure, Philadelphia, PA 19104 USA; [Buckanovich, Ronald J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Benencia, Fabian; Coukos, George] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Sasaroli, Dimitra] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Gimotty, Phyllis A.] Democritus Univ Thrace, Dept Mol Biol & Genet, Alexandroupolis 68100, Greece; [Katsaros, Dionysios] Univ Turin, Dept Obstet & Gynecol, I-10126 Turin, Italy	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Democritus University of Thrace; University of Turin	Coukos, G (corresponding author), Univ Penn, Ctr Res Ovarian Canc Early Detect & Cure, Philadelphia, PA 19104 USA.	gcks@mail.med.upenn.edu	Benencia, Fabian/AAH-1613-2020; Coukos, George/ABG-7389-2020; Balint, Klara/ABB-8816-2021; Gimotty, Phyllis/GWZ-4136-2022	Benencia, Fabian/0000-0003-3049-6150; Gimotty, Phyllis/0000-0002-3850-9799; Coukos, George/0000-0001-8813-7367	FIC NIH HHS [D43-TW00671] Funding Source: Medline; NCI NIH HHS [P50-CA083638, R01-CA098951, R01-CA112162] Funding Source: Medline; NICHD NIH HHS [K12-HD43459] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD043459] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA112162, R01CA098951] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baatz H, 2001, INFLAMM RES, V50, P534, DOI 10.1007/PL00000231; Bagnall AJ, 2006, HYPERTENSION, V48, P286, DOI 10.1161/01.HYP.0000229907.58470.4c; Bagnato A, 2005, ENDOCR-RELAT CANCER, V12, P761, DOI 10.1677/erc.1.01077; Bouzin C, 2007, J IMMUNOL, V178, P1505, DOI 10.4049/jimmunol.178.3.1505; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Buckanovich RJ, 2006, CANCER BIOL THER, V5, P635, DOI 10.4161/cbt.5.6.2676; Cardillo C, 1999, HYPERTENSION, V33, P753, DOI 10.1161/01.HYP.33.2.753; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Courreges MC, 2006, CANCER GENE THER, V13, P182, DOI 10.1038/sj.cgt.7700888; Cowburn PJ, 2005, EUR J HEART FAIL, V7, P37, DOI 10.1016/j.ejheart.2004.08.001; D'Orleans-Juste P, 2002, PHARMACOL THERAPEUT, V95, P221, DOI 10.1016/S0163-7258(02)00235-8; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Feuerer M, 2006, J IMMUNOL, V176, P2857, DOI 10.4049/jimmunol.176.5.2857; Fukami T, 1996, J MED CHEM, V39, P2313, DOI 10.1021/jm9600914; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; Grimshaw MJ, 2004, CANCER RES, V64, P2461, DOI 10.1158/0008-5472.CAN-03-1069; Halcox JPJ, 2007, HYPERTENSION, V49, P1134, DOI 10.1161/HYPERTENSIONAHA.106.083303; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hodi FS, 2006, ADV IMMUNOL, V90, P341, DOI 10.1016/S0065-2776(06)90009-1; Huddleston HG, 2005, GYNECOL ONCOL, V96, P77, DOI 10.1016/j.ygyno.2004.08.047; Iqbal J, 2005, MINI-REV MED CHEM, V5, P381, DOI 10.2174/1389557053544010; Kelleher ZT, 2007, J BIOL CHEM, V282, P30667, DOI 10.1074/jbc.M705929200; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Kubes P, 2000, GUT, V47, P6, DOI 10.1136/gut.47.1.6; Kuhlmann A, 2005, CORNEA, V24, P837, DOI 10.1097/01.ico.0000157400.81408.2b; Lelamali K, 2001, J CELL PHYSIOL, V188, P337, DOI 10.1002/jcp.1128; Levin ER, 1996, AM J NEPHROL, V16, P246, DOI 10.1159/000169004; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Marasciulo FL, 2006, CURR MED CHEM, V13, P1655, DOI 10.2174/092986706777441968; Morris CD, 2005, BRIT J CANCER, V92, P2148, DOI 10.1038/sj.bjc.6602676; Motte S, 2006, PHARMACOL THERAPEUT, V110, P386, DOI 10.1016/j.pharmthera.2005.08.012; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Ng QS, 2007, LANCET ONCOL, V8, P111, DOI 10.1016/S1470-2045(07)70001-3; Peng XH, 2007, CANCER IMMUNOL IMMUN, V56, P797, DOI 10.1007/s00262-006-0240-9; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Sampaio ALF, 2004, J LEUKOCYTE BIOL, V76, P210, DOI 10.1189/jlb.1003504; Sampaio ALF, 2000, J LEUKOCYTE BIOL, V67, P189, DOI 10.1002/jlb.67.2.189; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schlom J, 2007, CLIN CANCER RES, V13, P3776, DOI 10.1158/1078-0432.CCR-07-0588; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; Waldow T, 2006, NITRIC OXIDE-BIOL CH, V15, P103, DOI 10.1016/j.niox.2005.12.005; Wanecek M, 2000, EUR J PHARMACOL, V407, P1, DOI 10.1016/S0014-2999(00)00675-0; Wedgwood S, 2005, AM J PHYSIOL-LUNG C, V288, pL480, DOI 10.1152/ajplung.00283.2004; Wulfing P, 2003, CLIN CANCER RES, V9, P4125; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang L, 2002, AM J PATHOL, V161, P2295, DOI 10.1016/S0002-9440(10)64505-1	50	382	404	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					28	36		10.1038/nm1699	http://dx.doi.org/10.1038/nm1699			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157142				2022-12-27	WOS:000252222400019
J	Blois, SM; Ilarregui, JM; Tometten, M; Garcia, M; Orsal, AS; Cordo-Russo, R; Toscano, MA; Bianco, GA; Kobelt, P; Handjiski, B; Tirado, I; Markert, UR; Klapp, BF; Poirier, F; Szekeres-Bartho, J; Rabinovich, GA; Arck, PC				Blois, Sandra M.; Ilarregui, Juan M.; Tometten, Mareike; Garcia, Mariana; Orsal, Arif S.; Cordo-Russo, Rosalia; Toscano, Marta A.; Bianco, German A.; Kobelt, Peter; Handjiski, Bori; Tirado, Irene; Markert, Udo R.; Klapp, Burghard F.; Poirier, Francoise; Szekeres-Bartho, Julia; Rabinovich, Gabriel A.; Arck, Petra C.			A pivotal role for galectin-1 in fetomaternal tolerance	NATURE MEDICINE			English	Article							REGULATORY T-CELLS; MATERNAL-FETAL INTERFACE; EARLY HUMAN-PREGNANCY; DENDRITIC CELLS; RECOMBINANT GALECTIN-1; EXTRACELLULAR-MATRIX; MURINE PREGNANCIES; TROPHOBLAST CELLS; MOUSE PLACENTA; CROSS-TALK	A successful pregnancy requires synchronized adaptation of maternal immune-endocrine mechanisms to the fetus. Here we show that galectin-1 (Gal-1), an immunoregulatory glycan-binding protein, has a pivotal role in conferring fetomaternal tolerance. Consistently with a marked decrease in Gal-1 expression during failing pregnancies, Gal-1-deficient (Lgals1(-/-)) mice showed higher rates of fetal loss compared to wild-type mice in allogeneic matings, whereas fetal survival was unaffected in syngeneic matings. Treatment with recombinant Gal-1 prevented fetal loss and restored tolerance through multiple mechanisms, including the induction of tolerogenic dendritic cells, which in turn promoted the expansion of interleukin-10 (IL-10)-secreting regulatory T cells in vivo. Accordingly, Gal-1's protective effects were abrogated in mice depleted of regulatory T cells or deficient in IL-10. In addition, we provide evidence for synergy between Gal-1 and progesterone in the maintenance of pregnancy. Thus, Gal-1 is a pivotal regulator of fetomaternal tolerance that has potential therapeutic implications in threatened pregnancies.	Univ Med Berlin, Charite, Biomed Res Bldg, D-13353 Berlin, Germany; Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Immunopathol Lab, RA-1428 Buenos Aires, DF, Argentina; Univ Med Berlin, Charite, Dept Med, Div Hepatol Gastroenterol & Endocrinol, D-13353 Berlin, Germany; Univ Granada, Fac Med, Dept Bioquim & Biol Mol, Unidad Immunol, E-18012 Granada, Spain; Univ Jena, Dept Obstet, Placenta Labor, D-07740 Jena, Germany; Univ Paris 06, Inst Jacques Monod, Ctr Natl Rech, Dept Biol & Dev,UMR 7592, F-75251 Paris, France; Univ Paris 07, F-75221 Paris 05, France; Univ Pecs, Sch Med, Hungarian Acad Sci, Dept Med Microbiol & Immunol,Reprod & Tumor Immun, H-7643 Pecs, Hungary; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Granada; Friedrich Schiller University of Jena; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Pecs; University of Buenos Aires	Arck, PC (corresponding author), Univ Med Berlin, Charite, Biomed Res Bldg, Campus Virchow,Augusttenburger Platz 1, D-13353 Berlin, Germany.	sandra.blois@charite.de; gabyrabi@ciudad.com.ar; petra.arck@charite.de	Toscano, Marta/HGU-4103-2022; Russo, Rosalia Cordo/O-9149-2017; Arck, Petra C/D-7094-2013; MARKERT, UDO Rudolf/AAP-1663-2021	Russo, Rosalia Cordo/0000-0002-5984-9717; MARKERT, UDO Rudolf/0000-0001-5299-595X; Arck, Petra/0000-0002-2932-926X; Toscano, Marta/0000-0003-0502-8929; Ilarregui, Juan Martin/0000-0002-6871-6764; Blois, Sandra M/0000-0002-0434-2660				Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Arck P, 2007, AM J REPROD IMMUNOL, V58, P268, DOI 10.1111/j.1600-0897.2007.00512.x; Ayatollahi M, 2005, TRANSPL P, V37, P4603, DOI 10.1016/j.transproceed.2005.11.023; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; Blois S, 2005, J IMMUNOL, V174, P1820, DOI 10.4049/jimmunol.174.4.1820; Blois SM, 2004, J IMMUNOL, V172, P5893, DOI 10.4049/jimmunol.172.10.5893; Blois SM, 2004, BIOL REPROD, V70, P1018, DOI 10.1095/biolreprod.103.022640; Bozic M, 2004, PLACENTA, V25, P797, DOI 10.1016/j.placenta.2004.03.006; Chaouat G, 2005, CHEM IMMUNOL ALLERGY, V88, P34, DOI 10.1159/000087820; Chaouat G, 2002, J REPROD IMMUNOL, V53, P241, DOI 10.1016/S0165-0378(01)00119-X; Choe YS, 1997, MOL REPROD DEV, V48, P261, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;261::AID-MRD14&gt;3.0.CO;2-0; Chung CD, 2000, J IMMUNOL, V165, P3722, DOI 10.4049/jimmunol.165.7.3722; CLARK DA, 1993, AM J REPROD IMMUNOL, V29, P141, DOI 10.1111/j.1600-0897.1993.tb00579.x; Erlebacher A, 2004, J CLIN INVEST, V114, P39, DOI 10.1172/JC1200420645; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; Fulcher JA, 2006, J IMMUNOL, V177, P216, DOI 10.4049/jimmunol.177.1.216; Garcia MG, 2007, PLACENTA, V28, P650, DOI 10.1016/j.placenta.2006.09.010; Garin MI, 2007, BLOOD, V109, P2058, DOI 10.1182/blood-2006-04-016451; Guleria I, 2005, J EXP MED, V202, P231, DOI 10.1084/jem.20050019; IROWSDALE J, 2006, NAT IMMUNOL, V7, P241; Jeschke U, 2004, HISTOCHEM CELL BIOL, V121, P501, DOI 10.1007/s00418-004-0660-6; Kallikourdis M, 2007, P NATL ACAD SCI USA, V104, P594, DOI 10.1073/pnas.0604268104; Kammerer U, 2003, AM J PATHOL, V162, P887, DOI 10.1016/S0002-9440(10)63884-9; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; LIN H, 1993, J IMMUNOL, V151, P4562; Liu AX, 2006, BIOL REPROD, V75, P414, DOI 10.1095/biolreprod.105.049379; Maquoi E, 1997, PLACENTA, V18, P433, DOI 10.1016/S0143-4004(97)80044-6; Miyazaki S, 2003, J LEUKOCYTE BIOL, V74, P514, DOI 10.1189/jlb.1102566; Perone MJ, 2006, J IMMUNOL, V177, P5278, DOI 10.4049/jimmunol.177.8.5278; Phillips B, 1996, BIOL REPROD, V55, P548, DOI 10.1095/biolreprod55.3.548; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Poehlmann TG, 2005, CHEM IMMUNOL ALLERGY, V89, P26, DOI 10.1159/000087907; POIRIER F, 1993, DEVELOPMENT, V119, P1229; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 2007, SCAND J IMMUNOL, V66, P143, DOI 10.1111/j.1365-3083.2007.01986.x; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Sasaki Y, 2004, MOL HUM REPROD, V10, P347, DOI 10.1093/molehr/gah044; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778; Stowell SR, 2007, BLOOD, V109, P219, DOI 10.1182/blood-2006-03-007153; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Toscano MA, 2006, J IMMUNOL, V176, P6323, DOI 10.4049/jimmunol.176.10.6323; van der Leij J, 2007, MOL IMMUNOL, V44, P506, DOI 10.1016/j.molimm.2006.02.011; von Wolff M, 2005, MOL HUM REPROD, V11, P189, DOI 10.1093/molehr/gah144; Walzel H, 2004, GLYCOBIOLOGY, V14, P871, DOI 10.1093/glycob/cwh101; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhu XY, 2005, BIOL REPROD, V72, P338, DOI 10.1095/biolreprod.104.034108	49	370	388	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1450	1457		10.1038/nm1680	http://dx.doi.org/10.1038/nm1680			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18026113				2022-12-27	WOS:000251445400019
J	Chamberlain, JR; Chamberlain, JS				Chamberlain, Joel R.; Chamberlain, Jeffrey S.			Muscling in Gene therapies for muscular dystrophy target RNA	NATURE MEDICINE			English	Editorial Material							SYSTEMIC DELIVERY; EXPANSIONS; SEQUENCE		[Chamberlain, Joel R.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Chamberlain, Jeffrey S.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chamberlain, JR (corresponding author), Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.	jrcham@uw.edu; jsc5@uw.edu		Chamberlain, Jeffrey/0000-0001-5299-0059	NIAMS NIH HHS [R37 AR040864] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040864] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; Arnett ALH, 2009, CURR OPIN GENET DEV, V19, P290, DOI 10.1016/j.gde.2009.03.005; Goyenvalle A, 2009, MOL THER, V17, P1234, DOI 10.1038/mt.2009.113; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Kinali M, 2009, LANCET NEUROL, V8, P918, DOI 10.1016/S1474-4422(09)70211-X; Li LB, 2008, NATURE, V453, P1107, DOI 10.1038/nature06909; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Margolis JM, 2006, HUM MOL GENET, V15, P1808, DOI 10.1093/hmg/ddl103; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Svasti S, 2009, P NATL ACAD SCI USA, V106, P1205, DOI 10.1073/pnas.0812436106; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Wheeler TM, 2009, SCIENCE, V325, P336, DOI 10.1126/science.1173110; Yokota T, 2009, ANN NEUROL, V65, P667, DOI 10.1002/ana.21627	14	8	8	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					170	171		10.1038/nm0210-170	http://dx.doi.org/10.1038/nm0210-170			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20134472				2022-12-27	WOS:000274297000036
J	Delaney, C; Heimfeld, S; Brashem-Stein, C; Voorhies, H; Manger, RL; Bernstein, ID				Delaney, Colleen; Heimfeld, Shelly; Brashem-Stein, Carolyn; Voorhies, Howard; Manger, Ronald L.; Bernstein, Irwin D.			Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; REPOPULATING ABILITY; IN-VITRO; TRANSPLANTATION; MARROW; ENGRAFTMENT; PRECURSORS; ADULTS; TRIAL; UNITS	Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result from inadequate numbers of progenitor cells in the graft and is associated with increased early transplant-related morbidity and mortality. New culture strategies that increase the number of cord blood progenitors capable of rapid myeloid engraftment after CBT would allow more widespread use of this stem cell source for transplantation. Here we report the development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34(+) cord blood progenitors that results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice. Furthermore, when cord blood progenitors expanded ex vivo in the presence of Notch ligand were infused in a clinical setting after a myeloablative preparative regimen for stem cell transplantation, the time to neutrophil recovery was substantially shortened. To our knowledge, this is the first instance of rapid engraftment derived from ex vivo expanded stem/progenitor cells in humans.	[Delaney, Colleen; Heimfeld, Shelly; Brashem-Stein, Carolyn; Voorhies, Howard; Manger, Ronald L.; Bernstein, Irwin D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Delaney, Colleen; Bernstein, Irwin D.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Bernstein, ID (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	ibernste@fhcrc.org			National Institutes of Health [R24 HL74445, K23 HL077446, K12 CA076930, 5R01HL080245-02, CA15704, DK56465]; Damon Runyon Cancer Research Foundation [CI 35-07]; NATIONAL CANCER INSTITUTE [P30CA015704, K12CA076930] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL074445, R01HL080245, K23HL077446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants R24 HL74445, K23 HL077446, K12 CA076930, 5R01HL080245-02 ( from the National Institutes of Health), CA15704 and DK56465. C. D. is a Damon Runyon Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI# 35-07). I. D. B. is an American Cancer Society-F.M. Kirby Clinical Research Professor. We would like to thank F. Appelbaum for his contribution to clinical trial design and clinical consultation, J. Gutman for help in manuscript editing and clinical data coordination and D. Woodle for expert technical assistance. We also acknowledge the work of the clinical faculty and staff at the Seattle Cancer Care Alliance for the excellent clinical care provided to the patients.	Barker JN, 2005, BLOOD, V105, P1343, DOI 10.1182/blood-2004-07-2717; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bradstock K, 2009, INTERN MED J, V39, P744, DOI 10.1111/j.1445-5994.2008.01825.x; Brunstein CG, 2007, BLOOD, V110, P3064, DOI 10.1182/blood-2007-04-067215; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; de Lima M, 2008, BONE MARROW TRANSPL, V41, P771, DOI 10.1038/sj.bmt.1705979; Delaney C, 2005, BLOOD, V106, P2693, DOI 10.1182/blood-2005-03-1131; Gutman JA, 2010, BLOOD, V115, P757, DOI 10.1182/blood-2009-07-228999; Jaroscak J, 2003, BLOOD, V101, P5061, DOI 10.1182/blood-2001-12-0290; Kang HJ, 2006, BONE MARROW TRANSPL, V38, P197, DOI 10.1038/sj.bmt.1705423; MILNER LA, 1994, BLOOD, V83, P2057; Nitsche A, 2004, STEM CELLS DEV, V13, P197, DOI 10.1089/154732804323046800; Offner F, 1996, BLOOD, V88, P4058, DOI 10.1182/blood.V88.10.4058.bloodjournal88104058; Ohishi K, 2002, J CLIN INVEST, V110, P1165, DOI 10.1172/JCI200216167; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; Shpall EJ, 2002, BIOL BLOOD MARROW TR, V8, P368, DOI 10.1053/bbmt.2002.v8.pm12171483; Suzuki T, 2006, STEM CELLS, V24, P2456, DOI 10.1634/stemcells.2006-0258; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862	20	562	596	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					232	U143		10.1038/nm.2080	http://dx.doi.org/10.1038/nm.2080			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20081862	Green Accepted			2022-12-27	WOS:000274297000047
J	Kwakkenbos, MJ; Diehl, SA; Yasuda, E; Bakker, AQ; van Geelen, CMM; Lukens, MV; van Bleek, GM; Widjojoatmodjo, MN; Bogers, WMJM; Mei, H; Radbruch, A; Scheeren, FA; Spits, H; Beaumont, T				Kwakkenbos, Mark J.; Diehl, Sean A.; Yasuda, Etsuko; Bakker, Arjen Q.; van Geelen, Caroline M. M.; Lukens, Michael V.; van Bleek, Grada M.; Widjojoatmodjo, Myra N.; Bogers, Willy M. J. M.; Mei, Henrik; Radbruch, Andreas; Scheeren, Ferenc A.; Spits, Hergen; Beaumont, Tim			Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming	NATURE MEDICINE			English	Article							CLASS-SWITCH RECOMBINATION; SYNCYTIAL VIRUS-INFECTION; GERMINAL CENTER FORMATION; SECRETING PLASMA-CELLS; EPSTEIN-BARR-VIRUS; SOMATIC HYPERMUTATION; EXPRESSION; DIFFERENTIATION; BCL6; IL-21	The B cell lymphoma-6 (Bcl-6) and Bcl-xL proteins are expressed in germinal center B cells and enable them to endure the proliferative and mutagenic environment of the germinal center. By introducing these genes into peripheral blood memory B cells and culturing these cells with two factors produced by follicular helper T cells, CD40 ligand (CD40L) and interleukin-21 (IL-21), we convert them to highly proliferating, cell surface B cell receptor (BCR)-positive, immunoglobulin-secreting B cells with features of germinal center B cells, including expression of activation-induced cytidine deaminase (AID). We generated cloned lines of B cells specific for respiratory syncytial virus and used these cells as a source of antibodies that effectively neutralized this virus in vivo. This method provides a new tool to study B cell biology and signal transduction through antigen-specific B cell receptors and for the rapid generation of high-affinity human monoclonal antibodies. (C) 2010 Nature America, Inc. All rights reserved.	[Kwakkenbos, Mark J.; Yasuda, Etsuko; Bakker, Arjen Q.; van Geelen, Caroline M. M.; Spits, Hergen; Beaumont, Tim] Univ Amsterdam, Acad Med Ctr, AIMM Therapeut, NL-1105 AZ Amsterdam, Netherlands; [Kwakkenbos, Mark J.; Diehl, Sean A.; Yasuda, Etsuko; Bakker, Arjen Q.; van Geelen, Caroline M. M.; Scheeren, Ferenc A.; Spits, Hergen; Beaumont, Tim] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [Lukens, Michael V.; van Bleek, Grada M.] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Pediat, Utrecht, Netherlands; [Widjojoatmodjo, Myra N.] Netherlands Vaccine Inst, Bilthoven, Netherlands; [Bogers, Willy M. J. M.] Biomed Primate Res Ctr, Dept Virol, Rijswijk, Netherlands; [Mei, Henrik; Radbruch, Andreas] German Rheumatism Res Ctr, Berlin, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Deutsches Rheuma-Forschungszentrum (DRFZ)	Beaumont, T (corresponding author), Univ Amsterdam, Acad Med Ctr, AIMM Therapeut, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	tbeaumont@aimmtherapeutics.com	Spits, Hergen/N-2581-2019; Diehl, Sean/C-7166-2008; Diehl, Sean/AAE-2779-2020	Spits, Hergen/0000-0003-3269-8338; Diehl, Sean/0000-0001-9700-235X; Diehl, Sean/0000-0001-9700-235X; Radbruch, Andreas/0000-0001-5753-0000; Kwakkenbos, Mark/0000-0003-0340-5655; Scheeren, Ferenc/0000-0002-8304-9023	US National Institutes of Health-National Institute of Allergy and Infectious Diseases [F32AI063846]; Wilhelmina Research Fund [OZF-02-004]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI063846] Funding Source: NIH RePORTER	US National Institutes of Health-National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wilhelmina Research Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank B. Hooijbrink for his excellent help with FACS sorting and maintenance of the flow cytometry facility, J. Boes for her excellent work on virus titrations at the Netherlands Vaccine Institute and R. Molenkamp and D. Pajkrt of the Department of Clinical Virology of the Academic Medical Center for helpful discussions. Human cDNA encoding Bcl-xL was kindly provided by S. Korsmeyer (Howard Hughes Medical Institute, Harvard Medical School). Id-3 was a gift from C. Murre (University of California, San Diego). CD40L-L cells were from J. Banchereau (Baylor University). S. A. D. is supported by US National Institutes of Health-National Institute of Allergy and Infectious Diseases grant F32AI063846. M. V. L. is supported by grant OZF-02-004 from the Wilhelmina Research Fund.	BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Bryant VL, 2007, J IMMUNOL, V179, P8180, DOI 10.4049/jimmunol.179.12.8180; DEINHARDT F, 1974, CANCER RES, V34, P1241; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Diehl SA, 2008, J IMMUNOL, V180, P4805, DOI 10.4049/jimmunol.180.7.4805; Domachowske Joseph B, 2004, Pediatr Infect Dis J, V23, pS228, DOI 10.1097/01.inf.0000144672.81955.a4; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Heemskerk MHM, 1999, CELL IMMUNOL, V195, P10, DOI 10.1006/cimm.1999.1520; Jaleco AC, 1999, BLOOD, V94, P2637, DOI 10.1182/blood.V94.8.2637.420k22_2637_2646; Johnson S, 1999, J INFECT DIS, V180, P35, DOI 10.1086/314846; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Kuo TC, 2007, J EXP MED, V204, P819, DOI 10.1084/jem.20062104; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; McBride KM, 2008, J EXP MED, V205, P2585, DOI 10.1084/jem.20081319; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Peled JU, 2008, ANNU REV IMMUNOL, V26, P481, DOI 10.1146/annurev.immunol.26.021607.090236; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Prince GA, 1999, LAB INVEST, V79, P1385; Sayegh CE, 2003, NAT IMMUNOL, V4, P586, DOI 10.1038/ni923; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Sidwell RW, 2006, ANTIVIR RES, V71, P379, DOI 10.1016/j.antiviral.2006.05.014; Smit LA, 2003, CANCER RES, V63, P3894; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Zwick MB, 2008, NAT BIOTECHNOL, V26, P886, DOI 10.1038/nbt0808-886	34	205	251	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					123	U164		10.1038/nm.2071	http://dx.doi.org/10.1038/nm.2071			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20023635	Green Accepted			2022-12-27	WOS:000273395500046
J	Sawyers, CL				Sawyers, Charles L.			Shifting paradigms: the seeds of oncogene addiction	NATURE MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ABL KINASE INHIBITOR; PHILADELPHIA-CHROMOSOME; TYROSINE KINASE; CHRONIC PHASE; RESISTANCE; GENE; MUTATIONS; CANCER; CELLS		[Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Sawyers, Charles L.] Howard Hughes Med Inst, New York, NY USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Sawyers, CL (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.	sawyersc@mskcc.org	Sawyers, Charles/G-5327-2016					DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Shah NP, 2007, J CLIN INVEST, V117, P2562, DOI 10.1172/JCI30890; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	16	70	73	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2009	15	10					1158	1161		10.1038/nm1009-1158	http://dx.doi.org/10.1038/nm1009-1158			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812578				2022-12-27	WOS:000270596400027
J	Popovich, P; McTigue, D				Popovich, Phillip; McTigue, Dana			Beware the immune system in spinal cord injury	NATURE MEDICINE			English	Editorial Material							PREVENTIVE ANTIBACTERIAL THERAPY; CENTRAL-NERVOUS-SYSTEM; ACUTE ISCHEMIC-STROKE; INFLAMMATION; INFECTIONS; TRIAL; SCI		[Popovich, Phillip; McTigue, Dana] Ctr Brain & Spinal Cord Repair, Columbus, OH USA		Popovich, P (corresponding author), Ctr Brain & Spinal Cord Repair, Columbus, OH USA.	phillip.popovich@osumc.edu; dana.mctigue@osumc.edu	Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395				Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; CRUSE JM, 1992, IMMUNOL RES, V11, P104, DOI 10.1007/BF02918615; Dziedzic T, 2007, J NEUROL SCI, V252, P53, DOI 10.1016/j.jns.2006.10.007; GRIS D, 2008, EXP NEUROL; Harms H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002158; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; McColl BW, 2009, NEUROSCIENCE, V158, P1049, DOI 10.1016/j.neuroscience.2008.08.019; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Offner H, 2009, NEUROSCIENCE, V158, P1098, DOI 10.1016/j.neuroscience.2008.05.033; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Riegger T, 2009, NEUROSCIENCE, V158, P1194, DOI 10.1016/j.neuroscience.2008.08.021; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; Teeling JL, 2009, NEUROSCIENCE, V158, P1062, DOI 10.1016/j.neuroscience.2008.07.031	15	49	49	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2009	15	7					736	737		10.1038/nm0709-736	http://dx.doi.org/10.1038/nm0709-736			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584863				2022-12-27	WOS:000267806900024
J	Willand, N; Dirie, B; Carette, X; Bifani, P; Singhal, A; Desroses, M; Leroux, F; Willery, E; Mathys, V; Deprez-Poulain, R; Delcroix, G; Frenois, F; Aumercier, M; Locht, C; Villeret, V; Deprez, B; Baulard, AR				Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Bifani, Pablo; Singhal, Amit; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Mathys, Vanessa; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.			Synthetic EthR inhibitors boost antituberculous activity of ethionamide	NATURE MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID RESISTANCE; MOLECULAR-PROPERTIES; DRUG; ACTIVATION; REPRESSOR; PHARMACOKINETICS; THIACETAZONE; PYRAZINAMIDE; INFECTION	The side effects associated with tuberculosis therapy bring with them the risk of noncompliance and subsequent drug resistance. Increasing the therapeutic index of antituberculosis drugs should thus improve treatment effectiveness. Several antituberculosis compounds require in situ metabolic activation to become inhibitory. Various thiocarbamide-containing drugs, including ethionamide, are activated by the mycobacterial monooxygenase EthA, the production of which is controlled by the transcriptional repressor EthR. Here we identify drug-like inhibitors of EthR that boost the bioactivation of ethionamide. Compounds designed and screened for their capacity to inhibit EthR-DNA interaction were co-crystallized with EthR. We exploited the three-dimensional structures of the complexes for the synthesis of improved analogs that boosted the ethionamide potency in culture more than tenfold. In Mycobacterium tuberculosis-infected mice, one of these analogs, BDM31343, enabled a substantially reduced dose of ethionamide to lessen the mycobacterial load as efficiently as the conventional higher-dose treatment. This provides proof of concept that inhibiting EthR improves the therapeutic index of thiocarbamide derivatives, which should prompt reconsideration of their use as first-line drugs.	[Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Deprez-Poulain, Rebecca; Delcroix, Guy; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.] Inst Pasteur, Lille, France; [Willand, Nicolas; Dirie, Bertrand; Desroses, Matthieu; Leroux, Florence; Deprez-Poulain, Rebecca; Deprez, Benoit] INSERM, U761, F-59045 Lille, France; [Willand, Nicolas; Dirie, Bertrand; Desroses, Matthieu; Leroux, Florence; Deprez-Poulain, Rebecca; Deprez, Benoit] Univ Lille Nord France, Fac Pharm Lille, Lille, France; [Willand, Nicolas; Dirie, Bertrand; Carette, Xavier; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Deprez-Poulain, Rebecca; Frenois, Frederic; Aumercier, Marc; Locht, Camille; Villeret, Vincent; Deprez, Benoit; Baulard, Alain R.] Inst Federat Rech 142 Mol & Cellular Med, Lille, France; [Willand, Nicolas; Carette, Xavier; Desroses, Matthieu; Leroux, Florence; Willery, Eve; Deprez-Poulain, Rebecca; Deprez, Benoit; Baulard, Alain R.] Pole Rech Interdisciplinaire Medicament, Lille, France; [Carette, Xavier; Willery, Eve; Locht, Camille; Baulard, Alain R.] INSERM, U629, F-59045 Lille, France; [Bifani, Pablo; Singhal, Amit; Mathys, Vanessa] Inst Pasteur, Brussels, Belgium; [Frenois, Frederic; Aumercier, Marc; Villeret, Vincent] Univ Lille Nord France, CNRS, UMR 8161, Inst Pasteur Lille, Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Baulard, AR (corresponding author), Inst Pasteur, Lille, France.	alain.baulard@pasteur-lille.fr	Locht, Camille/L-3516-2018; nicolas, Willand/A-5322-2012; deprez, benoit/G-6749-2012; Deprez-Poulain, Rebecca/A-5444-2015; Baulard, Alain R/E-6830-2017; Leroux, Florence/R-8155-2017; Willand, Pr Nicolas/A-5653-2019	deprez, benoit/0000-0002-2777-4538; Deprez-Poulain, Rebecca/0000-0002-3318-5297; Baulard, Alain R/0000-0002-0150-5241; Leroux, Florence/0000-0003-0554-873X; Willand, Pr Nicolas/0000-0002-0784-0462; Singhal, Amit/0000-0003-3913-8798; Aumercier, Marc/0000-0002-0370-3452; Desroses, Matthieu/0000-0003-4152-3855; Villeret, Vincent/0000-0003-4504-056X; Carette, Xavier/0000-0003-4490-5752; Bifani, Pablo/0000-0001-9651-6439; Locht, Camille/0000-0001-7295-7336	INSERM; Universite de Lille 2 Droit et Sante; Institut Pasteur de Lille; CNRS; Region Nord-Pas de Calais; Ministere delegue a la Recherche et aux Nouvelles Technologies; European Union [FEDER OBJ2-4.1-2006/3-n1297/9360]; l'Agence Nationale de la Recherche, France [ANR-06-EMPB-033]; Ministere de la Recherche; MRC [G0500367] Funding Source: UKRI; Medical Research Council [G0500367] Funding Source: researchfish	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Lille 2 Droit et Sante; Institut Pasteur de Lille; CNRS(Centre National de la Recherche Scientifique (CNRS)); Region Nord-Pas de Calais(Region Hauts-de-FranceEuropean Commission); Ministere delegue a la Recherche et aux Nouvelles Technologies; European Union(European Commission); l'Agence Nationale de la Recherche, France(French National Research Agency (ANR)); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are indebted to G. Mahieu for his invaluable help with the synergistic experiments on M. tuberculosis, P. Rucktooa for crystal structure acquisitions and manipulations, F. Demirkaya for technical support, M. Flipo for support in chemical synthesis, M. Cynamon for sharing experimental data about ethionamide sensitivity in mice and S. Delaroche for data formatting. We thank H. Gras for critical reading of the manuscript and F. Jean, C. Desruelle and V. Dewailly for grants management. Nuclear magnetic resonance spectra acquisitions were done at the Laboratoire d'Application de Resonance Magnetique Nucleaire, Lille. This work was supported by INSERM, Universite de Lille 2 Droit et Sante, Institut Pasteur de Lille, CNRS, the Region Nord-Pas de Calais, Ministere delegue a la Recherche et aux Nouvelles Technologies and the European Union (FEDER OBJ2-4.1-2006/3-n1297/9360), l'Agence Nationale de la Recherche, France (ANR-06-EMPB-033). We are indebted to the European Synchrotron Radiation Facility for beam-time allocation (through the Block Allocation Group BAG MX-485) for this project. X. C. is a recipient of a doctoral fellowship from Institut Pasteur de Lille and the Region Nord-Pas de Calais. B. D. is a recipient of a doctoral fellowship of the Ministere de la Recherche. M. A. and V. V. are researchers from the CNRS.	Alahari A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001343; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baulard AR, 2000, J BIOL CHEM, V275, P28326; Boshoff HIM, 2000, J BACTERIOL, V182, P5479, DOI 10.1128/JB.182.19.5479-5485.2000; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Cox H, 2006, PLOS MED, V3, P1836, DOI 10.1371/journal.pmed.0030384; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Dover LG, 2004, J MOL BIOL, V340, P1095, DOI 10.1016/j.jmb.2004.06.003; Dover LG, 2007, ANTIMICROB AGENTS CH, V51, P1055, DOI 10.1128/AAC.01063-06; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engohang-Ndong J, 2004, MOL MICROBIOL, V51, P175, DOI 10.1046/j.1365-2958.2003.03809.x; Fajardo TT, 2006, AM J TROP MED HYG, V74, P457, DOI 10.4269/ajtmh.2006.74.457; Frenois F, 2006, TUBERCULOSIS, V86, P110, DOI 10.1016/j.tube.2005.07.005; Frenois F, 2004, MOL CELL, V16, P301, DOI 10.1016/j.molcel.2004.09.020; Guo HL, 2006, J MED MICROBIOL, V55, P1527, DOI 10.1099/jmm.0.46718-0; HASTINGS R C, 1988, Clinical Microbiology Reviews, V1, P330; HOLDINESS MR, 1987, MED TOXICOL ADV DRUG, V2, P33, DOI 10.1007/BF03259859; HOLDINESS MR, 1984, CLIN PHARMACOKINET, V9, P511, DOI 10.2165/00003088-198409060-00003; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h; Kordulakova J, 2007, ANTIMICROB AGENTS CH, V51, P3824, DOI 10.1128/AAC.00433-07; LEES AW, 1964, CHEST, V45, P247; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007; Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103; Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003; Phetsuksiri B, 2003, J BIOL CHEM, V278, P53123, DOI 10.1074/jbc.M311209200; Qian L, 2006, CHEM RES TOXICOL, V19, P443, DOI 10.1021/tx050328b; Schaaf HS, 2007, EUR J CLIN MICROBIOL, V26, P203, DOI 10.1007/s10096-007-0257-9; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; Snewin VA, 1999, INFECT IMMUN, V67, P4586, DOI 10.1128/IAI.67.9.4586-4593.1999; Tomioka H, 2006, CURR PHARM DESIGN, V12, P4047, DOI 10.2174/138161206778743646; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vieth M, 2004, J MED CHEM, V47, P224, DOI 10.1021/jm030267j; WEINSTEIN HJ, 1962, AM REV RESPIR DIS, V86, P576; Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 2005, MYCOBACTERIUM TUBERC, P115; Zhu M, 2002, TUBERCULOSIS, V82, P91, DOI 10.1054/tube.2002.0330	41	136	146	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					537	544		10.1038/nm.1950	http://dx.doi.org/10.1038/nm.1950			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19412174				2022-12-27	WOS:000265889300032
J	Lloyd-Evans, E; Morgan, AJ; He, XX; Smith, DA; Elliot-Smith, E; Sillence, DJ; Churchill, GC; Schuchman, EH; Galione, A; Platt, FM				Lloyd-Evans, Emyr; Morgan, Anthony J.; He, Xingxuan; Smith, David A.; Elliot-Smith, Elena; Sillence, Daniel J.; Churchill, Grant C.; Schuchman, Edward H.; Galione, Antony; Platt, Frances M.			Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium	NATURE MEDICINE			English	Article							INTRACELLULAR CA2+; NPC1 PROTEIN; CHOLESTEROL; BINDING; METABOLISM; STORES; CELLS; CERAMIDE; MODEL; MICE	Niemann-Pick type C1 (NPC1) disease is a neurodegenerative lysosomal storage disorder caused by mutations in the acidic compartment (which we define as the late endosome and the lysosome) protein, NPC1. The function of NPC1 is unknown, but when it is dysfunctional, sphingosine, glycosphingolipids, sphingomyelin and cholesterol accumulate. We have found that NPC1-mutant cells have a large reduction in the acidic compartment calcium store compared to wild-type cells. Chelating luminal endocytic calcium in normal cells with high-affinity Rhod-dextran induced an NPC disease cellular phenotype. In a drug-induced NPC disease cellular model, sphingosine storage in the acidic compartment led to calcium depletion in these organelles, which then resulted in cholesterol, sphingomyelin and glycosphingolipid storage in these compartments. Sphingosine storage is therefore an initiating factor in NPC1 disease pathogenesis that causes altered calcium homeostasis, leading to the secondary storage of sphingolipids and cholesterol. This unique calcium phenotype represents a new target for therapeutic intervention, as elevation of cytosolic calcium with curcumin normalized NPC1 disease cellular phenotypes and prolonged survival of the NPC1 mouse.	[Lloyd-Evans, Emyr; Morgan, Anthony J.; Smith, David A.; Elliot-Smith, Elena; Churchill, Grant C.; Galione, Antony; Platt, Frances M.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; [He, Xingxuan; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA	University of Oxford; Icahn School of Medicine at Mount Sinai	Lloyd-Evans, E (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	emyr.lloyd-evans@pharm.ox.ac.uk; frances.platt@pharm.ox.ac.uk	Galione, Antony/E-5884-2011; Platt, Frances/G-1004-2010; Sillence, Dan J/J-9513-2019	Sillence, Dan J/0000-0003-4747-5655; Platt, Frances/0000-0001-7614-0403; Galione, Antony/0000-0002-4132-7646	BBSRC [BB/D012694/1] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830, R56DK054830] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/D012694/1] Funding Source: Medline; NIDDK NIH HHS [NIHR01 DK54830] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babalola JO, 2007, BIOL CHEM, V388, P617, DOI 10.1515/BC.2007.063; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Bilmen JG, 2001, EUR J BIOCHEM, V268, P6318, DOI 10.1046/j.0014-2956.2001.02589.x; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; BUTLER JD, 1993, BIOCHEM BIOPH RES CO, V196, P154, DOI 10.1006/bbrc.1993.2228; Christensen KA, 2002, J CELL SCI, V115, P599; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Deisz RA, 2005, NEUROSCIENCE, V130, P867, DOI 10.1016/j.neuroscience.2004.09.065; Elliot-Smith E, 2008, MOL GENET METAB, V94, P204, DOI 10.1016/j.ymgme.2008.02.005; Erickson RP, 2000, J INHERIT METAB DIS, V23, P54, DOI 10.1023/A:1005650930330; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Ginzburg L, 2004, SEMIN CELL DEV BIOL, V15, P417, DOI 10.1016/j.semcdb.2004.03.003; He XX, 2005, ANAL BIOCHEM, V340, P113, DOI 10.1016/j.ab.2005.01.058; Houben E, 2006, J LIPID RES, V47, P1063, DOI 10.1194/jlr.M600001-JLR200; Infante RE, 2008, J BIOL CHEM, V283, P1064, DOI 10.1074/jbc.M707944200; Jeyakumar Mylvaganam, 2005, Nat Rev Neurosci, V6, P713; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Lachmann RH, 2004, NEUROBIOL DIS, V16, P654, DOI 10.1016/j.nbd.2004.05.002; LEMONS RM, 1991, J BIOL CHEM, V266, P14378; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Malathi K, 2004, J CELL BIOL, V164, P547, DOI 10.1083/jcb.200310046; MASSON M, 1992, J NEUROSCI RES, V31, P84, DOI 10.1002/jnr.490310112; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neville DCA, 2004, ANAL BIOCHEM, V331, P275, DOI 10.1016/j.ab.2004.03.051; Ozbay T, 2006, ENDOCRINOLOGY, V147, P1427, DOI 10.1210/en.2005-1091; PANDOL SJ, 1994, BBA-BIOMEMBRANES, V1195, P45, DOI 10.1016/0005-2736(94)90007-8; Parkesh R, 2008, CELL CALCIUM, V43, P531, DOI 10.1016/j.ceca.2007.08.006; Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1; Patterson MC, 2004, BBA-MOL CELL BIOL L, V1685, P77, DOI 10.1016/j.bbalip.2004.08.013; PATTERSON MC, 1993, NEUROLOGY, V43, P61, DOI 10.1212/WNL.43.1_Part_1.61; Pelled D, 1999, J NEUROCHEM, V72, P1139, DOI 10.1046/j.1471-4159.1999.0721139.x; Piper RC, 2004, TRENDS CELL BIOL, V14, P471, DOI 10.1016/j.tcb.2004.07.010; Rakovic S, 1999, J BIOL CHEM, V274, P17820, DOI 10.1074/jbc.274.25.17820; Somers KL, 2001, J INHERIT METAB DIS, V24, P427, DOI 10.1023/A:1010588112003; Srinivas SP, 2002, INVEST OPHTH VIS SCI, V43, P2341; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; Tettamanti G, 2003, BIOCHIMIE, V85, P423, DOI 10.1016/S0300-9084(03)00047-6; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; Vruchte DT, 2004, J BIOL CHEM, V279, P26167, DOI 10.1074/jbc.M311591200; Walter M, 2009, BIOL CELL, V101, P141, DOI 10.1042/BC20070171; Wu YP, 2008, HUM MOL GENET, V17, P2257, DOI 10.1093/hmg/ddn126; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamamoto T, 2000, J MED GENET, V37, P707, DOI 10.1136/jmg.37.9.707	50	581	597	2	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1247	1255		10.1038/nm.1876	http://dx.doi.org/10.1038/nm.1876			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18953351				2022-12-27	WOS:000260751200044
J	Matzuk, MM; Lamb, DJ				Matzuk, Martin M.; Lamb, Dolores J.			The biology of infertility: research advances and clinical challenges	NATURE MEDICINE			English	Review							INTRACYTOPLASMIC-SPERM-INJECTION; SPERMATOGONIAL STEM-CELLS; PREIMPLANTATION GENETIC DIAGNOSIS; TRANSMEMBRANE CONDUCTANCE REGULATOR; GROWTH-DIFFERENTIATION FACTOR-9; NON-SYNDROMIC ASTHENOZOOSPERMIA; CONGENITAL BILATERAL ABSENCE; PRIMARY CILIARY DYSKINESIA; FEMALE REPRODUCTIVE-TRACT; AUTOSOMAL SEX REVERSAL	Reproduction is required for the survival of all mammalian species, and thousands of essential 'sex' genes are conserved through evolution. Basic research helps to define these genes and the mechanisms responsible for the development, function and regulation of the male and female reproductive systems. However, many infertile couples continue to be labeled with the diagnosis of idiopathic infertility or given descriptive diagnoses that do not provide a cause for their defect. For other individuals with a known etiology, effective cures are lacking, although their infertility is often bypassed with assisted reproductive technologies (ART), some accompanied by safety or ethical concerns. Certainly, progress in the field of reproduction has been realized in the twenty-first century with advances in the understanding of the regulation of fertility, with the production of over 400 mutant mouse models with a reproductive phenotype and with the promise of regenerative gonadal stem cells. Indeed, the past six years have witnessed a virtual explosion in the identification of gene mutations or polymorphisms that cause or are linked to human infertility. Translation of these findings to the clinic remains slow, however, as do new methods to diagnose and treat infertile couples. Additionally, new approaches to contraception remain elusive. Nevertheless, the basic and clinical advances in the understanding of the molecular controls of reproduction are impressive and will ultimately improve patient care.	[Matzuk, Martin M.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mmatzuk@bcm.edu; dlamb@bcm.tmc.edu			US National Institutes of Health [P01 HD36289, R01 DK078121, R01 HD32067, R01 HD42500, R01 CA60651, R37 HD33438, U54 HD07495, T32 DK00763, K12 DK083014]; US Department of Defense; US Army Materiel Command [PC061154]; Ovarian Cancer Research Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495, R01HD032067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD036289, R01HD042500, R37HD033438] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK083014, R01DK078121] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); US Army Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Ovarian Cancer Research Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Reproductive biology and cancer research in the Matzuk and Lamb laboratories have been supported by US National Institutes of Health grants P01 HD36289, R01 DK078121, R01 HD32067, R01 HD42500, R01 CA60651, R37 HD33438, U54 HD07495, T32 DK00763 and K12 DK083014, by the US Department of Defense, US Army Materiel Command PC061154 and by the Ovarian Cancer Research Fund. We thank our many colleagues, S. Alexander, S. Han, M. Hsieh, R. Khavari, M. Louet, S. Mukhajee, A. Nagaraja, R. Nalam, S. Whirledge, and H. Yao, for their outstanding insights and critiques of this review. We apologize to colleagues whose work is not referenced herein because of space limitations. The supplementary information online contains more detailed references.	Aitken RJ, 2008, J CLIN INVEST, V118, P1330, DOI 10.1172/JCI33873; Alukal JP, 2008, UROL CLIN N AM, V35, P277, DOI 10.1016/j.ucl.2008.01.004; Andersen AN, 2007, HUM REPROD, V22, P1513, DOI 10.1093/humrep/dem053; ANDERSSON M, 1986, SCIENCE, V233, P786, DOI 10.1126/science.3738510; Ao A, 1998, J ASSIST REPROD GEN, V15, P140, DOI 10.1023/A:1023008921386; Bannister LA, 2007, PLOS BIOL, V5, P1016, DOI 10.1371/journal.pbio.0050105; Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513; Barsoum I, 2006, TRENDS ENDOCRIN MET, V17, P223, DOI 10.1016/j.tem.2006.06.009; Bartels I, 1998, HUM REPROD, V13, P3345, DOI 10.1093/humrep/13.12.3345; Begum S, 2008, HUM REPROD, V23, P2326, DOI 10.1093/humrep/den249; Behringer RR, 2006, REPROD FERT DEVELOP, V18, P99, DOI 10.1071/RD05137; Belva F, 2007, HUM REPROD, V22, P506, DOI 10.1093/humrep/del372; Bernard P, 2008, INT J BIOCHEM CELL B, V40, P2889, DOI 10.1016/j.biocel.2008.06.006; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104; Bogatcheva NV, 2003, MOL ENDOCRINOL, V17, P2639, DOI 10.1210/me.2003-0096; Brenner CA, 2000, FERTIL STERIL, V74, P573, DOI 10.1016/S0015-0282(00)00681-6; Brinster RL, 2007, SCIENCE, V316, P404, DOI 10.1126/science.1137741; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; Bristol-Gould SK, 2006, DEV BIOL, V298, P149, DOI 10.1016/j.ydbio.2006.06.023; Cao WL, 2006, MOL CELL PROTEOMICS, V5, P801, DOI 10.1074/mcp.M500322-MCP200; Capel B, 2006, NAT GENET, V38, P1233, DOI 10.1038/ng1106-1233; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Carmell MA, 2007, DEV CELL, V12, P503, DOI 10.1016/j.devcel.2007.03.001; Carrell DT, 2008, J ANDROL, V29, P124, DOI 10.2164/jandrol.107.003699; Carrell DT, 2001, FERTIL STERIL, V76, P1258, DOI 10.1016/S0015-0282(01)02904-1; Cayan S, 2001, FERTIL STERIL, V76, P612, DOI 10.1016/S0015-0282(01)01974-4; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; CHEMES HE, 1987, FERTIL STERIL, V48, P664; Chen C, 2005, NATURE, V436, P1030, DOI 10.1038/nature03894; Cherry SM, 2007, CURR BIOL, V17, P373, DOI 10.1016/j.cub.2006.12.048; Cheung SW, 2007, AM J MED GENET A, V143A, P1679, DOI 10.1002/ajmg.a.31740; Cheung SW, 2005, GENET MED, V7, P422, DOI 10.1097/01.GIM.0000170992.63691.32; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Claustres M, 2005, REPROD BIOMED ONLINE, V10, P14, DOI 10.1016/S1472-6483(10)60801-2; COBURN M, 1997, TESTICULAR BIOPSY MA, P219; Collier LS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-S1-S15; CONRAD S, 2008, NATURE          1008, DOI DOI 10.1038/NATURE07404; COSTES B, 1995, EUR J HUM GENET, V3, P285; d'Anglemont de Tassigny X, 2007, P NATL ACAD SCI USA, V104, P10714, DOI 10.1073/pnas.0704114104; D'Hauwers KWM, 2008, FERTIL STERIL, V89, P387, DOI 10.1016/j.fertnstert.2007.03.005; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Dalmia R, 2005, FERTIL STERIL, V83, P462, DOI 10.1016/j.fertnstert.2004.07.968; Dam AHDM, 2007, AM J HUM GENET, V81, P813, DOI 10.1086/521314; De Philippo RE, 2008, TRANSPLANTATION, V86, P208, DOI 10.1097/TP.0b013e31817f1686; de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100; De Vos A, 1998, MOL HUM REPROD, V4, P978, DOI 10.1093/molehr/4.10.978; DELHANTY JDA, 1994, LANCET, V343, P549, DOI 10.1016/S0140-6736(94)91505-9; Deng W, 2002, DEV CELL, V2, P819, DOI 10.1016/S1534-5807(02)00165-X; deRoux N, 1997, NEW ENGL J MED, V337, P1597, DOI 10.1056/NEJM199711273372205; DEVROEY P, 1994, FERTIL STERIL, V62, P639; Di Pasquale E, 2004, AM J HUM GENET, V75, P106, DOI 10.1086/422103; Dieterich K, 2007, NAT GENET, V39, P661, DOI 10.1038/ng2027; DiNapoli L, 2006, DEVELOPMENT, V133, P1519, DOI 10.1242/dev.02303; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Disset A, 2005, HUM MUTAT, V25, P72, DOI 10.1002/humu.20115; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; Eggan K, 2006, NATURE, V441, P1109, DOI 10.1038/nature04929; Egozcue J, 2005, CYTOGENET GENOME RES, V111, P337, DOI 10.1159/000086907; Ferlin A, 2006, J ENDOCRINOL INVEST, V29, P657, DOI 10.1007/BF03344168; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Funes S, 2003, BIOCHEM BIOPH RES CO, V312, P1357, DOI 10.1016/j.bbrc.2003.11.066; Geens M, 2008, HUM REPROD UPDATE, V14, P121, DOI 10.1093/humupd/dmm047; Gekas J, 2001, HUM REPROD, V16, P82, DOI 10.1093/humrep/16.1.82; GEREMIA R, 1977, CELL DIFFER DEV, V5, P343, DOI 10.1016/0045-6039(77)90072-0; GILBERT SF, 2006, DEV BIOL, pCH7; Gonsalves J, 2004, HUM MOL GENET, V13, P2875, DOI 10.1093/hmg/ddh302; Gorlov IP, 2002, HUM MOL GENET, V11, P2309, DOI 10.1093/hmg/11.19.2309; Greenbaum MP, 2007, DEV BIOL, V305, P389, DOI 10.1016/j.ydbio.2007.02.025; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARARI O, 1995, FERTIL STERIL, V63, P182, DOI 10.1016/S0015-0282(16)57315-4; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hassold T, 2007, HUM MOL GENET, V16, pR203, DOI 10.1093/hmg/ddm243; Hayashi K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001738; Hayashi K, 2007, SCIENCE, V316, P394, DOI 10.1126/science.1137545; Hermann BP, 2007, STEM CELLS, V25, P2330, DOI 10.1634/stemcells.2007-0143; Hinckley M, 2005, DEV BIOL, V287, P249, DOI 10.1016/j.ydbio.2005.08.019; Hodges CA, 2005, NAT GENET, V37, P1351, DOI 10.1038/ng1672; HONG X, 2008, ENDOCRINOLOGY   0814, DOI DOI 10.1210/EN.2008-0294; Hopps CV, 2003, HUM REPROD, V18, P1660, DOI 10.1093/humrep/deg348; Hou M, 2007, HUM REPROD, V22, P1899, DOI 10.1093/humrep/dem085; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; Iacobelli M, 2003, Reprod Biomed Online, V7, P558; Jahnukainen K, 2001, CANCER RES, V61, P706; JARVI K, 1995, LANCET, V345, P1578, DOI 10.1016/S0140-6736(95)91131-6; Jean M, 1997, FERTIL STERIL, V67, P164, DOI 10.1016/S0015-0282(97)81874-2; Jin JL, 2007, BIOL REPROD, V77, P37, DOI 10.1095/biolreprod.107.060186; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Johnson J, 2005, CELL, V122, P303, DOI 10.1016/j.cell.2005.06.031; Jordan BK, 2001, AM J HUM GENET, V68, P1102, DOI 10.1086/320125; Kanatsu-Shinohara M, 2004, BIOL REPROD, V71, P1202, DOI 10.1095/biolreprod.104.031294; Kanatsu-Shinohara M, 2008, BIOL REPROD, V78, P681, DOI 10.1095/biolreprod.107.066068; Kanatsu-Shinohara M, 2006, P NATL ACAD SCI USA, V103, P8018, DOI 10.1073/pnas.0601139103; Katz-Jaffe MG, 2006, FERTIL STERIL, V86, P678, DOI 10.1016/j.fertnstert.2006.05.022; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Hamra FK, 2007, J BIOL CHEM, V282, P721, DOI 10.1074/jbc.M608398200; Kent-First MG, 1996, MOL HUM REPROD, V2, P943, DOI 10.1093/molehr/2.12.943; KentFirst MG, 1996, LANCET, V348, P332, DOI 10.1016/S0140-6736(05)64498-4; Kerr JB, 2006, REPRODUCTION, V132, P95, DOI 10.1530/rep.1.01128; Kitada K, 2007, NAT METHODS, V4, P131, DOI 10.1038/nmeth1002; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Kramer JA, 1997, MOL HUM REPROD, V3, P473, DOI 10.1093/molehr/3.6.473; Krawetz Stephen A, 2005, Zhonghua Nan Ke Xue, V11, P170; Krisfalusi M, 2006, BIOL REPROD, V75, P270, DOI 10.1095/biolreprod.105.049684; KRUGER TF, 1988, FERTIL STERIL, V49, P112; KRUGER TF, 1987, UROLOGY, V30, P248, DOI 10.1016/0090-4295(87)90246-9; KUMAR G, 1993, CELL MOL BIOL RES, V39, P111; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Kuramochi-Miyagawa S, 2004, DEVELOPMENT, V131, P839, DOI 10.1242/dev.00973; Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708; Kuznetsov S, 2007, J CELL BIOL, V176, P581, DOI 10.1083/jcb.200608130; Lai R, 2002, J ASSIST REPROD GEN, V19, P245, DOI 10.1023/A:1015315020324; Lamb NE, 2005, CYTOGENET GENOME RES, V111, P250, DOI 10.1159/000086896; Lapatto R, 2007, ENDOCRINOLOGY, V148, P4927, DOI 10.1210/en.2007-0078; Layman LC, 1998, NAT GENET, V18, P14, DOI 10.1038/ng0198-14; Ledig S, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.05.029; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; Li HG, 2007, MOL HUM REPROD, V13, P299, DOI 10.1093/molehr/gam009; Lipshultz LI, 2007, NAT CLIN PRACT UROL, V4, P460, DOI 10.1038/ncpuro0879; LIU J, 1995, HUM REPROD, V10, P626, DOI 10.1093/oxfordjournals.humrep.a136000; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P1858, DOI 10.1001/jama.272.23.1858; Lofgren A, 1999, ANN NY ACAD SCI, V883, P460, DOI 10.1111/j.1749-6632.1999.tb08610.x; Maatouk DM, 2008, HUM MOL GENET, V17, P2949, DOI 10.1093/hmg/ddn193; Maatouk DM, 2008, BIOL REPROD, V79, P696, DOI 10.1095/biolreprod.108.067827; Mahmoud AM, 1996, ANDROLOGIA, V28, P141; Manno Massimo, 2003, Arch Ital Urol Androl, V75, P25; Martinez-Heredia J, 2008, HUM REPROD, V23, P783, DOI 10.1093/humrep/den024; Matzuk MM, 2005, NAT MED, V11, P24, DOI 10.1038/nm0105-24; Matzuk MM, 2002, NAT MED, V8, P41, DOI 10.1038/nm-fertilityS41; McArthur SJ, 2005, FERTIL STERIL, V84, P1628, DOI 10.1016/j.fertnstert.2005.05.063; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; McNatty KP, 2004, REPRODUCTION, V128, P379, DOI 10.1530/rep.1.00280; Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974; MEISTRICH ML, 1992, CANCER, V70, P2703, DOI 10.1002/1097-0142(19921201)70:11<2703::AID-CNCR2820701123>3.0.CO;2-X; MEISTRICH ML, 1989, CANCER, V63, P2115, DOI 10.1002/1097-0142(19890601)63:11<2115::AID-CNCR2820631108>3.0.CO;2-A; Menke MN, 2007, CLIN OBSTET GYNECOL, V50, P188, DOI 10.1097/GRF.0b013e3180305f7c; Meschede D, 1997, HUM REPROD, V12, P1913, DOI 10.1093/humrep/12.9.1913; MONESI V, 1965, EXP CELL RES, V39, P197, DOI 10.1016/0014-4827(65)90023-6; Montgomery GW, 2008, HUM REPROD UPDATE, V14, P447, DOI 10.1093/humupd/dmn016; MOOSANI N, 1995, FERTIL STERIL, V64, P811, DOI 10.1016/S0015-0282(16)57859-5; MORRIS JM, 1953, AM J OBSTET GYNECOL, V65, P1192, DOI 10.1016/0002-9378(53)90359-7; Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105; Murchison EP, 2007, GENE DEV, V21, P682, DOI 10.1101/gad.1521307; Nagano M, 2001, P NATL ACAD SCI USA, V98, P13090, DOI 10.1073/pnas.231473498; Nagaraja AK, 2008, MOL ENDOCRINOL, V22, P2336, DOI 10.1210/me.2008-0142; Navarro B, 2007, P NATL ACAD SCI USA, V104, P7688, DOI 10.1073/pnas.0702018104; Nayernia K, 2006, DEV CELL, V11, P125, DOI 10.1016/j.devcel.2006.05.010; Nayernia K, 2006, LAB INVEST, V86, P654, DOI 10.1038/labinvest.3700429; Naylor CS, 2001, J REPROD MED, V46, P497; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Nelson CP, 2004, NAT CLIN PRACT UROL, V1, P38, DOI 10.1038/ncpuro0028; Nijs M, 1996, HUM REPROD, V11, P2180; Nikpoor P, 2004, HUM REPROD, V19, P124, DOI 10.1093/humrep/deh043; Oates RD, 2003, J ANDROL, V24, P49; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Ostermeier GC, 2004, NATURE, V429, P154, DOI 10.1038/429154a; Ostermeier GC, 2002, LANCET, V360, P772, DOI 10.1016/S0140-6736(02)09899-9; Otsuka M, 2008, J CLIN INVEST, V118, P1944, DOI 10.1172/JCI33680; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Palmer JS, 2006, J CLIN ENDOCR METAB, V91, P4713, DOI 10.1210/jc.2006-0970; Papadimas J, 1997, FERTIL STERIL, V67, P562, DOI 10.1016/S0015-0282(97)80087-8; Papanikolaou EG, 2008, HUM REPROD, V23, P91, DOI 10.1093/humrep/dem339; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Pellestor F, 2003, HUM GENET, V112, P195, DOI 10.1007/s00439-002-0852-x; Pettigrew R, 2000, HUM REPROD, V15, P2650, DOI 10.1093/humrep/15.12.2650; Platts AE, 2007, HUM MOL GENET, V16, P763, DOI 10.1093/hmg/ddm012; Practice Committee of the Society for Reproductive Medicine and the Practice Committee of the American Society for Assisted Reproductive Medicine, 2006, FERTIL STERIL, V86, pS51; PRYZANT RM, 1993, J CLIN ONCOL, V11, P239, DOI 10.1200/JCO.1993.11.2.239; Puscheck EE, 2008, SEMIN REPROD MED, V26, P223, DOI 10.1055/s-2008-1076141; Qi HY, 2007, P NATL ACAD SCI USA, V104, P1219, DOI 10.1073/pnas.0610286104; Quill TA, 2006, MOL CELL ENDOCRINOL, V250, P84, DOI 10.1016/j.mce.2005.12.031; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Repping S, 2002, AM J HUM GENET, V71, P906, DOI 10.1086/342928; Repping S, 2003, NAT GENET, V35, P247, DOI 10.1038/ng1250; Ro S, 2007, RNA, V13, P1693, DOI 10.1261/rna.640307; Robins JC, 2008, UROL CLIN N AM, V35, P173, DOI 10.1016/j.ucl.2008.01.013; Ryu BY, 2007, J ANDROL, V28, P353, DOI 10.2164/jandrol.106.001511; Sakkas D, 2005, CURR OPIN OBSTET GYN, V17, P283, DOI 10.1097/01.gco.0000169106.69881.3e; Schuffner A, 2006, ARCH ANDROLOGY, V52, P145, DOI 10.1080/01485010500379863; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Schwabe GC, 2008, HUM MUTAT, V29, P289, DOI 10.1002/humu.20656; Sekido R, 2004, DEV BIOL, V274, P271, DOI 10.1016/j.ydbio.2004.07.011; Seminara SB, 2008, J NEUROENDOCRINOL, V20, P727, DOI 10.1111/j.1365-2826.2008.01731.x; Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322; Sermon K, 2001, MOL CELL ENDOCRINOL, V183, pS77, DOI 10.1016/S0303-7207(01)00572-X; SILBER SJ, 1994, HUM REPROD, V9, P1705, DOI 10.1093/oxfordjournals.humrep.a138778; Smyk M, 2007, HUM GENET, V122, P63, DOI 10.1007/s00439-007-0373-8; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; STEPTOE PC, 1978, LANCET, V2, P366; Su YQ, 2008, DEVELOPMENT, V135, P111, DOI 10.1242/dev.009068; Sugiura K, 2007, DEVELOPMENT, V134, P2593, DOI 10.1242/dev.006882; Sun F, 2008, MOL HUM REPROD, V14, P399, DOI 10.1093/molehr/gan030; Sun F, 2008, HUM REPROD, V23, P1691, DOI 10.1093/humrep/den027; Takehashi M, 2007, DEV BIOL, V312, P344, DOI 10.1016/j.ydbio.2007.09.029; Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904; Tang F, 2007, GENE DEV, V21, P644, DOI 10.1101/gad.418707; Tash JS, 2008, BIOL REPROD, V78, P1127, DOI 10.1095/biolreprod.106.057810; Testart J, 1996, HUM REPROD, V11, P2609; Tournaye H, 1996, HUM REPROD, V11, P1644; Trimborn M, 2005, J HISTOCHEM CYTOCHEM, V53, P351, DOI 10.1369/jhc.4B6412.2005; Turner RMO, 2001, J ANDROL, V22, P302; Urbanek M, 2007, NAT CLIN PRACT ENDOC, V3, P103, DOI 10.1038/ncpendmet0400; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Van Voorhis BJ, 2008, SEMIN REPROD MED, V26, P232, DOI 10.1055/s-2008-1076142; van's Gravesande KS, 2005, ANN MED, V37, P439, DOI 10.1080/07853890510011985; VanOpstal D, 1997, HUM REPROD, V12, P682, DOI 10.1093/humrep/12.4.682; Veld PAI, 1997, HUM REPROD, V12, P752; Verlinsky Y, 2001, JAMA-J AM MED ASSOC, V285, P3130, DOI 10.1001/jama.285.24.3130; Verpoest W, 2008, HUM REPROD, V23, P1654, DOI 10.1093/humrep/den105; Verpoest W, 2004, REPROD BIOMED ONLINE, V8, P240, DOI 10.1016/S1472-6483(10)60523-8; Vogt E, 2008, MUTAT RES-GEN TOX EN, V651, P14, DOI 10.1016/j.mrgentox.2007.10.015; von Zumbusch A, 1998, FERTIL STERIL, V70, P643, DOI 10.1016/S0015-0282(98)00246-5; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wang D, 2007, P NATL ACAD SCI USA, V104, P9325, DOI 10.1073/pnas.0611296104; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908; Wilhelm D, 2007, PHYSIOL REV, V87, P1, DOI 10.1152/physrev.00009.2006; Wolstenholme J, 2000, CHROMOSOMA, V109, P435, DOI 10.1007/s004120000088; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th; Yao HHC, 2006, BIOL REPROD, V74, P978, DOI 10.1095/biolreprod.105.050286; Yatsenko AN, 2006, HUM MOL GENET, V15, P3411, DOI 10.1093/hmg/ddl417; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681; Zuccarello D, 2008, HUM REPROD, V23, P1957, DOI 10.1093/humrep/den193; Zuccarello D, 2008, HUM REPROD, V23, P996, DOI 10.1093/humrep/dem400; 1999, FED REG, V65, P51891	238	637	678	4	161	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11		S			1197	1213		10.1038/nm.f.1895	http://dx.doi.org/10.1038/nm.f.1895			17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	397FU	18989307	Green Accepted			2022-12-27	WOS:000262649100031
J	Gargioli, C; Coletta, M; De Grandis, F; Cannata, SM; Cossu, G				Gargioli, Cesare; Coletta, Marcello; De Grandis, Fabrizio; Cannata, Stefano M.; Cossu, Giulio			PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GENE-EXPRESSION; SKELETAL-MUSCLE; MDX MICE; MOUSE; MATRIX-METALLOPROTEINASE-9; MESOANGIOBLASTS; ANGIOGENESIS; COLLAGEN	Sclerosis and reduced microvessel density characterize advanced stages of muscular dystrophy and hamper cell or gene delivery, precluding treatment of most individuals with Duchenne muscular dystrophy. Modified tendon fibroblasts expressing an angiogenic factor (placenta growth factor, PlGF) and a metalloproteinase (matrix metalloproteinase-9, MMP-9) are able to restore a vascular network and reduce collagen deposition, allowing efficient cell therapy in aged dystrophic mice. These data open the possibility of extending new therapies to currently untreatable individuals.	[Gargioli, Cesare; Coletta, Marcello; De Grandis, Fabrizio; Cossu, Giulio] San Raffaele Biomed Pk Fdn Rome, I-10028 Rome, Italy; [Gargioli, Cesare; De Grandis, Fabrizio; Cannata, Stefano M.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Cossu, Giulio] Ist Sci San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; [Cossu, Giulio] Univ Milan, Dept Biol, I-20129 Milan, Italy	University of Rome Tor Vergata; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan	Cossu, G (corresponding author), San Raffaele Biomed Pk Fdn Rome, 100 Via Castel Romano, I-10028 Rome, Italy.	cossu.giulio@hsr.it		Gargioli, Cesare/0000-0003-1742-3969	Italian Ministry of Health and of Research [RBINO63EWP]; European Community	Italian Ministry of Health and of Research; European Community(European Commission)	We would like to thank E. Dejana (University of Milan) for the gift of HUVECs, BV13 antibody to vascular endothelial cadherin and for helpful discussion; S. Bernardini for advice on histology; and S. Iacovelli for technical help. This work was supported by grants from Duchenne Parent Project Onlus, BMW, Association Francaise contre les Myopathies, the Italian Ministry of Health and of Research (grant RBINO63EWP) and the European Community (MyoAmp).	Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; Azeh I, 1998, NEUROSCI LETT, V256, P127, DOI 10.1016/S0304-3940(98)00776-9; Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Cossu G, 2007, TRENDS MOL MED, V13, P520, DOI 10.1016/j.molmed.2007.10.003; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; FERRARI G, 1995, HUM GENE THER, V6, P733, DOI 10.1089/hum.1995.6.6-733; Forst J, 1999, NEUROMUSCULAR DISORD, V9, P176, DOI 10.1016/S0960-8966(98)00113-8; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; GOLDSPINK G, 1994, NEUROMUSCULAR DISORD, V4, P183, DOI 10.1016/0960-8966(94)90019-1; Goodwin AM, 2007, MICROVASC RES, V74, P172, DOI 10.1016/j.mvr.2007.05.006; KIRKEBY S, 1988, BRIT J EXP PATHOL, V69, P597; Kobayashi K, 2006, ARTERIOSCL THROM VAS, V26, P1465, DOI 10.1161/01.ATV.0000223865.64812.26; MARSHALL PA, 1989, MUSCLE NERVE, V12, P528, DOI 10.1002/mus.880120703; Minasi MG, 2002, DEVELOPMENT, V129, P2773; Muntoni Francesco, 2005, Neuromuscul Disord, V15, P450, DOI 10.1016/j.nmd.2005.02.007; PASTORET C, 1995, J NEUROL SCI, V129, P97, DOI 10.1016/0022-510X(94)00276-T; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; ROWLAND LP, 1976, ARCH NEUROL-CHICAGO, V33, P315, DOI 10.1001/archneur.1976.00500050001001; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WEBSTER DF, 1982, BRIT J EXP PATHOL, V63, P50; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	26	100	102	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2008	14	9					973	978		10.1038/nm.1852	http://dx.doi.org/10.1038/nm.1852			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18660817				2022-12-27	WOS:000258988600031
J	Bustamante, JM; Bixby, LM; Tarleton, RL				Bustamante, Juan M.; Bixby, Lisa M.; Tarleton, Rick L.			Drug-induced cure drives conversion to a stable and protective CD8(+) T central memory response in chronic Chagas disease	NATURE MEDICINE			English	Article							TRYPANOSOMA-CRUZI INFECTION; CHRONIC VIRAL-INFECTION; PARASITOLOGICAL CURE; INTERFERON-GAMMA; CELL DYSFUNCTION; LEISHMANIA-MAJOR; PERSISTENCE; EFFECTOR; IMMUNITY; ANTIGEN	In this study, we document the development of stable, antigen-independent CD8(+) T cell memory after drug-induced cure of a chronic infection. By establishing a system for drug cure of chronic Trypanosoma cruzi infection, we present the first extensively documented case of total parasite clearance after drug treatment of this infection. Cure resulted in the emergence of a stable, parasite-specific CD8(+) T cell population with the characteristics of central memory cells, based upon expression of CD62L, CCR7, CD127, CD122, Bcl-2 and a reduced immediate in vivo CTL function. CD8(+) T cells from treated and cured mice also expanded more rapidly and provided greater protection following challenge than those from chronically infected mice. These results show that complete pathogen clearance results in stable, antigen-independent and protective T cell memory, despite the potentially exhausting effects of prior long-term exposure to antigen in this chronic infection.	[Bustamante, Juan M.; Bixby, Lisa M.; Tarleton, Rick L.] Univ Georgia, Coverdell Ctr, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA; [Bixby, Lisa M.; Tarleton, Rick L.] Univ Georgia, Coverdell Ctr, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Tarleton, RL (corresponding author), Univ Georgia, Coverdell Ctr, Ctr Trop & Emerging Global Dis, 500 DW Brooks Dr, Athens, GA 30602 USA.	Tarleton@cb.uga.edu	Tarleton, Rick/AES-8572-2022	Bustamante, Juan/0000-0003-2902-7111; Tarleton, Rick/0000-0002-9589-5243	NIAID NIH HHS [R01 AI022070-19, AI-33106, R01 AI033106, R01 AI022070, AI-22070, R01 AI033106-14] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022070, R01AI033106] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albareda MC, 2006, INT IMMUNOL, V18, P465, DOI 10.1093/intimm/dxh387; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Becker TC, 2002, J EXP MED, V195, P1541, DOI 10.1084/jem.20020369; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bengsch B, 2007, J VIROL, V81, P945, DOI 10.1128/JVI.01354-06; Boyman O, 2007, CURR OPIN IMMUNOL, V19, P320, DOI 10.1016/j.coi.2007.04.015; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; CANÇADO J. Romeu, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P29, DOI 10.1590/S0036-46652002000100006; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; Cummings KL, 2003, MOL BIOCHEM PARASIT, V129, P53, DOI 10.1016/S0166-6851(03)00093-8; Cush SS, 2007, J IMMUNOL, V179, P141, DOI 10.4049/jimmunol.179.1.141; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Ejrnaes M, 2006, J EXP MED, V203, P2461, DOI 10.1084/jem.20061462; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Gallimore A, 1998, J EXP MED, V187, P1647; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jabbari A, 2006, J EXP MED, V203, P919, DOI 10.1084/jem.20052237; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682; Martin DL, 2005, J IMMUNOL, V174, P1594, DOI 10.4049/jimmunol.174.3.1594; Martinez-Aran A, 2006, BIPOLAR DISORD, V8, P2; Penna A, 2007, HEPATOLOGY, V45, P588, DOI 10.1002/hep.21541; Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2; Rehermann B, 2007, SEMIN LIVER DIS, V27, P152, DOI 10.1055/s-2007-979468; Romanha AJ, 2002, J INFECT DIS, V186, P823, DOI 10.1086/342415; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; Shin H, 2007, CURR OPIN IMMUNOL, V19, P408, DOI 10.1016/j.coi.2007.06.004; Shin H, 2007, J EXP MED, V204, P941, DOI 10.1084/jem.20061937; TARLETON RL, 1994, INFECT IMMUN, V62, P1820, DOI 10.1128/IAI.62.5.1820-1829.1994; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TARLETON RL, 1990, J IMMUNOL, V144, P717; Urbina JA, 2003, INT J ANTIMICROB AG, V21, P39, DOI 10.1016/S0924-8579(02)00274-1; Vezys V, 2006, J EXP MED, V203, P2263, DOI 10.1084/jem.20060995; VIOTTI R, 1994, AM HEART J, V127, P151, DOI 10.1016/0002-8703(94)90521-5; Voehringer D, 2002, BLOOD, V100, P3698, DOI 10.1182/blood-2002-02-0657; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; WHO - World Health Organization, 2002, WHO TECHN REP SER, V905, P120; Yao ZQ, 2007, VIRAL IMMUNOL, V20, P276, DOI 10.1089/vim.2006.0096; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108; Zhang JY, 2007, BLOOD, V109, P4671, DOI 10.1182/blood-2006-09-044826; Zhang L, 1999, J INFECT DIS, V180, P480, DOI 10.1086/314889	49	161	163	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					542	550		10.1038/nm1744	http://dx.doi.org/10.1038/nm1744			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18425131	Green Accepted			2022-12-27	WOS:000255681800035
J	Bartlett, NW; Walton, RP; Edwards, MR; Aniscenko, J; Caramori, G; Zhu, J; Glanville, N; Choy, KJ; Jourdan, P; Burnet, J; Tuthill, TJ; Pedrick, MS; Hurle, MJ; Plumpton, C; Sharp, NA; Bussell, JN; Swallow, DM; Schwarze, J; Guy, B; WAlmond, J; Jeffery, PK; Lloyd, CM; Papi, A; Killington, RA; Rowlands, DJ; Blair, ED; Clarke, NJ; Johnston, SL				Bartlett, Nathan W.; Walton, Ross P.; Edwards, Michael R.; Aniscenko, Juliya; Caramori, Gaetano; Zhu, Jie; Glanville, Nicholas; Choy, Katherine J.; Jourdan, Patrick; Burnet, Jerome; Tuthill, Tobias J.; Pedrick, Michael S.; Hurle, Michael J.; Plumpton, Chris; Sharp, Nigel A.; Bussell, James N.; Swallow, Dallas M.; Schwarze, Jurgen; Guy, Bruno; WAlmond, Jeffrey; Jeffery, Peter K.; Lloyd, Clare M.; Papi, Alberto; Killington, Richard A.; Rowlands, David J.; Blair, Edward D.; Clarke, Neil J.; Johnston, Sebastian L.			Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation	NATURE MEDICINE			English	Article							BRONCHIAL EPITHELIAL-CELLS; POTENT ANTIVIRAL ACTIVITY; VIRUS-INDUCED ASTHMA; EFFICIENT REPLICATION; IN-VIVO; INFECTION; EXPRESSION; CHILDREN; ICAM-1; SEVERITY	Rhinoviruses cause serious morbidity and mortality as the major etiological agents of asthma exacerbations and the common cold. A major obstacle to understanding disease pathogenesis and to the development of effective therapies has been the lack of a small-animal model for rhinovirus infection. Of the 100 known rhinovirus serotypes, 90% (the major group) use human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor and do not bind mouse ICAM-1; the remaining 10% (the minor group) use a member of the low-density lipoprotein receptor family and can bind the mouse counterpart. Here we describe three novel mouse models of rhinovirus infection: minor-group rhinovirus infection of BALB/c mice, major-group rhinovirus infection of transgenic BALB/c mice expressing a mouse-human ICAM-1 chimera and rhinovirus- induced exacerbation of allergic airway inflammation. These models have features similar to those observed in rhinovirus infection in humans, including augmentation of allergic airway inflammation, and will be useful in the development of future therapies for colds and asthma exacerbations.	[Bartlett, Nathan W.; Walton, Ross P.; Edwards, Michael R.; Aniscenko, Juliya; Glanville, Nicholas; Jourdan, Patrick; Burnet, Jerome; Schwarze, Jurgen; Johnston, Sebastian L.] Wright Fleming Inst Infect & Immun, UK Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; [Bartlett, Nathan W.; Walton, Ross P.; Edwards, Michael R.; Aniscenko, Juliya; Glanville, Nicholas; Jourdan, Patrick; Burnet, Jerome; Schwarze, Jurgen; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, UK Ctr Allerg Mech Asthma, Med Res Council & Asthma, London W2 1PG, England; [Caramori, Gaetano; Papi, Alberto] Univ Ferrara, Res Ctr Asthma & Chron Obstruct Pulm Dis, I-44100 Ferrara, Italy; [Jeffery, Peter K.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Populat Genet & Gene Therapy, London SW3 6NP, England; [Choy, Katherine J.; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England; [Tuthill, Tobias J.; Killington, Richard A.; Rowlands, David J.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Pedrick, Michael S.; Hurle, Michael J.; Plumpton, Chris; Sharp, Nigel A.; Bussell, James N.; Blair, Edward D.; Clarke, Neil J.] Galxosmithkline Med Res Ctr, Stevenage SG1 2NY, Herts, England; [Swallow, Dallas M.] UCL, Dept Biol, Galton Lab, London WC1E 6BT, England; [WAlmond, Jeffrey] Sanofi Pasteur, F-69007 Lyon, France	Imperial College London; Imperial College London; University of Ferrara; Imperial College London; Imperial College London; University of Leeds; GlaxoSmithKline; University of London; University College London	Johnston, SL (corresponding author), Wright Fleming Inst Infect & Immun, UK Natl Heart & Lung Inst, Dept Resp Med, Norflok Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Caramori, Gaetano/AAS-8611-2020; Johnston, Sebastian Lennox/I-2423-2012; Schwarze, Jürgen/F-7396-2011; Papi, alberto/AAC-1888-2019	Caramori, Gaetano/0000-0002-9807-327X; Johnston, Sebastian Lennox/0000-0003-3009-9200; Schwarze, Jurgen/0000-0002-6899-748X; Edwards, Michael Robert/0000-0001-6837-0532; Glanville, Nicholas/0000-0003-0946-5050; PAPI, ALBERTO/0000-0002-6924-4500; Lloyd, Clare/0000-0001-8977-6726; Bartlett, Nathan/0000-0002-2715-5163	Medical Research Council [G0400503B, G9900991B] Funding Source: researchfish; Wellcome Trust [087618, 057704] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Bartlett NW, 2005, J GEN VIROL, V86, P1589, DOI 10.1099/vir.0.80904-0; Bertino JS, 2002, AM J MED, V112, p42S; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Harris JR, 2005, J VIROL, V79, P5363, DOI 10.1128/JVI.79.9.5363-5373.2005; Harris JR, 2003, J VIROL, V77, P4773, DOI 10.1128/JVI.77.8.4773-4780.2003; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Inoue D, 2006, RESP PHYSIOL NEUROBI, V154, P484, DOI 10.1016/j.resp.2005.11.006; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Liao F, 1999, J IMMUNOL, V162, P186; LOMAX NB, 1989, J VIROL, V63, P2396, DOI 10.1128/JVI.63.5.2396-2399.1989; MURPHY BR, 1990, VIRUS RES, V16, P153, DOI 10.1016/0168-1702(90)90019-8; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nakayama T, 2001, INT IMMUNOL, V13, P95, DOI 10.1093/intimm/13.1.95; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; REGISTER RB, 1991, J VIROL, V65, P6589, DOI 10.1128/JVI.65.12.6589-6596.1991; STAUNTON DE, 1992, J IMMUNOL, V148, P3271; Tuthill TJ, 2003, J GEN VIROL, V84, P2829, DOI 10.1099/vir.0.19109-0; Wark PAB, 2006, THORAX, V61, P909, DOI 10.1136/thx.2005.045187; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	30	277	285	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					199	204		10.1038/nm1713	http://dx.doi.org/10.1038/nm1713			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18246079	Green Accepted			2022-12-27	WOS:000252946700030
J	Fujikado, N; Saijo, S; Yonezawa, T; Shimamori, K; Ishii, A; Sugai, S; Kotaki, H; Sudo, K; Nose, M; Iwakura, Y				Fujikado, Noriyuki; Saijo, Shinobu; Yonezawa, Tomo; Shimamori, Kazusuke; Ishii, Akina; Sugai, Sho; Kotaki, Hayato; Sudo, Katsuko; Nose, Masato; Iwakura, Yoichiro			Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells	NATURE MEDICINE			English	Article							RESEMBLING RHEUMATOID-ARTHRITIS; MOTH-EATEN; T-CELLS; RECEPTOR; SUPPRESSION; MUTATIONS; INDUCTION; ITIM	The dendritic cell immunoreceptor (official gene symbol Clec4a2, called Dcir here) is a C-type lectin receptor expressed mainly in dendritic cells (DCs) that has a carbohydrate recognition domain in its extracellular portion and an immunoreceptor tyrosine-based inhibitory motif, which transduces negative signals into cells, in its cytoplasmic portion(1). We found high Dcir expression in the joints of two mouse rheumatoid arthritis models(2-4). Because the structural characteristics of Dcir suggest that it may have an immune regulatory role, and because autoimmune-related genes are mapped to the DCIR locus in humans, we generated Dcir(-/-) mice to learn more about the pathological roles of this molecule. We found that aged Dcir(-/-) mice spontaneously develop sialadenitis and enthesitis associated with elevated serum autoantibodies. Dcir(-/-) mice showed a markedly exacerbated response to collagen-induced arthritis. The DC population was expanded excessively in aged and type II collagen-immunized Dcir(-/-) mice. Upon treatment with granulocyte-macrophage colony-stimulating factor, Dcir(-/-) mouse-derived bone marrow cells (BMCs) differentiated into DCs more efficiently than did wild-type BMCs, owing to enhanced signal transducer and activator of transcription-5 phosphorylation. These observations indicate that Dcir is a negative regulator of DC expansion and has a crucial role in maintaining the homeostasis of the immune system.	[Fujikado, Noriyuki; Saijo, Shinobu; Yonezawa, Tomo; Shimamori, Kazusuke; Ishii, Akina; Sugai, Sho; Sudo, Katsuko; Iwakura, Yoichiro] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Minato Ku, Tokyo 108, Japan; [Yonezawa, Tomo] Genodive Pharma, Kanagawa 2591144, Japan; [Nose, Masato] Ehime Univ, Grad Sch Med, Dept Pathol, Toon, Ehime 7910295, Japan	University of Tokyo; Ehime University	Iwakura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Med Expt, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	iwakura@ims.u-tokyo.ac.jp	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Fujikado, Noriyuki/0000-0002-3183-5866; Fujikado, Noriyuki/0000-0002-0415-5929				Bates EEM, 1999, J IMMUNOL, V163, P1973; Chen M, 2006, SCIENCE, V311, P1160, DOI 10.1126/science.1122545; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Franceschini F, 2005, AUTOIMMUNITY, V38, P55, DOI 10.1080/08916930400022954; Fujikado N, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1985; Helenius LMJ, 2001, ANN RHEUM DIS, V60, P744, DOI 10.1136/ard.60.8.744; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Huang X, 2001, BIOCHEM BIOPH RES CO, V281, P131, DOI 10.1006/bbrc.2001.4322; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; Kanazawa N, 2002, J INVEST DERMATOL, V118, P261, DOI 10.1046/j.0022-202x.2001.01633.x; Lorentzen JC, 2007, ARTHRITIS RHEUM-US, V56, P2620, DOI 10.1002/art.22813; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Richard M, 2006, MOL IMMUNOL, V43, P1716, DOI 10.1016/j.molimm.2005.10.006; Saijo S, 2002, ARTHRITIS RHEUM-US, V46, P533, DOI 10.1002/art.10172; Shparago N, 1996, INT IMMUNOL, V8, P781, DOI 10.1093/intimm/8.5.781; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stranges PB, 2007, IMMUNITY, V26, P629, DOI 10.1016/j.immuni.2007.03.016; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Wandstrat A, 2001, NAT IMMUNOL, V2, P802, DOI 10.1038/ni0901-802; Yonezawa T, 2004, BIOCHEM BIOPH RES CO, V314, P805, DOI 10.1016/j.bbrc.2003.12.175; Zhao PL, 2006, EXP HEMATOL, V34, P951, DOI 10.1016/j.exphem.2006.04.015	23	151	157	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					176	180		10.1038/nm1697	http://dx.doi.org/10.1038/nm1697			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18204462				2022-12-27	WOS:000252946700026
J	Hollyfield, JG; Bonilha, VL; Rayborn, ME; Yang, XP; Shadrach, KG; Lu, L; Ufret, RL; Salomon, RG; Perez, VL				Hollyfield, Joe G.; Bonilha, Vera L.; Rayborn, Mary E.; Yang, Xiaoping; Shadrach, Karen G.; Lu, Liang; Ufret, Rafael L.; Salomon, Robert G.; Perez, Victor L.			Oxidative damage-induced inflammation initiates age-related macular degeneration	NATURE MEDICINE			English	Article							FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING; BRUCHS MEMBRANE; DRUSEN; LIPIDS; MODEL; RISK; MICE; PHOSPHOLIPIDS; PATHOGENESIS	Oxidative damage and inflammation are postulated to be involved in age-related macular degeneration (AMD). However, the molecular signal(s) linking oxidation to inflammation in this late-onset disease is unknown. Here we describe AMD-like lesions in mice after immunization with mouse serum albumin adducted with carboxyethylpyrrole, a unique oxidation fragment of docosahexaenoic acid that has previously been found adducting proteins in drusen from AMD donor eye tissues(1) and in plasma samples(2) from individuals with AMD. Immunized mice develop antibodies to this hapten, fix complement component-3 in Bruch's membrane, accumulate drusen below the retinal pigment epithelium during aging, and develop lesions in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry form of AMD. We hypothesize that these mice are sensitized to the generation of carboxyethylpyrrole adducts in the outer retina, where docosahexaenoic acid is abundant and conditions for oxidative damage are permissive. This new model provides a platform for dissecting the molecular pathology of oxidative damage in the outer retina and the immune response contributing to AMD.	[Hollyfield, Joe G.; Bonilha, Vera L.; Rayborn, Mary E.; Yang, Xiaoping; Shadrach, Karen G.; Ufret, Rafael L.; Perez, Victor L.] Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44195 USA; [Lu, Liang; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University	Hollyfield, JG (corresponding author), Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44195 USA.	hollyfj@ccf.org; vperez4@med.miami.edu	Bonilha, Vera/AAS-8566-2020; Salomon, Robert G/C-3463-2008; Mohammed, Imran/J-8271-2012; Perez, Victor L./AAY-8633-2020	Bonilha, Vera/0000-0002-6166-5124; Mohammed, Imran/0000-0002-8412-0768; Salomon, Robert/0000-0001-9456-3557	NATIONAL EYE INSTITUTE [R56EY014240, R24EY015638, R01EY014240, R21EY017153, K08EY014912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER; NEI NIH HHS [K08EY014912, R21 EY017153, K08 EY014912, R21EY017153, R56 EY014240, R01 EY014240-06, R01 EY014240, R56EY10240, R24 EY015638, R24 EY015638-05, R01EY014240, R56 EY014240-06, R24EY015638] Funding Source: Medline; NIGMS NIH HHS [R01GM21249, R01 GM021249] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X; ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6; Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529; Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039; Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PEAKMAN M, 1989, J CLIN PATHOL, V42, P1018, DOI 10.1136/jcp.42.10.1018; PERCOPO CM, 1990, J IMMUNOL, V145, P4101; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558; Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2; Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618	29	537	587	1	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					194	198		10.1038/nm1709	http://dx.doi.org/10.1038/nm1709			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18223656	Green Accepted			2022-12-27	WOS:000252946700029
J	Ghosn, Z				Ghosn, Zeinab			Crackdown on pharmacies in Lebanon spurs blame game	NATURE MEDICINE			English	News Item																			0	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					359	359		10.1038/nm0410-359a	http://dx.doi.org/10.1038/nm0410-359a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376022				2022-12-27	WOS:000276446800014
J	Barouch, DH; O'Brien, KL; Simmons, NL; King, SL; Abbink, P; Maxfield, LF; Sun, YH; La Porte, A; Riggs, AM; Lynch, DM; Clark, SL; Backus, K; Perry, JR; Seaman, MS; Carville, A; Mansfield, KG; Szinger, JJ; Fischer, W; Muldoon, M; Korber, B				Barouch, Dan H.; O'Brien, Kara L.; Simmons, Nathaniel L.; King, Sharon L.; Abbink, Peter; Maxfield, Lori F.; Sun, Ying-Hua; La Porte, Annalena; Riggs, Ambryice M.; Lynch, Diana M.; Clark, Sarah L.; Backus, Katherine; Perry, James R.; Seaman, Michael S.; Carville, Angela; Mansfield, Keith G.; Szinger, James J.; Fischer, Will; Muldoon, Mark; Korber, Bette			Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNOGENICITY; REPLICATION; VARIANTS; VECTORS; STEP	The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development(1,2). Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity(3). Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.	[Barouch, Dan H.; O'Brien, Kara L.; Simmons, Nathaniel L.; King, Sharon L.; Abbink, Peter; Maxfield, Lori F.; Sun, Ying-Hua; La Porte, Annalena; Riggs, Ambryice M.; Lynch, Diana M.; Clark, Sarah L.; Backus, Katherine; Perry, James R.; Seaman, Michael S.] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02215 USA; [Barouch, Dan H.] Massachusetts Gen Hosp, Ragon Inst, MIT, Boston, MA 02114 USA; [Barouch, Dan H.] Harvard Univ, Boston, MA 02115 USA; [Carville, Angela; Mansfield, Keith G.] New England Reg Primate Res Ctr, Southborough, MA 01772 USA; [Szinger, James J.; Fischer, Will; Korber, Bette] Los Alamos Natl Lab, Los Alamos, NM USA; [Muldoon, Mark] Univ Manchester, Sch Math, Manchester, Lancs, England; [Muldoon, Mark; Korber, Bette] Santa Fe Inst, Santa Fe, NM 87501 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Manchester; The Santa Fe Institute	Barouch, DH (corresponding author), Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02215 USA.	dbarouch@bidmc.harvard.edu	Barouch, Dan/Y-3918-2019; Muldoon, Mark/T-9192-2019; Fischer, Will/B-1323-2013; Muldoon, Mark R/C-7505-2009; Fischer, Will/AAD-2807-2019	Fischer, Will/0000-0003-4579-4062; Fischer, Will/0000-0003-4579-4062; Szinger, James/0000-0002-6605-9940; Simmons, Nathaniel/0000-0001-6080-2783; Maxfield, Lori/0000-0002-7595-6205; Muldoon, Mark/0000-0002-5004-7195; Korber, Bette/0000-0002-2026-5757	US National Institutes of Health (NIH) AIDS Research and Reference Reagent Program; NIH [AI058727, AI066305, AI066924, AI078526, AI084794, RR000168, AI067854, AI061734]; Los Alamos National Laboratory; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168, K26RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061734, P30AI060354, R01AI066924, R01AI058727, U19AI067854, U01AI067854, U19AI078526, R01AI084794, U19AI066305] Funding Source: NIH RePORTER	US National Institutes of Health (NIH) AIDS Research and Reference Reagent Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Los Alamos National Laboratory(United States Department of Energy (DOE)Los Alamos National Laboratory); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank B. Haynes, N. Letvin, P. Swanson, F. Stephens, B. Hahn, J. McElrath, J. Goudsmit, M. Pau, N. Michael, M. Marovich and M. Pensiero for generous advice and assistance. We obtained peptides from the US National Institutes of Health (NIH) AIDS Research and Reference Reagent Program. We acknowledge support from NIH grants AI058727 (D. H. B.), AI066305 (D. H. B.), AI066924 (D. H. B.), AI078526 (D. H. B.), AI084794 (D. H. B.), RR000168, AI067854 (B. K.), AI061734 (B. K.) and directed research funding from Los Alamos National Laboratory (B. K.).	Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06; Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352; Barouch DH, 2005, NAT IMMUNOL, V6, P247, DOI 10.1038/ni1167; Barry AP, 2007, J IMMUNOL, V178, P8002, DOI 10.4049/jimmunol.178.12.8002; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kong WP, 2009, J VIROL, V83, P2201, DOI 10.1128/JVI.02256-08; Korber BT, 2009, J VIROL, V83, P8300, DOI 10.1128/JVI.00114-09; Li FS, 2006, VACCINE, V24, P6893, DOI 10.1016/j.vaccine.2006.06.009; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; MONTEFIORI D, 2004, CURR PROTOC IMMUNOL, V64; Pinheiro J, 2001, MIXED EFFECTS MODELS; Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105; Sodora DL, 2009, NAT MED, V15, P861, DOI 10.1038/nm.2013; Thurmond J, 2008, BIOINFORMATICS, V24, P1639, DOI 10.1093/bioinformatics/btn251	20	291	333	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					319	U116		10.1038/nm.2089	http://dx.doi.org/10.1038/nm.2089			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20173752	Green Accepted, Bronze			2022-12-27	WOS:000275289500038
J	Corey, L; McElrath, MJ				Corey, Lawrence; McElrath, M. Juliana			HIV vaccines: mosaic approach to virus diversity	NATURE MEDICINE			English	Editorial Material							DOUBLE-BLIND; INFECTION; TRIAL; THAILAND	The extraordinary diversity of HIV is a major barrier in the path of developing a vaccine. One way forward may be mosaic antigens-biometrically designed genes that maximize overlap between sequences used in the vaccine and circulating HIV-1 strains worldwide (pages 319-323 and 324-328).	[Corey, Lawrence; McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA; [Corey, Lawrence] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Corey, Lawrence; McElrath, M. Juliana] Univ Washington, Dept Med, Seattle, WA 98195 USA; [McElrath, M. Juliana] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, 1124 Columbia St, Seattle, WA 98104 USA.	lcorey@u.washington.org	Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436				Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Li FS, 2007, CURR HIV RES, V5, P97, DOI 10.2174/157016207779316260; Liu Y, 2009, J VIROL, V83, P10821, DOI 10.1128/JVI.00839-09; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Santra S, 2010, NAT MED, V16, P324, DOI 10.1038/nm.2108	11	20	21	2	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					268	270		10.1038/nm0310-268	http://dx.doi.org/10.1038/nm0310-268			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208511	Bronze			2022-12-27	WOS:000275289500028
J	Houghton, AM; Rzymkiewicz, DM; Ji, HB; Gregory, AD; Egea, EE; Metz, HE; Stolz, DB; Land, SR; Marconcini, LA; Kliment, CR; Jenkins, KM; Beaulieu, KA; Mouded, M; Frank, SJ; Wong, KK; Shapiro, SD				Houghton, A. McGarry; Rzymkiewicz, Danuta M.; Ji, Hongbin; Gregory, Alyssa D.; Egea, Eduardo E.; Metz, Heather E.; Stolz, Donna B.; Land, Stephanie R.; Marconcini, Luiz A.; Kliment, Corrine R.; Jenkins, Kimberly M.; Beaulieu, Keith A.; Mouded, Majd; Frank, Stuart J.; Wong, Kwok K.; Shapiro, Steven D.			Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth	NATURE MEDICINE			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; LEUKOCYTE ELASTASE; G972R VARIANT; K-RAS; CANCER; INTERLEUKIN-8; ASSOCIATION; EXPRESSION; PHOSPHORYLATION; INFLAMMATION	Lung cancer is the leading cause of cancer death worldwide(1). Recent data suggest that tumor-associated inflammatory cells may modify lung tumor growth and invasiveness(2,3). To determine the role of neutrophil elastase (encoded by Elane) on tumor progression, we used the loxP-Stop-loxP K-ras(G12D) (LSL-K-ras) model of mouse lung adenocarcinoma(4) to generate LSL-K-ras-Elane(-/-) mice. Tumor burden was markedly reduced in LSL-K-ras-Elane(-/-) mice at all time points after induction of mutant K-ras expression. Kaplan-Meier survival analysis showed that whereas all LSL-K-ras-Elane(+/+) mice died, none of the mice lacking neutrophil elastase died. Neutrophil elastase directly induced tumor cell proliferation in both human and mouse lung adenocarcinomas by gaining access to an endosomal compartment within tumor cells, where it degraded insulin receptor substrate-1 (IRS-1). Immunoprecipitation studies showed that, as neutrophil elastase degraded IRS-1, there was increased interaction between phosphatidylinositol 3-kinase (PI3K) and the potent mitogen platelet-derived growth factor receptor (PDGFR), thereby skewing the PI3K axis toward tumor cell proliferation. The inverse relationship identified between neutrophil elastase and IRS-1 in LSL-K-ras mice was also identified in human lung adenocarcinomas, thus translating these findings to human disease. This study identifies IRS-1 as a key regulator of PI3K within malignant cells. Additionally, to our knowledge, this is the first description of a secreted proteinase gaining access to the inside of a cell and altering intracellular signaling.	[Houghton, A. McGarry; Gregory, Alyssa D.; Egea, Eduardo E.; Metz, Heather E.; Kliment, Corrine R.; Jenkins, Kimberly M.; Beaulieu, Keith A.; Mouded, Majd; Shapiro, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; [Houghton, A. McGarry; Gregory, Alyssa D.; Egea, Eduardo E.; Metz, Heather E.; Jenkins, Kimberly M.; Beaulieu, Keith A.; Mouded, Majd; Shapiro, Steven D.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; [Houghton, A. McGarry; Stolz, Donna B.; Land, Stephanie R.; Shapiro, Steven D.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA; [Rzymkiewicz, Danuta M.; Marconcini, Luiz A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Ji, Hongbin] Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Ji, Hongbin] Chinese Acad Sci, Shanghai, Peoples R China; [Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA; [Land, Stephanie R.] Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA USA; [Frank, Stuart J.] Univ Alabama, Div Endocrinol Diabet & Metab, Birmingham, AL USA; [Wong, Kwok K.] Dana Farber Canc Inst, Dept Med, Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA; [Wong, Kwok K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wong, Kwok K.] Harvard Univ, Sch Med, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Houghton, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.	houghtonm@dom.pitt.edu	Kliment, Corrine/HGE-0877-2022		US National Institutes of Health National Heart, Lung, and Blood Institute [K08HL085286, RO1HL054853, RO1DK058259]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054853, K08HL085286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058259] Funding Source: NIH RePORTER	US National Institutes of Health National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants K08HL085286 and RO1HL054853 from the US National Institutes of Health National Heart, Lung, and Blood Institute ( A. M. H. and S. D. S.) and by grant RO1DK058259 from the US National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (S.J.F.). ONO Pharmaceutical provided the ONO-5046. LSL-K-ras mice were provided by T. Jacks ( Massachusetts Institute of Technology). AdenoCre was obtained from the University of Iowa Gene Transfer Vector Core. We would like to recognize members of the Shapiro lab for their assistance and comments regarding the preparation of this manuscript.	ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Bellocq A, 1998, AM J PATHOL, V152, P83; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dearth RK, 2007, CELL CYCLE, V6, P705, DOI 10.4161/cc.6.6.4035; Foekens JA, 2003, CANCER RES, V63, P337; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Han CH, 2006, ONCOL REP, V16, P1205; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Houghton AM, 2008, NAT MED, V14, P1023, DOI 10.1038/nm1008-1023; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Karin M, 2005, NAT MED, V11, P20, DOI 10.1038/nm0105-20; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Liou TG, 1996, J IMMUNOL, V157, P2624; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Neuhausen SL, 2005, PROSTATE, V64, P168, DOI 10.1002/pros.20216; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Peto R, 1999, NAT MED, V5, P15, DOI 10.1038/4691; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Sentinelli F, 2006, J ENDOCRINOL, V188, P271, DOI 10.1677/joe.1.06290; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Tu YZ, 2001, BIOCHEM J, V354, P315, DOI 10.1042/0264-6021:3540315; Wada Y, 2007, ONCOL REP, V17, P161; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; Wilson DO, 2008, AM J RESP CRIT CARE, V178, P738, DOI 10.1164/rccm.200803-435OC; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	32	463	490	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2010	16	2					219	U127		10.1038/nm.2084	http://dx.doi.org/10.1038/nm.2084			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20081861	Green Accepted			2022-12-27	WOS:000274297000044
J	Chen, GL; Subbarao, K				Chen, Grace L.; Subbarao, Kanta			Attacking the flu Neutralizing antibodies may lead to 'universal' vaccine	NATURE MEDICINE			English	Editorial Material							INFLUENZA-A VIRUS; AVIAN INFLUENZA; UNITED-STATES; H5N1; EPITOPE; CELLS; HEMAGGLUTININS; H1; H2	Flu remains a major killer because of imperfect vaccines and widespread resistance to existing antivirals-problems particularly acute during a pandemic. New findings at the bedside and at the bench could lead to improvements on both fronts. Grace Chen and Kanta Subbarao discuss the implications of research identifying human antibodies than can neutralize a range of viral subtypes. The findings may help lead to a 'universal' vaccine against these diverse and rapidly evolving viruses. Estanislao Nistal-Villan and Adolfo Garcia-Sastre examine two recent studies that reveal the crystal structure of a promising viral drug target, the unique endonuclease domain of the viral polymerase. The findings open the door to the rational design of new influenza virus inhibitors.	[Chen, Grace L.; Subbarao, Kanta] NIAID, Infect Dis Lab, US Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chen, GL (corresponding author), NIAID, Infect Dis Lab, US Natl Inst Hlth, Bethesda, MD 20892 USA.	ksubbarao@niaid.nih.gov		Subbarao, Kanta/0000-0003-1713-3056	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000933] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000933-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Gioia C, 2008, EMERG INFECT DIS, V14, P121, DOI 10.3201/eid1401.061283; Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Roti M, 2008, J IMMUNOL, V180, P1758, DOI 10.4049/jimmunol.180.3.1758; Russell RJ, 2008, P NATL ACAD SCI USA, V105, P17736, DOI 10.1073/pnas.0807142105; Smirnov YA, 1999, ACTA VIROL, V43, P237; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; Wang TT, 2009, NAT STRUCT MOL BIOL, V16, P233, DOI 10.1038/nsmb.1574	13	28	30	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2009	15	11					1251	1252		10.1038/nm1109-1251	http://dx.doi.org/10.1038/nm1109-1251			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19893556	Green Accepted			2022-12-27	WOS:000271543700011
J	Johnson, PR; Schnepp, BC; Zhang, JC; Connell, MJ; Greene, SM; Yuste, E; Desrosiers, RC; Clark, KR				Johnson, Philip R.; Schnepp, Bruce C.; Zhang, Jianchao; Connell, Mary J.; Greene, Sean M.; Yuste, Eloisa; Desrosiers, Ronald C.; Clark, K. Reed			Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ADENOASSOCIATED VIRAL VECTORS; HUMAN MONOCLONAL-ANTIBODY; HIV-1 VACCINE; REGULATED EXPRESSION; THERAPEUTIC LEVELS; PRIMATE MUSCLE; AIDS VACCINE; DOUBLE-BLIND; IN-VIVO	The key to an effective HIV vaccine is development of an immunogen that elicits persisting antibodies with broad neutralizing activity against field strains of the virus. Unfortunately, very little progress has been made in finding or designing such immunogens. Using the simian immunodeficiency virus (SIV) model, we have taken a markedly different approach: delivery to muscle of an adeno-associated virus gene transfer vector expressing antibodies or antibody-like immunoadhesins having predetermined SIV specificity. With this approach, SIV-specific molecules are endogenously synthesized in myofibers and passively distributed to the circulatory system. Using such an approach in monkeys, we have now generated long-lasting neutralizing activity in serum and have observed complete protection against intravenous challenge with virulent SIV. In essence, this strategy bypasses the adaptive immune system and holds considerable promise as a unique approach to an effective HIV vaccine.	[Johnson, Philip R.; Schnepp, Bruce C.; Connell, Mary J.; Greene, Sean M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Johnson, Philip R.; Schnepp, Bruce C.; Connell, Mary J.; Greene, Sean M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Zhang, Jianchao; Clark, K. Reed] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Yuste, Eloisa; Desrosiers, Ronald C.] New England Primate Res Ctr, Southborough, MA USA; [Yuste, Eloisa; Desrosiers, Ronald C.] Harvard Univ, Sch Med, Southborough, MA 01772 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Harvard University	Johnson, PR (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	johnsonphi@chop.edu	Clark, Kelly/E-2900-2011; Johnson, Philip R/A-6892-2009; Yuste, Eloisa/R-9493-2019	Yuste, Eloisa/0000-0002-9484-9974	US National Institutes of Health National Institute of Allergy; Infectious Diseases Division of AIDS; National Institutes of Health National Center for Research Resources; The Children's Hospital of Philadelphia.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026507] Funding Source: NIH RePORTER	US National Institutes of Health National Institute of Allergy(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Infectious Diseases Division of AIDS; National Institutes of Health National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); The Children's Hospital of Philadelphia.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank A. Hessell and D. Burton (The Scripps Research Institute) for providing the SIV Fab molecular clones, D. McCarty (The Research Institute at Nationwide Children's Hospital) for the self-complementary AAV vector genome, R. Doms (University of Pennsylvania) for purified SIVmac gp 120, J. Bixby and E. Mackenzie for technical assistance and M. Piatek and J. Lifson for SIV viral load data. We also thank J. Hoxie and S. Douglas for helpful comments on the manuscript. Funding for this work was provided by grants from the US National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDS (P. R. J. and R. C. D.), National Institutes of Health National Center for Research Resources (R. C. D.) and support from The Children's Hospital of Philadelphia.	ALLAWAY GP, 1993, AIDS RES HUM RETROV, V9, P581, DOI 10.1089/aid.1993.9.581; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barash S, 2002, BIOCHEM BIOPH RES CO, V294, P835, DOI 10.1016/S0006-291X(02)00566-1; Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Cadogan M, 2008, LANCET INFECT DIS, V8, P675, DOI 10.1016/S1473-3099(08)70205-6; Chenuaud P, 2004, MOL THER, V9, P410, DOI 10.1016/j.ymthe.2003.12.015; Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427; Coura RD, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-99; Davidoff AM, 2005, MOL THER, V11, P875, DOI 10.1016/j.ymthe.2004.12.022; Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Fang JM, 2007, MOL THER, V15, P1153, DOI 10.1038/sj.mt.6300142; Fang JM, 2005, NAT BIOTECHNOL, V23, P584, DOI 10.1038/nbt1087; Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Frade R, 2008, CANCER GENE THER, V15, P591, DOI 10.1038/cgt.2008.51; He J, 2006, CYTOKINE, V36, P296, DOI 10.1016/j.cyto.2007.02.010; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Honegger A., 2008, V181, P47; Jiang MH, 2006, CLIN CANCER RES, V12, P6179, DOI 10.1158/1078-0432.CCR-06-0746; Johnson WE, 2003, J VIROL, V77, P9993, DOI 10.1128/JVI.77.18.9993-10003.2003; Jones TD, 2004, J INTERF CYTOK RES, V24, P560, DOI 10.1089/jir.2004.24.560; Kasuya K, 2005, MOL THER, V11, P237, DOI 10.1016/j.ymthe.2004.10.018; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; Lewis AD, 2002, J VIROL, V76, P8769, DOI 10.1128/JVI.76.17.8769-8775.2002; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McCarty DM, 2003, GENE THER, V10, P2112, DOI 10.1038/sj.gt.3302134; McCarty DM, 2008, MOL THER, V16, P1648, DOI 10.1038/mt.2008.171; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; Means RE, 2001, J VIROL, V75, P3903, DOI 10.1128/JVI.75.8.3903-3915.2001; Morgan C, 2008, PLOS MED, V5, P1200, DOI 10.1371/journal.pmed.0050173; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Ostedgaard LS, 2005, P NATL ACAD SCI USA, V102, P2952, DOI 10.1073/pnas.0409845102; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Penaud-Budloo M, 2008, J VIROL, V82, P7875, DOI 10.1128/JVI.00649-08; Pereboev A, 2008, ANTIVIR RES, V77, P6, DOI 10.1016/j.antiviral.2007.08.010; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501; Sandalon Z, 2004, J VIROL, V78, P12355, DOI 10.1128/JVI.78.22.12355-12365.2004; Sanhadji K, 2000, AIDS, V14, P2813, DOI 10.1097/00002030-200012220-00002; Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002; Schnepp BC, 2003, J VIROL, V77, P3495, DOI 10.1128/JVI.77.6.3495-3504.2003; Schnepp BC, 2009, J VIROL, V83, P1456, DOI 10.1128/JVI.01686-08; Skaricic D, 2008, VIROLOGY, V378, P79, DOI 10.1016/j.virol.2008.04.016; Swann PG, 2008, CURR OPIN IMMUNOL, V20, P493, DOI 10.1016/j.coi.2008.05.013; Toromanoff A, 2008, MOL THER, V16, P1291, DOI 10.1038/mt.2008.87; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622; Watkins David I, 2008, Top HIV Med, V16, P7; Yuvaraj S, 2008, MOL NUTR FOOD RES, V52, P913, DOI 10.1002/mnfr.200700132; Zuber C, 2008, J GEN VIROL, V89, P2055, DOI 10.1099/vir.0.83670-0; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	60	247	271	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2009	15	8					901	U99		10.1038/nm.1967	http://dx.doi.org/10.1038/nm.1967			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19448633	Green Accepted			2022-12-27	WOS:000268770400034
J	Sato, T; Onai, N; Yoshihara, H; Arai, F; Suda, T; Ohteki, T				Sato, Taku; Onai, Nobuyuki; Yoshihara, Hiroki; Arai, Fumio; Suda, Toshio; Ohteki, Toshiaki			Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion	NATURE MEDICINE			English	Article							OSTEOBLASTIC NICHE; DENDRITIC CELLS; IFN-ALPHA/BETA; IRF-2; VIVO; PROLIFERATION; INDUCTION; EXPANSION; RESPONSES; BETA	Type I interferons (IFNs), a family of cytokines, orchestrate numerous biological and cellular processes(1-3). Although it is well known that type I IFNs are essential for establishing the host antiviral state(4), their role in hematopoietic homeostasis has not been studied. Here we show that type I IFNs induce proliferation and exhaustion in hematopoietic stem cells (HSCs) and that interferon regulatory factor-2 (IRF2), a transcriptional suppressor of type I IFN signaling(5,6), preserves the self-renewal and multilineage differentiation capacity of HSCs. HSCs were substantially less abundant in the bone marrow of Irf2(-/-) as compared to Irf2(+/-) mice. Irf2(-/-) HSCs showed enhanced cell cycling status and failed to produce hematopoietic cells in competitive repopulation assays, and the reconstituting capacity of Irf2(-/-) HSCs was restored by disabling type I IFN signaling in these cells. In wild-type mice, injection of poly(I:C), an inducer of type I IFN signaling, or IFN-alpha induced HSC proliferation, and chronic type I IFN signaling further reduced the number of quiescent HSCs. Notably, combined poly(I:C) and 5-fluorouracil (5-FU) treatment allowed exogenous HSC engraftment and hematopoietic reconstitution in WT mice. Our findings provide insight into the molecular basis for the maintenance of HSC quiescence and may lead to improvements in bone marrow transplantation and type I IFN-based therapies for viral infection and cancer.	[Sato, Taku; Onai, Nobuyuki; Ohteki, Toshiaki] Akita Univ, Grad Sch Med, Dept Immunol, Akita 010, Japan; [Sato, Taku; Onai, Nobuyuki; Ohteki, Toshiaki] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Yoshihara, Hiroki; Arai, Fumio; Suda, Toshio] Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat, Tokyo, Japan; [Ohteki, Toshiaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Biodefense Res, Tokyo, Japan	Akita University; Japan Science & Technology Agency (JST); Keio University; Tokyo Medical & Dental University (TMDU)	Ohteki, T (corresponding author), Akita Univ, Grad Sch Med, Dept Immunol, Akita 010, Japan.	ohteki.bre@mri.tmd.ac.jp	Suda, Toshio/H-6761-2013; Arai, Fumio/J-5241-2013	Suda, Toshio/0000-0001-7540-1771; Arai, Fumio/0000-0003-1936-4907; Yoshihara, Hiroki/0000-0001-5128-4515; Onai, Nobuyuki/0000-0003-2246-4917	Ministry of Education, Science, Sports and Culture of Japan; Global Center of Excellence (COE) Program	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global Center of Excellence (COE) Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by a Grant-in-Aid for Young Scientists (B) (to T. Sato), a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports and Culture of Japan (T.O.) and a Grant-in-Aid for the Global Center of Excellence (COE) Program.	Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Arai F, 2007, ANN NY ACAD SCI, V1106, P41, DOI 10.1196/annals.1392.005; Biron CA, 1998, SEMIN IMMUNOL, V10, P383, DOI 10.1006/smim.1998.0138; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Honda K, 2004, P NATL ACAD SCI USA, V101, P2416, DOI 10.1073/pnas.0307336101; Huttmann A, 2001, EXP HEMATOL, V29, P1109, DOI 10.1016/S0301-472X(01)00684-1; Ichikawa E, 2004, P NATL ACAD SCI USA, V101, P3909, DOI 10.1073/pnas.0400610101; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LERNER C, 1990, EXP HEMATOL, V18, P114; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mizutani T, 2008, EXP HEMATOL, V36, P255, DOI 10.1016/j.exphem.2007.11.004; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Qian H, 2007, CELL STEM CELL, V1, P671, DOI 10.1016/j.stem.2007.10.008; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Van Zant G, 2003, EXP HEMATOL, V31, P659, DOI 10.1016/S0301-472X(03)00088-2; Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	27	307	313	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					696	U133		10.1038/nm.1973	http://dx.doi.org/10.1038/nm.1973			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19483695				2022-12-27	WOS:000266731600030
J	Nagahara, AH; Merrill, DA; Coppola, G; Tsukada, S; Schroeder, BE; Shaked, GM; Wang, L; Blesch, A; Kim, A; Conner, JM; Rockenstein, E; Chao, MV; Koo, EH; Geschwind, D; Masliah, E; Chiba, AA; Tuszynski, MH				Nagahara, Alan H.; Merrill, David A.; Coppola, Giovanni; Tsukada, Shingo; Schroeder, Brock E.; Shaked, Gideon M.; Wang, Ling; Blesch, Armin; Kim, Albert; Conner, James M.; Rockenstein, Edward; Chao, Moses V.; Koo, Edward H.; Geschwind, Daniel; Masliah, Eliezer; Chiba, Andrea A.; Tuszynski, Mark H.			Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease	NATURE MEDICINE			English	Article							ENTORHINAL CORTEX NEURONS; PHASE-I TRIAL; PARKINSONS-DISEASE; LAYER-II; COGNITIVE IMPAIRMENT; GENE-EXPRESSION; TRANSGENIC MICE; NERVOUS-SYSTEM; OPEN-LABEL; AGED RATS	Profound neuronal dysfunction in the entorhinal cortex contributes to early loss of short-term memory in Alzheimer's disease(1-3). Here we show broad neuroprotective effects of entorhinal brain-derived neurotrophic factor (BDNF) administration in several animal models of Alzheimer's disease, with extension of therapeutic benefits into the degenerating hippocampus. In amyloid-transgenic mice, BDNF gene delivery, when administered after disease onset, reverses synapse loss, partially normalizes aberrant gene expression, improves cell signaling and restores learning and memory. These outcomes occur independently of effects on amyloid plaque load. In aged rats, BDNF infusion reverses cognitive decline, improves age-related perturbations in gene expression and restores cell signaling. In adult rats and primates, BDNF prevents lesion-induced death of entorhinal cortical neurons. In aged primates, BDNF reverses neuronal atrophy and ameliorates age-related cognitive impairment. Collectively, these findings indicate that BDNF exerts substantial protective effects on crucial neuronal circuitry involved in Alzheimer's disease, acting through amyloid-independent mechanisms. BDNF therapeutic delivery merits exploration as a potential therapy for Alzheimer's disease.	[Nagahara, Alan H.; Merrill, David A.; Tsukada, Shingo; Schroeder, Brock E.; Shaked, Gideon M.; Wang, Ling; Blesch, Armin; Conner, James M.; Rockenstein, Edward; Koo, Edward H.; Masliah, Eliezer; Chiba, Andrea A.; Tuszynski, Mark H.] Univ Calif San Diego, Dept Neurosci 0626, La Jolla, CA 92093 USA; [Coppola, Giovanni; Geschwind, Daniel] Univ Calif Los Angeles, Program Neurogenet, Dept Neurol, Los Angeles, CA 90095 USA; [Kim, Albert; Chao, Moses V.] NYU, Sch Med, Mol Neurobiol Program, Skirball Inst Biomol Med, New York, NY 10016 USA; [Chiba, Andrea A.] Univ Calif San Diego, Dept Cognit Sci 0515, La Jolla, CA 92093 USA; [Tuszynski, Mark H.] Vet Affairs Med Ctr, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles; New York University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tuszynski, MH (corresponding author), Univ Calif San Diego, Dept Neurosci 0626, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mtuszynski@ucsd.edu	Kim, Albert H./HGF-0057-2022	Merrill, David/0000-0003-2181-3839; Chao, Moses/0000-0002-6969-3744; Blesch, Armin/0000-0003-1133-1174	US National Institutes of Health [AG10435]; California Regional Primate Research Center Base Grant; Veterans Administration; Alzheimer's Association; State of California [04-35530]; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Shiley Family Foundation; NATIONAL INSTITUTE ON AGING [P01AG010435, R37AG018440, P01AG022074] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Regional Primate Research Center Base Grant; Veterans Administration(US Department of Veterans Affairs); Alzheimer's Association(Alzheimer's Association); State of California; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Shiley Family Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank C. Glabe (University of California, Irvine) for A beta 1-42 peptide. We thank D. Amaral and P. Lavenex for assistance with the primate perforant path model, K. Loew, T. Mead, R. Torres and M. Mateling for technical support, and F. Gao for data analysis. This work was supported by the US National Institutes of Health (AG10435), the California Regional Primate Research Center Base Grant, the Veterans Administration, the Alzheimer's Association, the State of California (04-35530), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and The Shiley Family Foundation.	Boddaert J, 2007, AM J PATHOL, V170, P921, DOI 10.2353/ajpath.2007.060664; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gazzaley AH, 1997, NEUROBIOL AGING, V18, P549, DOI 10.1016/S0197-4580(97)00112-7; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gould RL, 2003, NEUROIMAGE, V20, P1006, DOI 10.1016/S1053-8119(03)00365-3; Hock C, 2000, ARCH NEUROL-CHICAGO, V57, P846, DOI 10.1001/archneur.57.6.846; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kordower JH, 1999, ANN NEUROL, V46, P419, DOI 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Merrill DA, 2000, J COMP NEUROL, V422, P396, DOI 10.1002/1096-9861(20000703)422:3<396::AID-CNE6>3.0.CO;2-R; Merrill DA, 2001, J COMP NEUROL, V438, P445, DOI 10.1002/cne.1327; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; NarisawaSaito M, 1996, NEUROREPORT, V7, P2925, DOI 10.1097/00001756-199611250-00024; OWEN AM, 1991, NEUROPSYCHOLOGIA, V29, P993, DOI 10.1016/0028-3932(91)90063-E; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; PETERSON DA, 1994, J NEUROSCI, V14, P6872; Price JL, 2001, ARCH NEUROL-CHICAGO, V58, P1395, DOI 10.1001/archneur.58.9.1395; Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140; Rohn TT, 2002, DRUG NEWS PERSPECT, V15, P549, DOI 10.1358/dnp.2002.15.9.740233; Rowe WB, 2007, J NEUROSCI, V27, P3098, DOI 10.1523/JNEUROSCI.4163-06.2007; Scherzer CR, 2007, P NATL ACAD SCI USA, V104, P955, DOI 10.1073/pnas.0610204104; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; SQUIRE LR, 2000, MEMORY, pCH5; Stoop R, 1996, PROG BRAIN RES, V109, P359; Taffe MA, 2004, BEHAV BRAIN RES, V149, P123, DOI 10.1016/S0166-4328(03)00214-6; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Winkler C, 1996, J NEUROSCI, V16, P7206; Yan Q, 1997, J COMP NEUROL, V378, P135	39	708	755	4	102	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					331	337		10.1038/nm.1912	http://dx.doi.org/10.1038/nm.1912			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19198615	Green Accepted			2022-12-27	WOS:000263914000035
J	Lee, JY; Huerta, PT; Zhang, J; Kowal, C; Bertini, E; Volpe, BT; Diamond, B				Lee, Ji Y.; Huerta, Patricio T.; Zhang, Jie; Kowal, Czeslawa; Bertini, Eva; Volpe, Bruce T.; Diamond, Betty			Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus	NATURE MEDICINE			English	Article							NMDA RECEPTORS; GLUTAMATE-RECEPTOR; NEURONAL MIGRATION; ERYTHEMATOSUS; ANTIBODIES; MECHANISMS; CHILDREN; INJURY; CORTEX; IDENTIFICATION	Systemic lupus erythematosus (SLE) is an autoimmune disease mediated by autoantibodies and preferentially affecting women of childbearing age. Because the offspring of mothers with SLE show a high frequency of learning disorders(1-5), we hypothesized that maternally transferred autoantibodies that bind DNA and the N-methyl-D-aspartate receptor (NMDAR)(6-12) could have a pathogenic role during fetal brain development. Here we describe a maternal SLE mouse model wherein pregnant dams harbored DNA-specific, NMDAR-specific autoantibodies throughout gestation. High titers of these autoantibodies in maternal circulation led to histological abnormalities in fetal brain and subsequent cognitive impairments in adult offspring. These data support a paradigm in which in utero exposure to neurotoxic autoantibodies causes abnormal brain development with long-term consequences. This paradigm may apply to multiple congenital neuropsychiatric disorders.	[Lee, Ji Y.; Kowal, Czeslawa; Diamond, Betty] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Huerta, Patricio T.; Volpe, Bruce T.] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Burke Cornell Med Res Inst, White Plains, NY 10605 USA; [Zhang, Jie; Kowal, Czeslawa; Bertini, Eva; Diamond, Betty] Autoimmune & Musculoskeletal Dis Ctr, Feinstein Inst Med Res, Manhasset, NY 11030 USA; [Bertini, Eva] Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy	Yeshiva University; Albert Einstein College of Medicine; Cornell University; Northwell Health; University of Genoa	Diamond, B (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	bdiamond@nshs.edu	Bertini, Enrico/ABG-1278-2020; volpe, b/U-8409-2019	Huerta, Patricio/0000-0003-0270-2308; Volpe, Bruce/0000-0002-1098-1848	US National Institutes of Health; Alliance for Lupus Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI073693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049126] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Lupus Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The work was supported by grants from the US National Institutes of Health ( B. D., P. T. H. and B. T. V.) and the Alliance for Lupus Research ( B. T. V.). We are grateful to L. DeGiorgio, S. Loncar, T. Huerta and R. Berlin for technical assistance; M. Scharff, E. Chang and T. Faust for suggestions on the manuscript; and S. Jones for help in preparing the manuscript.	Barker GRI, 2006, J NEUROSCI, V26, P3561, DOI 10.1523/JNEUROSCI.3154-05.2006; Buyon JP, 2003, CURR OPIN RHEUMATOL, V15, P535, DOI 10.1097/00002281-200309000-00003; Dalton P, 2003, ANN NEUROL, V53, P533, DOI 10.1002/ana.10557; DeGiorgio LA, 2001, NAT MED, V7, P1189, DOI 10.1038/nm1101-1189; Fragoso-Loyo H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003347; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; Goodrich-Hunsaker NJ, 2005, BEHAV NEUROSCI, V119, P1307, DOI 10.1037/0735-7044.119.5.1307; Hanashima C, 2002, J NEUROSCI, V22, P6526; Hanly John G, 2007, Curr Rheumatol Rep, V9, P116, DOI 10.1007/s11926-007-0005-2; Huerta PT, 2006, P NATL ACAD SCI USA, V103, P678, DOI 10.1073/pnas.0510055103; Husebye ES, 2005, ANN RHEUM DIS, V64, P1210, DOI 10.1136/ard.2004.029280; Kowal C, 2004, IMMUNITY, V21, P179, DOI 10.1016/j.immuni.2004.07.011; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Kriegstein AR, 2004, TRENDS NEUROSCI, V27, P392, DOI 10.1016/j.tins.2004.05.001; LAHITA RG, 1988, PSYCHONEUROENDOCRINO, V13, P385, DOI 10.1016/0306-4530(88)90045-5; Lapteva L, 2006, ARTHRITIS RHEUM, V54, P2505, DOI 10.1002/art.22031; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Manent JB, 2005, J NEUROSCI, V25, P4755, DOI 10.1523/JNEUROSCI.0553-05.2005; Martin LA, 2008, BRAIN BEHAV IMMUN, V22, P806, DOI 10.1016/j.bbi.2007.12.007; McAllister D L, 1997, J Int Neuropsychol Soc, V3, P370; MORPHIS LG, 1970, NATURE, V228, P573, DOI 10.1038/228573a0; Neri F, 2004, LUPUS, V13, P805, DOI 10.1191/0961203304lu2018oa; Newman J, 2003, J IMMUNOL METHODS, V272, P177, DOI 10.1016/S0022-1759(02)00499-4; Omdal R, 2005, EUR J NEUROL, V12, P392, DOI 10.1111/j.1468-1331.2004.00976.x; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; Quirk GJ, 2006, BIOL PSYCHIAT, V60, P337, DOI 10.1016/j.biopsych.2006.03.010; Rafael JA, 2000, MAMM GENOME, V11, P725, DOI 10.1007/s003350010149; Ritter LM, 2001, DEV BRAIN RES, V127, P123, DOI 10.1016/S0165-3806(01)00126-2; Ross G, 2003, ARCH PEDIAT ADOL MED, V157, P397, DOI 10.1001/archpedi.157.4.397; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Shi LM, 2003, J NEUROSCI, V23, P297, DOI 10.1523/jneurosci.23-01-00297.2003; Steup-Beekman GM, 2007, LUPUS, V16, P329, DOI 10.1177/0961203307078224; Ten VS, 2003, BEHAV BRAIN RES, V145, P209, DOI 10.1016/S0166-4328(03)00146-3; Tincani A, 2006, LUPUS, V15, P801, DOI 10.1177/0961203306071005; van Zundert B, 2004, TRENDS NEUROSCI, V27, P428, DOI 10.1016/j.tins.2004.05.010; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Walsh CA, 1999, NEURON, V23, P19, DOI 10.1016/S0896-6273(00)80749-7; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Yoshio T, 2006, ARTHRITIS RHEUM, V54, P675, DOI 10.1002/art.21547; Zhang J, 2008, J IMMUNOL METHODS, V338, P79, DOI 10.1016/j.jim.2008.07.015	40	119	121	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					91	96		10.1038/nm.1892	http://dx.doi.org/10.1038/nm.1892			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19079257	Green Accepted			2022-12-27	WOS:000262425100023
J	Faul, C; Donnelly, M; Merscher-Gomez, S; Chang, YH; Franz, S; Delfgaauw, J; Chang, JM; Choi, HY; Campbell, KN; Kim, K; Reiser, J; Mundel, P				Faul, Christian; Donnelly, Mary; Merscher-Gomez, Sandra; Chang, Yoon Hee; Franz, Stefan; Delfgaauw, Jacqueline; Chang, Jer-Ming; Choi, Hoon Young; Campbell, Kirk N.; Kim, Kwanghee; Reiser, Jochen; Mundel, Peter			The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A	NATURE MEDICINE			English	Article							GLOMERULAR SLIT DIAPHRAGM; CATHEPSIN-L; 14-3-3 PROTEINS; SYNAPTOPODIN; CALCINEURIN; BINDING; TRPC6; PHOSPHORYLATION; CLEAVAGE; MUTATION	The immunosuppressive action of the calcineurin inhibitor cyclosporine A (CsA) stems from the inhibition of nuclear factor of activated T cells ( NFAT) signaling in T cells. CsA is also used for the treatment of proteinuric kidney diseases. As it stands, the antiproteinuric effect of CsA is attributed to its immunosuppressive action. Here we show that the beneficial effect of CsA on proteinuria is not dependent on NFAT inhibition in T cells, but rather results from the stabilization of the actin cytoskeleton in kidney podocytes. CsA blocks the calcineurin-mediated dephosphorylation of synaptopodin, a regulator of Rho GTPases in podocytes, thereby preserving the phosphorylation-dependent synaptopodin-14-3-3 beta interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin L-mediated degradation. These results represent a new view of calcineurin signaling and shed further light on the treatment of proteinuric kidney diseases. Novel calcineurin substrates such as synaptopodin may provide promising starting points for antiproteinuric drugs that avoid the serious side effects of long-term CsA treatment.	[Faul, Christian; Donnelly, Mary; Merscher-Gomez, Sandra; Campbell, Kirk N.; Reiser, Jochen; Mundel, Peter] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Faul, Christian; Donnelly, Mary; Merscher-Gomez, Sandra; Chang, Yoon Hee; Franz, Stefan; Delfgaauw, Jacqueline; Choi, Hoon Young; Campbell, Kirk N.; Kim, Kwanghee; Mundel, Peter] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Chang, Jer-Ming] Kaohsiung Med Univ, Hsiao Kang Municipal Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Nephrol Div, Boston, MA 02129 USA; [Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Program Glomerular Dis, Boston, MA 02129 USA	University of Miami; Icahn School of Medicine at Mount Sinai; Kaohsiung Medical University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Mundel, P (corresponding author), Univ Miami, Miller Sch Med, Dept Med, 1600 NW 10th Ave, Miami, FL 33136 USA.	pmundel@med.miami.edu	Faul, Christian/D-1549-2011	Chang, Yoon Hee/0000-0003-1600-4842; Merscher, Sandra/0000-0002-4757-7494	Albert Einstein College of Medicine; Deutsche Forschungsgemeinschaft; US National Institutes of Health [DA18886, DK57683, DK062472]; George M.O'Brien Kidney Center [DK064236, DK073495]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073495, P50DK064236, R01DK062472, R01DK057683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA018886] Funding Source: NIH RePORTER	Albert Einstein College of Medicine; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George M.O'Brien Kidney Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank C. Chiu and S. Ratner for excellent technical assistance and T. Reinheckel for the analysis of CatL cleavage sites. We thank the Mount Sinai School of Medicine Mouse Genetics Research Facility for performing pronuclear injections. We also thank J.B. Kopp (US National Institutes of Health) for providing the podocin-rtTA mice, H. Fu (Emory University) for yellow fluorescence protein-tagged difopein and E.N. Olson (The University of Texas Southwestern Medical Center at Dallas) for wild-type and constitutively active calcineurin cDNA constructs. Y.H.C. was supported by a research fellowship from the Albert Einstein College of Medicine, S. F. was supported by Karger Stiftung and J.D. was supported by the Deutsche Forschungsgemeinschaft. This work was supported by US National Institutes of Health grants DA18886, DK57683 and DK062472 and the George M.O'Brien Kidney Center grants DK064236 (to P. M.) and DK073495 (to J.R.).	Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371; BARICOS WH, 1991, ARCH BIOCHEM BIOPHYS, V288, P468, DOI 10.1016/0003-9861(91)90222-5; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Charbit M, 2007, PEDIATR NEPHROL, V22, P57, DOI 10.1007/s00467-006-0227-y; Chen D, 2003, J AM SOC NEPHROL, V14, P690, DOI 10.1097/01.ASN.0000046964.15831.16; Cotelle V, 2000, EMBO J, V19, P2869, DOI 10.1093/emboj/19.12.2869; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Faul C, 2007, MOL CELL BIOL, V27, P8215, DOI 10.1128/MCB.00950-07; Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Halloran PF, 2004, NEW ENGL J MED, V351, P2715, DOI 10.1056/NEJMra033540; Heit JJ, 2006, NATURE, V443, P345, DOI 10.1038/nature05097; Horsley V, 2008, CELL, V132, P299, DOI 10.1016/j.cell.2007.11.047; Huber TB, 2006, J CLIN INVEST, V116, P1337, DOI 10.1172/JCI27400; Kim SA, 2005, ORAL ONCOL, V1, P148, DOI 10.1016/S1744-7895(05)80377-3; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lohmuller T, 2003, BIOL CHEM, V384, P899, DOI 10.1515/BC.2003.101; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Meyrier A, 2005, EXPERT OPIN PHARMACO, V6, P1539, DOI 10.1517/14656566.6.9.1539; Moeller CC, 2007, J AM SOC NEPHROL, V18, P29, DOI 10.1681/ASN.2006091010; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Reiser J, 2004, J BIOL CHEM, V279, P34827, DOI 10.1074/jbc.M401973200; Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Sever S, 2007, J CLIN INVEST, V117, P2095, DOI 10.1172/JCI32022; Shigehara T, 2003, J AM SOC NEPHROL, V14, P1998, DOI 10.1681/ASN.V1481998; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Tryggvason K, 2006, NEW ENGL J MED, V354, P1387, DOI 10.1056/NEJMra052131; Tryggvason K, 2006, CELL, V125, P221, DOI 10.1016/j.cell.2006.04.002; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yanagida-Asanuma E, 2007, AM J PATHOL, V171, P415, DOI 10.2353/ajpath.2007.070075; Zheng WP, 2005, J BIOL CHEM, V280, P10462, DOI 10.1074/jbc.M412283200	43	685	749	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					931	938		10.1038/nm.1857	http://dx.doi.org/10.1038/nm.1857			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18724379	Green Accepted			2022-12-27	WOS:000258988600025
J	Lutz, B; Monory, K				Lutz, Beat; Monory, Krisztina			Soothing the seizures of children	NATURE MEDICINE			English	Editorial Material							ENDOCANNABINOID SYSTEM; FEBRILE SEIZURES; PLASTICITY; HIPPOCAMPUS		[Lutz, Beat; Monory, Krisztina] Johannes Gutenberg Univ Mainz, Dept Phys Chem, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Lutz, B (corresponding author), Johannes Gutenberg Univ Mainz, Dept Phys Chem, Duesbergweg 6, D-55099 Mainz, Germany.	blutz@uni-mainz.de	Lutz, Beat/AFK-6229-2022; Lutz, Beat/AAG-4538-2022					Chen K, 2003, NEURON, V39, P599, DOI 10.1016/S0896-6273(03)00499-9; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Dube CM, 2007, TRENDS NEUROSCI, V30, P490, DOI 10.1016/j.tins.2007.07.006; Ludanyi A, 2008, J NEUROSCI, V28, P2976, DOI 10.1523/JNEUROSCI.4465-07.2008; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006	7	9	9	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					721	722		10.1038/nm0708-721	http://dx.doi.org/10.1038/nm0708-721			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18607372				2022-12-27	WOS:000257452700018
J	McLachlan, JB; Shelburne, CP; Hart, JP; Pizzo, SV; Goyal, R; Brooking-Dixon, R; Staats, HF; Abraham, SN				McLachlan, James B.; Shelburne, Christopher P.; Hart, Justin P.; Pizzo, Salvatore V.; Goyal, Rajen; Brooking-Dixon, Rhea; Staats, Herman F.; Abraham, Soman N.			Mast cell activators: a new class of highly effective vaccine adjuvants	NATURE MEDICINE			English	Article							NASAL IMMUNIZATION; MUCOSAL IMMUNITY; DENDRITIC CELLS; PROTECTIVE ANTIGEN; CHOLERA-TOXIN; IN-VIVO; RESPONSES; MIGRATION; HETEROGENEITY; INDUCTION	Mast cells ( MCs) have recently received recognition as prominent effectors in the regulation of immune cell migration to draining lymph nodes and lymphocyte activation. However, their role in the development of humoral immune responses is not clear. Here, we demonstrate that subcutaneous or nasal administration of small-molecule MC activators with vaccine antigens evokes large increases in antigen-specific serum immunoglobulin G ( IgG) responses. These responses were MC dependent and correlated with increased dendritic cell and lymphocyte recruitment to draining lymph nodes. Nasal instillation of these formulations also evoked antigen-specific secretory IgA and provided protection against anthrax lethal toxin challenge in vitro and against vaccinia virus infection in vivo. Collectively, these results define the MC as an integral sensory arm of the adaptive immune system. Moreover, they highlight MC activators as a new class of vaccine adjuvants, capable of inducing protective antigen-specific immune responses through needle-free routes of administration.	[McLachlan, James B.; Shelburne, Christopher P.; Hart, Justin P.; Pizzo, Salvatore V.; Goyal, Rajen; Brooking-Dixon, Rhea; Staats, Herman F.; Abraham, Soman N.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Staats, Herman F.; Abraham, Soman N.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; [Staats, Herman F.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Abraham, Soman N.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Abraham, SN (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	soman.abraham@duke.edu		Staats, Herman/0000-0003-1039-1087	NIAID NIH HHS [R21 AI059591-01A1, R56 AI074751, R01 AI050021, R21 AI059591, R01-AI50021] Funding Source: Medline; NIDDK NIH HHS [R37-DK50814, R37 DK050814, R21 DK077307, R01-DK077159, R01 DK077159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059591, R01AI050021, R56AI074751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050814, R21DK077307, R01DK077159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham SN, 1998, SEMIN IMMUNOL, V10, P373, DOI 10.1006/smim.1998.0140; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEFUS AD, 1982, J IMMUNOL, V128, P2475; Boyaka PN, 2003, J IMMUNOL, V170, P5636, DOI 10.4049/jimmunol.170.11.5636; BRUNET C, 1988, J ALLERGY CLIN IMMUN, V82, P398, DOI 10.1016/0091-6749(88)90011-5; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gaur R, 2002, VACCINE, V20, P2836, DOI 10.1016/S0264-410X(02)00207-4; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Hanna P, 1999, J APPL MICROBIOL, V87, P285, DOI 10.1046/j.1365-2672.1999.00891.x; Jawdat DM, 2004, J IMMUNOL, V173, P5275, DOI 10.4049/jimmunol.173.8.5275; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kruger PG, 2002, ANN NY ACAD SCI, V971, P349; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Palker TJ, 1996, VIROLOGY, V224, P415, DOI 10.1006/viro.1996.0548; Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210; PATON WDM, 1951, BRIT J PHARM CHEMOTH, V6, P499, DOI 10.1111/j.1476-5381.1951.tb00661.x; PEARCE FL, 1986, PHARMACOLOGY, V32, P61, DOI 10.1159/000138153; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; SNIDER DP, 1994, J IMMUNOL, V153, P647; Staats HF, 1999, J IMMUNOL, V162, P6141; Staats HF, 2001, J IMMUNOL, V167, P5386, DOI 10.4049/jimmunol.167.9.5386; Staats HF, 1996, J IMMUNOL, V157, P462; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233; Yamamoto S, 1997, P NATL ACAD SCI USA, V94, P5267, DOI 10.1073/pnas.94.10.5267; Zuercher AW, 2002, J IMMUNOL, V168, P1796, DOI 10.4049/jimmunol.168.4.1796	36	159	169	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					536	541		10.1038/nm1757	http://dx.doi.org/10.1038/nm1757			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18425129	Bronze			2022-12-27	WOS:000255681800034
J	Kawasaki, Y; Xu, ZZ; Wang, X; Park, JY; Zhuang, ZY; Tan, PH; Gao, YJ; Roy, K; Corfas, G; Lo, EH; Ji, RR				Kawasaki, Yasuhiko; Xu, Zhen-Zhong; Wang, Xiaoying; Park, Jong Yeon; Zhuang, Zhi-Ye; Tan, Ping-Heng; Gao, Yong-Jing; Roy, Kristine; Corfas, Gabriel; Lo, Eng H.; Ji, Ru-Rong			Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain	NATURE MEDICINE			English	Article							SPINAL NERVE LIGATION; ACTIVATED PROTEIN-KINASE; MECHANICAL ALLODYNIA; RAT MODEL; MICROGLIA; CONTRIBUTES; NEURONS; INHIBITION; ASTROCYTES; GENERATION	Treatment of neuropathic pain, triggered by multiple insults to the nervous system, is a clinical challenge because the underlying mechanisms of neuropathic pain development remain poorly understood(1-4). Most treatments do not differentiate between different phases of neuropathic pain pathophysiology and simply focus on blocking neurotransmission, producing transient pain relief. Here, we report that early- and late-phase neuropathic pain development in rats and mice after nerve injury require different matrix metalloproteinases (MMPs). After spinal nerve ligation, MMP-9 shows a rapid and transient upregulation in injured dorsal root ganglion (DRG) primary sensory neurons consistent with an early phase of neuropathic pain, whereas MMP-2 shows a delayed response in DRG satellite cells and spinal astrocytes consistent with a late phase of neuropathic pain. Local inhibition of MMP-9 by an intrathecal route inhibits the early phase of neuropathic pain, whereas inhibition of MMP-2 suppresses the late phase of neuropathic pain. Further, intrathecal administration of MMP-9 or MMP-2 is sufficient to produce neuropathic pain symptoms. After nerve injury, MMP-9 induces neuropathic pain through interleukin-1 beta cleavage and microglial activation at early times, whereas MMP-2 maintains neuropathic pain through interleukin-1b cleavage and astrocyte activation at later times. Inhibition of MMP may provide a novel therapeutic approach for the treatment of neuropathic pain at different phases.	[Kawasaki, Yasuhiko; Xu, Zhen-Zhong; Park, Jong Yeon; Zhuang, Zhi-Ye; Tan, Ping-Heng; Gao, Yong-Jing; Ji, Ru-Rong] Brigham & Womens Hosp, Dept Anesthesiol, Pain Res Ctr, Boston, MA 02115 USA; [Kawasaki, Yasuhiko; Xu, Zhen-Zhong; Park, Jong Yeon; Zhuang, Zhi-Ye; Tan, Ping-Heng; Gao, Yong-Jing; Roy, Kristine; Corfas, Gabriel; Ji, Ru-Rong] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA 02129 USA; [Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA; [Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA; [Roy, Kristine; Corfas, Gabriel] Harvard Univ, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Boston Children's Hospital	Ji, RR (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol, Pain Res Ctr, 75 Francis St, Boston, MA 02115 USA.	rrji@zeus.bwh.harvard.edu	Park, Jong Yeon/AAF-8743-2021; Ji, Ru-Rong/L-7070-2017; Gao, Yong-Jing/E-6939-2015; Corfas, Gabriel/AAH-2378-2020	Ji, Ru-Rong/0000-0002-9355-3688; Gao, Yong-Jing/0000-0002-7432-7458; Corfas, Gabriel/0000-0001-5412-9473; Xu, Zhen-Zhong/0000-0001-6578-211X; Park, Jong Yeon/0000-0003-0588-1903	FOGARTY INTERNATIONAL CENTER [R03TW007180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE017794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F30NS054362, R01NS048422, R01NS056458, R01NS054932, R37NS037074, R01NS035884, P01NS055104, R01NS037074, P50NS010828] Funding Source: NIH RePORTER; FIC NIH HHS [TW7180, R03 TW007180, R03 TW007180-03] Funding Source: Medline; NIDCR NIH HHS [R01 DE017794, R01 DE017794-02, R01-DE17794] Funding Source: Medline; NINDS NIH HHS [R01 NS037074, R01 NS056458-02, P01 NS055104, P50 NS010828, R01 NS048422-03, R01 NS054932-01A1, R37 NS037074, P50-NS10828, F30 NS054362, R01-NS54362, P01-NS55104, R01 NS056458, R01-NS56458, R01 NS093415, R01 NS035884, R01-NS37074, R01-NS48422, R01 NS037074-08, R01 NS048422, R01 NS054932] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chattopadhyay S, 2007, BRAIN BEHAV IMMUN, V21, P561, DOI 10.1016/j.bbi.2006.10.015; Chen SZ, 2003, NAT NEUROSCI, V6, P1186, DOI 10.1038/nn1139; Clark AK, 2006, J NEUROCHEM, V99, P868, DOI 10.1111/j.1471-4159.2006.04126.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ji Ru-Rong, 2004, Sci STKE, V2004, preE14; Jin SX, 2003, J NEUROSCI, V23, P4017; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Levin JI, 2001, BIOORG MED CHEM LETT, V11, P2975, DOI 10.1016/S0960-894X(01)00601-1; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Sung CS, 2005, J NEUROCHEM, V94, P742, DOI 10.1111/j.1471-4159.2005.03226.x; Sweitzer S, 2001, NEUROSCIENCE, V103, P529, DOI 10.1016/S0306-4522(00)00574-1; Tan PH, 2005, GENE THER, V12, P59, DOI 10.1038/sj.gt.3302376; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	29	546	564	2	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2008	14	3					331	336		10.1038/nm1723	http://dx.doi.org/10.1038/nm1723			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18264108	Green Accepted			2022-12-27	WOS:000253815700040
J	Darabi, R; Gehlbach, K; Bachoo, RM; Kamath, S; Osawa, M; Kamm, KE; Kyba, M; Perlingeiro, RCR				Darabi, Radbod; Gehlbach, Kimberly; Bachoo, Robert M.; Kamath, Shwetha; Osawa, Mitsujiro; Kamm, Kristine E.; Kyba, Michael; Perlingeiro, Rita C. R.			Functional skeletal muscle regeneration from differentiating embryonic stem cells	NATURE MEDICINE			English	Article							SATELLITE CELLS; PROGENITOR CELLS; MUSCULAR-DYSTROPHY; MYOBLAST TRANSFER; PRECURSOR CELLS; MDX MYOFIBERS; IN-VITRO; EXPRESSION; MYOGENESIS; TRANSPLANTATION	Little progress has been made toward the use of embryonic stem (ES) cells to study and isolate skeletal muscle progenitors. This is due to the paucity of paraxial mesoderm formation during embryoid body (EB) in vitro differentiation and to the lack of reliable identification and isolation criteria for skeletal muscle precursors. Here we show that expression of the transcription factor Pax3 during embryoid body differentiation enhances both paraxial mesoderm formation and the myogenic potential of the cells within this population. Transplantation of Pax3-induced cells results in teratomas, however, indicating the presence of residual undifferentiated cells. By sorting for the PDGF-alpha receptor, a marker of paraxial mesoderm, and for the absence of Flk-1, a marker of lateral plate mesoderm, we derive a cell population from differentiating ES cell cultures that has substantial muscle regeneration potential. Intramuscular and systemic transplantation of these cells into dystrophic mice results in extensive engraftment of adult myofibers with enhanced contractile function without the formation of teratomas. These data demonstrate the therapeutic potential of ES cells in muscular dystrophy.	[Darabi, Radbod; Gehlbach, Kimberly; Kamath, Shwetha; Osawa, Mitsujiro; Kyba, Michael; Perlingeiro, Rita C. R.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Bachoo, Robert M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Kamm, Kristine E.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Perlingeiro, RCR (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	rita.perlingeiro@utsouthwestern.edu		Kyba, Michael/0000-0002-5579-7534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081186] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL081186] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armour C, 1999, EXP CELL RES, V251, P79, DOI 10.1006/excr.1999.4567; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Bachrach E, 2006, MUSCLE NERVE, V34, P44, DOI 10.1002/mus.20560; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bhagavati S, 2005, BIOCHEM BIOPH RES CO, V333, P644, DOI 10.1016/j.bbrc.2005.05.135; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cornelison DDW, 2001, DEV BIOL, V239, P79, DOI 10.1006/dbio.2001.0416; Denetclaw WF, 1997, DEVELOPMENT, V124, P1601; Ema M, 2006, BLOOD, V107, P111, DOI 10.1182/blood-2005-05-1970; Eventov-Friedman S, 2005, P NATL ACAD SCI USA, V102, P2928, DOI 10.1073/pnas.0500177102; Fehling HJ, 2003, DEVELOPMENT, V130, P4217, DOI 10.1242/dev.00589; Fujikawa T, 2005, AM J PATHOL, V166, P1781, DOI 10.1016/S0002-9440(10)62488-1; GOULDING M, 1994, DEVELOPMENT, V120, P957; Gross JG, 1999, MUSCLE NERVE, V22, P174, DOI 10.1002/(SICI)1097-4598(199902)22:2<174::AID-MUS5>3.0.CO;2-S; Gussoni E, 1997, NAT MED, V3, P970, DOI 10.1038/nm0997-970; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; Partridge T, 1998, NAT MED, V4, P1208, DOI 10.1038/3167; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; ROBERTSON EJ, 1986, TRENDS GENET, V2, P9, DOI 10.1016/0168-9525(86)90161-7; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Sakurai H, 2006, STEM CELLS, V24, P575, DOI 10.1634/stemcells.2005-0256; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; Sherwood RI, 2004, STEM CELLS, V22, P1292, DOI 10.1634/stemcells.2004-0090; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takakura N, 1997, J HISTOCHEM CYTOCHEM, V45, P883, DOI 10.1177/002215549704500613; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; TREMBLAY JP, 1993, CELL TRANSPLANT, V2, P99, DOI 10.1177/096368979300200203; Weitzer G, 1995, DEV BIOL, V172, P422, DOI 10.1006/dbio.1995.8070; Yoshimura M, 2004, MOL THER, V10, P821, DOI 10.1016/j.ymthe.2004.07.025; YU J, 2007, SCIENCE	49	247	263	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					134	143		10.1038/nm1705	http://dx.doi.org/10.1038/nm1705			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18204461				2022-12-27	WOS:000252946700021
J	Pais-Correia, AM; Sachse, M; Guadagnini, S; Robbiati, V; Lasserre, R; Gessain, A; Gout, O; Alcover, A; Thoulouze, MI				Pais-Correia, Ana-Monica; Sachse, Martin; Guadagnini, Stephanie; Robbiati, Valentina; Lasserre, Remi; Gessain, Antoine; Gout, Olivier; Alcover, Andres; Thoulouze, Maria-Isabel			Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPARAN-SULFATE PROTEOGLYCANS; LYMPHOTROPIC-VIRUS; LEUKEMIA-VIRUS; IMMUNOLOGICAL SYNAPSE; HELICOBACTER-PYLORI; ANTIGEN-EXPRESSION; PERIPHERAL-BLOOD; LECTIN-BINDING; I TAX	Human T cell leukemia virus type 1 (HTLV-1) is a lymphotropic retrovirus whose cell-to-cell transmission requires cell contacts. HTLV-1-infected T lymphocytes form 'virological synapses', but the mechanism of HTLV-1 transmission remains poorly understood. We show here that HTLV-1-infected T lymphocytes transiently store viral particles as carbohydrate-rich extracellular assemblies that are held together and attached to the cell surface by virally-induced extracellular matrix components, including collagen and agrin, and cellular linker proteins, such as tetherin and galectin-3. Extracellular viral assemblies rapidly adhere to other cells upon cell contact, allowing virus spread and infection of target cells. Their removal strongly reduces the ability of HTLV-1-producing cells to infect target cells. Our findings unveil a novel virus transmission mechanism based on the generation of extracellular viral particle assemblies whose structure, composition and function resemble those of bacterial biofilms. HTLV-1 biofilm-like structures represent a major route for virus transmission from cell to cell.	[Pais-Correia, Ana-Monica; Robbiati, Valentina; Lasserre, Remi; Alcover, Andres; Thoulouze, Maria-Isabel] Inst Pasteur, CNRS, Unite Biol Cellulaire Lymphocytes, Unite Rech Associee 1961, Paris, France; [Gessain, Antoine] Inst Pasteur, CNRS, Unite Epidemiol & Physiopathol Virus Oncogenes, URA 1930, Paris, France; [Gout, Olivier] Fdn A Rothschild, Serv Neurol, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Alcover, A (corresponding author), Inst Pasteur, CNRS, Unite Biol Cellulaire Lymphocytes, Unite Rech Associee 1961, Paris, France.	andres.alcover@pasteur.fr; marie-isabelle.thoulouze@pasteur.fr	Sachse, Martin/W-7403-2019; Thoulouze, Maria-Isabel/AAK-6761-2021; Lasserre, Rémi/N-5646-2016	Thoulouze, Maria-Isabel/0000-0002-1780-0421; Lasserre, Rémi/0000-0002-6996-0179; Sachse, Martin/0000-0001-5981-9166; Alcover, Andres/0000-0002-9507-3450	La Ligue Contre le Cancer, l'Association pour la Recherche Contre le Cancer; l'Agence National de Recherche, l'Institut Pasteur [PTR-214]; CNRS; Fundacao para a Ciencia e a Tecnologia, Portugal; European Union	La Ligue Contre le Cancer, l'Association pour la Recherche Contre le Cancer; l'Agence National de Recherche, l'Institut Pasteur; CNRS(Centre National de la Recherche Scientifique (CNRS)); Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); European Union(European Commission)	This work has been funded by La Ligue Contre le Cancer, l'Association pour la Recherche Contre le Cancer, l'Agence National de Recherche, l'Institut Pasteur PTR-214, and the CNRS. A.-M. P.-C. is supported by Fundacao para a Ciencia e a Tecnologia, Portugal, V. R. by the European Union Marie Curie Actions Early Stage Training Program Intrapath and R. L. by a Bourse Roux, Institut Pasteur and l'Agence National de Recherche. We thank the US National Institutes of Health AIDS Research and Reference Reagent Program for providing MT2 cells and Env-specific 0.5 alpha antibodies. We thank M. Ruegg (University of Basel) for agrin-specific antibodies, C. Pique (Institut Cochin, Institut National de la Sante et de la Recherche Medicale (INSERM)) for Env gp46-specific antibody and S. Charrin and E. Rubinstein (Institut A. Lwoff, INSERM) for tetraspanin-specific antibodies. We thank S. Ozden and P.-E. Ceccaldi for the C91/PL cell line and expertise, F. Delebecque (Novartis) for the gift of pCS-HTLV-1, and A. Cartaud, J. Cartaud and U. Hazan for sharing expertise. We thank C. Cuche for technical assistance and S. Bassot for technical help with human samples. We thank ICAReB (plateforme d'investigation clinique et d'acces aux ressources biologiques) and the Centre d'Immunologie Humaine, Institut Pasteur for support in biomedical research. We thank, E. Perret, P. Roux, C. Machu A. Danckaert and M. C. Prevost for sharing expertise in microscopy, J. M. Ghigo and S. Wain-Hobson for helpful discussions and R. Mahieux (Ecole Normale Superieure de Lyon, INSERM) for pLTR-Luc plasmid and for suggestions and critical reading of the manuscript.	Alfsen A, 2005, MOL BIOL CELL, V16, P4267, DOI 10.1091/mbc.E05-03-0192; Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850; Bonifait L, 2008, APPL ENVIRON MICROB, V74, P4969, DOI 10.1128/AEM.00558-08; COFFIN JM, 1997, RETROVIRUSES, P27; Dityatev A, 2006, CELL TISSUE RES, V326, P647, DOI 10.1007/s00441-006-0217-1; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; ELNABOUT R, 1989, MATRIX, V9, P411, DOI 10.1016/S0934-8832(89)80047-2; Fowler M, 2006, CELL MICROBIOL, V8, P44, DOI 10.1111/j.1462-5822.2005.00599.x; Gauthier S, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-105; GESSAIN A, 1990, J GEN VIROL, V71, P333, DOI 10.1099/0022-1317-71-2-333; Ghez D, 2006, J VIROL, V80, P6844, DOI 10.1128/JVI.02719-05; Grange MP, 1998, INT J CANCER, V75, P804, DOI 10.1002/(SICI)1097-0215(19980302)75:5&lt;804::AID-IJC22&gt;3.0.CO;2-4; Gupta SK, 1997, INFECT IMMUN, V65, P2747, DOI 10.1128/IAI.65.7.2747-2753.1997; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; Hsu DK, 1996, AM J PATHOL, V148, P1661; Humbert M, 2006, AIDS REV, V8, P51; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; Jones KS, 2008, NAT MED, V14, P429, DOI 10.1038/nm1745; Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005; Joo HG, 2001, J LEUKOCYTE BIOL, V69, P555; Jouvenet N, 2009, J VIROL, V83, P1837, DOI 10.1128/JVI.02211-08; Kambara C, 2002, J NEUROIMMUNOL, V125, P179, DOI 10.1016/S0165-5728(02)00042-5; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Le Blanc I, 2001, VIRUS RES, V78, P5, DOI 10.1016/S0168-1702(01)00278-7; Mahieux R, 2005, J GEN VIROL, V86, P2489, DOI 10.1099/vir.0.80973-0; Majorovits E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002251; Mazurov D, 2006, VIROLOGY, V346, P194, DOI 10.1016/j.virol.2005.10.033; McClure SF, 1997, GLYCOCONJUGATE J, V14, P365, DOI 10.1023/A:1018526813159; Mikaty G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000314; Moran AP, 2008, CARBOHYD RES, V343, P1952, DOI 10.1016/j.carres.2007.12.012; MUNOZ E, 1995, J CLIN INVEST, V96, P2413, DOI 10.1172/JCI118298; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Neu TR, 1999, METHOD ENZYMOL, V310, P145; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812; Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sol-Foulon N, 2007, EMBO J, V26, P516, DOI 10.1038/sj.emboj.7601509; Stewart PS, 2008, NAT REV MICROBIOL, V6, P199, DOI 10.1038/nrmicro1838; Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6; Yi T, 2000, BIOCHEM BIOPH RES CO, V276, P579, DOI 10.1006/bbrc.2000.3517; ZACHAROPOULOS VR, 1992, J VIROL, V66, P4601, DOI 10.1128/JVI.66.7.4601-4605.1992; Zhang JP, 2006, FASEB J, V20, P50, DOI 10.1096/fj.04-3303com	51	211	218	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					83	U119		10.1038/nm.2065	http://dx.doi.org/10.1038/nm.2065			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20023636				2022-12-27	WOS:000273395500040
J	Winer, S; Chan, Y; Paltser, G; Truong, D; Tsui, H; Bahrami, J; Dorfman, R; Wang, YQ; Zielenski, J; Mastronardi, F; Maezawa, Y; Drucker, DJ; Engleman, E; Winer, D; Dosch, HM				Winer, Shawn; Chan, Yin; Paltser, Geoffrey; Truong, Dorothy; Tsui, Hubert; Bahrami, Jasmine; Dorfman, Ruslan; Wang, Yongqian; Zielenski, Julian; Mastronardi, Fabrizio; Maezawa, Yuko; Drucker, Daniel J.; Engleman, Edgar; Winer, Daniel; Dosch, H. -Michael			Normalization of obesity-associated insulin resistance through immunotherapy	NATURE MEDICINE			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; REGULATORY T-CELLS; ADIPOSE-TISSUE; ALTERNATIVE ACTIVATION; METABOLIC SYNDROME; ADAPTIVE IMMUNITY; TGF-BETA; MICE; INFLAMMATION; INFILTRATION	Obesity and its associated metabolic syndromes represent a growing global challenge, yet mechanistic understanding of this pathology and current therapeutics are unsatisfactory. We discovered that CD4(+) T lymphocytes, resident in visceral adipose tissue (VAT), control insulin resistance in mice with diet-induced obesity (DIO). Analyses of human tissue suggest that a similar process may also occur in humans. DIO VAT-associated T cells show severely biased T cell receptor V-alpha repertoires, suggesting antigen-specific expansion. CD4(+) T lymphocyte control of glucose homeostasis is compromised in DIO progression, when VAT accumulates pathogenic interferon-gamma (IFN-gamma)-secreting T helper type 1 (T(H)1) cells, overwhelming static numbers of T(H)2 (CD4(+) GATA-binding protein-3 (GATA-3)(+)) and regulatory forkhead box P3 (Foxp3)(+) T cells. CD4+ (but not CD8(+)) T cell transfer into lymphocyte-free Rag1-null DIO mice reversed weight gain and insulin resistance, predominantly through T(H)2 cells. In obese WT and ob/ob (leptin-deficient) mice, brief treatment with CD3-specific antibody or its F(ab')(2) fragment, reduces the predominance of T(H)1 cells over Foxp3(+) cells, reversing insulin resistance for months, despite continuation of a high-fat diet. Our data suggest that the progression of obesity-associated metabolic abnormalities is under the pathophysiological control of CD4(+) T cells. The eventual failure of this control, with expanding adiposity and pathogenic VAT T cells, can successfully be reversed by immunotherapy.	[Winer, Shawn; Chan, Yin; Paltser, Geoffrey; Truong, Dorothy; Tsui, Hubert; Mastronardi, Fabrizio; Maezawa, Yuko; Dosch, H. -Michael] Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Winer, Shawn; Chan, Yin; Paltser, Geoffrey; Truong, Dorothy; Tsui, Hubert; Mastronardi, Fabrizio; Maezawa, Yuko; Dosch, H. -Michael] Univ Toronto, Hosp Sick Children, Dept Immunol, Res Inst,Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Bahrami, Jasmine; Drucker, Daniel J.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada; [Engleman, Edgar; Winer, Daniel] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Dorfman, Ruslan; Wang, Yongqian; Zielenski, Julian] Univ Toronto, Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Stanford University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dosch, HM (corresponding author), Univ Toronto, Hosp Sick Children, Dept Pediat, Res Inst,Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada.	michael.dosch@me.com	Eckhardt, Erik/G-1567-2010; Drucker, Daniel J/A-4092-2010	Dorfman, Ruslan/0000-0002-3421-5582; Chan, Yin/0000-0003-2741-8258	CIHR [93749] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		ALEGRE M, 1990, EUR J IMMUNOL, V20, P707, DOI 10.1002/eji.1830200337; ALEGRE M, 1990, TRANSPLANT P, V22, P1920; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; Baker FJ, 2002, P NATL ACAD SCI USA, V99, P9374, DOI 10.1073/pnas.142284899; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; Caspar-Bauguil S, 2005, FEBS LETT, V579, P3487, DOI 10.1016/j.febslet.2005.05.031; Chatenoud L, 2007, NAT REV IMMUNOL, V7, P622, DOI 10.1038/nri2134; Cintra DE, 2008, J HEPATOL, V48, P628, DOI 10.1016/j.jhep.2007.12.017; Claycombe K, 2008, P NATL ACAD SCI USA, V105, P2017, DOI 10.1073/pnas.0712053105; Dahabreh IJ, 2008, CLIN TRIALS, V5, P116, DOI 10.1177/1740774508090212; Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Furuhashi M, 2008, J CLIN INVEST, V118, P2640, DOI 10.1172/JCI34750; Hanson RL, 2002, DIABETES, V51, P3120, DOI 10.2337/diabetes.51.10.3120; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; JENKINS RN, 1993, J CLIN INVEST, V92, P2688, DOI 10.1172/JCI116886; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kintscher U, 2008, ARTERIOSCL THROM VAS, V28, P1304, DOI 10.1161/ATVBAHA.108.165100; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kumpers P, 2007, AM J PHYSIOL-RENAL, V293, pF1355, DOI 10.1152/ajprenal.00003.2007; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Macia L, 2006, J IMMUNOL, V177, P5997, DOI 10.4049/jimmunol.177.9.5997; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Perruche S, 2008, NAT MED, V14, P528, DOI 10.1038/nm1749; Rausch ME, 2008, INT J OBESITY, V32, P451, DOI 10.1038/sj.ijo.0803744; Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Steffens S, 2008, CIRC RES, V102, P140, DOI 10.1161/CIRCRESAHA.107.170274; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104; Turner SJ, 2006, NAT REV IMMUNOL, V6, P883, DOI 10.1038/nri1977; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zeyda M, 2007, IMMUNOL LETT, V112, P61, DOI 10.1016/j.imlet.2007.07.003	46	1002	1035	4	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					921	U126		10.1038/nm.2001	http://dx.doi.org/10.1038/nm.2001			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19633657	Green Accepted			2022-12-27	WOS:000268770400037
J	Chiang, EY; Kolumam, GA; Yu, X; Francesco, M; Ivelja, S; Peng, I; Gribling, P; Shu, J; Lee, WP; Refino, CJ; Balazs, M; Paler-Martinez, A; Nguyen, A; Young, J; Barck, KH; Carano, RAD; Ferrando, R; Diehl, L; Chatterjea, D; Grogan, JL				Chiang, Eugene Y.; Kolumam, Ganesh A.; Yu, Xin; Francesco, Michelle; Ivelja, Sinisa; Peng, Ivan; Gribling, Peter; Shu, Jean; Lee, Wyne P.; Refino, Canio J.; Balazs, Mercedesz; Paler-Martinez, Andres; Nguyen, Allen; Young, Judy; Barck, Kai H.; Carano, Richard A. D.; Ferrando, Ron; Diehl, Lauri; Chatterjea, Devavani; Grogan, Jane L.			Targeted depletion of lymphotoxin-alpha-expressing T(H)1 and T(H)17 cells inhibits autoimmune disease	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; T-CELL; B-CELL; SURFACE LYMPHOTOXIN; IL-17-DEFICIENT MICE; HUMORAL RESPONSES; TH17 CELLS; INFLAMMATION; IL-17	Uncontrolled T helper type 1 (T(H)1) and T(H)17 cells are associated with autoimmune responses. We identify surface lymphotoxin-alpha (LT-alpha) as common to T(H)0, T(H)1 and T(H)17 cells and employ a unique strategy to target these subsets using a depleting monoclonal antibody (mAb) directed to surface LT-alpha. Depleting LT-alpha-specific mAb inhibited T cell-mediated models of delayed-type hypersensitivity and experimental autoimmune encephalomyelitis. In collagen-induced arthritis (CIA), preventive and therapeutic administration of LT-alpha-specific mAb inhibited disease, and immunoablated T cells expressing interleukin-17 (IL-17), interferon-gamma and tumor necrosis factor-alpha (TNF-alpha), whereas decoy lymphotoxin-beta receptor (LT-beta R) fusion protein had no effect. A mutation in the Fc tail, rendering the antibody incapable of Fc gamma receptor binding and antibody-dependent cellular cytotoxicity activity, abolished all in vivo effects. Efficacy in CIA was preceded by a loss of rheumatoid-associated cytokines IL-6, IL-1 beta and TNF-alpha within joints. These data indicate that depleting LT-alpha-expressing lymphocytes with LT-alpha-specific mAb may be beneficial in the treatment of autoimmune disease.	[Chiang, Eugene Y.; Kolumam, Ganesh A.; Yu, Xin; Francesco, Michelle; Ivelja, Sinisa; Peng, Ivan; Gribling, Peter; Shu, Jean; Lee, Wyne P.; Refino, Canio J.; Balazs, Mercedesz; Paler-Martinez, Andres; Chatterjea, Devavani; Grogan, Jane L.] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; [Nguyen, Allen; Young, Judy] Genentech Inc, Dept Assay & Automat Technol, San Francisco, CA 94080 USA; [Barck, Kai H.; Carano, Richard A. D.] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA; [Ferrando, Ron; Diehl, Lauri] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Grogan, JL (corresponding author), Genentech Inc, Dept Immunol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.	jgrogan@gene.com						Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Dunussi-Joannopoulos K, 2005, BLOOD, V106, P2235, DOI 10.1182/blood-2004-11-4547; Elson CO, 2007, GASTROENTEROLOGY, V132, P2359, DOI 10.1053/j.gastro.2007.03.104; Fava RA, 2003, J IMMUNOL, V171, P115, DOI 10.4049/jimmunol.171.1.115; Gommerman JL, 2003, NAT REV IMMUNOL, V3, P642, DOI 10.1038/nri1151; Gommerman JL, 2003, J CLIN INVEST, V112, P755, DOI 10.1172/JCI200318648; Gramaglia I, 1999, J IMMUNOL, V162, P1333; Han SH, 2005, ARTHRITIS RHEUM-US, V52, P3202, DOI 10.1002/art.21341; Jungbeck M, 2008, MOL IMMUNOL, V45, P34, DOI 10.1016/j.molimm.2007.05.007; Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liepinsh DJ, 2006, MOL CELL BIOL, V26, P4214, DOI 10.1128/MCB.01751-05; Locksley RM, 2008, IMMUNITY, V28, P437, DOI 10.1016/j.immuni.2008.03.009; Lubberts E, 2002, INFLAMM RES, V51, P102, DOI 10.1007/BF02684010; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mackay F, 1998, GASTROENTEROLOGY, V115, P1464, DOI 10.1016/S0016-5085(98)70025-3; Martin F, 2006, ANNU REV IMMUNOL, V24, P467, DOI 10.1146/annurev.immunol.24.021605.090517; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Miossec P, 2007, ARTHRITIS RHEUM-US, V56, P2111, DOI 10.1002/art.22733; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; O'Connor RA, 2008, J IMMUNOL, V181, P3750, DOI 10.4049/jimmunol.181.6.3750; Panayi GS, 2006, NAT CLIN PRACT RHEUM, V2, P58, DOI 10.1038/ncprheum0094; Pearl JP, 2005, AM J TRANSPLANT, V5, P465, DOI 10.1111/j.1600-6143.2005.00759.x; Segal BM, 1998, J EXP MED, V187, P537, DOI 10.1084/jem.187.4.537; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Summers-DeLuca LE, 2007, J EXP MED, V204, P1071, DOI 10.1084/jem.20061968; Svensson L, 1998, CLIN EXP IMMUNOL, V111, P521; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Tumanov AV, 2003, IMMUNOL REV, V195, P106, DOI 10.1034/j.1600-065X.2003.00071.x; Wang JS, 2006, J CLIN INVEST, V116, P414, DOI 10.1172/JCI26631; WARE CF, 1992, J IMMUNOL, V149, P3881; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719; Weiner HL, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-1002-8; Weyand CM, 2007, J RHEUMATOL, V34, P9; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	49	135	141	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					766	U10		10.1038/nm.1984	http://dx.doi.org/10.1038/nm.1984			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19561618				2022-12-27	WOS:000267806900029
J	Schulze-Topphoff, U; Prat, A; Prozorovski, T; Siffrin, V; Paterka, M; Herz, J; Bendix, I; Ifergan, I; Schadock, I; Mori, MA; Van Horssen, J; Schrotter, F; Smorodchenko, A; Han, MH; Bader, M; Steinman, L; Aktas, O; Zipp, F				Schulze-Topphoff, Ulf; Prat, Alexandre; Prozorovski, Timour; Siffrin, Volker; Paterka, Magdalena; Herz, Josephine; Bendix, Ivo; Ifergan, Igal; Schadock, Ines; Mori, Marcelo A.; Van Horssen, Jack; Schroetter, Friederike; Smorodchenko, Alina; Han, May Htwe; Bader, Michael; Steinman, Lawrence; Aktas, Orhan; Zipp, Frauke			Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system	NATURE MEDICINE			English	Article							ACTIVE MULTIPLE-SCLEROSIS; AUTOIMMUNE ENCEPHALOMYELITIS; NEURONAL DAMAGE; CELLS; EXPRESSION; LESIONS; MICE; NEUROINFLAMMATION; IMMUNOTHERAPY; INFLAMMATION	Previous proteomic and transcriptional analyses of multiple sclerosis lesions(1-3) revealed modulation of the renin-angiotensin and the opposing kallikrein-kinin pathways. Here we identify kinin receptor B1 (Bdkrb1) as a specific modulator of immune cell entry into the central nervous system (CNS). We demonstrate that the Bdkrb1 agonist R838 (Sar-[D-Phe]des-Arg(9)-bradykinin) markedly decreases the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in SJL mice(4-6), whereas the Bdkrb1 antagonist R715 (Ac-Lys-[D-beta Nal(7), Ile(8)]des-Arg(9)-bradykinin) resulted in earlier onset and greater severity of the disease. Bdkrb1-deficient (Bdkrb1(-/-)) C57BL/6 mice(7) immunized with a myelin oligodendrocyte glycoprotein fragment, MOG(35-55), showed more severe disease with enhanced CNS-immune cell infiltration. The same held true for mixed bone marrow-chimeric mice reconstituted with Bdkrb1(-/-) T lymphocytes, which showed enhanced T helper type 17 (T(H)17) cell invasion into the CNS. Pharmacological modulation of Bdkrb1 revealed that in vitro migration of human T(H)17 lymphocytes across blood-brain barrier endothelium is regulated by this receptor. Taken together, these results suggest that the kallikrein-kinin system is involved in the regulation of CNS inflammation, limiting encephalitogenic T lymphocyte infiltration into the CNS, and provide evidence that Bdkrb1 could be a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis.	[Schulze-Topphoff, Ulf; Prozorovski, Timour; Siffrin, Volker; Paterka, Magdalena; Herz, Josephine; Bendix, Ivo; Schroetter, Friederike; Smorodchenko, Alina; Aktas, Orhan; Zipp, Frauke] Charite, Cecilie Vogt Klin, Max Delbrueck Ctr Mol Med, Berlin, Germany; [Schulze-Topphoff, Ulf; Prozorovski, Timour; Siffrin, Volker; Paterka, Magdalena; Herz, Josephine; Bendix, Ivo; Schroetter, Friederike; Smorodchenko, Alina; Aktas, Orhan; Zipp, Frauke] NeuroCure Res Ctr, Berlin, Germany; [Prat, Alexandre; Ifergan, Igal] Ctr Hosp Univ Montreal, Neuroimmunol Res Lab, Montreal, PQ, Canada; [Schadock, Ines; Mori, Marcelo A.; Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany; [Van Horssen, Jack] Vrije Univ Amsterdam, Univ Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Han, May Htwe; Steinman, Lawrence] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universite de Montreal; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vrije Universiteit Amsterdam; Stanford University	Zipp, F (corresponding author), Charite, Cecilie Vogt Klin, Max Delbrueck Ctr Mol Med, Berlin, Germany.	frauke.zipp@charite.de	Smorodchenko, Alina/ABB-2411-2020; Smorodchenko, Alina/AAU-2854-2020; Bader, Michael/K-2124-2013; Mori, Marcelo A/R-2881-2018; Aktas, Orhan/B-7623-2009; Ifergan, Igal/AAI-9734-2020; Zipp, Frauke/C-9968-2015; Smorodchenko, Alina/D-1880-2010; Siffrin, Volker/AAR-3632-2021; Ifergan, Igal/AAR-7849-2021	Mori, Marcelo A/0000-0001-7112-5263; Aktas, Orhan/0000-0002-2020-9210; Zipp, Frauke/0000-0002-1231-1928; Ifergan, Igal/0000-0003-2945-2580; Bader, Michael/0000-0003-4780-4164; Siffrin, Volker/0000-0002-1532-2868; Smorodchenko, Alina/0000-0003-1415-1531; Bendix, Ivo/0000-0002-9751-3640; Schadock, Ines/0000-0002-6717-6276; van Horssen, Jack/0000-0003-4078-7402	Deutsche Forschungsgemeinschaft [SFB-TRR 43, GRK 1258/1, SFB 650]; Heinrich und Erna Schaufler-Stiftung; European Cooperation in Science and Technology (COST); Will Foundation; Multiple Sclerosis Society of Canada; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Heinrich und Erna Schaufler-Stiftung; European Cooperation in Science and Technology (COST)(European Cooperation in Science and Technology (COST)); Will Foundation; Multiple Sclerosis Society of Canada; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the Deutsche Forschungsgemeinschaft to O.A. (SFB-TRR 43) and F.Z. (GRK 1258/1, SFB-TRR 43, SFB 650), from the Heinrich und Erna Schaufler-Stiftung to O. A., by European Cooperation in Science and Technology (COST), by the Will Foundation and by a grant from the Multiple Sclerosis Society of Canada to A. P. A. P. is a Donald Paty Career Scientist from the Multiple Sclerosis Society of Canada. We thank T. Hohnstein and N. Nowakowski for expert technical assistance and A. Noon for reading the manuscript as a native speaker.	Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Aktas O, 2005, NEURON, V46, P421, DOI 10.1016/j.neuron.2005.03.018; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Betti M, 2006, ANN ONCOL, V17, P235; Cabarrocas J, 2006, P NATL ACAD SCI USA, V103, P8453, DOI 10.1073/pnas.0603086103; Calixto JB, 2004, BRIT J PHARMACOL, V143, P803, DOI 10.1038/sj.bjp.0706012; Cayla C, 2007, FASEB J, V21, P1689, DOI 10.1096/fj.06-7175com; Cayrol R, 2008, NAT IMMUNOL, V9, P137, DOI 10.1038/ni1551; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Dos Santos AC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-49; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377; Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559; Hoffmann O, 2007, J CLIN INVEST, V117, P2004, DOI 10.1172/JCI30356; Hohlfeid R, 2004, P NATL ACAD SCI USA, V101, P14599, DOI 10.1073/pnas.0404874101; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Kursar M, 2005, J EXP MED, V201, P1447, DOI 10.1084/jem.20041204; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Prat A, 1999, NEUROLOGY, V53, P2087, DOI 10.1212/WNL.53.9.2087; Prat A, 2000, J NEUROPATH EXP NEUR, V59, P896, DOI 10.1093/jnen/59.10.896; Prat A, 2005, ARCH NEUROL-CHICAGO, V62, P795, DOI 10.1001/archneur.62.5.795; Rohnelt RK, 1997, INT IMMUNOL, V9, P435, DOI 10.1093/intimm/9.3.435; Schmaier AH, 2002, J CLIN INVEST, V109, P1007, DOI 10.1172/JCI200215490; Steinman L, 2005, NAT REV DRUG DISCOV, V4, P510, DOI 10.1038/nrd1752; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502	29	104	107	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					788	793		10.1038/nm.1980	http://dx.doi.org/10.1038/nm.1980			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19561616	Green Accepted			2022-12-27	WOS:000267806900032
J	Moser, M; Bauer, M; Schmid, S; Ruppert, R; Schmidt, S; Sixt, M; Wang, HV; Sperandio, M; Fassler, R				Moser, Markus; Bauer, Martina; Schmid, Stephan; Ruppert, Raphael; Schmidt, Sarah; Sixt, Michael; Wang, Hao-Ven; Sperandio, Markus; Faessler, Reinhard			Kindlin-3 is required for beta(2) integrin-mediated leukocyte adhesion to endothelial cells	NATURE MEDICINE			English	Article							GDP-FUCOSE TRANSPORTER; LAD-III; DEFICIENCY; NEUTROPHILS; ACTIVATION; MOUSE; MICE; INFLAMMATION; EXPRESSION; SYSTEM	Integrin activation is essential for the function of all blood cells, including platelets and leukocytes(1). The blood cell-specific FERM domain protein Kindlin-3 is required for the activation of the beta(1) and beta(3) integrins on platelets(2). Impaired activation of beta(1), beta(2) and beta(3) integrins on platelets and leukocytes is the hallmark of a rare autosomal recessive leukocyte adhesion deficiency syndrome in humans called LAD-III, characterized by severe bleeding and impaired adhesion of leukocytes to inflamed endothelia(3). Here we show that Kindlin-3 also binds the beta(2) integrin cytoplasmic domain and is essential for neutrophil binding and spreading on beta(2) integrin-dependent ligands such as intercellular adhesion molecule-1 and the complement C3 activation product iC3b. Moreover, loss of Kindlin-3 expression abolished firm adhesion and arrest of neutrophils on activated endothelial cells in vitro and in vivo, whereas selectin-mediated rolling was unaffected. Thus, Kindlin-3 is essential to activate the beta(1), beta(2) and beta(3) integrin classes, and loss of Kindlin-3 function is sufficient to cause a LAD-III-like phenotype in mice.	[Moser, Markus; Bauer, Martina; Ruppert, Raphael; Schmidt, Sarah; Sixt, Michael; Wang, Hao-Ven; Faessler, Reinhard] Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; [Schmid, Stephan; Sperandio, Markus] Univ Munich, Walter Brendel Ctr Expt Med, D-81377 Munich, Germany	Max Planck Society; University of Munich	Fassler, R (corresponding author), Max Planck Inst Biochem, Dept Mol Med, Klopferspitz 18, D-82152 Martinsried, Germany.	faessler@biochem.mpg.de	Sixt, Michael/F-3925-2010	Wang, Hao-Ven/0000-0001-7523-087X; Sixt, Michael/0000-0002-6620-9179; Sperandio, Markus/0000-0002-7689-3613	Deutsche Forschungsgemeinschaft; Max Planck Society	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Max Planck Society(Max Planck Society)	We thank the members of the Fassler lab for discussions, R. Zent for careful reading of the manuscript, K. Kessenbrock for help with the oxidative burst experiment, T. Lammermann for help with the skin inflammation assay and S. Dietzel for help with generating the movie clips. The work was funded by the Deutsche Forschungsgemeinschaft and the Max Planck Society.	Alon R, 2003, TRENDS IMMUNOL, V24, P561, DOI 10.1016/j.it.2003.08.001; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Bergmeier W, 2007, J CLIN INVEST, V117, P1699, DOI 10.1172/JCI30575; Frommhold D, 2008, J EXP MED, V205, P1435, DOI 10.1084/jem.20070846; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jobard F, 2003, HUM MOL GENET, V12, P925, DOI 10.1093/hmg/ddg097; Jones SL, 1998, J BIOL CHEM, V273, P10556, DOI 10.1074/jbc.273.17.10556; Karsan A, 1998, J CLIN INVEST, V101, P2438, DOI 10.1172/JCI905; Kruger M, 2008, CELL, V134, P353, DOI 10.1016/j.cell.2008.05.033; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Kuijpers TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Long DS, 2004, P NATL ACAD SCI USA, V101, P10060, DOI 10.1073/pnas.0402937101; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Malinin NL, 2009, NAT MED, V15, P313, DOI 10.1038/nm.1917; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Montanez E, 2007, METHOD ENZYMOL, V426, P239, DOI 10.1016/S0076-6879(07)26012-4; Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Pasvolsky R, 2007, J EXP MED, V204, P1571, DOI 10.1084/jem.20070058; PRIES AR, 1988, INT J MICROCIRC, V7, P327; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Smith ML, 2004, J LEUKOCYTE BIOL, V76, P985, DOI 10.1189/jlb.1003483; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Sperandio M, 2006, METHOD ENZYMOL, V416, P346, DOI 10.1016/S0076-6879(06)16023-1; Svensson L, 2009, NAT MED, V15, P306, DOI 10.1038/nm.1931; Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030	30	279	287	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2009	15	3					300	305		10.1038/nm.1921	http://dx.doi.org/10.1038/nm.1921			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19234461				2022-12-27	WOS:000263914000030
J	Gill, WP; Harik, NS; Whiddon, MR; Liao, RP; Mittler, JE; Sherman, DR				Gill, Wendy P.; Harik, Nada S.; Whiddon, Molly R.; Liao, Reiling P.; Mittler, John E.; Sherman, David R.			A replication clock for Mycobacterium tuberculosis	NATURE MEDICINE			English	Article							HOST-PARASITE EQUILIBRIUM; STATIONARY-PHASE; HYPOXIC RESPONSE; INFECTED MICE; GRANULOMAS; CHEMOTHERAPY; ZEBRAFISH; IMMUNITY; MURINE	Few tools exist to assess replication of chronic pathogens during infection. This has been a considerable barrier to understanding latent tuberculosis, and efforts to develop new therapies generally assume that the bacteria are very slowly replicating or nonreplicating during latency(1-3). To monitor Mycobacterium tuberculosis replication within hosts, we exploit an unstable plasmid that is lost at a steady, quantifiable rate from dividing cells in the absence of antibiotic selection. By applying a mathematical model, we calculate bacterial growth and death rates during infection of mice. We show that during chronic infection, the cumulative bacterial burden enumerating total live, dead and removed organisms encountered by the mouse lung-is substantially higher than estimates from colony-forming units. Our data show that M. tuberculosis replicates throughout the course of chronic infection of mice and is restrained by the host immune system. This approach may also shed light on the replication dynamics of other chronic pathogens.	[Whiddon, Molly R.; Liao, Reiling P.; Sherman, David R.] Seattle Biomed Res Inst, Seattle, WA 98109 USA; [Gill, Wendy P.] Univ Washington, Med Ctr, Div Allerg & Infect Dis, Seattle, WA 98195 USA; [Harik, Nada S.] Univ Arkansas Med Sci, Div Pediat Infect Dis, Little Rock, AR 72202 USA; [Whiddon, Molly R.; Sherman, David R.] Univ Washington, Dept Global Hlth, Interdisciplinary Program Pathobiol, Seattle, WA 98195 USA; [Mittler, John E.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	Center for Infectious Disease Research; University of Washington; University of Washington Seattle; University of Arkansas System; University of Arkansas Medical Sciences; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sherman, DR (corresponding author), Seattle Biomed Res Inst, 307 Westlake Ave N,Suite 500, Seattle, WA 98109 USA.	david.sherman@sbri.org		Harik, Nada/0000-0003-0445-8652	US National Institutes of Health; Paul G. Allen Family Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047744] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Paul G. Allen Family Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank L. Ramakrishnan, J. Chang, K. Guinn, T. Walker and members of the Sherman lab for review of and contributions to this work, C. DeMille for expert help with manuscript preparation and K. G. Papavinasasundaram ( University of Massachusetts Medical School) for providing pBP10. This research was supported by grants from the US National Institutes of Health and the Paul G. Allen Family Foundation.	Aly S, 2006, J PATHOL, V210, P298, DOI 10.1002/path.2055; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; Bachrach G, 2000, MICROBIOL-UK, V146, P297, DOI 10.1099/00221287-146-2-297; Cho SH, 2007, ANTIMICROB AGENTS CH, V51, P1380, DOI 10.1128/AAC.00055-06; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; Cosma CL, 2004, NAT IMMUNOL, V5, P828, DOI 10.1038/ni1091; DAVISON AC, 1997, BOOTSTRAP METHODS TH, pCH2; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Harries AD, 2006, ANN TROP MED PARASIT, V100, P415, DOI 10.1179/136485906X91477; KANAI K, 1966, JPN J MED SCI BIOL, V19, P181, DOI 10.7883/yoken1952.19.181; Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567; Lazarevic V, 2005, J IMMUNOL, V175, P1107, DOI 10.4049/jimmunol.175.2.1107; Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1128/AAC.49.6.2294-2301.2005; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Meijer AH, 2008, DEV COMP IMMUNOL, V32, P36, DOI 10.1016/j.dci.2007.04.003; Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271; Munoz-Elias EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546-551.2005; Nuermberger E, 2005, AM J RESP CRIT CARE, V172, P1452, DOI 10.1164/rccm.200507-1047OC; Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x; REES RJ, 1961, BRIT J EXP PATHOL, V42, P83; Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2; Rivas-Santiago B, 2006, J INFECT DIS, V194, P697, DOI 10.1086/506454; Rustad TR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001502; Smeulders MJ, 1999, J BACTERIOL, V181, P270, DOI 10.1128/JB.181.1.270-283.1999; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Swaim LE, 2006, INFECT IMMUN, V74, P6108, DOI 10.1128/IAI.00887-06; Tsai MC, 2006, CELL MICROBIOL, V8, P218, DOI 10.1111/j.1462-5822.2005.00612.x; Via LE, 2008, INFECT IMMUN, V76, P2333, DOI 10.1128/IAI.01515-07; Wards BJ, 1996, FEMS MICROBIOL LETT, V145, P101, DOI 10.1016/0378-1097(96)00394-1; Warner DF, 2006, CLIN MICROBIOL REV, V19, P558, DOI 10.1128/CMR.00060-05; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219	32	218	222	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					211	214		10.1038/nm.1915	http://dx.doi.org/10.1038/nm.1915			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19182798	Green Accepted			2022-12-27	WOS:000263119400025
J	[Anonymous]				[Anonymous]			Reproductive biology	NATURE MEDICINE			English	Editorial Material								In what direction is the field of reproductive biology moving? Do funding priorities match hot research areas? In this special focus, we try to find out.											0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1166	1166		10.1038/nm1108-1166	http://dx.doi.org/10.1038/nm1108-1166			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18989283				2022-12-27	WOS:000260751200017
J	Kuznetsov, SG; Liu, PT; Sharan, SK				Kuznetsov, Sergey G.; Liu, Pentao; Sharan, Shyam K.			Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2	NATURE MEDICINE			English	Article							UNKNOWN CLINICAL-SIGNIFICANCE; SEQUENCE VARIANTS; HOMOLOGOUS RECOMBINATION; CANCER-RISK; CROSS-LINKS; MICE; HYPERSENSITIVITY; RADIATION; REPAIR; CHROMOSOME	Individuals with mutations in breast cancer susceptibility genes BRCA1 and BRCA2 have up to an 80% risk of developing breast cancer by the age of 70. Sequencing-based genetic tests are now available to identify mutation carriers in an effort to reduce mortality through prevention and early diagnosis. However, lack of a suitable functional assay hinders the risk assessment of more than 1,900 BRCA1 and BRCA2 variants in the Breast Cancer Information Core database that do not clearly disrupt the gene product. We have established a simple, versatile and reliable assay to test for the functional significance of mutations in BRCA2 using mouse embryonic stem cells (ES cells) and bacterial artificial chromosomes and have used it to classify 17 sequence variants. The assay is based on the ability of human BRCA2 to complement the loss of endogenous Brca2 in mouse ES cells. This technique may also serve as a paradigm for functional analysis of mutations found in other genes linked to human diseases.	[Kuznetsov, Sergey G.; Liu, Pentao; Sharan, Shyam K.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sharan, SK (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, 1050 Boyles St, Frederick, MD 21702 USA.	sharans@mail.nih.gov		Kuznetsov, Sergey/0000-0002-5662-9700	Intramural NIH HHS [Z01 BC010387-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010387, ZIABC011181] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atanassov BS, 2005, GENE CHROMOSOME CANC, V44, P429, DOI 10.1002/gcc.20255; Carvalho MA, 2007, INT J BIOCHEM CELL B, V39, P298, DOI 10.1016/j.biocel.2006.08.002; Court DL, 2003, GENE, V315, P63, DOI 10.1016/S0378-1119(03)00728-5; Deffenbaugh AM, 2002, GENET TEST, V6, P119, DOI 10.1089/10906570260199375; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Easton DF, 2007, AM J HUM GENET, V81, P873, DOI 10.1086/521032; Fackenthal JD, 2002, AM J HUM GENET, V71, P625, DOI 10.1086/342192; Freedman ML, 2004, HUM MOL GENET, V13, P2431, DOI 10.1093/hmg/ddh270; Godthelp BC, 2006, MUTAT RES-FUND MOL M, V601, P191, DOI 10.1016/j.mrfmmm.2006.07.003; Goldgar DE, 2004, AM J HUM GENET, V75, P535, DOI 10.1086/424388; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kuznetsov S, 2007, J CELL BIOL, V176, P581, DOI 10.1083/jcb.200608130; Marple T, 2006, MUTAT RES-FUND MOL M, V602, P110, DOI 10.1016/j.mrfmmm.2006.08.005; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Morimatsu M, 1998, CANCER RES, V58, P3441; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; Thompson D, 2003, AM J HUM GENET, V73, P652, DOI 10.1086/378100; Wong JMS, 2003, ONCOGENE, V22, P28, DOI 10.1038/sj.onc.1206071; Wu KJ, 2005, CANCER RES, V65, P417; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang YP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng080; Yang YP, 2003, HUM MOL GENET, V12, P2121, DOI 10.1093/hmg/ddg222; Yuan SSF, 1999, CANCER RES, V59, P3547	29	93	97	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2008	14	8					875	881		10.1038/nm.1719	http://dx.doi.org/10.1038/nm.1719			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18607349	Green Accepted			2022-12-27	WOS:000258237500036
J	Savaskan, NE; Heckel, A; Hahnen, E; Engelhorn, T; Doerfler, A; Ganslandt, O; Nimsky, C; Buchfelder, M; Eyupoglu, IY				Savaskan, Nicolai E.; Heckel, Alexandra; Hahnen, Eric; Engelhorn, Tobias; Doerfler, Arnd; Ganslandt, Oliver; Nimsky, Christopher; Buchfelder, Michael; Eyuepoglu, Ilker Y.			Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema	NATURE MEDICINE			English	Article							HUMAN GLIOBLASTOMA; GLUTAMATE; GROWTH; TUMORS; CYSTINE; CELLS; MICE	Neurodegeneration and brain edema are hallmarks of human malignant brain tumors. Here we show that genetic or pharmacological inhibition of the glutamate transporter xCT (X-c(-) system, encoded by SLC7a11) in vivo leads to abrogated neurodegeneration, attenuated perifocal edema and prolonged survival. These results show a crucial role for xCT in glioma-induced neurodegeneration and brain edema, corroborating the concept that edema formation may be in part a consequence of peritumoral cell death.	[Savaskan, Nicolai E.] Swiss Fed Inst Technol, Brain Res Inst, CH-8057 Zurich, Switzerland; [Savaskan, Nicolai E.] Univ Zurich, CH-8057 Zurich, Switzerland; [Savaskan, Nicolai E.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; [Heckel, Alexandra; Ganslandt, Oliver; Nimsky, Christopher; Buchfelder, Michael; Eyuepoglu, Ilker Y.] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany; [Hahnen, Eric] Univ Cologne, Inst Genet, Inst Human Genet, D-50674 Cologne, Germany; [Hahnen, Eric] Univ Cologne, Ctr Mol Med Colonge, D-50674 Cologne, Germany; [Hahnen, Eric] Univ Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany; [Engelhorn, Tobias; Doerfler, Arnd] Univ Erlangen Nurnberg, Dept Neuroradiol, D-91054 Erlangen, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Netherlands Cancer Institute; University of Erlangen Nuremberg; University of Cologne; University of Cologne; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Savaskan, NE (corresponding author), Swiss Fed Inst Technol, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	savaskan@gmx.net; ilker.eyupoglu@uk-erlangen.de	Nimsky, Christopher/E-3702-2014; Savaskan, Nicolai/D-2923-2018	Nimsky, Christopher/0000-0002-8216-9410; Savaskan, Nicolai/0000-0003-1348-094X; Eyupoglu, Ilker/0000-0002-8185-7764				Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishiuchi S, 2007, J NEUROSCI, V27, P7987, DOI 10.1523/JNEUROSCI.2180-07.2007; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Shih AY, 2006, J NEUROSCI, V26, P10514, DOI 10.1523/JNEUROSCI.3178-06.2006; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Wick W, 2004, ONKOLOGIE, V27, P261, DOI 10.1159/000077976; Ye ZC, 1999, CANCER RES, V59, P4383	15	136	137	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					629	632		10.1038/nm1772	http://dx.doi.org/10.1038/nm1772			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18469825				2022-12-27	WOS:000256468700028
J	Speier, S; Nyqvist, D; Cabrera, O; Yu, J; Molano, RD; Pileggi, A; Moede, T; Kohler, M; Wilbertz, J; Leibiger, B; Ricordi, C; Leibiger, IB; Caicedo, A; Berggren, PO				Speier, Stephan; Nyqvist, Daniel; Cabrera, Over; Yu, Jia; Molano, R. Damaris; Pileggi, Antonello; Moede, Tilo; Kohler, Martin; Wilbertz, Johannes; Leibiger, Barbara; Ricordi, Camillo; Leibiger, Ingo B.; Caicedo, Alejandro; Berggren, Per-Olof			Noninvasive in vivo imaging of pancreatic islet cell biology	NATURE MEDICINE			English	Article							ANTERIOR EYE CHAMBER; BETA-CELL; TRANSPLANTED ISLETS; RAT; APOPTOSIS; INSULIN; LANGERHANS; TISSUE; PROTEIN; HUMANS	the study of complex biological processes at the cellular level in biomedical research. Here, we introduce a new technical platform for noninvasive in vivo fluorescence imaging of pancreatic islets using the anterior chamber of the eye as a natural body window. Islets transplanted into the mouse eye engrafted on the iris, became vascularized, retained cellular composition, responded to stimulation and reverted diabetes. Laser-scanning microscopy allowed repetitive in vivo imaging of islet vascularization, beta cell function and death at cellular resolution. Our results thus establish the basis for noninvasive in vivo investigations of complex cellular processes, like beta cell stimulus-response coupling, which can be performed longitudinally under both physiological and pathological conditions.	[Cabrera, Over; Molano, R. Damaris; Pileggi, Antonello; Ricordi, Camillo; Caicedo, Alejandro; Berggren, Per-Olof] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA; [Speier, Stephan; Nyqvist, Daniel; Yu, Jia; Moede, Tilo; Kohler, Martin; Leibiger, Barbara; Leibiger, Ingo B.; Berggren, Per-Olof] Karolinska Univ Hosp L1, Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, SE-17176 Stockholm, Sweden; [Wilbertz, Johannes] Karolinska Inst, Dept Cellular & Mol Biol, SE-17177 Stockholm, Sweden	University of Miami; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Caicedo, A (corresponding author), Univ Miami, Miller Sch Med, Diabet Res Inst, NW 10th Ave, Miami, FL 33136 USA.	acaicedo@med.miami.edu; Per-Olof.Berggren@ki.se	Molano, Ruth Damaris/B-8633-2015; RICORDI, CAMILLO/AAA-4740-2019; Pileggi, Antonello/A-2394-2008; Speier, Stephan/E-8525-2010; Caicedo, Alejandro/AAC-8544-2020; Caicedo, Alejandro/F-1202-2010	Molano, Ruth Damaris/0000-0002-6132-8750; Pileggi, Antonello/0000-0001-7819-2813; Speier, Stephan/0000-0002-4561-7085; Ricordi, Camillo/0000-0001-8092-7153; Kohler, Martin/0000-0001-6487-4303; Moede, Tilo/0000-0002-2045-9244; Berggren, Per-Olof/0000-0001-8991-413X; Nyqvist, Daniel/0000-0002-6527-6716	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058508, R03DK075487] Funding Source: NIH RePORTER; NIDDK NIH HHS [R03 DK075487, R03 DK075487-02, R01 DK058508, R03 DK075487-01, DK-075487, DK-58508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adeghate E, 2001, EUR J MORPHOL, V39, P257, DOI 10.1076/ejom.39.5.0257; ADEGHATE E, 1990, PANCREAS, V5, P298, DOI 10.1097/00006676-199005000-00009; Berggren PO, 2006, NUTR METAB CARDIOVAS, V16, pS7, DOI 10.1016/j.numecd.2005.11.005; Berney T, 2001, TRANSPLANTATION, V71, P125, DOI 10.1097/00007890-200101150-00020; Boersma HH, 2005, J NUCL MED, V46, P2035; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; HOFFER B, 1974, BRAIN RES, V79, P165, DOI 10.1016/0006-8993(74)90409-0; KATOH N, 1991, CELL TISSUE RES, V266, P259, DOI 10.1007/BF00318181; Kohler M, 2003, DIABETES, V52, P2943, DOI 10.2337/diabetes.52.12.2943; Kohler Martin, 2004, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V4, P281, DOI 10.2174/1568013043357275; LIPP P, 1993, CELL CALCIUM, V14, P359, DOI 10.1016/0143-4160(93)90040-D; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Medarova Z, 2005, DIABETES, V54, P1780, DOI 10.2337/diabetes.54.6.1780; Meier JJ, 2006, DIABETES, V55, P2324, DOI 10.2337/db06-0069; Menger MD, 2001, WORLD J SURG, V25, P509, DOI 10.1007/s002680020345; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; Nikolova G, 2006, DEV CELL, V10, P397, DOI 10.1016/j.devcel.2006.01.015; Nyqvist D, 2005, DIABETES, V54, P2287, DOI 10.2337/diabetes.54.8.2287; Paty BW, 2004, TRANSPLANTATION, V77, P1133, DOI 10.1097/01.TP.0000113231.90613.0E; PORKSEN N, 1994, J CLIN INVEST, V94, P219, DOI 10.1172/JCI117310; Quesada I, 1999, DIABETES, V48, P2390, DOI 10.2337/diabetes.48.12.2390; RAHIER J, 1983, DIABETOLOGIA, V24, P366; Ricordi C, 2003, DIABETES, V52, P1595, DOI 10.2337/diabetes.52.7.1595; Speier S, 2003, PFLUG ARCH EUR J PHY, V446, P553, DOI 10.1007/s00424-003-1097-9; Strebel A, 2001, CYTOMETRY, V43, P126, DOI 10.1002/1097-0320(20010201)43:2<126::AID-CYTO1027>3.0.CO;2-J; Szkudelski T, 2001, PHYSIOL RES, V50, P537; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VETTERLEIN F, 1987, MICROVASC RES, V34, P231, DOI 10.1016/0026-2862(87)90056-2; Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038; WOODS SC, 1974, PHYSIOL REV, V54, P596, DOI 10.1152/physrev.1974.54.3.596	30	194	202	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					574	578		10.1038/nm1701	http://dx.doi.org/10.1038/nm1701			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18327249	Green Accepted			2022-12-27	WOS:000255681800039
J	Tabar, V; Tomishima, M; Panagiotakos, G; Wakayama, S; Menon, J; Chan, B; Mizutani, E; Al-Shamy, G; Ohta, H; Wakayama, T; Studer, L				Tabar, Viviane; Tomishima, Mark; Panagiotakos, Georgia; Wakayama, Sayaka; Menon, Jayanthi; Chan, Bill; Mizutani, Eiji; Al-Shamy, George; Ohta, Hiroshi; Wakayama, Teruhiko; Studer, Lorenz			Therapeutic cloning in individual parkinsonian mice	NATURE MEDICINE			English	Article							EMBRYONIC STEM-CELLS; NUCLEAR TRANSFER; FERTILIZATION; BLASTOCYSTS; DISEASE; LINES; MODEL	Cell transplantation with embryonic stem (ES) cell progeny requires immunological compatibility with host tissue. 'Therapeutic cloning' is a strategy to overcome this limitation by generating nuclear transfer (nt) ES cells that are genetically matched to an individual. Here we establish the feasibility of treating individual mice via therapeutic cloning. Derivation of 187 ntES cell lines from 24 parkinsonian mice, dopaminergic differentiation, and transplantation into individually matched host mice showed therapeutic efficacy and lack of immunological response.	[Tabar, Viviane; Panagiotakos, Georgia; Menon, Jayanthi; Chan, Bill; Al-Shamy, George; Studer, Lorenz] Sloan Kettering Inst, Dept Neurosurg, New York, NY 10065 USA; [Tabar, Viviane] Cornell Univ, Weil Med Coll, Dept Neurosurg, New York, NY 10065 USA; [Tomishima, Mark; Studer, Lorenz] Sloan Kettering Inst, Dev Biol Program, New York, NY 10065 USA; [Wakayama, Sayaka; Mizutani, Eiji; Ohta, Hiroshi; Wakayama, Teruhiko] RIKEN, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; RIKEN	Tabar, V (corresponding author), Sloan Kettering Inst, Dept Neurosurg, 1275 York Ave, New York, NY 10065 USA.	tabarv@mskcc.org; studerl@mskcc.org	Studer, Lorenz/ABH-1491-2021; Ohta, Hiroshi/C-3375-2009	Studer, Lorenz/0000-0003-0741-7987; PANAGIOTAKOS, GEORGIA/0000-0001-9444-2480	NINDS NIH HHS [R21 NS044231-01, R01 NS052671-03, R01 NS052671-01A2, R21 NS044231, R21 NS044231-02, R01 NS052671-02, R21NS44231, R01 NS052671, R01NS052671] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044231, R01NS052671] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bensadoun JC, 2000, EXP NEUROL, V164, P15, DOI 10.1006/exnr.2000.7409; Brambrink T, 2006, P NATL ACAD SCI USA, V103, P933, DOI 10.1073/pnas.0510485103; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023; *JACK LAB, 1991, HDB GENETICALLY STAN; Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Sortwell CE, 2001, EXP NEUROL, V169, P23, DOI 10.1006/exnr.2001.7644; Wakayama S, 2006, STEM CELLS, V24, P2023, DOI 10.1634/stemcells.2005-0537; Wakayama S, 2007, CURR BIOL, V17, pR120, DOI 10.1016/j.cub.2006.12.020; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632	15	79	85	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					379	381		10.1038/nm1732	http://dx.doi.org/10.1038/nm1732			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376409	Green Accepted			2022-12-27	WOS:000254674100023
J	Rivero, FD; Saura, A; Prucca, CG; Carranza, PG; Torri, A; Lujan, HD				Rivero, Fernando D.; Saura, Alicia; Prucca, Cesar G.; Carranza, Pedro G.; Torri, Alessandro; Lujan, Hugo D.			Disruption of antigenic variation is crucial for effective parasite vaccine	NATURE MEDICINE			English	Article							GIARDIA-LAMBLIA TROPHOZOITES; EXPERIMENTAL HUMAN INFECTIONS; MURIS TROPHOZOITES; MONGOLIAN GERBILS; SURFACE-PROTEINS; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSE; MICE; SUSCEPTIBILITY; DUODENALIS	Giardia lamblia is a human intestinal pathogen. Like many protozoan microorganisms, Giardia undergoes antigenic variation, a mechanism assumed to allow parasites to evade the host's immune response, producing chronic and/or recurrent infections. Recently, we found that the mechanism controlling variant-specific surface protein (VSP) switching in Giardia involves components of the RNA interference machinery and that disruption of this pathway generates trophozoites simultaneously expressing many VSPs. Here we use these altered trophozoites to determine the role of antigenic variation in a gerbil model of giardiasis. Our results show that either primary infection with trophozoites simultaneously expressing many VSPs or immunization with purified VSPs from the transgenic cells protects gerbils from subsequent Giardia infections. These results constitute, to our knowledge, the first experimental evidence that antigenic variation is essential for parasite survival within hosts and that artificial disruption of this mechanism might be useful in generating vaccines against major pathogens that show similar behavior.	[Rivero, Fernando D.; Saura, Alicia; Prucca, Cesar G.; Carranza, Pedro G.; Torri, Alessandro; Lujan, Hugo D.] Catholic Univ Cordoba, Lab Biochem & Mol Biol, Sch Med, Cordoba, Argentina	Catholic University of Cordoba	Lujan, HD (corresponding author), Catholic Univ Cordoba, Lab Biochem & Mol Biol, Sch Med, Cordoba, Argentina.	hlujan@ucc.edu.ar	Prucca, César Germán/AAC-4630-2021; Prucca, César/AAQ-4401-2020; RIVERO, Fernando/AFV-5689-2022	Prucca, César Germán/0000-0003-4165-4660; Torri, Alessandro/0000-0001-6340-5572	Agencia Nacional para la Promocion de la Ciencia y la Tecnologia; Consejo Nacional de Investigaciones Cientificas y Tecnicas; Catholic University of Cordoba; Howard Hughes Medical Institute; EU	Agencia Nacional para la Promocion de la Ciencia y la Tecnologia; Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Catholic University of Cordoba; Howard Hughes Medical Institute(Howard Hughes Medical Institute); EU(European Commission)	We thank T. E. Nash (National Institute of Allergy and Infectious Diseases, US National Institutes of Health) for providing VSP-specific mAbs and Giardia strains and M. E. Rivarola and the Pathology Service of the School of Medicine, Catholic University of Cordoba, for technical assistance. This work was supported by grants from the Agencia Nacional para la Promocion de la Ciencia y la Tecnologia, Consejo Nacional de Investigaciones Cientificas y Tecnicas, Catholic University of Cordoba, the Howard Hughes Medical Institute and the EU CONTENT Project. H. D. L. is a Howard Hughes Medical Institute International Research Scholar and a Member of the Scientific Investigator's Career of the Consejo Nacional de Investigaciones Cientificas y Tecnicas.	ADAM RD, 1988, J EXP MED, V167, P109, DOI 10.1084/jem.167.1.109; Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; AGGARWAL A, 1988, INFECT IMMUN, V56, P1420, DOI 10.1128/IAI.56.6.1420-1423.1988; AGGARWAL A, 1987, AM J TROP MED HYG, V36, P325, DOI 10.4269/ajtmh.1987.36.325; ANDERS RF, 1982, PARASITE IMMUNOL, V4, P47, DOI 10.1111/j.1365-3024.1982.tb00419.x; Anderson KA, 2004, CAN VET J, V45, P924; Barrett LG, 2008, TRENDS ECOL EVOL, V23, P678, DOI 10.1016/j.tree.2008.06.017; BELOSEVIC M, 1987, PARASITE IMMUNOL, V9, P11, DOI 10.1111/j.1365-3024.1987.tb00484.x; Bouza M, 2000, EXP PARASITOL, V96, P43, DOI 10.1006/expr.2000.4540; BURET A, 1992, GASTROENTEROLOGY, V103, P506, DOI 10.1016/0016-5085(92)90840-U; Buret AG, 2008, PARASITE, V15, P261, DOI 10.1051/parasite/2008153261; BUTSCHER WG, 1988, IMMUNOLOGY, V64, P175; BYRD LG, 1994, INFECT IMMUN, V62, P3583, DOI 10.1128/IAI.62.8.3583-3585.1994; Carranza PG, 2002, INFECT IMMUN, V70, P5265, DOI 10.1128/IAI.70.9.5265-5268.2002; Deitsch KW, 2009, NAT REV MICROBIOL, V7, P493, DOI 10.1038/nrmicro2145; DENG MY, 1992, APPL ENVIRON MICROB, V58, P2368, DOI 10.1128/AEM.58.8.2368-2374.1992; Deselliers LP, 1997, DIGEST DIS SCI, V42, P2411, DOI 10.1023/A:1018879621272; Dunn LA, 2001, INFECT IMMUN, V69, P6503, DOI 10.1128/IAI.69.10.6503-6510.2001; Eckmann L, 2003, PARASITE IMMUNOL, V25, P259, DOI 10.1046/j.1365-3024.2003.00634.x; Faubert G, 2000, CLIN MICROBIOL REV, V13, P35, DOI 10.1128/CMR.13.1.35-54.2000; Franzen O, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000560; Gardner TB, 2001, CLIN MICROBIOL REV, V14, P114, DOI 10.1128/CMR.14.1.114-128.2001; GOTTSTEIN B, 1993, PARASITOL RES, V79, P644, DOI 10.1007/BF00932506; GOTTSTEIN B, 1991, PARASITE IMMUNOL, V13, P649, DOI 10.1111/j.1365-3024.1991.tb00560.x; Hemphill A, 1996, PARASITOL RES, V82, P206, DOI 10.1007/s004360050096; HEYWORTH MF, 1992, J PARASITOL, V78, P73, DOI 10.2307/3283690; HILL DR, 1984, J IMMUNOL, V132, P2046; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; LUJAN HD, 1995, J BIOL CHEM, V270, P13807, DOI 10.1074/jbc.270.23.13807; Mann JFS, 2009, EXPERT REV VACCINES, V8, P103, DOI 10.1586/14760584.8.1.103; Monis PT, 2009, TRENDS PARASITOL, V25, P93, DOI 10.1016/j.pt.2008.11.006; Morrison HG, 2007, SCIENCE, V317, P1921, DOI 10.1126/science.1143837; MOSS DM, 1990, J CLIN MICROBIOL, V28, P254, DOI 10.1128/JCM.28.2.254-257.1990; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; Muller N, 2005, INT J PARASITOL, V35, P1339, DOI 10.1016/j.ijpara.2005.07.008; NASH T, 1992, PARASITOL TODAY, V8, P229, DOI 10.1016/0169-4758(92)90119-M; NASH TE, 1990, J IMMUNOL, V144, P4362; NASH TE, 1987, J INFECT DIS, V156, P974, DOI 10.1093/infdis/156.6.974; Nash TE, 2002, MOL MICROBIOL, V45, P585, DOI 10.1046/j.1365-2958.2002.03029.x; NASH TE, 1991, INFECT IMMUN, V59, P1334, DOI 10.1128/IAI.59.4.1334-1340.1991; Nash TE, 1997, PHILOS T R SOC B, V352, P1369, DOI 10.1098/rstb.1997.0122; NASH TE, 1986, J IMMUNOL, V136, P2628; Olson ME, 2000, PARASITOL TODAY, V16, P213, DOI 10.1016/S0169-4758(99)01623-3; Olson ME, 1997, CAN VET J, V38, P777; PIMENTA PFP, 1991, INFECT IMMUN, V59, P3989, DOI 10.1128/IAI.59.11.3989-3996.1991; Prucca CG, 2008, NATURE, V456, P750, DOI 10.1038/nature07585; Ropolo AS, 2005, INFECT IMMUN, V73, P5208, DOI 10.1128/IAI.73.8.5208-5211.2005; Savioli L, 2006, TRENDS PARASITOL, V22, P203, DOI 10.1016/j.pt.2006.02.015; Singer SM, 2000, J INFECT DIS, V181, P1510, DOI 10.1086/315409; Stager S, 1998, INFECT IMMUN, V66, P1287; Thompson RCA, 2000, PARASITOL TODAY, V16, P210, DOI 10.1016/S0169-4758(99)01624-5; Tonkin CJ, 2009, PLOS BIOL, V7, P771, DOI 10.1371/journal.pbio.1000084; Uehlinger FD, 2007, VET PARASITOL, V146, P182, DOI 10.1016/j.vetpar.2007.01.013; UPCROFT JA, 1990, INT J PARASITOL, V20, P489, DOI 10.1016/0020-7519(90)90196-T; Vonlaufen N, 2008, CELL MICROBIOL, V10, P2387, DOI 10.1111/j.1462-5822.2008.01210.x; Zarnbrano-Villa S, 2002, TRENDS PARASITOL, V18, P272, DOI 10.1016/S1471-4922(02)02289-4	58	51	56	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2010	16	5					551	U83		10.1038/nm.2141	http://dx.doi.org/10.1038/nm.2141			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20418884				2022-12-27	WOS:000277394700033
J	Hotamisligil, GS				Hotamisligil, Goekhan S.			Endoplasmic reticulum stress and atherosclerosis	NATURE MEDICINE			English	Article							UNFOLDED PROTEIN RESPONSE; INSULIN-RESISTANCE; ER STRESS; DEFICIENT MICE; APOLIPOPROTEIN-E; ADIPOSE-TISSUE; T-CELLS; OBESITY; APOPTOSIS; INFLAMMATION	Atherosclerosis and related cardiovascular diseases represent one of the greatest threats to human health worldwide. Despite important progress in prevention and treatment, these conditions still account for one third of all deaths annually. Often presented together with obesity, insulin resistance and type 2 diabetes, these chronic diseases are strongly influenced by pathways that lie at the interface of chronic inflammation and nutrient metabolism. Here I discuss recent advances in the study of endoplasmic reticulum stress as one mechanism that links immune response with nutrient sensing in the pathogenesis of atherosclerosis and its complications.	[Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Genet, Boston, MA 02115 USA; [Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Complex Dis, Boston, MA 02115 USA; [Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Broad Inst, Massachusetts Inst Technol & Harvard, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Broad Institute	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet, 665 Huntington Ave, Boston, MA 02115 USA.	ghotamis@hsph.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK064360, R01DK052539, R01DK064360] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK052539-11, R01 DK064360, R01 DK064360-07, R01 DK052539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AQEL NM, 1984, ATHEROSCLEROSIS, V53, P265, DOI 10.1016/0021-9150(84)90127-8; Baumgartl J, 2006, CELL METAB, V3, P247, DOI 10.1016/j.cmet.2006.02.010; Bowes AJ, 2009, AM J PATHOL, V174, P330, DOI 10.2353/ajpath.2009.080385; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Civelek M, 2009, CIRC RES, V105, P453, DOI 10.1161/CIRCRESAHA.109.203711; de Almeida SF, 2007, J IMMUNOL, V178, P3612, DOI 10.4049/jimmunol.178.6.3612; Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Gautier EL, 2009, CIRCULATION, V119, P1795, DOI 10.1161/CIRCULATIONAHA.108.806158; Granados DP, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-10; Gregor MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200; Han S, 2006, CELL METAB, V3, P257, DOI 10.1016/j.cmet.2006.02.008; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Lee AH, 2008, SCIENCE, V320, P1492, DOI 10.1126/science.1158042; Libby P, 2009, J LIPID RES, V50, pS352, DOI 10.1194/jlr.R800099-JLR200; Lim WS, 2008, CIRCULATION, V117, P940, DOI 10.1161/CIRCULATIONAHA.107.711275; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ota T, 2008, J CLIN INVEST, V118, P316, DOI 10.1172/JCI32752; Oyadomari S, 2008, CELL METAB, V7, P520, DOI 10.1016/j.cmet.2008.04.011; Ozawa K, 2005, DIABETES, V54, P657, DOI 10.2337/diabetes.54.3.657; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Rader DJ, 2008, NATURE, V451, P904, DOI 10.1038/nature06796; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Ricci R, 2004, SCIENCE, V306, P1558, DOI 10.1126/science.1101909; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rutkowski DT, 2008, DEV CELL, V15, P829, DOI 10.1016/j.devcel.2008.10.015; Seimon TA, 2009, J CLIN INVEST, V119, P886, DOI 10.1172/JCI37262; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Tabas I, 2009, ANTIOXID REDOX SIGN, V11, P2333, DOI [10.1089/ars.2009.2469, 10.1089/ARS.2009.2469]; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Xu K, 2009, ATHEROSCLEROSIS, V207, P123, DOI 10.1016/j.atherosclerosis.2009.04.019; Yang L, 2007, LAB INVEST, V87, P927, DOI 10.1038/labinvest.3700603; Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1; Zhou J, 2009, BIOFACTORS, V35, P120, DOI 10.1002/biof.17	50	219	232	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					396	399		10.1038/nm0410-396	http://dx.doi.org/10.1038/nm0410-396			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376052	Green Accepted			2022-12-27	WOS:000276446800041
J	Newgard, CB; Attie, AD				Newgard, Christopher B.; Attie, Alan D.			Getting biological about the genetics of diabetes	NATURE MEDICINE			English	Article							INSULIN-RESISTANCE; COMMON VARIANTS; OBESE; SUSCEPTIBILITY; GENES; EXPRESSION; CONTRIBUTE; LOCI; RETINOL-BINDING-PROTEIN-4; IDENTIFICATION	New technology has provided methods for collecting large amounts of data reflecting gene expression, metabolite and protein abundance, and post-translational modification of proteins. Integration of these various data sets enable the genetic mapping of many new phenotypes and facilitates the creation of network models that link genetic variation with intermediate traits leading to human disease. The first round of genome-wide association studies has not accounted for common human diseases to the extent that was expected. New phenotyping approaches and methods of data integration should bring these studies closer to their promised goals.	[Newgard, Christopher B.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27706 USA; [Newgard, Christopher B.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	Duke University; Duke University; University of Wisconsin System; University of Wisconsin Madison	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27706 USA.	newga002@mc.duke.edu; adattie@wisc.edu						Bain JR, 2009, DIABETES, V58, P2429, DOI 10.2337/db09-0580; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Chesler EJ, 2008, MAMM GENOME, V19, P382, DOI 10.1007/s00335-008-9135-8; Choi Y, 2009, BIOINFORMATICS, V25, P2780, DOI 10.1093/bioinformatics/btp502; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Dumas ME, 2007, NAT GENET, V39, P666, DOI 10.1038/ng2026; Farooqi IS, 2006, ENDOCR REV, V27, P710, DOI 10.1210/er.2006-0040; Farooqi IS, 2009, AM J CLIN NUTR, V89, p980S, DOI 10.3945/ajcn.2008.26788C; Ferrara CT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000034; Gieger C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000282; Gillum MP, 2008, CELL, V135, P813, DOI 10.1016/j.cell.2008.10.043; Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Huffman KM, 2009, DIABETES CARE, V32, P1678, DOI 10.2337/dc08-2075; Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291; Keller MP, 2008, GENOME RES, V18, P706, DOI 10.1101/gr.074914.107; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Lai YL, 2004, BIOINFORMATICS, V20, P3146, DOI 10.1093/bioinformatics/bth379; Loos RJF, 2008, NAT GENET, V40, P768, DOI 10.1038/ng.140; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Neto EC, 2008, GENETICS, V179, P1089, DOI 10.1534/genetics.107.085167; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; O'Rahilly S, 2009, NATURE, V462, P307, DOI 10.1038/nature08532; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Prokopenko I, 2008, TRENDS GENET, V24, P613, DOI 10.1016/j.tig.2008.09.004; Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257; Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; Tong Y, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-15; Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	42	27	27	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					388	391		10.1038/nm0410-388	http://dx.doi.org/10.1038/nm0410-388			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376050				2022-12-27	WOS:000276446800039
J	Gulbins, E				Gulbins, Erich			Lipids control mucus production in cystic fibrosis	NATURE MEDICINE			English	Editorial Material							ACTIVATED-RECEPTOR-GAMMA; ACCUMULATION; CELLS	Altered lipid metabolism underlies the production of excess mucus in a mouse model of cystic fibrosis (313-318). The findings point to the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) as a potential therapeutic target in this disease.	Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	University of Duisburg Essen	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Essen, Germany.	erich.gulbins@uni-due.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Bajwa PJ, 2009, AM J PHYSIOL-GASTR L, V297, pG82, DOI 10.1152/ajpgi.90640.2008; CHASE HP, 1978, LANCET, V2, P236, DOI 10.1016/S0140-6736(78)91746-4; Harmon GS, 2010, NAT MED, V16, P313, DOI 10.1038/nm.2101; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Manson ME, 2008, AM J PHYSIOL-LUNG C, V295, pL809, DOI 10.1152/ajplung.90402.2008; Ollero M, 2004, J CELL PHYSIOL, V200, P235, DOI 10.1002/jcp.20020; Perez A, 2008, AM J PHYSIOL-LUNG C, V295, pL303, DOI 10.1152/ajplung.90276.2008; Teichgraber V, 2008, NAT MED, V14, P382, DOI 10.1038/nm1748	8	5	5	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					267	268		10.1038/nm0310-267	http://dx.doi.org/10.1038/nm0310-267			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208510				2022-12-27	WOS:000275289500027
J	Lloyd, CM; Saglani, S				Lloyd, Clare M.; Saglani, Sejal			BEDSIDE TO BENCH The emerging epithelium	NATURE MEDICINE			English	Editorial Material							ASTHMA; MEPOLIZUMAB; CELLS		[Lloyd, Clare M.; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, UK Med Res Council, Leukocyte Biol Sect, London, England; [Lloyd, Clare M.; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Imperial College London; University of London; King's College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, UK Med Res Council, Leukocyte Biol Sect, London, England.	c.lloyd@imperial.ac.uk	Saglani, Sejal/AAE-5072-2019	Lloyd, Clare/0000-0001-8977-6726; Saglani, Sejal/0000-0001-5192-6418	Wellcome Trust [087618, 057704] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Siddiqui S, 2009, AM J RESP CRIT CARE, V180, P383, DOI 10.1164/rccm.200905-0788ED; Willis-Owen SAG, 2009, CURR ALLERGY ASTHM R, V9, P3, DOI 10.1007/s11882-009-0001-x; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	11	32	32	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					273	274		10.1038/nm0310-273	http://dx.doi.org/10.1038/nm0310-273			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208514	Green Accepted			2022-12-27	WOS:000275289500030
J	Okamoto, SI; Pouladi, MA; Talantova, M; Yao, DD; Xia, P; Ehrnhoefer, DE; Zaidi, R; Clemente, A; Kaul, M; Graham, RK; Zhang, DX; Chen, HSV; Tong, G; Hayden, MR; Lipton, SA				Okamoto, Shu-ichi; Pouladi, Mahmoud A.; Talantova, Maria; Yao, Dongdong; Xia, Peng; Ehrnhoefer, Dagmar E.; Zaidi, Rameez; Clemente, Arjay; Kaul, Marcus; Graham, Rona K.; Zhang, Dongxian; Chen, H-S Vincent; Tong, Gary; Hayden, Michael R.; Lipton, Stuart A.			Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; YAC128 MOUSE MODEL; IN-VIVO; MEDIATED EXCITOTOXICITY; AGGREGATION; DYSFUNCTION; MEMANTINE; NEUROPROTECTION; ABNORMALITIES; ACTIVATION	Huntington's disease is caused by an expanded CAG repeat in the gene encoding huntingtin (HTT), resulting in loss of striatal and cortical neurons. Given that the gene product is widely expressed, it remains unclear why neurons are selectively targeted. Here we show the relationship between synaptic and extrasynaptic activity, inclusion formation of mutant huntingtin protein (mtHtt) and neuronal survival. Synaptic N-methyl-d-aspartate-type glutamate receptor (NMDAR) activity induces mtHtt inclusions via a T complex-1 (TCP-1) ring complex (TRiC)-dependent mechanism, rendering neurons more resistant to mtHtt-mediated cell death. In contrast, stimulation of extrasynaptic NMDARs increases the vulnerability of mtHtt-containing neurons to cell death by impairing the neuroprotective cyclic AMP response element-binding protein (CREB)-peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) cascade and increasing the level of the small guanine nucleotide-binding protein Rhes, which is known to sumoylate and disaggregate mtHtt. Treatment of transgenic mice expressing a yeast artificial chromosome containing 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs and ameliorates neuropathological and behavioral manifestations. By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Our findings offer a rational therapeutic approach for protecting susceptible neurons in Huntington's disease.	[Okamoto, Shu-ichi; Talantova, Maria; Yao, Dongdong; Xia, Peng; Zaidi, Rameez; Clemente, Arjay; Kaul, Marcus; Zhang, Dongxian; Chen, H-S Vincent; Tong, Gary; Lipton, Stuart A.] Burnham Inst Med Res, Ctr Neurosci Aging & Stem Cell Res, La Jolla, CA USA; [Pouladi, Mahmoud A.; Ehrnhoefer, Dagmar E.; Graham, Rona K.; Hayden, Michael R.] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Chen, H-S Vincent] Univ Calif San Diego, Div Cardiol, La Jolla, CA 92093 USA; [Tong, Gary; Lipton, Stuart A.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of British Columbia; University of California System; University of California San Diego; University of California System; University of California San Diego	Lipton, SA (corresponding author), Burnham Inst Med Res, Ctr Neurosci Aging & Stem Cell Res, La Jolla, CA USA.	mrh@cmmt.ubc.ca; slipton@burnham.org	Graham, Rona K/R-7358-2018; Ehrnhoefer, Dagmar/B-7231-2008; Tong, Gary/AAC-9426-2022; Hayden, Michael R/D-8581-2011; Pouladi, Mahmoud A/B-8743-2016; Kaul, Marcus/AAS-8955-2020; Ehrnhöfer, Dagmar/O-2514-2016	Graham, Rona K/0000-0003-3722-6241; Ehrnhoefer, Dagmar/0000-0003-3411-5415; Hayden, Michael R/0000-0001-5159-1419; Pouladi, Mahmoud A/0000-0002-9030-0976; Ehrnhöfer, Dagmar/0000-0003-3411-5415; Lipton, Stuart/0000-0002-3490-1259	US National Institutes of Health [P01 HD29587, P01 ES016738, R01 EY09024, R01 EY05477, R01 NS41207]; Ellison Medical Foundation; National Institutes of Health [P30 NS057096]; Canadian Institute of Health Research; Michael Smith Foundation for Health Research; Canadian Institutes of Health Research; Huntington Society of Canada; Huntington's Disease Society of America, CHDI Foundation, Inc.; HighQ Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009024, R01EY005477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES016738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041207, P30NS057096] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Huntington Society of Canada; Huntington's Disease Society of America, CHDI Foundation, Inc.; HighQ Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank C. A. Ross (Johns Hopkins University School of Medicine) and L. M. Ellerby (Buck Institute for Age Research) for N-terminal and full-length constructs of huntingtin, T. F. Newmeyer and H. Fang (Burnham Institute for Medical Research) for preparing primary neuronal cultures, X.-J.Li (Emory University School of Medicine) for providing the EM48 antibody and E. Bossy-Wetzel, Y.S. Choo, W. Zago and T. Nakamura for assistance or discussion. This work was supported in part by US National Institutes of Health grants P01 HD29587, P01 ES016738, R01 EY09024, R01 EY05477 and R01 NS41207 and a Senior Scholar Award in Aging Research from the Ellison Medical Foundation (S. A. L.). Additional support was provided by the National Institutes of Health Blueprint Grant for La Jolla Interdisciplinary Neuroscience Center Cores P30 NS057096. M. A. P. was supported by the Canadian Institute of Health Research and the Michael Smith Foundation for Health Research. M. R. H. was supported by grants from the Canadian Institutes of Health Research, the Huntington Society of Canada, the Huntington's Disease Society of America, CHDI Foundation, Inc., and the HighQ Foundation.	Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Behrends C, 2006, MOL CELL, V23, P887, DOI 10.1016/j.molcel.2006.08.017; Beister A, 2004, J NEURAL TRANSM-SUPP, P117; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cui LB, 2006, CELL, V127, P59, DOI 10.1016/j.cell.2006.09.015; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Ferrante RJ, 2002, J NEUROSCI, V22, P1592, DOI 10.1523/JNEUROSCI.22-05-01592.2002; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Heng MY, 2009, J NEUROSCI, V29, P3200, DOI 10.1523/JNEUROSCI.5599-08.2009; Hesselink MB, 1999, PHARMACEUT RES, V16, P637, DOI 10.1023/A:1018856020583; King MA, 2008, J NEUROSCI, V28, P14401, DOI 10.1523/JNEUROSCI.4751-08.2008; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Li LJ, 2004, J NEUROPHYSIOL, V92, P2738, DOI 10.1152/jn.00308.2004; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Lipton SA, 2007, NAT REV NEUROSCI, V8, P803, DOI 10.1038/nrn2229; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Pickett J, 2006, NAT REV NEUROSCI, V7, P832, DOI 10.1038/nrn2034; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Slow EJ, 2003, HUM MOL GENET, V12, P1555, DOI 10.1093/hmg/ddg169; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Subramaniam S, 2009, SCIENCE, V324, P1327, DOI 10.1126/science.1172871; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tsai J, 2004, NAT NEUROSCI, V7, P1181, DOI 10.1038/nn1335; Van Raamsdonk JM, 2005, J NEUROSCI, V25, P4169, DOI 10.1523/JNEUROSCI.0590-05.2005; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	43	326	329	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1407	U8		10.1038/nm.2056	http://dx.doi.org/10.1038/nm.2056			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19915593	Green Accepted, Green Submitted			2022-12-27	WOS:000272407800021
J	Wu, SG; Rhee, KJ; Albesiano, E; Rabizadeh, S; Wu, XQ; Yen, HR; Huso, DL; Brancati, FL; Wick, E; McAllister, F; Housseau, F; Pardoll, DM; Sears, CL				Wu, Shaoguang; Rhee, Ki-Jong; Albesiano, Emilia; Rabizadeh, Shervin; Wu, Xinqun; Yen, Hung-Rong; Huso, David L.; Brancati, Frederick L.; Wick, Elizabeth; McAllister, Florencia; Housseau, Franck; Pardoll, Drew M.; Sears, Cynthia L.			A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses	NATURE MEDICINE			English	Article							ENTEROTOXIGENIC BACTEROIDES-FRAGILIS; COLITIS-ASSOCIATED CANCER; TUMOR MICROENVIRONMENT; COLORECTAL-CANCER; APC(MIN/+) MICE; MOUSE MODEL; INFLAMMATION; INFECTION; STAT3; IMMUNITY	The intestinal flora may promote colon tumor formation. Here we explore immunologic mechanisms of colonic carcinogenesis by a human colonic bacterium, enterotoxigenic Bacteroides fragilis (ETBF). ETBF that secretes B. fragilis toxin (BFT) causes human inflammatory diarrhea but also asymptomatically colonizes a proportion of the human population. Our results indicate that whereas both ETBF and nontoxigenic B. fragilis (NTBF) chronically colonize mice, only ETBF triggers colitis and strongly induces colonic tumors in multiple intestinal neoplasia (Min) mice. ETBF induces robust, selective colonic signal transducer and activator of transcription-3 (Stat3) activation with colitis characterized by a selective T helper type 17 (T(H)17) response distributed between CD4(+) T cell receptor-alpha beta (TCR alpha beta)(+) and CD4(-)8(-)TCR gamma alpha(+) T cells. Antibody-mediated blockade of interleukin-17 (IL-17) as well as the receptor for IL-23, a key cytokine amplifying T(H)17 responses, inhibits ETBF-induced colitis, colonic hyperplasia and tumor formation. These results show a Stat3- and T(H)17-dependent pathway for inflammation-induced cancer by a common human commensal bacterium, providing new mechanistic insight into human colon carcinogenesis.	[Wu, Shaoguang; Rhee, Ki-Jong; Wu, Xinqun; Brancati, Frederick L.; McAllister, Florencia; Pardoll, Drew M.; Sears, Cynthia L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Albesiano, Emilia; Wu, Xinqun; Yen, Hung-Rong; McAllister, Florencia; Housseau, Franck; Pardoll, Drew M.; Sears, Cynthia L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Albesiano, Emilia; Wu, Xinqun; Yen, Hung-Rong; McAllister, Florencia; Housseau, Franck; Pardoll, Drew M.; Sears, Cynthia L.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Yen, Hung-Rong] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Tao Yuan, Taiwan; [Yen, Hung-Rong] Chang Gung Mem Hosp, Ctr Tradit Chinese Med, Tao Yuan, Taiwan; [Huso, David L.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA; [Wick, Elizabeth] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Chang Gung University; Chang Gung Memorial Hospital; Johns Hopkins University; Johns Hopkins University	Sears, CL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	fhousse1@jhmi.edu; csears@jhmi.edu	Sears, Cynthia L/AAJ-6704-2020; Yen, Hung-Rong/M-1373-2013	Sears, Cynthia L/0000-0003-4059-1661; Rhee, Ki-Jong/0000-0001-5130-2728; Yen, Hung-Rong/0000-0002-0131-1658	Crohn's and Colitis Foundation [RO1 DK45496, RO1 DK080817]; US National Institutes of Health; Special Projects of Research Excellence [CA62924, R24 DK64388, RR00171]; Institutional Training for Pediatricians [5 T32 HD44355]; Clinical Pharmacology [2 T32GM066691];  [F32 DK079509]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD044355] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR000171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045496, F32DK079509, R24DK064388, R01DK080817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066691] Funding Source: NIH RePORTER	Crohn's and Colitis Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Special Projects of Research Excellence; Institutional Training for Pediatricians; Clinical Pharmacology; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Crohn's and Colitis Foundation through a Senior Investigator Award (to C. L. S.) and a Research Fellowship Award (to K.-J.R.), RO1 DK45496 (to C. L. S.), RO1 DK080817 (to C. L. S.), US National Institutes of Health grants (to D. M. P.), Special Projects of Research Excellence grant CA62924, R24 DK64388 (to M. Donowitz, the principal investigator of this grant that provided resource support to this project), RR00171 grant (to D. L. H.), Institutional Training for Pediatricians 5 T32 HD44355 (to G. Dover, the principal investigator of this grant that provided partial salary support to S. R.), Clinical Pharmacology Training Program 2 T32GM066691 (to T. Shapiro, the principal investigator of this grant that provided salary support to F. M.) and F32 DK079509 (to S. R.). This work was also supported by gifts from B. Schwartz, W. and B. Topercer, D. Needle, B. Swartz and the Commonwealth Foundation. D. M. P. is a Januey scholar and holds the Abeloff Chair in Oncology at Johns Hopkins University. We thank J. Wolfe for her assistance with some experiments; L. Myers (formerly Montana State University) for ETBF strain 86-5443-2-2; B. Vogelstein and K. Kinzler (Johns Hopkins University School of Medicine) for Min mice and E. Jaffee (Johns Hopkins University School of Medicine) for GK1.5 antibody.	Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Caruso R, 2008, EUR J IMMUNOL, V38, P470, DOI 10.1002/eji.200737635; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Hope ME, 2005, FEMS MICROBIOL LETT, V244, P1, DOI 10.1016/j.femsle.2005.01.029; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Laurence A, 2007, NAT IMMUNOL, V8, P903, DOI 10.1038/ni0907-903; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Muller-Hermelink N, 2008, CANCER CELL, V13, P507, DOI 10.1016/j.ccr.2008.04.001; Nagamine CM, 2008, INFECT IMMUN, V76, P2758, DOI 10.1128/IAI.01604-07; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Niess JH, 2008, J IMMUNOL, V180, P559, DOI 10.4049/jimmunol.180.1.559; Poutahidis T, 2007, CARCINOGENESIS, V28, P2614, DOI 10.1093/carcin/bgm180; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rao VP, 2006, CANCER RES, V66, P57, DOI 10.1158/0008-5472.CAN-05-3445; Rhee KJ, 2009, INFECT IMMUN, V77, P1708, DOI 10.1128/IAI.00814-08; Sears CL, 2008, CLIN INFECT DIS, V47, P797, DOI 10.1086/591130; Sears CL, 2009, CLIN MICROBIOL REV, V22, P349, DOI 10.1128/CMR.00053-08; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Toprak NU, 2006, CLIN MICROBIOL INFEC, V12, P782, DOI 10.1111/j.1469-0691.2006.01494.x; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wu SG, 1998, P NATL ACAD SCI USA, V95, P14979, DOI 10.1073/pnas.95.25.14979; Wu SG, 2003, GASTROENTEROLOGY, V124, P392, DOI 10.1053/gast.2003.50047; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995	46	1076	1135	7	182	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1016	U64		10.1038/nm.2015	http://dx.doi.org/10.1038/nm.2015			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19701202	Green Accepted			2022-12-27	WOS:000269979200021
J	Hansen, AM; Caspi, RR				Hansen, Anna M.; Caspi, Rachel R.			Targeting lymphotoxin depletes pathogenic T cells	NATURE MEDICINE			English	Editorial Material									[Hansen, Anna M.; Caspi, Rachel R.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Hansen, AM (corresponding author), NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	rcaspi@helix.nih.gov		Caspi, Rachel/0000-0002-7140-7671	Intramural NIH HHS [Z01 EY000184-25] Funding Source: Medline; NATIONAL EYE INSTITUTE [ZIAEY000184, Z01EY000184] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Caspi RR, 2008, NAT REV IMMUNOL, V8, P970, DOI 10.1038/nri2438; Chiang EY, 2009, NAT MED, V15, P766, DOI 10.1038/nm.1984; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010	7	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2009	15	7					732	733		10.1038/nm0709-732	http://dx.doi.org/10.1038/nm0709-732			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584860	Green Accepted			2022-12-27	WOS:000267806900022
J	Fan, AC; Deb-Basu, D; Orban, MW; Gotlib, JR; Natkunam, Y; O'Neill, R; Padua, RA; Xu, LW; Taketa, D; Shirer, AE; Beer, S; Yee, AX; Voehringer, DW; Felsher, DW				Fan, Alice C.; Deb-Basu, Debabrita; Orban, Mathias W.; Gotlib, Jason R.; Natkunam, Yasodha; O'Neill, Roger; Padua, Rose-Ann; Xu, Liwen; Taketa, Daryl; Shirer, Amy E.; Beer, Shelly; Yee, Ada X.; Voehringer, David W.; Felsher, Dean W.			Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens	NATURE MEDICINE			English	Article							HUMAN FOLLICULAR LYMPHOMA; CHRONIC MYELOID-LEUKEMIA; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; C-MYC ONCOGENE; BCR-ABL; PROTEIN EXPRESSION; PROGNOSTIC-SIGNIFICANCE; BCL-2 GENE; K562 CELLS	Current methods of protein detection are insensitive to detecting subtle changes in oncoprotein activation that underlie key cancer signaling processes. The requirement for large numbers of cells precludes serial tumor sampling for assessing a response to therapeutics. Therefore, we have developed a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes. Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin. Therefore, we have described a new and highly sensitive method for determining oncoprotein expression and phosphorylation in clinical specimens for the development of new therapeutics for cancer.	[Fan, Alice C.; Orban, Mathias W.; Xu, Liwen; Shirer, Amy E.; Beer, Shelly; Yee, Ada X.; Felsher, Dean W.] Stanford Univ, Sch Med, Div Oncol, Dept Med, Stanford, CA 94305 USA; [Fan, Alice C.; Orban, Mathias W.; Xu, Liwen; Shirer, Amy E.; Beer, Shelly; Yee, Ada X.; Felsher, Dean W.] Stanford Univ, Sch Med, Div Oncol, Dept Pathol, Stanford, CA 94305 USA; [Deb-Basu, Debabrita; O'Neill, Roger; Taketa, Daryl; Voehringer, David W.] Cell Biosci, Palo Alto, CA USA; [Gotlib, Jason R.] Stanford Univ, Sch Med, Div Hematol, Stanford Canc Ctr,Dept Med, Stanford, CA 94305 USA; [Padua, Rose-Ann] Hop St Louis, INSERM, Inst Univ Hematol, U718, Paris, France	Stanford University; Stanford University; Stanford Cancer Institute; Stanford University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Felsher, DW (corresponding author), Stanford Univ, Sch Med, Div Oncol, Dept Med, Stanford, CA 94305 USA.	dfelsher@stanford.edu	Natkunam, Yasodha/L-5454-2015; Padua, Rose Ann/GVT-5961-2022; Orban, Mathias/AAS-8461-2020; PADUA, Rose Ann/E-8621-2019; Yee, Ada/GRX-9171-2022	Natkunam, Yasodha/0000-0002-9816-1018; Orban, Mathias/0000-0001-7846-8808; PADUA, Rose Ann/0000-0001-9964-7864; 	US National Cancer Institute [CA89305, CA034233, P01 CA034233]; NIH/NCI ICMIC [P50]; Burroughs Welcome Fund; Damon Runyon Foundation; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [T32CA009151, R01CA089305, P01CA034233] Funding Source: NIH RePORTER	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI ICMIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Welcome Fund(Burroughs Wellcome Fund); Damon Runyon Foundation; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This manuscript is dedicated to the memory of Roger O'Neill. This work was supported, in part, by the US National Cancer Institute grants CA89305, CA034233, P01 CA034233, NIH/NCI ICMIC P50, Burroughs Welcome Fund, the Damon Runyon Foundation (to D. W. F.), and the Leukemia and Lymphoma Society (to D. W. F. and A. C. F.). We thank the members of the Felsher laboratory for their helpful suggestions. We thank W.- K. Weng (Stanford Bone Marrow Transplantation Division) for providing access to previously banked tumor samples and the Stanford Hematology Division Tissue Bank for the use of samples.	Barrans SL, 2002, BLOOD, V99, P1136, DOI 10.1182/blood.V99.4.1136; Bordeleau L, 2000, SEMIN ONCOL, V27, P42, DOI 10.1053/sonc.2000.20440; Brozik A, 2006, ANN NY ACAD SCI, V1090, P344, DOI 10.1196/annals.1378.038; Calvo KR, 2008, BLOOD, V112, P3818, DOI 10.1182/blood-2008-02-138933; Camacho FI, 2003, AM J SURG PATHOL, V27, P762, DOI 10.1097/00000478-200306000-00006; Colomo L, 2003, BLOOD, V101, P78, DOI 10.1182/blood-2002-04-1286; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; Dierlamm J, 1996, BLOOD, V87, P299; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Ferry JA, 2006, ONCOLOGIST, V11, P375, DOI 10.1634/theoncologist.11-4-375; Futreal PA, 2001, NATURE, V409, P850, DOI 10.1038/35057046; Gascoyne RD, 1997, BLOOD, V90, P244; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Giuriato S, 2004, SEMIN CANCER BIOL, V14, P3, DOI 10.1016/j.semcancer.2003.11.002; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Irish JM, 2006, BLOOD, V108, P3135, DOI 10.1182/blood-2006-02-003921; Johnson NA, 2008, GENE CHROMOSOME CANC, V47, P1038, DOI 10.1002/gcc.20606; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; MITANI S, 1988, CANCER, V62, P2085, DOI 10.1002/1097-0142(19881115)62:10<2085::AID-CNCR2820621003>3.0.CO;2-R; O'Neill RA, 2006, P NATL ACAD SCI USA, V103, P16153, DOI 10.1073/pnas.0607973103; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Shachaf CM, 2007, BLOOD, V110, P2674, DOI 10.1182/blood-2006-09-048033; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; WENNBORG AD, 1991, EUR J CANCER, V27, P1643, DOI 10.1016/0277-5379(91)90436-H	40	96	107	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					566	571		10.1038/nm.1903	http://dx.doi.org/10.1038/nm.1903			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19363496	Green Accepted			2022-12-27	WOS:000265889300036
J	Tiranti, V; Viscomi, C; Hildebrandt, T; Di Meo, I; Mineri, R; Tiveron, C; Levitt, MD; Prelle, A; Fagiolari, G; Rimoldi, M; Zeviani, M				Tiranti, Valeria; Viscomi, Carlo; Hildebrandt, Tatjana; Di Meo, Ivano; Mineri, Rossana; Tiveron, Cecilia; Levitt, Michael D.; Prelle, Alessandro; Fagiolari, Gigliola; Rimoldi, Marco; Zeviani, Massimo			Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy	NATURE MEDICINE			English	Article							HYDROGEN-SULFIDE; OXIDASE DEFICIENCY; ACIDURIA; PROTEIN; MUTATIONS; GENE; IDENTIFICATION; THIOSULFATE; OXIDATION; OXIDOREDUCTASE	Ethylmalonic encephalopathy is an autosomal recessive, invariably fatal disorder characterized by early-onset encephalopathy, microangiopathy, chronic diarrhea, defective cytochrome c oxidase (COX) in muscle and brain, high concentrations of C4 and C5 acylcarnitines in blood and high excretion of ethylmalonic acid in urine. ETHE1, a gene encoding a beta-lactamase-like, iron-coordinating metalloprotein, is mutated in ethylmalonic encephalopathy. In bacteria, ETHE1-like sequences are in the same operon of, or fused with, orthologs of TST, the gene encoding rhodanese, a sulfurtransferase. In eukaryotes, both ETHE1 and rhodanese are located within the mitochondrial matrix. We created a Ethe1(-/-) mouse that showed the cardinal features of ethylmalonic encephalopathy. We found that thiosulfate was excreted in massive amounts in urine of both Ethe1(-/-) mice and humans with ethylmalonic encephalopathy. High thiosulfate and sulfide concentrations were present in Ethe1(-/-) mouse tissues. Sulfide is a powerful inhibitor of COX and short-chain fatty acid oxidation, with vasoactive and vasotoxic effects that explain the microangiopathy in ethylmalonic encephalopathy patients. Sulfide is detoxified by a mitochondrial pathway that includes a sulfur dioxygenase. Sulfur dioxygenase activity was absent in Ethe1(-/-) mice, whereas it was markedly increased by ETHE1 overexpression in HeLa cells and Escherichia coli. Therefore, ETHE1 is a mitochondrial sulfur dioxygenase involved in catabolism of sulfide that accumulates to toxic levels in ethylmalonic encephalopathy.	[Tiranti, Valeria; Viscomi, Carlo; Di Meo, Ivano; Mineri, Rossana; Zeviani, Massimo] IRCCS Fdn, Inst Neurol Carlo Besta, Pierfranco & Luisa Mariani Ctr Res Childrens Mito, Unit Mol Neurogenet, I-20126 Milan, Italy; [Hildebrandt, Tatjana] Univ Dusseldorf, Inst Biochem, D-40225 Dusseldorf, Germany; [Tiveron, Cecilia] Fdn European Brain Res Inst EBRI Rita Levi Montal, Dis Modelling Facil, I-00143 Rome, Italy; [Levitt, Michael D.] Vet Affairs Med Ctr, Res Serv, Minneapolis, MN 55417 USA; [Prelle, Alessandro; Fagiolari, Gigliola] Mangiagalli & Regina Elena IRCCS Fdn, Osped Maggiore Policlin, Div Neurol, Dino Ferrari Ctr, I-20122 Milan, Italy; [Rimoldi, Marco] Inst Neurol Carlo Besta IRCCS Fdn, Unit Biochem & Genet, I-20133 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Neurologico Besta; Heinrich Heine University Dusseldorf; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Neurologico Besta	Tiranti, V (corresponding author), IRCCS Fdn, Inst Neurol Carlo Besta, Pierfranco & Luisa Mariani Ctr Res Childrens Mito, Unit Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.	tiranti@istituto-besta.it; zeviani@istituto-besta.it	Zeviani, Massimo/K-2891-2014; viscomi, Carlo/R-1940-2016; Di Meo, Ivano/H-7840-2014; Tiranti, Valeria/J-8233-2016; Zeviani, Massimo/AAU-2632-2021; Tiranti, Valeria/AFN-5783-2022; Di Meo, Ivano/A-4668-2009	Di Meo, Ivano/0000-0002-4616-5623; Tiranti, Valeria/0000-0002-3584-7338; Zeviani, Massimo/0000-0002-9067-5508; Tiranti, Valeria/0000-0002-3584-7338; Viscomi, Carlo/0000-0001-6050-0566; prelle, alessandro/0000-0002-7019-5291; Hildebrandt, Tatjana/0000-0002-3562-5241	Pierfranco and Luisa Mariani Foundation Italy, Fondazione Telethon-Italy [GGP07019]; Italian Ministry of University and Research [RBLA038RMA]; European Union; Deutsche Forschungsgemeinschaft [GR 456/22-1]	Pierfranco and Luisa Mariani Foundation Italy, Fondazione Telethon-Italy(Fondazione Telethon); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); European Union(European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank A. Bradley ( The Wellcome Trust Sanger Institute) for AB1 mouse embryonic stem cells. We are grateful to M. Bada for skillful technical assistance; to B. Garavaglia, E. Lamantea, F. Forlani and M. K. Grieshaber for valuable discussion; to the Chemical Analysis Laboratory, University of Georgia, for metal analysis; and to Primm for MALDI TOF mass spectometry analysis. This work was supported by the Pierfranco and Luisa Mariani Foundation Italy, Fondazione Telethon-Italy grant number GGP07019, the Italian Ministry of University and Research (FIRB 2003-project RBLA038RMA), MITOCIRCLE and EUMITOCOMBAT network grants from the European Union framework program 6 and by the Deutsche Forschungsgemeinschaft (GR 456/22-1).	BELLA DL, 1995, AM J PHYSIOL-ENDOC M, V269, pE910, DOI 10.1152/ajpendo.1995.269.5.E910; BENNETT MJ, 1984, J INHERIT METAB DIS, V7, P57, DOI 10.1007/BF01805802; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006; BURLINA AB, 1991, LANCET, V338, P1522, DOI 10.1016/0140-6736(91)92338-3; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Dell'Agnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477; DIDONATO S, 1986, NEUROLOGY, V36, P957; Dorman DC, 2002, TOXICOL SCI, V65, P18, DOI 10.1093/toxsci/65.1.18; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; Furne J, 2008, AM J PHYSIOL-REG I, V295, pR1479, DOI 10.1152/ajpregu.90566.2008; GARCIASILVA MT, 1994, J PEDIATR-US, V125, P843, DOI 10.1016/S0022-3476(06)80197-6; GarciaSilva MT, 1997, PEDIATR NEUROL, V17, P165, DOI 10.1016/S0887-8994(97)00048-9; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2007, J BIOL CHEM, V282, P13716, DOI 10.1074/jbc.M609751200; Hildebrandt TM, 2008, FEBS J, V275, P3352, DOI 10.1111/j.1742-4658.2008.06482.x; Koeberl DD, 2003, PEDIATR RES, V54, P219, DOI 10.1203/01.PDR.0000074972.36356.89; Leschelle X, 2005, BBA-GEN SUBJECTS, V1725, P201, DOI 10.1016/j.bbagen.2005.06.002; Linden DR, 2008, J NEUROCHEM, V106, P1577, DOI 10.1111/j.1471-4159.2008.05502.x; McCoy JG, 2006, ACTA CRYSTALLOGR D, V62, P964, DOI 10.1107/S0907444906020592; Mineri R, 2008, J MED GENET, V45, P473, DOI 10.1136/jmg.2008.058271; Moroni I, 2000, NEUROL SCI, V21, P103, DOI 10.1007/s100720070104; Psarra AMG, 2008, BBA-MOL CELL RES, V1783, P1, DOI 10.1016/j.bbamcr.2007.10.021; Roediger WEW, 1997, DIGEST DIS SCI, V42, P1571, DOI 10.1023/A:1018851723920; Sass JO, 2008, MOL GENET METAB, V93, P30, DOI 10.1016/j.ymgme.2007.09.002; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; SHIH VE, 1979, CLIN CHIM ACTA, V95, P143, DOI 10.1016/0009-8981(79)90348-6; SORBO B, 1987, METHOD ENZYMOL, V143, P3; SORBO BH, 1955, METHOD ENZYMOL, V2, P334, DOI 10.1016/S0076-6879(55)02207-6; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Theissen U, 2008, FEBS J, V275, P1131, DOI 10.1111/j.1742-4658.2008.06273.x; Tiranti V, 2006, J MED GENET, V43, P340, DOI 10.1136/jmg.2005.036210; Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; Vockley J, 2006, AM J MED GENET C, V142C, P95, DOI 10.1002/ajmg.c.30089	39	264	277	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2009	15	2					200	205		10.1038/nm.1907	http://dx.doi.org/10.1038/nm.1907			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19136963	Green Published			2022-12-27	WOS:000263119400023
J	Nemeth, K; Leelahavanichkul, A; Yuen, PST; Mayer, B; Parmelee, A; Doi, K; Robey, PG; Leelahavanichkul, K; Koller, BH; Brown, JM; Hu, XZ; Jelinek, I; Star, RA; Mezey, E				Nemeth, Krisztian; Leelahavanichkul, Asada; Yuen, Peter S. T.; Mayer, Balazs; Parmelee, Alissa; Doi, Kent; Robey, Pamela G.; Leelahavanichkul, Kantima; Koller, Beverly H.; Brown, Jared M.; Hu, Xuzhen; Jelinek, Ivett; Star, Robert A.; Mezey, Eva			Bone marrow stromal cells attenuate sepsis via prostaglandin E-2-dependent reprogramming of host macrophages to increase their interleukin-10 production	NATURE MEDICINE			English	Article							MESENCHYMAL STEM-CELLS; ACUTE-RENAL-FAILURE; ANTI-ASIALO GM1; ORGAN DAMAGE; INFLAMMATION; NEUTROPHIL; ISCHEMIA; MICE; PATHOGENESIS; EXPRESSION	Sepsis causes over 200,000 deaths yearly in the US; better treatments are urgently needed. Administering bone marrow stromal cells (BMSCs-also known as mesenchymal stem cells) to mice before or shortly after inducing sepsis by cecal ligation and puncture reduced mortality and improved organ function. The beneficial effect of BMSCs was eliminated by macrophage depletion or pretreatment with antibodies specific for interleukin-10 (IL-10) or IL-10 receptor. Monocytes and/or macrophages from septic lungs made more IL-10 when prepared from mice treated with BMSCs versus untreated mice. Lipopolysaccharide (LPS)-stimulated macrophages produced more IL-10 when cultured with BMSCs, but this effect was eliminated if the BMSCs lacked the genes encoding Toll-like receptor 4, myeloid differentiation primary response gene-88, tumor necrosis factor (TNF) receptor-1a or cyclooxygenase-2. Our results suggest that BMSCs ( activated by LPS or TNF-alpha) reprogram macrophages by releasing prostaglandin E-2 that acts on the macrophages through the prostaglandin EP2 and EP4 receptors. Because BMSCs have been successfully given to humans and can easily be cultured and might be used without human leukocyte antigen matching, we suggest that cultured, banked human BMSCs may be effective in treating sepsis in high-risk patient groups.	[Nemeth, Krisztian; Mayer, Balazs; Parmelee, Alissa; Robey, Pamela G.; Leelahavanichkul, Kantima; Mezey, Eva] NIDCR, Craniofacial & Skeletal Dis Branch, Bethesda, MD 20892 USA; [Leelahavanichkul, Asada; Yuen, Peter S. T.; Doi, Kent; Hu, Xuzhen; Star, Robert A.] NIDDK, Renal Diagnost & Therapeut Unit, Bethesda, MD 20892 USA; [Jelinek, Ivett] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; [Koller, Beverly H.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Brown, Jared M.] E Carolina Univ, Dept Pharmacol & Toxicol, Greenville, NC 27858 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; East Carolina University	Mezey, E (corresponding author), NIDCR, Craniofacial & Skeletal Dis Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.	mezeye@mail.nih.gov	Mayer, Balazs/B-7864-2013; Robey, Pamela Gehron/H-1429-2011; Mezey, Eva/A-8105-2008; ST Yuen, Peter/B-1954-2008	Mayer, Balazs/0000-0003-3577-3823; Robey, Pamela Gehron/0000-0002-5316-5576; Mezey, Eva/0000-0002-5907-4691; ST Yuen, Peter/0000-0001-9557-3909; Nemeth, Krisztian/0000-0002-7739-5085	Intramural NIH HHS [Z01 DE000714-03] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000380, ZIADE000714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043403] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Bal-Price A, 2006, NITRIC OXIDE-BIOL CH, V14, P238, DOI 10.1016/j.niox.2005.10.002; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bochud PY, 2003, BMJ-BRIT MED J, V326, P262, DOI 10.1136/bmj.326.7383.262; Bonder CS, 2005, AM J PATHOL, V167, P1647, DOI 10.1016/S0002-9440(10)61248-5; Calandra T, 2001, J CHEMOTHERAPY, V13, P173, DOI 10.1179/joc.2001.13.Supplement-2.173; Cassatella MA, 1998, INT J CLIN LAB RES, V28, P148, DOI 10.1007/s005990050036; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Crisostomo PR, 2007, J MOL CELL CARDIOL, V42, P142, DOI 10.1016/j.yjmcc.2006.09.016; HABU S, 1981, J IMMUNOL, V127, P34; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Jaeschke H, 1997, J LEUKOCYTE BIOL, V61, P647, DOI 10.1002/jlb.61.6.647; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; KASAI M, 1981, NATURE, V291, P334, DOI 10.1038/291334a0; Kubo S, 2004, J PHARMACOL EXP THER, V309, P1213, DOI 10.1124/jpet.103.062646; Lange C, 2005, KIDNEY INT, V68, P1613, DOI 10.1111/j.1523-1755.2005.00573.x; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Mansilla E, 2005, TRANSPL P, V37, P292, DOI 10.1016/j.transproceed.2005.01.070; Matthijsen RA, 2007, AM J PATHOL, V171, P1743, DOI 10.2353/ajpath.2007.070184; Miyaji T, 2003, KIDNEY INT, V64, P1620, DOI 10.1046/j.1523-1755.2003.00268.x; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; Nakao S, 2002, MOL CELL BIOCHEM, V238, P11, DOI 10.1023/A:1019927616000; Noel D, 2007, LEUKEMIA LYMPHOMA, V48, P1283, DOI 10.1080/10428190701361869; Nussler AK, 1999, LANGENBECK ARCH SURG, V384, P222, DOI 10.1007/s004230050196; Park YK, 2008, MOL PHARMACOL, V74, P236, DOI 10.1124/mol.108.045278; PERRETTI M, 1995, BRIT J PHARMACOL, V116, P2251, DOI 10.1111/j.1476-5381.1995.tb15061.x; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Rasmusson I, 2006, EXP CELL RES, V312, P2169, DOI 10.1016/j.yexcr.2006.03.019; Ringden O, 2007, LEUKEMIA, V21, P2271, DOI 10.1038/sj.leu.2404833; Semedo P, 2007, TRANSPL P, V39, P421, DOI 10.1016/j.transproceed.2007.01.036; Shinomiya S, 2001, BIOCHEM PHARMACOL, V61, P1153, DOI 10.1016/S0006-2952(01)00586-X; Sotiropoulou PA, 2006, STEM CELLS, V24, P74, DOI 10.1634/stemcells.2004-0359; Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007; van Laar JM, 2006, RHEUMATOLOGY, V45, P1187, DOI 10.1093/rheumatology/kel158; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Wang J, 1999, J CLIN INVEST, V103, P1023, DOI 10.1172/JCI6224; Yasuda H, 2006, KIDNEY INT, V69, P1535, DOI 10.1038/sj.ki.5000300	47	1675	1771	11	257	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					42	49		10.1038/nm.1905	http://dx.doi.org/10.1038/nm.1905			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19098906	Green Accepted, Green Published			2022-12-27	WOS:000262425100017
J	Fabene, PF; Mora, GN; Martinello, M; Rossi, B; Merigo, F; Ottoboni, L; Bach, S; Angiari, S; Benati, D; Chakir, A; Zanetti, L; Schio, F; Osculati, A; Marzola, P; Nicolato, E; Homeister, JW; Xia, LJ; Lowe, JB; McEver, RP; Osculati, F; Sbarbati, A; Butcher, EC; Constantin, G				Fabene, Paolo F.; Mora, Graciela Navarro; Martinello, Marianna; Rossi, Barbara; Merigo, Flavia; Ottoboni, Linda; Bach, Simona; Angiari, Stefano; Benati, Donatella; Chakir, Asmaa; Zanetti, Lara; Schio, Federica; Osculati, Antonio; Marzola, Pasquina; Nicolato, Elena; Homeister, Jonathon W.; Xia, Lijun; Lowe, John B.; McEver, Rodger P.; Osculati, Francesco; Sbarbati, Andrea; Butcher, Eugene C.; Constantin, Gabriela			A role for leukocyte-endothelial adhesion mechanisms in epilepsy	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; SELECTIN GLYCOPROTEIN LIGAND-1; INDUCED NEURONAL INJURY; TEMPORAL-LOBE EPILEPSY; MULTIPLE-SCLEROSIS; INFLAMMATION; PILOCARPINE; RECRUITMENT; SEIZURE; MICE	The mechanisms involved in the pathogenesis of epilepsy, a chronic neurological disorder that affects approximately one percent of the world population, are not well understood(1-3). Using a mouse model of epilepsy, we show that seizures induce elevated expression of vascular cell adhesion molecules and enhanced leukocyte rolling and arrest in brain vessels mediated by the leukocyte mucin P-selectin glycoprotein ligand-1 (PSGL-1, encoded by Selplg) and leukocyte integrins alpha(4)beta(1) and alpha(L)beta(2). Inhibition of leukocyte-vascular interactions, either with blocking antibodies or by genetically interfering with PSGL-1 function in mice, markedly reduced seizures. Treatment with blocking antibodies after acute seizures prevented the development of epilepsy. Neutrophil depletion also inhibited acute seizure induction and chronic spontaneous recurrent seizures. Blood-brain barrier (BBB) leakage, which is known to enhance neuronal excitability, was induced by acute seizure activity but was prevented by blockade of leukocyte-vascular adhesion, suggesting a pathogenetic link between leukocyte-vascular interactions, BBB damage and seizure generation. Consistent with the potential leukocyte involvement in epilepsy in humans, leukocytes were more abundant in brains of individuals with epilepsy than in controls. Our results suggest leukocyte-endothelial interaction as a potential target for the prevention and treatment of epilepsy.	[Fabene, Paolo F.; Mora, Graciela Navarro; Merigo, Flavia; Benati, Donatella; Chakir, Asmaa; Zanetti, Lara; Schio, Federica; Nicolato, Elena; Osculati, Francesco; Sbarbati, Andrea] Univ Verona, Dept Morphol Biomed Sci, Sect Anat, I-37134 Verona, Italy; [Martinello, Marianna; Rossi, Barbara; Ottoboni, Linda; Bach, Simona; Angiari, Stefano; Constantin, Gabriela] Univ Verona, Dept Pathol, Sect Gen Pathol, I-37134 Verona, Italy; [Osculati, Antonio] Univ Insubria, Sect Forens Med, Dept Med & Publ Hlth, I-21100 Varese, Italy; [Marzola, Pasquina] Univ Verona, Fac Med, Expt Magnet Resonance Imaging Ctr, I-37134 Verona, Italy; [Homeister, Jonathon W.] Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; [Xia, Lijun; McEver, Rodger P.] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; [Lowe, John B.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Osculati, Francesco] Carattere Sci Ctr Neurol Bonino Pulejo, Ist Ricovero & Cura, I-98124 Messina, Italy; [Butcher, Eugene C.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Butcher, Eugene C.] Palo Alto VA Hlth Care Syst, Stanford, CA 94305 USA	University of Verona; University of Verona; University of Insubria; University of Verona; University of North Carolina; University of North Carolina Chapel Hill; Oklahoma Medical Research Foundation; Case Western Reserve University; IRCCS Bonino Pulejo; Stanford University	Fabene, PF (corresponding author), Univ Verona, Dept Morphol Biomed Sci, Sect Anat, I-37134 Verona, Italy.	paolo.fabene@univr.it; gabriela.constantin@univr.it	Ottoboni, Linda/AAC-4508-2022; Martinello, Marianna/AAE-3863-2021	Ottoboni, Linda/0000-0001-5412-7785; Martinello, Marianna/0000-0001-9811-6308; Fabene, Paolo/0000-0002-9644-4399; Constantin, Gabriela/0000-0001-8978-3539; Angiari, Stefano/0000-0003-4434-2224; ROSSI, Barbara/0000-0003-4711-1528; MARZOLA, Pasquina/0000-0001-6936-8901	Fondazione Cariverona, Ministero dell'Universita e della Ricerca (MIUR)-Progetti di ricerca di interese nazionale; US National Multiple Sclerosis Society, Fondo Incentivazione Ricerca di Base; Italian Ministry of Health; Fondazione Italiana Sclerosi Multipla; University of Verona ex 60% MIUR; European Community Research [LSH-CT-2006-037315]; US National Institutes of Health; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085607, R01HL090823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072618] Funding Source: NIH RePORTER	Fondazione Cariverona, Ministero dell'Universita e della Ricerca (MIUR)-Progetti di ricerca di interese nazionale(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); US National Multiple Sclerosis Society, Fondo Incentivazione Ricerca di Base(National Multiple Sclerosis Society); Italian Ministry of Health(Ministry of Health, Italy); Fondazione Italiana Sclerosi Multipla(Fondazione Italiana Sclerosi Multipla (FISM)); University of Verona ex 60% MIUR(Ministry of Education, Universities and Research (MIUR)); European Community Research; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Antibody to PSGL-1 (4RA10) was kindly provided by D. Vestweber, Max Plank Institute. We wish to thank C. Laudanna for critically discussing the manuscript. This work was supported in part by grants from the Fondazione Cariverona, Ministero dell'Universita e della Ricerca (MIUR)-Progetti di ricerca di interese nazionale, the US National Multiple Sclerosis Society, Fondo Incentivazione Ricerca di Base, the Italian Ministry of Health; Fondazione Italiana Sclerosi Multipla, the University of Verona ex 60% MIUR (to G. C.); the European Community Research Grants LSH-CT-2006-037315 (EPICURE, thematic priority LIFESCIHEALTH; University of Verona ex 60% MIUR (to P. F. F.); and by US National Institutes of Health grants (to E. C. B., L. X., R. P. M. and J.B.L.). L.O. was supported in part by a fellowship from Fondazione Italiana Sclerosi Multipla. The authors are grateful to S. Fiorini, I. Cwojdzinski, P. Bernardi, M. Pellitteri, S. Becchi, L. Andrello and A. Calbi for their invaluable help in the experimental procedures.	Battistini L, 2003, BLOOD, V101, P4775, DOI 10.1182/blood-2002-10-3309; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Duncan JS, 2002, NEUROLOGY, V59, pS15, DOI 10.1212/WNL.59.9_suppl_5.S15; Fabene PF, 2003, NEUROIMAGE, V18, P375, DOI 10.1016/S1053-8119(02)00025-3; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Groticke I, 2007, EXP NEUROL, V207, P329, DOI 10.1016/j.expneurol.2007.06.021; Holmes GL, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.9_suppl_5.S3; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Klitgaard H, 2002, EPILEPSY RES, V51, P93, DOI 10.1016/S0920-1211(02)00099-2; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Ley K, 2004, NAT REV IMMUNOL, V4, P325, DOI 10.1038/nri1351; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marchi N, 2007, EPILEPSIA, V48, P1934, DOI 10.1111/j.1528-1167.2007.01185.x; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Piccio L, 2002, J IMMUNOL, V168, P1940, DOI 10.4049/jimmunol.168.4.1940; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; RUNGE V M, 1985, Magnetic Resonance Imaging, V3, P43, DOI 10.1016/0730-725X(85)90008-6; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Strzelczyk A, 2008, PHARMACOECONOMICS, V26, P463, DOI 10.2165/00019053-200826060-00002; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani Annamaria, 2005, Epilepsy Curr, V5, P1, DOI 10.1111/j.1535-7597.2005.05101.x; Xia LJ, 2002, J CLIN INVEST, V109, P939	30	363	377	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2008	14	12					1377	1383		10.1038/nm.1878	http://dx.doi.org/10.1038/nm.1878			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029985	Green Submitted, Green Accepted			2022-12-27	WOS:000261393600024
J	Houghton, AM; Mouded, M; Shapiro, SD				Houghton, A. McGarry; Mouded, Majd; Shapiro, Steven D.			Common origins of lung cancer and COPD	NATURE MEDICINE			English	Editorial Material							RISK; EMPHYSEMA; CELLS		[Houghton, A. McGarry; Mouded, Majd; Shapiro, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Houghton, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.	sds33@pitt.edu						Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Shapiro SD, 2005, NEW ENGL J MED, V352, P2016, DOI 10.1056/NEJMe058044; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; WILSON DO, AM J RESP CRIT CARE	9	122	128	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1023	1024		10.1038/nm1008-1023	http://dx.doi.org/10.1038/nm1008-1023			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841139				2022-12-27	WOS:000259892300027
J	[Anonymous]				[Anonymous]			Capturing cancer stem cells	NATURE MEDICINE			English	Editorial Material																		Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401	1	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					814	814		10.1038/nm0808-814	http://dx.doi.org/10.1038/nm0808-814			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18685595				2022-12-27	WOS:000258237500018
J	Isbell, TS; Sun, CW; Wu, LC; Teng, XJ; Vitturi, DA; Branch, BG; Kevil, CG; Peng, N; Wyss, JM; Ambalavanan, N; Schwiebert, L; Ren, JX; Pawlik, KM; Renfrow, MB; Patel, RP; Townes, TM				Isbell, T. Scott; Sun, Chiao-Wang; Wu, Li-Chen; Teng, Xinjun; Vitturi, Dario A.; Branch, Billy G.; Kevil, Christopher G.; Peng, Ning; Wyss, J. Michael; Ambalavanan, Namasivayam; Schwiebert, Lisa; Ren, Jinxiang; Pawlik, Kevin M.; Renfrow, Matthew B.; Patel, Rakesh P.; Townes, Tim M.			SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation	NATURE MEDICINE			English	Article							NITRIC-OXIDE; S-NITROSOHEMOGLOBIN; FLOW REGULATION; OXYGEN; DISEASE; NO; NITROSOTHIOLS; BIOACTIVITY; DEFICIENCY; BINDING	The coupling of hemoglobin sensing of physiological oxygen gradients to stimulation of nitric oxide ( NO) bioactivity is an established principle of hypoxic blood flow. One mechanism proposed to explain this oxygen-sensing-NO bioactivity linkage postulates an essential role for the conserved Cys93 residue of the hemoglobin beta-chain (beta Cys93) and, specifically, for S-nitrosation of beta Cys93 to form S-nitrosohemoglobin (SNO-Hb)(1). The SNO-Hb hypothesis, which conceptually links hemoglobin and NO biology, has been debated intensely in recent years(2,3). This debate has precluded a consensus on physiological mechanisms and on assessment of the potential role of SNO-Hb in pathology. Here we describe new mouse models that exclusively express either human wild-type hemoglobin or human hemoglobin in which the beta Cys93 residue is replaced with alanine to assess the role of SNO-Hb in red blood cell-mediated hypoxic vasodilation. Substitution of this residue, precluding hemoglobin S-nitrosation, did not change total red blood cell S-nitrosothiol abundance but did shift S-nitrosothiol distribution to lower molecular weight species, consistent with the loss of SNO-Hb. Loss of beta Cys93 resulted in no deficits in systemic or pulmonary hemodynamics under basal conditions and, notably, did not affect isolated red blood cell dependent hypoxic vasodilation. These results demonstrate that SNO-Hb is not essential for the physiologic coupling of erythrocyte deoxygenation with increased NO bioactivity in vivo.	[Isbell, T. Scott; Teng, Xinjun; Vitturi, Dario A.; Patel, Rakesh P.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Isbell, T. Scott; Teng, Xinjun; Vitturi, Dario A.; Patel, Rakesh P.] Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA; [Sun, Chiao-Wang; Wu, Li-Chen; Ren, Jinxiang; Pawlik, Kevin M.; Renfrow, Matthew B.; Townes, Tim M.] Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Branch, Billy G.; Kevil, Christopher G.] Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; [Peng, Ning; Wyss, J. Michael; Ambalavanan, Namasivayam] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Ambalavanan, Namasivayam] Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; [Schwiebert, Lisa] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Patel, RP (corresponding author), Univ Alabama, Dept Pathol, 901 19th St S, Birmingham, AL 35294 USA.	rakeshp@uab.edu; ttownes@uab.edu	Ambalavanan, Namasivayam/AAI-4088-2020; Kevil, Christopher/G-9318-2011; Vitturi, Dario/Z-3469-2019; Ambalavanan, Namasivayam/AAL-3832-2020	Ambalavanan, Namasivayam/0000-0003-0731-9092; Kevil, Christopher/0000-0003-0863-7260; Patel, Rakesh/0000-0002-1526-4303; Vitturi, Dario/0000-0003-0354-4567; Isbell, Timothy/0000-0003-0979-0582; Wyss, J Michael/0000-0003-1094-2934; Renfrow, Matthew B./0000-0002-4193-7305	NHLBI NIH HHS [R01 HL057619-11, HL057619, R01 HL057619-10, R01 HL057619] Funding Source: Medline; NINDS NIH HHS [NS 057098, P30 NS057098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS057098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bennett-Guerrero E, 2007, P NATL ACAD SCI USA, V104, P17063, DOI 10.1073/pnas.0708160104; Chen YF, 2006, LIFE SCI, V79, P1357, DOI 10.1016/j.lfs.2006.03.051; Cheng Y, 2002, BIOCHEMISTRY-US, V41, P11901, DOI 10.1021/bi0202880; Chidlow JH, 2006, AM J PATHOL, V169, P2014, DOI 10.2353/ajpath.2006.051021; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; Crawford JH, 2004, ANTIOXID REDOX SIGN, V6, P992, DOI 10.1089/ars.2004.6.992; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; Datta B, 2004, CIRCULATION, V109, P1339, DOI 10.1161/01.CIR.0000124450.07016.1D; Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102; Ellsworth ML, 2000, ACTA PHYSIOL SCAND, V168, P551, DOI 10.1046/j.1365-201x.2000.00708.x; Gladwin MT, 2006, AM J PHYSIOL-HEART C, V291, pH2026, DOI 10.1152/ajpheart.00407.2006; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gonzalez-Alonso J, 2001, J PHYSIOL-LONDON, V530, P331, DOI 10.1111/j.1469-7793.2001.0331l.x; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; James PE, 2004, CIRC RES, V94, P976, DOI 10.1161/01.RES.0000122044.21787.01; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Lang JD, 2007, J CLIN INVEST, V117, P2583, DOI 10.1172/JCI31892; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; McMahon TJ, 2005, P NATL ACAD SCI USA, V102, P14801, DOI 10.1073/pnas.0506957102; Palmer LA, 2007, J CLIN INVEST, V117, P2592, DOI 10.1172/JCI29444; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2005, P NATL ACAD SCI USA, V102, P2531, DOI 10.1073/pnas.0409876102; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Reynolds JD, 2007, P NATL ACAD SCI USA, V104, P17058, DOI 10.1073/pnas.0707958104; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Sprague RS, 2007, TRENDS ENDOCRIN MET, V18, P350, DOI 10.1016/j.tem.2007.08.008; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Wu LC, 2006, BLOOD, V108, P1183, DOI 10.1182/blood-2006-02-004812	30	115	119	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					773	777		10.1038/nm1771	http://dx.doi.org/10.1038/nm1771			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18516054	Green Accepted			2022-12-27	WOS:000257452700026
J	Perruche, S; Zhang, P; Liu, YZ; Saas, P; Bluestone, JA; Chen, WJ				Perruche, Sylvain; Zhang, Pin; Liu, Yongzhong; Saas, Philippe; Bluestone, Jeffrey A.; Chen, WanJun			CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells	NATURE MEDICINE			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; TGF-BETA; DENDRITIC CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; FOXP3 EXPRESSION; SELF-TOLERANCE; ACTIVATION; RECEPTOR; MICE; SUPPRESSION	Intact CD3-specific antibody transiently depletes large numbers of T cells and subsequently induces long-term immune tolerance. The underlying mechanisms for the systemic tolerance, however, remain unclear. We show here that treatment of normal mice with intact antibody to CD3 increases systemic transforming growth factor-beta ( TGF-beta) produced by phagocytes exposed to apoptotic T cells. Among the phagocytes, macrophages and immature dendritic cells (iDCs) secrete TGF-beta upon ingestion of apoptotic T cells, which induces CD4(+)Foxp3(+) regulatory T cells in culture and contributes to immune tolerance mediated by CD3-specific antibody in vivo. In accordance with these results, depletion of macrophages and iDCs not only abrogates CD3-specific antibody-mediated prevention of myelin oligodendrocyte glycoprotein-induced acute experimental autoimmune encephalomyelitis ( EAE), but also reverses the therapeutic effects of antibody to CD3 on established disease in a model of relapsing-remitting EAE. Thus, CD3-specific antibody-induced immune tolerance is associated with TGF-beta production in phagocytes involved in clearing apoptotic T cells, which suggests that apoptosis is linked to active suppression in immune tolerance.	[Perruche, Sylvain; Zhang, Pin; Liu, Yongzhong; Chen, WanJun] NIDCR, Mucosal Immunol Unit, Oral Infect & Immun Branch, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Saas, Philippe] Univ Franche Comte, Inst Nacl Sante & Rech Med, UMR645, IFR133,Etablissement Francais Sang Bourgogne Fran, F-25020 Besancon, France; [Bluestone, Jeffrey A.] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite de Franche-Comte; University of California System; University of California San Francisco	Chen, WJ (corresponding author), NIDCR, Mucosal Immunol Unit, Oral Infect & Immun Branch, US Natl Inst Hlth, 30 Convent Dr, Bethesda, MD 20892 USA.	wchen@mail.nih.gov	perruche, sylvain/T-2109-2019; SAAS, Philippe/M-3550-2015; perruche, sylvain/N-4813-2017; Saas, Philippe/M-9605-2019	perruche, sylvain/0000-0002-2334-3116; Saas, Philippe/0000-0002-8857-9939	NIAID NIH HHS [R37AI46643] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI046643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000101] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chatenoud L, 1997, J IMMUNOL, V158, P2947; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; Chatenoud L, 2007, NAT REV IMMUNOL, V7, P622, DOI 10.1038/nri2134; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Ferguson TA, 1999, NAT MED, V5, P1231, DOI 10.1038/15180; FERRAN C, 1994, J CLIN INVEST, V93, P2189, DOI 10.1172/JCI117215; FERRAN C, 1990, EUR J IMMUNOL, V20, P509, DOI 10.1002/eji.1830200308; Gandhi R, 2007, J IMMUNOL, V178, P4017, DOI 10.4049/jimmunol.178.7.4017; HIRSCH R, 1989, LANCET, V1, P1390; HIRSCH R, 1989, J IMMUNOL, V142, P737; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Kleinclauss F, 2006, CELL DEATH DIFFER, V13, P41, DOI 10.1038/sj.cdd.4401699; Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Liu YZ, 2006, TRANSPLANTATION, V82, P953, DOI 10.1097/01.tp.0000232330.46688.37; Luo XR, 2007, P NATL ACAD SCI USA, V104, P2821, DOI 10.1073/pnas.0611646104; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Masteller EL, 2002, CURR OPIN IMMUNOL, V14, P652, DOI 10.1016/S0952-7915(02)00375-8; Menoret A, 2006, J IMMUNOL, V177, P6091, DOI 10.4049/jimmunol.177.9.6091; NICOLLS MR, 1993, TRANSPLANTATION, V55, P459, DOI 10.1097/00007890-199303000-00001; Ochi H, 2006, NAT MED, V12, P627, DOI 10.1038/nm1408; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Perruche S, 2004, J IMMUNOL METHODS, V294, P53, DOI 10.1016/j.jim.2004.08.011; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Smith JA, 1997, CURR OPIN IMMUNOL, V9, P648, DOI 10.1016/S0952-7915(97)80044-1; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	46	183	196	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					528	535		10.1038/nm1749	http://dx.doi.org/10.1038/nm1749			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18438416				2022-12-27	WOS:000255681800033
J	Vignuzzi, M; Wendt, E; Andino, R				Vignuzzi, Marco; Wendt, Emily; Andino, Raul			Engineering attenuated virus vaccines by controlling replication fidelity	NATURE MEDICINE			English	Article							GENETIC-CHARACTERIZATION; POLIO ERADICATION; RNA; NEUROVIRULENCE; EVOLUTION; FITNESS; DEOPTIMIZATION; PATHOGENESIS; RESISTANCE; EXCRETION	Long-lasting protection against viral infection is best achieved by vaccination with attenuated viruses. Obtaining stably attenuated vaccine strains has traditionally been an empirical process, which greatly restricts the number of effective vaccines for viral diseases. Here we describe a rational approach for engineering stably attenuated viruses that can serve as safe and effective vaccines. Our approach exploits the observation that restricting viral population diversity by increasing replication fidelity greatly reduces viral tissue tropism and pathogenicity. We show that poliovirus variants with reduced genetic diversity elicit a protective immune response in an animal model of infection. Indeed, these novel vaccine candidates are comparable in efficacy to the currently available Sabin type 1 vaccine strain, but have the added advantage of being more stable, as their increased replication fidelity prevents reversion to the pathogenic wild-type phenotype. We propose that restricting viral quasispecies diversity provides a general approach for the rational design of stable, attenuated vaccines for a wide variety of viruses.	[Vignuzzi, Marco; Wendt, Emily; Andino, Raul] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Andino, R (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, 600 16th St, San Francisco, CA 94143 USA.	raul.andino@ucsf.edu		Vignuzzi, Marco/0000-0002-4400-771X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040085, R21AI036178, R01AI040085, R01AI036178] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aaskov J, 2006, SCIENCE, V311, P236, DOI 10.1126/science.1115030; ADA GL, 1989, FUNDAMENTAL IMMUNOLO, P985; Agol VI, 2005, NATURE, V435, P881, DOI 10.1038/435881b; Anderson JP, 2004, ANNU REV MICROBIOL, V58, P183, DOI 10.1146/annurev.micro.58.030603.123649; Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200; Burns CC, 2006, J VIROL, V80, P3259, DOI 10.1128/JVI.80.7.3259-3272.2006; CANN AJ, 1984, NUCLEIC ACIDS RES, V12, P7787, DOI 10.1093/nar/12.20.7787; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P641; Ciota AT, 2007, J GEN VIROL, V88, P865, DOI 10.1099/vir.0.82606-0; CONTRERAS G, 1992, BIOLOGICALS, V20, P15, DOI 10.1016/S1045-1056(05)80003-X; Crotty S, 2002, J GEN VIROL, V83, P1707, DOI 10.1099/0022-1317-83-7-1707; Domingo E, 2000, VIROLOGY, V270, P251, DOI 10.1006/viro.2000.0320; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Domingo E, 1996, FASEB J, V10, P859, DOI 10.1096/fasebj.10.8.8666162; Dowdle WR, 2003, REV MED VIROL, V13, P277, DOI 10.1002/rmv.401; Drake JW, 1999, ANN NY ACAD SCI, V870, P100, DOI 10.1111/j.1749-6632.1999.tb08870.x; Fernandez G, 2007, J VIROL, V81, P2485, DOI 10.1128/JVI.01594-06; Gitlin L, 2005, J VIROL, V79, P1027, DOI 10.1128/JVI.79.2.1027-1035.2005; Grard G, 2007, VIROLOGY, V361, P80, DOI 10.1016/j.virol.2006.09.015; Gromeier M, 1998, J VIROL, V72, P5056, DOI 10.1128/JVI.72.6.5056-5060.1998; Gromeier M, 1996, P NATL ACAD SCI USA, V93, P2370, DOI 10.1073/pnas.93.6.2370; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; Holmes EC, 2007, CURR TOP MICROBIOL, V315, P51; Holmes EC, 2006, P NATL ACAD SCI USA, V103, P4803, DOI 10.1073/pnas.0601166103; Holmes EC, 2004, PLOS BIOL, V2, P1267, DOI 10.1371/journal.pbio.0020307; Macadam AJ, 2006, J VIROL, V80, P8653, DOI 10.1128/JVI.00370-06; Minor PD, 2005, J MED VIROL, V75, P153, DOI 10.1002/jmv.20250; Minor PD, 2004, NAT REV MICROBIOL, V2, P473, DOI 10.1038/nrmicro906; MINOR PD, 1986, J GEN VIROL, V67, P693, DOI 10.1099/0022-1317-67-4-693; Mueller S, 2006, J VIROL, V80, P9687, DOI 10.1128/JVI.00738-06; OGRA PL, 1989, CURR TOP MICROBIOL, V146, P73; Ohka S, 1998, VIROLOGY, V250, P67, DOI 10.1006/viro.1998.9360; Palmenberg Ann C., 2002, P149; Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100; Pfeiffer JK, 2005, PLOS PATHOG, V1, P102, DOI 10.1371/journal.ppat.0010011; Racaniello VR, 2006, VIROLOGY, V344, P9, DOI 10.1016/j.virol.2005.09.015; Racaniello VR, 2000, B WORLD HEALTH ORGAN, V78, P359; Rotbart HA, 2002, ANTIVIR RES, V53, P83, DOI 10.1016/S0166-3542(01)00206-6; Sauder CJ, 2006, VIROLOGY, V350, P48, DOI 10.1016/j.virol.2006.01.035; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; Sierra M, 2007, J VIROL, V81, P2012, DOI 10.1128/JVI.01606-06; SUTTER RW, 1999, LIVE ATTENUATED POLI, P364; Tebbens RJD, 2006, RISK ANAL, V26, P1471, DOI 10.1111/j.1539-6924.2006.00827.x; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Vabret A, 2006, J GEN VIROL, V87, P3349, DOI 10.1099/vir.0.82065-0; Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388; Vignuzzi M, 2005, VIRUS RES, V107, P173, DOI 10.1016/j.virusres.2004.11.007; WHO, 2006, AIR QUAL GUID GLOB U, DOI DOI 10.1016/0004-6981(88)90109-6; Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045	49	211	221	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					154	161		10.1038/nm1726	http://dx.doi.org/10.1038/nm1726			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18246077	Bronze			2022-12-27	WOS:000252946700023
J	Hettmer, S; Wagers, AJ				Hettmer, Simone; Wagers, Amy J.			Muscling in Uncovering the origins of rhabdomyosarcoma	NATURE MEDICINE			English	Editorial Material							ALVEOLAR RHABDOMYOSARCOMA; STEM-CELLS; MOUSE; GENE		[Hettmer, Simone; Wagers, Amy J.] Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Hettmer, Simone; Wagers, Amy J.] Joslin Diabet Ctr, Cambridge, MA USA; [Hettmer, Simone] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Hettmer, Simone] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Hettmer, S (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	amy.wagers@joslin.harvard.edu		Hettmer, Simone/0000-0003-1709-4448	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Keller C, 2005, CANCER RES, V65, P7530, DOI 10.1158/0008-5472.CAN-05-0477; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Linardic CM, 2005, CANCER RES, V65, P4490, DOI 10.1158/0008-5472.CAN-04-3194; Linardic CM, 2007, CANCER RES, V67, P6691, DOI 10.1158/0008-5472.CAN-06-3210; Lisboa S, 2008, PEDIATR BLOOD CANCER, V51, P554, DOI 10.1002/pbc.21646; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Shinkoda Y, 2009, PEDIATR BLOOD CANCER, V52, P286, DOI 10.1002/pbc.21783; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	14	83	86	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2010	16	2					171	173		10.1038/nm0210-171	http://dx.doi.org/10.1038/nm0210-171			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20134473				2022-12-27	WOS:000274297000037
J	Erbay, E; Babaev, VR; Mayers, JR; Makowski, L; Charles, KN; Snitow, ME; Fazio, S; Wiest, MM; Watkins, SM; Linton, MF; Hotamisligil, GS				Erbay, Ebru; Babaev, Vladimir R.; Mayers, Jared R.; Makowski, Liza; Charles, Khanichi N.; Snitow, Melinda E.; Fazio, Sergio; Wiest, Michelle M.; Watkins, Steven M.; Linton, MacRae F.; Hotamisligil, Goekhan S.			Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis	NATURE MEDICINE			English	Article							ACID-BINDING PROTEIN; ER STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; METABOLIC DISEASES; COA DESATURASE; MICE LACKING; AP2; CHOLESTEROL; APOPTOSIS	Macrophages show endoplasmic reticulum (ER) stress when exposed to lipotoxic signals associated with atherosclerosis, although the pathophysiological importance and the underlying mechanisms of this phenomenon remain unknown. Here we show that mitigation of ER stress with a chemical chaperone results in marked protection against lipotoxic death in macrophages and prevents macrophage fatty acid-binding protein-4 (aP2) expression. Using genetic and chemical models, we show that aP2 is the predominant regulator of lipid-induced macrophage ER stress. The absence of lipid chaperones incites an increase in the production of phospholipids rich in monounsaturated fatty acids and bioactive lipids that render macrophages resistant to lipid-induced ER stress. Furthermore, the impact of aP2 on macrophage lipid metabolism and the ER stress response is mediated by upregulation of key lipogenic enzymes by the liver X receptor. Our results demonstrate the central role for lipid chaperones in regulating ER homeostasis in macrophages in atherosclerosis and show that ER responses can be modified, genetically or chemically, to protect the organism against the deleterious effects of hyperlipidemia.	[Erbay, Ebru; Mayers, Jared R.; Charles, Khanichi N.; Snitow, Melinda E.; Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Babaev, Vladimir R.; Fazio, Sergio; Linton, MacRae F.] Vanderbilt Univ, Dept Med, Nashville, TN USA; [Makowski, Liza] Duke Univ, Med Ctr, Sarah W Stedman Nutr Ctr, Chapel Hill, NC USA; [Wiest, Michelle M.; Watkins, Steven M.] Lip Technol, W Sacramento, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University; Duke University	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ghotamis@hsph.harvard.edu		Erbay, Ebru/0000-0001-9584-1803; Makowski, Liza/0000-0002-5337-8037; Mayers, Jared/0000-0002-8607-1787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL090258, R01HL065405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, U24DK059637, R01DK052539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES016645] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL065405-09, F32 HL090258, R01 HL065405, HL65405] Funding Source: Medline; NIDDK NIH HHS [DK DK52539, P30 DK040561-14, U24 DK059637, R01 DK052539, DK59637, P30 DK040561] Funding Source: Medline; NIEHS NIH HHS [T32 ES016645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AQEL NM, 1984, ATHEROSCLEROSIS, V53, P265, DOI 10.1016/0021-9150(84)90127-8; Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; Borradaile NM, 2006, J LIPID RES, V47, P2726, DOI 10.1194/jlr.M600299-JLR200; Brookheart RT, 2009, CELL METAB, V10, P9, DOI 10.1016/j.cmet.2009.03.011; Brown JM, 2008, CIRCULATION, V118, P1467, DOI 10.1161/CIRCULATIONAHA.108.793182; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Cao H, 2006, DIABETES, V55, P1915, DOI 10.2337/db05-1496; Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Erbay Ebru, 2007, Curr Atheroscler Rep, V9, P222, DOI 10.1007/s11883-007-0023-6; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Ferre P, 2007, HORM RES, V68, P72, DOI 10.1159/000100426; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Furuhashi M, 2007, NATURE, V447, P959, DOI 10.1038/nature05844; Gregor MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200; Gregor MF, 2009, DIABETES, V58, P693, DOI 10.2337/db08-1220; Han S, 2006, CELL METAB, V3, P257, DOI 10.1016/j.cmet.2006.02.008; Heinemann FS, 2003, PROSTAG LEUKOTR ESS, V68, P123, DOI 10.1016/S0952-3278(02)00262-4; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; KUEHL RO, 2000, DESIGN EXPT STAT PRI, P56; Lai E, 2008, AM J PHYSIOL-ENDOC M, V294, pE540, DOI 10.1152/ajpendo.00478.2007; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Makowski L, 2005, J BIOL CHEM, V280, P12888, DOI 10.1074/jbc.M413788200; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Oyadomari S, 2008, CELL METAB, V7, P520, DOI 10.1016/j.cmet.2008.04.011; Ozawa K, 2005, DIABETES, V54, P657, DOI 10.2337/diabetes.54.3.657; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Pan W, 2003, BIOINFORMATICS, V19, P1333, DOI 10.1093/bioinformatics/btg167; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Ramanadham S, 2004, BIOCHEMISTRY-US, V43, P918, DOI 10.1021/bi035536m; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rolph MS, 2006, J IMMUNOL, V177, P7794, DOI 10.4049/jimmunol.177.11.7794; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2008, DEV CELL, V15, P829, DOI 10.1016/j.devcel.2008.10.015; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; SHA RS, 1993, J BIOL CHEM, V268, P7885; Shum BOV, 2006, J CLIN INVEST, V116, P2183, DOI 10.1172/JCI24767; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tessitore A, 2004, MOL CELL, V15, P753, DOI 10.1016/j.molcel.2004.08.029; Tuncman G, 2006, P NATL ACAD SCI USA, V103, P6970, DOI 10.1073/pnas.0602178103; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700	50	379	399	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1383	U5		10.1038/nm.2067	http://dx.doi.org/10.1038/nm.2067			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966778	Green Accepted			2022-12-27	WOS:000272407800018
J	Zhou, YD; Lee, S; Jin, Z; Wright, M; Smith, SEP; Anderson, MP				Zhou, Yu-Dong; Lee, Sanghoon; Jin, Zhe; Wright, Moriah; Smith, Stephen E. P.; Anderson, Matthew P.			Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy	NATURE MEDICINE			English	Article							LONG-TERM POTENTIATION; DENTATE GRANULE CELLS; NMDA-RECEPTORS; HIPPOCAMPAL-FORMATION; CHROMOSOMAL GENES; AUDITORY FEATURES; GYRUS; RAT; LGI1; MUTATIONS	A subset of central glutamatergic synapses are coordinately pruned and matured by unresolved mechanisms during postnatal development. We report that the human epilepsy gene LGI1, encoding leucine-rich, glioma-inactivated protein-1 and mutated in autosomal dominant lateral temporal lobe epilepsy (ADLTE), mediates this process in hippocampus. We created transgenic mice either expressing a truncated mutant LGI1 (835delC) found in ADLTE or overexpressing a wild-type LGI1. We discovered that the normal postnatal maturation of presynaptic and postsynaptic functions was arrested by the 835delC mutant LGI1, and contrastingly, was magnified by excess wild-type LGI1. Concurrently, mutant LGI1 inhibited dendritic pruning and increased the spine density to markedly increase excitatory synaptic transmission. Inhibitory transmission, by contrast, was unaffected. Furthermore, mutant LGI1 promoted epileptiform discharge in vitro and kindling epileptogenesis in vivo with partial gamma-aminobutyric acid(A) (GABA(A)) receptor blockade. Thus, LGI1 represents a human gene mutated to promote epilepsy through impaired postnatal development of glutamatergic circuits.	[Zhou, Yu-Dong; Lee, Sanghoon; Jin, Zhe; Smith, Stephen E. P.; Anderson, Matthew P.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Zhou, Yu-Dong; Lee, Sanghoon; Jin, Zhe; Smith, Stephen E. P.; Anderson, Matthew P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Zhou, Yu-Dong; Lee, Sanghoon; Jin, Zhe; Smith, Stephen E. P.; Anderson, Matthew P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Wright, Moriah] Tufts Univ, Sch Med, Boston, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University	Anderson, MP (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	mpanders@bidmc.harvard.edu		Zhou, Yu-Dong/0000-0002-6364-3869; Anderson, Matthew/0000-0003-4602-1811	US National Institute of Neurological Disorders and Stroke [R01 NS057444, K02 NS054674-03]; Nancy Lurie Marks Family Foundation; Autism Speaks/US National Alliance for Autism Research; Beth Israel Deaconess Medical Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS054674, R03NS052521, R01NS057444] Funding Source: NIH RePORTER	US National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Nancy Lurie Marks Family Foundation; Autism Speaks/US National Alliance for Autism Research; Beth Israel Deaconess Medical Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank C.B. Saper, J.S. Flier, D.K. Simon, G.D. Rosen, M.R. Kasten and M.W. Anderson for comments and suggestions, and G.D. Rosen for help on the Neurolucida system. This work was supported in part by the US National Institute of Neurological Disorders and Stroke R01 NS057444 (M.P.A.), US National Institute of Neurological Disorders and Stroke K02 NS054674-03 (M.P.A.), the Nancy Lurie Marks Family Foundation (M.P.A.), Autism Speaks/US National Alliance for Autism Research (M.P.A.) and Beth Israel Deaconess Medical Center.	Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Barth AL, 2001, NAT NEUROSCI, V4, P235, DOI 10.1038/85070; Bermingham JR, 2006, NAT NEUROSCI, V9, P76, DOI 10.1038/nn1598; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; Brenner R, 2005, NAT NEUROSCI, V8, P1752, DOI 10.1038/nn1573; Buckmaster PS, 1997, J NEUROPHYSIOL, V77, P2685, DOI 10.1152/jn.1997.77.5.2685; Charych EI, 2006, J NEUROSCI, V26, P10164, DOI 10.1523/JNEUROSCI.2379-06.2006; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; Chen CF, 2000, NEURON, V28, P955, DOI 10.1016/S0896-6273(00)00166-5; Coulter DA, 2007, PROG BRAIN RES, V163, P235, DOI 10.1016/S0079-6123(07)63014-3; CUDMORE SB, 1991, J NEUROCHEM, V57, P1240, DOI 10.1111/j.1471-4159.1991.tb08285.x; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Fukata Y, 2006, SCIENCE, V313, P1792, DOI 10.1126/science.1129947; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Grosse G, 2000, J NEUROSCI, V20, P1869; Hsu D, 2007, PROG BRAIN RES, V163, P601, DOI 10.1016/S0079-6123(07)63032-5; Kalachikov S, 2002, NAT GENET, V30, P335, DOI 10.1038/ng832; Lau CG, 2007, NAT REV NEUROSCI, V8, P413, DOI 10.1038/nrn2153; Liu YB, 1996, J NEUROPHYSIOL, V76, P1074, DOI 10.1152/jn.1996.76.2.1074; Lozovaya NA, 2004, J PHYSIOL-LONDON, V558, P451, DOI 10.1113/jphysiol.2004.063792; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; Meiri N, 1998, P NATL ACAD SCI USA, V95, P15037, DOI 10.1073/pnas.95.25.15037; Min MY, 1998, P NATL ACAD SCI USA, V95, P4702, DOI 10.1073/pnas.95.8.4702; Monaghan MM, 2001, J NEUROSCI, V21, P5973, DOI 10.1523/JNEUROSCI.21-16-05973.2001; Morante-Redolat JM, 2002, HUM MOL GENET, V11, P1119, DOI 10.1093/hmg/11.9.1119; Ottman R, 2004, NEUROLOGY, V62, P1120, DOI 10.1212/01.WNL.0000120098.39231.6E; Patel LS, 2004, J NEUROSCI, V24, P9005, DOI 10.1523/JNEUROSCI.2943-04.2004; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Rahimi O, 2007, PROG BRAIN RES, V163, P167, DOI 10.1016/S0079-6123(07)63010-6; RIHN LL, 1990, DEV BRAIN RES, V54, P115, DOI 10.1016/0165-3806(90)90071-6; Schulte U, 2006, NEURON, V49, P697, DOI 10.1016/j.neuron.2006.01.033; Senechal KR, 2005, HUM MOL GENET, V14, P1613, DOI 10.1093/hmg/ddi169; Sirerol-Piquer MS, 2006, HUM MOL GENET, V15, P3436, DOI 10.1093/hmg/ddl421; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; Thompson CL, 2002, MOL BRAIN RES, V102, P55, DOI 10.1016/S0169-328X(02)00183-3; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Tovar KR, 1999, J NEUROSCI, V19, P4180; Uzzau S, 2001, P NATL ACAD SCI USA, V98, P15264, DOI 10.1073/pnas.261348198; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; Waites CL, 2005, ANNU REV NEUROSCI, V28, P251, DOI 10.1146/annurev.neuro.27.070203.144336; Wu C, 2008, J NEUROSCI METH, V171, P126, DOI 10.1016/j.jneumeth.2008.03.001; Yang P, 2006, PROG NEUROBIOL, V79, P73, DOI 10.1016/j.pneurobio.2006.05.001	43	135	136	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1208	U140		10.1038/nm.2019	http://dx.doi.org/10.1038/nm.2019			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19701204	Green Accepted			2022-12-27	WOS:000270596400034
J	Albuquerque, RJC; Hayashi, T; Cho, WG; Kleinman, ME; Dridi, S; Takeda, A; Baffi, JZ; Yamada, K; Kaneko, H; Green, MG; Chappell, J; Wilting, J; Weich, HA; Yamagami, S; Amano, S; Mizuki, N; Alexander, JS; Peterson, ML; Brekken, RA; Hirashima, M; Capoor, S; Usui, T; Ambati, BK; Ambati, J				Albuquerque, Romulo J. C.; Hayashi, Takahiko; Cho, Won Gil; Kleinman, Mark E.; Dridi, Sami; Takeda, Atsunobu; Baffi, Judit Z.; Yamada, Kiyoshi; Kaneko, Hiroki; Green, Martha G.; Chappell, Joe; Wilting, Joerg; Weich, Herbert A.; Yamagami, Satoru; Amano, Shiro; Mizuki, Nobuhisa; Alexander, Jonathan S.; Peterson, Martha L.; Brekken, Rolf A.; Hirashima, Masanori; Capoor, Seema; Usui, Tomohiko; Ambati, Balamurali K.; Ambati, Jayakrishna			Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth	NATURE MEDICINE			English	Article							PROMOTES TUMOR-METASTASIS; VEGF-C; CORNEAL LYMPHANGIOGENESIS; NODE METASTASIS; TRANSGENIC MICE; CELLS; ANGIOGENESIS; BINDING; EXPRESSION; MOUSE	Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. We report the existence of a splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2) that encodes a secreted form of the protein, designated soluble Vegfr-2 (sVegfr-2), that inhibits developmental and reparative lymphangiogenesis by blocking Vegf-c function. Tissue-specific loss of sVegfr-2 in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of sVegfr-2 inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring sVegfr-2 thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of sVegfr-2 might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.	[Albuquerque, Romulo J. C.; Cho, Won Gil; Kleinman, Mark E.; Dridi, Sami; Takeda, Atsunobu; Baffi, Judit Z.; Yamada, Kiyoshi; Kaneko, Hiroki; Green, Martha G.; Capoor, Seema; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA; [Albuquerque, Romulo J. C.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Hayashi, Takahiko; Mizuki, Nobuhisa] Yokohama City Univ, Dept Ophthalmol, Yokohama, Kanagawa 232, Japan; [Chappell, Joe] Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY USA; [Wilting, Joerg] Univ Gottingen, Dept Anat & Cell Biol, Gottingen, Germany; [Weich, Herbert A.] Helmholtz Ctr Infect Res, Dept Gene Regulat & Differentiat, Braunschweig, Germany; [Yamagami, Satoru; Amano, Shiro; Usui, Tomohiko] Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 113, Japan; [Alexander, Jonathan S.] Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71105 USA; [Peterson, Martha L.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA; [Brekken, Rolf A.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Hirashima, Masanori] Kobe Univ, Grad Sch Med, Div Vasc Biol, Dept Physiol & Cell Biol, Kobe, Hyogo 657, Japan; [Ambati, Balamurali K.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA; [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT USA	University of Kentucky; University of Kentucky; Yokohama City University; University of Kentucky; University of Gottingen; Helmholtz Association; Helmholtz-Center for Infection Research; University of Tokyo; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky; University of Texas System; University of Texas Southwestern Medical Center Dallas; Kobe University; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs	Ambati, J (corresponding author), Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.	jamba2@email.uky.edu	Hayashi, Takahiko/ABB-7168-2020; Kaneko, Hiroki/O-7695-2015; Dridi, Sami/Q-8207-2019; Hirashima, Masanori/ABC-9204-2021; Kaneko, Hiroki/AHA-2461-2022	Hayashi, Takahiko/0000-0001-8704-680X; Kaneko, Hiroki/0000-0003-0731-6465; Hirashima, Masanori/0000-0002-0190-4381; Kaneko, Hiroki/0000-0003-0731-6465; Peterson, Martha/0000-0002-7214-421X; Kleinman, Mark/0000-0001-8557-7949	US National Institutes of Health; National Eye Institute [EY015422, EY018350, EY018836, EY017182, EY017950]; Research to Prevent Blindness; University of Kentucky University Research Professorship; Fight for Sight; Japan Society for the Promotion of Science for Young Scientists; US Department of Defense; Doris Duke Distinguished Clinical Scientist; Burroughs Wellcome Fund; NATIONAL EYE INSTITUTE [R01EY018836, R01EY017182, R01EY018350, RC1EY020442, R01EY020672, R21EY019778, R01EY015422, R01EY017950] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); University of Kentucky University Research Professorship; Fight for Sight; Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); US Department of Defense(United States Department of Defense); Doris Duke Distinguished Clinical Scientist(Doris Duke Charitable Foundation (DDCF)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank R. Ashery-Padan (Tel Aviv University), P. Gruss (Max Planck Institute) and D. C. Beebe (Washington University) for LeCre mice, R. K. Nordeen (University of Colorado) for Cre plasmid, K. Miyazono (University of Tokyo) for pVegf-c and J.L. Arbiser (Emory University) and C. D. Kontos (Duke University) for endothelial cell lines; R. King, L. Xu, M. McConnell, K. Emerson, A. Blanford, M. Baker, S. Furlow, M. LaFalce and C. Long for technical assistance; and R. Mohan, F. Cambi, S. Bondada, M. Detmar, M. W. Fannon, T. V. Getchell, R. K. Jain, T. S. Khurana, B. J. Raisler, J. E. Springer, P. A. Pearson, C. W. Vander Kooi, J. G. Woodward, A. M. Rao, G. S. Rao, K. Ambati and L. Garcia for valuable discussions. This work was supported by US National Institutes of Health and National Eye Institute grants EY015422, EY018350 and EY018836 to J. A. and EY017182 and EY017950 to B. K. A.; a Research to Prevent Blindness Lew R. Wassermann Merit Award (J. A.); Physician Scientist Awards (J. A., B. K. A.); a Medical Student Fellowship (R. J. C. A.); a departmental unrestricted grant ( J. A.); a University of Kentucky University Research Professorship (J. A.); Fight for Sight (R. J. C. A.); Japan Society for the Promotion of Science for Young Scientists (A. T.); a VA Merit Award (B. K. A.); and the US Department of Defense (B. K. A.). J. A. is also supported by the Doris Duke Distinguished Clinical Scientist Award and the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research and is the Dr. E. Vernon Smith and Eloise C. Smith Macular Degeneration Endowed Chair.	Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Ando T., 2005, Lymphatic Research and Biology, V3, P105, DOI 10.1089/lrb.2005.3.105; Ashery-Padan R, 2000, GENE DEV, V14, P2701, DOI 10.1101/gad.184000; Azar Dimitri T, 2006, Trans Am Ophthalmol Soc, V104, P264; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Brakenhielm E, 2007, INT J CANCER, V121, P2153, DOI 10.1002/ijc.22900; Brideau G, 2007, CANCER RES, V67, P11528, DOI 10.1158/0008-5472.CAN-07-1458; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chen L, 2004, NAT MED, V10, P813, DOI 10.1038/nm1078; Cursiefen C, 2003, CORNEA, V22, P273, DOI 10.1097/00003226-200304000-00021; Cursiefen C, 2002, INVEST OPHTH VIS SCI, V43, P2127; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Ebos JML, 2004, MOL CANCER RES, V2, P315; Ebos JML, 2008, CANCER RES, V68, P521, DOI 10.1158/0008-5472.CAN-07-3217; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Fenwick A, 2006, SCIENCE, V313, P1077, DOI 10.1126/science.1127184; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Goldman J, 2005, CIRC RES, V96, P1193, DOI 10.1161/01.RES.0000168918.27576.78; Hamrah P, 2004, EXP EYE RES, V79, P553, DOI 10.1016/j.exer.2004.06.028; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Huang HY, 2001, LAB INVEST, V81, P1729, DOI 10.1038/labinvest.3780386; Huang XM, 1998, BIOCHEM BIOPH RES CO, V252, P643, DOI 10.1006/bbrc.1998.9717; Jeltsch M, 2006, J BIOL CHEM, V281, P12187, DOI 10.1074/jbc.M511593200; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2006, AM J PATHOL, V169, P708, DOI 10.2353/ajpath.2006.051200; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kirkin V, 2001, EUR J BIOCHEM, V268, P5530, DOI 10.1046/j.1432-1033.2001.02476.x; Kojima T, 2008, FEBS LETT, V582, P2515, DOI 10.1016/j.febslet.2008.06.014; Kubo H, 2002, P NATL ACAD SCI USA, V99, P8868, DOI 10.1073/pnas.062040199; Liu Y, 2002, J EXP MED, V195, P259, DOI 10.1084/jem.20010838; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; Norgall S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-105; Oka M, 2008, BLOOD, V111, P4571, DOI 10.1182/blood-2007-10-120337; Rajakumar A, 2009, PLACENTA, V30, P25, DOI 10.1016/j.placenta.2008.10.006; Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039; Sela S, 2008, CIRC RES, V102, P1566, DOI 10.1161/CIRCRESAHA.108.171504; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Streilein JW, 1996, INVEST OPHTH VIS SCI, V37, P413; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wilting J, 2007, NOVART FDN SYMP, V283, P227; Wilting J, 2007, NOVART FDN SYMP, V283, P238; WILTING J, 2007, NOVART FDN SYMP, V238, P220; Yamagami S, 2001, INVEST OPHTH VIS SCI, V42, P1293; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830	62	264	280	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1023	U74		10.1038/nm.2018	http://dx.doi.org/10.1038/nm.2018			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19668192	Green Accepted			2022-12-27	WOS:000269979200022
J	Gupta, PB; Chaffer, CL; Weinberg, RA				Gupta, Piyush B.; Chaffer, Christine L.; Weinberg, Robert A.			Cancer stem cells: mirage or reality?	NATURE MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; MOUSE MODEL; GROWTH; IDENTIFICATION; CARCINOMA; TUMORS; PROGRESSION; RESISTANCE	The similarities and differences between normal tissue stem cells and cancer stem cells (CSCs) have been the source of much contention, with some recent studies calling into question the very existence of CSCs. An examination of the literature indicates, however, that the CSC model rests on firm experimental foundations and that differences in the observed frequencies of CSCs within tumors reflect the various cancer types and hosts used to assay these cells. Studies of stem cells and the differentiation program termed the epithelial-mesenchymal transition (EMT) point to the possible existence of plasticity between stem cells and their more differentiated derivatives. If present, such plasticity would have major implications for the CSC model and for future therapeutic approaches.	[Chaffer, Christine L.; Weinberg, Robert A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Gupta, Piyush B.] Massachusetts Inst Technol & Harvard, Broad Inst, Cambridge, MA USA; [Chaffer, Christine L.; Weinberg, Robert A.] MIT, Ludwig Ctr Mol Oncol, Cambridge, MA 02139 USA; [Weinberg, Robert A.] MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu						Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; CLARKSON B, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309047871; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Harris MA, 2008, CANCER RES, V68, P10051, DOI 10.1158/0008-5472.CAN-08-0786; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kennedy JA, 2007, SCIENCE, V318, DOI 10.1126/science.1149590; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Singh SK, 2003, CANCER RES, V63, P5821; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Thon N, 2010, MOL CELL NEUROSCI, V43, P51, DOI 10.1016/j.mcn.2008.07.022; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Wu A, 2008, STEM CELLS DEV, V17, P173, DOI 10.1089/scd.2007.0133; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	30	750	788	2	141	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1010	1012		10.1038/nm0909-1010	http://dx.doi.org/10.1038/nm0909-1010			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19734877				2022-12-27	WOS:000269979200019
J	Shichita, T; Sugiyama, Y; Ooboshi, H; Sugimori, H; Nakagawa, R; Takada, I; Iwaki, T; Okada, Y; Iida, M; Cua, DJ; Iwakura, Y; Yoshimura, A				Shichita, Takashi; Sugiyama, Yuki; Ooboshi, Hiroaki; Sugimori, Hiroshi; Nakagawa, Ryusuke; Takada, Ichiro; Iwaki, Toru; Okada, Yasunori; Iida, Mitsuo; Cua, Daniel J.; Iwakura, Yoichiro; Yoshimura, Akihiko			Pivotal role of cerebral interleukin-17-producing gamma delta T cells in the delayed phase of ischemic brain injury	NATURE MEDICINE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; AUTOIMMUNE ENCEPHALOMYELITIS; INTERFERON-GAMMA; FOCAL ISCHEMIA; BARRIER DISRUPTION; ESCHERICHIA-COLI; ARTERY OCCLUSION; IL-17 PRODUCTION; NERVOUS-SYSTEM; INFLAMMATION	Lymphocyte recruitment and activation have been implicated in the progression of cerebral ischemia-reperfusion (I/R) injury, but the roles of specific lymphocyte subpopulations and cytokines during stroke remain to be clarified. Here we demonstrate that the infiltration of T cells into the brain, as well as the cytokines interleukin-23 (IL-23) and IL-17, have pivotal roles in the evolution of brain infarction and accompanying neurological deficits. Blockade of T cell infiltration into the brain by the immunosuppressant FTY720 reduced I/R-induced brain damage. The expression of IL-23, which was derived mostly from infiltrated macrophages, increased on day 1 after I/R, whereas IL-17 levels were elevated after day 3, and this induction of IL-17 was dependent on IL-23. These data, together with analysis of mice genetically disrupted for IL-17 and IL-23, suggest that IL-23 functions in the immediate stage of I/R brain injury, whereas IL-17 has an important role in the delayed phase of I/R injury during which apoptotic neuronal death occurs in the penumbra. Intracellular cytokine staining revealed that gamma delta T lymphocytes, but not CD4(+) helper T cells, were a major source of IL-17. Moreover, depletion of gamma delta T lymphocytes ameliorated the I/R injury. We propose that T lymphocytes, including gamma delta T lymphocytes, could be a therapeutic target for mitigating the inflammatory events that amplify the initial damage in cerebral ischemia.	[Shichita, Takashi; Sugiyama, Yuki; Nakagawa, Ryusuke; Takada, Ichiro; Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan; [Shichita, Takashi] Kyushu Univ, Grad Sch Med Sci, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 812, Japan; [Shichita, Takashi; Ooboshi, Hiroaki; Sugimori, Hiroshi; Iida, Mitsuo] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan; [Ooboshi, Hiroaki] Med & Dent Hosp, Fukuoka Dent Coll, Dept Internal Med, Fukuoka, Japan; [Iwaki, Toru] Kyushu Univ, Grad Sch Med Sci, Dept Neuropathol, Fukuoka 812, Japan; [Okada, Yasunori] Keio Univ, Sch Med, Dept Pathol, Shijuku Ku, Tokyo 160, Japan; [Cua, Daniel J.] Schering Plough SpA, Dept Immunol, Palo Alto, CA USA; [Iwakura, Yoichiro] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Tokyo, Japan; [Iwakura, Yoichiro] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Tokyo, Japan; [Yoshimura, Akihiko] Japan Sci & Technol Agcy, CREST, Tokyo, Japan	Keio University; Kyushu University; Kyushu University; Fukuoka Dental College (FDC); Kyushu University; Keio University; Merck & Company; Schering Plough Corporation; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yoshimura, A (corresponding author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan.	yoshimura@a6.keio.jp	Yoshimura, Akihiko/K-5515-2013; Iwakura, Yoichiro/E-5457-2011; Okada, Yasunori/B-5550-2014	Iwakura, Yoichiro/0000-0002-9934-5775; Okada, Yasunori/0000-0001-9208-4755	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation [NIBIO, 07-4]; Naito Foundation; Astellas Foundation for Research on Metabolic Disorders.	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Naito Foundation(Naito Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders.	We thank S. Hamano for TCR gamma delta-specific antibody hybridoma, T. Yoshioka, N. Shiino and M. Asakawa for technical assistance, E. Ishikawa and H. Noguchi for technical support for human ischemic brain section, T. Kobayashi for discussion and technical help and N. Soma for manuscript preparation. This study was supported by special Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO, 07-4), the Naito Foundation and the Astellas Foundation for Research on Metabolic Disorders.	Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gaudinski MR, 2008, STROKE, V39, P2765, DOI 10.1161/STROKEAHA.107.512269; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Ifergan I, 2008, BRAIN, V131, P785, DOI 10.1093/brain/awm295; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; Jensen KDC, 2008, IMMUNITY, V29, P90, DOI 10.1016/j.immuni.2008.04.022; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Li GZ, 2005, SCAND J IMMUNOL, V62, P481, DOI 10.1111/j.1365-3083.2005.01683.x; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Matsui T, 2002, J CEREBR BLOOD F MET, V22, P711, DOI 10.1097/00004647-200206000-00010; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakamura R, 2008, J IMMUNOL, V181, P2071, DOI 10.4049/jimmunol.181.3.2071; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Sacco RL, 2007, LANCET, V369, P331, DOI 10.1016/S0140-6736(07)60155-X; SCHROETER M, 1994, J NEUROIMMUNOL, V55, P195, DOI 10.1016/0165-5728(94)90010-8; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Shimosegawa E, 2005, ANN NEUROL, V57, P495, DOI 10.1002/ana.20427; Sugimori H, 2004, BRAIN RES PROTOC, V13, P189, DOI 10.1016/j.brainresprot.2004.06.001; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	33	607	643	2	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					946	U150		10.1038/nm.1999	http://dx.doi.org/10.1038/nm.1999			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19648929				2022-12-27	WOS:000268770400040
J	Nichols, J; Jones, K; Phillips, JM; Newland, SA; Roode, M; Mansfield, W; Smith, A; Cooke, A				Nichols, Jennifer; Jones, Kenneth; Phillips, Jenny M.; Newland, Stephen A.; Roode, Mila; Mansfield, William; Smith, Austin; Cooke, Anne			Validated germline-competent embryonic stem cell lines from nonobese diabetic mice	NATURE MEDICINE			English	Article							NOD MOUSE; RAT BLASTOCYSTS; GROUND-STATE; PLURIPOTENCY; TRANSMISSION; DERIVATION	Nonobese diabetic (NOD) mice provide an excellent model of type 1 diabetes. The genetic contribution to this disease is complex, with more than 20 loci implicated in diabetes onset. One of the challenges for researchers using the NOD mouse model (and, indeed, other models of spontaneous autoimmune disease) has been the high density of sequence variation within candidate chromosomal segments. Furthermore, the scope for analyzing many putative disease loci via gene targeting has been hampered by the lack of NOD embryonic stem (ES) cells. We describe here the derivation of NOD ES cell lines capable of generating chimeric mice after stable genetic modification. These NOD ES cell lines also show efficient germline transmission, with offspring developing diabetes. The availability of these cells will not only enable the dissection of closely linked loci and the role they have in the onset of type 1 diabetes but also facilitate the generation of new transgenics.	[Phillips, Jenny M.; Newland, Stephen A.; Cooke, Anne] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; [Nichols, Jennifer; Jones, Kenneth; Roode, Mila; Mansfield, William; Smith, Austin] Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Cambridge CB2 1QP, England; [Nichols, Jennifer; Jones, Kenneth; Roode, Mila] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 1QP, England; [Mansfield, William; Smith, Austin] Univ Cambridge, Dept Biochem, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Cooke, A (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	ac@mole.bio.cam.ac.uk	Mallat, Ziad/D-4041-2012; Cooke, Anne/E-8709-2012; Cooke, Anne/S-4763-2019	Mallat, Ziad/0000-0003-0443-7878; Cooke, Anne/0000-0003-3327-6081; Nichols, Jennifer/0000-0002-8650-1388; Smith, Austin/0000-0002-3029-4682	Medical Research Council [G0300723B] Funding Source: researchfish; MRC [G0601174, G9806702] Funding Source: UKRI; Medical Research Council [G0601174, G9806702] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Arai S, 2004, EXP DIABESITY RES, V5, P219, DOI 10.1080/15438600490486877; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Brode S, 2006, J IMMUNOL, V177, P6603, DOI 10.4049/jimmunol.177.10.6603; Brook FA, 2003, DIABETES, V52, P205, DOI 10.2337/diabetes.52.1.205; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; KIKUTANI H, 1992, ADV IMMUNOL, V51, P285, DOI 10.1016/S0065-2776(08)60490-3; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; McClive PJ, 2001, MOL REPROD DEV, V60, P225, DOI 10.1002/mrd.1081; Nagafuchi S, 1999, FEBS LETT, V455, P101, DOI 10.1016/S0014-5793(99)00801-7; Redondo MJ, 2001, RECENT PROG HORM RES, V56, P69, DOI 10.1210/rp.56.1.69; Serreze DV, 2001, CURR DIRECT AUTOIMMU, V4, P31; Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; Wang W, 2008, P NATL ACAD SCI USA, V105, P9290, DOI 10.1073/pnas.0801017105; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; Yang W, 2009, STEM CELLS, V27, P383, DOI 10.1634/stemcells.2008-0974; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780	19	157	164	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					814	U135		10.1038/nm.1996	http://dx.doi.org/10.1038/nm.1996			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19491843				2022-12-27	WOS:000267806900037
J	Chau, TA; McCully, ML; Brintnell, W; An, G; Kasper, KJ; Vines, ED; Kubes, P; Haeryfar, SMM; McCormick, JK; Cairns, E; Heinrichs, DE; Madrenas, J				Chau, Thu A.; McCully, Michelle L.; Brintnell, William; An, Gary; Kasper, Katherine J.; Vines, Enrique D.; Kubes, Paul; Haeryfar, S. M. Mansour; McCormick, John K.; Cairns, Ewa; Heinrichs, David E.; Madrenas, Joaquin			Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome	NATURE MEDICINE			English	Article							METHICILLIN-RESISTANT; BACTERIAL SUPERANTIGENS; LIPOTEICHOIC ACID; UNITED-STATES; LETHAL SHOCK; AUREUS; INTERLEUKIN-10; INDUCTION; IL-10; PREVALENCE	Staphylococcal superantigens are pyrogenic exotoxins that cause massive T cell activation leading to toxic shock syndrome and death. Despite the strong adaptive immune response induced by these toxins, infections by superantigen-producing staphylococci are very common clinical events. We hypothesized that this may be partly a result of staphylococcal strains having developed strategies that downregulate the T cell response to these toxins. Here we show that the human interleukin-2 response to staphylococcal superantigens is inhibited by the simultaneous presence of bacteria. Such a downregulatory effect is the result of peptidoglycan-embedded molecules binding to Toll-like receptor 2 and inducing interleukin-10 production and apoptosis of antigen-presenting cells. We corroborated these findings in vivo by showing substantial prevention of mortality after simultaneous administration of staphylococcal enterotoxin B with either heat-killed staphylococci or Staphylococcus aureus peptidoglycan in mouse models of superantigen-induced toxic shock syndrome.	[Chau, Thu A.; McCully, Michelle L.; Madrenas, Joaquin] Robarts Res Inst, FOCIS Ctr Clin Immunol & Immunotherapeut, London, ON N6A 5C1, Canada; [McCully, Michelle L.; Kasper, Katherine J.; Vines, Enrique D.; Haeryfar, S. M. Mansour; McCormick, John K.; Cairns, Ewa; Heinrichs, David E.; Madrenas, Joaquin] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Brintnell, William; Cairns, Ewa; Madrenas, Joaquin] Univ Western Ontario, Dept Med, London, ON, Canada; [An, Gary] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA; [Kubes, Paul] Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; [McCormick, John K.] Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Northwestern University; Feinberg School of Medicine; University of Calgary; Western University (University of Western Ontario)	Madrenas, J (corresponding author), Robarts Res Inst, FOCIS Ctr Clin Immunol & Immunotherapeut, London, ON N6A 5C1, Canada.	madrenas@robarts.ca	Madrenas, Quim/P-5008-2019; Cairns, Ewa/G-3284-2011; McCormick, John/E-4232-2015; McCully, Michelle/A-7705-2013; Heinrichs, David/ABD-5702-2021	McCully, Michelle/0000-0003-1543-3629; McCormick, John/0000-0003-3742-7289; An, Gary/0000-0003-4549-9004; Heinrichs, David/0000-0002-7217-2456	Canadian Institutes of Health Research; Kidney Foundation of Canada; Canadian Institutes of Health Research New Investigator Award; Calder Foundation; Tier I Canada Research Chair in Immunobiology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Kidney Foundation of Canada; Canadian Institutes of Health Research New Investigator Award(Canadian Institutes of Health Research (CIHR)); Calder Foundation; Tier I Canada Research Chair in Immunobiology	We thank K. C. Kain and Z. Lu (University Health Network, Toronto) for providing mice to harvest cells for in vitro experiments and the members of the Madrenas laboratory for helpful discussions and ideas. The human B lymphoblastoid cell line LG2 was provided by E. Long (US National Institutes of Health). This work was supported by grants from the Canadian Institutes of Health Research and the Kidney Foundation of Canada. J.K.M. is a recipient of a Canadian Institutes of Health Research New Investigator Award, E. C. is a recipient of an award from the Calder Foundation and J.M. holds a Tier I Canada Research Chair in Immunobiology.	Adem PV, 2005, NEW ENGL J MED, V353, P1245, DOI 10.1056/NEJMoa044194; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Annane D, 2004, EXPERT OPIN PHARMACO, V5, P1701, DOI 10.1517/14656566.5.8.1701; AOKI Y, 1995, BLOOD, V86, P1420, DOI 10.1182/blood.V86.4.1420.bloodjournal8641420; BEAN AGD, 1993, INFECT IMMUN, V61, P4937, DOI 10.1128/IAI.61.11.4937-4939.1993; Becker CE, 2007, SEMIN IMMUNOPATHOL, V29, P239, DOI 10.1007/s00281-007-0081-4; Becker K, 2003, J CLIN MICROBIOL, V41, P1434, DOI 10.1128/JCM.41.4.1434-1439.2003; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Bueno Clara, 2007, Chem Immunol Allergy, V93, P161, DOI 10.1159/000100894; Bueno C, 2006, IMMUNITY, V25, P67, DOI 10.1016/j.immuni.2006.04.012; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P421; Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204; Chuang Yu-Yu, 2005, Paediatr Drugs, V7, P11, DOI 10.2165/00148581-200507010-00002; Criado G, 2004, J IMMUNOL, V172, P222, DOI 10.4049/jimmunol.172.1.222; Dale SE, 2004, J BACTERIOL, V186, P8356, DOI 10.1128/JB.186.24.8356-8362.2004; DAVIS JP, 1980, NEW ENGL J MED, V303, P1429, DOI 10.1056/NEJM198012183032501; Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203; Faulkner L, 2005, J IMMUNOL, V175, P6870, DOI 10.4049/jimmunol.175.10.6870; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Guo H, 2008, IMMUNOL CELL BIOL, V86, P271, DOI 10.1038/sj.icb.7100158; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Haslinger-Loffler B, 2006, KIDNEY INT, V70, P1089, DOI 10.1038/sj.ki.5001710; Holtfreter S, 2006, J INFECT DIS, V193, P1275, DOI 10.1086/503048; Into T, 2004, CELL MICROBIOL, V6, P187, DOI 10.1046/j.1462-5822.2003.00356.x; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; Jankovic D, 2007, NAT IMMUNOL, V8, P1281, DOI 10.1038/ni1207-1281; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kanauchi O, 2005, CURR PHARM DESIGN, V11, P1047, DOI 10.2174/1381612053381675; Klein E, 2007, EMERG INFECT DIS, V13, P1840, DOI 10.3201/eid1312.070629; Komoriya K, 1999, MOL MICROBIOL, V34, P767, DOI 10.1046/j.1365-2958.1999.01639.x; KRAKAUER T, 1995, J INFECT DIS, V172, P988, DOI 10.1093/infdis/172.4.988; Kuehnert MJ, 2005, EMERG INFECT DIS, V11, P868; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Llewelyn M, 2002, LANCET INFECT DIS, V2, P156, DOI 10.1016/S1473-3099(02)00222-0; Madsen K, 2006, J CLIN GASTROENTEROL, V40, P232, DOI 10.1097/00004836-200603000-00014; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; Mempel M, 2003, EUR J CLIN MICROBIOL, V22, P306, DOI 10.1007/s10096-003-0928-0; Nakagawa Y, 2003, J INFECT DIS, V188, P1284, DOI 10.1086/379036; Nashev D, 2004, FEMS MICROBIOL LETT, V233, P45, DOI 10.1016/j.femsle.2004.01.032; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Parsonnet J, 2005, J CLIN MICROBIOL, V43, P4628, DOI 10.1128/JCM.43.9.4628-4634.2005; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Roy CR, 2007, NAT IMMUNOL, V8, P1179, DOI 10.1038/ni1528; Rubin RJ, 1999, EMERG INFECT DIS, V5, P9, DOI 10.3201/eid0501.990102; Schlievert PM, 2007, BIOCHEMISTRY-US, V46, P14349, DOI 10.1021/bi701202w; Schmitz FJ, 1997, EUR J EPIDEMIOL, V13, P699, DOI 10.1023/A:1007357206672; Sebulsky MT, 2004, J BIOL CHEM, V279, P53152, DOI 10.1074/jbc.M409793200; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Stiles BG, 1999, INFECT IMMUN, V67, P1521, DOI 10.1128/IAI.67.3.1521-1525.1999; Stuyt RJL, 2001, INFECT IMMUN, V69, P5025, DOI 10.1128/IAI.69.8.5025-5030.2001; Sundberg EJ, 2007, SEMIN IMMUNOL, V19, P262, DOI 10.1016/j.smim.2007.04.006; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Teft WA, 2007, J IMMUNOL, V179, P3631, DOI 10.4049/jimmunol.179.6.3631; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; Venet F, 2006, J IMMUNOL, V177, P6540, DOI 10.4049/jimmunol.177.9.6540; Wang JE, 2000, INFECT IMMUN, V68, P3965, DOI 10.1128/IAI.68.7.3965-3970.2000; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435; Young MH, 2006, EXPERT OPIN BIOL TH, V6, P155, DOI 10.1517/14712598.6.2.155	60	105	107	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					641	U143		10.1038/nm.1965	http://dx.doi.org/10.1038/nm.1965			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19465927				2022-12-27	WOS:000266731600023
J	Morris, ES; MacDonald, KPA; Kuns, RD; Morris, HM; Banovic, T; Don, ALJ; Rowe, V; Wilson, YA; Raffelt, NC; Engwerda, CR; Burman, AC; Markey, KA; Godfrey, DI; Smyth, MJ; Hill, GR				Morris, Edward S.; MacDonald, Kelli P. A.; Kuns, Rachel D.; Morris, Helen M.; Banovic, Tatjana; Don, Alistair L. J.; Rowe, Vanessa; Wilson, Yana A.; Raffelt, Neil C.; Engwerda, Christian R.; Burman, Angela C.; Markey, Kate A.; Godfrey, Dale I.; Smyth, Mark J.; Hill, Geoffrey R.			Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation	NATURE MEDICINE			English	Article							VERSUS-HOST-DISEASE; G-CSF ANALOGS; NKT CELLS; GASTROINTESTINAL-TRACT; GVHD; DEPLETION; MOBILIZATION; TOLERANCE; GVL	Granulocyte colony-stimulating factor (G-CSF) is often used to hasten neutrophil recovery after allogeneic bone marrow transplantation (BMT), but the clinical and immunological consequences evoked remain unclear(1). We examined the effect of G-CSF administration after transplantation in mouse models and found that exposure to either standard G-CSF or pegylated-G-CSF soon after BMT substantially increased graft-versus-host disease (GVHD). This effect was dependent on total body irradiation (TBI) rendering host dendritic cells (DCs) responsive to G-CSF by upregulating their expression of the G-CSF receptor. Stimulation of host DCs by G-CSF subsequently unleashed a cascade of events characterized by donor natural killer T cell (NKT cell) activation, interferon-gamma secretion and CD40-dependent amplification of donor cytotoxic T lymphocyte function during the effector phase of GVHD. Crucially, the detrimental effects of G-CSF were only present when it was administered after TBI conditioning and at a time when residual host antigen presenting cells were still present, perhaps explaining the conflicting and somewhat controversial clinical studies from the large European and North American BMT registries(2,3). These data have major implications for the use of G-CSF in disease states where NKT cell activation may have effects on outcome.	[Smyth, Mark J.] Peter MacCallum Canc Ctr, Trescowthick Labs, Canc Immunol Program, St Andrews Pl, Australia; [Godfrey, Dale I.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; [Morris, Edward S.; MacDonald, Kelli P. A.; Kuns, Rachel D.; Morris, Helen M.; Banovic, Tatjana; Don, Alistair L. J.; Rowe, Vanessa; Wilson, Yana A.; Raffelt, Neil C.; Engwerda, Christian R.; Burman, Angela C.; Markey, Kate A.; Hill, Geoffrey R.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia	Peter Maccallum Cancer Center; University of Melbourne; QIMR Berghofer Medical Research Institute	Hill, GR (corresponding author), Peter MacCallum Canc Ctr, Trescowthick Labs, Canc Immunol Program, St Andrews Pl, Australia.	geoff.hill@qimr.edu.au	MacDonald, Kelli/AAV-5365-2020; Hill, Geoffrey/O-2630-2016; Smyth, Mark J/H-8709-2014; MacDonald, Kelli PA/O-2722-2016; Engwerda, Christian/I-3072-2015; Markey, Kate/A-5385-2016	Hill, Geoffrey/0000-0003-2994-0429; Smyth, Mark J/0000-0001-7098-7240; MacDonald, Kelli PA/0000-0003-3451-4221; Godfrey, Dale/0000-0002-3009-5472; Engwerda, Christian/0000-0003-2813-4804; Wilson, Yana/0000-0002-6878-1806; Markey, Kate/0000-0002-7064-2362				Banovic T, 2005, BLOOD, V106, P2206, DOI 10.1182/blood-2005-01-0062; Burman AC, 2007, BLOOD, V110, P1064, DOI 10.1182/blood-2006-12-063982; Cooke KR, 2000, TRANSPLANTATION, V70, P272, DOI 10.1097/00007890-200007270-00006; Hammond KJL, 2001, J IMMUNOL, V167, P1164, DOI 10.4049/jimmunol.167.3.1164; Hashimoto D, 2005, J IMMUNOL, V174, P551, DOI 10.4049/jimmunol.174.1.551; Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Khoury HJ, 2006, BLOOD, V107, P1712, DOI 10.1182/blood-2005-07-2661; KLUMPP TR, 1995, J CLIN ONCOL, V13, P1323, DOI 10.1200/JCO.1995.13.6.1323; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; MacDonald KPA, 2003, BLOOD, V101, P2033, DOI 10.1182/blood-2002-05-1529; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Matte CC, 2004, NAT MED, V10, P987, DOI 10.1038/nm1089; McQuaker IG, 1997, J CLIN ONCOL, V15, P451, DOI 10.1200/JCO.1997.15.2.451; Merad M, 2004, NAT MED, V10, P510, DOI 10.1038/nm1038; Morecki S, 2004, EXP HEMATOL, V32, P630, DOI 10.1016/j.exphem.2004.04.005; Morris ES, 2006, BLOOD, V107, P3430, DOI 10.1182/blood-2005-10-4299; Morris ES, 2005, J CLIN INVEST, V115, P3093, DOI 10.1172/JCI25249; Morris ES, 2004, BLOOD, V103, P3573, DOI 10.1182/blood-2003-08-2864; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Pagliuca A, 2003, BRIT J HAEMATOL, V123, P22, DOI 10.1046/j.1365-2141.2003.04546.x; Patterson S, 2008, J IMMUNOL, V181, P3268, DOI 10.4049/jimmunol.181.5.3268; Pillai AB, 2007, J IMMUNOL, V178, P6242, DOI 10.4049/jimmunol.178.10.6242; Ringden O, 2004, J CLIN ONCOL, V22, P416, DOI 10.1200/JCO.2004.06.102; Rowe V, 2006, BLOOD, V108, P2485, DOI 10.1182/blood-2006-04-016063; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Vremec D, 2000, J IMMUNOL, V164, P2978, DOI 10.4049/jimmunol.164.6.2978; Westerhof GR, 2000, CANCER RES, V60, P5470; Zeng DF, 1999, J EXP MED, V189, P1073, DOI 10.1084/jem.189.7.1073	30	53	58	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					436	441		10.1038/nm.1948	http://dx.doi.org/10.1038/nm.1948			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19330008				2022-12-27	WOS:000264937200031
J	Lorenz, K; Schmitt, JP; Schmitteckert, EM; Lohse, MJ				Lorenz, Kristina; Schmitt, Joachim P.; Schmitteckert, Eva M.; Lohse, Martin J.			A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; BETA-GAMMA-SUBUNITS; SIGNAL-REGULATED KINASES-1/2; CHRONIC PRESSURE-OVERLOAD; HEART-FAILURE; MYOCARDIAL HYPERTROPHY; CARDIOMYOCYTE HYPERTROPHY; NUCLEAR TRANSLOCATION; MAP KINASES; IN-VIVO	The extracellular-regulated kinases ERK1 and ERK2 (commonly referred to as ERK1/2) have a crucial role in cardiac hypertrophy. ERK1/2 is activated by mitogen-activated protein kinase kinase-1 (MEK1) and MEK2 (commonly referred to as MEK1/2)-dependent phosphorylation in the TEY motif of the activation loop, but how ERK1/2 is targeted toward specific substrates is not well understood. Here we show that autophosphorylation of ERK1/2 on Thr188 directs ERK1/2 to phosphorylate nuclear targets known to cause cardiac hypertrophy. Thr188 autophosphorylation requires the activation and assembly of the entire Raf-MEK-ERK kinase cascade, phosphorylation of the TEY motif, dimerization of ERK1/2 and binding to G protein beta gamma subunits released from activated G(q). Thr188 phosphorylation of ERK1/2 was observed in isolated cardiomyocytes induced to undergo hypertrophic growth, in mice upon stimulation of G(q)-coupled receptors or after aortic banding and in failing human hearts. Experiments using transgenic mouse models carrying mutations at the Thr188 phosphorylation site of ERK2 suggested a causal relationship to cardiac hypertrophy. We propose that specific phosphorylation events on ERK1/2 integrate differing upstream signals (Raf1-MEK1/2 or G protein-coupled receptor-G(q)) to induce cardiac hypertrophy.	[Lorenz, Kristina; Schmitt, Joachim P.; Schmitteckert, Eva M.; Lohse, Martin J.] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; [Schmitteckert, Eva M.; Lohse, Martin J.] Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany	University of Wurzburg; German Research Foundation (DFG); University of Wurzburg	Lorenz, K (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lorenz@toxi.uni-wuerzburg.de	Schmitt, Joachim/GQP-7068-2022; Lohse, Martin J/A-7160-2012; Lorenz, Kristina/F-3522-2016	Lohse, Martin J/0000-0002-0599-3510; Lorenz, Kristina/0000-0002-5747-2207	Deutsche Forschungsgemeinschaft; Leducq Foundation and the Fonds der Chemischen Industrie	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Leducq Foundation and the Fonds der Chemischen Industrie	We wish to thank U. Quitterer for stimulating discussions during the early phase of this work; M. Maier-Peuschel, M. Vidal, K. Dei ,D. Calebiro, K. Hadameck, M. Frank, K. von Hayn and A. Zurn for their help; M. Fischer, M. Babl, M. Hoffmann, N. Ziegler and C. Dees for excellent technical assistance; S. Jacobs for help with the immunohistochemistry; and U. Zabel and R. Schreck for helpful discussion. This work was supported by the Deutsche Forschungsgemeinschaft, the Leducq Foundation and the Fonds der Chemischen Industrie.	Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Baliga RR, 1999, AM J PHYSIOL-HEART C, V277, pH2026, DOI 10.1152/ajpheart.1999.277.5.H2026; Bogoyevitch MA, 1996, INT J BIOCHEM CELL B, V28, P1, DOI 10.1016/1357-2725(95)00142-5; Brown JH, 1997, LIFE SCI, V60, P1077; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; FAURE M, 1994, J BIOL CHEM, V269, P7851; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Haq S, 2001, CIRCULATION, V103, P670; Hartkamp J, 1999, CANCER RES, V59, P2195; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Li Z, 2003, GENE THER, V10, P1354, DOI 10.1038/sj.gt.3301995; Lips DJ, 2003, EUR HEART J, V24, P883, DOI 10.1016/S0195-668X(02)00829-1; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Luo JS, 2008, MOL PHARMACOL, V74, P338, DOI 10.1124/mol.107.044750; Luttrell LM, 2003, J MOL ENDOCRINOL, V30, P117, DOI 10.1677/jme.0.0300117; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; Muslin AJ, 2005, TRENDS CARDIOVAS MED, V15, P225, DOI 10.1016/j.tcm.2005.06.008; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Purcell NH, 2007, P NATL ACAD SCI USA, V104, P14074, DOI 10.1073/pnas.0610906104; Rohrbach S, 1999, CIRCULATION, V100, P407, DOI 10.1161/01.CIR.100.4.407; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Sakata Y, 1998, CIRCULATION, V97, P1488; Samarel AM, 2001, J MOL CELL CARDIOL, V33, P1637, DOI 10.1006/jmcc.2001.1427; Schmitt JP, 2003, CIRCULATION, V108, P1133, DOI 10.1161/01.CIR.0000086469.85750.48; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Slupsky JR, 1999, CURR BIOL, V9, P971, DOI 10.1016/S0960-9822(99)80426-6; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Tachibana H, 2005, CIRCULATION, V111, P591, DOI 10.1161/01.CIR.0000142291.70954.DF; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Valks DM, 2002, J MOL CELL CARDIOL, V34, P749, DOI 10.1006/jmcc.2002.2014; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Zhong WG, 2006, EMBO J, V25, P3869, DOI 10.1038/sj.emboj.7601252	47	163	173	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2009	15	1					75	83		10.1038/nm.1893	http://dx.doi.org/10.1038/nm.1893			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19060905				2022-12-27	WOS:000262425100021
J	Chung, WH; Hung, SI; Yang, JY; Su, SC; Huang, SP; Wei, CY; Chin, SW; Chiou, CC; Chu, SC; Ho, HC; Yang, CH; Lu, CF; Wu, JY; Liao, YD; Chen, YT				Chung, Wen-Hung; Hung, Shuen-Iu; Yang, Jui-Yung; Su, Shih-Chi; Huang, Shien-Ping; Wei, Chun-Yu; Chin, See-Wen; Chiou, Chien-Chun; Chu, Sung-Chao; Ho, Hsin-Chun; Yang, Chih-Hsun; Lu, Chi-Fang; Wu, Jer-Yuarn; Liao, You-Di; Chen, Yuan-Tsong			Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis	NATURE MEDICINE			English	Article							SOLUBLE FAS LIGAND; CYTOTOXIC T-CELLS; CYTOLYTIC MOLECULE; INDUCED APOPTOSIS; MARKER; MECHANISM; SERUM	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening adverse drug reactions characterized by massive epidermal necrosis, in which the specific danger signals involved remain unclear. Here we show that blister cells from skin lesions of SJS-TEN primarily consist of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and both blister fluids and cells were cytotoxic. Gene expression profiling identified granulysin as the most highly expressed cytotoxic molecule, confirmed by quantitative PCR and immunohistochemistry. Granulysin concentrations in the blister fluids were two to four orders of magnitude higher than perforin, granzyme B or soluble Fas ligand concentrations, and depleting granulysin reduced the cytotoxicity. Granulysin in the blister fluids was a 15-kDa secretory form, and injection of it into mouse skin resulted in features mimicking SJS-TEN. Our findings demonstrate that secretory granulysin is a key molecule responsible for the disseminated keratinocyte death in SJS-TEN and highlight a mechanism for CTL- or NK cell-mediated cytotoxicity that does not require direct cellular contact.	[Chung, Wen-Hung; Hung, Shuen-Iu; Su, Shih-Chi; Huang, Shien-Ping; Wei, Chun-Yu; Wu, Jer-Yuarn; Liao, You-Di; Chen, Yuan-Tsong] Acad Sinica, Taiwan Int Grad Program, Program Mol Med, Inst Biomed Sci, Taipei 115, Taiwan; [Chung, Wen-Hung; Chiou, Chien-Chun; Ho, Hsin-Chun; Yang, Chih-Hsun] Chang Gung Univ, Dept Dermatol, Chang Gung Mem Hosp, Coll Med, Taipei 105, Taiwan; [Chung, Wen-Hung] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Sch Life Sci, Taipei 112, Taiwan; [Hung, Shuen-Iu; Chin, See-Wen] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; [Yang, Jui-Yung] Chang Gung Univ, Linkou Burn Ctr, Taipei 105, Taiwan; [Yang, Jui-Yung] Chang Gung Univ, Dept Plast Surg, Chang Gung Mem Hosp, Coll Med, Taipei 105, Taiwan; [Chu, Sung-Chao] Buddhist Tzu Chi Gen Hosp, Div Hematol & Oncol, Hualien 971, Taiwan; [Lu, Chi-Fang] Chung Shan Hosp, Dept Dermatol, Taipei 105, Taiwan; [Chen, Yuan-Tsong] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Academia Sinica - Taiwan; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Duke University	Chen, YT (corresponding author), Acad Sinica, Taiwan Int Grad Program, Program Mol Med, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	chen0010@ibms.sinica.edu.tw	Liao, You-Di/S-7018-2018; Wu, Jer-Yuarn/S-7010-2018; Hung, Shuen-Iu/HHS-9012-2022; Hung, Shuen-Iu/ABB-2139-2021	Liao, You-Di/0000-0001-5527-4736; Hung, Shuen-Iu/0000-0001-6531-5538	National Science Council, Taiwan [NSC95-2314-B-182A-048, 95-2314-B-010-096, 96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2]; Chang-Gung Memorial Hospital, Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); National Research Program for Genomic Medicine, Taiwan [NSC-95-3112-B-001-010, NSC-95-3112-B-001-011]; Genomics and Proteomics Program, Academia Sinica	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Chang-Gung Memorial Hospital, Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University)(Ministry of Education, Taiwan); National Research Program for Genomic Medicine, Taiwan(Ministry of Science and Technology, Taiwan); Genomics and Proteomics Program, Academia Sinica(Academia Sinica - Taiwan)	DH4 monoclonal antibody was a gift from A. M. Krensky (Stanford University). We thank H.-J. Lin, S.-J. Li, K.-H. Chen, L.-H. Lu of the Institute of Biomedical Sciences, Academia Sinica and members of the National Microarray & Gene Expression Analysis Core Facility, National Yang-Ming University, Taiwan, for excellent technical assistance. This work was supported by grants from the National Science Council, Taiwan (NSC95-2314-B-182A-048, 95-2314-B-010-096, 96-2320-B-010-021-MY2 and 96-2628-B-182A-065-MY2), Chang-Gung Memorial Hospital, Taiwan Ministry of Education (Aim for the Top University Plan, National Yang-Ming University), National Research Program for Genomic Medicine, Taiwan (National Clinical Core, NSC-95-3112-B-001-010 and National Genotyping Core, NSC-95-3112-B-001-011) and the Genomics and Proteomics Program, Academia Sinica.	Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Anderson DH, 2003, J MOL BIOL, V325, P355, DOI 10.1016/S0022-2836(02)01234-2; Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; Bronnimann M, 2005, CURR OPIN ALLERGY CL, V5, P317; Chave TA, 2005, BRIT J DERMATOL, V153, P241, DOI 10.1111/j.1365-2133.2005.06721.x; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Correia O, 2001, DERMATOLOGY, V203, P212, DOI 10.1159/000051751; Deng AM, 2005, J IMMUNOL, V174, P5243, DOI 10.4049/jimmunol.174.9.5243; Gamen S, 1998, J IMMUNOL, V161, P1758; Gomes ER, 2005, CURR OPIN ALLERGY CL, V5, P309, DOI 10.1097/01.all.0000173785.81024.33; Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Krensky AM, 2005, AM J TRANSPLANT, V5, P1789, DOI 10.1111/j.1600-6143.2005.00970.x; Nagasawa M, 2006, AM J HEMATOL, V81, P340, DOI 10.1002/ajh.20570; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Ogawa K, 2003, EUR J IMMUNOL, V33, P1925, DOI 10.1002/eji.200323977; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Pena SV, 1997, J IMMUNOL, V158, P2680; Pereira FA, 2007, J AM ACAD DERMATOL, V56, P181, DOI 10.1016/j.jaad.2006.04.048; Quinn AM, 2005, ARCH DERMATOL, V141, P683, DOI 10.1001/archderm.141.6.683; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1994, J INVEST DERMATOL, V102, P28; Roujeau Jean-Claude, 2006, Allergol Int, V55, P27, DOI 10.2332/allergolint.55.27; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stur K, 2007, J INVEST DERMATOL, V127, P802, DOI 10.1038/sj.jid.5700648; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490	28	477	520	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1343	1350		10.1038/nm.1884	http://dx.doi.org/10.1038/nm.1884			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029983				2022-12-27	WOS:000261393600018
J	Soares, MM; King, SW; Thorpe, PE				Soares, M. Melina; King, Steven W.; Thorpe, Philip E.			Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases	NATURE MEDICINE			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; CHRONIC HEPATITIS-C; LIPID RAFTS; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; ANIONIC PHOSPHOLIPIDS; INFLUENZA-VIRUSES; DENDRITIC CELLS; ACTINOMYCIN-D; ANNEXIN-V	There is a pressing need for antiviral agents that are effective against multiple classes of viruses. Broad specificity might be achieved by targeting phospholipids that are widely expressed on infected host cells or viral envelopes. We reasoned that events occurring during virus replication (for example, cell activation or preapoptotic changes) would trigger the exposure of normally intracellular anionic phospholipids on the outer surface of virus-infected cells. A chimeric antibody, bavituximab, was used to identify and target the exposed anionic phospholipids. Infection of cells with Pichinde virus (a model for Lassa fever virus, a potential bioterrorism agent) led to the exposure of anionic phospholipids. Bavituximab treatment cured overt disease in guinea pigs lethally infected with Pichinde virus. Direct clearance of infectious virus from the blood and antibody-dependent cellular cytotoxicity of virus-infected cells seemed to be the major antiviral mechanisms. Combination therapy with bavituximab and ribavirin was more effective than either drug alone. Bavituximab also bound to cells infected with multiple other viruses and rescued mice with lethal mouse cytomegalovirus infections. Targeting exposed anionic phospholipids with bavituximab seems to be safe and effective. Our study demonstrates that anionic phospholipids on infected host cells and virions may provide a new target for the generation of antiviral agents.	[Soares, M. Melina; Thorpe, Philip E.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [King, Steven W.] Peregrine Pharmaceut Inc, Tustin, CA 92780 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Thorpe, PE (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Philip.Thorpe@UTSouthwestern.edu			US National Institutes of Health [5 U01 AI1056412]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056412] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Rabbit Pichinde-specific antiserum was a gift from J. Aronson, University of Texas Medical Branch, Galveston. This work was supported by a US National Institutes of Health grant (5 U01 AI1056412) and a sponsored research agreement with Peregrine Pharmaceuticals. We thank G. Barbero, S. Mims, H. Arizpe, L. Ingram, S. Syed, L. Watkins, S. Li and J. Iglehart for technical assistance. We also thank W. Bresnahan, S. Ran, O. Ramilo, H. Jafri, S. Fussey, M. Roth and J. Albanesi for discussions and comments on the manuscript.	Bakht O, 2007, BIOPHYS J, V93, P4307, DOI 10.1529/biophysj.107.114967; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Briggs JAG, 2003, J GEN VIROL, V84, P757, DOI 10.1099/vir.0.18779-0; Brown G, 2002, J GEN VIROL, V83, P1841, DOI 10.1099/0022-1317-83-8-1841; Callahan MK, 2003, J IMMUNOL, V170, P4840, DOI 10.4049/jimmunol.170.9.4840; Chen X, 2004, J IMMUNOL, V173, P2985, DOI 10.4049/jimmunol.173.5.2985; Choe W, 2002, J VIROL, V76, P5274, DOI 10.1128/JVI.76.10.5274-5277.2002; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; de Laat B, 2006, BLOOD, V107, P1916, DOI 10.1182/blood-2005-05-1943; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Ferguson TA, 2002, J IMMUNOL, V168, P5589, DOI 10.4049/jimmunol.168.11.5589; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Gautier I, 2003, EXP CELL RES, V289, P174, DOI 10.1016/S0014-4827(03)00258-1; Godofsky EW, 2006, HEPATOLOGY, V44, p236A; Hoffmann PR, 2005, J IMMUNOL, V174, P1393, DOI 10.4049/jimmunol.174.3.1393; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Huang RTC, 1996, FEBS LETT, V392, P59, DOI 10.1016/0014-5793(96)00783-1; JAHRLING PB, 1981, INFECT IMMUN, V32, P872, DOI 10.1128/IAI.32.2.872-880.1981; Lawitz EJ, 2007, HEPATOLOGY, V46, p257A; LUKASHEVICH IS, 1984, VOP VIRUSOL+, P569; Luster TA, 2006, J BIOL CHEM, V281, P29863, DOI 10.1074/jbc.M605252200; MARCONESCU A, BIOCH BIOPHYS ACTA, V1778, P2217; Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PRYZDIAL ELG, 1994, BLOOD, V84, P3749, DOI 10.1182/blood.V84.11.3749.bloodjournal84113749; Ran S, 2005, CLIN CANCER RES, V11, P1551, DOI 10.1158/1078-0432.CCR-04-1645; RAWLS WE, 1976, J GEN VIROL, V33, P421, DOI 10.1099/0022-1317-33-3-421; Sanchez V, 2002, SCIENCE, V297, P778, DOI 10.1126/science.1075102; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Sutherland MR, 1997, P NATL ACAD SCI USA, V94, P13510, DOI 10.1073/pnas.94.25.13510; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	40	144	155	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1357	1362		10.1038/nm.1885	http://dx.doi.org/10.1038/nm.1885			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029986	Green Accepted			2022-12-27	WOS:000261393600020
J	Broady, R; Levings, MK				Broady, Raewyn; Levings, Megan K.			Graft-versus-host disease: suppression by statins	NATURE MEDICINE			English	Editorial Material							COA REDUCTASE INHIBITION; LEUKEMIA; THERAPY; CELLS		[Broady, Raewyn] Univ British Columbia, Dept Med, Vancouver, BC V6H 3Z6, Canada; [Levings, Megan K.] Univ British Columbia, Dept Surg, Vancouver, BC V6H 3Z6, Canada; [Levings, Megan K.] Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Broady, R (corresponding author), Univ British Columbia, Dept Med, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	mlevings@interchange.ubc.ca		Levings, Megan/0000-0002-0305-5790				Allan SE, 2008, IMMUNOL REV, V223, P391, DOI 10.1111/j.1600-065X.2008.00634.x; Chen X, 2007, BLOOD, V110, P3804, DOI 10.1182/blood-2007-05-091074; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hamadani M, 2008, BLOOD, V111, P3901, DOI 10.1182/blood-2008-01-132050; Hori A, 2005, TRANSPLANTATION, V79, P372, DOI 10.1097/01.TP.0000151001.64189.1D; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Mason RP, 2005, AM J CARDIOL, V96, p11F, DOI 10.1016/j.amjcard.2005.06.008; Mausner-Fainberg K, 2008, ATHEROSCLEROSIS, V197, P829, DOI 10.1016/j.atherosclerosis.2007.07.031; Mira E, 2008, J IMMUNOL, V181, P3524, DOI 10.4049/jimmunol.181.5.3524; Welniak LA, 2007, ANNU REV IMMUNOL, V25, P139, DOI 10.1146/annurev.immunol.25.022106.141606; Zeiser R, 2007, BLOOD, V110, P4588, DOI 10.1182/blood-2007-08-106005; Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988	12	39	44	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1155	1156		10.1038/nm1108-1155	http://dx.doi.org/10.1038/nm1108-1155			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18989280				2022-12-27	WOS:000260751200015
J	Kattah, MG; Coller, J; Cheung, RK; Oshidary, N; Utz, PJ				Kattah, Michael G.; Coller, John; Cheung, Regina K.; Oshidary, Neekaan; Utz, Paul J.			HIT: a versatile proteomics platform for multianalyte phenotyping of cytokines, intracellular proteins and surface molecules	NATURE MEDICINE			English	Article							ROLLING-CIRCLE AMPLIFICATION; T-CELLS; AUTOIMMUNE-DISEASES; PROXIMITY LIGATION; MICROARRAYS; ANTIBODIES; ANTIGEN; ACTIVATION; 2-COLOR; SERUM	We have developed a multianalyte fluid-phase protein array technology termed high-throughput immunophenotyping using transcription (HIT). This method employs a panel of monoclonal antibodies, each tagged with a unique oligonucleotide sequence that serves as a molecular bar code. After staining a sample, T7 polymerase amplifies the tags, which are then hybridized to a DNA microarray for indirect measurement of each analyte. Although there are many potential applications for this technology, here we report its suitability for profiling cytokines, intracellular molecules and cell surface markers. Using HIT, we profiled 90 surface markers on human naive T helper cells activated in vitro. The markers identified in this screen are consistent with previously described activation markers and were validated by flow cytometry. Additionally, a HIT screen of surface markers expressed on T helper cells activated in the presence of transforming growth factor-beta identified downregulation of CD26 in these cells. HIT arrays are an ideal platform for rapidly identifying markers for further characterization and therapeutic intervention.	[Kattah, Michael G.; Cheung, Regina K.; Oshidary, Neekaan; Utz, Paul J.] Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA; [Coller, John] Stanford Univ, Sch Med, Stanford Funct Genom Facil, Stanford, CA 94305 USA	Stanford University; Stanford University	Utz, PJ (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.	pjutz@stanford.edu		Kattah, Michael/0000-0002-6067-6585	Stanford Program in Immunology [5 T32 AI07290]; US National Institutes of Health [DK61934, AI50854, AI50865, AR49328]; National Heart, Lung, and Blood Institute Proteomics [N01-HV-28183]; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR049328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER	Stanford Program in Immunology; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute Proteomics(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank S. Chan, D. Thibault, J. Mollick, P. Teo, A. Venteicher, S. Wrenn, R. Tibshirani, M. Schaner, J. Chi and other members of our laboratory for helpful discussion and technical assistance. We thank A. Ting (Massachusetts Institute of Technology) for kindly providing mSA plasmids. We also thank the Stanford University Human Immune Monitoring Center for assistance with Luminex cytokine data acquisition. M. G. K. was funded by the Stanford Medical Scientist Training Program and the Floren Family Trust. N. O. was funded by the Center for Clinical Immunology at Stanford Summer Research Program and the Northern California Chapter of the Arthritis Foundation. R. K. C. was funded by the Stanford Program in Immunology training grant 5 T32 AI07290. P. J. U. is the recipient of a Donald E. and Delia B. Baxter Foundation Career Development Award and was supported by the Dana Foundation, the Floren Family Trust, the Northern California Chapter of the Arthritis Foundation, US National Institutes of Health Grants DK61934, AI50854, AI50865 and AR49328 and National Heart, Lung, and Blood Institute Proteomics Contract N01-HV-28183.	Balboni I, 2006, ANNU REV IMMUNOL, V24, P391, DOI 10.1146/annurev.immunol.24.021605.090709; Belov L, 2006, BRIT J HAEMATOL, V135, P184, DOI 10.1111/j.1365-2141.2006.06266.x; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Brown JK, 2004, J HISTOCHEM CYTOCHEM, V52, P1219, DOI 10.1369/jhc.3A6200.2004; Chan SM, 2005, ANN NY ACAD SCI, V1062, P61, DOI 10.1196/annals.1358.009; Chan SM, 2004, NAT MED, V10, P1390, DOI 10.1038/nm1139; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Fathman CG, 2005, NATURE, V435, P605, DOI 10.1038/nature03726; Fredriksson S, 2007, NAT METHODS, V4, P327, DOI 10.1038/NMETH1020; Gullberg M, 2004, P NATL ACAD SCI USA, V101, P8420, DOI 10.1073/pnas.0400552101; HENDRICKSON ER, 1995, NUCLEIC ACIDS RES, V23, P522, DOI 10.1093/nar/23.3.522; Howarth M, 2006, NAT METHODS, V3, P267, DOI 10.1038/NMETH861; Kattah MG, 2006, NAT METHODS, V3, P745, DOI 10.1038/nmeth910; Kozlov IA, 2004, BIOPOLYMERS, V73, P621, DOI 10.1002/bip.20009; Krakauer M, 2006, J NEUROIMMUNOL, V181, P157, DOI 10.1016/j.jneuroim.2006.09.006; Love JC, 2006, NAT BIOTECHNOL, V24, P703, DOI 10.1038/nbt1210; Michaud GA, 2003, NAT BIOTECHNOL, V21, P1509, DOI 10.1038/nbt910; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Nielsen UB, 2003, P NATL ACAD SCI USA, V100, P9330, DOI 10.1073/pnas.1633513100; Niemeyer CM, 2005, TRENDS BIOTECHNOL, V23, P208, DOI 10.1016/j.tibtech.2005.02.006; Reinhold D, 1998, J NEUROIMMUNOL, V87, P203, DOI 10.1016/S0165-5728(98)00100-3; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Wong J, 2007, J EXP MED, V204, P2039, DOI 10.1084/jem.20070822; Zhang HT, 2001, P NATL ACAD SCI USA, V98, P5497, DOI 10.1073/pnas.101124598; Zhang HT, 2006, NAT MED, V12, P473, DOI 10.1038/nm1378; Zhou HP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r28	32	26	26	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1284	1289		10.1038/nm.1755	http://dx.doi.org/10.1038/nm.1755			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18849997	Green Accepted			2022-12-27	WOS:000260751200049
J	Pule, MA; Savoldo, B; Myers, GD; Rossig, C; Russell, HV; Dotti, G; Huls, MH; Liu, EL; Gee, AP; Mei, Z; Yvon, E; Weiss, HL; Liu, H; Rooney, CM; Heslop, HE; Brenner, MK				Pule, Martin A.; Savoldo, Barbara; Myers, G. Doug; Rossig, Claudia; Russell, Heidi V.; Dotti, Gianpietro; Huls, M. Helen; Liu, Enli; Gee, Adrian P.; Mei, Zhuyong; Yvon, Eric; Weiss, Heidi L.; Liu, Hao; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.			Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; ADOPTIVE TRANSFER; TRANSPLANT RECIPIENTS; METASTATIC MELANOMA; CANCER-THERAPY; LYMPHOCYTES; IMMUNOTHERAPY; IMMUNOSURVEILLANCE; EXPRESSION; STRATEGIES	Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long term and have limited antitumor activity in vivo, in part because such tumor cells typically lack the appropriate costimulatory molecules. We therefore engineered Epstein-Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neuroblastoma cells. We reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumor activity mediated through their chimeric receptors. Here we show in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity. Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells.	[Pule, Martin A.; Savoldo, Barbara; Myers, G. Doug; Rossig, Claudia; Russell, Heidi V.; Dotti, Gianpietro; Huls, M. Helen; Liu, Enli; Gee, Adrian P.; Mei, Zhuyong; Yvon, Eric; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Pule, Martin A.; Savoldo, Barbara; Myers, G. Doug; Rossig, Claudia; Russell, Heidi V.; Dotti, Gianpietro; Huls, M. Helen; Liu, Enli; Gee, Adrian P.; Mei, Zhuyong; Yvon, Eric; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.] Methodist Hosp, Houston, TX 77030 USA; [Pule, Martin A.; Savoldo, Barbara; Myers, G. Doug; Rossig, Claudia; Russell, Heidi V.; Dotti, Gianpietro; Huls, M. Helen; Liu, Enli; Gee, Adrian P.; Mei, Zhuyong; Yvon, Eric; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.] Texas Childrens Hosp, Houston, TX 77030 USA; [Myers, G. Doug; Russell, Heidi V.; Rooney, Cliona M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Dotti, Gianpietro; Gee, Adrian P.; Heslop, Helen E.; Brenner, Malcolm K.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Weiss, Heidi L.; Liu, Hao] Baylor Coll Med, Biostat Core Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Rooney, Cliona M.] Baylor Coll Med, Dept Virol, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Brenner, MK (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 6621 Fannin St, Houston, TX 77030 USA.	mbrenner@bcm.edu	Rooney, Cliona/ABD-5475-2021; Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019; Wilson, Matthew H/K-3193-2013	Pule, Martin/0000-0002-8347-9867	US National Institutes of Health [PO1 CA94237]; General Clinical Research Centers at Baylor College of Medicine [RR00188]; NATIONAL CANCER INSTITUTE [P01CA094237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000188, M01RR000188] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Clinical Research Centers at Baylor College of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Maloney murine leukemia virus-based vector was generously provided by R. C. Mulligan (Harvard Stem Cell Institute). This work was supported by grant PO1 CA94237 from the US National Institutes of Health, the General Clinical Research Centers at Baylor College of Medicine (RR00188) and a Doris Duke Distinguished Clinical Scientist Award to H. E. H.	Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bollard CM, 2007, BLOOD, V110, P2838, DOI 10.1182/blood-2007-05-091280; Bollard CM, 2004, J EXP MED, V200, P1623, DOI 10.1084/jem.20040890; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Cooper LJN, 2005, BLOOD, V105, P1622, DOI 10.1182/blood-2004-03-1208; FISHER B, 1989, J CLIN ONCOL, V7, P250, DOI 10.1200/JCO.1989.7.2.250; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Heemskerk MHM, 2004, J EXP MED, V199, P885, DOI 10.1084/jem.20031110; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jaffe CC, 2006, J CLIN ONCOL, V24, P3245, DOI 10.1200/JCO.2006.06.5599; June CH, 2007, J CLIN INVEST, V117, P1204, DOI 10.1172/JCI31446; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Khanna R, 2005, NAT CLIN PRACT ONCOL, V2, P138, DOI 10.1038/ncponc0107; Krance RA, 2003, BIOL BLOOD MARROW TR, V9, P273, DOI 10.1053/bbmt.2003.50024; Leen AM, 2007, ANNU REV IMMUNOL, V25, P243, DOI 10.1146/annurev.immunol.25.022106.141527; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; O'Reilly RJ, 2007, IMMUNOL RES, V38, P237, DOI 10.1007/s12026-007-0059-2; Park JR, 2007, MOL THER, V15, P825, DOI 10.1038/sj.mt.6300104; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Rossig C, 2006, J IMMUNOTHER, V29, P21, DOI 10.1097/01.cji.0000175492.28723.d6; Rossig C, 2002, BLOOD, V99, P2009, DOI 10.1182/blood.V99.6.2009; Sadelain M, 2003, NAT REV CANCER, V3, P35, DOI 10.1038/nrc971; Savoldo B, 2007, BLOOD, V110, P2620, DOI 10.1182/blood-2006-11-059139; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Stauss HJ, 2007, MOL THER, V15, P1744, DOI 10.1038/sj.mt.6300216; Stephan MT, 2007, NAT MED, V13, P1440, DOI 10.1038/nm1676; Straathof KCM, 2005, BLOOD, V105, P1898, DOI 10.1182/blood-2004-07-2975; Wahl SM, 2006, IMMUNOL REV, V213, P213, DOI 10.1111/j.1600-065X.2006.00437.x; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	39	881	994	3	98	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1264	1270		10.1038/nm.1882	http://dx.doi.org/10.1038/nm.1882			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18978797	Green Accepted, Green Submitted			2022-12-27	WOS:000260751200046
J	Tager, AM; LaCamera, P; Shea, BS; Campanella, GS; Selman, M; Zhao, Z; Polosukhin, V; Wain, J; Karimi-Shah, BA; Kim, ND; Hart, WK; Pardo, A; Blackwell, TS; Xu, Y; Chun, J; Luster, AD				Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.			The lysophosphatidic acid receptor LPA(1) links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak	NATURE MEDICINE			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; EDG-FAMILY; RHO-KINASE; FIBROCYTES; EXPRESSION; MIGRATION; CELLS; IDENTIFICATION; INFLAMMATION; REQUIREMENT	Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA(1), are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.	[Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Luster, Andrew D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Div Rheumatol Allergy & Im, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA; [Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Karimi-Shah, Banu A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02129 USA; [Selman, Moises] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico; [Zhao, Zhenwen; Xu, Yan] Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; [Polosukhin, Vasiliy; Blackwell, Timothy S.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Wain, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Thorac Surg, Boston, MA 02114 USA; [Pardo, Annie] Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico; [Chun, Jerold] Scripps Res Inst, Helen L Dorris Inst Neurol & Psychiat Disorders, Dept Mol Biol, La Jolla, CA 92037 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; Vanderbilt University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Universidad Nacional Autonoma de Mexico; Scripps Research Institute	Luster, AD (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Div Rheumatol Allergy & Im, Ctr Immunol & Inflammatory Dis, CNY149-8301,149 13th St, Boston, MA 02129 USA.	aluster@mgh.harvard.edu	Pardo, Annie/A-4746-2008; Chun, Jerold/Y-4670-2019; Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NCI NIH HHS [R01-CA89228, R01-CA69212, R01-CA095042] Funding Source: Medline; NIMH NIH HHS [K02-MH01723, R01-MH51699] Funding Source: Medline; NINDS NIH HHS [R01-NS048478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095042, R01CA069212, R01CA089228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051699, K02MH001723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048478] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; BASSET F, 1986, AM J PATHOL, V122, P443; BEHR J, 1993, THORAX, V48, P736, DOI 10.1136/thx.48.7.736; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Chambers RC, 2002, BIOCHEM SOC T, V30, P194, DOI 10.1042/BST0300194; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; DiNubile MJ, 2007, AM J PHYSIOL-CELL PH, V292, pC1240, DOI 10.1152/ajpcell.00007.2007; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fireman E, 2001, LUNG, V179, P105, DOI 10.1007/s004080000051; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; HONDA Y, 1988, LUNG, V166, P293, DOI 10.1007/BF02714060; Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kim ND, 2006, J EXP MED, V203, P829, DOI 10.1084/jem.20052349; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Lawson WE, 2005, AM J RESP CRIT CARE, V171, P899, DOI 10.1164/rccm.200311-1535OC; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MAINO VC, 1995, CYTOMETRY, V20, P127, DOI 10.1002/cyto.990200205; Martinez A, 1997, ANN HEMATOL, V75, P81, DOI 10.1007/s002770050318; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Medoff BD, 2005, J EXP MED, V202, P97, DOI 10.1084/jem.20042481; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moore BB, 2005, AM J PATHOL, V166, P675, DOI 10.1016/S0002-9440(10)62289-4; Moore BB, 2006, AM J RESP CELL MOL, V35, P175, DOI 10.1165/rcmb.2005-0239OC; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Neidlinger NA, 2006, J BIOL CHEM, V281, P775, DOI 10.1074/jbc.M505790200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; PICKER LJ, 1990, J IMMUNOL, V145, P3247; Reutershan J, 2006, J CLIN INVEST, V116, P695, DOI 10.1172/JCI27009; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Selman M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000482; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sugimoto N, 2006, EXP CELL RES, V312, P1899, DOI 10.1016/j.yexcr.2006.02.020; Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; ZHANG K, 1994, AM J PATHOL, V145, P114; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	50	545	597	4	50	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					45	54		10.1038/nm1685	http://dx.doi.org/10.1038/nm1685			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18066075				2022-12-27	WOS:000252222400021
J	Santra, S; Liao, HX; Zhang, RJ; Muldoon, M; Watson, S; Fischer, W; Theiler, J; Szinger, J; Balachandran, H; Buzby, A; Quinn, D; Parks, RJ; Tsao, CY; Carville, A; Mansfield, KG; Pavlakis, GN; Felber, BK; Haynes, BF; Korber, BT; Letvin, NL				Santra, Sampa; Liao, Hua-Xin; Zhang, Ruijin; Muldoon, Mark; Watson, Sydeaka; Fischer, Will; Theiler, James; Szinger, James; Balachandran, Harikrishnan; Buzby, Adam; Quinn, David; Parks, Robert J.; Tsao, Chun-Yen; Carville, Angela; Mansfield, Keith G.; Pavlakis, George N.; Felber, Barbara K.; Haynes, Barton F.; Korber, Bette T.; Letvin, Norman L.			Mosaic vaccines elicit CD8(+) T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL RESPONSES; RHESUS-MONKEYS; AIDS	An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses(1,2). It must generate CD8(+) T lymphocytes that control HIV replication and CD4(+) T lymphocytes that provide help for the generation and maintenance of both cellular and humoral immune responses against the virus(3-5). Creating immunogens that can elicit cellular immune responses against the genetically varied circulating isolates of HIV presents a key challenge for creating an HIV vaccine(6,7). Polyvalent mosaic immunogens derived by in silico recombination of natural strains of HIV are designed to induce cellular immune responses that recognize genetically diverse circulating virus isolates(8). Here we immunized rhesus monkeys by plasmid DNA prime and recombinant vaccinia virus boost with vaccine constructs expressing either consensus or polyvalent mosaic proteins. As compared to consensus immunogens, the mosaic immunogens elicited CD8(+) T lymphocyte responses to more epitopes of each viral protein than did the consensus immunogens and to more variant sequences of CD8(+) T lymphocyte epitopes. This increased breadth and depth of epitope recognition may contribute both to protection against infection by genetically diverse viruses and to the control of variant viruses that emerge as they mutate away from recognition by cytotoxic T lymphocytes.	[Santra, Sampa; Balachandran, Harikrishnan; Buzby, Adam; Quinn, David; Letvin, Norman L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Liao, Hua-Xin; Zhang, Ruijin; Parks, Robert J.; Tsao, Chun-Yen; Haynes, Barton F.] Duke Univ, Med Ctr, Durham, NC USA; [Muldoon, Mark] Univ Manchester, Sch Math, Manchester, Lancs, England; [Watson, Sydeaka; Fischer, Will; Theiler, James; Szinger, James; Korber, Bette T.] Los Alamos Natl Lab, Los Alamos, NM USA; [Watson, Sydeaka] Baylor Univ, Dept Stat Sci, Waco, TX 76798 USA; [Carville, Angela; Mansfield, Keith G.] New England Reg Primate Res Ctr, Southborough, MA 01772 USA; [Pavlakis, George N.; Felber, Barbara K.] NCI, NIH, Frederick, MD 21701 USA; [Korber, Bette T.] Santa Fe Inst, Santa Fe, NM 87501 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Duke University; University of Manchester; United States Department of Energy (DOE); Los Alamos National Laboratory; Baylor University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Santa Fe Institute	Letvin, NL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	nletvin@bidmc.harvard.edu	Quinn, David/N-3730-2019; Fischer, Will/B-1323-2013; Muldoon, Mark/T-9192-2019; Fischer, Will/AAD-2807-2019; Muldoon, Mark R/C-7505-2009	Quinn, David/0000-0002-1411-0417; Fischer, Will/0000-0003-4579-4062; Fischer, Will/0000-0003-4579-4062; Muldoon, Mark/0000-0002-5004-7195; Quinn, David/0000-0002-5335-8968; Szinger, James/0000-0002-6605-9940; Korber, Bette/0000-0002-2026-5757; Balachandran, Harikrishnan/0000-0001-9336-0555	US National Institutes of Health [AI-0678501]; HIV Research and Design (HIVRAD) [P01 AI-61734]; National Institute of Allergy and Infectious Diseases [N01 AI-50010]; Los Alamos National Laboratory; NATIONAL CANCER INSTITUTE [ZIABC010350, ZIABC010749] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HIV Research and Design (HIVRAD); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Los Alamos National Laboratory(United States Department of Energy (DOE)Los Alamos National Laboratory); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G. Tomaras for generous advice and assistance with reagents and antibody data. We also thank C. Lord for assistance with reagents. This work was supported by US National Institutes of Health grant AI-0678501 (Center for HIV AIDS Vaccine Immunology), HIV Research and Design (HIVRAD) P01 AI-61734, National Institute of Allergy and Infectious Diseases contract N01 AI-50010 and a Los Alamos National Laboratory-directed research grant to B. T. K., W. F. and S. W.	Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352; Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Fischer W, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040015; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Harari A, 2008, J EXP MED, V205, P63, DOI 10.1084/jem.20071331; HEENEY JL, 2004, EXPERT REV VACCINES, V3, pE53; Kong WP, 2009, J VIROL, V83, P2201, DOI 10.1128/JVI.02256-08; Korber BT, 2009, J VIROL, V83, P8300, DOI 10.1128/JVI.00114-09; Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605; Moss CX, 2007, EMBO J, V26, P2137, DOI 10.1038/sj.emboj.7601660; Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Santra S, 2004, P NATL ACAD SCI USA, V101, P11088, DOI 10.1073/pnas.0401954101; Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105; SETTE A, 1989, J IMMUNOL, V143, P1265	18	183	215	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					324	U122		10.1038/nm.2108	http://dx.doi.org/10.1038/nm.2108			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20173754	Green Accepted, Bronze			2022-12-27	WOS:000275289500039
J	Lai, YP; Di Nardo, A; Nakatsuji, T; Leichtle, A; Yang, Y; Cogen, AL; Wu, ZR; Hooper, LV; Schmidt, RR; von Aulock, S; Radek, KA; Huang, CM; Ryan, AF; Gallo, RL				Lai, Yuping; Di Nardo, Anna; Nakatsuji, Teruaki; Leichtle, Anke; Yang, Yan; Cogen, Anna L.; Wu, Zi-Rong; Hooper, Lora V.; Schmidt, Richard R.; von Aulock, Sonja; Radek, Katherine A.; Huang, Chun-Ming; Ryan, Allen F.; Gallo, Richard L.			Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury	NATURE MEDICINE			English	Article							NF-KAPPA-B; STAPHYLOCOCCUS-EPIDERMIDIS; NOSOCOMIAL INFECTIONS; HISTONE ACETYLATION; HUMAN KERATINOCYTES; LIPOTEICHOIC ACID; HOST-DEFENSE; CELLS; EXPRESSION; MODULATION	The normal microflora of the skin includes staphylococcal species that will induce inflammation when present below the dermis but are tolerated on the epidermal surface without initiating inflammation. Here we reveal a previously unknown mechanism by which a product of staphylococci inhibits skin inflammation. This inhibition is mediated by staphylococcal lipoteichoic acid (LTA) and acts selectively on keratinocytes triggered through Toll-like receptor 3(TLR3). We show that TLR3 activation is required for normal inflammation after injury and that keratinocytes require TLR3 to respond to RNA from damaged cells with the release of inflammatory cytokines. Staphylococcal LTA inhibits both inflammatory cytokine release from keratinocytes and inflammation triggered by injury through a TLR2-dependent mechanism. To our knowledge, these findings show for the first time that the skin epithelium requires TLR3 for normal inflammation after wounding and that the microflora can modulate specific cutaneous inflammatory responses.	[Lai, Yuping; Di Nardo, Anna; Nakatsuji, Teruaki; Cogen, Anna L.; Radek, Katherine A.; Huang, Chun-Ming; Gallo, Richard L.] Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA; [Lai, Yuping; Di Nardo, Anna; Nakatsuji, Teruaki; Leichtle, Anke; Cogen, Anna L.; Radek, Katherine A.; Huang, Chun-Ming; Ryan, Allen F.; Gallo, Richard L.] VA San Diego Healthcare Syst, San Diego, CA USA; [Leichtle, Anke; Ryan, Allen F.] Univ Calif San Diego, Dept Surg Otolaryngol, San Diego, CA 92103 USA; [Yang, Yan; Wu, Zi-Rong] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Hooper, Lora V.] Univ Texas SW Med Ctr Dallas, Dept Immunol, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Hooper, Lora V.] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Schmidt, Richard R.; von Aulock, Sonja] Univ Konstanz, Dept Chem, Constance, Germany; [Gallo, Richard L.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; East China Normal University; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Konstanz; University of California System; University of California San Diego	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA.	rgallo@ucsd.edu	Nakatsuji, Teruaki/O-6794-2014; von Aulock, Sonja/AGQ-3420-2022; Gallo, Richard L/A-8931-2009; Leichtle, Anke/GPW-7895-2022; di nardo, anna/AAI-1629-2020; Leichtle, Anke/AAA-3505-2020; , Chun-Ming/AAM-1856-2020	Nakatsuji, Teruaki/0000-0002-6187-2991; Gallo, Richard L/0000-0002-1401-7861; di nardo, anna/0000-0002-5575-9968; , Chun-Ming/0000-0002-3352-5394; Lai, Yuping/0000-0001-7445-6738	US National Institutes of Health [R56AI083358, R01AR052728, R01 AI052453, DC00129, DC006279]; US Veterans Administration Merit Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI083358, R01AI083358, R37AI052453, R01AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006279, R01DC000129] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Veterans Administration Merit Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank A. Peschel for advice regarding blocking LTA activity by the antibody; E. Raz from the University of California-San Diego for providing a C57BL/6 Tlr3-deficient mouse breeding pair; V. Nizet and E. Tistiskov for helpful discussion; G. Cheng, B. Beutler, R. Modlin and E. Raz for critical reading and helpful advice; and D. Bird for histological sections. This work was supported by US National Institutes of Health grants R56AI083358, R01AR052728 and R01 AI052453 and a US Veterans Administration Merit Award to R. L. G. and US National Institutes of Health grants DC00129 and DC006279 to A. F. R.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baker BS, 2003, BRIT J DERMATOL, V148, P670, DOI 10.1046/j.1365-2133.2003.05287.x; BIBEL DJ, 1983, CAN J MICROBIOL, V29, P700, DOI 10.1139/m83-114; Brown DL, 1997, SURGERY, V121, P372, DOI 10.1016/S0039-6060(97)90306-8; Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Fujimoto C, 2004, INT IMMUNOL, V16, P55, DOI 10.1093/intimm/dxh025; Ghosh TK, 2007, INT IMMUNOPHARMACOL, V7, P1111, DOI 10.1016/j.intimp.2007.04.006; Grundling A, 2007, P NATL ACAD SCI USA, V104, P8478, DOI 10.1073/pnas.0701821104; Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hooper LV, 2009, NAT REV MICROBIOL, V7, P367, DOI 10.1038/nrmicro2114; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kelly D, 2005, TRENDS IMMUNOL, V26, P326, DOI 10.1016/j.it.2005.04.008; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Lambert PA, 2000, FEMS IMMUNOL MED MIC, V29, P195, DOI 10.1111/j.1574-695X.2000.tb01523.x; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Netea MG, 2004, TRENDS MICROBIOL, V12, P484, DOI 10.1016/j.tim.2004.09.004; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Schauber J, 2008, J INVEST DERMATOL, V128, P816, DOI 10.1038/sj.jid.5701102; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Szpaderska AM, 2005, SURGERY, V137, P571, DOI 10.1016/j.surg.2005.01.006; Thompson AJ, 2007, IMMUNOL CELL BIOL, V85, P435, DOI 10.1038/sj.icb.7100100; TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167, DOI 10.1128/IAI.61.10.4167-4172.1993; Vandenbroucke K, 2004, GASTROENTEROLOGY, V127, P502, DOI 10.1053/j.gastro.2004.05.020; Vanhoutte F, 2008, IMMUNOL LETT, V116, P86, DOI 10.1016/j.imlet.2007.11.014; Weidenmaier C, 2004, NAT MED, V10, P243, DOI 10.1038/nm991; Wetzler C, 2000, J INVEST DERMATOL, V115, P245, DOI 10.1046/j.1523-1747.2000.00029.x; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Yoshioka M, 2007, J ALLERGY CLIN IMMUN, V120, P452, DOI 10.1016/j.jaci.2007.03.027; Ziebuhr W, 2006, INT J ANTIMICROB AG, V28, pS14, DOI 10.1016/j.ijantimicag.2006.05.012	39	484	510	2	68	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1377	U4		10.1038/nm.2062	http://dx.doi.org/10.1038/nm.2062			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966777	Green Accepted, Green Submitted			2022-12-27	WOS:000272407800017
J	Hutnick, NA; Carnathan, DG; Dubey, SA; Cox, KS; Kierstead, L; Ratcliffe, SJ; Robertson, MN; Casimiro, DR; Ertl, HCJ; Betts, MR				Hutnick, Natalie A.; Carnathan, Diane G.; Dubey, Sheri A.; Cox, Kara S.; Kierstead, Lisa; Ratcliffe, Sarah J.; Robertson, Michael N.; Casimiro, Danilo R.; Ertl, Hildegund C. J.; Betts, Michael R.			Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4(+) T cells	NATURE MEDICINE			English	Article							STEP; IMMUNITY; TYPE-5; GENE	The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4(+) T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4(+) T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4(+) T cells in increasing HIV-1 susceptibility in the STEP trial. (C) 2009 Nature America, Inc. All rights reserved.	[Hutnick, Natalie A.; Carnathan, Diane G.; Betts, Michael R.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Hutnick, Natalie A.; Carnathan, Diane G.; Betts, Michael R.] Univ Penn, Sch Med, Ctr AIDS Res, Philadelphia, PA 19104 USA; [Dubey, Sheri A.; Cox, Kara S.; Kierstead, Lisa; Robertson, Michael N.; Casimiro, Danilo R.] Merck Res Labs, West Point, PA USA; [Ratcliffe, Sarah J.] Univ Penn, Sch Med, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Ertl, Hildegund C. J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Merck & Company; University of Pennsylvania; The Wistar Institute	Betts, MR (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.	betts@mail.med.upenn.edu	Ratcliffe, Sarah J/GYR-1110-2022	Ratcliffe, Sarah J/0000-0002-6644-8284	US National Institutes of Health Integrated Preclinical/Clinical AIDS Vaccine Development [U19AI074078]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI074078] Funding Source: NIH RePORTER	US National Institutes of Health Integrated Preclinical/Clinical AIDS Vaccine Development; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by US National Institutes of Health Integrated Preclinical/Clinical AIDS Vaccine Development grant U19AI074078 to M. R. B. and H. C. J. E. R. Doms, F. Bushman and D. Weiner provided critical evaluation of this manuscript.	Aste-Amezaga M, 2004, HUM GENE THER, V15, P293, DOI 10.1089/104303404322886147; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; BURGER SR, 1991, J GEN VIROL, V72, P359, DOI 10.1099/0022-1317-72-2-359; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993; Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681; Xiang ZQ, 1996, VIROLOGY, V219, P220, DOI 10.1006/viro.1996.0239	9	78	82	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2009	15	8					876	878		10.1038/nm.1989	http://dx.doi.org/10.1038/nm.1989			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19620962	Green Accepted			2022-12-27	WOS:000268770400030
J	Reynolds, AR; Hart, IR; Watson, AR; Welti, JC; Silva, RG; Robinson, SD; Da Violante, G; Gourlaouen, M; Salih, M; Jones, MC; Jones, DT; Saunders, G; Kostourou, V; Perron-Sierra, F; Norman, JC; Tucker, GC; Hodivala-Dilke, KM				Reynolds, Andrew R.; Hart, Ian R.; Watson, Alan R.; Welti, Jonathan C.; Silva, Rita G.; Robinson, Stephen D.; Da Violante, Georges; Gourlaouen, Morgane; Salih, Mishal; Jones, Matt C.; Jones, Dylan T.; Saunders, Garry; Kostourou, Vassiliki; Perron-Sierra, Francoise; Norman, Jim C.; Tucker, Gordon C.; Hodivala-Dilke, Kairbaan M.			Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors	NATURE MEDICINE			English	Article							ADVANCED SOLID TUMORS; ENDOTHELIAL-CELLS; IN-VIVO; PATHOLOGICAL ANGIOGENESIS; ALPHA-V-BETA-3 INTEGRIN; CILENGITIDE EMD-121974; MALIGNANT GLIOMA; BREAST-CANCER; PHASE-I; ALPHA	Inhibitors of alpha(v)beta(3) and alpha(v)beta(5) integrin have entered clinical trials as antiangiogenic agents for cancer treatment but generally have been unsuccessful. Here we present in vivo evidence that low (nanomolar) concentrations of RGD-mimetic alpha(v)beta(3) and alpha(v)beta(5) inhibitors can paradoxically stimulate tumor growth and tumor angiogenesis. We show that low concentrations of these inhibitors promote VEGF-mediated angiogenesis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 trafficking, thereby promoting endothelial cell migration to VEGF. The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans.	[Reynolds, Andrew R.; Watson, Alan R.; Silva, Rita G.; Robinson, Stephen D.; Salih, Mishal; Jones, Dylan T.; Kostourou, Vassiliki; Hodivala-Dilke, Kairbaan M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Canc,John Vane Sci Ctr, Adhes & Angiogenesis Lab, London, England; [Hart, Ian R.] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Canc,John Vane Sci Ctr, Tumor Biol Ctr, London, England; [Reynolds, Andrew R.; Welti, Jonathan C.; Gourlaouen, Morgane] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Tumour Angiogenesis Grp, London SW3 6JB, England; [Da Violante, Georges] Technol Servier, Orleans, France; [Jones, Matt C.; Norman, Jim C.] Beatson Inst Canc Res, Integrin Cell Biol Lab, Glasgow G61 1BD, Lanark, Scotland; [Saunders, Garry] Canc Res UK London Res Inst, Clare Hall Labs, S Mimms, Herts, England; [Tucker, Gordon C.] Inst Rech Servier, Canc Res & Drug Discovery Div, Croissy Sur Seine, France	University of London; Queen Mary University London; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Servier; Beatson Institute; Cancer Research UK; Servier; Institut de Recherches Internationales Servier	Hodivala-Dilke, KM (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Canc,John Vane Sci Ctr, Adhes & Angiogenesis Lab, London, England.	andrew.reynolds@icr.ac.uk; Kairbaan.Hodivala-Dilke@cancer.org.uk	Silva, Rita/AAC-8021-2020	Welti, Jonathan/0000-0002-9433-8138; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X; NORMAN, Jim/0000-0002-0098-3014; Jones, Matthew/0000-0003-4723-3277; Kostourou, Vassiliki/0000-0001-7053-6247; Robinson, Stephen/0000-0002-6606-7588	Cancer Research UK Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Bailly M, 2000, MOL BIOL CELL, V11, P3873, DOI 10.1091/mbc.11.11.3873; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; Calabrese EJ, 2005, CRIT REV TOXICOL, V35, P463, DOI 10.1080/10408440591034502; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Chatterjee S, 2000, J NEURO-ONCOL, V46, P135, DOI 10.1023/A:1006444300504; Chen XY, 2004, CANCER RES, V64, P8009, DOI 10.1158/0008-5472.CAN-04-1956; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Dormond O, 2004, THROMB HAEMOSTASIS, V92, P151, DOI 10.1160/th03-11-0728; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Eskens FALM, 2003, EUR J CANCER, V39, P917, DOI 10.1016/S0959-8049(03)00057-1; Ewan LC, 2006, TRAFFIC, V7, P1270, DOI 10.1111/j.1600-0854.2006.00462.x; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Friess H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-285; Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484; Hariharan S, 2007, ANN ONCOL, V18, P1400, DOI 10.1093/annonc/mdm140; Haubner R, 2001, CANCER RES, V61, P1781; Hodivala-Dilke K, 2008, CURR OPIN CELL BIOL, V20, P514, DOI 10.1016/j.ceb.2008.06.007; Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Jekely G, 2005, DEV CELL, V9, P197, DOI 10.1016/j.devcel.2005.06.004; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080; Legler DF, 2001, J CELL SCI, V114, P1545; MacDonald TJ, 2001, NEUROSURGERY, V48, P151, DOI 10.1097/00006123-200101000-00026; Mahabeleshwar GH, 2006, J EXP MED, V203, P2495, DOI 10.1084/jem.20060807; Maubant S, 2006, BLOOD, V108, P3035, DOI 10.1182/blood-2006-05-023580; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Mitjans F, 2000, INT J CANCER, V87, P716, DOI 10.1002/1097-0215(20000901)87:5<716::AID-IJC14>3.3.CO;2-I; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nabors LB, 2007, J CLIN ONCOL, V25, P1651, DOI 10.1200/JCO.2006.06.6514; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nisato Riccardo E., 2003, Angiogenesis, V6, P105, DOI 10.1023/B:AGEN.0000011801.98187.f2; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Perron-Sierra F, 2002, BIOORG MED CHEM LETT, V12, P3291, DOI 10.1016/S0960-894X(02)00696-0; Prewett M, 1999, CANCER RES, V59, P5209; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Stupp R, 2007, J CLIN ONCOL, V25, P1637, DOI 10.1200/JCO.2006.09.8376; Taga T, 2002, INT J CANCER, V98, P690, DOI 10.1002/ijc.10265; Tucker Gordon C, 2006, Curr Oncol Rep, V8, P96, DOI 10.1007/s11912-006-0043-3; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3	53	366	383	1	89	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2009	15	4					392	400		10.1038/nm.1941	http://dx.doi.org/10.1038/nm.1941			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19305413				2022-12-27	WOS:000264937200026
J	Falkow, S				Falkow, Stanley			I never met a microbe I didn't like	NATURE MEDICINE			English	Editorial Material							POLYNUCLEOTIDE SEQUENCE RELATIONSHIPS; ESCHERICHIA-COLI K-12; HELICOBACTER-PYLORI; MOLECULAR NATURE; YERSINIA-ENTEROCOLITICA; EPITHELIAL-CELLS; COMMON THEMES; R-FACTORS; PLASMIDS; PATHOGENICITY		Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Stanford University	Falkow, S (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, 299 Campus Dr,D039, Stanford, CA 94305 USA.	falkow@stanford.edu						Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Blaser MJ, 2008, GUT, V57, P561, DOI 10.1136/gut.2007.133462; DALLAS WS, 1979, NATURE, V277, P406, DOI 10.1038/277406a0; DEGRAAFF J, 1976, J BACTERIOL, V126, P439, DOI 10.1128/JB.126.1.439-446.1976; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; FALKOW S, 1974, J GEN MICROBIOL, V85, P65, DOI 10.1099/00221287-85-1-65; Falkow S, 2006, CELL, V124, P699, DOI 10.1016/j.cell.2006.02.004; Falkow S, 1998, EMERG INFECT DIS, V4, P495, DOI 10.3201/eid0403.980342; FALKOW S, 1962, J BACTERIOL, V84, P1303, DOI 10.1128/JB.84.6.1303-1312.1962; FALKOW S, 1963, J BACTERIOL, V86, P1251, DOI 10.1128/JB.86.6.1251-1258.1963; FALKOW S, 1988, REV INFECT DIS, V10, pS274; FALKOW S, 1987, REV INFECT DIS, V9, pS450; FALKOW S, 1961, GENETICS, V46, P703; Falkow S, 2001, ASM NEWS, V67, P555; FALKOW S, 1966, J MOL BIOL, V17, P102, DOI 10.1016/S0022-2836(66)80097-9; Falkow S, 2008, ANNU REV MICROBIOL, V62, P1, DOI 10.1146/annurev.micro.62.081307.162931; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; GUERRY P, 1971, J BACTERIOL, V107, P372, DOI 10.1128/JB.107.1.372-374.1971; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; HEFFRON F, 1975, J BACTERIOL, V122, P250, DOI 10.1128/JB.122.1.250-256.1975; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KAPER JB, 1982, J CLIN MICROBIOL, V16, P129, DOI 10.1128/JCM.16.1.129-134.1982; KOOMEY JM, 1982, P NATL ACAD SCI-BIOL, V79, P7881, DOI 10.1073/pnas.79.24.7881; MCELROY WD, 1957, CHEM BASIS HEREDITY; Medini D, 2008, NAT REV MICROBIOL, V6, P419, DOI 10.1038/nrmicro1901; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; Monack DM, 2004, NAT REV MICROBIOL, V2, P747, DOI 10.1038/nrmicro955; MOSELEY SL, 1980, J INFECT DIS, V142, P892, DOI 10.1093/infdis/142.6.892; Mueller A, 2005, CANCER EPIDEM BIOMAR, V14, P1859, DOI 10.1158/1055-9965.EPI-04-0820; NORMARK S, 1983, INFECT IMMUN, V41, P942, DOI 10.1128/IAI.41.3.942-949.1983; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; ROBERTS M, 1977, J BACTERIOL, V131, P557, DOI 10.1128/JB.131.2.557-563.1977; SMITH HW, 1967, J PATHOL BACTERIOL, V93, P531, DOI 10.1002/path.1700930212; SO M, 1976, J BACTERIOL, V128, P463, DOI 10.1128/JB.128.1.463-472.1976; TOMPKINS LS, 1980, J INFECT DIS, V141, P625, DOI 10.1093/infdis/141.5.625; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983	40	15	15	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1053	1057		10.1038/nm1008-1053	http://dx.doi.org/10.1038/nm1008-1053			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841148				2022-12-27	WOS:000259892300035
J	Wilensky, RL; Shi, Y; Mohler, ER; Hamamdzic, D; Burgert, ME; Li, J; Postle, A; Fenning, RS; Bollinger, JG; Hoffman, BE; Pelchovitz, DJ; Yang, JS; Mirabile, RC; Webb, CL; Zhang, LF; Zhang, P; Gelb, MH; Walker, MC; Zalewski, A; Macphee, CH				Wilensky, Robert L.; Shi, Yi; Mohler, Emile R., III; Hamamdzic, Damir; Burgert, Mark E.; Li, Jun; Postle, Anthony; Fenning, Robert S.; Bollinger, James G.; Hoffman, Bryan E.; Pelchovitz, Daniel J.; Yang, Jisheng; Mirabile, Rosanna C.; Webb, Christine L.; Zhang, LeFeng; Zhang, Ping; Gelb, Michael H.; Walker, Max C.; Zalewski, Andrew; Macphee, Colin H.			Inhibition of lipoprotein-associated phospholipase A(2) reduces complex coronary atherosclerotic plaque development	NATURE MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; FACTOR ACETYLHYDROLASE; CARDIOVASCULAR-DISEASE; OXIDIZED PHOSPHOLIPIDS; OXIDATION HYPOTHESIS; COMPLETE SET; RISK-FACTOR; ATHEROGENESIS; MECHANISMS	Increased lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity is associated with increased risk of cardiac events, but it is not known whether Lp-PLA(2) is a causative agent. Here we show that selective inhibition of Lp-PLA(2) with darapladib reduced development of advanced coronary atherosclerosis in diabetic and hypercholesterolemic swine. Darapladib markedly inhibited plasma and lesion Lp-PLA(2) activity and reduced lesion lysophosphatidylcholine content. Analysis of coronary gene expression showed that darapladib exerted a general anti-inflammatory action, substantially reducing the expression of 24 genes associated with macrophage and T lymphocyte functioning. Darapladib treatment resulted in a considerable decrease in plaque area and, notably, a markedly reduced necrotic core area and reduced medial destruction, resulting in fewer lesions with an unstable phenotype. These data show that selective inhibition of Lp-PLA(2) inhibits progression to advanced coronary atherosclerotic lesions and confirms a crucial role of vascular inflammation independent from hypercholesterolemia in the development of lesions implicated in the pathogenesis of myocardial infarction and stroke.	[Wilensky, Robert L.; Mohler, Emile R., III; Hamamdzic, Damir; Fenning, Robert S.; Pelchovitz, Daniel J.; Yang, Jisheng] Hosp Univ Penn, Philadelphia, PA 19104 USA; [Shi, Yi; Zhang, LeFeng; Zhang, Ping; Zalewski, Andrew] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Li, Jun; Hoffman, Bryan E.; Mirabile, Rosanna C.; Webb, Christine L.; Walker, Max C.; Zalewski, Andrew; Macphee, Colin H.] GlaxoSmithKline Inc, King Of Prussia, PA 19406 USA; [Postle, Anthony] Southampton Gen Hosp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; [Bollinger, James G.; Gelb, Michael H.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Bollinger, James G.; Gelb, Michael H.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University; GlaxoSmithKline; University of Southampton; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wilensky, RL (corresponding author), Hosp Univ Penn, 3400 Spruce St,9 Gates, Philadelphia, PA 19104 USA.	robert.wilensky@uphs.upenn.edu		Postle, Anthony/0000-0001-7361-0756; gelb, michael/0000-0001-7000-5219	GlaxoSmithKline air industry-academic alliance; US National Institutes of Health [R37HL036235]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235] Funding Source: NIH RePORTER	GlaxoSmithKline air industry-academic alliance(GlaxoSmithKline); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The superb animal husbandry of H. Profka is gratefully acknowledged. We greatly appreciate the input by M. Hurle into the design and confirmation of the Taqman probes and the advice and support related to immunofluorescence procedures of R Crino. These studies were supported by funding from GlaxoSmithKline air industry-academic alliance via the Alternative Drug Discovery Initiative with tire University of Pennsylvania School of Medicine. M.H.G. is funded by US National Institutes of Health grain R37HL036235.	Aprahamian T, 2004, J EXP MED, V199, P1121, DOI 10.1084/jem.20031557; Blackie JA, 2003, BIOORG MED CHEM LETT, V13, P1067, DOI 10.1016/S0960-894X(03)00058-1; Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97; Carpenter KLH, 2003, FEBS LETT, V553, P145, DOI 10.1016/S0014-5793(03)01007-X; Caslake MJ, 2000, ATHEROSCLEROSIS, V150, P413, DOI 10.1016/S0021-9150(99)00406-2; Chatzizisis YS, 2007, J AM COLL CARDIOL, V49, P2379, DOI 10.1016/j.jacc.2007.02.059; Collins R, 2003, LANCET, V361, P2005; Davis B, 2008, J BIOL CHEM, V283, P6428, DOI 10.1074/jbc.M709970200; Gardner AA, 2008, J BIOL CHEM, V283, P17099, DOI 10.1074/jbc.M802394200; Garza CA, 2007, MAYO CLIN PROC, V82, P159; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; Getz GS, 2006, ARTERIOSCL THROM VAS, V26, P242, DOI 10.1161/01.ATV.0000201071.49029.17; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Heller EA, 2006, CIRCULATION, V113, P2301, DOI 10.1161/CIRCULATIONAHA.105.605121; Jo H, 2006, ANTIOXID REDOX SIGN, V8, P1609, DOI 10.1089/ars.2006.8.1609; Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655; Kolodgie FD, 2006, ARTERIOSCL THROM VAS, V26, P2523, DOI 10.1161/01.ATV.0000244681.72738.bc; Kouglas P, 2006, MED SCI MONITOR, V12, pRA5; Macintyre Sally, 2005, Int J Behav Nutr Phys Act, V2, P16, DOI 10.1186/1479-5868-2-16; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Mohler ER, 2008, ARTERIOSCL THROM VAS, V28, P850, DOI 10.1161/ATVBAHA.107.154534; Moreno PR, 2000, CIRCULATION, V102, P2180; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Papaspyridonos M, 2006, ARTERIOSCL THROM VAS, V26, P1837, DOI 10.1161/01.ATV.0000229695.68416.76; Pennathur S, 2007, ANTIOXID REDOX SIGN, V9, P955, DOI 10.1089/ars.2007.1595; Perez R, 2006, J IMMUNOL, V176, P2555, DOI 10.4049/jimmunol.176.4.2555; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sangvanich P, 2003, BIOCHEM BIOPH RES CO, V300, P501, DOI 10.1016/S0006-291X(02)02849-8; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; Shah PK, 2007, CURR OPIN LIPIDOL, V18, P492, DOI 10.1097/MOL.0b013e3282efa326; Shi Y, 2007, ATHEROSCLEROSIS, V191, P54, DOI 10.1016/j.atherosclerosis.2006.05.001; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Smart BP, 2004, BIOORGAN MED CHEM, V12, P1737, DOI 10.1016/j.bmc.2004.01.022; Spagnoli LG, 2004, JAMA-J AM MED ASSOC, V292, P1845, DOI 10.1001/jama.292.15.1845; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Steinberg D, 2006, J LIPID RES, V47, P1339, DOI 10.1194/jlr.R600009-JLR200; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549; Tsimikas S, 2007, ARTERIOSCL THROM VAS, V27, P2094, DOI 10.1161/01.atv.0000280571.28102.d4; VanEck M, 1997, ARTERIOSCL THROM VAS, V17, P3117, DOI 10.1161/01.ATV.17.11.3117; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Zalewski A, 2005, ARTERIOSCL THROM VAS, V25, P923, DOI 10.1161/01.ATV.0000160551.21962.a7	46	300	320	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1059	1066		10.1038/nm.1870	http://dx.doi.org/10.1038/nm.1870			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18806801	Green Accepted			2022-12-27	WOS:000259892300036
J	Axtell, RC; de Jong, BA; Boniface, K; van der Voort, LF; Bhat, R; De Sarno, P; Naves, R; Han, M; Zhong, F; Castellanos, JG; Mair, R; Christakos, A; Kolkowitz, I; Katz, L; Killestein, J; Polman, CH; Malefyt, RD; Steinman, L; Raman, C				Axtell, Robert C.; de Jong, Brigit A.; Boniface, Katia; van der Voort, Laura F.; Bhat, Roopa; De Sarno, Patrizia; Naves, Rodrigo; Han, May; Zhong, Franklin; Castellanos, Jim G.; Mair, Robert; Christakos, Athena; Kolkowitz, Ilan; Katz, Liat; Killestein, Joep; Polman, Chris H.; Malefyt, Rene de Waal; Steinman, Lawrence; Raman, Chander			T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis	NATURE MEDICINE			English	Article							AUTOIMMUNE INFLAMMATION; NEUROMYELITIS-OPTICA; IFN-ALPHA; TGF-BETA; GAMMA; DIFFERENTIATION; THERAPY; IL-23; INHIBITION; ACTIVATION	Interferon-beta (IFN-beta) is the major treatment for multiple sclerosis. However, this treatment is not always effective. Here we have found congruence in outcome between responses to IFN-beta in experimental autoimmune encephalomyelitis (EAE) and relapsing-remitting multiple sclerosis (RRMS). IFN-beta was effective in reducing EAE symptoms induced by T helper type 1 (T(H)1) cells but exacerbated disease induced by T(H)17 cells. Effective treatment in T(H)1-induced EAE correlated with increased interleukin-10 (IL-10) production by splenocytes. In T(H)17-induced disease, the amount of IL-10 was unaltered by treatment, although, unexpectedly, IFN-beta treatment still reduced IL-17 production without benefit. Both inhibition of IL-17 and induction of IL-10 depended on IFN-gamma. In the absence of IFN-gamma signaling, IFN-beta therapy was ineffective in EAE. In RRMS patients, IFN-beta nonresponders had higher IL-17F concentrations in serum compared to responders. Nonresponders had worse disease with more steroid usage and more relapses than did responders. Hence, IFN-beta is proinflammatory in T(H)17-induced EAE. Moreover, a high IL-17F concentration in the serum of people with RRMS is associated with nonresponsiveness to therapy with IFN-beta.	[Axtell, Robert C.; de Jong, Brigit A.; Bhat, Roopa; Han, May; Zhong, Franklin; Castellanos, Jim G.; Mair, Robert; Christakos, Athena; Kolkowitz, Ilan; Katz, Liat; Steinman, Lawrence] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [de Jong, Brigit A.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [de Jong, Brigit A.; van der Voort, Laura F.; Killestein, Joep; Polman, Chris H.] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Boniface, Katia; Malefyt, Rene de Waal] Schering Plough Biopharma, Palo Alto, CA USA; [Boniface, Katia; Malefyt, Rene de Waal] DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; [De Sarno, Patrizia] Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, CA USA; [Naves, Rodrigo; Raman, Chander] Univ Alabama, Dept Med, Birmingham, CA USA	Stanford University; Radboud University Nijmegen; Vrije Universiteit Amsterdam; Merck & Company; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Steinman, L (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	steinman@stanford.edu; craman@uab.edu	Boniface, Katia/N-5577-2016; Axtell, Robert/AAJ-5053-2021; Naves, Rodrigo/H-4829-2014	Boniface, Katia/0000-0003-4428-1222; Naves, Rodrigo/0000-0002-1203-3593; de Waal Malefyt, Rene/0000-0002-2663-383X; Killestein, Joep/0000-0002-6347-5957; Steinman, Lawrence/0000-0002-2437-2250; Mair, Robert/0000-0001-5860-7276	US National Institutes of Health [R01NS 55997]; US National Multiple Sclerosis Society [RG3891-A1]; National Institutes of Health [RO1AI1076562-01]; National Multiple Sclerosis Society [FG 1817-A-1]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007051, R01AI076562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055997] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Multiple Sclerosis Society(National Multiple Sclerosis Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank J. Mountz (University of Alabama at Birmingham) for the kind gift of Rebif and Y. Rosenberg-Hasson for running the multiplex cytokine assay. This study was funded by US National Institutes of Health grant R01NS 55997 to L. S., US National Multiple Sclerosis Society grant RG3891-A1, National Institutes of Health grant RO1AI1076562-01 to C. R. and National Multiple Sclerosis Society grant FG 1817-A-1 to R. C. A.	Arnason BGW, 1999, ANNU REV MED, V50, P291; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; Bartosik-Psujek H, 2006, CLIN NEUROL NEUROSUR, V108, P644, DOI 10.1016/j.clineuro.2005.10.011; Benveniste Etty N, 2007, Sci STKE, V2007, ppe70, DOI 10.1126/stke.4162007pe70; Berenson LS, 2006, J IMMUNOL, V177, P5195, DOI 10.4049/jimmunol.177.8.5195; Betti M, 2006, ANN ONCOL, V17, P235; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fitzgerald DC, 2007, NAT IMMUNOL, V8, P1372, DOI 10.1038/ni1540; Graber JJ, 2007, J NEUROIMMUNOL, V185, P168, DOI 10.1016/j.jneuroim.2007.01.011; Guo BC, 2008, J CLIN INVEST, V118, P1680, DOI 10.1172/JCI33342; Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997; Harries-Rees K, 2005, CHEM WORLD-UK, V2, P6; Hengstman GJD, 2007, MULT SCLER, V13, P679, DOI 10.1177/1352458506070145; Ishizu T, 2005, BRAIN, V128, P988, DOI 10.1093/brain/awh453; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liang SC, 2007, J IMMUNOL, V179, P7791, DOI 10.4049/jimmunol.179.11.7791; Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Martin-Saavedra FM, 2008, MOL IMMUNOL, V45, P4008, DOI 10.1016/j.molimm.2008.06.006; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McRae BL, 1998, J IMMUNOL, V160, P4298; Nagai T, 2007, SCAND J IMMUNOL, V65, P107, DOI 10.1111/j.1365-3083.2006.01880.x; Nguyen KB, 2000, NAT IMMUNOL, V1, P70, DOI 10.1038/76940; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Shimizu Y, 2008, J NEUROL, V255, P305, DOI 10.1007/s00415-007-0730-5; Smith E, 2007, J IMMUNOL, V179, P8274, DOI 10.4049/jimmunol.179.12.8274; Tanabe Y, 2005, J IMMUNOL, V174, P609, DOI 10.4049/jimmunol.174.2.609; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wang K, 2006, NAT PROD COMMUN, V1, P537; Warabi Y, 2007, J NEUROL SCI, V252, P57, DOI 10.1016/j.jns.2006.10.008; Wong LH, 1998, J IMMUNOL, V160, P5475; Zhang ZL, 2009, CYTOKINE, V46, P79, DOI 10.1016/j.cyto.2008.12.019; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	36	423	436	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					406	U21		10.1038/nm.2110	http://dx.doi.org/10.1038/nm.2110			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20348925	Green Accepted			2022-12-27	WOS:000276446800044
J	Yadav, VK; Balaji, S; Suresh, PS; Liu, XS; Lu, X; Li, ZS; Guo, XE; Mann, JJ; Balapure, AK; Gershon, MD; Medhamurthy, R; Vidal, M; Karsenty, G; Ducy, P				Yadav, Vijay K.; Balaji, Santhanam; Suresh, Padmanaban S.; Liu, X. Sherry; Lu, Xin; Li, Zhishan; Guo, X. Edward; Mann, J. John; Balapure, Anil K.; Gershon, Michael D.; Medhamurthy, Rudraiah; Vidal, Marc; Karsenty, Gerard; Ducy, Patricia			Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis	NATURE MEDICINE			English	Article							TRYPTOPHAN-HYDROXYLASE INHIBITORS; PARATHYROID-HORMONE; DISORDERS; SYSTEM; MICE; MASS	Osteoporosis is a disease of low bone mass most often caused by an increase in bone resorption that is not sufficiently compensated for by a corresponding increase in bone formation(1). As gut-derived serotonin (GDS) inhibits bone formation(2), we asked whether hampering its biosynthesis could treat osteoporosis through an anabolic mechanism (that is, by increasing bone formation). We synthesized and used LP533401, a small molecule inhibitor of tryptophan hydroxylase-1 (Tph-1), the initial enzyme in GDS biosynthesis. Oral administration of this small molecule once daily for up to six weeks acts prophylactically or therapeutically, in a dose-dependent manner, to treat osteoporosis in ovariectomized rodents because of an isolated increase in bone formation. These results provide a proof of principle that inhibiting GDS biosynthesis could become a new anabolic treatment for osteoporosis.	[Yadav, Vijay K.; Karsenty, Gerard] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10027 USA; [Balaji, Santhanam; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Balaji, Santhanam; Vidal, Marc] Ctr Canc Syst Biol, Boston, MA USA; [Balaji, Santhanam; Vidal, Marc] Dana Farber Canc Inst, Boston, MA 02115 USA; [Suresh, Padmanaban S.; Medhamurthy, Rudraiah] Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; [Liu, X. Sherry; Lu, Xin; Guo, X. Edward] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Li, Zhishan; Gershon, Michael D.; Ducy, Patricia] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA; [Mann, J. John] Columbia Univ, Dept Psychiat, New York, NY USA; [Balapure, Anil K.] Cent Drug Res Inst, Tissue & Cell Culture Unit, Lucknow 226001, Uttar Pradesh, India	Columbia University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Indian Institute of Science (IISC) - Bangalore; Columbia University; Columbia University; Columbia University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Karsenty, G (corresponding author), Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10027 USA.	gk2172@columbia.edu; pd2193@columbia.edu	P.S, Suresh/AAX-9666-2020; Liu, Xiaowei Sherry/H-1664-2017; yadav, VIJAY k/Q-2540-2016	Liu, Xiaowei Sherry/0000-0001-7247-2232; yadav, VIJAY k/0000-0003-2345-2846; BALAPURE, ANIL/0000-0003-1213-4586	US National Institutes of Health; International Bone and Mineral Society; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K99DK085328] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Bone and Mineral Society; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank M.-T. Rached, Y.-Y. Huang, N. Suda and G. Ren for help in experiments and D. Landry (Organic Chemistry, Columbia University) for providing LP533401 for the initial stages of these experiments. Special thanks go to S. Kousteni and J. Martin for helpful suggestions. This work was supported by grants from the US National Institutes of Health (V.K.Y., G. K. and P. D.) and a Gideon and Sevgi Rodan fellowship from International Bone and Mineral Society (V.K.Y.).	Andersson N, 2004, ACTA ORTHOP SCAND, V75, P201, DOI 10.1080/00016470412331294465; Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]; Chen JJ, 2001, J NEUROSCI, V21, P6348, DOI 10.1523/JNEUROSCI.21-16-06348.2001; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; FELDKAMP LA, 1989, J BONE MINER RES, V4, P3, DOI 10.1002/jbmr.5650040103; Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756-3282(03)00202-3; FROST M, J BONE MINE IN PRESS; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; GUNDERSEN HJG, 1993, BONE, V14, P217, DOI 10.1016/8756-3282(93)90144-Y; Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167; Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004-0006; Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103; Liu QY, 2008, J PHARMACOL EXP THER, V325, P47, DOI 10.1124/jpet.107.132670; MANN JJ, 1992, ARCH GEN PSYCHIAT, V49, P442; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Shi ZC, 2008, J MED CHEM, V51, P3684, DOI 10.1021/jm800338j; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; Vegni FE, 2004, NEW ENGL J MED, V350, P189; Wang L, 2002, BIOCHEMISTRY-US, V41, P12569, DOI 10.1021/bi026561f; Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051; Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059	25	239	272	2	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					308	U103		10.1038/nm.2098	http://dx.doi.org/10.1038/nm.2098			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20139991	Green Accepted			2022-12-27	WOS:000275289500036
J	Roepke, TK; King, EC; Reyna-Neyra, A; Paroder, M; Purtell, K; Koba, W; Fine, E; Lerner, DJ; Carrasco, N; Abbott, GW				Roepke, Torsten K.; King, Elizabeth C.; Reyna-Neyra, Andrea; Paroder, Monika; Purtell, Kerry; Koba, Wade; Fine, Eugene; Lerner, Daniel J.; Carrasco, Nancy; Abbott, Geoffrey W.			Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis	NATURE MEDICINE			English	Article							LONG QT SYNDROME; FAMILIAL ATRIAL-FIBRILLATION; CARDIAC POTASSIUM CURRENT; GASTRIC-ACID-SECRETION; LANGE-NIELSEN-SYNDROME; OF-FUNCTION MUTATION; SUBCLINICAL HYPOTHYROIDISM; TARGETED DISRUPTION; IODIDE TRANSPORTER; SERUM THYROTROPIN	Thyroid dysfunction is a global health concern, causing defects including neurodevelopmental disorders, dwarfism and cardiac arrhythmia. Here, we show that the potassium channel subunits KCNQ1 and KCNE2 form a thyroid-stimulating hormone-stimulated, constitutively active, thyrocyte K+ channel required for normal thyroid hormone biosynthesis. Targeted disruption of Kcne2 in mice impaired thyroid iodide accumulation up to eightfold, impaired maternal milk ejection, halved milk tetraiodothyronine (T-4) content and halved litter size. Kcne2-deficient mice had hypothyroidism, dwarfism, alopecia, goiter and cardiac abnormalities including hypertrophy, fibrosis, and reduced fractional shortening. The alopecia, dwarfism and cardiac abnormalities were alleviated by triiodothyronine (T-3) and T-4 administration to pups, by supplementing dams with T-4 before and after they gave birth or by feeding the pups exclusively from Kcne2(+/+) dams; conversely, these symptoms were elicited in Kcne2(+/+) pups by feeding exclusively from Kcne2(-/-) dams. These data provide a new potential therapeutic target for thyroid disorders and raise the possibility of an endocrine component to previously identified KCNE2- and KCNQ1-linked human cardiac arrhythmias.	[Roepke, Torsten K.; King, Elizabeth C.; Purtell, Kerry; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Dept Med, Greenberg Div Cardiol, New York, NY 10021 USA; [Roepke, Torsten K.; King, Elizabeth C.; Purtell, Kerry; Abbott, Geoffrey W.] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; [Reyna-Neyra, Andrea; Paroder, Monika; Carrasco, Nancy] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Koba, Wade; Fine, Eugene] Albert Einstein Coll Med, Dept Nucl Med, M Donald Blaufox MicroPet Lab Mol Imaging, Bronx, NY 10467 USA; [Lerner, Daniel J.] CV Ingenu, San Francisco, CA USA; [Carrasco, Nancy] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10467 USA	Cornell University; Cornell University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Greenberg Div Cardiol, New York, NY 10021 USA.	gwa2001@med.cornell.edu	Carrasco, Nancy/AAH-1053-2019; Reyna-Neyra, Andrea/F-5621-2013	Carrasco, Nancy/0000-0003-4137-6162; Abbott, Geoffrey/0000-0003-4552-496X	US National Heart, Lung, and Blood Institute [HL079275]; American Heart Association [0855756D]; US National Institute of Diabetes and Digestive and Kidney Diseases [DK41544]; US National Cancer Institute [CA098390]; US National Institutes of Health [5T32GM002788]; NATIONAL CANCER INSTITUTE [R01CA098390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association(American Heart Association); US National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	G.W.A. is supported by the US National Heart, Lung, and Blood Institute (HL079275) and the American Heart Association (0855756D). N.C. is supported by the US National Institute of Diabetes and Digestive and Kidney Diseases (DK41544) and the US National Cancer Institute (CA098390). M.P. is supported by US National Institutes of Health Medical Scientist Training Grant 5T32GM002788. We are grateful for expert technical assistance from S. Backovic, L. Cohen-Gould, G.J.-S. Abbott, K. La Perle, the Molecular Cytology Core Facility of Memorial Sloan-Kettering Cancer Center and C. Basson and J. Chen (WCMC Center for Molecular Cardiology Small Animal Physiology Core Facility). We also thank T. Denecke for interpreting the radiographs and B. Abbott for critical reading of the manuscript.	Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Bakiner O, 2008, MED PRIN PRACT, V17, P390, DOI 10.1159/000141503; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Burman KD, 2006, CLIN DERMATOL, V24, P247, DOI 10.1016/j.clindermatol.2006.04.010; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Ehrlich JR, 2005, CARDIOVASC RES, V67, P520, DOI 10.1016/j.cardiores.2005.03.007; Elso CM, 2004, HUM MOL GENET, V13, P2813, DOI 10.1093/hmg/ddh307; FORFAR JC, 1979, AM J CARDIOL, V44, P9, DOI 10.1016/0002-9149(79)90243-1; FUKUDA H, 1980, ENDOCRINOLOGY, V107, P1711, DOI 10.1210/endo-107-6-1711; GAVIN LA, 1991, MED CLIN N AM, V75, P179, DOI 10.1016/S0025-7125(16)30478-3; GLUECK CJ, 1991, CLIN CHIM ACTA, V201, P113, DOI 10.1016/0009-8981(91)90032-8; Gnat D, 2003, CLIN CHEM, V49, P186, DOI 10.1373/49.1.186; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Gruters A, 2004, EUR J ENDOCRINOL, V151, pU39, DOI 10.1530/eje.0.151U039; HAGGERTY JJ, 1990, INT J PSYCHIAT MED, V20, P193, DOI 10.2190/ADLY-1UU0-1A8L-HPXY; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Hapon MB, 2003, REPRODUCTION, V126, P371, DOI 10.1530/rep.0.1260371; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; Imaizumi M, 2001, ENDOCRINOLOGY, V142, P823, DOI 10.1210/en.142.2.823; Kasatkina E P, 2006, Neurosci Behav Physiol, V36, P619, DOI 10.1007/s11055-006-0066-0; Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Levy S, 1998, J CARDIOVASC ELECTR, V9, pS78; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; NAKAZAWA HK, 1982, AM J MED, V72, P903, DOI 10.1016/0002-9343(82)90850-6; ODDIE TH, 1966, J CLIN ENDOCR METAB, V26, P1293, DOI 10.1210/jcem-26-12-1293; Olson TM, 2005, JAMA-J AM MED ASSOC, V293, P447, DOI 10.1001/jama.293.4.447; Opazo MC, 2008, ENDOCRINOLOGY, V149, P5097, DOI 10.1210/en.2008-0560; Palagiano A, 2006, Minerva Ginecol, V58, P471; PALLAS D, 1991, J ENDOCRINOL INVEST, V14, P743, DOI 10.1007/BF03347907; Quevedo-Corona L, 2000, LIFE SCI, V66, P2013, DOI 10.1016/S0024-3205(00)00528-2; Roepke TK, 2008, FASEB J, V22, P3648, DOI 10.1096/fj.08-110171; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shiels HA, 2008, J EXP BIOL, V211, P2005, DOI 10.1242/jeb.003145; Song L, 2006, BRAIN RES, V1101, P59, DOI 10.1016/j.brainres.2006.05.027; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tang YD, 2005, CIRCULATION, V112, P3122, DOI 10.1161/CIRCULATIONAHA.105.572883; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; Temple J, 2005, CIRC RES, V97, P62, DOI 10.1161/01.RES.0000173047.42236.88; Tester DJ, 2007, J AM COLL CARDIOL, V49, P240, DOI 10.1016/j.jacc.2006.10.010; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; van Wassenaer AG, 2002, CLIN ENDOCRINOL, V56, P621, DOI 10.1046/j.1365-2265.2002.01526.x; vanTol BL, 2007, AM J PHYSIOL-CELL PH, V293, pC1010, DOI 10.1152/ajpcell.00071.2007; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017; Yang YQ, 2004, AM J HUM GENET, V75, P899, DOI 10.1086/425342	55	101	104	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1186	U117		10.1038/nm.2029	http://dx.doi.org/10.1038/nm.2029			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19767733	Green Submitted, Green Accepted			2022-12-27	WOS:000270596400031
J	Caruso, R; Botti, E; Sarra, M; Esposito, M; Stolfi, C; Diluvio, L; Giustizieri, ML; Pacciani, V; Mazzotta, A; Campione, E; MacDonald, TT; Chimenti, S; Pallone, F; Costanzo, A; Monteleone, G				Caruso, Roberta; Botti, Elisabetta; Sarra, Massimiliano; Esposito, Maria; Stolfi, Carmine; Diluvio, Laura; Giustizieri, Maria Laura; Pacciani, Valentina; Mazzotta, Annamaria; Campione, Elena; MacDonald, Thomas T.; Chimenti, Sergio; Pallone, Francesco; Costanzo, Antonio; Monteleone, Giovanni			Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis	NATURE MEDICINE			English	Article							INFLAMMATION	T cells are crucial mediators of the skin damage in psoriasis. We here show that interleukin-21 (IL-21), a T cell-derived cytokine, is highly expressed in the skin of individuals with psoriasis, stimulates human keratinocytes to proliferate and causes epidermal hyperplasia when injected intradermally into mice. In the human psoriasis xenograft mouse model, blockade of IL-21 activity resolves inflammation and reduces keratinocyte proliferation. Blocking IL-21 may represent a new therapeutic strategy in psoriasis.	[Caruso, Roberta; Sarra, Massimiliano; Stolfi, Carmine; Pallone, Francesco; Monteleone, Giovanni] Univ Roma Tor Vergata, Gastroenterol Unit, Dept Internal Med, Rome, Italy; [Botti, Elisabetta; Esposito, Maria; Diluvio, Laura; Giustizieri, Maria Laura; Pacciani, Valentina; Mazzotta, Annamaria; Campione, Elena; Chimenti, Sergio; Costanzo, Antonio] Univ Roma Tor Vergata, Dermatol Unit, Dept Internal Med, Rome, Italy; [MacDonald, Thomas T.] Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, London, England	University of Rome Tor Vergata; University of Rome Tor Vergata; University of London; Queen Mary University London	Monteleone, G (corresponding author), Univ Roma Tor Vergata, Gastroenterol Unit, Dept Internal Med, Rome, Italy.	GiMonteleone@Med.uniroma2.it	Costanzo, Antonio/GZG-2433-2022; Costanzo, Antonio/D-3896-2012; Stolfi, Carmine/J-4524-2019; Campione, Elena/AAJ-4264-2021; Caruso, Roberta/AAA-7661-2020; Diluvio, Laura/AAM-7371-2020	Costanzo, Antonio/0000-0001-9697-2557; Campione, Elena/0000-0001-7447-6798; Diluvio, Laura/0000-0003-1844-9052; Stolfi, Carmine/0000-0002-6354-2443	Fondazione Umberto di Mario and Giuliani SpA, Milan, Italy	Fondazione Umberto di Mario and Giuliani SpA, Milan, Italy	This work received support from the Fondazione Umberto di Mario and Giuliani SpA, Milan, Italy. It is dedicated to the memory of A. Ribuffo, the Master of the Roman University School of Dermatology.	Caprioli F, 2008, J IMMUNOL, V180, P1800, DOI 10.4049/jimmunol.180.3.1800; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Liu Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000041; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Monteleone G, 2008, TRENDS IMMUNOL, V29, P290, DOI 10.1016/j.it.2008.02.008; Takahashi H, 2002, J DERMATOL SCI, V30, P94, DOI 10.1016/S0923-1811(02)00064-6; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	9	149	163	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1013	1015		10.1038/nm.1995	http://dx.doi.org/10.1038/nm.1995			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19684581				2022-12-27	WOS:000269979200020
J	Yen, CLE; Cheong, ML; Grueter, C; Zhou, P; Moriwaki, J; Wong, JS; Hubbard, B; Marmor, S; Farese, RV				Yen, Chi-Liang Eric; Cheong, Mei-Leng; Grueter, Carrie; Zhou, Ping; Moriwaki, Junya; Wong, Jinny S.; Hubbard, Brian; Marmor, Stephen; Farese, Robert V., Jr.			Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding	NATURE MEDICINE			English	Article							MONOACYLGLYCEROL ACYLTRANSFERASE; COENZYME-A; ABSORPTION; IDENTIFICATION; CLONING; GENE; COA	Animals are remarkably efficient in absorbing dietary fat and assimilating this energy-dense nutrient into the white adipose tissue (WAT) for storage. Although this metabolic efficiency may confer an advantage in times of calorie deprivation, it contributes to obesity and associated metabolic disorders when dietary fat is abundant(1,2). Here we show that the intestinal lipid synthesis enzyme acyl CoA: monoacylglycerol acyltransferase-2 (MGAT2) has a crucial role in the assimilation of dietary fat and the accretion of body fat in mice. Mice lacking MGAT2 have a normal phenotype on a low-fat diet. However, on a high-fat diet, MGAT2-deficient mice are protected against developing obesity, glucose intolerance, hypercholesterolemia and fatty livers. Caloric intake is normal in MGAT2-deficient mice, and dietary fat is absorbed fully. However, entry of dietary fat into the circulation occurs at a reduced rate. This altered kinetics of fat absorption apparently results in more partitioning of dietary fat toward energy dissipation rather than toward storage in the WAT. Thus, our studies identify MGAT2 as a key determinant of energy metabolism in response to dietary fat and suggest that the inhibition of this enzyme may prove to be a useful strategy for treating obesity and other metabolic diseases associated with excessive fat intake.	[Yen, Chi-Liang Eric; Cheong, Mei-Leng; Grueter, Carrie; Zhou, Ping; Moriwaki, Junya; Wong, Jinny S.; Farese, Robert V., Jr.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA; [Yen, Chi-Liang Eric; Grueter, Carrie; Farese, Robert V., Jr.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Hubbard, Brian; Marmor, Stephen] Novartis Inst Biomed Res, Cambridge, MA USA; [Farese, Robert V., Jr.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Farese, Robert V., Jr.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Farese, RV (corresponding author), Gladstone Inst Cardiovasc Dis, San Francisco, CA USA.	bfarese@gladstone.ucsf.edu		Grueter, Carrie/0000-0002-1913-2527	NCRR NIH HHS [C06 RR018928] Funding Source: Medline; NIDDK NIH HHS [R01 DK056084-01A1, DK-056084, R56 DK056084, R01 DK056084] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R56DK056084] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; Cao JS, 2004, J BIOL CHEM, V279, P18878, DOI 10.1074/jbc.M313272200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; HAMILTON RL, 1980, J LIPID RES, V21, P981; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; KAYDEN HJ, 1967, J CLIN INVEST, V46, P1695, DOI 10.1172/JCI105660; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MATTSON FH, 1964, J BIOL CHEM, V239, P2772; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; NEEL JV, 1962, AM J HUM GENET, V14, P353; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; SENIOR JR, 1962, J BIOL CHEM, V237, P1454; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; *UN FAO, 2008, FOOD CONS DIET EN PR; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	23	123	139	0	34	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					442	446		10.1038/nm.1937	http://dx.doi.org/10.1038/nm.1937			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19287392	Green Accepted			2022-12-27	WOS:000264937200032
J	Kleaveland, B; Zheng, XJ; Liu, JJ; Blum, Y; Tung, JJ; Zou, ZY; Chen, M; Guo, LL; Lu, MM; Zhou, D; Kitajewski, J; Affolter, M; Ginsberg, MH; Kahn, ML				Kleaveland, Benjamin; Zheng, Xiangjian; Liu, Jian J.; Blum, Yannick; Tung, Jennifer J.; Zou, Zhiying; Chen, Mei; Guo, Lili; Lu, Min-min; Zhou, Diane; Kitajewski, Jan; Affolter, Markus; Ginsberg, Mark H.; Kahn, Mark L.			Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway	NATURE MEDICINE			English	Article							VASCULAR DEVELOPMENT; CONCENTRIC GROWTH; GENE; MUTATIONS; KRIT1; CCM1; MORPHOGENESIS; PATHOGENESIS	Cerebral cavernous malformations (CCMs) are human vascular malformations caused by mutations in three genes of unknown function: KRIT1, CCM2 and PDCD10. Here we show that the heart of glass (HEG1) receptor, which in zebrafish has been linked to ccm gene function, is selectively expressed in endothelial cells. Heg1(-/-) mice showed defective integrity of the heart, blood vessels and lymphatic vessels. Heg1(-/-); Ccm2(lacZ/+) and Ccm2(lacZ/lacZ) mice had more severe cardiovascular defects and died early in development owing to a failure of nascent endothelial cells to associate into patent vessels. This endothelial cell phenotype was shared by zebrafish embryos deficient in heg, krit1 or ccm2 and reproduced in CCM2-deficient human endothelial cells in vitro. Defects in the hearts of zebrafish lacking heg or ccm2, in the aortas of early mouse embryos lacking CCM2 and in the lymphatic vessels of neonatal mice lacking HEG1 were associated with abnormal endothelial cell junctions like those observed in human CCMs. Biochemical and cellular imaging analyses identified a cell-autonomous pathway in which the HEG1 receptor couples to KRIT1 at these cell junctions. This study identifies HEG1-CCM protein signaling as a crucial regulator of heart and vessel formation and integrity.	[Kleaveland, Benjamin; Zheng, Xiangjian; Zou, Zhiying; Chen, Mei; Guo, Lili; Lu, Min-min; Zhou, Diane; Kahn, Mark L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Kleaveland, Benjamin; Zheng, Xiangjian; Zou, Zhiying; Chen, Mei; Guo, Lili; Lu, Min-min; Zhou, Diane; Kahn, Mark L.] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA; [Liu, Jian J.; Ginsberg, Mark H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Blum, Yannick; Affolter, Markus] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; [Kitajewski, Jan] Columbia Univ, Med Ctr, Inst Canc Genet & Herbert Irving, Dept Pathol, New York, NY 10032 USA; [Kitajewski, Jan] Columbia Univ, Med Ctr, Inst Canc Genet & Herbert Irving, Dept Obstet & Gynaecol, New York, NY 10032 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Diego; University of Basel; Columbia University; Columbia University	Kahn, ML (corresponding author), Univ Penn, Dept Med, 421 Curie Blvd, Philadelphia, PA 19104 USA.	markkahn@mail.med.upenn.edu	Liu, Jay/D-4711-2011	Affolter, Markus/0000-0002-5171-0016; Zheng, Xiangjian/0000-0001-6277-5168	Swiss National Science Foundation,; European Community; US National Institutes of Health [T32 HL07439, T32 HL07971, HL078784, AR27214, HL62454, HL075380, HL095326]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL078784, T32HL007439, R01HL094326, T32HL007971, R01HL062454, R01HL102138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER	Swiss National Science Foundation,(Swiss National Science Foundation (SNSF)European Commission); European Community(European Commission); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank C. Bertozzi, C. Chen, A. Granger, J. Lee, D. Li, P. Mericko, A. Schmaier, E. Sebzda, N. Shanbhag, S. Sweeney and K. Whitehead for valuable insights; M. Pack and J. He for assistance with zebrafish studies; R. Meade for preparation of the electron microscopy samples; and T. Branson for animal husbandry. This work was supported by the Swiss National Science Foundation, a Network of Excellence grant from the European Community ( M. A.) and the US National Institutes of Health grants T32 HL07439 ( to B. K.), T32 HL07971 ( to X. Z.), HL078784 and AR27214 ( to M. G.), HL62454 ( to J. K.) and HL075380 and HL095326 ( to M. L. K.).	Amsterdam A, 2004, METHOD CELL BIOL, V77, P3; Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Bergametti F, 2005, AM J HUM GENET, V76, P42, DOI 10.1086/426952; Blum Y, 2008, DEV BIOL, V316, P312, DOI 10.1016/j.ydbio.2008.01.038; Clatterbuck RE, 2001, J NEUROL NEUROSUR PS, V71, P188, DOI 10.1136/jnnp.71.2.188; Denier C, 2004, AM J HUM GENET, V74, P326, DOI 10.1086/381718; Eerola I, 2000, HUM MOL GENET, V9, P1351, DOI 10.1093/hmg/9.9.1351; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; Glading A, 2007, J CELL BIOL, V179, P247, DOI 10.1083/jcb.200705175; Hogan BM, 2008, HUM MOL GENET, V17, P2424, DOI 10.1093/hmg/ddn142; Jin SW, 2007, DEV BIOL, V307, P29, DOI 10.1016/j.ydbio.2007.03.526; Kamei M, 2006, NATURE, V442, P453, DOI 10.1038/nature04923; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lim CJ, 2007, NAT CELL BIOL, V9, P415, DOI 10.1038/ncb1561; Liquori CL, 2003, AM J HUM GENET, V73, P1459, DOI 10.1086/380314; Mably JD, 2003, CURR BIOL, V13, P2138, DOI 10.1016/j.cub.2003.11.055; Mably JD, 2006, DEVELOPMENT, V133, P3139, DOI 10.1242/dev.02469; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Plummer NW, 2006, MAMM GENOME, V17, P119, DOI 10.1007/s00335-005-0098-8; Revencu N, 2006, J MED GENET, V43, P716, DOI 10.1136/jmg.2006.041079; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Sebzda E, 2006, DEV CELL, V11, P349, DOI 10.1016/j.devcel.2006.07.007; Tu J, 2005, J NEUROSURG, V103, P903, DOI 10.3171/jns.2005.103.5.0903; Voss K, 2007, NEUROGENETICS, V8, P249, DOI 10.1007/s10048-007-0098-9; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Whitehead KJ, 2004, DEVELOPMENT, V131, P1437, DOI 10.1242/dev.01036; Wong JH, 2000, NEUROSURGERY, V46, P1454, DOI 10.1097/00006123-200006000-00027; Zawistowski JS, 2005, HUM MOL GENET, V14, P2521, DOI 10.1093/hmg/ddi256; Zhang J, 2007, NEUROSURGERY, V60, P353, DOI 10.1227/01.NEU.0000249268.11074.83	31	172	180	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					169	176		10.1038/nm.1918	http://dx.doi.org/10.1038/nm.1918			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19151727	Green Accepted			2022-12-27	WOS:000263119400019
J	Fu, DX; Tanhehco, Y; Chen, JM; Foss, CA; Fox, JJ; Chong, JM; Hobbs, RF; Fukayama, M; Sgouros, G; Kowalski, J; Pomper, MG; Ambinder, RF				Fu, De-Xue; Tanhehco, Yvette; Chen, Jianmeng; Foss, Catherine A.; Fox, James J.; Chong, Ja-Mun; Hobbs, Robert F.; Fukayama, Masashi; Sgouros, George; Kowalski, Jeanne; Pomper, Martin G.; Ambinder, Richard F.			Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors	NATURE MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; NON-HODGKINS-LYMPHOMA; THYMIDINE KINASE; IN-VIVO; CELLS; GENE; EXPRESSION; INDUCTION; FIAU; GANCICLOVIR	We investigated the possibility of using a pharmacologic agent to modulate viral gene expression to target radiotherapy to tumor tissue. In a mouse xenograft model, we had previously shown targeting of [[I-125]2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabinofuranoside ([I-125]FIAU) to tumors engineered to express the Epstein-Barr virus thymidine kinase (EBV-TK). Here we extend those results to targeting of a therapeutic radiopharmaceutical [I-131]FIAU to slow or stop tumor growth or to achieve tumor regression. These outcomes were achieved in xenografts with tumors that constitutively expressed the EBV-TK. With naturally infected EBV tumor cell lines (Burkitt's lymphoma and gastric carcinoma), activation of viral gene expression by pretreatment with bortezomib was required. Marked changes in tumor growth could also be achieved in naturally infected Kaposi's sarcoma herpesvirus tumors after pretreatment with bortezomib. Bortezomib-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy.	[Fu, De-Xue; Tanhehco, Yvette; Chen, Jianmeng; Chong, Ja-Mun; Kowalski, Jeanne; Pomper, Martin G.; Ambinder, Richard F.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21287 USA; [Foss, Catherine A.; Fox, James J.; Hobbs, Robert F.; Sgouros, George; Pomper, Martin G.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD 21287 USA; [Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Tokyo	Ambinder, RF (corresponding author), Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21287 USA.	ambinri@jhmi.edu	Tanhehco, Yvette/AAA-6906-2019	Kowalski, Jeanne/0000-0003-3458-3024	US National Institutes of Health [NIH/NCI P50 CA96888, P01 CA113239, U24 CA92871]; NATIONAL CANCER INSTITUTE [P01CA113239, P50CA096888, P01CA069266, P01CA081400, U24CA092871] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank S.D. Hayward (Johns Hopkins School of Medicine) for Burkitt's lymphoma cell lines and G. Hayward (Johns Hopkins School of Medicine) for primary effusion lymphoma cell lines. We think R. Wahl, S.D. Hayward, W.-S. Hsieh and M. Shamay for suggestions; S. Bonekamp, K.F. Kwok and J. Yu for reconstruction of imaging data; S. Wang for assistance in the syntheses of [<SUP>125</SUP>I]FIAU anti [<SUP>131</SUP>I]FIAU; G, Green for assistance with mouse imaging and therapy and S. Nimmagadda for assistance with mouse experiments. This work was supported by grants from the US National Institutes of Health (NIH/NCI P50 CA96888, P01 CA113239 and U24 CA92871).	Blasberg RG, 1999, Q J NUCL MED, V43, P163; Chong JM, 2002, J VIROL, V76, P6825, DOI 10.1128/JVI.76.13.6825-6831.2002; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; Diaz LA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001007; Dixon KL, 2003, NUCL MED COMMUN, V24, P951, DOI 10.1097/00006231-200309000-00002; Feng WH, 2004, J VIROL, V78, P1893, DOI 10.1128/JVI.78.4.1893-1902.2004; Fu DX, 2007, CLIN CANCER RES, V13, P1453, DOI 10.1158/1078-0432.CCR-06-2295; Gentry BG, 2005, GENE THER, V12, P1033, DOI 10.1038/sj.gt.3302487; Haubner R, 2000, EUR J NUCL MED, V27, P283, DOI 10.1007/s002590050035; Jacobs A, 2001, J NUCL MED, V42, P467; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JUWEID M, 1992, CANCER RES, V52, P5144; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; Moore SM, 2001, ANTIMICROB AGENTS CH, V45, P2082, DOI 10.1128/AAC.45.7.2082-2091.2001; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perrine SR, 2007, BLOOD, V109, P2571, DOI 10.1182/blood-2006-01-024703; Robe PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-32; Rodriguez A, 2001, J VIROL, V75, P4482, DOI 10.1128/JVI.75.10.4482-4489.2001; Schipper ML, 2007, MOL IMAGING BIOL, V9, P110, DOI 10.1007/s11307-007-0078-3; Sgouros G, 2003, J NUCL MED, V44, P260; Song H, 2007, J NUCL MED, V48, P150; Takada K, 2000, J CLIN PATHOL-MOL PA, V53, P255, DOI 10.1136/mp.53.5.255; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275; Wang XZ, 2003, GLOBAL CHANGE BIOL, V9, P612, DOI 10.1046/j.1365-2486.2003.00615.x; Westphal EM, 2000, CANCER RES, V60, P5781; Witzig TE, 2007, CANCER, V109, P1804, DOI 10.1002/cncr.22617; Wu FY, 2003, J VIROL, V77, P1481, DOI 10.1128/JVI.77.2.1481-1500.2003	30	71	74	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1118	1122		10.1038/nm.1864	http://dx.doi.org/10.1038/nm.1864			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18776891	Green Accepted			2022-12-27	WOS:000259892300043
J	Lee, H; Sun, E; Ham, D; Weissleder, R				Lee, Hakho; Sun, Eric; Ham, Donhee; Weissleder, Ralph			Chip-NMR biosensor for detection and molecular analysis of cells	NATURE MEDICINE			English	Article							MICROCOILS; BIOLOGY; MARKERS; SYSTEMS; DESIGN	Rapid and accurate measurement of biomarkers in tissue and fluid samples is a major challenge in medicine. Here we report the development of a new, miniaturized diagnostic magnetic resonance (DMR) system for multiplexed, quantitative and rapid analysis. By using magnetic particles as a proximity sensor to amplify molecular interactions, the handheld DMR system can perform measurements on unprocessed biological samples. We show the capability of the DMR system by using it to detect bacteria with high sensitivity, identify small numbers of cells and analyze them on a molecular level in real time, and measure a series of protein biomarkers in parallel. The DMR technology shows promise as a robust and portable diagnostic device.	[Lee, Hakho; Sun, Eric; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA; [Ham, Donhee] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University	Weissleder, R (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA.	rweissleder@mgh.harvard.edu		/0000-0003-0828-4143; Ham, Donhee/0000-0001-6925-2466	NCI NIH HHS [U54 CA119349-040003, U54 CA119349] Funding Source: Medline; NHLBI NIH HHS [U01 HL080731, U01 HL080731-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119349] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL080731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Aslan K, 2005, CURR OPIN CHEM BIOL, V9, P538, DOI 10.1016/j.cbpa.2005.08.021; BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; Boero G, 1998, SENSOR ACTUAT A-PHYS, V67, P18, DOI 10.1016/S0924-4247(97)01722-6; Cheng MMC, 2006, CURR OPIN CHEM BIOL, V10, P11, DOI 10.1016/j.cbpa.2006.01.006; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Dittrich PS, 2006, NAT REV DRUG DISCOV, V5, P210, DOI 10.1038/nrd1985; HALBACH K, 1980, NUCL INSTRUM METHODS, V169, P1, DOI 10.1016/0029-554X(80)90094-4; Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635; Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446; Koh I, 2008, ANGEW CHEM INT EDIT, V47, P4119, DOI 10.1002/anie.200800069; Lee H, 2006, IEEE J SOLID-ST CIRC, V41, P1471, DOI 10.1109/JSSC.2006.874331; Lee JH, 2007, NAT MED, V13, P95, DOI [10.1038/nm1467, 10.20659/jfp.13.1_95]; Lim Yee-Wei, 2006, Nature, V444 Suppl 1, P9, DOI 10.1038/nature05442; LIU Y, 2008, ISSCC DIG TECH PAPER, V1, P140; Massin C, 2003, J MAGN RESON, V164, P242, DOI 10.1016/S1090-7807(03)00151-4; Nair PR, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2211310; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; OLSON DL, 1995, SCIENCE, V270, P1967, DOI 10.1126/science.270.5244.1967; PECK TL, 1995, J MAGN RESON SER B, V108, P114, DOI 10.1006/jmrb.1995.1112; Perez JM, 2002, NAT BIOTECHNOL, V20, P816, DOI 10.1038/nbt720; Perlo J, 2007, SCIENCE, V315, P1110, DOI 10.1126/science.1135499; Ricci Karen A, 2006, Nature, V444 Suppl 1, P29; Schroder L, 2006, SCIENCE, V314, P446, DOI 10.1126/science.1131847; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Trumbull JD, 2000, IEEE T BIO-MED ENG, V47, P3, DOI 10.1109/10.817611; Urdea Mickey, 2006, Nature, V444 Suppl 1, P73, DOI 10.1038/nature05448; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043; Xia HM, 2005, LAB CHIP, V5, P748, DOI 10.1039/b502031j; Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138	30	454	497	4	205	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					869	874		10.1038/nm.1711	http://dx.doi.org/10.1038/nm.1711			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18607350	Green Accepted			2022-12-27	WOS:000258237500035
J	Su, EJ; Fredriksson, L; Geyer, M; Folestad, E; Cale, J; Andrae, J; Gao, Y; Pietras, K; Mann, K; Yepes, M; Strickland, DK; Betsholtz, C; Eriksson, U; Lawrence, DA				Su, Enming J.; Fredriksson, Linda; Geyer, Melissa; Folestad, Erika; Cale, Jacqueline; Andrae, Johanna; Gao, Yamei; Pietras, Kristian; Mann, Kris; Yepes, Manuel; Strickland, Dudley K.; Betsholtz, Christer; Eriksson, Ulf; Lawrence, Daniel A.			Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke	NATURE MEDICINE			English	Article							RECEPTOR-RELATED PROTEIN; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; TPA-DEFICIENT MICE; HEMORRHAGIC TRANSFORMATION; NEURONAL DEGENERATION; ALPHA-RECEPTOR; WILD-TYPE; T-PA; NEUROSERPIN	Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA be administered within 3 h of symptoms. Here we report that tPA activation of latent platelet-derived growth factor-CC (PDGF-CC) may explain these limitations. Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. In contrast, co-injection of neutralizing antibodies to PDGF-CC with tPA blocks this increased permeability, indicating that PDGF-CC is a downstream substrate of tPA within the neurovascular unit. These effects are mediated through activation of PDGF-alpha receptors (PDGFR-alpha) on perivascular astrocytes, and treatment of mice with the PDGFR-alpha antagonist imatinib after ischemic stroke reduces both cerebrovascular permeability and hemorrhagic complications associated with late administration of thrombolytic tPA. These data demonstrate that PDGF signaling regulates blood-brain barrier permeability and suggest potential new strategies for stroke treatment.	[Fredriksson, Linda; Folestad, Erika; Andrae, Johanna; Pietras, Kristian; Eriksson, Ulf] Karolinska Inst, Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; [Su, Enming J.; Geyer, Melissa; Cale, Jacqueline; Lawrence, Daniel A.] Univ Michigan, Div Cardiovasc Med, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA; [Andrae, Johanna; Betsholtz, Christer] Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Lab Vasc Biol, S-17177 Stockholm, Sweden; [Gao, Yamei; Strickland, Dudley K.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; [Gao, Yamei; Strickland, Dudley K.] Univ Maryland, Sch Med, Dept Surg & Physiol, Baltimore, MD 21201 USA; [Yepes, Manuel] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Yepes, Manuel] Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Karolinska Institutet; Ludwig Institute for Cancer Research; University of Michigan System; University of Michigan; Karolinska Institutet; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Emory University; Emory University	Eriksson, U (corresponding author), Karolinska Inst, Ludwig Inst Canc Res, Stockholm Branch, POB 240, S-17177 Stockholm, Sweden.	ulf.eriksson@licr.ki.se; dlawrenc@umich.edu	Andrae, Johanna/L-3875-2014; Pietras, Kristian/ABE-8727-2020; Pietras, Kristian/ABG-2097-2021; Yepes, Manuel/C-3576-2011	Pietras, Kristian/0000-0001-6738-4705; Fredriksson, Linda/0000-0003-4952-2742; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, R01HL055747, R01HL055374, P01HL057346, P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049478, R01NS079331, R01NS062073] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL55747, R01 HL055374-12, P01 HL054710-11A10006, R01 HL055747-10, R01 HL055374, P01 HL054710-11A1, P01 HL054710-120006, P01 HL054710, P01 HL054710-12, R01 HL050784-09, HL57346, R01 HL055374-10, HL55374, R01 HL055747, R01 HL055374-11A1, R01 HL050784, R01 HL055374-09, R01 HL055747-11, P01 HL057346-11A18577, P01 HL057346, HL50784] Funding Source: Medline; NINDS NIH HHS [R01 NS049478, R01 NS079331, R01 NS091201, NS49478, R01 NS049478-04, R01 NS062073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Breedveld P, 2005, CANCER RES, V65, P2577, DOI 10.1158/0008-5472.CAN-04-2416; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Cinelli P, 2001, MOL CELL NEUROSCI, V18, P443, DOI 10.1006/mcne.2001.1028; Ding H, 2004, NAT GENET, V36, P1111, DOI 10.1038/ng1415; Fredriksson L, 2005, J BIOL CHEM, V280, P26856, DOI 10.1074/jbc.M503388200; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hamilton TG, 2003, MOL CELL BIOL, V23, P4013, DOI 10.1128/MCB.23.11.4013-4025.2003; Hao ZF, 2006, BLOOD, V108, P200, DOI 10.1182/blood-2005-12-4884; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Herz J, 2003, J CLIN INVEST, V112, P1483, DOI 10.1172/JCI200320337; Hou ST, 2002, INT REV CYTOL, V221, P93; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Marler JR, 2003, SCIENCE, V301, P1677, DOI 10.1126/science.1090270; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; Nagai N, 2005, J THROMB HAEMOST, V3, P1379, DOI 10.1111/j.1538-7836.2005.01466.x; Nagai N, 2002, J CEREBR BLOOD F MET, V22, P648, DOI 10.1097/00004647-200206000-00002; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P443, DOI 10.1073/pnas.0406454102; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Ponten A, 2003, AM J PATHOL, V163, P673, DOI 10.1016/S0002-9440(10)63694-2; Tabrizi P, 1999, ARTERIOSCL THROM VAS, V19, P2801, DOI 10.1161/01.ATV.19.11.2801; Thomalla G, 2007, STROKE, V38, P313, DOI 10.1161/01.STR.0000254565.51807.22; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vora NA, 2007, AM J NEURORADIOL, V28, P1391, DOI 10.3174/ajnr.A0575; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WILLNOW TE, 1994, J CELL SCI, V107, P719; WOLF BB, 1992, AM J PATHOL, V141, P37; Yepes M, 2004, EXP BIOL MED, V229, P1097, DOI 10.1177/153537020422901103; Yepes M, 2004, TRENDS CARDIOVAS MED, V14, P173, DOI 10.1016/j.tcm.2004.03.004; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Yu H, 2001, EUR J NEUROSCI, V14, P799, DOI 10.1046/j.0953-816x.2001.01700.x; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754	44	331	344	1	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					731	737		10.1038/nm1787	http://dx.doi.org/10.1038/nm1787			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18568034	Green Accepted			2022-12-27	WOS:000257452700020
J	Finak, G; Bertos, N; Pepin, F; Sadekova, S; Souleimanova, M; Zhao, H; Chen, HY; Omeroglu, G; Meterissian, S; Omeroglu, A; Hallett, M; Park, M				Finak, Greg; Bertos, Nicholas; Pepin, Francois; Sadekova, Svetlana; Souleimanova, Margarita; Zhao, Hong; Chen, Haiying; Omeroglu, Gulbeyaz; Meterissian, Sarkis; Omeroglu, Atilla; Hallett, Michael; Park, Morag			Stromal gene expression predicts clinical outcome in breast cancer	NATURE MEDICINE			English	Article							T-CELLS; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; TUMOR-STROMA; SURVIVAL; ANGIOGENESIS; MACROPHAGES; SIGNATURE; METASTASIS; CARCINOMA	Although it is increasingly evident that cancer is influenced by signals emanating from tumor stroma, little is known regarding how changes in stromal gene expression affect epithelial tumor progression. We used laser capture microdissection to compare gene expression profiles of tumor stroma from 53 primary breast tumors and derived signatures strongly associated with clinical outcome. We present a new stroma-derived prognostic predictor ( SDPP) that stratifies disease outcome independently of standard clinical prognostic factors and published expression-based predictors. The SDPP predicts outcome in several published whole tumor-derived expression data sets, identifies poor-outcome individuals from multiple clinical subtypes, including lymph node-negative tumors, and shows increased accuracy with respect to previously published predictors, especially for HER2-positive tumors. Prognostic power increases substantially when the predictor is combined with existing outcome predictors. Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression.	[Finak, Greg; Bertos, Nicholas; Pepin, Francois; Sadekova, Svetlana; Souleimanova, Margarita; Zhao, Hong; Chen, Haiying; Omeroglu, Gulbeyaz; Park, Morag] McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; [Finak, Greg; Pepin, Francois; Hallett, Michael] McGill Univ, McGill Ctr Bioinformat, Montreal, PQ H3A 2B4, Canada; [Finak, Greg; Pepin, Francois; Hallett, Michael; Park, Morag] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Meterissian, Sarkis] McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada; [Park, Morag] McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; [Omeroglu, Atilla] McGill Univ, Dept Pathol, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca	Peng, Chunwei/F-6788-2010	Hallett, Michael/0000-0001-6738-6786; Finak, Greg/0000-0003-4341-9090	NCI NIH HHS [P01 CA097189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; Bosco MC, 2006, J IMMUNOL, V177, P1941, DOI 10.4049/jimmunol.177.3.1941; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Buess M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r191; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Dalberg U, 2007, INT IMMUNOL, V19, P447, DOI 10.1093/intimm/dxm009; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x; Finak G, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1608; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Hofmann HS, 2005, CLIN CANCER RES, V11, P1086; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kim JB, 2005, TUMOR BIOL, V26, P173, DOI 10.1159/000086950; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Nuyten Dimitry S A, 2006, Breast Dis, V26, P149; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pearl J, 1988, PROBABILISTIC REASON, P116; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; SINGER CF, 2007, BREAST CANC RES TREA; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Starnes T, 2006, EXP HEMATOL, V34, P1101, DOI 10.1016/j.exphem.2006.05.015; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828	49	1244	1285	1	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					518	527		10.1038/nm1764	http://dx.doi.org/10.1038/nm1764			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18438415				2022-12-27	WOS:000255681800032
J	Aujla, SJ; Chan, YR; Zheng, MQ; Fei, MJ; Askew, DJ; Pociask, DA; Reinhart, TA; McAllister, F; Edeal, J; Gaus, K; Husain, S; Kreindler, JL; Dubin, PJ; Pilewski, JM; Myerburg, MM; Mason, CA; Iwakura, Y; Kolls, JK				Aujla, Shean J.; Chan, Yvonne R.; Zheng, Mingquan; Fei, Mingjian; Askew, David J.; Pociask, Derek A.; Reinhart, Todd A.; McAllister, Florencia; Edeal, Jennifer; Gaus, Kristi; Husain, Shahid; Kreindler, James L.; Dubin, Patricia J.; Pilewski, Joseph M.; Myerburg, Mike M.; Mason, Carol A.; Iwakura, Yoichiro; Kolls, Jay K.			IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia	NATURE MEDICINE			English	Article							T-HELPER-CELLS; ESCHERICHIA-COLI INFECTION; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; NEUTROPHIL RECRUITMENT; IL-17 PRODUCTION; INFLAMMATION; DIFFERENTIATION; IMMUNITY; RECEPTOR	Emerging evidence supports the concept that T helper type 17 (T(H)17) cells, in addition to mediating autoimmunity, have key roles in mucosal immunity against extracellular pathogens. Interleukin-22 (IL-22) and IL-17A are both effector cytokines produced by the T(H)17 lineage, and both were crucial for maintaining local control of the Gram-negative pulmonary pathogen, Klebsiella pneumoniae. Although both cytokines regulated CXC chemokines and granulocyte colony-stimulating factor production in the lung, only IL-22 increased lung epithelial cell proliferation and increased transepithelial resistance to injury. These data support the concept that the T(H)17 cell lineage and its effector molecules have evolved to effect host defense against extracellular pathogens at mucosal sites.	[Aujla, Shean J.; Zheng, Mingquan; Fei, Mingjian; Pociask, Derek A.; McAllister, Florencia; Edeal, Jennifer; Kreindler, James L.; Dubin, Patricia J.; Kolls, Jay K.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Chan, Yvonne R.; Pilewski, Joseph M.; Myerburg, Mike M.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Askew, David J.] Univ Pittsburgh, Med Ctr, Newborn Med Program, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Askew, David J.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA; [Reinhart, Todd A.; Gaus, Kristi] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; [Husain, Shahid] Univ Pittsburgh, Med Ctr, Div Infect Dis, Transplant Infect Dis Unit, Pittsburgh, PA 15213 USA; [Mason, Carol A.] Louisiana Hlth Sci Ctr, Div Pulm & Crit Care Med, New Orleans, LA 70112 USA; [Iwakura, Yoichiro] Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Tokyo	Kolls, JK (corresponding author), Childrens Hosp Pittsburgh, Suite 3765,3705 5th Ave, Pittsburgh, PA 15213 USA.	jay.kolls@chp.edu	Pilewski, Joseph/AAF-5149-2021; Dubin, Patricia/AAB-9951-2020; Chan, Yvonne R/A-2513-2011; Kolls, Jay/AAH-1829-2019; Iwakura, Yoichiro/E-5457-2011	Kolls, Jay/0000-0001-5151-6304; Iwakura, Yoichiro/0000-0002-9934-5775; Husain, Shahid/0000-0002-9216-5229	NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NHLBI NIH HHS [P50HL084932, R01 HL079142, P50 HL084932, R01 HL079142-04, R37 HL079142, R01 HL061271, R01 HL061271-04, 5R01HL079142] Funding Source: Medline; NIDDK NIH HHS [P30 DK072506, P30DK072506] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079142, R37HL079142, R01HL061271, P50HL084932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072506] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chakinala MM, 2005, CLIN CHEST MED, V26, P113, DOI 10.1016/j.ccm.2004.10.010; Chung DR, 2003, J IMMUNOL, V170, P1958, DOI 10.4049/jimmunol.170.4.1958; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Fallert BA, 2002, J VIROL METHODS, V99, P23, DOI 10.1016/S0166-0934(01)00378-0; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lubberts Erik, 2003, Curr Opin Investig Drugs, V4, P572; Malley R, 2006, INFECT IMMUN, V74, P2187, DOI 10.1128/IAI.74.4.2187-2195.2006; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376; TASWELL C, 1981, J IMMUNOL, V126, P1614; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wu Q, 2007, MICROBES INFECT, V9, P78, DOI 10.1016/j.micinf.2006.10.012; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023	40	897	956	3	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					275	281		10.1038/nm1710	http://dx.doi.org/10.1038/nm1710			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18264110	Green Accepted			2022-12-27	WOS:000253815700033
J	Engin, FZ; Yao, ZQ; Yang, T; Zhou, G; Bertin, T; Jiang, MM; Chen, YQ; Wang, L; Zheng, H; Sutton, RE; Boyce, BF; Lee, B				Engin, Feyza; Yao, Zhenqiang; Yang, Tao; Zhou, Guang; Bertin, Terry; Jiang, Ming Ming; Chen, Yuqing; Wang, Lisa; Zheng, Hui; Sutton, Richard E.; Boyce, Brendan F.; Lee, Brendan			Dimorphic effects of Notch signaling in bone homeostasis	NATURE MEDICINE			English	Article							OSTEOBLASTIC CELL-DIFFERENTIATION; POSTMENOPAUSAL WOMEN; WNT/BETA-CATENIN; MINERAL DENSITY; OSTEOPROTEGERIN; RUNX2; WNT; EXPRESSION; MASS; SKELETOGENESIS	Notch signaling is a key mechanism in the control of embryogenesis. However, its in vivo function during mesenchymal cell differentiation, and, specifically, in bone homeostasis, remains largely unknown. Here, we show that osteoblast-specific gain of Notch function causes severe osteosclerosis owing to increased proliferation of immature osteoblasts. Under these pathological conditions, Notch stimulates early osteoblastic proliferation by upregulating the genes encoding cyclin D, cyclin E and Sp7 (osterix). The intracellular domain of Notch1 also regulates terminal osteoblastic differentiation by directly binding Runx2 and repressing its transactivation function. In contrast, loss of all Notch signaling in osteoblasts, generated by deletion of the genes encoding presenilin-1 and presenilin-2 in bone, is associated with late-onset, age-related osteoporosis, which in turn results from increased osteoblast-dependent osteoclastic activity due to decreased osteoprotegerin mRNA expression in these cells. Together, these findings highlight the potential dimorphic effects of Notch signaling in bone homeostasis and may provide direction for novel therapeutic applications.	[Engin, Feyza; Yang, Tao; Zhou, Guang; Bertin, Terry; Jiang, Ming Ming; Chen, Yuqing; Zheng, Hui; Lee, Brendan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Yao, Zhenqiang; Boyce, Brendan F.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Yao, Zhenqiang; Boyce, Brendan F.] Univ Rochester, Med Ctr, Lab Med, Rochester, NY 14642 USA; [Jiang, Ming Ming; Chen, Yuqing; Lee, Brendan] Howard Hughes Med Inst, Houston, TX 77030 USA; [Wang, Lisa] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Sutton, Richard E.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; University of Rochester; University of Rochester; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Lee, B (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl, Houston, TX 77030 USA.	blee@bcm.tmc.edu		Engin, Feyza/0000-0002-7987-5381	NIAMS NIH HHS [AR43510, R01 AR043510] Funding Source: Medline; NICHD NIH HHS [P01 HD022657, HD22657] Funding Source: Medline; NIDCR NIH HHS [DE016990, R01 DE016990, R01 DE016990-04] Funding Source: Medline; NIEHS NIH HHS [ES11253, P01 ES011253] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011253] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arko B, 2005, MATURITAS, V51, P270, DOI 10.1016/j.maturitas.2004.08.006; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Boyce BF, 2006, NAT MED, V12, P1356, DOI 10.1038/nm1206-1356; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan CA, 2000, CELL MOL LIFE SCI, V57, P195, DOI 10.1007/PL00000684; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Choi JY, 2005, CALCIFIED TISSUE INT, V77, P152, DOI 10.1007/s00223-004-0264-0; Dai C, 2004, J VIROL, V78, P6209, DOI 10.1128/JVI.78.12.6209-6221.2004; Daudet N, 2005, DEVELOPMENT, V132, P541, DOI 10.1242/dev.01589; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Fahrleitner-Pammer A, 2003, WIEN KLIN WOCHENSCHR, V115, P291, DOI 10.1007/BF03040334; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Mezquita-Raya P, 2005, OSTEOPOROSIS INT, V16, P1368, DOI 10.1007/s00198-005-1844-1; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Pratap J, 2003, CANCER RES, V63, P5357; Sakamoto K, 2005, EXP CELL RES, V302, P281, DOI 10.1016/j.yexcr.2004.09.016; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Segall HI, 2003, MOL THER, V8, P118, DOI 10.1016/S1525-0016(03)00134-5; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103	37	289	322	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					299	305		10.1038/nm1712	http://dx.doi.org/10.1038/nm1712			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18297084	Green Accepted			2022-12-27	WOS:000253815700036
J	Song, XT; Evel-Kabler, K; Shen, L; Rollins, L; Huang, XF; Chen, SY				Song, Xiao-Tong; Evel-Kabler, Kevin; Shen, Lei; Rollins, Lisa; Huang, Xue F.; Chen, Si-Yi			A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression	NATURE MEDICINE			English	Article							NF-KAPPA-B; DENDRITIC CELLS; ANTITUMOR IMMUNITY; TUMOR-IMMUNITY; CUTTING EDGE; CANCER-IMMUNOTHERAPY; LYMPHOCYTE ANTIGEN-4; B16 MELANOMA; ACTIVATION; BLOCKADE	Regulatory T cells (T-reg cells) suppress autoreactive immune responses and limit the efficacy of tumor vaccines; however, it remains a challenge to selectively eliminate or inhibit T-reg cells. In this study, the zinc-finger A20, a negative regulator of the Toll-like receptor and tumor necrosis factor receptor signaling pathways, was found to play a crucial part in controlling the maturation, cytokine production and immunostimulatory potency of dendritic cells (DCs). A20-silenced DCs showed spontaneous and enhanced expression of costimulatory molecules and proinflammatory cytokines and had different effects on T cell subsets: they inhibited T-reg cells and hyperactivated tumor-infiltrating cytotoxic T lymphocytes and T helper cells that produced interleukin-6 and tumor necrosis factor-alpha and were refractory to T-reg cell-mediated suppression. Hence, this study identifies A20 as an antigen presentation attenuator in control of antitumor immune responses during both the priming and the effector phases and provides a strategy to overcome T-reg cell-mediated suppression in an antigen-specific manner, reducing the need to directly target T-reg cells.	[Song, Xiao-Tong; Evel-Kabler, Kevin; Shen, Lei; Rollins, Lisa; Huang, Xue F.; Chen, Si-Yi] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Huang, Xue F.; Chen, Si-Yi] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA	Baylor College of Medicine; University of Southern California	Chen, SY (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza, Houston, TX 77030 USA.	siyichen@usc.edu	Song, Xiao-Tong/AAI-8424-2020		NATIONAL CANCER INSTITUTE [R01CA100841, R01CA116677, R01CA090427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068472] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090427-02, R01CA90427, R01 CA116677-04, R01 CA090427-03, R01 CA090427-05, R01 CA116677, R01 CA116677-05, R01 CA100841, R01 CA090427-04, R01 CA090427, R01CA116677] Funding Source: Medline; NIAID NIH HHS [R01 AI068472-05, R01 AI068472, R01 AI068472-04, R01AI68472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLOUCHE M, 1990, LEUKEMIA RES, V14, P353, DOI 10.1016/0145-2126(90)90163-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Evel-Kabler K, 2006, J CLIN INVEST, V116, P90, DOI 10.1172/JCI26169; Evel-Kabler K, 2006, MOL THER, V13, P850, DOI 10.1016/j.ymthe.2006.02.009; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; King IL, 2005, J IMMUNOL, V175, P641, DOI 10.4049/jimmunol.175.2.641; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Maker AV, 2005, J IMMUNOL, V175, P7746, DOI 10.4049/jimmunol.175.11.7746; Overwijk WW, 2005, CURR OPIN IMMUNOL, V17, P187, DOI 10.1016/j.coi.2005.01.011; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Prasad SJ, 2005, J IMMUNOL, V174, P90, DOI 10.4049/jimmunol.174.1.90; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Ramirez-Montagut T, 2006, J IMMUNOL, V176, P6434, DOI 10.4049/jimmunol.176.11.6434; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schroers Roland, 2004, Methods Mol Biol, V246, P451; Shen L, 2004, NAT BIOTECHNOL, V22, P1546, DOI 10.1038/nbt1035; Shimizu J, 1999, J IMMUNOL, V163, P5211; Siegel S, 2003, BRIT J HAEMATOL, V122, P911, DOI 10.1046/j.1365-2141.2003.04535.x; So T, 2007, J IMMUNOL, V179, P1427, DOI 10.4049/jimmunol.179.3.1427; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; Vu MD, 2007, BLOOD, V110, P2501, DOI 10.1182/blood-2007-01-070748; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Woo EY, 2001, CANCER RES, V61, P4766; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	46	135	149	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					258	265		10.1038/nm1721	http://dx.doi.org/10.1038/nm1721			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18311150	Green Accepted			2022-12-27	WOS:000253815700031
J	Bekar, L; Libionka, W; Tian, GF; Xu, QW; Torres, A; Wang, XH; Lovatt, D; Williams, E; Takano, TH; Schnermann, J; Bakos, R; Nedergaard, M				Bekar, Lane; Libionka, Witold; Tian, Guo-Feng; Xu, Qiwu; Torres, Arnulfo; Wang, Xiaohai; Lovatt, Ditte; Williams, Erika; Takano, Takahiro; Schnermann, Jurgen; Bakos, Robert; Nedergaard, Maiken			Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor	NATURE MEDICINE			English	Article							HARMALINE-INDUCED TREMOR; ATP RELEASE; RAT; INHIBITION; DISORDERS; SYNAPSES; MICE	Deep brain stimulation (DBS) is a widely used neurosurgical approach to treating tremor and other movement disorders(1-3). In addition, the use of DBS in a number of psychiatric diseases, including obsessive-compulsive disorders and depression, is currently being tested(4-6). Despite the rapid increase in the number of individuals with surgically implanted stimulation electrodes, the cellular pathways involved in mediating the effects of DBS remain unknown(1). Here we show that DBS is associated with a marked increase in the release of ATP, resulting in accumulation of its catabolic product, adenosine. Adenosine A1 receptor activation depresses excitatory transmission in the thalamus and reduces both tremor-and DBS-induced side effects. Intrathalamic infusion of A1 receptor agonists directly reduces tremor, whereas adenosine A1 receptor-null mice show involuntary movements and seizure at stimulation intensities below the therapeutic level. Furthermore, our data indicate that endogenous adenosine mechanisms are active in tremor, thus supporting the clinical notion that caffeine, a nonselective adenosine receptor antagonist, can trigger or exacerbate essential tremor(7). Our findings suggest that nonsynaptic mechanisms involving the activation of A1 receptors suppress tremor activity and limit stimulation-induced side effects, thereby providing a new pharmacological target to replace or improve the efficacy of DBS.	[Bekar, Lane; Libionka, Witold; Tian, Guo-Feng; Xu, Qiwu; Torres, Arnulfo; Wang, Xiaohai; Lovatt, Ditte; Williams, Erika; Takano, Takahiro; Bakos, Robert; Nedergaard, Maiken] Univ Rochester, Dept Neurosurg, Div Glial Dis & Therapeut, Rochester, NY 14642 USA; [Schnermann, Jurgen] NIDDKD, Natl Inst Hlth, Bethesda, MD 20892 USA	University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bekar, L (corresponding author), Univ Rochester, Dept Neurosurg, Div Glial Dis & Therapeut, 601 Elmwood Ave, Rochester, NY 14642 USA.	lane_bekar@urmc.rochester.edu; nedergaard@urmc.rochester.edu	Bekar, Lane K./AAI-2645-2021	Bekar, Lane/0000-0001-5083-0967; Takano, Takahiro/0000-0002-6235-6673; Wang, Xiaohai/0000-0001-5814-4072	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043413, Z01DK043413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030007, R01NS039559, R29NS030007, P01NS050315] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39559, NS30007, NS050315] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson TR, 2006, J NEUROSCI, V26, P841, DOI 10.1523/JNEUROSCI.3523-05.2006; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; Boulet S, 2006, J NEUROSCI, V26, P10768, DOI 10.1523/JNEUROSCI.3065-06.2006; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cousins MS, 1997, EUR J PHARMACOL, V322, P137, DOI 10.1016/S0014-2999(97)00008-3; Dunwiddie TV, 1997, J NEUROSCI, V17, P7673; Gomes P, 2005, INVEST OPHTH VIS SCI, V46, P1208, DOI 10.1167/iovs.04-1181; Hamani C, 2006, PAIN, V125, P188, DOI 10.1016/j.pain.2006.05.019; Jiang L, 2001, NEURON, V30, P503, DOI 10.1016/S0896-6273(01)00298-7; JOLICOEUR FB, 1991, BRAIN RES BULL, V26, P317, DOI 10.1016/0361-9230(91)90245-F; Kuncel AM, 2004, CLIN NEUROPHYSIOL, V115, P2431, DOI 10.1016/j.clinph.2004.05.031; Louis ED, 2004, MOVEMENT DISORD, V19, P499, DOI 10.1002/mds.20035; Lozano Andres M, 2004, Suppl Clin Neurophysiol, V57, P733; Marks William J, 2005, Curr Treat Options Neurol, V7, P237, DOI 10.1007/s11940-005-0017-z; Martin FC, 2005, MOVEMENT DISORD, V20, P298, DOI 10.1002/mds.20331; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; McIntyre CC, 2004, J CLIN NEUROPHYSIOL, V21, P40, DOI 10.1097/00004691-200401000-00006; McIntyre CC, 2002, J NEUROPHYSIOL, V88, P1592, DOI 10.1152/jn.2002.88.4.1592; MILNER TE, 1995, J NEUROPHYSIOL, V73, P2568, DOI 10.1152/jn.1995.73.6.2568; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Perlmutter JS, 2006, ANNU REV NEUROSCI, V29, P229, DOI 10.1146/annurev.neuro.29.051605.112824; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Wall MJ, 2007, J PHYSIOL-LONDON, V581, P553, DOI 10.1113/jphysiol.2006.126417; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703; Wichmann T, 2006, NEURON, V52, P197, DOI 10.1016/j.neuron.2006.09.022; Wilms H, 1999, MOVEMENT DISORD, V14, P557, DOI 10.1002/1531-8257(199907)14:4<557::AID-MDS1004>3.0.CO;2-G; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7	30	194	204	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					75	80		10.1038/nm1693	http://dx.doi.org/10.1038/nm1693			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157140				2022-12-27	WOS:000252222400025
J	Liu, XB; Leung, S; Wang, CX; Tan, Z; Wang, J; Guo, TB; Fang, L; Zhao, YG; Wan, B; Qin, X; Lu, LM; Li, RS; Pan, H; Song, MJ; Liu, AL; Hong, J; Lu, HT; Zhang, JZ				Liu, Xuebin; Leung, Stewart; Wang, Chunxia; Tan, Zhu; Wang, Ji; Guo, Taylor B.; Fang, Lei; Zhao, Yonggang; Wan, Bing; Qin, Xia; Lu, Limin; Li, Runsheng; Pan, Heng; Song, Mingjuan; Liu, Ailian; Hong, Jian; Lu, Hongtao; Zhang, Jingwu Z.			RETRACTED: Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease (Retracted article. See vol. 19, pg. 1673, 2013)	NATURE MEDICINE			English	Article; Retracted Publication							CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MULTIPLE-SCLEROSIS; T(H)17 CELLS; FAMILY CYTOKINES; DEFICIENT MICE; TH17 CELLS; TGF-BETA; RECEPTOR; ENCEPHALOMYELITIS	Interleukin-7 receptor (IL-7R) is genetically associated with susceptibility to multiple sclerosis. Here we describe that IL-7 is essential for survival and expansion of pathogenic T helper type 17 (T(H)17) cells in experimental autoimmune encephalomyelitis (EAE). IL-7 directly expanded effector T(H)17 cells in EAE and human T(H)17 cells from subjects with multiple sclerosis, whereas it was not required for T(H)17 differentiation. IL-7R antagonism rendered differentiated T(H)17 cells susceptible to apoptosis through the inhibition of Janus kinase-signal transducer and activator of transcription-5 (JAK-STAT5) pathway and altered expression of the prosurvival protein Bcl-2 and the proapoptotic protein Bax, leading to decreased severity of EAE. In contrast, T(H)1 and regulatory T (T-reg) cells were less susceptible to or not affected by IL-7R antagonism in vivo. The selectivity was attributable to minimal expression of IL-7R alpha in T-reg cells and correlated with a high level of Socs1 (encoding suppressor of cytokine signaling-1) expression in T(H)1 cells. The study reveals a unique, previously undescribed role of IL-7-IL-7R in T(H)17 cell survival and expansion and has implications in the treatment of autoimmune disease.	[Liu, Xuebin; Leung, Stewart; Wang, Chunxia; Tan, Zhu; Wang, Ji; Guo, Taylor B.; Fang, Lei; Zhao, Yonggang; Wan, Bing; Qin, Xia; Lu, Limin; Li, Runsheng; Pan, Heng; Song, Mingjuan; Liu, Ailian; Lu, Hongtao; Zhang, Jingwu Z.] GlaxoSmithKline, Ctr Res & Dev, Dept Neuroimmunol, Shanghai, Peoples R China; [Hong, Jian] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	GlaxoSmithKline; Baylor College of Medicine	Zhang, JZ (corresponding author), GlaxoSmithKline, Ctr Res & Dev, Dept Neuroimmunol, Shanghai, Peoples R China.	jingwu.z.zang@gsk.com						Akirav EM, 2009, J NEUROSCI RES, V87, P3511, DOI 10.1002/jnr.21981; Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585; Bettelli E, 2007, ANN NY ACAD SCI, V1103, P11, DOI 10.1196/annals.1394.021; Betti M, 2006, ANN ONCOL, V17, P235; Bielekova B, 1999, J NEUROIMMUNOL, V100, P115, DOI 10.1016/S0165-5728(99)00200-3; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Egwuagu CE, 2009, CYTOKINE, V47, P149, DOI 10.1016/j.cyto.2009.07.003; Elder JT, 2007, J INVEST DERMATOL, V127, P2495, DOI 10.1038/sj.jid.5700855; Fry TJ, 2005, J IMMUNOL, V174, P6571, DOI 10.4049/jimmunol.174.11.6571; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Isaksen DE, 2002, J IMMUNOL, V168, P3288, DOI 10.4049/jimmunol.168.7.3288; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Jiang Q, 2005, CYTOKINE GROWTH F R, V16, P513, DOI 10.1016/j.cytogfr.2005.05.004; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kumar M, 2006, J NEUROIMMUNOL, V180, P178, DOI 10.1016/j.jneuroim.2006.08.003; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lu N, 2009, J EXP MED, V206, P2111, DOI 10.1084/jem.20090153; Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; McFarland HF, 2007, NAT IMMUNOL, V8, P913, DOI 10.1038/ni1507; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Palmer MJ, 2008, CELL MOL IMMUNOL, V5, P79, DOI 10.1038/cmi.2008.10; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Seki Y, 2007, J IMMUNOL, V178, P262, DOI 10.4049/jimmunol.178.1.262; Serada S, 2008, P NATL ACAD SCI USA, V105, P9041, DOI 10.1073/pnas.0802218105; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2009, J EXP MED, V206, P43, DOI 10.1084/jem.20081438; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Weiner HL, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-1002-8; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021	56	107	127	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					191	U97		10.1038/nm.2077	http://dx.doi.org/10.1038/nm.2077			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20062065				2022-12-27	WOS:000274297000040
J	Barlow, JL; Drynan, LF; Hewett, DR; Holmes, LR; Lorenzo-Abalde, S; Lane, AL; Jolin, HE; Pannell, R; Middleton, AJ; Wong, SH; Warren, AJ; Wainscoat, JS; Boultwood, J; McKenzie, ANJ				Barlow, Jillian L.; Drynan, Lesley F.; Hewett, Duncan R.; Holmes, Luke R.; Lorenzo-Abalde, Silvia; Lane, Alison L.; Jolin, Helen E.; Pannell, Richard; Middleton, Angela J.; Wong, See Heng; Warren, Alan J.; Wainscoat, James S.; Boultwood, Jacqueline; McKenzie, Andrew N. J.			A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome	NATURE MEDICINE			English	Article							COMMONLY DELETED REGION; RIBOSOMAL-PROTEIN S19; TCOF1 GENE-PRODUCT; P53; RNA; ACTIVATION; COLLINSSYNDROME,TREACHER; HAPLOINSUFFICIENCY; IDENTIFICATION; INACTIVATION	The identification of the genes associated with chromosomal translocation breakpoints has fundamentally changed understanding of the molecular basis of hematological malignancies. By contrast, the study of chromosomal deletions has been hampered by the large number of genes deleted and the complexity of their analysis. We report the generation of a mouse model for human 5q-syndrome using large-scale chromosomal engineering. Haploinsufficiency of the Cd74-Nid67 interval (containing Rps14, encoding the ribosomal protein S14) caused macrocytic anemia, prominent erythroid dysplasia and monolobulated megakaryocytes in the bone marrow. These effects were associated with defective bone marrow progenitor development, the appearance of bone marrow cells expressing high amounts of the tumor suppressor p53 and increased bone marrow cell apoptosis. Notably, intercrossing with p53-deficient mice completely rescued the progenitor cell defect, restoring common myeloid progenitor and megakaryocytic-erythroid progenitor, granulocyte-monocyte progenitor and hematopoietic stem cell bone marrow populations. This mouse model suggests that a p53-dependent mechanism underlies the pathophysiology of the 5q-syndrome.	[Barlow, Jillian L.; Drynan, Lesley F.; Hewett, Duncan R.; Holmes, Luke R.; Lorenzo-Abalde, Silvia; Lane, Alison L.; Jolin, Helen E.; Pannell, Richard; Middleton, Angela J.; Wong, See Heng; Warren, Alan J.; McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England; [Wainscoat, James S.; Boultwood, Jacqueline] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Leukaemia Res Fund Mol Haematol Unit, Oxford OX3 9DU, England; [Warren, Alan J.] Univ Cambridge, Dept Haematol, Cambridge, England	MRC Laboratory Molecular Biology; University of Oxford; University of Cambridge	McKenzie, ANJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	anm@mrc-lmb.cam.ac.uk	Lorenzo, Silvia/K-1110-2014; Drynan, Lesley/V-2984-2019	Holmes, Luke/0000-0002-6389-5425; Boultwood, Jacqueline/0000-0002-4330-2928; Barlow, Jillian Lynne/0000-0002-8680-3589	Leukaemia Research UK; Medical Research Council [MC_U105178805, MC_U105161083] Funding Source: researchfish; MRC [MC_U105161083, MC_U105178805] Funding Source: UKRI	Leukaemia Research UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Thanks go to members of the McKenzie lab for their comments on the manuscript. We are grateful to the Laboratory of Molecular Biology animal facility staff, especially V. Smith. We are also grateful to K. Grobe (University of Munster) for providing blood from the Ndst1<SUP>+/-</SUP> mice and T. Rabbitts (Leeds Institute of Molecular Medicine) for providing Lmo2Cre mice. A.N.J.M., D.R.H., S.L.-A., A. L. L., J.S.W., J.B. and A.J.W. were funded by Leukaemia Research UK.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BOULTWOOD J, 1994, BLOOD, V84, P3253; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Boultwood J, 2007, BRIT J HAEMATOL, V139, P578, DOI 10.1111/j.1365-2141.2007.06833.x; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Deller T, 2003, P NATL ACAD SCI USA, V100, P10494, DOI 10.1073/pnas.1832384100; Dixon J, 2000, HUM MOL GENET, V9, P1473, DOI 10.1093/hmg/9.10.1473; Dixon J, 2006, P NATL ACAD SCI USA, V103, P13403, DOI 10.1073/pnas.0603730103; Dokal I, 2008, BLOOD REV, V22, P141, DOI 10.1016/j.blre.2007.11.003; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ferreira-Cerca S, 2005, MOL CELL, V20, P263, DOI 10.1016/j.molcel.2005.09.005; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Giagounidis A A N, 2004, Hematology, V9, P271, DOI 10.1080/10245330410001723824; Gonzales B, 2005, HUM MOL GENET, V14, P2035, DOI 10.1093/hmg/ddi208; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; Jakovljevic J, 2004, MOL CELL, V14, P331, DOI 10.1016/S1097-2765(04)00215-1; Janov AJ, 1996, MEDICINE, V75, P77, DOI 10.1097/00005792-199603000-00004; Jones NC, 2008, NAT MED, V14, P125, DOI 10.1038/nm1725; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Lai F, 2001, GENOMICS, V71, P235, DOI 10.1006/geno.2000.6414; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lehmann S, 2007, LEUKEMIA, V21, P1931, DOI 10.1038/sj.leu.2404852; LePage DF, 2000, P NATL ACAD SCI USA, V97, P10471, DOI 10.1073/pnas.97.19.10471; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994; Montaville P, 2006, BBA-MOL CELL RES, V1763, P1335, DOI 10.1016/j.bbamcr.2006.09.003; Panic L, 2006, MOL CELL BIOL, V26, P8880, DOI 10.1128/MCB.00751-06; Patel SR, 2005, BLOOD, V106, P4076, DOI 10.1182/blood-2005-06-2204; Pellagatti A, 2008, BRIT J HAEMATOL, V142, P57, DOI 10.1111/j.1365-2141.2008.07178.x; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Vician L, 2001, J NEUROSCI RES, V64, P108, DOI 10.1002/jnr.1058; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	49	250	259	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					59	U93		10.1038/nm.2063	http://dx.doi.org/10.1038/nm.2063			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	19966810	Green Submitted, Green Accepted			2022-12-27	WOS:000273395500037
J	del Zoppo, GJ				del Zoppo, Gregory J.			Bleeding in the brain Amyloid-beta may keep clots away	NATURE MEDICINE			English	Editorial Material							SERINE PROTEINASE-INHIBITORS; PROTEASE NEXIN-II; PRECURSOR; COAGULATION; ISCHEMIA		Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	del Zoppo, GJ (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave, Seattle, WA 98104 USA.	grgdlzop@u.washington.edu			NINDS NIH HHS [R37 NS038710, R37 NS038710-09, R01 NS053716-05, R01 NS053716] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS038710, R01NS053716] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CORRALRODRIGUEZ MA, 2009, INSECT BIOCHEM MOLEC, V39, P1; Milner R, 2008, STROKE, V39, P191, DOI 10.1161/STROKEAHA.107.486134; OKADA Y, 1994, STROKE, V25, P1847, DOI 10.1161/01.STR.25.9.1847; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Tagaya M, 2001, J CEREBR BLOOD F MET, V21, P835, DOI 10.1097/00004647-200107000-00009; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1989, NATURE, V341, P546; Xu F, 2007, STROKE, V38, P2598, DOI 10.1161/STROKEAHA.106.480103; Xu F, 2009, J NEUROSCI, V29, P5666, DOI 10.1523/JNEUROSCI.0095-09.2009	12	8	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1132	1133		10.1038/nm1009-1132	http://dx.doi.org/10.1038/nm1009-1132			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812571	Green Accepted			2022-12-27	WOS:000270596400021
J	Korpal, M; Yan, J; Lu, X; Xu, SW; Lerit, DA; Kang, YB				Korpal, Manav; Yan, Jun; Lu, Xin; Xu, Shuwa; Lerit, Dorothy A.; Kang, Yibin			Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis	NATURE MEDICINE			English	Article							RECEPTOR-TYPE-I; TGF-BETA; ORAL IBANDRONATE; TUMOR; DISEASE; CELLS; VIVO; INHIBITORS; MICE; BISPHOSPHONATES	Although the transforming growth factor-beta (TGF-beta) pathway has been implicated in breast cancer metastasis, its in vivo dynamics and temporal-spatial involvement in organ-specific metastasis have not been investigated. Here we engineered a xenograft model system with a conditional control of the TGF-beta-SMAD signaling pathway and a dual-luciferase reporter system for tracing both metastatic burden and TGF-beta signaling activity in vivo. Strong TGF-beta signaling in osteolytic bone lesions is suppressed directly by genetic and pharmacological disruption of the TGF-beta-SMAD pathway and indirectly by inhibition of osteoclast function with bisphosphonates. Notably, disruption of TGF-beta signaling early in metastasis can substantially reduce metastasis burden but becomes less effective when bone lesions are well established. Our in vivo system for real-time manipulation and detection of TGF-beta signaling provides a proof of principle for using similar strategies to analyze the in vivo dynamics of other metastasis-associated signaling pathways and will expedite the development and characterization of therapeutic agents.	[Korpal, Manav; Yan, Jun; Lu, Xin; Xu, Shuwa; Lerit, Dorothy A.; Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Kang, Yibin] Canc Inst New Jersey, Breast Canc Program, New Brunswick, NJ USA	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Kang, YB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	ykang@princeton.edu	lu, xuemin/A-8741-2011	Kang, Yibin/0000-0002-1626-6730; Yan, Jun/0000-0002-5641-5710	Department of Defense Era of Hope Scholar Award; American Cancer Society; Susan G. Komen Foundation; New Jersey Commission on Cancer Research; Department of Defense Breast Cancer Research Program.	Department of Defense Era of Hope Scholar Award(United States Department of Defense); American Cancer Society(American Cancer Society); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); New Jersey Commission on Cancer Research; Department of Defense Breast Cancer Research Program.(United States Department of Defense)	We thank members of the Kang laboratory for insightful discussions and technical suggestions, J. Yingling (Eli Lilly and Company) for the TGF-beta receptor I kinase inhibitor and suggestions for the manuscript, S. Gambhir (Stanford University) for triple-reporter plasmids, R. Agami (The Netherlands Cancer Institute) for pRS-GFP, T. Guise and K. Mohammad for technical advice in bone histology and G. Hu for statistical support. Y. K. is a Champalimaud Investigator funded by a Department of Defense Era of Hope Scholar Award and grants from the American Cancer Society, the Susan G. Komen Foundation and the New Jersey Commission on Cancer Research. M. K. is supported by a predoctoral fellowship from the Department of Defense Breast Cancer Research Program.	Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663; Coleman R, 2007, BREAST, V16, pS21, DOI 10.1016/j.breast.2007.10.006; Coleman RE, 1997, CANCER, V80, P1686, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.3.CO;2-T; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; Deroose CM, 2007, J NUCL MED, V48, P295; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; El-Abdaimi K, 2003, INT J ONCOL, V22, P883; Fritz V, 2007, BONE, V40, P1032, DOI 10.1016/j.bone.2006.11.026; Gross S, 2005, CANCER CELL, V7, P5, DOI 10.1016/j.ccr.2004.12.011; Guise Theresa A, 2005, Clin Breast Cancer, V5 Suppl, pS46, DOI 10.3816/CBC.2005.s.004; Hoffman RM, 2009, CLIN EXP METASTAS, V26, P345, DOI 10.1007/s10585-008-9205-z; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Li HY, 2008, J MED CHEM, V51, P2302, DOI 10.1021/jm701199p; Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535-7163.MCT-07-0337; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; Ray P, 2004, CANCER RES, V64, P1323, DOI 10.1158/0008-5472.CAN-03-1816; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089; Tjuvajev JG, 2003, CANCER CELL, V3, P327, DOI 10.1016/S1535-6108(03)00082-5; Tripathy D, 2004, ANN ONCOL, V15, P743, DOI 10.1093/annonc/mdh173; van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	35	159	167	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					960	U169		10.1038/nm.1943	http://dx.doi.org/10.1038/nm.1943			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19597504				2022-12-27	WOS:000268770400043
J	Kass, DA				Kass, David A.			Rescuing a failing heart: putting on the squeeze	NATURE MEDICINE			English	Editorial Material							FAILURE; THERAPY		Johns Hopkins Univ, Inst Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Kass, DA (corresponding author), Johns Hopkins Univ, Inst Med, Dept Med, Ross 858,720 Rutland Ave, Baltimore, MD 21205 USA.	dkass@jhmi.edu						CHAKIR K, CIRCULATION IN PRESS; Endoh M, 2006, EXPERT OPIN PHARMACO, V7, P2179, DOI 10.1517/14656566.7.16.2179; Kawase Y, 2008, NAT CLIN PRACT CARD, V5, P554, DOI 10.1038/ncpcardio1301; Landmesser Ulf, 2007, Curr Treat Options Cardiovasc Med, V9, P443, DOI 10.1007/s11936-007-0039-9; Mebazaa A, 2007, JAMA-J AM MED ASSOC, V297, P1883, DOI 10.1001/jama.297.17.1883; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Paolocci N, 2007, PHARMACOL THERAPEUT, V113, P442, DOI 10.1016/j.pharmthera.2006.11.002; Phan HM, 2007, TRENDS CARDIOVAS MED, V17, P215, DOI 10.1016/j.tcm.2007.07.001; Pleger ST, 2007, J CARD FAIL, V13, P401, DOI 10.1016/j.cardfail.2007.01.003; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Spragg DD, 2006, PROG CARDIOVASC DIS, V49, P26, DOI 10.1016/j.pcad.2006.05.001; Yan L, 2007, CELL, V130, P247, DOI 10.1016/j.cell.2007.05.038	12	9	10	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2009	15	1					24	25		10.1038/nm0109-24	http://dx.doi.org/10.1038/nm0109-24			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19129779				2022-12-27	WOS:000262425100013
J	Marumoto, T; Tashiro, A; Friedmann-Morvinski, D; Scadeng, M; Soda, Y; Gage, FH; Verma, IM				Marumoto, Tomotoshi; Tashiro, Ayumu; Friedmann-Morvinski, Dinorah; Scadeng, Miriam; Soda, Yasushi; Gage, Fred H.; Verma, Inder M.			Development of a novel mouse glioma model using lentiviral vectors	NATURE MEDICINE			English	Article							HUMAN-BRAIN; GLIOBLASTOMA-MULTIFORME; GENETIC ALTERATIONS; TRANSGENIC MICE; EGF RECEPTOR; EXPRESSION; CELLS; IDENTIFICATION; PROLIFERATION; ASTROCYTES	We report the development of a new method to induce glioblastoma multiforme in adult immunocompetent mice by injecting Cre-loxP-controlled lentiviral vectors expressing oncogenes. Cell type- or region-specific expression of activated forms of the oncoproteins Harvey-Ras and AKT in fewer than 60 glial fibrillary acidic protein-positive cells in the hippocampus, subventricular zone or cortex of mice heterozygous for the gene encoding the tumor suppressor Tp53 were tested. Mice developed glioblastoma multiforme when transduced either in the subventricular zone or the hippocampus. However, tumors were rarely detected when the mice were transduced in the cortex. Transplantation of brain tumor cells into naive recipient mouse brain resulted in the formation of glioblastoma multiforme-like tumors, which contained CD133(+) cells, formed tumorspheres and could differentiate into neurons and astrocytes. We suggest that the use of Cre-loxP-controlled lentiviral vectors is a novel way to generate a mouse glioblastoma multiforme model in a region- and cell type-specific manner in adult mice.	[Marumoto, Tomotoshi; Friedmann-Morvinski, Dinorah; Soda, Yasushi; Gage, Fred H.; Verma, Inder M.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; [Marumoto, Tomotoshi] Kobe Med Ctr Natl Hosp Org, Dept Neurosurg, Suma Ku, Kobe, Hyogo 6540155, Japan; [Tashiro, Ayumu] Memory Norwegian Univ Sci & Technol, Kavli Inst Syst Neurosci, Med Tech Res Ctr, NO-7489 Trondheim, Norway; [Tashiro, Ayumu] Memory Norwegian Univ Sci & Technol, Ctr Biol, Med Tech Res Ctr, NO-7489 Trondheim, Norway; [Scadeng, Miriam] Univ Calif San Diego, Ctr Funct Magnet Resonance Imaging, La Jolla, CA 92093 USA	Salk Institute; Kobe City Medical Center General Hospital; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of California System; University of California San Diego	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	verma@salk.edu	Tashiro, Ayumu/Z-2900-2019; Tashiro, Ayumu/A-2675-2008	Tashiro, Ayumu/0000-0001-7967-7409; Tashiro, Ayumu/0000-0001-7967-7409; Scadeng, Miriam/0000-0002-9593-2956; Friedmann-Morvinski, Dinorah/0000-0002-6394-9876	American Brain Tumor Association; US National Institutes of Health; H. N. and Frances C. Berger Foundation; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053670] Funding Source: NIH RePORTER	American Brain Tumor Association; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); H. N. and Frances C. Berger Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank R. Shaw for discussions and critical reading of the manuscript; N. Varki and H. Powell for pathological analyses; S. Yla-Herttuala, K. Suzuki, N. Tanaka, G. Pao, A. Parker and H. Suh for useful discussions; T. Sawai, G. Estepa and M. Lawrence for technical assistance; M. Schmitt and B. Coyne for administrative assistance; and S. Withoff (St. Jude Hospital), V. Tergaonkar (Bioprocessing Technology Institute), O. Singer (Salk Institute) and G. Wahl (Salk Institute) for providing pSETB mRFP1, pGEM H-RasV12, p156RRLsin PPTCMVIRESPRE myr-AKT vectors and Tp53<SUP>-/-</SUP> mice, respectively. T. M. is supported by the American Brain Tumor Association. I. M. V. is an American Cancer Society Professor of Molecular Biology and is supported in part by grants from the US National Institutes of Health and the H. N. and Frances C. Berger Foundation. The project described was supported in part by the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FINKELSTEIN SD, 1994, NEUROSURGERY, V34, P136; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gagneux P, 2003, J BIOL CHEM, V278, P48245, DOI 10.1074/jbc.M309813200; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hesselager G, 2003, NEUROSURGERY, V53, P685, DOI 10.1227/01.NEU.0000081304.57547.B5; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; HOUCHENS DP, 1983, EUR J CANCER CLIN ON, V19, P799, DOI 10.1016/0277-5379(83)90012-3; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Ikawa M, 2003, MOL THER, V8, P666, DOI 10.1016/S1525-0016(03)00240-5; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LANTOS PL, 1976, EXPERIENTIA, V32, P1467, DOI 10.1007/BF01937439; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Uhrbom L, 1998, CANCER RES, V58, P5275; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	35	224	232	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					110	116		10.1038/nm.1863	http://dx.doi.org/10.1038/nm.1863			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19122659	Green Accepted			2022-12-27	WOS:000262425100026
J	Eirew, P; Stingl, J; Raouf, A; Turashvili, G; Aparicio, S; Emerman, JT; Eaves, CJ				Eirew, Peter; Stingl, John; Raouf, Afshin; Turashvili, Gulisa; Aparicio, Samuel; Emerman, Joanne T.; Eaves, Connie J.			A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability	NATURE MEDICINE			English	Article							BREAST; GLAND; PURIFICATION; VITRO	Previous studies have demonstrated that normal mouse mammary tissue contains a rare subset of mammary stem cells. We now describe a method for detecting an analogous subpopulation in normal human mammary tissue. Dissociated cells are suspended with fibroblasts in collagen gels, which are then implanted under the kidney capsule of hormone-treated immunodeficient mice. After 2-8 weeks, the gels contain bilayered mammary epithelial structures, including luminal and myoepithelial cells, their in vitro clonogenic progenitors and cells that produce similar structures in secondary transplants. The regenerated clonogenic progenitors provide an objective indicator of input mammary stem cell activity and allow the frequency and phenotype of these human mammary stem cells to be determined by limiting-dilution analysis. This new assay procedure sets the stage for investigations of mechanisms regulating normal human mammary stem cells (and possibly stem cells in other tissues) and their relationship to human cancer stem cell populations.	[Eirew, Peter; Stingl, John; Raouf, Afshin; Eaves, Connie J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Turashvili, Gulisa; Aparicio, Samuel] British Columbia Canc Agcy, Mol Oncol & Breast Canc Program, Vancouver, BC V5Z 1L3, Canada; [Aparicio, Samuel] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; [Emerman, Joanne T.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; [Eaves, Connie J.] Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Eaves, CJ (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	ceaves@bccrc.ca	Turashvili, Gulisa/A-6056-2008	Turashvili, Gulisa/0000-0001-6125-5865; Aparicio, Samuel/0000-0002-0487-9599	Terry Fox Laboratory; Centre for Translational and Applied Genomics; Genome British Columbia and Genome Canada; Canadian Stem Cell Network; Canadian Breast Cancer Foundation British Columbia and Yukon Division; Canada Research Chair in Molecular Oncology; Medical Research Council [G0300723, G0300723B] Funding Source: researchfish; MRC [G0300723] Funding Source: UKRI	Terry Fox Laboratory; Centre for Translational and Applied Genomics; Genome British Columbia and Genome Canada; Canadian Stem Cell Network; Canadian Breast Cancer Foundation British Columbia and Yukon Division; Canada Research Chair in Molecular Oncology(Canada Research Chairs); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	C3H 10T<SUP>1/2</SUP> mouse embryonic fibroblasts were a kind gift from G. Cunha, University of California, San Francisco. The authors acknowledge the excellent technical contributions of D. Wilkinson, G. Edin, the staff of the Flow Cytometry Facility of the Terry Fox Laboratory and the Centre for Translational and Applied Genomics. Mammoplasty tissue was obtained with the assistance of J. Sproul, P. Lennox, N. Van Laeken and R. Warren. This project was funded by grants from Genome British Columbia and Genome Canada, the Canadian Stem Cell Network and the Canadian Breast Cancer Foundation British Columbia and Yukon Division. P. E. was a recipient of a US Department of Defense Breast Cancer Research Program Studentship, a Terry Fox Foundation Research Studentship from the National Cancer Institute of Canada, a Canadian Imperial Bank of Commerce interdisciplinary award and a Canadian Stem Cell Network Studentship. J. S. held a Canadian Breast Cancer Foundation British Columbia and Yukon Division Fellowship and a Canadian National Science and Engineering Research Council Industrial Fellowship. A. R. held a Canadian Breast Cancer Foundation British Columbia and Yukon Division Fellowship and a Canadian Institutes of Health Research Fellowship. G. T. holds a Canadian Institutes of Health Research Pathology Training Fellowship. S. A. is supported by a Canada Research Chair in Molecular Oncology. The Centre for Translational and Applied Genomics laboratory is supported by a Canadian Institutes for Health Research Resource award.	Bonnefoix T, 1996, J IMMUNOL METHODS, V194, P113, DOI 10.1016/0022-1759(96)00077-4; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; EAVES CJ, 1991, SEMIN HEMATOL, V28, P126; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Kordon EC, 1998, DEVELOPMENT, V125, P1921; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; MILLER CL, 2002, METHODS MOL MED HEMA, P123; OHARE MJ, 1991, DIFFERENTIATION, V46, P209, DOI 10.1111/j.1432-0436.1991.tb00883.x; Parmar H, 2002, ENDOCRINOLOGY, V143, P4886, DOI 10.1210/en.2002-220570; PLOEMACHER RE, 1989, BLOOD, V74, P2755; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; RICHARDS J, 1983, METHODS CELL SCI, V8, P31; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; STINGL J, 2005, METHODS MOL BIOL BAS, P249; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Tsai YC, 1996, CANCER RES, V56, P402; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114	24	238	245	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1384	1389		10.1038/nm.1791	http://dx.doi.org/10.1038/nm.1791			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029987				2022-12-27	WOS:000261393600025
J	Grewal, PK; Uchiyama, S; Ditto, D; Varki, N; Le, DT; Nizet, V; Marth, JD				Grewal, Prabhjit K.; Uchiyama, Satoshi; Ditto, David; Varki, Nissi; Le, Dzung T.; Nizet, Victor; Marth, Jamey D.			The Ashwell receptor mitigates the lethal coagulopathy of sepsis	NATURE MEDICINE			English	Article							LIVER ASIALOGLYCOPROTEIN RECEPTOR; PLATELET SIALIC-ACID; STREPTOCOCCUS-PNEUMONIAE; MICE LACKING; RESPIRATORY-TRACT; LIGAND-BINDING; MAJOR SUBUNIT; NEURAMINIDASE; SURFACE; GLYCOPROTEINS	The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine. This asialoglycoprotein receptor activity remains a key factor in the development and administration of glycoprotein pharmaceuticals, yet a biological purpose of the Ashwell receptor has remained elusive. We have identified endogenous ligands of the Ashwell receptor as glycoproteins and regulatory components in blood coagulation and thrombosis that include von Willebrand factor (vWF) and platelets. The Ashwell receptor normally modulates vWF homeostasis and is responsible for thrombocytopenia during systemic Streptococcus pneumoniae infection by eliminating platelets desialylated by the bacterium's neuraminidase. Hemostatic adaptation by the Ashwell receptor moderates the onset and severity of disseminated intravascular coagulation during sepsis and improves the probability of host survival.	[Grewal, Prabhjit K.; Marth, Jamey D.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Grewal, Prabhjit K.; Marth, Jamey D.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Uchiyama, Satoshi; Nizet, Victor] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Ditto, David; Varki, Nissi; Le, Dzung T.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Nizet, Victor] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Marth, JD (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jmarth@ucsd.edu	Nizet, Victor/AAF-3190-2019	Nizet, Victor/0000-0003-3847-0422	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [HL-57345, P01 HL057345-110006, P01 HL057345-109004, P01 HL057345, P01 HL057345-100001] Funding Source: Medline; NIAID NIH HHS [AI-051796] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 2003, Wkly Epidemiol Rec, V78, P97; Ashwell G, 1978, Methods Enzymol, V50, P287; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; Braun JR, 1996, J BIOL CHEM, V271, P21160, DOI 10.1074/jbc.271.35.21160; Bryant AE, 2003, CLIN MICROBIOL REV, V16, P451, DOI 10.1128/CMR.16.3.451-462.2003; CAMARA M, 1994, INFECT IMMUN, V62, P3688; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; Franchini M, 2006, THROMB J, V4, DOI 10.1186/1477-9560-4-4; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; HONG WJ, 1988, HEPATOLOGY, V8, P553, DOI 10.1002/hep.1840080320; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; Manco S, 2006, INFECT IMMUN, V74, P4014, DOI 10.1128/IAI.01237-05; Mandic R, 2002, THROMB RES, V106, P137, DOI 10.1016/S0049-3848(02)00087-7; MORELL AG, 1971, J BIOL CHEM, V246, P1461; Nakamura M, 1998, J HEPATOL, V28, P991, DOI 10.1016/S0168-8278(98)80348-6; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Park EI, 2005, P NATL ACAD SCI USA, V102, P17125, DOI 10.1073/pnas.0508537102; Park EI, 2004, J BIOL CHEM, V279, P40954, DOI 10.1074/jbc.M406647200; PATON JC, 1993, ANNU REV MICROBIOL, V47, P89, DOI 10.1146/annurev.mi.47.100193.000513; Remick DG, 2007, AM J PATHOL, V170, P1435, DOI 10.2353/ajpath.2007.060872; Rice KG, 2003, METHOD ENZYMOL, V363, P90; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; Ruiz NI, 1996, GLYCOBIOLOGY, V6, P551, DOI 10.1093/glycob/6.5.551; Rumjantseva V, 2006, BLOOD, V108, p438A, DOI 10.1182/blood.V108.11.1523.1523; Saxena A, 2002, J BIOL CHEM, V277, P35297, DOI 10.1074/jbc.M205653200; Shakhnovich EA, 2002, INFECT IMMUN, V70, P7161, DOI 10.1128/IAI.70.12.7161-7164.2002; Soong G, 2006, J CLIN INVEST, V116, P2297, DOI 10.1172/JCI27920; Soukharev S, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e21; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STRATTON JR, 1989, J NUCL MED, V30, P629; Suzuki Y, 2005, BIOL PHARM BULL, V28, P399, DOI 10.1248/bpb.28.399; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; Tong HH, 2002, ACTA OTO-LARYNGOL, V122, P413, DOI 10.1080/00016480260000111; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; Tribulatti MV, 2005, INFECT IMMUN, V73, P201, DOI 10.1128/IAI.73.1.201-207.2005; VANDENHA.CJ, 1970, J BIOL CHEM, V245, P4397; Wahrenbrock MG, 2006, CANCER RES, V66, P2433, DOI 10.1158/0008-5472.CAN-05-3851; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; Winter AJ, 1997, INFECT IMMUN, V65, P4411, DOI 10.1128/IAI.65.11.4411-4418.1997; ZALIK SE, 1991, ANAT EMBRYOL, V183, P521	52	261	272	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2008	14	6					648	655		10.1038/nm1760	http://dx.doi.org/10.1038/nm1760			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18488037	Green Accepted			2022-12-27	WOS:000256468700031
J	Rawson, PM; Molette, C; Videtta, M; Altieri, L; Franceschini, D; Donato, T; Finocchi, L; Propato, A; Paroli, M; Meloni, F; Mastroianni, CM; d'Ettorre, G; Sidney, J; Sette, A; Barnaba, V				Rawson, Pisana Moroni; Molette, Caroline; Videtta, Melissa; Altieri, Laura; Franceschini, Debora; Donato, Tiziana; Finocchi, Luigi; Propato, Antonella; Paroli, Marino; Meloni, Francesca; Mastroianni, Claudio M.; d'Ettorre, Gabriella; Sidney, John; Sette, Alessandro; Barnaba, Vincenzo			Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; CD8(+) T-CELLS; DENDRITIC CELLS; IMMUNE ACTIVATION; IN-VIVO; B-CELLS; LYMPHOCYTES; DEATH; IDENTIFICATION; MOLECULES	We found that the proteome of apoptotic T cells includes prominent fragments of cellular proteins generated by caspases and that a high proportion of distinct T cell epitopes in these fragments is recognized by CD8(+) T cells during HIV infection. The frequencies of effector CD8(+) T cells that are specific for apoptosis-dependent epitopes correlate with the frequency of circulating apoptotic CD4(+) T cells in HIV-1-infected individuals. We propose that these self-reactive effector CD8(+) T cells may contribute to the systemic immune activation during chronic HIV infection. The caspase-dependent cleavage of proteins associated with apoptotic cells has a key role in the induction of self-reactive CD8(+) T cell responses, as the caspase-cleaved fragments are efficiently targeted to the processing machinery and are cross-presented by dendritic cells. These findings demonstrate a previously undescribed role for caspases in immunopathology.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, I-00161 Rome, Italy; Univ Roma La Sapienza, Dipartimento Malattie Infett & Trop, I-00161 Rome, Italy; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Univ Roma La Sapienza, Ist Pasteur Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; La Jolla Institute for Immunology; Fondazione Cenci Bolognetti; Sapienza University Rome	Barnaba, V (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, Piazzale Aldo Moro 5, I-00161 Rome, Italy.	vincenzo.barnaba@uniroma1.it	Barnaba, Vincenzo/AAB-1945-2019; Sette, Alessandro/AFO-8916-2022; d'Ettorre, Gabriella/K-4511-2016; MASTROIANNI, Claudio Maria/O-9741-2019	MASTROIANNI, Claudio Maria/0000-0002-1286-467X; d'Ettorre, Gabriella/0000-0002-3571-5677; PAROLI, Marino/0000-0001-7919-9128				Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106; Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bangs SC, 2006, TRENDS IMMUNOL, V27, P518, DOI 10.1016/j.it.2006.09.006; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; Basta S, 2005, J IMMUNOL, V175, P796, DOI 10.4049/jimmunol.175.2.796; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; Binder RJ, 2005, NAT IMMUNOL, V6, P593, DOI 10.1038/ni1201; Blacher NE, 2005, PLOS BIOL, V3, P1070, DOI 10.1371/journal.pbio.0030185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chernysheva AD, 2002, J IMMUNOL, V169, P1241, DOI 10.4049/jimmunol.169.3.1241; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Francavilla V, 2004, EUR J IMMUNOL, V34, P427, DOI 10.1002/eji.200324539; Graham KL, 2005, CURR OPIN RHEUMATOL, V17, P513, DOI 10.1097/01.bor.0000171215.87993.6b; Groothuis TAM, 2005, J EXP MED, V202, P1313, DOI 10.1084/jem.20051379; Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahoney JA, 2005, CURR OPIN IMMUNOL, V17, P583, DOI 10.1016/j.coi.2005.09.018; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Meffre E, 2004, J EXP MED, V199, P145, DOI 10.1084/jem.20031550; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Scognamiglio P, 1999, J IMMUNOL, V162, P6681; Shen LJ, 2004, P NATL ACAD SCI USA, V101, P3035, DOI 10.1073/pnas.0308345101; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sidney J, 2001, HUM IMMUNOL, V62, P1200, DOI 10.1016/S0198-8859(01)00319-6; Silvestri G, 2003, J CLIN INVEST, V112, P821, DOI 10.1172/JCI200319799; Steen H, 2004, NAT REV MOL CELL BIO, V5, P699, DOI 10.1038/nrm1468; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Summers Donald F., 1996, P699, DOI 10.1007/978-1-60327-259-9_121; Thiede B, 2004, MASS SPECTROM REV, V23, P333, DOI 10.1002/mas.10079; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268	49	66	71	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1431	1439		10.1038/nm1679	http://dx.doi.org/10.1038/nm1679			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18026114				2022-12-27	WOS:000251445400017
J	Willyard, C				Willyard, Cassandra			Combination antimalarials confound anticounterfeit tests	NATURE MEDICINE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					362	362		10.1038/nm0410-362a	http://dx.doi.org/10.1038/nm0410-362a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376030				2022-12-27	WOS:000276446800020
J	Winnay, JN; Boucher, J; Mori, MA; Ueki, K; Kahn, CR				Winnay, Jonathon N.; Boucher, Jeremie; Mori, Marcelo A.; Ueki, Kohjiro; Kahn, C. Ronald			A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM STRESS; INSULIN-RESISTANCE; PHOSPHATIDYLINOSITOL 3-KINASE; ER STRESS; SKELETAL-MUSCLE; MESSENGER-RNA; PURIFICATION METHOD; METABOLIC SYNDROME; P85-ALPHA SUBUNIT; ADIPOSE-TISSUE	Class Ia phosphoinositide 3-kinase (PI3K), an essential mediator of the metabolic actions of insulin, is composed of a catalytic (p110 alpha or p110 beta) and regulatory (p85 alpha, p85 beta or p55 gamma) subunit. Here we show that p85 alpha interacts with X-box-binding protein-1 (XBP-1), a transcriptional mediator of the unfolded protein response (UPR), in an endoplasmic reticulum (ER) stress-dependent manner. Cell lines with knockout or knockdown of p85 alpha show marked alterations in the UPR, including reduced ER stress-dependent accumulation of nuclear XBP-1, decreased induction of UPR target genes and increased rates of apoptosis. This is associated with a decreased activation of inositol-requiring protein-1 alpha (IRE1 alpha) and activating transcription factor-6 alpha (ATF6 alpha). Mice with deletion of p85 alpha in liver (L-Pik3r1(-/-)) show a similar attenuated UPR after tunicamycin administration, leading to an increased inflammatory response. Thus, p85 alpha forms a previously unrecognized link between the PI3K pathway, which is central to insulin action, and the regulation of the cellular response to ER stress, a state that when unresolved leads to insulin resistance.	[Winnay, Jonathon N.; Boucher, Jeremie; Mori, Marcelo A.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab,Res Div, Boston, MA 02115 USA; [Ueki, Kohjiro] Univ Tokyo, Dept Metab Dis, Grad Sch Med, Tokyo, Japan	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Tokyo	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab,Res Div, Boston, MA 02115 USA.	c.ronald.kahn@joslin.harvard.edu	Kahn, Ronald/AAY-2435-2021; Boucher, Jeremie/G-6602-2015; Mori, Marcelo A/R-2881-2018	Kahn, Ronald/0000-0002-7583-9228; Mori, Marcelo A/0000-0001-7112-5263	US National Institutes of Health [DK55545, DK07260-30]; Joslin Diabetes and Endocrine Research Center [DK36836]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055545, T32DK007260, P30DK036836] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Joslin Diabetes and Endocrine Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank D. Ron (New York University School of Medicine) for providing the Flag-XBP-1u and Flag-XBP-1s expression plasmids. This work was supported by US National Institutes of Health grant DK55545 and National Institutes of Health training grant DK07260-30, as well as Core laboratory support from the Joslin Diabetes and Endocrine Research Center grant DK36836. We would also like to thank U. Ozcan for useful advice and discussion and S. Green and S. Flaherty for assistance in preparation of this manuscript.	Bandyopadhyay GK, 2005, DIABETES, V54, P2351, DOI 10.2337/diabetes.54.8.2351; Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604; Brachmann SM, 2005, MOL CELL BIOL, V25, P1596, DOI 10.1128/MCB.25.5.1596-1607.2005; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 2004, MOL CELL BIOL, V24, P320, DOI 10.1128/MCB.24.1.320-329.2004; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Eizirik DL, 2008, ENDOCR REV, V29, P42, DOI 10.1210/er.2007-0015; Elouil H, 2007, DIABETOLOGIA, V50, P1442, DOI 10.1007/s00125-007-0674-4; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Fonseca SG, 2007, ANTIOXID REDOX SIGN, V9, P2335, DOI 10.1089/ars.2007.1790; Ford ES, 2004, DIABETES CARE, V27, P2444, DOI 10.2337/diacare.27.10.2444; Forler D, 2003, NAT BIOTECHNOL, V21, P89, DOI 10.1038/nbt773; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Garcia Z, 2006, EMBO J, V25, P4740, DOI 10.1038/sj.emboj.7601324; Gotto AM, 2006, CORONARY ARTERY DIS, V17, P77, DOI 10.1097/00019501-200602000-00013; Gregor MF, 2009, DIABETES, V58, P693, DOI 10.2337/db08-1220; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833; Herschkovitz A, 2007, J BIOL CHEM, V282, P18018, DOI 10.1074/jbc.M610949200; HEYDRICK SJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE604, DOI 10.1152/ajpendo.1995.268.4.E604; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Khalfallah Y, 2001, J ENDOCRINOL, V171, P285, DOI 10.1677/joe.0.1710285; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ozawa K, 2005, DIABETES, V54, P657, DOI 10.2337/diabetes.54.3.657; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Park SW, 2010, NAT MED, V16, P429, DOI 10.1038/nm.2099; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ron D, 2008, CELL, V132, P24, DOI 10.1016/j.cell.2007.12.017; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Taniguchi CM, 2007, MOL CELL BIOL, V27, P2830, DOI 10.1128/MCB.00079-07; Tanti JF, 2004, ANN ENDOCRINOL-PARIS, V65, P43, DOI 10.1016/S0003-4266(04)95629-6; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Yeates LC, 1999, ANTICANCER RES, V19, P4171; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145	57	140	150	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					438	U120		10.1038/nm.2121	http://dx.doi.org/10.1038/nm.2121			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20348923	Green Accepted			2022-12-27	WOS:000276446800048
J	Echtermeyer, F; Bertrand, J; Dreier, R; Meinecke, I; Neugebauer, K; Fuerst, M; Lee, YJ; Song, YW; Herzog, C; Theilmeier, G; Pap, T				Echtermeyer, Frank; Bertrand, Jessica; Dreier, Rita; Meinecke, Ingmar; Neugebauer, Katja; Fuerst, Martin; Lee, Yun Jong; Song, Yeong Wook; Herzog, Christine; Theilmeier, Gregor; Pap, Thomas			Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis	NATURE MEDICINE			English	Article							ARTICULAR-CARTILAGE; AGGRECAN DEGRADATION; KNEE-JOINTS; IN-VITRO; METALLOPROTEINASE; KINASE; MICE; EXPRESSION; EXPLANTS; DELETION	Aggrecan cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 5 (ADAMTS-5) is crucial for the breakdown of cartilage matrix during osteoarthritis(1,2), a degenerative joint disease that leads to the progressive destruction of articular structures. The mechanisms of ADAMTS-5 activation and their links to the pathogenesis of osteoarthritis remain poorly understood, but syndecans have been shown to be involved in the activation of ADAMTS-4 (ref. 3). Here we show that syndecan-4 is specifically induced in type X collagen-producing chondrocytes both in human osteoarthritis and in murine models of the disease. The loss of syndecan-4 in genetically modified mice and intra-articular injections of syndecan-4-specific antibodies into wild-type mice protect from proteoglycan loss and thereby prevent osteoarthritic cartilage damage in a surgically induced model of osteoarthritis. The occurrence of less severe osteoarthritis-like cartilage destruction in both syndecan-4-deficient mice and syndecan-4-specific antibody-treated wild-type mice results from a marked decrease in ADAMTS-5 activity. Syndecan-4 controls the activation of ADAMTS-5 through direct interaction with the protease and through regulating mitogen-activated protein kinase (MAPK)-dependent synthesis of matrix metalloproteinase-3 (MMP-3). Our data suggest that strategies aimed at the inhibition of syndecan-4 will be of great value for the treatment of cartilage damage in osteoarthritis.	[Echtermeyer, Frank; Herzog, Christine; Theilmeier, Gregor] Hannover Med Sch, Dept Anesthesiol & Intens Care Med, Hannover, Germany; [Dreier, Rita] Univ Hosp Munster, Inst Physiol Chem & Pathobiochem, Munster, Germany; [Meinecke, Ingmar] Univ Hosp Munster, Dept Trauma Hand & Reconstruct Surg, Munster, Germany; [Fuerst, Martin] Univ Med Ctr Hamburg Eppendorf, Dept Orthoped Surg, Hamburg, Germany; [Lee, Yun Jong; Song, Yeong Wook] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Bertrand, Jessica; Meinecke, Ingmar; Neugebauer, Katja; Pap, Thomas] Univ Hosp Munster, Inst Expt Musculoskeletal Med, Munster, Germany	Hannover Medical School; University of Munster; University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; Seoul National University (SNU); University of Munster	Echtermeyer, F (corresponding author), Hannover Med Sch, Dept Anesthesiol & Intens Care Med, Hannover, Germany.	echtermeyer.frank@mh-hannover.de; Thomas.pap@uni-muenster.de	Song, Yeong-Wook/J-2765-2012	Bertrand, Jessica/0000-0001-9511-4999	German Research Foundation; Deutsche Forschungsgemeinschaft [Pa689/7-1, Th667/6-1]; Collaborative Research Centres [SFB 492]; Deutsche Arthrosehilfe [p77-a117-Ruther-EP2-fuer1-knie-ko-49k-2006-7];  [B18];  [B19]	German Research Foundation(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Collaborative Research Centres; Deutsche Arthrosehilfe; ; 	We would like to thank A. Forsberg, S. Niehues, S. Ecklebe and K. Reher for technical assistance. This work was supported by the German Research Foundation ( Deutsche Forschungsgemeinschaft; Pa689/7-1 to T. P. and F. E. and Th667/6-1 to G. T. and C. H.), the Collaborative Research Centres (SFB 492; project B18 to R. D. and B19 to T. P.) and Deutsche Arthrosehilfe e.V (p77-a117-Ruther-EP2-fuer1-knie-ko-49k-2006-7 to M. F.).	Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Barre PE, 2000, OSTEOARTHR CARTILAGE, V8, P34, DOI 10.1053/joca.1999.0286; Blom AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337; Bondeson J, 2008, CLIN EXP RHEUMATOL, V26, P139; Brooks PM, 2006, CLIN RHEUMATOL, V25, P778, DOI 10.1007/s10067-006-0240-3; Clements KM, 2003, ARTHRITIS RHEUM-US, V48, P3452, DOI 10.1002/art.11355; Cornelison DDW, 2001, DEV BIOL, V239, P79, DOI 10.1006/dbio.2001.0416; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004; Lim ST, 2003, J BIOL CHEM, V278, P13795, DOI 10.1074/jbc.M208300200; Longpre JM, 2009, INT J BIOCHEM CELL B, V41, P1116, DOI 10.1016/j.biocel.2008.10.008; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; Molteni A, 1999, BONE, V24, P337, DOI 10.1016/S8756-3282(98)00191-4; Ostergaard K, 1999, ANN RHEUM DIS, V58, P208, DOI 10.1136/ard.58.4.208; Pap G, 1998, PATHOL RES PRACT, V194, P41, DOI 10.1016/S0344-0338(98)80010-1; Pattoli MA, 2005, J PHARMACOL EXP THER, V315, P382, DOI 10.1124/jpet.105.087569; Poole AR, 2003, BIOCHEM SOC SYMP, V70, P115, DOI 10.1042/bss0700115; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Song RH, 2007, ARTHRITIS RHEUM-US, V56, P575, DOI 10.1002/art.22334; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Tkachenko E, 2005, CIRC RES, V96, P488, DOI 10.1161/01.RES.0000159708.71142.c8; Tortorella MD, 2005, ARCH BIOCHEM BIOPHYS, V444, P34, DOI 10.1016/j.abb.2005.09.018; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200	29	245	255	2	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2009	15	9					1072	U127		10.1038/nm.1998	http://dx.doi.org/10.1038/nm.1998			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19684582				2022-12-27	WOS:000269979200029
J	Jandial, R; Snyder, EY				Jandial, Rahul; Snyder, Evan Y.			On guard against cancer	NATURE MEDICINE			English	Editorial Material							CELLS; MODEL; IDENTIFICATION; NEURONS; BRAIN		[Jandial, Rahul; Snyder, Evan Y.] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Jandial, Rahul] Div Neurosurg, Duarte, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Jandial, R (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	esnyder@burnham.org						Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Keller C, 2005, CANCER RES, V65, P7530, DOI 10.1158/0008-5472.CAN-05-0477; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; Singh SK, 2003, CANCER RES, V63, P5821; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	13	29	30	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					999	1001		10.1038/nm0909-999	http://dx.doi.org/10.1038/nm0909-999			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19734873				2022-12-27	WOS:000269979200016
J	O'Brien, KL; Liu, JY; King, SL; Sun, YH; Schmitz, JE; Lifton, MA; Hutnick, NA; Betts, MR; Dubey, SA; Goudsmit, J; Shiver, JW; Robertson, MN; Casimiro, DR; Barouch, DH				O'Brien, Kara L.; Liu, Jinyan; King, Sharon L.; Sun, Ying-Hua; Schmitz, Joern E.; Lifton, Michelle A.; Hutnick, Natalie A.; Betts, Michael R.; Dubey, Sheri A.; Goudsmit, Jaap; Shiver, John W.; Robertson, Michael N.; Casimiro, Danilo R.; Barouch, Dan H.			Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans	NATURE MEDICINE			English	Article							RHESUS-MONKEYS; IMMUNOGENICITY; REPLICATION; VECTORS; SAFETY; STEP	The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study. (C) 2009 Nature America, Inc. All rights reserved.	[O'Brien, Kara L.; Liu, Jinyan; King, Sharon L.; Sun, Ying-Hua; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02215 USA; [Schmitz, Joern E.; Lifton, Michelle A.] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA; [Hutnick, Natalie A.; Betts, Michael R.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Dubey, Sheri A.; Shiver, John W.; Robertson, Michael N.; Casimiro, Danilo R.] Merck Res Labs, West Point, PA USA; [Goudsmit, Jaap] Crucell Holland BV, Leiden, Netherlands; [Barouch, Dan H.] MIT, Ragon Inst Massachusetts Gen Hosp, Cambridge, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania; Merck & Company; Johnson & Johnson; Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute	Barouch, DH (corresponding author), Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02215 USA.	dbarouch@bidmc.harvard.edu	Barouch, Dan/Y-3918-2019; Schmitz, Joern/A-4929-2018	Schmitz, Joern/0000-0001-8803-0922	Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery [38614]; US National Institutes of Health [AI066305, AI066924, AI078526, AI074078, AI076066]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI078526, U19AI074078, U19AI066305, R01AI066924, R01AI076066] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery(Bill & Melinda Gates Foundation); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank J. Custers, M. Pau, P. Abbink, A. La Porte, N. Letvin, F. Stephens and T. Swanson for generous advice and assistance. We acknowledge support from the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (38614) and the US National Institutes of Health (AI066305, AI066924, AI078526, AI074078 and AI076066).	Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06; Barouch DH, 2004, J IMMUNOL, V172, P6290, DOI 10.4049/jimmunol.172.10.6290; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258; Liu JY, 2008, J VIROL, V82, P4844, DOI 10.1128/JVI.02616-07; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; Perreau M, 2008, J EXP MED, V205, P2717, DOI 10.1084/jem.20081786; Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993; Sprangers MC, 2003, J CLIN MICROBIOL, V41, P5046, DOI 10.1128/JCM.41.11.5046-5052.2003; Thorner AR, 2006, J CLIN MICROBIOL, V44, P3781, DOI 10.1128/JCM.01249-06; Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003	12	109	117	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					873	875		10.1038/nm.1991	http://dx.doi.org/10.1038/nm.1991			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19620961	Green Accepted			2022-12-27	WOS:000268770400029
J	Fawcett, JW; Curt, A				Fawcett, James W.; Curt, Armin			Rehabilitation in a plastic environment	NATURE MEDICINE			English	Editorial Material							SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; RECOVERY; RATS; REGENERATION; EXERCISE; STROKE; IMPACT; TRIAL; NOGO	People with damage to the central nervous system often undergo rehabilitation therapy. James Fawcett and Armin Curt examine how such therapy might work in conjunction with experimental approaches that increase the ability of neurons to form new connections. They discuss how animal studies raise questions about how to test such approaches in people in a field where firm data are already hard to come by. Phillip Popovich and Dana McTigue take a look at a specific type of nervous system damage spinal cord injury-and argue that the role of the immune system is underappreciated. They also suggest that one common therapy, application of glucocorticoids, might actually exacerbate the condition.	[Curt, Armin] Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland; [Fawcett, James W.] Univ Cambridge, Ctr Brain Repair, Dept Clin Neurosci, Cambridge, England	University of Zurich; University of Cambridge	Fawcett, JW (corresponding author), Univ Cambridge, Ctr Brain Repair, Dept Clin Neurosci, Cambridge, England.	jf108@cam.ac.uk		Fawcett, James/0000-0002-7990-4568	Medical Research Council [G9828345] Funding Source: Medline; MRC [G9828345] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Dietz V, 2009, BRAIN RES BULL, V78, pI, DOI 10.1016/S0361-9230(08)00410-3; Dobkin B, 2007, NEUROREHAB NEURAL RE, V21, P25, DOI 10.1177/1545968306295556; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; GARCIAALIAS G, NAT NEUROSC IN PRESS; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Harvey LA, 2009, SPINAL CORD, V47, P184, DOI 10.1038/sc.2008.100; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Maier IC, 2009, BRAIN, V132, P1426, DOI 10.1093/brain/awp085; Montour-Proulx I, 2004, J CHILD NEUROL, V19, P935, DOI 10.1177/08830738040190120501; SMITH R, 2009, J NEUROTRAUMA   0128, DOI DOI 10.1089/NEU.2008-0829; Tawashy AE, 2009, SPINAL CORD, V47, P301, DOI 10.1038/sc.2008.120; Valent LJ, 2008, ARCH PHYS MED REHAB, V89, P1016, DOI 10.1016/j.apmr.2007.10.034; Vega SR, 2008, NEUROSCIENCE, V153, P1064, DOI 10.1016/j.neuroscience.2008.03.037; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057	17	21	22	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					735	736		10.1038/nm0709-735	http://dx.doi.org/10.1038/nm0709-735			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584862				2022-12-27	WOS:000267806900023
J	Nesbitt, WS; Westein, E; Tovar-Lopez, FJ; Tolouei, E; Mitchell, A; Fu, J; Carberry, J; Fouras, A; Jackson, SP				Nesbitt, Warwick S.; Westein, Erik; Tovar-Lopez, Francisco Javier; Tolouei, Elham; Mitchell, Arnan; Fu, Jia; Carberry, Josie; Fouras, Andreas; Jackson, Shaun P.			A shear gradient-dependent platelet aggregation mechanism drives thrombus formation	NATURE MEDICINE			English	Article							ADHESIVE INTERACTIONS; IN-VIVO; ACTIVATION; MODEL; FLOW; IDENTIFICATION; TRANSLOCATION	Platelet aggregation at sites of vascular injury is essential for hemostasis and arterial thrombosis. It has long been assumed that platelet aggregation and thrombus growth are initiated by soluble agonists generated at sites of vascular injury. By using high-resolution intravital imaging techniques and hydrodynamic analyses, we show that platelet aggregation is primarily driven by changes in blood flow parameters (rheology), with soluble agonists having a secondary role, stabilizing formed aggregates. We find that in response to vascular injury, thrombi initially develop through the progressive stabilization of discoid platelet aggregates. Analysis of blood flow dynamics revealed that discoid platelets preferentially adhere in low-shear zones at the downstream face of forming thrombi, with stabilization of aggregates dependent on the dynamic restructuring of membrane tethers. These findings provide insight into the prothrombotic effects of disturbed blood flow parameters and suggest a fundamental reinterpretation of the mechanisms driving platelet aggregation and thrombus growth.	[Nesbitt, Warwick S.; Westein, Erik; Fu, Jia; Jackson, Shaun P.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [Tovar-Lopez, Francisco Javier; Mitchell, Arnan] RMIT Univ, Sch Elect & Comp Engn, Microelect & Mat Technol Ctr, Melbourne, Vic, Australia; [Tolouei, Elham; Carberry, Josie] Monash Univ, Dept Mech Engn, Clayton, Vic 3168, Australia; [Fouras, Andreas] Monash Univ, Div Biol Engn, Clayton, Vic, Australia	Monash University; Royal Melbourne Institute of Technology (RMIT); Monash University; Monash University	Nesbitt, WS (corresponding author), Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia.	warwick.nesbitt@med.monash.edu.au; shaun.jackson@med.monash.edu.au	Jackson, Shaun P/E-9633-2011; Tovar, Francisco/AGG-3400-2022; Carberry, Josie/E-9321-2010; Mitchell, Arnan/C-5017-2008; Fouras, Andreas/A-9410-2008	Carberry, Josie/0000-0002-4463-641X; Mitchell, Arnan/0000-0002-2463-2956; Fouras, Andreas/0000-0002-8933-1759; Nesbitt, Warwick/0000-0001-5644-7053; Tolouei, Elham/0000-0002-3595-0060; Jackson, Shaun/0000-0002-4750-1991; Tovar-Lopez, Francisco J/0000-0001-8578-7786	National Health and Medical Research Council of Australia; Australian Research Council; National Heart Foundation of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); National Heart Foundation of Australia(National Heart Foundation of Australia)	This work was supported by project funding from the National Health and Medical Research Council of Australia and the Australian Research Council. E. W. was supported by the National Heart Foundation of Australia.	Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DINTENFASS L, 1964, ANGIOLOGY, V15, P333, DOI 10.1177/000331976401500802; Dopheide SM, 2002, BLOOD, V99, P159, DOI 10.1182/blood.V99.1.159; Dubois C, 2007, J CLIN INVEST, V117, P953, DOI 10.1172/JCI30537; ECKSTEIN EC, 1988, MICROVASC RES, V36, P31, DOI 10.1016/0026-2862(88)90036-2; Edmondson KE, 2005, BIOPHYS J, V89, P3603, DOI 10.1529/biophysj.105.066134; Fouras A, 1998, EXP FLUIDS, V25, P409, DOI 10.1007/s003480050248; Fouras A, 2008, EXP FLUIDS, V44, P317, DOI 10.1007/s00348-007-0404-1; Furie B, 2005, J CLIN INVEST, V115, P3355, DOI 10.1172/JCI26987; Giuliano S, 2003, BIOCHEM J, V372, P163, DOI 10.1042/BJ20020868; Goncalves I, 2005, J BIOL CHEM, V280, P15430, DOI 10.1074/jbc.M410235200; Jackson SP, 2007, BLOOD, V109, P5087, DOI 10.1182/blood-2006-12-027698; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Kulkarni Suhasini, 2004, Methods Mol Biol, V272, P165; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; Leon C, 1999, J CLIN INVEST, V104, P1731, DOI 10.1172/JCI8399; Mangin P, 2006, BLOOD, V107, P4346, DOI 10.1182/blood-2005-10-4244; Maxwell MJ, 2007, BLOOD, V109, P566, DOI 10.1182/blood-2006-07-028282; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MUSTARD JF, 1962, AM J MED, V33, P621, DOI 10.1016/0002-9343(62)90243-7; MUSTARD JF, 1966, THROMB DIATH HAEMOST, VS, P131; Nesbitt WS, 2003, J CELL BIOL, V160, P1151, DOI 10.1083/jcb.200207119; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; Rosen ED, 2001, AM J PATHOL, V158, P1613, DOI 10.1016/S0002-9440(10)64117-X; Ruggeri ZM, 2007, THROMB RES, V120, pS5, DOI 10.1016/j.thromres.2007.03.011; Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab; Ruggeri ZM, 2006, BLOOD, V108, P1903, DOI 10.1182/blood-2006-04-011551; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Schoenwaelder SM, 2007, J BIOL CHEM, V282, P28648, DOI 10.1074/jbc.M704358200; SCHOEPHOERSTER RT, 1993, ARTERIOSCLER THROMB, V13, P1806, DOI 10.1161/01.ATV.13.12.1806; STEIN PD, 1974, CIRC RES, V35, P608, DOI 10.1161/01.RES.35.4.608; Sturgeon SA, 2008, EUR J PHARMACOL, V587, P209, DOI 10.1016/j.ejphar.2008.03.017; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; van Gestel MA, 2002, J VASC RES, V39, P534, DOI 10.1159/000067208; Versteeg H.K., 2007, INTRO COMPUTATIONAL; VIRCHOW R, 1856, MEIDINGER SOHN, P219; WANG SK, 1992, BIORHEOLOGY, V29, P353; Weibel DB, 2007, NAT REV MICROBIOL, V5, P209, DOI 10.1038/nrmicro1616; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; YOGANATHAN AP, 1978, CIRCULATION, V58, P70, DOI 10.1161/01.CIR.58.1.70	44	592	609	3	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					665	U146		10.1038/nm.1955	http://dx.doi.org/10.1038/nm.1955			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19465929				2022-12-27	WOS:000266731600026
J	Wu, C; Ivars, F; Anderson, P; Hallmann, R; Vestweber, D; Nilsson, P; Robenek, H; Tryggvason, K; Song, J; Korpos, E; Loser, K; Beissert, S; Georges-Labouesse, E; Sorokin, LM				Wu, Chuan; Ivars, Fredrik; Anderson, Per; Hallmann, Rupert; Vestweber, Dietmar; Nilsson, Per; Robenek, Horst; Tryggvason, Karl; Song, Jian; Korpos, Eva; Loser, Karin; Beissert, Stefan; Georges-Labouesse, Elisabeth; Sorokin, Lydia M.			Endothelial basement membrane laminin alpha 5 selectively inhibits T lymphocyte extravasation into the brain	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; CELL-ADHESION; LEUKOCYTE EXTRAVASATION; G-PROTEIN; IN-VIVO; MIGRATION; EXPRESSION; INTEGRIN; BARRIER; ANTIGEN	Specific inhibition of the entry of encephalitogenic T lymphocytes into the central nervous system in multiple sclerosis would provide a means of inhibiting disease without compromising innate immune responses. We show here that targeting lymphocyte interactions with endothelial basement membrane laminins provides such a possibility. In mouse experimental autoimmune encephalomyelitis, T lymphocyte extravasation correlates with sites expressing laminin alpha 4 and small amounts of laminin alpha 5. In mice lacking laminin alpha 4, laminin alpha 5 is ubiquitously expressed along the vascular tree, resulting in marked and selective reduction of T lymphocyte infiltration into the brain and reduced disease susceptibility and severity. Vessel phenotype and immune response were not affected in these mice. Rather, laminin alpha 5 directly inhibited integrin alpha(6)beta(1)-mediated migration of T lymphocytes through laminin alpha 4. The data indicate that T lymphocytes use mechanisms distinct from other immune cells to penetrate the endothelial basement membrane barrier, permitting specific targeting of this immune cell population.	[Wu, Chuan; Hallmann, Rupert; Song, Jian; Korpos, Eva; Sorokin, Lydia M.] Univ Munster, Inst Physiol Chem & Pathobiochem, D-4400 Munster, Germany; [Ivars, Fredrik; Anderson, Per] Lund Univ, Immunol Sect, Dept Expt Med Sci, Lund, Sweden; [Vestweber, Dietmar] Max Planck Inst Mol Biomed, Munster, Germany; [Robenek, Horst] Univ Munster, Leibniz Inst Arterosclerosis Res, D-4400 Munster, Germany; [Tryggvason, Karl] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Loser, Karin; Beissert, Stefan] Univ Munster, Dept Dermatol, D-4400 Munster, Germany; [Georges-Labouesse, Elisabeth] Inst Genet & Biol Mol & Cellulaire, Strasbourg, France	University of Munster; Lund University; Max Planck Society; University of Munster; Karolinska Institutet; University of Munster; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sorokin, LM (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-4400 Munster, Germany.	sorokin@uni-muenster.de	Song, Jian/Q-5216-2018; Korpos, Eva/AAF-6988-2021; Wu, Chuan/H-6379-2013	Song, Jian/0000-0002-2459-7046; Vestweber, Dietmar/0000-0002-3517-732X; Sorokin, Lydia/0000-0001-7704-7921; Wu, Chuan/0000-0003-2288-353X; Anderson, Per/0000-0002-0958-7990; , Jian/0000-0003-2159-9190	German [SFB293 A14, B8, A1, SFB492 Z3]; Swedish Research Councils [K2005-06X-14184-04A, 621-2001-2142]; Alfred Osterlunds Foundation; Knut and Alice Wallenbergs Foundation [KAW 2002.0056]; Crafoord Foundation; Greta; Johan Kocks Foundation; Interdisciplinary Clinical Research Center [Lo2/017/07]	German; Swedish Research Councils(Swedish Research Council); Alfred Osterlunds Foundation; Knut and Alice Wallenbergs Foundation(Knut & Alice Wallenberg Foundation); Crafoord Foundation; Greta; Johan Kocks Foundation; Interdisciplinary Clinical Research Center	This work was supported by the German (SFB293 A14, B8, A1; SFB492 Z3) and Swedish Research Councils (K2005-06X-14184-04A, 621-2001-2142), Alfred Osterlunds Foundation, Knut and Alice Wallenbergs Foundation (KAW 2002.0056), the Crafoord Foundation, the Greta and Johan Kocks Foundation and the Interdisciplinary Clinical Research Center (IZKF; Lo2/017/07) in Munster, Germany. We thank M. Sixt for initial studies on Lama4<SUP>-/-</SUP> mice, J. Eble (Frankfurt University) for recombinant integrin alpha<INF>6</INF>beta<INF>1</INF>, A. Sonnenberg (Division of Cell Biology, The Netherlands Cancer Institute) for GoH3, A. De Arcangelis for tissue collection, G. Roos for technical assistance and F. Kiefer and R. Bohmer for assistance with confocal microscopy.	Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Alt C, 2002, EUR J IMMUNOL, V32, P2133, DOI 10.1002/1521-4141(200208)32:8<2133::AID-IMMU2133>3.0.CO;2-W; Babcock AA, 2003, J NEUROSCI, V23, P7922; Bai XF, 2004, J EXP MED, V200, P447, DOI 10.1084/jem.20040131; Bixel MG, 2007, BLOOD, V109, P5327, DOI 10.1182/blood-2006-08-043109; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Engelhardt B, 2006, J NEURAL TRANSM, V113, P477, DOI 10.1007/s00702-005-0409-y; ENGELHARDT B, 1997, ADHESION MOL CHEMOKI, P173; Engelhardt B, 2008, CURR PHARM DESIGN, V14, P1555, DOI 10.2174/138161208784705432; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; FORD AL, 1995, J IMMUNOL, V154, P4309; Frieser M, 1997, EUR J BIOCHEM, V246, P727, DOI 10.1111/j.1432-1033.1997.t01-1-00727.x; Fujiwara H, 2004, EXP CELL RES, V292, P67, DOI 10.1016/j.yexcr.2003.08.010; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Galea I, 2007, J EXP MED, V204, P2023, DOI 10.1084/jem.20070064; Geberhiwot T, 2001, J CELL SCI, V114, P423; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Gimond C, 1998, J CELL BIOL, V143, P253, DOI 10.1083/jcb.143.1.253; Glabinski AR, 1995, BRAIN BEHAV IMMUN, V9, P315, DOI 10.1006/brbi.1995.1030; Gorfu G, 2008, J LEUKOCYTE BIOL, V84, P701, DOI 10.1189/jlb.0108048; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Hallmann R, 2005, PHYSIOL REV, V85, P979, DOI 10.1152/physrev.00014.2004; Hoshi O, 2004, ARCH HISTOL CYTOL, V67, P107, DOI 10.1679/aohc.67.107; Kawakami N, 2005, J EXP MED, V201, P1805, DOI 10.1084/jem.20050011; Kerfoot SM, 2002, J IMMUNOL, V169, P1000, DOI 10.4049/jimmunol.169.2.1000; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Ohashi K. L., 1996, Microcirculation (Philadelphia), V3, P199, DOI 10.3109/10739689609148289; Patton BL, 2001, NAT NEUROSCI, V4, P597, DOI 10.1038/88414; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Rehder D, 2006, EXP CELL RES, V312, P3389, DOI 10.1016/j.yexcr.2006.07.004; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Sixt M, 2001, J BIOL CHEM, V276, P18878, DOI 10.1074/jbc.M010898200; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Thompson RD, 2001, BLOOD, V97, P1854, DOI 10.1182/blood.V97.6.1854; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Toft-Hansen H, 2006, J IMMUNOL, V177, P7242, DOI 10.4049/jimmunol.177.10.7242; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; Wang JM, 2006, J BIOL CHEM, V281, P213, DOI 10.1074/jbc.M505061200; Wang SJ, 2006, J EXP MED, V203, P1519, DOI 10.1084/jem.20051210; Yadav R, 2003, THROMB HAEMOSTASIS, V90, P598, DOI 10.1160/TH03-04-0220; Yurchenco PD, 2002, METHOD CELL BIOL, V69, P111, DOI 10.1016/S0091-679X(02)69010-7	42	177	186	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					519	527		10.1038/nm.1957	http://dx.doi.org/10.1038/nm.1957			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19396173				2022-12-27	WOS:000265889300030
J	Rosen, CJ				Rosen, Clifford J.			Breaking into bone biology Serotonin's secrets	NATURE MEDICINE			English	Editorial Material							TRANSPORTER INHIBITION EVIDENCE; DENSITY		Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA	Maine Medical Center	Rosen, CJ (corresponding author), Maine Med Ctr, Res Inst, 81 Res Dr, Scarborough, ME 04074 USA.	rosenc@mmc.org						Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Clowes JA, 2002, BONE, V30, P886, DOI 10.1016/S8756-3282(02)00728-7; Diem SJ, 2007, ARCH INTERN MED, V167, P1240, DOI 10.1001/archinte.167.12.1240; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Haney E. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P133; Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Warden S. J., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P121; Warden SJ, 2008, MENOPAUSE, V15, P1176, DOI 10.1097/gme.0b013e318173566b; Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059	12	16	17	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					145	146		10.1038/nm0209-145	http://dx.doi.org/10.1038/nm0209-145			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19197289				2022-12-27	WOS:000263119400016
J	Skokowa, J; Lan, D; Thakur, BK; Wang, F; Gupta, K; Cario, G; Brechlin, AM; Schambach, A; Hinrichsen, L; Meyer, G; Gaestel, M; Stanulla, M; Tong, Q; Welte, K				Skokowa, Julia; Lan, Dan; Thakur, Basant Kumar; Wang, Fei; Gupta, Kshama; Cario, Gunnar; Brechlin, Annette Mueller; Schambach, Axel; Hinrichsen, Lars; Meyer, Gustav; Gaestel, Matthias; Stanulla, Martin; Tong, Qiang; Welte, Karl			NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway	NATURE MEDICINE			English	Article							COLONY-ENHANCING FACTOR; SEVERE CONGENITAL NEUTROPENIA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; AXONAL DEGENERATION; NAD BIOSYNTHESIS; CYCLIC NEUTROPENIA; STIMULATING FACTOR; GENE-EXPRESSION; C/EBP-BETA; SIRT1	We identified nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B cell colony enhancing factor (PBEF), as an essential enzyme mediating granulocyte colony-stimulating factor (G-CSF)-triggered granulopoiesis in healthy individuals and in individuals with severe congenital neutropenia. Intracellular NAMPT and NAD+ amounts in myeloid cells, as well as plasma NAMPT and NAD+ levels, were increased by G-CSF treatment of both healthy volunteers and individuals with congenital neutropenia. NAMPT administered both extracellularly and intracellularly induced granulocytic differentiation of CD34(+) hematopoietic progenitor cells and of the promyelocytic leukemia cell line HL-60. Treatment of healthy individuals with high doses of vitamin B3 ( nicotinamide), a substrate of NAMPT, induced neutrophilic granulocyte differentiation. The molecular events triggered by NAMPT include NAD(+)-dependent sirtuin-1 activation, subsequent induction of CCAAT/enhancer binding protein-alpha and CCAAT/enhancer binding protein-beta, and, ultimately, upregulation of G-CSF synthesis and G-CSF receptor expression. G-CSF, in turn, further increases NAMPT levels. These results reveal a decisive role of the NAD+ metabolic pathway in G-CSF-triggered myelopoiesis.	[Skokowa, Julia; Lan, Dan; Thakur, Basant Kumar; Gupta, Kshama; Brechlin, Annette Mueller; Hinrichsen, Lars; Stanulla, Martin; Welte, Karl] Hannover Med Sch, Dept Mol Hematopoiesis, D-30625 Hannover, Germany; [Wang, Fei; Tong, Qiang] Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Cario, Gunnar; Stanulla, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, D-24105 Kiel, Germany; [Meyer, Gustav; Gaestel, Matthias] Hannover Med Sch, Dept Biochem, D-30625 Hannover, Germany; [Schambach, Axel] Hannover Med Sch, Dept Expt Hematol, D-30625 Hannover, Germany	Hannover Medical School; Baylor College of Medicine; United States Department of Agriculture (USDA); University of Kiel; Schleswig Holstein University Hospital; Hannover Medical School; Hannover Medical School	Skokowa, J (corresponding author), Hannover Med Sch, Dept Mol Hematopoiesis, Carl Neuberg Str 1, D-30625 Hannover, Germany.	skokowa.julia@mh-hannover.de; Welte.Karl.H@mh-hannover.de	Wang, Fei/F-8015-2010; Gupta, Kshama/GRS-8778-2022; Stanulla, Martin/D-2528-2010; Skokowa, Julia/AAU-3622-2021; Stanulla, Martin/N-4674-2017; Cario, Gunnar/D-2535-2010; Schambach, Axel/C-5491-2011; Gaestel, Matthias/A-6560-2013	Skokowa, Julia/0000-0002-4399-2324; Stanulla, Martin/0000-0002-3834-0727; Gaestel, Matthias/0000-0002-4944-4652; Thakur, Barun Kumar/0000-0002-1713-9186	Elternverein Krebskranker Kinder Hannover e. V.; MadeleineSchickedanz- Kinderkrebsstiftung; Deutsche Jose Carreras Leukamia Stiftung e. V; REBIRTH Excellence Cluster; Else Kroner Foundation; American Federation for Aging Research senior postdoctoral fellowship; US Department of Agriculture; National Institutes of Health	Elternverein Krebskranker Kinder Hannover e. V.; MadeleineSchickedanz- Kinderkrebsstiftung; Deutsche Jose Carreras Leukamia Stiftung e. V; REBIRTH Excellence Cluster; Else Kroner Foundation; American Federation for Aging Research senior postdoctoral fellowship; US Department of Agriculture(United States Department of Agriculture (USDA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank M. Uenalan for helpful discussion, M. Morgan for critically reading the manuscript and M. Ballmaier and C. Reimer for assistance in cell sorting. We also thank C. Zeidler and the physicians within the Severe Chronic Neutropenia International Registry for providing subject material ( bone marrow cells, peripheral blood neutrophils and plasma). Special thanks to study subjects and colleagues, especially M. Schatz, for their great cooperation. This work was supported by Elternverein Krebskranker Kinder Hannover e. V., MadeleineSchickedanz- Kinderkrebsstiftung, Deutsche Jose Carreras Leukamia Stiftung e. V., REBIRTH Excellence Cluster ( A. S.), Else Kroner Foundation ( A. S.), an American Federation for Aging Research senior postdoctoral fellowship ( F. W.) and the US Department of Agriculture and National Institutes of Health ( Q. T.).	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; De Flora A, 2004, ANN NY ACAD SCI, V1028, P176, DOI 10.1196/annals.1322.021; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; Hasmann M, 2003, CANCER RES, V63, P7436; Hirai H, 2006, NAT IMMUNOL, V7, P732, DOI 10.1038/ni1354; Iqbal J, 2006, BIOCHEM BIOPH RES CO, V342, P1312, DOI 10.1016/j.bbrc.2006.02.109; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI [10.1172/JCI19930, 10.1172/JCI200419930]; Kaneko S, 2006, J NEUROSCI, V26, P9794, DOI 10.1523/JNEUROSCI.2116-06.2006; KASPER B, 1997, LEUKOCYTE TYPING, V4, P1072; Kendal CE, 2007, PLACENTA, V28, P305, DOI 10.1016/j.placenta.2006.03.011; Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105; Klein C, 2007, NAT GENET, V39, P86, DOI 10.1038/ng1940; Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536; KYAS U, 1992, BLOOD, V79, P1144; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; Libert S, 2008, NAT CELL BIOL, V10, P373, DOI 10.1038/ncb0408-373; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Nowell MA, 2006, ARTHRITIS RHEUM-US, V54, P2084, DOI 10.1002/art.21942; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Revollo JR, 2007, CELL METAB, V6, P363, DOI 10.1016/j.cmet.2007.09.003; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Skokowa J, 2006, NAT MED, V12, P1191, DOI 10.1038/nm1484; Skokowa J, 2007, CURR OPIN HEMATOL, V14, P22; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Tanaka T, 2007, CELL METAB, V6, P341, DOI 10.1016/j.cmet.2007.10.004; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Welte K, 2006, SEMIN HEMATOL, V43, P189, DOI 10.1053/j.seminhematol.2006.04.004; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yang TL, 2006, AAPS J, V8, pE632, DOI 10.1208/aapsj080472; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	42	165	179	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2009	15	2					151	158		10.1038/nm.1913	http://dx.doi.org/10.1038/nm.1913			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19182797				2022-12-27	WOS:000263119400017
J	Poeck, H; Besch, R; Maihoefer, C; Renn, M; Tormo, D; Morskaya, SS; Kirschnek, S; Gaffal, E; Landsberg, J; Hellmuth, J; Schmidt, A; Anz, D; Bscheider, M; Schwerd, T; Berking, C; Bourquin, C; Kalinke, U; Kremmer, E; Kato, H; Akira, S; Meyers, R; Hacker, G; Neuenhahn, M; Busch, D; Ruland, J; Rothenfusser, S; Prinz, M; Hornung, V; Endres, S; Tuting, T; Hartmann, G				Poeck, Hendrik; Besch, Robert; Maihoefer, Cornelius; Renn, Marcel; Tormo, Damia; Morskaya, Svetlana Shulga; Kirschnek, Susanne; Gaffal, Evelyn; Landsberg, Jennifer; Hellmuth, Johannes; Schmidt, Andreas; Anz, David; Bscheider, Michael; Schwerd, Tobias; Berking, Carola; Bourquin, Carole; Kalinke, Ulrich; Kremmer, Elisabeth; Kato, Hiroki; Akira, Shizuo; Meyers, Rachel; Haecker, Georg; Neuenhahn, Michael; Busch, Dirk; Ruland, Juergen; Rothenfusser, Simon; Prinz, Marco; Hornung, Veit; Endres, Stefan; Tueting, Thomas; Hartmann, Gunther			5 '-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma	NATURE MEDICINE			English	Article							INTERFERON INDUCTION; ANTIVIRAL RESPONSES; DENDRITIC CELLS; RNA; CANCER; DEFENSE; SIRNA; STIMULATION; RECOGNITION; DISEASE	Genetic and epigenetic plasticity allows tumors to evade single-targeted treatments. Here we direct Bcl2-specific short interfering RNA ( siRNA) with 5'-triphosphate ends (3p-siRNA) against melanoma. Recognition of 5'-triphosphate by the cytosolic antiviral helicase retinoic acid - induced protein I ( Rig-I, encoded by Ddx58) activated innate immune cells such as dendritic cells and directly induced expression of interferons (IFNs) and apoptosis in tumor cells. These Rig-I- mediated activities synergized with siRNA-mediated Bcl2 silencing to provoke massive apoptosis of tumor cells in lung metastases in vivo. The therapeutic activity required natural killer cells and IFN, as well as silencing of Bcl2, as evidenced by rescue with a mutated Bcl2 target, by site-specific cleavage of Bcl2 messenger RNA in lung metastases and downregulation of Bcl-2 protein in tumor cells in vivo. Together, 3p-siRNA represents a single molecule - based approach in which Rig-I activation on both the immune- and tumor cell level corrects immune ignorance and in which gene silencing corrects key molecular events that govern tumor cell survival.	[Renn, Marcel; Tormo, Damia; Gaffal, Evelyn; Landsberg, Jennifer; Tueting, Thomas] Univ Bonn, Dept Dermatol & Allergol, Lab Expt Dermatol, D-53105 Bonn, Germany; [Poeck, Hendrik; Hellmuth, Johannes; Hornung, Veit; Hartmann, Gunther] Univ Bonn, Univ Hosp, Inst Clin Chem & Pharmacol, D-53127 Bonn, Germany; [Maihoefer, Cornelius; Schmidt, Andreas; Anz, David; Bscheider, Michael; Schwerd, Tobias; Bourquin, Carole; Rothenfusser, Simon; Endres, Stefan] Univ Munich, Dept Internal Med, Div Clin Pharmacol, D-80336 Munich, Germany; [Poeck, Hendrik; Maihoefer, Cornelius; Bscheider, Michael; Ruland, Juergen] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-81675 Munich, Germany; [Besch, Robert; Berking, Carola] Univ Munich, Dept Dermatol & Allergol, D-80337 Munich, Germany; [Morskaya, Svetlana Shulga; Meyers, Rachel] Alnylam Pharmaceut, Cambridge, MA 02142 USA; [Kirschnek, Susanne; Haecker, Georg; Neuenhahn, Michael; Busch, Dirk] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; [Kalinke, Ulrich] Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany; [Kremmer, Elisabeth] Univ Munich, Helmholtz Zentrum Munchen, Inst Mol Immunol, D-81377 Munich, Germany; [Kato, Hiroki; Akira, Shizuo] Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita, Osaka 5650871, Japan; [Prinz, Marco] Univ Freiburg, Dept Neuropathol, D-79106 Freiburg, Germany	University of Bonn; University of Bonn; University of Munich; Technical University of Munich; University of Munich; Technical University of Munich; Paul Ehrlich Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Osaka University; University of Freiburg	Tuting, T (corresponding author), Univ Bonn, Dept Dermatol & Allergol, Lab Expt Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	thomas.tueting@ukb.uni-bonn.de; gunther.hartmann@ukb.uni-bonn.de	Bourquin, Carole/AAU-1418-2020; Landsberg, Jennifer/AAF-5113-2019; Tüting, Thomas/AAJ-3610-2021; Landsberg, Jenny/AGI-0216-2022; Hartmann, Gunther/P-7492-2017; Hornung, Veit/C-3565-2012; Ruland, Jurgen/Q-6680-2018	Bourquin, Carole/0000-0003-3862-4583; Tüting, Thomas/0000-0001-7146-0934; Landsberg, Jenny/0000-0001-8029-3883; Maihofer, Cornelius/0000-0002-0506-4519; Hartmann, Gunther/0000-0003-1021-2018; Hellmuth, Johannes C./0000-0001-8409-3037; Hornung, Veit/0000-0002-4150-194X; Ruland, Jurgen/0000-0002-8381-3597; Kalinke, Ulrich/0000-0003-0503-9564; Renn, Marcel/0000-0002-0120-4035				Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Melchjorsen J, 2005, J VIROL, V79, P12944, DOI 10.1128/JVI.79.20.12944-12951.2005; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pei Y, 2006, NAT METHODS, V3, P670, DOI 10.1038/NMETH911; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Schlee M, 2006, MOL THER, V14, P463, DOI 10.1016/j.ymthe.2006.06.001; Stetson DB, 2006, J EXP MED, V203, P1837, DOI 10.1084/jem.20061377; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200	31	293	312	4	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1256	1263		10.1038/nm.1887	http://dx.doi.org/10.1038/nm.1887			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18978796				2022-12-27	WOS:000260751200045
J	Du, H; Guo, L; Fang, F; Chen, D; Sosunov, AA; McKhann, GM; Yan, YL; Wang, CY; Zhang, H; Molkentin, JD; Gunn-Moore, FJ; Vonsattel, JP; Arancio, O; Chen, JX; Du Yan, S				Du, Heng; Guo, Lan; Fang, Fang; Chen, Doris; Sosunov, Alexander A.; McKhann, Guy M.; Yan, Yilin; Wang, Chunyu; Zhang, Hong; Molkentin, Jeffery D.; Gunn-Moore, Frank J.; Vonsattel, Jean Paul; Arancio, Ottavio; Chen, John Xi; Du Yan, Shi			Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease	NATURE MEDICINE			English	Article							PERMEABILITY TRANSITION PORE; AMYLOID PRECURSOR PROTEIN; LONG-TERM POTENTIATION; MANGANESE SUPEROXIDE-DISMUTASE; ADENINE-NUCLEOTIDE TRANSLOCASE; SURFACE-PLASMON RESONANCE; FOCAL CEREBRAL-ISCHEMIA; FREE-RADICAL GENERATION; CYTOCHROME-C-OXIDASE; A-BETA	Cyclophilin D (CypD, encoded by Ppif) is an integral part of the mitochondrial permeability transition pore, whose opening leads to cell death. Here we show that interaction of CypD with mitochondrial amyloid-beta protein (A beta) potentiates mitochondrial, neuronal and synaptic stress. The CypD-deficient cortical mitochondria are resistant to A beta- and Ca2+-induced mitochondrial swelling and permeability transition. Additionally, they have an increased calcium buffering capacity and generate fewer mitochondrial reactive oxygen species. Furthermore, the absence of CypD protects neurons from A beta- and oxidative stress-induced cell death. Notably, CypD deficiency substantially improves learning and memory and synaptic function in an Alzheimer's disease mouse model and alleviates A beta-mediated reduction of long-term potentiation. Thus, the CypD-mediated mitochondrial permeability transition pore is directly linked to the cellular and synaptic perturbations observed in the pathogenesis of Alzheimer's disease. Blockade of CypD may be a therapeutic strategy in Alzheimer's disease.	[Yan, Yilin; Wang, Chunyu] Rensselaer Polytech Inst, Dept Biol, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12180 USA; [Du, Heng; Guo, Lan; Fang, Fang; Chen, Doris; Du Yan, Shi] Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Du, Heng; Guo, Lan; Fang, Fang; Chen, Doris; Du Yan, Shi] Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; [Zhang, Hong; Vonsattel, Jean Paul; Arancio, Ottavio; Du Yan, Shi] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Zhang, Hong; Arancio, Ottavio; Du Yan, Shi] Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Molkentin, Jeffery D.] Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Gunn-Moore, Frank J.] Univ St Andrews, Sch Biol, St Andrews KY16 9TS, Fife, Scotland; [Chen, John Xi] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA	Rensselaer Polytechnic Institute; Columbia University; Columbia University; Columbia University; Columbia University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of St Andrews; Cornell University; Memorial Sloan Kettering Cancer Center	Du Yan, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Surg, 630 W 168th St, New York, NY 10032 USA.	sdyl@columbia.edu	Wang, Chunyu/AAH-5952-2019; arancio, ottavio/AAB-7959-2019; Yan, Yi/GSO-3046-2022	Molkentin, Jeffery/0000-0002-3558-6529; arancio, ottavio/0000-0001-6335-164X; Wang, Chunyu/0000-0001-5165-7959	US Public Health Service Commissioned Corps [1101 AG17490, 11050 AG08702]; Alzheimer's Association; NATIONAL INSTITUTE ON AGING [P50AG008702, P01AG017490] Funding Source: NIH RePORTER	US Public Health Service Commissioned Corps(United States Department of Health & Human ServicesUnited States Public Health Service); Alzheimer's Association(Alzheimer's Association); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the US Public Health Service Commissioned Corps (1101 AG17490, 11050 AG08702) and the Alzheimer's Association. We thank S. Katz for assistance with performing the behavioral experiments.	Aguilar MI, 2005, NEUROTOX RES, V7, P17, DOI 10.1007/BF03033773; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bergersen LH, 2008, NAT PROTOC, V3, P144, DOI 10.1038/nprot.2007.525; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Blass JP, 2000, ANN NY ACAD SCI, V924, P170; Cardoso SM, 2004, J NEUROCHEM, V89, P1417, DOI 10.1111/j.1471-4159.2004.02438.x; Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Caspersen C, 2005, FASEB J, V19, P2040, DOI 10.1096/fj.05-3735fje; CHEN X, 2007, NEUROBIOLOGY ALZHEIM, P227; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Crouch PJ, 2005, J NEUROSCI, V25, P672, DOI 10.1523/JNEUROSCI.4276-04.2005; Devi L, 2006, J NEUROSCI, V26, P9057, DOI 10.1523/JNEUROSCI.1469-06.2006; Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022; Esposito L, 2006, J NEUROSCI, V26, P5167, DOI 10.1523/JNEUROSCI.0482-06.2006; Fernandez-Vizarra P, 2004, HISTOL HISTOPATHOL, V19, P823, DOI 10.14670/HH-19.823; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hou FF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351296; Kamsler A, 2003, J NEUROSCI, V23, P10359; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Lin MT, 2006, NAT MED, V12, P1241, DOI 10.1038/nm1106-1241; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Maragos WF, 2000, BRAIN RES, V878, P218, DOI 10.1016/S0006-8993(00)02707-4; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Moreira PI, 2002, J NEUROSCI RES, V69, P257, DOI 10.1002/jnr.10282; Murakami K, 1998, J NEUROSCI, V18, P205; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Origlia N, 2008, J NEUROSCI, V28, P3521, DOI 10.1523/JNEUROSCI.0204-08.2008; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reddy PH, 2006, J NEUROCHEM, V96, P1, DOI 10.1111/j.1471-4159.2005.03530.x; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Sheehan JP, 1997, J NEUROSCI, V17, P4612; Shukkur EA, 2006, HUM MOL GENET, V15, P2752, DOI 10.1093/hmg/ddl211; Takuma K, 2005, FASEB J, V19, P597, DOI 10.1096/fj.04-2582fje; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Wang JD, 2006, FEBS LETT, V580, P4392, DOI 10.1016/j.febslet.2006.07.002; Xie CW, 2004, NEUROMOL MED, V6, P53, DOI 10.1385/NMM:6:1:053; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan YL, 2007, BIOCHEMISTRY-US, V46, P1724, DOI 10.1021/bi061314n; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682	56	712	739	1	62	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1097	1105		10.1038/nm.1868	http://dx.doi.org/10.1038/nm.1868			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18806802	Green Accepted			2022-12-27	WOS:000259892300040
J	Mandl, JN; Barry, AP; Vanderford, TH; Kozyr, N; Chavan, R; Mucking, S; Barrat, FJ; Coffman, RL; Staprans, SI; Feinberg, MB				Mandl, Judith N.; Barry, Ashley P.; Vanderford, Thomas H.; Kozyr, Natalia; Chavan, Rahul; Mucking, Sara; Barrat, Franck J.; Coffman, Robert L.; Staprans, Silvija I.; Feinberg, Mark B.			Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections	NATURE MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; PLASMACYTOID DENDRITIC CELLS; CD4(+) T-CELLS; TOLL-LIKE RECEPTORS; SOOTY MANGABEYS; NATURAL-KILLER; HIV-INFECTION; TRANSCRIPTION FACTORS; IMMUNE ACTIVATION; INNATE IMMUNITY	Pathogenic HIV infections of humans and simian immunodeficiency virus (SIV) infections of rhesus macaques are characterized by generalized immune activation and progressive CD4(+) T cell depletion. In contrast, natural reservoir hosts for SIV, such as sooty mangabeys, do not progress to AIDS and show a lack of aberrant immune activation and preserved CD4(+) T cell populations, despite high levels of SIV replication. Here we show that sooty mangabeys have substantially reduced levels of innate immune system activation in vivo during acute and chronic SIV infection and that sooty mangabey plasmacytoid dendritic cells (pDCs) produce markedly less interferon-a in response to SIV and other Toll-like receptor 7 and 9 ligands ex vivo. We propose that chronic stimulation of pDCs by SIV and HIV in non-natural hosts may drive the unrelenting immune system activation and dysfunction underlying AIDS progression. Such a vicious cycle of continuous virus replication and immunopathology is absent in natural sooty mangabey hosts.	[Mandl, Judith N.; Barry, Ashley P.; Vanderford, Thomas H.; Kozyr, Natalia; Chavan, Rahul; Mucking, Sara; Staprans, Silvija I.; Feinberg, Mark B.] Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Mandl, Judith N.] Emory Univ, Grad Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA; [Barrat, Franck J.; Coffman, Robert L.] Dynavax Technol, Berkeley, CA 94710 USA; [Staprans, Silvija I.; Feinberg, Mark B.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30329 USA; [Staprans, Silvija I.; Feinberg, Mark B.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30329 USA; [Mandl, Judith N.; Barry, Ashley P.; Vanderford, Thomas H.; Kozyr, Natalia; Chavan, Rahul; Mucking, Sara; Staprans, Silvija I.; Feinberg, Mark B.] Emory Vaccine Ctr, Atlanta, GA 30329 USA	Emory University; Emory University; Emory University; Emory University	Feinberg, MB (corresponding author), Merck & Co Inc, Merck Vaccines & Infect Dis, WP97-A337,770 Sumneytown Pike,POB 4, West Point, PA 19486 USA.	mark_feinberg@merck.com			US National Institutes of Health [R01 HL075766, R01 AI049155]; Yerkes National primate Research Center [RR000165]; Emory Center for AIDS Research [P30-AI-50409]; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050409, R01AI049155] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yerkes National primate Research Center; Emory Center for AIDS Research; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors would like to thank B. Weaver, J. Skvarich, B. O'Hara and M. Mulligan for their help coordinating blood draws from HIV-infected humans, S. Ehnert and E. Strobert lot their care of the study animals, B. Lawson and 1). Lee for performing the SIVsm and SIVmac239 viral load assays, J. Ingersoll tot performing, the HIV viral load assays, A. McCrary for assistance with cloning and sequencing, K. Dalbey for help with running ELISAs, H.Yi for help with electron microscopy, J. Bess and J. Lifson at the US National Cancer Institute for providing the aldrithiol-2-inactivated SIV and HIV strains and microvesicle controls, 3M Pharmaceuticals lot providing the R-848 and anonymous human volunteers for providing blood samples for these studies. We would also like to thank G. Silvestri for his input. We gratefully acknowledge the support of the US National Institutes of Health grants R01 HL075766 and R01 AI049155, the Yerkes National primate Research Center Grant RR000165 and the Emory Center for AIDS Research Grant P30-AI-50409. The authors apologize for not citing all relevant publications due to Space limitations.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957; Barry AP, 2007, J IMMUNOL, V178, P8002, DOI 10.4049/jimmunol.178.12.8002; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Bochud PY, 2007, LANCET INFECT DIS, V7, P531, DOI 10.1016/S1473-3099(07)70185-8; Bosinger SE, 2004, J IMMUNOL, V173, P6858, DOI 10.4049/jimmunol.173.11.6858; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Coates PTH, 2003, BLOOD, V102, P2513, DOI 10.1182/blood-2002-09-2929; Decalf J, 2007, J EXP MED, V204, P2423, DOI 10.1084/jem.20070814; Dunham R, 2006, BLOOD, V108, P209, DOI 10.1182/blood-2005-12-4897; Ferlazzo G, 2005, IMMUNOL LETT, V101, P12, DOI 10.1016/j.imlet.2005.04.015; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fonteneau JF, 2004, J VIROL, V78, P5223, DOI 10.1128/JVI.78.10.5223-5232.2004; Giavedoni LD, 2000, J VIROL, V74, P1648, DOI 10.1128/JVI.74.4.1648-1657.2000; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Gordon SN, 2008, J VIROL, V82, P3725, DOI 10.1128/JVI.02408-07; Gordon SN, 2007, J IMMUNOL, V179, P3026, DOI 10.4049/jimmunol.179.5.3026; Gowen BB, 2006, J IMMUNOL, V177, P6301, DOI 10.4049/jimmunol.177.9.6301; Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Hellerstein MK, 2003, J CLIN INVEST, V112, P956, DOI 10.1172/JCI200317533; Herbeuval JP, 2007, CLIN IMMUNOL, V123, P121, DOI 10.1016/j.clim.2006.09.016; Herbeuval JP, 2005, P NATL ACAD SCI USA, V102, P13974, DOI 10.1073/pnas.0505251102; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Kamath AT, 2005, J IMMUNOL, V174, P767, DOI 10.4049/jimmunol.174.2.767; Kaser A, 1999, CYTOKINE, V11, P736, DOI 10.1006/cyto.1998.0484; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Kottilil S, 2007, JAIDS-J ACQ IMM DEF, V46, P151, DOI 10.1097/QAI.0b013e3180dc9909; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Markowitz M, 2003, J VIROL, V77, P5037, DOI 10.1128/JVI.77.8.5037-5038.2003; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; Moir S, 2004, J EXP MED, V200, P587, DOI 10.1084/jem.20032236; Pandrea IV, 2007, J IMMUNOL, V179, P3035, DOI 10.4049/jimmunol.179.5.3035; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sedaghat AR, 2008, J VIROL, V82, P1870, DOI 10.1128/JVI.02228-07; Silvestri G, 2005, J VIROL, V79, P4043, DOI 10.1128/JVI.79.7.4043-4054.2005; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Stewart TA, 2003, CYTOKINE GROWTH F R, V14, P139, DOI 10.1016/S1359-6101(02)00088-6; Sumpter B, 2007, J IMMUNOL, V178, P1680, DOI 10.4049/jimmunol.178.3.1680; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Tilton JC, 2008, J VIROL, V82, P3997, DOI 10.1128/JVI.01545-07; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Zhang SY, 2007, IMMUNOL REV, V220, P225, DOI 10.1111/j.1600-065X.2007.00564.x	60	294	314	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1077	1087		10.1038/nm.1871	http://dx.doi.org/10.1038/nm.1871			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18806803				2022-12-27	WOS:000259892300038
J	Kahn, ML				Kahn, Mark L.			Counteracting clotting in sepsis	NATURE MEDICINE			English	Editorial Material							ACTIVATED PROTEIN-C; COAGULATION; RECEPTOR-1		Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Kahn, ML (corresponding author), Univ Penn, 925 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	markkahn@med.upenn.edu						Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Camerer E, 2006, BLOOD, V107, P3912, DOI 10.1182/blood-2005-08-3130; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; MANASSE P, 1982, VIRCHOWS ARCH, V130, P217; Niessen F, 2008, NATURE, V452, P654, DOI 10.1038/nature06663; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Zheng X, 2007, J THROMB HAEMOST, V5, P1394, DOI 10.1111/j.1538-7836.2007.02592.x	13	6	7	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					918	919		10.1038/nm0908-918	http://dx.doi.org/10.1038/nm0908-918			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18776884				2022-12-27	WOS:000258988600015
J	Yamamoto, S; Shimizu, S; Kiyonaka, S; Takahashi, N; Wajima, T; Hara, Y; Negoro, T; Hiroi, T; Kiuchi, Y; Okada, T; Kaneko, S; Lange, I; Fleig, A; Penner, R; Nishi, M; Takeshima, H; Mori, Y				Yamamoto, Shinichiro; Shimizu, Shunichi; Kiyonaka, Shigeki; Takahashi, Nobuaki; Wajima, Teruaki; Hara, Yuji; Negoro, Takaharu; Hiroi, Toshihito; Kiuchi, Yuji; Okada, Takaharu; Kaneko, Shuji; Lange, Ingo; Fleig, Andrea; Penner, Reinhold; Nishi, Miyuki; Takeshima, Hiroshi; Mori, Yasuo			TRPM2-mediated Ca(2+) influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration	NATURE MEDICINE			English	Article							SODIUM-INDUCED COLITIS; NF-KAPPA-B; OXIDATIVE STRESS; ADP-RIBOSE; ULCERATIVE-COLITIS; GENE-EXPRESSION; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; BOWEL-DISEASE; TRP CHANNELS	Reactive oxygen species (ROS) induce chemokines responsible for the recruitment of inflammatory cells to sites of injury or infection. Here we show that the plasma membrane Ca(2+)-permeable channel TRPM2 controls ROS-induced chemokine production in monocytes. In human U937 monocytes, hydrogen peroxide (H(2)O(2)) evokes Ca(2+) influx through TRPM2 to activate Ca(2+)-dependent tyrosine kinase Pyk2 and amplify Erk signaling via Ras GTPase. This elicits nuclear translocation of nuclear factor-kappa B essential for the production of the chemokine interleukin-8 (CXCL8). In monocytes from Trpm2-deficient mice, H(2)O(2)-induced Ca(2+) influx and production of the macrophage inflammatory protein-2 (CXCL2), the mouse CXCL8 functional homolog, were impaired. In the dextran sulfate sodium-induced colitis inflammation model, CXCL2 expression, neutrophil infiltration and ulceration were attenuated by Trpm2 disruption. Thus, TRPM2 Ca(2+) influx controls the ROS-induced signaling cascade responsible for chemokine production, which aggravates inflammation. We propose functional inhibition of TRPM2 channels as a new therapeutic strategy for treating inflammatory diseases.	[Yamamoto, Shinichiro; Kiyonaka, Shigeki; Takahashi, Nobuaki; Wajima, Teruaki; Hara, Yuji; Okada, Takaharu; Mori, Yasuo] Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan; [Negoro, Takaharu] Showa Univ, Sch Pharmaceut Sci, Dept Med Informat, Shinagawa Ku, Tokyo 1428555, Japan; [Shimizu, Shunichi; Hiroi, Toshihito; Kiuchi, Yuji] Showa Univ, Dept Pathophysiol, Tokyo 1428555, Japan; [Kaneko, Shuji] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; [Lange, Ingo; Fleig, Andrea; Penner, Reinhold] Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signalling, Honolulu, HI 96813 USA; [Lange, Ingo; Fleig, Andrea; Penner, Reinhold] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA; [Takeshima, Hiroshi] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Showa University; Showa University; Kyoto University; The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Kyoto University	Mori, Y (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Synth Chem & Biol Chem, Nishikyo Ku, Kyoto 6158510, Japan.	mori@sbchem.kyoto-u.ac.jp	Kaneko, Shuji/AAR-1005-2021; Takahashi, Nobuaki/AAG-9411-2019; Okada, Takaharu/N-7931-2015; Kiyonaka, Shigeki/AAM-7303-2021	Takahashi, Nobuaki/0000-0002-0606-3921; Lange, Ingo/0000-0002-6703-0015; Fleig, Andrea/0000-0001-8396-7249; Takeshima, Hiroshi/0000-0003-4525-3725; Kaneko, Shuji/0000-0001-5152-5809; Penner, Reinhold/0000-0002-5366-1537	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063954] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [20249015] Funding Source: KAKEN; NIGMS NIH HHS [R01 GM063954-06, R01 GM063954] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anezaki K, 1998, INTERNAL MED, V37, P253, DOI 10.2169/internalmedicine.37.253; Araki Y, 2006, INT J MOL MED, V17, P331; Barnes PJ, 2004, CURR OPIN PHARMACOL, V4, P263, DOI 10.1016/j.coph.2004.03.001; Blackburn AC, 1998, FREE RADICAL BIO MED, V25, P305, DOI 10.1016/S0891-5849(98)00068-9; Buanne P, 2007, J LEUKOCYTE BIOL, V82, P1239, DOI 10.1189/jlb.0207118; Cavaillon JM, 2005, CRIT CARE MED, V33, pS506, DOI 10.1097/01.CCM.0000185502.21012.37; Chiu LL, 2007, J IMMUNOL, V178, P5237, DOI 10.4049/jimmunol.178.8.5237; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cuzzocrea S, 2007, FREE RADICAL BIO MED, V42, P90, DOI 10.1016/j.freeradbiomed.2006.09.025; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Grip Olof, 2003, Current Drug Targets - Inflammation and Allergy, V2, P155, DOI 10.2174/1568010033484179; Han XB, 2004, AM J PHYSIOL-GASTR L, V287, pG1220, DOI 10.1152/ajpgi.00231.2004; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Henricks PAJ, 2001, PULM PHARMACOL THER, V14, P409, DOI 10.1006/pupt.2001.0319; Hermosura MC, 2007, BBA-MOL BASIS DIS, V1772, P822, DOI 10.1016/j.bbadis.2007.02.008; Jaramillo M, 2002, J IMMUNOL, V169, P7026, DOI 10.4049/jimmunol.169.12.7026; Josse C, 2001, BIOCHEM J, V360, P321, DOI 10.1042/0264-6021:3600321; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Keshavarzian A, 1999, AM J GASTROENTEROL, V94, P704, DOI 10.1111/j.1572-0241.1999.00940.x; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kim DS, 2003, MOL IMMUNOL, V40, P633, DOI 10.1016/j.molimm.2003.07.001; Korenaga D, 2002, J SURG RES, V102, P144, DOI 10.1006/jsre.2001.6314; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee KM, 2001, CELL SIGNAL, V13, P645, DOI 10.1016/S0898-6568(01)00178-4; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mahida YR, 2000, INFLAMM BOWEL DIS, V6, P21, DOI 10.1097/00054725-200002000-00004; Massullo P, 2006, SEMIN CELL DEV BIOL, V17, P654, DOI 10.1016/j.semcdb.2006.11.006; Mendez-Samperio P, 2004, MEDIAT INFLAMM, V13, P45, DOI 10.1080/09629350410001664743; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Ohtsuka Y, 2003, PEDIATR RES, V53, P143, DOI 10.1203/01.PDR.0000041519.16507.06; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Roose JP, 2005, MOL CELL BIOL, V25, P4426, DOI 10.1128/MCB.25.11.4426-4441.2005; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; Smith PD, 2005, IMMUNOL REV, V206, P149, DOI 10.1111/j.0105-2896.2005.00288.x; Sonoda Y, 1998, J IMMUNOL, V160, P6159; Videla LA, 2003, BIOMETALS, V16, P103, DOI 10.1023/A:1020707811707; WILSON L, 1993, FEBS LETT, V325, P295, DOI 10.1016/0014-5793(93)81092-E; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Zeng XK, 2003, CIRC RES, V93, P311, DOI 10.1161/01.RES.0000087642.01082.E4; Zhang WY, 2007, AM J PHYSIOL-CELL PH, V292, pC1746, DOI 10.1152/ajpcell.00569.2006	50	425	446	2	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					738	747		10.1038/nm1758	http://dx.doi.org/10.1038/nm1758			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18542050	Green Accepted			2022-12-27	WOS:000257452700021
J	Teichgraber, V; Ulrich, M; Endlich, N; Riethmuller, J; Wilker, B; De Oliveira-Munding, CC; van Heeckeren, AM; Barr, ML; von Kurthy, G; Schmid, KW; Weller, M; Tummler, B; Lang, F; Grassme, H; Doring, G; Gulbins, E				Teichgraeber, Volker; Ulrich, Martina; Endlich, Nicole; Riethmueller, Joachim; Wilker, Barbara; De Oliveira-Munding, Cheyla Conceicao; van Heeckeren, Anna M.; Barr, Mark L.; von Kuerthy, Gabriele; Schmid, Kurt W.; Weller, Michael; Tuemmler, Burkhard; Lang, Florian; Grassme, Heike; Doering, Gerd; Gulbins, Erich			Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; AIRWAY EPITHELIAL-CELLS; NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; ACID SPHINGOMYELINASE; MICE; ACIDIFICATION; DISEASE; CFTR; ACTIVATION	Microbial lung infections are the major cause of morbidity and mortality in the hereditary metabolic disorder cystic fibrosis, yet the molecular mechanisms leading from the mutation of cystic fibrosis transmembrane conductance regulator ( CFTR) to lung infection are still unclear. Here, we show that ceramide age-dependently accumulates in the respiratory tract of uninfected Cftr-deficient mice owing to an alkalinization of intracellular vesicles in Cftr-deficient cells. This change in pH results in an imbalance between acid sphingomyelinase ( Asm) cleavage of sphingomyelin to ceramide and acid ceramidase consumption of ceramide, resulting in the higher levels of ceramide. The accumulation of ceramide causes Cftr-deficient mice to suffer from constitutive age-dependent pulmonary inflammation, death of respiratory epithelial cells, deposits of DNA in bronchi and high susceptibility to severe Pseudomonas aeruginosa infections. Partial genetic deficiency of Asm in Cftr(-/-) Smpd1(+/-) mice or pharmacological treatment of Cftr-deficient mice with the Asm blocker amitriptyline normalizes pulmonary ceramide and prevents all pathological findings, including susceptibility to infection. These data suggest inhibition of Asm as a new treatment strategy for cystic fibrosis.	[Teichgraeber, Volker; Wilker, Barbara; Grassme, Heike; Gulbins, Erich] Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany; [Ulrich, Martina; De Oliveira-Munding, Cheyla Conceicao; Doering, Gerd] Inst Med Microbiol & Hyg, D-72074 Tubingen, Germany; [Endlich, Nicole] Ernst Moritz Arndt Univ Greifswald, Dept Anat, D-17487 Greifswald, Germany; [Riethmueller, Joachim] Childrens Clin, D-72076 Tubingen, Germany; [van Heeckeren, Anna M.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Barr, Mark L.] Univ So Calif, Dept Cardiothorac Surg, Los Angeles, CA 90033 USA; [von Kuerthy, Gabriele; Weller, Michael] Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; [Schmid, Kurt W.] Univ Duisburg Essen, Dept Pathol & Neuropathol, D-45122 Essen, Germany; [Tuemmler, Burkhard] Med Univ Sch, D-30625 Hannover, Germany; [Lang, Florian] Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany	University of Duisburg Essen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ernst Moritz Arndt Universitat Greifswald; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Case Western Reserve University; University of Southern California; Eberhard Karls University of Tubingen; University of Duisburg Essen; Eberhard Karls University of Tubingen	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-due.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X				BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BHUVANESWARAN C, 1985, EUR J CELL BIOL, V73, P98; Borowitz D, 2005, J PEDIATR GASTR NUTR, V41, P273, DOI 10.1097/01.mpg.0000178439.64675.8d; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Boujaoude LC, 2001, J BIOL CHEM, V276, P35258, DOI 10.1074/jbc.M105442200; Cannon CL, 2003, AM J RESP CELL MOL, V29, P188, DOI 10.1165/rcmb.4898; Coleman FT, 2003, P NATL ACAD SCI USA, V100, P1949, DOI 10.1073/pnas.0437901100; Cottart CH, 2007, PEDIATR RES, V62, P528, DOI 10.1203/PDR.0b013e318155a61d; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Dbaibo GS, 1998, APOPTOSIS, V3, P317, DOI 10.1023/A:1009668802718; Di A, 2006, NAT CELL BIOL, V8, P933, DOI 10.1038/ncb1456; Elojeimy S, 2006, FEBS LETT, V580, P4751, DOI 10.1016/j.febslet.2006.07.071; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FORBES AR, 1977, ANESTHESIOLOGY, V46, P319, DOI 10.1097/00000542-197705000-00002; Freedman SD, 1999, P NATL ACAD SCI USA, V96, P13995, DOI 10.1073/pnas.96.24.13995; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Guilbault C, 2008, AM J RESP CELL MOL, V38, P47, DOI 10.1165/rcmb.2007-0036OC; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Haggie PM, 2007, J BIOL CHEM, V282, P31422, DOI 10.1074/jbc.M705296200; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Hariharan K, 1996, NAHRUNG, V40, P325, DOI 10.1002/food.19960400607; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Joseph T, 2005, AM J PHYSIOL-LUNG C, V288, pL471, DOI 10.1152/ajplung.00066.2004; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Maiuri L, 1997, FEBS LETT, V408, P225, DOI 10.1016/S0014-5793(97)00347-5; Menaldino DS, 2003, PHARMACOL RES, V47, P373, DOI 10.1016/S1043-6618(03)00054-9; MOL MJ, 1986, LANCET, V328, P936; MOSCONI C, 1988, ATHEROSCLEROSIS, V72, P129, DOI 10.1016/0021-9150(88)90073-1; Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; Whitchurch CB, 2002, SCIENCE, V295, P1487, DOI 10.1126/science.295.5559.1487; White NM, 2004, AM J RESP CELL MOL, V31, P538, DOI 10.1165/rcmb.2004-0117OC; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zahm JM, 1997, AM J PHYSIOL-CELL PH, V272, pC853, DOI 10.1152/ajpcell.1997.272.3.C853	50	428	443	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					382	391		10.1038/nm1748	http://dx.doi.org/10.1038/nm1748			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376404	Green Accepted			2022-12-27	WOS:000254674100024
J	Hauck, L; Harms, C; An, JF; Rohne, J; Gertz, K; Dietz, R; Endres, M; von Harsdorf, R				Hauck, Ludger; Harms, Christoph; An, Junfeng; Rohne, Jens; Gertz, Karen; Dietz, Rainer; Endres, Matthias; von Harsdorf, Ruediger			Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart	NATURE MEDICINE			English	Article							DEPENDENT-KINASE; INHIBITOR P27(KIP1); MICE LACKING; REGULATES PROTEOLYSIS; UBIQUITIN LIGASE; MAMMALIAN-CELLS; P27; PHOSPHORYLATION; DEGRADATION; CDK	p27(Kip1) (p27) blocks cell proliferation through the inhibition of cyclin-dependent kinase-2 (Cdk2). Despite its robust expression in the heart, little is known about both the function and regulation of p27 in this and other nonproliferative tissues, in which the expression of its main target, cyclin E-Cdk2, is known to be very low. Here we show that angiotensin II, a major cardiac growth factor, induces the proteasomal degradation of p27 through protein kinase CK2-alpha'-dependent phosphorylation. Conversely, unphosphorylated p27 potently inhibits CK2-alpha'. Thus, the p27-CK2-alpha' interaction is regulated by hypertrophic signaling events and represents a regulatory feedback loop in differentiated cardiomyocytes analogous to, but distinct from, the feedback loop arising from the interaction of p27 with Cdk2 that controls cell proliferation. Our data show that extracellular growth factor signaling regulates p27 stability in postmitotic cells, and that inactivation of p27 by CK2-alpha' is crucial for agonist- and stress-induced cardiac hypertrophic growth.	[Hauck, Ludger; von Harsdorf, Ruediger] Univ Network Hosp, Div Cardiol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada; [Hauck, Ludger; von Harsdorf, Ruediger] Toronto Geb Res Inst, Toronto, ON M5G 2C4, Canada; [Hauck, Ludger; von Harsdorf, Ruediger] McEwen Ctr Regenerat Med, Toronto, ON M5G 2C4, Canada; [Endres, Matthias] Charite, Ctr Stroke Res Berlin, D-10117 Berlin, Germany; [Harms, Christoph; Gertz, Karen; Endres, Matthias] Charite, Dept Neurol, D-10117 Berlin, Germany; [An, Junfeng; Rohne, Jens; Dietz, Rainer] Humboldt Univ, Dept Cardiol, Charite, D-13353 Berlin, Germany; [Dietz, Rainer] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	University of Toronto; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	von Harsdorf, R (corresponding author), Univ Network Hosp, Div Cardiol, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	rudiger.vonharsdorf@uhn.on.ca	Harms, Christoph/HIK-2989-2022; Harms, Christoph/AAD-7895-2021; Gertz, Karen/J-1603-2015	Harms, Christoph/0000-0002-2063-2860; Gertz, Karen/0000-0002-1203-641X; Endres, Matthias/0000-0001-6520-3720				Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Burton PBJ, 1999, EUR HEART J, V20, P604, DOI 10.1053/euhj.1998.1231; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Kotoshiba S, 2005, J BIOL CHEM, V280, P17694, DOI 10.1074/jbc.M500866200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Satoh M, 2006, P NATL ACAD SCI USA, V103, P7432, DOI 10.1073/pnas.0510444103; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	50	82	83	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2008	14	3					315	324		10.1038/nm1729	http://dx.doi.org/10.1038/nm1729			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18311148				2022-12-27	WOS:000253815700038
J	Verhasselt, V; Milcent, V; Cazareth, J; Kanda, A; Fleury, S; Dombrowicz, D; Glaichenhaus, N; Julia, V				Verhasselt, Valerie; Milcent, Valerie; Cazareth, Julie; Kanda, Akira; Fleury, Sebastien; Dombrowicz, David; Glaichenhaus, Nicolas; Julia, Valerie			Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELLS; IMMUNE-RESPONSES; INHALED ANTIGEN; ORAL TOLERANCE; MICE; PROTEIN; ABSORPTION; EXPRESSION	Allergic asthma is a chronic disease characterized by airway obstruction in response to allergen exposure. It results from an inappropriate T helper type 2 response to environmental airborne antigens and affects 300 million individuals(1). Its prevalence has increased markedly in recent decades, most probably as a result of changes in environmental factors(2). Exposure to environmental antigens during infancy is crucial to the development of asthma(3). Epidemiological studies on the relationship between breastfeeding and allergic diseases have reached conflicting results(4-8). Here, we have investigated whether the exposure of lactating mice to an airborne allergen affects asthma development in progeny. We found that airborne antigens were efficiently transferred from the mother to the neonate through milk and that tolerance induction did not require the transfer of immunoglobulins. Breastfeeding-induced tolerance relied on the presence of transforming growth factor (TGF)-beta during lactation, was mediated by regulatory CD4(+) T lymphocytes and depended on TGF-beta signaling in T cells. In conclusion, breast milk-mediated transfer of an antigen to the neonate resulted in oral tolerance induction leading to antigen-specific protection from allergic airway disease. This study may pave the way for the design of new strategies to prevent the development of allergic diseases.	[Verhasselt, Valerie; Milcent, Valerie; Glaichenhaus, Nicolas; Julia, Valerie] Univ Nice Sophie Antipolis, U924, INSERM, F-06560 Valbonne, France; [Cazareth, Julie] Univ Nice Sophie Antipolis, UMR 6097, CNRS, F-06560 Valbonne, France; [Kanda, Akira; Fleury, Sebastien; Dombrowicz, David] Univ Lille, Inst Pasteur, INSERM, U547, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Verhasselt, V (corresponding author), Univ Nice Sophie Antipolis, U924, INSERM, 660 Route Lucioles, F-06560 Valbonne, France.	verhasselt@unice.fr; vjulia@unice.fr	Verhasselt, Valerie/AAO-2373-2020; Dombrowicz, David/F-7044-2013; Eckhardt, Erik/G-1567-2010	Dombrowicz, David/0000-0002-0485-8923; Fleury, Sebastien/0000-0002-0679-3086; verhasselt, valerie/0000-0002-5732-9048				Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; BENSCH KG, 1967, SCIENCE, V157, P1204, DOI 10.1126/science.157.3793.1204; BRALEY JF, 1978, J CLIN INVEST, V61, P1240, DOI 10.1172/JCI109040; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Guilbert TW, 2007, AM J RESP CRIT CARE, V176, P843, DOI 10.1164/rccm.200610-1507OC; HANSON DG, 1981, J IMMUNOL, V127, P1518; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Labbok MH, 2004, NAT REV IMMUNOL, V4, P565, DOI 10.1038/nri1393; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; Palmer DJ, 2006, CURR OPIN CLIN NUTR, V9, P284, DOI 10.1097/01.mco.0000222113.46042.50; Penttila I, 2006, PEDIATR RES, V59, P650, DOI 10.1203/01.pdr.0000203149.75465.74; Penttila IA, 1998, PEDIATR RES, V44, P524, DOI 10.1203/00006450-199810000-00010; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; WILLOUGHBY JB, 1977, J IMMUNOL, V119, P2137	30	299	308	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					170	175		10.1038/nm1718	http://dx.doi.org/10.1038/nm1718			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18223654				2022-12-27	WOS:000252946700025
J	Link, H; Martin, R				Link, Hans; Martin, Roland			New drugs may improve, complicate treatment for multiple sclerosis	NATURE MEDICINE			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ORAL FINGOLIMOD		[Link, Hans] Karolinska Inst, Dept Neurology, Stockholm, Sweden; [Martin, Roland] Univ Med Ctr Eppendorf, Inst Neuroimmunology & Clin Multiple Sclerosis Res, Hamburg, Germany	Karolinska Institutet; University of Hamburg; University Medical Center Hamburg-Eppendorf	Link, H (corresponding author), Karolinska Inst, Dept Neurology, Stockholm, Sweden.			Martin, Roland/0000-0002-0982-1329				Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494	3	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					272	272		10.1038/nm0310-272	http://dx.doi.org/10.1038/nm0310-272			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208513	Bronze			2022-12-27	WOS:000275289500043
J	Guilluy, C; Bregeon, J; Toumaniantz, G; Rolli-Derkinderen, M; Retailleau, K; Loufrani, L; Henrion, D; Scalbert, E; Bril, A; Torres, RM; Offermanns, S; Pacaud, P; Loirand, G				Guilluy, Christophe; Bregeon, Jeremy; Toumaniantz, Gilles; Rolli-Derkinderen, Malvyne; Retailleau, Kevin; Loufrani, Laurent; Henrion, Daniel; Scalbert, Elizabeth; Bril, Antoine; Torres, Raul M.; Offermanns, Stephan; Pacaud, Pierre; Loirand, Gervaise			The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; HETEROTRIMERIC G-PROTEINS; CARDIAC-HYPERTROPHY; MYOSIN PHOSPHATASE; AT(1) RECEPTOR; IN-VIVO; HYPERTENSION; KINASE; ACTIVATION; ALDOSTERONE	Hypertension is one of the most frequent pathologies in the industrialized world. Although recognized to be dependent on a combination of genetic and environmental factors, its molecular basis remains elusive. Increased activity of the monomeric G protein RhoA in arteries is a common feature of hypertension. However, how RhoA is activated and whether it has a causative role in hypertension remains unclear. Here we provide evidence that Arhgef1 is the RhoA guanine exchange factor specifically responsible for angiotensin II-induced activation of RhoA signaling in arterial smooth muscle cells. We found that angiotensin II activates Arhgef1 through a previously undescribed mechanism in which Jak2 phosphorylates Tyr738 of Arhgef1. Arhgef1 inactivation in smooth muscle induced resistance to angiotensin II-dependent hypertension in mice, but did not affect normal blood pressure regulation. Our results show that control of RhoA signaling through Arhgef1 is central to the development of angiotensin II-dependent hypertension and identify Arhgef1 as a potential target for the treatment of hypertension.	[Guilluy, Christophe; Bregeon, Jeremy; Toumaniantz, Gilles; Rolli-Derkinderen, Malvyne; Pacaud, Pierre; Loirand, Gervaise] INSERM, U915, Nantes, France; [Guilluy, Christophe; Bregeon, Jeremy; Toumaniantz, Gilles; Rolli-Derkinderen, Malvyne; Pacaud, Pierre; Loirand, Gervaise] Univ Nantes, Inst Thorax, Nantes, France; [Retailleau, Kevin; Loufrani, Laurent; Henrion, Daniel] INSERM, U771, F-75654 Paris 13, France; [Retailleau, Kevin; Loufrani, Laurent; Henrion, Daniel] CNRS, UMR6214, Fac Med Angers, F-75700 Paris, France; [Scalbert, Elizabeth; Bril, Antoine] Inst Rech Servier, F-92150 Suresnes, France; [Torres, Raul M.] Univ Colorado, Integrated Dept Immunol, Denver, CO 80202 USA; [Offermanns, Stephan] Max Planck Inst Heart & Lung Res, Dept Pharmacol, Bad Nauheim, Germany; [Loirand, Gervaise] CHU Nantes, Inst Thorax, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Servier; Institut de Recherches Internationales Servier; University of Colorado System; University of Colorado Denver; Max Planck Society; Nantes Universite; CHU de Nantes	Loirand, G (corresponding author), INSERM, U915, Nantes, France.	pierre.pacaud@univ-nantes.fr; gervaise.loirand@univ-nantes.fr	loufrani, laurent/K-1713-2015; Loirand, Gervaise/K-1834-2014; Henrion, Daniel/AAK-1995-2021; Pacaud, Pierre/D-6392-2015; TOUMANIANTZ, GILLES/D-6692-2015; Guilluy, Christophe/Z-1015-2019; Henrion, Daniel/N-7023-2015; Rolli-Derkinderen, Malvyne/K-2406-2015; Henrion, Daniel/J-8141-2015; guilluy, christophe/C-6002-2014; Offermanns, Stefan/L-3313-2017	Loirand, Gervaise/0000-0002-2306-3931; Henrion, Daniel/0000-0003-1094-0285; Guilluy, Christophe/0000-0003-1141-0809; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285; guilluy, christophe/0000-0003-1141-0809; Offermanns, Stefan/0000-0001-8676-6805	Institut National de la Sante et de la Recherche Medicale; Agence Nationale de la Recherche [ANR-05-PCOD-015-01, ANR-08-GEN-O040-01]; Fondation pour la Recherche Medicale [20051205767]; Programme National de Recherche Maladies Cardiovasculaires; Societe Francaise d'hypertension arterielle; Centre National de la Recherche Scientifique; Institut de Recherches Servier	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Programme National de Recherche Maladies Cardiovasculaires; Societe Francaise d'hypertension arterielle; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut de Recherches Servier	The authors are grateful to K. Burridge (University of North Carolina, Chapel Hill), V. Perrot (University of Rouen) and J. Ihle (St. Jude Children's Research Hospital, Memphis) for providing us with GST-RhoA constructs, Arhgef1 and Jak2 plasmids, respectively. We thank C. Schleder, N. Vaillant and M. Rio for excellent technical assistance and the IBISA platform Cardiex for functional explorations. This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Agence Nationale de la Recherche (ANR-05-PCOD-015-01 and ANR-08-GEN-O040-01), the Fondation pour la Recherche Medicale (Dequation (20051205767)), the Programme National de Recherche Maladies Cardiovasculaires and the Societe Francaise d'hypertension arterielle (PNRC 2007), the Centre National de la Recherche Scientifique (Groupement de Recherche 2823) and the Institut de Recherches Servier.	Banes-Berceli AKL, 2007, AM J PHYSIOL-HEART C, V293, pH1291, DOI 10.1152/ajpheart.00181.2007; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Chrissobolis S, 2001, CIRC RES, V88, P774, DOI 10.1161/hh0801.090441; CLINE WH, 1981, J PHARMACOL EXP THER, V216, P104; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; de Gasparo M, 2000, PHARMACOL REV, V52, P415; FALCON JC, 1978, AM J PHYSIOL, V235, pH392, DOI 10.1152/ajpheart.1978.235.4.H392; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; FERRARIO CM, 1979, HYPERTENSION, V1, P235, DOI 10.1161/01.HYP.1.3.235; Frank GD, 2002, MOL ENDOCRINOL, V16, P367, DOI 10.1210/me.16.2.367; FUJII AM, 1985, HYPERTENSION, V7, P253, DOI 10.1161/01.HYP.7.2.253; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kataoka C, 2002, HYPERTENSION, V39, P245, DOI 10.1161/hy0202.103271; Keys JR, 2002, HYPERTENSION, V40, P660, DOI 10.1161/01.HYP.0000035397.73223.CE; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lemarie CA, 2008, J MOL MED, V86, P673, DOI 10.1007/s00109-008-0323-5; Loirand G, 2006, CIRC RES, V98, P322, DOI 10.1161/01.RES.0000201960.04223.3c; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Masumoto A, 2001, HYPERTENSION, V38, P1307, DOI 10.1161/hy1201.096541; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Mills PA, 2000, J APPL PHYSIOL, V88, P1537, DOI 10.1152/jappl.2000.88.5.1537; Montezano AC, 2008, ARTERIOSCL THROM VAS, V28, P1511, DOI 10.1161/ATVBAHA.108.168021; Moriki N, 2004, HYPERTENS RES, V27, P263, DOI 10.1291/hypres.27.263; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; Ohtsu H, 2008, ENDOCRINOLOGY, V149, P3569, DOI 10.1210/en.2007-1694; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; ROWE BP, 1979, PFLUG ARCH EUR J PHY, V382, P269, DOI 10.1007/BF00583712; Rubtsov A, 2005, IMMUNITY, V23, P527, DOI 10.1016/j.immuni.2005.09.018; RUILOPE LM, 1994, HYPERTENSION, V23, P3, DOI 10.1161/01.HYP.23.1.3; Schiffrin EL, 2006, HYPERTENSION, V47, P312, DOI 10.1161/01.HYP.0000201443.63240.a7; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; Shaw S, 2003, J BIOL CHEM, V278, P30634, DOI 10.1074/jbc.M305008200; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Struthers AD, 2004, CARDIOVASC RES, V61, P663, DOI 10.1016/j.cardiores.2003.11.037; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wirth A, 2008, NAT MED, V14, P64, DOI 10.1038/nm1666	50	174	183	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					183	U89		10.1038/nm.2079	http://dx.doi.org/10.1038/nm.2079			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20098430				2022-12-27	WOS:000274297000039
J	Muoio, D; Vidal-Puig, A; Nair, KS; Ravussin, E				Muoio, Debbie; Vidal-Puig, Antonio; Nair, K. Sreekumaran; Ravussin, Eric			Burning fat not so sweet	NATURE MEDICINE			English	Editorial Material									[Muoio, Debbie] Duke Univ, Stedman Ctr, Durham, NC 27706 USA; [Vidal-Puig, Antonio] Univ Cambridge, Cambridge, England; [Nair, K. Sreekumaran] Mayo Clin, Rochester, MN USA; [Ravussin, Eric] Pennington Biomed Res Ctr, Nutr Obes Res Ctr, Baton Rouge, LA USA	Duke University; University of Cambridge; Mayo Clinic; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Muoio, D (corresponding author), Duke Univ, Stedman Ctr, Durham, NC 27706 USA.		Ravussin, Eric/N-1985-2017	Ravussin, Eric/0000-0003-2129-547X				Hoehn KL, 2010, CELL METAB, V11, P70, DOI 10.1016/j.cmet.2009.11.008	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					169	169		10.1038/nm0210-169	http://dx.doi.org/10.1038/nm0210-169			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20134471	Bronze			2022-12-27	WOS:000274297000035
J	Gonfloni, S; Di Tella, L; Caldarola, S; Cannata, SM; Klinger, FG; Di Bartolomeo, C; Mattei, M; Candi, E; De Felici, M; Melino, G; Cesareni, G				Gonfloni, Stefania; Di Tella, Lucia; Caldarola, Sara; Cannata, Stefano M.; Klinger, Francesca G.; Di Bartolomeo, Claudia; Mattei, Maurizio; Candi, Eleonora; De Felici, Massimo; Melino, Gerry; Cesareni, Gianni			Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death	NATURE MEDICINE			English	Article							C-ABL ACTIVATION; DNA-DAMAGE; APOPTOTIC RESPONSE; TYROSINE KINASE; GENOTOXIC STRESS; REGULATES P73; P63; P53; PHOSPHORYLATION; CHECKPOINTS	Germ cells are sensitive to genotoxins, and ovarian failure and infertility are major side effects of chemotherapy in young patients with cancer. Here we describe the c-Abl-TAp63 pathway activated by chemotherapeutic DNA-damaging drugs in model human cell lines and in mouse oocytes and its role in cell death. In cell lines, upon cisplatin treatment, c-Abl phosphorylates TAp63 on specific tyrosine residues. Such modifications affect p63 stability and induce a p63-dependent activation of proapoptotic promoters. Similarly, in oocytes, cisplatin rapidly promotes TAp63 accumulation and eventually cell death. Treatment with the c-Abl kinase inhibitor imatinib counteracts these cisplatin-induced effects. Taken together, these data support a model in which signals initiated by DNA double-strand breaks are detected by c-Abl, which, through its kinase activity, modulates the p63 transcriptional output. Moreover, they suggest a new use for imatinib, aimed at preserving oocytes of the follicle reserve during chemotherapeutic treatments.	[Gonfloni, Stefania; Di Tella, Lucia; Caldarola, Sara; Cannata, Stefano M.; Di Bartolomeo, Claudia; Mattei, Maurizio; Cesareni, Gianni] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Klinger, Francesca G.; De Felici, Massimo] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; [Candi, Eleonora; Melino, Gerry] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy; [Melino, Gerry] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; University of Leicester	Gonfloni, S (corresponding author), Univ Roma Tor Vergata, Dept Biol, Rome, Italy.	stefania.gonfloni@uniroma2.it	Mattei, Maurizio/AAC-1303-2019; De Felici, Massimo/J-4845-2018; Klinger, Francesca Gioia/AAO-5349-2021; Cesareni, Gianni/AAW-1382-2020	Mattei, Maurizio/0000-0002-0814-8873; Klinger, Francesca Gioia/0000-0001-6744-0850; De Felici, Massimo/0000-0001-8479-8264; GONFLONI, STEFANIA/0000-0002-9392-4258	Associazione Italiana per la Ricerca sul Cancro; EU; EPISTEM; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); EU(European Commission); EPISTEM; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank G. Mazzeo for critical suggestions and support. We thank G. Superti-Furga for critical reading of the manuscript. We thank R. Sacco for help in preparing some figures. We thank S. Bernardini, M. Angelini, A.M. Lena, A. Gamboi-Miraglia, M. Ranalli and G. Palmieri for technical advice. This work was supported by Associazione Italiana per la Ricerca sul Cancro to S.G. and G.C., and the EU integrated projects Interaction Proteome to G.C. and EPISTEM to G.M.	Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; BLOMMAERT FA, 1995, NUCLEIC ACIDS RES, V23, P1300, DOI 10.1093/nar/23.8.1300; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; De Felici M, 2004, HUM REPROD UPDATE, V10, P197, DOI 10.1093/humupd/dmh020; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KATOH MA, 1990, MUTAT RES, V230, P205, DOI 10.1016/0027-5107(90)90058-C; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Livera G, 2008, REPRODUCTION, V135, P3, DOI 10.1530/REP-07-0054; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Melino G, 2006, CELL CYCLE, V5, P1735; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Tsai KKC, 2003, CANCER RES, V63, P3418; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	35	240	248	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2009	15	10					1179	U107		10.1038/nm.2033	http://dx.doi.org/10.1038/nm.2033			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19783996				2022-12-27	WOS:000270596400030
J	Vakoc, BJ; Lanning, RM; Tyrrell, JA; Padera, TP; Bartlett, LA; Stylianopoulos, T; Munn, LL; Tearney, GJ; Fukumura, D; Jain, RK; Bouma, BE				Vakoc, Benjamin J.; Lanning, Ryan M.; Tyrrell, James A.; Padera, Timothy P.; Bartlett, Lisa A.; Stylianopoulos, Triantafyllos; Munn, Lance L.; Tearney, Guillermo J.; Fukumura, Dai; Jain, Rakesh K.; Bouma, Brett E.			Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging	NATURE MEDICINE			English	Article							COHERENCE TOMOGRAPHY; LYMPHATIC METASTASIS; GROWTH; ANGIOGENESIS; VASCULATURE; FLOW; NORMALIZATION; ARCHITECTURE; SENSITIVITY; PRESSURE	Intravital multiphoton microscopy has provided powerful mechanistic insights into health and disease and has become a common instrument in the modern biological laboratory. The requisite high numerical aperture and exogenous contrast agents that enable multiphoton microscopy, however, limit the ability to investigate substantial tissue volumes or to probe dynamic changes repeatedly over prolonged periods. Here we introduce optical frequency domain imaging (OFDI) as an intravital microscopy that circumvents the technical limitations of multiphoton microscopy and, as a result, provides unprecedented access to previously unexplored, crucial aspects of tissue biology. Using unique OFDI-based approaches and entirely intrinsic mechanisms of contrast, we present rapid and repeated measurements of tumor angiogenesis, lymphangiogenesis, tissue viability and both vascular and cellular responses to therapy, thereby demonstrating the potential of OFDI to facilitate the exploration of physiological and pathological processes and the evaluation of treatment strategies.	[Lanning, Ryan M.; Tyrrell, James A.; Padera, Timothy P.; Stylianopoulos, Triantafyllos; Munn, Lance L.; Fukumura, Dai; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; [Vakoc, Benjamin J.; Bartlett, Lisa A.; Tearney, Guillermo J.; Bouma, Brett E.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA USA; [Vakoc, Benjamin J.; Bouma, Brett E.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Vakoc, Benjamin J.; Lanning, Ryan M.; Tearney, Guillermo J.; Bouma, Brett E.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Tearney, Guillermo J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.	jain@steele.mgh.harvard.edu; bouma@helix.mgh.harvard.edu	Padera, Timothy/R-2982-2019; Lanning, Ryan/GSM-9167-2022; Munn, Lance L/L-3950-2016; Jain, Rakesh K/I-1384-2017; Stylianopoulos, Triantafyllos/AGF-9544-2022; Tyrrell, James/A-6359-2010	Padera, Timothy/0000-0002-3453-9384; Munn, Lance L/0000-0003-0698-7232; Jain, Rakesh K/0000-0001-7571-3548; Stylianopoulos, Triantafyllos/0000-0002-3093-1696; 	US National Institutes of Health [P01-CA080124, R01-CA085140, R01-CA115767, R01 CA126642, R33-CA125560, K25-CA127465, K99-CA137167, R01-CA096915]; US Department of Defense Breast Cancer Research Program fellowship [W81XWH-06-1-0436]; NATIONAL CANCER INSTITUTE [K25CA127465, K99CA137167, R01CA126642, T32CA073479, R01CA085140, P01CA080124, R01CA096915, R33CA125560, R24CA085140, R00CA137167, R01CA115767] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense Breast Cancer Research Program fellowship(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank J. Baish for insightful input regarding fractal analysis. We also thank J. Kahn and S. Roberge for preparation of animal models, P. Huang for animal care and colony maintenance, and E. di Tomaso and C. Smith for histological preparations. We thank Genentech for supplying the MDA-MB-361HK mammary carcinoma cells and J. B. Little of the Harvard School for Public Health for HSTS26T. This research was funded in part by US National Institutes of Health grants P01-CA080124, R01-CA085140, R01-CA115767, R01 CA126642, R33-CA125560, K25-CA127465, K99-CA137167, and R01-CA096915. R.M.L. is supported in part by US Department of Defense Breast Cancer Research Program fellowship W81XWH-06-1-0436.	Arbiser JL, 1999, AM J PATHOL, V155, P723, DOI 10.1016/S0002-9440(10)65171-1; Baish JW, 2000, CANCER RES, V60, P3683; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chen ZP, 1997, OPT LETT, V22, P64, DOI 10.1364/OL.22.000064; Collins HA, 2008, NAT PHOTONICS, V2, P420, DOI 10.1038/nphoton.2008.100; Gazit Y, 1997, MICROCIRCULATION-LON, V4, P395, DOI 10.3109/10739689709146803; GAZIT Y, 1995, PHYS REV LETT, V75, P2428, DOI 10.1103/PhysRevLett.75.2428; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Izatt JA, 1997, OPT LETT, V22, P1439, DOI 10.1364/OL.22.001439; Jain R. K., 2005, LIVE CELL IMAGING LA, P435; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; LEUNIG M, 1992, CANCER RES, V52, P6553; MASTERS BR, 2008, HDB BIOMEDICAL NONLI, P735; Padera TP, 2008, MOL CANCER THER, V7, P2272, DOI 10.1158/1535-7163.MCT-08-0182; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Sharma M, 2007, BIOTECHNOL LETT, V29, P273, DOI 10.1007/s10529-006-9232-2; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Tyrrell JA, 2007, IEEE T MED IMAGING, V26, P223, DOI 10.1109/TMI.2006.889722; Vakoc BJ, 2005, OPT EXPRESS, V13, P5483, DOI 10.1364/OPEX.13.005483; Wang RKK, 2007, OPT EXPRESS, V15, P11402, DOI 10.1364/OE.15.011402; YUAN F, 1994, CANCER RES, V54, P4564; Yun SH, 2006, NAT MED, V12, P1429, DOI 10.1038/nm1450; Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953; Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114	28	538	551	2	131	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1219	U151		10.1038/nm.1971	http://dx.doi.org/10.1038/nm.1971			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19749772	Green Accepted, Green Submitted			2022-12-27	WOS:000270596400036
J	Liu, J; Divoux, A; Sun, J; Zhang, J; Clement, K; Glickman, JN; Sukhova, GK; Wolters, PJ; Du, J; Gorgun, CZ; Doria, A; Libby, P; Blumberg, RS; Kahn, BB; Hotamisligil, GS; Shi, GP				Liu, Jian; Divoux, Adeline; Sun, Jiusong; Zhang, Jie; Clement, Karine; Glickman, Jonathan N.; Sukhova, Galina K.; Wolters, Paul J.; Du, Juan; Gorgun, Cem Z.; Doria, Alessandro; Libby, Peter; Blumberg, Richard S.; Kahn, Barbara B.; Hotamisligil, Goekhan S.; Shi, Guo-Ping			Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice	NATURE MEDICINE			English	Article							BROWN ADIPOSE-TISSUE; TUMOR-GROWTH; CATHEPSIN-S; ANGIOGENESIS; INFLAMMATION; EXPRESSION; RESPONSES; ACCUMULATION; INFILTRATION; DEPRIVATION	Although mast cell functions have classically been related to allergic responses(1-3), recent studies indicate that these cells contribute to other common diseases such as multiple sclerosis, rheumatoid arthritis, atherosclerosis, aortic aneurysm and cancer(4-8). This study presents evidence that mast cells also contribute to diet-induced obesity and diabetes. For example, white adipose tissue (WAT) from obese humans and mice contain more mast cells than WAT from their lean counterparts. Furthermore, in the context of mice on a Western diet, genetically induced deficiency of mast cells, or their pharmacological stabilization, reduces body weight gain and levels of inflammatory cytokines, chemokines and proteases in serum and WAT, in concert with improved glucose homeostasis and energy expenditure. Mechanistic studies reveal that mast cells contribute to WAT and muscle angiogenesis and associated cell apoptosis and cathepsin activity. Adoptive transfer experiments of cytokine-deficient mast cells show that these cells, by producing interleukin-6 (IL-6) and interferon-c (IFN-gamma), contribute to mouse adipose tissue cysteine protease cathepsin expression, apoptosis and angiogenesis, thereby promoting diet-induced obesity and glucose intolerance. Our results showing reduced obesity and diabetes in mice treated with clinically available mast cell-stabilizing agents suggest the potential of developing new therapies for these common human metabolic disorders.	[Liu, Jian; Sun, Jiusong; Zhang, Jie; Glickman, Jonathan N.; Sukhova, Galina K.; Du, Juan; Libby, Peter; Blumberg, Richard S.; Shi, Guo-Ping] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Liu, Jian; Sun, Jiusong; Zhang, Jie; Glickman, Jonathan N.; Sukhova, Galina K.; Du, Juan; Doria, Alessandro; Libby, Peter; Blumberg, Richard S.; Kahn, Barbara B.; Shi, Guo-Ping] Harvard Univ, Sch Med, Boston, MA USA; [Divoux, Adeline; Clement, Karine] Inst Natl Sante & Rech Med, U872, Paris, France; [Clement, Karine] Univ Paris 06, Cordeliers Res Ctr, Paris, France; [Clement, Karine] Hop La Pitie Salpetriere, AP HP, Dept Nutr, Paris, France; [Wolters, Paul J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Gorgun, Cem Z.; Hotamisligil, Goekhan S.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Doria, Alessandro] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA; [Kahn, Barbara B.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center	Shi, GP (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	gshi@rics.bwh.harvard.edu	Clément, karine/R-1120-2017; Eckhardt, Erik/G-1567-2010; Libby, Peter/AAY-6404-2021; Doria, Alessandro/H-9157-2018; Wolters, Paul/A-7181-2009	Libby, Peter/0000-0002-1502-502X; Doria, Alessandro/0000-0002-3830-4304; 	American Heart Association [0840118N]; US National Institutes of Health [HL60942, HL67283, HL81090, HL88547, HL34636, DK57521, DK56116, DK52539, DK64360]; Programme Hospitalier de Recherche Clinique; Assistance Publique des Hopitaux de Paris [AOR 02076]; French National Agency of Research [NdegreesANR05-PCOD-030-02]; Commission of the European Communities; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034636, R01HL075026, R01HL067283, R37HL034636, R01HL060942, R01HL088547, R01HL081090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, P01DK056116, R37DK044319, R01DK052539, P30DK057521] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Programme Hospitalier de Recherche Clinique; Assistance Publique des Hopitaux de Paris; French National Agency of Research(French National Research Agency (ANR)); Commission of the European Communities(European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank S. Rizkalla and C. Poitou, who contributed to the clinical investigation program. We also thank B. Spiegelman and R. K. Gupta for their help with the 3T3-L1 culture. This study was supported partially by the Established Investigator Award from the American Heart Association (0840118N) (to G.-P. S.) and by US National Institutes of Health grants HL60942, HL67283, HL81090, HL88547 (G.-P. S.), HL34636 (P. L.), DK57521, DK56116 (B. B. K.) and DK52539 and DK64360 (G. S. H.). The clinical work was supported by the Programme Hospitalier de Recherche Clinique, Assistance Publique des Hopitaux de Paris (AOR 02076), a grant from French National Agency of Research (RIOMA program N degrees ANR05-PCOD-030-02), and by the Commission of the European Communities (ADAPT project) (to K. C.).	Bingham CO, 2000, J ALLERGY CLIN IMMUN, V105, pS527, DOI 10.1016/S0091-6749(00)90056-3; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; DUTTLINGER R, 1995, P NATL ACAD SCI USA, V92, P3754, DOI 10.1073/pnas.92.9.3754; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; GALLI SJ, 1987, AM J PATHOL, V127, P191; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Hadigan C, 1999, J CLIN ENDOCR METAB, V84, P1932, DOI 10.1210/jc.84.6.1932; Kintscher U, 2008, ARTERIOSCL THROM VAS, V28, P1304, DOI 10.1161/ATVBAHA.108.165100; Koban M, 2005, AM J PHYSIOL-ENDOC M, V289, pE68, DOI 10.1152/ajpendo.00543.2004; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Pang C, 2008, AM J PHYSIOL-ENDOC M, V295, pE313, DOI 10.1152/ajpendo.90296.2008; Paterson WG, 1998, AM J PHYSIOL-GASTR L, V274, pG385, DOI 10.1152/ajpgi.1998.274.2.G385; Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1; Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Santone DJ, 2008, AM J PHYSIOL-HEART C, V294, pH2456, DOI 10.1152/ajpheart.00925.2007; Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Serna H, 2006, J PHARMACOL EXP THER, V319, P1104, DOI 10.1124/jpet.106.104620; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shin HY, 2004, LIFE SCI, V74, P2877, DOI 10.1016/j.lfs.2003.10.026; Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123; Sun J, 2007, J CLIN INVEST, V117, P3359, DOI 10.1172/JCI31311; Sun JS, 2007, NAT MED, V13, P719, DOI 10.1038/nm1601; Wang B, 2006, J BIOL CHEM, V281, P6020, DOI 10.1074/jbc.M509134200; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yang M, 2007, NAT CELL BIOL, V9, P970, DOI 10.1038/ncb1623	35	548	579	2	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					940	U144		10.1038/nm.1994	http://dx.doi.org/10.1038/nm.1994			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19633655	Green Accepted, Green Submitted			2022-12-27	WOS:000268770400039
J	[Anonymous]				[Anonymous]			Back to basics	NATURE MEDICINE			English	Editorial Material								Basic HIV research has, over the past two decades, brought about enormous advances that have transformed a fatal disease into a manageable illness. HIV vaccine research has suffered more setbacks than successes, but a renewed focus on fundamental questions about HIV pathogenesis will provide new glimmers of hope.											0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2009	15	8					821	821		10.1038/nm0809-821	http://dx.doi.org/10.1038/nm0809-821			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19661964	Bronze			2022-12-27	WOS:000268770400001
J	Erkizan, HV; Kong, YL; Merchant, M; Schlottmann, S; Barber-Rotenberg, JS; Yuan, LS; Abaan, OD; Chou, TH; Dakshanamurthy, S; Brown, ML; Uren, A; Toretsky, JA				Erkizan, Hayriye V.; Kong, Yali; Merchant, Melinda; Schlottmann, Silke; Barber-Rotenberg, Julie S.; Yuan, Linshan; Abaan, Ogan D.; Chou, Tsu-hang; Dakshanamurthy, Sivanesan; Brown, Milton L.; Uren, Aykut; Toretsky, Jeffrey A.			A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma	NATURE MEDICINE			English	Article							PRIMITIVE NEUROECTODERMAL TUMOR; POLYMERASE-II; A INTERACTS; CELLS; TRANSCRIPTION; CANCER; FUSION; MODEL; GENE; IDENTIFICATION	Many sarcomas and leukemias carry nonrandom chromosomal translocations encoding tumor-specific mutant fusion transcription factors that are essential to their molecular pathogenesis. Ewing's sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1. EWS-FLI1 is a disordered protein that precludes standard structure-based small-molecule inhibitor design. EWS-FLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. We therefore used surface plasmon resonance screening to identify compounds that bind EWS-FLI1 and might block its interaction with RHA. YK-4-279, a derivative of the lead compound from the screen, blocks RHA binding to EWS-FLI1, induces apoptosis in ESFT cells and reduces the growth of ESFT orthotopic xenografts. These findings provide proof of principle that inhibiting the interaction of mutant cancer-specific transcription factors with the normal cellular binding partners required for their oncogenic activity provides a promising strategy for the development of uniquely effective, tumor-specific anticancer agents.	[Erkizan, Hayriye V.; Kong, Yali; Schlottmann, Silke; Barber-Rotenberg, Julie S.; Yuan, Linshan; Abaan, Ogan D.; Dakshanamurthy, Sivanesan; Brown, Milton L.; Uren, Aykut; Toretsky, Jeffrey A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA; [Merchant, Melinda; Chou, Tsu-hang] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Toretsky, Jeffrey A.] Georgetown Univ, Dept Pediat, Washington, DC 20057 USA	Georgetown University; Memorial Sloan Kettering Cancer Center; Georgetown University	Toretsky, JA (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA.	jat42@georgetown.edu	ERKIZAN, HAYRIYE VERDA/C-2341-2011; Dakshanamurthy, Sivanesan/CAF-4258-2022	Dakshanamurthy, Sivanesan/0000-0003-3681-4121	Children's Cancer Foundation of Baltimore; Go4theGoal Foundation; Foundation of Denver; Liddy Shriver Sarcoma Initiative; Amschwand Sarcoma Cancer Foundation; Burroughs-Wellcome Clinical Scientist Award; US National Institutes of Health [R01CA138212, R01CA133662, P30 CA051008]; Georgetown University Medical Center Drug Discovery Program; NATIONAL CANCER INSTITUTE [R01CA138212, R01CA088004, P01CA047179, T32CA009686, P30CA051008, R01CA133662] Funding Source: NIH RePORTER	Children's Cancer Foundation of Baltimore; Go4theGoal Foundation; Foundation of Denver; Liddy Shriver Sarcoma Initiative; Amschwand Sarcoma Cancer Foundation; Burroughs-Wellcome Clinical Scientist Award(Burroughs Wellcome Fund); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgetown University Medical Center Drug Discovery Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was generously supported by the Children's Cancer Foundation of Baltimore (J.T. and A.U.), Go4theGoal Foundation (J.T.), Dani's Foundation of Denver (J.T.), the Liddy Shriver Sarcoma Initiative (J.T.), the Amschwand Sarcoma Cancer Foundation (J.T.), the Burroughs-Wellcome Clinical Scientist Award in Translational Research (J.T.), US National Institutes of Health grants R01CA138212 (J.T.) and R01CA133662 (J.T.), and the Georgetown University Medical Center Drug Discovery Program. US National Institutes of Health support is through the Cancer Center Support Grant P30 CA051008 for use of Flow Cytometry and Cell Sorting, Biacore Molecular Interaction, Tissue Culture and microscopy core facilities and grant P01 CA47179 (M. M.). We would like to thank S. Metallo for training in fluorescence polarization. Also, T. Cripe and L. Whitesell provided critical review of our manuscript. We also thank S. Lessnick from Hunstamn Cancer Institute, for providing NROB1 reporter plasmid, J.V. Frangioni from Beth Israel Deaconess Medical Center for providing pG, pGN and pGC vectors, O. Delattre from INSERM France for providing the A673 shEWS-FLI1 cell line, and R. Schlegel, Lombardi Comprehensive Cancer Center, for providing HFK and HEC cell lines. We thank the Developmental Therapeutics Program of the US National Cancer Institute for providing the Diversity set of compounds for screening. This article is dedicated to our patients who have fought but succumbed to ESFT.	Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bhalla J, 2006, MOL CELL PROTEOMICS, V5, P1212, DOI 10.1074/mcp.M500315-MCP200; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cheng Y, 2006, TRENDS BIOTECHNOL, V24, P435, DOI 10.1016/j.tibtech.2006.07.005; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRANGIONI JV, 1993, J CELL SCI, V105, P481; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Hartman TR, 2006, NAT STRUCT MOL BIOL, V13, P509, DOI 10.1038/nsmb1092; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Knoop LL, 2001, J BIOL CHEM, V276, P22317, DOI 10.1074/jbc.M008950200; Kovar H, 2003, SEMIN CANCER BIOL, V13, P275, DOI 10.1016/S1044-579X(03)00041-5; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Ng KP, 2007, P NATL ACAD SCI USA, V104, P479, DOI 10.1073/pnas.0607007104; Palermo CM, 2008, LEUKEMIA RES, V32, P633, DOI 10.1016/j.leukres.2007.08.002; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Poppe B, 2004, BLOOD, V103, P229, DOI 10.1182/blood-2003-06-2163; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; Uren A, 2004, BIOCHEMISTRY-US, V43, P13579, DOI 10.1021/bi048776q; Valineva T, 2006, NUCLEIC ACIDS RES, V34, P3938, DOI 10.1093/nar/gkl539; Voss SD, 2002, ANAL BIOCHEM, V308, P364, DOI 10.1016/S0003-2697(02)00268-3; Xie HB, 2007, J PROTEOME RES, V6, P1882, DOI 10.1021/pr060392u; Zhong XL, 2004, J BIOL CHEM, V279, P17134, DOI 10.1074/jbc.M311057200	40	296	320	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					750	U8		10.1038/nm.1983	http://dx.doi.org/10.1038/nm.1983			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584866	Green Accepted			2022-12-27	WOS:000267806900027
J	Iqbal, J; Sun, L; Zaidi, M				Iqbal, Jameel; Sun, Li; Zaidi, Mone			Coupling bone degradation to formation	NATURE MEDICINE			English	Editorial Material							GROWTH-FACTOR-BETA; TGF-BETA; INHIBITION; KINASE; CELLS		[Iqbal, Jameel; Sun, Li; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Iqbal, J (corresponding author), Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.	mone.zaidi@mssm.edu						BONEWALD LF, 1989, CONNECT TISSUE RES, V23, P201, DOI 10.3109/03008208909002418; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Gupta Shaili, 2005, Endocr Pract, V11, P399; Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kurihara N, 2006, J BONE MINER RES, V21, pP55, DOI 10.1359/JBMR.06S210; LUCAS PA, 1989, BONE, V10, P459, DOI 10.1016/8756-3282(89)90079-3; Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593	12	19	21	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					729	731		10.1038/nm0709-729	http://dx.doi.org/10.1038/nm0709-729			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584858				2022-12-27	WOS:000267806900020
J	Midwood, K; Sacre, S; Piccinini, AM; Inglis, J; Trebaul, A; Chan, E; Drexler, S; Sofat, N; Kashiwagi, M; Orend, G; Brennan, F; Foxwell, B				Midwood, Kim; Sacre, Sandra; Piccinini, Anna M.; Inglis, Julia; Trebaul, Annette; Chan, Emma; Drexler, Stefan; Sofat, Nidhi; Kashiwagi, Masahide; Orend, Gertraud; Brennan, Fionula; Foxwell, Brian			Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease	NATURE MEDICINE			English	Article							GROUP BOX CHROMOSOMAL-PROTEIN-1; ANTIGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; TOLL-LIKE-RECEPTOR-4; EXPRESSION; RECOGNITION; CARTILAGE; CYTOKINE; MODEL	Although there have been major advances in the treatment of rheumatoid arthritis with the advent of biological agents, the mechanisms that drive cytokine production and sustain disease chronicity remain unknown. Tenascin-C (encoded by Tnc) is an extracellular matrix glycoprotein specifically expressed at areas of inflammation and tissue damage in inflamed rheumatoid joints. Here we show that mice that do not express tenascin-C show rapid resolution of acute joint inflammation and are protected from erosive arthritis. Intra-articular injection of tenascin-C promotes joint inflammation in vivo in mice, and addition of exogenous tenascin-C induces cytokine synthesis in explant cultures from inflamed synovia of individuals with rheumatoid arthritis. Moreover, in human macrophages and fibroblasts from synovia of individuals with rheumatoid arthritis, tenascin-C induces synthesis of proinflammatory cytokines via activation of Toll-like receptor 4 (TLR4). Thus, we have identified tenascin-C as a novel endogenous activator of TLR4-mediated immunity that mediates persistent synovial inflammation and tissue destruction in arthritic joint disease.	[Midwood, Kim; Sacre, Sandra; Piccinini, Anna M.; Inglis, Julia; Trebaul, Annette; Chan, Emma; Drexler, Stefan; Sofat, Nidhi; Kashiwagi, Masahide; Brennan, Fionula; Foxwell, Brian] Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, Fac Med, London, England; [Orend, Gertraud] Univ Strasbourg, INSERM U682, Strasbourg, France	Imperial College London; University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Midwood, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, Fac Med, London, England.	k.midwood@imperial.ac.uk	Sofat, Nidhi/AAQ-7358-2020; Sacre, Sandra/AAE-2297-2020; Orend, Gertraud/E-8446-2015	Sofat, Nidhi/0000-0002-6963-6475; Sacre, Sandra/0000-0003-1665-1142; Orend, Gertraud/0000-0003-2522-1195; Piccinini, Anna Maria/0000-0002-7588-0415	Arthritis Research Campaign; The Kennedy Institute of Rheumatology Trustees; UK Medical Research Council New Investigators Research Grant; UK National Institute for Health Research Biomedical Research Centre; Institut National du Cancer-Institut National de la Sante et de la Recherche Medicale; Contrat d'interface with the Hospital Hautepierre; MRC [G0700108] Funding Source: UKRI; Medical Research Council [G0700108] Funding Source: researchfish	Arthritis Research Campaign(Versus Arthritis); The Kennedy Institute of Rheumatology Trustees; UK Medical Research Council New Investigators Research Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Institut National du Cancer-Institut National de la Sante et de la Recherche Medicale; Contrat d'interface with the Hospital Hautepierre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This paper is dedicated to B. Foxwell, an inspirational colleague and a good friend, who will be sadly missed. We thank R. Best for processing tissue, D. Essex for immunohistology and C. ffrench-Constant (University of Edinburgh) for the gift of the Tnc<SUP>-/-</SUP> mice. This work was funded by the Arthritis Research Campaign, The Kennedy Institute of Rheumatology Trustees and a UK Medical Research Council New Investigators Research Grant awarded to K. M. We are also grateful for support from the UK National Institute for Health Research Biomedical Research Centre funding scheme. G.O. was supported by Institut National du Cancer-Institut National de la Sante et de la Recherche Medicale and a Contrat d'interface with the Hospital Hautepierre.	Abdollahi-Roodsaz S, 2007, ARTHRITIS RHEUM, V56, P2957, DOI 10.1002/art.22848; Amin K, 2001, RESP MED, V95, P904, DOI 10.1053/rmed.2001.1174; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; BRENNAN FM, 1989, LANCET, V2, P244; Brentano F, 2005, CELL IMMUNOL, V233, P90, DOI 10.1016/j.cellimm.2005.04.018; CHEVALIER X, 1994, ARTHRITIS RHEUM, V37, P1013, DOI 10.1002/art.1780370706; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Choe JY, 2003, J EXP MED, V197, P537, DOI 10.1084/jem.20021850; Coats SR, 2007, CELL MICROBIOL, V9, P1191, DOI 10.1111/j.1462-5822.2006.00859.x; CUTOLO M, 1992, J RHEUMATOL, V19, P1439; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; Foell D, 2007, NAT CLIN PRACT RHEUM, V3, P382, DOI 10.1038/ncprheum0531; Gondokaryono SP, 2007, J LEUKOCYTE BIOL, V82, P657, DOI 10.1189/jlb.1206730; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gutowski NJ, 1999, NEUROPATH APPL NEURO, V25, P207; Hasegawa M, 2007, J ORTHOP RES, V25, P563, DOI 10.1002/jor.20366; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; KEYSTONE EC, 1977, ARTHRITIS RHEUM, V20, P1396, DOI 10.1002/art.1780200714; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Lee EK, 2005, INT IMMUNOL, V17, P325, DOI 10.1093/intimm/dxh212; Loots MAM, 1998, J INVEST DERMATOL, V111, P850, DOI 10.1046/j.1523-1747.1998.00381.x; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MCCACHREN SS, 1992, ARTHRITIS RHEUM, V35, P1185, DOI 10.1002/art.1780351011; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; O'Neill LA, 2008, NAT CLIN PRACT RHEUM, V4, P319, DOI 10.1038/ncprheum0802; Orend G, 2005, INT J BIOCHEM CELL B, V37, P1066, DOI 10.1016/j.biocel.2004.12.002; Pullerits R, 2003, ARTHRITIS RHEUM, V48, P1693, DOI 10.1002/art.11028; Radstake TRDJ, 2004, ARTHRITIS RHEUM-US, V50, P3856, DOI 10.1002/art.20678; Roelofs MF, 2005, ARTHRITIS RHEUM, V52, P2313, DOI 10.1002/art.21278; Sacre SM, 2007, AM J PATHOL, V170, P518, DOI 10.2353/ajpath.2007.060657; Sacre SM, 2008, J IMMUNOL, V181, P8002, DOI 10.4049/jimmunol.181.11.8002; SALTER DM, 1993, BRIT J RHEUMATOL, V32, P780; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; Smolen JS, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1969; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Van Lent PL, 2006, ARTHRITIS RHEUM-US, V54, P3868, DOI 10.1002/art.22253; Vanags D, 2006, LANCET, V368, P855, DOI 10.1016/S0140-6736(06)69210-6; Williams RO, 2007, CURR OPIN PHARMACOL, V7, P412, DOI 10.1016/j.coph.2007.06.001	42	521	537	2	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					774	U11		10.1038/nm.1987	http://dx.doi.org/10.1038/nm.1987			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19561617				2022-12-27	WOS:000267806900030
J	Goldfine, AB; Shoelson, SE; Aguirre, V				Goldfine, Allison B.; Shoelson, Steven E.; Aguirre, Vincent			Expansion and contraction Treating diabetes with bariatric surgery	NATURE MEDICINE			English	Editorial Material							Y GASTRIC BYPASS; WEIGHT-LOSS; MORTALITY	Bariatric surgery is not only one of the most immediate and effective ways to slim down: recent clinical data show that certain procedures are also particularly good at quelling type 2 diabetes. In "Bedside to Bench," Allison Goldfine, Steven Shoelson and Vincent Aguirre outline how researchers can better understand these new clinical findings at the mechanistic level. In the accompanying "Bench to Bedside," Jorge Plutzky takes a look how proper regulation of the storage of fatty acids helps maintain their effectiveness as signaling molecules and reins in their potential pathological effects. Such research is leading to new ways of thinking about how to combat type 2 diabetes.	[Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA; [Goldfine, Allison B.; Shoelson, Steven E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Aguirre, Vincent] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA; [Aguirre, Vincent] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Goldfine, AB (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.	allison.goldfine@joslin.harvard.edu		Goldfine, Allison/0000-0002-0345-1048				Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Aguirre V, 2008, OBESITY, V16, P2585, DOI 10.1038/oby.2008.502; Borg CM, 2006, BRIT J SURG, V93, P210, DOI 10.1002/bjs.5227; Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041; Cummings David E., 2004, Journal of Clinical Endocrinology & Metabolism, V89, P2608, DOI 10.1210/jc.2004-0433; Dixon JB, 2008, JAMA-J AM MED ASSOC, V299, P316, DOI 10.1001/jama.299.3.316; Faraj M, 2003, J CLIN ENDOCR METAB, V88, P1594, DOI 10.1210/jc.2002-021309; Goldfine ABM, 2006, CURR OPIN ENDOCRINOL, V13, P419; Morinigo R, 2006, J CLIN ENDOCR METAB, V91, P1735, DOI 10.1210/jc.2005-0904; Rodriguez-Grunert L, 2008, SURG OBES RELAT DIS, V4, P55, DOI 10.1016/j.soard.2007.07.012; Schauer PR, 2003, ANN SURG, V238, P467, DOI 10.1097/01.sla.0000089851.41115.1b; Schauer PR, 2003, ANN SURG, V238, P484; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Vetter ML, 2009, ANN INTERN MED, V150, P94, DOI 10.7326/0003-4819-150-2-200901200-00007	15	25	25	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					616	617		10.1038/nm0609-616	http://dx.doi.org/10.1038/nm0609-616			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19498374				2022-12-27	WOS:000266731600018
J	Whitehead, KJ; Chan, AC; Navankasattusas, S; Koh, W; London, NR; Ling, J; Mayo, AH; Drakos, SG; Marchuk, DA; Davis, GE; Li, DY				Whitehead, Kevin J.; Chan, Aubrey C.; Navankasattusas, Sutip; Koh, Wonshill; London, Nyall R.; Ling, Jing; Mayo, Anne H.; Drakos, Stavros G.; Marchuk, Douglas A.; Davis, George E.; Li, Dean Y.			The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases	NATURE MEDICINE			English	Article							TRUNCATING MUTATIONS; ENCODING KRIT1; GENE; PROTEIN; EXPRESSION; KINASE; CCM1; ACTIVATION; HEMORRHAGE; STRESS	Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.	[Whitehead, Kevin J.; Li, Dean Y.] Univ Utah, Dept Med, Div Cardiol, Salt Lake City, UT 84132 USA; [Whitehead, Kevin J.; Chan, Aubrey C.; Navankasattusas, Sutip; London, Nyall R.; Ling, Jing; Drakos, Stavros G.; Li, Dean Y.] Univ Utah, Program Mol Med, Salt Lake City, UT 84132 USA; [Koh, Wonshill; Mayo, Anne H.] Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA; [Marchuk, Douglas A.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Missouri System; University of Missouri Columbia; Duke University	Whitehead, KJ (corresponding author), Univ Utah, Dept Med, Div Cardiol, 30 North 1900 East,Room 4A100, Salt Lake City, UT 84132 USA.	kevin.whitehead@hsc.utah.edu; dean.li@hmbg.utah.edu		Chan, Aubrey/0000-0002-9191-2173; Marchuk, Douglas/0000-0002-3110-6671	US National Institutes of Health [T32-GM007464]; Ruth L. Kirschstein National Research Service award; American Heart Association; Edna Benning Foundation; Juvenile Diabetes Research Foundation, the Burroughs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065648, R01HL077671, R01HL084516, R01HL068873, K02HL069774, K08HL079095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L. Kirschstein National Research Service award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Edna Benning Foundation; Juvenile Diabetes Research Foundation, the Burroughs(Juvenile Diabetes Research Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Colvin, C. Jones, W. Zhu and A. Frias for technical assistance; M. Sanguinetti, S. Odelberg and I. Benjamin for critical comments; M. Kahn, K. Thomas, M. Ginsberg and R. Stockton for helpful scientific discussions; and A. Hall ( Memorial Sloan- Kettering Cancer Center) for GTPase complementary DNA constructs. This work was funded by the US National Institutes of Health ( K. J. W., D. A. M., G. E. D. and D. Y. L.), including training grant T32-GM007464 ( A. C. C.) and a Ruth L. Kirschstein National Research Service award ( N. R. L.), the American Heart Association ( K. J. W. and D. Y. L.), the H. A. and Edna Benning Foundation, the Juvenile Diabetes Research Foundation, the Burroughs	Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bergametti F, 2005, AM J HUM GENET, V76, P42, DOI 10.1086/426952; CHAPPELL PM, 1992, RADIOLOGY, V183, P719, DOI 10.1148/radiology.183.3.1584926; Clatterbuck RE, 2001, J NEUROL NEUROSUR PS, V71, P188, DOI 10.1136/jnnp.71.2.188; Collisson EA, 2002, J INVEST DERMATOL, V119, P1172, DOI 10.1046/j.1523-1747.2002.19519.x; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Denier C, 2004, AM J HUM GENET, V74, P326, DOI 10.1086/381718; Gault J, 2005, STROKE, V36, P872, DOI 10.1161/01.STR.0000157586.20479.fd; Glading A, 2007, J CELL BIOL, V179, P247, DOI 10.1083/jcb.200705175; Hasegawa T, 2002, NEUROSURGERY, V50, P1190, DOI 10.1097/00006123-200206000-00003; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Im E, 2007, J BIOL CHEM, V282, P29122, DOI 10.1074/jbc.M702637200; Jung KH, 2003, ARCH NEUROL-CHICAGO, V60, P1613, DOI 10.1001/archneur.60.11.1613; Kamei M, 2006, NATURE, V442, P453, DOI 10.1038/nature04923; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Laberge-le Couteulx S, 1999, NAT GENET, V23, P189, DOI 10.1038/13815; Larson JJ, 1998, J NEUROSURG, V88, P51, DOI 10.3171/jns.1998.88.1.0051; Lepore JJ, 2005, GENESIS, V41, P179, DOI 10.1002/gene.20112; Liquori CL, 2003, AM J HUM GENET, V73, P1459, DOI 10.1086/380314; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Petit N, 2006, GENE EXPR PATTERNS, V6, P495, DOI 10.1016/j.modgep.2005.11.001; Plummer NW, 2006, MAMM GENOME, V17, P119, DOI 10.1007/s00335-005-0098-8; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Saunders WB, 2006, J CELL BIOL, V175, P179, DOI 10.1083/jcb.200603176; Sclafani AM, 2006, GENESIS, V44, P336, DOI 10.1002/dvg.20220; Seker A, 2006, STROKE, V37, P518, DOI 10.1161/01.STR.0000198835.49387.25; Shi C, 2007, J NEUROSURG, V107, P1023, DOI 10.3171/JNS-07/11/1023; Su H, 2002, GENESIS, V32, P187, DOI 10.1002/gene.10043; Toldo I, 2009, SURG NEUROL, V71, P167, DOI 10.1016/j.surneu.2007.07.067; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Whitehead KJ, 2004, DEVELOPMENT, V131, P1437, DOI 10.1242/dev.01036; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Zeng LX, 2005, FASEB J, V19, P1845, DOI 10.1096/fj.05-4240fje	41	259	266	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					177	184		10.1038/nm.1911	http://dx.doi.org/10.1038/nm.1911			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19151728	Green Accepted			2022-12-27	WOS:000263119400020
J	Delgado, MF; Coviello, S; Monsalvo, AC; Melendi, GA; Hernandez, JZ; Batalle, JP; Diaz, L; Trento, A; Chang, HY; Mitzner, W; Ravetch, J; Melero, JA; Irusta, PM; Polack, FP				Florencia Delgado, Maria; Coviello, Silvina; Clara Monsalvo, A.; Melendi, Guillermina A.; Zea Hernandez, Johanna; Batalle, Juan P.; Diaz, Leandro; Trento, Alfonsina; Chang, Herng-Yu; Mitzner, Wayne; Ravetch, Jeffrey; Melero, Jose A.; Irusta, Pablo M.; Polack, Fernando P.			Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease	NATURE MEDICINE			English	Article							IMMUNIZED BALB/C MICE; COTTON RATS; PULMONARY HISTOPATHOLOGY; RSV CHALLENGE; MONOCLONAL-ANTIBODIES; FUSION GLYCOPROTEIN; PRIMARY INFECTION; DENDRITIC CELLS; INNATE IMMUNITY; PATHOLOGY	Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-inactivated RSV vaccine was used to immunize children and elicited nonprotective, pathogenic antibody. Immunized infants experienced increased morbidity after subsequent RSV exposure. No vaccine has been licensed since that time. A widely accepted hypothesis attributed the vaccine failure to formalin disruption of protective antigens. Here we show that the lack of protection was not due to alterations caused by formalin but instead to low antibody avidity for protective epitopes. Lack of antibody affinity maturation followed poor Toll-like receptor (TLR) stimulation. This study explains why the inactivated RSV vaccine did not protect the children and consequently led to severe disease, hampering vaccine development for 42 years. It also suggests that inactivated RSV vaccines may be rendered safe and effective by inclusion of TLR agonists in their formulation, and it identifies affinity maturation as a key factor for the safe immunization of infants.	[Florencia Delgado, Maria; Coviello, Silvina; Clara Monsalvo, A.; Melendi, Guillermina A.; Zea Hernandez, Johanna; Batalle, Juan P.; Diaz, Leandro; Irusta, Pablo M.; Polack, Fernando P.] INFANT Fdn, RA-1406 Buenos Aires, DF, Argentina; [Melendi, Guillermina A.; Zea Hernandez, Johanna; Polack, Fernando P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Trento, Alfonsina; Melero, Jose A.] Inst Salud Carlos III, Madrid 28220, Spain; [Trento, Alfonsina; Melero, Jose A.] CIBER Enfermedades Resp, Madrid 28220, Spain; [Chang, Herng-Yu; Mitzner, Wayne] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth, Baltimore, MD 21205 USA; [Ravetch, Jeffrey] Rockefeller Univ, New York, NY 10065 USA; [Irusta, Pablo M.] Georgetown Univ, Dept Human Sci, Washington, DC 20007 USA; [Polack, Fernando P.] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Polack, Fernando P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Rockefeller University; Georgetown University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Polack, FP (corresponding author), INFANT Fdn, Gavilan 94, RA-1406 Buenos Aires, DF, Argentina.	fpolack@jhsph.edu	Ravetch, Jeffrey/Z-1596-2019; Trento, Alfonsina/L-3315-2017; Trento, Alfonsina/C-2755-2012	Ravetch, Jeffrey/0000-0003-2024-9041; Trento, Alfonsina/0000-0002-2045-9690; 	Thomas and Carol McCann Innovative Research Fund; Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina; Thrasher Research Fund Early Career Award;  [AI-054952]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054952, R21AI054952] Funding Source: NIH RePORTER	Thomas and Carol McCann Innovative Research Fund; Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Thrasher Research Fund Early Career Award; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	PFP was a generous gift from V. Randolph ( Wyeth Lederle) and Gk2.43 monoclonal antibody for CD8<SUP>+</SUP> T lymphocyte depletion was generously provided by B. Graham and T. Johnson ( National Institute of Allergy and Infectious Diseases, US National Institutes of Health). We thank M. del Carmen Puggioli for excellent technical assistance. This work was supported by AI-054952 ( F. P. P.) and the Thomas and Carol McCann Innovative Research Fund for Asthma and Respiratory Diseases ( F. P. P.). M. F. D., A. C. M., J. P. B. and S. C. are recipients of Doctoral Awards from the Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina. G. A. M. is a recipient of the Thrasher Research Fund Early Career Award.	Abramson JS, 2003, PEDIATRICS, V112, P1442; ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; Barbey-Martin C, 2002, VIROLOGY, V294, P70, DOI 10.1006/viro.2001.1320; Bhoj VG, 2008, P NATL ACAD SCI USA, V105, P14046, DOI 10.1073/pnas.0804717105; BROKSTAD KA, 1995, VACCINE, V13, P1522, DOI 10.1016/0264-410X(95)00095-I; COLLINS PL, 2001, FIELDS VIROLOGY, P1443; CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992; CONNORS M, 1992, VACCINE, V10, P475, DOI 10.1016/0264-410X(92)90397-3; CONNORS M, 1994, J VIROL, V68, P5321, DOI 10.1128/JVI.68.8.5321-5325.1994; Fleury D, 1999, NAT STRUCT BIOL, V6, P530, DOI 10.1038/9299; GARCIABARRENO B, 1989, J VIROL, V63, P925; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; Hussell T, 1997, EUR J IMMUNOL, V27, P3341, DOI 10.1002/eji.1830271233; Johnson S, 1999, J INFECT DIS, V180, P35, DOI 10.1086/314846; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Knossow M, 2002, VIROLOGY, V302, P294, DOI 10.1006/viro.2002.1625; Kolokoltsov AA, 2007, J VIROL, V81, P7786, DOI 10.1128/JVI.02780-06; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lindemans CA, 2006, J IMMUNOL, V176, P5529, DOI 10.4049/jimmunol.176.9.5529; Liu P, 2007, J VIROL, V81, P1401, DOI 10.1128/JVI.01740-06; Mapletoft JW, 2008, J GEN VIROL, V89, P250, DOI 10.1099/vir.0.83300-0; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Melendi GA, 2007, J VIROL, V81, P991, DOI 10.1128/JVI.01783-06; Moghaddam A, 2006, NAT MED, V12, P905, DOI 10.1038/nm1456; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; MURPHY BR, 1990, VACCINE, V8, P497, DOI 10.1016/0264-410X(90)90253-I; MURPHY BR, 1989, VACCINE, V7, P533, DOI 10.1016/0264-410X(89)90278-8; Neuzil KM, 1997, VACCINE, V15, P525, DOI 10.1016/S0264-410X(97)00218-1; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Polack FP, 2005, P NATL ACAD SCI USA, V102, P8996, DOI 10.1073/pnas.0409478102; Polack FP, 1999, NAT MED, V5, P629, DOI 10.1038/9473; Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; PRINCE GA, 1986, J VIROL, V57, P721, DOI 10.1128/JVI.57.3.721-728.1986; Rudd BD, 2006, J IMMUNOL, V176, P1937, DOI 10.4049/jimmunol.176.3.1937; Rudd BD, 2007, VIRAL IMMUNOL, V20, P531, DOI 10.1089/vim.2007.0057; Rudd BD, 2007, J IMMUNOL, V178, P5820, DOI 10.4049/jimmunol.178.9.5820; SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Smit JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001720; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; Wu H, 2007, J MOL BIOL, V368, P652, DOI 10.1016/j.jmb.2007.02.024	48	340	363	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					34	41		10.1038/nm.1894	http://dx.doi.org/10.1038/nm.1894			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19079256	Bronze, Green Accepted			2022-12-27	WOS:000262425100016
J	Sapieha, P; Sirinyan, M; Hamel, D; Zaniolol, K; Joyal, JS; Cho, JH; Honore, JC; Kermorvant-Duchemin, E; Varma, DR; Tremblay, S; Leduc, M; Rihakova, L; Hardy, P; Klein, WH; Mu, XQ; Mamer, O; Lachapelle, P; Di Polo, A; Beausiour, C; Andelfinger, G; Mitchell, G; Sennlaub, F; Chemtob, S				Sapieha, Przemyslaw; Sirinyan, Mirna; Hamel, David; Zaniolol, Karine; Joyal, Jean-Sebastien; Cho, Jang-Hyeon; Honore, Jean-Claude; Kermorvant-Duchemin, Elsa; Varma, Daya R.; Tremblay, Sophie; Leduc, Martin; Rihakova, Lenka; Hardy, Pierre; Klein, William H.; Mu, Xiuqian; Mamer, Orval; Lachapelle, Pierre; Di Polo, Adriana; Beausiour, Christian; Andelfinger, Gregor; Mitchell, Grant; Sennlaub, Florian; Chemtob, Sylvain			The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; GANGLION-CELLS; ACID CYCLE; ALPHA-KETOGLUTARATE; MOUSE MODEL; HYPOXIA; EXPRESSION; VEGF; MECHANISMS; ISCHEMIA	Vascularization is essential for tissue development and in restoration of tissue integrity after an ischemic injury. in studies of vascularization, the focus has largely been placed on vascular endothelial growth factor (VEGF), yet other factors may also orchestrate this process. Here we show that succinate accumulates in the hypoxic retina of rodents and, via its cognate receptor G protein-coupled receptor-91 (GPR91), is a potent mediator of vessel growth in the settings of both normal retinal development and proliferative ischemic retinopathy. The effects of GPR91 are mediated by retinal ganglion neurons (RGCs), which, in response to increased succinate levels, regulate the production of numerous angiogenic factors including VEGF. Accordingly, succinate did not have proangiogenic effects in RGC-deficient rats. Our observations show a pathway of metabolite signaling where succinate, acting through GPR91, governs retinal angiogenesis and show the propensity of RGCs to act as sensors of ischemic stress. These findings provide a new therapeutic target for modulating revascularization.	[Sapieha, Przemyslaw; Sirinyan, Mirna; Joyal, Jean-Sebastien; Varma, Daya R.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; [Cho, Jang-Hyeon; Klein, William H.; Mu, Xiuqian] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Kermorvant-Duchemin, Elsa; Sennlaub, Florian] Ctr Rech Cordeliers, Unite Mixte Rech Sci S 872, Inst Natl Sante & Rech Med, F-75006 Paris, France; [Mamer, Orval] McGill Univ Montreal, Dept Med, Mass Spectrometry Facil, Quebec City, PQ H3A 1A4, Canada; [Lachapelle, Pierre] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Ophthalmol, Montreal, PQ H3H 1P3, Canada; [Lachapelle, Pierre] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Neurol Neurosurg, Montreal, PQ H3H 1P3, Canada; [Sapieha, Przemyslaw; Sirinyan, Mirna; Hamel, David; Zaniolol, Karine; Joyal, Jean-Sebastien; Honore, Jean-Claude; Tremblay, Sophie; Leduc, Martin; Rihakova, Lenka; Hardy, Pierre; Beausiour, Christian; Andelfinger, Gregor; Mitchell, Grant; Chemtob, Sylvain] Univ Montreal, Ctr Hosp Univ St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada; [Sapieha, Przemyslaw; Sirinyan, Mirna; Hamel, David; Zaniolol, Karine; Joyal, Jean-Sebastien; Honore, Jean-Claude; Tremblay, Sophie; Leduc, Martin; Rihakova, Lenka; Hardy, Pierre; Beausiour, Christian; Andelfinger, Gregor; Mitchell, Grant; Chemtob, Sylvain] Univ Montreal, Ctr Hosp Univ St Justine, Res Ctr, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada; [Di Polo, Adriana] Univ Montreal, Dept Pathol & Cell Biol, Montreal, PQ H3T 1J4, Canada; [Sennlaub, Florian] Univ Paris 06, Unite Mixte Rech Sci S 872, F-75006 Paris, France; [Sennlaub, Florian] Univ Paris 05, Unite Mixte Rech Sci 872, F-75006 Paris, France	McGill University; University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; McGill University; McGill University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Chemtob, S (corresponding author), Univ Montreal, Ctr Hosp Univ St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada.	sylvain.chemtob@umontreal.ca	Mu, Xiuqian/I-9146-2014; Sennlaub, Florian/F-2756-2017	Mu, Xiuqian/0000-0002-8003-7529; Sennlaub, Florian/0000-0003-4412-1341; Lachapelle, Pierre/0000-0002-7792-1102	Canadian Institutes of Health Research; March of Dimes Birth Defects Foundation; Heart and Stroke Foundation of Quebec; Fonds de la Recherche en Sante du Quebec; Heart and Stroke Foundation of Canada; Foundation Fighting Blindness Postdoctoral Fellowship Award; US National Eye Institute [EY011930]; Robert A. Welch Foundation [G-0010]; NATIONAL EYE INSTITUTE [R01EY011930] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); March of Dimes Birth Defects Foundation(March of Dimes); Heart and Stroke Foundation of Quebec; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Foundation Fighting Blindness Postdoctoral Fellowship Award; US National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Robert A. Welch Foundation(The Welch Foundation); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by grants from the Canadian Institutes of Health Research, the March of Dimes Birth Defects Foundation, the Heart and Stroke Foundation of Quebec and the Fonds de la Recherche en Sante du Quebec. P.S. and M.S. hold a Research Fellowship Award and a studentship from the Heart and Stroke Foundation of Canada, respectively. K.Z. is a recipient of The Foundation Fighting Blindness Postdoctoral Fellowship Award. F.S. and S.C are recipients of a fellowship and scientist awards, respectively, from the Canadian Institutes of Health Research. S.C. also holds a Canada Research Chair (perinatology). Generation of brn3b<SUP>Z-dtaf+</SUP>; six3-cre mice and J.-H.C's salart were supported by a US National Eye Institute grant EY011930 to W.H.K. and by the Robert A. Welch Foundation (G-0010), respectively. We wish to thank H. Fernandez and S. Leclere for valuable technical assistance	ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542; Burns P. A., 2003, Angiogenesis, V6, P73, DOI 10.1023/A:1025862731653; Cai WY, 2000, INVEST OPHTH VIS SCI, V41, P1885; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Cringle SJ, 2006, INVEST OPHTH VIS SCI, V47, P4072, DOI 10.1167/iovs.05-1638; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DREHER B, 1988, BRAIN BEHAV EVOLUT, V31, P369, DOI 10.1159/000116602; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; FOLBERGR.J, 1974, BRAIN RES, V80, P265, DOI 10.1016/0006-8993(74)90690-8; FRANCOIS J, 1974, EYE, V5, P1; Frassetto LJ, 2006, INVEST OPHTH VIS SCI, V47, P427, DOI 10.1167/iovs.05-0340; Fruttiger M, 1996, NEURON, V17, P1117, DOI 10.1016/S0896-6273(00)80244-5; Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482; GUTMAN M, 1980, BIOCHIM BIOPHYS ACTA, V591, P400, DOI 10.1016/0005-2728(80)90171-1; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; HEMS DA, 1970, BIOCHEM J, V120, P105, DOI 10.1042/bj1200105; Higgins RD, 1999, CURR EYE RES, V18, P20, DOI 10.1076/ceyr.18.1.20.5390; HOYER S, 1986, NEUROBIOL AGING, V7, P23, DOI 10.1016/0197-4580(86)90022-9; Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217; HUXLIN KR, 1995, GLIA, V15, P105, DOI 10.1002/glia.440150203; Ikeda M, 2000, J PATHOL, V191, P426; Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309; JOHNSON FM, 1968, BIOCHEM GENET, V2, P1, DOI 10.1007/BF01458447; JOHNSON RN, 1975, BIOCHEM J, V146, P527, DOI 10.1042/bj1460527; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Kushnir MM, 2001, CLIN CHEM, V47, P1993; Lee MS, 2001, CANCER RES, V61, P3290; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; MATTHEWS PM, 1994, CLIN NEUROPATHOL, V13, P139; McColm J, 2004, MOL VIS, V10, P512; MEIXNERMONORI B, 1985, J BACTERIOL, V161, P265, DOI 10.1128/JB.161.1.265-271.1985; MICHAELSON IC, 1954, RETINAL CIRCULATION, pCH1; Mu XQ, 2005, CURR BIOL, V15, P525, DOI 10.1016/j.cub.2005.01.043; Murray Brenda, 2001, Angiogenesis, V4, P71, DOI 10.1023/A:1016792319207; NEUMAN RE, 1958, P SOC EXP BIOL MED, V98, P303, DOI 10.3181/00379727-98-24025; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; PENN JS, 1994, PEDIATR RES, V36, P724, DOI 10.1203/00006450-199412000-00007; Piao YS, 2006, NEUROPATHOLOGY, V26, P218, DOI 10.1111/j.1440-1789.2006.00686.x; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Sapieha PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; Stowe AM, 2007, J CEREBR BLOOD F MET, V27, P76, DOI 10.1038/sj.jcbfm.9600320; Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106; Van Adel BA, 2003, HUM GENE THER, V14, P103, DOI 10.1089/104303403321070801; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773; Wittenberger T, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-17; Zhu T, 2006, ARTERIOSCL THROM VAS, V26, P744, DOI 10.1161/01.ATV.0000205591.88522.d4	59	260	274	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1067	1076		10.1038/nm.1873	http://dx.doi.org/10.1038/nm.1873			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18836459				2022-12-27	WOS:000259892300037
J	Ting, LM; Gissot, M; Coppi, A; Sinnis, P; Kim, K				Ting, Li-Min; Gissot, Mathieu; Coppi, Alida; Sinnis, Photini; Kim, Kami			Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity	NATURE MEDICINE			English	Article							BIFUNCTIONAL ORNITHINE-DECARBOXYLASE; TRANSITION-STATE ANALOG; HUMAN MALARIA; CIRCUMSPOROZOITE PROTEIN; IRRADIATED SPOROZOITES; FALCIPARUM; VACCINES; BERGHEI; POLYAMINES; INHIBITORS	Malaria continues to devastate sub-Saharan Africa owing to the emergence of drug resistance to established antimalarials and to the lack of an efficacious vaccine. Plasmodium species have a unique streamlined purine pathway in which the dual specificity enzyme purine nucleoside phosphorylase (PNP) functions in both purine recycling and purine salvage(1-4). To evaluate the importance of PNP in an in vivo model of malaria, we disrupted PyPNP, the gene encoding PNP in the lethal Plasmodium yoelii YM strain. P. yoelii parasites lacking PNP were attenuated and cleared in mice. Although able to form gametocytes, PNP-deficient parasites did not form oocysts in mosquito midguts and were not transmitted from mosquitoes to mice. Mice given PNP-deficient parasites were immune to subsequent challenge to a lethal inoculum of P. yoelii YM and to challenge from P. yoelii 17XNL, another strain. These in vivo studies with PNP-deficient parasites support purine salvage as a target for antimalarials. They also suggest a strategy for the development of attenuated nontransmissible metabolic mutants as blood-stage malaria vaccine strains.	[Ting, Li-Min; Gissot, Mathieu; Kim, Kami] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Ting, Li-Min; Gissot, Mathieu; Kim, Kami] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Coppi, Alida; Sinnis, Photini] NYU, Sch Med, Dept Med Parasitol, New York, NY 10010 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York University	Kim, K (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	kkim@aecom.yu.edu	Gissot, Mathieu/AFN-3127-2022	Gissot, Mathieu/0000-0003-0047-8189; Kim, Kami/0000-0003-3384-152X	US National Institutes of Health [R21AI052469, R01 AI056840]; US Army Research [W81XWH-05-2-0025]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056840, R21AI052469] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Research(United States Department of DefenseUS Army Research Laboratory (ARL)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by US National Institutes of Health grant R21AI052469 and US Army Research Grant W81XWH-05-2-0025 (both to K. K.). P. S. and A. C. were supported by US National Institutes of Health grant R01 AI056840. We gratefully thank V. Schramm for review of the manuscript before submission, J. Nonon and S. Gonzalez for technical support during mosquito rearing and infection, V. Lagal for advice on PCR and A. Mwakingwe for assistance with sporozoite challenge experiments. We also thank V. Schramm for advice on biochemical assays and many stimulating discussions during the course of this work.	Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; Ecker A, 2006, MOL BIOCHEM PARASIT, V145, P265, DOI 10.1016/j.molbiopara.2005.10.006; El Bissati K, 2006, P NATL ACAD SCI USA, V103, P9286, DOI 10.1073/pnas.0602590103; HOFFMAN SL, 1989, J IMMUNOL, V142, P3581; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Jongco AM, 2006, MOL BIOCHEM PARASIT, V146, P242, DOI 10.1016/j.molbiopara.2006.01.001; Kadekoppala M, 2000, INFECT IMMUN, V68, P2328, DOI 10.1128/IAI.68.4.2328-2332.2000; KHAN ZM, 1991, INFECT IMMUN, V59, P2529, DOI 10.1128/IAI.59.8.2529-2534.1991; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; Kicska GA, 2002, J BIOL CHEM, V277, P3219, DOI 10.1074/jbc.M105905200; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337629100; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Mota MM, 2001, MOL BIOCHEM PARASIT, V113, P271, DOI 10.1016/S0166-6851(01)00228-6; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; Sambandamurthy VK, 2005, MICROBES INFECT, V7, P955, DOI 10.1016/j.micinf.2005.04.001; SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Ting LM, 2005, J BIOL CHEM, V280, P9547, DOI 10.1074/jbc.M412693200; WEISS WR, 1989, J IMMUNOL, V143, P4263; WEISS WR, 1990, IMMUNOL LETT, V25, P39, DOI 10.1016/0165-2478(90)90088-8; Wrenger C, 2001, J BIOL CHEM, V276, P29651, DOI 10.1074/jbc.M100578200; Wykes M, 2007, INT J PARASITOL, V37, P705, DOI 10.1016/j.ijpara.2007.02.007	30	57	61	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2008	14	9					954	958		10.1038/nm.1867	http://dx.doi.org/10.1038/nm.1867			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18758447	Green Accepted			2022-12-27	WOS:000258988600028
J	Joffre, O; Santolaria, T; Calise, D; Al Saati, T; Hudrisier, D; Romagnoli, P; van Meerwijk, JPM				Joffre, Olivier; Santolaria, Thibault; Calise, Denis; Al Saati, Talal; Hudrisier, Denis; Romagnoli, Paola; van Meerwijk, Joost P. M.			Prevention of acute and chronic allograft rejection with CD4(+)CD25(+)Foxp3(+) regulatory T lymphocytes	NATURE MEDICINE			English	Article							TRANSPLANTATION TOLERANCE; MIXED CHIMERISM; MARROW-TRANSPLANTATION; AUTOIMMUNE-DISEASE; IN-VIVO; CELLS; INDUCTION	A major challenge in transplantation medicine is controlling the very strong immune responses to foreign antigens that are responsible for graft rejection. Although immunosuppressive drugs efficiently inhibit acute graft rejection, a substantial proportion of patients suffer chronic rejection that ultimately leads to functional loss of the graft(1). Induction of immunological tolerance to transplants would avoid rejection and the need for lifelong treatment with immunosuppressive drugs(1,2). Tolerance to self-antigens is ensured naturally by several mechanisms(3); one major mechanism depends on the activity of regulatory T lymphocytes(4,5). Here we show that in mice treated with clinically acceptable levels of irradiation, regulatory CD4(+)CD25(+)Foxp3(+) T cells stimulated in vitro with alloantigens induced long-term tolerance to bone marrow and subsequent skin and cardiac allografts. Regulatory T cells specific for directly presented donor antigens prevented only acute rejection, despite hematopoietic chimerism. By contrast, regulatory T cells specific for both directly and indirectly presented alloantigens prevented both acute and chronic rejection. Our findings demonstrate the potential of appropriately stimulated regulatory T cells for future cell-based therapeutic approaches to induce lifelong immunological tolerance to allogeneic transplants.	[Joffre, Olivier; Santolaria, Thibault; Hudrisier, Denis; Romagnoli, Paola; van Meerwijk, Joost P. M.] INSERM, U563, Tolerance & Autoimmun Sect, F-31300 Toulouse, France; [Joffre, Olivier; Santolaria, Thibault; Hudrisier, Denis; Romagnoli, Paola; van Meerwijk, Joost P. M.] Univ Toulouse 3, F-31400 Toulouse, France; [Calise, Denis] INSERM, Inst Louis Bugnard, Inst Fed Rech 31, F-31403 Toulouse, France; [Al Saati, Talal] INSERM, Inst Claude Preval, Inst Fed Rech 30, F-31300 Toulouse, France; [van Meerwijk, Joost P. M.] Inst Univ France, F-75000 Paris, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Universitaire de France	van Meerwijk, JPM (corresponding author), INSERM, U563, Tolerance & Autoimmun Sect, F-31300 Toulouse, France.	joost.van-meerwijk@toulouse.inserm.fr	van Meerwijk, Joost P.M./K-1345-2014; Joffre, Olivier P/K-1235-2014; Romagnoli, Paola/K-2237-2014	van Meerwijk, Joost P.M./0000-0001-8231-1897; Joffre, Olivier P/0000-0003-1168-8165; Hudrisier, Denis/0000-0002-3631-9561				Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; BOYSE EA, 1970, NATURE, V227, P901, DOI 10.1038/227901a0; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; Cosimi AB, 2004, TRANSPLANTATION, V77, P943, DOI 10.1097/01.TP.0000117779.23431.3F; Coudert RD, 2002, J IMMUNOL, V169, P2979, DOI 10.4049/jimmunol.169.6.2979; Fudaba Y, 2006, AM J TRANSPLANT, V6, P2121, DOI 10.1111/j.1600-6143.2006.01434.x; Golshayan D, 2007, BLOOD, V109, P827, DOI 10.1182/blood-2006-05-025460; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; ILDSTAD ST, 1985, J EXP MED, V162, P231, DOI 10.1084/jem.162.1.231; Izcue A, 2006, IMMUNOL REV, V212, P256, DOI 10.1111/j.0105-2896.2006.00423.x; Jiang SP, 2003, BLOOD, V102, P2180, DOI 10.1182/blood-2003-04-1164; Joffre O, 2004, BLOOD, V103, P4216, DOI 10.1182/blood-2004-01-0005; Joffre O, 2006, SEMIN IMMUNOL, V18, P128, DOI 10.1016/j.smim.2006.01.005; Le Moine A, 1999, J CLIN INVEST, V103, P1659, DOI 10.1172/JCI5504; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Luo B, 2007, EUR J IMMUNOL, V37, P1233, DOI 10.1002/eji.200636938; Nishimura E, 2004, INT IMMUNOL, V16, P1189, DOI 10.1093/intimm/dxh122; Rocha PN, 2003, IMMUNOL REV, V196, P51, DOI 10.1046/j.1600-065X.2003.00090.x; Rouse BT, 2006, IMMUNOL REV, V212, P272, DOI 10.1111/j.0105-2896.2006.00412.x; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Salama AD, 2007, J IMMUNOL, V178, P5419, DOI 10.4049/jimmunol.178.9.5419; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Stockinger B, 1999, Adv Immunol, V71, P229; Sykes M, 2001, IMMUNITY, V14, P417, DOI 10.1016/S1074-7613(01)00122-4; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Vriesendorp HM, 2003, EXP HEMATOL, V31, P844, DOI 10.1016/S0301-472X(03)00229-7; Waldmann H, 2004, SCIENCE, V305, P209, DOI 10.1126/science.1099538	30	405	434	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					88	92		10.1038/nm1688	http://dx.doi.org/10.1038/nm1688			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18066074	Green Accepted, Green Submitted			2022-12-27	WOS:000252222400027
J	Hartl, D; Latzin, P; Hordijk, P; Marcos, V; Rudolph, C; Woischnik, M; Krauss-Etschmann, S; Koller, B; Reinhardt, D; Roscher, AA; Roos, D; Griese, M				Hartl, Dominik; Latzin, Philipp; Hordijk, Peter; Marcos, Veronica; Rudolph, Carsten; Woischnik, Markus; Krauss-Etschmann, Susanne; Koller, Barbara; Reinhardt, Dietrich; Roscher, Adelbert A.; Roos, Dirk; Griese, Matthias			Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease	NATURE MEDICINE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; CHEMOKINE RECEPTORS; PHOSPHOLIPASE-D; NADPH-OXIDASE; SEVERE ASTHMA; GRO-ALPHA; EXPRESSION; INFLAMMATION; ELASTASE; PSEUDOMONAS	Interleukin-8 (IL-8) activates neutrophils via the chemokine receptors CXCR1 and CXCR2. However, the airways of individuals with cystic fibrosis are frequently colonized by bacterial pathogens, despite the presence of large numbers of neutrophils and IL-8. Here we show that IL-8 promotes bacterial killing by neutrophils through CXCR1 but not CXCR2. Unopposed proteolytic activity in the airways of individuals with cystic fibrosis cleaved CXCR1 on neutrophils and disabled their bacterial-killing capacity. These effects were protease concentration-dependent and also occurred to a lesser extent in individuals with chronic obstructive pulmonary disease. Receptor cleavage induced the release of glycosylated CXCR1 fragments that were capable of stimulating IL-8 production in bronchial epithelial cells via Toll-like receptor 2. In vivo inhibition of proteases by inhalation of alpha 1-antitrypsin restored CXCR1 expression and improved bacterial killing in individuals with cystic fibrosis. The cleavage of CXCR1, the functional consequences of its cleavage, and the identification of soluble CXCR1 fragments that behave as bioactive components represent a new pathophysiologic mechanism in cystic fibrosis and other chronic lung diseases.	Univ Munich, Childrens Hosp, Res Ctr, D-80337 Munich, Germany; Yale Univ, Sch Med, Pulm & Crit Care Sect, New Haven, CT 06520 USA; Univ Bern, Childrens Hosp, CH-3010 Bern, Switzerland; Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1066 Amsterdam, Netherlands; Natl Res Ctr Environm & Hlth, Gesellschaft Strahlenforshung, D-85764 Munich, Germany	University of Munich; Yale University; University of Bern; University Hospital of Bern; University of Amsterdam; University of Munich	Hartl, D (corresponding author), Univ Munich, Childrens Hosp, Res Ctr, D-80337 Munich, Germany.	dhartl@med.uni-muenchen.de	Krauss-Etschmann, Susanne/H-5198-2018; Rudolph, Carsten/B-9379-2011; Latzin, Philipp/F-2206-2017	Krauss-Etschmann, Susanne/0000-0001-5945-5702; Latzin, Philipp/0000-0002-5239-1571; Hordijk, Peter/0000-0002-3348-078X				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Allen L, 2005, J IMMUNOL, V174, P3643, DOI 10.4049/jimmunol.174.6.3643; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; BONFIELD TL, 1995, AM J RESP CRIT CARE, V152, P2111, DOI 10.1164/ajrccm.152.6.8520783; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DANIELS RH, 1992, IMMUNOLOGY, V75, P157; DJEU JY, 1990, J IMMUNOL, V144, P2205; DORING G, 1994, AM J RESP CRIT CARE, V150, pS114; Frizzell RA, 2004, NAT MED, V10, P452, DOI 10.1038/nm0504-452; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Khandaker MH, 1998, J IMMUNOL, V161, P1930; Kobayashi SD, 2003, P NATL ACAD SCI USA, V100, P10948, DOI 10.1073/pnas.1833375100; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mayer-Hamblett N, 2007, AM J RESP CRIT CARE, V175, P822, DOI 10.1164/rccm.200609-1354OC; MCELVANEY NG, 1991, LANCET, V337, P392, DOI 10.1016/0140-6736(91)91167-S; Moepps B, 2006, MOL IMMUNOL, V43, P897, DOI 10.1016/j.molimm.2005.06.043; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Panina P, 2006, CURR DRUG TARGETS, V7, P669, DOI 10.2174/138945006777435272; Pease James E, 2002, Am J Respir Med, V1, P19; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Pignatti P, 2005, J ALLERGY CLIN IMMUN, V115, P88, DOI 10.1016/j.jaci.2004.08.048; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; Roos D, 2002, SCIENCE, V296, P669, DOI 10.1126/science.1071271; Sabroe I, 2005, IMMUNOLOGY, V115, P90, DOI 10.1111/j.1365-2567.2005.02133.x; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; Stockley RA, 2002, CHEST, V121, p151S, DOI 10.1378/chest.121.5_suppl.151S; STOCKLEY RA, 1994, AM J RESP CRIT CARE, V150, pS190; Taggart CC, 2005, AM J RESP CRIT CARE, V171, P1070, DOI 10.1164/rccm.200407-881PP; TOSI MF, 1990, J CLIN INVEST, V86, P300, DOI 10.1172/JCI114699; Tsang KW, 2000, CHEST, V117, P420, DOI 10.1378/chest.117.2.420; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; vanPelt LJ, 1996, J IMMUNOL METHODS, V191, P187, DOI 10.1016/0022-1759(96)00024-5; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wuyts A, 1998, EUR J BIOCHEM, V255, P67, DOI 10.1046/j.1432-1327.1998.2550067.x	50	244	247	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1423	1430		10.1038/nm1690	http://dx.doi.org/10.1038/nm1690			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18059279				2022-12-27	WOS:000251445400016
J	Wan, YH; Chong, LW; Evans, RM				Wan, Yihong; Chong, Ling-Wa; Evans, Ronald M.			PPAR-gamma regulates osteoclastogenesis in mice	NATURE MEDICINE			English	Article							ACTIVATED-RECEPTOR-GAMMA; BONE-RESORPTION; INSULIN-RESISTANCE; IN-VIVO; C-FOS; ROSIGLITAZONE; DIFFERENTIATION; AGONIST; HEMATOPOIESIS; DISEASE	Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis(1). Although peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has been shown to inhibit osteoblast differentiation(2,3), its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR-gamma agonists, ''such as thiazolidinediones-'' a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients(4,5). Here we have uncovered a pro-osteoclastogenic effect of PPAR-gamma by using a Tie2Cre/flox mouse model in which PPAR-gamma is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-kappa B ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR-gamma by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR-gamma functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis(6). Therefore, PPAR-gamma and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA.	evans@salk.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK057978] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL569898, HL07770] Funding Source: Medline; NIDDK NIH HHS [DK57978] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004-0735; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chui PC, 2005, J CLIN INVEST, V115, P2244, DOI 10.1172/JCI24130; Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; GREY A, 2007, OSTEOPOROS INT  0928; Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006-2646; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li M, 2006, BONE, V39, P796, DOI 10.1016/j.bone.2006.04.008; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003-0746; Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223-004-0224-8; Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood-2004-06-2480; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Wan YH, 2007, GENE DEV, V21, P1895, DOI 10.1101/gad.1567207	30	410	438	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1496	1503		10.1038/nm1672	http://dx.doi.org/10.1038/nm1672			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18059282				2022-12-27	WOS:000251445400025
J	Xu, ZZ; Zhang, L; Liu, T; Park, JY; Berta, T; Yang, R; Serhan, CN; Ji, RR				Xu, Zhen-Zhong; Zhang, Ling; Liu, Tong; Park, Jong Yeon; Berta, Temugin; Yang, Rong; Serhan, Charles N.; Ji, Ru-Rong			Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions	NATURE MEDICINE			English	Article							PRIMARY SENSORY NEURONS; SPINAL NERVE LIGATION; NECROSIS-FACTOR-ALPHA; CENTRAL SENSITIZATION; NEUROPATHIC PAIN; ANTIINFLAMMATORY PROPERTIES; INTRATHECAL MORPHINE; RECEPTOR; MECHANISMS; RESOLUTION	Inflammatory pain, such as arthritis pain, is a growing health problem(1). Inflammatory pain is generally treated with opioids and cyclooxygenase (COX) inhibitors, but both are limited by side effects. Recently, resolvins, a unique family of lipid mediators, including RvE1 and RvD1 derived from omega-3 polyunsaturated fatty acid, have shown marked potency in treating disease conditions associated with inflammation(2,3). Here we report that peripheral (intraplantar) or spinal (intrathecal) administration of RvE1 or RvD1 in mice potently reduces inflammatory pain behaviors induced by intraplantar injection of formalin, carrageenan or complete Freund's adjuvant (CFA), without affecting basal pain perception. Intrathecal RvE1 injection also inhibits spontaneous pain and heat and mechanical hypersensitivity evoked by intrathecal capsaicin and tumor necrosis factor-alpha (TNF-alpha). RvE1 has anti-inflammatory activity by reducing neutrophil infiltration, paw edema and proinflammatory cytokine expression. RvE1 also abolishes transient receptor potential vanilloid subtype-1 (TRPV1)- and TNF-alpha-induced excitatory postsynaptic current increases and TNF-alpha-evoked N-methyl-d-aspartic acid (NMDA) receptor hyperactivity in spinal dorsal horn neurons via inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. Thus, we show a previously unknown role for resolvins in normalizing the spinal synaptic plasticity that has been implicated in generating pain hypersensitivity. Given the potency of resolvins and the well-known side effects of opioids and COX inhibitors, resolvins may represent new analgesics for treating inflammatory pain.	[Xu, Zhen-Zhong; Zhang, Ling; Liu, Tong; Park, Jong Yeon; Berta, Temugin; Ji, Ru-Rong] Brigham & Womens Hosp, Sensory Plast Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Xu, Zhen-Zhong; Zhang, Ling; Liu, Tong; Park, Jong Yeon; Berta, Temugin; Yang, Rong; Serhan, Charles N.; Ji, Ru-Rong] Harvard Univ, Sch Med, Boston, MA USA; [Yang, Rong; Serhan, Charles N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Ji, RR (corresponding author), Brigham & Womens Hosp, Sensory Plast Lab, Pain Res Ctr, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu; rrji@zeus.bwh.harvard.edu	Liu, Tong/E-3648-2010; Berta, Temugin/A-6908-2016; Yang, Rong/ABA-7587-2021; Park, Jong Yeon/AAF-8743-2021; Liu, Tong/C-7810-2012; Ji, Ru-Rong/L-7070-2017; Berta, Temugin/AAK-6365-2020	Berta, Temugin/0000-0002-4486-8288; Ji, Ru-Rong/0000-0002-9355-3688; Berta, Temugin/0000-0002-4486-8288; Xu, Zhen-Zhong/0000-0001-6578-211X; Yang, Rong/0000-0001-8837-0089; Park, Jong Yeon/0000-0003-0588-1903; Zhang, Ling/0000-0002-8308-6553	US National Institutes of Health [R01-DE17794, R01-NS54362, R37 GM38765, R01-DE019938, R01-DK074448, NS67686]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019938, R01DE017794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R37GM038765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS067686, R01NS054932, F30NS054362] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by US National Institutes of Health grants R01-DE17794 and R01-NS54362 to R.-R.J., R37 GM38765, R01-DE019938 and R01-DK074448 to C.N.S. and NS67686 to both R.-R.J. and C.N.S.	Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2006, J BIOL CHEM, V281, P22847, DOI 10.1074/jbc.M603766200; Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1; Cash JL, 2008, J EXP MED, V205, P767, DOI 10.1084/jem.20071601; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Chiang N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001879; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d; Gao YJ, 2009, J NEUROSCI, V29, P4096, DOI 10.1523/JNEUROSCI.3623-08.2009; Gavva NR, 2008, TRENDS PHARMACOL SCI, V29, P550, DOI 10.1016/j.tips.2008.08.003; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Hucho T, 2007, NEURON, V55, P365, DOI 10.1016/j.neuron.2007.07.008; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Jin XC, 2006, J NEUROSCI, V26, P246, DOI 10.1523/JNEUROSCI.3858-05.2006; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Junger H, 2000, PAIN, V85, P145, DOI 10.1016/S0304-3959(99)00262-6; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Liu XJ, 2008, NAT MED, V14, P1325, DOI 10.1038/nm.1883; Nicol GD, 1997, J NEUROSCI, V17, P975; Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schafers M, 2003, J NEUROSCI, V23, P2517; Schnitzer TJ, 2006, CLIN RHEUMATOL, V25, pS22, DOI 10.1007/s10067-006-0203-8; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Vara H, 2009, P NATL ACAD SCI USA, V106, P9872, DOI 10.1073/pnas.0900077106; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Woolf CJ, 2009, CELL, V137, P987, DOI 10.1016/j.cell.2009.05.033; Yaksh TL, 1999, TRENDS PHARMACOL SCI, V20, P329, DOI 10.1016/S0165-6147(99)01370-X; YAMAMOTO T, 1992, ANESTHESIOLOGY, V77, P757, DOI 10.1097/00000542-199210000-00021; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004	40	411	435	5	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2010	16	5					592	U129		10.1038/nm.2123	http://dx.doi.org/10.1038/nm.2123			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20383154	Green Accepted			2022-12-27	WOS:000277394700039
J	Greinacher, A; Wesche, J; Hammer, E; Furll, B; Volker, U; Reil, A; Bux, J				Greinacher, Andreas; Wesche, Jan; Hammer, Elke; Fuerll, Birgitt; Voelker, Uwe; Reil, Angelika; Bux, Juergen			Characterization of the human neutrophil alloantigen-3a	NATURE MEDICINE			English	Article							ACUTE LUNG INJURY; TRANSFUSION; ALLOANTIBODIES; PATHOGENESIS; PROTEIN; KDA; 5B	Transfusion-related acute lung injury (TRALI) is a frequent cause of transfusion-associated morbidity and mortality. Severe TRALI is often due to antibodies in blood components directed against the human neutrophil alloantigen-3a (HNA-3a). We show here that the HNA-3a antigen arises from a nucleotide polymorphism in the choline transporter-like protein-2 gene (SLC44A2), with the resulting variation at amino acid position 154 determining the reactivity of the protein with HNA-3a-specific antibodies; the variant with an arginine at this position, rather than a glutamine, constitutes the HNA-3a antigen. The molecular identification of this antigen should facilitate the development of assays for blood donor screening to lower the risk of TRALI.	[Greinacher, Andreas; Wesche, Jan; Fuerll, Birgitt] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany; [Hammer, Elke; Voelker, Uwe] Ernst Moritz Arndt Univ Greifswald, Interfak Inst Genet & Funkt Genomforsch, Greifswald, Germany; [Reil, Angelika; Bux, Juergen] Ruhr Univ Bochum, Bochum, Germany; [Reil, Angelika; Bux, Juergen] Deutsch Rotes Kreuz Blutspendedienst W, Hagen, Germany	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ruhr University Bochum	Greinacher, A (corresponding author), Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, Greifswald, Germany.	greinach@uni-greifswald.de		Hammer, Elke/0000-0002-1507-0402; Volker, Uwe/0000-0002-5689-3448	Deutsche Rote Kreuz-Blutspendedienst West, Hagen, Germany; Land Mecklenburg-Vorpommern, Exzellenzinitiative [UG 07-064]; Bundesministerium fur Bildung und Forschung, Zentrum fur Innovationskompetenz Humorale Immunreaktionen bei Herz-Kreislauf Erkrankungen (ZIK-HIKE) [03Z2CK1, 03Z2CI1]; Zentrum fur Innovationskompetenz Funktionelle Genomforschung [ZIK FunGene 03ZIK331]	Deutsche Rote Kreuz-Blutspendedienst West, Hagen, Germany; Land Mecklenburg-Vorpommern, Exzellenzinitiative; Bundesministerium fur Bildung und Forschung, Zentrum fur Innovationskompetenz Humorale Immunreaktionen bei Herz-Kreislauf Erkrankungen (ZIK-HIKE)(Federal Ministry of Education & Research (BMBF)); Zentrum fur Innovationskompetenz Funktionelle Genomforschung	We thank A. Teumer for running the data analysis of the Study on Health in Pomerania for population-wide gene frequency analysis of the HNA-3a-encoding polymorphism. We highly appreciate the expertise and support of J. Hoppen and H. Hippe (Chromatec) for expression of recombinant protein fragments. We thank T. E. Warkentin for valuable discussion and suggestions. This work was supported by an unrestricted grant of the Deutsche Rote Kreuz-Blutspendedienst West, Hagen, Germany; by the Land Mecklenburg-Vorpommern, Exzellenzinitiative UG 07-064; by the Bundesministerium fur Bildung und Forschung, Zentrum fur Innovationskompetenz Humorale Immunreaktionen bei Herz-Kreislauf Erkrankungen (ZIK-HIKE) 03Z2CK1 and 03Z2CI1 and Zentrum fur Innovationskompetenz Funktionelle Genomforschung (ZIK FunGene 03ZIK331).	Bierling P, 2009, VOX SANG, V96, P266, DOI 10.1111/j.1423-0410.2008.01144.x; Bux J, 2007, BRIT J HAEMATOL, V136, P788, DOI 10.1111/j.1365-2141.2007.06492.x; Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x; Davoren A, 2003, TRANSFUSION, V43, P641, DOI 10.1046/j.1537-2995.2003.00374.x; de Haas M, 2000, TRANSFUSION, V40, P222, DOI 10.1046/j.1537-2995.2000.40020222.x; Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004; Keller-Stanislawski B, 2010, VOX SANG, V98, P70, DOI 10.1111/j.1423-0410.2009.01232.x; Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251; Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x; Kopko PM, 2002, JAMA-J AM MED ASSOC, V287, P1968, DOI 10.1001/jama.287.15.1968; Middelburg RA, 2008, TRANSFUSION, V48, P2167, DOI 10.1111/j.1537-2995.2008.01810.x; Nair TS, 2004, J NEUROSCI, V24, P1772, DOI 10.1523/JNEUROSCI.5063-03.2004; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; Reil A, 2008, VOX SANG, V95, P313, DOI 10.1111/j.1423-0410.2008.01092.x; SEEGER W, 1990, BLOOD, V76, P1438; Silliman CC, 2003, BLOOD, V101, P454, DOI 10.1182/blood-2002-03-0958; Soehnlein O, 2009, J LEUKOCYTE BIOL, V85, P344, DOI 10.1189/jlb.0808495; Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643; VANLEEUWEN A, 1964, VOX SANG, V9, P431; Yasui K, 2008, TRANSFUSION, V48, P978, DOI 10.1111/j.1537-2995.2007.01632.x	20	106	114	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					45	48		10.1038/nm.2070	http://dx.doi.org/10.1038/nm.2070			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20037594				2022-12-27	WOS:000273395500035
J	Karumanchi, SA; Thadhani, R				Karumanchi, S. Ananth; Thadhani, Ravi			Why don't statins always work?	NATURE MEDICINE			English	Editorial Material							CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; KIDNEY-DISEASE; BLOOD-PRESSURE; HEMODIALYSIS; UREMIA; ATHEROGENESIS; INFLAMMATION; ASSOCIATION; PREVENTION		[Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Ctr Vasc Biol, Boston, MA 02215 USA; [Karumanchi, S. Ananth; Thadhani, Ravi] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Thadhani, Ravi] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Karumanchi, SA (corresponding author), Beth Israel Deaconess Med Ctr, Howard Hughes Med Inst, Ctr Vasc Biol, Boston, MA 02215 USA.	sananth@bidmc.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Brown MS, 1996, SCIENCE, V272, P629, DOI 10.1126/science.272.5262.629; Buzello M, 2003, J AM SOC NEPHROL, V14, P311, DOI 10.1097/01.ASN.0000045048.71975.FC; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Kennedy DJ, 2006, HYPERTENSION, V47, P488, DOI 10.1161/01.HYP.0000202594.82271.92; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Rabkin R, 2008, J AM SOC NEPHROL, V19, P1774, DOI 10.1681/ASN.2007121386; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Siedlecki AM, 2009, KIDNEY INT, V75, P800, DOI 10.1038/ki.2008.690; Stenvinkel P, 2008, CLIN J AM SOC NEPHRO, V3, P505, DOI 10.2215/CJN.03670807; Tepel M, 2003, CIRCULATION, V107, P992, DOI 10.1161/01.CIR.0000050628.11305.30; Thadhani R, 2009, J AM SOC NEPHROL, V20, P2285, DOI 10.1681/ASN.2009050494; Wang Z, 2007, NAT MED, V13, P1176, DOI 10.1038/nm1637; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	16	11	11	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2010	16	1					38	40		10.1038/nm0110-38	http://dx.doi.org/10.1038/nm0110-38			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20057425				2022-12-27	WOS:000273395500033
J	Geraldes, P; Hiraoka-Yamamoto, J; Matsumoto, M; Clermont, A; Leitges, M; Marette, A; Aiello, LP; Kern, TS; King, GL				Geraldes, Pedro; Hiraoka-Yamamoto, Junko; Matsumoto, Motonobu; Clermont, Allen; Leitges, Michael; Marette, Andre; Aiello, Lloyd P.; Kern, Timothy S.; King, George L.			Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; MOTH-EATEN MICE; TYROSINE-PHOSPHATASE; FACTOR RECEPTOR; GLUCOSE; EXPRESSION; INDUCTION; RATS	Cellular apoptosis induced by hyperglycemia occurs in many vascular cells and is crucial for the initiation of diabetic pathologies. In the retina, pericyte apoptosis and the formation of acellular capillaries, the most specific vascular pathologies attributed to hyperglycemia, is linked to the loss of platelet-derived growth factor (PDGF)-mediated survival actions owing to unknown mechanisms. Here we show that hyperglycemia persistently activates protein kinase C-delta (PKC-delta, encoded by Prkcd) and p38 alpha mitogen-activated protein kinase (MAPK) to increase the expression of a previously unknown target of PKC-delta signaling, Src homology-2 domain-containing phosphatase-1 (SHP-1), a protein tyrosine phosphatase. This signaling cascade leads to PDGF receptor-beta dephosphorylation and a reduction in downstream signaling from this receptor, resulting in pericyte apoptosis independently of nuclear factor-kappa B (NF-kappa B) signaling. We observed increased PKC-delta activity and an increase in the number of acellular capillaries in diabetic mouse retinas, which were not reversible with insulin treatment that achieved normoglycemia. Unlike diabetic age-matched wild-type mice, diabetic Prkcd(-/-) mice did not show activation of p38 alpha MAPK or SHP-1, inhibition of PDGF signaling in vascular cells or the presence of acellular capillaries. We also observed PKC-delta, p38 alpha MAPK and SHP-1 activation in brain pericytes and in the renal cortex of diabetic mice. These findings elucidate a new signaling pathway by which hyperglycemia can induce PDGF resistance and increase vascular cell apoptosis to cause diabetic vascular complications.	[Geraldes, Pedro; Hiraoka-Yamamoto, Junko; Matsumoto, Motonobu; Clermont, Allen; Aiello, Lloyd P.; King, George L.] Joslin Diabet Ctr, Dianne Nunnally Hoppes Lab Diabet Complicat, Boston, MA 02215 USA; [Aiello, Lloyd P.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, Oslo, Norway; [Marette, Andre] Univ Laval, Dept Anat & Physiol, Quebec City, PQ, Canada; [Aiello, Lloyd P.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; [Kern, Timothy S.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [King, George L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; University of Oslo; Laval University; Harvard University; Harvard Medical School; Case Western Reserve University; Harvard University; Harvard Medical School	King, GL (corresponding author), Joslin Diabet Ctr, Dianne Nunnally Hoppes Lab Diabet Complicat, Boston, MA 02215 USA.	george.king@joslin.harvard.edu	Marette, Andre/E-9342-2013; Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995; Marette, Andre/0000-0003-3950-5973	US National Eye Institute [5R01EY016150-02]; Canadian Institute of Health Research [165453]; NATIONAL EYE INSTITUTE [R01EY016150] Funding Source: NIH RePORTER	US National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Prkcd<SUP>-/-</SUP> mice were provided by M. Leitges (University of Oslo). Adenoviral vectors expressing dominant-negative p38 alpha and p38 beta MAPK were generously provided by Y. Wang (University of California, Los Angeles). Adenoviral vector expressing dominant-negative of SHP-1 (Ad-DN SHP-1) was generously provided by A. Marette (University of Laval). P. G. is a recipient of awards from the Juvenile Diabetes Research Foundation. This study was supported by the US National Eye Institute (grant 5R01EY016150-02 to G. L. K.) and by the Canadian Institute of Health Research (grant 165453) to A. M. We thank W.-C. Li and S. Bonner-Weir for the technical support on confocal microscopy imaging.	Aiello LP, 2005, DIABETES, V54, P2188; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Bhattacharya Resham, 2008, J Mol Signal, V3, P8, DOI 10.1186/1750-2187-3-8; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520; Dubois MJ, 2006, NAT MED, V12, P549, DOI 10.1038/nm1397; El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Kanthasamy AG, 2003, ANTIOXID REDOX SIGN, V5, P609, DOI 10.1089/152308603770310275; Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280; KERN TS, 1994, CURR EYE RES, V13, P863, DOI 10.3109/02713689409015087; KING GL, 1987, DIABETES, V36, P1460, DOI 10.2337/diabetes.36.12.1460; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Leitges M, 2001, J CLIN INVEST, V108, P1505; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544; Lyons BL, 2006, INVEST OPHTH VIS SCI, V47, P1201, DOI 10.1167/iovs.05-1161; Miao F, 2007, J BIOL CHEM, V282, P13854, DOI 10.1074/jbc.M609446200; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nakase K, 2009, J LEUKOCYTE BIOL, V85, P165, DOI 10.1189/jlb.0608383; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Peter PS, 2007, J CLIN INVEST, V117, P1335, DOI 10.1172/JCI29576; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Ryer EJ, 2005, J BIOL CHEM, V280, P35310, DOI 10.1074/jbc.M507187200; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Villeneuve LM, 2008, P NATL ACAD SCI USA, V105, P9047, DOI 10.1073/pnas.0803623105; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Yokota T, 2003, DIABETES, V52, P838, DOI 10.2337/diabetes.52.3.838; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	44	282	298	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1298	U133		10.1038/nm.2052	http://dx.doi.org/10.1038/nm.2052			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19881493	Green Submitted, Green Accepted			2022-12-27	WOS:000271543700018
J	Zhao, BH; Takami, M; Yamada, A; Wang, XG; Koga, T; Hu, XY; Tamura, T; Ozato, K; Choi, YW; Ivashkiv, LB; Takayanagi, H; Kamijo, R				Zhao, Baohong; Takami, Masamichi; Yamada, Atsushi; Wang, Xiaogu; Koga, Takako; Hu, Xiaoyu; Tamura, Tomohiko; Ozato, Keiko; Choi, Yongwon; Ivashkiv, Lionel B.; Takayanagi, Hiroshi; Kamijo, Ryutaro			Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis	NATURE MEDICINE			English	Article							SEQUENCE-BINDING-PROTEIN; TOLL-LIKE RECEPTORS; NF-KAPPA-B; DENDRITIC CELLS; KEY REGULATOR; CROSS-TALK; IFN-GAMMA; C-FOS; DIFFERENTIATION; ACTIVATION	Bone metabolism results from a balance between osteoclast-driven bone resorption and osteoblast-mediated bone formation. Diseases such as periodontitis and rheumatoid arthritis are characterized by increased bone destruction due to enhanced osteoclastogenesis(1,2). Here we report that interferon regulatory factor-8 (IRF-8), a transcription factor expressed in immune cells, is a key regulatory molecule for osteoclastogenesis. IRF-8 expression in osteoclast precursors was downregulated during the initial phase of osteoclast differentiation induced by receptor activator of nuclear factor-kappa B ligand (RANKL), which is encoded by the Tnfsf11 gene. Mice deficient in Irf8 showed severe osteoporosis, owing to increased numbers of osteoclasts, and also showed enhanced bone destruction after lipopolysaccharide (LPS) administration. Irf8(-/-) osteoclast precursors underwent increased osteoclastogenesis in response to RANKL and tumor necrosis factor-alpha (TNF-alpha). IRF-8 suppressed osteoclastogenesis by inhibiting the function and expression of nuclear factor of activated T cells c1 (NFATc1). Our results show that IRF-8 inhibits osteoclast formation under physiological and pathological conditions and suggest a model where downregulation of inhibitory factors such as IRF-8 contributes to RANKL-mediated osteoclastogenesis.	[Zhao, Baohong; Takami, Masamichi; Yamada, Atsushi; Wang, Xiaogu; Kamijo, Ryutaro] Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 142, Japan; [Zhao, Baohong; Hu, Xiaoyu; Ivashkiv, Lionel B.] Hosp Special Surg, Arthritis & Tissue Degenerat Program, New York, NY 10021 USA; [Koga, Takako; Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Dept Cell Signaling, Grad Sch, Bunkyo Ku, Tokyo, Japan; [Koga, Takako; Takayanagi, Hiroshi] Int Res Ctr Mol Sci Tooth & Bone Dis, Global Ctr Excellence Program, Tokyo, Japan; [Hu, Xiaoyu; Ivashkiv, Lionel B.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Tamura, Tomohiko; Ozato, Keiko] NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; [Choi, Yongwon] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Ivashkiv, Lionel B.] Cornell Univ, Grad Program Immunol & Microbial Pathogenesis, Weill Grad Sch Med Sci, New York, NY 10021 USA	Showa University; Tokyo Medical & Dental University (TMDU); Cornell University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pennsylvania; Cornell University	Takami, M (corresponding author), Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 142, Japan.	takami@dent.showa-u.ac.jp	Hu, Xiaoyu/D-5403-2017	Hu, Xiaoyu/0000-0002-4289-6998; Takami, Masamichi/0000-0002-4506-3975	Ministry of Education, Culture, Sports, Science and Technology, Japan; Japan Society for the Promotion of Science [20390474]; US National Institutes of Health [AR053843, DE19381, DE019420, AR46713]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046713, R01AR053843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019420, R01DE019381] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We are grateful to M. Asagiri for technical assistance. We thank T. Kitamura ( University of Tokyo) for providing the retrovirus expression system. We also thank A. Mochizuki and all members of the Department of Biochemistry, School of Dentistry, Showa University for valuable discussions. This work is supported in part by the High-Tech Research Center Project for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology, Japan, 2005-2009, by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science ( 20390474 to M. T.) and by grants from the US National Institutes of Health (AR053843 and DE19381 to Y. C. and DE019420 and AR46713 to L. B. I.).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Lee SK, 2006, CURR OPIN RHEUMATOL, V18, P411, DOI 10.1097/01.bor.0000231911.42666.78; Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007-0038; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Mochizuki A, 2006, J IMMUNOL, V177, P4360, DOI 10.4049/jimmunol.177.7.4360; Nelson N, 1996, J IMMUNOL, V156, P3711; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Zhao J, 2006, J BIOL CHEM, V281, P10073, DOI 10.1074/jbc.M507788200; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200	29	220	227	2	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1066	U121		10.1038/nm.2007	http://dx.doi.org/10.1038/nm.2007			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19718038	Green Accepted			2022-12-27	WOS:000269979200028
J	Plantier, JC; Leoz, M; Dickerson, JE; De Oliveira, F; Cordonnier, F; Lemee, V; Damond, F; Robertson, DL; Simon, F				Plantier, Jean-Christophe; Leoz, Marie; Dickerson, Jonathan E.; De Oliveira, Fabienne; Cordonnier, Francois; Lemee, Veronique; Damond, Florence; Robertson, David L.; Simon, Francois			A new human immunodeficiency virus derived from gorillas	NATURE MEDICINE			English	Article							HIV-1	We have identified a new human immunodeficiency virus in a Cameroonian woman. It is closely related to gorilla simian immunodeficiency virus (SIVgor) and shows no evidence of recombination with other HIV-1 lineages. This new virus seems to be the prototype of a new HIV-1 lineage that is distinct from HIV-1 groups M, N and O. We propose to designate it HIV-1 group	[Plantier, Jean-Christophe; Leoz, Marie; De Oliveira, Fabienne; Lemee, Veronique] Univ Rouen, Fac Med Pharm, CHU Rouen,Lab Associe,Equipe Accueil EA2656, Ctr Natl Reference Virus Immunodeficience Humaine, F-76821 Mont St Aignan, France; [Dickerson, Jonathan E.; Robertson, David L.] Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England; [Cordonnier, Francois] Hop Louis Mourier, F-92701 Colombes, France; [Damond, Florence] Hop Bichat Claude Bernard, F-75877 Paris, France; [Simon, Francois] Univ Paris Diderot, Hop St Louis, Inst Natl Sante & Rech Med, U941,Fac Med, Paris, France	CHU de Rouen; Universite de Rouen Normandie; University of Manchester; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Plantier, JC (corresponding author), Univ Rouen, Fac Med Pharm, CHU Rouen,Lab Associe,Equipe Accueil EA2656, Ctr Natl Reference Virus Immunodeficience Humaine, F-76821 Mont St Aignan, France.	jean-christophe.plantier@univ-rouen.fr		PLANTIER, Jean-Christophe/0000-0001-6417-4083	Institut de Veille Sanitaire; Agence Nationale de Recherches sur le Sida et les Hepatites; Rouen University Hospital, France; Wellcome Trust studentship	Institut de Veille Sanitaire; Agence Nationale de Recherches sur le Sida et les Hepatites; Rouen University Hospital, France; Wellcome Trust studentship(Wellcome Trust)	We thank H. Ichou for field assistance and all the staff of the Rouen Virology Laboratory. Funding was provided by Institut de Veille Sanitaire, Agence Nationale de Recherches sur le Sida et les Hepatites and Rouen University Hospital, France. J.E.D. is supported by a Wellcome Trust studentship.	Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Gueudin M, 2004, JAIDS-J ACQ IMM DEF, V36, P639, DOI 10.1097/00126334-200405010-00014; Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531; Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d; Rouet F, 2007, JAIDS-J ACQ IMM DEF, V45, P380, DOI 10.1097/QAI.0b013e3180640cf5; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Takehisa J, 2009, J VIROL, V83, P1635, DOI 10.1128/JVI.02311-08; Van Heuverswyn F, 2006, NATURE, V444, P164, DOI 10.1038/444164a; Wain LV, 2007, MOL BIOL EVOL, V24, P1853, DOI 10.1093/molbev/msm110	9	323	338	0	72	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					871	872		10.1038/nm.2016	http://dx.doi.org/10.1038/nm.2016			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19648927				2022-12-27	WOS:000268770400028
J	Shibata, S; Nagase, M; Yoshida, S; Kawarazaki, W; Kurihara, H; Tanaka, H; Miyoshi, J; Takai, Y; Fujita, T				Shibata, Shigeru; Nagase, Miki; Yoshida, Shigetaka; Kawarazaki, Wakako; Kurihara, Hidetake; Tanaka, Hirotoshi; Miyoshi, Jun; Takai, Yoshimi; Fujita, Toshiro			Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease	NATURE MEDICINE			English	Article							ESTROGEN-RECEPTOR; HYPERTENSIVE-RATS; OXIDATIVE STRESS; PODOCYTE INJURY; RHO-GDI; ACTIVATION; ALDOSTERONE; KINASE; MODULATION; CELLS	Blockade of mineralocorticoid receptor has been shown to improve the clinical outcomes of proteinuric kidney diseases(1,2). However, little is known about the regulation of mineralocorticoid receptor-dependent transcriptional activity in renal disease. Here we identify a new role for Rac1, a member of the Rho family GTPases, as a potent activator of mineralocorticoid receptor signal transduction both in vitro and in vivo. Transient transfection assays in HEK 293 cells revealed that constitutively active Rac1 (CA-Rac1) enhanced mineralocorticoid receptor-dependent reporter activity, which was accompanied by increased nuclear translocation of mineralocorticoid receptor. CA-Rac1 facilitated mineralocorticoid receptor nuclear accumulation also in podocytes via p21-activated kinase phosphorylation. In mice lacking Rho GDP-dissociation inhibitor-alpha (Arhgdia(-/-) mice)(3), renal abnormalities, including heavy albuminuria and podocyte damage, were associated with increased Rac1 (but not RhoA) and mineralocorticoid receptor signaling in the kidney, without alteration in systemic aldosterone status. Pharmacological intervention with a Rac-specific small-molecule inhibitor(4,5) diminished mineralocorticoid receptor overactivity and renal damage in this model. Furthermore, albuminuria and histological changes in Arhgdia(-/-) mice were suppressed by mineralocorticoid receptor blockade, confirming the pathological role of Rac1-mineralocorticoid receptor interaction. Our results provide evidence that signaling cross-talk between Rac1 and mineralocorticoid receptor modulates mineralocorticoid receptor activity and identify Rac1 as a therapeutic target for chronic kidney disease.	[Shibata, Shigeru; Nagase, Miki; Yoshida, Shigetaka; Kawarazaki, Wakako; Fujita, Toshiro] Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; [Kurihara, Hidetake] Juntendo Univ, Sch Med, Dept Anat, Bunkyo Ku, Tokyo 1138421, Japan; [Tanaka, Hirotoshi] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; [Miyoshi, Jun] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Mol Biol, Higashinari Ku, Osaka 5378511, Japan; [Takai, Yoshimi] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Chuo Ku, Kobe, Hyogo 6500017, Japan	University of Tokyo; Juntendo University; University of Tokyo; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kobe University	Fujita, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	fujita-dis@h.u-tokyo.ac.jp		Kawarazaki, Wakako/0000-0002-1332-8537; Shibata, Shigeru/0000-0002-6868-0626; Fujita, Toshiro/0000-0001-9141-7060				Brown NJ, 2000, KIDNEY INT, V58, P1219, DOI 10.1046/j.1523-1755.2000.00277.x; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274; Chrysostomou A, 2001, NEW ENGL J MED, V345, P925, DOI 10.1056/NEJM200109203451215; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eto N, 2007, KIDNEY INT, V72, P455, DOI 10.1038/sj.ki.5002311; Funder JW, 2004, TRENDS ENDOCRIN MET, V15, P139, DOI 10.1016/j.tem.2004.03.006; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Iida T, 2000, KIDNEY INT, V58, P1450, DOI 10.1046/j.1523-1755.2000.00307.x; Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kino T, 2006, J BIOL CHEM, V281, P9118, DOI 10.1074/jbc.M509339200; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Le Menuet D, 2001, J BIOL CHEM, V276, P38911, DOI 10.1074/jbc.M103984200; Liu WF, 2007, CIRC RES, V101, pE44, DOI 10.1161/CIRCRESAHA.107.158329; Massaad C, 1999, MOL ENDOCRINOL, V13, P57, DOI 10.1210/me.13.1.57; Nagase M, 2007, HYPERTENSION, V50, P877, DOI 10.1161/HYPERTENSIONAHA.107.091058; Nagase M, 2006, HYPERTENSION, V47, P1084, DOI 10.1161/01.HYP.0000222003.28517.99; Niranjan T, 2008, NAT MED, V14, P290, DOI 10.1038/nm1731; Pitt B, 2005, J MOL CELL CARDIOL, V39, P415, DOI 10.1016/j.yjmcc.2005.05.005; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Shibata S, 2007, HYPERTENSION, V49, P355, DOI 10.1161/01.HYP.0000255636.11931.a2; Shibata S, 2006, J AM SOC NEPHROL, V17, P754, DOI 10.1681/ASN.2005050571; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAKENAKA T, 1992, CIRC RES, V71, P471, DOI 10.1161/01.RES.71.2.471; Togawa A, 1999, ONCOGENE, V18, P5373, DOI 10.1038/sj.onc.1202921; Tronche F, 2004, GENE DEV, V18, P492, DOI 10.1101/gad.284704; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Williams GH, 2004, AM J CARDIOL, V93, P990, DOI 10.1016/j.amjcard.2004.01.007; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Zhao LX, 2006, NAT NEUROSCI, V9, P234, DOI 10.1038/nn1630	34	308	329	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1370	1376		10.1038/nm.1879	http://dx.doi.org/10.1038/nm.1879			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029984				2022-12-27	WOS:000261393600023
J	Bonci, D; Coppola, V; Musumeci, M; Addario, A; Giuffrida, R; Memeo, L; D'Urso, L; Pagliuca, A; Biffoni, M; Labbaye, C; Bartucci, M; Muto, G; Peschle, C; De Maria, R				Bonci, Desiree; Coppola, Valeria; Musumeci, Maria; Addario, Antonio; Giuffrida, Raffaella; Memeo, Lorenzo; D'Urso, Leonardo; Pagliuca, Alfredo; Biffoni, Mauro; Labbaye, Catherine; Bartucci, Monica; Muto, Giovanni; Peschle, Cesare; De Maria, Ruggero			The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities	NATURE MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-LINES; MICRORNA TARGETS; IN-VIVO; GENE; 13Q14; APOPTOSIS; VECTORS; REGIONS	MicroRNAs (miRNAs) are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs. miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2. These miRNAs form a cluster at the chromosomal region 13q14, which is frequently deleted in cancer. Here, we report that the miR-15a and miR-16-1 cluster targets CCND1 (encoding cyclin D1) and WNT3A, which promotes several tumorigenic features such as survival, proliferation and invasion. In cancer cells of advanced prostate tumors, the miR-15a and miR-16 level is significantly decreased, whereas the expression of BCL2, CCND1 and WNT3A is inversely upregulated. Delivery of antagomirs specific for miR-15a and miR-16 to normal mouse prostate results in marked hyperplasia, and knockdown of miR-15a and miR-16 promotes survival, proliferation and invasiveness of untransformed prostate cells, which become tumorigenic in immunodeficient NOD-SCID mice. Conversely, reconstitution of miR-15a and miR-16-1 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts. Altogether, we propose that miR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion. These findings have therapeutic implications and may be exploited for future treatment of prostate cancer.	[Bonci, Desiree; Coppola, Valeria; Musumeci, Maria; Addario, Antonio; Pagliuca, Alfredo; Biffoni, Mauro; Labbaye, Catherine; Bartucci, Monica; Peschle, Cesare; De Maria, Ruggero] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Giuffrida, Raffaella; Memeo, Lorenzo; De Maria, Ruggero] Mediterranean Inst Oncol, Dept Expt Oncol, I-95029 Catania, Italy; [D'Urso, Leonardo; Muto, Giovanni] San Giovanni Bosco Hosp, Dept Urol, I-10154 Turin, Italy; [Peschle, Cesare] Ist Ricovero & Cura Carattere Sci, I-20138 Milan, Italy	Istituto Superiore di Sanita (ISS); Mediterranean Institute of Oncology; IRCCS Ca Granda Ospedale Maggiore Policlinico	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	demaria@iss.it	De Maria, Ruggero/S-6385-2019; Labbaye, Catherine/J-9930-2016; Bonci, Desiree/K-6488-2016; Addario, Antonio/AAC-4707-2022; Jackson, Benjamin L/C-4297-2012; pagliuca, alfredo/J-3107-2012; Biffoni, Mauro/J-8318-2016; Coppola, Valeria/K-5120-2016; Pagliuca, Alfredo/AAI-3689-2020	De Maria, Ruggero/0000-0003-2255-0583; Bonci, Desiree/0000-0002-2472-5140; Addario, Antonio/0000-0001-8527-8738; pagliuca, alfredo/0000-0002-8703-2077; Biffoni, Mauro/0000-0002-1304-9060; Coppola, Valeria/0000-0002-5745-2572; Labbaye, Catherine/0000-0003-1255-4396; Muto, Giovanni/0000-0003-3593-6450; Memeo, Lorenzo/0000-0003-4251-7203; Musumeci, Maria/0000-0001-6680-8158	Italian Health Ministry, the Italian Ministry of University and Research [RBIP06ZJ78]; Italian Association for Cancer Research	Italian Health Ministry, the Italian Ministry of University and Research(Ministry of Health, Italy); Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	We thank G. Loreto, A. Di Virgilio and M. Blasi for technical assistance and E. Palio and M. Gulisano for valuable discussion and suggestions. This work was supported by the Italian Health Ministry, the Italian Ministry of University and Research (project number RBIP06ZJ78), and the Italian Association for Cancer Research. M. Bartucci is a recipient of a fellowship from the Italian Association for Cancer Research.	Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bonci D, 2003, GENE THER, V10, P630, DOI 10.1038/sj.gt.3301936; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Navone NM, 2004, METH MOLEC MED, V88, P121; Nelson PT, 2006, RNA, V12, P187, DOI 10.1261/rna.2258506; Nupponen NN, 1998, CANCER GENET CYTOGEN, V101, P53, DOI 10.1016/S0165-4608(97)00060-5; Pienta KJ, 2005, CA-CANCER J CLIN, V55, P300, DOI 10.3322/canjclin.55.5.300; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tolcher AW, 2005, CLIN CANCER RES, V11, P3854, DOI 10.1158/1078-0432.CCR-04-2145; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	33	777	851	0	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1271	1277		10.1038/nm.1880	http://dx.doi.org/10.1038/nm.1880			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18931683				2022-12-27	WOS:000260751200047
J	Katona, I; Freund, TF				Katona, Istvan; Freund, Tamas F.			Endocannabinoid signaling as a synaptic circuit breaker in neurological disease	NATURE MEDICINE			English	Review							LONG-TERM DEPRESSION; METABOTROPIC GLUTAMATE RECEPTORS; DIACYLGLYCEROL-LIPASE-ALPHA; CB1 CANNABINOID RECEPTORS; IN-VIVO EXPOSURE; ENDOGENOUS CANNABINOIDS; MONOACYLGLYCEROL LIPASE; DOWN-REGULATION; AXON TERMINALS; SYSTEM	Cannabis sativa is one of the oldest herbal plants in the history of medicine. It was used in various therapeutic applications from pain to epilepsy, but its psychotropic effect has reduced its usage in recent medical practice. However, renewed interest has been fueled by major discoveries revealing that cannabis-derived compounds act through a signaling pathway in the human body. Here we review recent advances showing that endocannabinoid signaling is a key regulator of synaptic communication throughout the central nervous system. Its underlying molecular architecture is highly conserved in synapses from the spinal cord to the neocortex, and as a negative feed-back signal, it provides protection against excess presynaptic activity. The endocannabinoid signaling machinery operates on demand in a synapse-specific manner; therefore, its modulation offers new therapeutic opportunities for the selective control of deleterious neuronal activity in several neurological disorders.	[Katona, Istvan; Freund, Tamas F.] Hungarian Acad Sci, Inst Expt Med, H-1083 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine	Katona, I (corresponding author), Hungarian Acad Sci, Inst Expt Med, Szigonyutca 43, H-1083 Budapest, Hungary.	katona@koki.hu; freund@koki.hu	Katona, Istvan/D-9729-2011	Katona, Istvan/0000-0003-2808-3330	Howard Hughes Medical Institute; the Egeszsegugyi Tudomanyos Tanacs 561/2006; the Janos Bolyai scholarship; the US National Institutes of Health [DA009158]; European Union Contract [LSHM-CT-2004-005166]; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009158] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); the Egeszsegugyi Tudomanyos Tanacs 561/2006; the Janos Bolyai scholarship(Hungarian Academy of Sciences); the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union Contract(European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the Howard Hughes Medical Institute, the Egeszsegugyi Tudomanyos Tanacs 561/2006, the Janos Bolyai scholarship ( I. K.) and the US National Institutes of Health DA009158 and European Union Contract LSHM-CT-2004-005166. We are very grateful to N. Hajos, K. Mackie, D. Piomelli and M. Watanabe for their long-term collaborative support of our work on the endocannabinoid system and to I. Mody and N. Hajos for their comments on the manuscript. We are also indebted to B. Baksa, G. Nyiri and B. Dudok for their help with the preparation of figures.	Agarwal N, 2007, NAT NEUROSCI, V10, P870, DOI 10.1038/nn1916; Azad SC, 2004, J NEUROSCI, V24, P9953, DOI 10.1523/JNEUROSCI.2134-04.2004; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Balazsa T, 2008, NEUROCHEM INT, V52, P95, DOI 10.1016/j.neuint.2007.07.008; Best AR, 2008, J NEUROSCI, V28, P6508, DOI 10.1523/JNEUROSCI.0678-08.2008; Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brown SP, 2004, J NEUROSCI, V24, P5623, DOI 10.1523/JNEUROSCI.0918-04.2004; Chevaleyre V, 2003, NEURON, V38, P461, DOI 10.1016/S0896-6273(03)00235-6; Chevaleyre V, 2007, NEURON, V54, P801, DOI 10.1016/j.neuron.2007.05.020; Chevaleyre V, 2006, ANNU REV NEUROSCI, V29, P37, DOI 10.1146/annurev.neuro.29.051605.112834; Comelli F, 2007, BRIT J PHARMACOL, V152, P787, DOI 10.1038/sj.bjp.0707425; Degroot A, 2006, MOL PHARMACOL, V70, P1236, DOI 10.1124/mol.106.024661; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di S, 2003, J NEUROSCI, V23, P4850; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Drew GM, 2008, J NEUROSCI, V28, P808, DOI 10.1523/JNEUROSCI.4876-07.2008; Fourgeaud L, 2004, J NEUROSCI, V24, P6939, DOI 10.1523/JNEUROSCI.0671-04.2004; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Gerdeman GL, 2002, NAT NEUROSCI, V5, P446, DOI 10.1038/nn832; Gobbi G, 2005, P NATL ACAD SCI USA, V102, P18620, DOI 10.1073/pnas.0509591102; Guindon J, 2008, BRIT J PHARMACOL, V153, P319, DOI 10.1038/sj.bjp.0707531; Gulyas AI, 2004, EUR J NEUROSCI, V20, P441, DOI 10.1111/j.1460-9568.2004.03428.x; Hashimotodani Y, 2008, NEUROPHARMACOLOGY, V54, P58, DOI 10.1016/j.neuropharm.2007.06.002; Hashimotodani Y, 2007, J NEUROSCI, V27, P1211, DOI 10.1523/JNEUROSCI.4159-06.2007; Heifets BD, 2008, P NATL ACAD SCI USA, V105, P10250, DOI 10.1073/pnas.0711880105; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Hohmann AG, 2005, NATURE, V435, P1108, DOI 10.1038/nature03658; Huestis MA, 2001, ARCH GEN PSYCHIAT, V58, P322, DOI 10.1001/archpsyc.58.4.322; Jayamanne A, 2006, BRIT J PHARMACOL, V147, P281, DOI 10.1038/sj.bjp.0706510; Jo YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021; Jung KM, 2005, MOL PHARMACOL, V68, P1196, DOI 10.1124/mol.105.013961; Jung KM, 2007, MOL PHARMACOL, V72, P612, DOI 10.1124/mol.107.037796; Kammermeier PJ, 2007, P NATL ACAD SCI USA, V104, P6055, DOI 10.1073/pnas.0608991104; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Katona I, 1999, J NEUROSCI, V19, P4544; Katona I, 2006, J NEUROSCI, V26, P5628, DOI 10.1523/JNEUROSCI.0309-06.2006; Kawamura Y, 2006, J NEUROSCI, V26, P2991, DOI 10.1523/JNEUROSCI.4872-05.2006; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; Kim J, 2004, NAT NEUROSCI, V7, P697, DOI 10.1038/nn1262; Kirschstein T, 2007, J NEUROSCI, V27, P7696, DOI 10.1523/JNEUROSCI.4572-06.2007; Kreitzer AC, 2007, NATURE, V445, P643, DOI 10.1038/nature05506; Lafourcade M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000709; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Ludanyi A, 2008, J NEUROSCI, V28, P2976, DOI 10.1523/JNEUROSCI.4465-07.2008; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Lutz B, 2004, BIOCHEM PHARMACOL, V68, P1691, DOI 10.1016/j.bcp.2004.07.007; Maccarrone M, 2008, NAT NEUROSCI, V11, P152, DOI 10.1038/nn2042; Maejima T, 2001, NEURON, V31, P463, DOI 10.1016/S0896-6273(01)00375-0; Makara JK, 2005, NAT NEUROSCI, V8, P1139, DOI 10.1038/nn1521; Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mato S, 2004, NAT NEUROSCI, V7, P585, DOI 10.1038/nn1251; Mato S, 2008, NEUROPHARMACOLOGY, V54, P87, DOI 10.1016/j.neuropharm.2007.04.014; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matyas F, 2008, NEUROPHARMACOLOGY, V54, P95, DOI 10.1016/j.neuropharm.2007.05.028; McPartland JM, 2007, GENE, V397, P126, DOI 10.1016/j.gene.2007.04.017; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melis M, 2004, J NEUROSCI, V24, P10707, DOI 10.1523/JNEUROSCI.3502-04.2004; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006; Monory Krisztina, 2007, PLoS Biol, V5, pe269, DOI 10.1371/journal.pbio.0050269; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nomura DK, 2008, NAT CHEM BIOL, V4, P373, DOI 10.1038/nchembio.86; Nyiri G, 2005, NEUROSCIENCE, V136, P811, DOI 10.1016/j.neuroscience.2005.01.026; Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1; Oropeza VC, 2007, BRAIN RES, V1127, P36, DOI 10.1016/j.brainres.2006.09.110; Palomaki VAB, 2007, J NEUROCHEM, V101, P972, DOI 10.1111/j.1471-4159.2006.04403.x; Pan B, 2008, J NEUROSCI, V28, P1385, DOI 10.1523/JNEUROSCI.4033-07.2008; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Piomelli D, 2007, NAT REV NEUROSCI, V8, P743, DOI 10.1038/nrn2233; Robbe D, 2002, P NATL ACAD SCI USA, V99, P8384, DOI 10.1073/pnas.122149199; Saario SM, 2004, BIOCHEM PHARMACOL, V67, P1381, DOI 10.1016/j.bcp.2003.12.003; Sjostrom PJ, 2003, NEURON, V39, P641, DOI 10.1016/S0896-6273(03)00476-8; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Straiker A, 2005, J PHYSIOL-LONDON, V569, P501, DOI 10.1113/jphysiol.2005.091918; Straiker A, 2007, J PHYSIOL-LONDON, V578, P773, DOI 10.1113/jphysiol.2006.117499; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2006, PROG LIPID RES, V45, P405, DOI 10.1016/j.plipres.2006.03.003; Uchigashima M, 2007, J NEUROSCI, V27, P3663, DOI 10.1523/JNEUROSCI.0448-07.2007; Van Gaal L, 2008, DIABETES CARE, V31, pS229, DOI 10.2337/dc08-s258; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Wallace MJ, 2002, EUR J PHARMACOL, V452, P295, DOI 10.1016/S0014-2999(02)02331-2; Wettschureck N, 2006, MOL CELL BIOL, V26, P5888, DOI 10.1128/MCB.00397-06; Wilson RI, 2001, NEURON, V31, P453, DOI 10.1016/S0896-6273(01)00372-5; Witting A, 2006, P NATL ACAD SCI USA, V103, P6362, DOI 10.1073/pnas.0510418103; Witting A, 2004, P NATL ACAD SCI USA, V101, P3214, DOI 10.1073/pnas.0306707101; Wittmann G, 2007, J COMP NEUROL, V503, P270, DOI 10.1002/cne.21383; Yin HH, 2006, P NATL ACAD SCI USA, V103, P8251, DOI 10.1073/pnas.0510797103; Yoshida T, 2006, J NEUROSCI, V26, P4740, DOI 10.1523/JNEUROSCI.0054-06.2006; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	97	416	425	1	78	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					923	930		10.1038/nm.f.1869	http://dx.doi.org/10.1038/nm.f.1869			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18776886				2022-12-27	WOS:000258988600024
J	Wei, A; Jackson, SP				Wei, Andrew; Jackson, Shaun P.			Boosting platelet production	NATURE MEDICINE			English	Editorial Material							IMMUNE THROMBOCYTOPENIC PURPURA; THROMBOPOIETIN; ELTROMBOPAG; ITP		[Wei, Andrew; Jackson, Shaun P.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia	Monash University	Wei, A (corresponding author), Monash Univ, Australian Ctr Blood Dis, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	Shaun.Jackson@med.monash.edu.au	Jackson, Shaun P/E-9633-2011; Wei, Andrew H/F-3707-2012	Jackson, Shaun/0000-0002-4750-1991; Wei, Andrew/0000-0002-7514-3298				BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; Bussel JB, 2007, NEW ENGL J MED, V357, P2237, DOI 10.1056/NEJMoa073275; Bussel JB, 2006, NEW ENGL J MED, V355, P1672, DOI 10.1056/NEJMoa054626; Chang M, 2003, BLOOD, V102, P887, DOI 10.1182/blood-2002-05-1475; Feudjo-Tepie MA, 2008, J THROMB HAEMOST, V6, P711, DOI 10.1111/j.1538-7836.2008.02911.x; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; Kojouri K, 2004, BLOOD, V104, P2623, DOI 10.1182/blood-2004-03-1168; Kosugi S, 1996, BRIT J HAEMATOL, V93, P704, DOI 10.1046/j.1365-2141.1996.d01-1702.x; Kuter DJ, 2008, LANCET, V371, P395, DOI 10.1016/S0140-6736(08)60203-2; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; McHutchison JG, 2007, NEW ENGL J MED, V357, P2227, DOI 10.1056/NEJMoa073255; PISCIOTTA AV, 1953, BLOOD, V8, P703, DOI 10.1182/blood.V8.8.703.703	13	3	3	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2008	14	9					917	918		10.1038/nm0908-917	http://dx.doi.org/10.1038/nm0908-917			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18776883				2022-12-27	WOS:000258988600014
J	Hsiung, PL; Hardy, J; Friedland, S; Soetikno, R; Du, CB; Wu, AP; Sahbaie, P; Crawford, JM; Lowe, AW; Contag, CH; Wang, TD				Hsiung, Pei-Lin; Hardy, Jonathan; Friedland, Shai; Soetikno, Roy; Du, Christine B.; Wu, Amy P.; Sahbaie, Peyman; Crawford, James M.; Lowe, Anson W.; Contag, Christopher H.; Wang, Thomas D.			Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy	NATURE MEDICINE			English	Article							COLORECTAL-CANCER; PHAGE DISPLAY; CARCINOEMBRYONIC ANTIGEN; PEPTIDE; ENDOSCOPY; EXPRESSION; DIAGNOSIS; ANTIBODY; RECEPTOR; LIBRARY	A combination of targeted probes and new imaging technologies provides a powerful set of tools with the potential to improve the early detection of cancer. To develop a probe for detecting colon cancer, we screened phage display peptide libraries against fresh human colonic adenomas for high- affinity ligands with preferential binding to premalignant tissue. We identified a specific heptapeptide sequence, VRPMPLQ, which we synthesized, conjugated with fluorescein and tested in patients undergoing colonoscopy. We imaged topically administered peptide using a fluorescence confocal microendoscope delivered through the instrument channel of a standard colonoscope. In vivo images were acquired at 12 frames per second with 50-mu m working distance and 2.5-mu m ( transverse) and 20-mu m ( axial) resolution. The fluorescein- conjugated peptide bound more strongly to dysplastic colonocytes than to adjacent normal cells with 81% sensitivity and 82% specificity. This methodology represents a promising diagnostic imaging approach for the early detection of colorectal cancer and potentially of other epithelial malignancies.	[Friedland, Shai; Soetikno, Roy; Sahbaie, Peyman; Wang, Thomas D.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; [Hsiung, Pei-Lin; Hardy, Jonathan; Du, Christine B.; Wu, Amy P.; Contag, Christopher H.] Stanford Univ, Sch Med, Dept Pediat Radiol & Microbiol & Immunol, Stanford, CA 94305 USA; [Friedland, Shai; Soetikno, Roy; Lowe, Anson W.; Wang, Thomas D.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Crawford, James M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; State University System of Florida; University of Florida	Wang, TD (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave,Bldg 100, Palo Alto, CA 94304 USA.	thomaswa@umich.edu	Hardy, Jonathan/AAO-9306-2020	Contag, Christopher/0000-0002-1011-8278	NATIONAL CANCER INSTITUTE [U54CA136429, U54CA105296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK075603, P30DK056339, K08DK067618] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA136429-01, U54 CA136429, U54 CA105296] Funding Source: Medline; NIDDK NIH HHS [P30 DK56339, K08 DK067618-06, R03 DK075603-03, K08 DK067618, R03 DK075603, P30 DK056339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000964; American Cancer Society, 2006, CANC FACTS FIG 2007; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Carson-Walter EB, 2001, CANCER RES, V61, P6649; FOLLI S, 1992, P NATL ACAD SCI USA, V89, P7973, DOI 10.1073/pnas.89.17.7973; Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892; Garcea G, 2003, EUR J CANCER, V39, P1041, DOI 10.1016/S0959-8049(03)00027-3; Goldsmith SJ, 1997, SEMIN NUCL MED, V27, P85, DOI 10.1016/S0001-2998(97)80041-4; Haringsma J, 2001, GASTROINTEST ENDOSC, V53, P642, DOI 10.1067/mge.2001.114419; HO SB, 1993, CANCER RES, V53, P641; Keller R, 2002, ENDOSCOPY, V34, P801, DOI 10.1055/s-2002-34254; Kelly K, 2004, CANCER RES, V64, P6247, DOI 10.1158/0008-5472.CAN-04-0817; Kelly KA, 2003, NEOPLASIA, V5, P437, DOI 10.1016/S1476-5586(03)80046-5; Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050; Kudo S, 2000, WORLD J SURG, V24, P1081, DOI 10.1007/s002680010154; Machida H, 2004, ENDOSCOPY, V36, P1094, DOI 10.1055/s-2004-826040; Mayer R, 1999, DIS COLON RECTUM, V42, P343, DOI 10.1007/BF02236351; Messmann H, 1999, GASTROINTEST ENDOSC, V49, P97, DOI 10.1016/S0016-5107(99)70453-0; Moore A, 2004, CANCER RES, V64, P1821, DOI 10.1158/0008-5472.CAN-03-3230; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Su JL, 2006, CANCER RES, V66, P2553, DOI 10.1158/0008-5472.CAN-05-2645; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219; Wang TD, 1996, GASTROENTEROLOGY, V111, P1182, DOI 10.1053/gast.1996.v111.pm8898631; Wang TD, 2007, CLIN GASTROENTEROL H, V5, P1300, DOI 10.1016/j.cgh.2007.07.013; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Zangani D, 1999, DIFFERENTIATION, V64, P91, DOI 10.1046/j.1432-0436.1999.6420091.x	30	351	371	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					454	458		10.1038/nm1692	http://dx.doi.org/10.1038/nm1692			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18345013	Green Accepted			2022-12-27	WOS:000254674100034
J	Millay, DP; Sargent, MA; Osinska, H; Baines, CP; Barton, ER; Vuagniaux, G; Sweeney, HL; Robbins, J; Molkentin, JD				Millay, Douglas P.; Sargent, Michelle A.; Osinska, Hanna; Baines, Christopher P.; Barton, Elisabeth R.; Vuagniaux, Gregoire; Sweeney, H. Lee; Robbins, Jeffrey; Molkentin, Jeffery D.			Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy	NATURE MEDICINE			English	Article							PERMEABILITY TRANSITION PORE; CYCLOPHILIN-D; GLYCOPROTEIN COMPLEX; CELL-DEATH; MOUSE MODELS; MDX MICE; MUSCLE; DYSFUNCTION; APOPTOSIS; CALCIUM	Muscular dystrophies comprise a diverse group of genetic disorders that lead to muscle wasting and, in many instances, premature death(-1). Many mutations that cause muscular dystrophy compromise the support network that connects myofilament proteins within the cell to the basal lamina outside the cell, rendering the sarcolemma more permeable or leaky. Here we show that deletion of the gene encoding cyclophilin D ( Ppif) rendered mitochondria largely insensitive to the calcium overload - induced swelling associated with a defective sarcolemma, thus reducing myofiber necrosis in two distinct models of muscular dystrophy. Mice lacking delta- sarcoglycan ( Scgd(-/-) mice) showed markedly less dystrophic disease in both skeletal muscle and heart in the absence of Ppif. Moreover, the premature lethality associated with deletion of Lama2, encoding the alpha- 2 chain of laminin- 2, was rescued, as were other indices of dystrophic disease. Treatment with the cyclophilin inhibitor Debio- 025 similarly reduced mitochondrial swelling and necrotic disease manifestations in mdx mice, a model of Duchenne muscular dystrophy, and in Scgd(-/-) mice. Thus, mitochondrial- dependent necrosis represents a prominent disease mechanism in muscular dystrophy, suggesting that inhibition of cyclophilin D could provide a new pharmacologic treatment strategy for these diseases.	[Millay, Douglas P.; Sargent, Michelle A.; Osinska, Hanna; Baines, Christopher P.; Robbins, Jeffrey; Molkentin, Jeffery D.] Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Millay, Douglas P.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; [Barton, Elisabeth R.] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Vuagniaux, Gregoire] DebioPharm SA Chemin Messidor, CH-1002 Lausanne, Switzerland; [Sweeney, H. Lee] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Pennsylvania; Debiopharm; University of Pennsylvania	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Sweeney, H Lee/F-1862-2010; Tuluc, Petronel/C-2527-2011	Baines, Christopher/0000-0002-4473-3869; Molkentin, Jeffery/0000-0002-3558-6529	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [5 T32 HL07382, R01 HL062927-10A1, P01 HL069779, P50 HL077101-050004, R01 HL060562, R01 HL081104, P50 HL077101, R01 HL081104-04, T32 HL007382, R01 HL060562-11, R01 HL062927, P01 HL069779-06A10003] Funding Source: Medline; NIAMS NIH HHS [U54 AR052646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060562, P50HL077101, P01HL069779, T32HL007382, R01HL062927, R01HL081104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U54AR052646] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angelin A, 2007, P NATL ACAD SCI USA, V104, P991, DOI 10.1073/pnas.0610270104; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Flisiak R, 2006, HEPATOLOGY, V44, p609A; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Hack AA, 2000, J CELL SCI, V113, P2535; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Li BS, 1999, CIRC RES, V84, P1007, DOI 10.1161/01.RES.84.9.1007; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakayama H, 2007, J CLIN INVEST, V117, P2431, DOI 10.1172/JCI31060; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Stupka N, 2004, ACTA NEUROPATHOL, V107, P299, DOI 10.1007/s00401-003-0807-x; Stupka N, 2006, J PHYSIOL-LONDON, V575, P645, DOI 10.1113/jphysiol.2006.108472; SUZUKI K, 2001, CIRCULATION S1, V104, P308; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; Whitehead NP, 2006, CLIN EXP PHARMACOL P, V33, P657, DOI 10.1111/j.1440-1681.2006.04394.x; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	30	255	270	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					442	447		10.1038/nm1736	http://dx.doi.org/10.1038/nm1736			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18345011	Green Accepted			2022-12-27	WOS:000254674100032
J	Courtine, G; Song, BB; Roy, RR; Zhong, H; Herrmann, JE; Ao, Y; Qi, JW; Edgerton, VR; Sofroniew, MV				Courtine, Gregoire; Song, Bingbing; Roy, Roland R.; Zhong, Hui; Herrmann, Julia E.; Ao, Yan; Qi, Jingwei; Edgerton, V. Reggie; Sofroniew, Michael V.			Recovery of supraspinal control of stepping via indirect propriospinal relay connections after spinal cord injury	NATURE MEDICINE			English	Article							QUADRUPEDAL LOCOMOTION; FUNCTIONAL RECOVERY; NEURONS CONTRIBUTE; ADULT RATS; PLASTICITY; REGENERATION; PROJECTIONS; SYSTEMS; RHESUS	l Spinal cord injuries (SCIs) in humans(1,2) and experimental animals(3-6) are often associated with varying degrees of spontaneous functional recovery during the first months after injury. Such recovery is widely attributed to axons spared from injury that descend from the brain and bypass incomplete lesions, but its mechanisms are uncertain. To investigate the neural basis of spontaneous recovery, we used kinematic, physiological and anatomical analyses to evaluate mice with various combinations of spatially and temporally separated lateral hemisections with or without the excitotoxic ablation of intrinsic spinal cord neurons. We show that propriospinal relay connections that bypass one or more injury sites are able to mediate spontaneous functional recovery and supraspinal control of stepping, even when there has been essentially total and irreversible interruption of long descending supraspinal pathways in mice. Our findings show that pronounced functional recovery can occur after severe SCI without the maintenance or regeneration of direct projections from the brain past the lesion and can be mediated by the reorganization of descending and propriospinal connections(4,7-9). Targeting interventions toward augmenting the remodeling of relay connections may provide new therapeutic strategies to bypass lesions and restore function after SCI and in other conditions such as stroke and multiple sclerosis.	[Song, Bingbing; Herrmann, Julia E.; Ao, Yan; Qi, Jingwei; Sofroniew, Michael V.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; [Courtine, Gregoire; Roy, Roland R.; Zhong, Hui; Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Roy, Roland R.; Edgerton, V. Reggie; Sofroniew, Michael V.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sofroniew, MV (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA.	sofroniew@mednet.ucla.edu	courtine, gregoire/AAJ-1694-2020; Sofroniew, Michael/ABE-8857-2020	courtine, gregoire/0000-0002-5744-4142; 	NIBIB NIH HHS [R01 EB007615] Funding Source: Medline; NINDS NIH HHS [NS16333, P01 NS016333-26, P01 NS016333] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016333] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASBAUM AI, 1973, EXP NEUROL, V40, P699, DOI 10.1016/0014-4886(73)90105-2; Courtine G, 2005, BRAIN, V128, P2338, DOI 10.1093/brain/awh604; Courtine G, 2005, J NEUROPHYSIOL, V93, P3127, DOI 10.1152/jn.01073.2004; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Dobkin B, 2007, NEUROREHAB NEURAL RE, V21, P25, DOI 10.1177/1545968306295556; DUFFY MT, 1990, J COMP NEUROL, V293, P208, DOI 10.1002/cne.902930205; Edgerton VR, 2001, J PHYSIOL-LONDON, V533, P15, DOI 10.1111/j.1469-7793.2001.0015b.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fong AJ, 2005, J NEUROSCI, V25, P11738, DOI 10.1523/JNEUROSCI.1523-05.2005; Irwin N, 2006, P NATL ACAD SCI USA, V103, P18320, DOI 10.1073/pnas.0605135103; JANE JA, 1964, J NEUROSURG, V21, P167, DOI 10.3171/jns.1964.21.3.0167; Jankowska E, 2006, NEUROSCIENTIST, V12, P67, DOI 10.1177/1073858405283392; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; Leblond H, 2003, J NEUROSCI, V23, P11411; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; Nantwi KD, 1999, NEUROREHAB NEURAL RE, V13, P225, DOI 10.1177/154596839901300404; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Recktenwald MR, 1999, J NEUROPHYSIOL, V81, P2451, DOI 10.1152/jn.1999.81.5.2451; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SOFRONIEW MV, 1990, SCIENCE, V247, P338, DOI 10.1126/science.1688664; STELZNER DJ, 1991, EXP NEUROL, V114, P193, DOI 10.1016/0014-4886(91)90036-C; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Zaporozhets E, 2006, J PHYSIOL-LONDON, V572, P443, DOI 10.1113/jphysiol.2005.102376	30	505	516	3	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					69	74		10.1038/nm1682	http://dx.doi.org/10.1038/nm1682			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157143	Green Accepted			2022-12-27	WOS:000252222400024
J	Wang, R; Braughton, KR; Kretschmer, D; Bach, THL; Queck, SY; Li, M; Kennedy, AD; Dorward, DW; Klebanoff, SJ; Peschel, A; Deleo, FR; Otto, M				Wang, Rong; Braughton, Kevin R.; Kretschmer, Dorothee; Bach, Thanh-Huy L.; Queck, Shu Y.; Li, Min; Kennedy, Adam D.; Dorward, David W.; Klebanoff, Seymour J.; Peschel, Andreas; DeLeo, Frank R.; Otto, Michael			Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA	NATURE MEDICINE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; PANTON-VALENTINE LEUKOCIDIN; NECROTIZING PNEUMONIA; GENOME; EPIDERMIDIS; EVOLUTION; STRAINS; INFECTIONS; INSIGHTS; DISEASE	Methicillin-resistant Staphylococcus aureus (MRSA) remains a major human pathogen. Traditionally, MRSA infections occurred exclusively in hospitals and were limited to immunocompromised patients or individuals with predisposing risk factors. However, recently there has been an alarming epidemic caused by community-associated (CA)-MRSA strains, which can cause severe infections that can result in necrotizing fasciitis or even death in otherwise healthy adults outside of healthcare settings(1,2). In the US, CA-MRSA is now the cause of the majority of infections that result in trips to the emergency room(3). It is unclear what makes CA-MRSA strains more successful in causing human disease compared with their hospital-associated counterparts. Here we describe a class of secreted staphylococcal peptides that have a remarkable ability to recruit, activate and subsequently lyse human neutrophils, thus eliminating the main cellular defense against S. aureus infection. These peptides are produced at high concentrations by standard CA-MRSA strains and contribute significantly to the strains' ability to cause disease in animal models of infection. Our study reveals a previously uncharacterized set of S. aureus virulence factors that account at least in part for the enhanced virulence of CA-MRSA.	NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, US NIH, Hamilton, MT 59840 USA; Univ Tubingen, Cellular & Mol Microbiol Unit, Med Microbiol & Hyg Dept, D-72076 Tubingen, Germany; NIAID, Microscopy Unit, Res Technol Sect, Rocky Mt Labs,US NIH, Hamilton, MT 59840 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Eberhard Karls University of Tubingen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle	Otto, M (corresponding author), NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, US NIH, 903 S 4th St, Hamilton, MT 59840 USA.	motto@niaid.nih.gov		Otto, Michael/0000-0002-2222-4115; DeLeo, Frank/0000-0003-3150-2516	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000904, ZIAAI001079, ZIAAI000904, Z01AI001079] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adem PV, 2005, NEW ENGL J MED, V353, P1245, DOI 10.1056/NEJMoa044194; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Bae T, 2006, PLASMID, V55, P58, DOI 10.1016/j.plasmid.2005.05.005; Chambers HF, 2005, NEW ENGL J MED, V352, P1485, DOI 10.1056/NEJMe058023; CRIBIER B, 1992, DERMATOLOGY, V185, P175, DOI 10.1159/000247443; Diep BA, 2006, J INFECT DIS, V193, P1495, DOI 10.1086/503777; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; GROJEC PL, 1981, ZBL BAKT-INT J MED M, V250, P446; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; Kong KF, 2006, INT J MED MICROBIOL, V296, P133, DOI 10.1016/j.ijmm.2006.01.042; Kravitz GR, 2005, CLIN INFECT DIS, V40, P941, DOI 10.1086/428573; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Labandeira-Rey M, 2007, SCIENCE, V315, P1130, DOI 10.1126/science.1137165; Mehlin C, 1999, J EXP MED, V189, P907, DOI 10.1084/jem.189.6.907; MELLOR IR, 1988, BIOCHIM BIOPHYS ACTA, V942, P280, DOI 10.1016/0005-2736(88)90030-2; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Peschel A, 1996, FEMS MICROBIOL LETT, V137, P279; Redfield RJ, 2002, TRENDS MICROBIOL, V10, P365, DOI 10.1016/S0966-842X(02)02400-9; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; Voyich JA, 2005, J IMMUNOL, V175, P3907, DOI 10.4049/jimmunol.175.6.3907; Voyich JM, 2006, J INFECT DIS, V194, P1761, DOI 10.1086/509506; Vuong C, 2000, INFECT IMMUN, V68, P1048, DOI 10.1128/IAI.68.3.1048-1053.2000	27	757	796	6	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1510	1514		10.1038/nm1656	http://dx.doi.org/10.1038/nm1656			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	17994102				2022-12-27	WOS:000251445400027
J	Harmon, GS; Dumlao, DS; Ng, DT; Barrett, KE; Dennis, EA; Dong, H; Glass, CK				Harmon, Gregory S.; Dumlao, Darren S.; Ng, Damian T.; Barrett, Kim E.; Dennis, Edward A.; Dong, Hui; Glass, Christopher K.			Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice	NATURE MEDICINE			English	Article							ACTIVATED-RECEPTOR-GAMMA; INFLAMMATORY-BOWEL-DISEASE; CYSTIC-FIBROSIS; PROSTAGLANDIN E-2; EPITHELIAL-CELLS; BICARBONATE SECRETION; LIGAND ROSIGLITAZONE; FATTY-ACIDS; GENE; PROTEIN	Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (encoded by Cftr) that impair its role as an apical chloride channel that supports bicarbonate transport(1). Individuals with cystic fibrosis show retained, thickened mucus that plugs airways and obstructs luminal organs(2) as well as numerous other abnormalities that include inflammation of affected organs(1), alterations in lipid metabolism(3) and insulin resistance(4). Here we show that colonic epithelial cells and whole lung tissue from Cftr-deficient mice show a defect in peroxisome proliferator activated receptor-gamma (PPAR-gamma, encoded by Pparg) function that contributes to a pathological program of gene expression. Lipidomic analysis of colonic epithelial cells suggests that this defect results in part from reduced amounts of the endogenous PPAR-gamma ligand 15-keto-prostaglandin E(2) (15-keto-PGE(2)). Treatment of Cftr-deficient mice with the synthetic PPAR-gamma ligand rosiglitazone partially normalizes the altered gene expression pattern associated with Cftr deficiency and reduces disease severity. Rosiglitazone has no effect on chloride secretion in the colon, but it increases expression of the genes encoding carbonic anhydrases 4 and 2 (Car4 and Car2), increases bicarbonate secretion and reduces mucus retention. These studies reveal a reversible defect in PPAR-gamma signaling in Cftr-deficient cells that can be pharmacologically corrected to	[Harmon, Gregory S.; Barrett, Kim E.; Dong, Hui; Glass, Christopher K.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Dumlao, Darren S.; Dennis, Edward A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Dumlao, Darren S.; Dennis, Edward A.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Ng, Damian T.; Glass, Christopher K.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Harmon, GS (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	gharmon@ucsd.edu; ckg@ucsd.edu	Barrett, Kim Elaine/AAE-7762-2019; Dennis, Edward A./M-5554-2019; Glass, Christopher/AAI-3933-2021; Barrett, Kim/AAE-2794-2022	Barrett, Kim Elaine/0000-0002-6704-998X; Dennis, Edward A./0000-0003-3738-3140; Glass, Christopher/0000-0003-4344-3592; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491, P01DK074868, R01DK091183, T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK007202, P01 DK074868-029001, P01 DK074868-01A1, P01 DK074868, P30 DK063491, P01DK074868, DK007202, DK063491, P30 DK063491-019003, P01 DK074868-030001, R01 DK091183] Funding Source: Medline; NIGMS NIH HHS [GM 069338-03, U54 GM069338-010002, U54 GM069338] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2006, GUT, V55, P1104, DOI 10.1136/gut.2005.081745; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Ashburner M, 2001, GENOME RES, V11, P1425; Blaho VA, 2009, J BIOL CHEM, V284, P21599, DOI 10.1074/jbc.M109.003822; Chou WL, 2007, J BIOL CHEM, V282, P18162, DOI 10.1074/jbc.M702289200; Clarke LL, 1996, LAB ANIM SCI, V46, P612; ECKMAN EA, 1995, AM J PHYSIOL-LUNG C, V269, pL625, DOI 10.1152/ajplung.1995.269.5.L625; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Garcia MAS, 2009, J CLIN INVEST, V119, P2613, DOI 10.1172/JCI38662; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; Hardin DS, 1997, J PEDIATR-US, V130, P948, DOI 10.1016/S0022-3476(97)70282-8; Konstan MW, 2003, J PHARMACOL EXP THER, V306, P1086, DOI 10.1124/jpet.103.052449; Leppilampi M, 2005, P NATL ACAD SCI USA, V102, P15247, DOI 10.1073/pnas.0508007102; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Lucidi V, 2008, FREE RADICAL BIO MED, V45, P913, DOI 10.1016/j.freeradbiomed.2008.06.026; Lytle C, 2005, INFLAMM BOWEL DIS, V11, P231, DOI 10.1097/01.MIB.0000160805.46235.eb; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; McMurtrie HL, 2004, J ENZYM INHIB MED CH, V19, P231, DOI 10.1080/14756360410001704443; Nichols DP, 2008, CLIN REV ALLERG IMMU, V35, P135, DOI 10.1007/s12016-008-8081-2; O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Ollero M, 2004, J CELL PHYSIOL, V200, P235, DOI 10.1002/jcp.20020; Perez A, 2008, AM J PHYSIOL-LUNG C, V295, pL303, DOI 10.1152/ajplung.90276.2008; Quehenberger O, 2008, PROSTAG LEUKOTR ESS, V79, P123, DOI 10.1016/j.plefa.2008.09.021; Quinton PM, 2008, LANCET, V372, P415, DOI 10.1016/S0140-6736(08)61162-9; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Rogler G, 1998, LAB INVEST, V78, P889; Sellers ZM, 2005, AM J PHYSIOL-GASTR L, V288, pG654, DOI 10.1152/ajpgi.00386.2004; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Tachibana Keisuke, 2005, Nucl Recept, V3, P3, DOI 10.1186/1478-1336-3-3; Wigren J, 2003, J ENDOCRINOL, V177, P207, DOI 10.1677/joe.0.1770207; Yu ST, 2001, J BIOL CHEM, V276, P42485, DOI 10.1074/jbc.M106480200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zarini S, 2006, J BIOL CHEM, V281, P10134, DOI 10.1074/jbc.M510783200; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; ZUELZER WW, 1949, PEDIATRICS, V4, P53	40	77	79	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					313	U110		10.1038/nm.2101	http://dx.doi.org/10.1038/nm.2101			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20154695	Green Accepted			2022-12-27	WOS:000275289500037
J	Gabriel, R; Eckenberg, R; Paruzynski, A; Bartholomae, CC; Nowrouzi, A; Arens, A; Howe, SJ; Recchia, A; Cattoglio, C; Wang, W; Faber, K; Schwarzwaelder, K; Kirsten, R; Deichmann, A; Ball, CR; Balaggan, KS; Yanez-Munoz, RJ; Ali, RR; Gaspar, HB; Biasco, L; Aiuti, A; Cesana, D; Montini, E; Naldini, L; Cohen-Haguenauer, O; Mavilio, F; Thrasher, AJ; Glimm, H; von Kalle, C; Saurin, W; Schmidt, M				Gabriel, Richard; Eckenberg, Ralph; Paruzynski, Anna; Bartholomae, Cynthia C.; Nowrouzi, Ali; Arens, Anne; Howe, Steven J.; Recchia, Alessandra; Cattoglio, Claudia; Wang, Wei; Faber, Katrin; Schwarzwaelder, Kerstin; Kirsten, Romy; Deichmann, Annette; Ball, Claudia R.; Balaggan, Kamaljit S.; Yanez-Munoz, Rafael J.; Ali, Robin R.; Gaspar, H. Bobby; Biasco, Luca; Aiuti, Alessandro; Cesana, Daniela; Montini, Eugenio; Naldini, Luigi; Cohen-Haguenauer, Odile; Mavilio, Fulvio; Thrasher, Adrian J.; Glimm, Hanno; von Kalle, Christof; Saurin, William; Schmidt, Manfred			Comprehensive genomic access to vector integration in clinical gene therapy	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; SCID-X1; GENOTOXICITY	Retroviral vectors have induced subtle clonal skewing in many gene therapy patients and severe clonal proliferation and leukemia in some of them, emphasizing the need for comprehensive integration site analyses to assess the biosafety and genomic pharmacokinetics of vectors and clonal fate of gene-modified cells in vivo. Integration site analyses such as linear amplification-mediated PCR (LAM-PCR) require a restriction digest generating unevenly small fragments of the genome. Here we show that each restriction motif allows for identification of only a fraction of all genomic integrants, hampering the understanding and prediction of biological consequences after vector insertion. We developed a model to define genomic access to the viral integration site that provides optimal restriction motif combinations and minimizes the percentage of nonaccessible insertion loci. We introduce a new nonrestrictive LAM-PCR approach that has superior capabilities for comprehensive unbiased integration site retrieval in preclinical and clinical samples independent of restriction motifs and amplification inefficiency.	[Gabriel, Richard; Paruzynski, Anna; Bartholomae, Cynthia C.; Nowrouzi, Ali; Arens, Anne; Wang, Wei; Faber, Katrin; Schwarzwaelder, Kerstin; Kirsten, Romy; Deichmann, Annette; Ball, Claudia R.; Glimm, Hanno; von Kalle, Christof; Schmidt, Manfred] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany; [Arens, Anne] German Canc Res Ctr, Genom & Prote Core Facil, D-6900 Heidelberg, Germany; [Eckenberg, Ralph; Saurin, William] Genomining, Montrouge, France; [Howe, Steven J.; Ali, Robin R.] UCL, Inst Child Hlth, Mol Immunol Unit, London, England; [Recchia, Alessandra; Mavilio, Fulvio] Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; [Cattoglio, Claudia; Mavilio, Fulvio] Inst Sci H San Raffaele, Canc Immunotherapy & Gene Therapy Program, Milan, Italy; [Balaggan, Kamaljit S.; Ali, Robin R.] UCL, Inst Ophthalmol, London, England; [Yanez-Munoz, Rafael J.] Royal Holloway Univ London, Sch Biol Sci, Egham, Surrey, England; [Gaspar, H. Bobby; Thrasher, Adrian J.] Great Ormond St Hosp NHS Trust, Dept Clin Immunol, London, England; [Biasco, Luca; Aiuti, Alessandro; Cesana, Daniela; Montini, Eugenio; Naldini, Luigi] San Raffaele Telethon Inst Gene Therapy, Milan, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; [Cohen-Haguenauer, Odile] Ecole Normale Super, Lab Biotechnol & Pharmacol Genet Appl, Cachan, France; [Cohen-Haguenauer, Odile] Hop St Louis, Dept Clin Oncol, Paris, France; [von Kalle, Christof] Cincinnati Childrens Res Fdn, Mol & Gene Therapy Program, Cincinnati, OH USA	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of London; University College London; Universita di Modena e Reggio Emilia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London; University of London; Royal Holloway University London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Rome Tor Vergata; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	von Kalle, C (corresponding author), Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany.	christof.kalle@nct-heidelberg.de	Howe, Steven J/C-4801-2008; Montini, Eugenio/L-1152-2016; AIUTI, ALESSANDRO/K-3918-2016; Recchia, Alessandra/B-7954-2015; Naldini, Luigi/E-9083-2012; MAVILIO, Fulvio/J-6125-2013	Howe, Steven J/0000-0003-2940-2874; Montini, Eugenio/0000-0003-1771-6067; AIUTI, ALESSANDRO/0000-0002-5398-1717; Recchia, Alessandra/0000-0002-3467-1094; Cesana, Daniela/0000-0001-6366-4224; Ali, Robin/0000-0003-3126-6517; Yanez-Munoz, Rafael J/0000-0001-7113-1938; Ball, Claudia/0000-0002-1749-3791; Mavilio, Fulvio/0000-0003-0459-4320; NALDINI, Luigi/0000-0002-7835-527X; Thrasher, Adrian/0000-0002-6097-6115	Deutsche Forschungsgemeinschaft [SPP1230]; Bundesministerium fur Bildung und Forschung (iGene); European Commission; Helmholtz Association; Great Ormond Street Hospital Childrens Charity [V1223] Funding Source: researchfish; Fondazione Telethon Funding Source: Custom	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (iGene)(Federal Ministry of Education & Research (BMBF)); European Commission(European CommissionEuropean Commission Joint Research Centre); Helmholtz Association(Helmholtz Association); Great Ormond Street Hospital Childrens Charity; Fondazione Telethon(Fondazione Telethon)	We thank I. Kutschera, N. Krenzer, C. Lulay, S. Braun and D. Glagow for technical assistance and O. Danos for fruitful discussions about the model. Funding was provided by the Deutsche Forschungsgemeinschaft (SPP1230, grant of the Tumor Center Heidelberg/Mannheim), by the Bundesministerium fur Bildung und Forschung (iGene), by the VIth + VIIth Framework Programs of the European Commission (Concerted Safety & Efficiency Evaluation of Retroviral Transgenesis in Gene Therapy of Inherited Diseases (CONSERT), European Network for the Advancement of Clinical Gene Transfer and Therapy (CLINIGENE) and Persisting Transgenesis (PERSIST)) and by the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2007, J CLIN INVEST, V117, P2233, DOI 10.1172/JCI31666; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bohne J, 2008, CURR OPIN MOL THER, V10, P214; Bovee D, 2008, NAT GENET, V40, P96, DOI 10.1038/ng.2007.34; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deichmann A, 2007, J CLIN INVEST, V117, P2225, DOI 10.1172/JCI31659; Flotte TR, 2007, J CELL PHYSIOL, V213, P301, DOI 10.1002/jcp.21173; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Harkey MA, 2007, STEM CELLS DEV, V16, P381, DOI 10.1089/scd.2007.0015; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Manfred S, 2007, NAT METHODS, V4, P1051, DOI 10.1038/nmeth1103; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood-2005-08-024976; Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schwarzwaelder K, 2007, J CLIN INVEST, V117, P2241, DOI 10.1172/JCI31661; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Wang GP, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn125	28	136	142	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1431	U13		10.1038/nm.2057	http://dx.doi.org/10.1038/nm.2057			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966782				2022-12-27	WOS:000272407800025
J	Druker, BJ				Druker, Brian J.			Perspectives on the development of imatinib and the future of cancer research	NATURE MEDICINE			English	Article							CLINICAL-TRIALS; LUNG-CANCER; MUTATIONS; MESYLATE; TUMORS		[Druker, Brian J.] Howard Hughes Med Inst, Portland, OR USA; [Druker, Brian J.] Leukemia Res, Portland, OR USA; [Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA	Howard Hughes Medical Institute; Oregon Health & Science University	Druker, BJ (corresponding author), Howard Hughes Med Inst, Portland, OR USA.	drukerb@ohsu.edu		Druker, Brian/0000-0001-8331-8206	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dilts DM, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.6543; Dilts DM, 2006, J CLIN ONCOL, V24, P4553, DOI 10.1200/JCO.2006.06.7819; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Flaherty K, 2009, J CLIN ONCOL, V27; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kwak EL, 2009, J CLIN ONCOL, V27; LIVINGSTON DM, 1987, CELL, V49, P577, DOI 10.1016/0092-8674(87)90529-0; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; O'Brien SG, 2008, BLOOD, V112, P76; O'Shaughnessy J, 2009, J CLIN ONCOL, V27; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Ramsey S, 2008, ONCOLOGIST, V13, P925, DOI 10.1634/theoncologist.2008-0133; TURA S, 1994, NEW ENGL J MED, V330, P820	23	80	82	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1149	1152		10.1038/nm1009-1149	http://dx.doi.org/10.1038/nm1009-1149			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812576				2022-12-27	WOS:000270596400025
J	Chomont, N; El-Far, M; Ancuta, P; Trautmann, L; Procopio, FA; Yassine-Diab, B; Boucher, G; Boulassel, MR; Ghattas, G; Brenchley, JM; Schacker, TW; Hill, BJ; Douek, DC; Routy, JP; Haddad, EK; Sekaly, RP				Chomont, Nicolas; El-Far, Mohamed; Ancuta, Petronela; Trautmann, Lydie; Procopio, Francesco A.; Yassine-Diab, Bader; Boucher, Genevieve; Boulassel, Mohamed-Rachid; Ghattas, Georges; Brenchley, Jason M.; Schacker, Timothy W.; Hill, Brenna J.; Douek, Daniel C.; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre			HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; EFFECTOR MEMORY CD4(+); LATENT RESERVOIR; INFECTED INDIVIDUALS; PROGRAMMED DEATH-1; IMMUNE ACTIVATION; GENE-EXPRESSION; VIRAL LOAD; IN-VIVO	HIV persists in a reservoir of latently infected CD4(+) T cells in individuals treated with highly active antiretroviral therapy (HAART). Here we identify central memory (T-CM) and transitional memory (T-TM) CD4(+) T cells as the major cellular reservoirs for HIV and find that viral persistence is ensured by two different mechanisms. HIV primarily persists in T-CM cells in subjects showing reconstitution of the CD4(+) compartment upon HAART. This reservoir is maintained through T cell survival and low-level antigen-driven proliferation and is slowly depleted with time. In contrast, proviral DNA is preferentially detected in T-TM cells from aviremic individuals with low CD4(+) counts and higher amounts of interleukin-7-mediated homeostatic proliferation, a mechanism that ensures the persistence of these cells. Our results suggest that viral eradication might be achieved through the combined use of strategic interventions targeting viral replication and, as in cancer, drugs that interfere with the self renewal and persistence of proliferating memory T cells. (C) 2009 Nature America, Inc. All rights reserved.	[Chomont, Nicolas; El-Far, Mohamed; Trautmann, Lydie; Procopio, Francesco A.; Yassine-Diab, Bader; Boucher, Genevieve; Haddad, Elias K.; Sekaly, Rafick-Pierre] CR CHUM St Luc, Immunol Lab, Montreal, PQ, Canada; [Chomont, Nicolas; El-Far, Mohamed; Trautmann, Lydie; Procopio, Francesco A.; Yassine-Diab, Bader; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, Dept Microbiol & Immunol, Immunol Lab, Quebec City, PQ, Canada; [Chomont, Nicolas; El-Far, Mohamed; Ancuta, Petronela; Trautmann, Lydie; Procopio, Francesco A.; Yassine-Diab, Bader; Haddad, Elias K.; Sekaly, Rafick-Pierre] Univ Montreal, CR CHUM, U743, Inst Natl Sante & Rech Med, Montreal, PQ, Canada; [Boulassel, Mohamed-Rachid; Routy, Jean-Pierre] McGill Univ, MUHC, Immunodeficiency Serv, Montreal, PQ, Canada; [Boulassel, Mohamed-Rachid; Routy, Jean-Pierre] McGill Univ, MUHC, Div Hematol, Montreal, PQ, Canada; [Ghattas, Georges] MUHC, Dept Gastroenterol, Montreal, PQ, Canada; [Brenchley, Jason M.] NIAID, Mol Microbiol Lab, US Natl Inst Hlth, Bethesda, MD USA; [Schacker, Timothy W.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Hill, Brenna J.; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Sekaly, Rafick-Pierre] Oregon Hlth & Sci Univ, Dept Microbiol & Immunol, Portland, OR 97201 USA	Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McGill University; Oregon Health & Science University	Sekaly, RP (corresponding author), CR CHUM St Luc, Immunol Lab, Montreal, PQ, Canada.	rafick-pierre.sekaly@umontreal.ca	Chomont, Nicolas/ABG-2545-2020; Procopio, Francesco/ABD-8065-2021; Brenchley, Jason/AAC-5085-2019	Chomont, Nicolas/0000-0001-9747-5018; Trautmann, Lydie/0000-0002-3012-0009; Brenchley, Jason/0000-0001-8357-2984; El-Far, Mohamed/0000-0002-6458-4207; Ancuta, Petronela/0000-0003-1922-5640; Boucher, Genevieve/0000-0001-6389-9007	Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005033, ZIAAI005034, ZIAAI001029] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anthony KB, 2003, JAIDS-J ACQ IMM DEF, V33, P125, DOI 10.1097/00126334-200306010-00002; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; Catalfamo M, 2008, P NATL ACAD SCI USA, V105, P19851, DOI 10.1073/pnas.0810032105; Chomont N, 2007, AIDS, V21, P153, DOI 10.1097/QAD.0b013e328011f94b; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 2003, P NATL ACAD SCI USA, V100, P1908, DOI 10.1073/pnas.0437640100; Chun TW, 2002, J INFECT DIS, V185, P1672, DOI 10.1086/340521; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Combadiere B, 2004, J EXP MED, V199, P1585, DOI 10.1084/jem.20032083; Combadiere B, 2000, EUR J IMMUNOL, V30, P3598, DOI 10.1002/1521-4141(200012)30:12<3598::AID-IMMU3598>3.0.CO;2-E; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983; Geginat J, 2003, PATHOL BIOL, V51, P64, DOI 10.1016/S0369-8114(03)00098-1; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hermankova M, 2003, J VIROL, V77, P7383, DOI 10.1128/JVI.77.13.7383-7392.2003; Hokey DA, 2008, EUR J IMMUNOL, V38, P1435, DOI 10.1002/eji.200737857; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Kim HJ, 2006, PLOS COMPUT BIOL, V2, P1232, DOI 10.1371/journal.pcbi.0020135; Kinter AL, 2008, J IMMUNOL, V181, P6738, DOI 10.4049/jimmunol.181.10.6738; Koelsch KK, 2008, J INFECT DIS, V197, P411, DOI 10.1086/525283; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Lin SJ, 2007, J EXP MED, V204, P2321, DOI 10.1084/jem.20062150; Llano A, 2001, J VIROL, V75, P10319, DOI 10.1128/JVI.75.21.10319-10325.2001; Mens H, 2007, AIDS RES HUM RETROV, V23, P107, DOI 10.1089/aid.2006.0089; Mercier F, 2008, CLIN EXP IMMUNOL, V152, P72, DOI 10.1111/j.1365-2249.2008.03610.x; Napolitano LA, 2001, NAT MED, V7, P73, DOI 10.1038/83381; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004; Persaud D, 2007, AIDS RES HUM RETROV, V23, P381, DOI 10.1089/aid.2006.0175; Plana M, 2000, AIDS, V14, P1921, DOI 10.1097/00002030-200009080-00007; Poulin JF, 2003, BLOOD, V102, P4600, DOI 10.1182/blood-2003-05-1428; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Riou C, 2007, J EXP MED, V204, P79, DOI 10.1084/jem.20061681; Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sedaghat AR, 2007, PLOS PATHOG, V3, P1165, DOI 10.1371/journal.ppat.0030122; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Siddique MA, 2006, J INFECT DIS, V194, P661, DOI 10.1086/505913; Sieg SF, 2008, J LEUKOCYTE BIOL, V83, P1382, DOI 10.1189/jlb.0907643; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Skrabal K, 2007, J CLIN MICROBIOL, V45, P279, DOI 10.1128/JCM.01118-06; Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400; Strain MC, 2005, J INFECT DIS, V191, P1410, DOI 10.1086/428777; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; van Grevenynghe J, 2008, NAT MED, V14, P266, DOI 10.1038/nm1728; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Younes SA, 2007, J IMMUNOL, V178, P788, DOI 10.4049/jimmunol.178.2.788; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	56	1216	1247	0	86	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					893	U92		10.1038/nm.1972	http://dx.doi.org/10.1038/nm.1972			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19543283	Green Accepted			2022-12-27	WOS:000268770400033
J	Kirchner, H; Gutierrez, JA; Solenberg, PJ; Pfluger, PT; Czyzyk, TA; Willency, JA; Schurmann, A; Joost, HG; Jandacek, RJ; Hale, JE; Heiman, ML; Tschop, MH				Kirchner, Henriette; Gutierrez, Jesus A.; Solenberg, Patricia J.; Pfluger, Paul T.; Czyzyk, Traci A.; Willency, Jill A.; Schuermann, Annette; Joost, Hans-Georg; Jandacek, Ronald J.; Hale, John E.; Heiman, Mark L.; Tschoep, Matthias H.			GOAT links dietary lipids with the endocrine control of energy balance	NATURE MEDICINE			English	Article							CHAIN FATTY-ACIDS; FOOD-INTAKE; GHRELIN; HORMONE; IDENTIFICATION; METABOLISM; SECRETION; PEPTIDE	Central nervous system nutrient sensing and afferent endocrine signaling have been established as parallel systems communicating metabolic status and energy availability in vertebrates. The only afferent endocrine signal known to require modification with a fatty acid side chain is the orexigenic hormone ghrelin. We find that the ghrelin O-acyl transferase (GOAT), which is essential for ghrelin acylation, is regulated by nutrient availability, depends on specific dietary lipids as acylation substrates and links ingested lipids to energy expenditure and body fat mass. These data implicate the ghrelin-GOAT system as a signaling pathway that alerts the central nervous system to the presence of dietary calories, rather than to their absence as is commonly accepted.	[Kirchner, Henriette; Pfluger, Paul T.; Jandacek, Ronald J.; Tschoep, Matthias H.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA; [Kirchner, Henriette; Pfluger, Paul T.; Jandacek, Ronald J.; Tschoep, Matthias H.] Univ Cincinnati, Coll Med, Dept Med, Obes Res Ctr, Cincinnati, OH USA; [Kirchner, Henriette; Pfluger, Paul T.; Jandacek, Ronald J.; Tschoep, Matthias H.] Univ Cincinnati, Coll Med, Genome Res Inst, Cincinnati, OH USA; [Kirchner, Henriette; Schuermann, Annette; Joost, Hans-Georg; Tschoep, Matthias H.] German Inst Human Nutr, Dept Pharmacol, Potsdam, Germany; [Gutierrez, Jesus A.; Solenberg, Patricia J.; Czyzyk, Traci A.; Willency, Jill A.; Hale, John E.; Heiman, Mark L.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Eli Lilly	Tschop, MH (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA.	matthias.tschoep@uc.edu	Kirchner, Henriette/D-6699-2011; Pfluger, Paul T/A-3770-2019; Joost, Hans-Georg/J-4462-2013; Pfluger, Paul/B-4889-2010; Tschoep, Matthias H/I-5443-2014	Pfluger, Paul T/0000-0002-8118-7588; Joost, Hans-Georg/0000-0002-5860-606X; Tschoep, Matthias/0000-0002-4744-371X; Schurmann, Annette/0000-0002-4113-4377; Czyzyk, Traci/0000-0002-3888-8338	Leibniz Graduate College; US National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK069987]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077975, R01DK069987, P01DK056863] Funding Source: NIH RePORTER	Leibniz Graduate College; US National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank J.E. Baker, B. Berger and J. Holland for their outstanding technical support. This manuscript was supported by the Leibniz Graduate College ( H. K.) and by the US National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK069987 ( to M. H. T.).	Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; DOLE VP, 1961, J LIPID RES, V2, P90; Drazen DL, 2006, ENDOCRINOLOGY, V147, P23, DOI 10.1210/en.2005-0973; Gauna C, 2007, AM J PHYSIOL-ENDOC M, V293, pE697, DOI 10.1152/ajpendo.00219.2007; Gillum MP, 2008, CELL, V135, P813, DOI 10.1016/j.cell.2008.10.043; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Kamegai J, 2001, DIABETES, V50, P2438, DOI 10.2337/diabetes.50.11.2438; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Liu JH, 2008, J CLIN ENDOCR METAB, V93, P1980, DOI 10.1210/jc.2007-2235; Lopez M, 2008, CELL METAB, V7, P389, DOI 10.1016/j.cmet.2008.03.006; Nishi Y, 2005, ENDOCRINOLOGY, V146, P2255, DOI 10.1210/en.2004-0695; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007; PRIOR IA, 1981, AM J CLIN NUTR, V34, P1552, DOI 10.1093/ajcn/34.8.1552; Schwartz GJ, 2008, CELL METAB, V8, P281, DOI 10.1016/j.cmet.2008.08.005; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tschop M, 2001, J ENDOCRINOL INVEST, V24, pRC19, DOI 10.1007/BF03351037; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; ZURIER RB, 1966, NEW ENGL J MED, V274, P490, DOI 10.1056/NEJM196603032740904	20	301	312	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					741	745		10.1038/nm.1997	http://dx.doi.org/10.1038/nm.1997			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19503064	Green Accepted			2022-12-27	WOS:000267806900025
J	Farmer, P; Bonnefoi, H; Anderle, P; Cameron, D; Wirapati, P; Becette, V; Andree, S; Piccart, M; Campone, M; Brain, E; MacGrogan, G; Petit, T; Jassem, J; Bibeau, F; Blot, E; Bogaerts, J; Aguet, M; Bergh, J; Iggo, R; Delorenzi, M				Farmer, Pierre; Bonnefoi, Herve; Anderle, Pascale; Cameron, David; Wirapati, Pratyakasha; Becette, Veronique; Andre, Sylvie; Piccart, Martine; Campone, Mario; Brain, Etienne; MacGrogan, Gaetan; Petit, Thierry; Jassem, Jacek; Bibeau, Frederic; Blot, Emmanuel; Bogaerts, Jan; Aguet, Michel; Bergh, Jonas; Iggo, Richard; Delorenzi, Mauro			A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer	NATURE MEDICINE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; DRUG-RESISTANCE; PREOPERATIVE CHEMOTHERAPY; EXPRESSION SIGNATURE; MOLECULAR PORTRAITS; TUMORS; CELLS; CARCINOMAS; DOCETAXEL; PROGNOSIS	To better understand the relationship between tumor-host interactions and the efficacy of chemotherapy, we have developed an analytical approach to quantify several biological processes observed in gene expression data sets. We tested the approach on tumor biopsies from individuals with estrogen receptor-negative breast cancer treated with chemotherapy. We report that increased stromal gene expression predicts resistance to preoperative chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in subjects in the EORTC 10994/BIG 00-01 trial. The predictive value of the stromal signature was successfully validated in two independent cohorts of subjects who received chemotherapy but not in an untreated control group, indicating that the signature is predictive rather than prognostic. The genes in the signature are expressed in reactive stroma, according to reanalysis of data from microdissected breast tumor samples. These findings identify a previously undescribed resistance mechanism to FEC treatment and suggest that antistromal agents may offer new ways to overcome resistance to chemotherapy.	[Farmer, Pierre; Anderle, Pascale; Andre, Sylvie; Aguet, Michel; Iggo, Richard; Delorenzi, Mauro] Swiss Natl Ctr Competence Res Mol Oncol, Swiss Inst Expt Canc Res, Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland; [Farmer, Pierre; Wirapati, Pratyakasha; Delorenzi, Mauro] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland; [Bonnefoi, Herve; MacGrogan, Gaetan; Iggo, Richard] Inst Bergonie, F-33076 Bordeaux, France; [Bonnefoi, Herve; MacGrogan, Gaetan; Iggo, Richard] Univ Bordeaux 2, Inst Natl Sante, F-33076 Bordeaux, France; [Bonnefoi, Herve; MacGrogan, Gaetan; Iggo, Richard] Univ Bordeaux 2, Rech Med Unit, U916, F-33076 Bordeaux, France; [Bonnefoi, Herve] Hop Univ Geneve, CH-1211 Geneva, Switzerland; [Bonnefoi, Herve] Swiss Grp Clin Canc Res, CH-3008 Bern, Switzerland; [Bonnefoi, Herve; Bogaerts, Jan] EORTC, B-1200 Brussels, Belgium; [Anderle, Pascale] Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland; [Cameron, David] Western Gen Hosp, Univ Dept Oncol, Anglocelt Cooperat Oncol Grp, Edinburgh EH4 2XU, Midlothian, Scotland; [Becette, Veronique; Brain, Etienne] Ctr Rene Huguenin, F-92210 St Cloud, France; [Piccart, Martine] Inst Jules Bordet, B-1000 Brussels, Belgium; [Campone, Mario] Ctr Cancerol, Inst Canc Nantes Atlant, Ctr Lutte Canc Rene Gauducheau, Inst Natl Sante & Rech Med 892, F-44805 Nantes, Saint Herbalin, France; [Petit, Thierry] Ctr Paul Strauss, F-67065 Strasbourg, France; [Jassem, Jacek] Med Univ, PL-80211 Gdansk, Poland; [Bibeau, Frederic] Ctr Val Aurelle Paul Lamarque, F-34298 Montpellier 5, France; [Blot, Emmanuel] Ctr Henri Becquerel, F-76038 Rouen, France; [Bergh, Jonas] Karolinska Inst, Swedish Breast Canc Grp, S-17176 Stockholm, Sweden; [Bergh, Jonas] Karolinska Univ Hosp, S-17176 Stockholm, Sweden; [Iggo, Richard] Univ St Andrews, Bute Med Sch, St Andrews KY16 9TS, Fife, Scotland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics; UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of Geneva; Swiss Group for Clinical Cancer Research (SAKK); European Organisation for Research & Treatment of Cancer; Institute of Oncology Research (IOR); University of Edinburgh; Rene Huguenin Hospital; Institut Jules Bordet; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Paul Strauss; Fahrenheit Universities; Medical University Gdansk; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Centre Henri Becquerel; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of St Andrews	Delorenzi, M (corresponding author), Swiss Natl Ctr Competence Res Mol Oncol, Swiss Inst Expt Canc Res, Ecole Polytech Fed Lausanne, Sch Life Sci, 155 Chemin Boveresses,1066 Epalinges S, Lausanne, Switzerland.	mauro.delorenzi@isb-sib.ch	Iggo, Richard/G-3546-2014; Cameron, David A/C-7781-2013	Cameron, David A/0000-0002-2717-7979; MacGrogan, Gaetan/0000-0002-3483-9758; Bergh, Jonas/0000-0001-5526-1847	EORTC [10994/BIG01]; Fondation Medic; Fondation Widmer,; Oncosuisse; Swiss National Science Foundation and Swiss National Center for Competence in Research ( NCCR) Molecular Oncology; EORTC Translational Research Fund; Swedish Cancer Society; King Gustav the Fifth Jubilee Fund; Swedish Research Council	EORTC; Fondation Medic; Fondation Widmer,; Oncosuisse; Swiss National Science Foundation and Swiss National Center for Competence in Research ( NCCR) Molecular Oncology(Swiss National Science Foundation (SNSF)); EORTC Translational Research Fund; Swedish Cancer Society(Swedish Cancer Society); King Gustav the Fifth Jubilee Fund; Swedish Research Council(Swedish Research CouncilEuropean Commission)	We thank the subjects, doctors and nurses involved in the EORTC 10994/BIG01 study for their generous participation. We thank the staff of the EORTC data center ( M. de Vos, S. Lejeune, I. Delmotte and M. Karina) and the technician in the Iggo laboratory (A.-L. Nicoulaz) for assistance with data management and sample processing. We thank I. Xenarios, V. Praz and T. Sengstag for support with bioinformatics. We thank H. Chebab ( Pathology Institute, University Lausanne) for supplying human colon tumors. We thank M. Zahn for critical reading of the manuscript. We thank the University of Lausanne DNA array facility and the Swiss Institute for Bioinformatics Vital- IT project for infrastructure support. We thank the Fondation Medic, Fondation Widmer, Oncosuisse, Swiss National Science Foundation and Swiss National Center for Competence in Research ( NCCR) Molecular Oncology, EORTC Translational Research Fund, Swedish Cancer Society, King Gustav the Fifth Jubilee Fund and Swedish Research Council for financial support.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Finak G, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1608; Fisher ER, 2002, CANCER-AM CANCER SOC, V95, P681, DOI 10.1002/cncr.10741; Gianni L, 2005, J CLIN ONCOL, V23, P7265, DOI 10.1200/JCO.2005.02.0818; Guarneri V, 2006, J CLIN ONCOL, V24, P1037, DOI 10.1200/JCO.2005.02.6914; Hannemann J, 2005, J CLIN ONCOL, V23, P3331, DOI 10.1200/JCO.2005.09.077; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; HEDGES L, 1985, STAT METHODS METAANA, V39; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; R Development Core Team, 2005, R LANG ENV STAT COMP; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; UICC/AJCC, 1997, TNM CLASS MAL TUM; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187; WESTFALL P, 1993, RESAMPLING BASED MUL, pCH2; Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124	36	473	500	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					68	74		10.1038/nm.1908	http://dx.doi.org/10.1038/nm.1908			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19122658				2022-12-27	WOS:000262425100020
J	Real, PJ; Tosello, V; Palomero, T; Castillo, M; Hernando, E; de Stanchina, E; Sulis, ML; Barnes, K; Sawai, C; Homminga, I; Meijerink, J; Aifantis, I; Basso, G; Cordon-Cardo, C; Ai, W; Ferrando, A				Real, Pedro J.; Tosello, Valeria; Palomero, Teresa; Castillo, Mireia; Hernando, Eva; de Stanchina, Elisa; Sulis, Maria Luisa; Barnes, Kelly; Sawai, Catherine; Homminga, Irene; Meijerink, Jules; Aifantis, Iannis; Basso, Giuseppe; Cordon-Cardo, Carlos; Ai, Walden; Ferrando, Adolfo			gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia	NATURE MEDICINE			English	Article							INDUCED APOPTOSIS; RECEPTOR EXPRESSION; NOTCH1 CONFERS; GOBLET CELLS; CYCLE ARREST; GENE; DIFFERENTIATION; PROMOTER; SRG3; LINE	Gamma-secretase inhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acute lymphoblastic leukemia (T-ALL). However, limited antileukemic cytotoxicity and severe gastrointestinal toxicity have restricted the clinical application of these targeted drugs. Here we show that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo. Inhibition of NOTCH1 signaling in glucocorticoid-resistant T-ALL restored glucocorticoid receptor autoupregulation and induced apoptotic cell death through induction of the gene encoding BCL-2-like apoptosis initiator-11 (BCL2L11). GSI treatment resulted in cell cycle arrest and accumulation of goblet cells in the gut mediated by upregulation of the gene encoding the transcription factor Kruppel-like factor-4 (Klf4), a negative regulator of the cell cycle required for goblet cell differentiation. In contrast, glucocorticoid treatment induced transcriptional upregulation of cyclin D2 (Ccnd2) and protected mice from developing the intestinal goblet cell metaplasia typically induced by inhibition of NOTCH signaling with GSIs. These results support a role for glucocorticoids plus GSIs in the treatment of glucocorticoid-resistant T-ALL.	[Real, Pedro J.; Tosello, Valeria; Palomero, Teresa; Sulis, Maria Luisa; Barnes, Kelly; Ferrando, Adolfo] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Real, Pedro J.] Ctr Invest Biomed, Andalusian Stem Cell Bank, Granada 18100, Spain; [Palomero, Teresa; Castillo, Mireia; Cordon-Cardo, Carlos; Ferrando, Adolfo] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA; [Hernando, Eva] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [de Stanchina, Elisa] Zuckerman Res Ctr, Mem Sloan Kettering Canc Ctr, Antitumor Assessment Core Facil, New York, NY 10021 USA; [Sulis, Maria Luisa; Ferrando, Adolfo] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA; [Sawai, Catherine; Aifantis, Iannis] NYU, Inst Canc, Dept Pathol, New York, NY 10016 USA; [Homminga, Irene; Meijerink, Jules] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Basso, Giuseppe] Univ Padua, Dept Pediat Salus Pueri, Lab Oncohematol, I-35128 Padua, Italy; [Ai, Walden] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA	Columbia University; Columbia University; New York University; Memorial Sloan Kettering Cancer Center; Columbia University; New York University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; University of Padua; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ferrando, A (corresponding author), Columbia Univ, Inst Canc Genet, 1130 St Nicholas Ave, New York, NY 10032 USA.	af2196@columbia.edu	Pillay, Nischalan/F-9536-2012; Castillo-Martin, Mireia/H-6152-2013; Sawai, Catherine M/E-5023-2018; Real, Pedro J./K-2994-2014; Ferrando, Adolfo A/Q-7026-2016; Real, Pedro J./ABH-3493-2021; Meijerink, Jules P/D-4393-2017; Tosello, Valeria/N-1010-2016	Sawai, Catherine M/0000-0002-2509-474X; Real, Pedro J./0000-0001-7968-5353; Meijerink, Jules P/0000-0002-6860-798X; Homminga, Irene/0000-0002-6794-2102; BASSO, GIUSEPPE/0000-0002-2634-9302; Hernando, Eva/0000-0003-1023-0312; Tosello, Valeria/0000-0001-9560-340X	US National Institutes of Health [R01CA120196, R01CA129382, R56AI070310, 1R01CA105129, 1R01CA133379]; Leukemia and Lymphoma Society [1287-08, 6237-08]; American Cancer Society [RSG0806801]; Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, and the Fondo de Investigacion Sanitaria [CD07/00033]; Leukemia & Lymphoma Society Scholars; Alex's Lemonade Stand Foundation; Dutch Cancer Society; NATIONAL CANCER INSTITUTE [R01CA120196, R01CA105129, R01CA129382, R01CA133379, R01CA149655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI070310] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); American Cancer Society(American Cancer Society); Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, and the Fondo de Investigacion Sanitaria; Leukemia & Lymphoma Society Scholars(Leukemia and Lymphoma Society); Alex's Lemonade Stand Foundation; Dutch Cancer Society(KWF Kankerbestrijding); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank U. Klein for help with flow cytometry analysis; T. Matos for the processing of histological, histochemical and imunohistochemical assays; P. Sicinski (Dana-Farber Cancer Institute) for the Ccnd2-knockout mouse; T. Honjo ( Kyoto University) and B. Reitzis ( Columbia University) for the Rbpjflox/flox conditional knockout mouse; T. Ludwig ( Columbia University) for the Cre-Tam mouse line; A. Kung (Dana-Farber Cancer Institute) for the FUW-Luc neo vector; J. Aster (Brigham and Women's Hospital) for the MigR1 and MigR1ICN1 retroviral constructs and for the NOTCH1-TAD antibody; W. Hahn (DanaFarber Cancer Institute) for the pLKO shRNA vector; R. Dalla Favera ( Columbia University) for the pCM8-cMYB vector; M. J. Garabedian ( New York University) for the pCMV-HA-hGR vector; and N. Wu and C. Wa for pharmacokinetic and drug metabolism analysis. This work was supported by the US National Institutes of Health (R01CA120196 and R01CA129382 to A. F. and R56AI070310, 1R01CA105129 and 1R01CA133379 to I. A.); the Wipe Out Leukemia Forever Foundation ( A. F.), the Leukemia and Lymphoma Society ( grants 1287-08 and 6237-08 to A. F.), the Charlotte Geyer Foundation ( A. F.), the Cancer Research Institute ( A. F.), the Swim Across America Foundation ( A. F.), the Golfers Against Cancer Foundation ( A. F.), the American Cancer Society ( RSG0806801 to I. A.), the Citta` della Speranza Foundation, a Cassa di Risparmio di Padova e Rovigo research grant, a Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, and the Fondo de Investigacion Sanitaria ( grant CD07/00033 to P. J. R.). A. F. and I. A. are Leukemia & Lymphoma Society Scholars. T. P. is a recipient of a Young Investigator Award from the Alex's Lemonade Stand Foundation. I. H. is supported by the Dutch Cancer Society.	Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Deangelo DJ, 2006, J CLIN ONCOL, V24, p357S; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; EISEN LP, 1988, J BIOL CHEM, V263, P12044; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Evin G, 2006, CNS DRUGS, V20, P351, DOI 10.2165/00023210-200620050-00002; Geley S, 1996, CANCER RES, V56, P5033; Geng CD, 2005, J BIOL CHEM, V280, P43264, DOI 10.1074/jbc.M508245200; Guo KY, 2007, ENDOCRINOLOGY, V148, P3987, DOI 10.1210/en.2007-0261; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Jang J, 2006, CELL DEATH DIFFER, V13, P1495, DOI 10.1038/sj.cdd.4401827; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Katz JP, 2002, DEVELOPMENT, V129, P2619; LEVENTHAL BG, 1981, CANCER RES, V41, P4861; LEVINE EG, 1985, LEUKEMIA RES, V9, P993, DOI 10.1016/0145-2126(85)90069-4; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Nunez BS, 2002, MOL CELL ENDOCRINOL, V189, P191, DOI 10.1016/S0303-7207(01)00676-1; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Palomero T, 2008, CLIN CANCER RES, V14, P5314, DOI 10.1158/1078-0432.CCR-07-4864; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pear WS, 2003, SEMIN IMMUNOL, V15, P69, DOI 10.1016/S1044-5323(03)00003-4; Pedersen KB, 2004, BIOCHEMISTRY-US, V43, P10851, DOI 10.1021/bi049458u; Pedersen KB, 2003, BIOCHEMISTRY-US, V42, P10978, DOI 10.1021/bi034651u; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ramdas J, 1999, CANCER RES, V59, P1378; Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Schmidt S, 2006, FASEB J, V20, P2600, DOI 10.1096/fj.06-6214fje; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200	47	337	348	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					50	58		10.1038/nm.1900	http://dx.doi.org/10.1038/nm.1900			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19098907	Green Accepted			2022-12-27	WOS:000262425100018
J	Kleen, JK; Holmes, GL				Kleen, Jonathan K.; Holmes, Gregory L.			Brain inflammation initiates seizures	NATURE MEDICINE			English	Editorial Material							STATUS-EPILEPTICUS; BARRIER; DEATH		[Kleen, Jonathan K.; Holmes, Gregory L.] Dartmouth Med Sch, Dept Neurol, Lebanon, NH 03756 USA	Dartmouth College	Kleen, JK (corresponding author), Dartmouth Med Sch, Dept Neurol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Gregory.L.Holmes@Dartmouth.edu		Kleen, Jonathan/0000-0003-2622-3205				Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Cavalheiro EA, 2006, MODELS OF SEIZURES AND EPILEPSY, P433, DOI 10.1016/B978-012088554-1/50037-2; Fabene PF, 2008, NAT MED, V14, P1377, DOI 10.1038/nm.1878; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Logroscino G, 2008, ARCH NEUROL-CHICAGO, V65, P221, DOI 10.1001/archneurol.2007.43; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; Sahin M, 2001, EPILEPSIA, V42, P1461, DOI 10.1046/j.1528-1157.2001.21301.x; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Uva L, 2008, NEUROSCIENCE, V151, P303, DOI 10.1016/j.neuroscience.2007.10.037; Vignatelli L, 2003, EPILEPSIA, V44, P964, DOI 10.1046/j.1528-1157.2003.63702.x	11	23	27	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1309	1310		10.1038/nm1208-1309	http://dx.doi.org/10.1038/nm1208-1309			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057551				2022-12-27	WOS:000261393600010
J	Chaouat, G				Chaouat, Gerard			Funding for research in reproduction in the European Union	NATURE MEDICINE			English	Editorial Material									Univ Paris Sud Orsay & Assistance Publ, INSERM, Equipe Implantat & Dialogue Cytokin Mere Conceptu, U782, F-92141 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Chaouat, G (corresponding author), Univ Paris Sud Orsay & Assistance Publ, INSERM, Equipe Implantat & Dialogue Cytokin Mere Conceptu, U782, 3E Rue Carnets, F-92141 Clamart, France.	gerard_chaouat@wanadoo.fr						Bischof P, 2006, GYNECOL OBSTET INVES, V62, P206, DOI 10.1159/000094005; MARIOMON R, 2004, EVALUATION EFFECTIVE, V6; REDMAN CWE, 1992, PREECLAMPSIA FACTS H; Swan SH, 1997, ENVIRON HEALTH PERSP, V105, P1228; Zondervan K, 2000, BEST PRACT RES CL OB, V14, P403, DOI 10.1053/beog.1999.0083; 2007, J REPROD IMMUNOL, V76, P1	6	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1218	1220		10.1038/nm1108-1218	http://dx.doi.org/10.1038/nm1108-1218			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18989309				2022-12-27	WOS:000260751200040
J	Kelly, EJ; Hadac, EM; Greiner, S; Russell, SJ				Kelly, Elizabeth J.; Hadac, Elizabeth M.; Greiner, Suzanne; Russell, Stephen J.			Engineering microRNA responsiveness to decrease virus pathogenicity	NATURE MEDICINE			English	Article							ONCOLYTIC VIROTHERAPY; TRANSGENE EXPRESSION; ENDOGENOUS MICRORNA; COXSACKIEVIRUS A21; TUMORS; COMBINATION; ADENOVIRUS; EFFICACY; THERAPY; TISSUE	The cellular tropisms of eukaryotic viruses are shaped by their need for entry receptors and intracellular transcription factors. Here we show that viral tropisms can also be regulated by tissue-specific microRNAs ( miRNAs). Target sequences complementary to muscle-specific miRNAs were inserted into the 3' untranslated region (UTR) of an oncolytic picornavirus that causes lethal myositis in tumor-bearing mice. The recombinant virus still propagated in subcutaneous tumors, causing total regression and sustained viremia, but could not replicate in cells expressing complementary miRNAs and therefore did not cause myositis. This altered tropism was not due to insertional attenuation, as a control virus containing a 3' UTR insert with a disrupted miRNA target sequence fully retained its lethal myotropism. Tissue-specific destabilization of viral genomes by miRNA target insertion provides a potentially versatile new mechanism for controlling the tropism of replicating viruses for therapy and may serve as a new modality for attenuating viruses for vaccine purposes.	[Kelly, Elizabeth J.; Hadac, Elizabeth M.; Greiner, Suzanne; Russell, Stephen J.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA	Mayo Clinic	Russell, SJ (corresponding author), Mayo Clin, Coll Med, Dept Mol Med, 200 1st St SW, Rochester, MN 55905 USA.	sjr@mayo.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Alonso MM, 2007, CANCER GENE THER, V14, P756, DOI 10.1038/sj.cgt.7701067; Au GG, 2005, INT J ONCOL, V26, P1471; Barber GN, 2004, VIRAL IMMUNOL, V17, P516, DOI 10.1089/vim.2004.17.516; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Brown BD, 2006, NAT MED, V12, P585, DOI 10.1038/nm1398; Dekel B, 2002, ACTA PAEDIATR, V91, P357, DOI 10.1080/08035250252834067; Domingo E, 1997, REV MED VIROL, V7, P87, DOI 10.1002/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0; Dufresne AT, 2004, P NATL ACAD SCI USA, V101, P13636, DOI 10.1073/pnas.0403998101; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Grimm D, 2007, MOL THER, V15, P878, DOI 10.1038/sj.mt.6300116; Heise CC, 1999, CANCER RES, V59, P2623; Hingorani M, 2007, CURR CANCER DRUG TAR, V7, P389, DOI 10.2174/156800907780809787; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Knipe D. M., 2007, FIELDS VIROLOGY; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Nelson PT, 2004, NAT METHODS, V1, P155, DOI 10.1038/NMETH717; Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750; Qiao J, 2008, NAT MED, V14, P37, DOI 10.1038/nm1681; Qiao J, 2008, CLIN CANCER RES, V14, P259, DOI 10.1158/1078-0432.CCR-07-1510; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Roberts L, 2007, SCIENCE, V317, P1842, DOI 10.1126/science.317.5846.1842; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; Schiff GM, 2000, J INFECT DIS, V181, P20, DOI 10.1086/315176; Skelding KA, 2009, BREAST CANCER RES TR, V113, P21, DOI 10.1007/s10549-008-9899-2; Thorne SH, 2005, SEMIN ONCOL, V32, P537, DOI 10.1053/j.seminoncol.2005.09.007; van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao CM, 2007, ADV INTEL SYS RES, V2, P317	31	177	200	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1278	1283		10.1038/nm.1776	http://dx.doi.org/10.1038/nm.1776			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18953352	Bronze			2022-12-27	WOS:000260751200048
J	Kain, R; Exner, M; Brandes, R; Ziebermayr, R; Cunningham, D; Alderson, CA; Davidovits, A; Raab, I; Jahn, R; Ashour, O; Spitzauer, S; Sunder-Plassmann, G; Fukuda, M; Klemm, P; Rees, AJ; Kerjaschki, D				Kain, Renate; Exner, Markus; Brandes, Ricarda; Ziebermayr, Reinhard; Cunningham, Dawn; Alderson, Carol A.; Davidovits, Agnes; Raab, Ingrid; Jahn, Renate; Ashour, Oliver; Spitzauer, Susanne; Sunder-Plassmann, Gere; Fukuda, Minoru; Klemm, Per; Rees, Andrew J.; Kerjaschki, Dontscho			Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis	NATURE MEDICINE			English	Article							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; LYSOSOMAL MEMBRANE GLYCOPROTEIN; CHAPERONE-MEDIATED AUTOPHAGY; CLASS-II PRESENTATION; CRESCENTIC GLOMERULONEPHRITIS; WEGENERS-GRANULOMATOSIS; FIMH-ADHESIN; BACTERIAL LIPOPOLYSACCHARIDE; ENDOTHELIAL-CELLS; ESCHERICHIA-COLI	Pauci-immune focal necrotizing glomerulonephritis (FNGN) is a severe inflammatory disease associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA). Here we characterize autoantibodies to lysosomal membrane protein-2 (LAMP-2) and show that they are a new ANCA subtype present in almost all individuals with FNGN. Consequently, its prevalence is nearly twice that of the classical ANCAs that recognize myeloperoxidase or proteinase-3. Furthermore, antibodies to LAMP-2 cause pauci-immune FNGN when injected into rats, and a monoclonal antibody to human LAMP-2 (H4B4) induces apoptosis of human microvascular endothelium in vitro. The autoantibodies in individuals with pauci-immune FNGN commonly recognize a human LAMP-2 epitope (designated P41-49) with 100% homology to the bacterial adhesin FimH, with which they cross-react. Rats immunized with Ill develop pauci-immune FNGN and also develop antibodies to rat and human LAMP-2. Finally, we show that infections with fimbriated pathogens are common before the onset of FNGN. Thus, FimH-triggered autoimmunity to LAMP-2 provides a previously undescribed clinically relevant molecular mechanism for the development of pauci-immune FNGN.	[Kain, Renate; Brandes, Ricarda; Ziebermayr, Reinhard; Davidovits, Agnes; Raab, Ingrid; Jahn, Renate; Ashour, Oliver; Rees, Andrew J.; Kerjaschki, Dontscho] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria; [Exner, Markus; Spitzauer, Susanne] Med Univ Vienna, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; [Cunningham, Dawn; Alderson, Carol A.; Rees, Andrew J.] Univ Aberdeen, Sch Med, Immunol Programme, Aberdeen AB25 2ZD, Scotland; [Cunningham, Dawn; Alderson, Carol A.; Rees, Andrew J.] Univ Aberdeen, Sch Med Sci, Immunol Programme, Aberdeen AB25 2ZD, Scotland; [Sunder-Plassmann, Gere] Med Univ Vienna, Dept Nephrol, A-1090 Vienna, Austria; [Fukuda, Minoru] Burnham Inst, La Jolla, CA 92037 USA; [Klemm, Per] Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark	Medical University of Vienna; Medical University of Vienna; University of Aberdeen; University of Aberdeen; Medical University of Vienna; Sanford Burnham Prebys Medical Discovery Institute; Technical University of Denmark	Kain, R (corresponding author), Med Univ Vienna, Dept Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	renate.kain@meduniwien.ac.at	Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X; Sunder-Plassmann, Gere/0000-0002-9253-9921	R.K.'s Senior Research Fellowship [KRUK SF3/2000-2005]; University of Aberdeen and Scottish Hospitals Endowment Research Trust [RG15/02]; EU Marie Curie Excellence Chair [MEXC-CT-2006-042742]; Austrian Federal Ministry of Science and Research;  [RO1CA48737]; NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER	R.K.'s Senior Research Fellowship; University of Aberdeen and Scottish Hospitals Endowment Research Trust; EU Marie Curie Excellence Chair(European Commission); Austrian Federal Ministry of Science and Research; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This paper is dedicated to the memory of Fokko van der Woude. We thank A. Jungbauer (University of Agriculture and Forestry, Vienna) for synthetic peptides. We thank Kidney Research UK, who generously funded R.K.'s Senior Research Fellowship (KRUK SF3/2000-2005) at the University of Aberdeen and Scottish Hospitals Endowment Research Trust (RG15/02) for supporting parts of this project. A.R. is funded by an EU Marie Curie Excellence Chair (MEXC-CT-2006-042742). Parts of this work were funded by the Austrian Federal Ministry of Science and Research. M.F.'s research is supported by grant RO1CA48737. We are indebted to H. Schachner tor technical assistance and to A. Jager for his help in preparing the figures. We also would like to thank the many physicians who provided sera and subject details.	CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Connell I, 1996, P NATL ACAD SCI USA, V93, P9827, DOI DOI 10.1073/PNAS.93.18.9827; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144; Eskelinen EL, 2005, TRAFFIC, V6, P1058, DOI 10.1111/j.1600-0854.2005.00337.x; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Fourneau JM, 2004, MOL IMMUNOL, V40, P1095, DOI 10.1016/j.molimm.2003.11.011; Franssen CFM, 1999, J AM SOC NEPHROL, V10, P1506; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HASLETT C, 1985, AM J PATHOL, V119, P101; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; Huugen D, 2005, AM J PATHOL, V167, P47, DOI 10.1016/S0002-9440(10)62952-5; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Jennette JC, 2006, J AM SOC NEPHROL, V17, P1235, DOI 10.1681/ASN.2005101048; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; Kain R, 1998, J BIOL CHEM, V273, P981, DOI 10.1074/jbc.273.2.981; Kerjaschki D, 1996, J EXP MED, V183, P2007, DOI 10.1084/jem.183.5.2007; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Langermann S, 2000, J INFECT DIS, V181, P774, DOI 10.1086/315258; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; Little MA, 2005, BLOOD, V106, P2050, DOI 10.1182/blood-2005-03-0921; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Morgan MD, 2006, J AM SOC NEPHROL, V17, P1224, DOI 10.1681/ASN.2005080882; Neumann I, 2005, NEPHROL DIAL TRANSPL, V20, P96, DOI 10.1093/ndt/gfh563; Pendergraft WF, 2004, NAT MED, V10, P72, DOI 10.1038/nm968; Pfister H, 2004, BLOOD, V104, P1411, DOI 10.1182/blood-2004-01-0267; PINCHING AJ, 1980, BRIT MED J, V281, P836, DOI 10.1136/bmj.281.6244.836; Ruth AJ, 2006, J AM SOC NEPHROL, V17, P1940, DOI 10.1681/ASN.2006020108; Savige J, 2002, Clin Exp Rheumatol, V20, P783; Savige J, 2003, AM J CLIN PATHOL, V120, P312, DOI 10.1309/WAEPADW0K4LPUHFN; SAWADA R, 1993, J BIOL CHEM, V268, P12675; Schembri MA, 2000, FEMS MICROBIOL LETT, V188, P147, DOI 10.1111/j.1574-6968.2000.tb09186.x; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; Tse WY, 2005, KIDNEY INT, V67, P130, DOI 10.1111/j.1523-1755.2005.00063.x; van der Geld YM, 2007, ANN RHEUM DIS, V66, P1679, DOI 10.1136/ard.2006.064626; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Wegener F, 1936, VERHANDLUNGEN DTSCH, V29, P202; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101; Zhou DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009	50	297	337	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1088	1096		10.1038/nm.1874	http://dx.doi.org/10.1038/nm.1874			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18836458	Green Accepted			2022-12-27	WOS:000259892300039
J	Schilling, S; Zeitschel, U; Hoffmann, T; Heiser, U; Francke, M; Kehlen, A; Holzer, M; Hutter-Paier, B; Prokesch, M; Windisch, M; Jagla, W; Schlenzig, D; Lindner, C; Rudolph, T; Reuter, G; Cynis, H; Montag, D; Demuth, HU; Rossner, S				Schilling, Stephan; Zeitschel, Ulrike; Hoffmann, Torsten; Heiser, Ulrich; Francke, Mike; Kehlen, Astrid; Holzer, Max; Hutter-Paier, Birgit; Prokesch, Manuela; Windisch, Manfred; Jagla, Wolfgang; Schlenzig, Dagmar; Lindner, Christiane; Rudolph, Thomas; Reuter, Gunter; Cynis, Holger; Montag, Dirk; Demuth, Hans-Ulrich; Rossner, Steffen			Glutaminyl cyclase inhibition attenuates pyroglutamate A beta and Alzheimer's disease-like pathology	NATURE MEDICINE			English	Article							PEPTIDES IN-VITRO; MOUSE MODEL; SENILE PLAQUES; DEPOSITION; PROTEIN; A-BETA-42(43); COMPONENT; DEMENTIA; BRAIN	Because of their abundance, resistance to proteolysis, rapid aggregation and neurotoxicity, N-terminally truncated and, in particular, pyroglutamate (pE)-modified A beta peptides have been suggested as being important in the initiation of pathological cascades resulting in the development of Alzheimer's disease(1-6). We found that the N-terminal pE-formation is catalyzed by glutaminyl cyclase in vivo. Glutaminyl cyclase expression was upregulated in the cortices of individuals with Alzheimer's disease and correlated with the appearance of pE-modified A beta. Oral application of a glutaminyl cyclase inhibitor resulted in reduced A beta(3(pE)-42) burden in two different transgenic mouse models of Alzheimer's disease and in a new Drosophila model. Treatment of mice was accompanied by reductions in A beta(x-40/42), diminished plaque formation and gliosis and improved performance in context memory and spatial learning tests. These observations are consistent with the hypothesis that A beta(3(pE)-42) acts as a seed for A beta aggregation by self-aggregation and co-aggregation with A beta(1-40/42). Therefore, A beta(3(pE)-40/42) peptides seem to represent A beta forms with exceptional potency for disturbing neuronal function. The reduction of brain pE-A beta by inhibition of glutaminyl cyclase offers a new therapeutic option for the treatment of Alzheimer's disease and provides implications for other amyloidoses, such as familial Danish dementia.	[Schilling, Stephan; Hoffmann, Torsten; Heiser, Ulrich; Kehlen, Astrid; Schlenzig, Dagmar; Cynis, Holger; Demuth, Hans-Ulrich] Probiodrug AG, D-06120 Halle, Germany; [Zeitschel, Ulrike; Francke, Mike; Holzer, Max; Rossner, Steffen] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany; [Hutter-Paier, Birgit; Prokesch, Manuela; Windisch, Manfred] JSW CNS Res GmbH, A-8074 Grambach Graz, Austria; [Jagla, Wolfgang; Demuth, Hans-Ulrich] Ingenim Pharmaceut GmbH, D-82152 Munich, Germany; [Lindner, Christiane; Rudolph, Thomas; Reuter, Gunter] Univ Halle Wittenberg, Dept Genet, Inst Biol, D-06120 Halle, Germany; [Montag, Dirk] Leibniz Inst Neurobiol, Res Grp Neurogenet, D-39118 Magdeburg, Germany	Vivoryon Therapeutics; Leipzig University; Martin Luther University Halle Wittenberg; Leibniz Institut fur Neurobiologie (LIN)	Demuth, HU (corresponding author), Probiodrug AG, Weinbergweg 22, D-06120 Halle, Germany.	hans-ulrich.demuth@probiodrug.de	Montag, Dirk/D-3925-2014; Zeitschel, Ulrike/A-8930-2017; Francke, Mike/A-7505-2017; Rossner, Steffen/A-5184-2017; Holzer, Max/A-1729-2008	Montag, Dirk/0000-0002-4964-1330; Holzer, Max/0000-0003-1754-9932; Cynis, Holger/0000-0001-6655-7539	German Federal Department of Education, Science and Technology BMBF [3013185]	German Federal Department of Education, Science and Technology BMBF(Federal Ministry of Education & Research (BMBF))	We thank K. Sowa, R. Jendrek, K. Schulz, M, Bornack, E. Scheel and NI. Buchholz for technical assistance. The authors would like to express their gratitude to K. Hsiao (University of Minnesota) for kindly providing Tg2576 mice and E. Masliah (University of California, San Diego) for providing the TASD-41 mice. Thanks are due to T.C. Saido (Riken Brain Science Institute) for the gift of the APP-NLE vector. S. Winter maintained and analyzed organotypic brain slice cultures from Tg2576 mice. We are also grateful to J. Heins for statistical analysis and to M.T. Stubbs, K. Glund and M. Hartlage-Rubsamen for helpful discussion. This work was supported by, German Federal Department of Education, Science and Technology BMBF grant #3013185 to H.-U.D.	Buchholz M, 2006, J MED CHEM, V49, P664, DOI 10.1021/jm050756e; Cynis H, 2006, BBA-PROTEINS PROTEOM, V1764, P1618, DOI 10.1016/j.bbapap.2006.08.003; Ghiso J, 2001, AMYLOID, V8, P277, DOI 10.3109/13506120108993826; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Liu KN, 2006, ACTA NEUROPATHOL, V112, P163, DOI 10.1007/s00401-006-0077-5; Miravalle L, 2005, BIOCHEMISTRY-US, V44, P10810, DOI 10.1021/bi0508237; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Piccini A, 2005, J BIOL CHEM, V280, P34186, DOI 10.1074/jbc.M501694200; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; POHL T, 1991, P NATL ACAD SCI USA, V88, P10059, DOI 10.1073/pnas.88.22.10059; Rockenstein E, 2001, J NEUROSCI RES, V66, P573, DOI 10.1002/jnr.1247; Russo C, 2000, NATURE, V405, P531, DOI 10.1038/35014735; Russo C, 2002, J NEUROCHEM, V82, P1480, DOI 10.1046/j.1471-4159.2002.01107.x; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Schilling S, 2004, FEBS LETT, V563, P191, DOI 10.1016/S0014-5793(04)00300-X; Schilling S, 2006, BIOCHEMISTRY-US, V45, P12393, DOI 10.1021/bi0612667; Schilling S, 2008, J NEUROCHEM, V106, P1225, DOI 10.1111/j.1471-4159.2008.05471.x; Shirotani K, 2002, NEUROSCI LETT, V327, P25, DOI 10.1016/S0304-3940(02)00351-8; Sykes PA, 1999, FEBS LETT, V455, P159, DOI 10.1016/S0014-5793(99)00872-8; Tomidokoro Y, 2005, J BIOL CHEM, V280, P36883, DOI 10.1074/jbc.M504038200; Vanderstichele H, 2005, CLIN CHEM, V51, P1650, DOI 10.1373/clinchem.2005.051201; Yu L, 2006, J PHARMACEUT BIOMED, V42, P455, DOI 10.1016/j.jpba.2006.05.008	30	283	295	2	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	OCT	2008	14	10					1106	1111		10.1038/nm.1872	http://dx.doi.org/10.1038/nm.1872			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18836460				2022-12-27	WOS:000259892300041
J	Shedden, K; Taylor, JMG; Enkemann, SA; Tsao, MS; Yeatman, TJ; Gerald, WL; Eschrich, S; Jurisica, I; Giordano, TJ; Misek, DE; Chang, AC; Zhu, CQ; Strumpf, D; Hanash, S; Shepherd, FA; Ding, K; Seymour, L; Naoki, K; Pennell, N; Weir, B; Verhaak, R; Ladd-Acosta, C; Golub, T; Gruidl, M; Sharma, A; Szoke, J; Zakowski, M; Rusch, V; Kris, M; Viale, A; Motoi, N; Travis, W; Conley, B; Seshan, VE; Meyerson, M; Kuick, R; Dobbin, KK; Lively, T; Jacobson, JW; Beer, DG				Shedden, Kerby; Taylor, Jeremy M. G.; Enkemann, Steven A.; Tsao, Ming-Sound; Yeatman, Timothy J.; Gerald, William L.; Eschrich, Steven; Jurisica, Igor; Giordano, Thomas J.; Misek, David E.; Chang, Andrew C.; Zhu, Chang Qi; Strumpf, Daniel; Hanash, Samir; Shepherd, Frances A.; Ding, Keyue; Seymour, Lesley; Naoki, Katsuhiko; Pennell, Nathan; Weir, Barbara; Verhaak, Roel; Ladd-Acosta, Christine; Golub, Todd; Gruidl, Michael; Sharma, Anupama; Szoke, Janos; Zakowski, Maureen; Rusch, Valerie; Kris, Mark; Viale, Agnes; Motoi, Noriko; Travis, William; Conley, Barbara; Seshan, Venkatraman E.; Meyerson, Matthew; Kuick, Rork; Dobbin, Kevin K.; Lively, Tracy; Jacobson, James W.; Beer, David G.		Director's Challenge Consortium Mo	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study	NATURE MEDICINE			English	Article							CANCER	Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across different subject populations and in different laboratories. Here we report a large, training-testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The hypotheses proposed examined whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) could be used to predict overall survival in lung cancer subjects. Several models examined produced risk scores that substantially correlated with actual subject outcome. Most methods performed better with clinical data, supporting the combined use of clinical and molecular information when building prognostic models for early-stage lung cancer. This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas.	[Lively, Tracy; Jacobson, James W.] NCI, Cancer Diag Program, Rockville, MD 20852 USA; [Shedden, Kerby] Univ Michigan, S Univ 1085, Dept Stat, Ann Arbor, MI 48109 USA; [Shedden, Kerby; Taylor, Jeremy M. G.; Misek, David E.; Chang, Andrew C.; Hanash, Samir; Kuick, Rork; Beer, David G.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA; [Taylor, Jeremy M. G.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Enkemann, Steven A.; Yeatman, Timothy J.; Gruidl, Michael; Sharma, Anupama] Univ S Florida, Dept Surg, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Tsao, Ming-Sound; Jurisica, Igor; Zhu, Chang Qi; Strumpf, Daniel; Shepherd, Frances A.] Ontario Canc Inst, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; [Tsao, Ming-Sound; Jurisica, Igor; Zhu, Chang Qi; Strumpf, Daniel; Shepherd, Frances A.] Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; [Gerald, William L.; Szoke, Janos; Zakowski, Maureen; Rusch, Valerie; Kris, Mark; Viale, Agnes; Motoi, Noriko; Travis, William] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Giordano, Thomas J.] Univ Michigan, Dept Pathol, Univ Hosp 2G3320054, Ann Arbor, MI 48109 USA; [Misek, David E.; Chang, Andrew C.; Beer, David G.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Ding, Keyue; Seymour, Lesley] Queens Univ, Kingston, ON K7L 3N6, Canada; [Ding, Keyue; Seymour, Lesley] Inst Canc Res, Canada Clin Trials Grp, Kingston, ON K7L 3N6, Canada; [Naoki, Katsuhiko; Pennell, Nathan; Weir, Barbara; Verhaak, Roel; Meyerson, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, Boston, MA 02115 USA; [Ladd-Acosta, Christine; Golub, Todd; Meyerson, Matthew] 7 Cambridge Ctr, Broad Inst, Cambridge, MA 02142 USA; [Conley, Barbara] Michigan State Univ, Dept Med, Clin Ctr B414, E Lansing, MI 48824 USA; [Seshan, Venkatraman E.] Columbia Univ, New York, NY 10032 USA; [Dobbin, Kevin K.] Natl Canc Inst, Biometr Res Branch, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Memorial Sloan Kettering Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Queens University - Canada; Queens University - Canada; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Michigan State University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jacobson, JW (corresponding author), NCI, Cancer Diag Program, EPN 6035A,6130 Execut Blvd, Rockville, MD 20852 USA.	jacobsonj@ctep.nci.nih.gov; dgbeer@umich.edu	Naoki, Katsuhiko/J-5937-2019; Motoi, Noriko/A-9718-2009; Meyerson, Matthew L/E-7123-2012; Pennell, Nathan/AAH-9303-2021; Tsao, Ming Sound/AFQ-7332-2022; Eschrich, Steven/K-6848-2013; Motoi, Noriko/AAO-5642-2020; Verhaak, Roel/ABE-7058-2020; Tsao, Ming-Sound/M-3503-2017	Naoki, Katsuhiko/0000-0002-9637-1388; Motoi, Noriko/0000-0001-7098-3311; Pennell, Nathan/0000-0002-1458-0064; Tsao, Ming Sound/0000-0002-9160-5405; Eschrich, Steven/0000-0002-9833-2788; Motoi, Noriko/0000-0001-7098-3311; Chang, Andrew/0000-0001-9506-0425; Giordano, Thomas/0000-0003-0641-8873; Shedden, Kerby/0000-0001-7222-6664; Zhu, ChangQi/0000-0002-9992-0258; Rusch, Valerie/0000-0003-2345-6900; Kris, Mark/0000-0002-7317-5341	NATIONAL CANCER INSTITUTE [R01CA154365, P30CA046592, U01CA085052, U19CA084953, U01CA084995, R01CA098522, U01CA084999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046952] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA084999, U01 CA084995-05, U01 CA084995, CA84999, CA85052, CA84953, CA84995, R01 CA098522-05, U19 CA084953-050003, P30 CA046592, U01 CA085052, R01 CA154365, R01 CA098522, U01 CA084999-05, U19 CA084953, U01 CA085052-05, CA46592] Funding Source: Medline; NIDDK NIH HHS [R01 DK046952-14, R01 DK046952] Funding Source: Medline; PHS HHS [263-MQ-319735, 263-MQ-319746, 263-MQ-319740, 263-MQ-510430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Booth CM, 2006, J THORAC ONCOL, V1, P180, DOI 10.1097/01243894-200602000-00016; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Dobbin KK, 2005, CLIN CANCER RES, V11, P565; Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9; Gandara DR, 2007, J THORAC ONCOL, V2, pS125, DOI 10.1097/JTO.0b013e318074fe31; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Wigle DA, 2002, CANCER RES, V62, P3005	18	815	844	3	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					822	827		10.1038/nm.1790	http://dx.doi.org/10.1038/nm.1790			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18641660	Green Accepted			2022-12-27	WOS:000258237500028
J	Appay, V; Douek, DC; Price, DA				Appay, Victor; Douek, Daniel C.; Price, David A.			CD8(+) T cell efficacy in vaccination and disease	NATURE MEDICINE			English	Review							PRIME-BOOST IMMUNIZATION; BLOOD MONONUCLEAR-CELLS; HIGH-AVIDITY CTL; IN-VIVO; CANCER REGRESSION; MELANOMA PATIENTS; TUMOR REACTIVITY; PD-1 EXPRESSION; HIGH-FREQUENCY; SELF-ANTIGENS	Much effort has been devoted to the design of vaccines that induce adaptive cellular immunity, in particular CD8(+) T cells, which have a central role in the host response to viral infections and cancers. To date, however, the development of effective T cell vaccines remains elusive. This is due, in part, to the lack of clearly defined correlates of protection and the inherent difficulties that hinder full characterization of the determinants of successful T cell immunity in humans. Recent data from the disparate fields of infectious disease and tumor immunology have converged, with an emphasis on the functional attributes of individual antigen-specific T cell clonotypes, to provide a better understanding of CD8(+) T cell efficacy. This new knowledge paves the way to the design of more effective T cell vaccines and highlights the importance of comprehensive immunomonitoring.	[Appay, Victor] Univ Paris 06, Hop Pitie Salpetriere, Ave Grp, Inst Natl Sante & Rech Med U543, F-75013 Paris, France; [Douek, Daniel C.; Price, David A.] US Natl Inst Hlth, Vaccine Res Ctr, Human Immunol Sect, Bethesda, MD 20892 USA; [Price, David A.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, Wales	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; National Institutes of Health (NIH) - USA; Cardiff University	Appay, V (corresponding author), Univ Paris 06, Hop Pitie Salpetriere, Ave Grp, Inst Natl Sante & Rech Med U543, 91 Blvd Hop, F-75013 Paris, France.	appay@chups.jussieu.fr	Price, David A/C-7876-2013; Appay, Victor/AAM-7701-2021; Appay, Victor/M-4830-2017	Price, David A/0000-0001-9416-2737; Appay, Victor/0000-0001-5434-3963	Medical Research Council [G0501963] Funding Source: Medline; MRC [G0501963] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Appay V, 2006, EUR J IMMUNOL, V36, P1805, DOI 10.1002/eji.200535805; Appay V, 2006, J IMMUNOL, V177, P1670, DOI 10.4049/jimmunol.177.3.1670; Belyakov IM, 2007, J IMMUNOL, V178, P7211, DOI 10.4049/jimmunol.178.11.7211; Belyakov IM, 2006, BLOOD, V107, P3258, DOI 10.1182/blood-2005-11-4374; Bennett MS, 2007, J VIROL, V81, P4973, DOI 10.1128/JVI.02362-06; Berger C, 2008, J CLIN INVEST, V118, P294, DOI 10.1172/JCI32103; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Betts MR, 2004, J IMMUNOL, V172, P6407, DOI 10.4049/jimmunol.172.10.6407; Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.200737504; Bihl F, 2006, J IMMUNOL, V176, P4094, DOI 10.4049/jimmunol.176.7.4094; Bullock TNJ, 2003, J IMMUNOL, V170, P1822, DOI 10.4049/jimmunol.170.4.1822; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; Cawthon AG, 2001, J IMMUNOL, V167, P2577, DOI 10.4049/jimmunol.167.5.2577; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Critchfield JW, 2007, J VIROL, V81, P5460, DOI 10.1128/JVI.02535-06; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; Davenport MP, 2007, CURR OPIN IMMUNOL, V19, P294, DOI 10.1016/j.coi.2007.04.001; Davenport MP, 2002, J IMMUNOL, V168, P3309, DOI 10.4049/jimmunol.168.7.3309; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Douek DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/jimmunol.168.6.3099; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunbar PR, 2000, J IMMUNOL, V165, P6644, DOI 10.4049/jimmunol.165.11.6644; Dutoit V, 2001, CANCER RES, V61, P5850; Dzutsev AH, 2007, INT IMMUNOL, V19, P497, DOI 10.1093/intimm/dxm016; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Estcourt MJ, 2002, INT IMMUNOL, V14, P31, DOI 10.1093/intimm/14.1.31; Finney HM, 2004, J IMMUNOL, V172, P104, DOI 10.4049/jimmunol.172.1.104; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203; Harari A, 2008, J EXP MED, V205, P63, DOI 10.1084/jem.20071331; Hodge JW, 2005, J IMMUNOL, V174, P5994, DOI 10.4049/jimmunol.174.10.5994; Huse M, 2007, IMMUNITY, V27, P76, DOI 10.1016/j.immuni.2007.05.017; Jenkins M, 1998, BLOOD, V91, P2672, DOI 10.1182/blood.V91.8.2672.2672_2672_2678; Johnson LA, 2006, J IMMUNOL, V177, P6548, DOI 10.4049/jimmunol.177.9.6548; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Kroger CJ, 2007, J IMMUNOL, V179, P748, DOI 10.4049/jimmunol.179.2.748; La Gruta NL, 2004, J IMMUNOL, V172, P5553, DOI 10.4049/jimmunol.172.9.5553; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Lichterfeld M, 2007, J EXP MED, V204, P2813, DOI 10.1084/jem.20061865; Lichterfeld M, 2007, J VIROL, V81, P4199, DOI 10.1128/JVI.01388-06; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Monsurro V, 2004, BLOOD, V104, P1970, DOI 10.1182/blood-2004-02-0525; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Mortarini R, 2003, CANCER RES, V63, P2535; Narayan S, 2007, EUR J IMMUNOL, V37, P406, DOI 10.1002/eji.200535688; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Oh S, 2003, J IMMUNOL, V170, P2523, DOI 10.4049/jimmunol.170.5.2523; Park JH, 2007, NAT IMMUNOL, V8, P1049, DOI 10.1038/ni1512; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Price DA, 2005, J EXP MED, V202, P1349, DOI 10.1084/jem.20051357; Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010; Ranasinghe C, 2007, J IMMUNOL, V178, P2370, DOI 10.4049/jimmunol.178.4.2370; Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746; Sacre K, 2005, J EXP MED, V201, P1999, DOI 10.1084/jem.20042408; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Sauce D, 2007, AIDS, V21, P2005, DOI 10.1097/QAD.0b013e3282eee548; Schamel WWA, 2005, J EXP MED, V202, P493, DOI 10.1084/jem.20042155; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Sedlik C, 2000, J VIROL, V74, P5769, DOI 10.1128/JVI.74.13.5769-5775.2000; Speiser DE, 2008, P NATL ACAD SCI USA, V105, P3849, DOI 10.1073/pnas.0800080105; Speiser DE, 2006, J IMMUNOL, V177, P1338, DOI 10.4049/jimmunol.177.2.1338; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Speiser DE, 2002, EUR J IMMUNOL, V32, P731, DOI 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO;2-H; SPEISER DE, 1992, J IMMUNOL, V149, P972; Stuge TB, 2004, PLOS MED, V1, P149, DOI 10.1371/journal.pmed.0010028; Trautmann L, 2005, J IMMUNOL, V175, P6123, DOI 10.4049/jimmunol.175.9.6123; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105; Valitutti S, 1996, J EXP MED, V183, P1917, DOI 10.1084/jem.183.4.1917; Vezys V, 2006, J EXP MED, V203, P2263, DOI 10.1084/jem.20060995; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Walter S, 2003, J IMMUNOL, V171, P4974, DOI 10.4049/jimmunol.171.10.4974; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Yee C, 1999, J IMMUNOL, V162, P2227; Zeh HJ, 1999, J IMMUNOL, V162, P989; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737; Zhou JH, 2005, J IMMUNOL, V175, P7046, DOI 10.4049/jimmunol.175.10.7046; Zhou JH, 2004, J IMMUNOL, V173, P7622, DOI 10.4049/jimmunol.173.12.7622	100	277	287	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2008	14	6					623	628		10.1038/nm.f.1774	http://dx.doi.org/10.1038/nm.f.1774			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18535580				2022-12-27	WOS:000256468700027
J	Sayed, AA; Simeonov, A; Thomas, CJ; Inglese, J; Austin, CP; Williams, DL				Sayed, Ahmed A.; Simeonov, Anton; Thomas, Craig J.; Inglese, James; Austin, Christopher P.; Williams, David L.			Identification of oxadiazoles as new drug leads for the control of schistosomiasis	NATURE MEDICINE			English	Article							TROPICAL DISEASES; MANSONI; RESISTANCE; INFECTION; PRAZIQUANTEL; THIOREDOXIN; FUROXANS; METAANALYSIS; GLUTATHIONE; LIBRARIES	Treatment for schistosomiasis, which is responsible for more than 280,000 deaths annually, depends almost exclusively on praziquantel. Millions of people are treated annually with praziquantel, and drug- resistant parasites thus are likely to evolve. Phosphinic amides and oxadiazole 2- oxides, identified from a quantitative high- throughput screen, were shown to inhibit a parasite enzyme, thioredoxin glutathione reductase ( TGR), with activities in the low micromolar to low nanomolar range. Incubation of parasites with these compounds led to rapid inhibition of TGR activity and parasite death. The activity of the oxadiazole 2- oxides was associated with a donation of nitric oxide. Treatment of schistosome- infected mice with 4- phenyl- 1,2,5- oxadiazole- 3-carbonitrile- 2- oxide led to marked reductions in worm burdens from treatments against multiple parasite stages and egg- associated pathologies. The compound was active against the three major schistosome species infecting humans. These protective effects exceed benchmark activity criteria set by the World Health Organization for lead compound development for schistosomiasis.	[Sayed, Ahmed A.; Williams, David L.] Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA; [Simeonov, Anton; Thomas, Craig J.; Inglese, James; Austin, Christopher P.] NHGRI, NIH Chem Genom Ctr, NIH, Bethesda, MD 20892 USA	Illinois State University; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); NIH National Human Genome Research Institute (NHGRI)	Williams, DL (corresponding author), Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA.	austinc@mail.nih.gov; dlwilli@ilstu.edu		Thomas, Craig/0000-0001-9386-9001	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065622, R01AI030026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH076449] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HG200319-04] Funding Source: Medline; NIAID NIH HHS [N01AI30026, R01 AI065622, R01 AI065622-02, R01AI065622] Funding Source: Medline; NIMH NIH HHS [R03 MH076449, R03MH076449] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abdulla MH, 2007, PLOS MED, V4, P130, DOI 10.1371/journal.pmed.0040014; Aguirre G, 2006, PHARMAZIE, V61, P54; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Moreira LSA, 2007, T ROY SOC TROP MED H, V101, P385, DOI 10.1016/j.trstmh.2006.06.006; Austin CP, 2004, SCIENCE, V306, P1138, DOI 10.1126/science.1105511; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; Cerecetto H, 2005, MINI-REV MED CHEM, V5, P57, DOI 10.2174/1389557053402864; CIOLI D, 1993, PARASITOL TODAY, V9, P162, DOI 10.1016/0169-4758(93)90138-6; FALLON PG, 1994, AM J TROP MED HYG, V51, P83, DOI 10.4269/ajtmh.1994.51.83; FEELISCH M, 1992, BIOCHEM PHARMACOL, V44, P1149, DOI 10.1016/0006-2952(92)90379-W; Fenwick A, 2006, CURR OPIN INFECT DIS, V19, P577, DOI 10.1097/01.qco.0000247591.13671.6a; HERWALDT BL, 1995, CLIN INFECT DIS, V20, P309, DOI 10.1093/clinids/20.2.309; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; JAMES SL, 1989, J IMMUNOL, V143, P4208; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206; Lewis R, 1998, CAN REV AM STUD, V28, P1, DOI 10.3138/CRAS-028-02-01; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; MEDANA C, 1994, J MED CHEM, V37, P4412, DOI 10.1021/jm00051a020; MurraySmith SQ, 1996, MED J AUSTRALIA, V165, P458, DOI 10.5694/j.1326-5377.1996.tb138598.x; Nims Raymond W., 1995, Methods (Orlando), V7, P48, DOI 10.1006/meth.1995.1007; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53; SABAH AA, 1986, EXP PARASITOL, V61, P294, DOI 10.1016/0014-4894(86)90184-0; Simeonov A, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000127; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7; Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Utzinger J, 2007, CURR OPIN INVEST DR, V8, P105; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Xiao SH, 2000, PARASITOL INT, V49, P19, DOI 10.1016/S1383-5769(00)00028-3	36	214	233	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					407	412		10.1038/nm1737	http://dx.doi.org/10.1038/nm1737			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18345010	Green Accepted			2022-12-27	WOS:000254674100027
J	Ott, HC; Matthiesen, TS; Goh, SK; Black, LD; Kren, SM; Netoff, TI; Taylor, DA				Ott, Harald C.; Matthiesen, Thomas S.; Goh, Saik-Kia; Black, Lauren D.; Kren, Stefan M.; Netoff, Theoden I.; Taylor, Doris A.			Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart	NATURE MEDICINE			English	Article							CARDIAC TISSUE; RECELLULARIZATION; SCAFFOLD	About 3,000 individuals in the United States are awaiting a donor heart; worldwide, 22 million individuals are living with heart failure. A bioartificial heart is a theoretical alternative to transplantation or mechanical left ventricular support. Generating a bioartificial heart requires engineering of cardiac architecture, appropriate cellular constituents and pump function. We decellularized hearts by coronary perfusion with detergents, preserved the underlying extracellular matrix, and produced an acellular, perfusable vascular architecture, competent acellular valves and intact chamber geometry. To mimic cardiac cell composition, we reseeded these constructs with cardiac or endothelial cells. To establish function, we maintained eight constructs for up to 28 d by coronary perfusion in a bioreactor that simulated cardiac physiology. By day 4, we observed macroscopic contractions. By day 8, under physiological load and electrical stimulation, constructs could generate pump function (equivalent to about 2% of adult or 25% of 16-week fetal heart function) in a modified working heart preparation.	[Matthiesen, Thomas S.; Goh, Saik-Kia; Kren, Stefan M.; Taylor, Doris A.] Univ Minnesota, Ctr Cardiovasc Repair, Minneapolis, MN 55455 USA; [Ott, Harald C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA; [Black, Lauren D.; Netoff, Theoden I.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA; [Taylor, Doris A.] Univ Minnesota, Dept Integrat Biol & Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Taylor, DA (corresponding author), Univ Minnesota, Ctr Cardiovasc Repair, 312 Church St SE,7-105A NHH, Minneapolis, MN 55455 USA.	dataylor@umn.edu	aksel, hacer/H-1572-2015; Sano, Michael/E-1715-2011	Netoff, Theoden/0000-0002-0115-1930; Kren, Stefan/0000-0001-8015-543X; Black, Lauren/0000-0002-7486-5811				BODNAR E, 1986, THORAC CARDIOV SURG, V34, P82, DOI 10.1055/s-2007-1020381; Chen RN, 2004, BIOMATERIALS, V25, P2679, DOI 10.1016/j.biomaterials.2003.09.070; COURTMAN DW, 1994, J BIOMED MATER RES, V28, P655, DOI 10.1002/jbm.820280602; Dellgren G, 2002, EUR J CARDIO-THORAC, V22, P912, DOI 10.1016/S1010-7940(02)00584-5; Eschenhagen T, 2005, CIRC RES, V97, P1220, DOI 10.1161/01.RES.0000196562.73231.7d; Furuta A, 2006, CIRC RES, V98, P705, DOI 10.1161/01.RES.0000209515.59115.70; Gerecht-Nir S, 2006, INT J DEV BIOL, V50, P233, DOI 10.1387/ijdb.052041sg; Gilbert TW, 2006, BIOMATERIALS, V27, P3675, DOI 10.1016/j.biomaterials.2006.02.014; Grabow N, 2004, ARTIF ORGANS, V28, P971, DOI 10.1111/j.1525-1594.2004.00007.x; Johnson P, 2000, HEART, V84, P59, DOI 10.1136/heart.84.1.59; Ketchedjian A, 2005, ANN THORAC SURG, V79, P888, DOI 10.1016/j.athoracsur.2004.09.033; Kobashigawa JA, 2006, NAT CLIN PRACT CARD, V3, P203, DOI 10.1038/ncpcardio0510; Mirsadraee S, 2006, TISSUE ENG, V12, P763, DOI 10.1089/ten.2006.12.763; Miyagawa S, 2005, TRANSPLANTATION, V80, P1586, DOI 10.1097/01.tp.0000181163.69108.dd; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; OSSIPOW V, 1993, NUCLEIC ACIDS RES, V21, P6040, DOI 10.1093/nar/21.25.6040; Park H, 2005, IN VITRO CELL DEV-AN, V41, P188; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; PRESS WH, 1992, NUMERICAL RECIPES C, pCH12; Radisic M, 2005, AM J PHYSIOL-HEART C, V288, pH1278, DOI 10.1152/ajpheart.00787.2004; Rieder E, 2004, J THORAC CARDIOV SUR, V127, P399, DOI 10.1016/j.jtcvs.2003.06.017; Robinson KA, 2005, CIRCULATION, V112, pI135, DOI 10.1161/CIRCULATIONAHA.104.525436; Roy S, 2005, AM J PHYSIOL-HEART C, V289, pH1567, DOI 10.1152/ajpheart.00564.2004; RUSS JC, 2002, IMAGE PROCESSING HDB, pCH4; Sekine H, 2006, J HEART LUNG TRANSPL, V25, P324, DOI 10.1016/j.healun.2005.09.017; Zimmermann WH, 2006, NAT MED, V12, P452, DOI 10.1038/nm1394	26	1862	2017	10	503	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					213	221		10.1038/nm1684	http://dx.doi.org/10.1038/nm1684			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18193059				2022-12-27	WOS:000252946700032
J	Himburg, HA; Muramoto, GG; Daher, P; Meadows, SK; Russell, JL; Doan, P; Chi, JT; Salter, AB; Lento, WE; Reya, T; Chao, NJ; Chute, JP				Himburg, Heather A.; Muramoto, Garrett G.; Daher, Pamela; Meadows, Sarah K.; Russell, J. Lauren; Doan, Phuong; Chi, Jen-Tsan; Salter, Alice B.; Lento, William E.; Reya, Tannishtha; Chao, Nelson J.; Chute, John P.			Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells	NATURE MEDICINE			English	Article							EX-VIVO CULTURE; ENDOTHELIAL-CELLS; SELF-RENEWAL; IN-VIVO; CD34(+)CD38(-) CELLS; PATHWAYS; NICHE; RECONSTITUTION; TRANSDUCTION; ENGRAFTMENT	Hematopoietic stem cell (HSC) self-renewal is regulated by both intrinsic and extrinsic signals. Although some of the pathways that regulate HSC self-renewal have been uncovered, it remains largely unknown whether these pathways can be triggered by deliverable growth factors to induce HSC growth or regeneration. Here we show that pleiotrophin, a neurite outgrowth factor with no known function in hematopoiesis, efficiently promotes HSC expansion in vitro and HSC regeneration in vivo. Treatment of mouse bone marrow HSCs with pleiotrophin caused a marked increase in long-term repopulating HSC numbers in culture, as measured in competitive repopulating assays. Treatment of human cord blood CD34+CDCD38(-)Lin(-) cells with pleiotrophin also substantially increased severe combined immunodeficient (SCID)-repopulating cell counts in culture, compared to input and cytokine-treated cultures. Systemic administration of pleiotrophin to irradiated mice caused a pronounced expansion of bone marrow stem and progenitor cells in vivo, indicating that pleiotrophin is a regenerative growth factor for HSCs. Mechanistically, pleiotrophin activated phosphoinositide 3-kinase (PI3K) signaling in HSCs; antagonism of PI3K or Notch signaling inhibited pleiotrophin-mediated expansion of HSCs in culture. We identify the secreted growth factor pleiotrophin as a new regulator of both HSC expansion and regeneration.	[Himburg, Heather A.; Muramoto, Garrett G.; Daher, Pamela; Meadows, Sarah K.; Russell, J. Lauren; Doan, Phuong; Chi, Jen-Tsan; Salter, Alice B.; Chao, Nelson J.; Chute, John P.] Duke Univ, Dept Med, Div Cellular Therapy, Durham, NC 27706 USA; [Chi, Jen-Tsan] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Lento, William E.; Reya, Tannishtha; Chute, John P.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Chao, Nelson J.] Duke Univ, Dept Immunol, Durham, NC USA	Duke University; Duke University; Duke University; Duke University	Chute, JP (corresponding author), Duke Univ, Dept Med, Div Cellular Therapy, Durham, NC 27706 USA.	john.chute@duke.edu	Doan, Phuong L./Q-2093-2019; Chi, Jen-Tsan/AAI-4125-2020	Doan, Phuong L./0000-0003-1361-2068; Chi, Jen-Tsan/0000-0003-3433-903X	US National Institutes of Health [AI067798]; Center for Biomolecular and Tissue Engineering; US National Institute of Biomedical Imaging and Bioengineering; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067798] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Biomolecular and Tissue Engineering; US National Institute of Biomedical Imaging and Bioengineering(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We acknowledge J. Whitesides for assistance with cell sorting procedures. This work was supported in part by US National Institutes of Health grant AI067798 to J. P. C., H. A. H. is supported by a post-doctoral training grant from the Center for Biomolecular and Tissue Engineering, US National Institute of Biomedical Imaging and Bioengineering.	Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Blank U, 2008, BLOOD, V111, P492, DOI 10.1182/blood-2007-07-075168; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chang YC, 2007, P NATL ACAD SCI USA, V104, P10888, DOI 10.1073/pnas.0704366104; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Chute JP, 2007, BLOOD, V109, P2365, DOI 10.1182/blood-2006-05-022640; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Chute JP, 2005, BLOOD, V105, P576, DOI 10.1182/blood-2004-04-1467; Chute JP, 2002, BLOOD, V100, P4433, DOI 10.1182/blood-2002-04-1238; Congdon KL, 2008, STEM CELLS, V26, P1202, DOI 10.1634/stemcells.2007-0768; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Dorrell C, 2000, BLOOD, V95, P102; Dressman HK, 2007, PLOS MED, V4, P690, DOI 10.1371/journal.pmed.0040106; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gottschling S, 2007, STEM CELLS, V25, P798, DOI 10.1634/stemcells.2006-0513; Gu DY, 2007, FEBS LETT, V581, P382, DOI 10.1016/j.febslet.2006.12.043; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006; Karlsson G, 2007, J EXP MED, V204, P467, DOI 10.1084/jem.20060465; Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279; Kunisato A, 2003, BLOOD, V101, P1777, DOI 10.1182/blood-2002-07-2051; Landgraf P, 2008, J BIOL CHEM, V283, P25036, DOI 10.1074/jbc.M800963200; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Orkin SH, 2008, CELL, V132, P712, DOI 10.1016/j.cell.2008.02.013; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Perez-Pinera P, 2008, CURR OPIN HEMATOL, V15, P210, DOI 10.1097/MOH.0b013e3282fdc69e; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Salter AB, 2009, BLOOD, V113, P2104, DOI 10.1182/blood-2008-06-162941; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Yeh HJ, 1998, J NEUROSCI, V18, P3699; Zhang CC, 2006, NAT MED, V12, P240, DOI 10.1038/nm1342; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zon LI, 2008, NATURE, V453, P306, DOI 10.1038/nature07038	40	216	231	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					475	U163		10.1038/nm.2119	http://dx.doi.org/10.1038/nm.2119			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20305662	Green Accepted			2022-12-27	WOS:000276446800054
J	Park, SW; Zhou, YJ; Lee, J; Lu, A; Sun, C; Chung, J; Ueki, K; Ozcan, U				Park, Sang Won; Zhou, Yingjiang; Lee, Justin; Lu, Allen; Sun, Cheng; Chung, Jason; Ueki, Kohjiro; Ozcan, Umut			The regulatory subunits of PI3K, p85 alpha and p85 beta, interact with XBP-1 and increase its nuclear translocation	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSMEMBRANE PROTEIN; SIGNALING PATHWAYS; MESSENGER-RNA; ER; DEPHOSPHORYLATION; TRANSCRIPTION; BIOSYNTHESIS; TRANSLATION; ACTIVATION	Despite the fact that X-box binding protein-1 (XBP-1) is one of the main regulators of the unfolded protein response (UPR), the modulators of XBP-1 are poorly understood. Here, we show that the regulatory subunits of phosphotidyl inositol 3-kinase (PI3K), p85 alpha (encoded by Pik3r1) and p85 beta (encoded by Pik3r2) form heterodimers that are disrupted by insulin treatment. This disruption of heterodimerization allows the resulting monomers of p85 to interact with, and increase the nuclear translocation of, the spliced form of XBP-1 (XBP-1s). The interaction between p85 and XBP-1s is lost in ob/ob mice, resulting in a severe defect in XBP-1s translocation to the nucleus and thus in the resolution of endoplasmic reticulum (ER) stress. These defects are ameliorated when p85 alpha and p85 beta are overexpressed in the liver of ob/ob mice. Our results define a previously unknown insulin receptor signaling pathway and provide new mechanistic insight into the development of ER stress during obesity.	[Ueki, Kohjiro] Univ Tokyo, Dept Metab Dis, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Park, Sang Won; Zhou, Yingjiang; Lee, Justin; Lu, Allen; Sun, Cheng; Chung, Jason; Ozcan, Umut] Harvard Univ, Sch Med, Div Endocrinol Childrens Hosp Boston, Boston, MA USA	University of Tokyo; Harvard University; Harvard Medical School	Ueki, K (corresponding author), Univ Tokyo, Dept Metab Dis, Grad Sch Med, Bunkyo Ku, Tokyo, Japan.	ueki-tky@umin.net; umut.ozcan@childrens.harvard.edu	Longo, Kenneth A/A-5631-2010		Children's Hospital Boston; Translational Research Award; Timothy Murphy funds;  [R01DK081009]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081009] Funding Source: NIH RePORTER	Children's Hospital Boston; Translational Research Award; Timothy Murphy funds; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the Ozcan laboratory for their contributions to this project. We are grateful to L. Cantley (Harvard Medical School) for kindly providing us with the Pik3r1<SUP>f/f</SUP>; Pik3r2<SUP>-/-</SUP> mice. We would like to thank the Children's Hospital Boston Proteomics Core Facility and H. Steen for the tandem mass spectroscopy analysis. This study was supported by junior faculty start-up funds provided to U.O. by Children's Hospital Boston, Translational Research Award, an RO1 grant (R01DK081009) provided to U.O., and Timothy Murphy funds provided to Division of Endocrinology, Children's Hospital Boston.	Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Dai YX, 2007, J PSYCHIATR NEUROSCI, V32, P323; Deleris P, 2006, J CELL BIOCHEM, V98, P469, DOI 10.1002/jcb.20695; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Furuya F, 2007, STEROIDS, V72, P171, DOI 10.1016/j.steroids.2006.11.005; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; MORI K, 1993, CELL, V74, P743; Nandi A, 2004, PHYSIOL REV, V84, P623, DOI 10.1152/physrev.00032.2003; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Okkenhaug K, 2001, Sci STKE, V2001, ppe1; Oyadomari S, 2008, CELL METAB, V7, P520, DOI 10.1016/j.cmet.2008.04.011; Ozcan L, 2009, CELL METAB, V9, P35, DOI 10.1016/j.cmet.2008.12.004; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sephton CF, 2008, J NEUROSCI RES, V86, P675, DOI 10.1002/jnr.21516; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Sriburi R, 2007, J BIOL CHEM, V282, P7024, DOI 10.1074/jbc.M609490200; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Tsuboi N, 2008, BIOCHEM J, V413, P193, DOI 10.1042/BJ20071317; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	33	206	218	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					429	U111		10.1038/nm.2099	http://dx.doi.org/10.1038/nm.2099			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20348926	Green Accepted			2022-12-27	WOS:000276446800047
J	Li, HH; Rybicki, AC; Suzuka, SM; von Bonsdorff, L; Breuer, W; Hall, CB; Cabantchik, ZI; Bouhassira, EE; Fabry, ME; Ginzburg, YZ				Li, Huihui; Rybicki, Anne C.; Suzuka, Sandra M.; von Bonsdorff, Leni; Breuer, William; Hall, Charles B.; Cabantchik, Z. Ioav; Bouhassira, Eric E.; Fabry, Mary E.; Ginzburg, Yelena Z.			Transferrin therapy ameliorates disease in beta-thalassemic mice	NATURE MEDICINE			English	Article							LABILE PLASMA IRON; INEFFECTIVE ERYTHROPOIESIS; HEPCIDIN EXPRESSION; REDOX ACTIVITY; ALPHA-GLOBIN; MOUSE MODEL; BINDING; PATHOPHYSIOLOGY; QUANTIFICATION; IDENTIFICATION	Individuals with beta-thalassemia develop progressive systemic iron overload, resulting in high morbidity and mortality. These complications are caused by labile plasma iron, which is taken up by parenchymal cells in a dysregulated manner; in contrast, erythropoiesis depends on transferrin-bound iron uptake via the transferrin receptor. We hypothesized that the ineffective erythropoiesis and anemia observed in beta-thalassemia might be ameliorated by increasing the amount of circulating transferrin. We tested the ability of transferrin injections to modulate iron metabolism and erythropoiesis in Hbb(th1/th1) mice, an experimental model of beta-thalassemia. Injected transferrin reversed or markedly improved the thalassemia phenotype in these mice. Specifically, transferrin injections normalized labile plasma iron concentrations, increased hepcidin expression, normalized red blood cell survival and increased hemoglobin production; this treatment concomitantly decreased reticulocytosis, erythropoietin abundance and splenomegaly. These results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human beta-thalassemia.	[Li, Huihui; Ginzburg, Yelena Z.] New York Blood Ctr, Lindsley F Kimball Res Inst, Erythropoiesis Lab, New York, NY 10021 USA; [Rybicki, Anne C.] Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA; [Suzuka, Sandra M.; Bouhassira, Eric E.; Fabry, Mary E.] Albert Einstein Coll Med, Div Hematol, Bronx, NY 10467 USA; [von Bonsdorff, Leni] Sanquin, Helsinki, Finland; [Breuer, William; Cabantchik, Z. Ioav] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91905 Jerusalem, Israel; [Hall, Charles B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA	New York Blood Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Hebrew University of Jerusalem; Yeshiva University; Albert Einstein College of Medicine	Ginzburg, YZ (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Erythropoiesis Lab, New York, NY 10021 USA.	yginzburg@nybloodcenter.org	Hall, Charles B./AAX-8216-2020; Bouhassira, Eric/AAZ-4184-2021	Hall, Charles/0000-0001-9982-8120	US National Institutes of Health-National Heart, Lung, and Blood Institute [HL68962, HL07556]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068962] Funding Source: NIH RePORTER	US National Institutes of Health-National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We extend special thanks to M. Knutson ( University of Florida, Gainesville) for providing mouse antibodies to FPN-1, Jacobi Medical Center for sample analysis, T. Ganz, E. Nemeth and S. Rivella for stimulating discussions and R. Nagel and M. Narla for unparalleled guidance and support. This work was supported in part by contract grant sponsor US National Institutes of Health-National Heart, Lung, and Blood Institute number HL68962 and HL07556.	Adamsky K, 2004, BRIT J HAEMATOL, V124, P123, DOI 10.1046/j.1365-2141.2003.04734.x; Beauchemin H, 2004, J BIOL CHEM, V279, P19471, DOI 10.1074/jbc.M309989200; Centis F, 2000, BLOOD, V96, P3624; Chaudhury C, 2006, J NUTR, V136, P2993, DOI 10.1093/jn/136.12.2993; Chen JJ, 2007, BLOOD, V109, P2693, DOI 10.1182/blood-2006-08-041830; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; De Franceschi L, 2006, HAEMATOLOGICA, V91, P1336; de Jong K, 2001, BLOOD, V98, P1577, DOI 10.1182/blood.V98.5.1577; Esposito BP, 2003, BLOOD, V102, P2670, DOI 10.1182/blood-2003-03-0807; FINCH C, 1994, BLOOD, V84, P1697; Gardenghi S, 2007, BLOOD, V109, P5027, DOI 10.1182/blood-2006-09-048868; GARRICK LM, 1989, EXP HEMATOL, V17, P423; Ginzburg YZ, 2009, EXP HEMATOL, V37, P172, DOI 10.1016/j.exphem.2008.10.004; HOSAIN F, 1967, J CLIN INVEST, V46, P1, DOI 10.1172/JCI105501; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; HUEBERS HA, 1984, P NATL ACAD SCI-BIOL, V81, P4326, DOI 10.1073/pnas.81.14.4326; HUEBERS HA, 1983, P NATL ACAD SCI-BIOL, V80, P300, DOI 10.1073/pnas.80.1.300; Kattamis A, 2006, HAEMATOLOGICA, V91, P809; Kean LS, 2002, EXP HEMATOL, V30, P394, DOI 10.1016/S0301-472X(02)00780-4; Kong Y, 2004, J CLIN INVEST, V114, P1457, DOI 10.1172/JCI200421982; Libani IV, 2008, BLOOD, V112, P875, DOI 10.1182/blood-2007-12-126938; Liu Y, 2006, BLOOD, V108, P123, DOI 10.1182/blood-2005-11-4458; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Papanikolaou G, 2005, BLOOD, V105, P4103, DOI 10.1182/blood-2004-12-4844; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Parkkinen J, 2006, BRIT J HAEMATOL, V135, P228, DOI 10.1111/j.1365-2141.2006.06273.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinheiro J. C., 1995, J COMPUTATIONAL GRAP, V4, P12, DOI [DOI 10.2307/1390625, 10.1080/10618600.1995.10474663, DOI 10.1080/10618600.1995.10474663]; PIPPARD MJ, 1979, LANCET, V2, P819; Pootrakul P, 2004, BLOOD, V104, P1504, DOI 10.1182/blood-2004-02-0630; POOTRAKUL P, 1988, BLOOD, V71, P1124; Raja KB, 1999, BLOOD, V94, P3185, DOI 10.1182/blood.V94.9.3185.421a20_3185_3192; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Silva AMN, 2009, BBA-PROTEINS PROTEOM, V1794, P1449, DOI 10.1016/j.bbapap.2009.06.003; SKOW LC, 1983, CELL, V34, P1043, DOI 10.1016/0092-8674(83)90562-7; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; SORENSEN S, 1990, BLOOD, V75, P1333; Tanno T, 2007, NAT MED, V13, P1096, DOI 10.1038/nm1629; Tanno T, 2009, BLOOD, V114, P181, DOI 10.1182/blood-2008-12-195503; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; Vokurka M, 2006, PHYSIOL RES, V55, P667, DOI 10.33549/physiolres.930841; von Bonsdorff L, 2001, BIOLOGICALS, V29, P27, DOI 10.1006/biol.2001.0273; Weatherall DJ, 1998, BAILLIERE CLIN HAEM, V11, P127, DOI 10.1016/S0950-3536(98)80072-3	44	148	157	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					177	U80		10.1038/nm.2073	http://dx.doi.org/10.1038/nm.2073			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20098432				2022-12-27	WOS:000274297000038
J	Stein, S; Ott, MG; Schultze-Strasser, S; Jauch, A; Burwinkel, B; Kinner, A; Schmidt, M; Kramer, A; Schwable, J; Glimm, H; Koehl, U; Preiss, C; Ball, C; Martin, H; Gohring, G; Schwarzwaelder, K; Hofmann, WK; Karakaya, K; Tchatchou, S; Yang, RX; Reinecke, P; Kuhlcke, K; Schlegelberger, B; Thrasher, AJ; Hoelzer, D; Seger, R; von Kalle, C; Grez, M				Stein, Stefan; Ott, Marion G.; Schultze-Strasser, Stephan; Jauch, Anna; Burwinkel, Barbara; Kinner, Andrea; Schmidt, Manfred; Kraemer, Alwin; Schwaeble, Joachim; Glimm, Hanno; Koehl, Ulrike; Preiss, Carolin; Ball, Claudia; Martin, Hans; Goehring, Gudrun; Schwarzwaelder, Kerstin; Hofmann, Wolf-Karsten; Karakaya, Kadin; Tchatchou, Sandrine; Yang, Rongxi; Reinecke, Petra; Kuehlcke, Klaus; Schlegelberger, Brigitte; Thrasher, Adrian J.; Hoelzer, Dieter; Seger, Reinhard; von Kalle, Christof; Grez, Manuel			Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; RETROVIRAL VECTOR INSERTION; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; EXPRESSION; METHYLATION; MLL5; PROLIFERATION; INTEGRATION; REPRESSION	Gene-modified autologous hematopoietic stem cells (HSC) can provide ample clinical benefits to subjects suffering from X-linked chronic granulomatous disease (X-CGD), a rare inherited immunodeficiency characterized by recurrent, often life-threatening bacterial and fungal infections. Here we report on the molecular and cellular events observed in two young adults with X-CGD treated by gene therapy in 2004. After the initial resolution of bacterial and fungal infections, both subjects showed silencing of transgene expression due to methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional activation of ecotropic viral integration site 1 (EVI1). One subject died from overwhelming sepsis 27 months after gene therapy, whereas a second subject underwent an allogeneic HSC transplantation. Our data show that forced overexpression of EVI1 in human cells disrupts normal centrosome duplication, linking EVI1 activation to the development of genomic instability, monosomy 7 and clonal progression toward myelodysplasia.	[Stein, Stefan; Schultze-Strasser, Stephan; Kinner, Andrea; Preiss, Carolin; Grez, Manuel] Inst Biomed Res, Frankfurt, Germany; [Ott, Marion G.; Schwaeble, Joachim; Martin, Hans; Hoelzer, Dieter] Univ Med Sch, Dept Hematol Oncol, Frankfurt, Germany; [Jauch, Anna] Univ Heidelberg Hosp, Inst Human Genet, Heidelberg, Germany; [Burwinkel, Barbara; Tchatchou, Sandrine; Yang, Rongxi] German Canc Res Ctr, Mol Epidemiol Grp, D-6900 Heidelberg, Germany; [Burwinkel, Barbara; Tchatchou, Sandrine; Yang, Rongxi] Univ Womens Clin, Div Mol Biol Breast Canc, Heidelberg, Germany; [Schmidt, Manfred; Glimm, Hanno; Ball, Claudia; Schwarzwaelder, Kerstin; von Kalle, Christof] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany; [Kraemer, Alwin; Karakaya, Kadin] German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, D-6900 Heidelberg, Germany; [Kraemer, Alwin; Karakaya, Kadin] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Koehl, Ulrike] Hannover Med Sch, Dept Cell & Mol Pathol, D-3000 Hannover, Germany; [Goehring, Gudrun; Schlegelberger, Brigitte] Charite, Dept Hematol Oncol & Transfus Med, Berlin, Germany; [Hofmann, Wolf-Karsten] Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; [Reinecke, Petra] EUFETS AG, Idar Oberstein, Germany; [Kuehlcke, Klaus] UCL Inst Child Hlth, Ctr Immunodeficiency, London, England; [Kuehlcke, Klaus] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Thrasher, Adrian J.] Univ Childrens Hosp Zurich, Div Hematol Immunol, Zurich, Switzerland	University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Hannover Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University Children's Hospital Zurich	Grez, M (corresponding author), Inst Biomed Res, Frankfurt, Germany.	grez@em.uni-frankfurt.de		Thrasher, Adrian/0000-0002-6097-6115; Ball, Claudia/0000-0002-1749-3791; Stein, Stefan/0000-0003-1473-9706; Koehl, Ulrike/0000-0002-8159-9160	Bundesministerium fur Bildung und Forschung [01GU0507, TP6b]; Chronic Granulomatous Disorder Research Trust, London [J4G/04B/GT]; Georg-Speyer-Haus [T300131]; EU; Deutsche Forschungsgemeinschaft; Wellcome Trust; Department of Health [HTH/011/025/004]; Deutsche Krebshilfe [108560]; Bundesministerium fur Gesundheit and the Hessisches Ministerium fur Wissenschaft und Kunst; Great Ormond Street Hospital Childrens Charity [V1223] Funding Source: researchfish	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Chronic Granulomatous Disorder Research Trust, London; Georg-Speyer-Haus; EU(European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wellcome Trust(Wellcome Trust); Department of Health; Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Gesundheit and the Hessisches Ministerium fur Wissenschaft und Kunst; Great Ormond Street Hospital Childrens Charity	We are indebted to K. Bleuel and S. Wehner for contributions and advice during the study; to H. Holtgreve-Grez and B. Schoell for I-FISH and M-FISH analysis, respectively; to H. Konrad Muller-Hermelink for reference pathology; to B. Staehle for quantitative PCR; to M. C. Dinauer ( Indiana University School of Medicine) for plasmid gp91<SUP>phox</SUP>(P415H) and to H. Kunkel, E. Rudolf, A. Dillmann, R. Kramer, B. Moreno, I. Vogler and L. Chen-Wichmann for assistance during this work. This work was supported by the Bundesministerium fur Bildung und Forschung ( grant 01GU0507, TP6b), the Chronic Granulomatous Disorder Research Trust, London ( grant J4G/04B/GT), the Georg-Speyer-Haus (T300131), the EU ( VIth Framework Program, CONSERT), the Research Priority Program 1230 from the Deutsche Forschungsgemeinschaft and, in part, by a grant of the Tumorzentrum Heidelberg/Mannheim to A.J.A.J.T. is also supported by the Wellcome Trust and the Department of Health ( HTH/011/025/004). A. Kramer is supported by the Deutsche Krebshilfe ( grant 108560). The Georg-Speyer-Haus is supported by the Bundesministerium fur Gesundheit and the Hessisches Ministerium fur Wissenschaft und Kunst.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Burns WR, 2009, BLOOD, V114, P2888, DOI 10.1182/blood-2009-01-199216; Calmels B, 2005, BLOOD, V106, P2530, DOI 10.1182/blood-2005-03-1115; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Charrin Christiane, 2002, Hematol J, V3, P21, DOI 10.1038/sj.thj.6200143; Chi YQ, 2003, J BIOL CHEM, V278, P49806, DOI 10.1074/jbc.M309645200; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; DINAUER MC, 1993, CRIT REV CL LAB SCI, V30, P329, DOI 10.3109/10408369309082591; DREYFUS F, 1995, LEUKEMIA, V9, P203; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Frank O, 2004, BLOOD, V104, P3543, DOI 10.1182/blood-2004-03-0852; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gaspar HB, 2006, MOL THER, V14, P505, DOI 10.1016/j.ymthe.2006.06.007; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hamaguchi H, 1997, BRIT J HAEMATOL, V98, P399, DOI 10.1046/j.1365-2141.1997.2143029.x; Heuser M, 2009, BLOOD, V113, P1432, DOI [10.1182/blood-2008-02-162263, 10.1182/blood-2008-06-162263]; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Kearns WG, 2004, GENE CHROMOSOME CANC, V40, P329, DOI 10.1002/gcc.20043; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kustikova OS, 2007, BLOOD, V109, P1897, DOI 10.1182/blood-2006-08-044156; Laricchia-Robbio L, 2008, BLOOD CELL MOL DIS, V40, P141, DOI 10.1016/j.bcmd.2007.07.012; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Lin P, 2006, CANCER GENET CYTOGEN, V166, P82, DOI 10.1016/j.cancergencyto.2005.10.007; Madan V, 2009, BLOOD, V113, P1444, DOI 10.1182/blood-2008-02-142638; Malech HL, 2007, CURR OPIN HEMATOL, V14, P29, DOI 10.1097/00062752-200701000-00007; Manfred S, 2007, NAT METHODS, V4, P1051, DOI 10.1038/nmeth1103; Metais JY, 2008, MOL THER, V16, P439, DOI 10.1038/sj.mt.6300372; Modlich U, 2008, LEUKEMIA, V22, P1519, DOI 10.1038/leu.2008.118; Neben K, 2003, BLOOD, V101, P289, DOI 10.1182/blood-2002-04-1188; Nolte F, 2008, ANN HEMATOL, V87, P777, DOI 10.1007/s00277-008-0502-z; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; Sebastian S, 2009, P NATL ACAD SCI USA, V106, P4719, DOI 10.1073/pnas.0807136106; Segal AW, 1996, MOL MED TODAY, V2, P129, DOI 10.1016/1357-4310(96)88723-5; Senyuk V, 2007, CANCER RES, V67, P5658, DOI 10.1158/0008-5472.CAN-06-3962; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Spensberger D, 2008, BIOCHEMISTRY-US, V47, P6418, DOI 10.1021/bi800267f; Stevens-Kroef M, 2004, LEUKEMIA, V18, P1108, DOI 10.1038/sj.leu.2403346; Trubia M, 2006, LEUKEMIA, V20, P48, DOI 10.1038/sj.leu.2404020; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Wang LJ, 1998, HUM GENE THER, V9, P2321, DOI 10.1089/hum.1998.9.16-2321; Zhang Y, 2009, BLOOD, V113, P1455, DOI 10.1182/blood-2008-05-159905	59	584	600	0	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					198	U105		10.1038/nm.2088	http://dx.doi.org/10.1038/nm.2088			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20098431	Green Published			2022-12-27	WOS:000274297000041
J	Lin, AC; Seeto, BL; Bartoszko, JM; Khoury, MA; Whetstone, H; Ho, L; Hsu, C; Ali, AS; Alman, BA				Lin, Alvin C.; Seeto, Brian L.; Bartoszko, Justyna M.; Khoury, Michael A.; Whetstone, Heather; Ho, Louisa; Hsu, Claire; Ali, Amanda S.; Alman, Benjamin A.			Modulating hedgehog signaling can attenuate the severity of osteoarthritis	NATURE MEDICINE			English	Article							SMALL-MOLECULE INHIBITOR; INDIAN-HEDGEHOG; CHONDROCYTE DIFFERENTIATION; ARTICULAR-CARTILAGE; II COLLAGEN; HUMAN ADAMTS-5; BONE-FORMATION; GROWTH-PLATE; EXPRESSION; DEGRADATION	Osteoarthritis is associated with the irreversible degeneration of articular cartilage. Notably, in this condition, articular cartilage chondrocytes undergo phenotypic and gene expression changes that are reminiscent of their end-stage differentiation in the growth plate during skeletal development(1,2). Hedgehog (Hh) signaling regulates normal chondrocyte growth and differentiation(3-8); however, the role of Hh signaling in chondrocytes in osteoarthritis is unknown. Here we examine human osteoarthritic samples and mice in which osteoarthritis was surgically induced and find that Hh signaling is activated in osteoarthritis. Using several genetically modified mice, we found that higher levels of Hh signaling in chondrocytes cause a more severe osteoarthritic phenotype. Furthermore, we show in mice and in human cartilage explants that pharmacological or genetic inhibition of Hh signaling reduces the severity of osteoarthritis and that runt-related transcription factor-2 (RUNX2) potentially mediates this process by regulating a disintegrin and metalloproteinase with thrombospondin type 1 motif-5 (ADAMTS5) expression. Together, these findings raise the possibility that Hh blockade can be used as a therapeutic approach to inhibit articular cartilage degeneration.	[Lin, Alvin C.; Seeto, Brian L.; Bartoszko, Justyna M.; Khoury, Michael A.; Whetstone, Heather; Ho, Louisa; Hsu, Claire; Ali, Amanda S.; Alman, Benjamin A.] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; [Lin, Alvin C.; Hsu, Claire; Ali, Amanda S.; Alman, Benjamin A.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Lin, Alvin C.; Ho, Louisa; Hsu, Claire; Ali, Amanda S.; Alman, Benjamin A.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Alman, Benjamin A.] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada; [Alman, Benjamin A.] Univ Toronto, Div Orthopaed Surg, Toronto, ON, Canada; [Alman, Benjamin A.] Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca		Khoury, Michael/0000-0001-6112-6860; Ali, Shabana/0000-0002-4339-9467	Canadian Institutes of Health Research [FRN: 79436]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We wish to thank D. Backstein and A. Gross (Mount Sinai Hospital, Toronto) for assistance obtaining human cartilage samples, T. Mak (University Health Network, Toronto) for assistance obtaining the hedgehog blocking agent, L. Morikawa for assistance with sectioning and histology, P. Roughley (McGill University) for providing the COL2-rtTA-Cre mice and R. Ward and C.-C. Hui for their assistance with the Ptch1+/-mice. The Canada Research Chair program supports B. A. A. A. C. L. and C. H. are supported by Canadian Institutes of Health Research studentships; L. H. and A. S. A. are supported by Ontario graduate scholarships. This work was supported by the Canadian Institutes of Health Research grant FRN: 79436.	ADAMS ME, 1995, J RHEUMATOL, V22, P94; Adams SL, 2007, J CELL PHYSIOL, V213, P635, DOI 10.1002/jcp.21262; Aigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534; Arai M, 2004, OSTEOARTHR CARTILAGE, V12, P599, DOI 10.1016/j.joca.2004.05.001; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Everts V, 2008, METHODS, V45, P86, DOI 10.1016/j.ymeth.2008.01.009; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grover J, 2006, MATRIX BIOL, V25, P158, DOI 10.1016/j.matbio.2005.11.003; Hilton MJ, 2007, DEV BIOL, V308, P93, DOI 10.1016/j.ydbio.2007.05.011; Ho L, 2009, CANCER CELL, V16, P126, DOI 10.1016/j.ccr.2009.05.013; Hopyan S, 2005, J PATHOL, V206, P143, DOI 10.1002/path.1761; Hopyan S, 2002, NAT GENET, V30, P306, DOI 10.1038/ng844; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kamekura S, 2006, ARTHRITIS RHEUM, V54, P2462, DOI 10.1002/art.22041; Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397; Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365-2559.2006.02508.x; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Li Y, 2004, TISSUE ENG, V10, P575, DOI 10.1089/107632704323061933; Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104; Mainil-Varlet P, 2003, J BONE JOINT SURG AM, V85A, P45, DOI 10.2106/00004623-200300002-00007; Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044; Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003; Ng TCS, 2006, FRONT BIOSCI-LANDMRK, V11, P943; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sarangi A, 2009, ONCOGENE, V28, P3468, DOI 10.1038/onc.2009.208; Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06-08-0743; Slagboom E, 2008, NAT CLIN PRACT RHEUM, V4, P563, DOI 10.1038/ncprheum0935; Steinert AF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2195; Takamoto M, 2003, J ENDOCRINOL, V177, P413, DOI 10.1677/joe.0.1770413; Taniguchi H, 2007, J PATHOL, V213, P131, DOI 10.1002/path.2216; Tchetina EV, 2005, J RHEUMATOL, V32, P876; Thirunavukkarasu K, 2007, MOL BIOL REP, V34, P225, DOI 10.1007/s11033-006-9037-3; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Wunder JS, 2007, LANCET ONCOL, V8, P513, DOI 10.1016/S1470-2045(07)70169-9; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	41	233	252	2	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1421	U11		10.1038/nm.2055	http://dx.doi.org/10.1038/nm.2055			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19915594	Green Submitted			2022-12-27	WOS:000272407800023
J	Taghibiglou, C; Martin, HGS; Lai, TW; Cho, T; Prasad, S; Kojic, L; Lu, J; Liu, YT; Lo, E; Zhang, S; Wu, JZZ; Li, YP; Wen, YH; Imm, JH; Cynader, MS; Wang, YT				Taghibiglou, Changiz; Martin, Henry G. S.; Lai, Ted Weita; Cho, Taesup; Prasad, Shiv; Kojic, Luba; Lu, Jie; Liu, Yitao; Lo, Edmund; Zhang, Shu; Wu, Julia Z. Z.; Li, Yu Ping; Wen, Yan Hua; Imm, Joon-Hyuk; Cynader, Max S.; Wang, Yu Tian			Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries	NATURE MEDICINE			English	Article							ELEMENT-BINDING PROTEINS; PANCREATIC BETA-CELLS; NF-KAPPA-B; BRAIN-INJURY; IN-VITRO; CHOLESTEROL-SYNTHESIS; TRANSCRIPTION FACTORS; GLUCOSE DEPRIVATION; MEMBRANE-PROTEIN; GENE-EXPRESSION	Excitotoxic neuronal damage caused by overactivation of N-methyl-D-aspartate glutamate receptors (NMDARs) is thought to be a principal cause of neuronal loss after stroke and brain trauma. Here we report that activation of sterol regulatory element binding protein-1 (SREBP-1) transcription factor in affected neurons is an essential step in NMDAR-mediated excitotoxic neuronal death in both in vitro and in vivo models of stroke. The NMDAR-mediated activation of SREBP-1 is a result of increased insulin-induced gene-1 (Insig-1) degradation, which can be inhibited with an Insig-1-derived interference peptide (Indip) that we have developed. Using a focal ischemia model of stroke, we show that systemic administration of Indip not only prevents SREBP-1 activation but also substantially reduces neuronal damage and improves behavioral outcome. Our study suggests that agents that reduce SREBP-1 activation such as Indip may represent a new class of neuroprotective therapeutics against stroke.	[Taghibiglou, Changiz; Martin, Henry G. S.; Lai, Ted Weita; Cho, Taesup; Prasad, Shiv; Kojic, Luba; Lu, Jie; Liu, Yitao; Lo, Edmund; Zhang, Shu; Wu, Julia Z. Z.; Li, Yu Ping; Wen, Yan Hua; Imm, Joon-Hyuk; Cynader, Max S.; Wang, Yu Tian] Univ British Columbia, Brain Res Ctr, Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada; [Taghibiglou, Changiz; Martin, Henry G. S.; Lai, Ted Weita; Cho, Taesup; Prasad, Shiv; Kojic, Luba; Lu, Jie; Liu, Yitao; Lo, Edmund; Zhang, Shu; Wu, Julia Z. Z.; Li, Yu Ping; Wen, Yan Hua; Imm, Joon-Hyuk; Cynader, Max S.; Wang, Yu Tian] Univ British Columbia, Dept Med, Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada; [Wang, Yu Tian] China Med Univ Hosp, Ctr Neuropsychiat, Taichung, Taiwan; [Wang, Yu Tian] China Med Univ Hosp, Grad Inst Immunol, Taichung, Taiwan	University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health Research Institute; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Wang, YT (corresponding author), Univ British Columbia, Brain Res Ctr, Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada.	ytwang@interchange.ubc.ca	Taghibiglou, Changiz/H-4590-2019; Lai, Ted Weita/E-9392-2016; Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015	Lai, Ted Weita/0000-0002-6229-4134; Martin, Henry/0000-0002-6504-1044	Heart and Stroke Foundation of British Columbia and the Yukon; Canadian Institutes of Health Research and CHDI (Cure Huntington's Disease Initiative) Foundation; Michael Smith Foundation for Health	Heart and Stroke Foundation of British Columbia and the Yukon; Canadian Institutes of Health Research and CHDI (Cure Huntington's Disease Initiative) Foundation(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health(Michael Smith Foundation for Health Research)	We thank J.Ye (University of Texas Southwestern Medical Center) for myc-Insig-1 plasmid, T. Osborne (University of California-Irvine) for Flag-nt-SREBP-1 and Y.P. Auberson (Novartis Pharma AG) for the generous gift of NVP AAM077. We also thank J. Wang for his technical support. This work was supported by the Heart and Stroke Foundation of British Columbia and the Yukon, the Canadian Institutes of Health Research and CHDI (Cure Huntington's Disease Initiative) Foundation. Y.T.W. is a Howard Hughes Medical Institute International Scholar and Heart and Stroke Foundation of British Columbia and the Yukon Chair in Stroke Research. C. T. was supported by post-doctoral fellowships from the Canadian Institutes of Health Research and Michael Smith Foundation for Health.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Adibhatla RM, 2006, AAPS J, V8, pE314; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Camandola S, 2007, EXPERT OPIN THER TAR, V11, P123, DOI 10.1517/14728222.11.2.123; Chang YC, 2007, MOL MICROBIOL, V64, P614, DOI 10.1111/j.1365-2958.2007.05676.x; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Lee JN, 2006, P NATL ACAD SCI USA, V103, P4958, DOI 10.1073/pnas.0600422103; Lee JN, 2006, J BIOL CHEM, V281, P39308, DOI 10.1074/jbc.M608999200; Lee SH, 2008, SCIENCE, V319, P1253, DOI 10.1126/science.1150541; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu XJ, 2008, NAT MED, V14, P1325, DOI 10.1038/nm.1883; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; Mielke JG, 2005, J NEUROCHEM, V92, P103, DOI 10.1111/j.1471-4159.2004.02841.x; Mutel V, 1998, J NEUROCHEM, V70, P2147; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Park HJ, 2002, CIRC RES, V91, P32, DOI 10.1161/01.RES.0000026502.79063.66; Park HJ, 2008, J CLIN INVEST, V118, P259, DOI 10.1172/JCI32011; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Rao VR, 2007, TRENDS NEUROSCI, V30, P284, DOI 10.1016/j.tins.2007.03.012; Sandberg MB, 2005, MOL CELL ENDOCRINOL, V240, P94, DOI 10.1016/j.mce.2005.05.005; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SIESJO BK, 1992, ADV EXP MED BIOL, V318, P41; Sun LP, 2005, J BIOL CHEM, V280, P26483, DOI 10.1074/jbc.M504041200; Taghibiglou C, 2009, FEBS LETT, V583, P831, DOI 10.1016/j.febslet.2009.01.045; Takahashi A, 2005, DIABETES, V54, P492, DOI 10.2337/diabetes.54.2.492; Tigaret CM, 2006, MOL PHARMACOL, V69, P1251, DOI 10.1124/mol.105.018580; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang HY, 2003, J BIOL CHEM, V278, P16622, DOI 10.1074/jbc.M212488200; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; Wong TP, 2007, P NATL ACAD SCI USA, V104, P11471, DOI 10.1073/pnas.0702308104; Yamashita T, 2004, ENDOCRINOLOGY, V145, P3566, DOI 10.1210/en.2003-1602; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhou M, 2006, J NEUROSCI, V26, P2956, DOI 10.1523/JNEUROSCI.4299-05.2006; Zou J, 2006, CELL MOL NEUROBIOL, V26, P385, DOI 10.1007/s10571-006-9045-9	54	105	114	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1399	U7		10.1038/nm.2064	http://dx.doi.org/10.1038/nm.2064			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966780				2022-12-27	WOS:000272407800020
J	Hassel, D; Dahme, T; Erdmann, J; Meder, B; Huge, A; Stoll, M; Just, S; Hess, A; Ehlermann, P; Weichenhan, D; Grimmler, M; Liptau, H; Hetzer, R; Regitz-Zagrosek, V; Fischer, C; Nurnberg, P; Schunkert, H; Katus, HA; Rottbauer, W				Hassel, David; Dahme, Tillman; Erdmann, Jeanette; Meder, Benjamin; Huge, Andreas; Stoll, Monika; Just, Steffen; Hess, Alexander; Ehlermann, Philipp; Weichenhan, Dieter; Grimmler, Matthias; Liptau, Henrike; Hetzer, Roland; Regitz-Zagrosek, Vera; Fischer, Christine; Nuernberg, Peter; Schunkert, Heribert; Katus, Hugo A.; Rottbauer, Wolfgang			Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy	NATURE MEDICINE			English	Article							MECHANICAL STRETCH SENSOR; GENETIC-BASIS; HYPERTROPHIC CARDIOMYOPATHY; HEART; ZEBRAFISH; CONTRACTILITY; PHENOTYPES; PROTEIN; COMPONENT; DISEASE	Z-disks, the mechanical integration sites of heart and skeletal muscle cells, link anchorage of myofilaments to force reception and processing. The key molecules that enable the Z-disk to persistently withstand the extreme mechanical forces during muscle contraction have not yet been identified. Here we isolated nexilin (encoded by NEXN) as a novel Z-disk protein. Loss of nexilin in zebrafish led to perturbed Z-disk stability and heart failure. To evaluate the role of nexilin in human heart failure, we performed a genetic association study on individuals with dilated cardiomyopathy and found several mutations in NEXN associated with the disease. Nexilin mutation carriers showed the same cardiac Z-disk pathology as observed in nexilin-deficient zebrafish. Expression in zebrafish of nexilin proteins encoded by NEXN mutant alleles induced Z-disk damage and heart failure, demonstrating a dominant-negative effect and confirming the disease-causing nature of these mutations. Increasing mechanical strain aggravated Z-disk damage in nexilin-deficient skeletal muscle, implying a unique role of nexilin in protecting Z-disks from mechanical trauma.	[Hassel, David; Dahme, Tillman; Meder, Benjamin; Just, Steffen; Hess, Alexander; Ehlermann, Philipp; Weichenhan, Dieter; Katus, Hugo A.; Rottbauer, Wolfgang] Univ Heidelberg, Dept Med 3, Heidelberg, Germany; [Erdmann, Jeanette; Liptau, Henrike; Schunkert, Heribert] Med Univ Lubeck, Med Klin 2, Lubeck, Germany; [Huge, Andreas; Stoll, Monika] Univ Munster, Dept Genet Epidemiol Vasc Dis, Leibniz Inst Arteriosclerosis Res, Munster, Germany; [Grimmler, Matthias] Univ Wurzburg, Dept Biochem, Bioctr, Wurzburg, Germany; [Hetzer, Roland; Regitz-Zagrosek, Vera] German Heart Ctr, Berlin, Germany; [Regitz-Zagrosek, Vera] Charite, Cardiovasc Res Ctr, Berlin, Germany; [Fischer, Christine] Univ Heidelberg, Dept Human Genet, Heidelberg, Germany; [Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany	Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Munster; University of Wurzburg; German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; University of Cologne	Rottbauer, W (corresponding author), Univ Heidelberg, Dept Med 3, Heidelberg, Germany.	wolfgang.rottbauer@med.uni-heidelberg.de	Erdmann, Jeanette/A-4417-2009; Dahme, Tillman/AAN-4511-2021; Erdmann, Jeanette/P-7513-2014	Dahme, Tillman/0000-0002-6211-7162; Erdmann, Jeanette/0000-0002-4486-6231; Grimmler, Matthias/0000-0003-2860-3391; Regitz-Zagrosek, Vera/0000-0002-3566-3467	Deutsche Forschungsgemeinschaft [Ro2173/1-1, Ro2173/2-1, Ro2173/2-2, Ro2173/3-1]; Bundesministerium fur Bildung und Forschung [01GS0108, 01GS0420, 01GS0836]; Postdoc-Fellowship YIA of the medical faculty of the University of Heidelberg	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Postdoc-Fellowship YIA of the medical faculty of the University of Heidelberg	We thank S. Marquart, S. Weber, S. Kolb, H. Hosser, O. Mucke and S. Manthey as well as S. Wrobel for their excellent technical support. We thank B. Jurmann for human subject work-up and evaluation of clinical data and N. Frey (University of Heidelberg) for providing the calsarcin-specific antibody. We thank R. Knoll and L. Thierfelder for critical discussion of patient data. This work was supported by Deutsche Forschungsgemeinschaft Ro2173/1-1, Ro2173/2-1, Ro2173/2-2 and Ro2173/3-1 (W. R.), Bundesministerium fur Bildung und Forschung 01GS0108, 01GS0420 and 01GS0836 (W. R., B. M., D. W. and H. A. K.) and the Postdoc-Fellowship YIA of the medical faculty of the University of Heidelberg (T. D.). We are indebted to all probands for their participation. We thank M. C. Fishman for critical discussion of the manuscript.	Ahmad F, 2005, ANNU REV GENOM HUM G, V6, P185, DOI 10.1146/annurev.genom.6.080604.162132; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bendig G, 2006, GENE DEV, V20, P2361, DOI 10.1101/gad.1448306; Burkett EL, 2005, J AM COLL CARDIOL, V45, P969, DOI 10.1016/j.jacc.2004.11.066; Dahme T, 2009, DIS MODEL MECH, V2, P18, DOI 10.1242/dmm.000687; Erdmann J, 2001, J AM COLL CARDIOL, V38, P322, DOI 10.1016/S0735-1097(01)01387-0; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Goebel HH, 1997, CURR OPIN NEUROL, V10, P426, DOI 10.1097/00019052-199710000-00012; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Kerr TP, 2001, HUM GENET, V109, P402, DOI 10.1007/s004390100598; Khuchua Z, 2006, CIRC RES, V99, P201, DOI 10.1161/01.RES.0000233378.95325.ce; Knoll R, 2003, J MOL MED, V81, P750, DOI 10.1007/s00109-003-0488-x; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; Morita H, 2005, J CLIN INVEST, V115, P518, DOI 10.1172/JCI200524351; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Pyle WG, 2004, CIRC RES, V94, P296, DOI 10.1161/01.RES.0000116143.74830.A9; Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rottbauer W, 2005, GENE DEV, V19, P1624, DOI 10.1101/gad.1319405; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Rottbauer W, 2006, CIRC RES, V99, P323, DOI 10.1161/01.RES.0000234807.16034.fe; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schonberger J, 2005, NAT GENET, V37, P418, DOI 10.1038/ng1527; Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SHIMIZU T, 1985, J CELL BIOL, V101, P1115, DOI 10.1083/jcb.101.3.1115; Shin JT, 2002, ANNU REV GENOM HUM G, V3, P311, DOI 10.1146/annurev.genom.3.031402.131506; Xu XL, 2002, NAT GENET, V30, P205, DOI 10.1038/ng816; Zeller R, 2006, J MOL MED-JMM, V84, P682, DOI 10.1007/s00109-006-0056-2; Zemljic-Harpf AE, 2004, AM J PATHOL, V165, P1033, DOI 10.1016/S0002-9440(10)63364-0	37	132	135	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1281	U78		10.1038/nm.2037	http://dx.doi.org/10.1038/nm.2037			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19881492				2022-12-27	WOS:000271543700016
J	Yamada, M; Yoshida, Y; Mori, D; Takitoh, T; Kengaku, M; Umeshima, H; Takao, K; Miyakawa, T; Sato, M; Sorimachi, H; Wynshaw-Boris, A; Hirotsune, S				Yamada, Masami; Yoshida, Yuko; Mori, Daisuke; Takitoh, Takako; Kengaku, Mineko; Umeshima, Hiroki; Takao, Keizo; Miyakawa, Tsuyoshi; Sato, Makoto; Sorimachi, Hiroyuki; Wynshaw-Boris, Anthony; Hirotsune, Shinji			Inhibition of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a mouse model of lissencephaly	NATURE MEDICINE			English	Article							NEURONAL MIGRATION DEFECTS; CYCLIN-DEPENDENT KINASE-5; GENE-TRANSFER; SUBUNIT; CLEAVAGE; NDEL1; P35; PHOSPHORYLATION; DOUBLECORTIN; PROTEOLYSIS	Lissencephaly is a devastating neurological disorder caused by defective neuronal migration. LIS1 (official symbol PAFAH1B1, for platelet-activating factor acetylhydrolase, isoform 1b, subunit 1) was identified as the gene mutated in individuals with lissencephaly, and it was found to regulate cytoplasmic dynein function and localization. Here we show that inhibition or knockdown of calpains protects LIS1 from proteolysis, resulting in the augmentation of LIS1 amounts in Lis1(+/-) mouse embryonic fibroblast cells and rescue of the aberrant distribution of cytoplasmic dynein, mitochondria and beta-COP-positive vesicles. We also show that calpain inhibitors improve neuronal migration of Lis1(+/-) cerebellar granular neurons. Intraperitoneal injection of the calpain inhibitor ALLN to pregnant Lis1(+/-) dams rescued apoptotic neuronal cell death and neuronal migration defects in Lis1(+/-) offspring. Furthermore, in utero knockdown of calpain by short hairpin RNA rescued defective cortical layering in Lis1(+/-) mice. Thus, calpain inhibition is a potential therapeutic intervention for lissencephaly.	[Yamada, Masami; Yoshida, Yuko; Mori, Daisuke; Takitoh, Takako; Hirotsune, Shinji] Osaka City Univ, Grad Sch Med, Dept Genet Dis Res, Osaka 558, Japan; [Kengaku, Mineko; Umeshima, Hiroki] Kyoto Univ, Inst Integrated Cell Mat Sci, Sakyo Ku, Kyoto, Japan; [Takao, Keizo; Miyakawa, Tsuyoshi] Fujita Hlth Univ, Inst Comprehens Med Sci, Div Syst Med Sci, Aichi, Japan; [Takao, Keizo; Miyakawa, Tsuyoshi] Kyoto Univ, Fac Med, Frontier Technol Ctr, Genet Engn & Funct Genom Grp,Sakyo Ku, Kyoto, Japan; [Takao, Keizo; Miyakawa, Tsuyoshi] Japan Sci & Technol Agcy, Inst Bioinformat Res & Dev & Core Res Evolut Sci, Kawaguchi, Saitama, Japan; [Sato, Makoto] Univ Fukui, Fac Med Sci, Dept Morphol & Physiol Sci, Div Cell Biol & Neurosci, Fukui 910, Japan; [Sato, Makoto] Univ Fukui, Fac Med Sci, Res & Educ Program Life Sci, Fukui 910, Japan; [Sorimachi, Hiroyuki] Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci Rinshoken, Dept Enzymat Regulat Cell Funct, Calpain Project,Setagaya Ku, Tokyo, Japan; [Wynshaw-Boris, Anthony] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; [Wynshaw-Boris, Anthony] Univ Calif San Francisco, Sch Med, Inst Human Genet, San Francisco, CA USA	Osaka Metropolitan University; Kyoto University; Fujita Health University; Kyoto University; Japan Science & Technology Agency (JST); University of Fukui; University of Fukui; Tokyo Metropolitan Institute of Medical Science; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hirotsune, S (corresponding author), Osaka City Univ, Grad Sch Med, Dept Genet Dis Res, Asahi Machi, Osaka 558, Japan.	shinjih@med.osaka-cu.ac.jp	Takao, Keizo/B-9527-2008; Miyakawa, Tsuyoshi/A-7741-2008; Sorimachi, Hiroyuki/C-6448-2009; Sorimachi, Hiroyuki/Q-6956-2017; Mori, Daisuke/M-4952-2014	Takao, Keizo/0000-0002-4734-3583; Miyakawa, Tsuyoshi/0000-0003-0137-8200; Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727; Mori, Daisuke/0000-0002-9072-2546; Umeshima, Hiroki/0000-0001-9957-1468	Ministry of Education, Science, Sports and Culture of Japan; Sagawa Foundation for Promotion of Cancer Research; The Cell Science Research Foundation; The Japan Spina Bifida & Hydrocephalus Research Foundation; Takeda Science Foundation; The Hoh-ansha Foundation; Knowledge Cluster Initiative (Stage-2) Research Foundation; US National Institutes of Health [NS41030, HD47380]; MEXT; Neuroinformatics Japan Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041030] Funding Source: NIH RePORTER	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sagawa Foundation for Promotion of Cancer Research; The Cell Science Research Foundation(Cell Science Research Foundation, Japan); The Japan Spina Bifida & Hydrocephalus Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); The Hoh-ansha Foundation; Knowledge Cluster Initiative (Stage-2) Research Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Neuroinformatics Japan Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank S. Kawashima (Tokyo Metropolitan Institute of Medical Science) for providing us with a calpain-specific antibody (1D10A7)<SUP>36</SUP>. We thank Y. Funae, H. Iwao, T. Yamauch, M. Muramatsu and Y. Nagai for generous support and encouragement. We also thank Y. Kira, Y. Yabunaka and R. Zako for technical support, H. Nishimura and K. Fujimoto for mouse breeding, T. Bando for in utero injection and K. Nakanishi for behavior study. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan from the Ministry of Education, Science, Sports and Culture of Japan to M. S. and S. H. This work was also supported by The Sagawa Foundation for Promotion of Cancer Research, The Cell Science Research Foundation, The Japan Spina Bifida & Hydrocephalus Research Foundation, Takeda Science Foundation, The Hoh-ansha Foundation and Knowledge Cluster Initiative (Stage-2) Research Foundation to Shinji Hirotsune and by US National Institutes of Health grants NS41030 and HD47380 to A.W.-B. This work was also supported by a Grant-in-Aid for Scientific Research on Priority Areas-Integrative Brain Research (Shien)-from MEXT and a Grant-in-Aid from Neuroinformatics Japan Center to T. M.	Amende Ivo, 2005, J Neuroeng Rehabil, V2, P20, DOI 10.1186/1743-0003-2-20; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bhatt A, 2002, J CELL SCI, V115, P3415; Bi WM, 2009, NAT GENET, V41, P168, DOI 10.1038/ng.302; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gressens P, 2006, CURR OPIN NEUROL, V19, P135, DOI 10.1097/01.wco.0000218228.73678.e1; Hampton TG, 2004, PHYSIOL BEHAV, V82, P381, DOI 10.1016/j.physbeh.2004.04.006; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; KASAI Y, 1986, J BIOCHEM-TOKYO, V100, P183, DOI 10.1093/oxfordjournals.jbchem.a121691; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; McEvilly RJ, 2002, SCIENCE, V295, P1528, DOI 10.1126/science.1067132; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Paylor R, 1999, LEARN MEMORY, V6, P521, DOI 10.1101/lm.6.5.521; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; Powell E, 1999, PHYSIOL BEHAV, V67, P819, DOI 10.1016/S0031-9384(99)00127-4; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Saito T, 2001, DEV BIOL, V240, P237, DOI 10.1006/dbio.2001.0439; Sasaki S, 2005, MOL CELL BIOL, V25, P7812, DOI 10.1128/MCB.25.17.7812-7827.2005; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Serrano K, 2004, CELL MOTIL CYTOSKEL, V58, P242, DOI 10.1002/cm.20011; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Tanaka T, 2004, J CELL BIOL, V165, P709, DOI 10.1083/jcb.200309025; Toyo-Oka K, 2005, HUM MOL GENET, V14, P3113, DOI 10.1093/hmg/ddi339; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; Wynshaw-Boris A, 2007, CLIN GENET, V72, P296, DOI 10.1111/j.1399-0004.2007.00888.x; Xi XD, 2006, J BIOL CHEM, V281, P29426, DOI 10.1074/jbc.C600039200; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yamada M, 2008, EMBO J, V27, P2471, DOI 10.1038/emboj.2008.182; Yamasaki N, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-6; Yingling J, 2008, CELL, V132, P474, DOI 10.1016/j.cell.2008.01.026	41	54	56	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1202	U132		10.1038/nm.2023	http://dx.doi.org/10.1038/nm.2023			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19734909	Green Accepted			2022-12-27	WOS:000270596400033
J	Clarke, L; van der Kooy, D				Clarke, Laura; van der Kooy, Derek			Inducing pluripotency	NATURE MEDICINE			English	Editorial Material							STEM-CELLS; GENERATION; FIBROBLASTS; INDUCTION		[Clarke, Laura; van der Kooy, Derek] Univ Toronto, Toronto, ON, Canada	University of Toronto	Clarke, L (corresponding author), Univ Toronto, Toronto, ON, Canada.	derek.van.der.kooy@utoronto.ca						Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Gonzalez F, 2009, P NATL ACAD SCI USA, V106, P8918, DOI 10.1073/pnas.0901471106; Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864; Kang L, 2009, CELL STEM CELL, V5, P135, DOI 10.1016/j.stem.2009.07.001; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267	17	8	9	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1001	1002		10.1038/nm0909-1001	http://dx.doi.org/10.1038/nm0909-1001			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19734874				2022-12-27	WOS:000269979200017
J	Minamino, T; Orimo, M; Shimizu, I; Kunieda, T; Yokoyama, M; Ito, T; Nojima, A; Nabetani, A; Oike, Y; Matsubara, H; Ishikawa, F; Komuro, I				Minamino, Tohru; Orimo, Masayuki; Shimizu, Ippei; Kunieda, Takeshige; Yokoyama, Masataka; Ito, Takashi; Nojima, Aika; Nabetani, Akira; Oike, Yuichi; Matsubara, Hisahiro; Ishikawa, Fuyuki; Komuro, Issei			A crucial role for adipose tissue p53 in the regulation of insulin resistance	NATURE MEDICINE			English	Article							ACID-BINDING PROTEIN; CELLULAR SENESCENCE; MICE LACKING; LIFE-SPAN; FAT-BODY; KAPPA-B; TELOMERASE; OBESITY; CELLS; RECEPTOR	Various stimuli, such as telomere dysfunction and oxidative stress, can induce irreversible cell growth arrest, which is termed 'cellular senescence'(1,2). This response is controlled by tumor suppressor proteins such as p53 and pRb. There is also evidence that senescent cells promote changes related to aging or age-related diseases(3-6). Here we show that p53 expression in adipose tissue is crucially involved in the development of insulin resistance, which underlies age-related cardiovascular and metabolic disorders. We found that excessive calorie intake led to the accumulation of oxidative stress in the adipose tissue of mice with type 2 diabetes-like disease and promoted senescence-like changes, such as increased activity of senescence-associated beta-galactosidase, increased expression of p53 and increased production of proinflammatory cytokines. Inhibition of p53 activity in adipose tissue markedly ameliorated these senescence-like changes, decreased the expression of proinflammatory cytokines and improved insulin resistance in mice with type 2 diabetes-like disease. Conversely, upregulation of p53 in adipose tissue caused an inflammatory response that led to insulin resistance. Adipose tissue from individuals with diabetes also showed senescence-like features. Our results show a previously unappreciated role of adipose tissue p53 expression in the regulation of insulin resistance and suggest that cellular aging signals in adipose tissue could be a new target for the treatment of diabetes.	[Minamino, Tohru; Orimo, Masayuki; Shimizu, Ippei; Kunieda, Takeshige; Yokoyama, Masataka; Ito, Takashi; Nojima, Aika; Komuro, Issei] Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba, Japan; [Minamino, Tohru; Oike, Yuichi] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan; [Nabetani, Akira; Ishikawa, Fuyuki] Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Kyoto, Japan; [Oike, Yuichi] Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Genet, Kumamoto, Japan; [Matsubara, Hisahiro] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chuo Ku, Chiba, Japan; [Komuro, Issei] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan	Chiba University; Japan Science & Technology Agency (JST); Kyoto University; Kumamoto University; Chiba University; Osaka University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba, Japan.	komuro-tky@umin.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021; Minamino, Tohru/P-8145-2018	Ishikawa, Fuyuki/0000-0002-5580-2305; Minamino, Tohru/0000-0003-1627-6151; Shimizu, Ippei/0000-0003-3333-8131	Ministry of Education, Science, Sports and Culture and Health and Labor Sciences Research Grants; Ministry of Education, Culture, Sports, Science and Technology of Japan; Suzuken Memorial Foundation; Japan Diabetes Foundation; Ichiro Kanehara Foundation; Tokyo Biochemical Research Foundation; Takeda Science Foundation; Cell Science Research Foundation; Japan Foundation of Applied Enzymology; Grants-in-Aid for Scientific Research [21390237] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture and Health and Labor Sciences Research Grants; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Suzuken Memorial Foundation; Japan Diabetes Foundation; Ichiro Kanehara Foundation; Tokyo Biochemical Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Japan Foundation of Applied Enzymology(Japan Foundation of Applied Enzymology); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H. Karagiri for discussion, W. C. Greene ( University of California) and T. Fujita ( The Tokyo Metropolitan Institute of Medical Science) for expression vector encoding constitutively active I.B and p55-A2-Luc ( luciferase reporter vector containing the kappa B binding sites), respectively, A. Berns ( The Netherlands Cancer Institute) for floxed Trp53 mice, and E. Fujita, Y. Ishiyama, R. Kobayashi and Y. Ishikawa for their excellent technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture and Health and Labor Sciences Research Grants ( to I. K.); a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and grants from the Suzuken Memorial Foundation, the Japan Diabetes Foundation, the Ichiro Kanehara Foundation, the Tokyo Biochemical Research Foundation, the Takeda Science Foundation, the Cell Science Research Foundation and the Japan Foundation of Applied Enzymology ( to T. M.).	Benoit V, 2006, ONCOGENE, V25, P5708, DOI 10.1038/sj.onc.1209579; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Gardner JP, 2005, CIRCULATION, V111, P2171, DOI 10.1161/01.CIR.0000163550.70487.0B; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Makowski L, 2005, J BIOL CHEM, V280, P12888, DOI 10.1074/jbc.M413788200; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Marino S, 2000, GENE DEV, V14, P994; Minamino T, 2008, NAT CLIN PRACT CARD, V5, P637, DOI 10.1038/ncpcardio1324; Minamino T, 2007, CIRC RES, V100, P15, DOI 10.1161/01.RES.0000256837.40544.4a; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x	31	564	579	6	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1082	U140		10.1038/nm.2014	http://dx.doi.org/10.1038/nm.2014			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19718037				2022-12-27	WOS:000269979200031
J	Tang, Y; Wu, XW; Lei, WQ; Pang, LJ; Wan, C; Shi, ZQ; Zhao, L; Nagy, TR; Peng, XY; Hu, JB; Feng, X; Van Hul, W; Wan, M; Cao, X				Tang, Yi; Wu, Xiangwei; Lei, Weiqi; Pang, Lijuan; Wan, Chao; Shi, Zhenqi; Zhao, Ling; Nagy, Timothy R.; Peng, Xinyu; Hu, Junbo; Feng, Xu; Van Hul, Wim; Wan, Mei; Cao, Xu			TGF-beta 1-induced migration of bone mesenchymal stem cells couples bone resorption with formation	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; CAMURATI-ENGELMANN-DISEASE; LATENCY-ASSOCIATED PEPTIDE; DOMAIN-SPECIFIC MUTATIONS; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; DIFFERENT POPULATIONS; ACTIVATION; COMPLEX; MATRIX	Bone remodeling depends on the precise coordination of bone resorption and subsequent bone formation. Disturbances of this process are associated with skeletal diseases, such as Camurati-Engelmann disease (CED). We show using in vitro and in vivo models that active TGF-beta 1 released during bone resorption coordinates bone formation by inducing migration of bone marrow stromal cells, also known as bone mesenchymal stem cells, to the bone resorptive sites and that this process is mediated through a SMAD signaling pathway. Analyzing mice carrying a CED-derived mutant TGFB1 (encoding TGF-beta 1), which show the typical progressive diaphyseal dysplasia seen in the human disease, we found high levels of active TGF-beta 1 in the bone marrow. Treatment with a TGF-beta type I receptor inhibitor partially rescued the uncoupled bone remodeling and prevented the fractures. Thus, as TGF-beta 1 functions to couple bone resorption and formation, modulation of TGF-beta 1 activity could be an effective treatment for bone remodeling diseases.	[Tang, Yi; Wu, Xiangwei; Lei, Weiqi; Pang, Lijuan; Wan, Chao; Shi, Zhenqi; Zhao, Ling; Feng, Xu; Wan, Mei; Cao, Xu] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Wu, Xiangwei; Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Wu, Xiangwei; Peng, Xinyu] Shihezi Univ, Sch Med, Affiliated Hosp 1, Shihezi, Xinjiang, Peoples R China; [Pang, Lijuan] Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China; [Nagy, Timothy R.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; [Van Hul, Wim] Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium	University of Alabama System; University of Alabama Birmingham; Huazhong University of Science & Technology; Shihezi University; Shihezi University; University of Alabama System; University of Alabama Birmingham; University of Antwerp	Cao, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	cao@uab.edu	Sui, Yanwei/AAH-9928-2021; zhang, xu/GRX-9733-2022; Wan, Chao/J-9277-2013; zhang, xu/GYE-3558-2022	Wan, Chao/0000-0001-6780-2006; Nagy, Tim/0000-0002-2371-7114; Van Hul, Wim/0000-0002-5065-7858	US National Institutes of Health [AR 053973, DK057501]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057501, Z01DK057501] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank F. Hunter and T. Clemens for critical review and discussion of the manuscript and H. L. Moses (Vanderbilt University), C. Deng (US National Institutes of Health), J. Murphy-Ullrich (University of Alabama at Birmingham) and W. Xiong (Medical College of Georgia) for reagents. We thank the UAB Center for Metabolic Bone Disease Cores for mouse phenotyping, histomorphometry and molecular analyses. This research was supported by US National Institutes of Health grants AR 053973 and DK057501.	Atti E, 2002, BONE, V31, P675, DOI 10.1016/S8756-3282(02)00905-5; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bismar H, 1999, BONE, V24, P565, DOI 10.1016/S8756-3282(99)00082-4; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182; Engle SJ, 2002, CANCER RES, V62, P6362; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRONTHOS S, 1994, BLOOD, V84, P4164, DOI 10.1182/blood.V84.12.4164.bloodjournal84124164; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hecht JT, 2001, CLIN GENET, V59, P198, DOI 10.1034/j.1399-0004.2001.590310.x; Hill P A, 1998, Br J Orthod, V25, P101; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169-6009(92)90844-4; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Janssens K, 2003, J BIOL CHEM, V278, P7718, DOI 10.1074/jbc.M208857200; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Leucht P, 2007, BONE, V40, P919, DOI 10.1016/j.bone.2006.10.027; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; MARTIN TJ, 1993, GROWTH REGULAT, V3, P209; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365-2141.2003.04669.x; Mirmalek-Sani SH, 2006, STEM CELLS, V24, P1042, DOI 10.1634/stemcells.2005-0368; MUNDY GR, 1994, RHEUM DIS CLIN N AM, V20, P577; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OWEN M, 1988, CIBA F SYMP, V136, P42; Ozaki Y, 2007, STEM CELLS DEV, V16, P119, DOI 10.1089/scd.2006.0032; Pedrozo HA, 1999, ENDOCRINOLOGY, V140, P5806, DOI 10.1210/en.140.12.5806; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P49, DOI 10.1002/jbmr.5650050109; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; ROBERTS AB, 1983, FED PROC, V42, P2621; Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281; Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025; Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593; Zink AR, 2005, JAMA-J AM MED ASSOC, V293, P40, DOI 10.1001/jama.293.1.40-c	57	774	817	8	190	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					757	U9		10.1038/nm.1979	http://dx.doi.org/10.1038/nm.1979			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584867	Green Accepted			2022-12-27	WOS:000267806900028
J	Choi, YW; Walsh, MC; Arron, JR				Choi, Yongwon; Walsh, Matthew C.; Arron, Joseph R.			Breaking into bone biology Target practice	NATURE MEDICINE			English	Editorial Material							OSTEOIMMUNOLOGY; MECHANISMS; IMMUNE; MASS		[Choi, Yongwon; Walsh, Matthew C.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Arron, Joseph R.] Genentech Inc, Immunol Tissue Growth & Repair Biomarker Grp, San Francisco, CA 94080 USA	University of Pennsylvania; Roche Holding; Genentech	Choi, YW (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 421 Curie Blvd, Philadelphia, PA 19104 USA.	ychoi3@mail.med.upenn.edu		Arron, Joseph/0000-0001-7677-9979	NIAMS NIH HHS [R01 AR053843, R01 AR053843-03] Funding Source: Medline; NIDCR NIH HHS [R01 DE019381-01, R01 DE019381] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019381] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110; Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]; Iwasaki R, 2008, BIOCHEM BIOPH RES CO, V377, P899, DOI 10.1016/j.bbrc.2008.10.076; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; RAISZ LG, 2002, WILLIAMS TXB ENDOCRI, V10, P1373; Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089; Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; U.S. Public Health Service, 2004, BON HLTH OST REP SUR; Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646	10	2	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2009	15	2					144	145		10.1038/nm0209-144	http://dx.doi.org/10.1038/nm0209-144			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19197288	Green Accepted			2022-12-27	WOS:000263119400015
J	Wu, D; Vu, Q; Nguyen, A; Stone, JR; Stubbs, H; Kuhlmann, G; Sholl, LM; Iafrate, AJ				Wu, David; Vu, Quynh; Nguyen, Anhthu; Stone, James R.; Stubbs, Hannah; Kuhlmann, Georgiana; Sholl, Lynette M.; Iafrate, A. John			In situ genetic analysis of cellular chimerism	NATURE MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; HUMAN GENOME; STEM-CELLS; EPITHELIAL-CELLS; POLYMORPHISMS; TRANSPLANTATION; ENGRAFTMENT; HEART	Copy number variants are a recently discovered source of large-scale genomic diversity present in all individuals. We capitalize on these inherent genomic differences, focusing on deletion polymorphisms, to develop informative fluorescence in situ hybridization probes with the ability to unequivocally distinguish between donor and recipient cells in situ. These probes are accurate, specific, highly polymorphic and, notably, can be used to assign genetic identity in situ in a completely gender-independent fashion. We anticipate that these polymorphic deletion probes will be useful in further understanding the dynamics of cellular chimerism after transplantation, including the details of chronic organ rejection, post-transplant lymphoproliferative disorder and graft-versus-host disease, and in optimizing future tissue engineering and pluripotent stem cell therapies.	[Wu, David; Vu, Quynh; Nguyen, Anhthu; Stone, James R.; Stubbs, Hannah; Kuhlmann, Georgiana; Sholl, Lynette M.; Iafrate, A. John] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Wu, David; Sholl, Lynette M.] Harvard Univ, Sch Mol Genet Pathol Fellowship, Boston, MA 02115 USA; [Wu, David; Stone, James R.; Sholl, Lynette M.; Iafrate, A. John] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard Medical School	Iafrate, AJ (corresponding author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.	aiafrate@partners.org			Department of Pathology, Massachusetts General Hospital	Department of Pathology, Massachusetts General Hospital	We thank M. Han, J. Miller-Batten and J. Reid for excellent technical assistance. We thank C. Lee (Brigham and Women's Hospital) and S. Kantarci (Beth Israel Deaconess Medical Center) for helpful discussions and reagents. We thank S. Ogino for helpful discussions. This work was supported in part by intramural funding from the Department of Pathology, Massachusetts General Hospital to A.J.I.	Braak H, 2008, NAT MED, V14, P483, DOI 10.1038/nm0508-483; BUCKLE VJ, 1994, CURR OPIN GENET DEV, V4, P374, DOI 10.1016/0959-437X(94)90024-8; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Grimm PC, 2001, NEW ENGL J MED, V345, P93, DOI 10.1056/NEJM200107123450203; Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695; Hochberg EP, 2003, BLOOD, V101, P363, DOI 10.1182/blood-2002-05-1365; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jeffreys AJ, 2005, NAT MED, V11, P1035, DOI 10.1038/nm1005-1035; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; LITT M, 1989, AM J HUM GENET, V44, P397; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Minami E, 2005, CIRCULATION, V112, P2951, DOI 10.1161/CIRCULATIONAHA.105.576017; Mullally A, 2007, BLOOD, V109, P1355, DOI 10.1182/blood-2006-06-030858; Oliver DH, 2000, J MOL DIAGN, V2, P202, DOI 10.1016/S1525-1578(10)60638-1; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sermon K, 2004, LANCET, V363, P1633, DOI 10.1016/S0140-6736(04)16209-0; Tran SD, 2003, LANCET, V361, P1084, DOI 10.1016/S0140-6736(03)12894-2; WEBER JL, 1989, AM J HUM GENET, V44, P388	24	11	13	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					215	219		10.1038/nm.1862	http://dx.doi.org/10.1038/nm.1862			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19151730				2022-12-27	WOS:000263119400026
J	Engelman, JA; Chen, L; Tan, XH; Crosby, K; Guimaraes, AR; Upadhyay, R; Maira, M; McNamara, K; Perera, SA; Song, YC; Chirieac, LR; Kaur, R; Lightbown, A; Simendinger, J; Li, T; Padera, RF; Garcia-Echeverria, C; Weissleder, R; Mahmood, U; Cantley, LC; Wong, KK				Engelman, Jeffrey A.; Chen, Liang; Tan, Xiaohong; Crosby, Katherine; Guimaraes, Alexander R.; Upadhyay, Rabi; Maira, Michel; McNamara, Kate; Perera, Samanthi A.; Song, Youngchul; Chirieac, Lucian R.; Kaur, Ramneet; Lightbown, Angela; Simendinger, Jessica; Li, Timothy; Padera, Robert F.; Garcia-Echeverria, Carlos; Weissleder, Ralph; Mahmood, Umar; Cantley, Lewis C.; Wong, Kwok-Kin			Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers	NATURE MEDICINE			English	Article							CATALYTIC SUBUNIT; RAS; MUTATIONS; TUMORIGENESIS; SENSITIVITY; EXPRESSION; P110-ALPHA; ABSENCE; POTENT; GENE	Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-alpha catalytic subunit (encoded by PIK3CA)(1). They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the p110-alpha mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models. Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies. In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p110-alpha H1047R. Treatment of these tumors with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clinical development, led to marked tumor regression as shown by positron emission tomography-computed tomography, magnetic resonance imaging and microscopic examination. In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235. However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers. These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.	Beth Israel Hosp, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Engelman, Jeffrey A.; Song, Youngchul; Kaur, Ramneet] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Engelman, Jeffrey A.; Kaur, Ramneet; Cantley, Lewis C.; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Chen, Liang; Tan, Xiaohong; McNamara, Kate; Perera, Samanthi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, Liang; Tan, Xiaohong; McNamara, Kate; Perera, Samanthi A.; Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA; [Crosby, Katherine; Lightbown, Angela; Simendinger, Jessica] Cell Signaling Technol, Danvers, MA 01923 USA; [Guimaraes, Alexander R.; Upadhyay, Rabi; Weissleder, Ralph; Mahmood, Umar] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; [Guimaraes, Alexander R.; Upadhyay, Rabi; Weissleder, Ralph; Mahmood, Umar] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA; [Maira, Michel; Garcia-Echeverria, Carlos] Novartis Inst Biomed Res, Oncol Dis Area, CH-4057 Basel, Switzerland; [Chirieac, Lucian R.; Padera, Robert F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Weissleder, Ralph; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Cantley, LC (corresponding author), Beth Israel Hosp, Beth Israel Deaconess Med Ctr, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	lewis_cantley@hms.harvard.edu; KWONG1@PARTNERS.ORG	Cantley, Lewis C/D-1800-2014; Chirieac, Lucian R./AAD-2030-2019	Cantley, Lewis C/0000-0002-1298-7653; wong, kwok kin/0000-0001-6323-235X; Upadhyay, Rabi/0000-0002-2154-0132; Mahmood, Umar/0000-0001-7414-6123; /0000-0003-0828-4143; Chen, Liang/0000-0001-7300-6604	US National Institutes of Health (NIH) [CA120060-01]; American Association for Cancer Research; International Association for the Study of Lung Cancer; NIH [CA089021, P01 CA117969, R01 GM41890, K08 AG024004, R01 CA122794, R01 AG2400401]; Dana-Farber-Harvard Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE) [P50 CA090578]; Dana-Farber-Harvard Cancer Center Gastrointestinal Cancer SPORE [P50 CA127003, U24-CA092782]; Joan Scarangello Foundation to Conquer Lung Cancer; Cecily and Robert Harris Foundation; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE [P50CA127003, R01CA122794, K08CA120060, U24CA092782, P50CA090578, P01CA117969, R01CA137008, P01CA089021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM036624, R01GM041890, R01GM056203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association for Cancer Research; International Association for the Study of Lung Cancer; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana-Farber-Harvard Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE); Dana-Farber-Harvard Cancer Center Gastrointestinal Cancer SPORE; Joan Scarangello Foundation to Conquer Lung Cancer; Cecily and Robert Harris Foundation; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	CCSP-rtTA mice were generously provided by J. Whitsett at the University of Cincinnati. Tet-op-Kras mice were generously provided by H. Varmus (Memorial Sloan-Kettering Cancer Center). LSL-Kras G12D mice were kindly provided by T. Jacks (Massachusetts Institute of Technology). This work was supported by US National Institutes of Health (NIH) K08 grant CA120060-01 (J. A. E.), the American Association for Cancer Research (J. A. E.), the International Association for the Study of Lung Cancer (J. A. E.), NIH prostate cancer grant P01 CA089021 (L. C. C.), NIH pancreatic cancer grant P01 CA117969 (L. C. C.), NIH grant R01 GM41890 (L. C. C.), a Dana-Farber-Harvard Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE) grant P50 CA090578 (J. A. E. and K.-K.W.) and Dana-Farber-Harvard Cancer Center Gastrointestinal Cancer SPORE grants P50 CA127003 (J. A. E., R. W., U. M. and L. C. C.) and U24-CA092782 (R. W., U. M., A. R. G.). K.-K.W. was supported by NIH grants K08 AG024004, R01 CA122794 and R01 AG2400401; the Joan Scarangello Foundation to Conquer Lung Cancer; the Cecily and Robert Harris Foundation; and the Flight Attendant Medical Research Institute.	Brachmann SM, 2005, MOL CELL BIOL, V25, P1596, DOI 10.1128/MCB.25.5.1596-1607.2005; Engelman JA, 2007, CLIN CANCER RES, V13, p4637S, DOI 10.1158/1078-0432.CCR-07-0653; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Luo J, 2005, P NATL ACAD SCI USA, V102, P10238, DOI 10.1073/pnas.0504378102; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Yang Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002220; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	21	1077	1139	4	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1351	1356		10.1038/nm.1890	http://dx.doi.org/10.1038/nm.1890			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029981	Green Accepted			2022-12-27	WOS:000261393600019
J	Draper, SJ; Moore, AC; Goodman, AL; Long, CA; Holder, AA; Gilbert, SC; Hill, F; Hill, AVS				Draper, Simon J.; Moore, Anne C.; Goodman, Anna L.; Long, Carole A.; Holder, Anthony A.; Gilbert, Sarah C.; Hill, Fergal; Hill, Adrian V. S.			Effective induction of high-titer antibodies by viral vector vaccines	NATURE MEDICINE			English	Article							MEROZOITE SURFACE PROTEIN-1; C4B-BINDING PROTEIN; MALARIA VACCINE; PROTECTION; IMMUNITY; ANTIGEN; MICE; IMMUNOGENICITY; IMMUNIZATION; FRAGMENT	Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria. Here we show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro.	[Draper, Simon J.; Moore, Anne C.; Goodman, Anna L.; Gilbert, Sarah C.; Hill, Adrian V. S.] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England; [Long, Carole A.] NIAID, Lab Malaria & Vector Res, US NIH, Rockville, MD 20852 USA; [Holder, Anthony A.] Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; [Hill, Fergal] Imaxio, F-69007 Lyon, France	University of Oxford; Jenner Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); MRC National Institute for Medical Research	Draper, SJ (corresponding author), Univ Oxford, Jenner Inst, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.	simon.draper@ndm.ox.ac.uk	Gilbert, Sarah C./H-2857-2019; Hill, Fergal/AAI-1329-2021; HILL, Adrian V>S>/C-1306-2008; Holder, Anthony A/A-7554-2013; Draper, Simon J/F-1758-2011	Gilbert, Sarah C./0000-0002-6823-9750; Holder, Anthony A/0000-0002-8490-6058; Draper, Simon J/0000-0002-9415-1357; Moore, Anne/0000-0003-3656-4230; Goodman, Anna/0000-0003-0643-9017	MRC [G0700735, MC_U117532067, G0600424] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001020] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI001020-02, Z01 AI001020-01] Funding Source: Medline; Medical Research Council [MC_U117532067, G0600424, G0700735] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahlborg N, 2002, INFECT IMMUN, V70, P820, DOI 10.1128/IAI.70.2.820-825.2002; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Bruna-Romera O, 2001, P NATL ACAD SCI USA, V98, P11491, DOI 10.1073/pnas.191380898; Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258; Genton B, 2007, CURR OPIN INFECT DIS, V20, P467, DOI 10.1097/QCO.0b013e3282dd7a29; Gilbert SC, 2002, VACCINE, V20, P1039, DOI 10.1016/S0264-410X(01)00450-9; Hensmann M, 2004, EUR J IMMUNOL, V34, P639, DOI 10.1002/eji.200324514; Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; OGUN SA, 2008, INFECT IMMUN    0512; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311; Tian JH, 1996, J IMMUNOL, V157, P1176; Wipasa J, 2002, J IMMUNOL, V169, P944, DOI 10.4049/jimmunol.169.2.944	16	123	136	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2008	14	8					819	821		10.1038/nm.1850	http://dx.doi.org/10.1038/nm.1850			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18660818	Green Accepted, Bronze			2022-12-27	WOS:000258237500027
J	Kim, EY; Battaile, JT; Patel, AC; You, Y; Agapov, E; Grayson, MH; Benoit, LA; Byers, DE; Alevy, Y; Tucker, J; Swanson, S; Tidwell, R; Tyner, JW; Morton, JD; Castro, M; Polineni, D; Patterson, GA; Schwendener, RA; Allard, JD; Peltz, G; Holtzman, MJ				Kim, Edy Y.; Battaile, John T.; Patel, Anand C.; You, Yingjian; Agapov, Eugene; Grayson, Mitchell H.; Benoit, Loralyn A.; Byers, Derek E.; Alevy, Yael; Tucker, Jennifer; Swanson, Suzanne; Tidwell, Rose; Tyner, Jeffrey W.; Morton, Jeffrey D.; Castro, Mario; Polineni, Deepika; Patterson, G. Alexander; Schwendener, Reto A.; Allard, John D.; Peltz, Gary; Holtzman, Michael J.			Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease	NATURE MEDICINE			English	Article							KILLER T-CELLS; V(ALPHA)14 NKT CELLS; AIRWAY INFLAMMATION; GENETIC SEGREGATION; EXPERIMENTAL ASTHMA; ALLERGIC-ASTHMA; IL-13; PATHWAY; MICE; HYPERREACTIVITY	To understand the pathogenesis of chronic inflammatory disease, we analyzed an experimental mouse model of chronic lung disease with pathology that resembles asthma and chronic obstructive pulmonary disease ( COPD) in humans. In this model, chronic lung disease develops after an infection with a common type of respiratory virus is cleared to only trace levels of noninfectious virus. Chronic inflammatory disease is generally thought to depend on an altered adaptive immune response. However, here we find that this type of disease arises independently of an adaptive immune response and is driven instead by interleukin-13 produced by macrophages that have been stimulated by CD1d-dependent T cell receptor-invariant natural killer T (NKT) cells. This innate immune axis is also activated in the lungs of humans with chronic airway disease due to asthma or COPD. These findings provide new insight into the pathogenesis of chronic inflammatory disease with the discovery that the transition from respiratory viral infection into chronic lung disease requires persistent activation of a previously undescribed NKT cell-macrophage innate immune axis.	[Kim, Edy Y.; Battaile, John T.; You, Yingjian; Agapov, Eugene; Grayson, Mitchell H.; Benoit, Loralyn A.; Byers, Derek E.; Alevy, Yael; Tucker, Jennifer; Swanson, Suzanne; Tidwell, Rose; Tyner, Jeffrey W.; Morton, Jeffrey D.; Castro, Mario; Holtzman, Michael J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Patel, Anand C.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Polineni, Deepika; Patterson, G. Alexander] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Schwendener, Reto A.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Allard, John D.; Peltz, Gary] Dept Genet & Gen, Palo Alto, CA 94304 USA; [Holtzman, Michael J.] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Zurich; Washington University (WUSTL)	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	holtzmanm@wustl.edu	Schwendener, Reto A/F-6373-2011; Patel, Anand/B-1441-2009; Kim, Edy/ABF-7592-2021; Grayson, Mitchell H/A-3693-2008; Grayson, Mitchell/AAX-3674-2020	Patel, Anand/0000-0002-6570-8582; Kim, Edy/0000-0002-9095-3109; Grayson, Mitchell H/0000-0002-4673-2122; Grayson, Mitchell/0000-0002-4673-2122; Tyner, Jeffrey/0000-0002-2133-0960; Byers, Derek/0000-0001-7371-9153	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL083095, T32HL007317, R01HL073159, P50HL084922] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007317-28, P50 HL084922-02, K08 HL083095-02, T32 HL007317, R01 HL073159-03, R01 HL073159-01, T32 HL007317-30, R01 HL073159-02, K08 HL083095, T32 HL007317-31, P50 HL084922-020004, T32 HL007317-29, R01 HL073159, T32 HL007317-26, R01 HL073159-04, T32 HL007317-27, P50 HL084922-01, P50 HL084922, P50 HL084922-010004] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cheng L, 2007, J IMMUNOL, V178, P2755, DOI 10.4049/jimmunol.178.5.2755; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grayson MH, 2007, J IMMUNOL, V179, P1438, DOI 10.4049/jimmunol.179.3.1438; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelin ME, 2006, J INFECT DIS, V193, P1634, DOI 10.1086/504262; Hegde S, 2007, J LEUKOCYTE BIOL, V81, P1224, DOI 10.1189/jlb.1206718; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; Jones EY, 2006, NAT REV IMMUNOL, V6, P271, DOI 10.1038/nri1805; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Patel AC, 2006, PHYSIOL GENOMICS, V25, P502, DOI 10.1152/physiolgenomics.00321.2005; Pouladi MA, 2004, AM J RESP CELL MOL, V30, P84, DOI 10.1165/rcmb.2003-0051OC; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Seino K, 2004, FRONT BIOSCI-LANDMRK, V9, P2577, DOI 10.2741/1418; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Skold M, 2003, INFECT IMMUN, V71, P5447, DOI 10.1128/IAI.71.10.5447-5455.2003; Tyner JW, 2006, J CLIN INVEST, V116, P309, DOI 10.1172/JCI25167; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Webb DC, 2001, J BIOL CHEM, V276, P41969, DOI 10.1074/jbc.M106223200; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang S, 2005, J IMMUNOL, V175, P4914, DOI 10.4049/jimmunol.175.8.4914; Zhong WM, 2000, J IMMUNOL, V164, P3274, DOI 10.4049/jimmunol.164.6.3274; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	37	395	418	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2008	14	6					633	640		10.1038/nm1770	http://dx.doi.org/10.1038/nm1770			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18488036	Green Accepted			2022-12-27	WOS:000256468700029
J	Mooney, P				Mooney, Paul			China cracks down on counterfeiters	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					360	360		10.1038/nm0410-360a	http://dx.doi.org/10.1038/nm0410-360a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376025	Bronze			2022-12-27	WOS:000276446800016
J	Clarke, TB; Davis, KM; Lysenko, ES; Zhou, AY; Yu, YM; Weiser, JN				Clarke, Thomas B.; Davis, Kimberly M.; Lysenko, Elena S.; Zhou, Alice Y.; Yu, Yimin; Weiser, Jeffrey N.			Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity	NATURE MEDICINE			English	Article							TOLL-LIKE RECEPTORS; STREPTOCOCCUS-PNEUMONIAE; MURAMYL PEPTIDES; HOST-DEFENSE; ACTIVATION; COMMENSAL; RESPONSES; MICROFLORA; INFECTION; BACTERIA	Humans are colonized by a large and diverse bacterial flora (the microbiota) essential for the development of the gut immune system(1-3). A broader role for the microbiota as a major modulator of systemic immunity has been proposed(4,5); however, evidence and a mechanism for this role have remained elusive. We show that the microbiota are a source of peptidoglycan that systemically primes the innate immune system, enhancing killing by bone marrow-derived neutrophils of two major pathogens: Streptococcus pneumoniae and Staphylococcus aureus. This requires signaling via the pattern recognition receptor nucleotide-binding, oligomerization domain-containing protein-1 (Nod1, which recognizes meso-diaminopimelic acid (mesoDAP)-containing peptidoglycan found predominantly in Gram-negative bacteria), but not Nod2 ( which detects peptidoglycan found in Gram-positive and Gram-negative bacteria) or Toll-like receptor 4 (Tlr4, which recognizes lipopolysaccharide)(6,7). We show translocation of peptidoglycan from the gut to neutrophils in the bone marrow and show that peptidoglycan concentrations in sera correlate with neutrophil function. In vivo administration of Nod1 ligands is sufficient to restore neutrophil function after microbiota depletion. Nod1(-/-) mice are more susceptible than wild-type mice to early pneumococcal sepsis, demonstrating a role for Nod1 in priming innate defenses facilitating a rapid response to infection. These data establish a mechanism for systemic immunomodulation by the microbiota and highlight potential adverse consequences of microbiota disruption by broad-spectrum antibiotics on innate immune defense to infection.	[Clarke, Thomas B.; Davis, Kimberly M.; Lysenko, Elena S.; Zhou, Alice Y.; Weiser, Jeffrey N.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; [Yu, Yimin] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Weiser, Jeffrey N.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Weiser, JN (corresponding author), Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.	weiser@mail.med.upenn.edu		Weiser, Jeffrey/0000-0001-7168-8090; Davis, Kimberly/0000-0003-1870-3137	US Public Health Service [AI038446, AI044231, AI078538, AI037108]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037108, R01AI078538, R01AI044231, R01AI038446, R21AI044231, R37AI037108] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank C. G. Dowson and D. I. Roper (University of Warwick) for peptidoglycan fragments, D. J. Philpott (University of Toronto) for Nod vector, and D. Kobuley for assistance with germ-free mice. This work was supported by grants AI038446 (J.N.W.), AI044231 (J.N.W.), AI078538 (J.N.W.) and AI037108 (Y.Y.) from the US Public Health Service.	Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Clarke TB, 2009, BIOCHEMISTRY-US, V48, P2675, DOI 10.1021/bi801993x; Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Ismair MG, 2006, CAN J PHYSIOL PHARM, V84, P1313, DOI 10.1139/Y06-076; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KRUEGER JM, 1984, J BIOL CHEM, V259, P2659; Kufer TA, 2006, INFECT IMMUN, V74, P3115, DOI 10.1128/IAI.00035-06; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Lysenko ES, 2007, PLOS PATHOG, V3, P1073, DOI 10.1371/journal.ppat.0030118; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Matthias KA, 2008, J IMMUNOL, V180, P6246, DOI 10.4049/jimmunol.180.9.6246; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; MINE Y, 1983, J ANTIBIOT, V36, P1059, DOI 10.7164/antibiotics.36.1059; Noverr MC, 2005, CLIN EXP ALLERGY, V35, P1511, DOI 10.1111/j.1365-2222.2005.02379.x; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Pamer EG, 2007, NAT IMMUNOL, V8, P1173, DOI 10.1038/ni1526; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; REDL H, 1993, IMMUNOBIOLOGY, V187, P330, DOI 10.1016/S0171-2985(11)80348-7; Roche AM, 2007, INFECT IMMUN, V75, P2469, DOI 10.1128/IAI.01972-06; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Standish AJ, 2009, J IMMUNOL, V183, P2602, DOI 10.4049/jimmunol.0900688; Swaan PW, 2008, AM J RESP CELL MOL, V39, P536, DOI 10.1165/rcmb.2008-0059OC; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Xu XL, 2008, CELL HOST MICROBE, V4, P28, DOI 10.1016/j.chom.2008.05.014	31	769	799	10	161	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					228	U137		10.1038/nm.2087	http://dx.doi.org/10.1038/nm.2087			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20081863	Green Accepted			2022-12-27	WOS:000274297000046
J	Cheng, ZY; Guo, SD; Copps, K; Dong, XC; Kollipara, R; Rodgers, JT; Depinho, RA; Puigserver, P; White, MF				Cheng, Zhiyong; Guo, Shaodong; Copps, Kyle; Dong, Xiaochen; Kollipara, Ramya; Rodgers, Joseph T.; Depinho, Ronald A.; Puigserver, Pere; White, Morris F.			Foxo1 integrates insulin signaling with mitochondrial function in the liver	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR FOXO1; HEPATIC GLUCOSE-PRODUCTION; HUMAN SKELETAL-MUSCLE; DYSFUNCTION; RECEPTOR; ALPHA; EXPRESSION; RESISTANCE; INDUCTION; OXIDATION	Type 2 diabetes is a complex disease that is marked by the dysfunction of glucose and lipid metabolism. Hepatic insulin resistance is especially pathogenic in type 2 diabetes, as it dysregulates fasting and postprandial glucose tolerance and promotes systemic dyslipidemia and nonalcoholic fatty liver disease(1,2). Mitochondrial dysfunction is closely associated with insulin resistance and might contribute to the progression of diabetes(3,4). Here we used previously generated mice(5) with hepatic insulin resistance owing to the deletion of the genes encoding insulin receptor substrate-1 (Irs-1) and Irs-2 (referred to here as double-knockout (DKO) mice) to establish the molecular link between dysregulated insulin action and mitochondrial function. The expression of several forkhead box O1 (Foxo1) target genes increased in the DKO liver, including heme oxygenase-1 (Hmox1), which disrupts complex III and IV of the respiratory chain and lowers the NAD(+)/NADH ratio and ATP production. Although peroxisome proliferator-activated receptor-gamma coactivator-1 gamma (Ppargc-1 alpha) was also upregulated in DKO liver, it was acetylated and failed to promote compensatory mitochondrial biogenesis or function. Deletion of hepatic Foxo1 in DKO liver normalized the expression of Hmox1 and the NAD(+)/NADH ratio, reduced Ppargc-1 alpha acetylation and restored mitochondrial oxidative metabolism and biogenesis. Thus, Foxo1 integrates insulin signaling with mitochondrial function, and inhibition of Foxo1 can improve hepatic metabolism during insulin resistance and the metabolic syndrome.	[Cheng, Zhiyong; Guo, Shaodong; Copps, Kyle; Dong, Xiaochen; White, Morris F.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Endocrinol,Childrens Hosp Boston, Boston, MA 02115 USA; [Kollipara, Ramya; Depinho, Ronald A.] Harvard Univ, Sch Med, Dept Med, Dept Med Oncol,Belfer Inst Appl Canc Sci, Boston, MA USA; [Kollipara, Ramya; Depinho, Ronald A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Rodgers, Joseph T.; Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol,Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	White, MF (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Div Endocrinol,Childrens Hosp Boston, Boston, MA 02115 USA.	morris.white@childrens.harvard.edu	Guo, Shaodong/W-5552-2019	Rodgers, Joseph/0000-0002-6598-5520; Cheng, Zhiyong/0000-0001-7615-9788; DePinho, Ronald/0000-0002-5625-577X	US National Institutes of Health [DK38712, DK55326]; American Diabetes Association [7-08-MN-63, JF-7-07-27]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R01DK038712, R29DK038712, K99DK077505, R01DK055326, R55DK038712] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank B. Spiegelman and L. M. Rohas for help with respiration assays, S. Orkin for help with fluorescent assays and R. de Cabo for the communication on flow cytometric assay. We are also grateful to Y. Long for his valuable comments and discussion. This project was supported by US National Institutes of Health grants DK38712 and DK55326 (M. F. W.), American Diabetes Association Mentor-Based Postdoctoral Fellowship 7-08-MN-63 (M. F. W. and Z.C.) and American Diabetes Association Junior Faculty Grant JF-7-07-27 (S. G.).	ALAM J, 1994, J BIOL CHEM, V269, P1001; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Brown MS, 2008, CELL METAB, V7, P95, DOI 10.1016/j.cmet.2007.12.009; Converso DP, 2006, FASEB J, V20, P1236, DOI 10.1096/fj.05-4204fje; Dong XC, 2008, CELL METAB, V8, P65, DOI 10.1016/j.cmet.2008.06.006; Edgerton DS, 2009, FRONT BIOSCI-LANDMRK, V14, P1169, DOI 10.2741/3301; Friedman JR, 2004, P NATL ACAD SCI USA, V101, P12986, DOI 10.1073/pnas.0402875101; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; Gottlieb E, 2002, P NATL ACAD SCI USA, V99, P12801, DOI 10.1073/pnas.202477599; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hwang JH, 2009, DIABETES, V58, P965, DOI 10.2337/db08-1183; Kamagate A, 2008, J CLIN INVEST, V118, P2347, DOI [10.1172/JCI32914, 10.1172/JC132914]; Kamei Y, 2008, ENDOCRINOLOGY, V149, P2293, DOI 10.1210/en.2007-1461; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kubota N, 2008, CELL METAB, V8, P49, DOI 10.1016/j.cmet.2008.05.007; KUNZ WS, 1988, BIOCHIM BIOPHYS ACTA, V932, P8, DOI 10.1016/0005-2728(88)90134-X; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; LUMENG L, 1976, J BIOL CHEM, V251, P277; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; Peterside IE, 2003, AM J PHYSIOL-ENDOC M, V285, pE1258, DOI 10.1152/ajpendo.00437.2002; Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Soriano FX, 2006, DIABETES, V55, P1783, DOI 10.2337/db05-0509; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	34	213	220	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1307	U105		10.1038/nm.2049	http://dx.doi.org/10.1038/nm.2049			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19838201	Green Accepted			2022-12-27	WOS:000271543700019
J	Plum, L; Lin, HV; Dutia, R; Tanaka, J; Aizawa, KS; Matsumoto, M; Kim, AJ; Cawley, NX; Paik, JH; Loh, YP; DePinho, RA; Wardlaw, SL; Accili, D				Plum, Leona; Lin, Hua V.; Dutia, Roxanne; Tanaka, Jun; Aizawa, Kumiko S.; Matsumoto, Michihiro; Kim, Andrea J.; Cawley, Niamh X.; Paik, Ji-Hye; Loh, Y. Peng; DePinho, Ronald A.; Wardlaw, Sharon L.; Accili, Domenico			The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake	NATURE MEDICINE			English	Article							PROTHYROTROPIN-RELEASING HORMONE; PROHORMONE CONVERTASES; BETA-ENDORPHIN; BODY-WEIGHT; CPE(FAT)/CPE(FAT) MICE; STIMULATING HORMONE; ENERGY HOMEOSTASIS; LEPTIN; PEPTIDE; INSULIN	Reduced food intake brings about an adaptive decrease in energy expenditure that contributes to the recidivism of obesity after weight loss. Insulin and leptin inhibit food intake through actions in the central nervous system that are partly mediated by the transcription factor FoxO1. We show that FoxO1 ablation in pro-opiomelanocortin (Pomc)-expressing neurons in mice (here called Pomc-Foxo1(-/-) mice) increases Carboxypeptidase E (Cpe) expression, resulting in selective increases of alpha-melanocyt-estimulating hormone (alpha-Msh) and carboxy-cleaved beta-endorphin, the products of Cpe-dependent processing of Pomc. This neuropeptide profile is associated with decreased food intake and normal energy expenditure in Pomc-Foxo1(-/-) mice. We show that Cpe expression is downregulated by diet-induced obesity and that FoxO1 deletion offsets the decrease, protecting against weight gain. Moreover, moderate Cpe overexpression in the arcuate nucleus phenocopies features of the FoxO1 mutation. The dissociation of food intake from energy expenditure in Pomc-Foxo1(-/-) mice represents a model for therapeutic intervention in obesity and raises the possibility of targeting Cpe to develop weight loss medications.	[Plum, Leona; Lin, Hua V.; Dutia, Roxanne; Tanaka, Jun; Aizawa, Kumiko S.; Matsumoto, Michihiro; Kim, Andrea J.; Wardlaw, Sharon L.; Accili, Domenico] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA; [Plum, Leona; Lin, Hua V.; Dutia, Roxanne; Tanaka, Jun; Aizawa, Kumiko S.; Matsumoto, Michihiro; Kim, Andrea J.; Wardlaw, Sharon L.; Accili, Domenico] Columbia Univ, Dept Med, New York, NY USA; [Matsumoto, Michihiro] Int Med Ctr Japan, Dept Clin Pharmacol, Tokyo, Japan; [Cawley, Niamh X.; Loh, Y. Peng] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Dev Neurosci, Cellular Neurobiol Sect, Bethesda, MD USA; [Paik, Ji-Hye; DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Paik, Ji-Hye; DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Paik, Ji-Hye; DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Paik, Ji-Hye; DePinho, Ronald A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA	Columbia University; Columbia University; National Center for Global Health & Medicine - Japan; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Accili, D (corresponding author), Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA.	da230@columbia.edu	Plum-Mörschel, Leona/W-9413-2019	Plum-Mörschel, Leona/0000-0002-1907-761X; DePinho, Ronald/0000-0002-5625-577X; Lin, Hua/0000-0001-5001-5567	Deutsche Forschungsgemeinschaft [PL542/1-1]; US National Institutes of Health [DK57539, DK58282, DK80003, DK63608]; Robert A. and Renee E. Belfer Family Institute for Innovative Cancer Science; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK058282, R01DK058282, R01DK080003, R01DK064819, R01DK057539, P30DK063608] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. and Renee E. Belfer Family Institute for Innovative Cancer Science; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Deutsche Forschungsgemeinschaft PL542/1-1 (L.P.), US National Institutes of Health DK57539 and DK58282 (D.A.), DK80003 (S.L.W.) and DK63608 (Columbia Diabetes and Endocrinology Research Center). We thank R. Leibel for insightful discussions, L. Zeltser and S. Padilla for help with in situ hybridization, N. Seidah (Clinical Research Institute of Montreal) and D. Good (University of Massachusetts) for plasmids encoding pCsk1, A. White (University of Manchester) for neuropeptide antisera, and M. Low (Oregon Health Sciences University) for Pomc-Gfp transgenic mice, Y. Liu for technical assistance and members of the Accili and Wardlaw laboratories for stimulating discussions. R.A.D. is an American Cancer Society Research Professor and an Ellison Medical Foundation Senior Scholar and is supported by the Robert A. and Renee E. Belfer Family Institute for Innovative Cancer Science.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Allen RG, 2001, J NEUROSCI, V21, P5864, DOI 10.1523/JNEUROSCI.21-16-05864.2001; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Belgardt BF, 2008, CELL METAB, V7, P291, DOI 10.1016/j.cmet.2008.01.006; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; Benoit SC, 2002, J NEUROSCI, V22, P9048; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; Brakch N, 1997, BIOCHEMISTRY-US, V36, P16309, DOI 10.1021/bi9714767; Bray GA, 2008, J CLIN ENDOCR METAB, V93, pS81, DOI 10.1210/jc.2008-1294; Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775; Cawley NX, 2004, ENDOCRINOLOGY, V145, P5807, DOI 10.1210/en.2004-0847; Che FY, 2001, P NATL ACAD SCI USA, V98, P9971, DOI 10.1073/pnas.161542198; Chen MS, 2001, ASIA PAC J OPER RES, V18, P131; Creemers JWM, 2006, ENDOCRINOLOGY, V147, P1621, DOI 10.1210/en.2005-1373; Fox DL, 2008, MOL ENDOCRINOL, V22, P1438, DOI 10.1210/me.2008-0010; Fukuda M, 2008, J NEUROSCI, V28, P13640, DOI 10.1523/JNEUROSCI.4023-08.2008; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; JAFFE SB, 1994, BRAIN RES, V648, P24, DOI 10.1016/0006-8993(94)91900-3; Kim MS, 2006, NAT NEUROSCI, V9, P901, DOI 10.1038/nn1731; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lloyd DJ, 2006, HUM MOL GENET, V15, P1884, DOI 10.1093/hmg/ddl111; MCGOWAN MK, 1993, PHYSIOL BEHAV, V54, P1031, DOI 10.1016/0031-9384(93)90320-F; Miller R, 2003, J NEUROCHEM, V86, P556, DOI 10.1046/j.1471-4159.2003.01856.x; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; NICOLAS P, 1985, P NATL ACAD SCI USA, V82, P3178, DOI 10.1073/pnas.82.10.3178; Nilaweera KN, 2003, NEUROSCIENCE, V119, P713, DOI 10.1016/S0306-4522(02)00869-2; Nillni EA, 2007, ENDOCRINOLOGY, V148, P4191, DOI 10.1210/en.2007-0173; Overton JM, 2004, PHYSIOL BEHAV, V81, P749, DOI 10.1016/j.physbeh.2004.04.025; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Papadopoulos AD, 1999, J NEUROENDOCRINOL, V11, P315; Perone MJ, 1996, BIOCHEM SOC T, V24, pS497, DOI 10.1042/bst024497s; Plum L, 2007, CELL METAB, V6, P431, DOI 10.1016/j.cmet.2007.10.012; Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123; Plum L, 2006, J CLIN INVEST, V116, P1761, DOI 10.1172/JCI29063; Pritchard LE, 2007, ENDOCRINOLOGY, V148, P4201, DOI 10.1210/en.2006-1686; Rosenbaum M, 2005, J CLIN INVEST, V115, P3579, DOI 10.1172/JCI25977; Sanchez VC, 2004, J CLIN INVEST, V114, P357, DOI 10.1172/jci200421620; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; TSIGOS C, 1993, J CLIN ENDOCR METAB, V76, P620, DOI 10.1210/jc.76.3.620; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; WARDLAW SL, 1986, ENDOCRINOLOGY, V119, P19, DOI 10.1210/endo-119-1-19; Wertz-Lutz AE, 2008, J ANIM SCI, V86, P564, DOI 10.2527/jas.2007-0556; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woronowicz A, 2008, HIPPOCAMPUS, V18, P1051, DOI 10.1002/hipo.20462; Yach D, 2006, NAT MED, V12, P62, DOI 10.1038/nm0106-62; Yanagita K, 2008, NEUROSCI LETT, V442, P140, DOI 10.1016/j.neulet.2008.07.018; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	55	120	123	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1195	U125		10.1038/nm.2026	http://dx.doi.org/10.1038/nm.2026			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19767734	Green Accepted			2022-12-27	WOS:000270596400032
J	Jin, A; Ozawa, T; Tajiri, K; Obata, T; Kondo, S; Kinoshita, K; Kadowaki, S; Takahashi, K; Sugiyama, T; Kishi, H; Muraguchi, A				Jin, Aishun; Ozawa, Tatsuhiko; Tajiri, Kazuto; Obata, Tsutomu; Kondo, Sachiko; Kinoshita, Koshi; Kadowaki, Shinichi; Takahashi, Kazuo; Sugiyama, Toshiro; Kishi, Hiroyuki; Muraguchi, Atsushi			A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood	NATURE MEDICINE			English	Article								Antigen-specific human monoclonal antibodies (mAbs) are key candidates for therapeutic agents. However, the availability of a suitable screening system for antigen-specific antibody-secreting cells (ASCs) is limited in humans. Here we present a unique method for detecting individual ASCs using microwell array chips, which enables the analysis of live cells on a single-cell basis and offers a rapid, efficient and high-throughput (up to 234,000 individual cells) system for identifying and recovering objective ASCs. We applied the system to detect and retrieve ASCs for hepatitis B virus and influenza viruses from human peripheral blood lymphocytes and produced human mAbs with virus-neutralizing activities within a week. Furthermore, we show that the system is useful for detecting ASCs for multiple antigens as well as for selection of ASCs secreting high-affinity antibodies on a chip. Our method can open the way for the generation of therapeutic antibodies for individual patients.	[Jin, Aishun; Ozawa, Tatsuhiko; Tajiri, Kazuto; Kondo, Sachiko; Kinoshita, Koshi; Kadowaki, Shinichi; Kishi, Hiroyuki; Muraguchi, Atsushi] Toyama Univ, Dept Immunol, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan; [Jin, Aishun] SC World Inc, Toyama, Japan; [Tajiri, Kazuto; Sugiyama, Toshiro] Toyama Univ, Dept Internal Med 3, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan; [Obata, Tsutomu] Toyama Ind Technol Ctr, Cent Res Inst, Toyama 9300866, Japan; [Takahashi, Kazuo] Osaka Prefectural Inst Publ Hlth, Dept Infect Dis, Osaka 537, Japan	University of Toyama; University of Toyama; Osaka Prefectural Institute of Public Health	Kishi, H (corresponding author), Toyama Univ, Dept Immunol, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan.	immkishi@med.u-toyama.ac.jp		Ozawa, Tatsuhiko/0000-0002-3112-452X				Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Laermer Franz, 1996, Google Patents, US Patent, Patent No. [5,501,893, 5501893]; OKUNO Y, 1990, J CLIN MICROBIOL, V28, P1308, DOI 10.1128/JCM.28.6.1308-1313.1990	3	190	234	3	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1088	U146		10.1038/nm.1966	http://dx.doi.org/10.1038/nm.1966			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19684583	Bronze			2022-12-27	WOS:000269979200032
J	Yamayoshi, S; Yamashita, Y; Li, JF; Hanagata, N; Minowa, T; Takemura, T; Koike, S				Yamayoshi, Seiya; Yamashita, Yasuko; Li, Jifen; Hanagata, Nobutaka; Minowa, Takashi; Takemura, Taro; Koike, Satoshi			Scavenger receptor B2 is a cellular receptor for enterovirus 71	NATURE MEDICINE			English	Article							MOUTH-DISEASE; POLIOVIRUS RECEPTOR; MEMBRANE-PROTEINS; PUBLIC-HEALTH; INFECTION; OUTBREAK; SYSTEM; FOOT; HAND; EVOLUTION	Enterovirus 71 (EV71) belongs to human enterovirus species A of the genus Enterovirus within the family Picornaviridae(1). EV71, together with coxsackievirus A16 (CVA16), are most frequently associated with hand, foot and mouth disease (HFMD)(1). Although HFMD is considered a mild exanthematous infection, infections involving EV71, but not CVA16, can progress to severe neurological disease, including fatal encephalitis, aseptic meningitis and acute flaccid paralysis(2). In recent years, epidemic and sporadic outbreaks of neurovirulent EV71 infections have been reported in Taiwan, Malaysia, Singapore, Japan and China(3-7). Here, we show that human scavenger receptor class B, member 2 (SCARB2, also known as lysosomal integral membrane protein II or CD36b like-2) is a receptor for EV71. EV71 binds soluble SCARB2 or cells expressing SCARB2, and the binding is inhibited by an antibody to SCARB2. Expression of human SCARB2 enables normally unsusceptible cell lines to support EV71 propagation and develop cytopathic effects. EV71 infection is hampered by the antibody to SCARB2 and soluble SCARB2. SCARB2 also supports the infection of the milder pathogen CVA16. The identification of SCARB2 as an EV71 and CVA16 receptor contributes to a better understanding of the pathogenicity of these viruses.	[Yamayoshi, Seiya; Yamashita, Yasuko; Li, Jifen; Koike, Satoshi] Tokyo Metropolitan Org Med Res, Dept Microbiol & Immunol, Tokyo Metropolitan Inst Neurosci, Tokyo, Japan; [Yamayoshi, Seiya] Japan Hlth Sci Fdn, Tokyo, Japan; [Hanagata, Nobutaka; Minowa, Takashi; Takemura, Taro] Natl Inst Mat Sci, Nanotechnol Innovat Ctr, Ibaraki, Japan; [Hanagata, Nobutaka] Natl Inst Mat Sci, Ctr Biomat, Ibaraki, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; National Institute for Materials Science; National Institute for Materials Science	Koike, S (corresponding author), Tokyo Metropolitan Org Med Res, Neurovirol Project, Tokyo Metropolitan Inst Med Sci, Tokyo, Japan.	koike-st@igakuken.or.jp	Yamayoshi, Seiya/C-1982-2013; Yamayoshi, Seiya/Y-7430-2019	Yamayoshi, Seiya/0000-0001-7768-5157; Yamayoshi, Seiya/0000-0001-7768-5157; Hanagata, Nobutaka/0000-0001-6079-3426	Japan Society for the Promotion of Science [20590243]; Ministry of Health, Labour and Welfare, Japan	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We thank H. Shimizu (Japan National Institute of Infectious Diseases) for providing us with all viruses used in this report and critical reading of this manuscript, Y. Kawaoka (University of Tokyo) for providing us with pCAGGS-PUR, Y. Yanagi for critical reading of this manuscript and Y. Matsumoto and K. Kohyama for supporting flow cytometry. This work was supported in part by a grant-in-aid for Scientific Research (C) (20590243) from the Japan Society for the Promotion of Science and in part by a grant-in-aid for Research on Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan.	Ahmad K, 2000, LANCET, V356, P1338, DOI 10.1016/S0140-6736(05)74253-7; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; Chan LG, 2000, CLIN INFECT DIS, V31, P678, DOI 10.1086/314032; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; Fujimoto T, 2002, MICROBIOL IMMUNOL, V46, P621, DOI 10.1111/j.1348-0421.2002.tb02743.x; Gamp AC, 2003, HUM MOL GENET, V12, P631, DOI 10.1093/hmg/ddg062; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kuronita T, 2002, J CELL SCI, V115, P4117, DOI 10.1242/jcs.00075; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Nagata N, 2002, J MED VIROL, V67, P207, DOI 10.1002/jmv.2209; Pallansch M., 2006, FIELDS VIROLOGY, VVolume 1, P839; Qiu J, 2008, LANCET NEUROL, V7, P868, DOI 10.1016/S1474-4422(08)70207-2; Yamayoshi S, 2008, CELL HOST MICROBE, V3, P168, DOI 10.1016/j.chom.2008.02.001; Yan JJ, 2000, J CLIN VIROL, V17, P13, DOI 10.1016/S1386-6532(00)00067-6; Yanagiya A, 2005, J VIROL, V79, P1523, DOI 10.1128/JVI.79.3.1523-1532.2005	18	370	428	6	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					798	U15		10.1038/nm.1992	http://dx.doi.org/10.1038/nm.1992			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19543282				2022-12-27	WOS:000267806900034
J	Manicassamy, S; Ravindran, R; Deng, JS; Oluoch, H; Denning, TL; Kasturi, SP; Rosenthal, KM; Evavold, BD; Pulendran, B				Manicassamy, Santhakumar; Ravindran, Rajesh; Deng, Jiusheng; Oluoch, Herold; Denning, Timothy L.; Kasturi, Sudhir Pai; Rosenthal, Kristen M.; Evavold, Brian D.; Pulendran, Bali			Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity	NATURE MEDICINE			English	Article							TRANS-RETINOIC ACID; ACTIVATED PROTEIN-KINASE; BETA-GLUCANS; TGF-BETA; C-FOS; DECTIN-1; DIFFERENTIATION; IMMUNITY; MACROPHAGES; GENERATION	Immune sensing of a microbe occurs via multiple receptors. How signals from different receptors are coordinated to yield a specific immune response is poorly understood. We show that two pathogen recognition receptors, Toll-like receptor 2 (TLR2) and dectin-1, recognizing the same microbial stimulus, stimulate distinct innate and adaptive responses. TLR2 signaling induced splenic dendritic cells (DCs) to express the retinoic acid metabolizing enzyme retinaldehyde dehydrogenase type 2 and interleukin-10 (IL-10) and to metabolize vitamin A and stimulate Foxp(3+) T regulatory cells (T-reg cells). Retinoic acid acted on DCs to induce suppressor of cytokine signaling-3 expression, which suppressed activation of p38 mitogen-activated protein kinase and proinflammatory cytokines. Consistent with this finding, TLR2 signaling induced Treg cells and suppressed IL-23 and T helper type 17 (T(H)17) and T(H)1-mediated autoimmune responses in vivo. In contrast, dectin-1 signaling mostly induced IL-23 and proinflammatory cytokines and augmented T(H)17 and T(H)1-mediated autoimmune responses in vivo. These data define a new mechanism for the systemic induction of retinoic acid and immune suppression against autoimmunity.	[Manicassamy, Santhakumar; Ravindran, Rajesh; Deng, Jiusheng; Oluoch, Herold; Denning, Timothy L.; Kasturi, Sudhir Pai; Pulendran, Bali] Emory Vaccine Ctr, Atlanta, GA 30329 USA; [Manicassamy, Santhakumar; Ravindran, Rajesh; Deng, Jiusheng; Oluoch, Herold; Denning, Timothy L.; Kasturi, Sudhir Pai; Pulendran, Bali] Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Rosenthal, Kristen M.; Evavold, Brian D.] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; [Pulendran, Bali] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Pulendran, B (corresponding author), Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.	bpulend@emory.edu	Pulendran, Bali/AAW-9550-2021; Denning, Timothy/F-2271-2011	Pulendran, Bali/0000-0001-6517-4333; Evavold, Brian/0000-0002-3561-3494; Denning, Timothy/0000-0002-1072-7444	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057266, R21AI056947, U54AI057157, R01AI056499, R01AI048638, R56AI048638, N01AI050025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057665] Funding Source: NIH RePORTER; NCRR NIH HHS [P51 RR000165-485850, P51 RR000165-477484, P51 RR000165-440250, P51 RR000165-440176, P51 RR000165-477423, P51 RR000165, P51 RR000165-436421, P51 RR000165-450176, P51 RR000165-450178, P51 RR000165-436422, P51 RR000165-440177, P51 RR000165-485851, P51 RR000165-436423, P51 RR000165-477422, P51 RR000165-450177, P51 RR000165-440178, P51 RR000165-460177, P51 RR000165-460295, P51 RR000165-457321, P51 RR000165-485900, P51 RR000165-460178, P51 RR000165-477421, P51 RR000165-460176] Funding Source: Medline; NIAID NIH HHS [R21 AI056947-01A1, R01 AI048638-06, U54 AI057157-06S10017, R01 AI056499-04, U19 AI057266-010002, U19 AI057266-05S10002, R01 AI048638-09A1, R01 AI048638-01, U19 AI057266, N01 AI050025, U54 AI057157, R01 AI048638-08, R56 AI048638, R01 AI056499-01, R21 AI056947, N01 AI050019, R01 AI048638-04, R01 AI056499-03, R01 AI048638-07, R01 AI048638, R56 AI048638-09, R01 AI048638-02, R01 AI056499, R01 AI048638-05A1, R01 AI048638-03, R01 AI056499-02] Funding Source: Medline; NIDDK NIH HHS [R01 DK057665-03, R01 DK057665-09, R01 DK057665-10, R01 DK057665-04, R01 DK057665, R01 DK057665-02, R01 DK057665-08, R01 DK057665-07, R01 DK057665-05, R01 DK057665-01, R01 DK057665-06] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Cao WP, 2008, NAT IMMUNOL, V9, P1157, DOI 10.1038/ni.1645; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; DEIHE H, 1990, NATURE, V343, P177; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Geissmann F, 2003, J EXP MED, V198, P623, DOI 10.1084/jem.20030390; Gerosa F, 2008, J EXP MED, V205, P1447, DOI 10.1084/jem.20071450; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Johansson-Lindbom B, 2007, IMMUNOL REV, V215, P226, DOI 10.1111/j.1600-065X.2006.00482.x; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Palucka AK, 2007, IMMUNOL REV, V220, P129, DOI 10.1111/j.1600-065X.2007.00575.x; Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006; Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Saurer L, 2007, J IMMUNOL, V179, P3504, DOI 10.4049/jimmunol.179.6.3504; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Singh M, 2007, EXPERT REV VACCINES, V6, P797, DOI 10.1586/14760584.6.5.797; Slack EC, 2007, EUR J IMMUNOL, V37, P1600, DOI 10.1002/eji.200636830; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Szatmari I, 2006, J EXP MED, V203, P2351, DOI 10.1084/jem.20060141; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tao YH, 2006, FEMS IMMUNOL MED MIC, V47, P444, DOI 10.1111/j.1574-695X.2006.00108.x; Underhill DM, 2007, IMMUNOL REV, V219, P75, DOI 10.1111/j.1600-065X.2007.00548.x; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006; Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758; Zapata-Gonzalez F, 2007, J IMMUNOL, V178, P6130, DOI 10.4049/jimmunol.178.10.6130; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	51	240	249	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					401	409		10.1038/nm.1925	http://dx.doi.org/10.1038/nm.1925			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19252500	Green Accepted			2022-12-27	WOS:000264937200027
J	Malinin, NL; Zhang, L; Choi, J; Ciocea, A; Razorenova, O; Ma, YQ; Podrez, EA; Tosi, M; Lennon, DP; Caplan, AI; Shurin, SB; Plow, EF; Byzova, TV				Malinin, Nikolay L.; Zhang, Li; Choi, Jeongsuk; Ciocea, Alieta; Razorenova, Olga; Ma, Yan-Qing; Podrez, Eugene A.; Tosi, Michael; Lennon, Donald P.; Caplan, Arnold I.; Shurin, Susan B.; Plow, Edward F.; Byzova, Tatiana V.			A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans	NATURE MEDICINE			English	Article							CELL-MATRIX ADHESION; LAD-III; PLATELET-AGGREGATION; LOCALIZATION; GLYCOPROTEIN; DEFICIENCY; COMPONENT; MEMBRANE; UNC-112; GENE	Monogenic deficiency diseases provide unique opportunities to define the contributions of individual molecules to human physiology and to identify pathologies arising from their dysfunction. Here we describe a deficiency disease in two human siblings that presented with severe bleeding, frequent infections and osteopetrosis at an early age. These symptoms are consistent with but more severe than those reported for people with leukocyte adhesion deficiency III (LAD-III). Mechanistically, these symptoms arose from an inability to activate the integrins expressed on hematopoietic cells, including platelets and leukocytes. Immortalized lymphocyte cell lines isolated from the two individuals showed integrin activation defects. Several proteins previously implicated in integrin activation, including Ras-associated protein-1 (RAP1)(1) and calcium and diacylglycerol-regulated guanine nucleotide exchange factor-1 (CALDAG-GEF1)(2), were present and functional in these cell lines. The genetic basis for this disease was traced to a point mutation in the coding region of the KINDLIN3 (official gene symbol FERMT3) gene(3). When wild-type KINDLIN-3 was expressed in the immortalized lymphocytes, their integrins became responsive to activation signals. These results identify a genetic disease that severely compromises the health of the affected individuals and establish an essential role of KINDLIN-3 in integrin activation in humans. Furthermore, allogeneic bone marrow transplantation was shown to alleviate the symptoms of the disease.	[Malinin, Nikolay L.; Choi, Jeongsuk; Ciocea, Alieta; Razorenova, Olga; Ma, Yan-Qing; Podrez, Eugene A.; Plow, Edward F.; Byzova, Tatiana V.] Cleveland Clin, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; [Zhang, Li] Univ Maryland, Ctr Vasc & Inflammatory Dis, Dept Physiol, Sch Med, Baltimore, MD 21201 USA; [Tosi, Michael] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Lennon, Donald P.; Caplan, Arnold I.] Case Western Reserve Univ, Skeletal Res Ctr, Dept Biol, Cleveland, OH 44106 USA; [Shurin, Susan B.] NHLBI, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Byzova, TV (corresponding author), Cleveland Clin, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org	Malinin, Nikolay/Z-5308-2019; Razorenova, Olga V/A-6400-2014; Malinin, Nikolay/J-4271-2012	Malinin, Nikolay/0000-0002-2654-1783; Byzova, Tatiana/0000-0002-2615-875X; Caplan, Arnold/0000-0002-8677-6621	US National Institutes of Health [HL073311, HL071625]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077213, P01HL054710, R01HL061589, P01HL073311, R01HL071625] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Roswell Park Cancer Institute Proteomics Resources, Lerner Research Institute Proteomics and Imaging Cores (J. Drazba) and Stranad Fellows I. Byzov and R. Swaninger for help with the project, A. Graybiel (Massachusetts Institute of Technology) for providing antibodies to CALDAG-GEF1 and L. Parise (University of North Carolina) for providing the GST-RALGDS fusion cDNA construct. This study was supported by HL073311 and HL071625 US National Institutes of Health grants.	Alon R, 2003, TRENDS IMMUNOL, V24, P561, DOI 10.1016/j.it.2003.08.001; Alon R, 2003, BLOOD, V101, P4437, DOI 10.1182/blood-2002-11-3427; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; Dowling JJ, 2008, CIRC RES, V102, P423, DOI 10.1161/CIRCRESAHA.107.161489; Dowling JJ, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-36; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; Kasirer-Friede A, 2007, IMMUNOL REV, V218, P247, DOI 10.1111/j.1600-065X.2007.00532.x; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Kinashi T, 2004, BLOOD, V103, P1033, DOI 10.1182/blood-2003-07-2499; Kruger M, 2008, CELL, V134, P353, DOI 10.1016/j.cell.2008.05.033; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Ma YQ, 2008, J CELL BIOL, V181, P439, DOI 10.1083/jcb.200710196; Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102; Mory A, 2008, BLOOD, V112, P2591, DOI 10.1182/blood-2008-06-163162; Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; MOYLE M, 1994, J BIOL CHEM, V269, P10008; NEWMAN PJ, 1991, P NATL ACAD SCI USA, V88, P3160, DOI 10.1073/pnas.88.8.3160; Quinn MJ, 2003, ARTERIOSCL THROM VAS, V23, P945, DOI 10.1161/01.ATV.0000066686.46338.F1; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030	27	247	253	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					313	318		10.1038/nm.1917	http://dx.doi.org/10.1038/nm.1917			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19234460	Green Accepted			2022-12-27	WOS:000263914000032
J	Manent, JB; Wang, Y; Chang, Y; Paramasivam, M; LoTurco, JJ				Manent, Jean-Bernard; Wang, Yu; Chang, YoonJeung; Paramasivam, Murugan; LoTurco, Joseph J.			Dcx reexpression reduces subcortical band heterotopia and seizure threshold in an animal model of neuronal migration disorder	NATURE MEDICINE			English	Article							DOUBLE CORTEX SYNDROME; CORTICAL DEVELOPMENT; GENETIC MALFORMATIONS; LAMINAR HETEROTOPIA; CEREBRAL-CORTEX; RAT NEOCORTEX; EPILEPSY; DOUBLECORTIN; METHYLAZOXYMETHANOL; SUSCEPTIBILITY	Disorders of neuronal migration can lead to malformations of the cerebral neocortex that greatly increase the risk of seizures. It remains untested whether malformations caused by disorders in neuronal migration can be reduced by reactivating cellular migration and whether such repair can decrease seizure risk. Here we show, in a rat model of subcortical band heterotopia (SBH) generated by in utero RNA interference of the Dcx gene, that aberrantly positioned neurons can be stimulated to migrate by reexpressing Dcx after birth. Restarting migration in this way both reduces neocortical malformations and restores neuronal patterning. We further find that the capacity to reduce SBH continues into early postnatal development. Moreover, intervention after birth reduces the convulsant-induced seizure threshold to a level similar to that in malformation-free controls. These results suggest that disorders of neuronal migration may be eventually treatable by reengaging developmental programs both to reduce the size of cortical malformations and to reduce seizure risk.	[Manent, Jean-Bernard; Wang, Yu; Chang, YoonJeung; Paramasivam, Murugan; LoTurco, Joseph J.] Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	University of Connecticut	LoTurco, JJ (corresponding author), Univ Connecticut, Dept Physiol & Neurobiol, 75 N Eagleville Rd,U-3156, Storrs, CT 06269 USA.	joseph.loturco@uconn.edu	Manent, Jean-Bernard/A-2162-2015	Manent, Jean-Bernard/0000-0002-2436-8593; Chang, YoonJeung/0000-0001-9549-8208	US National Institutes of Health [MH056524, NS062416]; Jerome Lejeune foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD055655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056524, R29MH056524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS062416] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jerome Lejeune foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	CALNL-eGFP and CAG-ERT2CreERT2 were gifts from T. Matsuda and C. Cepko, Harvard Medical School. ImageJ software was from W. Rasband, US National Institutes of Health. NeuronJ 1.2 was from E. Meijering ( Erasmus University Medical Center Rotterdam). This work was supported by the US National Institutes of Health ( MH056524 and NS062416 to J. J. L.) and the Jerome Lejeune foundation ( research fellowship to J.-B.M.).	Andres M, 2005, CEREB CORTEX, V15, P194, DOI 10.1093/cercor/bhh122; Bai JL, 2003, NAT NEUROSCI, V6, P1277, DOI 10.1038/nn1153; Baraban SC, 1996, EPILEPSY RES, V23, P189, DOI 10.1016/0920-1211(95)00094-1; Baraban SC, 1997, DEV BRAIN RES, V102, P189, DOI 10.1016/S0165-3806(97)00096-5; Baraban Scott C., 2001, Epilepsy Curr, V1, P6, DOI 10.1046/j.1535-7597.2001.00011.x; BARKOVICH AJ, 1994, ANN NEUROL, V36, P609, DOI 10.1002/ana.410360409; BARKOVICH AJ, 1989, RADIOLOGY, V171, P455, DOI 10.1148/radiology.171.2.2468173; Bernasconi A, 2001, EPILEPSIA, V42, P1124, DOI 10.1046/j.1528-1157.2001.39900.x; Cepeda C, 2005, DEV NEUROSCI-BASEL, V27, P59, DOI 10.1159/000084533; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chevassus-au-Louis N, 1999, EPILEPSIA, V40, P811, DOI 10.1111/j.1528-1157.1999.tb00786.x; Chevassus-Au-Louis N, 1998, J COMP NEUROL, V394, P520, DOI 10.1002/(SICI)1096-9861(19980518)394:4<520::AID-CNE9>3.0.CO;2-3; Coquelle FM, 2006, CELL CYCLE, V5, P976, DOI 10.4161/cc.5.9.2715; Corbo JC, 2002, J NEUROSCI, V22, P7548; Crino PB, 2004, ADV EXP MED BIOL, V548, P175; D'Agostino MD, 2002, BRAIN, V125, P2507, DOI 10.1093/brain/awf248; des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Guerrini R, 2005, EPILEPSIA, V46, P32, DOI 10.1111/j.0013-9580.2005.461010.x; Guerrini R, 1999, Neurologia, V14 Suppl 3, P32; Guerrini R, 2001, AM J MED GENET, V106, P160, DOI 10.1002/ajmg.1569; Hablitz JJ, 1998, EPILEPSY RES, V32, P75, DOI 10.1016/S0920-1211(98)00041-2; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jacobs KM, 1999, EPILEPSY RES, V36, P165, DOI 10.1016/S0920-1211(99)00050-9; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Kalman M, 2001, INT J DEV NEUROSCI, V19, P101, DOI 10.1016/S0736-5748(00)00058-7; Koizumi H, 2006, NEURON, V49, P55, DOI 10.1016/j.neuron.2005.10.040; Kuzniecky RI, 2001, BRAIN DEV-JPN, V23, P2, DOI 10.1016/S0387-7604(00)00195-9; Lee KS, 1997, J NEUROSCI, V17, P6236; Lim DA, 2007, NEUROSURG CLIN N AM, V18, P81, DOI 10.1016/j.nec.2006.10.002; Luhmann HJ, 1996, EPILEPSY RES, V26, P67, DOI 10.1016/S0920-1211(96)00041-1; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Matsumoto N, 2001, EUR J HUM GENET, V9, P5, DOI 10.1038/sj.ejhg.5200548; Nosten-Bertrand M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002473; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; PINARD JM, 1994, J NEUROL NEUROSUR PS, V57, P914, DOI 10.1136/jnnp.57.8.914; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; Ramos RL, 2006, CEREB CORTEX, V16, P1323, DOI 10.1093/cercor/bhj074; ROPER SN, 1995, EPILEPSY RES, V21, P205, DOI 10.1016/0920-1211(95)00027-8; Schwartzkroin PA, 2000, MENT RETARD DEV D R, V6, P268, DOI 10.1002/1098-2779(2000)6:4<268::AID-MRDD6>3.0.CO;2-B; Sheen Volney L, 2003, Curr Neurol Neurosci Rep, V3, P433, DOI 10.1007/s11910-003-0027-8; Sisodiya SM, 2004, LANCET NEUROL, V3, P29, DOI 10.1016/S1474-4422(03)00620-3; Sisodiya SM, 2000, BRAIN, V123, P1075, DOI 10.1093/brain/123.6.1075; STICHEL CC, 1991, J NEUROCYTOL, V20, P97, DOI 10.1007/BF01279614	46	111	113	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					84	90		10.1038/nm.1897	http://dx.doi.org/10.1038/nm.1897			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19098909	Green Accepted			2022-12-27	WOS:000262425100022
J	Watkins, DI; Burton, DR; Kallas, EG; Moore, JP; Koff, WC				Watkins, David I.; Burton, Dennis R.; Kallas, Esper G.; Moore, John P.; Koff, Wayne C.			Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans	NATURE MEDICINE			English	Article							SIMIAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; ANKARA BOOST REGIMEN; I DOWN-REGULATION; RHESUS MACAQUES; ANTIVIRAL ACTIVITY; INFECTED-CELLS; HETEROSEXUAL TRANSMISSION; ANTIRETROVIRAL THERAPY; SIVMAC239 INFECTION	The adenovirus type 5 (Ad5)-based vaccine developed by Merck failed to either prevent HIV-1 infection or suppress viral load in subsequently infected subjects in the STEP human Phase 2b efficacy trial. Analogous vaccines had previously also failed in the simian immunodeficiency virus (SIV) challenge-rhesus macaque model. In contrast, vaccine protection studies that used challenge with a chimeric simian-human immunodeficiency virus (SHIV89.6P) in macaques did not predict the human trial results. Ad5 vector -based vaccines did not protect macaques from infection after SHIV89.6P challenge but did cause a substantial reduction in viral load and a preservation of CD4(+) T cell counts after infection, findings that were not reproduced in the human trials. Although the SIV challenge model is incompletely validated, we propose that its expanded use can help facilitate the prioritization of candidate HIV-1 vaccines, ensuring that resources are focused on the most promising candidates. Vaccine designers must now develop T cell vaccine strategies that reduce viral load after heterologous challenge.	[Watkins, David I.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; [Watkins, David I.] Univ Wisconsin, Dept Pathol & Lab Med, Med Sci Ctr 6152, Madison, WI 53706 USA; [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Lab Invest Med 60, BR-02146903 Sao Paulo, Brazil; [Kallas, Esper G.] Univ Fed Sao Paulo, Div Infect Dis, BR-04044010 Sao Paulo, Brazil; [Moore, John P.] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; [Koff, Wayne C.] IAVI, New York, NY 10038 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Cornell University; International AIDS Vaccine Initiative	Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, 1220 Capitol Court, Madison, WI 53715 USA.	watkins@primate.wisc.edu	Kallas, Esper G/C-9539-2012	Kallas, Esper/0000-0003-2026-6925	NCRR NIH HHS [R24 RR015371, R24 RR016038] Funding Source: Medline; NIAID NIH HHS [R01 AI45463, R01 AI052056, R01 AI055332, U01 AI069420, R37 AI033292, R37 AI36082, R01 AI049120, R37 AI036082, U01 AI69420, R01 AI045463, R37 AI33292] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016038, R24RR015371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036082, R01AI049120, R01AI052056, R01AI045463, U01AI069420, R37AI033292, R01AI055332] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdel-Motal UM, 2005, VIROLOGY, V333, P226, DOI 10.1016/j.virol.2004.12.030; Ali A, 2004, J VIROL, V78, P561, DOI 10.1128/JVI.78.2.561-567.2004; Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Allen TM, 2002, J VIROL, V76, P10507, DOI 10.1128/JVI.76.20.10507-10511.2002; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; [Anonymous], 2007, Nature, V449, P390; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Bennett MS, 2008, J INFECT DIS, V197, P390, DOI 10.1086/525281; Bennett MS, 2007, J VIROL, V81, P4973, DOI 10.1128/JVI.02362-06; Benson J, 1998, J VIROL, V72, P4170, DOI 10.1128/JVI.72.5.4170-4182.1998; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; Chung C, 2007, J VIROL, V81, P1517, DOI 10.1128/JVI.01780-06; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Excler JL, 2007, AIDS, V21, P2259, DOI 10.1097/QAD.0b013e3282eee70c; Feinberg MB, 2002, NAT MED, V8, P207, DOI 10.1038/nm0302-207; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Gray RH, 2003, AIDS, V17, P1941, DOI 10.1097/00002030-200309050-00013; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Hel Z, 2002, J IMMUNOL, V169, P4778, DOI 10.4049/jimmunol.169.9.4778; Hel Z, 2002, VIROLOGY, V304, P125, DOI 10.1006/viro.2002.1722; Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Johnson RP, 1999, J VIROL, V73, P4952, DOI 10.1128/JVI.73.6.4952-4961.1999; Kastenmuller W, 2007, J EXP MED, V204, P2187, DOI 10.1084/jem.20070489; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Leynaert B, 1998, AM J EPIDEMIOL, V148, P88, DOI 10.1093/oxfordjournals.aje.a009564; Lifson JD, 2002, NATURE, V415, P272, DOI 10.1038/415272b; Loffredo JT, 2005, J VIROL, V79, P14986, DOI 10.1128/JVI.79.23.14986-14991.2005; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657; McDermott AB, 2005, J VIROL, V79, P15556, DOI 10.1128/JVI.79.24.15556-15566.2005; McNeil JG, 2004, SCIENCE, V303, P961, DOI 10.1126/science.1096161; Nilsson C, 1998, AIDS, V12, P2261, DOI 10.1097/00002030-199817000-00006; O'Connor DH, 2004, J VIROL, V78, P14012, DOI 10.1128/JVI.78.24.14012-14022.2004; Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002; Palmowski MJ, 2002, J IMMUNOL, V168, P4391, DOI 10.4049/jimmunol.168.9.4391; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Priddy FH, 2008, CLIN INFECT DIS, V46, P1769, DOI 10.1086/587993; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rodriguez F, 2002, J VIROL, V76, P4251, DOI 10.1128/JVI.76.9.4251-4259.2002; Rollman E, 2007, J IMMUNOL, V179, P4571, DOI 10.4049/jimmunol.179.7.4571; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Sacha JB, 2007, J IMMUNOL, V178, P2746, DOI 10.4049/jimmunol.178.5.2746; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Smith CL, 2005, J IMMUNOL, V175, P8431, DOI 10.4049/jimmunol.175.12.8431; THAKALLAPALLY R, 2000, HIV MOL IMMUNOLOGY 2, P73; Tomiyama H, 2005, J IMMUNOL, V174, P36, DOI 10.4049/jimmunol.174.1.36; Valentine LE, 2008, J VIROL, V82, P575, DOI 10.1128/JVI.00275-07; Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998; *VAXGEN, 2003, VAXGEN ANN RES ITS P; Vogel TU, 2003, J VIROL, V77, P13348, DOI 10.1128/JVI.77.24.13348-13360.2003; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Willis RA, 2006, P NATL ACAD SCI USA, V103, P12063, DOI 10.1073/pnas.0605130103; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06; Wyand MS, 1999, J VIROL, V73, P8356, DOI 10.1128/JVI.73.10.8356-8363.1999; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; Yang OO, 2003, TRENDS IMMUNOL, V24, P67, DOI 10.1016/S1471-4906(02)00034-0; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005	76	210	217	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					617	621		10.1038/nm.f.1759	http://dx.doi.org/10.1038/nm.f.1759			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18535579	Green Accepted			2022-12-27	WOS:000256468700026
J	Ding, Y; Shen, SQ; Lino, AC; de Lafaille, MAC; Lafaille, JJ				Ding, Yi; Shen, Shiqian; Lino, Andreia C.; de lafaille, Maria A. Curotto; Lafaille, Juan J.			Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR FOXP3; MYC-INDUCED APOPTOSIS; THYMOCYTE DEVELOPMENT; STEM-CELLS; IN-VIVO; BAX; PROTEIN; PROLIFERATION; POPULATIONS; SUPPRESSION	beta-catenin is a central molecule in the Wnt pathway. Expression of a stable form of beta-catenin on CD4(+)CD25(+) regulatory T (T-reg) cells resulted in a marked enhancement of survival of these cells in vitro. Furthermore, stable beta-catenin-expressing CD4(+)CD25(+) T-reg cells outcompeted control T-reg cells in vivo, and the number of T-reg cells necessary for protection against inflammatory bowel disease could be substantially reduced when stable beta-catenin-expressing CD4(+)CD25(+) T-reg cells were used instead of control T-reg cells. Expression of stable beta-catenin on potentially pathogenic CD4(+)CD25(-) T cells rendered these cells anergic, and the beta-catenin-mediated induction of anergy occurred even in Foxp3-deficient T cells. Thus, through enhanced survival of existing regulatory T cells, and through induction of unresponsiveness in precursors of T effector cells, beta-catenin stabilization has a powerful effect on the prevention of inflammatory disease.	[Ding, Yi; Shen, Shiqian; Lino, Andreia C.; de lafaille, Maria A. Curotto; Lafaille, Juan J.] NYU, Sch Med, Mol Pathogenesis Program, New York, NY 10016 USA; [Ding, Yi; Shen, Shiqian; Lino, Andreia C.; de lafaille, Maria A. Curotto; Lafaille, Juan J.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; [Ding, Yi] NYU, Sch Med, Sackler Inst Grad Biomed Sci, New York, NY 10016 USA; [de lafaille, Maria A. Curotto; Lafaille, Juan J.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Lafaille, JJ (corresponding author), NYU, Sch Med, Mol Pathogenesis Program, 540 1st Ave, New York, NY 10016 USA.	lafaille@saturn.med.nyu.edu	Lino, Andreia/GOV-5217-2022	Lino, Andreia C/0000-0002-3791-8232; Curotto de Lafaille, Maria Alicia/0000-0002-3510-3777				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; de Lafaille MAC, 2004, J IMMUNOL, V173, P7259, DOI 10.4049/jimmunol.173.12.7259; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gavin M, 2003, CURR OPIN IMMUNOL, V15, P690, DOI 10.1016/j.coi.2003.09.011; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Knoechel B, 2005, J EXP MED, V202, P1375, DOI 10.1084/jem.20050855; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LOMBARDI G, 1994, SCIENCE, V264, P1587, DOI 10.1126/science.8202711; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Mitchell KO, 2000, CANCER RES, V60, P6318; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mulroy T, 2003, INT IMMUNOL, V15, P1485, DOI 10.1093/intimm/dxg146; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Shen SQ, 2005, J CLIN INVEST, V115, P3517, DOI 10.1172/JCI25463; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042	39	152	163	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					162	169		10.1038/nm1707	http://dx.doi.org/10.1038/nm1707			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18246080				2022-12-27	WOS:000252946700024
J	Bechtel, W; McGoohan, S; Zeisberg, EM; Muller, GA; Kalbacher, H; Salant, DJ; Muller, CA; Kalluri, R; Zeisberg, M				Bechtel, Wibke; McGoohan, Scott; Zeisberg, Elisabeth M.; Mueller, Gerhard A.; Kalbacher, Hubert; Salant, David J.; Mueller, Claudia A.; Kalluri, Raghu; Zeisberg, Michael			Methylation determines fibroblast activation and fibrogenesis in the kidney	NATURE MEDICINE			English	Article							TO-MESENCHYMAL TRANSITION; HUMAN RENAL FIBROBLASTS; DNA METHYLATION; INTERSTITIAL FIBROSIS; TGF-BETA; DISEASE; CANCER; PROTEIN; CELLS; IDENTIFICATION	Fibrogenesis is a pathological wound repair process that fails to cease, even when the initial insult has been removed. Fibroblasts are principal mediators of fibrosis, and fibroblasts from fibrotic tissues fail to return to their quiescent stage, including when cultured in vitro. In a search for underlying molecular mechanisms, we hypothesized that this perpetuation of fibrogenesis is caused by epigenetic modifications. We demonstrate here that hypermethylation of RASAL1, encoding an inhibitor of the Ras oncoprotein, is associated with the perpetuation of fibroblast activation and fibrogenesis in the kidney. RASAL1 hypermethylation is mediated by the methyltransferase Dnmt1 in renal fibrogenesis, and kidney fibrosis is ameliorated in Dnmt1(+/-) heterozygous mice. These studies demonstrate that epigenetic modifications may provide a molecular basis for perpetuated fibroblast activation and fibrogenesis in the kidney.	[Bechtel, Wibke; McGoohan, Scott; Zeisberg, Elisabeth M.; Kalluri, Raghu; Zeisberg, Michael] Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA; [Bechtel, Wibke; McGoohan, Scott; Zeisberg, Elisabeth M.; Kalluri, Raghu; Zeisberg, Michael] Harvard Univ, Sch Med, Boston, MA USA; [Mueller, Gerhard A.] Univ Gottingen, Med Ctr, Dept Nephrol & Rheumatol, Gottingen, Germany; [Kalbacher, Hubert; Mueller, Claudia A.] Univ Med Clin, Sect Transplantat Immunol & Immunohematol, Med Res Ctr, Tubingen, Germany; [Salant, David J.] Boston Univ, Med Ctr, Renal Sect, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Gottingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Boston University	Zeisberg, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA.	mzeisber@bidmc.harvard.edu	Zeisberg, Elisabeth/ABG-4970-2021; Kalluri, Raghu/E-2677-2015	Bechtel-Walz, Wibke/0000-0001-6032-3627; Kalluri, Raghu/0000-0002-2190-547X; Salant, David/0000-0002-3866-3120	National Institutes of Health [R01DK081576, R03DK081687, R01DK30932, R01DK55001, R01CA125550, 1K08 CA129204, K08 DK074558]; American Society of Nephrology; American Heart Association [SDG0735602T]; Deutsche Forschungsgemeinschaft-Stipendium [BE4211/1-1]; Champalimaud Metastasis Research Program; Beth Israel Deaconess Medical Center for the Division of Matrix Biology; NATIONAL CANCER INSTITUTE [K08CA129204, R01CA125550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081576, R01DK055001, R01DK030932, K08DK074558, R03DK081687] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Nephrology; American Heart Association(American Heart Association); Deutsche Forschungsgemeinschaft-Stipendium; Champalimaud Metastasis Research Program; Beth Israel Deaconess Medical Center for the Division of Matrix Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was partially funded by research grants R01DK081576 (M.Z.), R03DK081687 (M.Z.), R01DK30932 (D.J.S.), R01DK55001 (R. K.), R01CA125550 (R. K.), Mentored Clinical Scientist Development Awards 1K08 CA129204 (E. M.Z.) and K08 DK074558 (M.Z.) from the National Institutes of Health, the American Society of Nephrology Carl W. Gottschalk Scholar Grant (M.Z.), American Heart Association Scientist Development Grant SDG0735602T, Deutsche Forschungsgemeinschaft-Stipendium BE4211/1-1 (W. B.), Champalimaud Metastasis Research Program (R. K.) and research funds from the Beth Israel Deaconess Medical Center for the Division of Matrix Biology. We thank A. Lau and T. Zhong Hu for technical assistance. FSP-1-specific antibodies were a gift from E. Neilson (Vanderbilt University).	Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Basile DP, 2005, AM J PHYSIOL-RENAL, V288, pF953, DOI 10.1152/ajprenal.00329.2004; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BOS JL, 1989, CANCER RES, V49, P4682; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Chatterjee PK, 2001, KIDNEY INT, V59, P2073, DOI 10.1046/j.1523-1755.2001.00722.x; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; Ding M, 2006, NAT MED, V12, P1081, DOI 10.1038/nm1460; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304; Forbes JM, 1999, KIDNEY INT, V55, P198, DOI 10.1046/j.1523-1755.1999.00253.x; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Gius D, 2005, CANCER, V104, P1789, DOI 10.1002/cncr.21395; Hendry Bruce M., 2003, Nephron, V93, pe129, DOI 10.1159/000070236; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Khwaja A, 2005, KIDNEY INT, V68, P474, DOI 10.1111/j.1523-1755.2005.00425.x; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; KUNCIO GS, 1991, KIDNEY INT, V39, P550, DOI 10.1038/ki.1991.63; Lafyatis Robert, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P395; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; MULLER GA, 1991, AM J KIDNEY DIS, V17, P680; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oliver JA, 2004, J CLIN INVEST, V114, P795, DOI 10.1172/JCI200420921; RODEMANN HP, 1991, AM J KIDNEY DIS, V17, P684, DOI 10.1016/S0272-6386(12)80352-0; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Strutz F, 2006, J AM SOC NEPHROL, V17, P2992, DOI 10.1681/ASN.2006050420; Villanueva S, 2006, AM J PHYSIOL-REG I, V290, pR861, DOI 10.1152/ajpregu.00384.2005; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; WEBER KT, 1992, BASIC RES CARDIOL, V87, P291; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Zaidi N, 2007, FEBS J, V274, P3138, DOI 10.1111/j.1742-4658.2007.05846.x; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	47	455	478	1	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2010	16	5					544	U75		10.1038/nm.2135	http://dx.doi.org/10.1038/nm.2135			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20418885	Green Accepted			2022-12-27	WOS:000277394700032
J	Rudolph, V; Andrie, RP; Rudolph, TK; Friedrichs, K; Klinke, A; Hirsch-Hoffmann, B; Schwoerer, AP; Lau, D; Fu, XM; Klingel, K; Sydow, K; Didie, M; Seniuk, A; von Leitner, EC; Szoecs, K; Schrickel, JW; Treede, H; Wenzel, U; Lewalter, T; Nickenig, G; Zimmermann, WH; Meinertz, T; Boger, RH; Reichenspurner, H; Freeman, BA; Eschenhagen, T; Ehmke, H; Hazen, SL; Willems, S; Baldus, S				Rudolph, Volker; Andrie, Rene P.; Rudolph, Tanja K.; Friedrichs, Kai; Klinke, Anna; Hirsch-Hoffmann, Birgit; Schwoerer, Alexander P.; Lau, Denise; Fu, XiaoMing; Klingel, Karin; Sydow, Karsten; Didie, Michael; Seniuk, Anika; von Leitner, Eike-Christin; Szoecs, Katalin; Schrickel, Jan W.; Treede, Hendrik; Wenzel, Ulrich; Lewalter, Thorsten; Nickenig, Georg; Zimmermann, Wolfram-Hubertus; Meinertz, Thomas; Boeger, Rainer H.; Reichenspurner, Hermann; Freeman, Bruce A.; Eschenhagen, Thomas; Ehmke, Heimo; Hazen, Stanley L.; Willems, Stephan; Baldus, Stephan			Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation	NATURE MEDICINE			English	Article							C-REACTIVE PROTEIN; OXIDATIVE MECHANISM; CATALYZED OXIDATION; FIBROSIS; MATRIX; MICE; INFLAMMATION; INVOLVEMENT; MATRILYSIN; SUBSTRATE	Observational clinical and ex vivo studies have established a strong association between atrial fibrillation and inflammation(1). However, whether inflammation is the cause or the consequence of atrial fibrillation and which specific inflammatory mediators may increase the atria's susceptibility to fibrillation remain elusive. Here we provide experimental and clinical evidence for the mechanistic involvement of myeloperoxidase (MPO), a heme enzyme abundantly expressed by neutrophils, in the pathophysiology of atrial fibrillation. MPO-deficient mice pretreated with angiotensin II (AngII) to provoke leukocyte activation showed lower atrial tissue abundance of the MPO product 3-chlorotyrosine, reduced activity of matrix metalloproteinases and blunted atrial fibrosis as compared to wild-type mice. Upon right atrial electrophysiological stimulation, MPO-deficient mice were protected from atrial fibrillation, which was reversed when MPO was restored. Humans with atrial fibrillation had higher plasma concentrations of MPO and a larger MPO burden in right atrial tissue as compared to individuals devoid of atrial fibrillation. In the atria, MPO colocalized with markedly increased formation of 3-chlorotyrosine. Our data demonstrate that MPO is a crucial prerequisite for structural remodeling of the myocardium, leading to an increased vulnerability to atrial fibrillation.	[Rudolph, Volker; Rudolph, Tanja K.; Friedrichs, Kai; Klinke, Anna; Lau, Denise; Sydow, Karsten; von Leitner, Eike-Christin; Szoecs, Katalin; Meinertz, Thomas; Willems, Stephan; Baldus, Stephan] Univ Heart Ctr, Dept Gen & Intervent Cardiol, Hamburg, Germany; [Rudolph, Volker; Rudolph, Tanja K.; Friedrichs, Kai; Klinke, Anna; Lau, Denise; Sydow, Karsten; von Leitner, Eike-Christin; Szoecs, Katalin; Meinertz, Thomas; Willems, Stephan; Baldus, Stephan] Univ Heart Ctr, Cardiovasc Res Ctr, Hamburg, Germany; [Andrie, Rene P.; Schrickel, Jan W.; Lewalter, Thorsten; Nickenig, Georg] Univ Bonn, Dept Med Cardiol, D-5300 Bonn, Germany; [Hirsch-Hoffmann, Birgit; Schwoerer, Alexander P.; Seniuk, Anika; Ehmke, Heimo] Univ Hosp Eppendorf, Dept Physiol, Hamburg, Germany; [Fu, XiaoMing; Hazen, Stanley L.] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44106 USA; [Klingel, Karin] Univ Tubingen Hosp, Inst Pathol, Dept Mol Pathol, Tubingen, Germany; [Didie, Michael; Zimmermann, Wolfram-Hubertus; Boeger, Rainer H.; Eschenhagen, Thomas] Univ Hosp Eppendorf, Inst Expt & Clin Pharmacol & Toxicol, Hamburg, Germany; [Didie, Michael; Zimmermann, Wolfram-Hubertus] Univ Gottingen, Dept Pharmacol, Gottingen, Germany; [Treede, Hendrik; Reichenspurner, Hermann] Univ Heart Ctr Hamburg, Dept Cardiovasc Surg, Hamburg, Germany; [Wenzel, Ulrich] Univ Hosp Eppendorf, Div Nephrol, Dept Med, Hamburg, Germany; [Freeman, Bruce A.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; Cleveland Clinic Foundation; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Baldus, S (corresponding author), Univ Heart Ctr, Dept Gen & Intervent Cardiol, Hamburg, Germany.	baldus@uke.uni-hamburg.de	Freeman, Bruce A/H-9342-2012; Zimmermann, Wolfram-Hubertus H/I-6838-2012; Treede, Hendrik/I-3630-2017; Hazen, Stanley L/ABD-5845-2021	Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040; 	Deutsche Forschungsgemeinschaft [BA 1870/3-2, BA 1870/7-1, Ru 1472/1-1, SFB-TR19]; US National Institutes of Health [P01 HL076491-055328, P01 HL087018-02001]; Deutsche Herzstiftung; Werner Otto Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL087018, R37HL058115, P01HL076491] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Herzstiftung; Werner Otto Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We wish to thank H. Wieboldt for expert technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (BA 1870/3-2 and BA 1870/7-1 to S. B., Ru 1472/1-1 to T. K. R. and SFB-TR19 to K. K.), the US National Institutes of Health (P01 HL076491-055328 and P01 HL087018-02001 to S. H.), the Deutsche Herzstiftung (to V. R. and R. P. A.) and the Werner Otto Stiftung (to S. B.).	Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F; Baldus S, 2001, J CLIN INVEST, V108, P1759; Burstein B, 2008, J AM COLL CARDIOL, V51, P802, DOI 10.1016/j.jacc.2007.09.064; Burstein B, 2007, CARDIOVASC RES, V76, P442, DOI 10.1016/j.cardiores.2007.07.013; Butz GM, 2001, PHYSIOL GENOMICS, V5, P89, DOI 10.1152/physiolgenomics.2001.5.2.89; Casaclang-Verzosa G, 2008, J AM COLL CARDIOL, V51, P1, DOI 10.1016/j.jacc.2007.09.026; Cheitlin MD, 2003, CIRCULATION, V108, P1146, DOI 10.1161/01.CIR.0000073597.57414.A9; Chen CL, 2008, J MOL CELL CARDIOL, V45, P742, DOI 10.1016/j.yjmcc.2008.07.007; Conway DSG, 2004, AM HEART J, V148, P462, DOI 10.1016/j.ahj.2004.01.026; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; El Bekay R, 2003, BLOOD, V102, P662, DOI 10.1182/blood-2002-09-2785; Fontes ML, 2005, ANESTH ANALG, V101, P17, DOI 10.1213/01.ANE.0000155260.93406.29; Frustaci A, 1997, CIRCULATION, V96, P1180, DOI 10.1161/01.CIR.96.4.1180; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Issac TT, 2007, J AM COLL CARDIOL, V50, P2021, DOI 10.1016/j.jacc.2007.06.054; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KANNEL WB, 1998, AM J CARDIOL, V0082; Lang C, 2008, J MOL MED-JMM, V86, P49, DOI 10.1007/s00109-007-0249-3; Lin CS, 2008, CELL MOL LIFE SCI, V65, P1489, DOI 10.1007/s00018-008-7408-8; Mihm MJ, 2001, CIRCULATION, V104, P174, DOI 10.1161/01.CIR.104.2.174; Nakamura Y, 2003, THROMB RES, V111, P137, DOI 10.1016/S0049-3848(03)00405-5; Nattel S, 2006, LANCET, V367, P262, DOI 10.1016/S0140-6736(06)68037-9; Polyakova V, 2008, J CELL MOL MED, V12, P189, DOI 10.1111/j.1582-4934.2008.00219.x; Roell W, 2007, NATURE, V450, P819, DOI 10.1038/nature06321; Rossi MA, 1998, J HYPERTENS, V16, P1031, DOI 10.1097/00004872-199816070-00018; Sata N, 2004, JPN HEART J, V45, P441, DOI 10.1536/jhj.45.441; Schrickel JW, 2007, CARDIOVASC RES, V76, P257, DOI 10.1016/j.cardiores.2007.07.001; Schrickel JW, 2002, BASIC RES CARDIOL, V97, P452, DOI 10.1007/s003950200052; Schwoerer AP, 2008, J MOL CELL CARDIOL, V45, P846, DOI 10.1016/j.yjmcc.2008.09.003; Verheule S, 2004, CIRC RES, V94, P1458, DOI 10.1161/01.RES.0000129579.59664.9d; Wang Y, 2007, J BIOL CHEM, V282, P31826, DOI 10.1074/jbc.M704894200; Xiao HD, 2004, AM J PATHOL, V165, P1019, DOI 10.1016/S0002-9440(10)63363-9; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109	37	229	237	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					470	U19		10.1038/nm.2124	http://dx.doi.org/10.1038/nm.2124			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20305660	Green Accepted			2022-12-27	WOS:000276446800053
J	Cerchietti, LC; Lopes, EC; Yang, SN; Hatzi, K; Bunting, KL; Tsikitas, LA; Mallik, A; Robles, AI; Walling, J; Varticovski, L; Shaknovich, R; Bhalla, KN; Chiosis, G; Melnick, A				Cerchietti, Leandro C.; Lopes, Eloisi C.; Yang, Shao Ning; Hatzi, Katerina; Bunting, Karen L.; Tsikitas, Lucas A.; Mallik, Alka; Robles, Ana I.; Walling, Jennifer; Varticovski, Lyuba; Shaknovich, Rita; Bhalla, Kapil N.; Chiosis, Gabriela; Melnick, Ari			A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas	NATURE MEDICINE			English	Article							KINASE; EXPRESSION; DEGRADATION; APOPTOSIS; CHAPERONE; BINDING; HEAT-SHOCK-PROTEIN-90; PHOSPHORYLATION; DIFFERENTIATION; GELDANAMYCIN	We report that heat shock protein 90 (Hsp90) inhibitors selectively kill diffuse large B cell lymphomas (DLBCLs) that depend on the BCL-6 transcriptional repressor. We found that endogenous Hsp90 interacts with BCL-6 in DLBCL cells and can stabilize BCL-6 mRNA and protein. Hsp90 formed a complex with BCL-6 at its target promoters, and Hsp90 inhibitors derepressed BCL-6 target genes. A stable mutant of BCL-6 rescued DLBCL cells from Hsp90 inhibitor-induced apoptosis. BCL-6 and Hsp90 were almost invariantly coexpressed in the nuclei of primary DLBCL cells, suggesting that their interaction is relevant in this disease. We examined the pharmacokinetics, toxicity and efficacy of PU-H71, a recently developed purine-derived Hsp90 inhibitor. PU-H71 preferentially accumulated in lymphomas compared to normal tissues and selectively suppressed BCL-6-dependent DLBCLs in vivo, inducing reactivation of key BCL-6 target genes and apoptosis. PU-H71 also induced cell death in primary human DLBCL specimens.	[Lopes, Eloisi C.; Chiosis, Gabriela] Sloan Kettering Inst, Dept Mol Pharmacol & Chem, New York, NY USA; [Cerchietti, Leandro C.; Yang, Shao Ning; Hatzi, Katerina; Bunting, Karen L.; Tsikitas, Lucas A.; Mallik, Alka; Melnick, Ari] Cornell Univ, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY 10021 USA; [Cerchietti, Leandro C.; Hatzi, Katerina; Bunting, Karen L.; Melnick, Ari] Cornell Univ, Weill Cornell Med Coll, Dept Pharmacol, New York, NY 10021 USA; [Robles, Ana I.; Varticovski, Lyuba] NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; [Walling, Jennifer] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA; [Shaknovich, Rita] Cornell Univ, Weill Cornell Med Coll, Dept Pathol, New York, NY 10021 USA; [Bhalla, Kapil N.] Georgia Canc Ctr, Coll Med, Augusta, GA USA	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University	Chiosis, G (corresponding author), Sloan Kettering Inst, Dept Mol Pharmacol & Chem, New York, NY USA.	chiosisg@mskcc.org; amm2014@med.cornell.edu	Melnick, Ari/AAA-5763-2020	Varticovski, Lyuba/0000-0002-5105-9008; Robles, Ana/0000-0001-5019-4374; Cerchietti, Leandro/0000-0003-0608-1350	Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NCI NIH HHS [R56 CA104348-06, R56 CA104348, R01-CA10434, R01 CA104348, R01 CA104348-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA104348, R01CA104348] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson JS, 2009, BRIT J HAEMATOL, V144, P358, DOI 10.1111/j.1365-2141.2008.07484.x; Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bonvini P, 2002, CANCER RES, V62, P1559; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Caldas-Lopes E, 2009, P NATL ACAD SCI USA, V106, P8368, DOI 10.1073/pnas.0903392106; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Chiosis G., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P1, DOI 10.2174/187152006774755483; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; Chiosis G, 2002, BIOORGAN MED CHEM, V10, P3555, DOI 10.1016/S0968-0896(02)00253-5; Chiosis G, 2006, CURR TOP MED CHEM, V6, P1183, DOI 10.2174/156802606777812013; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; Ci WM, 2008, CURR OPIN HEMATOL, V15, P381, DOI 10.1097/MOH.0b013e328302c7df; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; He HZ, 2006, J MED CHEM, V49, P381, DOI 10.1021/jm0508078; Ing NH, 2008, J BIOL CHEM, V283, P1764, DOI 10.1074/jbc.M704745200; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Robles AI, 2006, CLIN CANCER RES, V12, P6547, DOI 10.1158/1078-0432.CCR-06-1178; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Shinozaki F, 2006, J BIOL CHEM, V281, P16361, DOI 10.1074/jbc.M600891200; Sinsimer KS, 2008, MOL CELL BIOL, V28, P5223, DOI 10.1128/MCB.00431-08; Taldone T, 2008, CURR OPIN PHARMACOL, V8, P370, DOI 10.1016/j.coph.2008.06.015; Valbuena JR, 2005, MODERN PATHOL, V18, P1343, DOI 10.1038/modpathol.3800459; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Wax S, 2003, ARTHRITIS RHEUM, V48, P541, DOI 10.1002/art.10780; Zhao RM, 2005, BIOCHEM CELL BIOL, V83, P703, DOI 10.1139/O05-158	37	130	142	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1369	U3		10.1038/nm.2059	http://dx.doi.org/10.1038/nm.2059			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966776	Green Accepted			2022-12-27	WOS:000272407800016
J	Lim, E; Vaillant, F; Wu, D; Forrest, NC; Pal, B; Hart, AH; Asselin-Labat, ML; Gyorki, DE; Ward, T; Partanen, A; Feleppa, F; Huschtscha, LI; Thorne, HJ; Fox, SB; Yan, M; French, JD; Brown, MA; Smyth, GK; Visvader, JE; Lindeman, GJ				Lim, Elgene; Vaillant, Francois; Wu, Di; Forrest, Natasha C.; Pal, Bhupinder; Hart, Adam H.; Asselin-Labat, Marie-Liesse; Gyorki, David E.; Ward, Teresa; Partanen, Audrey; Feleppa, Frank; Huschtscha, Lily I.; Thorne, Heather J.; Fox, Stephen B.; Yan, Max; French, Juliet D.; Brown, Melissa A.; Smyth, Gordon K.; Visvader, Jane E.; Lindeman, Geoffrey J.			Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers	NATURE MEDICINE			English	Article							MAMMARY EPITHELIAL-CELLS; REDUCING SALPINGO-OOPHORECTOMY; HUMAN BREAST-TUMORS; ADULT HUMAN BREAST; STEM-CELLS; CANCER SUSCEPTIBILITY; MICE; DIFFERENTIATION; GLAND; RISK	Basal-like breast cancers arising in women carrying mutations in the BRCA1 gene, encoding the tumor suppressor protein BRCA1, are thought to develop from the mammary stem cell. To explore early cellular changes that occur in BRCA1 mutation carriers, we have prospectively isolated distinct epithelial subpopulations from normal mammary tissue and preneoplastic specimens from individuals heterozygous for a BRCA1 mutation. We describe three epithelial subsets including basal stem/progenitor, luminal progenitor and mature luminal cells. Unexpectedly, we found that breast tissue from BRCA1 mutation carriers harbors an expanded luminal progenitor population that shows factor-independent growth in vitro. Moreover, gene expression profiling revealed that breast tissue heterozygous for a BRCA1 mutation and basal breast tumors were more similar to normal luminal progenitor cells than any other subset, including the stem cell-enriched population. The c-KIT tyrosine kinase receptor (encoded by KIT) emerged as a key marker of luminal progenitor cells and was more highly expressed in BRCA1-associated preneoplastic tissue and tumors. Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors.	[Lim, Elgene; Vaillant, Francois; Wu, Di; Forrest, Natasha C.; Pal, Bhupinder; Asselin-Labat, Marie-Liesse; Gyorki, David E.; Ward, Teresa; Smyth, Gordon K.; Visvader, Jane E.; Lindeman, Geoffrey J.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; [Lim, Elgene; Wu, Di; Gyorki, David E.] Univ Melbourne, Parkville, Vic 3052, Australia; [Hart, Adam H.] Monash Univ, Dept Anat & Dev Biol, Melbourne, Vic 3004, Australia; [Partanen, Audrey; Feleppa, Frank; Lindeman, Geoffrey J.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia; [Huschtscha, Lily I.] Childrens Med Res Inst, Westmead, NSW, Australia; [Thorne, Heather J.; Fox, Stephen B.; Yan, Max] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [French, Juliet D.; Brown, Melissa A.] Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; Monash University; Royal Melbourne Hospital; Children's Medical Research Institute - Australia; Peter Maccallum Cancer Center; University of Queensland	Visvader, JE (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au; lindeman@wehi.edu.au	Pal, Bhupinder/AAF-4011-2020; Wu, Di/AAB-7566-2021; French, Juliet D/A-4982-2011; Lim, Elgene/AAS-7280-2020; Brown, Melissa A/F-1451-2010; McKay, Michael/ABA-9029-2021; Smyth, Gordon/B-5276-2008; Hart, Adam/C-1196-2011; French, Juliet/AAV-4435-2020; Fox, Stephen/G-9719-2016	Wu, Di/0000-0001-8331-2357; Lim, Elgene/0000-0001-8065-8838; Smyth, Gordon/0000-0001-9221-2892; Hart, Adam/0000-0001-8129-3877; French, Juliet/0000-0002-9770-0198; Brown, Melissa/0000-0002-2830-9259; Pal, Bhupinder/0000-0002-3684-4331; Thorne, Heather/0000-0003-3610-2511; Lindeman, Geoffrey/0000-0001-9386-2416; Fox, Stephen/0000-0002-7648-8896				Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267; Bouwman P, 2008, CELL CYCLE, V7, P2647, DOI 10.4161/cc.7.17.6266; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; DEOME KB, 1959, CANCER RES, V19, P515; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Ganesan S, 2005, COLD SH Q B, V70, P93, DOI 10.1101/sqb.2005.70.045; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kauff ND, 2008, J CLIN ONCOL, V26, P1331, DOI 10.1200/JCO.2007.13.9626; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488; Mann GJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1377; Michaud J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-363; NAGLE RB, 1986, J HISTOCHEM CYTOCHEM, V34, P869, DOI 10.1177/34.7.2423579; Narod SA, 2006, ONCOGENE, V25, P5832, DOI 10.1038/sj.onc.1209870; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; ROMIJN HJ, 1984, NEUROSCI BIOBEHAV R, V8, P301, DOI 10.1016/0149-7634(84)90055-1; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Simon R, 2004, CLIN CANCER RES, V10, P178, DOI 10.1158/1078-0432.CCR-0597-3; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	44	954	976	2	67	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					907	913		10.1038/nm.2000	http://dx.doi.org/10.1038/nm.2000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19648928				2022-12-27	WOS:000268770400035
J	Sodora, DL; Allan, JS; Apetrei, C; Brenchley, JM; Douek, DC; Else, JG; Estes, JD; Hahn, BH; Hirsch, VM; Kaur, A; Kirchhoff, F; Muller-Trutwin, M; Pandrea, I; Schmitz, JE; Silvestri, G				Sodora, Donald L.; Allan, Jonathan S.; Apetrei, Cristian; Brenchley, Jason M.; Douek, Daniel C.; Else, James G.; Estes, Jacob D.; Hahn, Beatrice H.; Hirsch, Vanessa M.; Kaur, Amitinder; Kirchhoff, Frank; Muller-Trutwin, Michaela; Pandrea, Ivona; Schmitz, Joern E.; Silvestri, Guido			Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts	NATURE MEDICINE			English	Article							T-CELL DEPLETION; SOOTY MANGABEY MONKEYS; GREEN MONKEYS; SIV INFECTION; IMMUNE ACTIVATION; VIRAL REPLICATION; MANDRILLUS-SPHINX; HIV; RESPONSES; DISEASE	The design of an effective AIDS vaccine has eluded the efforts of the scientific community to the point that alternative approaches to classic vaccine formulations have to be considered. We propose here that HIV vaccine research could greatly benefit from the study of natural simian immunodeficiency virus (SIV) infections of African nonhuman primates. Natural SIV hosts (for example, sooty mangabeys, African green monkeys and mandrills) share many features of HIV infection of humans; however, they usually do not develop immunodeficiency. These natural, nonprogressive SIV infections represent an evolutionary adaptation that allows a peaceful coexistence of primate lentiviruses and the host immune system. This adaptation does not result in reduced viral replication but, rather, involves phenotypic changes to CD4(+) T cell subsets, limited immune activation and preserved mucosal immunity, all of which contribute to the avoidance of disease progression and, possibly, to the reduction of vertical SIV transmission. Here we summarize the current understanding of SIV infection of African nonhuman primates and discuss how unraveling these evolutionary adaptations may provide clues for new vaccine designs that might induce effective immune responses without the harmful consequences of excessive immune activation. (C) 2009 Nature America, Inc. All rights reserved.	[Else, James G.; Silvestri, Guido] Yerkes Natl Primate Res Ctr, Atlanta, GA USA; [Sodora, Donald L.] Seattle Biomed Res Inst, Seattle, WA 98109 USA; [Allan, Jonathan S.] SW Natl Primate Res Ctr, San Antonio, TX USA; [Apetrei, Cristian; Pandrea, Ivona] Tulane Univ, Tulane Natl Primate Res Ctr, Covington, LA USA; [Apetrei, Cristian; Pandrea, Ivona] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA; [Brenchley, Jason M.; Hirsch, Vanessa M.] NIAID, Mol Microbiol Lab, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Douek, Daniel C.] Vaccine Res Ctr, Atlanta, GA USA; [Estes, Jacob D.] US Natl Canc Inst, Frederick, MD USA; [Hahn, Beatrice H.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Hahn, Beatrice H.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kaur, Amitinder] Harvard Univ, Sch Med, New England Primate Res Ctr, Southborough, MA 01772 USA; [Kirchhoff, Frank] Univ Ulm, Inst Mol Virol, Ulm, Germany; [Muller-Trutwin, Michaela] Inst Pasteur, Unite Regulat Infect Retrovirales, Paris, France; [Schmitz, Joern E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Viral Pathogenesis, Boston, MA 02215 USA; [Silvestri, Guido] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Center for Infectious Disease Research; Texas Biomedical Research Institute; Tulane University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Ulm University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania	Silvestri, G (corresponding author), Yerkes Natl Primate Res Ctr, Atlanta, GA USA.	gsilvest@mail.med.upenn.edu	Brenchley, Jason/AAC-5085-2019; Schmitz, Joern/A-4929-2018; Apetrei, Cristian/AAG-9032-2021; Kirchhoff, Frank/O-8367-2018	Schmitz, Joern/0000-0001-8803-0922; Apetrei, Cristian/0000-0002-0322-7185; Kirchhoff, Frank/0000-0002-7052-2360; Brenchley, Jason/0000-0001-8357-2984; Hahn, Beatrice/0000-0002-9400-9887; Muller-Trutwin, Michaela/0000-0002-3854-2396	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065335, ZIAAI000370, ZIAAI000686, ZIAAI005033] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NIAID NIH HHS [R01 AI065335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barry AP, 2007, J IMMUNOL, V178, P8002, DOI 10.4049/jimmunol.178.12.8002; Beaumier CM, 2009, NAT MED, V15, P879, DOI 10.1038/nm.1970; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; Chakrabarti LA, 2000, J VIROL, V74, P1209, DOI 10.1128/JVI.74.3.1209-1223.2000; Choudhary SK, 2007, J VIROL, V81, P8838, DOI 10.1128/JVI.02663-06; Diop OM, 2000, J VIROL, V74, P7538, DOI 10.1128/JVI.74.16.7538-7547.2000; Dunham R, 2006, BLOOD, V108, P209, DOI 10.1182/blood-2005-12-4897; Estes JD, 2008, J IMMUNOL, V180, P6798, DOI 10.4049/jimmunol.180.10.6798; Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; Goldstein S, 2000, J VIROL, V74, P11744, DOI 10.1128/JVI.74.24.11744-11753.2000; Gordon SN, 2008, J VIROL, V82, P3725, DOI 10.1128/JVI.02408-07; Gordon SN, 2007, J IMMUNOL, V179, P3026, DOI 10.4049/jimmunol.179.5.3026; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967; Kaur A, 2008, J VIROL, V82, P1084, DOI 10.1128/JVI.02197-07; Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200; Kirchhoff F, 2009, NAT REV MICROBIOL, V7, P467, DOI 10.1038/nrmicro2111; Klatt NR, 2008, J CLIN INVEST, V118, P2039, DOI 10.1172/JCI33814; Kornfeld C, 2005, J CLIN INVEST, V115, P1082, DOI 10.1172/JCI200523006; Kosub DA, 2008, J VIROL, V82, P1155, DOI 10.1128/JVI.01275-07; Lederer S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000296; Letvin NL, 2007, IMMUNITY, V27, P366, DOI 10.1016/j.immuni.2007.09.001; Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871; Meythaler M, 2009, J VIROL, V83, P572, DOI 10.1128/JVI.01715-08; Milush JM, 2007, J IMMUNOL, V179, P3047, DOI 10.4049/jimmunol.179.5.3047; Onanga R, 2006, J VIROL, V80, P3301, DOI 10.1128/JVI.80.7.3301-3309.2006; OTSYULA MG, 1995, ANN TROP MED PARASIT, V89, P573, DOI 10.1080/00034983.1995.11812990; Paiardini M, 2009, ANNU REV MED, V60, P485, DOI 10.1146/annurev.med.60.041807.123753; Pandrea I, 2003, VIROLOGY, V317, P119, DOI 10.1016/j.virol.2003.08.015; Pandrea I, 2008, J IMMUNOL, V181, P6687, DOI 10.4049/jimmunol.181.10.6687; Pandrea I, 2008, TRENDS IMMUNOL, V29, P419, DOI 10.1016/j.it.2008.05.004; Pandrea I, 2008, J VIROL, V82, P5501, DOI 10.1128/JVI.02555-07; Pandrea I, 2008, J VIROL, V82, P3713, DOI 10.1128/JVI.02402-07; Pandrea I, 2007, BLOOD, V109, P1069, DOI 10.1182/blood-2006-05-024364; Pandrea I, 2009, CURR HIV RES, V7, P57, DOI 10.2174/157016209787048456; Pandrea IV, 2007, J IMMUNOL, V179, P3035, DOI 10.4049/jimmunol.179.5.3035; Reina JML, 2009, J VIROL, V83, P2770, DOI 10.1128/JVI.01841-08; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033; Sharp PM, 2005, J VIROL, V79, P3891, DOI 10.1128/JVI.79.7.3891-3902.2005; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034; Stebbing J, 2004, NEW ENGL J MED, V350, P1872, DOI 10.1056/NEJMra032395; VandeWoude S, 2006, CLIN MICROBIOL REV, V19, P728, DOI 10.1128/CMR.00009-06; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Wang ZC, 2006, J VIROL, V80, P2771, DOI 10.1128/JVI.80.6.2771-2783.2006; Zahn RC, 2008, J VIROL, V82, P11577, DOI 10.1128/JVI.01779-08	51	170	173	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					861	865		10.1038/nm.2013	http://dx.doi.org/10.1038/nm.2013			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19661993	Green Accepted, Bronze			2022-12-27	WOS:000268770400026
J	Melese, T; Lin, SM; Chang, JL; Cohen, NH				Melese, Teri; Lin, Salima M.; Chang, Julia L.; Cohen, Neal H.			Open innovation networks between academia and industry: an imperative for breakthrough therapies	NATURE MEDICINE			English	Article							CONFLICTS-OF-INTEREST; TECHNOLOGIES; SCIENCE; TIME		[Melese, Teri; Cohen, Neal H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Lin, Salima M.; Chang, Julia L.] IBM Corp, Global Business Serv, Armonk, NY 10504 USA; [Cohen, Neal H.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA USA	University of California System; University of California San Francisco; International Business Machines (IBM); University of California System; University of California San Francisco	Melese, T (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	meleset@medsch.ucsf.edu						Altar CA, 2008, CLIN PHARMACOL THER, V83, P361, DOI 10.1038/sj.clpt.6100471; BERNSTEIN K, 2006, BIOCENTURY, V14, pA1; Blow N, 2008, NAT METHODS, V5, P361, DOI 10.1038/nmeth0408-361; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Carpenter Siri, 2007, Science, V317, P966, DOI 10.1126/science.317.5840.966; Chesbrough H., 2003, OPEN INNOVATION NEW; Chesbrough H., 2006, OPEN BUSINESS MODELS; Chesbrough HW, 2007, CALIF MANAGE REV, V50, P57, DOI 10.2307/41166416; Deverka PA, 2007, CLIN PHARMACOL THER, V82, P427, DOI 10.1038/sj.clpt.6100319; Gordon M., 2007, POINT DEAL NEGOTIATE; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Hughes B, 2008, NAT REV DRUG DISCOV, V7, P631, DOI 10.1038/nrd2648; Jarvis L, 2008, CHEM ENG NEWS, V86, P13; Jones A, 2005, NAT REV DRUG DISCOV, V4, P807, DOI 10.1038/nrd1856; Korn D, 2000, JAMA-J AM MED ASSOC, V284, P2234, DOI 10.1001/jama.284.17.2234; MELESE T, 2006, RES MANAGE REV, V15, P13; Nathan C, 2007, NAT MED, V13, P304, DOI 10.1038/nm0307-304; Phillips KA, 2008, JAMA-J AM MED ASSOC, V300, P2542, DOI 10.1001/jama.2008.754; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Stossel TP, 2005, NEW ENGL J MED, V353, P1060, DOI 10.1056/NEJMsb051758; Travis J, 2008, SCIENCE, V319, P1750, DOI 10.1126/science.319.5871.1750; Verrills Nicole M, 2006, Clin Biochem Rev, V27, P99; White AP, 2007, SPINE, V32, pS53, DOI 10.1097/BRS.0b013e318053d54f; Wilan KH, 2007, CELL, V129, P847, DOI 10.1016/j.cell.2007.05.032; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723	25	101	104	2	67	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					502	507		10.1038/nm0509-502	http://dx.doi.org/10.1038/nm0509-502			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19424212				2022-12-27	WOS:000265889300028
J	Lee, DJ; Modlin, RL				Lee, Delphine J.; Modlin, Robert L.			DNA transportation authority	NATURE MEDICINE			English	Editorial Material							ANTIMICROBIAL PEPTIDE; ATOPIC-DERMATITIS; RESPONSES; TLR2		[Lee, Delphine J.; Modlin, Robert L.] Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA; [Modlin, Robert L.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lee, DJ (corresponding author), Univ Calif Los Angeles, Div Dermatol, Dept Med, 10833 Le Conte Ave,CHS 52-121, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073539, R37AI047868] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI073539-01A2, R37 AI047868, R01 AI073539, R37 AI047868-09] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Kuner N, 2003, HAUTARZT, V54, P274, DOI 10.1007/s00105-002-0470-5; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142	10	3	3	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2008	14	12					1319	1320		10.1038/nm1208-1319	http://dx.doi.org/10.1038/nm1208-1319			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057557	Green Accepted			2022-12-27	WOS:000261393600015
J	Shankar, GM; Li, SM; Mehta, TH; Garcia-Munoz, A; Shepardson, NE; Smith, I; Brett, FM; Farrell, MA; Rowan, MJ; Lemere, CA; Regan, CM; Walsh, DM; Sabatini, BL; Selkoe, DJ				Shankar, Ganesh M.; Li, Shaomin; Mehta, Tapan H.; Garcia-Munoz, Amaya; Shepardson, Nina E.; Smith, Imelda; Brett, Francesca M.; Farrell, Michael A.; Rowan, Michael J.; Lemere, Cynthia A.; Regan, Ciaran M.; Walsh, Dominic M.; Sabatini, Bernardo L.; Selkoe, Dennis J.			Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory	NATURE MEDICINE			English	Article							LONG-TERM POTENTIATION; A-BETA; NATURAL OLIGOMERS; TRANSGENIC MICE; AREA CA1; DISEASE; DEPRESSION; HIPPOCAMPUS; EXPRESSION; A-BETA(1-42)	Alzheimer's disease constitutes a rising threat to public health. Despite extensive research in cellular and animal models, identifying the pathogenic agent present in the human brain and showing that it confers key features of Alzheimer's disease has not been achieved. We extracted soluble amyloid-beta protein (Ab) oligomers directly from the cerebral cortex of subjects with Alzheimer's disease. The oligomers potently inhibited long-term potentiation (LTP), enhanced long-term depression (LTD) and reduced dendritic spine density in normal rodent hippocampus. Soluble Ab from Alzheimer's disease brain also disrupted the memory of a learned behavior in normal rats. These various effects were specifically attributable to Ab dimers. Mechanistically, metabotropic glutamate receptors were required for the LTD enhancement, and N-methyl D-aspartate receptors were required for the spine loss. Co-administering antibodies to the Ab N-terminus prevented the LTP and LTD deficits, whereas antibodies to the midregion or C-terminus were less effective. Insoluble amyloid plaque cores from Alzheimer's disease cortex did not impair LTP unless they were first solubilized to release Ab dimers, suggesting that plaque cores are largely inactive but sequester Ab dimers that are synaptotoxic. We conclude that soluble Ab oligomers extracted from Alzheimer's disease brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species.	[Shankar, Ganesh M.; Li, Shaomin; Mehta, Tapan H.; Shepardson, Nina E.; Lemere, Cynthia A.; Selkoe, Dennis J.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; [Shankar, Ganesh M.; Sabatini, Bernardo L.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Garcia-Munoz, Amaya; Regan, Ciaran M.] Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 4, Ireland; [Smith, Imelda; Walsh, Dominic M.] Univ Coll Dublin, Lab Neurodegenerat Res, Dublin 4, Ireland; [Brett, Francesca M.; Farrell, Michael A.] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland; [Brett, Francesca M.; Farrell, Michael A.] Royal Coll Surgeons Ireland, Dublin 9, Ireland; [Rowan, Michael J.] Trinity Coll Dublin, Dept Pharmacol, Dublin 2, Ireland; [Regan, Ciaran M.] Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University College Dublin; University College Dublin; Royal College of Surgeons - Ireland; Trinity College Dublin; Trinity College Dublin	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu	Sancheti, Harsh/H-3538-2012	Brett, Francesca/0000-0002-7453-4027; Rowan, Michael Joseph/0000-0002-3867-9536	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027443] Funding Source: NIH RePORTER; NIA NIH HHS [AG R01 027443, R01 AG027443-03, R01 AG027443-04, R01 AG027443-01, R01 AG027443, R01 AG027443-02] Funding Source: Medline; NINDS NIH HHS [R01 NS046579, R01 NS046579-06A1] Funding Source: Medline; Wellcome Trust [067660] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FOX GB, 1995, J NEUROCHEM, V65, P2796; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Kemp N, 2001, PROG NEUROBIOL, V65, P339, DOI 10.1016/S0301-0082(01)00013-2; Klyubin I, 2008, J NEUROSCI, V28, P4231, DOI 10.1523/JNEUROSCI.5161-07.2008; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Martins IC, 2008, EMBO J, V27, P224, DOI 10.1038/sj.emboj.7601953; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; O'Sullivan NC, 2007, J NEUROCHEM, V101, P1085, DOI 10.1111/j.1471-4159.2006.04418.x; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tyszkiewicz JP, 2005, J NEUROPHYSIOL, V93, P3102, DOI 10.1152/jn.00939.2004; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s	30	2761	2860	9	706	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2008	14	8					837	842		10.1038/nm1782	http://dx.doi.org/10.1038/nm1782			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18568035	Green Accepted			2022-12-27	WOS:000258237500030
J	Buettner, C; Muse, ED; Cheng, A; Chen, L; Scherer, T; Pocai, A; Su, K; Cheng, B; Li, X; Harvey-White, J; Schwartz, GJ; Kunos, G; Rossetti, L				Buettner, Christoph; Muse, Evan D.; Cheng, Andrew; Chen, Linghong; Scherer, Thomas; Pocai, Alessandro; Su, Kai; Cheng, Bob; Li, Xiasong; Harvey-White, Judith; Schwartz, Gary J.; Kunos, George; Rossetti, Luciano			Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms	NATURE MEDICINE			English	Article							HORMONE-SENSITIVE LIPASE; ENERGY-BALANCE; PPAR-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; SYMPATHETIC DENERVATION; ENDOCANNABINOID SYSTEM; SKELETAL-MUSCLE; PROTEIN-KINASE; RISK-FACTORS	Leptin (encoded by Lep) controls body weight by regulating food intake and fuel partitioning. Obesity is characterized by leptin resistance and increased endocannabinoid tone. Here we show that leptin infused into the mediobasal hypothalamus (MBH) of rats inhibits white adipose tissue (WAT) lipogenesis, which occurs independently of signal transducer and activator of transcription-3 (STAT3) signaling. Correspondingly, transgenic inactivation of STAT3 signaling by mutation of the leptin receptor (s/s mice) leads to reduced adipose mass compared to db/db mice (complete abrogation of leptin receptor signaling). Conversely, the ability of hypothalamic leptin to suppress WAT lipogenesis in rats is lost when hypothalamic phosphoinositide 3-kinase signaling is prevented or when sympathetic denervation of adipose tissue is performed. MBH leptin suppresses the endocannabinoid anandamide in WAT, and, when this suppression of endocannabinoid tone is prevented by systemic CB1 receptor activation, MBH leptin fails to suppress WAT lipogenesis. These data suggest that the increased endocannabinoid tone observed in obesity is linked to a failure of central leptin signaling to restrain peripheral endocannabinoids.	[Buettner, Christoph; Chen, Linghong; Scherer, Thomas; Su, Kai; Cheng, Bob] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Muse, Evan D.; Cheng, Andrew; Rossetti, Luciano] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; [Cheng, Andrew; Pocai, Alessandro; Li, Xiasong; Schwartz, Gary J.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Muse, Evan D.; Pocai, Alessandro; Li, Xiasong; Rossetti, Luciano] Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; [Harvey-White, Judith; Kunos, George] US Natl Inst Hlth, US Natl Inst Alcohol Abuse & Alcoholism, Bethesda, MD 20892 USA	Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Buettner, C (corresponding author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl,Box 1005, New York, NY 10029 USA.	christoph.buettner@mssm.edu	Buettner, Christoph/F-5793-2013; su, kai/F-2072-2011	Buettner, Christoph/0000-0003-0412-4062; Scherer, Thomas/0000-0003-4980-706X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048321, R01DK048321, R01DK083658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000351, Z01AA000350] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AA000351-07] Funding Source: Medline; NIDDK NIH HHS [R01 DK083658, DK066618, R01 DK066618, P30 DK026687, K08 DK074873, R01 DK048321, DK048321, DK026687, DK074873, R37 DK048321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Bates SH, 2005, CELL METAB, V1, P169, DOI 10.1016/j.cmet.2005.02.001; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bluher M, 2006, DIABETES, V55, P3053, DOI 10.2337/db06-0812; Bouaboula M, 2005, EUR J PHARMACOL, V517, P174, DOI 10.1016/j.ejphar.2005.05.032; Buettner C, 2006, CELL METAB, V4, P49, DOI 10.1016/j.cmet.2006.04.014; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; COUSIN B, 1993, ENDOCRINOLOGY, V133, P2255, DOI 10.1210/en.133.5.2255; de Luca C, 2005, J CLIN INVEST, V115, P3484, DOI 10.1172/JCI24059; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Giordano A, 2006, AM J PHYSIOL-REG I, V291, pR1243, DOI 10.1152/ajpregu.00679.2005; Gonthier MP, 2007, OBESITY, V15, P837, DOI 10.1038/oby.2007.581; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Guo KY, 2007, ENDOCRINOLOGY, V148, P3987, DOI 10.1210/en.2007-0261; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Jo YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021; Kageyama H, 2003, BIOCHEM BIOPH RES CO, V305, P22, DOI 10.1016/S0006-291X(03)00663-6; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Kreier F, 2007, AM J PHYSIOL-REG I, V293, pR548, DOI 10.1152/ajpregu.00890.2006; Matias I, 2006, J CLIN ENDOCR METAB, V91, P3171, DOI 10.1210/jc.2005-2679; Metlakunta AS, 2008, ENDOCRINOLOGY, V149, P1121, DOI 10.1210/en.2007-1307; Muzumdar R, 2003, FASEB J, V17, P1130, DOI 10.1096/fj.02-0991fje; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pagano C, 2007, J CLIN ENDOCR METAB, V92, P4810, DOI 10.1210/jc.2007-0768; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Potapova IA, 2000, BIOCHEMISTRY-US, V39, P1169, DOI 10.1021/bi992159y; Reidy SP, 2000, COMP BIOCHEM PHYS A, V125, P285, DOI 10.1016/S1095-6433(00)00159-8; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Rooks CR, 2005, AM J PHYSIOL-REG I, V289, pR92, DOI 10.1152/ajpregu.00858.2004; Ruderman NB, 2006, DIABETES, V55, pS48, DOI 10.2337/db06-S007; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; Schweiger M, 2006, J BIOL CHEM, V281, P40236, DOI 10.1074/jbc.M608048200; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 2000, INT J OBESITY, V24, pS8, DOI 10.1038/sj.ijo.0801492; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang MY, 2005, P NATL ACAD SCI USA, V102, P18011, DOI 10.1073/pnas.0509001102; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; Woods SC, 2007, AM J MED, V120, pS9, DOI 10.1016/j.amjmed.2006.11.013; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Youngstrom TG, 1998, AM J PHYSIOL-REG I, V275, pR1488, DOI 10.1152/ajpregu.1998.275.5.R1488; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zvonic S, 2005, J BIOL CHEM, V280, P33856, DOI 10.1074/jbc.M508020200	50	253	261	2	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2008	14	6					667	675		10.1038/nm1775	http://dx.doi.org/10.1038/nm1775			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18516053	Green Accepted			2022-12-27	WOS:000256468700033
J	Chiarle, R; Martinengo, C; Mastini, C; Ambrogio, C; D'Escamard, V; Forni, G; Inghirami, G				Chiarle, Roberto; Martinengo, Cinzia; Mastini, Cristina; Ambrogio, Chiara; D'Escamard, Valentina; Forni, Guido; Inghirami, Giorgio			The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination	NATURE MEDICINE			English	Article							LARGE-CELL LYMPHOMA; TYROSINE KINASE; TUMOR-ANTIGEN; ALK PROTEIN; CANCER; VACCINES; IDENTIFICATION; IMMUNOTHERAPY; EXPRESSION; STRATEGIES	An ideal vaccination strategy against tumors relies on specific antigens that are required for tumor maintenance(1). For lymphoma, vaccination with subject-specific immunoglobulin idiotypes has had the most promising results(2,3). Here we show that DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK), which has been translocated in different fusion proteins necessary for the growth of anaplastic large cell lymphoma (ALCL)(4), protects mice from local and systemic lymphoma growth. The protection is potent and long lasting and elicits ALK-specific interferon-c responses and CD8(+) T cell-mediated cytotoxicity. A combination of chemotherapy and vaccination significantly enhanced the survival of mice challenged with ALK(+) lymphomas. These findings indicate that ALK represents an ideal tumor antigen for vaccination-based therapies of ALCL and possibly other ALK(+) human tumors(4-7).	[Chiarle, Roberto; Martinengo, Cinzia; Mastini, Cristina; Ambrogio, Chiara; Inghirami, Giorgio] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; [Chiarle, Roberto; Ambrogio, Chiara; Inghirami, Giorgio] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy; [Mastini, Cristina; Forni, Guido] Univ Turin, Dept Clin & Biol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [D'Escamard, Valentina; Inghirami, Giorgio] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [D'Escamard, Valentina; Inghirami, Giorgio] NYU, Sch Med, New York Canc Ctr, New York, NY 10016 USA	University of Turin; University of Turin; University of Turin; New York University; New York University	Chiarle, R (corresponding author), Univ Turin, Ctr Expt Res & Med Studies, Via Santena 7, I-10126 Turin, Italy.	roberto.chiarle@unito.it; giorgio.inghirami@unito.it		Ambrogio, Chiara/0000-0003-4122-701X; CHIARLE, Roberto/0000-0003-1564-8531	NCI NIH HHS [R01-CA90773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Tahar K, 2007, CANCER RES, V67, P1898, DOI 10.1158/0008-5472.CAN-06-4427; Ait-Taharl K, 2006, INT J CANCER, V118, P688, DOI 10.1002/ijc.21410; Biragyn A, 2000, NAT MED, V6, P966, DOI 10.1038/79649; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Dar Mohammed M, 2003, Curr Oncol Rep, V5, P380, DOI 10.1007/s11912-003-0022-x; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Egloff AM, 2006, CANCER RES, V66, P6, DOI 10.1158/0008-5472.CAN-05-3389; Ingulli Elizabeth, 2007, Methods Mol Biol, V380, P365; Jaffe Elaine S, 2004, Am J Clin Pathol, V122 Suppl, pS110; Lollini PL, 2006, NAT REV CANCER, V6, P204, DOI 10.1038/nrc1815; Packard BZ, 2007, J IMMUNOL, V179, P3812, DOI 10.4049/jimmunol.179.6.3812; Passoni L, 2003, LEUKEMIA LYMPHOMA, V44, P1675, DOI 10.1080/1042819031000099625; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; Perez-Pinera P, 2007, BIOCHEM BIOPH RES CO, V358, P399, DOI 10.1016/j.bbrc.2007.04.137; Piva R, 2006, BLOOD, V107, P689, DOI 10.1182/blood-2005-05-2125; Pulford K, 2000, BLOOD, V96, P1605, DOI 10.1182/blood.V96.4.1605.h8001605_1605_1607; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Radford KJ, 2005, PATHOLOGY, V37, P534, DOI 10.1080/00313020500376462; Rizvi MA, 2006, BLOOD, V107, P1255, DOI 10.1182/blood-2005-03-1306; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Scheich F, 2007, BLOOD, V110, P2556, DOI 10.1182/blood-2007-01-071001; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Vernersson E, 2006, GENE EXPR PATTERNS, V6, P448, DOI 10.1016/j.modgep.2005.11.006; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Williams DM, 2002, BRIT J HAEMATOL, V117, P812, DOI 10.1046/j.1365-2141.2002.03482.x; Yu M, 2006, CANCER IMMUNOL IMMUN, V55, P119, DOI 10.1007/s00262-005-0008-7	30	87	91	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2008	14	6					676	680		10.1038/nm1769	http://dx.doi.org/10.1038/nm1769			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18469826				2022-12-27	WOS:000256468700034
J	Varthakavi, V; Heimann-Nichols, E; Smith, RM; Sun, Y; Bram, RJ; Ali, S; Rose, J; Ding, L; Spearman, P				Varthakavi, Vasundhara; Heimann-Nichols, Ellen; Smith, Rita M.; Sun, Yuehui; Bram, Richard J.; Ali, Showkat; Rose, Jeremy; Ding, Lingmei; Spearman, Paul			RETRACTED: Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu (Retracted article. See vol. 16, pg. 238, 2010)	NATURE MEDICINE			English	Article; Retracted Publication							VIRUS TYPE-1 VPU; PARTICLE RELEASE; ENVELOPE PROTEIN; F-BOX; CD4; RETROVIRUSES; DEGRADATION; LYMPHOCYTES; MACHINERY; PATHWAY	The HIV-1 Vpu protein is required for efficient viral release from human cells. For HIV-2, the envelope (Env) protein replaces the role of Vpu. Both Vpu and HIV-2 Env enhance virus release by counteracting an innate host-cell block within human cells that is absent in African green monkey (AGM) cells. Here we identify calcium-modulating cyclophilin ligand (CAML) as a Vpu-interacting host factor that restricts HIV-1 release. Expression of human CAML (encoded by CAMLG) in AGM cells conferred a strong restriction of virus release that was reversed by Vpu and HIV-2 Env, suggesting that CAML is the mechanistic link between these two viral regulators. Depletion of CAML in human cells eliminated the need for Vpu in enhancing HIV-1 and murine leukemia virus release. These results point to CAML as a Vpu-sensitive host restriction factor that inhibits HIV release from human cells. The ability of CAML to inhibit virus release should illuminate new therapeutic strategies against HIV.	[Varthakavi, Vasundhara; Heimann-Nichols, Ellen; Smith, Rita M.; Sun, Yuehui] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat, Nashville, TN 37232 USA; [Bram, Richard J.] Mayo Clin, Mayo Med Sch, Div Pediat, Dept Pediat & Adolescent Med,Res Labs, Rochester, MN 55905 USA; [Ali, Showkat; Rose, Jeremy; Ding, Lingmei; Spearman, Paul] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA	Vanderbilt University; Mayo Clinic; Emory University	Varthakavi, V (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat, 1161 21st Ave S,D-7235 MCN, Nashville, TN 37232 USA.	vasundhara.varthakavi@vanderbilt.edu; paul.spearman@emory.edu			NCI NIH HHS [5R01CA112414, R01 CA112414-02, R01 CA112414] Funding Source: Medline; NIAID NIH HHS [AI058828, P30 AI054999, R01 AI058828, P30 AI054999-03, R01 AI058828-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058828, P30AI054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abada P, 2005, J VIROL, V79, P3627, DOI 10.1128/JVI.79.6.3627-3638.2005; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bartee E, 2006, PLOS PATHOG, V2, P975, DOI 10.1371/journal.ppat.0020107; Bour S, 1996, J VIROL, V70, P8285, DOI 10.1128/JVI.70.12.8285-8300.1996; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Callahan MA, 1998, J VIROL, V72, P5189, DOI 10.1128/JVI.72.6.5189-5197.1998; Cervantes-Acosta G, 2001, J VIROL METHODS, V92, P207, DOI 10.1016/S0166-0934(00)00289-5; Feng PH, 2002, J VIROL, V76, P11491, DOI 10.1128/JVI.76.22.11491-11504.2002; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gomez TS, 2006, IMMUNITY, V24, P741, DOI 10.1016/j.immuni.2006.03.022; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Neil Stuart J. D., 2006, PLoS Pathogens, V2, DOI 10.1371/jounral.ppat.0020039; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schwartz MD, 1996, VIROLOGY, V224, P302, DOI 10.1006/viro.1996.0532; SMITH AJ, 1990, J VIROL, V64, P2743, DOI 10.1128/JVI.64.6.2743-2750.1990; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; Tovey SC, 2000, BIOCHEM BIOPH RES CO, V276, P97, DOI 10.1006/bbrc.2000.3442; Tram DD, 2005, IMMUNITY, V23, P139, DOI 10.1016/j.immuni.2005.06.006; Tran DD, 2003, DEV CELL, V5, P245, DOI 10.1016/S1534-5807(03)00207-7; Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x; Varthakavi V, 2003, P NATL ACAD SCI USA, V100, P15154, DOI 10.1073/pnas.2433165100; Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992	32	32	32	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2008	14	6					641	647		10.1038/nm1778	http://dx.doi.org/10.1038/nm1778			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309NY	18500349	Green Accepted			2022-12-27	WOS:000256468700030
J	Firestein, GS; Lopez, JC				Firestein, Gary S.; Lopez, Juan Carlos			Metabolism: from bench to bedside INTRODUCTION	NATURE MEDICINE			English	Article									[Firestein, Gary S.] Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Firestein, GS (corresponding author), Univ Calif San Diego, La Jolla, CA 92093 USA.								0	0	0	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					387	387		10.1038/nm0410-387	http://dx.doi.org/10.1038/nm0410-387			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376049	Bronze			2022-12-27	WOS:000276446800038
J	Wang, YT; Liu, HZ; McKenzie, G; Witting, PK; Stasch, JP; Hahn, M; Changsirivathanathamrong, D; Wu, BJ; Ball, HJ; Thomas, SR; Kapoor, V; Celermajer, DS; Mellor, AL; Keaney, JF; Hunt, NH; Stocker, R				Wang, Yutang; Liu, Hanzhong; McKenzie, Gavin; Witting, Paul K.; Stasch, Johannes-Peter; Hahn, Michael; Changsirivathanathamrong, Dechaboon; Wu, Ben J.; Ball, Helen J.; Thomas, Shane R.; Kapoor, Vimal; Celermajer, David S.; Mellor, Andrew L.; Keaney, John F., Jr.; Hunt, Nicholas H.; Stocker, Roland			Kynurenine is an endothelium-derived relaxing factor produced during inflammation	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; STIMULATED PHOSPHOPROTEIN VASP; SOLUBLE GUANYLYL CYCLASE; TRYPTOPHAN-METABOLISM; ENDOTOXIC-SHOCK; BLOOD-PRESSURE; L-ARGININE; MALARIA; INHIBITION	Control of blood vessel tone is central to vascular homeostasis. Here we show that metabolism of tryptophan to kynurenine by indoleamine 2,3-dioxygenase (Ido) expressed in endothelial cells contributes to arterial vessel relaxation and the control of blood pressure. Infection of mice with malarial parasites (Plasmodium berghei) or induction of endotoxemia in mice led to endothelial expression of Ido, decreased plasma tryptophan concentration, increased kynurenine concentration and hypotension. Pharmacological inhibition of Ido increased blood pressure in systemically inflamed mice but not in mice deficient in Ido or interferon-gamma, which is required for Ido induction. Both tryptophan and kynurenine dilated preconstricted porcine coronary arteries; the dilating effect of tryptophan required the presence of active Ido and an intact endothelium, whereas the effect of kynurenine was endothelium independent. The arterial relaxation induced by kynurenine was mediated by activation of the adenylate and soluble guanylate cyclase pathways. Kynurenine administration decreased blood pressure in a dose-dependent manner in spontaneously hypertensive rats. Our results identify tryptophan metabolism by Ido as a new pathway contributing to the regulation of vascular tone.	[Wang, Yutang; Changsirivathanathamrong, Dechaboon; Stocker, Roland] Univ Sydney, Fac Med, Sch Med Sci Pathol, Ctr Vasc Res, Sydney, NSW 2006, Australia; [Wang, Yutang; Witting, Paul K.; Changsirivathanathamrong, Dechaboon; Stocker, Roland] Univ Sydney, Fac Med, Bosch Inst, Sydney, NSW 2006, Australia; [Wang, Yutang; Liu, Hanzhong; Wu, Ben J.; Thomas, Shane R.; Stocker, Roland] Univ New S Wales, Ctr Vasc Res, Sydney, NSW, Australia; [McKenzie, Gavin] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Stasch, Johannes-Peter] Bayer HealthCare, Cardiovasc Res, Wuppertal, Germany; [Hahn, Michael] Bayer HealthCare, Med Chem, Wuppertal, Germany; [Kapoor, Vimal] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Celermajer, David S.] Univ Sydney, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia; [Mellor, Andrew L.] Med Coll Georgia, Immunotherapy Ctr, Augusta, GA 30912 USA; [Keaney, John F., Jr.] Univ Massachusetts, Sch Med, Worcester, MA USA	University of Sydney; University of Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals; University of Western Australia; University of Sydney; University System of Georgia; Augusta University; University of Massachusetts System; University of Massachusetts Worcester	Stocker, R (corresponding author), Univ Sydney, Fac Med, Sch Med Sci Pathol, Ctr Vasc Res, Sydney, NSW 2006, Australia.	roland.stocker@sydney.edu.au	Stocker, Roland/AAV-4489-2021; Witting, Paul/ABD-2053-2020; Wang, Yutang/ABC-0592-2022; Ball, Helen J/A-4242-2010; Witting, Paul/L-9786-2019; Hunt, Nick H/A-3636-2011	Witting, Paul/0000-0003-2237-7004; Ball, Helen J/0000-0003-3733-9748; Celermajer, David/0000-0001-7640-0439; Wu, Ben/0000-0003-2826-4190; Keaney, John/0000-0002-0866-1837; Wang, Yutang/0000-0002-6264-6443	Australian National Heart Foundation [G03S1177]; National Health & Medical Research Council (NHMRC) of Australia [400992, 401106, 512469]; Australian Research Council [DP0987074, DP0343325]; National Heart Foundation [OS 98S0008]; University of Sydney Medical Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041187] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027081] Funding Source: NIH RePORTER	Australian National Heart Foundation(National Heart Foundation of Australia); National Health & Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); National Heart Foundation(National Heart Foundation of Australia); University of Sydney Medical Foundation(University of Sydney); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank E. Andriambeloson, K. Choy, M. Finnemore, A. Mitchell and H. Salahifar for assistance and preliminary experiments, J. Whitworth for the suggestion to test the effect of kynurenine on blood pressure in spontaneously hypertensive rats, G. Head for advice on telemetry and B. H. Chong (University of New South Wales) for providing MEG-01 cells. This work was supported by project grants G03S1177 from the Australian National Heart Foundation to R. S., 400992 and 401106 from the National Health & Medical Research Council (NHMRC) of Australia to R. S., DP0987074 from the Australian Research Council to N.H.H. 512469 from the NHMRC to N.H.H. and National Heart Foundation (OS 98S0008) and Australian Research Council (DP0343325) fellowships to P. K. W. R. S. holds an NHMRC Senior Principal Research Fellowship and University of Sydney Medical Foundation and Professorial Research Fellowships.	ARMSTRONG RS, 1980, BIOCHEM BIOPH RES CO, V95, P682, DOI 10.1016/0006-291X(80)90839-6; Bakker J, 2004, CRIT CARE MED, V32, P1, DOI 10.1097/01.CCM.0000105118.66983.19; Ball HJ, 2002, BRAIN RES PROTOC, V9, P206, DOI 10.1016/S1385-299X(02)00147-2; Becker EM, 2000, J CARDIOVASC PHARM, V35, P390, DOI 10.1097/00005344-200003000-00007; Bruneel F, 1997, INTENS CARE MED, V23, P698, DOI 10.1007/s001340050396; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; Chang WL, 2001, INFECT IMMUN, V69, P7341, DOI 10.1128/IAI.69.12.7341-7348.2001; CHRISTEN S, 1990, P NATL ACAD SCI USA, V87, P2506, DOI 10.1073/pnas.87.7.2506; Connelly L, 2005, J BIOL CHEM, V280, P10040, DOI 10.1074/jbc.M411991200; CRAWFORD A, 1978, J ENDOCRINOL, V77, P213, DOI 10.1677/joe.0.0770213; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499; Hansen AM, 2004, INT J PARASITOL, V34, P1309, DOI 10.1016/j.ijpara.2004.07.008; Hansen AM, 2000, REDOX REP, V5, P112, DOI 10.1179/135100000101535384; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Jung ID, 2009, J IMMUNOL, V182, P3146, DOI 10.4049/jimmunol.0803104; Kirkeboen KA, 1999, ACTA ANAESTH SCAND, V43, P275; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Lau AK, 2003, CIRCULATION, V107, P2031, DOI 10.1161/01.CIR.0000062682.40051.43; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; Luria A, 2007, J BIOL CHEM, V282, P2891, DOI 10.1074/jbc.M608057200; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; MEYER J, 1992, J APPL PHYSIOL, V73, P324, DOI 10.1152/jappl.1992.73.1.324; Mitchell AJ, 2005, INFECT IMMUN, V73, P5645, DOI 10.1128/IAI.73.9.5645-5653.2005; Miu J, 2009, INT J PARASITOL, V39, P363, DOI 10.1016/j.ijpara.2008.10.005; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; NEILL AL, 1992, PARASITOLOGY, V105, P165, DOI 10.1017/S0031182000074072; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Owe-Young R, 2008, J NEUROCHEM, V105, P1346, DOI 10.1111/j.1471-4159.2008.05241.x; Palmer D, 1998, CIRC RES, V82, P852; Quaschning T, 2007, J AM SOC NEPHROL, V18, P730, DOI 10.1681/ASN.2006050541; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Sakash JB, 2002, INFECT IMMUN, V70, P3959, DOI 10.1128/IAI.70.7.3959-3961.2002; Sanni LA, 1998, AM J PATHOL, V152, P611; Schmidt Harald H. H. W., 2009, V191, P309, DOI 10.1007/978-3-540-68964-5_14; Schmidt P, 2003, PROTEIN EXPRES PURIF, V31, P42, DOI 10.1016/S1046-5928(03)00142-6; Stasch JP, 2006, J CLIN INVEST, V116, P2552, DOI 10.1172/JCI28371; Stasch JP, 2002, BRIT J PHARMACOL, V136, P773, DOI 10.1038/sj.bjp.0704778; Tetsutani K, 2007, PARASITOLOGY, V134, P923, DOI 10.1017/S0031182007002326; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Thomas SR, 2001, J IMMUNOL, V166, P6332, DOI 10.4049/jimmunol.166.10.6332; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; WERNER ER, 1987, BIOL CHEM H-S, V368, P1407, DOI 10.1515/bchm3.1987.368.2.1407; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wiesel P, 2001, CIRC RES, V88, P1088, DOI 10.1161/hh1001.091521; YOSHIDA R, 1981, P NATL ACAD SCI-BIOL, V78, P129, DOI 10.1073/pnas.78.1.129	51	303	320	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					279	U72		10.1038/nm.2092	http://dx.doi.org/10.1038/nm.2092			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20190767	Green Accepted			2022-12-27	WOS:000275289500032
J	Rask-Madsen, C; King, GL				Rask-Madsen, Christian; King, George L.			Factors that protect the diabetic vasculature	NATURE MEDICINE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; VEGF		[Rask-Madsen, Christian; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Rask-Madsen, C (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.	george.king@joslin.harvard.edu		Rask-Madsen, Christian/0000-0002-8548-466X				Chen S, 2008, CURR DIABETES REP, V8, P470, DOI 10.1007/s11892-008-0081-3; Dorrell MI, 2010, GLIA, V58, P43, DOI 10.1002/glia.20900; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330; Eremina V, 2006, J AM SOC NEPHROL, V17, P724, DOI 10.1681/ASN.2005080810; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Isermann B, 2007, NAT MED, V13, P1349, DOI 10.1038/nm1667; Keenan HA, 2007, DIABETES CARE, V30, P1995, DOI 10.2337/dc06-2222; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9	10	28	31	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					40	41		10.1038/nm0110-40	http://dx.doi.org/10.1038/nm0110-40			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	20057426				2022-12-27	WOS:000273395500034
J	Li, XD; Zhang, XX; Leathers, R; Makino, A; Huang, CQ; Parsa, P; Macias, J; Yuan, JXJ; Jamieson, SW; Thistlethwaite, PA				Li, Xiaodong; Zhang, Xiaoxue; Leathers, Robin; Makino, Ayako; Huang, Chengqun; Parsa, Pouria; Macias, Jesus; Yuan, Jason X-J; Jamieson, Stuart W.; Thistlethwaite, Patricia A.			Notch3 signaling promotes the development of pulmonary arterial hypertension	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; TGF-BETA; INTRACELLULAR DOMAIN; NEOINTIMAL FORMATION; CROSS-TALK; RECEPTOR; EXPRESSION; PROLIFERATION; DIFFERENTIATION; MUTATIONS	Notch receptor signaling is implicated in controlling smooth muscle cell proliferation and in maintaining smooth muscle cells in an undifferentiated state. Pulmonary arterial hypertension is characterized by excessive vascular resistance, smooth muscle cell proliferation in small pulmonary arteries, leading to elevation of pulmonary vascular resistance, right ventricular failure and death. Here we show that human pulmonary hypertension is characterized by overexpression of NOTCH3 in small pulmonary artery smooth muscle cells and that the severity of disease in humans and rodents correlates with the amount of NOTCH3 protein in the lung. We further show that mice with homozygous deletion of Notch3 do not develop pulmonary hypertension in response to hypoxic stimulation and that pulmonary hypertension can be successfully treated in mice by administration of N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a gamma-secretase inhibitor that blocks activation of Notch3 in smooth muscle cells. We show a mechanistic link from NOTCH3 receptor signaling through the Hairy and enhancer of Split-5 (HES-5) protein to smooth muscle cell proliferation and a shift to an undifferentiated smooth muscle cell phenotype. These results suggest that the NOTCH3-HES-5 signaling pathway is crucial for the development of pulmonary arterial hypertension and provide a target pathway for therapeutic intervention.	[Li, Xiaodong; Zhang, Xiaoxue; Leathers, Robin; Huang, Chengqun; Parsa, Pouria; Jamieson, Stuart W.; Thistlethwaite, Patricia A.] Univ Calif San Diego, Div Cardiothorac Surg, La Jolla, CA 92093 USA; [Makino, Ayako; Yuan, Jason X-J] Univ Calif San Diego, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA; [Macias, Jesus] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Thistlethwaite, PA (corresponding author), Univ Calif San Diego, Div Cardiothorac Surg, La Jolla, CA 92093 USA.	pthistlethwaite@ucsd.edu			US National Institutes of Health [2R01HL70852]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070852] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to thank T. Gridley (The Jackson Laboratory) for providing the Notch3-knockout mice strain used in this study. This work was supported by a grant from the US National Institutes of Health (2R01HL70852 to P. A. T.).	Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Bai G, 2007, DEV CELL, V13, P283, DOI 10.1016/j.devcel.2007.05.014; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Broughton BRS, 2008, AM J PHYSIOL-LUNG C, V294, pL797, DOI 10.1152/ajplung.00253.2007; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; CHANTEMELE EJ, 2008, ARTERIOSCLER THROMB, V28, P2216; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; HAUSMANN G, 2008, J CLIN INVEST, V118, P1846; Havrda MC, 2006, THROMB HAEMOSTASIS, V96, P361, DOI 10.1160/TH06-04-0224; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hyduk Alexandra, 2005, Morbidity and Mortality Weekly Report, V54, P1; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Jin S, 2008, CIRC RES, V102, P1483, DOI 10.1161/CIRCRESAHA.107.167965; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Kluppel M, 2005, BIOESSAYS, V27, P115, DOI 10.1002/bies.20187; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Li YX, 2009, CIRCULATION, V119, P2686, DOI 10.1161/CIRCULATIONAHA.108.790485; Lin Q, 2006, J BIOL CHEM, V281, P30678, DOI 10.1074/jbc.C600120200; Morrow D, 2005, AM J PHYSIOL-CELL PH, V289, pC1188, DOI 10.1152/ajpcell.00198.2005; Morrow D, 2008, CIRC RES, V103, P1370, DOI 10.1161/CIRCRESAHA.108.187534; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Proweller A, 2005, J BIOL CHEM, V280, P8994, DOI 10.1074/jbc.M413316200; Real PJ, 2009, NAT MED, V15, P50, DOI 10.1038/nm.1900; Roca C, 2007, GENE DEV, V21, P2511, DOI 10.1101/gad.1589207; Sakata Y, 2004, ARTERIOSCL THROM VAS, V24, P2069, DOI 10.1161/01.ATV.0000143936.77094.a4; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; Sullivan CC, 2003, P NATL ACAD SCI USA, V100, P12331, DOI 10.1073/pnas.1933740100; Thomas M, 2009, AM J PATHOL, V174, P380, DOI 10.2353/ajpath.2009.080565; Tuchscherer HA, 2007, J BIOMECH, V40, P993, DOI 10.1016/j.jbiomech.2006.03.023; Wang WL, 2003, BIOCHEM BIOPH RES CO, V308, P596, DOI 10.1016/S0006-291X(03)01453-0; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yuan JXJ, 2005, CIRCULATION, V111, P534, DOI 10.1161/01.CIR.0000156326.48823.55; Zhang LZ, 2008, J BIOL CHEM, V283, P4304, DOI 10.1074/jbc.M708673200	40	241	273	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1289	U89		10.1038/nm.2021	http://dx.doi.org/10.1038/nm.2021			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19855400	Green Accepted			2022-12-27	WOS:000271543700017
J	Gurdon, J				Gurdon, John			Nuclear reprogramming in eggs	NATURE MEDICINE			English	Article							DNA-REPLICATION; XENOPUS-LAEVIS; SOMATIC NUCLEI; DEVELOPMENTAL CAPACITY; AMPHIBIAN OOCYTES; GENE-EXPRESSION; RNA SYNTHESIS; CELLS; TRANSPLANTATION; ACTIVATION		[Gurdon, John] Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1TN, England; [Gurdon, John] Univ Cambridge, Dept Zool, Cambridge CB2 1TN, England	University of Cambridge; University of Cambridge	Gurdon, J (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1TN, England.	j.gurdon@gurdon.cam.ac.uk		GURDON, JOHN/0000-0002-5621-3799	Medical Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline; Medical Research Council [G0300723B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRIGGS ROBERT, 1957, J MORPH, V100, P269, DOI 10.1002/jmor.1051000204; BROMHALL JD, 1975, NATURE, V258, P719, DOI 10.1038/258719a0; BROWN DD, 1964, P NATL ACAD SCI USA, V51, P139, DOI 10.1073/pnas.51.1.139; Byrne JA, 2003, CURR BIOL, V13, P1206, DOI 10.1016/S0960-9822(03)00462-7; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli J, 2007, SCIENCE, V316, P990, DOI 10.1126/science.1143512; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEROBERTIS EM, 1977, P NATL ACAD SCI USA, V74, P2470; Eggan E, 2004, NATURE, V428, P44, DOI 10.1038/nature02375; ELSDALE TR, 1960, J EMBRYOL EXP MORPH, V8, P437; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; GRAHAM CF, 1966, DEV BIOL, V14, P349, DOI 10.1016/0012-1606(66)90020-0; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Gurdon JB, 2000, INT J DEV BIOL, V44, P43; GURDON JB, 1975, J EMBRYOL EXP MORPH, V34, P93; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; GURDON JB, 1966, NATURE, V210, P1240, DOI 10.1038/2101240a0; GURDON JB, 1977, PROC R SOC SER B-BIO, V198, P211, DOI 10.1098/rspb.1977.0095; HARRIS H, 1967, J CELL SCI, V2, P23; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; KORN LJ, 1982, NATURE, V300, P354, DOI 10.1038/300354a0; Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062; LASKEY RA, 1970, NATURE, V228, P1332, DOI 10.1038/2281332a0; Li JS, 2004, NATURE, V428, P393, DOI 10.1038/nature02433; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Ng RK, 2008, NAT CELL BIOL, V10, P102, DOI 10.1038/ncb1674; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Terranova R, 2006, J CELL SCI, V119, P2065, DOI 10.1242/jcs.02945; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WICKENS MP, 1980, NATURE, V285, P628, DOI 10.1038/285628a0; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WOODLAND HR, 1969, DEV BIOL, V20, P89, DOI 10.1016/0012-1606(69)90007-4; Yamanaka S, 2009, NATURE, V460, P49, DOI 10.1038/nature08180; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	39	12	12	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1141	1144		10.1038/nm1009-1141	http://dx.doi.org/10.1038/nm1009-1141			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812574				2022-12-27	WOS:000270596400023
J	Lancaster, MA; Louie, CM; Silhavy, JL; Sintasath, L; DeCambre, M; Nigam, SK; Willert, K; Gleeson, JG				Lancaster, Madeline A.; Louie, Carrie M.; Silhavy, Jennifer L.; Sintasath, Louis; DeCambre, Marvalyn; Nigam, Sanjay K.; Willert, Karl; Gleeson, Joseph G.			Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy	NATURE MEDICINE			English	Article							FINGER PROTEIN GLIS2; JOUBERT-SYNDROME; CEREBELLAR DEVELOPMENT; NEGATIVE REGULATOR; EPITHELIAL-CELLS; COLON-CARCINOMA; MOUSE KIDNEY; CANCER-CELLS; AHI1 GENE; DISEASE	Cystic kidney disease represents a major cause of end-stage renal disease, yet the molecular mechanisms of pathogenesis remain largely unclear. Recent emphasis has been placed on a potential role for canonical Wnt signaling, but investigation of this pathway in adult renal homeostasis is lacking. Here we provide evidence of a previously unidentified canonical Wnt activity in adult mammalian kidney homeostasis, the loss of which leads to cystic kidney disease. Loss of the Jouberin (Jbn) protein in mouse leads to the cystic kidney disease nephronophthisis, owing to an unexpected decrease in endogenous Wnt activity. Jbn interacts with and facilitates beta-catenin nuclear accumulation, resulting in positive modulation of downstream transcription. Finally, we show that Jbn is required in vivo for a Wnt response to injury and renal tubule repair, the absence of which triggers cystogenesis.	[Lancaster, Madeline A.; Louie, Carrie M.; Silhavy, Jennifer L.; Nigam, Sanjay K.; Gleeson, Joseph G.] Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; [Lancaster, Madeline A.; Louie, Carrie M.; Silhavy, Jennifer L.; DeCambre, Marvalyn; Nigam, Sanjay K.; Gleeson, Joseph G.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Lancaster, Madeline A.; Louie, Carrie M.; Silhavy, Jennifer L.; Nigam, Sanjay K.; Gleeson, Joseph G.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Sintasath, Louis; Nigam, Sanjay K.; Willert, Karl] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [DeCambre, Marvalyn] Univ Calif San Diego, Rady Childrens Hosp, Dept Urol, La Jolla, CA 92093 USA; [DeCambre, Marvalyn] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; [Gleeson, Joseph G.] Univ Calif San Diego, Howard Hughes Med Inst, Dept Pediat, La Jolla, CA 92093 USA; [Gleeson, Joseph G.] Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Gleeson, JG (corresponding author), Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA.	jogleeson@ucsd.edu		Lancaster, Madeline/0000-0003-2324-8853	US National Institutes of Health-National Institute of General Medical Sciences [T32 GM08666]; US National Institutes of Health; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101, R01NS048453, R01NS052455] Funding Source: NIH RePORTER	US National Institutes of Health-National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to members of the Gleeson lab for technical expertise and feedback and the Nigam lab for helpful kidney-related discussions and reagents, as well as B. Brinkman and the UCSD Neuroscience Microscopy Core. We also thank the K. Kaushansky, M. Karin, and P. L. Mellon labs, as well as E. L. Stone for technical expertise. We are grateful to S. Piccolo at the Departments of Histology, Microbiology and Medical Biotechnologies, University of Padua, for the BATGAL mice. We thank S. Pleasure at the Department of Neurology, University of California-San Francisco, for Lrp6-mutant mice. We also thank M. G. Rosenfeld at the School of Medicine, UCSD, for the beta-cat Delta N construct and R. T. Moon at the Department of Pharmacology, University of Washington, for the Super Topflash construct. M. A. L. and C. M. L received support from the US National Institutes of Health-National Institute of General Medical Sciences-funded UCSD Genetics Training Program (T32 GM08666). This work was supported by the US National Institutes of Health and the Burroughs Wellcome Fund in Translational Research (J. G. G.). J. G. G. is an investigator with Howard Hughes Medical Institute.	Attanasio M, 2007, NAT GENET, V39, P1018, DOI 10.1038/ng2072; Badano JL, 2006, ANNU REV GENOM HUM G, V7, P125, DOI 10.1146/annurev.genom.7.080505.115610; Bergmann C, 2008, AM J HUM GENET, V82, P959, DOI 10.1016/j.ajhg.2008.02.017; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Bonventre JV, 2004, KIDNEY INT, V66, P480, DOI 10.1111/j.1523-1755.2004.761_2.x; Calvet J P, 1994, Curr Opin Nephrol Hypertens, V3, P340, DOI 10.1097/00041552-199405000-00017; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Davenport JR, 2007, CURR BIOL, V17, P1586, DOI 10.1016/j.cub.2007.08.034; Davison AMA, 2005, OXFORD TXB CLIN NEPH; Dixon-Salazar T, 2004, AM J HUM GENET, V75, P979, DOI 10.1086/425985; Duffield JS, 2005, J CLIN INVEST, V115, P1743, DOI 10.1172/JCI22593; Eley L, 2008, KIDNEY INT, V74, P1139, DOI 10.1038/ki.2008.377; FARAGGIANA T, 1982, J HISTOCHEM CYTOCHEM, V30, P451, DOI 10.1177/30.5.7077075; Ferland RJ, 2004, NAT GENET, V36, P1008, DOI 10.1038/ng1419; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Harris PC, 2002, CURR OPIN NEPHROL HY, V11, P309, DOI 10.1097/00041552-200205000-00007; Hildebrandt F, 2007, J AM SOC NEPHROL, V18, P1855, DOI 10.1681/ASN.2006121344; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Iglesias DM, 2007, AM J PHYSIOL-RENAL, V293, pF494, DOI 10.1152/ajprenal.00416.2006; Jauregui AR, 2008, J CELL BIOL, V180, P973, DOI 10.1083/jcb.200707090; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Kim YS, 2008, MOL CELL BIOL, V28, P2358, DOI 10.1128/MCB.01722-07; Kim YS, 2007, FEBS LETT, V581, P858, DOI 10.1016/j.febslet.2007.01.058; Kishimoto N, 2008, DEV CELL, V14, P954, DOI 10.1016/j.devcel.2008.03.010; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krishnan R, 2008, KIDNEY BLOOD PRESS R, V31, P152, DOI 10.1159/000129648; Kuure S, 2007, J AM SOC NEPHROL, V18, P1130, DOI 10.1681/ASN.2006111206; Lal M, 2008, HUM MOL GENET, V17, P3105, DOI 10.1093/hmg/ddn208; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Louie CM, 2005, HUM MOL GENET, V14, pR235, DOI 10.1093/hmg/ddi264; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Marose TD, 2008, DEV BIOL, V314, P112, DOI 10.1016/j.ydbio.2007.11.016; Meldrum KK, 2002, AM J PHYSIOL-HEART C, V282, pH540, DOI 10.1152/ajpheart.00072.2001; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Osafune K, 2006, DEVELOPMENT, V133, P151, DOI 10.1242/dev.02174; Parisi MA, 2006, J MED GENET, V43, P334, DOI 10.1136/jmg.2005.036608; Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155; Patel V, 2008, HUM MOL GENET, V17, P1578, DOI 10.1093/hmg/ddn045; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675; Qian CN, 2005, J BIOL CHEM, V280, P3938, DOI 10.1074/jbc.M410697200; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Schmidt-Ott KM, 2008, KIDNEY INT, V74, P1004, DOI 10.1038/ki.2008.322; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Surendran K, 2005, J AM SOC NEPHROL, V16, P2373, DOI 10.1681/ASN.2004110949; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Utsch B, 2006, PEDIATR NEPHROL, V21, P32, DOI 10.1007/s00467-005-2054-y; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Weiss DJ, 1999, HISTOCHEM J, V31, P231, DOI 10.1023/A:1003642025421; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Zhang K, 2007, CELL BIOCHEM FUNCT, V25, P767, DOI 10.1002/cbf.1417; Zheng R, 2008, CELL BIOL INT, V32, P427, DOI 10.1016/j.cellbi.2007.12.014	58	130	131	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1046	U101		10.1038/nm.2010	http://dx.doi.org/10.1038/nm.2010			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19718039	Green Accepted			2022-12-27	WOS:000269979200025
J	Huffaker, SJ; Chen, JS; Nicodemus, KK; Sambataro, F; Yang, F; Mattay, V; Lipska, BK; Hyde, TM; Song, J; Rujescu, D; Giegling, I; Mayilyan, K; Proust, MJ; Soghoyan, A; Caforio, G; Callicott, JH; Bertolino, A; Meyer-Lindenberg, A; Chang, J; Ji, YJ; Egan, MF; Goldberg, TE; Kleinman, JE; Lu, B; Weinberger, DR				Huffaker, Stephen J.; Chen, Jingshan; Nicodemus, Kristin K.; Sambataro, Fabio; Yang, Feng; Mattay, Venkata; Lipska, Barbara K.; Hyde, Thomas M.; Song, Jian; Rujescu, Dan; Giegling, Ina; Mayilyan, Karine; Proust, Morgan J.; Soghoyan, Armen; Caforio, Grazia; Callicott, Joseph H.; Bertolino, Alessandro; Meyer-Lindenberg, Andreas; Chang, Jay; Ji, Yuanyuan; Egan, Michael F.; Goldberg, Terry E.; Kleinman, Joel E.; Lu, Bai; Weinberger, Daniel R.			A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia	NATURE MEDICINE			English	Article							GENOME-WIDE ASSOCIATION; GENOTYPE-PHENOTYPE ASSOCIATIONS; DORSOLATERAL PREFRONTAL CORTEX; GENETIC ASSOCIATIONS; WORKING-MEMORY; RELATIVE RISK; K+ CHANNELS; HERG; SIBLINGS; OSCILLATIONS	Organized neuronal firing is crucial for cortical processing and is disrupted in schizophrenia. Using rapid amplification of 5' complementary DNA ends in human brain, we identified a primate-specific isoform (3.1) of the ether-a-go-go-related K+ channel KCNH2 that modulates neuronal firing. KCNH2-3.1 messenger RNA levels are comparable to full-length KCNH2 (1A) levels in brain but three orders of magnitude lower in heart. In hippocampus from individuals with schizophrenia, KCNH2-3.1 expression is 2.5-fold greater than KCNH2-1A expression. A meta-analysis of five clinical data sets (367 families, 1,158 unrelated cases and 1,704 controls) shows association of single nucleotide polymorphisms in KCNH2 with schizophrenia. Risk-associated alleles predict lower intelligence quotient scores and speed of cognitive processing, altered memory-linked functional magnetic resonance imaging signals and increased KCNH2-3.1 mRNA levels in postmortem hippocampus. KCNH2-3.1 lacks a domain that is crucial for slow channel deactivation. Overexpression of KCNH2-3.1 in primary cortical neurons induces a rapidly deactivating K+ current and a high-frequency, nonadapting firing pattern. These results identify a previously undescribed KCNH2 channel isoform involved in cortical physiology, cognition and psychosis, providing a potential new therapeutic drug target.	[Huffaker, Stephen J.; Chen, Jingshan; Nicodemus, Kristin K.; Sambataro, Fabio; Mattay, Venkata; Lipska, Barbara K.; Hyde, Thomas M.; Song, Jian; Proust, Morgan J.; Callicott, Joseph H.; Meyer-Lindenberg, Andreas; Egan, Michael F.; Goldberg, Terry E.; Kleinman, Joel E.; Weinberger, Daniel R.] NIMH, Clin Brain Disorders Branch, Bethesda, MD 20892 USA; [Huffaker, Stephen J.; Chen, Jingshan; Nicodemus, Kristin K.; Sambataro, Fabio; Mattay, Venkata; Lipska, Barbara K.; Hyde, Thomas M.; Song, Jian; Meyer-Lindenberg, Andreas; Chang, Jay; Goldberg, Terry E.; Kleinman, Joel E.; Lu, Bai; Weinberger, Daniel R.] NIMH, Genes Cognit & Psychosis Program, Bethesda, MD 20892 USA; [Yang, Feng; Chang, Jay; Ji, Yuanyuan; Lu, Bai] NICHD, Sect Neural Dev & Plast, Bethesda, MD USA; [Rujescu, Dan; Giegling, Ina] Univ Munich, Dept Psychiat, D-8000 Munich, Germany; [Mayilyan, Karine; Soghoyan, Armen] Yerevan State Med Univ, Dept Psychiat & Med Psychol, Hlth Minist Armenian, Yerevan, Armenia; [Caforio, Grazia; Bertolino, Alessandro] Univ Bari, Dept Neurol & Psychiat Sci, Sect Mental Disorders, Psychiat Neurosci Grp, Bari, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Munich; Yerevan State Medical University; Universita degli Studi di Bari Aldo Moro	Weinberger, DR (corresponding author), NIMH, Clin Brain Disorders Branch, Bethesda, MD 20892 USA.	weinberd@mail.nih.gov	Lu, Bai/A-4018-2012; Sambataro, Fabio/E-3426-2010; Lipska, Barbara K/E-4569-2017; Yang, Feng/C-9530-2011; Callicott, Joseph H/AAE-7243-2022; Bertolino, Alessandro/O-6352-2016; Callicott, Joseph H/C-9102-2009; Giegling, Ina/ABA-3677-2021; Rujescu, Dan/GRS-3875-2022; Meyer-Lindenberg, Andreas/H-1076-2011	Sambataro, Fabio/0000-0003-2102-416X; Bertolino, Alessandro/0000-0002-1251-1380; Callicott, Joseph H/0000-0003-1298-3334; Meyer-Lindenberg, Andreas/0000-0001-5619-1123; Lu, Bai/0000-0001-5418-9759; Mayilyan, Karine R/0000-0001-9712-4939	US National Institutes of Health/Cambridge University Health Science; NATIONAL INSTITUTE OF MENTAL HEALTH [ZICMH002903, ZIAMH002399, ZIAMH002904, ZIAMH002716, ZIAMH002734, ZICMH002905] Funding Source: NIH RePORTER	US National Institutes of Health/Cambridge University Health Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank J. Hardy, J. Duckworth and P. Momeni for technical assistance with high G-C content sequencing. We also thank J. Hardy, D. Goldman, A. Law and W. Chen for their very helpful review of the manuscript. We thank R. Straub and M. Mayhew for their input on statistical genetics analysis, M. Barenboim for help with bioinformatics and M. Herman and S. Mitkus for their help with postmortem tissue. We are extremely grateful for the assistance of G. Liu and S. Chen in the cloning and sequencing of KCNH2-3.1. We also would like to thank H.-J. Moller, P. Muglia and coworkers at the Department of Psychiatry, Ludwig Maximilians University for their help with subject recruitment and evaluation. S. J. Huffaker was partially supported by the US National Institutes of Health/Cambridge University Health Science Scholars and Medical Scientist Training Programs. Recruitment of the individuals with schizophrenia at Ludwig Maximilians University was supported by GlaxoSmithKline. Human fetal tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland.	Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Bracci E, 1999, J NEUROSCI, V19, P8104; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Callicott JH, 2000, CEREB CORTEX, V10, P1078, DOI 10.1093/cercor/10.11.1078; Callicott JH, 2003, AM J PSYCHIAT, V160, P709, DOI 10.1176/appi.ajp.160.4.709; Cannon TD, 2000, AM J HUM GENET, V67, P369, DOI 10.1086/303006; Canolty RT, 2006, SCIENCE, V313, P1626, DOI 10.1126/science.1128115; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Cloninger CR, 1998, AM J MED GENET, V81, P275, DOI 10.1002/(SICI)1096-8628(19980710)81:4<275::AID-AJMG1>3.3.CO;2-U; Davachi L, 2001, J NEUROPHYSIOL, V85, P2590, DOI 10.1152/jn.2001.85.6.2590; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; Egan G, 2003, P NATL ACAD SCI USA, V100, P15241, DOI 10.1073/pnas.2136650100; Egan MF, 2001, BIOL PSYCHIAT, V50, P98, DOI 10.1016/S0006-3223(01)01133-7; Egan MF, 2000, AM J PSYCHIAT, V157, P1309, DOI 10.1176/appi.ajp.157.8.1309; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Genderson MR, 2007, SCHIZOPHR RES, V94, P231, DOI 10.1016/j.schres.2006.12.031; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Grarup N, 2007, DIABETES, V56, P3105, DOI 10.2337/db07-0856; Gray JR, 2003, NAT NEUROSCI, V6, P316, DOI 10.1038/nn1014; Guasti L, 2005, J COMP NEUROL, V491, P157, DOI 10.1002/cne.20721; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hariri AR, 2003, BRIT MED BULL, V65, P259, DOI 10.1093/bmb/65.1.259; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Honea RA, 2008, BIOL PSYCHIAT, V63, P465, DOI 10.1016/j.biopsych.2007.05.027; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Kongsamut S, 2002, EUR J PHARMACOL, V450, P37, DOI 10.1016/S0014-2999(02)02074-5; Lipska BK, 2006, HUM MOL GENET, V15, P1245, DOI 10.1093/hmg/ddl040; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Luna A, 2007, BIOINFORMATICS, V23, P774, DOI 10.1093/bioinformatics/btl657; Nagappan G, 2009, P NATL ACAD SCI USA, V106, P1267, DOI 10.1073/pnas.0807322106; Nicodemus KK, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-130; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; Peirce TR, 2006, ARCH GEN PSYCHIAT, V63, P18, DOI 10.1001/archpsyc.63.1.18; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Sacco T, 2003, J NEUROPHYSIOL, V90, P1817, DOI 10.1152/jn.00104.2003; Sanguinetti MC, 2006, NATURE, V440, P463, DOI 10.1038/nature04710; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Straub RE, 2006, BIOL PSYCHIAT, V60, P81, DOI 10.1016/j.biopsych.2006.06.002; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; Talkowski ME, 2006, SCHIZOPHRENIA BULL, V32, P203, DOI 10.1093/schbul/sbj058; Trikalinos TA, 2004, EUR J HUM GENET, V12, P762, DOI 10.1038/sj.ejhg.5201227; Wang Y, 2006, NAT NEUROSCI, V9, P534, DOI 10.1038/nn1670; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866; Wimmers S, 2002, PFLUG ARCH EUR J PHY, V445, P423, DOI 10.1007/s00424-002-0936-4; Winterer G, 2004, TRENDS NEUROSCI, V27, P683, DOI 10.1016/j.tins.2004.08.002; Winterer G, 2004, AM J PSYCHIAT, V161, P490, DOI 10.1176/appi.ajp.161.3.490; Witchel HJ, 2003, BRIT J PSYCHIAT, V182, P171, DOI 10.1192/bjp.182.2.171-a	57	195	199	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					509	518		10.1038/nm.1962	http://dx.doi.org/10.1038/nm.1962			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19412172	Green Accepted			2022-12-27	WOS:000265889300029
J	Shoelson, SE; Goldfine, AB				Shoelson, Steven E.; Goldfine, Allison B.			Fanning the flames of obesity-induced inflammation	NATURE MEDICINE			English	Editorial Material							INDUCED INSULIN-RESISTANCE; DIABETES-MELLITUS; IKK-BETA; DISEASE; EXPRESSION		[Shoelson, Steven E.; Goldfine, Allison B.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA; [Shoelson, Steven E.; Goldfine, Allison B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Shoelson, SE (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.	steven.shoelson@joslin.harvard.edu		Goldfine, Allison/0000-0002-0345-1048	NCRR NIH HHS [M01 RR001032, M01 RR002635] Funding Source: Medline; NHLBI NIH HHS [P50 HL083813] Funding Source: Medline; NIDDK NIH HHS [U01 DK074556, R37 DK051729, RC4 DK090792, R01 DK051729, R01 DK043123, R01 DK045943, P30 DK036836, R01 DK073547, R01 DK095327] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032, M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL083813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051729, P30DK036836, R01DK073547, R01DK095327, R01DK043123, R37DK051729, R01DK045943, U01DK074556, RC4DK090792] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bernstein LE, 2006, ARCH INTERN MED, V166, P902, DOI 10.1001/archinte.166.8.902; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Goldfine AB, 2008, CTS-CLIN TRANSL SCI, V1, P36, DOI 10.1111/j.1752-8062.2008.00026.x; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Solinas G, 2007, CELL METAB, V6, P386, DOI 10.1016/j.cmet.2007.09.011; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	14	77	79	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2009	15	4					373	374		10.1038/nm0409-373	http://dx.doi.org/10.1038/nm0409-373			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19350009	Green Accepted			2022-12-27	WOS:000264937200019
J	Sarasin-Filipowicz, M; Krol, J; Markiewicz, I; Heim, MH; Filipowicz, W				Sarasin-Filipowicz, Magdalena; Krol, Jacek; Markiewicz, Ilona; Heim, Markus H.; Filipowicz, Witold			Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy	NATURE MEDICINE			English	Article							PLUS RIBAVIRIN; VIRUS-INFECTION; EXPRESSION; MODULATION	Several microRNAs (miRNAs), including liver-specific miR-122, have been implicated in the control of hepatitis C virus (HCV) RNA replication and its response to interferon (IFN) in human hepatoma cells. Our analysis of liver biopsies from subjects with chronic hepatitis C (CHC) undergoing IFN therapy revealed no correlation of miR-122 expression with viral load and markedly decreased pretreatment miR-122 levels in subjects who had no virological response during later IFN therapy; other investigated miRNAs showed only limited changes. These data have implications for the prospect of targeting miRNAs for CHC therapy.	[Sarasin-Filipowicz, Magdalena; Heim, Markus H.] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland; [Sarasin-Filipowicz, Magdalena; Heim, Markus H.] Univ Basel Hosp, Div Gastroenterol & Hepatol, CH-4031 Basel, Switzerland; [Krol, Jacek; Markiewicz, Ilona; Filipowicz, Witold] Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	University of Basel; University of Basel; Friedrich Miescher Institute for Biomedical Research	Heim, MH (corresponding author), Univ Basel, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.	markus.heim@unibas.ch; witold.filipowicz@fmi.ch	Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894; Filipowicz, Magdalena/0000-0002-0356-8836	Swiss National Science Foundation [32-116106]; Swiss Cancer League [KLS-01832-02-2006]; Krebsliga Basel [8/05]; Roche Research Foundation; Novartis Research Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Basel; Roche Research Foundation; Novartis Research Foundation	We would like to thank the subjects who participated in this study. The work done in the laboratory of M. H. H. is supported by Swiss National Science Foundation grant 32-116106, the Swiss Cancer League grant KLS-01832-02-2006, grant 8/05 from the Krebsliga Basel and a grant from the Roche Research Foundation to M. S.-F. The work done in the laboratory of W. F. is supported partially by the EC FP6 Program "Sirocco''. J.K. is the recipient of a Long-Term European Molecular Biology Organization Fellowship, and the Friedrich Miescher Institute is supported by the Novartis Research Foundation.	Asselah T, 2008, GUT, V57, P516, DOI 10.1136/gut.2007.128611; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Chen LM, 2005, GASTROENTEROLOGY, V128, P1437, DOI 10.1053/j.gastro.2005.01.059; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205; Randall G, 2007, P NATL ACAD SCI USA, V104, P12884, DOI 10.1073/pnas.0704894104; Sarasin-Filipowicz M, 2008, P NATL ACAD SCI USA, V105, P7034, DOI 10.1073/pnas.0707882105	11	264	285	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					31	33		10.1038/nm.1902	http://dx.doi.org/10.1038/nm.1902			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19122656				2022-12-27	WOS:000262425100015
J	Valiante, N; De Gregorio, E; Rappuoli, R				Valiante, Nicholas; De Gregorio, Ennio; Rappuoli, Rino			Taking on Toll-like receptors	NATURE MEDICINE			English	Editorial Material							BACTERIAL-INFECTIONS; DEFICIENCY; ENCEPHALITIS		[Valiante, Nicholas; Rappuoli, Rino] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA; [De Gregorio, Ennio; Rappuoli, Rino] Novartis Vaccines & Diagnost, I-53100 Siena, Italy	Novartis; Novartis	Valiante, N (corresponding author), Novartis Vaccines & Diagnost, 45 Sidney St, Cambridge, MA 02139 USA.	rino.rappuoli@novartis.com	De Gregorio, Ennio/J-8073-2012					Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Bustarnante J, 2008, CURR OPIN IMMUNOL, V20, P39, DOI 10.1016/j.coi.2007.10.005; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Ku CL, 2007, J EXP MED, V204, P2407, DOI 10.1084/jem.20070628; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	7	4	5	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2008	14	12					1318	1319		10.1038/nm1208-1318	http://dx.doi.org/10.1038/nm1208-1318			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057556				2022-12-27	WOS:000261393600014
J	Friese, MA; Jakobsen, KB; Friis, L; Etzensperger, R; Craner, MJ; McMahon, RM; Jensen, LT; Huygelen, V; Jones, EY; Bell, JI; Fugger, L				Friese, Manuel A.; Jakobsen, Karen B.; Friis, Lone; Etzensperger, Ruth; Craner, Matthew J.; McMahon, Roisin M.; Jensen, Lise T.; Huygelen, Veronique; Jones, E. Yvonne; Bell, John I.; Fugger, Lars			Opposing effects of HLA class I molecules in tuning autoreactive CD8(+) T cells in multiple sclerosis	NATURE MEDICINE			English	Article							GENETIC SUSCEPTIBILITY; DOUBLE-BLIND; PHASE-II; MHC; REGION; ANTIBODY; LINKAGE; DISEASE; ENCEPHALOMYELITIS; ASSOCIATION	The major known genetic risk factors in multiple sclerosis reside in the major histocompatibility complex (MHC) region. Although there is strong evidence implicating MHC class II alleles and CD4(+) T cells in multiple sclerosis pathogenesis, possible contributions from MHC class I genes and CD8(+) T cells are controversial. We have generated humanized mice expressing the multiple sclerosis-associated MHC class I alleles HLA-A*0301 (encoding human leukocyte antigen-A3 (HLA-A3)) and HLA-A*0201 (encoding HLA-A2) and a myelin-specific autoreactive T cell receptor (TCR) derived from a CD8(+) T cell clone from an individual with multiple sclerosis to study mechanisms of disease susceptibility. We demonstrate roles for HLA-A3-restricted CD8(+) T cells in induction of multiple sclerosis-like disease and for CD4(+) T cells in its progression, and we also define a possible mechanism for HLA-A*0201-mediated protection. To our knowledge, these data provide the first direct evidence incriminating MHC class I genes and CD8(+) T cells in the pathogenesis of human multiple sclerosis and reveal a network of MHC interactions that shape the risk of multiple sclerosis.	[Friese, Manuel A.; Jakobsen, Karen B.; Friis, Lone; Etzensperger, Ruth; McMahon, Roisin M.; Huygelen, Veronique; Bell, John I.; Fugger, Lars] Univ Oxford, Human Immunol Unit, MRC, Oxford OX3 9DS, England; [Craner, Matthew J.; Fugger, Lars] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Clin Neurol, Oxford OX3 9DS, England; [Friese, Manuel A.] Univ Klinikum Hamburg Eppendorf, Zentrum Mol Neurobiol, Klin MS Forsch, D-20251 Hamburg, Germany; [Friese, Manuel A.] Univ Klinikum Hamburg Eppendorf, Inst Neuroimmunol, D-20251 Hamburg, Germany; [McMahon, Roisin M.; Jones, E. Yvonne] Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England; [Jensen, Lise T.; Fugger, Lars] Aarhus Univ Hosp, Inst Clin, DK-8200 Aarhus N, Denmark; [Bell, John I.] Univ Oxford, Off Regius Prof Med, Oxford OX3 7BN, England	University of Oxford; University of Oxford; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Oxford; Aarhus University; University of Oxford	Fugger, L (corresponding author), Univ Oxford, Human Immunol Unit, MRC, Headley Way, Oxford OX3 9DS, England.	lars.fugger@imm.ox.ac.uk	McMahon, Roisin/A-9823-2014; Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	McMahon, Roisin/0000-0001-5437-0355; Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Friese, Manuel A./0000-0001-6380-2420	Deutsche Forschungsgemeinschaft [DFG FR1720/1-1]; Deutsche Forschungsgemeinschaft Emmy Noether Programme [FR1720/3-1]; Schweizerische MS Gesellschaft; Cancer Research UK Principal Research Fellow; MRC [G9900061, MC_U137884178, MC_U137881016] Funding Source: UKRI; Medical Research Council [MC_U137884178, MC_U137881016, G9900061] Funding Source: researchfish	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft Emmy Noether Programme(German Research Foundation (DFG)); Schweizerische MS Gesellschaft; Cancer Research UK Principal Research Fellow(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank H. von Boehmer (Dana-Farber Cancer Institute) for the BW58TCR-alpha beta<SUP>-</SUP> T cell hybridoma, A. McMichael (University of Oxford) for GAP.A3, W. E. Biddison (US National Institutes of Health) for providing DNA and RNA from the 2D1 T cell clone and N. Willcox and A. Vincent for critical reading of the manuscript. Work in the authors' laboratories is supported by the Danish (to L. Fugger) and UK (to L. Fugger and E. Y. J.) Medical Research Councils, the Karen Elise Jensen Foundation, the Lundbeck Foundation, the Danish Multiple Sclerosis Society, the European Union (European Commission Descartes Prize and FP6 Neuropromise, Mugen and ARDIS) and GB Holding (Viby) Aps (L. Fugger). M. A. F. was supported by the Deutsche Forschungsgemeinschaft (DFG FR1720/1-1) and a Medical Research Council UK Career Development Fellowship and is supported by the Deutsche Forschungsgemeinschaft Emmy Noether Programme (FR1720/3-1). R. E. is supported by the Schweizerische MS Gesellschaft and a Berrow Scholarship. E. Y. J. is a Cancer Research UK Principal Research Fellow.	Alam SM, 1998, J IMMUNOL, V160, P3883; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; BOOSS J, 1983, J NEUROL SCI, V62, P219, DOI 10.1016/0022-510X(83)90201-0; Brynedal B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000664; Burfoot RK, 2008, TISSUE ANTIGENS, V71, P42, DOI 10.1111/j.1399-0039.2007.00962.x; Chao MJ, 2007, HUM MOL GENET, V16, P1951, DOI 10.1093/hmg/ddm142; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Fogdell-Hahn A, 2000, TISSUE ANTIGENS, V55, P140, DOI 10.1034/j.1399-0039.2000.550205.x; Friese MA, 2005, BRAIN, V128, P1747, DOI 10.1093/brain/awh578; Govermant Joan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P239, DOI 10.2174/1568010053586264; Gregersen JW, 2006, NATURE, V443, P574, DOI 10.1038/nature05133; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Haines JL, 1998, HUM MOL GENET, V7, P1229, DOI 10.1093/hmg/7.8.1229; Harbo HF, 2004, TISSUE ANTIGENS, V63, P237, DOI 10.1111/j.0001-2815.2004.00173.x; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; Honma K, 1997, J NEUROIMMUNOL, V73, P7, DOI 10.1016/S0165-5728(96)00161-0; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; JERSILD C, 1973, LANCET, V2, P1221; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; Junker A, 2007, BRAIN, V130, P2789, DOI 10.1093/brain/awm214; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1017/S0003480000008095; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; Lassmann H, 2004, TRENDS IMMUNOL, V25, P132, DOI 10.1016/j.it.2004.01.007; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338; Marrosu MG, 2001, HUM MOL GENET, V10, P2907, DOI 10.1093/hmg/10.25.2907; McGargill MA, 2000, NAT IMMUNOL, V1, P336, DOI 10.1038/79790; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; Najafian N, 2003, J CLIN INVEST, V112, P1037, DOI 10.1172/JCI200317935; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rubio JP, 2002, AM J HUM GENET, V70, P1125, DOI 10.1086/339932; Sawcer S, 2005, AM J HUM GENET, V77, P454; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; Serafini B, 2007, J EXP MED, V204, P2899, DOI 10.1084/jem.20071030; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Sim BC, 1998, CURR BIOL, V8, P701, DOI 10.1016/S0960-9822(98)70276-3; Sospedra M, 2005, ANNU REV IMMUNOL, V23, P683, DOI 10.1146/annurev.immunol.23.021704.115707; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127; vanOosten BW, 1997, NEUROLOGY, V49, P351, DOI 10.1212/WNL.49.2.351; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Wallstrom E, 1998, EUR J IMMUNOL, V28, P3329, DOI 10.1002/(SICI)1521-4141(199810)28:10<3329::AID-IMMU3329>3.0.CO;2-B	50	143	149	2	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1227	1235		10.1038/nm.1881	http://dx.doi.org/10.1038/nm.1881			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18953350				2022-12-27	WOS:000260751200042
J	Li, XG; Magenheimer, BS; Xia, S; Johnson, T; Wallace, DP; Calvet, JP; Li, R				Li, Xiaogang; Magenheimer, Brenda S.; Xia, Sheng; Johnson, Teri; Wallace, Darren P.; Calvet, James P.; Li, Rong			A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease	NATURE MEDICINE			English	Article							MTOR PATHWAY; RECEPTORS; EXPRESSION; STABILIZATION; INHIBITOR; CYTOKINES; PROTEIN; TNF	Autosomal dominant polycystic kidney disease (ADPKD) is caused by heterozygous mutations in either PKD1 or PKD2, genes that encode polycystin-1 and polycystin-2, respectively(1). We show here that tumor necrosis factor-alpha (TNF-alpha), an inflammatory cytokine present in the cystic fluid of humans with ADPKD, disrupts the localization of polycystin-2 to the plasma membrane and primary cilia through a scaffold protein, FIP2, which is induced by TNF-alpha. Treatment of mouse embryonic kidney organ cultures with TNF-alpha resulted in formation of cysts, and this effect was exacerbated in the Pkd2(+/-) kidneys. TNF-alpha also stimulated cyst formation in vivo in Pkd2(+/)- mice. In contrast, treatment of Pkd2(+/-) mice with the TNF-alpha inhibitor etanercept prevented cyst formation. These data reveal a pathway connecting TNF-alpha signaling, polycystins and cystogenesis, the activation of which may reduce functional polycystin-2 below a critical threshold, precipitating the ADPKD cellular phenotype.	[Li, Xiaogang; Xia, Sheng; Johnson, Teri; Li, Rong] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Magenheimer, Brenda S.; Calvet, James P.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; [Wallace, Darren P.] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66160 USA; [Li, Rong] Univ Kansas, Med Ctr, Dept Physiol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Li, R (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	rli@stowers-institute.org		Wallace, Darren/0000-0003-4616-7669	NIDDK NIH HHS [P50 DK057301, P50 DK05301-07] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; DEGROOTE D, 1993, EUR CYTOKINE NETW, V4, P359; Dell KM, 2001, KIDNEY INT, V60, P1240, DOI 10.1046/j.1523-1755.2001.00963.x; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; FISHER RA, 1922, P J ROY STAT SOC, V85, P87; GARDNER KD, 1991, KIDNEY INT, V39, P718, DOI 10.1038/ki.1991.87; Geng L, 2006, J CELL SCI, V119, P1383, DOI 10.1242/jcs.02818; Hattula K, 2000, CURR BIOL, V10, P1603, DOI 10.1016/S0960-9822(00)00864-2; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Lantinga-van Leeuwen IS, 2004, HUM MOL GENET, V13, P3069, DOI 10.1093/hmg/ddh336; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Magenheimer BS, 2006, J AM SOC NEPHROL, V17, P3424, DOI 10.1681/ASN.2006030295; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; MARTINEZ JR, 1995, DM-DIS MON, V41, P698, DOI 10.1016/S0011-5029(05)80007-0; NAKAMURA T, 1993, J AM SOC NEPHROL, V4, P1064; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Peters DJM, 2001, LANCET, V358, P1439, DOI 10.1016/S0140-6736(01)06531-X; Pfeffer K, 2003, CYTOKINE GROWTH F R, V14, P185, DOI 10.1016/S1359-6101(03)00022-4; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; Todorov V, 2002, AM J PHYSIOL-REG I, V283, pR1046, DOI 10.1152/ajpregu.00142.2002; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vielhauer V, 2007, SEMIN NEPHROL, V27, P286, DOI 10.1016/j.semnephrol.2007.02.004; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	29	114	124	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2008	14	8					863	868		10.1038/nm1783	http://dx.doi.org/10.1038/nm1783			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18552856	Green Accepted			2022-12-27	WOS:000258237500034
J	Li, JY; Englund, E; Holton, JL; Soulet, D; Hagell, P; Lees, AJ; Lashley, T; Quinn, NP; Rehncrona, S; Bjorklund, A; Widner, H; Revesz, T; Lindvall, O; Brundin, P				Li, Jia-Yi; Englund, Elisabet; Holton, Janice L.; Soulet, Denis; Hagell, Peter; Lees, Andrew J.; Lashley, Tammaryn; Quinn, Niall P.; Rehncrona, Stig; Bjorklund, Anders; Widner, Hakan; Revesz, Tamas; Lindvall, Olle; Brundin, Patrik			Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation	NATURE MEDICINE			English	Article							SUBSTANTIA-NIGRA; ALPHA-SYNUCLEIN; TRANSPLANTATION	Two subjects with Parkinson's disease who had long-term survival of transplanted fetal mesencephalic dopaminergic neurons (11-16 years) developed alpha-synuclein-positive Lewy bodies in grafted neurons. Our observation has key implications for understanding Parkinson's pathogenesis by providing the first evidence, to our knowledge, that the disease can propagate from host to graft cells. However, available data suggest that the majority of grafted cells are functionally unimpaired after a decade, and recipients can still experience long-term symptomatic relief.	[Li, Jia-Yi; Soulet, Denis; Brundin, Patrik] Wallenberg Neurosci Ctr, Neuronal Survival Unit, Dept Expt Med Sci, S-22184 Lund, Sweden; [Englund, Elisabet] Univ Lund Hosp, Div Neuropathol, S-22185 Lund, Sweden; [Holton, Janice L.; Lees, Andrew J.; Lashley, Tammaryn; Revesz, Tamas] UCL, Inst Neurol, Queen Square Brain Bank Neurol Disorders, Dept Mol Neurosci, London WC1N 3BG, England; [Hagell, Peter; Widner, Hakan; Lindvall, Olle] Univ Lund Hosp, Div Neurol, S-22185 Lund, Sweden; [Quinn, Niall P.] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England; [Rehncrona, Stig] Univ Lund Hosp, Div Neurosurg, S-22185 Lund, Sweden; [Bjorklund, Anders] Wallenberg Neurosci Ctr, Neurobiol Unit, S-22184 Lund, Sweden; [Lindvall, Olle] Wallenberg Neurosci Ctr, Sect Restorat Neurol, S-22184 Lund, Sweden	Lund University; Skane University Hospital; University of London; University College London; Lund University; Skane University Hospital; University of London; University College London; Lund University; Skane University Hospital	Brundin, P (corresponding author), Wallenberg Neurosci Ctr, Neuronal Survival Unit, Dept Expt Med Sci, S-22184 Lund, Sweden.	patrik.brundin@med.lu.se	Holton, Janice L/F-6831-2011; Soulet, Denis/P-4940-2019; Bjørklund, Geir/B-7319-2014; Shahmoradian, Sarah H/C-7465-2015; Lashley, Tammaryn/D-2583-2009; Lees, Andrew J/A-6605-2009; Hagell, Peter/G-9559-2014; Soulet, Denis/E-8677-2011; Hagell, Peter/F-5915-2010; Björklund, Anders/ABA-1326-2020; Revesz, Tamas/A-8732-2010	Holton, Janice L/0000-0002-3882-5249; Bjørklund, Geir/0000-0003-2632-3935; Shahmoradian, Sarah H/0000-0001-9752-7287; Lees, Andrew J/0000-0002-2476-4385; Hagell, Peter/0000-0003-2174-372X; Hagell, Peter/0000-0003-2174-372X; Revesz, Tamas/0000-0003-2501-0259; Lashley, Tammaryn/0000-0001-7389-0348; Soulet, Denis/0000-0002-0937-7061; Englund, Elisabet/0000-0002-2708-2443; Li, Jia-Yi/0000-0002-7770-7376; Bjorklund, Anders/0000-0002-5676-6203	Parkinson&apos;s UK [G-4062] Funding Source: Medline	Parkinson&apos;s UK(Parkinson&apos;s UK)		Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chu YP, 2007, NEUROBIOL DIS, V25, P134, DOI 10.1016/j.nbd.2006.08.021; DOUCET G, 1989, EXP NEUROL, V106, P1, DOI 10.1016/0014-4886(89)90139-8; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Hagell P, 1999, BRAIN, V122, P1121, DOI 10.1093/brain/122.6.1121; Hardy J, 2005, BIOCHEM SOC T, V33, P578, DOI 10.1042/BST0330578; Kordower J H, 2000, Prog Brain Res, V127, P333; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Sigurdsson EM, 2002, TRENDS MOL MED, V8, P411, DOI 10.1016/S1471-4914(02)02403-6; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x	16	1221	1248	0	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					501	503		10.1038/nm1746	http://dx.doi.org/10.1038/nm1746			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18391963				2022-12-27	WOS:000255681800028
J	Liggett, SB; Cresci, S; Kelly, RJ; Syed, FM; Matkovich, SJ; Hahn, HS; Diwan, A; Martini, JS; Sparks, L; Parekh, RR; Spertus, JA; Koch, WJ; Kardia, SLR; Dorn, GW				Liggett, Stephen B.; Cresci, Sharon; Kelly, Reagan J.; Syed, Faisal M.; Matkovich, Scot J.; Hahn, Harvey S.; Diwan, Abhinav; Martini, Jeffrey S.; Sparks, Li; Parekh, Rohan R.; Spertus, John A.; Koch, Walter J.; Kardia, Sharon L. R.; Dorn, Gerald W., II			A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure	NATURE MEDICINE			English	Article							CONVERTING ENZYME-INHIBITORS; PRESERVES CARDIAC-FUNCTION; FAILING HUMAN HEART; KINASES; EXPRESSION; MICE; DESENSITIZATION; OVEREXPRESSION; POPULATION; METOPROLOL	beta-adrenergic receptor (beta AR) blockade is a standard therapy for cardiac failure and ischemia. G protein-coupled receptor kinases ( GRKs) desensitize beta ARs, suggesting that genetic GRK variants might modify outcomes in these syndromes. Re-sequencing of GRK2 and GRK5 revealed a nonsynonymous polymorphism of GRK5, common in African Americans, in which leucine is substituted for glutamine at position 41. GRK5-Leu41 uncoupled isoproterenol-stimulated responses more effectively than did GRK5-Gln41 in transfected cells and transgenic mice, and, like pharmacological bAR blockade, GRK5-Leu41 protected against experimental catecholamine-induced cardiomyopathy. Human association studies showed a pharmacogenomic interaction between GRK5- Leu41 and beta-blocker treatment, in which the presence of the GRK5-Leu41 polymorphism was associated with decreased mortality in African Americans with heart failure or cardiac ischemia. In 375 prospectively followed African-American subjects with heart failure, GRK5- Leu41 protected against death or cardiac transplantation. Enhanced bAR desensitization of excessive catecholamine signaling by GRK5- Leu41 provides a 'genetic beta-blockade' that improves survival in African Americans with heart failure, suggesting a reason for conflicting results of beta-blocker clinical trials in this population.	[Liggett, Stephen B.; Syed, Faisal M.; Hahn, Harvey S.; Diwan, Abhinav; Sparks, Li; Parekh, Rohan R.; Dorn, Gerald W., II] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; [Cresci, Sharon; Matkovich, Scot J.; Dorn, Gerald W., II] Washington Univ, Ctr Pharmacogenom, St Louis, MO 63110 USA; [Kelly, Reagan J.; Kardia, Sharon L. R.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Martini, Jeffrey S.; Koch, Walter J.] Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA; [Spertus, John A.] Univ Missouri, Kansas City, MO 64111 USA	University System of Ohio; University of Cincinnati; Washington University (WUSTL); University of Michigan System; University of Michigan; Jefferson University; University of Missouri System; University of Missouri Kansas City	Dorn, GW (corresponding author), Univ Cincinnati, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	gdorn@im.wustl.edu	Matkovich, Scot J/AFP-0908-2022; liggett, stephen b/E-7453-2012; Matkovich, Scot J/B-9077-2009; Spertus, John/ABD-3075-2021	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [P50 HL077113, P50 HL077101-040002, R01 HL087871, P50 HL077101-039003, P50 HL077101, R01 HL87871, P50 HL077101-039001, P50 HL077101-03, P50 HL77101, HL77113, R01 HL087871-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087871, P50HL077101, P50HL077113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; Barnholtz-Sloan JS, 2005, CANCER EPIDEM BIOMAR, V14, P1545, DOI 10.1158/1055-9965.EPI-04-0832; BECHHOFFER RE, 1986, SEQUENTIAL IDENTIFIC; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; BRISTOW MR, 1998, LANCET S1, V352, pS18; Chen EP, 2001, ANN THORAC SURG, V71, P1320, DOI 10.1016/S0003-4975(00)01754-9; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cox D. R., 1989, ANAL BINARY DATA, P208; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dzimiri N, 2002, CLIN EXP PHARMACOL P, V29, P181, DOI 10.1046/j.1440-1681.2002.03625.x; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Franz WM, 2001, LANCET, V358, P1627, DOI 10.1016/S0140-6736(01)06657-0; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Hjalmarson A, 1999, LANCET, V353, P2001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Koch WJ, 2004, MOL CELL BIOCHEM, V263, P5, DOI 10.1023/B:MCBI.0000041843.64809.48; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; Liggett SB, 2000, CIRCULATION, V101, P1707; Liggett SB, 2001, NAT MED, V7, P281, DOI 10.1038/85411; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; Liggett SB, 2006, P NATL ACAD SCI USA, V103, P11288, DOI 10.1073/pnas.0509937103; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; LYNCH M, 1998, GENETICS ANAL QUANTI, P51; Matkovich SJ, 2006, CIRC RES, V99, P996, DOI 10.1161/01.RES.0000247932.71270.2c; Odley A, 2004, P NATL ACAD SCI USA, V101, P7082, DOI 10.1073/pnas.0308335101; Okumura S, 2003, P NATL ACAD SCI USA, V100, P9986, DOI 10.1073/pnas.1733772100; Oyama N, 2006, CIRC J, V70, P362, DOI 10.1253/circj.70.362; PACKER M, 2001, AM J MED, V110, P81; Parmar MKB, 1995, SURVIVAL ANAL PRACTI, P115; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Pritchard JK, 2000, GENETICS, V155, P945; Province MA, 2000, GENET EPIDEMIOL, V19, P301, DOI 10.1002/1098-2272(200012)19:4<301::AID-GEPI3>3.0.CO;2-G; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; Roger VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344; Shekelle PG, 2003, J AM COLL CARDIOL, V41, P1529, DOI 10.1016/S0735-1097(03)00262-6; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; van Campen LCMC, 1998, J CARDIOVASC PHARM, V32, pS31, DOI 10.1097/00005344-199806321-00006; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Wagoner LE, 2000, CIRC RES, V86, P834, DOI 10.1161/01.RES.86.8.834	48	241	249	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					510	517		10.1038/nm1750	http://dx.doi.org/10.1038/nm1750			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18425130	Green Accepted			2022-12-27	WOS:000255681800031
J	Wei, C; Moeller, CC; Altintas, MM; Li, J; Schwarz, K; Zacchigna, S; Xie, L; Henger, A; Schmid, H; Rastaldi, MP; Cowan, P; Kretzler, M; Parrilla, R; Bendayan, S; Gupta, V; Nikolic, B; Kalluri, R; Carmeliet, P; Mundel, P; Reiser, J				Wei, Changli; Moeller, Clemens C.; Altintas, Mehmet M.; Li, Jing; Schwarz, Karin; Zacchigna, Serena; Xie, Liang; Henger, Anna; Schmid, Holger; Rastaldi, Maria P.; Cowan, Peter; Kretzler, Matthias; Parrilla, Roberto; Bendayan, Se; Gupta, Vineet; Nikolic, Boris; Kalluri, Raghu; Carmeliet, Peter; Mundel, Peter; Reiser, Jochen			Modification of kidney barrier function by the urokinase receptor	NATURE MEDICINE			English	Article							GLOMERULAR SLIT DIAPHRAGM; INTEGRIN ALPHA(V)BETA(3); GENE-EXPRESSION; CATHEPSIN-L; MIGRATION; PROTEINURIA; PODOCYTES; ACTIN; BETA-1-INTEGRIN; SYNAPTOPODIN	Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease. Therapies aimed at the cellular level of the disease are currently not available. Here we show that induction of urokinase receptor ( uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of alpha v beta 3 integrin. Mice lacking uPAR (Plaur(-/-)) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active beta 3 integrin. Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria. Mechanistically, uPAR is required to activate alpha v beta 3 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1. Blockade of alpha v beta 3 integrin reduces podocyte motility in vitro and lowers proteinuria in mice. Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.	[Wei, Changli; Moeller, Clemens C.; Altintas, Mehmet M.; Li, Jing; Gupta, Vineet; Nikolic, Boris; Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Nephrol Div, Boston, MA 02129 USA; [Wei, Changli; Moeller, Clemens C.; Altintas, Mehmet M.; Li, Jing; Gupta, Vineet; Nikolic, Boris; Reiser, Jochen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Program Glamerular Dis, Boston, MA 02129 USA; Univ Homburg, Inst Anat & Cell Biol, D-66421 Homburg, Germany; [Zacchigna, Serena; Carmeliet, Peter] Katholieke Univ Leuven, Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; [Zacchigna, Serena; Carmeliet, Peter] Vlaans Interuniv Inst Biotechnol, Dept Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; [Xie, Liang; Kalluri, Raghu] Beth Israel Deaconess Med Ctr, Dept Med, Div Matrix Biol, Boston, MA 02215 USA; [Henger, Anna; Kretzler, Matthias] Univ Michigan Hosp, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; [Schmid, Holger] Univ Munich, Med Poliklin, D-80336 Munich, Germany; [Rastaldi, Maria P.] San Carlo Borromeo Hosp, Assoc Nuova Nefrol & Fdn Damico Ricerca Malattie, Renal Immunopathol Lab, I-20153 Milan, Italy; [Cowan, Peter] St Vincents Hosp, Immunol Res Ctr, Fitzroy, Vic 3065, Australia; [Parrilla, Roberto] CSIC, Ctr Invest Biol, Dept Pathophysiol & Human Mol Genet, Madrid 28040, Spain; [Bendayan, Se] Univ Montreal, Dept Pathol, Montreal, PQ H3T 1J4, Canada; [Mundel, Peter] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; KU Leuven; Harvard University; Beth Israel Deaconess Medical Center; University of Michigan System; University of Michigan; University of Munich; San Carlo Borromeo Hospital; St Vincent's Hospital Melbourne; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universite de Montreal; Icahn School of Medicine at Mount Sinai	Reiser, J (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Nephrol Div, Boston, MA 02129 USA.	jreiser@partners.org	Parrilla, Roberto/B-6307-2008; Cowan, Peter/AAH-7218-2020; Altintas, Mehmet Mete/ABI-5904-2020; Cowan, Peter J/B-8730-2013; Altintas, Mehmet Mete/T-5333-2018; Schwarz, Karin/AAO-2819-2020; Carmeliet, Peter/AAQ-5140-2020; Kalluri, Raghu/E-2677-2015; ZACCHIGNA, SERENA/E-9496-2017	Cowan, Peter J/0000-0001-9016-4954; Altintas, Mehmet Mete/0000-0002-1871-6985; Carmeliet, Peter/0000-0001-7961-1821; Kalluri, Raghu/0000-0002-2190-547X; Schwarz, Karin/0000-0002-7328-1427; Gupta, Vineet/0000-0001-6987-2550; ZACCHIGNA, SERENA/0000-0001-6705-3076	NIDDK NIH HHS [K01 DK068253-05, DK38452, DK073495, DK057683, DK064236, DK062472, T32DK007540, K01 DK068253] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064236, R01DK062472, P01DK038452, T32DK007540, R01DK073495, R01DK057683, K01DK068253] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfano M, 2002, P NATL ACAD SCI USA, V99, P8862, DOI 10.1073/pnas.142078099; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530; CARMELIET P, 1995, ANN NY ACAD SCI, V748, P367; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; de Jong PE, 2004, KIDNEY INT, V66, P2109, DOI 10.1111/j.1523-1755.2004.66001.x; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; GUGLIUCCI A, 1995, J HISTOCHEM CYTOCHEM, V43, P591, DOI 10.1177/43.6.7769229; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KELLEY VE, 1976, LAB INVEST, V35, P213; KERJASCHKI D, 1989, AM J PATHOL, V134, P481; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058; MAUER SM, 1974, CANCER RES, V34, P1643; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; Moeller MJ, 2004, J AM SOC NEPHROL, V15, P61, DOI 10.1097/01.ASN.0000102468.37809.C6; Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; NAKAMURA T, 1991, LAB INVEST, V64, P640; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Reiser J, 2004, J BIOL CHEM, V279, P34827, DOI 10.1074/jbc.M401973200; Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402; Schmid H, 2003, KIDNEY INT, V64, P356, DOI 10.1046/j.1523-1755.2003.00074.x; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; Sever S, 2007, J CLIN INVEST, V117, P2095, DOI 10.1172/JCI32022; Shankland SJ, 2007, KIDNEY INT, V72, P26, DOI 10.1038/sj.ki.5002291; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tryggvason K, 2006, NEW ENGL J MED, V354, P1387, DOI 10.1056/NEJMra052131; van den Berg JG, 2004, KIDNEY INT, V66, P1901, DOI 10.1111/j.1523-1755.2004.00964.x; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 2007, J BIOL CHEM, V282, P3929, DOI 10.1074/jbc.M607989200; Zandi-Nejad K, 2004, KIDNEY INT, V66, pS76, DOI 10.1111/j.1523-1755.2004.09220.x; Zeisberg EM, 2007, NAT MED, V13, P952, DOI 10.1038/nm1613; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	51	415	447	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					55	63		10.1038/nm1696	http://dx.doi.org/10.1038/nm1696			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18084301	Green Submitted			2022-12-27	WOS:000252222400022
J	Wirth, A; Benyo, Z; Lukasova, M; Leutgeb, B; Wettschureck, N; Gorbey, S; Orsy, P; Horvath, B; Maser-Gluth, C; Greiner, E; Lemmer, B; Schuetz, N; Gutkind, S; Offermanns, S				Wirth, Angela; Benyo, Zoltan; Lukasova, Martina; Leutgeb, Barbara; Wettschureck, Nina; Gorbey, Stefan; Orsy, Petra; Horvath, Bela; Maser-Gluth, Christiane; Greiner, Erich; Lemmer, Bjoern; Schuetz, Nther; Gutkind, Silvio; Offermanns, Stefan			G(12)-G(13)-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension	NATURE MEDICINE			English	Article							BLOOD-PRESSURE; DIETARY SALT; G-PROTEINS; ACTIVATION; REORGANIZATION; KINASE; RHOA	The tone of vascular smooth muscle cells is a primary determinant of the total peripheral vascular resistance and hence the arterial blood pressure. Most forms of hypertension ultimately result from an increased vascular tone that leads to an elevated total peripheral resistance(1-3). Regulation of vascular resistance under normotensive and hypertensive conditions involves multiple mediators, many of which act through G protein-coupled receptors on vascular smooth muscle cells(4). Receptors that mediate vasoconstriction couple with the G-proteins G(q)-G(11) and G(12)-G(13) to stimulate phosphorylation of myosin light chain (MLC) via the Ca2+/MLC kinase- and Rho/Rho kinase-mediated signaling pathways, respectively(4-6). Using genetically altered mouse models that allow for the acute abrogation of both signaling pathways by inducible Cre/loxP-mediated mutagenesis in smooth muscle cells, we show that G(q)-G(11)-mediated signaling in smooth muscle cells is required for maintenance of basal blood pressure and for the development of salt-induced hypertension. In contrast, lack of G(12)-G(13), as well as of their major effector, the leukemiaassociated Rho guanine nucleotide exchange factor (LARG), did not alter normal blood pressure regulation but did block the development of salt-induced hypertension. This identifies the G(12)-G(13)-LARG-mediated signaling pathway as a new target for antihypertensive therapies that would be expected to leave normal blood pressure regulation unaffected.	[Wirth, Angela; Benyo, Zoltan; Lukasova, Martina; Leutgeb, Barbara; Wettschureck, Nina; Orsy, Petra; Horvath, Bela; Maser-Gluth, Christiane; Offermanns, Stefan] Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany; [Benyo, Zoltan] Semmelweis Univ, Inst Human Physiol & Clin Expt Res, H-1082 Budapest, Hungary; [Gorbey, Stefan; Lemmer, Bjoern] Heidelberg Univ, Med Fac Mannheim, Inst Pharmacol, D-68169 Mannheim, Germany; [Greiner, Erich; Schuetz, Nther] German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany; [Gutkind, Silvio] Natl Inst Dent & Craniofacial Res, Natl Inst Hlth, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; [Leutgeb, Barbara; Greiner, Erich] EvotecOAI AG, D-22525 Hamburg, Germany	Ruprecht Karls University Heidelberg; Semmelweis University; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	Stefan.Offermanns@pharma.uni-heidelberg.de	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Gorbey, Stefan/P-3874-2015; Benyo, Zoltan/C-9184-2009; Horvath, Bela/A-7368-2009; Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Gutkind, J. Silvio/0000-0002-5150-4482; Gorbey, Stefan/0000-0002-6852-1756; Wettschureck, Nina/0000-0001-6858-1460; Benyo, Zoltan/0000-0001-6015-0359; Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Becknell B, 2003, CELL TISSUE RES, V314, P361, DOI 10.1007/s00441-003-0802-5; Blaustein MP, 2006, AM J PHYSIOL-REG I, V290, pR514, DOI 10.1152/ajpregu.00819.2005; BROWN R, 2004, MOL BASIS CARDIOVASC, P566; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COWLEY AW, 1992, PHYSIOL REV, V72, P231, DOI 10.1152/physrev.1992.72.1.231; Dostanic I, 2005, AM J PHYSIOL-HEART C, V288, pH477, DOI 10.1152/ajpheart.00083.2004; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Iwamoto T, 2004, NAT MED, V10, P1193, DOI 10.1038/nm1118; Khalil RA, 2006, AM J PHYSIOL-REG I, V290, pR509, DOI 10.1152/ajpregu.00600.2005; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Maguire JJ, 2005, TRENDS PHARMACOL SCI, V26, P448, DOI 10.1016/j.tips.2005.07.007; Meneton P, 2005, PHYSIOL REV, V85, P679, DOI 10.1152/physrev.00056.2003; Mills PA, 2000, J APPL PHYSIOL, V88, P1537, DOI 10.1152/jappl.2000.88.5.1537; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; Moriki N, 2004, HYPERTENS RES, V27, P263, DOI 10.1291/hypres.27.263; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Noma K, 2006, AM J PHYSIOL-CELL PH, V290, pC661, DOI 10.1152/ajpcell.00459.2005; O'Shaughnessy KM, 2004, J CLIN INVEST, V113, P1075, DOI 10.1172/JCI200421560; Seasholtz TM, 2004, MOL INTERV, V4, P348, DOI 10.1124/mi.4.6.8; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236	30	444	450	0	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2008	14	1					64	68		10.1038/nm1666	http://dx.doi.org/10.1038/nm1666			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18084302				2022-12-27	WOS:000252222400023
J	Isermann, B; Vinnikov, IA; Madhusudhan, T; Herzog, S; Kashif, M; Blautzik, J; Corat, MAF; Zeier, M; Blessing, E; Oh, J; Gerlitz, B; Berg, DT; Grinnell, BW; Chavakis, T; Esmon, CT; Weiler, H; Bierhaus, A; Nawroth, PP				Isermann, Berend; Vinnikov, Ilya A.; Madhusudhan, Thati; Herzog, Stefanie; Kashif, Muhammed; Blautzik, Janusch; Corat, Marcus A. F.; Zeier, Martin; Blessing, Erwin; Oh, Jun; Gerlitz, Bruce; Berg, David T.; Grinnell, Brian W.; Chavakis, Triantafyllos; Esmon, Charles T.; Weiler, Hartmut; Bierhaus, Angelika; Nawroth, Peter P.			Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis	NATURE MEDICINE			English	Article							POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; SEVERE SEPSIS; ANTICOAGULANT PATHWAY; CELL; THROMBOMODULIN; ALPHA; RECEPTOR-1; MOUSE; INFLAMMATION; DYSFUNCTION	Data providing direct evidence for a causative link between endothelial dysfunction, microvascular disease and diabetic end-organ damage are scarce. Here we show that activated protein C (APC) formation, which is regulated by endothelial thrombomodulin, is reduced in diabetic mice and causally linked to nephropathy. Thrombomodulin-dependent APC formation mediates cytoprotection in diabetic nephropathy by inhibiting glomerular apoptosis. APC prevents glucose-induced apoptosis in endothelial cells and podocytes, the cellular components of the glomerular filtration barrier. APC modulates the mitochondrial apoptosis pathway via the protease-activated receptor PAR-1 and the endothelial protein C receptor EPCR in glucose-stressed cells. These experiments establish a new pathway, in which hyperglycemia impairs endothelial thrombomodulin-dependent APC formation. Loss of thrombomodulin-dependent APC formation interrupts cross-talk between the vascular compartment and podocytes, causing glomerular apoptosis and diabetic nephropathy. Conversely, maintaining high APC levels during long-term diabetes protects against diabetic nephropathy.	Univ Heidelberg, Dept Med & Clin Chem 1, D-69120 Heidelberg, Germany; Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA; Univ Heidelberg, Dept Med 1, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Med 3, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Pediat Nephrol, D-69120 Heidelberg, Germany; Lilly Res Labs, BioTechnol Discovery Res, Indianapolis, IN 46285 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Ruprecht Karls University Heidelberg; Versiti Blood Center of Wisconsin; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Eli Lilly; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oklahoma Medical Research Foundation; Howard Hughes Medical Institute	Isermann, B (corresponding author), Univ Heidelberg, Dept Med & Clin Chem 1, INF 410, D-69120 Heidelberg, Germany.	berend.isermann@med.uni-heidelberg.de	Corat, Marcus Alexandre Finzi/AAH-2882-2020; Corat, Marcus/M-2301-2013; Chavakis, Triantafyllos/ABE-8845-2020	Corat, Marcus/0000-0002-8801-2318; Vinnikov, Ilya/0000-0003-0488-8484				Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371; Baba K, 2004, NEPHROLOGY, V9, P94, DOI 10.1111/j.1440-1797.2004.00238.x; Bernard GR, 2003, CRIT CARE, V7, P155, DOI 10.1186/cc2167; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Borcea V, 1999, VASA-J VASCULAR DIS, V28, P172, DOI 10.1024/0301-1526.28.3.172; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Calkin AC, 2006, NEPHROL DIAL TRANSPL, V21, P2399, DOI 10.1093/ndt/gfl212; Chae SS, 2004, PROSTAG OTH LIPID M, V73, P141, DOI 10.1016/j.prostaglandins.2004.01.006; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200; Dalla Vestra M, 2003, DIABETES, V52, P1031, DOI 10.2337/diabetes.52.4.1031; Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA; Esmon CT, 2006, SEMIN THROMB HEMOST, V32, P49, DOI 10.1055/s-2006-939554; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Festa A, 2000, KIDNEY INT, V58, P1703, DOI 10.1046/j.1523-1755.2000.00331.x; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Fujiwara Y, 1998, J Atheroscler Thromb, V5, P21; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; Goligorsky MS, 2001, HYPERTENSION, V37, P744, DOI 10.1161/01.HYP.37.2.744; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; Haraldsson B, 2004, NEWS PHYSIOL SCI, V19, P7, DOI 10.1152/nips.01461.2003; Isermann B, 2001, J CLIN INVEST, V108, P537, DOI 10.1172/JCI13077; Isermann B, 2003, NAT MED, V9, P331, DOI 10.1038/nm825; Kelly KJ, 2004, AM J PHYSIOL-RENAL, V287, pF760, DOI 10.1152/ajprenal.00050.2004; Kerlin BA, 2003, BLOOD, V102, P3085, DOI 10.1182/blood-2003-06-1789; Kiss L, 2005, MEM I OSWALDO CRUZ, V100, P29, DOI 10.1590/S0074-02762005000900007; Kumar D, 2004, MOL CELL BIOCHEM, V259, P67, DOI 10.1023/B:MCBI.0000021346.03260.7e; Liaw PCY, 2004, BLOOD, V104, P3958, DOI 10.1182/blood-2004-03-1203; Macias WL, 2005, CRIT CARE, V9, pS38, DOI 10.1186/cc3747; Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Murata I, 2002, AM J NEPHROL, V22, P587, DOI 10.1159/000065284; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Szabo C, 2006, DIABETES, V55, P3004, DOI 10.2337/db06-0147; Taylor FB, 2004, J THROMB HAEMOST, V2, P708, DOI 10.1111/j.1538-7836.2004.00751.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; *USRDS, 1998, NIH PUBL; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Yamaji K, 2005, THROMB RES, V115, P319, DOI 10.1016/j.thromres.2004.09.011; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198	49	312	327	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1349	1358		10.1038/nm1667	http://dx.doi.org/10.1038/nm1667			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	17982464				2022-12-27	WOS:000250736900028
J	Lee, JS; Gladwin, MT				Lee, Janet S.; Gladwin, Mark T.			Bad Blood The risks of red cell storage	NATURE MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; CARDIAC-SURGERY; TRANSFUSION; HEMOGLOBIN	Blood transfusion saves many lives but carries the risk of injury, such as severe damage to the lungs. In 'Bedside to Bench', Janet S. Lee and Mark T. Gladwin examine the implications of clinical studies assessing such damage. The risk of injury seems to increase with the number of units transfused and may be greater with blood that has been stored longer. Researchers have yet to understand why, but several mechanisms are under scrutiny. In 'Bench to Bedside', Paul S. Frenette and Narla Mohandas discuss recent studies pinpointing a trigger-a specific antigen on neutrophils for a severe form of transfusion-related acute lung injury (TRALI). The findings could lead to new ways to diagnose TRALI and identify people at risk.	[Lee, Janet S.; Gladwin, Mark T.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, JS (corresponding author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.	gladwinmt@upmc.edu		Lee, Janet/0000-0002-6812-6043	NHLBI NIH HHS [R01 HL086884] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086884] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boretti FS, 2009, J CLIN INVEST, V119, P2271, DOI 10.1172/JCI39115; COLLINS JA, 1978, ANN SURG, V188, P513, DOI 10.1097/00000658-197810000-00008; Dzik W, 2008, TRANSFUSION MED, V18, P260, DOI 10.1111/j.1365-3148.2008.00870.x; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582; Gladwin MT, 2009, CURR OPIN HEMATOL, V16, P515, DOI 10.1097/MOH.0b013e32833157f4; Hidalgo A, 2009, NAT MED, V15, P384, DOI 10.1038/nm.1939; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Silliman CC, 2009, BLOOD REV, V23, P245, DOI 10.1016/j.blre.2009.07.005; Valles J, 2002, BLOOD, V99, P3978, DOI 10.1182/blood.V99.11.3978	12	59	60	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					381	382		10.1038/nm0410-381	http://dx.doi.org/10.1038/nm0410-381			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376046	Bronze, Green Accepted			2022-12-27	WOS:000276446800036
J	Akahata, W; Yang, ZY; Andersen, H; Sun, SY; Holdaway, HA; Kong, WP; Lewis, MG; Higgs, S; Rossmann, MG; Rao, S; Nabel, GJ				Akahata, Wataru; Yang, Zhi-Yong; Andersen, Hanne; Sun, Siyang; Holdaway, Heather A.; Kong, Wing-Pui; Lewis, Mark G.; Higgs, Stephen; Rossmann, Michael G.; Rao, Srinivas; Nabel, Gary J.			A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection	NATURE MEDICINE			English	Article							IMMUNOGENICITY; GLYCOPROTEIN; ORGANIZATION; EXPRESSION	Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe and Asia(1,2) since this alphavirus reemerged from Kenya in 2004. The severity of the disease and the spread of this epidemic virus present a serious public health threat in the absence of vaccines or antiviral therapies. Here, we describe a new vaccine that protects against CHIKV infection of nonhuman primates. We show that selective expression of viral structural proteins gives rise to virus-like particles (VLPs) in vitro that resemble replication-competent alpha-viruses. Immunization with these VLPs elicited neutralizing antibodies against envelope proteins from alternative CHIKV strains. Monkeys immunized with VLPs produced high-titer neutralizing antibodies that protected against viremia after high-dose challenge. We transferred these antibodies into immunodeficient mice, where they protected against subsequent lethal CHIKV challenge, indicating a humoral mechanism of protection. Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans.	[Akahata, Wataru; Yang, Zhi-Yong; Kong, Wing-Pui; Rao, Srinivas; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; [Sun, Siyang; Holdaway, Heather A.; Rossmann, Michael G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Andersen, Hanne; Lewis, Mark G.] Bioqual Inc, Rockville, MD USA; [Higgs, Stephen] Univ Texas Med Branch, Dept Pathol, Galveston, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Purdue University System; Purdue University; Purdue University West Lafayette Campus; BIOQUAL Inc.; University of Texas System; University of Texas Medical Branch Galveston	Nabel, GJ (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	gnabel@nih.gov		Elyard, Hanne/0000-0003-1103-9608	Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005097] Funding Source: NIH RePORTER	Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank K. Nagashima for help with electron microscopy and J. D. Yoder for initiating cryoelectron microscopy reconstruction. We also thank A. Tislerics and J. Stein for help with manuscript preparation, B. Hartman for graphic arts and members of the Nabel lab for helpful discussions. We thank R. Seder and D. D. Pinschewer (Department of Pathology and Immunology, University of Geneva) for their kind gift of Ifnar1<SUP>-/-</SUP> mice, A. Ault, J.-P. Todd, A. Zajac, C. Chiedi (Vaccine Research Center) and D. Gordon (Bioqual) for plaque assay and processed animal blood samples, J. Greenhouse for RT-PCR assay, B. W. Finneyfrock, T. Jenkins and A. Dodson for animal sampling and care, K. Foulds, M. Donaldson and M. Roederer for monkey sample procedures and J. Lee for preparing 293F cells for VLP production. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health.	Akahata W, 2005, J VIROL, V79, P626, DOI 10.1128/JVI.79.1.626-631.2005; Arankalle VA, 2007, J GEN VIROL, V88, P1967, DOI 10.1099/vir.0.82714-0; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381; CHENG RH, 1995, CELL, V80, P621; Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029; Couderc T, 2009, J INFECT DIS, V200, P516, DOI 10.1086/600381; ECKELS KH, 1970, APPL MICROBIOL, V19, P321, DOI 10.1128/AEM.19.2.321-325.1970; Edelman R, 2000, AM J TROP MED HYG, V62, P681, DOI 10.4269/ajtmh.2000.62.681; Enserink M, 2008, SCIENCE, V320, P864, DOI 10.1126/science.320.5878.864; HARRISON VR, 1971, J IMMUNOL, V107, P643; HARRISON VR, 1967, AM J TROP MED HYG, V16, P786, DOI 10.4269/ajtmh.1967.16.786; LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264-410X(86)90003-4; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013; McClain DJ, 1998, J INFECT DIS, V177, P634, DOI 10.1086/514240; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; Muthumani K, 2008, VACCINE, V26, P5128, DOI 10.1016/j.vaccine.2008.03.060; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0; ROSS R. W., 1956, JOUR HYG, V54, P177; Simon F, 2008, MED CLIN N AM, V92, P1323, DOI 10.1016/j.mcna.2008.07.008; Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089; Staples JE, 2009, CLIN INFECT DIS, V49, P942, DOI 10.1086/605496; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009; Tiwari M, 2009, VACCINE, V27, P2513, DOI 10.1016/j.vaccine.2009.02.062; Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201; Wang E, 2008, VACCINE, V26, P5030, DOI 10.1016/j.vaccine.2008.07.054; Yang ZY, 2007, SCIENCE, V317, P825, DOI 10.1126/science.1135165; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; Zhang W, 2002, J VIROL, V76, P11645, DOI 10.1128/JVI.76.22.11645-11658.2002	35	329	355	1	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					334	U134		10.1038/nm.2105	http://dx.doi.org/10.1038/nm.2105			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20111039	Green Accepted, Bronze			2022-12-27	WOS:000275289500041
J	Flatz, L; Hegazy, AN; Bergthaler, A; Verschoor, A; Claus, C; Fernandez, M; Gattinoni, L; Johnson, S; Kreppel, F; Kochanek, S; van den Broek, M; Radbruch, A; Levy, F; Lambert, PH; Siegrist, CA; Restifo, NP; Lohning, M; Ochsenbein, AF; Nabel, GJ; Pinschewer, DD				Flatz, Lukas; Hegazy, Ahmed N.; Bergthaler, Andreas; Verschoor, Admar; Claus, Christina; Fernandez, Marylise; Gattinoni, Luca; Johnson, Susan; Kreppel, Florian; Kochanek, Stefan; van den Broek, Maries; Radbruch, Andreas; Levy, Frederic; Lambert, Paul-Henri; Siegrist, Claire-Anne; Restifo, Nicholas P.; Loehning, Max; Ochsenbein, Adrian F.; Nabel, Gary J.; Pinschewer, Daniel D.			Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8(+) T cell immunity	NATURE MEDICINE			English	Article							DENDRITIC CELLS; LISTERIA-MONOCYTOGENES; CYTOLYTIC ACTIVITY; ANTIBODIES; MICE; RESPONSES; ADENOVIRUS; IMMUNIZATION; PREVALENCE; PROTECTION	Lymphocytic choriomeningitis virus (LCMV) exhibits natural tropism for dendritic cells and represents the prototypic infection that elicits protective CD8(+) T cell (cytotoxic T lymphocyte (CTL)) immunity. Here we have harnessed the immunobiology of this arenavirus for vaccine delivery. By using producer cells constitutively synthesizing the viral glycoprotein (GP), it was possible to replace the gene encoding LCMV GP with vaccine antigens to create replication-defective vaccine vectors. These rLCMV vaccines elicited CTL responses that were equivalent to or greater than those elicited by recombinant adenovirus 5 or recombinant vaccinia virus in their magnitude and cytokine profiles, and they exhibited more effective protection in several models. In contrast to recombinant adenovirus 5, rLCMV failed to elicit vector-specific antibody immunity, which facilitated re-administration of the same vector for booster vaccination. In addition, rLCMV elicited T helper type 1 CD4(+) T cell responses and protective neutralizing antibodies to vaccine antigens. These features, together with low seroprevalence in humans, suggest that rLCMV may show utility as a vaccine platform against infectious diseases and cancer.	[Flatz, Lukas; Bergthaler, Andreas; Fernandez, Marylise; Johnson, Susan; Siegrist, Claire-Anne; Pinschewer, Daniel D.] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland; [Flatz, Lukas; Hegazy, Ahmed N.; Bergthaler, Andreas; Verschoor, Admar; van den Broek, Maries; Loehning, Max; Pinschewer, Daniel D.] Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; [Flatz, Lukas; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; [Hegazy, Ahmed N.; Radbruch, Andreas; Loehning, Max] Charite, Dept Rheumatol & Clin Immunol, D-13353 Berlin, Germany; [Hegazy, Ahmed N.; Radbruch, Andreas; Loehning, Max] Deutsch Rheuma Forschungszentrum, Berlin, Germany; [Bergthaler, Andreas] Inst Syst Biol, Seattle, WA USA; [Verschoor, Admar] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Claus, Christina; Ochsenbein, Adrian F.] Univ Bern, Dept Clin Res, Bern, Switzerland; [Fernandez, Marylise; Johnson, Susan; Lambert, Paul-Henri; Siegrist, Claire-Anne; Pinschewer, Daniel D.] Univ Geneva, World Hlth Org Collaborating Ctr Neonatal Vaccino, Geneva, Switzerland; [Gattinoni, Luca; Restifo, Nicholas P.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Kreppel, Florian; Kochanek, Stefan] Univ Ulm, Div Gene Therapy, Ulm, Germany; [van den Broek, Maries] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Levy, Frederic] Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; [Siegrist, Claire-Anne] Univ Geneva, Dept Pediat, Geneva, Switzerland	University of Geneva; University of Zurich; University Zurich Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); Institute for Systems Biology (ISB); Technical University of Munich; University of Bern; University of Geneva; World Health Organization; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ulm University; University of Zurich; University Zurich Hospital; Ludwig Institute for Cancer Research; University of Geneva	Pinschewer, DD (corresponding author), Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland.	lukas.flatz@gmail.com; daniel.pinschewer@gmx.ch	van den Broek, Maries/L-6532-2019; Löhning, Max/AAL-2967-2021; Bergthaler, Andreas/ABG-5047-2020; Restifo, Nicholas Phillip/M-6549-2019; Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/Z-1614-2019; Gattinoni, Luca/A-2281-2008	Löhning, Max/0000-0001-6382-7281; Bergthaler, Andreas/0000-0003-0597-1976; Gattinoni, Luca/0000-0003-2239-3282; Radbruch, Andreas/0000-0001-5753-0000; Hegazy, Ahmed N./0000-0002-2946-8251; Restifo, Nicholas P./0000-0003-4229-4580; Ochsenbein, Adrian/0000-0003-1773-5436; Pinschewer, Daniel/0000-0002-1594-3189	Schweizerische Stiftung fur medizinisch-biologische Stipendien; German Research Foundation [GRAKO1121]; Volkswagen Foundation; Boehringer Ingelheim Fonds; Roche Research Foundation; Swiss National Science Foundation [PP00A-114913, 3100A0-104067/1]; NATIONAL CANCER INSTITUTE [ZIABC010763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005002] Funding Source: NIH RePORTER	Schweizerische Stiftung fur medizinisch-biologische Stipendien; German Research Foundation(German Research Foundation (DFG)); Volkswagen Foundation(Volkswagen); Boehringer Ingelheim Fonds(Boehringer Ingelheim); Roche Research Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Hengartner and R. Zinkernagel for critical comments, suggestions, discussions and long-term support; E. Horvath for technical assistance; S. A. Rosenberg and J. R. Wunderlich for samples from patients with melanoma; M. Roederer and K. Foulds for reagents and flow cytometry support; A. Oxenius, R. Sprri and N. Joller for providing access to their flow cytometry facility; A. Pegu, R. Roychoudhuri and C. Cheng for discussions and advice on human DC cultures; D. von Laer (Georg-Speyer-Haus) for plasmid M369 and GP-expressing 293T cells; H. Shen (University of Pennsylvania School of Medicine) for rLM-OVA; M. Groettrup (University of Constance) for VACC-OVA, originally generated by J. Yewdell (National Institute of Allergy and Infectious Diseases); and R. Schirmbeck (University of Ulm) for StT-OVA-G cDNA. L. F. was supported by a fellowship of the Schweizerische Stiftung fur medizinisch-biologische Stipendien. A. N. H. is a fellow of GRAKO1121 of the German Research Foundation. M. L. is a Lichtenberg fellow funded by the Volkswagen Foundation. A. B. was supported by a PhD scholarship of the Boehringer Ingelheim Fonds and by a post-doctoral fellowship of the Roche Research Foundation. D. D. P. holds a stipendiary professorship of the Swiss National Science Foundation (PP00A-114913) and was supported by grant 3100A0-104067/1 of the Swiss National Science Foundation.	Anton LC, 1998, J IMMUNOL, V160, P4859; Bellier B, 2006, VACCINE, V24, P2643, DOI 10.1016/j.vaccine.2005.11.034; Buchmeier MJ, 2001, FIELDS VIROLOGY, P1635; Ciurea A, 1999, P NATL ACAD SCI USA, V96, P11964, DOI 10.1073/pnas.96.21.11964; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; de Lamballerie X, 2007, TRANSFUSION, V47, P172, DOI 10.1111/j.1537-2995.2007.01081.x; Elbers ARW, 1999, VET QUART, V21, P50, DOI 10.1080/01652176.1999.9694991; Fischer SA, 2006, NEW ENGL J MED, V354, P2235, DOI 10.1056/NEJMoa053240; Flatz L, 2006, P NATL ACAD SCI USA, V103, P4663, DOI 10.1073/pnas.0600652103; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; Harari A, 2008, J EXP MED, V205, P63, DOI 10.1084/jem.20071331; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Jensen ER, 1997, IMMUNOL REV, V158, P147, DOI 10.1111/j.1600-065X.1997.tb01001.x; Kostense S, 2004, AIDS, V18, P1213, DOI 10.1097/00002030-200405210-00019; Krebs P, 2005, J IMMUNOL, V174, P4559, DOI 10.4049/jimmunol.174.8.4559; Kurts C, 1999, P NATL ACAD SCI USA, V96, P12703, DOI 10.1073/pnas.96.22.12703; Lledo L, 2003, J MED VIROL, V70, P273, DOI 10.1002/jmv.10389; Lohning M, 2008, J EXP MED, V205, P53, DOI 10.1084/jem.20071855; Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320; Matter M, 2007, CANCER RES, V67, P7467, DOI 10.1158/0008-5472.CAN-06-4372; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; Peters BS, 2007, VACCINE, V25, P2120, DOI 10.1016/j.vaccine.2006.11.016; Pinschewer DD, 2004, J CLIN INVEST, V114, P988, DOI 10.1172/JCI200422374; Pinschewer DD, 2003, P NATL ACAD SCI USA, V100, P7895, DOI 10.1073/pnas.1332709100; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Pope C, 2001, J IMMUNOL, V166, P3402, DOI 10.4049/jimmunol.166.5.3402; Prevost-Blondel A, 1998, J IMMUNOL, V161, P2187; Probst HC, 2003, J IMMUNOL, V171, P5415, DOI 10.4049/jimmunol.171.10.5415; Probst HC, 2003, IMMUNITY, V18, P713, DOI 10.1016/S1074-7613(03)00120-1; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Seaman MS, 2005, J VIROL, V79, P2956, DOI 10.1128/JVI.79.5.2956-2963.2005; Seiler P, 1998, J EXP MED, V187, P649, DOI 10.1084/jem.187.4.649; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; Steinman RM, 2007, NAT MED, V13, P1155, DOI 10.1038/nm1643; STEPHENSEN CB, 1992, J MED VIROL, V38, P27, DOI 10.1002/jmv.1890380107; Valmori D, 2000, J IMMUNOL, V164, P1125, DOI 10.4049/jimmunol.164.2.1125; Wortmann A, 2008, MOL THER, V16, P154, DOI 10.1038/sj.mt.6300306	40	104	119	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					339	U142		10.1038/nm.2104	http://dx.doi.org/10.1038/nm.2104			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20139992	Green Accepted, Green Published			2022-12-27	WOS:000275289500042
J	Hawrylowicz, C; Ryanna, K				Hawrylowicz, Catherine; Ryanna, Kimuli			BENCH TO BEDSIDE The early beginnings	NATURE MEDICINE			English	Editorial Material							ASTHMA; DISEASE; PREVENTION; MICE		[Hawrylowicz, Catherine; Ryanna, Kimuli] Kings Coll London, UK Med Res Council, London WC2R 2LS, England; [Hawrylowicz, Catherine; Ryanna, Kimuli] Guys Hosp, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Hawrylowicz, C (corresponding author), Kings Coll London, UK Med Res Council, London WC2R 2LS, England.	catherine.hawrylowicz@kcl.ac.uk; kimuli.ryanna@kcl.ac.uk	Hawrylowicz, Catherine/Q-8483-2017	Hawrylowicz, Catherine/0000-0002-2337-7463				Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Devereux G, 2007, PEDIATR PULM, V42, P663, DOI 10.1002/ppul.20640; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; Johannsen H, 2009, CLIN EXP ALLERGY, V39, P1801, DOI 10.1111/j.1365-2222.2009.03368.x; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Ozkan S, 2010, FERTIL STERIL, V94, P1314, DOI 10.1016/j.fertnstert.2009.05.019; Polte T, 2008, J ALLERGY CLIN IMMUN, V122, P1022, DOI 10.1016/j.jaci.2008.09.014; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259	13	14	14	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					274	275		10.1038/nm0310-274	http://dx.doi.org/10.1038/nm0310-274			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208515				2022-12-27	WOS:000275289500031
J	Manganaro, L; Lusic, M; Gutierrez, MI; Cereseto, A; Del Sal, G; Giacca, M				Manganaro, Lara; Lusic, Marina; Gutierrez, Maria Ines; Cereseto, Anna; Del Sal, Giannino; Giacca, Mauro			Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4(+) T lymphocytes	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PIN1-DEPENDENT PROLYL ISOMERIZATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; VIRAL-DNA; CELLS; INFECTION; PHOSPHORYLATION; REPLICATION; ENTRY	Long-standing evidence indicates that quiescent human peripheral blood T lymphocytes (PBLs) do not support efficient HIV infection. In resting PBLs, reverse transcription of viral RNA takes longer than in activated cells(1), partially because formation of the late products of reverse transcription is decreased by RNA binding by apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G)(2). In a subsequent step, integration of the viral complementary DNA that is eventually formed is markedly impaired(3,4). Here we show that cellular c-Jun N-terminal kinase (JNK), an enzyme that is not expressed in resting CD4(+) T cells, regulates permissiveness to HIV-1 infection, and we unravel a new, sequential post-translational pathway of protein modification that regulates viral DNA integration. We found that, in activated T lymphocytes, viral integrase, which mediates HIV-1 cDNA integration into the host cell genome, is phosphorylated by JNK on a highly conserved serine residue in its core domain. Phosphorylated integrase, in turn, becomes a substrate for the cellular peptidyl prolyl-isomerase enzyme Pin1, which catalyzes a conformational modification of integrase. These concerted activities increase integrase stability and are required for efficient HIV-1 integration and infection. Lack of these modifications restricts viral infection in nonactivated, primary CD4(+) T lymphocytes.	[Manganaro, Lara; Lusic, Marina; Gutierrez, Maria Ines; Giacca, Mauro] Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Trieste, Italy; [Cereseto, Anna] Scuola Normale Super Pisa, Mol Biol Lab, Pisa, Italy; [Del Sal, Giannino] Lab Nazl Consorzio Interuniv Biotechnol, Trieste, Italy; [Del Sal, Giannino] Univ Trieste, Dipartimento Sci Vita, Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB); Scuola Normale Superiore di Pisa; University of Trieste	Giacca, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Area Sci Pk, Trieste, Italy.	lusic@icgeb.org; giacca@icgeb.org	Manganaro, Lara/AAL-8632-2020; Lusic, Marina/AAS-9704-2020; Giacca, Mauro/J-9287-2016	Manganaro, Lara/0000-0003-2743-2658; Lusic, Marina/0000-0002-0120-3569; Giacca, Mauro/0000-0003-2927-7225; DEL SAL, GIANNINO/0000-0003-2185-6003; Cereseto, Anna/0000-0003-4453-2597	Italian National Research Programme on AIDS of the Istituto Superiore di Sanita, Italy; Associazione Italiana per la Ricerca sul Cancro	Italian National Research Programme on AIDS of the Istituto Superiore di Sanita, Italy; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We wish to thank A. Engelman (Dana-Farber Cancer Institute) for the pFlag-IN codon-optimized expression vector, L. Collavin (Laboratorio Nazionale CIB and University of Trieste) for the p-Cs2-JNK plasmid and F. Kirchhoff (Institute of Molecular Virology, Universitatsklinikum Ulm) for the HIV-2-Rod Luc clone. We are grateful to S. Kerbavcic for excellent editorial assistance and to M. Sturnega for the technical support in raising the rabbit phospho-integrase-specific antibody. This work was supported by grants from the Italian National Research Programme on AIDS of the Istituto Superiore di Sanita, Italy to M. G. and from the Associazione Italiana per la Ricerca sul Cancro to G. D. S.	Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cereseto A, 2005, EMBO J, V24, P3070, DOI 10.1038/sj.emboj.7600770; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; de Sio FRS, 2006, BLOOD, V107, P4257, DOI 10.1182/blood-2005-10-4047; Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856; Llano M, 2004, J BIOL CHEM, V279, P55570, DOI 10.1074/jbc.M408508200; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mousnier A, 2007, P NATL ACAD SCI USA, V104, P13615, DOI 10.1073/pnas.0705162104; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Pierson TC, 2002, J VIROL, V76, P8518, DOI 10.1128/JVI.76.17.8518-8513.2002; Repnik U, 2003, J IMMUNOL METHODS, V278, P283, DOI 10.1016/S0022-1759(03)00231-X; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Suzuki Y, 2007, NAT REV MICROBIOL, V5, P187, DOI 10.1038/nrmicro1579; Tan WJ, 2004, J VIROL, V78, P1301, DOI 10.1128/JVI.78.3.1301-1313.2004; Todorovic V, 2005, MOL CELL, V19, P567, DOI 10.1016/j.molcel.2005.07.005; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Yamashita M, 2006, VIROLOGY, V344, P88, DOI 10.1016/j.virol.2005.09.012; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou Y, 2005, J VIROL, V79, P2199, DOI 10.1128/JVI.79.4.2199-2210.2005	39	82	85	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					329	U128		10.1038/nm.2102	http://dx.doi.org/10.1038/nm.2102			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20173753				2022-12-27	WOS:000275289500040
J	Cooney, R; Baker, J; Brain, O; Danis, B; Pichulik, T; Allan, P; Ferguson, DJP; Campbell, BJ; Jewell, D; Simmons, A				Cooney, Rachel; Baker, John; Brain, Oliver; Danis, Benedicte; Pichulik, Tica; Allan, Philip; Ferguson, David J. P.; Campbell, Barry J.; Jewell, Derek; Simmons, Alison			NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation	NATURE MEDICINE			English	Article							INVASIVE ESCHERICHIA-COLI; GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; SUSCEPTIBILITY; INFECTION; ATG16L1; LOCI	Nucleotide-binding oligomerization domain-containing-2 (NOD2) acts as a bacterial sensor in dendritic cells (DCs), but it is not clear how bacterial recognition links with antigen presentation after NOD2 stimulation. NOD2 variants are associated with Crohn's disease, where breakdown in self-recognition of commensal bacteria leads to gastrointestinal inflammation. Here we show NOD2 triggering by muramyldipeptide induces autophagy in DCs. This effect requires receptor-interacting serine-threonine kinase-2 (RIPK-2), autophagy-related protein-5 (ATG5), ATG7 and ATG16L1 but not NLR family, pyrin domain containing-3 (NALP3). We show that NOD2-mediated autophagy is required for both bacterial handling and generation of major histocompatibility complex (MHC) class II antigen-specific CD4(+) T cell responses in DCs. DCs from individuals with Crohn's disease expressing Crohn's disease-associated NOD2 or ATG16L1 risk variants are defective in autophagy induction, bacterial trafficking and antigen presentation. Our findings link two Crohn's disease-associated susceptibility genes in a single functional pathway and reveal defects in this pathway in Crohn's disease DCs that could lead to bacterial persistence via impaired lysosomal destruction and immune mediated clearance.	[Cooney, Rachel; Baker, John; Brain, Oliver; Danis, Benedicte; Pichulik, Tica; Allan, Philip; Simmons, Alison] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England; [Cooney, Rachel; Brain, Oliver; Allan, Philip; Jewell, Derek; Simmons, Alison] John Radcliffe Hosp, Dept Gastroenterol, Oxford OX3 9DU, England; [Ferguson, David J. P.] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; [Campbell, Barry J.] Univ Liverpool, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England	University of Oxford; University of Oxford; University of Oxford; University of Liverpool	Simmons, A (corresponding author), John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.	alison.simmons@imm.ox.ac.uk		Allan, Philip/0000-0003-2682-772X; Simmons, Alison/0000-0003-3454-0710; Ferguson, David/0000-0001-5045-819X; Cooney, Rachel/0000-0003-3710-157X	UK Medical Research Council; UK Higher Education Funding Council; Oxford National Institute for Health Research Biomedical Research Centre; National Institute of Health Research Specialist Biomedical Research Centre in Microbial Disease [01CD1]; Action Medical Research; Digestive Disorders Foundation and National Association for Crohn's and Colitis and The Barbour Trust in Memory of Simon Ash; Fondation Philippe Weiner Maurice Anspach; Wellcome Trust	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Higher Education Funding Council; Oxford National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); National Institute of Health Research Specialist Biomedical Research Centre in Microbial Disease; Action Medical Research; Digestive Disorders Foundation and National Association for Crohn's and Colitis and The Barbour Trust in Memory of Simon Ash; Fondation Philippe Weiner Maurice Anspach; Wellcome Trust(Wellcome TrustEuropean Commission)	We would like to acknowledge the previous researchers in our department involved in genotyping of the Oxford Crohn's disease cohort and thank A.-K. Simon and A. McMichael for helpful discussions. Most particularly, we would like to thank all of our donors who generously gave blood samples for this study. We are supported by grants from the UK Medical Research Council (J.B., T. P. and A. S.), the UK Higher Education Funding Council (A. S.), Oxford National Institute for Health Research Biomedical Research Centre (A. S.) and the National Institute of Health Research Specialist Biomedical Research Centre in Microbial Disease (01CD1) (B. J. C.), Action Medical Research (R. C.), Digestive Disorders Foundation and National Association for Crohn's and Colitis and The Barbour Trust in Memory of Simon Ash (O.B.), Fondation Philippe Weiner Maurice Anspach (B. D.) and the Wellcome Trust (P. A.). The GFP-LC3 construct was a kind gift from H. Mellor (University of Oxford) GFP-S. enterica typhimurium was a kind gift from D. Holden (Imperial College, University of London) and SL5338 pTECH1 was a kind gift from K. Turner (Sanger Centre).	Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cummings JRF, 2007, INFLAMM BOWEL DIS, V13, P941, DOI 10.1002/ibd.20162; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Darfeuille-Michaud A, 2002, INT J MED MICROBIOL, V292, P185, DOI 10.1078/1438-4221-00201; Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Magalhaes JG, 2008, J IMMUNOL, V181, P7925, DOI 10.4049/jimmunol.181.11.7925; Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yang YB, 2007, J BIOL CHEM, V282, P36223, DOI 10.1074/jbc.M703079200	25	790	824	3	100	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2010	16	1					90	U128		10.1038/nm.2069	http://dx.doi.org/10.1038/nm.2069			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	541EA	19966812				2022-12-27	WOS:000273395500041
J	Mukundan, L; Odegaard, JI; Morel, CR; Heredia, JE; Mwangi, JW; Ricardo-Gonzalez, RR; Goh, YPS; Eagle, AR; Dunn, SE; Awakuni, JUH; Nguyen, KD; Steinman, L; Michie, SA; Chawla, A				Mukundan, Lata; Odegaard, Justin I.; Morel, Christine R.; Heredia, Jose E.; Mwangi, Julia W.; Ricardo-Gonzalez, Roberto R.; Goh, Y. P. Sharon; Eagle, Alex Red; Dunn, Shannon E.; Awakuni, Jennifer U. H.; Nguyen, Khoa D.; Steinman, Lawrence; Michie, Sara A.; Chawla, Ajay			PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance	NATURE MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACTIVATED RECEPTOR-DELTA; PHOSPHATIDYLSERINE RECEPTOR; INSULIN-RESISTANCE; NUCLEAR RECEPTORS; BALB/C MICE; GLOMERULONEPHRITIS; AUTOANTIBODIES; PHAGOCYTOSIS; DEFICIENCY	Macrophages rapidly engulf apoptotic cells to limit the release of noxious cellular contents and to restrict autoimmune responses against self antigens. Although factors participating in recognition and engulfment of apoptotic cells have been identified, the transcriptional basis for the sensing and the silent disposal of apoptotic cells is unknown. Here we show that peroxisome proliferator-activated receptor-delta (PPAR-delta) is induced when macrophages engulf apoptotic cells and functions as a transcriptional sensor of dying cells. Genetic deletion of PPAR-delta decreases expression of opsonins such as complement component-1qb (C1qb), resulting in impairment of apoptotic cell clearance and reduction in anti-inflammatory cytokine production. This increases autoantibody production and predisposes global and macrophage-specific Ppard(-/-) mice to autoimmune kidney disease, a phenotype resembling the human disease systemic lupus erythematosus. Thus, PPAR-delta has a pivotal role in orchestrating the timely disposal of apoptotic cells by macrophages, ensuring that tolerance to self is maintained.	[Mukundan, Lata; Odegaard, Justin I.; Morel, Christine R.; Heredia, Jose E.; Mwangi, Julia W.; Ricardo-Gonzalez, Roberto R.; Goh, Y. P. Sharon; Eagle, Alex Red; Awakuni, Jennifer U. H.; Nguyen, Khoa D.; Chawla, Ajay] Stanford Univ, Dept Med, Sch Med, Div Endocrinol Metab & Gerontol, Stanford, CA 94305 USA; [Odegaard, Justin I.; Michie, Sara A.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Morel, Christine R.] Baylor Univ, Baylor Inst Immunol Res, Grad Program Biomed Sci, Dallas, TX USA; [Ricardo-Gonzalez, Roberto R.; Goh, Y. P. Sharon; Nguyen, Khoa D.; Chawla, Ajay] Stanford Univ, Sch Med, Grad Program Immunol, Stanford, CA 94305 USA; [Eagle, Alex Red] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Dunn, Shannon E.; Steinman, Lawrence] Stanford Univ, Dept Neurol & Neurol Studies, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Baylor Scott & White Health; Baylor University; Stanford University; Stanford University; Stanford University	Chawla, A (corresponding author), Stanford Univ, Dept Med, Sch Med, Div Endocrinol Metab & Gerontol, Stanford, CA 94305 USA.	achawla@stanford.edu		Ricardo-Gonzalez, Roberto/0000-0002-6135-4035; Steinman, Lawrence/0000-0002-2437-2250; Nguyen, Khoa/0000-0002-6720-2470	US National Institutes of Health [DK062386, HL076746, DK081405, DK67592, DE14385, AI066402]; Rita Allen Foundation; US National Multiple Sclerosis Society; Stanford Medical Scientist Training Program; American Heart Association; Howard Hughes Medical Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290, F31AI066402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062386, R01DK081405, R01DK076760, R01DK067592] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rita Allen Foundation; US National Multiple Sclerosis Society(National Multiple Sclerosis Society); Stanford Medical Scientist Training Program; American Heart Association(American Heart Association); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the Chawla lab for valuable comment and C. H. Lee and A. Loh for critique on the manuscript. This work was supported by grants made available to A. C. (US National Institutes of Health (DK062386, HL076746 and DK081405) and Rita Allen Foundation), to L. S. (US National Multiple Sclerosis Society) and to S. A. M. (US National Institutes of Health (DK67592 and DE14385)). Support was provided by Stanford Medical Scientist Training Program (J.I.O. and A. R. E.), American Heart Association (J.I.O.), Dean's Fellowship (J.E.H.), Howard Hughes Medical Institute Gilliam fellowship (A. R. E.) and US National Institutes of Health AI066402 (R.R.R.-G.).	Armbrust T, 1997, HEPATOLOGY, V26, P98; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Breitkopf K, 2005, GUT, V54, P673, DOI 10.1136/gut.2004.042911; Castrillo A, 2004, ANNU REV CELL DEV BI, V20, P455, DOI 10.1146/annurev.cellbio.20.012103.134432; Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Erwig LP, 2008, CELL DEATH DIFFER, V15, P243, DOI 10.1038/sj.cdd.4402184; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787; GONZALEZ N, 2009, IMMUNITY, V31, P245, DOI DOI 10.1016/J.IMMUNI.2009.06.018; Graham RR, 2009, J INTERN MED, V265, P680, DOI 10.1111/j.1365-2796.2009.02096.x; GUNNIA UB, 1991, KIDNEY INT, V39, P882, DOI 10.1038/ki.1991.111; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Harley JB, 2006, SPRINGER SEMIN IMMUN, V28, P119, DOI 10.1007/s00281-006-0040-5; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Hess KL, 1997, CYTOMETRY, V27, P145; Hicks J, 2006, ULTRASTRUCT PATHOL, V30, P345, DOI 10.1080/01913120600932677; Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002; KELLEY VE, 1985, CLIN IMMUNOL IMMUNOP, V37, P220, DOI 10.1016/0090-1229(85)90153-9; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Morel L, 1996, MAMM GENOME, V7, P335, DOI 10.1007/s003359900098; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Odegaard JI, 2008, CELL METAB, V7, P496, DOI 10.1016/j.cmet.2008.04.003; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Petry F, 2001, J IMMUNOL, V167, P4033, DOI 10.4049/jimmunol.167.7.4033; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; SATOH M, 1995, P NATL ACAD SCI USA, V92, P10934, DOI 10.1073/pnas.92.24.10934; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Slingsby JH, 1996, ARTHRITIS RHEUM, V39, P663, DOI 10.1002/art.1780390419; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Sznaidman ML, 2003, BIOORG MED CHEM LETT, V13, P1517, DOI 10.1016/S0960-894X(03)00207-5; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wermeling F, 2007, J EXP MED, V204, P2259, DOI 10.1084/jem.20070600	45	267	273	3	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1266	U59		10.1038/nm.2048	http://dx.doi.org/10.1038/nm.2048			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19838202	Green Accepted			2022-12-27	WOS:000271543700014
J	Wong, SY; Seol, AD; So, PL; Ermilov, AN; Bichakjian, CK; Epstein, EH; Dlugosz, AA; Reiter, JF				Wong, Sunny Y.; Seol, Allen D.; So, Po-Lin; Ermilov, Alexandre N.; Bichakjian, Christopher K.; Epstein, Ervin H., Jr.; Dlugosz, Andrzej A.; Reiter, Jeremy F.			Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis	NATURE MEDICINE			English	Article							BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; SONIC-HEDGEHOG; INTRAFLAGELLAR TRANSPORT; REPRESSOR FUNCTIONS; MOUSE MODEL; STEM-CELLS; SKIN; EXPRESSION; GLI2	Primary cilia are present on most mammalian cells and are implicated in transducing Hedgehog (Hh) signals during development; however, the prevalence of cilia on human tumors remains unclear, and the role of cilia in cancer has not been examined. Here we show that human basal cell carcinomas (BCCs) are frequently ciliated, and we test the role of cilia in BCC by conditionally deleting Kif3a (encoding kinesin family member 3A) or Ift88 (encoding intraflagellar transport protein 88), genes required for ciliogenesis, in two Hh pathway-dependent mouse tumor models. Ciliary ablation strongly inhibited BCC-like tumors induced by an activated form of Smoothened. In contrast, removal of cilia accelerated tumors induced by activated Gli2, a transcriptional effector of Hh signaling. These seemingly paradoxical effects are consistent with a dual role for cilia in mediating both the activation and the repression of the Hh signaling pathway. Our findings demonstrate that cilia function as unique signaling organelles that can either mediate or suppress tumorigenesis depending on the nature of the oncogenic initiating event.	[Wong, Sunny Y.; Seol, Allen D.; Reiter, Jeremy F.] Univ Calif San Francisco, Dept Biochem & Biophys, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [So, Po-Lin; Epstein, Ervin H., Jr.] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; [Ermilov, Alexandre N.; Bichakjian, Christopher K.; Dlugosz, Andrzej A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA	University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Michigan System; University of Michigan	Reiter, JF (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	jeremy.reiter@ucsf.edu			US National Institutes of Health [RO1AR054396, RO1CA087837]; Burroughs Wellcome Fund; Packard Foundation; Sandler Family Supporting Foundation; A.P. Giannini Foundation; Herbert W. Boyer Fund; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA087837, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054396, R01AR045973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Packard Foundation(The David & Lucile Packard Foundation); Sandler Family Supporting Foundation; A.P. Giannini Foundation; Herbert W. Boyer Fund; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank D. Hanahan, O. Nolan-Stevaux, G. Evan and the members of the Reiter lab for critical reading of this manuscript; K. Thorn and the UCSF Nikon Imaging Center for assistance with confocal microscopy; C. Miller and J. D. Fish for assistance with histology; and R. T. Bronson for help with pathology. We thank T. Li, Harvard Medical School, for rabbit antibody to rootletin; K. V. Anderson, Sloan-Kettering Institute, for Ift172<SUP>-/-</SUP> MEFs; S. Scales, Genentech, for mouse antibody to Gli3; J. T. Eggenschwiler, Princeton University, for guinea pig antibody to Gli2; B. Yoder, University of Alabama at Birmingham, for Ift88<SUP>flox</SUP> mice; L. Goldstein, University of California, San Diego, for Kif3a<SUP>flox</SUP>-knockout mice; and L. V. Goodrich, Harvard Medical School, for Ptch1 riboprobe plasmid. This work was funded by grants from the US National Institutes of Health (RO1AR054396), the Burroughs Wellcome Fund, the Packard Foundation and the Sandler Family Supporting Foundation to J. F. R. A. A. D. acknowledges the support of the US National Institutes of Health ( RO1CA087837). S. Y. W. acknowledges the support of the A.P. Giannini Foundation, the Herbert W. Boyer Fund and the American Cancer Society.	Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Cho A, 2008, DEV BIOL, V321, P27, DOI 10.1016/j.ydbio.2008.05.558; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Hu MC, 2006, DEVELOPMENT, V133, P569, DOI 10.1242/dev.02220; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Lehman JM, 2009, J INVEST DERMATOL, V129, P438, DOI 10.1038/jid.2008.279; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Reifenberger J, 1998, CANCER RES, V58, P1798; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Tojo M, 2003, BRIT J DERMATOL, V148, P892, DOI 10.1046/j.1365-2133.2003.05284.x; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; WILSON RB, 1963, LAB INVEST, V12, P242; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275	40	323	342	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1055	U109		10.1038/nm.2011	http://dx.doi.org/10.1038/nm.2011			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19701205	Green Accepted			2022-12-27	WOS:000269979200026
J	Hotchkiss, RS; Coopersmith, CM; McDunn, JE; Ferguson, TA				Hotchkiss, Richard S.; Coopersmith, Craig M.; McDunn, Jonathan E.; Ferguson, Thomas A.			Tilting toward immunosuppression	NATURE MEDICINE			English	Editorial Material							SEPSIS; APOPTOSIS		[Hotchkiss, Richard S.; Coopersmith, Craig M.; McDunn, Jonathan E.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Med & Surg, St Louis, MO 63110 USA; [Coopersmith, Craig M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Ferguson, Thomas A.] Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.	hotch@wustl.edu	McDunn, Jonathan/A-6816-2009	McDunn, Jonathan/0000-0001-8792-828X	NATIONAL EYE INSTITUTE [R01EY006765, P30EY002687, R01EY015570] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY015570, R01 EY006765, P30 EY002687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adib-Conquy M, 2009, THROMB HAEMOSTASIS, V101, P36, DOI 10.1160/TH08-07-0421; Cheever MAM, 2008, IMMUNOL REV, V222, P357, DOI 10.1111/j.1600-065X.2008.00604.x; CHOILEAIN NN, 2006, J IMMUNOL, V176, P225, DOI 10.4049/jimmunol.176.1.225; Deans KJ, 2005, J TRAUMA, V58, P867, DOI 10.1097/01.TA.0000158244.69179.94; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413; Luyt CE, 2007, AM J RESP CRIT CARE, V175, P935, DOI 10.1164/rccm.200609-1322OC; Osuchowski MF, 2006, J IMMUNOL, V177, P1967, DOI 10.4049/jimmunol.177.3.1967; Schwulst SJ, 2006, J IMMUNOL, V177, P557, DOI 10.4049/jimmunol.177.1.557; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; [No title captured]	15	416	441	4	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2009	15	5					496	497		10.1038/nm0509-496	http://dx.doi.org/10.1038/nm0509-496			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19424209	Bronze, Green Accepted			2022-12-27	WOS:000265889300026
J	Vanneste, E; Voet, T; Le Caignec, C; Ampe, M; Konings, P; Melotte, C; Debrock, S; Amyere, M; Vikkula, M; Schuit, F; Fryns, JP; Verbeke, G; D'Hooghe, T; Moreau, Y; Vermeesch, JR				Vanneste, Evelyne; Voet, Thierry; Le Caignec, Cedric; Ampe, Michele; Konings, Peter; Melotte, Cindy; Debrock, Sophie; Amyere, Mustapha; Vikkula, Miikka; Schuit, Frans; Fryns, Jean-Pierre; Verbeke, Geert; D'Hooghe, Thomas; Moreau, Yves; Vermeesch, Joris R.			Chromosome instability is common in human cleavage-stage embryos	NATURE MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; UNIPARENTAL DISOMY UPD; PREIMPLANTATION EMBRYOS; SPONTANEOUS-ABORTIONS; TERMINAL DELETIONS; SINGLE CELLS; YOUNG-WOMEN; ARRAY-CGH; ANEUPLOIDY; ABNORMALITIES	Chromosome instability is a hallmark of tumorigenesis. This study establishes that chromosome instability is also common during early human embryogenesis. A new array-based method allowed screening of genome-wide copy number and loss of heterozygosity in single cells. This revealed not only mosaicism for whole-chromosome aneuploidies and uniparental disomies in most cleavage-stage embryos but also frequent segmental deletions, duplications and amplifications that were reciprocal in sister blastomeres, implying the occurrence of breakage-fusion-bridge cycles. This explains the low human fecundity and identifies post-zygotic chromosome instability as a leading cause of constitutional chromosomal disorders.	[Vanneste, Evelyne; Voet, Thierry; Le Caignec, Cedric; Melotte, Cindy; Fryns, Jean-Pierre; Vermeesch, Joris R.] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium; [Vanneste, Evelyne; Debrock, Sophie; D'Hooghe, Thomas] Univ Hosp Gasthuisberg, Leuven Univ Fertil Ctr, B-3000 Leuven, Belgium; [Le Caignec, Cedric] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France; [Le Caignec, Cedric] Inst Natl Sante & Rech Med, Inst Thorax, Nantes, France; [Ampe, Michele; Verbeke, Geert] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium; [Konings, Peter; Moreau, Yves] Katholieke Univ Leuven, ESAT SISTA, Heverlee, Belgium; [Amyere, Mustapha; Vikkula, Miikka] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium; [Schuit, Frans] Univ Hosp Gasthuisberg, Gene Express Grp, B-3000 Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Hasselt University; KU Leuven; KU Leuven; Universite Catholique Louvain; KU Leuven; University Hospital Leuven	Vermeesch, JR (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium.	joris.vermeesch@uz.kuleuven.be	Voet, Thierry/E-8877-2017; Le Caignec, Cedric/K-8467-2015; Melotte, Cindy/GXV-5465-2022; Vikkula, Miikka/Q-1038-2018; Verbeke, Geert/I-5587-2015	Voet, Thierry/0000-0003-1204-9963; Le Caignec, Cedric/0000-0002-0598-653X; Vikkula, Miikka/0000-0002-6236-338X; Verbeke, Geert/0000-0001-8430-7576; Moreau, Yves/0000-0002-4647-6560; Konings, Peter/0000-0002-8637-5916; Vermeesch, Joris/0000-0002-3071-1191	Institute for the Promotion of Innovation through Science and Technology (IWT-Flanders) [SBO-60848, GOA/2006/12]; Research Council K. U. Leuven [EF/05/007]; Fonds de la Recherche Scientifique; Institute for the Promotion of Innovation through Science and Technology in Flanders	Institute for the Promotion of Innovation through Science and Technology (IWT-Flanders)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Research Council K. U. Leuven(KU Leuven); Fonds de la Recherche Scientifique(Fonds de la Recherche Scientifique - FNRS); Institute for the Promotion of Innovation through Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	We thank all families who participated in the study, the Leuven University Fertility Center for technical assistance and S. Jackmaert for her help with the SNP arrays. We are also grateful to the Mapping Core and Map finishing groups of the Wellcome Trust Sanger Institute for initial BAC clone supply and verification and to the microarray facility of the Flanders Interuniversity Institute for Biotechnology for their help in spotting the arrays. We would like to thank C. Spiessens, E. Legius, T. de Ravel de l'Argentiere, H. van Esch and K. Devriendt for the critical reading of the manuscript. This work was made possible by grants from the Institute for the Promotion of Innovation through Science and Technology (IWT-Flanders) (SBO-60848) and GOA/2006/12 and Center of Excellence SymBioSys (Research Council K. U. Leuven EF/05/007) to J. R. V. and Fonds de la Recherche Scientifique to M. V. E. V. was supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders.	Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baart EB, 2006, HUM REPROD, V21, P223, DOI 10.1093/humrep/dei291; Ballif BC, 2006, PRENATAL DIAG, V26, P333, DOI 10.1002/pd.1411; Ballif BC, 2003, HUM MOL GENET, V12, P2153, DOI 10.1093/hmg/ddg231; Benkhalifa M, 2005, PRENATAL DIAG, V25, P894, DOI 10.1002/pd.1230; Bignell GR, 2007, GENOME RES, V17, P1296, DOI 10.1101/gr.6522707; BRAUDE P, 1988, NATURE, V332, P459, DOI 10.1038/332459a0; Daphnis DD, 2008, MOL HUM REPROD, V14, P117, DOI 10.1093/molehr/gam087; Delhanty JDA, 2005, CYTOGENET GENOME RES, V111, P237, DOI 10.1159/000086894; Fiegler H, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1030; Fritz B, 2001, EUR J HUM GENET, V9, P539, DOI 10.1038/sj.ejhg.5200669; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Harper JC, 2008, HUM REPROD, V23, P741, DOI 10.1093/humrep/dem354; Harper J, 2008, HUM REPROD, V23, P478, DOI 10.1093/humrep/dem424; Iwamoto K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001306; Kotzot D, 1999, AM J MED GENET, V82, P265, DOI 10.1002/(SICI)1096-8628(19990129)82:3<265::AID-AJMG14>3.3.CO;2-Y; Kotzot D, 2001, J MED GENET, V38, P497, DOI 10.1136/jmg.38.8.497; Le Caignec C, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl336; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li M, 2005, FERTIL STERIL, V84, P1395, DOI 10.1016/j.fertnstert.2005.04.068; Macklon NS, 2002, HUM REPROD UPDATE, V8, P333, DOI 10.1093/humupd/8.4.333; Marshall OJ, 2008, AM J HUM GENET, V82, P261, DOI 10.1016/j.ajhg.2007.11.009; Munne S, 1997, HUM REPROD, V12, P780, DOI 10.1093/humrep/12.4.780; Munne S, 2004, PRENATAL DIAG, V24, P638, DOI 10.1002/pd.957; Munne S, 2005, FERTIL STERIL, V84, P1328, DOI 10.1016/j.fertnstert.2005.06.025; Perry J, 2004, CHROMOSOME RES, V12, P627, DOI 10.1023/B:CHRO.0000036594.38997.59; Pflueger SMV, 1999, PRINCIPLES OF CLINICAL CYTOGENETICS, P317; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rossi E, 2008, J MED GENET, V45, P147, DOI 10.1136/jmg.2007.054007; Rubio C, 2003, HUM REPROD, V18, P182, DOI 10.1093/humrep/deg015; Schinzel A., 2001, CATALOGUE UNBALANCED; Staessen C, 2004, HUM REPROD, V19, P2849, DOI 10.1093/humrep/deh536; Voullaire L, 2000, HUM GENET, V106, P210, DOI 10.1007/s004390051030; Weghofer A, 2008, HUM REPROD, V23, P499, DOI 10.1093/humrep/dem412; Wells D, 2000, MOL HUM REPROD, V6, P1055, DOI 10.1093/molehr/6.11.1055; Yurov YB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000558	38	560	595	2	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					577	583		10.1038/nm.1924	http://dx.doi.org/10.1038/nm.1924			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19396175				2022-12-27	WOS:000265889300038
J	Gross, S; Gammon, ST; Moss, BL; Rauch, D; Harding, J; Heinecke, JW; Ratner, L; Piwnica-Worms, D				Gross, Shimon; Gammon, Seth T.; Moss, Britney L.; Rauch, Daniel; Harding, John; Heinecke, Jay W.; Ratner, Lee; Piwnica-Worms, David			Bioluminescence imaging of myeloperoxidase activity in vivo	NATURE MEDICINE			English	Article							LUMINOL-DEPENDENT CHEMILUMINESCENCE; HUMAN-NEUTROPHILS; CHEMI-LUMINESCENCE; MICE; ATHEROSCLEROSIS; DISEASE; OXIDASE; GRANULOCYTES; INFLAMMATION; MACROPHAGES	The myeloperoxidase (MPO) system of activated phagocytes is central to normal host defense mechanisms, and dysregulated MPO contributes to the pathogenesis of inflammatory disease states ranging from atherosclerosis to cancer. Here we show that upon systemic administration, the small molecule luminol enables noninvasive bioluminescence imaging (BLI) of MPO activity in vivo. Luminol-BLI allowed quantitative longitudinal monitoring of MPO activity in animal models of acute dermatitis, mixed allergic contact hypersensitivity, focal arthritis and spontaneous large granular lymphocytic tumors. Bioluminescence colocalized with histological sites of inflammation and was totally abolished in gene-deleted Mpo(-/-) mice, despite massive tissue infiltration of neutrophils and activated eosinophils, indicating that eosinophil peroxidase did not contribute to luminol-BLI in vivo. Thus, luminol-BLI provides a noninvasive, specific and highly sensitive optical readout of phagocyte-mediated MPO activity in vivo and may enable new diagnostic applications in a wide range of acute and chronic inflammatory conditions.	[Rauch, Daniel; Harding, John; Ratner, Lee] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; [Gross, Shimon; Gammon, Seth T.; Moss, Britney L.; Piwnica-Worms, David] Washington Univ, Sch Med, Dept Med, Mallinckrodt Inst Radiol,Mol Imaging Ctr, St Louis, MO 63110 USA; [Heinecke, Jay W.] Univ Washington, Dept Med, Seattle, WA USA; [Piwnica-Worms, David] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); University of Washington; University of Washington Seattle; Washington University (WUSTL)	Piwnica-Worms, D (corresponding author), Washington Univ, Sch Med, Dept Med, Mallinckrodt Inst Radiol,Mol Imaging Ctr, St Louis, MO 63110 USA.	piwnica-wormsd@mir.wustl.edu	Gammon, Seth/C-8778-2014	Gammon, Seth/0000-0001-8647-0975; Moss, Britney/0000-0002-1037-5717; Ratner, Lee/0000-0003-2744-7294	NATIONAL CANCER INSTITUTE [R01CA063417, P01CA100730, P50CA094056, R01CA105218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NCI NIH HHS [CA105218, CA10073, P50 CA094056, P01 CA100730-07S10005, P50 CA094056-090003, P01 CA100730-01, P50 CA94056, R01 CA063417, R01 CA105218, CA63417, P01 CA100730, R01 CA063417-11] Funding Source: Medline; NHLBI NIH HHS [P01 HL030086, P01 HL030086.] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN RC, 1976, BIOCHEM BIOPH RES CO, V69, P245, DOI 10.1016/S0006-291X(76)80299-9; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; Bednar MM, 1996, J LEUKOCYTE BIOL, V60, P619, DOI 10.1002/jlb.60.5.619; BENDER JG, 1986, INFLAMMATION, V10, P443, DOI 10.1007/BF00915828; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; BRESTEL EP, 1985, BIOCHEM BIOPH RES CO, V126, P482, DOI 10.1016/0006-291X(85)90631-X; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; Chen JW, 2006, RADIOLOGY, V240, P473, DOI 10.1148/radiol.2402050994; Chen Wei-Tsung, 2004, Mol Imaging, V3, P159, DOI 10.1162/1535350042380290; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DECHATELET LR, 1982, J IMMUNOL, V129, P1589; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; FREIBURGHAUS J, 1991, J BIOLUM CHEMILUM, V6, P115, DOI 10.1002/bio.1170060209; FRETLAND DJ, 1995, INFLAMMATION, V19, P333, DOI 10.1007/BF01534391; Gerber CE, 1996, EUR J CLIN CHEM CLIN, V34, P901; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Gross S, 2005, METHOD ENZYMOL, V399, P512, DOI 10.1016/S0076-6879(05)99035-6; GROSS S, 2009, NAT PROTOC      0322, DOI DOI 10.1038/NPR0T.2009.73; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hallett Maurice B, 2003, Methods Mol Biol, V225, P61; Haqqani AS, 1999, ANAL BIOCHEM, V273, P126, DOI 10.1006/abio.1999.4206; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; IRIE S, 1960, Curr Ther Res Clin Exp, V2, P107; Jancinova V, 2006, REDOX REP, V11, P110, DOI 10.1179/135100006X116592; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Komatsu J, 2006, INFLAMM RES, V55, P200, DOI 10.1007/s00011-006-0071-3; Lundqvist H, 1996, FREE RADICAL BIO MED, V20, P785, DOI 10.1016/0891-5849(95)02189-2; Malle E, 2003, KIDNEY INT, V64, P1956, DOI 10.1046/j.1523-1755.2003.00336.x; Nahrendorf M, 2008, CIRCULATION, V117, P1153, DOI 10.1161/CIRCULATIONAHA.107.756510; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Querol M, 2006, ORG BIOMOL CHEM, V4, P1887, DOI 10.1039/b601540a; RAY MC, 1983, J IMMUNOL, V131, P1096; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; Sanders JM, 2000, XENOBIOTICA, V30, P263, DOI 10.1080/004982500237659; Sans MQ, 2005, MOL IMAGING BIOL, V7, P403, DOI 10.1007/s11307-005-0020-5; Shepherd J, 2007, CHEM BIOL, V14, P1221, DOI 10.1016/j.chembiol.2007.10.005; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; STEVENS P, 1978, INFECT IMMUN, V22, P41, DOI 10.1128/IAI.22.1.41-51.1978	41	242	264	7	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					455	461		10.1038/nm.1886	http://dx.doi.org/10.1038/nm.1886			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19305414	Green Accepted			2022-12-27	WOS:000264937200034
J	Loane, DJ; Pocivavsek, A; Moussa, CEH; Thompson, R; Matsuoka, Y; Faden, AI; Rebeck, GW; Burns, MP				Loane, David J.; Pocivavsek, Ana; Moussa, Charbel E-H; Thompson, Rachel; Matsuoka, Yasuji; Faden, Alan I.; Rebeck, G. William; Burns, Mark P.			Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury	NATURE MEDICINE			English	Article							LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; BETA-SECRETASE; HEAD TRAUMA; PRESENILIN-1; MOUSE; EXPRESSION; DEPOSITION; AXONS; INHIBITORS	Amyloid-beta (A beta) peptides, found in Alzheimer's disease brain, accumulate rapidly after traumatic brain injury (TBI) in both humans and animals. Here we show that blocking either beta- or gamma-secretase, enzymes required for production of A beta from amyloid precursor protein (APP), can ameliorate motor and cognitive deficits and reduce cell loss after experimental TBI in mice. Thus, APP secretases are promising targets for treatment of TBI.	[Loane, David J.; Pocivavsek, Ana; Moussa, Charbel E-H; Thompson, Rachel; Faden, Alan I.; Rebeck, G. William; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Matsuoka, Yasuji] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA.	mpb37@georgetown.edu	Rebeck, George William/J-2192-2012; Pocivavsek, Ana/AAW-8923-2020; Loane, David/ABD-5177-2021	Rebeck, George William/0000-0001-6276-248X; Loane, David/0000-0003-0393-3503; Pocivavsek, Ana/0000-0002-3817-3201; Burns, Mark P/0000-0003-4750-2000	National Institutes of Health [R03NS57635, R24HD050845]; Klingel Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R24HD050845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS057635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG030378] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Klingel Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to thank A. Pajoohesh-Ganji and P. Washington for technical assistance; S. Fricke and O. Rodriguez of the Small Animal Imaging Laboratory at Georgetown University; and P. Mathews (Nathan S. Kline Institute) for antibody C1/6.1. This work was funded by grant R03NS57635 (M. P. B.) and a pilot award from the National Capital Area Rehabilitation Research Network R24HD050845 (M. P. B.), both from the US National Institutes of Health, and by the Klingel Family Foundation (M. P. B.).	Abramowski D, 2008, J PHARMACOL EXP THER, V327, P411, DOI 10.1124/jpet.108.140327; Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; El Mouedden M, 2006, CURR PHARM DESIGN, V12, P671; Esposito L, 2004, J NEUROCHEM, V91, P1260, DOI 10.1111/j.1471-4159.2004.02816.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	29	189	217	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					377	379		10.1038/nm.1940	http://dx.doi.org/10.1038/nm.1940			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19287391	Green Accepted			2022-12-27	WOS:000264937200023
J	Sun, J; Madan, R; Karp, CL; Braciale, TJ				Sun, Jie; Madan, Rajat; Karp, Christopher L.; Braciale, Thomas J.			Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10	NATURE MEDICINE			English	Article							DENDRITIC CELLS; CUTTING EDGE; LYMPH-NODES; INTERLEUKIN-10; RESPONSES; MACROPHAGES; ACTIVATION; INDUCTION; MEMORY	Activated antigen-specific T cells produce a variety of effector molecules for clearing infection but also contribute to inflammation and tissue injury. Here we report an anti-inflammatory property of antiviral CD8(+) and CD4(+) effector T cells (T-eff cells) in the infected periphery during acute virus infection. We find that, during acute influenza infection, interleukin-10 (IL-10) is produced in the infected lungs in large amounts-exclusively by infiltrating virus-specific Teff cells, with CD8(+) Teff cells contributing a larger fraction of the IL-10 produced. These Teff cells in the periphery simultaneously produce IL-10 and proinflammatory cytokines and express lineage markers characteristic of conventional T helper type 1 or T cytotoxic type 1 cells. Notably, blocking the action of the T-eff cell-derived IL-10 results in enhanced pulmonary inflammation and lethal injury. Our results show that antiviral Teff cells exert regulatory functions-that is, they fine-tune the extent of lung inflammation and injury associated with influenza infection by producing an anti-inflammatory cytokine. We discuss the potential implications of these findings for infection with highly pathogenic influenza viruses.	[Sun, Jie; Braciale, Thomas J.] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; [Madan, Rajat; Karp, Christopher L.] Cincinnati Childrens Hosp Res Fdn, Div Mol Immunol, Cincinnati, OH 45229 USA; [Madan, Rajat; Karp, Christopher L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Braciale, Thomas J.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Braciale, Thomas J.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Virginia; University of Virginia	Braciale, TJ (corresponding author), Univ Virginia, Beirne B Carter Ctr Immunol Res, 409 Lane Rd, Charlottesville, VA 22908 USA.	tjb2r@virginia.edu	Madan, Rajat/V-6168-2019	Madan, Rajat/0000-0002-9821-1257; Karp, Christopher/0000-0002-0832-2659	US National Institutes of Health [AI-15608, HL-33391, AI37293, AI057992]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057992, R37AI015608, R01AI015608, R01AI037293] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank M. Hufford and T. Kim for critical comments and B. Small and S. Gill for excellent technical assistance. This work was supported by the US National Institutes of Health (grants AI-15608, HL-33391 and AI37293 to T.J.B. and AI057992 to C.L.K.).	Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Belz GT, 2002, J VIROL, V76, P12388, DOI 10.1128/JVI.76.23.12388-12393.2002; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Doyle AG, 1999, J EXP MED, V190, P1081, DOI 10.1084/jem.190.8.1081; Ejrnaes M, 2006, J EXP MED, V203, P2461, DOI 10.1084/jem.20061462; Endharti AT, 2005, J IMMUNOL, V175, P7093, DOI 10.4049/jimmunol.175.11.7093; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Humphreys IR, 2007, J EXP MED, V204, P1217, DOI 10.1084/jem.20062424; Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175; Jelley-Gibbs DM, 2007, J IMMUNOL, V178, P7563, DOI 10.4049/jimmunol.178.12.7563; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Lawrence CW, 2004, J IMMUNOL, V173, P1209, DOI 10.4049/jimmunol.173.2.1209; Lawrence CW, 2005, J IMMUNOL, V174, P5332, DOI 10.4049/jimmunol.174.9.5332; Legge KL, 2005, IMMUNITY, V23, P649, DOI 10.1016/j.immuni.2005.11.006; Lin KL, 2008, J IMMUNOL, V180, P2562, DOI 10.4049/jimmunol.180.4.2562; Liu F, 2005, J IMMUNOL, V174, P5936, DOI 10.4049/jimmunol.174.10.5936; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Noble A, 2006, BLOOD, V107, P4475, DOI 10.1182/blood-2005-10-3994; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; SARAWAR SR, 1994, J VIROL, V68, P3112, DOI 10.1128/JVI.68.5.3112-3119.1994; Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053; Smith TRF, 2008, TRENDS IMMUNOL, V29, P337, DOI 10.1016/j.it.2008.04.002; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Sun J, 2007, J IMMUNOL, V178, P1635, DOI 10.4049/jimmunol.178.3.1635; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tumpey TM, 2005, J VIROL, V79, P14933, DOI 10.1128/JVI.79.23.14933-14944.2005; Yoon H, 2007, J IMMUNOL, V179, P391, DOI 10.4049/jimmunol.179.1.391	37	441	459	2	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					277	284		10.1038/nm.1929	http://dx.doi.org/10.1038/nm.1929			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19234462	Green Accepted, Bronze			2022-12-27	WOS:000263914000027
J	Svensson, L; Howarth, K; McDowall, A; Patzak, I; Evans, R; Ussar, S; Moser, M; Metin, A; Fried, M; Tomlinson, I; Hogg, N				Svensson, Lena; Howarth, Kimberley; McDowall, Alison; Patzak, Irene; Evans, Rachel; Ussar, Siegfried; Moser, Markus; Metin, Ayse; Fried, Mike; Tomlinson, Ian; Hogg, Nancy			Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation	NATURE MEDICINE			English	Article							CALDAG-GEFI; PLATELET-AGGREGATION; BETA(2) INTEGRINS; GENETIC-ANALYSIS; EXCHANGE FACTOR; T-LYMPHOCYTES; CAIDAG-GEFI; LAD-III; PROTEIN; TALIN	Integrins are the major adhesion receptors of leukocytes and platelets. beta(1) and beta(2) integrin function on leukocytes is crucial for a successful immune response and the platelet integrin alpha(IIb)beta(3) initiates the process of blood clotting through binding fibrinogen(1-3). Integrins on circulating cells bind poorly to their ligands but become active after 'inside-out' signaling through other membrane receptors(4,5). Subjects with leukocyte adhesion deficiency-1 (LAD-I) do not express beta(2) integrins because of mutations in the gene specifying the beta(2) subunit, and they suffer recurrent bacterial infections(6,7). Mutations affecting aIIbb3 integrin cause the bleeding disorder termed Glanzmann's thrombasthenia(3). Subjects with LAD-III show symptoms of both LAD-I and Glanzmann's thrombasthenia. Their hematopoietically-derived cells express beta(1), beta(2) and beta(3) integrins, but defective inside-out signaling causes immune deficiency and bleeding problems(8). The LAD-III lesion has been attributed to a C -> A mutation in the gene encoding calcium and diacylglycerol guanine nucleotide exchange factor (CALDAGGEF1; official symbol RASGRP2) specifying the CALDAG-GEF1 protein(9), but we show that this change is not responsible for the LAD-III disorder. Instead, we identify mutations in the KINDLIN3 (official symbol FERMT3) gene specifying the KINDLIN-3 protein as the cause of LAD-III in Maltese and Turkish subjects. Two independent mutations result in decreased KINDLIN3 messenger RNA levels and loss of protein expression. Notably, transfection of the subjects' lymphocytes with KINDLIN3 complementary DNA but not CALDAGGEF1 cDNA reverses the LAD-III defect, restoring integrin-mediated adhesion and migration.	[Svensson, Lena; McDowall, Alison; Patzak, Irene; Evans, Rachel; Hogg, Nancy] Canc Res UK London Res Inst, Leukocyte Adhes Lab, London WC2A 3PX, England; [Howarth, Kimberley; Tomlinson, Ian] Canc Res UK London Res Inst, Mol & Populat Genet Lab, London WC2A 3PX, England; [Ussar, Siegfried; Moser, Markus] Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; [Metin, Ayse] SB Ankara Diskapi Childrens Hosp, Div Immunol, TR-06110 Ankara, Turkey; [Fried, Mike] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	Cancer Research UK; Cancer Research UK; Max Planck Society; Ankara Children's Hematology Oncology Training & Research Hospital; University of California System; University of California San Francisco	Hogg, N (corresponding author), Canc Res UK London Res Inst, Leukocyte Adhes Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	nancy.hogg@cancer.org.uk	Evans, Rachel/GYU-7083-2022; Ussar, Siegfried/AAL-4331-2021; METIN, AYSE/AAS-2382-2020	Ussar, Siegfried/0000-0001-7575-0920; McDowall, Alison/0000-0003-2018-1462; Evans, Rachel/0000-0002-3723-2249; METIN, AYSE/0000-0002-0731-5799	Cancer Research UK [A3582] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Alon R, 2003, BLOOD, V101, P4437, DOI 10.1182/blood-2002-11-3427; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Bergmeier W, 2007, J CLIN INVEST, V117, P1699, DOI 10.1172/JCI30575; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Cifuni SM, 2008, BLOOD, V112, P1696, DOI 10.1182/blood-2008-02-139733; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Coller BS, 2008, BLOOD, V112, P3011, DOI 10.1182/blood-2008-06-077891; Crittenden JR, 2004, NAT MED, V10, P982, DOI 10.1038/nm1098; Etzioni A, 2004, CURR OPIN ALLERGY CL, V4, P485, DOI 10.1097/00130832-200412000-00003; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Ghandour H, 2007, BLOOD, V110, P3682, DOI 10.1182/blood-2007-03-077628; Harris ES, 2001, BLOOD, V97, P767, DOI 10.1182/blood.V97.3.767; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; Hogg N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4; Jobard F, 2003, HUM MOL GENET, V12, P925, DOI 10.1093/hmg/ddg097; Kellermann SA, 2002, IMMUNOL REV, V186, P172, DOI 10.1034/j.1600-065X.2002.18615.x; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; Kuijpers TW, 2007, BLOOD, V109, P3529, DOI 10.1182/blood-2006-05-021402; Kuijpers TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Ma YQ, 2008, J CELL BIOL, V181, P439, DOI 10.1083/jcb.200710196; McDowall A, 2003, J CLIN INVEST, V111, P51, DOI 10.1172/JCI200314076; Montanez E, 2008, GENE DEV, V22, P1325, DOI 10.1101/gad.469408; Mory A, 2008, BLOOD, V112, P2591, DOI 10.1182/blood-2008-06-163162; Moser M, 2008, NAT MED, V14, P325, DOI 10.1038/nm1722; Moser M, 2009, NAT MED, V15, P300, DOI 10.1038/nm.1921; Pasvolsky R, 2007, J EXP MED, V204, P1571, DOI 10.1084/jem.20070058; Siegel DH, 2003, AM J HUM GENET, V73, P174, DOI 10.1086/376609; Smith A, 2005, J CELL BIOL, V170, P141, DOI 10.1083/jcb.200412032; Springett GM, 2004, BIOESSAYS, V26, P730, DOI 10.1002/bies.20057; Stone JC, 2006, BIOCHEM SOC T, V34, P858, DOI 10.1042/BST0340858; Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Weinstein EJ, 2003, BBA-MOL BASIS DIS, V1637, P207, DOI 10.1016/S0925-4439(03)00035-8	36	285	290	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					306	312		10.1038/nm.1931	http://dx.doi.org/10.1038/nm.1931			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19234463	Green Accepted			2022-12-27	WOS:000263914000031
J	Wood, K				Wood, Kathryn			Outlook for longer-lasting islets	NATURE MEDICINE			English	Editorial Material							MEMORY T-CELLS; TRANSPLANTATION; HOMEOSTASIS; TOLERANCE		John Radcliffe Hosp, Nuffield Dept Surg, Transplantat Res Immunol Grp, Oxford OX3 9DU, England	University of Oxford	Wood, K (corresponding author), John Radcliffe Hosp, Nuffield Dept Surg, Transplantat Res Immunol Grp, Headley Way, Oxford OX3 9DU, England.	kathryn.wood@nds.ox.ac.uk						Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Huurman VAL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002435; Marleau AM, 2005, J LEUKOCYTE BIOL, V78, P575, DOI 10.1189/jlb.0105050; Monti P, 2008, J CLIN INVEST, V118, P1806, DOI 10.1172/JCI35197; Pearson T, 2003, ANN NY ACAD SCI, V1005, P148, DOI 10.1196/annals.1288.016; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Surh CD, 2006, IMMUNOL REV, V211, P154, DOI 10.1111/j.0105-2896.2006.00401.x; Trzonkowski P, 2006, TRANSPLANTATION, V82, P1342, DOI 10.1097/01.tp.0000239268.64408.84	9	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2008	14	11					1156	1157		10.1038/nm1108-1156	http://dx.doi.org/10.1038/nm1108-1156			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18989281				2022-12-27	WOS:000260751200016
J	Endo, A				Endo, Akira			A gift from nature: the birth of the statins	NATURE MEDICINE			English	Editorial Material							COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; HYPOCHOLESTEROLEMIC ACTIVITY; COMPETITIVE INHIBITOR; ML-236B; HYPERCHOLESTEROLEMIA; DISCOVERY		Biopharm Res Labs Inc, Tokyo 1810013, Japan		Endo, A (corresponding author), Biopharm Res Labs Inc, 3-41-3 501 Shimorenjaku, Tokyo 1810013, Japan.	aerdo@biopharm.co.jp						ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; ENDO A, 1992, J LIPID RES, V33, P1569; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902; Steinberg D, 2006, J LIPID RES, V47, P1339, DOI 10.1194/jlr.R600009-JLR200; TSUJITA Y, 1979, ATHEROSCLEROSIS, V32, P307, DOI 10.1016/0021-9150(79)90174-6; YAMAMOTO A, 1980, ATHEROSCLEROSIS, V35, P259, DOI 10.1016/0021-9150(80)90124-0	9	78	82	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1050	1052		10.1038/nm1008-1050	http://dx.doi.org/10.1038/nm1008-1050			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841147				2022-12-27	WOS:000259892300034
J	Gutterman, JU; Hunt, N				Gutterman, Jordan U.; Hunt, Neen			Three catalytic lives linked by the Lasker Awards FOREWORD	NATURE MEDICINE			English	Editorial Material									[Gutterman, Jordan U.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Gutterman, JU (corresponding author), Univ Texas MD Anderson Canc Ctr, 7435 Fannin St, Houston, TX 77054 USA.	jgutterm@mdanderson.org						ISAACSON W, 2007, EINSTEIN HIS LIFE UN, V9	1	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1033	1035		10.1038/nm1008-1033	http://dx.doi.org/10.1038/nm1008-1033			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841143				2022-12-27	WOS:000259892300030
J	Ruvkun, G				Ruvkun, Gary			The perfect storm of tiny RNAs	NATURE MEDICINE			English	Editorial Material							HETEROCHRONIC GENE LIN-14; CAENORHABDITIS-ELEGANS; C-ELEGANS; REGULATORY RNA; MESSENGER-RNAS; CELL LINEAGES; INTERFERENCE; EXPRESSION; PROTEIN; IDENTIFICATION		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Ruvkun, G (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Fruit St, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu						AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; Blower MD, 2007, J CELL BIOL, V179, P1365, DOI 10.1083/jcb.200705163; Brodersen P, 2008, SCIENCE, V320, P1185, DOI 10.1126/science.1159151; Buhtz A, 2008, PLANT J, V53, P739, DOI 10.1111/j.1365-313X.2007.03368.x; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FISCHER SEJ, NATURE IN PRESS; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Kim JK, 2005, SCIENCE, V308, P1164, DOI 10.1126/science.1109267; Klattenhoff C, 2008, DEVELOPMENT, V135, P3, DOI 10.1242/dev.006486; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Parry DH, 2007, CURR BIOL, V17, P2013, DOI 10.1016/j.cub.2007.10.058; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; RUVKUN G, 1989, GENETICS, V121, P501; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wang D, 2005, NATURE, V436, P593, DOI 10.1038/nature04010; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	47	95	95	1	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1041	1045		10.1038/nm1008-1041	http://dx.doi.org/10.1038/nm1008-1041			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841145				2022-12-27	WOS:000259892300032
J	Ehninger, D; Han, S; Shilyansky, C; Zhou, Y; Li, WD; Kwiatkowski, DJ; Ramesh, V; Silva, AJ				Ehninger, Dan; Han, Sangyeul; Shilyansky, Carrie; Zhou, Yu; Li, Weidong; Kwiatkowski, David J.; Ramesh, Vijaya; Silva, Alcino J.			Reversal of learning deficits in a Tsc2(+/-) mouse model of tuberous sclerosis	NATURE MEDICINE			English	Article							SYNAPTIC PLASTICITY; COGNITIVE DEFICITS; RAT MODEL; FRAGILE-X; COMPLEX; MEMORY; HIPPOCAMPUS; TSC1; TRANSLATION; IDENTIFICATION	Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene(1,2) and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%)(3-5) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits(6,7). Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice)(8) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved(5,9-11). We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.	[Ehninger, Dan; Shilyansky, Carrie; Zhou, Yu; Li, Weidong; Silva, Alcino J.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; [Ehninger, Dan; Shilyansky, Carrie; Zhou, Yu; Li, Weidong; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Ehninger, Dan; Shilyansky, Carrie; Zhou, Yu; Li, Weidong; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Ehninger, Dan; Shilyansky, Carrie; Zhou, Yu; Li, Weidong; Silva, Alcino J.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; [Han, Sangyeul; Ramesh, Vijaya] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Human Genet Res,Richard B Simches Res Ctr, Boston, MA 02114 USA; [Kwiatkowski, David J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Genet Lab,Div Translat Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Silva, AJ (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, 695 Charles E Young Dr S, Los Angeles, CA 90095 USA.	silvaa@mednet.ucla.edu	Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Li, Weidong/0000-0001-5384-4838; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279, R01NS038480] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS038480-06, P01 NS024279, R01 NS038480, P01 NS024279-160011, NS24279, R01-NS38480, R01 NS038480-08] Funding Source: Medline; Autism Speaks [AS1862] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Autism Speaks		Banko JL, 2005, J NEUROSCI, V25, P9581, DOI 10.1523/JNEUROSCI.2423-05.2005; Bear MF, 2008, NEUROPSYCHOPHARMACOL, V33, P84, DOI 10.1038/sj.npp.1301610; Dash PK, 2006, J NEUROSCI, V26, P8048, DOI 10.1523/JNEUROSCI.0671-06.2006; de Vries PJ, 2007, TRENDS MOL MED, V13, P319, DOI 10.1016/j.molmed.2007.06.003; de Vries PJ, 2007, NEW ENGL J MED, V356, P92; Dragatsis I, 2000, GENESIS, V26, P133, DOI 10.1002/(SICI)1526-968X(200002)26:2<133::AID-GENE10>3.0.CO;2-V; Floresco SB, 1997, J NEUROSCI, V17, P1880; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Goorden SMI, 2007, ANN NEUROL, V62, P648, DOI 10.1002/ana.21317; Harrison JE, 1999, AM J MED GENET, V88, P642, DOI 10.1002/(SICI)1096-8628(19991215)88:6<642::AID-AJMG12>3.0.CO;2-O; Jaworski J, 2006, MOL NEUROBIOL, V34, P205, DOI 10.1385/MN:34:3:205; Joinson C, 2003, PSYCHOL MED, V33, P335, DOI 10.1017/S0033291702007092; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Lewis JC, 2004, J MED GENET, V41, P203, DOI 10.1136/jmg.2003.012757; Murthy V, 2001, ACTA NEUROPATHOL, V101, P202; NELLIST M, 1993, CELL, V75, P1305; O'Callaghan FJK, 2004, ARCH DIS CHILD, V89, P530, DOI 10.1136/adc.2003.026815; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Raznahan A, 2007, PSYCHOL MED, V37, P1293, DOI 10.1017/S0033291707000177; Ridler K, 2007, CEREB CORTEX, V17, P261, DOI 10.1093/cercor/bhj144; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; Vanderklish PW, 2005, GENES BRAIN BEHAV, V4, P360, DOI 10.1111/j.1601-183X.2005.00134.x; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; von der Brelie C, 2006, EUR J NEUROSCI, V23, P686, DOI 10.1111/j.1460-9568.2006.04594.x; Waltereit R, 2006, J NEUROCHEM, V96, P407, DOI 10.1111/j.1471-4159.2005.03538.x	30	602	624	2	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2008	14	8					843	848		10.1038/nm1788	http://dx.doi.org/10.1038/nm1788			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18568033	Green Accepted			2022-12-27	WOS:000258237500031
J	Neubert, K; Meister, S; Moser, K; Weisel, F; Maseda, D; Amann, K; Wiethe, C; Winkler, TH; Kalden, JR; Manz, RA; Voll, RE				Neubert, Kirsten; Meister, Silke; Moser, Katrin; Weisel, Florian; Maseda, Damian; Amann, Kerstin; Wiethe, Carsten; Winkler, Thomas H.; Kalden, Joachim R.; Manz, Rudolf A.; Voll, Reinhard E.			The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis	NATURE MEDICINE			English	Article							ENDOPLASMIC-RETICULUM STRESS; BONE-MARROW-TRANSPLANTATION; TRANSCRIPTION FACTOR XBP-1; PANCREATIC-CANCER CELLS; MYELOMA CELLS; B-CELLS; ERYTHEMATOSUS; ANTIBODY; DIFFERENTIATION; ACTIVATION	Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge. In particular, long-lived plasma cells producing autoantibodies resist current therapeutic and experimental approaches. Recently, we showed that the sensitivity of myeloma cells toward proteasome inhibitors directly correlates with their immunoglobulin synthesis rates. Therefore, we hypothesized that normal plasma cells are also hypersensitive to proteasome inhibition owing to their extremely high amount of protein biosynthesis. Here we show that the proteasome inhibitor bortezomib, which is approved for the treatment of multiple myeloma, eliminates both short- and long-lived plasma cells by activation of the terminal unfolded protein response. Treatment with bortezomib depleted plasma cells producing antibodies to double-stranded DNA, eliminated autoantibody production, ameliorated glomerulonephritis and prolonged survival of two mouse strains with lupus-like disease, NZB/W F1 and MRL/lpr mice. Hence, the elimination of autoreactive plasma cells by proteasome inhibitors might represent a new treatment strategy for antibody-mediated diseases.	[Neubert, Kirsten; Meister, Silke; Maseda, Damian; Voll, Reinhard E.] Univ Hosp, Interdisciplinary Ctr Clin Res, Nikolaus Fiebiger Ctr Mol Med, Res Grp N2, D-91054 Erlangen, Germany; [Moser, Katrin; Manz, Rudolf A.] German Arthrit Res Ctr, D-10117 Berlin, Germany; [Weisel, Florian; Winkler, Thomas H.] Univ Erlangen Nurnberg, Dept Biol, Hematopoiesis Unit, D-91054 Erlangen, Germany; [Amann, Kerstin] Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany; [Wiethe, Carsten] Univ Hosp, Dept Dermatol, D-91054 Erlangen, Germany; [Kalden, Joachim R.; Voll, Reinhard E.] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; [Kalden, Joachim R.; Voll, Reinhard E.] Univ Erlangen Nurnberg, Inst Clin Immunol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Voll, RE (corresponding author), Univ Hosp, Interdisciplinary Ctr Clin Res, Nikolaus Fiebiger Ctr Mol Med, Res Grp N2, Gluckstr 6, D-91054 Erlangen, Germany.	rvoll@molmed.uni-erlangen.de	Manz, Rudolf A/C-8340-2011	Maseda, Damian/0000-0003-0722-6881; Frey, Silke/0000-0001-9411-8357				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Ang HA, 1997, BLOOD, V89, P4646, DOI 10.1182/blood.V89.12.4646; Benner R., 1981, IMMUNOLOGICAL METHOD, VII, P247; Cambridge G, 2006, ARTHRITIS RHEUM-US, V54, P3612, DOI 10.1002/art.22211; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; HIBI T, 1986, EUR J IMMUNOL, V16, P139, DOI 10.1002/eji.1830160206; Hideshima Teru, 2003, Rev Clin Exp Hematol, V7, P191; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; KLINMAN DM, 1995, IMMUNOL REV, V144, P157; Leandro MJ, 2002, ARTHRITIS RHEUM-US, V46, P2673, DOI 10.1002/art.10541; Lefkowith JB, 1996, ARTHRITIS RHEUM, V39, P894, DOI 10.1002/art.1780390605; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Manz RA, 2002, EUR J IMMUNOL, V32, P923, DOI 10.1002/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1; Maseda D, 2008, CELL DEATH DIFFER, V15, P600, DOI 10.1038/sj.cdd.4402297; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; MILLER JJ, 1967, J EXP MED, V126, P109, DOI 10.1084/jem.126.1.109; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; Moran ST, 2007, J IMMUNOL, V179, P195, DOI 10.4049/jimmunol.179.1.195; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nencioni A, 2006, BLOOD, V108, P551, DOI 10.1182/blood-2005-08-3494; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Sasaki Y, 2006, IMMUNITY, V24, P729, DOI 10.1016/j.immuni.2006.04.005; Schaumann DHS, 2007, MOL IMMUNOL, V44, P1606, DOI 10.1016/j.molimm.2006.08.021; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P501, DOI 10.1002/art.20858; Slifka MK, 1998, CURR OPIN IMMUNOL, V10, P252, DOI 10.1016/S0952-7915(98)80162-3; Straube C, 2007, LEUKEMIA, V21, P1464, DOI 10.1038/sj.leu.2404734; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; vanTol MJD, 1996, BLOOD, V87, P818, DOI 10.1182/blood.V87.2.818.bloodjournal872818; Wellmann U, 2001, INT IMMUNOL, V13, P1461, DOI 10.1093/intimm/13.12.1461; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WINFIELD JB, 1977, J CLIN INVEST, V59, P90, DOI 10.1172/JCI108626	49	451	476	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					748	755		10.1038/nm1763	http://dx.doi.org/10.1038/nm1763			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18542049				2022-12-27	WOS:000257452700022
J	Cirl, C; Wieser, A; Yadav, M; Duerr, S; Schubert, S; Fischer, H; Stappert, D; Wantia, N; Rodriguez, N; Wagner, H; Svanborg, C; Miethke, T				Cirl, Christine; Wieser, Andreas; Yadav, Manisha; Duerr, Susanne; Schubert, Soeren; Fischer, Hans; Stappert, Dominik; Wantia, Nina; Rodriguez, Nuria; Wagner, Hermann; Svanborg, Catharina; Miethke, Thomas			Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins	NATURE MEDICINE			English	Article							ANTIMICROBIAL DRUG SUSCEPTIBILITY; UROPATHOGENIC ESCHERICHIA-COLI; EFFLUX PUMP INHIBITOR; BRUCELLA-ABORTUS; VIRULENCE FACTOR; VACCINIA VIRUS; URINARY-TRACT; INFECTION; 1-(1-NAPHTHYLMETHYL)-PIPERAZINE; INVASION	Pathogenic microbes have evolved sophisticated molecular strategies to subvert host defenses. Here we show that virulent bacteria interfere directly with Toll- like receptor ( TLR) function by secreting inhibitory homologs of the Toll/ interleukin- 1 receptor ( TIR) domain. Genes encoding TIR domain containing - proteins ( Tcps) were identified in Escherichia coli CFT073 ( TcpC) and Brucella melitensis ( TcpB). We found that TcpC is common in the most virulent uropathogenic E. coli strains and promotes bacterial survival and kidney pathology in vivo. In silico analysis predicted significant tertiary structure homology to the TIR domain of human TLR1, and we show that the Tcps impede TLR signaling through the myeloid differentiation factor 88 ( MyD88) adaptor protein, owing to direct binding of Tcps to MyD88. Tcps represent a new class of virulence factors that act by inhibiting TLR- and MyD88- specific signaling, thus suppressing innate immunity and increasing virulence.	[Cirl, Christine; Duerr, Susanne; Wantia, Nina; Rodriguez, Nuria; Wagner, Hermann; Miethke, Thomas] Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-81675 Munich, Germany; [Wieser, Andreas; Schubert, Soeren] Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; [Yadav, Manisha; Fischer, Hans; Stappert, Dominik; Svanborg, Catharina] Lund Univ, Inst Lab Med, Dept Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden	Technical University of Munich; University of Munich; Lund University	Miethke, T (corresponding author), Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, Trogerstr 30, D-81675 Munich, Germany.	Thomas.Miethke@lrz.tum.de						Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; BEAN MA, 1974, INT J CANCER, V14, P186, DOI 10.1002/ijc.2910140207; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Comerci DJ, 2001, CELL MICROBIOL, V3, P159, DOI 10.1046/j.1462-5822.2001.00102.x; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Delrue RM, 2001, CELL MICROBIOL, V3, P487, DOI 10.1046/j.1462-5822.2001.00131.x; DETILLEUX PG, 1990, INFECT IMMUN, V58, P2320, DOI 10.1128/IAI.58.7.2320-2328.1990; Frendeus B, 2001, MOL MICROBIOL, V40, P37, DOI 10.1046/j.1365-2958.2001.02361.x; Gorvel JP, 2002, VET MICROBIOL, V90, P281, DOI 10.1016/S0378-1135(02)00214-6; HAGBERG L, 1983, INFECT IMMUN, V40, P265, DOI 10.1128/IAI.40.1.265-272.1983; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kern WV, 2006, J ANTIMICROB CHEMOTH, V57, P339, DOI 10.1093/jac/dki445; Lafont F, 2005, CELL MICROBIOL, V7, P613, DOI 10.1111/j.1462-5822.2005.00515.x; Lapaque N, 2005, CURR OPIN MICROBIOL, V8, P60, DOI 10.1016/j.mib.2004.12.003; Newman RM, 2006, INFECT IMMUN, V74, P594, DOI 10.1128/IAI.74.1.594-601.2006; Pannek S, 2006, J ANTIMICROB CHEMOTH, V57, P970, DOI 10.1093/jac/dkl081; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radons JR, 2003, J BIOL CHEM, V278, P49145, DOI 10.1074/jbc.M306077200; Rodriguez N, 2006, EUR J IMMUNOL, V36, P1145, DOI 10.1002/eji.200535152; Samuelsson P, 2004, INFECT IMMUN, V72, P3179, DOI 10.1128/IAI.72.6.3179-3186.2004; Schumacher A, 2006, J ANTIMICROB CHEMOTH, V57, P344, DOI 10.1093/jac/dki446; Sola-Landa A, 1998, MOL MICROBIOL, V29, P125, DOI 10.1046/j.1365-2958.1998.00913.x; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Svanborg C, 2006, CURR OPIN MICROBIOL, V9, P33, DOI 10.1016/j.mib.2005.12.012; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Torres D, 2004, INFECT IMMUN, V72, P2131, DOI 10.1128/IAI.72.4.2131-2139.2004; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799	32	293	315	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					399	406		10.1038/nm1734	http://dx.doi.org/10.1038/nm1734			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18327267				2022-12-27	WOS:000254674100026
J	Kosaka, H; Yoshimoto, T; Yoshimoto, T; Fujimoto, J; Nakanishi, K				Kosaka, Hisashi; Yoshimoto, Tomohiro; Yoshimoto, Takayuki; Fujimoto, Jiro; Nakanishi, Kenji			Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; V-ALPHA-14 NKT CELLS; NEUROKININ-1 RECEPTOR; MICE; FIBRINOLYSIS; PERITONEUM; DISEASE; SURGERY; CLONING; GENE	Intestinal adhesions are bands of fibrous tissue that connect the loops of the intestine to each other, to other abdominal organs or to the abdominal wall(1-3). Fibrous tissue formation is regulated by the balance between plasminogen activator inhibitor type 1 ( PAI- 1) and tissue- type plasminogen activator ( tPA), which reciprocally regulate fibrin deposition. Several components of the inflammatory system, including cytokines(4), chemokines, cell adhesion molecules and neuropeptide substance P, have been reported to participate in adhesion formation(4-7). We have used cecal cauterization to develop a unique experimental mouse model of intestinal adhesion. Mice developed severe intestinal adhesion after this treatment. Adhesion development depended upon the interferon-gamma ( IFN-gamma) and signal transducer and activator of transcription- 1 ( STAT1) system. Natural killer T ( NKT) cell - deficient mice developed adhesion poorly, whereas they developed severe adhesion after reconstitution with NKT cells from wild- type mice, suggesting that NKT cell IFN-gamma production is indispensable for adhesion formation. This response does not depend on STAT4, STAT6, interleukin- 12 ( IL- 12), IL- 18, tumor necrosis factor-alpha, Toll- like receptor 4 or myeloid differentiation factor- 88 - mediated signals. Wild- type mice increased the ratio of PAI- 1 to tPA after cecal cauterization, whereas Ifng(-/-) or Stat1(-/-) mice did not, suggesting that IFN-gamma has a crucial role in the differential regulation of PAI- 1 and tPA. Additionally, hepatocyte growth factor, a potent mitogenic factor for hepatocytes(8,9), strongly inhibited intestinal adhesion by diminishing IFN-gamma production, providing a potential new way to prevent postoperative adhesions.	[Yoshimoto, Tomohiro; Nakanishi, Kenji] Hyogo Coll Med, Dept Immunol & Med Zool, Nishinomiya, Hyogo 6638501, Japan; [Kosaka, Hisashi; Fujimoto, Jiro] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo 6638501, Japan; [Yoshimoto, Tomohiro; Nakanishi, Kenji] Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; [Yoshimoto, Takayuki] Tokyo Med Univ, Intractable Immune Syst Dis Res Ctr, Tokyo 1608402, Japan	Hyogo College of Medicine; Hyogo College of Medicine; Japan Science & Technology Agency (JST); Tokyo Medical University	Nakanishi, K (corresponding author), Hyogo Coll Med, Dept Immunol & Med Zool, 1-1 Mukogawa, Nishinomiya, Hyogo 6638501, Japan.	nakaken@hyo-med.ac.jp	Yoshimoto, Tomohiro/E-2224-2014; Yoshimoto, Takayuki/AAN-7995-2020	Yoshimoto, Takayuki/0000-0002-2847-0341				Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Chung DR, 2002, J EXP MED, V195, P1471, DOI 10.1084/jem.20020028; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Ellis H, 1997, EUR J SURG, V163, P5; Ellis H, 1999, LANCET, V353, P1476, DOI 10.1016/S0140-6736(98)09337-4; FANCIULLACCI M, 1993, EXPERIENTIA, V49, P242, DOI 10.1007/BF01923533; Ghellai AM, 2000, J GASTROINTEST SURG, V4, P316, DOI 10.1016/S1091-255X(00)80082-7; Holmdahl L, 1996, SURGERY, V119, P701, DOI 10.1016/S0039-6060(96)80196-6; Holmdahl L, 1997, EUR J SURG, V163, P24; Ido A, 2005, J GASTROENTEROL, V40, P925, DOI 10.1007/s00535-005-1705-x; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Katayama I, 1997, J DERMATOL SCI, V15, P201, DOI 10.1016/S0923-1811(97)00608-7; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Kennedy R, 1996, SURGERY, V120, P866, DOI 10.1016/S0039-6060(96)80096-1; Kocak I, 1999, FERTIL STERIL, V72, P873, DOI 10.1016/S0015-0282(99)00368-4; Kuroiwa T, 2001, J CLIN INVEST, V107, P1365, DOI 10.1172/JCI11808; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Parker M C, 2004, Colorectal Dis, V6, P506, DOI 10.1111/j.1463-1318.2004.00709.x; RAFTERY AT, 1979, J ANAT, V129, P659; Reed KL, 2004, P NATL ACAD SCI USA, V101, P9115, DOI 10.1073/pnas.0403210101; Reed KL, 2002, J SURG RES, V108, P165, DOI 10.1006/jsre.2002.6533; Sulaiman H, 2002, BIOCHEM SOC T, V30, P126, DOI 10.1042/BST0300126; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Tjarnstrom J, 1999, EUR J SURG, V165, P834; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	30	80	86	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2008	14	4					437	441		10.1038/nm1733	http://dx.doi.org/10.1038/nm1733			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18345012				2022-12-27	WOS:000254674100031
J	Zheng, Y; Valdez, PA; Danilenko, DM; Hu, Y; Sa, SM; Gong, Q; Abbas, AR; Modrusan, Z; Ghilardi, N; de Sauvage, FJ; Ouyang, W				Zheng, Yan; Valdez, Patricia A.; Danilenko, Dimitry M.; Hu, Yan; Sa, Susan M.; Gong, Qian; Abbas, Alexander R.; Modrusan, Zora; Ghilardi, Nico; de Sauvage, Frederic J.; Ouyang, Wenjun			Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens	NATURE MEDICINE			English	Article							INFLAMMATORY-BOWEL-DISEASE; CITROBACTER-RODENTIUM; CUTTING EDGE; EXPRESSION; IL-22; CELLS; GENE; LYMPHOCYTES; RESPONSES; CYTOKINE	Infections by attaching and effacing (A/E) bacterial pathogens, such as Escherichia coli O157:H7, pose a serious threat to public health. Using a mouse A/E pathogen, Citrobacter rodentium, we show that interleukin-22 (IL-22) has a crucial role in the early phase of host defense against C. rodentium. Infection of IL-22 knockout mice results in increased intestinal epithelial damage, systemic bacterial burden and mortality. We also find that IL-23 is required for the early induction of IL-22 during C. rodentium infection, and adaptive immunity is not essential for the protective role of IL-22 in this model. Instead, IL-22 is required for the direct induction of the Reg family of antimicrobial proteins, including RegIII beta and RegIII gamma, in colonic epithelial cells. Exogenous mouse or human RegIII gamma substantially improves survival of IL-22 knockout mice after C. rodentium infection. Together, our data identify a new innate immune function for IL-22 in regulating early defense mechanisms against A/E bacterial pathogens.	[Zheng, Yan; Valdez, Patricia A.; Hu, Yan; Gong, Qian; Ouyang, Wenjun] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; [Danilenko, Dimitry M.; Sa, Susan M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Abbas, Alexander R.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; [Modrusan, Zora; Ghilardi, Nico; de Sauvage, Frederic J.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ouyang, W (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way, San Francisco, CA 94080 USA.	ouyang.wenjun@gene.com	Zheng, Yan/A-6993-2008; Ouyang, Wenjun/ABA-8763-2020; de Sauvage, Frederic/ABE-8400-2020	Zheng, Yan/0000-0002-7002-277X; de Sauvage, Frederic/0000-0002-5275-2584; Ouyang, Wenjun/0000-0002-1811-5864; Hu, Yan Helen/0000-0003-3269-4505; Danilenko, Dimitry/0000-0002-8326-1921; Ghilardi, Nico/0000-0003-4945-3097				Andoh A, 2005, GASTROENTEROLOGY, V129, P969, DOI 10.1053/j.gastro.2005.06.071; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Bry L, 2004, J IMMUNOL, V172, P433, DOI 10.4049/jimmunol.172.1.433; CAMERINI V, 1993, J IMMUNOL, V151, P1765; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1045; Eckmann L, 2006, ANN NY ACAD SCI, V1072, P28, DOI 10.1196/annals.1326.008; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; Ghilardi N, 2004, J IMMUNOL, V172, P2827, DOI 10.4049/jimmunol.172.5.2827; Goncalves NS, 2001, INFECT IMMUN, V69, P6651, DOI 10.1128/IAI.69.11.6651-6659.2001; Gurney AL, 2004, INT IMMUNOPHARMACOL, V4, P669, DOI 10.1016/j.intimp.2004.01.016; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Keilbaugh SA, 2005, GUT, V54, P623, DOI 10.1136/gut.2004.056028; Kuestner RE, 2007, J IMMUNOL, V179, P5462, DOI 10.4049/jimmunol.179.8.5462; Levillayer F, 2007, GENETICS, V176, P1835, DOI 10.1534/genetics.107.073536; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Maaser C, 2004, INFECT IMMUN, V72, P3315, DOI 10.1128/IAI.72.6.3315-3324.2004; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; Misse D, 2007, J IMMUNOL, V178, P407, DOI 10.4049/jimmunol.178.1.407; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P577, DOI 10.1016/j.intimp.2004.01.007; Ogawa H, 2000, AM J PHYSIOL-GASTR L, V279, pG492, DOI 10.1152/ajpgi.2000.279.3.G492; Ogawa H, 2003, INFLAMM BOWEL DIS, V9, P162, DOI 10.1097/00054725-200305000-00003; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; SCHAUER DB, 1993, INFECT IMMUN, V61, P2486, DOI 10.1128/IAI.61.6.2486-2492.1993; Simmons CP, 2002, J IMMUNOL, V168, P1804, DOI 10.4049/jimmunol.168.4.1804; Takahashi A, 2001, FEBS LETT, V508, P484, DOI 10.1016/S0014-5793(01)03088-5; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Vallance BA, 2002, INFECT IMMUN, V70, P2070, DOI 10.1128/IAI.70.4.2070-2081.2002; Weber GF, 2007, INFECT IMMUN, V75, P1690, DOI 10.1128/IAI.01564-06; Witowski J, 2004, CELL MOL LIFE SCI, V61, P567, DOI 10.1007/s00018-003-3228-z; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; World Health Organization, 2004, WORLD HLTH REP 2004; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	44	1391	1460	4	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2008	14	3					282	289		10.1038/nm1720	http://dx.doi.org/10.1038/nm1720			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18264109				2022-12-27	WOS:000253815700034
J	Sackstein, R; Merzaban, JS; Cain, DW; Dagia, NM; Spencer, JA; Lin, CP; Wohlgemuth, R				Sackstein, Robert; Merzaban, Jasmeen S.; Cain, Derek W.; Dagia, Nilesh M.; Spencer, Joel A.; Lin, Charles P.; Wohlgemuth, Roland			Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone	NATURE MEDICINE			English	Article							L-SELECTIN LIGAND; STEM-CELLS; ADHESION MOLECULE-1; P-SELECTIN; EXPRESSION; BINDING; FUCOSYLATION; DISTINCT; MN2+	The capacity to direct migration ('homing') of blood-borne cells to a predetermined anatomic compartment is vital to stem cell based tissue engineering and other adoptive cellular therapies. Although multipotent mesenchymal stromal cells (MSCs, also termed 'mesenchymal stem cells') hold the potential for curing generalized skeletal diseases, their clinical effectiveness is constrained by the poor osteotropism of infused MSCs (refs. 1-3). Cellular recruitment to bone occurs within specialized marrow vessels that constitutively express vascular E-selectin(4,5), a lectin that recognizes sialofucosylated determinants on its various ligands. We show here that human MSCs do not express E-selectin ligands, but express a CD44 glycoform bearing alpha-2,3-sialyl modifications. Using an alpha-1,3-fucosyltransferase preparation and enzymatic conditions specifically designed for treating live cells, we converted the native CD44 glycoform on MSCs into hematopoietic cell E-selectin/L-selectin ligand (HCELL)(6), which conferred potent E-selectin binding without effects on cell viability or multipotency. Real-time intravital microscopy in immunocompromised (NOD/SCID) mice showed that intravenously infused HCELL+ MSCs infiltrated marrow within hours of infusion, with ensuing rare foci of endosteally localized cells and human osteoid generation. These findings establish that the HCELL glycoform of CD44 confers tropism to bone and unveil a readily translatable roadmap for programming cellular trafficking by chemical engineering of glycans on a distinct membrane glycoprotein.	[Sackstein, Robert; Merzaban, Jasmeen S.; Cain, Derek W.; Dagia, Nilesh M.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; [Sackstein, Robert; Merzaban, Jasmeen S.; Cain, Derek W.; Dagia, Nilesh M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Sackstein, Robert; Merzaban, Jasmeen S.; Cain, Derek W.; Dagia, Nilesh M.] Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; [Sackstein, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Spencer, Joel A.; Lin, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Wohlgemuth, Roland] Sigma Aldrich, CH-9470 Buchs, Switzerland	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital	Sackstein, R (corresponding author), Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu	Wohlgemuth, Roland/A-6340-2016; Spencer, Joel/GLT-9687-2022; Spencer, Joel/A-4590-2013; Merzaban, Jasmeen/V-3147-2018	Wohlgemuth, Roland/0000-0001-6166-3228; Spencer, Joel/0000-0002-4013-8763; Merzaban, Jasmeen/0000-0002-7276-2907	NHLBI NIH HHS [R01 HL60528, R01 HL73714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060528, R01HL073714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; Hidalgo A, 2005, BLOOD, V105, P567, DOI 10.1182/blood-2004-03-1026; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; JIN XF, 2004, EXP HEMATOL, V32, P1204; Kobzdej MMA, 2002, BLOOD, V100, P4485, DOI 10.1182/blood-2002-06-1799; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mauney JR, 2005, TISSUE ENG, V11, P787, DOI 10.1089/ten.2005.11.787; Mazo IB, 2002, BLOOD, V99, P4182, DOI 10.1182/blood.V99.11.4182; Mocco J, 2002, CIRC RES, V91, P907, DOI 10.1161/01.RES.0000042063.15901.20; Mohler W, 2003, METHODS, V29, P97, DOI 10.1016/S1046-2023(02)00292-X; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Sackstein R, 2000, BLOOD, V96, P2765, DOI 10.1182/blood.V96.8.2765.h8002765_2765_2774; Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79; Schrantz N, 1999, CELL DEATH DIFFER, V6, P445, DOI 10.1038/sj.cdd.4400508; Schweitzer KM, 1996, AM J PATHOL, V148, P165; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Takamatsu Y, 1998, CELL ADHES COMMUN, V5, P349, DOI 10.3109/15419069809010781; Xia LJ, 2004, BLOOD, V104, P3091, DOI 10.1182/blood-2004-02-0650; Yao LB, 1999, BLOOD, V94, P3820, DOI 10.1182/blood.V94.11.3820	30	438	470	1	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					181	187		10.1038/nm1703	http://dx.doi.org/10.1038/nm1703			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18193058				2022-12-27	WOS:000252946700027
J	Friese, MA; Craner, MJ; Etzensperger, R; Vergo, S; AWemmie, J; Welsh, MJ; Vincent, A; Fugger, L				Friese, Manuel A.; Craner, Matthew J.; Etzensperger, Ruth; Vergo, Sandra; AWemmie, John; Welsh, Michael J.; Vincent, Angela; Fugger, Lars			Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system	NATURE MEDICINE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; MOLECULAR-CHANGES; WHITE-MATTER; SPINAL-CORD; INJURY; MECHANISMS; CALCIUM; NEURONS; LESIONS	Multiple sclerosis is a neuroinflammatory disease associated with axonal degeneration(1,2). The neuronally expressed, protongated acid-sensing ion channel-1 (ASIC1)(3,4) is permeable to Na+ and Ca2+, and excessive accumulation of these ions is associated with axonal degeneration(5). We tested the hypothesis that ASIC1 contributes to axonal degeneration in inflammatory lesions of the central nervous system (CNS). After induction of experimental autoimmune encephalomyelitis (EAE), Asic1(-/-) mice showed both a markedly reduced clinical deficit and reduced axonal degeneration compared to wild-type mice. Consistently with acidosis-mediated injury, pH measurements in the spinal cord of EAE mice showed tissue acidosis sufficient to open ASIC1. The acidosis-related protective effect of Asic1 disruption was also observed in nerve explants in vitro. Amiloride, a licensed and clinically safe blocker of ASICs, was equally neuroprotective in nerve explants and in EAE. Although ASICs are also expressed by immune cells, this expression is unlikely to explain the neuroprotective effect of Asic1 inactivation, as CNS inflammation was similar in wild-type and Asic1(-/-) mice. In addition, adoptive transfer of T cells from wild-type mice did not affect the protection mediated by Asic1 disruption. These results suggest that ASIC1 blockers could provide neuroprotection in multiple sclerosis.	Univ Oxford, John Radcliffe Hosp, Dept Clin Neurol, Med Res Council Human Immunol Unit, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England; Univ Iowa, Vet Affairs Hosp, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Aarhus Univ Hosp, Inst Clin, DK-8200 Aarhus, Denmark	University of Oxford; University of Oxford; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Howard Hughes Medical Institute; University of Iowa; Aarhus University	Fugger, L (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Clin Neurol, Med Res Council Human Immunol Unit, Oxford OX3 9DS, England.	lars.fugger@imm.ox.ac.uk	Vincent, Angela/AAE-7310-2019	Friese, Manuel A./0000-0001-6380-2420; Welsh, Michael/0000-0002-1646-6206; Wemmie, John/0000-0001-7531-9065	MRC [MC_U137881016] Funding Source: UKRI; Medical Research Council [MC_U137881016] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aboul-Enein F, 2003, J NEUROPATH EXP NEUR, V62, P25, DOI 10.1093/jnen/62.1.25; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Beeton C, 2006, P NATL ACAD SCI USA, V103, P17414, DOI 10.1073/pnas.0605136103; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Craner MJ, 2004, BRAIN, V127, P294, DOI 10.1093/brain/awh032; Craner MJ, 2003, J NEUROPATH EXP NEUR, V62, P968, DOI 10.1093/jnen/62.9.968; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Graumann U, 2003, BRAIN PATHOL, V13, P554, DOI 10.1111/j.1750-3639.2003.tb00485.x; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Lassmann H, 2007, J NEUROL SCI, V259, P3, DOI 10.1016/j.jns.2006.08.016; Lovas G, 2000, BRAIN, V123, P308, DOI 10.1093/brain/123.2.308; Mamet J, 2002, J NEUROSCI, V22, P10662; Steinman L, 2006, ANN NEUROL, V60, P12, DOI 10.1002/ana.20913; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Stys PK, 1998, NEUROSCIENCE, V82, P21; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waxman SG, 2006, TRENDS MOL MED, V12, P192, DOI 10.1016/j.molmed.2006.03.001; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Zha XM, 2006, P NATL ACAD SCI USA, V103, P16556, DOI 10.1073/pnas.0608018103	30	304	318	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1483	1489		10.1038/nm1668	http://dx.doi.org/10.1038/nm1668			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	17994101				2022-12-27	WOS:000251445400023
J	Muraski, JA; Rota, M; Misao, Y; Fransioli, J; Cottage, C; Gude, N; Esposito, G; Delucchi, F; Arcarese, M; Alvarez, R; Siddiqi, S; Emmanuel, GN; Wu, W; Fischer, K; Martindale, JJ; Glembotski, CC; Leri, A; Kajstura, J; Magnuson, N; Berns, A; Beretta, RM; Houser, SR; Schaefer, EM; Anversa, P; Sussman, MA				Muraski, John A.; Rota, Marcello; Misao, Yu; Fransioli, Jenna; Cottage, Christopher; Gude, Natalie; Esposito, Grazia; Delucchi, Francesca; Arcarese, Michael; Alvarez, Roberto; Siddiqi, Sailay; Emmanuel, Gregory N.; Wu, Weitao; Fischer, Kimberlee; Martindale, Joshua J.; Glembotski, Christopher C.; Leri, Annarosa; Kajstura, Jan; Magnuson, Nancy; Berns, Anton; Beretta, Remus M.; Houser, Steven R.; Schaefer, Erik M.; Anversa, Piero; Sussman, Mark A.			Pim-1 regulates cardiomyocyte survival downstream of Akt	NATURE MEDICINE			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; HEART-FAILURE; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; CELL; NUCLEAR; MICE; OVEREXPRESSION; TRANSCRIPTION	The serine-threonine kinases Pim-1 and Akt regulate cellular proliferation and survival. Although Akt is known to be a crucial signaling protein in the myocardium, the role of Pim-1 has been overlooked. Pim-1 expression in the myocardium of mice decreased during postnatal development, re-emerged after acute pathological injury in mice and was increased in failing hearts of both mice and humans. Cardioprotective stimuli associated with Akt activation induced Pim-1 expression, but compensatory increases in Akt abundance and phosphorylation after pathological injury by infarction or pressure overload did not protect the myocardium in Pim-1-deficient mice. Transgenic expression of Pim-1 in the myocardium protected mice from infarction injury, and Pim-1 expression inhibited cardiomyocyte apoptosis with concomitant increases in Bcl-2 and Bcl-X-L protein levels, as well as in Bad phosphorylation levels. Relative to nontransgenic controls, calcium dynamics were significantly enhanced in Pim-1-overexpressing transgenic hearts, associated with increased expression of SERCA2a, and were depressed in Pim-1-deficient hearts. Collectively, these data suggest that Pim-1 is a crucial facet of cardioprotection downstream of Akt.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; New York Med Coll, Cardiovasc Res Inst, Valhalla, NY 10595 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Temple Univ, Sch Med, Cardiovasc Res Inst, Philadelphia, PA 19140 USA; Invitrogen Corp, Hopkinton, MA 01748 USA	California State University System; San Diego State University; New York Medical College; Washington State University; Netherlands Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Thermo Fisher Scientific	Sussman, MA (corresponding author), San Diego State Univ, Inst Heart, 5500 Campanile Dr, San Diego, CA 92182 USA.	sussman@heart.sdsu.edu	Sussman, Mark/H-2284-2014	Sussman, Mark/0000-0002-0104-4799	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067245, P01HL085577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG023071] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R01HL067245, 1R01HL091102, 1P01HL085577] Funding Source: Medline; NIA NIH HHS [1P01AG023071] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; del Monte F, 2004, P NATL ACAD SCI USA, V101, P5622, DOI 10.1073/pnas.0305778101; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Dupays L, 2005, J MOL CELL CARDIOL, V38, P787, DOI 10.1016/j.yjmcc.2005.02.021; Eiken HG, 2001, EUR J CLIN INVEST, V31, P389, DOI 10.1046/j.1365-2362.2001.00795.x; Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-4; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Gude N, 2006, CIRC RES, V99, P381, DOI 10.1161/01.RES.0000236754.21499.1c; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Hoefnagel JJ, 2005, BLOOD, V105, P3671, DOI 10.1182/blood-2004-04-1594; Ionov Y, 2003, ANTICANCER RES, V23, P167; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jacobs MD, 2005, J BIOL CHEM, V280, P13728, DOI 10.1074/jbc.M413155200; Katakami N, 2004, J BIOL CHEM, V279, P54742, DOI 10.1074/jbc.M409140200; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Kim YK, 2003, J BIOL CHEM, V278, P47622, DOI 10.1074/jbc.M305909200; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Krishnan N, 2003, ENDOCRINE, V20, P123, DOI 10.1385/ENDO:20:1-2:123; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Krumenacker JS, 2001, J NEUROIMMUNOL, V113, P249, DOI 10.1016/S0165-5728(00)00430-6; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Palaty CK, 1997, J BIOL CHEM, V272, P10514; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Phoon CKL, 2004, CIRC RES, V95, P92, DOI 10.1161/01.RES.0000133681.99617.28; Poolman RA, 1998, INT J CARDIOL, V67, P133, DOI 10.1016/S0167-5273(98)00320-9; Prasad AM, 2007, AM J PHYSIOL-CELL PH, V292, pC2269, DOI 10.1152/ajpcell.00441.2006; Rahman Z, 2001, IMMUNOL LETT, V75, P199, DOI 10.1016/S0165-2478(00)00322-9; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Sakata S, 2007, J MOL CELL CARDIOL, V42, P852, DOI 10.1016/j.yjmcc.2007.01.003; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Suarez J, 2004, AM J PHYSIOL-HEART C, V287, pH2164, DOI 10.1152/ajpheart.00428.2004; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Takizawa T, 1999, J MOL CELL CARDIOL, V31, P2167, DOI 10.1006/jmcc.1999.1045; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Tsujita Y, 2006, P NATL ACAD SCI USA, V103, P11946, DOI 10.1073/pnas.0510138103; Wang Z, 2001, J Vet Sci, V2, P167; Wingett D, 1996, J IMMUNOL, V156, P549; Zhu N, 2002, J IMMUNOL, V168, P744, DOI 10.4049/jimmunol.168.2.744	50	192	203	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2007	13	12					1467	1475		10.1038/nm1671	http://dx.doi.org/10.1038/nm1671			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18037896				2022-12-27	WOS:000251445400021
J	Erion, DM; Shulman, GI				Erion, Derek M.; Shulman, Gerald I.			Diacylglycerol-mediated insulin resistance	NATURE MEDICINE			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; INDUCED HEPATIC STEATOSIS; MUSCLE GLYCOGEN-SYNTHESIS; A-ZIP/F-1 FATLESS MICE; FATTY LIVER-DISEASE; SKELETAL-MUSCLE; DIABETES-MELLITUS; GLUCOSE-TRANSPORT; KNOCKOUT MICE	Understanding the molecular mechanisms of insulin resistance remains a major medical challenge of the twenty-first century. Over the last half-century, many hypotheses have been proposed to explain insulin resistance, and, most recently, inflammation associated with alterations in adipocytokines has become the prevailing hypothesis. Here we discuss diacylglycerol-mediated insulin resistance as an alternative and unifying hypothesis to explain the most common forms of insulin resistance associated with obesity and type 2 diabetes mellitus, as well as lipodystrophy and aging.	[Erion, Derek M.; Shulman, Gerald I.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Internal Med, New Haven, CT 06520 USA; [Erion, Derek M.; Shulman, Gerald I.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, New Haven, CT USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Erion, DM (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Internal Med, New Haven, CT 06520 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, R01DK040936, U24DK059635] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, P30 DK034989, U24 DK059635] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Befroy DE, 2007, DIABETES, V56, P1376, DOI 10.2337/db06-0783; Belfort R, 2006, NEW ENGL J MED, V355, P2297, DOI 10.1056/NEJMoa060326; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Chibalin AV, 2008, CELL, V132, P375, DOI 10.1016/j.cell.2007.12.035; Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104; Choi CS, 2007, J CLIN INVEST, V117, P1995, DOI 10.1172/JCI13579; Choi CS, 2007, J BIOL CHEM, V282, P22678, DOI 10.1074/jbc.M704213200; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hoehn KL, 2010, CELL METAB, V11, P70, DOI 10.1016/j.cmet.2009.11.008; Hotamisligil GS, 2008, INT J OBESITY, V32, pS52, DOI 10.1038/ijo.2008.238; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; Liu L, 2007, J CLIN INVEST, V117, P1679, DOI 10.1172/JCI30565; Luzi L, 2003, AM J PHYSIOL-ENDOC M, V284, pE274, DOI 10.1152/ajpendo.00391.2001; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151; Nagai Y, 2009, CELL METAB, V9, P252, DOI 10.1016/j.cmet.2009.01.011; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neschen S, 2007, DIABETES, V56, P1034, DOI 10.2337/db06-1206; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; Pedersen BK, 2007, J APPL PHYSIOL, V102, P814, DOI 10.1152/japplphysiol.01208.2006; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Petersen KF, 2010, NEW ENGL J MED, V362, P1082, DOI 10.1056/NEJMoa0907295; RANDLE PJ, 1965, ANN NY ACAD SCI, V131, P324, DOI 10.1111/j.1749-6632.1965.tb34800.x; RANDLE PJ, 1963, LANCET, V1, P785; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; Taubes G, 2009, SCIENCE, V325, P256, DOI 10.1126/science.325_256; Weigert C, 2007, J APPL PHYSIOL, V102, P820, DOI 10.1152/japplphysiol.01353.2006; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss R, 2003, LANCET, V362, P951, DOI 10.1016/S0140-6736(03)14364-4; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YALOW RS, 1960, J CLIN INVEST, V39, P1157, DOI 10.1172/JCI104130; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang DY, 2007, P NATL ACAD SCI USA, V104, P17075, DOI 10.1073/pnas.0707060104	57	322	336	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					400	402		10.1038/nm0410-400	http://dx.doi.org/10.1038/nm0410-400			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376053	Green Accepted			2022-12-27	WOS:000276446800042
J	Mullard, A				Mullard, Asher			The anticounterfeiter's technological tool kit	NATURE MEDICINE			English	News Item																			0	23	23	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					361	361		10.1038/nm0410-361a	http://dx.doi.org/10.1038/nm0410-361a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376027	Bronze			2022-12-27	WOS:000276446800018
J	Stowell, SR; Arthur, CM; Dias-Baruffi, M; Rodrigues, LC; Gourdine, JP; Heimburg-Molinaro, J; Ju, TZ; Molinaro, RJ; Rivera-Marrero, C; Xia, BY; Smith, DF; Cummings, RD				Stowell, Sean R.; Arthur, Connie M.; Dias-Baruffi, Marcelo; Rodrigues, Lilian C.; Gourdine, Jean-Philippe; Heimburg-Molinaro, Jamie; Ju, Tongzhong; Molinaro, Ross J.; Rivera-Marrero, Carlos; Xia, Baoyun; Smith, David F.; Cummings, Richard D.			Innate immune lectins kill bacteria expressing blood group antigen	NATURE MEDICINE			English	Article							HUMAN COLON ECOSYSTEMS; ENTERIC BACTERIA; GENE-CLUSTER; GALECTIN-8; RECOGNITION; DEGRADATION	The expression of ABO(H) blood group antigens causes deletion of cells that generate self-specific antibodies to these antigens but this deletion limits adaptive immunity toward pathogens bearing cognate blood group antigens. To explore potential defense mechanisms against such pathogens, given these limitations in adaptive immunity, we screened for innate proteins that could recognize human blood group antigens. Here we report that two innate immune lectins, galectin-4 (Gal-4) and Gal-8, which are expressed in the intestinal tract, recognize and kill human blood group antigen-expressing Escherichia coli while failing to alter the viability of other E. coli strains or other Gram-negative or Gram-positive organisms both in vitro and in vivo. The killing activity of both Gal-4 and Gal-8 is mediated by their C-terminal domains, occurs rapidly and independently of complement and is accompanied by disruption of membrane integrity. These results demonstrate that innate defense lectins can provide immunity against pathogens that express blood group-like antigens on their surface.	[Stowell, Sean R.; Arthur, Connie M.; Gourdine, Jean-Philippe; Heimburg-Molinaro, Jamie; Ju, Tongzhong; Rivera-Marrero, Carlos; Xia, Baoyun; Smith, David F.; Cummings, Richard D.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; [Dias-Baruffi, Marcelo; Rodrigues, Lilian C.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Sao Paulo, Brazil; [Molinaro, Ross J.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University; Universidade de Sao Paulo; Emory University	Cummings, RD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	rdcummi@emory.edu	Gourdine, Jean-Philippe/P-4323-2018; Gourdine, Jean-Philippe F/E-3739-2012; Baruffi, Marcelo D/I-7199-2015; Terra, Lilian Cataldi Rodrigues/GYV-2597-2022	Gourdine, Jean-Philippe/0000-0001-9969-8610; Gourdine, Jean-Philippe F/0000-0001-9969-8610; Baruffi, Marcelo D/0000-0002-2039-1884; Terra, Lilian Cataldi Rodrigues/0000-0002-2014-2263; Ju, Tongzhong/0000-0002-4429-1976	US National Institutes of Health [HL085607, GM085448]; Consortium for Functional Glycomics; US National Institute of General Medical Sciences/US National of Institutes of Health [GM62116]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL085607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R01GM085448] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Consortium for Functional Glycomics; US National Institute of General Medical Sciences/US National of Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. Cummings and M. Willard for technical assistance. We also thank P. G. Wang (Ohio State University) for providing the original E. coli O86:B7 strain, as well as the a-Gal bacteria mutant versions of this strain lacking expression of either the wzy or waaL genes. We obtained P. aeruginosa strain 8830 from A. Chakrabaty (University of Illinois College of Medicine) and plasmid pSMC21 encoding GFP from G. O'Toole (Dartmouth Medical School). We also thank the staff at the Robert P. Apkarian Integrated Electron Microscopy Core Facility at Emory University for their help with electron microscopy. This work was supported by grants from the US National Institutes of Health to R. D. C. (HL085607) and D. F. S. (GM085448) and by resources from the Consortium for Functional Glycomics (Core D and Core H), funded by the US National Institute of General Medical Sciences/US National of Institutes of Health (GM62116).	Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Garratty G, 2000, TRANSFUS MED REV, V14, P291, DOI 10.1053/tmrv.2000.16228; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Guo HJ, 2005, APPL ENVIRON MICROB, V71, P7995, DOI 10.1128/AEM.71.12.7995-8001.2005; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hansson G C, 1988, Adv Exp Med Biol, V228, P465; HOSKINS LC, 1976, J CLIN INVEST, V57, P74, DOI 10.1172/JCI108271; HOSKINS LC, 1976, J CLIN INVEST, V57, P63, DOI 10.1172/JCI108270; Houzelstein D, 2004, MOL BIOL EVOL, V21, P1177, DOI 10.1093/molbev/msh082; Huflejt ME, 2003, GLYCOCONJUGATE J, V20, P247, DOI 10.1023/B:GLYC.0000025819.54723.a0; Kohatsu L, 2006, J IMMUNOL, V177, P4718, DOI 10.4049/jimmunol.177.7.4718; LARSON G, 1987, FEBS LETT, V214, P41, DOI 10.1016/0014-5793(87)80009-1; Linden S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040002; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; REEVES P, 1995, TRENDS MICROBIOL, V3, P381, DOI 10.1016/S0966-842X(00)88983-0; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; Rowe JA, 2007, P NATL ACAD SCI USA, V104, P17471, DOI 10.1073/pnas.0705390104; Sebban LE, 2007, J IMMUNOL, V179, P1225, DOI 10.4049/jimmunol.179.2.1225; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; SPRINGER GF, 1961, J EXP MED, V113, P1077, DOI 10.1084/jem.113.6.1077; Stowell SR, 2008, J BIOL CHEM, V283, P20547, DOI 10.1074/jbc.M802495200; Stowell SR, 2008, J BIOL CHEM, V283, P10109, DOI 10.1074/jbc.M709545200; Stowell SR, 2009, MOL BIOL CELL, V20, P1408, DOI 10.1091/mbc.E08-07-0786; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203; Vasta GR, 2009, NAT REV MICROBIOL, V7, P424, DOI 10.1038/nrmicro2146; Wooters MA, 2005, J HISTOCHEM CYTOCHEM, V53, P197, DOI 10.1369/jhc.4A6439.2005; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Yi W, 2005, J AM CHEM SOC, V127, P2040, DOI 10.1021/ja045021y	31	208	212	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					295	U90		10.1038/nm.2103	http://dx.doi.org/10.1038/nm.2103			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20154696	Green Accepted			2022-12-27	WOS:000275289500034
J	Lefevre, S; Knedla, A; Tennie, C; Kampmann, A; Wunrau, C; Dinser, R; Korb, A; Schnaker, EM; Tarner, IH; Robbins, PD; Evans, CH; Sturz, H; Steinmeyer, J; Gay, S; Scholmerich, J; Pap, T; Muller-Ladner, U; Neumann, E				Lefevre, Stephanie; Knedla, Anette; Tennie, Christoph; Kampmann, Andreas; Wunrau, Christina; Dinser, Robert; Korb, Adelheid; Schnaeker, Eva-Maria; Tarner, Ingo H.; Robbins, Paul D.; Evans, Christopher H.; Stuerz, Henning; Steinmeyer, Juergen; Gay, Steffen; Schoelmerich, Juergen; Pap, Thomas; Mueller-Ladner, Ulf; Neumann, Elena			Synovial fibroblasts spread rheumatoid arthritis to unaffected joints	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELL ADHESION; GENE-TRANSFER; IN-VITRO; CARTILAGE; MIGRATION; DESTRUCTION; OSTEOARTHRITIS; PROLIFERATION; SYNOVIOCYTES; PATHOGENESIS	Active rheumatoid arthritis originates from few joints but subsequently affects the majority of joints. Thus far, the pathways of the progression of the disease are largely unknown. As rheumatoid arthritis synovial fibroblasts (RASFs) which can be found in RA synovium are key players in joint destruction and are able to migrate in vitro, we evaluated the potential of RASFs to spread the disease in vivo. To simulate the primary joint of origin, we implanted healthy human cartilage together with RASFs subcutaneously into severe combined immunodeficient (SCID) mice. At the contralateral flank, we implanted healthy cartilage without cells. RASFs showed an active movement to the naive cartilage via the vasculature independent of the site of application of RASFs into the SCID mouse, leading to a marked destruction of the target cartilage. These findings support the hypothesis that the characteristic clinical phenomenon of destructive arthritis spreading between joints is mediated, at least in part, by the transmigration of activated RASFs.	[Lefevre, Stephanie; Knedla, Anette; Tennie, Christoph; Kampmann, Andreas; Dinser, Robert; Tarner, Ingo H.; Mueller-Ladner, Ulf; Neumann, Elena] Univ Giessen, Dept Internal Med & Rheumatol, Kerckhoff Clin, Bad Nauheim, Germany; [Wunrau, Christina; Pap, Thomas] Univ Hosp Muenster, Inst Expt Musculoskeletal Med, Munster, Germany; [Korb, Adelheid] Univ Hosp Muenster, Dept Internal Med Nephrol & Rheumatol D, Munster, Germany; [Schnaeker, Eva-Maria] Univ Hosp Muenster, Dept Dermatol, Munster, Germany; [Robbins, Paul D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Evans, Christopher H.] Harvard Univ, Sch Med, Ctr Mol Orthoped, Boston, MA USA; [Stuerz, Henning] Univ Hosp Giessen & Marburg, Dept Orthoped & Orthoped Surg, Giessen, Germany; [Steinmeyer, Juergen] Univ Hosp Giessen & Marburg, Dept Orthoped & Expt Orthoped, Giessen, Germany; [Gay, Steffen] USZ, Zurich Ctr Integrat Human Physiol, Ctr Expt Rheumatol, Zurich, Switzerland; [Schoelmerich, Juergen] Univ Regensburg, Dept Internal Med 1, Regensburg, Germany	Justus Liebig University Giessen; Kerckhoff Clinic; University of Munster; University of Munster; University of Munster; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; University Hospital of Giessen & Marburg; University Hospital of Giessen & Marburg; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Regensburg	Neumann, E (corresponding author), Univ Giessen, Dept Internal Med & Rheumatol, Kerckhoff Clin, Bad Nauheim, Germany.	e.neumann@kerckhoff-klinik.de	Neumann, Elena/A-1418-2011	Steinmeyer, Juergen/0000-0002-4053-503X	German Society of Rheumatology; German Research Foundation (Deutsche Forschungsgemeinschaft) [NE1174/3-1, MU1383/14-1, FOR 696]; Swiss National Fond [32000-116842]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051456] Funding Source: NIH RePORTER	German Society of Rheumatology; German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Swiss National Fond(Swiss National Science Foundation (SNSF)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was funded by a start-up grant of the German Society of Rheumatology, by research grants of the German Research Foundation (Deutsche Forschungsgemeinschaft: NE1174/3-1, MU1383/14-1, FOR 696), by the Swiss National Fond 32000-116842 and by the Sixth Framework Programme Autocure and Seventh Framework Programme Masterswitch of the EU initiatives. We wish to thank S. Benninghoff, B. Riepl, S. Bruckmann and C. Schreiyack for technical assistance.	ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bresnihan B, 1999, J RHEUMATOL, V26, P717; BROMLEY M, 1985, ANN RHEUM DIS, V44, P676, DOI 10.1136/ard.44.10.676; Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Clark RAF, 2003, J INVEST DERMATOL, V121, P695, DOI 10.1046/j.1523-1747.2003.12484.x; Clements KM, 2001, OSTEOARTHR CARTILAGE, V9, P499, DOI 10.1053/joca.2000.0417; Davidson ENB, 2007, ARTHRITIS RHEUM, V56, P4065, DOI 10.1002/art.23034; ElGabalawy H, 1996, ARTHRITIS RHEUM-US, V39, P1913, DOI 10.1002/art.1780391119; Felix R, 1996, J CELL PHYSIOL, V166, P311, DOI 10.1002/(SICI)1097-4652(199602)166:2<311::AID-JCP9>3.0.CO;2-S; Garcia-Vicuna R, 2004, ARTHRITIS RHEUM-US, V50, P3866, DOI 10.1002/art.20615; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84; Hajiioannou JK, 2006, ARCH OTOLARYNGOL, V132, P1363, DOI 10.1001/archotol.132.12.1363; Hall H, 2004, MICROVASC RES, V68, P169, DOI 10.1016/j.mvr.2004.07.001; Hashimoto Atsushi, 2007, Mod Rheumatol, V17, P185; HUBBELL JA, 2007, SWISS MED WKLY S155, V137, pS75; Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; ISHIKAWA H, 1984, RHEUMATOL INT, V4, P1, DOI 10.1007/BF00683876; Judex M, 2004, METH MOLEC MED, V101, P93; Judex M, 2001, Mod Rheumatol, V11, P145, DOI 10.3109/s101650170027; Karouzakis E, 2006, IMMUNOL LETT, V106, P8, DOI 10.1016/j.imlet.2006.04.011; Knedla A, 2009, ANN RHEUM DIS, V68, P124, DOI 10.1136/ard.2007.086116; Lechman ER, 1999, J IMMUNOL, V163, P2202; Lechner S, 2003, GUT, V52, P1148, DOI 10.1136/gut.52.8.1148; Little CB, 2005, ARTHRITIS RHEUM-US, V52, P1461, DOI 10.1002/art.21022; Looney RJ, 2006, DRUGS, V66, P625, DOI 10.2165/00003495-200666050-00004; Ma YY, 2005, CURR PHARM DESIGN, V11, P569, DOI 10.2174/1381612053381927; MORALESDUCRET J, 1992, J IMMUNOL, V149, P1424; Muller-Ladner U, 2005, NAT CLIN PRACT RHEUM, V1, P102, DOI 10.1038/ncprheum0047; Muller-Ladner U, 1999, ARTHRITIS RHEUM, V42, P490, DOI 10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO;2-L; MullerLadner U, 1996, AM J PATHOL, V149, P1607; MullerLadner U, 1997, J IMMUNOL, V158, P3492; MullerLadner U, 1997, J RHEUMATOL, V24, P1873; Neumann E, 2002, GENE THER, V9, P1508, DOI 10.1038/sj.gt.3301811; Neumann E, 2002, ARTHRITIS RHEUM-US, V46, P52, DOI 10.1002/1529-0131(200201)46:1<52::AID-ART10048>3.0.CO;2-1; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OWSIANIK WDJ, 1980, ANN RHEUM DIS, V39, P508, DOI 10.1136/ard.39.5.508; Pap T, 2005, ANN RHEUM DIS, V64, P52, DOI 10.1136/ard.2005.042424; Pap T, 2000, ARTHRITIS RES, V2, P361, DOI 10.1186/ar113; Saint-Geniez M, 2009, INVEST OPHTH VIS SCI, V50, P311, DOI 10.1167/iovs.08-2461; Schedel J, 2004, SCAND J IMMUNOL, V60, P514, DOI 10.1111/j.0300-9475.2004.01507.x; Skapenko A, 2005, ARTHRITIS RES THER, V7, pS4, DOI 10.1186/ar1703; Takahara K, 2004, HUM PATHOL, V35, P150, DOI 10.1016/j.humpath.2003.11.010; van Beurden HE, 2003, WOUND REPAIR REGEN, V11, P55, DOI 10.1046/j.1524-475X.2003.11109.x; Van der Laan WH, 2000, ARTHRITIS RHEUM, V43, P1710, DOI 10.1002/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y; Woods JM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1999; Yasuda Tadashi, 2006, Mod Rheumatol, V16, P197; Zak J, 2000, PFLUG ARCH EUR J PHY, V440, P179, DOI 10.1007/s004240000282	50	424	446	3	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1414	U10		10.1038/nm.2050	http://dx.doi.org/10.1038/nm.2050			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19898488	Green Accepted			2022-12-27	WOS:000272407800022
J	Yamanaka, S				Yamanaka, Shinya			Ekiden to iPS Cells	NATURE MEDICINE			English	Article							PLURIPOTENT STEM-CELLS; MESSENGER-RNA; MOUSE; GENERATION; ROLES		[Yamanaka, Shinya] Kyoto Univ, Ctr IPS Cell Res & Applicat, Kyoto, Japan; [Yamanaka, Shinya] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA	Kyoto University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Yamanaka, S (corresponding author), Kyoto Univ, Ctr IPS Cell Res & Applicat, Kyoto, Japan.	yamanaka@cira.kyoto-u.ac.jp						Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; Imamura M, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-34; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Maruyama M, 2005, J BIOL CHEM, V280, P24371, DOI 10.1074/jbc.M501423200; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tsubooka N, 2009, GENES CELLS, V14, P683, DOI 10.1111/j.1365-2443.2009.01301.x; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YAMANAKA S, 1992, CIRC RES, V70, P893, DOI 10.1161/01.RES.70.5.893; Yamanaka S, 2000, EMBO J, V19, P5533, DOI 10.1093/emboj/19.20.5533; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yamanaka S, 2009, NATURE, V460, P49, DOI 10.1038/nature08180; Yamanaka S, 2009, CELL, V137, P13, DOI 10.1016/j.cell.2009.03.034; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	26	11	18	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1145	1148		10.1038/nm1009-1145	http://dx.doi.org/10.1038/nm1009-1145			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19812575	Bronze			2022-12-27	WOS:000270596400024
J	Stamatatos, L; Morris, L; Burton, DR; Mascola, JR				Stamatatos, Leonidas; Morris, Lynn; Burton, Dennis R.; Mascola, John R.			Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODIES; CHIMERIC VIRUS; ENV CLONES; GLYCOPROTEIN; PROTECTION; MACAQUES; SUBTYPES; SEROTYPES; RESPONSES	Most existing viral vaccines generate antibodies that either block initial infection or help eradicate the virus before it can cause disease. For HIV-1, obstacles to eliciting protective neutralizing antibodies (NAbs) have often seemed insurmountable. The target of HIV-specific NAbs, the viral envelope glycoprotein (Env), is highly variable in amino acid sequence and glycosylation pattern. Conserved elements of HIV-1 Env seem to be poorly immunogenic, and previous attempts to generate broadly reactive NAbs by vaccination have proven ineffective. However, recent studies show that in the sera of some HIV-1-infected individuals can neutralize diverse HIV-1 isolates. Detailed analyses of these sera provide new insights into the viral epitopes targeted by broadly reactive NAbs. The findings discussed here suggest that the natural NAb response to HIV-1 can inform future vaccine design. A concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV-1.	[Stamatatos, Leonidas] Seattle Biomed Res Inst, Seattle, WA 98109 USA; [Stamatatos, Leonidas] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Morris, Lynn] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa; [Morris, Lynn] Ctr AIDS Programme Res S Africa, Johannesburg, South Africa; [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, La Jolla, CA 92037 USA; [Mascola, John R.] NIAID, Vaccine Res Ctr, US Natl Inst Hlth, Bethesda, MD 20892 USA	Center for Infectious Disease Research; University of Washington; University of Washington Seattle; National Institute for Communicable Diseases (NICD); Scripps Research Institute; International AIDS Vaccine Initiative; Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Stamatatos, L (corresponding author), Seattle Biomed Res Inst, 4 Nickerson St, Seattle, WA 98109 USA.	leo.stamatatos@sbri.org	Mascola, John/AAI-7193-2021; Morris, Lynn/V-3941-2018	Morris, Lynn/0000-0003-3961-7828				Amanna IJ, 2008, HUM VACCINES, V4, P316, DOI 10.4161/hv.4.4.5751; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352; Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08; Brown BK, 2008, VIROLOGY, V375, P529, DOI 10.1016/j.virol.2008.02.022; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510; Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06; Doria-Rose NA, 2009, J VIROL, V83, P188, DOI 10.1128/JVI.01583-08; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Gray ES, 2007, J VIROL, V81, P6187, DOI 10.1128/JVI.00239-07; Haynes BF, 2006, EXPERT REV VACCINES, V5, P578; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974; Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433; Kostrikis LG, 1996, J VIROL, V70, P445, DOI 10.1128/JVI.70.1.445-458.1996; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003; Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Li YX, 2009, J VIROL, V83, P1045, DOI 10.1128/JVI.01992-08; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862; Rademeyer C, 2007, VIROLOGY, V368, P172, DOI 10.1016/j.virol.2007.06.013; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Shen XY, 2009, J VIROL, V83, P3617, DOI 10.1128/JVI.02631-08; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; SIMEK DM, 2009, J VIROL, DOI DOI 10.1128/JVI.00110-09; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	46	342	372	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					866	870		10.1038/nm.1949	http://dx.doi.org/10.1038/nm.1949			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19525964	Bronze			2022-12-27	WOS:000268770400027
J	Patel, KP; Bergelson, JM				Patel, Kunal P.; Bergelson, Jeffrey M.			Receptors identified for hand, foot and mouth virus	NATURE MEDICINE			English	Editorial Material							INFECTIONS		[Patel, Kunal P.; Bergelson, Jeffrey M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Patel, KP (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.	bergelson@chop.edu		Patel, Kunal/0000-0001-5504-3030				Eckhardt ERM, 2006, J BIOL CHEM, V281, P4348, DOI 10.1074/jbc.M513154200; FAN Y, 2009, J CLIN MICROBIO 0513; Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302; Lin TY, 2003, CLIN INFECT DIS, V36, P269, DOI 10.1086/345905; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; Nishimura Y, 2009, NAT MED, V15, P794, DOI 10.1038/nm.1961; Philips JA, 2005, SCIENCE, V309, P1251, DOI 10.1126/science.1116006; Vishnyakova TG, 2006, P NATL ACAD SCI USA, V103, P16888, DOI 10.1073/pnas.0602126103; Yamayoshi S, 2009, NAT MED, V15, P798, DOI 10.1038/nm.1992	11	31	47	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2009	15	7					728	729		10.1038/nm0709-728	http://dx.doi.org/10.1038/nm0709-728			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584857				2022-12-27	WOS:000267806900019
J	Schweizerhof, M; Stosser, S; Kurejova, M; Njoo, C; Gangadharan, V; Agarwal, N; Schmelz, M; Bali, KK; Michalski, CW; Brugger, S; Dickenson, A; Simone, DA; Kuner, R				Schweizerhof, Matthias; Stoesser, Sebastian; Kurejova, Martina; Njoo, Christian; Gangadharan, Vijayan; Agarwal, Nitin; Schmelz, Martin; Bali, Kiran Kumar; Michalski, Christoph W.; Brugger, Stefan; Dickenson, Anthony; Simone, Donald A.; Kuner, Rohini			Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain	NATURE MEDICINE			English	Article							FACTOR GM-CSF; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; FUNCTIONAL INTERACTIONS; PANCREATIC-CANCER; PERIPHERAL-NERVE; HUMAN MONOCYTES; MURINE MODEL; EXPRESSION; PROTEIN	Pain is one of the most severe and debilitating symptoms associated with several forms of cancer(1,2). Various types of carcinomas and sarcomas metastasize to skeletal bones and cause spontaneous bone pain and hyperalgesia, which is accompanied by bone degradation and remodeling of peripheral nerves(2). Despite recent advances, the molecular mechanisms underlying the development and maintenance of cancer-evoked pain are not well understood(2). Several types of non-hematopoietic tumors secrete hematopoietic colony-stimulating factors that act on myeloid cells(3) and tumor cells(4). Here we report that receptors and signaling mediators of granulocyte-and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF)(3) are also functionally expressed on sensory nerves. GM-CSF sensitized nerves to mechanical stimuli in vitro and in vivo, potentiated CGRP release and caused sprouting of sensory nerve endings in the skin. Interruption of G-CSF and GM-CSF signaling in vivo led to reduced tumor growth and nerve remodeling, and abrogated bone cancer pain. The key significance of GM-CSF signaling in sensory neurons was revealed by an attenuation of tumor-evoked pain following a sensory nerve-specific knockdown of GM-CSF receptors. These results show that G-CSF and GM-CSF are important in tumor-nerve interactions and suggest that their receptors on primary afferent nerve fibers constitute potential therapeutic targets in cancer pain.	[Schweizerhof, Matthias; Stoesser, Sebastian; Kurejova, Martina; Njoo, Christian; Gangadharan, Vijayan; Agarwal, Nitin; Bali, Kiran Kumar; Michalski, Christoph W.; Brugger, Stefan; Kuner, Rohini] Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany; [Schmelz, Martin] Heidelberg Univ, Dept Anesthesiol & Intens Care Med, Med Fac Mannheim, D-6800 Mannheim, Germany; [Michalski, Christoph W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany; [Dickenson, Anthony] UCL, Dept Pharmacol, London, England; [Simone, Donald A.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of London; University College London; University of Minnesota System; University of Minnesota Twin Cities	Kuner, R (corresponding author), Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de	Michalski, Christoph/U-9167-2019; Schmelz, Martin/A-9327-2013; Bali, Kiran/F-6828-2013; Kuner, Rohini/AGU-0204-2022	Schmelz, Martin/0000-0002-9736-7241; Bali, Kiran/0000-0002-9503-1402; Gangadharan, Vijayan/0000-0002-2385-045X	Association of International Cancer Research; Landesstiftung Baden-Wurttemberg; US National Institutes of Health [DA11471, CA91007]; NATIONAL CANCER INSTITUTE [R01CA091007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011471] Funding Source: NIH RePORTER	Association of International Cancer Research; Landesstiftung Baden-Wurttemberg; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors thank H.-J. Wrede, C. Harding-Rose and D. Baumgartl-Ahlert for technical assistance and R. LeFaucheur for secretarial help. This work was supported by grants from the Association of International Cancer Research and the Landesstiftung Baden-Wurttemberg (Program RNAi) to R. K. and by US National Institutes of Health grants DA11471 and CA91007 to D. A. S.	Angst MS, 2008, PAIN, V139, P15, DOI 10.1016/j.pain.2008.02.028; Cain DM, 2001, J NEUROSCI, V21, P9367, DOI 10.1523/JNEUROSCI.21-23-09367.2001; Carvalho B, 2008, J PAIN, V9, P650, DOI 10.1016/j.jpain.2008.02.004; Cook AD, 2001, ARTHRITIS RES, V3, P293, DOI 10.1186/ar318; DANIS VA, 1991, CLIN EXP IMMUNOL, V85, P143; Davar G, 2001, PAIN MED, V2, P24, DOI 10.1046/j.1526-4637.2001.002001024.x; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; Giron-Michel J, 2003, J EXP MED, V197, P763, DOI 10.1084/jem.20020150; Glatzel W, 2000, P NATL ACAD SCI USA, V97, P442, DOI 10.1073/pnas.97.1.442; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Hansen G, 2008, CELL, V134, P496, DOI 10.1016/j.cell.2008.05.053; Honore E, 2007, NAT REV NEUROSCI, V8, P251, DOI 10.1038/nrn2117; Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526-4637.2000.00047.x; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kasper B, 1997, BLOOD, V90, P2839, DOI 10.1182/blood.V90.7.2839.2839_2839_2840; Khasabova IA, 2007, J NEUROSCI, V27, P10289, DOI 10.1523/JNEUROSCI.2851-07.2007; Lehtonen A, 2002, J LEUKOCYTE BIOL, V71, P511; LINDEMANN A, 1989, BLOOD, V74, P2644; Lindsay TH, 2005, PAIN, V119, P233, DOI 10.1016/j.pain.2005.10.019; McIntyre GJ, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-1; Monfardini C, 1998, J BIOL CHEM, V273, P7657, DOI 10.1074/jbc.273.13.7657; Owen JL, 2005, CELL IMMUNOL, V235, P122, DOI 10.1016/j.cellimm.2005.08.032; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Salh B, 1998, IMMUNOLOGY, V95, P473, DOI 10.1046/j.1365-2567.1998.00614.x; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Tachibana M, 1998, CYTOKINES CELL MOL T, V4, P113; Tigue CC, 2007, BONE MARROW TRANSPL, V40, P185, DOI 10.1038/sj.bmt.1705722; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; Wacnik PW, 2005, NEUROSCIENCE, V132, P479, DOI 10.1016/j.neuroscience.2004.12.035; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001; Waller EK, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S2-22; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	34	151	162	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					802	U122		10.1038/nm.1976	http://dx.doi.org/10.1038/nm.1976			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19525966				2022-12-27	WOS:000267806900035
J	Plutzky, J				Plutzky, Jorge			The mighty, mighty fatty acid	NATURE MEDICINE			English	Editorial Material							ADIPOSE-TISSUE; INSULIN-RESISTANCE; OBESITY; METABOLISM; CONTRIBUTE; MICE		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Plutzky, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA.	jplutzky@rics.bwh.harvard.edu	Plutzky, Jorge/V-3410-2019		NHLBI NIH HHS [P01 HL048743] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Cao HM, 2008, CELL, V134, P933, DOI 10.1016/j.cell.2008.07.048; Eleftheriadou I, 2008, CURR DIABETES REV, V4, P340, DOI 10.2174/157339908786241133; Furuhashi M, 2008, J CLIN INVEST, V118, P2640, DOI 10.1172/JCI34750; Garg A, 2009, BBA-MOL CELL BIOL L, V1791, P507, DOI 10.1016/j.bbalip.2008.12.014; Kanda T, 2009, J CLIN INVEST, V119, P110, DOI 10.1172/JCI36233; Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291; Kim JY, 2007, J CLIN INVEST, V117, P2621, DOI 10.1172/JCI31021; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Slawik M, 2007, GENES NUTR, V2, P41, DOI 10.1007/s12263-007-0014-9; Speakman J, 2008, LAB ANIM-UK, V42, P413, DOI 10.1258/la.2007.006067; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487; Wang SP, 2008, MOL GENET METAB, V95, P117, DOI 10.1016/j.ymgme.2008.06.012; Wildman RP, 2008, ARCH INTERN MED, V168, P1617, DOI 10.1001/archinte.168.15.1617; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	19	10	10	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2009	15	6					618	619		10.1038/nm0609-618	http://dx.doi.org/10.1038/nm0609-618			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19498375	Green Accepted			2022-12-27	WOS:000266731600019
J	Satoh, K; Nigro, P; Matoba, T; O'Dell, MR; Cui, ZQ; Shi, X; Mohan, A; Yan, C; Abe, J; Illig, KA; Berk, BC				Satoh, Kimio; Nigro, Patrizia; Matoba, Tetsuya; O'Dell, Michael R.; Cui, Zhaoqiang; Shi, Xi; Mohan, Amy; Yan, Chen; Abe, Jun-ichi; Illig, Karl A.; Berk, Bradford C.			Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; E-DEFICIENT MICE; MATRIX METALLOPROTEINASES; INDUCED ATHEROSCLEROSIS; RHO-KINASE; PATHOGENESIS; MMP-2; GENE; HYPERTENSION; ACTIVATION	Inflammation and oxidative stress are pathogenic mediators of many diseases, but molecules that could be therapeutic targets remain elusive. Inflammation and matrix degradation in the vasculature are crucial for abdominal aortic aneurysm (AAA) formation. Cyclophilin A (CypA, encoded by Ppia) is highly expressed in vascular smooth muscle cells (VSMCs), is secreted in response to reactive oxygen species (ROS) and promotes inflammation. Using the angiotensin II (AngII)-induced AAA model in Apoe(-/-) mice, we show that Apoe(-/-) Ppia(-/-) mice are completely protected from AngII-induced AAA formation, in contrast to Apoe(-/-) Ppia(+/+) mice. Apoe(-/-) Ppia(-/-) mice show decreased inflammatory cytokine expression, elastic lamina degradation and aortic expansion. These features were not altered by reconstitution of bone marrow cells from Ppia(+/+) mice. Mechanistic studies showed that VSMC-derived intracellular and extracellular CypA are required for ROS generation and matrix metalloproteinase-2 activation. These data define a previously undescribed role for CypA in AAA formation and suggest CypA as a new target for treating cardiovascular disease.	[Satoh, Kimio; Nigro, Patrizia; Matoba, Tetsuya; O'Dell, Michael R.; Cui, Zhaoqiang; Shi, Xi; Mohan, Amy; Yan, Chen; Abe, Jun-ichi; Berk, Bradford C.] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA; [Satoh, Kimio; Nigro, Patrizia; Matoba, Tetsuya; O'Dell, Michael R.; Cui, Zhaoqiang; Shi, Xi; Mohan, Amy; Yan, Chen; Abe, Jun-ichi; Berk, Bradford C.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY USA; [Illig, Karl A.] Univ Rochester, Sch Med & Dent, Div Vasc Surg, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, Rochester, NY 14627 USA.	bradford_berk@urmc.rochester.edu	Matoba, Tetsuya/M-1920-2013; Satoh, Kimio/O-7794-2019	Nigro, Patrizia/0000-0003-0182-4346; Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358; Matoba, Tetsuya/0000-0003-4563-304X	US National Institutes of Health grant [HL49192]; Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192] Funding Source: NIH RePORTER	US National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by US National Institutes of Health grant HL49192 (to B. C. B.) and Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad (to K. S.). We are grateful to the Aab Cardiovascular Research Institute members for useful suggestions and R. Winterkorn, M. A. Georger and A. T. Paxhia for technical assistance.	Bharadwaj U, 2005, J SURG RES, V127, P29, DOI 10.1016/j.jss.2005.02.020; Browatzki M, 2005, J VASC RES, V42, P415, DOI 10.1159/000087451; Bruemmer D, 2003, J CLIN INVEST, V112, P1318, DOI 10.1172/JCI200318141; Cassis LA, 2007, ARTERIOSCL THROM VAS, V27, P380, DOI 10.1161/01.ATV.0000254680.71485.92; Castier Y, 2005, CIRC RES, V97, P533, DOI 10.1161/01.RES.0000181759.63239.21; CHEN XF, 2008, IN VITRO CLIN SCI LO, DOI DOI 10.1042/CS20080235; Chen XL, 1998, CIRC RES, V83, P952; Clempus RE, 2006, CARDIOVASC RES, V71, P216, DOI 10.1016/j.cardiores.2006.02.033; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Daugherty A, 2004, ARTERIOSCL THROM VAS, V24, P429, DOI 10.1161/01.ATV.0000118013.72016.ea; Eagleton MJ, 2006, J SURG RES, V135, P345, DOI 10.1016/j.jss.2006.03.026; Ejiri J, 2003, CARDIOVASC RES, V59, P988, DOI 10.1016/S0008-6363(03)00523-6; Gavazzi G, 2007, HYPERTENSION, V50, P189, DOI 10.1161/HYPERTENSIONAHA.107.089706; Gavrila D, 2005, ARTERIOSCL THROM VAS, V25, P1671, DOI 10.1161/01.ATV.0000172631.50972.0f; Golledge J, 2006, ARTERIOSCL THROM VAS, V26, P2605, DOI 10.1161/01.ATV.0000245819.32762.cb; Griendling KK, 2003, CIRCULATION, V108, P2034, DOI 10.1161/01.CIR.0000093661.90582.c4; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Haug C, 2004, ARTERIOSCL THROM VAS, V24, P1823, DOI 10.1161/01.ATV.0000142806.59283.11; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Khromykh LM, 2007, CELL IMMUNOL, V249, P46, DOI 10.1016/j.cellimm.2007.11.002; Kunieda T, 2006, CIRCULATION, V114, P953, DOI 10.1161/CIRCULATIONAHA.106.626606; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Luchtefeld M, 2005, BIOCHEM BIOPH RES CO, V328, P183, DOI 10.1016/j.bbrc.2004.12.152; Manning MW, 2003, ARTERIOSCL THROM VAS, V23, P483, DOI 10.1161/01.ATV.0000058404.92759.32; McCormick ML, 2007, ARTERIOSCL THROM VAS, V27, P461, DOI 10.1161/01.ATV.0000257552.94483.14; Mehta PK, 2007, AM J PHYSIOL-CELL PH, V292, pC82, DOI 10.1152/ajpcell.00287.2006; Pyo R, 2000, J CLIN INVEST, V105, P1641, DOI 10.1172/JCI8931; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Saraff K, 2003, ARTERIOSCL THROM VAS, V23, P1621, DOI 10.1161/01.ATV.0000085631.76095.64; Satoh K, 2006, CIRCULATION, V113, P1442, DOI 10.1161/CIRCULATIONAHA.105.583732; Satoh K, 2008, CIRCULATION, V117, P3088, DOI 10.1161/CIRCULATIONAHA.107.756106; Shimokawa H, 2005, ARTERIOSCL THROM VAS, V25, P1767, DOI 10.1161/01.ATV.0000176193.83629.c8; Sun JS, 2007, NAT MED, V13, P719, DOI 10.1038/nm1601; Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Thomas M, 2006, CIRCULATION, V114, P404, DOI 10.1161/CIRCULATIONAHA.105.607168; Thompson RW, 1999, ANN NY ACAD SCI, V878, P159, DOI 10.1111/j.1749-6632.1999.tb07682.x; Valentin F, 2005, FUND CLIN PHARMACOL, V19, P661, DOI 10.1111/j.1472-8206.2005.00371.x; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang YX, 2005, CIRCULATION, V111, P2219, DOI 10.1161/01.CIR.0000163544.17221.BE; Yoshimura K, 2005, NAT MED, V11, P1330, DOI 10.1038/nm1335; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200	46	295	311	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					649	U144		10.1038/nm.1958	http://dx.doi.org/10.1038/nm.1958			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19430489	Green Accepted			2022-12-27	WOS:000266731600024
J	Yao, CC; Sakata, D; Esaki, Y; Li, YX; Matsuoka, T; Kuroiwa, K; Sugimoto, Y; Narumiya, S				Yao, Chengcan; Sakata, Daiji; Esaki, Yoshiyasu; Li, Youxian; Matsuoka, Toshiyuki; Kuroiwa, Kenji; Sugimoto, Yukihiko; Narumiya, Shuh			Prostaglandin E-2-EP4 signaling promotes immune inflammation through T(H)1 cell differentiation and T(H)17 cell expansion	NATURE MEDICINE			English	Article							GENOME-WIDE ASSOCIATION; BOWEL-DISEASE; TH17 CELLS; MULTIPLE-SCLEROSIS; T-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; DENDRITIC CELLS; CROHN-DISEASE; E-2; ACTIVATION	Two distinct helper T (T-H) subsets, T(H)1 and T(H)17, mediate tissue damage and inflammation in animal models of various immune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases and allergic skin disorders. These experimental findings, and the implication of these TH subsets in human diseases, suggest the need for pharmacological measures to manipulate these TH subsets. Here we show that prostaglandin E-2 (PGE(2)) acting on its receptor EP4 on T cells and dendritic cells not only facilitates T(H)1 cell differentiation but also amplifies interleukin-23-mediated T(H)17 cell expansion in vitro. Administration of an EP4-selective antagonist in vivo decreases accumulation of both T(H)1 and T(H)17 cells in regional lymph nodes and suppresses the disease progression in mice subjected to experimental autoimmune encephalomyelitis or contact hypersensitivity. Thus, PGE(2)-EP4 signaling promotes immune inflammation through T(H)1 differentiation and T(H)17 expansion, and EP4 antagonism may be therapeutically useful for various immune diseases.	[Yao, Chengcan; Sakata, Daiji; Esaki, Yoshiyasu; Li, Youxian; Matsuoka, Toshiyuki; Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; [Kuroiwa, Kenji; Sugimoto, Yukihiko] Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 606, Japan	Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Yao, Chengcan/0000-0003-3754-2842; Li, Youxian/0000-0003-3213-1358				Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Betti M, 2006, ANN ONCOL, V17, P235; BETZ M, 1991, J IMMUNOL, V146, P108; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Capon F, 2007, HUM GENET, V122, P201, DOI 10.1007/s00439-007-0397-0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chemnitz JM, 2006, CANCER RES, V66, P1114, DOI 10.1158/0008-5472.CAN-05-3252; Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood-2008-05-155408; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Fassbender K, 1998, NEUROLOGY, V51, P753, DOI 10.1212/WNL.51.3.753; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; GOLD KN, 1994, ARTHRITIS RHEUM, V37, P925, DOI 10.1002/art.1780370623; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; HASLER F, 1983, J IMMUNOL, V131, P768; Herve M, 2003, EUR J IMMUNOL, V33, P2764, DOI 10.1002/eji.200324143; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Khayrullina T, 2008, J IMMUNOL, V181, P721, DOI 10.4049/jimmunol.181.1.721; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402; Moldovan IR, 2003, J NEUROIMMUNOL, V141, P132, DOI 10.1016/S0165-5728(03)00221-2; Murray AJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.122re4; Mustelin T, 2003, BIOCHEM J, V371, P15, DOI 10.1042/BJ20021637; Nagamachi M, 2007, J EXP MED, V204, P2865, DOI 10.1084/jem.20070773; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Narumiya S, 2007, P JPN ACAD B-PHYS, V83, P296, DOI [10.2183/pjab.83.296, 10.2183/pjab/83.296]; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; Neurath MF, 2007, NAT MED, V13, P26, DOI 10.1038/nm0107-26; Nurieva R, 2009, J IMMUNOL, V182, P2565, DOI 10.4049/jimmunol.0803931; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Serada S, 2008, P NATL ACAD SCI USA, V105, P9041, DOI 10.1073/pnas.0802218105; Sheibanie AF, 2007, J IMMUNOL, V178, P8138, DOI 10.4049/jimmunol.178.12.8138; Steinman L, 2008, J EXP MED, V205, P1517, DOI 10.1084/jem.20072066; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	57	414	431	2	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					633	U141		10.1038/nm.1968	http://dx.doi.org/10.1038/nm.1968			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19465928	Green Submitted			2022-12-27	WOS:000266731600022
J	June, C; Moore, JP; von Laer, D				June, Carl; Moore, John P.; von Laer, Dorothee			Bone marrow transplant muffles HIV	NATURE MEDICINE			English	Editorial Material									[June, Carl] Univ Penn, Philadelphia, PA 19104 USA; [Moore, John P.] Weill Cornell Med Coll, New York, NY USA; [von Laer, Dorothee] Georg Speyer Haus, Appl Virol & Gene Therapy, Frankfurt, Germany	University of Pennsylvania; Cornell University; Octapharma	June, C (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.							Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410; Rapoport AP, 2005, NAT MED, V11, P1230, DOI 10.1038/nm1310; von Laer D, 2006, J GENE MED, V8, P658, DOI 10.1002/jgm.908	4	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2009	15	4					371	371		10.1038/nm0409-371	http://dx.doi.org/10.1038/nm0409-371			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19350007				2022-12-27	WOS:000264937200017
J	Lemon, SM; Burton, DR; Abrignani, S; Bartenschlager, R				Lemon, Stanley M.; Burton, Dennis R.; Abrignani, Sergio; Bartenschlager, Ralf			Moving closer to a mouse model for hepatitis C	NATURE MEDICINE			English	Editorial Material							CELLS; REPLICATION; INFECTION		[Lemon, Stanley M.] Univ Texas Galveston, Med Branch, Inst Human Infect & Immun, Galveston, TX 77550 USA; [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Abrignani, Sergio] Natl Inst Mol Genet, Milan, Italy; [Bartenschlager, Ralf] Heidelberg Univ, Dept Mol Virol, D-6900 Heidelberg, Germany	University of Texas System; University of Texas Medical Branch Galveston; Scripps Research Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Ruprecht Karls University Heidelberg	Lemon, SM (corresponding author), Univ Texas Galveston, Med Branch, Inst Human Infect & Immun, Galveston, TX 77550 USA.		Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012; Liu SF, 2009, J VIROL, V83, P2011, DOI 10.1128/JVI.01888-08; Ploss A, 2009, NATURE, V457, P882, DOI 10.1038/nature07684; Uprichard SL, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-89; Zhu Q, 2003, J VIROL, V77, P9204, DOI 10.1128/JVI.77.17.9204-9210.2003	5	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					251	251		10.1038/nm0309-251	http://dx.doi.org/10.1038/nm0309-251			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19265825				2022-12-27	WOS:000263914000022
J	Strauss, JF; De Paolo, LV				Strauss, Jerome F., III; De Paolo, Louis V.			Funding for the reproductive sciences in the US	NATURE MEDICINE			English	Editorial Material							ANIMAL REPRODUCTION; AGRICULTURE; TECHNOLOGY; PRIORITIES; BIOLOGY		[Strauss, Jerome F., III] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23298 USA; [De Paolo, Louis V.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strauss, JF (corresponding author), Virginia Commonwealth Univ, Sch Med, 1101 E Marshall St, Richmond, VA 23298 USA.	jfstrauss@vcu.edu						Behrman RE, 2007, PRETERM BIRTH CAUSES; Clarke Adele, 1998, DISCIPLINING REPRODU; HARRISON PJ, 1996, CONTRACEPTIVE RES AN; Ireland JJ, 2008, J ANIM SCI, V86, P2797, DOI 10.2527/jas.2008-1088; Longo LD, 2008, AM J OBSTET GYNECOL, V198, P489, DOI 10.1016/j.ajog.2008.02.032; Makinson C, 1999, INT J GYNECOL OBSTET, V67, pS101, DOI 10.1016/S0020-7292(99)00153-8; Mirando MA, 2007, J ANIM SCI, V85, pE11, DOI 10.2527/jas.2006-506; Mirando MA, 2006, BIOL REPROD, V74, P459, DOI 10.1095/biolreprod.105.048686; NASS S, 2004, NEW FRONTIERS CONTRA; Pion GA, 2006, BIOL REPROD, V74, P230, DOI 10.1095/biolreprod.105.045427; Population Reference Bureau, 2008, WORLD POP DAT SHEET; Romundstad LB, 2008, LANCET, V372, P737, DOI 10.1016/S0140-6736(08)61041-7; Strauss JF, 2007, FERTIL STERIL, V87, P717, DOI 10.1016/j.fertnstert.2006.11.003; Strauss JF, 2004, NATURE, V432, P43, DOI 10.1038/432043a; Townsend J, 1992, STRENGTHENING RES AC	15	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2008	14	11					1214	1217		10.1038/nm1108-1214	http://dx.doi.org/10.1038/nm1108-1214			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	370GR	18989308				2022-12-27	WOS:000260751200039
J	Adair-Kirk, TL; Atkinson, JJ; Senior, RM				Adair-Kirk, Tracy L.; Atkinson, Jeffrey J.; Senior, Robert M.			Smoke particulates stress lung cells	NATURE MEDICINE			English	Editorial Material							NALP3 INFLAMMASOME; CIGARETTE-SMOKING; PROTEIN RESPONSE; GENE-EXPRESSION; ACTIVATION; SILICA		[Adair-Kirk, Tracy L.; Atkinson, Jeffrey J.; Senior, Robert M.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Senior, Robert M.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Adair-Kirk, TL (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Box 8052, St Louis, MO 63110 USA.	tkirk@im.wustl.edu		Atkinson, Jeffrey/0000-0001-9125-7968				Adair-Kirk TL, 2008, AM J RESP CELL MOL, V39, P400, DOI 10.1165/rcmb.2007-0295OC; BERNARD AM, 1994, ENVIRON RES, V66, P96, DOI 10.1006/enrs.1994.1047; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chen JP, 2007, CANCER EPIDEM BIOMAR, V16, P577, DOI 10.1158/1055-9965.EPI-06-0923; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Hackett NR, 2003, AM J RESP CELL MOL, V29, P331, DOI 10.1165/rcmb.2002-0321OC; Heguy A, 2006, J MOL MED, V84, P318, DOI 10.1007/s00109-005-0008-2; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Jung EJ, 2007, PROTEOMICS, V7, P3906, DOI 10.1002/pmic.200700377; Kelsen SG, 2008, AM J RESP CELL MOL, V38, P541, DOI 10.1165/rcmb.2007-0221OC; Sin DD, 2008, AM J RESP CRIT CARE, V177, P1207, DOI 10.1164/rccm.200709-1356OC; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC	12	16	17	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1024	1025		10.1038/nm1008-1024	http://dx.doi.org/10.1038/nm1008-1024			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841140				2022-12-27	WOS:000259892300028
J	Altarejos, JY; Goebel, N; Conkright, MD; Inotiel, H; Xie, JX; Arias, CM; Sawchenko, PE; Montminy, M				Altarejos, Judith Y.; Goebel, Naomi; Conkright, Michael D.; Inotiel, Hiroshi; Xie, Jianxin; Arias, Carlos M.; Sawchenko, Paul E.; Montminy, Marc			The Creb1 coactivator Crtc1 is required for energy balance and fertility	NATURE MEDICINE			English	Article							CORTICOTROPIN-RELEASING FACTOR; HYPOTHALAMIC CART; HORMONE NEURONS; GENE PROMOTER; POMC NEURONS; LEPTIN; ACTIVATION; TRANSCRIPTION; KISSPEPTIN; TORC2	The adipocyte-derived hormone leptin maintains energy balance by acting on hypothalamic leptin receptors (Leprs) that act on the signal transducer and activator of transcription 3 (Stat3)(1-4). Although disruption of Lepr-Stat3 signaling promotes obesity in mice, other features of Lepr function, such as fertility, seem normal, pointing to the involvement of additional regulators. Here we show that the cyclic AMP responsive element-binding protein-1 (Creb1)-regulated transcription coactivator-1 (Crtc1) is required for energy balance and reproduction-Crtc1(-/-) mice are hyperphagic, obese and infertile. Hypothalamic Crtc1 was phosphorylated and inactive in leptin-deficient ob/ob mice, while leptin administration increased amounts of dephosphorylated nuclear Crtc1. Dephosphorylated Crtc1 stimulated expression of the Cartpt and Kiss1 genes, which encode hypothalamic neuropeptides that mediate leptin's effects on satiety and fertility(5-7). Crtc1 overexpression in hypothalamic cells increased Cartpt and Kiss1 gene expression, whereas Crtc1 depletion decreased it. Indeed, leptin enhanced Crtc1 activity over the Cartpt and Kiss1 promoters in cells overexpressing Lepr, and these effects were disrupted by expression of a dominant-negative Creb1 polypeptide. As leptin administration increased recruitment of hypothalamic Crtc1 to Cartpt and Kissl promoters, our results indicate that the Creb1-Crtc1 pathway mediates the central effects of hormones and nutrients on energy balance and fertility.	[Altarejos, Judith Y.; Goebel, Naomi; Inotiel, Hiroshi; Montminy, Marc] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA; [Conkright, Michael D.] Scripps Res Inst, Jupiter, FL 33458 USA; [Xie, Jianxin] Cell Signaling Technol, Danvers, MA 01923 USA; [Arias, Carlos M.; Sawchenko, Paul E.] Salk Inst Biol Studies, Neuronal Struct & Funct Lab, La Jolla, CA 92037 USA	Salk Institute; Scripps Research Institute; Salk Institute	Montminy, M (corresponding author), Salk Inst Biol Studies, Peptide Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	montminy@salk.edu		Inoue, Hiroshi/0000-0002-7724-6637	US National Institutes of Health [DK049777]; Foundation for Medical Research and the Keickhefer Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049777] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for Medical Research and the Keickhefer Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank M. Myers (University of Michigan School of Medicine) for leptin receptor expression plasmid, P. Mellon (University of California at San Diego) for mouse GTI-7 hypothalamic cells and M. Kuhar (Emory University School of Medicine) for Cartpt-luciferase reporter. This work was supported by the US National Institutes of Health (DK049777) the Foundation for Medical Research and the Keickhefer Foundation.	Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Badman MK, 2007, GASTROENTEROLOGY, V132, P2103, DOI 10.1053/j.gastro.2007.03.058; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; Barrett P, 2002, OBES RES, V10, P1291, DOI 10.1038/oby.2002.175; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Castellano JM, 2005, ENDOCRINOLOGY, V146, P3917, DOI 10.1210/en.2005-0337; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; d'Anglemont de Tassigny X, 2007, P NATL ACAD SCI USA, V104, P10714, DOI 10.1073/pnas.0704114104; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Dominguez G, 2002, J NEUROCHEM, V80, P885, DOI 10.1046/j.0022-3042.2002.00775.x; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Han SK, 2005, J NEUROSCI, V25, P11349, DOI 10.1523/JNEUROSCI.3328-05.2005; Irwig MS, 2004, NEUROENDOCRINOLOGY, V80, P264, DOI 10.1159/000083140; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lakatos A, 2002, MOL BRAIN RES, V104, P81, DOI 10.1016/S0169-328X(02)00321-2; Lambert PD, 1998, SYNAPSE, V29, P293, DOI 10.1002/(SICI)1098-2396(199808)29:4<293::AID-SYN1>3.0.CO;2-0; LIPOSITS Z, 1991, ENDOCRINOLOGY, V129, P1575, DOI 10.1210/endo-129-3-1575; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; SAWCHENKO PE, 1984, J NEUROSCI, V4, P1118; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; Smith JT, 2006, J NEUROENDOCRINOL, V18, P298, DOI 10.1111/j.1365-2826.2006.01417.x; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	37	155	164	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1112	1117		10.1038/nm.1866	http://dx.doi.org/10.1038/nm.1866			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18758446	Green Accepted			2022-12-27	WOS:000259892300042
J	Chang, EJ; Ha, J; Oerlemans, F; Lee, YJ; Lee, SW; Ryu, J; Kim, HJ; Lee, Y; Kim, HM; Choi, JY; Kim, JY; Shin, CS; Pak, YK; Tanaka, S; Wieringa, B; Lee, ZH; Kim, HH				Chang, Eun-Ju; Ha, Jeongim; Oerlemans, Frank; Lee, You Jin; Lee, Soo Woong; Ryu, Jiyoon; Kim, Hyung Joon; Lee, Youngkyun; Kim, Hyun-Man; Choi, Je-Yong; Kim, Jin Young; Shin, Chan Soo; Pak, Youngmi Kim; Tanaka, Sakae; Wieringa, Be; Lee, Zang Hee; Kim, Hong-Hee			Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption	NATURE MEDICINE			English	Article							VACUOLAR PROTON PUMP; IN-VIVO; MICE; DIFFERENTIATION; ATPASE; OSTEOPETROSIS; PROTEOMICS; DEFICIENT; SUBUNIT; SYSTEM	Osteoclasts differentiate from precursor cells of the monocyte-macrophage lineage and subsequently become activated to be competent for bone resorption through programs primarily governed by receptor activator of nuclear factor-kappa B ligand in cooperation with macrophage colony-stimulating factor(1-3). Proteins prominently expressed at late phases of osteoclastogenesis and with a supportive role in osteoclast function are potential therapeutic targets for bone-remodeling disorders. In this study, we used a proteomics approach to show that abundance of the brain-type cytoplasmic creatine kinase (Ckb) is greatly increased during osteoclastogenesis. Decreasing Ckb abundance by RNA interference or blocking its enzymatic activity with a pharmacological inhibitor, cyclocreatine, suppressed the bone-resorbing activity of osteoclasts grown in vitro via combined effects on actin ring formation, RhoA GTPase activity and vacuolar ATPase function. Activities of osteoclasts derived from Ckb(-/-) mice were similarly affected. In vivo studies showed that Ckb(-/-) mice were better protected against bone loss induced by ovariectomy, lipopolysaccharide challenge or interleukin-1 treatment than wild-type controls. Furthermore, administration of cyclocreatine or adenoviruses harboring Ckb small hairpin RNA attenuated bone loss in rat and mouse models. Our findings establish an important role for Ckb in the bone-resorbing function of osteoclasts and underscore its potential as a new molecular target for antiresorptive drug development.	[Chang, Eun-Ju; Ha, Jeongim; Ryu, Jiyoon; Kim, Hyung Joon; Lee, Youngkyun; Kim, Hyun-Man; Lee, Zang Hee; Kim, Hong-Hee] Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea; [Oerlemans, Frank] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6500 HB Nijmegen, Netherlands; [Lee, You Jin] Jeonnam Biotechnol Res Ctr, Div Res, Hwasun Gun 519801, Jeollanamdo, South Korea; [Lee, Soo Woong] Inje Univ, Coll Med, Ctr Viral Dis Res, Dept Microbiol, Pusan 614735, South Korea; [Choi, Je-Yong] Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea; [Choi, Je-Yong] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Taegu 700422, South Korea; [Kim, Jin Young] Korea Basic Sci Inst, Taejon 305333, South Korea; [Shin, Chan Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; [Pak, Youngmi Kim] Kyung Hee Univ, Dept Nanopharmaceut & Life Sci, Agerelated & Brain Dis Res Ctr, Seoul 130701, South Korea; [Tanaka, Sakae] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo 1130033, Japan	Seoul National University (SNU); Radboud University Nijmegen; Inje University; Kyungpook National University; Kyungpook National University; Korea Basic Science Institute (KBSI); Seoul National University (SNU); Kyung Hee University; University of Tokyo	Kim, HH (corresponding author), Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, 28 Yeongon Dong, Seoul 110749, South Korea.	b.wieringa@ncmls.ru.nl; hhbkim@snu.ac.kr	Tanaka, Sakae/Y-3061-2019; Ryu, Jiyoon/M-8573-2019; Kim, Hyung Joon/D-6123-2012; Wieringa, Berend/A-5346-2011; Pak, Youngmi Kim/AAI-1091-2020; Lee, Youngkyun/D-2667-2011; Kim, Hyung-Joon/ABD-3143-2020; Shin, Chan Soo/I-7320-2012	Tanaka, Sakae/0000-0001-9210-9414; Ryu, Jiyoon/0000-0001-7365-0555; Wieringa, Berend/0000-0001-9192-8020; Pak, Youngmi Kim/0000-0001-7424-3484; Kim, Hyung-Joon/0000-0002-2962-9553; Shin, Chan Soo/0000-0002-5829-4465	21C Frontier Functional Proteomics Project [FPR08B1-170, FPR08A1-070]; Research Program for New Drug Target Discovery [M10748000257-07N4800-25710]; Ministry of Education, Science & Technology, Korea; NKB-KWF [2002-2763]	21C Frontier Functional Proteomics Project(Ministry of Education, Science & Technology (MEST), Republic of Korea); Research Program for New Drug Target Discovery(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ministry of Education, Science & Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea); NKB-KWF	We thank S. I. Kim, H. B. Kwak, J. Y. Yang, T. K. Yu and J. S. Ko for technical help and discussion. We also thank T. Kitamura (University of Tokyo) for Plat-E cells. This work was supported by the 21C Frontier Functional Proteomics Project grants FPR08B1-170 (to H.-H. K.) and FPR08A1-070 (to Y. K. P.), the Research Program for New Drug Target Discovery grant M10748000257-07N4800-25710 (to H.-H. K.) from the Ministry of Education, Science & Technology, Korea and NKB-KWF grant 2002-2763 (to B. W.).	BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chang EJ, 2004, FEBS LETT, V564, P166, DOI 10.1016/S0014-5793(04)00338-2; Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Crozatier B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0652com; Dzeja PP, 2004, MOL CELL BIOCHEM, V256, P13, DOI 10.1023/B:MCBI.0000009856.23646.38; Fernandez R, 1998, J MEMBRANE BIOL, V163, P137, DOI 10.1007/s002329900378; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jost CR, 2002, EUR J NEUROSCI, V15, P1692, DOI 10.1046/j.1460-9568.2002.02001.x; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kuiper JWP, 2008, PLOS BIOL, V6, P568, DOI 10.1371/journal.pbio.0060051; Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514; Lee Y, 2008, BLOOD, V111, P885, DOI 10.1182/blood-2007-03-082941; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430; SISTERMANS EA, 1995, BIOCHEM J, V311, P445, DOI 10.1042/bj3110445; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vaananen Kalervo, 1996, P103; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; ZHANG D, 1995, J CELL SCI, V108, P2285	27	77	78	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					966	972		10.1038/nm.1860	http://dx.doi.org/10.1038/nm.1860			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18724377				2022-12-27	WOS:000258988600030
J	Bochkis, IM; Rubins, NE; White, P; Furth, EE; Friedman, JR; Kaestner, KH				Bochkis, Irina M.; Rubins, Nir E.; White, Peter; Furth, Emma E.; Friedman, Joshua R.; Kaestner, Klaus H.			Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress	NATURE MEDICINE			English	Article							PRIMARY SCLEROSING CHOLANGITIS; NUCLEAR FACTOR 3-BETA; FARNESOID-X-RECEPTOR; P-GLYCOPROTEIN; TRANSCRIPTION FACTORS; DEFINITIVE ENDODERM; FEEDBACK-REGULATION; KNOCKOUT MICE; LIVER-DISEASE; CHOLESTASIS	Production of bile by the liver is crucial for the absorption of lipophilic nutrients. Dysregulation of bile acid homeostasis can lead to cholestatic liver disease and endoplasmic reticulum ( ER) stress. We show by global location analysis ('ChIP-on-chip') and cell type-specific gene ablation that the winged helix transcription factor Foxa2 is required for normal bile acid homeostasis. As suggested by the location analysis, deletion of Foxa2 in hepatocytes in mice using the Cre-lox system leads to decreased transcription of genes encoding bile acid transporters on both the basolateral and canalicular membranes, resulting in intrahepatic cholestasis. Foxa2-deficient mice are strikingly sensitive to a diet containing cholic acid, which results in toxic accumulation of hepatic bile salts, ER stress and liver injury. In addition, we show that expression of FOXA2 is markedly decreased in liver samples from individuals with different cholestatic syndromes, suggesting that reduced FOXA2 abundance could exacerbate the injury.	[Bochkis, Irina M.; Rubins, Nir E.; White, Peter; Kaestner, Klaus H.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; [Bochkis, Irina M.; Rubins, Nir E.; White, Peter; Kaestner, Klaus H.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Furth, Emma E.] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; [Friedman, Joshua R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Kaestner, KH (corresponding author), Univ Penn, Sch Med, Dept Genet, 415 Curie Blvd, Philadelphia, PA 19104 USA.	kaestner@mail.med.upenn.edu	White, Peter/E-4301-2011; Friedman, Joshua/Q-9367-2019; Bochkis, Irina/AAR-8865-2020	White, Peter/0000-0002-5218-5903; Friedman, Joshua/0000-0001-9382-8429; Bochkis, Irina/0000-0001-8073-8408	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, U01DK056947, R24DK056947, P01DK049210] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG000046, T32-HG000046] Funding Source: Medline; NIDDK NIH HHS [P30 DK019525, P30DK19525, P01 DK049210, DK-056947, DK-049210, R24 DK056947, U01 DK056947] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANG SL, 1993, DEVELOPMENT, V119, P1301; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; Besnard V, 2004, GENE EXPR PATTERNS, V5, P193, DOI 10.1016/j.modgep.2004.08.006; Bombail V, 2004, DRUG METAB DISPOS, V32, P525, DOI 10.1124/dmd.32.5.525; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Coffinier C, 2002, DEVELOPMENT, V129, P1829; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Eloranta JJ, 2005, ARCH BIOCHEM BIOPHYS, V433, P397, DOI 10.1016/j.abb.2004.09.019; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; Fischer S, 1996, CLIN CHIM ACTA, V251, P173, DOI 10.1016/0009-8981(96)06305-X; Geier A, 2005, J HEPATOL, V43, P1021, DOI 10.1016/j.jhep.2005.05.031; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Hagenbuch B, 2003, BBA-BIOMEMBRANES, V1609, P1, DOI 10.1016/S0005-2736(02)00633-8; Hubbard B, 2006, GASTROENTEROLOGY, V130, P1259, DOI 10.1053/j.gastro.2006.02.012; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kullak-Ublick GA, 2004, GASTROENTEROLOGY, V126, P322, DOI 10.1053/j.gastro.2003.06.005; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Lam P, 2005, BIOCHEMISTRY-US, V44, P12598, DOI 10.1021/bi050943e; Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Mennone A, 2006, HEPATOLOGY, V43, P1013, DOI 10.1002/hep.21158; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Oswald M, 2001, LIVER, V21, P247, DOI 10.1034/j.1600-0676.2001.021004247.x; Pauli-Magnus C, 2004, HEPATOLOGY, V39, P779, DOI 10.1002/hep.20159; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4; Rubins NE, 2005, MOL CELL BIOL, V25, P7069, DOI 10.1128/MCB.25.16.7069-7077.2005; Ruiz ML, 2007, DRUG METAB DISPOS, V35, P2060, DOI 10.1124/dmd.107.016519; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Suzuki K, 2006, MOL CELL ENDOCRINOL, V250, P184, DOI 10.1016/j.mce.2005.12.043; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vendemiale G, 2002, J HEPATOL, V37, P601, DOI 10.1016/S0168-8278(02)00234-9; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wang RX, 2003, HEPATOLOGY, V38, P1489, DOI 10.1016/j.hep.2003.09.037; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200; Zhao LH, 2005, NAT GENET, V37, P974, DOI 10.1038/ng1620; Zollner G, 2002, AM J PHYSIOL-GASTR L, V282, pG184, DOI 10.1152/ajpgi.00215.2001; Zollner G, 2005, AM J PHYSIOL-GASTR L, V289, pG798, DOI 10.1152/ajpgi.00319.2004; Zollner G, 2001, HEPATOLOGY, V33, P633, DOI 10.1053/jhep.2001.22646; Zollner G, 2006, MOL PHARMACEUT, V3, P231, DOI 10.1021/mp060010s	54	130	131	1	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2008	14	8					828	836		10.1038/nm.1853	http://dx.doi.org/10.1038/nm.1853			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	334QY	18660816	Green Accepted			2022-12-27	WOS:000258237500029
J	Radu, CG; Shu, CJ; Nair-Gill, E; Shelly, SM; Barrio, JR; Satyamurthy, N; Phelps, ME; Witte, ON				Radu, Caius G.; Shu, Chengyi J.; Nair-Gill, Evan; Shelly, Stephanie M.; Barrio, Jorge R.; Satyamurthy, Nagichettiar; Phelps, Michael E.; Witte, Owen N.			Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [F-18]-labeled 2 '-deoxycytidine analog	NATURE MEDICINE			English	Article							NUCLEOSIDE TRANSPORTER FAMILY; IN-VIVO; DEOXYRIBONUCLEOSIDE KINASES; ANTITUMOR RESPONSE; T-CELLS; MICE; GEMCITABINE; REGRESSION; GENE; PROLIFERATION	Monitoring immune function with molecular imaging could have a considerable impact on the diagnosis and treatment evaluation of immunological disorders and therapeutic immune responses. Positron emission tomography ( PET) is a molecular imaging modality with applications in cancer and other diseases. PET studies of immune function have been limited by a lack of specialized probes. We identified [F-18]FAC (1-(2'-deoxy-2'[F-18] fluoroarabinofuranosyl) cytosine) by differential screening as a new PET probe for the deoxyribonucleotide salvage pathway. [F-18]FAC enabled visualization of lymphoid organs and was sensitive to localized immune activation in a mouse model of antitumor immunity. [F-18] FAC microPET also detected early changes in lymphoid mass in systemic autoimmunity and allowed evaluation of immunosuppressive therapy. These data support the use of [F-18]FAC PET for immune monitoring and suggest a wide range of clinical applications in immune disorders and in certain types of cancer.	[Radu, Caius G.; Nair-Gill, Evan; Shelly, Stephanie M.; Barrio, Jorge R.; Satyamurthy, Nagichettiar; Phelps, Michael E.; Witte, Owen N.] 23 120 Ctr Hlth Sci, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Shu, Chengyi J.; Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Radu, Caius G.; Phelps, Michael E.] Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; [Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Radu, CG (corresponding author), 23 120 Ctr Hlth Sci, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	cradu@mednet.ucla.edu	Radu, Caius/D-3936-2013	Radu, Caius/0000-0002-9338-5397; Nair-Gill, Evan/0000-0002-9876-7853	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P50 CA86306, P50 CA086306, 5U54 CA119347, R24 CA092865, P50 CA086306-10, R24 CA92865, U54 CA119347, U54 CA119347-03] Funding Source: Medline; NIGMS NIH HHS [T32 GM008042, T32 GM008042-23, T32 GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA086306, R24CA092865, U54CA119347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Chow PL, 2006, PHYS MED BIOL, V51, P379, DOI 10.1088/0031-9155/51/2/013; Dubey P, 2003, P NATL ACAD SCI USA, V100, P1232, DOI 10.1073/pnas.0337418100; Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x; FEFER A, 1968, CANCER RES, V28, P1577; Gray JH, 2004, PFLUG ARCH EUR J PHY, V447, P728, DOI 10.1007/s00424-003-1107-y; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; HAMACHER K, 1986, J NUCL MED, V27, P235; KELLEY VE, 1985, CLIN IMMUNOL IMMUNOP, V37, P220, DOI 10.1016/0090-1229(85)90153-9; Koehne G, 2003, NAT BIOTECHNOL, V21, P405, DOI 10.1038/nbt805; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; Mangner TJ, 2003, NUCL MED BIOL, V30, P215, DOI 10.1016/S0969-8051(02)00445-6; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; MORSE HC, 1982, J IMMUNOL, V129, P2612; Nakano Y, 2007, BRIT J CANCER, V96, P457, DOI 10.1038/sj.bjc.6603559; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Pankiewicz KW, 2000, CARBOHYD RES, V327, P87, DOI 10.1016/S0008-6215(00)00089-6; Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Radu CG, 2007, P NATL ACAD SCI USA, V104, P1937, DOI 10.1073/pnas.0610544104; Schepers K, 2002, J IMMUNOL, V169, P3191, DOI 10.4049/jimmunol.169.6.3191; Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337; SHIPLEY LA, 1992, DRUG METAB DISPOS, V20, P849; Shu CYJ, 2005, P NATL ACAD SCI USA, V102, P17412, DOI 10.1073/pnas.0508698102; Su H, 2004, MOL IMAGING BIOL, V6, P139, DOI 10.1016/j.mibio.2004.02.001; Su H, 2006, J IMMUNOL, V176, P4459, DOI 10.4049/jimmunol.176.7.4459; Sun HH, 2005, J NUCL MED, V46, P292; Van der Wilt CL, 2000, ADV EXP MED BIOL, V486, P287; Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001	30	158	168	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2008	14	7					783	788		10.1038/nm1724	http://dx.doi.org/10.1038/nm1724			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18542051	Green Accepted, Green Submitted			2022-12-27	WOS:000257452700028
J	Ahuja, SK; Kulkarni, H; Catano, G; Agan, BK; Camargo, JF; He, W; O'Connell, RJ; Marconi, VC; Delmar, J; Eron, J; Clark, RA; Frost, S; Martin, J; Ahuja, SS; Deeks, SG; Little, S; Richman, D; Hecht, FM; Dolan, MJ				Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Agan, Brian K.; Camargo, Jose F.; He, Weijing; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Eron, Joseph; Clark, Robert A.; Frost, Simon; Martin, Jeffrey; Ahuja, Seema S.; Deeks, Steven G.; Little, Susan; Richman, Douglas; Hecht, Frederick M.; Dolan, Matthew J.			CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED ADULTS; CD4(+) CELL COUNT; PLASMA VIRAL LOAD; DISEASE PROGRESSION; VIROLOGICAL SUPPRESSION; GENETIC PROFILES; RNA LEVEL; AIDS; MORTALITY	The basis for the extensive variability seen in the reconstitution of CD4(+) T cell counts in HIV- infected individuals receiving highly active antiretroviral therapy ( HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility complex HLA alleles, influence immune reconstitution, especially when HAART is initiated at <350 CD4(+) T cells/ mm(3). The CCL3L1- CCR5 genotypes favoring CD4(+) T cell recovery are similar to those that blunted CD4(+) T cell depletion during the time before HAART became available ( pre- HAART era), suggesting that a common CCL3L1- CCR5 genetic pathway regulates the balance between pathogenic and reparative processes from early in the disease course. Hence, CCL3L1-CCR5 variations influence HIV pathogenesis even in the presence of HAART and, therefore, may prospectively identify subjects in whom earlier initiation of therapy is more likely to mitigate immunologic failure despite viral suppression by HAART. Furthermore, as reconstitution of CD4(+) cells during HAART is more sensitive to CCL3L1 dose than to CCR5 genotypes, CCL3L1 analogs might be efficacious in supporting immunological reconstitution.	[Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Camargo, Jose F.; He, Weijing; Clark, Robert A.; Ahuja, Seema S.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV1 Infect, San Antonio, TX 78229 USA; [Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Camargo, Jose F.; He, Weijing; Clark, Robert A.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Agan, Brian K.; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA; [Agan, Brian K.; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA; [Agan, Brian K.; Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA; [Agan, Brian K.; Marconi, Vincent C.; Delmar, Judith; Dolan, Matthew J.] San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA; [Eron, Joseph] Univ N Carolina, Chapel Hill, NC 27599 USA; [Frost, Simon; Little, Susan; Richman, Douglas] Univ Calif San Diego, Antiviral Res Ctr, Dept Med, San Diego, CA 92103 USA; [Frost, Simon; Richman, Douglas] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; [Martin, Jeffrey] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA; [Deeks, Steven G.; Hecht, Frederick M.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; San Antonio Military Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Ahuja, SK (corresponding author), S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV1 Infect, 7400 Merton Minister, San Antonio, TX 78229 USA.	ahujas@uthscsa.edu; mdolan@hjf.org	Clark, Robert/Q-6764-2019; Marconi, Vincent/N-3210-2014; Frost, Simon/F-3648-2010; Marconi, Vincent/GRJ-4553-2022; Marconi, Vincent/AFK-5812-2022; Little, Susan/AAA-6116-2019; Kulkarni, Hemant/AEM-5750-2022; Catano, Gabriel/AAQ-5387-2020	Clark, Robert/0000-0002-4892-3619; Marconi, Vincent/0000-0001-8409-4689; Frost, Simon/0000-0002-5207-9879; Marconi, Vincent/0000-0001-8409-4689; Hecht, Frederick/0000-0002-5782-1171; Agan, Brian/0000-0002-5114-1669	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI046326, R24AI106039, P30AI050410, P01AI074621] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI074621-01A10002, R37 AI046326, P01 AI074621, P30 AI050410, R24 AI106039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anastos K, 2004, ANN INTERN MED, V140, P256, DOI 10.7326/0003-4819-140-4-200402170-00007; Brumme ZL, 2007, J INFECT DIS, V195, P1694, DOI 10.1086/516789; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Carrington M, 2001, IMMUNOL LETT, V79, P131, DOI 10.1016/S0165-2478(01)00275-9; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 2001, JAMA-J AM MED ASSOC, V286, P224, DOI 10.1001/jama.286.2.224; Dolan MJ, 2007, NAT IMMUNOL, V8, P1324, DOI 10.1038/ni1521; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Garcia F, 2004, JAIDS-J ACQ IMM DEF, V36, P702, DOI 10.1097/00126334-200406010-00007; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; Grabar S, 2005, JAIDS-J ACQ IMM DEF, V39, P284, DOI 10.1097/01.qai.0000160925.33935.72; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Gutierrez F, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000089; Hecht FM, 2006, J INFECT DIS, V194, P725, DOI 10.1086/506616; Holmberg SD, 2004, CLIN INFECT DIS, V39, P1699, DOI 10.1086/425743; Hunt PW, 2003, AIDS, V17, P1907, DOI 10.1097/00002030-200309050-00009; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kaslow RA, 2005, J INFECT DIS, V191, pS68, DOI 10.1086/425269; Kasten S, 2000, Eur J Med Res, V5, P323; Kaufmann GR, 2003, ARCH INTERN MED, V163, P2187, DOI 10.1001/archinte.163.18.2187; Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484; Ledergerber B, 2004, LANCET, V364, P51, DOI 10.1016/S0140-6736(04)16589-6; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Mangano A, 2001, J INFECT DIS, V183, P1574, DOI 10.1086/320705; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; MEHANDRU S, 2006, PLOS MED, V484, P1; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Moore DM, 2006, AIDS, V20, P371, DOI 10.1097/01.aids.0000196180.11293.9a; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Nguyen L, 2004, JAIDS-J ACQ IMM DEF, V37, P1318, DOI 10.1097/01.qai.0000127059.98621.55; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; O'Brien TR, 2000, AIDS, V14, P821, DOI 10.1097/00002030-200005050-00008; Pahwa S, 2007, IMMUNOL RES, V38, P373, DOI 10.1007/s12026-007-0036-9; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1, P1; Podlekareva D, 2006, J INFECT DIS, V194, P633, DOI 10.1086/506366; RAUCH A, 2004, IN PRESS CLIN INFECT; Rodriguez B, 2006, JAMA-J AM MED ASSOC, V296, P1498, DOI 10.1001/jama.296.12.1498; Saah AJ, 1998, AIDS, V12, P2107, DOI 10.1097/00002030-199816000-00005; Tang JM, 2002, AIDS, V16, P2275, DOI 10.1097/00002030-200211220-00007; Tarwater PM, 2001, J ACQ IMMUN DEF SYND, V27, P168, DOI 10.1097/00126334-200106010-00012; Tenorio AR, 2003, JAIDS-J ACQ IMM DEF, V34, P491, DOI 10.1097/00126334-200312150-00007; Valdez H, 1999, JAMA-J AM MED ASSOC, V282, P734, DOI 10.1001/jama.282.8.734; Valdez H, 2002, AIDS, V16, P1859, DOI 10.1097/00002030-200209270-00002; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009; Zhang ZQ, 2004, VIROLOGY, V320, P75, DOI 10.1016/j.virol.2003.11.017	50	101	103	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					413	420		10.1038/nm1741	http://dx.doi.org/10.1038/nm1741			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376407	Green Submitted, Green Accepted			2022-12-27	WOS:000254674100028
J	Tsai, YC; Mendoza, A; Mariano, JM; Zhou, M; Kostova, Z; Chen, B; Veenstra, T; Hewitt, SM; Helman, LJ; Khanna, C; Weissman, AM				Tsai, Yien Che; Mendoza, Arnulfo; Mariano, Jennifer M.; Zhou, Ming; Kostova, Zlatka; Chen, Bo; Veenstra, Timothy; Hewitt, Stephen M.; Helman, Lee J.; Khanna, Chand; Weissman, Allan M.			The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation	NATURE MEDICINE			English	Article							AUTOCRINE MOTILITY FACTOR; RETICULUM-ASSOCIATED DEGRADATION; FACTOR-RECEPTOR; ENDOPLASMIC-RETICULUM; SUPPRESSOR GENES; TETRASPANIN CD82; PROTEIN LIGASE; EXPRESSION; CELLS; IDENTIFICATION	Metastasis is the primary cause of mortality from cancer, but the mechanisms leading to metastasis are poorly understood. In particular, relatively little is known about metastasis in cancers of mesenchymal origins, which are known as sarcomas. Approximately ten proteins have been characterized as 'metastasis suppressors', but how these proteins function and are regulated is, in general, not well understood. Gp78 (also known as AMFR or RNF45) is a RING finger E3 ubiquitin ligase that is integral to the endoplasmic reticulum (ER) and involved in ER-associated degradation (ERAD) of diverse substrates(1-6). Here we report that expression of gp78 has a causal role in the metastasis of an aggressive human sarcoma and that this prometastatic activity requires the E3 activity of gp78. Further, gp78 associates with and targets the transmembrane metastasis suppressor, KAI1 (also known as CD82), for degradation. Suppression of gp78 increases KAI1 abundance and reduces the metastatic potential of tumor cells, an effect that is largely blocked by concomitant suppression of KAI1. An inverse relationship between these proteins was confirmed in a human sarcoma tissue microarray. Whereas most previous efforts have focused on genetic mechanisms for the loss of metastasis suppressor genes, our results provide new evidence for post-translational downregulation of a metastasis suppressor by its ubiquitin ligase, resulting in abrogation of its metastasis suppressing effects.	NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Lab Protein Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA; NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA; NCI, Biomed Proteom Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Khanna, C (corresponding author), NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	khannac@mail.nih.gov; amw@nih.gov		Hewitt, Stephen/0000-0001-8283-1788; Tsai, Yien Che/0000-0001-9624-1092	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; Bass R, 2005, J BIOL CHEM, V280, P14811, DOI 10.1074/jbc.M414189200; Berger JC, 2005, CANCER BIOL THER, V4, P805, DOI 10.4161/cbt.4.8.1865; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Hammond C, 1998, J IMMUNOL, V161, P3282; Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kim JH, 2006, NAT CELL BIOL, V8, P631, DOI 10.1038/ncb1415; Lee JN, 2006, J BIOL CHEM, V281, P39308, DOI 10.1074/jbc.M608999200; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; NABI IR, 1990, CANCER RES, V50, P409; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 1999, CANCER RES, V59, P2335; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Shen YX, 2006, BIOCHEM BIOPH RES CO, V349, P1285, DOI 10.1016/j.bbrc.2006.08.173; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; WATANABE H, 1991, J BIOL CHEM, V266, P13442; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200	27	140	149	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1504	1509		10.1038/nm1686	http://dx.doi.org/10.1038/nm1686			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18037895				2022-12-27	WOS:000251445400026
J	Maroso, M; Balosso, S; Ravizza, T; Liu, J; Aronica, E; Iyer, AM; Rossetti, C; Molteni, M; Casalgrandi, M; Manfredi, AA; Bianchi, ME; Vezzani, A				Maroso, Mattia; Balosso, Silvia; Ravizza, Teresa; Liu, Jaron; Aronica, Eleonora; Iyer, Anand M.; Rossetti, Carlo; Molteni, Monica; Casalgrandi, Maura; Manfredi, Angelo A.; Bianchi, Marco E.; Vezzani, Annamaria			Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; CHROMATIN PROTEIN HMGB1; HIPPOCAMPAL SCLEROSIS; MOUSE MODEL; RAT HIPPOCAMPUS; CELLS; MICE; INFLAMMATION; ANTAGONISTS; EXPRESSION	Brain inflammation is a major factor in epilepsy, but the impact of specific inflammatory mediators on neuronal excitability is incompletely understood. Using models of acute and chronic seizures in C57BL/6 mice, we discovered a proconvulsant pathway involving high-mobility group box-1 (HMGB1) release from neurons and glia and its interaction with Toll-like receptor 4 (TLR4), a key receptor of innate immunity. Antagonists of HMGB1 and TLR4 retard seizure precipitation and decrease acute and chronic seizure recurrence. TLR4-defective C3H/HeJ mice are resistant to kainate-induced seizures. The proconvulsant effects of HMGB1, like those of interleukin-1 beta (IL-1 beta), are partly mediated by ifenprodil-sensitive N-methyl-D-aspartate (NMDA) receptors. Increased expression of HMGB1 and TLR4 in human epileptogenic tissue, like that observed in the mouse model of chronic seizures, suggests a role for the HMGB1-TLR4 axis in human epilepsy. Thus, HMGB1-TLR4 signaling may contribute to generating and perpetuating seizures in humans and might be targeted to attain anticonvulsant effects in epilepsies that are currently resistant to drugs.	[Maroso, Mattia; Balosso, Silvia; Ravizza, Teresa; Vezzani, Annamaria] Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy; [Liu, Jaron; Bianchi, Marco E.] San Raffaele Univ, Dept Genet & Cell Biol, Milan, Italy; [Liu, Jaron; Manfredi, Angelo A.; Bianchi, Marco E.] San Raffaele Res Inst, Milan, Italy; [Aronica, Eleonora; Iyer, Anand M.] Acad Med Centrum, Dept Neuro Pathol, Amsterdam, Netherlands; [Aronica, Eleonora] Netherlands Fdn Stichting Epilepsie Instellingen, Heemstede, Netherlands; [Rossetti, Carlo] Univ Insubria, Dept Biotechnol & Mol Sci, Varese, Italy; [Rossetti, Carlo; Molteni, Monica] Mario Negri Inst Pharmacol Res, Dept Environm Hlth Sci, I-20157 Milan, Italy; [Casalgrandi, Maura] HMGBiotech Srl, Milan, Italy; [Manfredi, Angelo A.] San Raffaele Univ, Dept Regenerat Med, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Vita-Salute San Raffaele University; University of Amsterdam; Academic Medical Center Amsterdam; University of Insubria; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Vita-Salute San Raffaele University	Vezzani, A (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.	vezzani@marionegri.it	Ravizza, Teresa/AAB-1440-2020; Manfredi, Angelo A./C-7018-2014; Balosso, Silvia/AAB-1887-2020; Vezzani, Annamaria/AAB-1882-2020; Bianchi, Marco Emilio/K-3417-2018	Ravizza, Teresa/0000-0002-9578-018X; Manfredi, Angelo A./0000-0001-8370-6970; Balosso, Silvia/0000-0001-6712-8023; Vezzani, Annamaria/0000-0003-0573-6175; Bianchi, Marco Emilio/0000-0002-5329-6445; Casalgrandi, Maura/0000-0002-2710-1608; Molteni, Monica/0000-0002-5990-3971; Iyer, Anand/0000-0001-6821-1048; ROSSETTI, CARLO/0000-0002-6806-2975; Aronica, Eleonora/0000-0002-3542-3770	CARIPLO Foundation; Parents Against Childhood Epilepsy; Associazione Italiana Contro l'Epilessia; EU [LSH-CT-2006-037315, 202167]; National Epilepsy Fund [NEF 09-05]; Regione Lombardia	CARIPLO Foundation(Fondazione Cariplo); Parents Against Childhood Epilepsy; Associazione Italiana Contro l'Epilessia; EU(European Commission); National Epilepsy Fund; Regione Lombardia(Regione Lombardia)	This work was supported by a CARIPLO Foundation grant (A. V., M. E. B. and C. R.), by Parents Against Childhood Epilepsy (A. V.), Associazione Italiana Contro l'Epilessia (T. R.), EU FP6 project EPICURE (LSH-CT-2006-037315) (A. V.), EU FP7 project NeuroGlia (No. 202167) and National Epilepsy Fund (NEF 09-05) (E. A.) and a grant from Regione Lombardia to HMGBiotech. J.L. is a recipient of an EU fellowship in the International Graduate Programme in Molecular Medicine training program. We acknowledge F. De Ceglie for technical support in photograph preparation.	Andrassy M, 2008, CIRCULATION, V117, P3216, DOI 10.1161/CIRCULATIONAHA.108.769331; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balosso S, 2008, BRAIN, V131, P3256, DOI 10.1093/brain/awn271; Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794; Boer K, 2008, EPILEPSY RES, V78, P7, DOI 10.1016/j.eplepsyres.2007.10.002; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; Chakravarty S, 2005, J NEUROSCI, V25, P1788, DOI 10.1523/jneurosci.4268-04.2005; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; Crespel A, 2002, BRAIN RES, V952, P159, DOI 10.1016/S0006-8993(02)03050-0; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; DESARRO GB, 1993, NEUROPHARMACOLOGY, V32, P43, DOI 10.1016/0028-3908(93)90128-P; Ebert U, 1997, EUR J PHARMACOL, V322, P179, DOI 10.1016/S0014-2999(97)00084-8; Franklin K. B., 1997, MOUSE BRAIN STEREOTA; Galic MA, 2008, J NEUROSCI, V28, P6904, DOI 10.1523/JNEUROSCI.1901-08.2008; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kralic JE, 2005, EUR J NEUROSCI, V22, P1916, DOI 10.1111/j.1460-9568.2005.04386.x; Kutuzova GD, 2001, J IMMUNOL, V167, P482, DOI 10.4049/jimmunol.167.1.482; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Macagno A, 2006, J EXP MED, V203, P1481, DOI 10.1084/jem.20060136; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Perucca E, 2007, LANCET NEUROL, V6, P793, DOI 10.1016/S1474-4422(07)70215-6; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Ravizza T, 2006, NEUROBIOL DIS, V24, P128, DOI 10.1016/j.nbd.2006.06.003; Ravizza T, 2008, NEUROBIOL DIS, V31, P327, DOI 10.1016/j.nbd.2008.05.007; Ravizza T, 2008, NEUROBIOL DIS, V29, P142, DOI 10.1016/j.nbd.2007.08.012; Ravizza T, 2006, EPILEPSIA, V47, P1160, DOI 10.1111/j.1528-1167.2006.00590.x; Riban V, 2002, NEUROSCIENCE, V112, P101, DOI 10.1016/S0306-4522(02)00064-7; Rodgers KM, 2009, BRAIN, V132, P2478, DOI 10.1093/brain/awp177; Sayyah M, 2003, NEUROSCIENCE, V122, P1073, DOI 10.1016/j.neuroscience.2003.08.043; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SHENG JG, 1994, J NEUROCHEM, V63, P1872; Singh G, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01748.x; Sitia G, 2007, J LEUKOCYTE BIOL, V81, P100, DOI 10.1189/jlb.0306173; Suzuki F, 2005, EPILEPSIA, V46, P193, DOI 10.1111/j.0013-9580.2005.35504.x; Trisciuoglio L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006234; Tsung A, 2007, J EXP MED, V204, P2913, DOI 10.1084/jem.20070247; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009; Viviani B, 2003, J NEUROSCI, V23, P8692; Yang H, 2002, J ENDOTOXIN RES, V8, P469, DOI 10.1179/096805102125001091; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yourick DL, 1999, EUR J PHARMACOL, V371, P147, DOI 10.1016/S0014-2999(99)00183-1; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhao MR, 2009, J NEUROSCI, V29, P2814, DOI 10.1523/JNEUROSCI.4667-08.2009	55	637	686	1	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					413	U91		10.1038/nm.2127	http://dx.doi.org/10.1038/nm.2127			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20348922	Green Published			2022-12-27	WOS:000276446800045
J	Padilla, SL; Carmody, JS; Zeltser, LM				Padilla, Stephanie L.; Carmody, Jill S.; Zeltser, Lori M.			Pomc-expressing progenitors give rise to antagonistic neuronal populations in hypothalamic feeding circuits	NATURE MEDICINE			English	Article							ARCUATE NUCLEUS; LEPTIN; OBESITY; HOMEOSTASIS; ORIGIN; IMPACT; BRAIN; TIME; RAT	Hypothalamic neuron circuits regulating energy balance are highly plastic and develop in response to nutrient and hormonal cues. To identify processes that might be susceptible to gestational influences in mice, we characterized the ontogeny of proopiomelanocortin (POMC) and neuropeptide Y (NPY) cell populations, which exert opposing influences on food intake and body weight. These analyses revealed that Pomc is broadly expressed in immature hypothalamic neurons and that half of embryonic Pomc-expressing precursors subsequently adopt a non-POMC fate in adult mice. Moreover, nearly one quarter of the mature NPY+ cell population shares a common progenitor with POMC+ cells.	[Padilla, Stephanie L.; Carmody, Jill S.; Zeltser, Lori M.] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA; [Zeltser, Lori M.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA; [Padilla, Stephanie L.; Carmody, Jill S.] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Zeltser, LM (corresponding author), Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA.	lz146@columbia.edu			Irving Institute Clinical and Translational Science Award; FACS core (National Center for Research Resources) [UL1 RR024156]; US Institute of Human Nutrition Training [2T32DK007647-21]; American Diabetes Association [7-07RA-195]; Columbia Diabetes and Endocrinology Research Center Pilot and Feasibility Award [P30 DK63608-07]; NY Obesity Research Center Pilot and Feasibility Grant [P30 DK26687-26];  [RO1 DK52431-16];  [F31DK079372]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052431, P30DK026687, P30DK063608, T32DK007647, F31DK079372] Funding Source: NIH RePORTER	Irving Institute Clinical and Translational Science Award; FACS core (National Center for Research Resources)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); US Institute of Human Nutrition Training; American Diabetes Association(American Diabetes Association); Columbia Diabetes and Endocrinology Research Center Pilot and Feasibility Award; NY Obesity Research Center Pilot and Feasibility Grant; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank L. Sussel, H. Wichterle and D. Accili for critical reading of our manuscript and helpful comments; R. Leibel for support and major funding for this project (RO1 DK52431-16); J. Overton for help with confocal imaging; L. Yang of the Diabetes and Endocrinology Research Center Pathology Core for cryosectioning and C. Liu of the Irving Institute Clinical and Translational Science Award, FACS core (National Center for Research Resources UL1 RR024156); M. Low for Pomc-GFP mice (University of Michigan Health Center), J. Elmquist for Pomc-Cre mice Univerisity of Texas Southwestern Medical Center) and B. Lowell for Npy-hrGFP mice (Beth Israel Deaconess Medical Center) for generously providing mouse reagents. This work was supported by F31DK079372 (S. L. P.), US Institute of Human Nutrition Training Grant 2T32DK007647-21 (J. S. C.), American Diabetes Association Grant 7-07RA-195 (L.M.Z.), Columbia Diabetes and Endocrinology Research Center Pilot and Feasibility Award P30 DK63608-07 (L.M.Z.) and NY Obesity Research Center Pilot and Feasibility Grant P30 DK26687-26 (L.M.Z.).	ALTMAN J, 1978, J COMP NEUROL, V182, P945, DOI 10.1002/cne.901820511; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Broad KD, 2009, DEV NEUROBIOL, V69, P314, DOI 10.1002/dneu.20702; Chen H, 2008, ENDOCRINOLOGY, V149, P5348, DOI 10.1210/en.2008-0582; Cottrell EC, 2009, AM J PHYSIOL-REG I, V296, pR631, DOI 10.1152/ajpregu.90690.2008; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Fioramonti X, 2007, DIABETES, V56, P1219, DOI 10.2337/db06-0567; Levin BE, 2006, PHILOS T R SOC B, V361, P1107, DOI 10.1098/rstb.2006.1851; Nilsson I, 2005, DEV BRAIN RES, V155, P147, DOI 10.1016/j.devbrainres.2005.01.009; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Shankar K, 2008, AM J PHYSIOL-REG I, V294, pR528, DOI 10.1152/ajpregu.00316.2007; SHIMADA M, 1973, EXP NEUROL, V41, P163, DOI 10.1016/0014-4886(73)90187-8; Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854; Van den Top M, 2007, NEUROSCIENCE, V144, P815, DOI 10.1016/j.neuroscience.2006.09.059; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	20	200	202	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					403	405		10.1038/nm.2126	http://dx.doi.org/10.1038/nm.2126			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20348924	Green Accepted			2022-12-27	WOS:000276446800043
J	Hofmann, F				Hofmann, Franz			Ido brings down the pressure in systemic inflammation	NATURE MEDICINE			English	Editorial Material							NITRIC-OXIDE; INDOLEAMINE 2,3-DIOXYGENASE; ENDOTHELIUM; SEPSIS	Systemic inflammation results in a life-threatening drop in blood pressure. Targeting known players of blood pressure regulation has so far failed to improve outcomes for individuals with sepsis. But a study points to a regulatory pathway involving the amino acid metabolite kynurenine that may provide new avenues for therapies (pages 279-285).	Tech Univ Munich, Inst Pharmacol & Toxicol, Forschergrp 923, D-8000 Munich, Germany	Technical University of Munich	Hofmann, F (corresponding author), Tech Univ Munich, Inst Pharmacol & Toxicol, Forschergrp 923, D-8000 Munich, Germany.	Hofmann@lrz.tum.de						Bakker J, 2004, CRIT CARE MED, V32, P1, DOI 10.1097/01.CCM.0000105118.66983.19; Huttunen R, 2010, SHOCK, V33, P149, DOI 10.1097/SHK.0b013e3181ad3195; Jung ID, 2009, J IMMUNOL, V182, P3146, DOI 10.4049/jimmunol.0803104; Kirkeboen KA, 1999, ACTA ANAESTH SCAND, V43, P275; Lob S, 2009, NAT REV CANCER, V9, P445, DOI 10.1038/nrc2639; Meurer S, 2009, CIRC RES, V105, P33, DOI 10.1161/CIRCRESAHA.109.198234; Noll G, 1997, INT J MICROCIRC, V17, P273, DOI 10.1159/000179239; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Sugimoto H, 2006, P NATL ACAD SCI USA, V103, P2611, DOI 10.1073/pnas.0508996103; Tetsutani K, 2007, PARASITOLOGY, V134, P923, DOI 10.1017/S0031182007002326; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; YAMAMOTO S, 1967, J BIOL CHEM, V242, P5260	13	18	19	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2010	16	3					265	267		10.1038/nm0310-265	http://dx.doi.org/10.1038/nm0310-265			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208509				2022-12-27	WOS:000275289500026
J	Gaster, RS; Hall, DA; Nielsen, CH; Osterfeld, SJ; Yu, H; Mach, KE; Wilson, RJ; Murmann, B; Liao, JC; Gambhir, SS; Wang, SX				Gaster, Richard S.; Hall, Drew A.; Nielsen, Carsten H.; Osterfeld, Sebastian J.; Yu, Heng; Mach, Kathleen E.; Wilson, Robert J.; Murmann, Boris; Liao, Joseph C.; Gambhir, Sanjiv S.; Wang, Shan X.			Matrix-insensitive protein assays push the limits of biosensors in medicine	NATURE MEDICINE			English	Article							SPIN-VALVE SENSORS; OVARIAN-CANCER; SUPERPARAMAGNETIC NANOPARTICLES; BIOLOGICAL APPLICATIONS; DNA DETECTION; MICROARRAYS; LACTOFERRIN; BIOMARKER	Advances in biosensor technologies for in vitro diagnostics have the potential to transform the practice of medicine. Despite considerable work in the biosensor field, there is still no general sensing platform that can be ubiquitously applied to detect the constellation of biomolecules in diverse clinical samples (for example, serum, urine, cell lysates or saliva) with high sensitivity and large linear dynamic range. A major limitation confounding other technologies is signal distortion that occurs in various matrices due to heterogeneity in ionic strength, pH, temperature and autofluorescence. Here we present a magnetic nanosensor technology that is matrix insensitive yet still capable of rapid, multiplex protein detection with resolution down to attomolar concentrations and extensive linear dynamic range. The matrix insensitivity of our platform to various media demonstrates that our magnetic nanosensor technology can be directly applied to a variety of settings such as molecular biology, clinical diagnostics and biodefense.	[Hall, Drew A.; Murmann, Boris; Wang, Shan X.] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; [Gaster, Richard S.; Gambhir, Sanjiv S.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Gaster, Richard S.] Stanford Univ, Med Scientist Training Program, Stanford, CA 94305 USA; [Nielsen, Carsten H.; Gambhir, Sanjiv S.] Stanford Univ, Dept Radiol, Mol Imaging Program Stanford, Stanford, CA 94305 USA; [Nielsen, Carsten H.] Rigshosp, Dept Clin Physiol Nucl Med & Positron Emiss Tomog, Copenhagen, Denmark; [Nielsen, Carsten H.] Univ Copenhagen, DK-1168 Copenhagen, Denmark; [Nielsen, Carsten H.] Tech Univ Denmark, Dept Elect Engn, Sect Biomed Engn, Lyngby, Denmark; [Osterfeld, Sebastian J.; Wilson, Robert J.; Wang, Shan X.] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA; [Osterfeld, Sebastian J.; Yu, Heng] MagArray Inc, Sunnyvale, CA USA; [Mach, Kathleen E.; Liao, Joseph C.] Stanford Univ, Dept Urol, Stanford, CA 94305 USA; [Liao, Joseph C.; Gambhir, Sanjiv S.; Wang, Shan X.] Stanford Univ, Biox Program, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Rigshospitalet; University of Copenhagen; University of Copenhagen; Technical University of Denmark; Stanford University; Stanford University; Stanford University	Wang, SX (corresponding author), Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.	sgambhir@stanford.edu; sxwang@stanford.edu	Hall, Drew A/C-6068-2012	Hall, Drew A/0000-0003-0674-074X; Liao, Joseph/0000-0003-2448-5463; Osterfeld, Sebastian/0000-0003-2822-990X; Murmann, Boris/0000-0003-3417-8782	US National Cancer Institute [1U54CA119367, N44CM-2009-00011]; US National Science Foundation [ECCS-0801385-000]; US Defense Threat Reduction Agency [HDTRA1-07-1-0030-P00005]; US Defense Advanced Research Projects Agency/Navy [N00014-02-1-0807]; NCI ICMIC [P50 CA114747]; US Department of Veterans Affairs Merit Review [B4872]; Canary Foundation; The National Semiconductor Corporation; Stanford Medical School Medical Scientist Training Program; National Science Foundation; Denmark-American Foundation; Lundbeck Foundation; NATIONAL CANCER INSTITUTE [P50CA114747, U54CA119367] Funding Source: NIH RePORTER	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US National Science Foundation(National Science Foundation (NSF)); US Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); US Defense Advanced Research Projects Agency/Navy(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NCI ICMIC; US Department of Veterans Affairs Merit Review(US Department of Veterans Affairs); Canary Foundation; The National Semiconductor Corporation; Stanford Medical School Medical Scientist Training Program; National Science Foundation(National Science Foundation (NSF)); Denmark-American Foundation; Lundbeck Foundation(Lundbeckfonden); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by US National Cancer Institute grants 1U54CA119367 and N44CM-2009-00011, US National Science Foundation grant ECCS-0801385-000, US Defense Threat Reduction Agency grant HDTRA1-07-1-0030-P00005, the US Defense Advanced Research Projects Agency/Navy Grant N00014-02-1-0807, NCI ICMIC P50 CA114747, the US Department of Veterans Affairs Merit Review B4872, the Canary Foundation and The National Semiconductor Corporation. R. S. G. acknowledges financial support from Stanford Medical School Medical Scientist Training Program and a National Science Foundation graduate research fellowship. C. H. N. acknowledges financial support from the Denmark-American Foundation and the Lundbeck Foundation.	Arao S, 1999, J CLIN MICROBIOL, V37, P553, DOI 10.1128/JCM.37.3.553-557.1999; BARNAS J, 1990, PHYS REV B, V42, P8110, DOI 10.1103/PhysRevB.42.8110; Baselt DR, 1998, BIOSENS BIOELECTRON, V13, P731, DOI 10.1016/S0956-5663(98)00037-2; Chan SM, 2004, NAT MED, V10, P1390, DOI 10.1038/nm1139; Chen Z, 2008, NAT BIOTECHNOL, V26, P1285, DOI 10.1038/nbt.1501; Cheng MMC, 2006, CURR OPIN CHEM BIOL, V10, P11, DOI 10.1016/j.cbpa.2006.01.006; Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711; Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Ghosh S, 2003, SCIENCE, V299, P1042, DOI 10.1126/science.1079080; Gorelik E, 2005, CANCER EPIDEM BIOMAR, V14, P981, DOI 10.1158/1055-9965.EPI-04-0404; Graham DL, 2002, J APPL PHYS, V91, P7786, DOI 10.1063/1.1451898; Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523; Ji HF, 2008, ANALYST, V133, P434, DOI 10.1039/b713330h; Li GX, 2006, SENSOR ACTUAT A-PHYS, V126, P98, DOI 10.1016/j.sna.2005.10.001; Li GX, 2003, J APPL PHYS, V93, P7557, DOI 10.1063/1.1540176; Lopez MF, 2007, CLIN CHEM, V53, P1067, DOI 10.1373/clinchem.2006.080721; Millen RL, 2005, ANAL CHEM, V77, P6581, DOI 10.1021/ac0509049; Mitchell P, 2002, NAT BIOTECHNOL, V20, P225, DOI 10.1038/nbt0302-225; Mukherjee S, 1997, BIOL TRACE ELEM RES, V57, P1, DOI 10.1007/BF02803864; Osterfeld SJ, 2008, P NATL ACAD SCI USA, V105, P20637, DOI 10.1073/pnas.0810822105; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Schotter J, 2004, BIOSENS BIOELECTRON, V19, P1149, DOI 10.1016/j.bios.2003.11.007; Shingyoji M, 2005, TALANTA, V67, P472, DOI 10.1016/j.talanta.2005.06.064; Srinivas PR, 2001, CLIN CHEM, V47, P1901; Stern E, 2007, NATURE, V445, P519, DOI 10.1038/nature05498; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856; Xu L, 2008, BIOSENS BIOELECTRON, V24, P99, DOI 10.1016/j.bios.2008.03.030; Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138; Zheng YY, 2007, CLIN CANCER RES, V13, P6984, DOI 10.1158/1078-0432.CCR-07-1409; ZIMMERMAN R, 1980, CANCER-AM CANCER SOC, V46, P1802, DOI 10.1002/1097-0142(19801015)46:8<1802::AID-CNCR2820460818>3.0.CO;2-5	33	302	317	7	133	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1327	U130		10.1038/nm.2032	http://dx.doi.org/10.1038/nm.2032			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19820717	Green Accepted			2022-12-27	WOS:000271543700023
J	Bellinger, AM; Reiken, S; Carlson, C; Mongillo, M; Liu, XP; Rothman, L; Matecki, S; Lacampagne, A; Marks, AR				Bellinger, Andrew M.; Reiken, Steven; Carlson, Christian; Mongillo, Marco; Liu, Xiaoping; Rothman, Lisa; Matecki, Stefan; Lacampagne, Alain; Marks, Andrew R.			Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MDX MOUSE; S-NITROSYLATION; DEFECTIVE REGULATION; HEART-FAILURE; PHOSPHORYLATION; PROTEIN; FIBERS	Duchenne muscular dystrophy is characterized by progressive muscle weakness and early death resulting from dystrophin deficiency. Loss of dystrophin results in disruption of a large dystrophin glycoprotein complex, leading to pathological calcium (Ca2+)-dependent signals that damage muscle cells(1-5). We have identified a structural and functional defect in the ryanodine receptor (RyR1), a sarcoplasmic reticulum Ca2+ release channel, in the mdx mouse model of muscular dystrophy that contributes to altered Ca2+ homeostasis in dystrophic muscles. RyR1 isolated from mdx skeletal muscle showed an age-dependent increase in S-nitrosylation coincident with dystrophic changes in the muscle. RyR1 S-nitrosylation depleted the channel complex of FKBP12 (also known as calstabin-1, for calcium channel stabilizing binding protein), resulting in 'leaky' channels. Preventing calstabin-1 depletion from RyR1 with S107, a compound that binds the RyR1 channel and enhances the binding affinity of calstabin-1 to the nitrosylated channel, inhibited sarcoplasmic reticulum Ca2+ leak, reduced biochemical and histological evidence of muscle damage, improved muscle function and increased exercise performance in mdx mice. On the basis of these findings, we propose that sarcoplasmic reticulum Ca2+ leak via RyR1 due to S-nitrosylation of the channel and calstabin-1 depletion contributes to muscle weakness in muscular dystrophy, and that preventing the RyR1-mediated sarcoplasmic reticulum Ca2+ leak may provide a new therapeutic approach.	[Bellinger, Andrew M.; Reiken, Steven; Carlson, Christian; Mongillo, Marco; Liu, Xiaoping; Rothman, Lisa; Marks, Andrew R.] Columbia Univ, Coll Phys & Surg, Clyde & Helen Wu Ctr Mol Cardiol, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; [Bellinger, Andrew M.; Reiken, Steven; Carlson, Christian; Mongillo, Marco; Liu, Xiaoping; Rothman, Lisa; Marks, Andrew R.] Columbia Univ, Coll Phys & Surg, Clyde & Helen Wu Ctr Mol Cardiol, Dept Med, New York, NY 10032 USA; [Matecki, Stefan] INSERM, ERI 25, F-34295 Montpellier, France; [Matecki, Stefan; Lacampagne, Alain] Univ Montpellier 1, Unite Format & Rech Med, F-34295 Montpellier, France; [Lacampagne, Alain] INSERM, U 637, F-34295 Montpellier, France	Columbia University; Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Clyde & Helen Wu Ctr Mol Cardiol, Dept Physiol & Cellular Biophys, 630 W 168th St, New York, NY 10032 USA.	arm42@columbia.edu	Lacampagne, Alain/S-3719-2016	Lacampagne, Alain/0000-0003-0264-1787	Leducq Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180] Funding Source: NIH RePORTER	Leducq Foundation(Leducq Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by a grant from the Leducq Foundation. We thank J. Shan for assistance with analyses of histologic sections and J. Fauconnier for help with voluntary exercise measurements in mice.	Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Bellinger AM, 2008, P NATL ACAD SCI USA, V105, P2198, DOI 10.1073/pnas.0711074105; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BODENSTEINER JB, 1978, NEUROLOGY, V28, P439, DOI 10.1212/WNL.28.5.439; Boittin FX, 2006, J CELL SCI, V119, P3733, DOI 10.1242/jcs.03184; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRADLEY WG, 1978, NEUROLOGY, V28, P670, DOI 10.1212/WNL.28.7.670; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GLESBY MJ, 1988, MUSCLE NERVE, V11, P852, DOI 10.1002/mus.880110809; Goyenvalle A, 2004, SCIENCE, V306, P1796, DOI 10.1126/science.1104297; Gregorevic P, 2006, NAT MED, V12, P787, DOI 10.1038/nm1439; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kobayashi YM, 2008, NATURE, V456, P511, DOI 10.1038/nature07414; Krag TOB, 2004, P NATL ACAD SCI USA, V101, P13856, DOI 10.1073/pnas.0405972101; Louboutin JP, 2001, MOL MED, V7, P355, DOI 10.1007/BF03402218; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; Sun JH, 2003, J BIOL CHEM, V278, P8184, DOI 10.1074/jbc.M211940200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vilquin JT, 1998, MUSCLE NERVE, V21, P567, DOI 10.1002/(SICI)1097-4598(199805)21:5<567::AID-MUS2>3.0.CO;2-6; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; Wehrens XHT, 2005, P NATL ACAD SCI USA, V102, P9607, DOI 10.1073/pnas.0500353102; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275; Zaccagnini G, 2007, J BIOL CHEM, V282, P31453, DOI 10.1074/jbc.M702511200	42	359	369	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					325	330		10.1038/nm.1916	http://dx.doi.org/10.1038/nm.1916			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19198614	Green Accepted			2022-12-27	WOS:000263914000034
J	Urano, Y; Asanuma, D; Hama, Y; Koyama, Y; Barrett, T; Kamiya, M; Nagano, T; Watanabe, T; Hasegawa, A; Choyke, PL; Kobayashi, H				Urano, Yasuteru; Asanuma, Daisuke; Hama, Yukihiro; Koyama, Yoshinori; Barrett, Tristan; Kamiya, Mako; Nagano, Tetsuo; Watanabe, Toshiaki; Hasegawa, Akira; Choyke, Peter L.; Kobayashi, Hisataka			Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes	NATURE MEDICINE			English	Article							PRIMARY BREAST-CANCER; IN-VIVO; RATIONAL DESIGN; ANTITUMOR-ACTIVITY; METASTATIC SITES; LIVE CELLS; RHODAMINE; ANTIBODY; HER2/NEU; MICE	A long-term goal of cancer diagnosis is to develop tumor-imaging techniques that have sufficient specificity and sensitivity. To achieve this goal, minimizing the background signal originating from nontarget tissues is crucial. Here we achieve highly specific in vivo cancer visualization by using a newly designed targeted 'activatable' fluorescent imaging probe. This agent is activated after cellular internalization by sensing the pH change in the lysosome. Novel acidic pH-activatable probes based on the boron-dipyrromethene fluorophore were synthesized and then conjugated to a cancer-targeting monoclonal antibody. As proof of concept, ex vivo and in vivo imaging of human epidermal growth factor receptor type 2-positive lung cancer cells in mice was performed. The probe was highly specific for tumors with minimal background signal. Furthermore, because the acidic pH in lysosomes is maintained by the energy-consuming proton pump, only viable cancer cells were successfully visualized. The design concept can be widely adapted to cancer-specific, cell surface-targeting molecules that result in cellular internalization.	[Urano, Yasuteru; Asanuma, Daisuke; Kamiya, Mako; Nagano, Tetsuo] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Urano, Yasuteru] Japan Sci & Technol Agcy, PRESTO, Chiyoda Ku, Tokyo 1020075, Japan; [Hama, Yukihiro; Koyama, Yoshinori; Barrett, Tristan; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Watanabe, Toshiaki; Hasegawa, Akira] Olympus Corp, Div Res & Dev, Adv Core Technol Dept, Mol Diagnost Technol Grp, Tokyo 1928512, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Olympus Corporation	Urano, Y (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	urano@mol.f.u-tokyo.ac.jp; kobayash@mail.nih.gov	Urano, Yasuteru/H-1380-2012	Barrett, Tristan/0000-0002-1180-1474	Precursory Research for Embryonic Sciences and Technology from the Japan Science and Technology Agency [19021010, 19205021]; Intramural Research Program of the US National Institutes of Health; National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010657] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [20117003] Funding Source: KAKEN	Precursory Research for Embryonic Sciences and Technology from the Japan Science and Technology Agency; Intramural Research Program of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by the Precursory Research for Embryonic Sciences and Technology from the Japan Science and Technology Agency, by research grants 19021010 and 19205021 to Y. U. and by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research to Y. H., Y. K., T. B., P. L. C. and H. K.	Adie EJ, 2002, BIOTECHNIQUES, V33, P1152, DOI 10.2144/02335dd10; Alencar H, 2007, RADIOLOGY, V244, P232, DOI 10.1148/radiol.2441052114; Baselga J, 1998, CANCER RES, V58, P2825; De Grand AM, 2003, TECHNOL CANCER RES T, V2, P553, DOI 10.1177/153303460300200607; de Silva AP, 1997, CHEM REV, V97, P1515, DOI 10.1021/cr960386p; Gabe Y, 2004, J AM CHEM SOC, V126, P3357, DOI 10.1021/ja037944j; Gancberg D, 2002, ANN ONCOL, V13, P1036, DOI 10.1093/annonc/mdf252; Hama Y, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2779351; Hama Y, 2007, CANCER RES, V67, P2791, DOI 10.1158/0008-5472.CAN-06-3315; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Kamiya M, 2007, J AM CHEM SOC, V129, P3918, DOI 10.1021/ja067710a; Kollmannsberger M, 1998, J PHYS CHEM A, V102, P10211, DOI 10.1021/jp982701c; Koyama Y, 2007, CLIN CANCER RES, V13, P2936, DOI 10.1158/1078-0432.CCR-06-2240; Levenson RM, 2006, CYTOM PART A, V69A, P748, DOI 10.1002/cyto.a.20319; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Mandler R, 2004, CANCER RES, V64, P1460, DOI 10.1158/0008-5472.CAN-03-2485; MINTA A, 1989, J BIOL CHEM, V264, P8171; Miura T, 2003, J AM CHEM SOC, V125, P8666, DOI 10.1021/ja035282s; NWOKOLO CU, 1994, GUT, V35, P299, DOI 10.1136/gut.35.3.299; PARADISO AM, 1984, P NATL ACAD SCI-BIOL, V81, P7436, DOI 10.1073/pnas.81.23.7436; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Tanaka K, 2001, J AM CHEM SOC, V123, P2530, DOI 10.1021/ja0035708; Ueno T, 2004, J AM CHEM SOC, V126, P14079, DOI 10.1021/ja048241k; Urano Y, 2005, J AM CHEM SOC, V127, P4888, DOI 10.1021/ja043919h; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Yamamoto N, 2004, CANCER RES, V64, P4251, DOI 10.1158/0008-5472.CAN-04-0643; Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063; Yang M, 2007, CANCER RES, V67, P5195, DOI 10.1158/0008-5472.CAN-06-4590; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zidan J, 2005, BRIT J CANCER, V93, P552, DOI 10.1038/sj.bjc.6602738	32	648	678	10	428	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2009	15	1					104	109		10.1038/nm.1854	http://dx.doi.org/10.1038/nm.1854			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19029979	Green Accepted			2022-12-27	WOS:000262425100025
J	Nasr, R; Guillemin, MC; Ferhi, O; Soilihi, H; Peres, L; Berthier, C; Rousselot, P; Robledo-Sarmiento, M; Lallemand-Breitenbach, V; Gourmel, B; Vitoux, D; Pandolfi, PP; Rochette-Egly, C; Zhu, J; The, H				Nasr, Rihab; Guillemin, Marie-Claude; Ferhi, Omar; Soilihi, Hassan; Peres, Laurent; Berthier, Caroline; Rousselot, Philippe; Robledo-Sarmiento, Macarena; Lallemand-Breitenbach, Valerie; Gourmel, Bernard; Vitoux, Dominique; Pandolfi, Pier Paolo; Rochette-Egly, Cecile; Zhu, Jun; de The, Hugues			Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation	NATURE MEDICINE			English	Article							TRANS-RETINOIC ACID; ARSENIC-TRIOXIDE; MYELOID-LEUKEMIA; STEM-CELLS; CROSS-TALK; ALPHA; PROTEIN; RXR; DIFFERENTIATION; APOPTOSIS	Retinoic acid and arsenic trioxide target the protein stability and transcriptional repression activity of the fusion oncoprotein PML-RARA, resulting in regression of acute promyelocytic leukemia (APL). Phenotypically, retinoic acid induces differentiation of APL cells. Here we show that retinoic acid also triggers growth arrest of leukemia-initiating cells (LICs) ex vivo and their clearance in PML-RARA mouse APL in vivo. Retinoic acid treatment of mouse APLs expressing the fusion protein PLZF-RARA triggers full differentiation, but not LIC loss or disease remission, establishing that differentiation and LIC loss can be uncoupled. Although retinoic acid and arsenic synergize to clear LICs through cooperative PML-RARA degradation, this combination does not enhance differentiation. A cyclic AMP (cAMP)-dependent phosphorylation site in PML-RARA is crucial for retinoic acid-induced PML-RARA degradation and LIC clearance. Moreover, activation of cAMP signaling enhances LIC loss by retinoic acid, identifying cAMP as another potential APL therapy. Thus, whereas transcriptional activation of PML-RARA is likely to control differentiation, its catabolism triggers LIC eradication and long-term remission of mouse APL. Therapy-triggered degradation of oncoproteins could be a general strategy to eradicate cancer stem cells.	[Rousselot, Philippe] Univ Paris 05, UFR Med, F-78157 Le Chesnay, France; [Nasr, Rihab; Guillemin, Marie-Claude; Ferhi, Omar; Soilihi, Hassan; Peres, Laurent; Berthier, Caroline; Robledo-Sarmiento, Macarena; Lallemand-Breitenbach, Valerie; Gourmel, Bernard; Vitoux, Dominique; Zhu, Jun; de The, Hugues] Univ Paris 07, CNRS, Hop St Louis,UMR 7151, Serv Biochim,Equipe Labellisee Ligue Natl Ctr Can, F-75475 Paris, France; [Rousselot, Philippe] Hop Mignot, F-78157 Le Chesnay, France; [Pandolfi, Pier Paolo] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Rochette-Egly, Cecile] Inst Genet & Biol Mol & Cellulaire, Dept Funct Genom, F-67400 Illkirch Graffenstaden, France; [Zhu, Jun; de The, Hugues] Rui Jin Hosp, Shanghai Inst Hematol, CNRS, Lab Associe MPC, Shanghai 200025, Peoples R China	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier de Versailles; Harvard University; Beth Israel Deaconess Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	The, H (corresponding author), Univ Paris 07, CNRS, Hop St Louis,UMR 7151, Serv Biochim,Equipe Labellisee Ligue Natl Ctr Can, 1 Av C Vellefaux, F-75475 Paris, France.	dethe@univ-paris-diderot.fr	Nasr, Rihab/AAF-1606-2020	Nasr, Rihab/0000-0003-1166-4999; Lallemand, Valerie/0000-0001-9852-204X	Lady Tata Foundation (London); ARECA; EPITRON [LSHC-CT-2005-518417]; INCa/Canceropole	Lady Tata Foundation (London); ARECA; EPITRON; INCa/Canceropole(Institut National du Cancer (INCA) France)	R.N. was supported by the Lady Tata Foundation (London). This work was supported by the ARECA, EPITRON (an integrated project funded by the European Union under the sixth framework program (LSHC-CT-2005-518417)) and INCa/Canceropole programs. We thank J. Godet and the Comite des Yvelines de la Ligue contre le Cancer for their continuous support of this project; M. Pla and the animal housing facility; C. Leboeuf, L. Legres and A. Janin for facilitation of the pathological analysis of the mice; M. Kawatika, M. Giovanini and F. Riaucoux for the derivation of MRP8-PML-RARAS873A transgenic mice; P. Chambon for the antibody to RARA; S. Kogan for the APLs and the MSCV-luciferase vector; B. Arnulf for bortezomib; H. Tenor (Altana/Nycomed) for piclamilast; O. Hermine and F. Valensi for help with the t(11;17) human data; the Treilles and IPSEN foundations for providing the setting where this work was first presented and developed; and A. Saib, J.C. Gluckman and F. Sigaux for critical reading of the manuscript.	Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Chen GQ, 1996, LEUKEMIA, V10, P825; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Estey E, 2006, BLOOD, V107, P3469, DOI 10.1182/blood-2005-10-4006; Gaillard E, 2006, P NATL ACAD SCI USA, V103, P9548, DOI 10.1073/pnas.0509717103; Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Lallemand-Breitenbach V, 2005, NAT REV CANCER, V5, P821, DOI 10.1038/nrc1719; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Mann KK, 2005, J CLIN INVEST, V115, P2924, DOI 10.1172/JCI23628; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MUINDI J, 1992, BLOOD, V79, P299; Nervi C, 1998, BLOOD, V92, P2244; Parrella E, 2004, J BIOL CHEM, V279, P42026, DOI 10.1074/jbc.M406530200; Purton LE, 2006, J EXP MED, V203, P1283, DOI 10.1084/jem.20052105; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P1062, DOI 10.1080/10428190500463932; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; van Wageningen S, 2008, BLOOD, V111, P1634, DOI 10.1182/blood-2007-04-081125; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; VOM BE, 1996, EMBO J, V15, P110; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Westervelt P, 2002, P NATL ACAD SCI USA, V99, P9468, DOI 10.1073/pnas.132657799; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102; Zheng XM, 2007, HAEMATOLOGICA, V92, P323, DOI 10.3324/haematol.10541; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103; Zhu J, 2005, CANCER CELL, V7, P143, DOI 10.1016/j.ccr.2005.01.005; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	50	265	282	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1333	1342		10.1038/nm.1891	http://dx.doi.org/10.1038/nm.1891			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19029980				2022-12-27	WOS:000261393600017
J	Baulcombe, D				Baulcombe, David			Of maize and men, or peas and people: case histories to justify plants and other model systems	NATURE MEDICINE			English	Editorial Material							DOUBLE-STRANDED-RNA; TRANSGENIC PLANTS; GENE-EXPRESSION; HOMOLOGOUS GENES; INTERFERING RNA; TOBACCO PLANTS; ANTISENSE RNA; MOSAIC-VIRUS; C-ELEGANS; SUPPRESSION		Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	University of Cambridge	Baulcombe, D (corresponding author), Univ Cambridge, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.	dcb40@cam.ac.uk		Baulcombe, David/0000-0003-0780-6878	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ABEL PP, 1986, SCIENCE, V232, P738, DOI 10.1126/science.3457472; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Comfort NC, 2001, TRENDS BIOCHEM SCI, V26, P454, DOI 10.1016/S0968-0004(01)01898-9; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; Cullen BR, 2006, NAT IMMUNOL, V7, P563, DOI 10.1038/ni1352; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISCHHOFF DA, 1987, BIO-TECHNOL, V5, P807, DOI 10.1038/nbt0887-807; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; Herr AJ, 2006, P NATL ACAD SCI USA, V103, P14994, DOI 10.1073/pnas.0606536103; Hooke R, 1664, MICROGRAPHIA; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kasschau KD, 2007, PLOS BIOL, V5, P479, DOI 10.1371/journal.pbio.0050057; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; LONGSTAFF M, 1993, EMBO J, V12, P379, DOI 10.1002/j.1460-2075.1993.tb05669.x; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Matzke MA, 2004, PLOS BIOL, V2, P582, DOI 10.1371/journal.pbio.0020133; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Mosher RA, 2008, P NATL ACAD SCI USA, V105, P3145, DOI 10.1073/pnas.0709632105; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; Ogawa Y, 2008, SCIENCE, V320, P1336, DOI 10.1126/science.1157676; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pontes O, 2006, CELL, V126, P79, DOI 10.1016/j.cell.2006.05.031; Potrykus I, 2001, PLANT PHYSIOL, V125, P1157, DOI 10.1104/pp.125.3.1157; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SHAH DM, 1986, SCIENCE, V233, P478, DOI 10.1126/science.233.4762.478; SMITH CJS, 1990, MOL GEN GENET, V224, P477, DOI 10.1007/BF00262443; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; van Kammen A, 1999, ARCH VIROL, P1; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; VANDUN CMP, 1987, VIROLOGY, V159, P299, DOI 10.1016/0042-6822(87)90467-3; Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zamore PD, 2006, CELL, V127, P1083, DOI 10.1016/j.cell.2006.12.001; Zhang XY, 2007, P NATL ACAD SCI USA, V104, P4536, DOI 10.1073/pnas.0611456104	53	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2008	14	10					1046	1049		10.1038/nm1008-1046	http://dx.doi.org/10.1038/nm1008-1046			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	358BU	18841146				2022-12-27	WOS:000259892300033
J	Piomelli, D				Piomelli, Daniele			The element of surprise	NATURE MEDICINE			English	Editorial Material							CANNABINOID-1 RECEPTOR BLOCKER; CARDIOMETABOLIC RISK-FACTORS; OVERWEIGHT PATIENTS; RIMONABANT; WEIGHT		[Piomelli, Daniele] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; [Piomelli, Daniele] Italian Inst Technol, Unit Drug Discovery & Dev, I-161631 Genoa, Italy	University of California System; University of California Irvine; Istituto Italiano di Tecnologia - IIT	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	piomelli@uci.edu						Bortolato M, 2007, BIOL PSYCHIAT, V62, P1103, DOI 10.1016/j.biopsych.2006.12.001; Colombo G, 1998, LIFE SCI, V63, pPL113, DOI 10.1016/S0024-3205(98)00322-1; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cote M, 2007, INT J OBESITY, V31, P692, DOI 10.1038/sj.ijo.0803539; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Garnier JP, 2008, HARVARD BUS REV, V86, P68; Jeong WI, 2008, CELL METAB, V7, P227, DOI 10.1016/j.cmet.2007.12.007; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Meltzer HY, 2004, AM J PSYCHIAT, V161, P975, DOI 10.1176/appi.ajp.161.6.975; MOREAU J, 1945, HACHICH ALIENATION M; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Scheen AJ, 2006, LANCET, V368, P1660, DOI 10.1016/S0140-6736(06)69571-8; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; VANGAAL L, 2008, EUR HEART J     0415	15	6	6	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					720	721		10.1038/nm0708-720	http://dx.doi.org/10.1038/nm0708-720			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18607371	Green Submitted			2022-12-27	WOS:000257452700017
J	Shen, L; Peterson, S; Sedaghat, AR; McMahon, MA; Callender, M; Zhang, HL; Zhou, Y; Pitt, E; Anderson, KS; Acosta, EP; Siliciano, RF				Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.; McMahon, Moira A.; Callender, Marc; Zhang, Haili; Zhou, Yan; Pitt, Eleanor; Anderson, Karen S.; Acosta, Edward P.; Siliciano, Robert F.			Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DARUNAVIR-RITONAVIR; VIRAL DYNAMICS; INFECTION; THERAPY; PHARMACODYNAMICS; SUSCEPTIBILITY; REPLICATION; ZIDOVUDINE	Highly active antiretroviral therapy (HAART) can control HIV-1 replication(1,2), but suboptimal treatment allows for the evolution of resistance and rebound viremia(3-8). A comparative measure of antiviral activity under clinically relevant conditions would guide drug development and the selection of regimens that maximally suppress replication. Here we show that current measures of antiviral activity, including IC(50) and inhibitory quotient, neglect a key dimension, the dose-response curve slope. Using infectivity assays with wide dynamic range, we show that this slope has noteworthy effects on antiviral activity. Slope values are class specific for antiviral drugs and define intrinsic limitations on antiviral activity for some classes. Nucleoside reverse transcriptase inhibitors and integrase inhibitors have slopes of similar to 1, characteristic of noncooperative reactions, whereas non-nucleoside reverse transcriptase inhibitors, protease inhibitors and fusion inhibitors unexpectedly show slopes >1. Instantaneous inhibitory potential (IIP), the log reduction in single-round infectivity at clinical drug concentrations, is strongly influenced by slope and varies by >8 logs for anti-HIV drugs. IIP provides a more accurate measure of antiviral activity and in general correlates with clinical outcomes. Only agents with slopes >1 achieve high-level inhibition of single-round infectivity, a finding with profound implications for drug and vaccine development.	[Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.; McMahon, Moira A.; Callender, Marc; Zhang, Haili; Zhou, Yan; Pitt, Eleanor; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Shen, Lin; McMahon, Moira A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Acosta, Edward P.] Univ Alabama, Med Sch Birmingham, Div Clin Pharmacol, Birmingham, AL 35294 USA; [Siliciano, Robert F.] Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Yale University; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 733 N Broadway, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu		Shen, Lin/0000-0003-2392-3353; McMahon, Moira/0000-0001-9810-8623; Wilson, Eleanor/0000-0002-4855-514X	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI051178, R37 AI051178-07, AI43222, R01 AI051178-05, R01 AI043222-08, R37 AI051178-06A1, R37 AI051178, AI51178, R01 AI043222-09, R01 AI043222, R01 AI043222-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043222, R01AI051178, R37AI051178] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACOSTA EP, 2007, ANTIRETROVIRAL PHARM, P115; Ambrose Z, 2006, J VIROL, V80, P2578, DOI 10.1128/JVI.80.5.2578-2581.2006; BARTLETT JG, 2007, 2007 MED MANAGEMENT, V510; CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Ferguson NM, 2001, TRENDS PHARMACOL SCI, V22, P97, DOI 10.1016/S0165-6147(00)01615-1; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hoefnagel JGM, 2005, ANTIVIR THER, V10, P879; HOFFMAN A, 1994, J PHARMACOKINET BIOP, V2, P449; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; McMahon MA, 2007, NEW ENGL J MED, V356, P2614, DOI 10.1056/NEJMoa067710; Morse GD, 2006, LANCET INFECT DIS, V6, P215, DOI 10.1016/S1473-3099(06)70436-4; ORTIZ R, 1948, AIDS IN PRESS; Pandey KK, 2007, J VIROL, V81, P12189, DOI 10.1128/JVI.02863-06; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sedaghat AR, 2008, P NATL ACAD SCI USA, V105, P4832, DOI 10.1073/pnas.0711372105; Talal AH, 2006, HEPATOLOGY, V43, P943, DOI 10.1002/hep.21136; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zhang HL, 2004, J VIROL, V78, P1718, DOI 10.1128/JVI.78.4.1718-1729.2004; 2008, PANEL ANTIRETROVIRAL	29	237	241	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					762	766		10.1038/nm1777	http://dx.doi.org/10.1038/nm1777			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18552857	Green Accepted, Bronze			2022-12-27	WOS:000257452700024
J	Danial, NN; Walensky, LD; Zhang, CY; Choi, CS; Fisher, JK; Molina, AJA; Datta, SR; Pitter, KL; Bird, GH; Wikstrom, JD; Deeney, JT; Robertson, K; Morash, J; Kulkarni, A; Neschen, S; Kim, S; Greenberg, ME; Corkey, BE; Shirihai, OS; Shulman, GI; Lowell, BB; Korsmeyer, SJ				Danial, Nika N.; Walensky, Loren D.; Zhang, Chen-Yu; Choi, Cheol Soo; Fisher, Jill K.; Molina, Anthony J. A.; Datta, Sandeep Robert; Pitter, Kenneth L.; Bird, Gregory H.; Wikstrom, Jakob D.; Deeney, Jude T.; Robertson, Kirsten; Morash, Joel; Kulkarni, Ameya; Neschen, Susanne; Kim, Sheene; Greenberg, Michael E.; Corkey, Barbara E.; Shirihai, Orian S.; Shulman, Gerald I.; Lowell, Bradford B.; Korsmeyer, Stanley J.			Dual role of proapoptotic BAD in insulin secretion and beta cell survival	NATURE MEDICINE			English	Article							GLUCOSE-HOMEOSTASIS; DIABETES-MELLITUS; PANCREATIC-ISLETS; GLUCOKINASE GENE; BH3 DOMAIN; KINASE; PHOSPHORYLATION; PROTEIN; GROWTH; MODEL	The proapoptotic BCL-2 family member BAD resides in a glucokinase-containing complex that regulates glucose-driven mitochondrial respiration. Here, we present genetic evidence of a physiologic role for BAD in glucose- stimulated insulin secretion by beta cells. This novel function of BAD is specifically dependent upon the phosphorylation of its BH3 sequence, previously defined as an essential death domain. We highlight the pharmacologic relevance of phosphorylated BAD BH3 by using cell-permeable, hydrocarbon-stapled BAD BH3 helices that target glucokinase, restore glucose- driven mitochondrial respiration and correct the insulin secretory response in Bad-deficient islets. Our studies uncover an alternative target and function for the BAD BH3 domain and emphasize the therapeutic potential of phosphorylated BAD BH3 mimetics in selectively restoring beta cell function. Furthermore, we show that BAD regulates the physiologic adaptation of beta cell mass during high-fat feeding. Our findings provide genetic proof of the bifunctional activities of BAD in both beta cell survival and insulin secretion.	[Danial, Nika N.; Fisher, Jill K.; Robertson, Kirsten; Lowell, Bradford B.; Korsmeyer, Stanley J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Walensky, Loren D.; Pitter, Kenneth L.; Bird, Gregory H.; Morash, Joel] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Danial, Nika N.; Walensky, Loren D.; Fisher, Jill K.; Pitter, Kenneth L.; Bird, Gregory H.; Robertson, Kirsten; Morash, Joel] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Danial, Nika N.; Walensky, Loren D.; Fisher, Jill K.; Pitter, Kenneth L.; Bird, Gregory H.; Robertson, Kirsten; Morash, Joel] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA; [Walensky, Loren D.; Pitter, Kenneth L.; Bird, Gregory H.; Morash, Joel] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Zhang, Chen-Yu] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China; [Choi, Cheol Soo; Kulkarni, Ameya; Neschen, Susanne; Kim, Sheene; Shulman, Gerald I.; Korsmeyer, Stanley J.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Choi, Cheol Soo; Kulkarni, Ameya; Neschen, Susanne; Kim, Sheene; Shulman, Gerald I.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Molina, Anthony J. A.; Wikstrom, Jakob D.; Shirihai, Orian S.] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA; [Datta, Sandeep Robert; Greenberg, Michael E.] Childrens Hosp, Dept Neurol, Neurobiol Program, Boston, MA 02115 USA; [Deeney, Jude T.; Corkey, Barbara E.] Boston Univ, Med Ctr, Evans Dept Med, Obes Res Ctr, Boston, MA 02118 USA; [Lowell, Bradford B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrionol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Nanjing University; Howard Hughes Medical Institute; Yale University; Yale University; Tufts University; Harvard University; Boston Children's Hospital; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Danial, NN (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 44 Binney St, Boston, MA 02115 USA.	nika_danial@dfci.harvard.edu	Shulman, Gerald I./P-7176-2019; Corkey, Barbara/E-7712-2015	Shulman, Gerald I./0000-0003-1529-5668; Molina, Anthony/0000-0002-5786-4622; Corkey, Barbara/0000-0002-5467-1630; Shirihai, Orian/0000-0002-9502-2661; Pitter, Kenneth/0000-0002-9450-313X; Datta, Sandeep/0000-0002-8068-3862; Deeney, Jude/0000-0003-0988-9419; Wikstrom, Jakob/0000-0002-4287-1774	NCI NIH HHS [K01 CA106596-03, K01 CA106596-04, K01 CA106596-02, K01CA10659, K01 CA106596-01, R01 CA050239, K01 CA106596, 5R01CA50239] Funding Source: Medline; NHLBI NIH HHS [K08 HL074049, 5K08HL074049] Funding Source: Medline; NICHD NIH HHS [P30 HD018655] Funding Source: Medline; NIDDK NIH HHS [R01 DK040936, 5R01DK68781, U24 DK059635, R01 DK068781] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA050239, K01CA106596] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068781, R01DK040936, U24DK059635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili Domenico, 2001, Current Molecular Medicine (Hilversum), V1, P9, DOI 10.2174/1566524013364040; Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; Arden C, 2006, FEBS LETT, V580, P2065, DOI 10.1016/j.febslet.2006.03.009; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BURCH PT, 1981, DIABETES, V30, P923, DOI 10.2337/diabetes.30.11.923; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Gao Z, 2003, ENDOCRINOLOGY, V144, P1949, DOI 10.1210/en.2002-0072; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hara MR, 2006, CELL MOL NEUROBIOL, V26, P527, DOI 10.1007/s10571-006-9011-6; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heart E, 2006, AM J PHYSIOL-ENDOC M, V290, pE143, DOI 10.1152/ajpendo.00216.2005; Jetton TL, 2005, DIABETES, V54, P2294, DOI 10.2337/diabetes.54.8.2294; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; MAGNUSON MA, 2004, GLUCOKINASE GLYCEMIC; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Proks P, 2002, DIABETES, V51, pS368, DOI 10.2337/diabetes.51.2007.S368; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Wiederkehr A, 2006, ENDOCRINOLOGY, V147, P2643, DOI 10.1210/en.2006-0057; Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou YP, 2003, J BIOL CHEM, V278, P51316, DOI 10.1074/jbc.M307972200; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340	50	239	260	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					144	153		10.1038/nm1717	http://dx.doi.org/10.1038/nm1717			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18223655	Green Accepted			2022-12-27	WOS:000252946700022
J	Qiu, L; Pleskow, DK; Chuttani, R; Vitkin, E; Leyden, J; Ozden, N; Itani, S; Guo, LY; Sacks, A; Goldsmith, JD; Modell, MD; Hanlon, EB; Itzkan, I; Perelman, LT				Qiu, Le; Pleskow, Douglas K.; Chuttani, Ram; Vitkin, Edward; Leyden, Jan; Ozden, Nuri; Itani, Sara; Guo, Lianyu; Sacks, Alana; Goldsmith, Jeffrey D.; Modell, Mark D.; Hanlon, Eugene B.; Itzkan, Irving; Perelman, Lev T.			Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus	NATURE MEDICINE			English	Article							LIGHT-SCATTERING SPECTROSCOPY; HIGH-GRADE DYSPLASIA; EARLY ADENOCARCINOMA; EARLY NEOPLASIA; CLASSIFICATION; REFLECTANCE	Esophageal cancer is increasing in frequency in the United States faster than any other cancer. Barrett's esophagus, an otherwise benign complication of esophageal reflux, affects approximately three million Americans and precedes almost all cases of esophageal cancer. If detected as high-grade dysplasia (HGD), most esophageal cancers can be prevented. Standard-of-care screening for dysplasia uses visual endoscopy and a prescribed pattern of biopsy. This procedure, in which a tiny fraction of the affected tissue is selected for pathological examination, has a low probability of detection because dysplasia is highly focal and visually indistinguishable. We developed a system called endoscopic polarized scanning spectroscopy (EPSS), which performs rapid optical scanning and multispectral imaging of the entire esophageal surface and provides diagnoses in near real time. By detecting and mapping suspicious sites, guided biopsy of invisible, precancerous dysplasia becomes practicable. Here we report the development of EPSS and its application in several clinical cases, one of which merits special consideration.	[Qiu, Le; Vitkin, Edward; Itani, Sara; Guo, Lianyu; Modell, Mark D.; Hanlon, Eugene B.; Itzkan, Irving; Perelman, Lev T.] Harvard Univ, Biomed Imaging & Spect Lab, Boston, MA 02115 USA; [Qiu, Le; Vitkin, Edward; Itani, Sara; Guo, Lianyu; Modell, Mark D.; Hanlon, Eugene B.; Itzkan, Irving; Perelman, Lev T.] Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [Qiu, Le; Vitkin, Edward; Itani, Sara; Guo, Lianyu; Modell, Mark D.; Hanlon, Eugene B.; Itzkan, Irving; Perelman, Lev T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Pleskow, Douglas K.; Chuttani, Ram; Leyden, Jan; Ozden, Nuri; Sacks, Alana] Harvard Univ, Div Gastroenterol, Dept Med, Boston, MA 02115 USA; [Goldsmith, Jeffrey D.] Harvard Univ, Dept Pathol, Boston, MA 02115 USA; [Hanlon, Eugene B.] Dept Vet Affairs, Med Res Serv, Bedford, MA USA; [Hanlon, Eugene B.] Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Bedford, MA USA	Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Geriatric Research Education & Clinical Center	Perelman, LT (corresponding author), Harvard Univ, Biomed Imaging & Spect Lab, Boston, MA 02115 USA.	ltperel@bidmc.harvard.edu	Pleskow, Douglas K/F-3319-2016	Pleskow, Douglas K/0000-0003-0092-9496	US National Institutes of Health [EB003472, RR017361]; US National Science Foundation [BES0116833]; US Department of Veterans Affairs Office of Research and Development; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR017361, R33RR017361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006462, R01EB003472] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Science Foundation(National Science Foundation (NSF)); US Department of Veterans Affairs Office of Research and Development(US Department of Veterans Affairs); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This study was supported by US National Institutes of Health grants EB003472 and RR017361, by US National Science Foundation grant BES0116833 and, in part, by the US Department of Veterans Affairs Office of Research and Development. We thank R. Chinnock and F. Bargoot of Optimum Technologies, Inc., for help with the fiber optic probe development. We thank Olympus for the loan of the endoscope used in the animal experiments.	Backman V, 1999, IEEE J SEL TOP QUANT, V5, P1019, DOI 10.1109/2944.796325; Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; Cameron AJ, 1997, AM J GASTROENTEROL, V92, P586; Cameron AJ, 1998, MAYO CLIN PROC, V73, P457; Curvers WL, 2008, GUT, V57, P167, DOI 10.1136/gut.2007.134213; Fang H, 2003, IEEE J SEL TOP QUANT, V9, P267, DOI 10.1109/JSTQE.2003.812515; Georgakoudi I, 2001, GASTROENTEROLOGY, V120, P1620, DOI 10.1053/gast.2001.24842; Gurjar RS, 2001, NAT MED, V7, P1245, DOI 10.1038/nm1101-1245; Kara MA, 2005, GASTROINTEST ENDOSC, V61, P679, DOI 10.1016/S0016-5107(04)02577-5; Kara MA, 2006, GASTROINTEST ENDOSC, V64, P155, DOI 10.1016/j.gie.2005.11.049; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Macdonald CE, 2000, BMJ-BRIT MED J, V321, P1252, DOI 10.1136/bmj.321.7271.1252; Perelman LT, 1998, PHYS REV LETT, V80, P627, DOI 10.1103/PhysRevLett.80.627; Pohl H, 2008, GUT, V57, P1648, DOI 10.1136/gut.2008.157461; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Wallace MB, 2000, GASTROENTEROLOGY, V119, P677, DOI 10.1053/gast.2000.16511	16	124	128	6	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2010	16	5					603	U140		10.1038/nm.2138	http://dx.doi.org/10.1038/nm.2138			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20383155	Green Accepted			2022-12-27	WOS:000277394700041
J	Gadina, M; O'Shea, JJ				Gadina, Massimo; O'Shea, John J.			BENCH TO BEDSIDE Turncoat regulatory T cells	NATURE MEDICINE			English	Editorial Material							IN-VIVO; LINEAGE; GENERATION; PLASTICITY; LEADS		[Gadina, Massimo] NIAMSD, Translat Immunol Sect, Bethesda, MD 20892 USA; [O'Shea, John J.] NIAMSD, Mol Immunol & Inflammat Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Gadina, M (corresponding author), NIAMSD, Translat Immunol Sect, Bethesda, MD 20892 USA.	gadinama@mail.nih.gov	Gadina, Massimo/R-4195-2019		Intramural NIH HHS [ZIA AR041167-02, ZIA AR041106-15, Z01 AR041167-01, Z01 AR041132-07, Z01 AR041106-13, ZIA AR041161-02, ZIA AR041159-02, Z01 AR041160-01, Z01 AR041106-14, Z01 AR041159-01, ZIC AR041181-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041132, ZIGAR041168, ZIAAR041159, Z01AR041160, ZIAAR041106, Z01AR041167] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Lochner M, 2008, J EXP MED, V205, P1381, DOI 10.1084/jem.20080034; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	9	3	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2009	15	12					1365	1365		10.1038/nm1209-1365	http://dx.doi.org/10.1038/nm1209-1365			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966774	Green Accepted			2022-12-27	WOS:000272407800015
J	Oga, T; Matsuoka, T; Yao, CC; Nonomura, K; Kitaoka, S; Sakata, D; Kita, Y; Tanizawa, K; Taguchi, Y; Chin, K; Mishima, M; Shimizu, T; Narumiya, S				Oga, Toru; Matsuoka, Toshiyuki; Yao, Chengcan; Nonomura, Kimiko; Kitaoka, Shiho; Sakata, Daiji; Kita, Yoshihiro; Tanizawa, Kiminobu; Taguchi, Yoshio; Chin, Kazuo; Mishima, Michiaki; Shimizu, Takao; Narumiya, Shuh			Prostaglandin F-2 alpha receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta	NATURE MEDICINE			English	Article							INDUCED LUNG FIBROSIS; MICE LACKING; TGF-BETA; GENE; EXPRESSION; INHIBITOR; ACTIVATION; TGF-BETA-1; COLLAGEN; ELEMENTS	Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by fibroblast proliferation and excess deposition of collagen and other extracellular matrix (ECM) proteins, which lead to distorted lung architecture and function(1). Given that anti-inflammatory or immunosuppressive therapy currently used for IPF does not improve disease progression therapies targeted to blocking the mechanisms of fibrogenesis are needed(1). Although transforming growth factor-beta (TGF-beta) functions are crucial in fibrosis(2,3), antagonizing this pathway in bleomycin-induced pulmonary fibrosis, an animal model of IPF, does not prevent fibrosis completely(4-7), indicating an additional pathway also has a key role in fibrogenesis. Given that the loss of cytosolic phospholipase A(2) (cPLA(2)) suppresses bleomycin-induced pulmonary fibrosis(8), we examined the roles of prostaglandins using mice lacking each prostoaglandin receptor(9-15). Here we show that loss of prostaglandin F (PGF) receptor (FP) selectively attenuates pulmonary fibrosis while maintaining similar levels of alveolar inflammation and TGF-beta stimulation as compared to wild-type (WT) mice, and that FP deficiency and inhibition of TGF-beta signaling additively decrease fibrosis. Furthermore, PGF(2 alpha) is abundant in bronchoalveolar lavage fluid (BALF) of subjects with IPF and stimulates proliferation and collagen production of lung fibroblasts via FP, independently of TGF-beta. These findings show that PGF(2 alpha)-FP signaling facilitates pulmonary fibrosis independently of TGF-beta and suggests this signaling pathway as a therapeutic target for IPF.	[Oga, Toru; Matsuoka, Toshiyuki; Yao, Chengcan; Nonomura, Kimiko; Kitaoka, Shiho; Sakata, Daiji; Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan; [Oga, Toru; Chin, Kazuo] Kyoto Univ, Fac Med, Dept Resp Care & Sleep Control Med, Kyoto 606, Japan; [Kita, Yoshihiro; Shimizu, Takao] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; [Tanizawa, Kiminobu; Mishima, Michiaki] Kyoto Univ, Fac Med, Dept Resp Med, Kyoto 606, Japan; [Taguchi, Yoshio] Tenri Hosp, Dept Resp Med, Nara, Japan	Kyoto University; Kyoto University; University of Tokyo; Kyoto University; Tenri Hospital	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Shimizu, Takao/AAV-7052-2021	Yao, Chengcan/0000-0003-3754-2842; Tanizawa, Kiminobu/0000-0002-5719-0744	Ministry of Education, Culture, Sports, Science and Technology of Japan [18002015]; National Institute of Biomedical Innovation of Japan; Ono Research Foundation	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation of Japan(National Institute of Biomedical Innovation); Ono Research Foundation	We thank M. Trojanowska (Medical University of South Carolina) and H. Ihn (Kumamoto University) for the - 3500COL1A2/CAT construct, and Ono Pharmaceutical Company for ONO-AE3-208. We also thank Y. Kobashi for BALF analysis, T. Fujiwara for animal care and T. Arai for assistance. This work was supported in part by a Grant-in-Aid for Scientific Research (18002015) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant of the Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation of Japan and a grant from Ono Research Foundation.	Aono Y, 2005, AM J RESP CRIT CARE, V171, P1279, DOI 10.1164/rccm.200404-531OC; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Bhatt N, 2006, CURR OPIN PHARMACOL, V6, P284, DOI 10.1016/j.coph.2006.03.003; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; Handa T, 2005, RESPIRATION, V72, P243, DOI 10.1159/000085364; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jinnin M, 2006, BIOCHEM BIOPH RES CO, V343, P904, DOI 10.1016/j.bbrc.2006.03.037; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kapoun AM, 2006, MOL PHARMACOL, V70, P518, DOI 10.1124/mol.105.021600; Kita Y, 2005, BIOCHEM BIOPH RES CO, V330, P898, DOI 10.1016/j.bbrc.2005.03.055; Ley K, 2008, NAT MED, V14, P20, DOI 10.1038/nm0108-20; Lovgren AK, 2006, AM J PHYSIOL-LUNG C, V291, pL144, DOI 10.1152/ajplung.00492.2005; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Moore BB, 2005, J IMMUNOL, V174, P5644, DOI 10.4049/jimmunol.174.9.5644; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Narumiya S, 2007, P JPN ACAD B-PHYS, V83, P296, DOI [10.2183/pjab.83.296, 10.2183/pjab/83.296]; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Yoshikawa K, 2006, J BIOL CHEM, V281, P14663, DOI 10.1074/jbc.M511089200	36	130	141	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2009	15	12					1426	U12		10.1038/nm.2066	http://dx.doi.org/10.1038/nm.2066			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	527YS	19966781				2022-12-27	WOS:000272407800024
J	Rafei, M; Hsieh, J; Zehntner, S; Li, MY; Forner, K; Birman, E; Boivin, MN; Young, YK; Perreault, C; Galipeau, J				Rafei, Moutih; Hsieh, Jeremy; Zehntner, Simone; Li, MengYang; Forner, Kathy; Birman, Elena; Boivin, Marie-Noelle; Young, Yoon Kow; Perreault, Claude; Galipeau, Jacques			A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PLACEBO-CONTROLLED TRIAL; REMITTING MULTIPLE-SCLEROSIS; T-CELLS; DOUBLE-BLIND; INTERFERON BETA-1B; GLATIRAMER ACETATE; PROGRESSIVE MS; PROTECTS MICE; IN-VIVO	We have previously shown that a granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-15 (IL-15) 'fusokine' (GIFT15) exerts immune suppression via aberrant signaling through the IL-15 receptor on lymphomyeloid cells. We show here that ex vivo GIFT15 treatment of mouse splenocytes generates suppressive regulatory cells of B cell ontogeny (hereafter called GIFT15 B-reg cells). Arising from CD19(+) B cells, GIFT15 B-reg cells express major histocompatibility complex class I (MHCI) and MHCII, surface IgM and IgD, and secrete IL-10, akin to previously described B10 and T2-MZP B-reg cells, but lose expression of the transcription factor PAX5, coupled to upregulation of CD138 and reciprocal suppression of CD19. Mice with experimental autoimmune encephalomyelitis went into complete remission after intravenous infusion of GIFT15 B-reg cells paralleled by suppressed neuroinflammation. The clinical effect was abolished when GIFT15 B-reg cells were derived from m mu MT (lacking B cells), MHCII-knockout, signal transducer and activator of transcription-6 (STAT-6)-knockout, IL-10-knockout or allogeneic splenocytes, consistent with a pivotal role for MHCII and IL-10 by sygeneic B cells for the observed therapeutic effect. We propose that autologous GIFT15 B-reg cells may serve as a new treatment for autoimmune ailments.	[Rafei, Moutih; Hsieh, Jeremy; Li, MengYang; Forner, Kathy; Birman, Elena; Boivin, Marie-Noelle; Young, Yoon Kow; Galipeau, Jacques] McGill Univ, Jewish Gen Hosp, Montreal Ctr Expt Therapeut Canc, Montreal, PQ H3T 1E2, Canada; [Zehntner, Simone] McGill Univ, Mol Oncol Lab, Montreal, PQ H3T 1E2, Canada; [Zehntner, Simone] McGill Univ, Neuroimmunol Grp, Montreal Neurol Inst, Montreal, PQ H3T 1E2, Canada; [Perreault, Claude] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Galipeau, Jacques] McGill Univ, Jewish Gen Hosp, Div Hematol Oncol, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; McGill University; Universite de Montreal; McGill University	Galipeau, J (corresponding author), McGill Univ, Jewish Gen Hosp, Montreal Ctr Expt Therapeut Canc, Montreal, PQ H3T 1E2, Canada.	jacques.galipeau@mcgill.ca	Galipeau, Jacques/R-9909-2019; Perreault, Claude/A-7220-2008	Galipeau, Jacques/0000-0002-9374-1996; Perreault, Claude/0000-0001-9453-7383	Canadian Institute of Health Research [MOP-15017]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	M. R. is a recipient of a Fonds de Recherches en Sante du Quebec Scholarship, and J. G. is a Fonds de Recherches en Sante du Quebec chercheur-boursier senior. C. P. holds a Canada Research Chair in Immunobiology. This work was supported by the Canadian Institute of Health Research grant MOP-15017.	Arnold DL, 2008, J NEUROL, V255, P1473, DOI 10.1007/s00415-008-0911-x; Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x; Brummel R, 2005, J IMMUNOL, V174, P2429, DOI 10.4049/jimmunol.174.4.2429; Dhib-Jalbut S, 2002, MULT SCLER, V8, P485, DOI 10.1191/1352458502ms862oa; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Fornek JL, 2006, BLOOD, V107, P1085, DOI 10.1182/blood-2005-07-2871; Giorgini A, 2007, J LEUKOCYTE BIOL, V82, P1053, DOI 10.1189/jlb.0407227; Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jamin C, 2008, ARTHRITIS RHEUM-US, V58, P1900, DOI 10.1002/art.23487; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Karim M, 2005, BLOOD, V105, P4871, DOI 10.1182/blood-2004-10-3888; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kozak T, 2002, J NEUROL, V249, P1088, DOI 10.1007/s00415-002-0800-7; Krapf H, 2005, NEUROLOGY, V65, P690, DOI 10.1212/01.wnl.0000174439.70369.7a; Kuhlmann T, 2006, AM J PATHOL, V169, P584, DOI 10.2353/ajpath.2006.051086; Lau AWT, 2008, J IMMUNOL, V180, P3889, DOI 10.4049/jimmunol.180.6.3889; Mann MK, 2007, J IMMUNOL, V178, P3447, DOI 10.4049/jimmunol.178.6.3447; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; O'Connor KC, 2001, J CLIN IMMUNOL, V21, P81, DOI 10.1023/A:1011064007686; Panitch H, 2004, NEUROLOGY, V63, P1788; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Prele CM, 2008, J IMMUNOL, V181, P8018, DOI 10.4049/jimmunol.181.11.8018; Rafei M, 2007, BLOOD, V109, P2234, DOI 10.1182/blood-2006-07-037473; Rafei M, 2009, J IMMUNOL, V182, P2620, DOI 10.4049/jimmunol.0803495; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Singh A, 2008, J IMMUNOL, V180, P7318, DOI 10.4049/jimmunol.180.11.7318; Stern JNH, 2008, P NATL ACAD SCI USA, V105, P5172, DOI 10.1073/pnas.0712131105; Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017	35	94	100	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2009	15	9					1038	U91		10.1038/nm.2003	http://dx.doi.org/10.1038/nm.2003			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	496MT	19668193				2022-12-27	WOS:000269979200024
J	Ward, PA				Ward, Peter A.			Seeking a heart salve	NATURE MEDICINE			English	Editorial Material							SEPSIS; DYSFUNCTION; ENDOTOXIN		Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	pward@med.umich.edu						Boyd JH, 2008, CIRC RES, V102, P1239, DOI 10.1161/CIRCRESAHA.107.167544; Fernandes CJ, 2008, SHOCK, V30, P14, DOI 10.1097/SHK.0b013e3181818617; Flierl MA, 2008, FASEB J, V22, P2198, DOI 10.1096/fj.07-105221; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Gross S, 2009, NAT MED, V15, P455, DOI 10.1038/nm.1886; Hotchkiss RS, 2009, NAT MED, V15, P496, DOI 10.1038/nm0509-496; Johnston GR, 2009, BRIT J ANAESTH, V102, P453, DOI 10.1093/bja/aep037; LORTS A, 2008, SHOCK           1222; Opal SM, 2007, CONTRIB NEPHROL, V156, P220; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Singh MV, 2009, J CLIN INVEST, V119, P986, DOI 10.1172/JCI35814; Soriano FG, 2006, CRIT CARE MED, V34, P1073, DOI 10.1097/01.CCM.0000206470.47721.8D	13	28	30	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2009	15	5					497	499		10.1038/nm0509-497	http://dx.doi.org/10.1038/nm0509-497			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19424210				2022-12-27	WOS:000265889300027
J	Cao, L; Lin, EJD; Cahill, MC; Wang, CS; Liu, XL; During, MJ				Cao, Lei; Lin, En-Ju D.; Cahill, Michael C.; Wang, Chuansong; Liu, Xianglan; During, Matthew J.			Molecular therapy of obesity and diabetes by a physiological autoregulatory approach	NATURE MEDICINE			English	Article							NEUROTROPHIC FACTOR; GENE-EXPRESSION; ENERGY-EXPENDITURE; NONHUMAN-PRIMATES; AAV VECTORS; PPAR-GAMMA; BRAIN; MICE; BDNF; PROTEIN	Hypothalamic brain-derived neurotrophic factor (BDNF) is a key element in the regulation of energy balance. Here we investigated the therapeutic efficacy of BDNF by gene transfer in mouse models of obesity and diabetes. Gene transfer of BDNF led to marked weight loss and alleviation of obesity-associated insulin resistance. To facilitate clinical translation and ensure that BDNF protein expression was appropriately decreased as weight loss progressed, thus preventing cachexia, we developed a molecular autoregulatory system involving a single recombinant adeno-associated virus vector harboring two expression cassettes, one constitutively driving BDNF and the other driving a specific microRNA targeting BDNF. The microRNA element was controlled by a promoter (that controlling the Agrp gene encoding agouti-related peptide) responsive to BDNF-induced physiological changes. Hence, as body weight decreased and agouti-related protein is induced, microRNA expression was activated, inhibiting transgene expression. In contrast to the progressive weight loss associated with a nonregulated approach, this microRNA-approach led to a sustainable plateau of body weight after notable weight loss was achieved. This strategy mimics the body's endogenous physiological feedback mechanisms, thereby resetting the hypothalamic set point to reverse obesity and metabolic syndrome.	[During, Matthew J.] Ohio State Univ, Canc Genet & Neurosci Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	During, MJ (corresponding author), Ohio State Univ, Canc Genet & Neurosci Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	during.1@osu.edu	Cao, Lei/H-3185-2019; During, Matthew/AAC-1388-2020; Cao, Lei/E-2841-2011	Cao, Lei/0000-0003-0322-4985	NCI NIH HHS [P30 CA016058] Funding Source: Medline; NINDS NIH HHS [R01 NS044576, NS44576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anghel SI, 2007, CELL RES, V17, P486, DOI 10.1038/cr.2007.48; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bariohay B, 2005, ENDOCRINOLOGY, V146, P5612, DOI 10.1210/en.2005-0419; Batsis JA, 2007, CLIN PHARMACOL THER, V82, P509, DOI 10.1038/sj.clpt.6100355; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bertile F, 2003, BIOCHEM BIOPH RES CO, V303, P1106, DOI 10.1016/S0006-291X(03)00481-9; Brown AM, 2001, GENE, V277, P231, DOI 10.1016/S0378-1119(01)00705-3; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104; Dhillo WS, 2007, THYROID, V17, P433, DOI 10.1089/thy.2007.0018; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gray J, 2006, DIABETES, V55, P3366, DOI 10.2337/db06-0550; Jiang L, 2004, GENE THER, V11, P1057, DOI 10.1038/sj.gt.3302245; Kaspar BK, 2002, P NATL ACAD SCI USA, V99, P2320, DOI 10.1073/pnas.042678699; Le Bec C, 2006, GENE THER, V13, P805, DOI 10.1038/sj.gt.3302724; Lebherz C, 2005, HUM GENE THER, V16, P178, DOI 10.1089/hum.2005.16.178; Li XG, 2006, MOL THER, V13, P160, DOI 10.1016/j.ymthe.2005.08.009; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; McMillan DC, 2006, BRIT MED J, V333, P1109, DOI 10.1136/bmj.39042.565035.BE1; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naert G, 2006, NEUROSCIENCE, V139, P779, DOI 10.1016/j.neuroscience.2005.12.028; Nakagawa T, 2003, INT J OBESITY, V27, P557, DOI 10.1038/sj.ijo.0802265; Nakagawa T, 2002, DIABETES-METAB RES, V18, P185, DOI 10.1002/dmrr.290; Nguyen M, 2007, MOL THER, V15, P912, DOI 10.1038/mt.sj.6300079; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; Qi Y, 2004, NAT MED, V10, P524, DOI 10.1038/nm1029; Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198-007-0492-z; Ricquier D, 2005, P NUTR SOC, V64, P47, DOI 10.1079/PNS2004408; Stieger K, 2006, MOL THER, V13, P967, DOI 10.1016/j.ymthe.2005.12.001; Takahashi N, 2004, J HEPATOL, V41, P391, DOI 10.1016/j.jhep.2004.05.006; TOWNSEND KL, 2008, ENDOCRINE, V33; Unger TJ, 2007, J NEUROSCI, V27, P14265, DOI 10.1523/JNEUROSCI.3308-07.2007; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Wang CF, 2007, AM J PHYSIOL-REG I, V293, pR1003, DOI 10.1152/ajpregu.00011.2007; Wisse BE, 2003, NAT NEUROSCI, V6, P655, DOI 10.1038/nn0703-655; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88; Yeo GSH, 2004, NAT NEUROSCI, V7, P1187, DOI 10.1038/nn1336; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	40	83	86	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					447	454		10.1038/nm.1933	http://dx.doi.org/10.1038/nm.1933			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19270710	Green Accepted			2022-12-27	WOS:000264937200033
J	Mitsuyasu, RT; Merigan, TC; Carr, A; Zack, JA; Winters, MA; Workman, C; Bloch, M; Lalezari, J; Becker, S; Thornton, L; Akil, B; Khanlou, H; Finlayson, R; McFarlane, R; Smith, DE; Garsia, R; Ma, D; Law, M; Murray, JM; von Kalle, C; Ely, JA; Patino, SM; Knop, AE; Wong, P; Todd, AV; Haughton, M; Fuery, C; Macpherson, JL; Symonds, GP; Evans, LA; Pond, SM; Cooper, DA				Mitsuyasu, Ronald T.; Merigan, Thomas C.; Carr, Andrew; Zack, Jerome A.; Winters, Mark A.; Workman, Cassy; Bloch, Mark; Lalezari, Jacob; Becker, Stephen; Thornton, Lorna; Akil, Bisher; Khanlou, Homayoon; Finlayson, Robert; McFarlane, Robert; Smith, Don E.; Garsia, Roger; Ma, David; Law, Matthew; Murray, John M.; von Kalle, Christof; Ely, Julie A.; Patino, Sharon M.; Knop, Alison E.; Wong, Philip; Todd, Alison V.; Haughton, Margaret; Fuery, Caroline; Macpherson, Janet L.; Symonds, Geoff P.; Evans, Louise A.; Pond, Susan M.; Cooper, David A.			Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34(+) cells	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC GRANULOMATOUS-DISEASE; PERIPHERAL-BLOOD LYMPHOCYTES; T-LYMPHOCYTES; LENTIVIRAL VECTOR; TYPE-1 INFECTION; BONE-MARROW; TAR DECOY; REPLICATION; INHIBITION	Gene transfer has potential as a once-only treatment that reduces viral load, preserves the immune system and avoids lifetime highly active antiretroviral therapy. This study, which is to our knowledge the first randomized, double-blind, placebo-controlled, phase 2 cell-delivered gene transfer clinical trial, was conducted in 74 HIV-1-infected adults who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34(+) hematopoietic progenitor cells. There were no OZ1-related adverse events. There was no statistically significant difference in viral load between the OZ1 and placebo group at the primary end point (average at weeks 47 and 48), but time-weighted areas under the curve from weeks 40-48 and 40-100 were significantly lower in the OZ1 group. Throughout the 100 weeks, CD4(+) lymphocyte counts were higher in the OZ1 group. This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product.	[Mitsuyasu, Ronald T.] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA 90035 USA; [Merigan, Thomas C.; Winters, Mark A.] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; [Carr, Andrew; Ma, David; Cooper, David A.] St Vincents Clin, Darlinghurst, NSW 2010, Australia; [Zack, Jerome A.] Univ Calif Los Angeles, Dept Med & Microbiol, Los Angeles, CA 90095 USA; [Workman, Cassy] AIDS Res Initiat, Darlinghurst, NSW 2010, Australia; [Bloch, Mark] Holdsworth House Med Practice, Darlinghurst, NSW 2010, Australia; [Lalezari, Jacob] Quest Clin Res, San Francisco, CA 94115 USA; [Becker, Stephen; Thornton, Lorna] Pacific Horizon Med Grp, San Francisco, CA 94115 USA; [Akil, Bisher] Hlth Innovat Res, Los Angeles, CA 90069 USA; [Khanlou, Homayoon] AIDS Healthcare Fdn Res Ctr, Los Angeles, CA 90028 USA; [Finlayson, Robert] Taylor Sq Private Clin, Darlinghurst, NSW 2010, Australia; [McFarlane, Robert] E Sydney Doctors, Darlinghurst, NSW 2010, Australia; [Smith, Don E.] Alb St Ctr, Darlinghurst, NSW 2010, Australia; [Garsia, Roger] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia; [Law, Matthew; Murray, John M.; Cooper, David A.] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia; [Murray, John M.] Univ New S Wales, Sch Math & Stat, Randwick, NSW 2052, Australia; [von Kalle, Christof] Cincinnati Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; [von Kalle, Christof] German Canc Res Ctr, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; [Ely, Julie A.; Patino, Sharon M.; Knop, Alison E.; Wong, Philip; Todd, Alison V.; Haughton, Margaret; Fuery, Caroline; Macpherson, Janet L.; Symonds, Geoff P.; Evans, Louise A.; Pond, Susan M.] Johnson & Johnson Res Proprietary Ltd, Sydney, NSW 1430, Australia	University of California System; University of California Los Angeles; Stanford University; University of California System; University of California Los Angeles; University of Sydney; University of New South Wales Sydney; Kirby Institute; University of New South Wales Sydney; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Johnson & Johnson	Mitsuyasu, RT (corresponding author), Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, 9911 W Pico Blvd,Suite 980, Los Angeles, CA 90035 USA.	rmitsuya@mednet.ucla.edu	Macpherson, Janet/D-8702-2012; Merigan, Thomas/AGQ-7464-2022; Haughton, Margaret/F-8033-2010; Murray, John/B-5481-2009	Macpherson, Janet/0000-0003-0702-9546; Murray, John/0000-0001-9314-2283; Law, Matthew/0000-0002-3540-8837	US National Institutes of Health [AI28697, M01-RR00865]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The following clinicians, research nurses and coordinators contributed substantially to the trial: S. Agrawal, R. Amado, C. Anderson, P. Cain, R. Cordova, G. Dolan, C. Farthing, E. Glutzer, M. Gonzalez, M. Harbour, N. Hyland, A. Lebel, S. Lundy, K. Macrae, S. Miller, J. Norris, L. O'Donnell, L. Pearce, J. Perram, V. Rees, R. Richardson, J. Sarangapany, D. Slamowitz, R. Vale, G. Vasquez, B. Williams and A. Zolopa. We also acknowledge the contribution of the leukapheresis collection and cell processing staff, W. Quan for assistance with quality assurance and A. Miller of the Biologics Group for assistance with regulatory aspects. S. Margrie had a key role in the development of the statistical analysis plan and in the statistical analyses. C. Ang and A. King assisted with the preparation of the manuscript. We acknowledge W. Gerlach, D. Wade, J. Peacock, R. de Feyter and L. Farrell for their vital role during the early stages of the development of OZ1. We sincerely thank the participants who enrolled in this intensive study and the members of the Data Safety Monitoring Board. The University of California-Los Angeles Center for AIDS Research and University of California-Los Angeles General Clinical Research Center were supported by US National Institutes of Health grants AI28697 and M01-RR00865.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Amado RG, 2004, HUM GENE THER, V15, P251, DOI 10.1089/104303404322886101; An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104; Anderson J, 2007, MOL THER, V15, P1182, DOI 10.1038/sj.mt.6300157; BAHNER I, 1993, J VIROL, V67, P3199, DOI 10.1128/JVI.67.6.3199-3207.1993; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; Cagnon L, 1997, Methods Mol Biol, V74, P451; Cavallaro AM, 2000, BONE MARROW TRANSPL, V25, P85, DOI 10.1038/sj.bmt.1702072; *CTR BIOL EV RES, 2006, GUID IND GEN THER CL; *CTR BIOL EV RES, 2006, GUID IND SUPPL GUID; Dropulic B, 1993, Antisense Res Dev, V3, P87; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Fanning G, 2003, J GENE MED, V5, P645, DOI 10.1002/jgm.436; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Kohn DB, 1999, BLOOD, V94, P368, DOI 10.1182/blood.V94.1.368.413a47_368_371; Kohn DB, 1999, CURR OPIN MOL THER, V1, P437; Levine BL, 2006, P NATL ACAD SCI USA, V103, P17372, DOI 10.1073/pnas.0608138103; Li MJ, 2006, ANN NY ACAD SCI, V1082, P172, DOI 10.1196/annals.1348.006; Lo A. S. -Y., 2008, V181, P343; MacPherson Janet L., 1999, Frontiers in Bioscience, V4, pD497, DOI 10.2741/Macpherson; Macpherson JL, 2005, J GENE MED, V7, P552, DOI 10.1002/jgm.705; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; Manfred S, 2007, NAT METHODS, V4, P1051, DOI 10.1038/nmeth1103; Marasco WA, 1999, J IMMUNOL METHODS, V231, P223, DOI 10.1016/S0022-1759(99)00159-3; Mautino MR, 2000, HUM GENE THER, V11, P2025, DOI 10.1089/10430340050143444; Morgan RA, 2005, HUM GENE THER, V16, P1065, DOI 10.1089/hum.2005.16.1065; Morris KV, 2006, HUM GENE THER, V17, P479, DOI 10.1089/hum.2006.17.479; Nicolini FE, 2004, EXP HEMATOL, V32, P1033, DOI 10.1016/j.exphem.2004.07.021; Novotny J, 1998, BRIT J HAEMATOL, V100, P695, DOI 10.1046/j.1365-2141.1998.00629.x; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Podsakoff GM, 2005, MOL THER, V12, P77, DOI 10.1016/j.ymthe.2005.02.024; Rossi JJ, 2000, ADV DRUG DELIVER REV, V44, P71, DOI 10.1016/S0169-409X(00)00085-5; Rossi JJ, 1999, CURR OPIN MOL THER, V1, P316; Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Schambach A, 2006, GENE THER, V13, P1037, DOI 10.1038/sj.gt.3302755; Strayer DS, 2005, MOL THER, V11, P823, DOI 10.1016/j.ymthe.2005.01.020; SUN LQ, 1995, P NATL ACAD SCI USA, V92, P7272, DOI 10.1073/pnas.92.16.7272; SUN LQ, 1995, NUCLEIC ACIDS RES, V23, P2909, DOI 10.1093/nar/23.15.2909; Sun LQ, 1997, MOL BIOTECHNOL, V7, P241, DOI 10.1007/BF02740815; TAYLOR BS, 2008, N ENGL J MED; Taylor JA, 2008, MOL THER, V16, P46, DOI 10.1038/sj.mt.6300335; von Laer D, 2006, J GENE MED, V8, P658, DOI 10.1002/jgm.908; Wang L, 1998, HUM GENE THER, V9, P1283, DOI 10.1089/hum.1998.9.9-1283; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Zahn RC, 2008, GENE THER, V15, P1210, DOI 10.1038/gt.2008.73	46	195	211	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					285	292		10.1038/nm.1932	http://dx.doi.org/10.1038/nm.1932			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19219022	Green Submitted, Green Accepted			2022-12-27	WOS:000263914000028
J	Stein, U; Walther, W; Arlt, F; Schwabe, H; Smith, J; Fichtner, I; Birchmeier, W; Schlag, PM				Stein, Ulrike; Walther, Wolfgang; Arlt, Franziska; Schwabe, Holger; Smith, Janice; Fichtner, Iduna; Birchmeier, Walter; Schlag, Peter M.			MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; SMALL INTERFERING RNA; C-MET; COLORECTAL-CANCER; INVASIVE GROWTH; FACTOR RECEPTOR; EPITHELIAL-CELLS; TRANSGENIC MICE; IN-VIVO; EXPRESSION	We identified a previously undescribed gene associated with colon cancer by genome-wide expression analysis in primary and metastatic carcinomas: metastasis-associated in colon cancer-1, MACC1. MACC1 expression in tumor specimens is an independent prognostic indicator of metastasis formation and metastasis- free survival. We show that the gene encoding the hepatocyte growth factor (HGF) receptor, MET, is a transcriptional target of MACC1. MACC1 promotes proliferation, invasion and HGF-induced scattering of colon cancer cells in cell culture and tumor growth and metastasis in mouse models. These phenotypes are lost in cells expressing MACC1 mutants lacking the SH3 domain or the proline-rich motif. For clinical practice, MACC1 will be useful for the identification of poor prognosis subjects with colorectal cancer and is a promising new target for intervention in metastasis formation.	[Stein, Ulrike; Walther, Wolfgang; Arlt, Franziska; Smith, Janice; Fichtner, Iduna; Birchmeier, Walter] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Stein, Ulrike; Walther, Wolfgang; Arlt, Franziska; Schwabe, Holger; Schlag, Peter M.] Charite, Robert Rossle Canc Hosp, Dept Surg & Surg Oncol, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	ustein@mdc-berlin.de		Walther, Wolfgang/0000-0003-2360-1370; Stein, Ulrike/0000-0001-7006-282X	Wilhelm-Sander Foundation, Germany	Wilhelm-Sander Foundation, Germany	This work was supported by a grant from the Wilhelm-Sander Foundation, Germany.	BEAHRS OH, 1992, CANCER, V70, P1393, DOI 10.1002/1097-0142(19920901)70:3+<1393::AID-CNCR2820701530>3.0.CO;2-P; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boon EMJ, 2002, CANCER RES, V62, P5126; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cardoso J, 2007, BBA-REV CANCER, V1775, P103, DOI 10.1016/j.bbcan.2006.08.004; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021; Dunlevy JR, 1999, GENOMICS, V62, P519, DOI 10.1006/geno.1999.5994; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita S, 1997, JPN J CLIN ONCOL, V27, P378, DOI 10.1093/jjco/27.6.378; Giles RH, 2006, ONCOGENE, V25, P3065, DOI 10.1038/sj.onc.1209330; Horiguchi N, 2002, ONCOGENE, V21, P1791, DOI 10.1038/sj.onc.1205248; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liang HY, 2004, INT J ONCOL, V24, P1057; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu YH, 1998, GENE, V215, P159, DOI 10.1016/S0378-1119(98)00264-9; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev; MILLER RG, 1998, SURVIVAL ANAL, pCH6; Moshitch-Moshkovitz S, 2006, NEOPLASIA, V8, P353, DOI 10.1593/neo.05634; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4; Stein Ulrike, 2007, V176, P61; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; STOKER M, 1985, J CELL SCI, V77, P209; Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WORKMAN P, 1989, CANCER METAST REV, V8, P82; Zhang SZ, 2005, MOL CANCER THER, V4, P1577, DOI 10.1158/1535-7163.MCT-05-0106	50	393	448	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2009	15	1					59	67		10.1038/nm.1889	http://dx.doi.org/10.1038/nm.1889			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	394DF	19098908				2022-12-27	WOS:000262425100019
J	McKinney, EF; Lyons, PA; Carr, EJ; Hollis, JL; Jayne, DRW; Willcocks, LC; Koukoulaki, M; Brazma, A; Jovanovic, V; Kemeny, DM; Pollard, AJ; MacAry, PA; Chaudhry, AN; Smith, KGC				McKinney, Eoin F.; Lyons, Paul A.; Carr, Edward J.; Hollis, Jane L.; Jayne, David R. W.; Willcocks, Lisa C.; Koukoulaki, Maria; Brazma, Alvis; Jovanovic, Vojislav; Kemeny, D. Michael; Pollard, Andrew J.; MacAry, Paul A.; Chaudhry, Afzal N.; Smith, Kenneth G. C.			A CD8(+) T cell transcription signature predicts prognosis in autoimmune disease	NATURE MEDICINE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; GENE-EXPRESSION; WEGENERS-GRANULOMATOSIS; MICROARRAY ANALYSIS; CLASS DISCOVERY; BREAST-CANCER; MEMORY; EFFECTOR; VASCULITIS	Autoimmune diseases are common and debilitating, but their severe manifestations could be reduced if biomarkers were available to allow individual tailoring of potentially toxic immunosuppressive therapy. Gene expression-based biomarkers facilitating such tailoring of chemotherapy in cancer, but not autoimmunity, have been identified and translated into clinical practice(1,2). We show that transcriptional profiling of purified CD8(+) T cells, which avoids the confounding influences of unseparated cells(3,4), identifies two distinct subject subgroups predicting long-term prognosis in two autoimmune diseases, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a chronic, severe disease characterized by inflammation of medium-sized and small blood vessels(5), and systemic lupus erythematosus (SLE), characterized by autoantibodies, immune complex deposition and diverse clinical manifestations ranging from glomerulonephritis to neurological dysfunction(6). We show that the subset of genes defining the poor prognostic group is enriched for genes involved in the interleukin-7 receptor (IL-7R) pathway and T cell receptor (TCR) signaling and those expressed by memory T cells. Furthermore, the poor prognostic group is associated with an expanded CD8(+) T cell memory population. These subgroups, which are also found in the normal population and can be identified by measuring expression of only three genes, raise the prospect of individualized therapy and suggest new potential therapeutic targets in autoimmunity.	[McKinney, Eoin F.; Lyons, Paul A.; Carr, Edward J.; Willcocks, Lisa C.; Koukoulaki, Maria; Smith, Kenneth G. C.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; [McKinney, Eoin F.; Lyons, Paul A.; Carr, Edward J.; Hollis, Jane L.; Jayne, David R. W.; Willcocks, Lisa C.; Koukoulaki, Maria; Chaudhry, Afzal N.; Smith, Kenneth G. C.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2QQ, England; [Brazma, Alvis] European Bioinformat Inst, European Mol Biol Lab, Hinxton, England; [Jovanovic, Vojislav; Kemeny, D. Michael; MacAry, Paul A.] Natl Univ Singapore, Immunol Programme, Singapore 117548, Singapore; [Jovanovic, Vojislav; Kemeny, D. Michael; MacAry, Paul A.] Natl Univ Singapore, Dept Microbiol, Ctr Life Sci, Singapore 117548, Singapore; [Pollard, Andrew J.] Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Ctr Clin Vaccinol & Trop Med, Oxford, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; European Molecular Biology Laboratory (EMBL); National University of Singapore; National University of Singapore; University of Oxford	Smith, KGC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England.	pal34@cam.ac.uk; kgcs2@cam.ac.uk		MacAry, Paul/0000-0002-1139-8996; Brazma, Alvis/0000-0001-5988-7409; Carr, Edward/0000-0001-9343-4593; McKinney, Eoin/0000-0003-3516-3072; Smith, Kenneth/0000-0003-3829-4326; Jayne, David/0000-0002-1712-0637	UK National Institute of Health Research; Cambridge Biomedical Research Centre; Wellcome Trust [083650/Z/07/Z, 079895]; UK Medical Research Council; Evelyn Trust, Kidney Research UK; National Medical Research Council of Singapore [IRG07nov089]; Wellcome Fellowship; Medical Research Council; Medical Research Council [G0400929] Funding Source: researchfish; MRC [G0400929] Funding Source: UKRI	UK National Institute of Health Research(National Institute for Health Research (NIHR)); Cambridge Biomedical Research Centre(General Electric); Wellcome Trust(Wellcome Trust); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Evelyn Trust, Kidney Research UK; National Medical Research Council of Singapore(National Medical Research Council, Singapore); Wellcome Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank D. Fearon and J. Todd for critical review of the manuscript, T. Rayner, M. Kapushesky and M. Clatworthy for helpful discussions, K. Townsend for help with subject recruitment, H. Woffendin and T. Freeman for help with optimizing the custom array platform and A. Hatton and H. Ratlamwala for technical support, along with all subjects and clinicians involved in enrollment and clinical follow up. We are grateful to E. Clutterbuck, R. Lazarus and the volunteers at the Oxford Vaccine Group for their help with recruitment of healthy controls. This work was supported by the UK National Institute of Health Research, the Cambridge Biomedical Research Centre, the Wellcome Trust (Programme Grant number 083650/Z/07/Z), the UK Medical Research Council, the Evelyn Trust, Kidney Research UK and the National Medical Research Council of Singapore (grant reference IRG07nov089). E. F. M. holds a Wellcome Fellowship, and L. C. W. a Medical Research Council, Clinical Training Fellowship. K. G. C. S. is a Lister Prize Fellow and Khoo Oon Teik Professor of Nephrology at the National University of Singapore. The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (079895).	Abdulahad WH, 2007, ANN NY ACAD SCI, V1107, P22, DOI 10.1196/annals.1381.003; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413; Blanco P, 2005, ARTHRITIS RHEUM, V52, P201, DOI 10.1002/art.20745; Booth AD, 2003, AM J KIDNEY DIS, V41, P776, DOI 10.1016/S0272-6386(03)00025-8; Bryant PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004427; Buentke E, 2006, BLOOD, V108, P1949, DOI 10.1182/blood-2006-04-016857; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Illei Gabor G, 2004, Curr Rheumatol Rep, V6, P382, DOI 10.1007/s11926-004-0013-4; Ippolito A, 2008, CLIN EXP RHEUMATOL, V26, pS72; Jennette JC, 2006, J AM SOC NEPHROL, V17, P1235, DOI 10.1681/ASN.2005101048; Joshi NS, 2008, J IMMUNOL, V180, P1309, DOI 10.4049/jimmunol.180.3.1309; Lamprecht P, 2005, CLIN EXP IMMUNOL, V141, P201, DOI 10.1111/j.1365-2249.2005.02808.x; Lane SE, 2005, QJM-INT J MED, V98, P97, DOI 10.1093/qjmed/hci015; Langford CA, 2004, CLIN EXP RHEUMATOL, V22, pS3; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lyons PA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-64; Lyons PA, 2010, ANN RHEUM DIS, V69, P1208, DOI 10.1136/ard.2009.108043; Mao M, 2004, GENOMICS, V83, P989, DOI 10.1016/j.ygeno.2003.12.019; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Stone JH, 2001, ARTHRITIS RHEUM, V44, P912, DOI 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Torrente A, 2005, BIOINFORMATICS, V21, P3993, DOI 10.1093/bioinformatics/bti644; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vezys V, 2009, NATURE, V457, P196, DOI 10.1038/nature07486; Willcocks LC, 2008, J EXP MED, V205, P1573, DOI 10.1084/jem.20072413; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Willinger T, 2005, J IMMUNOL, V175, P5895, DOI 10.4049/jimmunol.175.9.5895	37	254	263	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2010	16	5					586	U122		10.1038/nm.2130	http://dx.doi.org/10.1038/nm.2130			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	592QP	20400961	Green Submitted, Green Accepted			2022-12-27	WOS:000277394700038
J	Torres, C				Torres, Christian			Counterfeiting goes cinematic in public campaigns	NATURE MEDICINE			English	News Item																			0	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					363	363		10.1038/nm0410-363a	http://dx.doi.org/10.1038/nm0410-363a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376032				2022-12-27	WOS:000276446800023
J	Li, Y; Zou, LH; Li, QY; Haibe-Kains, B; Tian, RY; Li, Y; Desmedt, C; Sotiriou, C; Szallasi, Z; Iglehart, JD; Richardson, AL; Wang, ZC				Li, Yang; Zou, Lihua; Li, Qiyuan; Haibe-Kains, Benjamin; Tian, Ruiyang; Li, Yan; Desmedt, Christine; Sotiriou, Christos; Szallasi, Zoltan; Iglehart, J. Dirk; Richardson, Andrea L.; Wang, Zhigang Charles			Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer	NATURE MEDICINE			English	Article							GENE-EXPRESSION; MULTIDRUG-RESISTANCE; HISTOLOGIC GRADE; SIGNATURE; ABERRATIONS; METASTASIS; PREDICTION; PROFILES; SURVIVAL; TUMORS	Adjuvant chemotherapy for breast cancer after surgery has effectively lowered metastatic recurrence rates(1). However, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adjuvant treatment. Identification of the genes crucial for tumor response to specific chemotherapy drugs is a challenge but is necessary to improve outcomes(2). By using integrated genomics, we identified a small number of overexpressed and amplified genes from chromosome 8q22 that were associated with early disease recurrence despite anthracycline-based adjuvant chemotherapy. We confirmed the association in an analysis of multiple independent cohorts. SiRNA-mediated knockdown of either of two of these genes, the antiapoptotic gene YWHAZ and a lysosomal gene LAPTM4B, sensitized tumor cells to anthracyclines, and overexpression of either of the genes induced anthracycline resistance. Overexpression of LAPTM4B resulted in sequestration of the anthracycline doxorubicin, delaying its appearance in the nucleus. Overexpression of these two genes was associated with poor tumor response to anthracycline treatment in a neoadjuvant chemotherapy trial in women with primary breast cancer. Our results suggest that 8q22 amplification and overexpression of LAPTM4B and YWHAZ contribute to de novo chemoresistance to anthracyclines and are permissive for metastatic recurrence. Overexpression of these two genes may predict anthracycline resistance and influence selection of chemotherapy.	[Li, Yang; Zou, Lihua; Tian, Ruiyang; Li, Yan; Iglehart, J. Dirk; Richardson, Andrea L.; Wang, Zhigang Charles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Li, Yang; Iglehart, J. Dirk; Wang, Zhigang Charles] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; [Zou, Lihua] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Li, Qiyuan; Szallasi, Zoltan] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; [Haibe-Kains, Benjamin; Desmedt, Christine; Sotiriou, Christos] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium; [Haibe-Kains, Benjamin] Univ Libre Bruxelles, Machine Learning Grp, Brussels, Belgium; [Szallasi, Zoltan] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Childrens Hosp Informat Program, Boston, MA USA; [Richardson, Andrea L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Technical University of Denmark; Institut Jules Bordet; Universite Libre de Bruxelles; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Richardson, AL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.	arichardson@partners.org; zhigang_wang@dfci.harvard.edu	Desmedt, Christine/P-7438-2017; Zou, Lihua/E-6748-2010; Haibe-Kains, Benjamin/D-3702-2011	Desmedt, Christine/0000-0002-5223-5579; Haibe-Kains, Benjamin/0000-0002-7684-0079; Szallasi, Zoltan/0000-0001-5395-7509	NATIONAL CANCER INSTITUTE [P50CA089393] Funding Source: NIH RePORTER; NCI NIH HHS [BC053041, P50 CA089393, P50 CA089393-01, CA89393, P50 CA089393-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Dowsett M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1798; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gyorffy B, 2005, ONCOGENE, V24, P7542, DOI 10.1038/sj.onc.1208908; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Ingvarsson S, 1999, SEMIN CANCER BIOL, V9, P277, DOI 10.1006/scbi.1999.0124; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Liedtke C, 2010, BREAST CANCER RES TR, V121, P301, DOI 10.1007/s10549-009-0445-7; Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Niemantsverdriet M, 2008, ONCOGENE, V27, P1315, DOI 10.1038/sj.onc.1210742; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; SILVER DP, J CLIN ONCO IN PRESS; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van Vliet MH, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-375; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; ZWEIG MH, 1993, CLIN CHEM, V39, P561	36	257	268	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					214	U121		10.1038/nm.2090	http://dx.doi.org/10.1038/nm.2090			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20098429	Green Accepted			2022-12-27	WOS:000274297000043
J	Rumjantseva, V; Grewal, PK; Wandall, HH; Josefsson, EC; Sorensen, AL; Larson, G; Marth, JD; Hartwig, JH; Hoffmeister, KM				Rumjantseva, Viktoria; Grewal, Prabhjit K.; Wandall, Hans H.; Josefsson, Emma C.; Sorensen, Anne Louise; Larson, Goran; Marth, Jamey D.; Hartwig, John H.; Hoffmeister, Karin M.			Dual roles for hepatic lectin receptors in the clearance of chilled platelets	NATURE MEDICINE			English	Article							VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IB; ASIALOGLYCOPROTEIN RECEPTOR; BLOOD-PLATELETS; IN-VITRO; CARBOHYDRATE MOIETY; GLYCOCALICIN; MEMBRANES; BINDING; ALPHA	Rapid chilling causes glycoprotein-Ib (GPIb) receptors to cluster on blood platelets. Hepatic macrophage beta(2) integrin binding to beta-N-acetylglucosamine (beta-GlcNAc) residues in the clusters leads to rapid clearance of acutely chilled platelets after transfusion. Although capping the beta-GlcNAc moieties by galactosylation prevents clearance of short-term-cooled platelets, this strategy is ineffective after prolonged refrigeration. We report here that prolonged refrigeration increased the density and concentration of exposed galactose residues on platelets such that hepatocytes, through Ashwell-Morell receptor binding, become increasingly involved in platelet removal. Macrophages rapidly removed a large fraction of transfused platelets independent of their storage conditions. With prolonged platelet chilling, hepatocyte-dependent clearance further diminishes platelet recovery and survival after transfusion. Inhibition of chilled platelet clearance by both beta(2) integrin and Ashwell-Morell receptors may afford a potentially simple method for storing platelets in the cold.	[Rumjantseva, Viktoria; Wandall, Hans H.; Josefsson, Emma C.; Sorensen, Anne Louise; Hartwig, John H.; Hoffmeister, Karin M.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA; [Rumjantseva, Viktoria; Wandall, Hans H.; Josefsson, Emma C.; Sorensen, Anne Louise; Hartwig, John H.; Hoffmeister, Karin M.] Harvard Univ, Sch Med, Boston, MA USA; [Rumjantseva, Viktoria; Larson, Goran] Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, Gothenburg, Sweden; [Grewal, Prabhjit K.; Marth, Jamey D.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Grewal, Prabhjit K.; Marth, Jamey D.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Sorensen, Anne Louise] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen Ctr Glyc, Copenhagen, Denmark	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Sahlgrenska University Hospital; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Copenhagen	Hoffmeister, KM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Translat Med, 75 Francis St, Boston, MA 02115 USA.	khoffmeister@rics.bwh.harvard.edu	Josefsson, Emma/CAF-4970-2022; Larson, Göran/AAF-3404-2019; Sørensen, Anne Louise Tølbøll/AAA-3211-2022	Sørensen, Anne Louise Tølbøll/0000-0003-4537-2505; Wandall, Hans H./0000-0003-0240-9232; Josefsson, Emma/0000-0001-6478-5204	US National Institutes of Health [PO1 HL056949, HL089224]; The Pew Scholars Award; Howard Hughes Medical Institute; The Swedish Medical Research Council; Goteborg University Jubileums; ZymeQuest, Inc;  [PO1HL57345]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949, P01HL057345, R01HL089224] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Pew Scholars Award; Howard Hughes Medical Institute(Howard Hughes Medical Institute); The Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Goteborg University Jubileums; ZymeQuest, Inc; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank S. Nayeb-Hashemi for excellent technical assistance, H. Clausen for helpful discussions and F. Maignen for statistical expertise. This work was supported by US National Institutes of Health grant PO1 HL056949 (to J.H.H. and K. M. H.) and grant HL089224 (to K. M. H.); The Pew Scholars Award to K. M. H.; PO1HL57345 (to J.D.M.); Howard Hughes Medical Institute to J. D. M.; and The Swedish Medical Research Council, Goteborg University Jubileums stipend to V. R. and K. M. H. V. R. and H. H. W. received sponsored research support form ZymeQuest, Inc. We obtained macros for K-function analysis from J. Hancock at the Institute for Molecular Bioscience, University of Queensland.	Alves-Rosa F, 2003, BRIT J HAEMATOL, V121, P130, DOI 10.1046/j.1365-2141.2003.04259.x; BARBER AJ, 1971, BIOCHIM BIOPHYS ACTA, V252, P533, DOI 10.1016/0304-4165(71)90156-5; BAUVOIS B, 1981, FEBS LETT, V125, P277, DOI 10.1016/0014-5793(81)80737-5; BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; Bergmeier W, 2004, CIRC RES, V95, P677, DOI 10.1161/01.RES.0000143899.73453.11; Bergmeier W, 2003, BLOOD, V102, P4229, DOI 10.1182/blood-2003-04-1305; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Blajchman MA, 2001, TRANSFUS APHER SCI, V24, P245, DOI 10.1016/S1473-0502(01)00063-5; Crowe JH, 2003, CHEM PHYS LIPIDS, V122, P41, DOI 10.1016/S0009-3084(02)00177-9; Denis CV, 2008, THROMB HAEMOSTASIS, V99, P271, DOI 10.1160/TH07-10-0629; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; Gousset K, 2004, BBA-BIOMEMBRANES, V1660, P7, DOI 10.1016/j.bbamem.2003.09.009; Grewal PK, 2008, NAT MED, V14, P648, DOI 10.1038/nm1760; Hoffmeister KM, 2003, SCIENCE, V301, P1531, DOI 10.1126/science.1085322; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; Hoffmeister KM, 2001, J BIOL CHEM, V276, P24751, DOI 10.1074/jbc.M011642200; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; Josefsson EC, 2005, J BIOL CHEM, V280, P18025, DOI 10.1074/jbc.M501178200; KOLBBACHOFEN V, 1984, BIOL CELL, V51, P219, DOI 10.1111/j.1768-322X.1984.tb00302.x; KORREL SAM, 1988, FEBS LETT, V228, P321, DOI 10.1016/0014-5793(88)80024-3; KORREL SAM, 1984, EUR J BIOCHEM, V140, P571, DOI 10.1111/j.1432-1033.1984.tb08140.x; Kuehnert MJ, 2001, TRANSFUSION, V41, P1493, DOI 10.1046/j.1537-2995.2001.41121493.x; Leidy C, 2004, CELL BIOCHEM BIOPHYS, V40, P123, DOI 10.1385/CBB:40:2:123; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; MCCULLOUGH J, 2003, TRANSFUSION MED 2011; MCGILL M, 1978, J LAB CLIN MED, V92, P971; McGill M, 1978, Prog Clin Biol Res, V28, P119; MURPHY S, 1969, NEW ENGL J MED, V280, P1094, DOI 10.1056/NEJM196905152802004; OZAKI K, 1995, GLYCOCONJUGATE J, V12, P268, DOI 10.1007/BF00731329; Prior I. A., 2003, SCI STKE, V2003, pPL9; Reimers H J, 1977, Adv Exp Med Biol, V82, P231; Rensen PCN, 2001, J BIOL CHEM, V276, P37577, DOI 10.1074/jbc.M101786200; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; Soukharev S, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e21; SULLIVAN MT, 2001, TRANSFUSION, V3; TSUJI T, 1987, J BIOCHEM-TOKYO, V101, P241, DOI 10.1093/oxfordjournals.jbchem.a121897; TSUJI T, 1983, J BIOL CHEM, V258, P6335; Valeri CR, 2002, VOX SANG, V83, P347, DOI 10.1046/j.1423-0410.2002.00229.x; van Rooijen N, 2003, METHOD ENZYMOL, V373, P3; VANROOIJEN N, 1984, CELL TISSUE RES, V238, P355, DOI 10.1007/BF00217308; Wahrenbrock MG, 2006, CANCER RES, V66, P2433, DOI 10.1158/0008-5472.CAN-05-3851; Wandall HH, 2008, BLOOD, V111, P3249, DOI 10.1182/blood-2007-06-097295; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Webert KE, 2008, TRANSFUS MED REV, V22, P1, DOI 10.1016/j.tmrv.2007.09.001	46	151	164	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1273	U68		10.1038/nm.2030	http://dx.doi.org/10.1038/nm.2030			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19783995	Green Accepted, Green Submitted			2022-12-27	WOS:000271543700015
J	Xu, J; Zhang, XM; Pelayo, R; Monestier, M; Ammollo, CT; Semeraro, F; Taylor, FB; Esmon, NL; Lupu, F; Esmon, CT				Xu, Jun; Zhang, Xiaomei; Pelayo, Rosana; Monestier, Marc; Ammollo, Concetta T.; Semeraro, Fabrizio; Taylor, Fletcher B.; Esmon, Naomi L.; Lupu, Florea; Esmon, Charles T.			Extracellular histones are major mediators of death in sepsis	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-C; INFLAMMATION; TRAPS; MICE	Hyperinflammatory responses can lead to a variety of diseases, including sepsis(1). We now report that extracellular histones released in response to inflammatory challenge contribute to endothelial dysfunction, organ failure and death during sepsis. They can be targeted pharmacologically by antibody to histone or by activated protein C (APC). Antibody to histone reduced the mortality of mice in lipopolysaccharide (LPS), tumor necrosis factor (TNF) or cecal ligation and puncture models of sepsis. Extracellular histones are cytotoxic toward endothelium in vitro and are lethal in mice. In vivo, histone administration resulted in neutrophil margination, vacuolated endothelium, intra-alveolar hemorrhage and macro- and microvascular thrombosis. We detected histone in the circulation of baboons challenged with Escherichia coli, and the increase in histone levels was accompanied by the onset of renal dysfunction. APC cleaves histones and reduces their cytotoxicity. Co-infusion of APC with E. coli in baboons or histones in mice prevented lethality. Blockade of protein C activation exacerbated sublethal LPS challenge into lethality, which was reversed by treatment with antibody to histone. We conclude that extracellular histones are potential molecular targets for therapeutics for sepsis and other inflammatory diseases.	[Xu, Jun; Ammollo, Concetta T.; Semeraro, Fabrizio; Taylor, Fletcher B.; Esmon, Naomi L.; Lupu, Florea; Esmon, Charles T.] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; [Zhang, Xiaomei; Esmon, Charles T.] Howard Hughes Med Inst, Oklahoma City, OK USA; [Pelayo, Rosana] Oklahoma Med Res Fdn, Immunol & Canc Res Program, Oklahoma City, OK 73104 USA; [Monestier, Marc] Temple Univ, Sch Med, Dept Microbiol & Immunol, Temple Autoimmun Ctr, Philadelphia, PA 19122 USA	Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA.	esmonc@omrf.org	Lupu, Florea/C-3162-2009; Lupu, Florea/AAV-3257-2021	Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278	US National Institutes of Health [R01GM037704]; University of Bari, Italy; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037704] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Bari, Italy; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Jackson for protein sequencing and identification; A. Matveev for preparing liposomes; C. J. Edgell, University of North Carolina, Chapel Hill, for providing EA.hy926 cells; G. Kinasewitz, University of Oklahoma Health Science Center, for providing plasma samples from humans with sepsis; K. Deatherage for preparing the manuscript; and P. Kincade for reviewing the original manuscript. C. T. E. is an investigator of the Howard Hughes Medical Institute. F. L. and F. B. T. are supported by US National Institutes of Health grant R01GM037704. C. T. A. and F. S. are supported by fellowships from the University of Bari, Italy.	Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Kerschen EJ, 2007, J EXP MED, V204, P2439, DOI 10.1084/jem.20070404; Lay AJ, 2007, BLOOD, V109, P1984, DOI 10.1182/blood-2006-07-037945; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; Macias WL, 2004, CRIT CARE MED, V32, pS223, DOI 10.1097/01.CCM.0000126120.49367.AC; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Russell JA, 2006, NEW ENGL J MED, V355, P1699, DOI 10.1056/NEJMra043632; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Xu J, 2009, J THROMB HAEMOST, V7, P851, DOI 10.1111/j.1538-7836.2009.03333.x; Zeerleder S, 2003, CRIT CARE MED, V31, P1947, DOI 10.1097/01.CCM.0000074719.40109.95	21	982	1061	7	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2009	15	11					1318	U117		10.1038/nm.2053	http://dx.doi.org/10.1038/nm.2053			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	516LM	19855397	Green Accepted			2022-12-27	WOS:000271543700021
J	Schinke, T; Schilling, AF; Baranowsky, A; Seitz, S; Marshall, RP; Linn, T; Blaeker, M; Huebner, AK; Schulz, A; Simon, R; Gebauer, M; Priemel, M; Kornak, U; Perkovic, S; Barvencik, F; Beil, FT; Del Fattore, A; Frattini, A; Streichert, T; Pueschel, K; Villa, A; Debatin, KM; Rueger, JM; Teti, A; Zustin, J; Sauter, G; Amling, M				Schinke, Thorsten; Schilling, Arndt F.; Baranowsky, Anke; Seitz, Sebastian; Marshall, Robert P.; Linn, Tilman; Blaeker, Michael; Huebner, Antje K.; Schulz, Ansgar; Simon, Ronald; Gebauer, Matthias; Priemel, Matthias; Kornak, Uwe; Perkovic, Sandra; Barvencik, Florian; Beil, F. Timo; Del Fattore, Andrea; Frattini, Annalisa; Streichert, Thomas; Pueschel, Klaus; Villa, Anna; Debatin, Klaus-Michael; Rueger, Johannes M.; Teti, Anna; Zustin, Jozef; Sauter, Guido; Amling, Michael			Impaired gastric acidification negatively affects calcium homeostasis and bone mass	NATURE MEDICINE			English	Article							AUTOSOMAL RECESSIVE OSTEOPETROSIS; VACUOLAR PROTON PUMP; TARGETED DISRUPTION; MICE; SUBUNIT; MUTATIONS; DISEASE; LEADS; DEFICIENCY; ABSORPTION	Activation of osteoclasts and their acidification-dependent resorption of bone is thought to maintain proper serum calcium levels. Here we show that osteoclast dysfunction alone does not generally affect calcium homeostasis. Indeed, mice deficient in Src, encoding a tyrosine kinase critical for osteoclast activity, show signs of osteopetrosis, but without hypocalcemia or defects in bone mineralization. Mice deficient in Cckbr, encoding a gastrin receptor that affects acid secretion by parietal cells, have the expected defects in gastric acidification but also secondary hyperparathyroidism and osteoporosis and modest hypocalcemia. These results suggest that alterations in calcium homeostasis can be driven by defects in gastric acidification, especially given that calcium gluconate supplementation fully rescues the phenotype of the Cckbr-mutant mice. Finally, mice deficient in Tcirg1, encoding a subunit of the vacuolar proton pump specifically expressed in both osteoclasts and parietal cells, show hypocalcemia and osteopetrorickets. Although neither Src- nor Cckbr-deficient mice have this latter phenotype, the combined deficiency of both genes results in osteopetrorickets. Thus, we find that osteopetrosis and osteopetrorickets are distinct phenotypes, depending on the site or sites of defective acidification.	[Schinke, Thorsten; Schilling, Arndt F.; Baranowsky, Anke; Seitz, Sebastian; Marshall, Robert P.; Linn, Tilman; Huebner, Antje K.; Gebauer, Matthias; Priemel, Matthias; Perkovic, Sandra; Barvencik, Florian; Beil, F. Timo; Rueger, Johannes M.; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Ctr Biomech & Skeletal Biol, Hamburg, Germany; [Blaeker, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany; [Schulz, Ansgar; Debatin, Klaus-Michael] Univ Med Ctr Ulm, Dept Pediat, Ulm, Germany; [Simon, Ronald; Zustin, Jozef; Sauter, Guido] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Hamburg, Germany; [Kornak, Uwe] Charite Univ Med Ctr, Inst Med Genet, Berlin, Germany; [Del Fattore, Andrea; Teti, Anna] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; [Frattini, Annalisa; Villa, Anna] CNR, Italian Natl Res Council, Ist Tecnol Biomed, Human Genome Dept, Segrate, Italy; [Frattini, Annalisa; Villa, Anna] IRCCS, Ist Clin Humanitas, Rozzano, Italy; [Streichert, Thomas] Univ Med Ctr Hamburg Eppendrof, Inst Clin Chem, Hamburg, Germany; [Pueschel, Klaus] Univ Med Ctr Hamburg Eppendrof, Inst Forens Med, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Humanitas Research Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Amling, M (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Ctr Biomech & Skeletal Biol, Hamburg, Germany.	amling@uke.uni-hamburg.de	Del Fattore, Andrea/H-4409-2015; Debatin, Klaus-Michael/J-9704-2014; Del Fattore, Andrea/AAP-2045-2020; Frattini, Annalisa/B-7684-2015; Marshall, Robert Percy/AAD-5269-2022	Del Fattore, Andrea/0000-0003-3848-412X; Debatin, Klaus-Michael/0000-0002-8397-1886; Del Fattore, Andrea/0000-0003-3848-412X; Frattini, Annalisa/0000-0002-1166-3091; Marshall, Robert Percy/0000-0003-4247-1006; Simon, Ronald/0000-0003-0158-4258; Teti, Anna Maria/0000-0002-5887-4419; Villa, Anna/0000-0003-4428-9013	Deutsche Forschungsgemeinschaft [AM103/14-1, BL423/4-3]; Deutsches Zentrum fur Luft- und Raumfahrt; Telethon [GGP06119]; NOBEL	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsches Zentrum fur Luft- und Raumfahrt(Helmholtz AssociationGerman Aerospace Centre (DLR)); Telethon(Fondazione Telethon); NOBEL	This work was supported by grants from the Deutsche Forschungsgemeinschaft to M. A. (AM103/14-1) and M. B. (BL423/4-3), from the Deutsches Zentrum fur Luft- und Raumfahrt within the framework of the E-Rare JTC 2007 to M. A., A. S., U. K., A. T. and A. V., from Telethon to A. T. (GGP06119) and by the NOBEL program from Fondazione Cariplo to A. V.	Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Aoki K, 2005, ANN EPIDEMIOL, V15, P598, DOI 10.1016/j.annepidem.2004.11.002; BANCO R, 1985, CLIN ORTHOP RELAT R, P238; Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673; Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029; Driessen GJA, 2003, BONE MARROW TRANSPL, V32, P657, DOI 10.1038/sj.bmt.1704194; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740; Gawenis LR, 2004, J BIOL CHEM, V279, P30531, DOI 10.1074/jbc.M403779200; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218; Huebner AK, 2006, J BONE MINER RES, V21, P1924, DOI 10.1359/JBMR.060820; Jacobson BC, 2003, AM J GASTROENTEROL, V98, P51, DOI 10.1111/j.1572-0241.2003.07186.x; KAPLAN FS, 1993, CLIN ORTHOP RELAT R, P64; Karaplis A C, 2000, Rev Endocr Metab Disord, V1, P331, DOI 10.1023/A:1026526703898; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; KASSARJIAN Z, 1989, ANNU REV NUTR, V9, P271, DOI 10.1146/annurev.nu.09.070189.001415; Kirubakaran C, 2004, J TROP PEDIATRICS, V50, P185, DOI 10.1093/tropej/50.3.185; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007; Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; RECKER RR, 1985, NEW ENGL J MED, V313, P70, DOI 10.1056/NEJM198507113130202; Schmidt K, 2005, J CELL BIOL, V168, P899, DOI 10.1083/jcb.200408013; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Seitz S, 2009, J BONE MINER RES, V24, P62, DOI 10.1359/JBMR.080907; Simon R, 2004, BIOTECHNIQUES, V36, P98, DOI 10.2144/04361RV01; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Straub DA, 2007, NUTR CLIN PRACT, V22, P286, DOI 10.1177/0115426507022003286; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002-9440(10)63798-4; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947	45	140	144	1	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2009	15	6					674	U111		10.1038/nm.1963	http://dx.doi.org/10.1038/nm.1963			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	455BS	19448635				2022-12-27	WOS:000266731600027
J	Gerzanich, V; Woo, SK; Vennekens, R; Tsymbalyuk, O; Ivanova, S; Ivanov, A; Geng, ZH; Chen, Z; Nilius, B; Flockerzi, V; Freichel, M; Simard, JM				Gerzanich, Volodymyr; Woo, S. Kyoon; Vennekens, Rudi; Tsymbalyuk, Orest; Ivanova, Svetlana; Ivanov, Alexander; Geng, Zhihua; Chen, Zheng; Nilius, Bernd; Flockerzi, Veit; Freichel, Marc; Simard, J. Marc			De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury	NATURE MEDICINE			English	Article							ANOXIC NEURONAL DEATH; CATION CHANNEL TRPM4; ENDOTHELIAL PERMEABILITY; VASCULAR MECHANISMS; CELL-ACTIVATION; ISCHEMIC-STROKE; MOUSE STRAINS; TRAUMA; RATS; HEMOGLOBIN	The role of transient receptor potential M4 (Trpm4), an unusual member of the Trp family of ion channels, is poorly understood. Using rodent models of spinal cord injury, we studied involvement of Trpm4 in the progressive expansion of secondary hemorrhage associated with capillary fragmentation, the most destructive mechanism of secondary injury in the central nervous system. Trpm4 mRNA and protein were abundantly upregulated in capillaries preceding their fragmentation and formation of petechial hemorrhages. Trpm4 expression in vitro rendered COS-7 cells highly susceptible to oncotic swelling and oncotic death following ATP depletion. After spinal cord injury, in vivo gene suppression in rats treated with Trpm4 antisense or in Trpm4(-/-) mice preserved capillary structural integrity, eliminated secondary hemorrhage, yielded a threefold to fivefold reduction in lesion volume and produced a substantial improvement in neurological function. To our knowledge, this is the first example of a Trp channel that must undergo de novo expression for manifestation of central nervous system pathology.	[Gerzanich, Volodymyr; Woo, S. Kyoon; Tsymbalyuk, Orest; Ivanova, Svetlana; Ivanov, Alexander; Geng, Zhihua; Chen, Zheng; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Vennekens, Rudi; Nilius, Bernd] Katholieke Univ Leuven, Dept Mol Celbiol, Div Physiol, Lab Channel Res, B-3000 Louvain, Belgium; [Flockerzi, Veit; Freichel, Marc] Univ Saarland, D-66421 Homburg, Germany; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; KU Leuven; Saarland University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Vennekens, Rudi/AAQ-1664-2020	Vennekens, Rudi/0000-0002-2564-5150	US National Heart, Lung, and Blood Institute [HL082517]; US National Institute of Neurological Disorders and Stroke [NS048260, NS061934]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048260, R01NS061934] Funding Source: NIH RePORTER	US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants to J. M. S. from the US National Heart, Lung, and Blood Institute ( HL082517), the US National Institute of Neurological Disorders and Stroke ( NS048260), the US Department of Veterans Affairs and the Christopher and Dana Reeve Foundation; to V. G. from the US National Institute of Neurological Disorders and Stroke ( NS061934); and to M. F. and V. F. from the Deutsche Forschungsgemeinschaft. R. V. is supported by the FWO Vlaanderen. The mTrpm4-GFP plasmid was kindly provided by E. R. Liman ( University of Southern California).	Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; BALENTINE JD, 1978, LAB INVEST, V39, P236; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Colak A, 2003, J NEUROSURG, V98, P275, DOI 10.3171/spi.2003.98.3.0275; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; Guinamard R, 2007, BBA-MOL BASIS DIS, V1772, P885, DOI 10.1016/j.bbadis.2007.02.007; Guinamard R, 2006, HYPERTENSION, V48, P587, DOI 10.1161/01.HYP.0000237864.65019.a5; Guth L, 1999, ANN NY ACAD SCI, V890, P366, DOI 10.1111/j.1749-6632.1999.tb08017.x; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; IIZUKA H, 1987, J NEUROSURG, V66, P595, DOI 10.3171/jns.1987.66.4.0595; Kawata Kazuhiro, 1993, Neurological Surgery, V21, P45; KHAN M, 1985, CAN J NEUROL SCI, V12, P259, DOI 10.1017/S0317167100047120; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Nicotera P, 2003, CELL, V115, P768, DOI 10.1016/S0092-8674(03)01019-5; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Nilius B, 2007, BBA-MOL BASIS DIS, V1772, P805, DOI 10.1016/j.bbadis.2007.02.002; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OSTERHOLM JL, 1984, NEUROSURGERY, V15, P373, DOI 10.1227/00006123-198409000-00013; Pena F, 2008, MINI-REV MED CHEM, V8, P812, DOI 10.2174/138955708784912166; Regan RF, 1998, J NEUROTRAUM, V15, P645, DOI 10.1089/neu.1998.15.645; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Tiruppathi C, 2006, MICROCIRCULATION, V13, P693, DOI 10.1080/10739680600930347; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vennekens R., 2007, V179, P269; Vennekens R, 2007, NAT IMMUNOL, V8, P312, DOI 10.1038/ni1441; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zhao QY, 1998, ANTISENSE NUCLEIC A, V8, P451, DOI 10.1089/oli.1.1998.8.451	44	152	156	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2009	15	2					185	191		10.1038/nm.1899	http://dx.doi.org/10.1038/nm.1899			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	403ZB	19169264	Green Published, Green Accepted			2022-12-27	WOS:000263119400021
J	Varela-Rohena, A; Molloy, PE; Dunn, SM; Li, Y; Suhoski, MM; Carroll, RG; Milicic, A; Mahon, T; Sutton, DH; Laugel, B; Moysey, R; Cameron, BJ; Vuidepot, A; Purbhoo, MA; Cole, DK; Phillips, RE; June, CH; Jakobsen, BK; Sewell, AK; Riley, JL				Varela-Rohena, Angel; Molloy, Peter E.; Dunn, Steven M.; Li, Yi; Suhoski, Megan M.; Carroll, Richard G.; Milicic, Anita; Mahon, Tara; Sutton, Deborah H.; Laugel, Bruno; Moysey, Ruth; Cameron, Brian J.; Vuidepot, Annelise; Purbhoo, Marco A.; Cole, David K.; Phillips, Rodney E.; June, Carl H.; Jakobsen, Bent K.; Sewell, Andrew K.; Riley, James L.			Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE RESPONSES; INFECTION; EPITOPE; TYPE-1; GAG; IMMUNODOMINANT; EVOLUTION; REVERSION; MUTATION	HIV's considerable capacity to vary its HLA-I-restricted peptide antigens allows it to escape from host cytotoxic T lymphocytes (CTLs). Nevertheless, therapeutics able to target HLA-I-associated antigens, with specificity for the spectrum of preferred CTL escape mutants, could prove effective. Here we use phage display to isolate and enhance a T-cell antigen receptor (TCR) originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A*02-restricted, HIVgag-specific peptide SLYNTVATL (SL9). High-affinity (K-D < 400 pM) TCRs were produced that bound with a half-life in excess of 2.5 h, retained specificity, targeted HIV-infected cells and recognized all common escape variants of this epitope. CD8 T cells transduced with this supraphysiologic TCR produced a greater range of soluble factors and more interleukin-2 than those transduced with natural SL9-specific TCR, and they effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T-cell therapy.	[Jakobsen, Bent K.] Adaptimmune Ltd, Abingdon OX14 4RX, Oxon, England; [Varela-Rohena, Angel; Suhoski, Megan M.; Carroll, Richard G.; June, Carl H.; Riley, James L.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Varela-Rohena, Angel; Suhoski, Megan M.; Carroll, Richard G.; June, Carl H.; Riley, James L.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Molloy, Peter E.; Dunn, Steven M.; Li, Yi; Mahon, Tara; Sutton, Deborah H.; Moysey, Ruth; Cameron, Brian J.; Vuidepot, Annelise; Purbhoo, Marco A.] Immunocore Ltd, Abingdon OX14 4RX, Oxon, England; [Milicic, Anita; Laugel, Bruno; Phillips, Rodney E.; Sewell, Andrew K.] Univ Oxford, Oxford OX1 3SY, England; [Cole, David K.; Sewell, Andrew K.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Oxford; Cardiff University	Jakobsen, BK (corresponding author), Adaptimmune Ltd, 57C Milton Pk, Abingdon OX14 4RX, Oxon, England.	bent.jakobsen@adaptimmune.com; rileyj@exchange.upenn.edu	Cole, David/C-8387-2012; Milicic, Anita/B-7693-2011; Sewell, Andrew/GPT-4220-2022	Milicic, Anita/0000-0002-7984-1317; Sewell, Andrew/0000-0003-3194-3135; Cole, David/0000-0003-0028-9396; Riley, James/0000-0002-1057-576X; June, Carl/0000-0003-0241-3557; Molloy, Peter/0000-0002-0238-4744	Wellcome Trust Senior Fellow; Cardiff University; US National Institutes of Health [R21 AI060477, R01 CA105216, PO1 AI066290]; NATIONAL CANCER INSTITUTE [R01CA105216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI060477, U19AI082628, U19AI066290] Funding Source: NIH RePORTER	Wellcome Trust Senior Fellow(Wellcome Trust); Cardiff University; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to R. Ashfield, B. Classon and R. Vonderheide for their help in initiating collaborations. We thank P. Goulder, A. Leslie and T. Scriba for encouragement, critical reading of the manuscript and helpful suggestions. A. Bennett designed the TCR expression constructs. M. Milone confirmed the SL9 sequence of 92BR-017, 92BR-018 and 92BR-028. A. K. S. was a Wellcome Trust Senior Fellow and is funded by Cardiff University. This work was also supported in part by US National Institutes of Health grants R21 AI060477, R01 CA105216 and PO1 AI066290. The authors would like to dedicate this study to the memory of our colleague and friend Jonathan Michael Boulter, who contributed immensely in the field of soluble T cell receptors.	Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Cole DK, 2007, J IMMUNOL, V178, P5727, DOI 10.4049/jimmunol.178.9.5727; Crawford H, 2007, J VIROL, V81, P8346, DOI 10.1128/JVI.00465-07; Darden JM, 2000, CYTOMETRY, V40, P141, DOI 10.1002/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.3.CO;2-6; Edwards CTT, 2005, J VIROL, V79, P9363, DOI 10.1128/JVI.79.14.9363-9366.2005; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; Iversen AKN, 2006, NAT IMMUNOL, V7, P179, DOI 10.1038/ni1298; Kan-Mitchell J, 2006, J IMMUNOL, V176, P6690, DOI 10.4049/jimmunol.176.11.6690; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Li Y, 2005, NAT BIOTECHNOL, V23, P349, DOI 10.1038/nbt1070; Martinez-Hackert E, 2006, J BIOL CHEM, V281, P20205, DOI 10.1074/jbc.M601934200; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Molloy PE, 2005, CURR OPIN PHARMACOL, V5, P438, DOI 10.1016/j.coph.2005.02.004; Morikawa Y, 1998, J VIROL, V72, P7659, DOI 10.1128/JVI.72.9.7659-7663.1998; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1998, J MOL MED-JMM, V76, P699, DOI 10.1007/s001090050270; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; Sewell AK, 2000, STEM CELLS, V18, P230, DOI 10.1634/stemcells.18-4-230; Suhoski MM, 2007, MOL THER, V15, P981, DOI 10.1038/mt.sj.6300134; Whelan JA, 1999, J IMMUNOL, V163, P4342; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102	30	196	248	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1390	1395		10.1038/nm.1779	http://dx.doi.org/10.1038/nm.1779			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	18997777	Green Accepted			2022-12-27	WOS:000261393600026
J	Traykova-Brauch, M; Schonig, K; Greiner, O; Miloud, T; Jauch, A; Bode, M; Felsher, DW; Glick, AB; Kwiatkowski, DJ; Bujard, H; Horst, J; Doeberitz, MV; Niggli, FK; Kriz, W; Groene, HJ; Koesters, R				Traykova-Brauch, Milena; Schoenig, Kai; Greiner, Oliver; Miloud, Tewfik; Jauch, Anna; Bode, Manja; Felsher, Dean W.; Glick, Adam B.; Kwiatkowski, David J.; Bujard, Hermann; Horst, Juergen; Doeberitz, Magnus von Knebel; Niggli, Felix K.; Kriz, Wilhelm; Groene, Hermann-Josef; Koesters, Robert			An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice	NATURE MEDICINE			English	Article							PAIRED BOX GENE; MAMMALIAN-CELLS; THYROID-GLAND; MOUSE MODEL; EXPRESSION; KIDNEY; LETHALITY; TSC1; PAX8; TGF-BETA-1	We describe a transgenic mouse line, Pax8-rtTA, which, under control of the mouse Pax8 promoter, directs high levels of expression of the reverse tetracycline-dependent transactivator (rtTA) to all proximal and distal tubules and the entire collecting duct system of both embryonic and adult kidneys. Using crosses of Pax8-rtTA mice with tetracycline-responsive c-MYC mice, we established a new, inducible model of polycystic kidney disease that can mimic adult onset and that shows progression to renal malignant disease. When targeting the expression of transforming growth factor-beta 1 to the kidney, we avoided early lethality by discontinuous treatment and successfully established an inducible model of renal fibrosis. Finally, a conditional knockout of the gene encoding tuberous sclerosis complex-1 was achieved, which resulted in the early outgrowth of giant polycystic kidneys reminiscent of autosomal recessive polycystic kidney disease. These experiments establish Pax8-rtTA mice as a powerful tool for modeling renal diseases in transgenic mice.	[Greiner, Oliver; Koesters, Robert] Univ Childrens Hosp Zurich, CH-8032 Zurich, Switzerland; [Traykova-Brauch, Milena; Groene, Hermann-Josef] Deutsch Krebsforschungszentrum, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; [Schoenig, Kai] Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany; [Miloud, Tewfik] Deutsch Krebsforschungszentrum, Dept Immunol, D-69120 Heidelberg, Germany; [Jauch, Anna; Koesters, Robert] Heidelberg Univ, Inst Human Genet, D-69120 Heidelberg, Germany; [Felsher, Dean W.] Ctr Clin Sci Res, Stanford, CA 94305 USA; [Glick, Adam B.] Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16801 USA; [Kwiatkowski, David J.] Brigham & Womens Hosp, Dept Med, Translat Med Div, Boston, MA 02115 USA; [Bujard, Hermann] Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; [Horst, Juergen] Univ Munster, Inst Human Genet, D-48149 Munster, Germany; [Doeberitz, Magnus von Knebel; Koesters, Robert] Heidelberg Univ, Inst Pathol, Dept Appl Tumor Biol, D-69120 Heidelberg, Germany; [Kriz, Wilhelm] Heidelberg Univ, Med Fac Mannheim, Dept Anat & Dev Biol, D-68167 Mannheim, Germany	University Children's Hospital Zurich; Helmholtz Association; German Cancer Research Center (DKFZ); Central Institute of Mental Health; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Harvard University; Brigham & Women's Hospital; Ruprecht Karls University Heidelberg; University of Munster; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Koesters, R (corresponding author), Univ Childrens Hosp Zurich, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	robert.koesters@med.uni-heidelberg.de	von Knebel Doeberitz, Magnus/D-2372-2016; Niggli, Felix/L-6547-2017	von Knebel Doeberitz, Magnus/0000-0002-0498-6781; Niggli, Felix/0000-0002-7553-3712	Deutsche Forschungsgemeinschaft [FOR406]; SFB [405 B10]; US National Institutes of Health [R01-CA85610, R01-CA105102, 3R01CA089305-03S1]; NIH/NCI ICMIC [P50, 1P20 CA112973]; NATIONAL CANCER INSTITUTE [U56CA112973, P01CA120964, R01CA089305, R01CA105102, R01CA085610] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); SFB(Austrian Science Fund (FWF)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI ICMIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Deutsche Forschungsgemeinschaft grants FOR406 (to W. K. and R. K.) and SFB 405 B10 ( to H.-J. G.), by Schweizerische Forschungsstiftung Kind und Krebs (O. G.), by Prof. Dr. Karl und Gerhard Schiller-Stiftung (W. K.) and by US National Institutes of Health grants R01-CA85610, R01-CA105102, 3R01CA089305-03S1, NIH/NCI ICMIC P50 and NIH/NCI 1P20 CA112973 (D. W. F.). We thank P. Soriano (Fred Hutchinson Cancer Research Center) for providing Rosa26R mice; F. Zimmermann and S. Dlugosz for DNA microinjection; I. Voehringer, J. Charon-Alvarez, H. Hosser and B. Hahnel for technical assistance; the teams of the animal facilities at Deutsches Krebsforschungszentrum and Interfakultare Biomedizinische Forschungseinrichtung Heidelberg for animal caretaking; T. P. Sijmonsma for skillful and expert handling of the mice; S. Wang for help with tissue preservation; M. Schorpp-Kistner and C. Gebhardt for expert advice in mouse embryology; R. Nonnenmacher for graphical work; and W. A. Grandy for carefully reading the manuscript.	Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; KAISSLING B, 1982, KIDNEY INT, pS9; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lavoie JL, 2004, AM J PHYSIOL-RENAL, V286, pF965, DOI 10.1152/ajprenal.00402.2003; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Meikle L, 2005, HUM MOL GENET, V14, P429, DOI 10.1093/hmg/ddi039; Nelson RD, 1998, AM J PHYSIOL-CELL PH, V275, pC216, DOI 10.1152/ajpcell.1998.275.1.C216; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1992, DEVELOPMENT, V116, P611; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; Schonig K, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf134; Schonig Kai, 2003, Methods Mol Biol, V209, P69; Sepulveda AR, 1997, J BIOL CHEM, V272, P11959, DOI 10.1074/jbc.272.18.11959; Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016444.90348.50; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Srinivas S, 1999, DEV GENET, V24, P241; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; Ueberham E, 2003, HEPATOLOGY, V37, P1067, DOI 10.1053/jhep.2003.50196; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197	25	191	195	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					979	984		10.1038/nm.1865	http://dx.doi.org/10.1038/nm.1865			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18724376	Green Accepted			2022-12-27	WOS:000258988600032
J	Zhang, C; Cuervo, AM				Zhang, Cong; Cuervo, Ana Maria			Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function	NATURE MEDICINE			English	Article							AGE; DEGRADATION; PROTEIN; LYSOSOMES; DISEASE; HEPATOCYTES; RECEPTOR	Chaperone-mediated autophagy (CMA), a selective mechanism for degradation of cytosolic proteins in lysosomes, contributes to the removal of altered proteins as part of the cellular quality-control systems(1,2). We have previously found that CMA activity declines in aged organisms and have proposed that this failure in cellular clearance could contribute to the accumulation of altered proteins, the abnormal cellular homeostasis and, eventually, the functional loss characteristic of aged organisms. To determine whether these negative features of aging can be prevented by maintaining efficient autophagic activity until late in life, in this work we have corrected the CMA defect in aged rodents. We have generated a double transgenic mouse model in which the amount of the lysosomal receptor for CMA, previously shown to decrease in abundance with age(3), can be modulated. We have analyzed in this model the consequences of preventing the age-dependent decrease in receptor abundance in aged rodents at the cellular and organ levels. We show here that CMA activity is maintained until advanced ages if the decrease in the receptor abundance is prevented and that preservation of autophagic activity is associated with lower intracellular accumulation of damaged proteins, better ability to handle protein damage and improved organ function.	[Cuervo, Ana Maria] Marion Bessin Liver Res Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Marion Bessin Liver Res Ctr, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Aging Res, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Cuervo, AM (corresponding author), Marion Bessin Liver Res Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	amcuervo@aecom.yu.edu	Zhang, Cong/A-1616-2013	Zhang, Cong/0000-0002-6074-9836; Cuervo, Ana Maria/0000-0002-0771-700X	US National Institutes of Health National Institute on Aging [AG021904, AG19834]; National Institute of Diabetes and Digestive and Kidney Diseases [DK041918]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021904, R37AG021904, R03AG019834] Funding Source: NIH RePORTER	US National Institutes of Health National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to S. Kaushik and A. C. Massey for assistance in the preparation of this manuscript. The pUHD10-3 plasmid and the Alb-tTA mice were generous gifts from H. Bujard (University of Heidelberg) and the antibody to the asialoglycoprotein receptor was kindly supplied by A. Wolkoff (Albert Einstein College of Medicine). This work was supported in part by US National Institutes of Health National Institute on Aging grants AG021904 and AG19834, National Institute of Diabetes and Digestive and Kidney Diseases DK041918, an Ellison Medical Foundation Award and a Glenn Foundation Award.	Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; BARRET A, 1998, HDB PROTEOLYTIC ENZY, P850; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Cavallini G, 2007, AUTOPHAGY, V3, P26, DOI 10.4161/auto.3268; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017; Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144; Finn PF, 2005, J BIOL CHEM, V280, P25864, DOI 10.1074/jbc.M502456200; Higami Y, 1997, AM J PATHOL, V151, P659; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152; Kiffin R, 2007, J CELL SCI, V120, P782, DOI 10.1242/jcs.001073; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Massey AC, 2006, CURR TOP DEV BIOL, V73, P205, DOI 10.1016/S0070-2153(05)73007-6; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Pappas P, 1998, EUR J DRUG METAB PH, V23, P461, DOI 10.1007/BF03189996; Salvador N, 2000, J BIOL CHEM, V275, P27447; Schmucker DL, 2005, EXP GERONTOL, V40, P650, DOI 10.1016/j.exger.2005.06.009; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TANAKA K, 1988, DIABETES RES CLIN PR, V5, P71, DOI 10.1016/S0168-8227(88)80081-0; Terman A, 1995, GERONTOLOGY, V41, P319; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349	27	369	381	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2008	14	9					959	965		10.1038/nm.1851	http://dx.doi.org/10.1038/nm.1851			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18690243	Green Accepted			2022-12-27	WOS:000258988600029
J	Lang, PA; Contaldo, C; Georgiev, P; El-Badry, AM; Recher, M; Kurrer, M; Cervantes-Barragan, L; Ludewig, B; Calzascia, T; Bolinger, B; Merkler, D; Odermatt, B; Bader, M; Graf, R; Clavien, PA; Hegazy, AN; Loehning, M; Harris, NL; Ohashi, PS; Hengartner, H; Zinkernagel, RM; Lang, KS				Lang, Philipp A.; Contaldo, Claudio; Georgiev, Panco; El-Badry, Ashraf Mohammad; Recher, Mike; Kurrer, Michael; Cervantes-Barragan, Luisa; Ludewig, Burkhard; Calzascia, Thomas; Bolinger, Beatrice; Merkler, Doron; Odermatt, Bernhard; Bader, Michael; Graf, Rolf; Clavien, Pierre-Alain; Hegazy, Ahmed N.; Loehning, Max; Harris, Nicola L.; Ohashi, Pamela S.; Hengartner, Hans; Zinkernagel, Rolf M.; Lang, Karl S.			Aggravation of viral hepatitis by platelet-derived serotonin	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICROVASCULAR REGULATORY MECHANISMS; B-VIRUS; T-CELLS; BLOOD-PLATELETS; LIVER-DAMAGE; P-SELECTIN; INFECTION; CLEARANCE; ACTIVATION	More than 500 million people worldwide are persistently infected with hepatitis B virus or hepatitis C virus(1). Although both viruses are poorly cytopathic, persistence of either virus carries a risk of chronic liver inflammation, potentially resulting in liver steatosis, liver cirrhosis, end-stage liver failure or hepatocellular carcinoma. Virus-specific T cells are a major determinant of the outcome of hepatitis, as they contribute to the early control of chronic hepatitis viruses, but they also mediate immunopathology during persistent virus infection(1-4). We have analyzed the role of platelet-derived vasoactive serotonin during virus-induced CD8(+) T cell-dependent immunopathological hepatitis in mice infected with the noncytopathic lymphocytic choriomeningitis virus. After virus infection, platelets were recruited to the liver, and their activation correlated with severely reduced sinusoidal microcirculation, delayed virus elimination and increased immunopathological liver cell damage. Lack of platelet-derived serotonin in serotonin-deficient mice normalized hepatic microcirculatory dysfunction, accelerated virus clearance in the liver and reduced CD8(+) T cell-dependent liver cell damage. In keeping with these observations, serotonin treatment of infected mice delayed entry of activated CD8(+) T cells into the liver, delayed virus control and aggravated immunopathological hepatitis. Thus, vasoactive serotonin supports virus persistence in the liver and aggravates virus-induced immunopathology.	[Lang, Philipp A.; Recher, Mike; Merkler, Doron; Hegazy, Ahmed N.; Loehning, Max; Harris, Nicola L.; Hengartner, Hans; Zinkernagel, Rolf M.; Lang, Karl S.] Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; [Lang, Philipp A.; Calzascia, Thomas; Ohashi, Pamela S.; Lang, Karl S.] UHN, Campbell Family Inst Breast Canc Res, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; [Contaldo, Claudio] Univ Zurich Hosp, Div Plast & Reconstruct Surg, CH-8091 Zurich, Switzerland; [Georgiev, Panco; El-Badry, Ashraf Mohammad; Graf, Rolf; Clavien, Pierre-Alain] Univ Zurich Hosp, Swiss Hepato Pancreato Biliary Ctr, Dept Surg, CH-8091 Zurich, Switzerland; [Kurrer, Michael; Odermatt, Bernhard] Univ Zurich Hosp, Dept Surg Pathol, CH-8091 Zurich, Switzerland; [Cervantes-Barragan, Luisa; Ludewig, Burkhard; Bolinger, Beatrice] Kantonal Hosp St Gallen, Res Dept, CH-9007 St Gallen, Switzerland; [Merkler, Doron] Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; [Bader, Michael] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Hegazy, Ahmed N.; Loehning, Max] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany; [Hegazy, Ahmed N.; Loehning, Max] Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany	University of Zurich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Kantonsspital St. Gallen; University of Gottingen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ)	Zinkernagel, RM (corresponding author), Univ Zurich, Inst Expt Immunol, Schmelzberstr 12, CH-8091 Zurich, Switzerland.	rolf.zinkernagel@usz.ch; karlslang@gmail.com	Bader, Michael/K-2124-2013; harris, nicola/E-5342-2019; Merkler, Doron/N-9157-2016; Lang, Karl S/R-2505-2016; El-Badry, Ashraf Mohammad/X-7818-2019; Löhning, Max/AAL-2967-2021	harris, nicola/0000-0003-2922-0210; Merkler, Doron/0000-0002-0247-2007; El-Badry, Ashraf Mohammad/0000-0003-4125-3373; Löhning, Max/0000-0001-6382-7281; Calzascia, Thomas/0000-0001-8225-6744; Hegazy, Ahmed N./0000-0002-2946-8251; Graf, Rolf/0000-0001-7449-7302; Lang, Karl/0000-0001-9783-7605; Bader, Michael/0000-0003-4780-4164; Recher, Mike/0000-0002-9121-6936; Ohashi, Pamela S./0000-0003-2915-9317				Bergthaler A, 2007, J GEN VIROL, V88, P592, DOI 10.1099/vir.0.82428-0; Bertoletti A, 2006, J GEN VIROL, V87, P1439, DOI 10.1099/vir.0.81920-0; BLANKENSHIP LL, 1991, MICROCIRC ENDOTH LYM, V7, P57; Blann AD, 1997, ATHEROSCLEROSIS, V128, P135, DOI 10.1016/S0021-9150(96)05980-1; BORN GVR, 1972, BRIT J PHARMACOL, V44, P117, DOI 10.1111/j.1476-5381.1972.tb07244.x; Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770; Contaldo C, 2005, ANESTH ANALG, V100, P817, DOI 10.1213/01.ANE.0000144427.90174.B6; CUMMINGS JL, 1993, INT J MICROCIRC, V13, P99; GREGORY PB, 1976, NEW ENGL J MED, V294, P681, DOI 10.1056/NEJM197603252941301; Iannacone M, 2005, NAT MED, V11, P1167, DOI 10.1038/nm1317; Iannacone M, 2008, P NATL ACAD SCI USA, V105, P629, DOI 10.1073/pnas.0711200105; Lang KS, 2006, J CLIN INVEST, V116, P2456, DOI 10.1172/JCI28349; Lesurtel M, 2006, SCIENCE, V312, P104, DOI 10.1126/science.1123842; Maini MK, 2000, J EXP MED, V191, P1269, DOI 10.1084/jem.191.8.1269; Murray JM, 2005, P NATL ACAD SCI USA, V102, P17780, DOI 10.1073/pnas.0508913102; Nakamura I, 2001, HEPATOLOGY, V33, P439, DOI 10.1053/jhep.2001.21748; Panasiuk A, 2001, HEPATO-GASTROENTEROL, V48, P818; Recher M, 2007, NAT MED, V13, P1316, DOI 10.1038/nm1670; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Sobao Y, 2002, J HEPATOL, V36, P105, DOI 10.1016/S0168-8278(01)00264-1; Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; Uhlmann S, 1999, J INVEST SURG, V12, P179; Urbani S, 2005, J EXP MED, V201, P675, DOI 10.1084/jem.20041058; VANNUETEN JM, 1985, PHARMACOL RES COMMUN, V17, P585, DOI 10.1016/0031-6989(85)90067-0; VANNUETEN JM, 1985, J CARDIOVASC PHARM, V7, pS49; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075	29	183	187	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					756	761		10.1038/nm1780	http://dx.doi.org/10.1038/nm1780			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18516052	Green Submitted, Green Published			2022-12-27	WOS:000257452700023
J	Kashiwagi, S; Tsukada, K; Xu, L; Miyazaki, J; Kozin, SV; Tyrrell, JA; Sessa, WC; Gerweck, LE; Jain, RK; Fukumura, D				Kashiwagi, Satoshi; Tsukada, Kosuke; Xu, Lei; Miyazaki, Junichi; Kozin, Sergey V.; Tyrrell, James A.; Sessa, William C.; Gerweck, Leo E.; Jain, Rakesh K.; Fukumura, Dai			Perivascular nitric oxide gradients normalize tumor vasculature	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MURAL CELL RECRUITMENT; SYNTHASE; ANGIOGENESIS	Normalization of tumor vasculature is an emerging strategy to improve cytotoxic therapies. Here we show that eliminating nitric oxide (NO) production from tumor cells via neuronal NO synthase silencing or inhibition establishes perivascular gradients of NO in human glioma xenografts in mice and normalizes the tumor vasculature, resulting in improved tumor oxygenation and response to radiation treatment. Creation of perivascular NO gradients may be an effective strategy for normalizing abnormal vasculature.	[Kashiwagi, Satoshi; Tsukada, Kosuke; Xu, Lei; Miyazaki, Junichi; Kozin, Sergey V.; Tyrrell, James A.; Gerweck, Leo E.; Jain, Rakesh K.; Fukumura, Dai] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; [Sessa, William C.] Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; [Kashiwagi, Satoshi; Tsukada, Kosuke; Xu, Lei; Miyazaki, Junichi; Kozin, Sergey V.; Tyrrell, James A.; Gerweck, Leo E.; Jain, Rakesh K.; Fukumura, Dai] Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Yale University; Harvard University; Harvard Medical School	Fukumura, D (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, 100 Blossom St, Boston, MA 02114 USA.	dai@steele.mgh.harvard.edu	Kashiwagi, Satoshi/T-2420-2019; Jain, Rakesh K/I-1384-2017; Sessa, William C/B-6844-2011; Tsukada, Kosuke/C-9986-2014; Tyrrell, James/A-6359-2010; Xu, Lei/GRR-9174-2022	Jain, Rakesh K/0000-0001-7571-3548; Sessa, William C/0000-0001-5759-1938; Tsukada, Kosuke/0000-0003-1463-2204; 	NCI NIH HHS [P01 CA080124, R01-CA96915, R01 CA096915, P01-CA80124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA080124, R01CA096915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Babaei S, 2003, AM J PATHOL, V162, P1927, DOI 10.1016/S0002-9440(10)64326-X; Dulak J, 2000, ARTERIOSCL THROM VAS, V20, P659, DOI 10.1161/01.ATV.20.3.659; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; HALL EJ, 1985, RADIOBIOLOGY RADIOBI; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kashiwagi S, 2005, J CLIN INVEST, V115, P1816, DOI 10.1172/JCI24015; MITCHELL JB, 1993, CANCER RES, V53, P5845; POU S, 1992, J BIOL CHEM, V267, P24173; vanderZee R, 1997, CIRCULATION, V95, P1030; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845	15	115	122	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					255	257		10.1038/nm1730	http://dx.doi.org/10.1038/nm1730			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18278052				2022-12-27	WOS:000253815700030
J	Moser, M; Nieswandt, B; Ussar, S; Pozgajova, M; Fassler, R				Moser, Markus; Nieswandt, Bernhard; Ussar, Siegfried; Pozgajova, Miroslava; Faessler, Reinhard			Kindlin-3 is essential for integrin activation and platelet aggregation	NATURE MEDICINE			English	Article							GLYCOPROTEIN-IIB-IIIA; GLANZMANN THROMBASTHENIA; CYTOSKELETAL PROTEINS; MEDIATED ADHESION; TALIN; DOMAIN; BETA; COLLAGEN; MODULATION; RECEPTOR	Integrin-mediated platelet adhesion and aggregation are essential for sealing injured blood vessels and preventing blood loss, and excessive platelet aggregation can initiate arterial thrombosis, causing heart attacks and stroke(1). To ensure that platelets aggregate only at injury sites, integrins on circulating platelets exist in a low-affinity state and shift to a high-affinity state (in a process known as integrin activation or priming) after contacting a wounded vessel(2). The shift is mediated through binding of the cytoskeletal protein Talin to the beta subunit cytoplasmic tail(3-5). Here we show that platelets lacking the adhesion plaque protein Kindlin-3 cannot activate integrins despite normal Talin expression. As a direct consequence, Kindlin-3 deficiency results in severe bleeding and resistance to arterial thrombosis. Mechanistically, Kindlin-3 can directly bind to regions of beta-integrin tails distinct from those of Talin and trigger integrin activation. We have therefore identified Kindlin-3 as a novel and essential element for platelet integrin activation in hemostasis and thrombosis.	[Moser, Markus; Ussar, Siegfried; Faessler, Reinhard] Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; [Nieswandt, Bernhard; Pozgajova, Miroslava] Univ Wurzburg, Rudolf Virchow Ctr, Deutsch Forsch Sgemeinschaft Res Ctr Expt Biomed, D-97080 Wurzburg, Germany; [Nieswandt, Bernhard] Inst Clin Biochem & Pathobiochem, D-97078 Wurzburg, Germany	Max Planck Society; University of Wurzburg	Fassler, R (corresponding author), Max Planck Inst Biochem, Dept Mol Med, Klopferspitz 18, D-82152 Martinsried, Germany.	faessler@biochem.mpg.de	Pozgajova, Miroslava/AAG-1841-2019; Ussar, Siegfried/AAL-4331-2021; Pozgajova, Miroslava/AAG-2513-2019	Ussar, Siegfried/0000-0001-7575-0920; Pozgajova, Miroslava/0000-0003-3713-0717				Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Critchley DR, 2004, BIOCHEM SOC T, V32, P831, DOI 10.1042/BST0320831; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; McCarty OJT, 2005, J BIOL CHEM, V280, P39474, DOI 10.1074/jbc.M504672200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; NIESWANDT B, IN PRESS J EXP MED; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takahashi S, 2007, J CELL BIOL, V178, P167, DOI 10.1083/jcb.200703021; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030; Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048; Weinstein EJ, 2003, BBA-MOL BASIS DIS, V1637, P207, DOI 10.1016/S0925-4439(03)00035-8	23	498	513	2	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2008	14	3					325	330		10.1038/nm1722	http://dx.doi.org/10.1038/nm1722			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18278053				2022-12-27	WOS:000253815700039
J	Law, M; Maruyama, T; Lewis, J; Giang, E; Tarr, AW; Stamataki, Z; Gastaminza, P; Chisari, FV; Jones, IM; Fox, RI; Ball, JK; McKeating, JA; Kneteman, NM; Burton, DR				Law, Mansun; Maruyama, Toshiaki; Lewis, Jamie; Giang, Erick; Tarr, Alexander W.; Stamataki, Zania; Gastaminza, Pablo; Chisari, Francis V.; Jones, Ian M.; Fox, Robert I.; Ball, Jonathan K.; McKeating, Jane A.; Kneteman, Norman M.; Burton, Dennis R.			Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge	NATURE MEDICINE			English	Article							E2 ENVELOPE GLYCOPROTEIN; BINDING; CHIMPANZEES; PARTICLES; CULTURE; CD81	A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.	[Law, Mansun; Maruyama, Toshiaki; Giang, Erick; Burton, Dennis R.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; [Burton, Dennis R.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Gastaminza, Pablo; Chisari, Francis V.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Lewis, Jamie; Kneteman, Norman M.] Univ Alberta, Dept Surg, Edmonton, AB T6G 2S2, Canada; [Tarr, Alexander W.; Ball, Jonathan K.] Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England; [Stamataki, Zania; McKeating, Jane A.] Univ Birmingham, Sch Med, Inst Biomed Res, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England; [Jones, Ian M.] Univ Reading, Sch Biol Sci, Reading RG6 6AH, Berks, England; [Fox, Robert I.] Scripps Mem Hosp, Rheumatol Clin, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of Alberta; University of Nottingham; University of Birmingham; University of Reading	Law, M (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	norm.kneteman@capitalhealth.ca; burton@scripps.edu	Cheng, Yushao/E-6256-2011; Stamataki, Zania/H-6541-2011; Ball, Jonathan/HGU-3130-2022; Chisari, Francis V/A-3086-2008; Tarr, Alexander W/B-7953-2008; Stamataki, Zania/P-4681-2019; Law, Mansun/A-3899-2008; Gastaminza, Pablo/K-5444-2014	Tarr, Alexander W/0000-0003-1009-0823; Stamataki, Zania/0000-0003-3823-4497; Chisari, Francis/0000-0002-4832-1044; McKeating, Jane/0000-0002-7229-5886; Law, Mansun/0000-0002-8934-9756; ball, jonathan/0000-0001-5773-8733; Gastaminza Landart, Pablo/0000-0002-7873-5491	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071084] Funding Source: NIH RePORTER; MRC [G0200000, G0400802] Funding Source: UKRI; Medical Research Council [G0801976, G0400802, G0200000] Funding Source: Medline; NIAID NIH HHS [R01 AI071084] Funding Source: Medline; Medical Research Council [G9818340B] Funding Source: researchfish	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Cocquerel L, 2003, J VIROL, V77, P10677, DOI 10.1128/JVI.77.19.10677-10683.2003; Elmowalid GA, 2007, P NATL ACAD SCI USA, V104, P8427, DOI 10.1073/pnas.0702162104; Folgori A, 2006, NAT MED, V12, P190, DOI 10.1038/nm1353; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Kneteman NM, 2006, HEPATOLOGY, V43, P1346, DOI 10.1002/hep.21209; Lindenbach BD, 2006, P NATL ACAD SCI USA, V103, P3805, DOI 10.1073/pnas.0511218103; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Owsianka AM, 2006, J VIROL, V80, P8695, DOI 10.1128/JVI.00271-06; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Tarr AW, 2006, HEPATOLOGY, V43, P592, DOI 10.1002/hep.21088; Troesch M, 2006, VIROLOGY, V352, P357, DOI 10.1016/j.virol.2006.05.015; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268	15	467	489	2	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					25	27		10.1038/nm1698	http://dx.doi.org/10.1038/nm1698			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18064037				2022-12-27	WOS:000252222400018
J	Gandotra, S; Schnappinger, D; Monteleone, M; Hillen, W; Ehrt, S				Gandotra, Sheetal; Schnappinger, Dirk; Monteleone, Mercedes; Hillen, Wolfgang; Ehrt, Sabine			In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice	NATURE MEDICINE			English	Article							20S PROTEASOME; ATPASE HOMOLOG; RESISTANCE; SMEGMATIS; PROTEINS; INACTIVATION; EXPRESSION; INFECTION	The success of Mycobacterium tuberculosis (Mtb) as a human pathogen relies on its ability to resist eradication by the immune system. The identification of mechanisms that enable Mtb to persist is key for finding ways to limit latent tuberculosis, which affects one-third of the world's population. Here we show that conditional gene silencing can be used to determine whether an Mtb gene required for optimal growth in vitro is also important for virulence and, if so, during which phase of an infection it is required. Application of this approach to the prcBA genes, which encode the core of the mycobacterial proteasome, revealed an unpredicted requirement of the core proteasome for the persistence of Mtb during the chronic phase of infection in mice. Proteasome depletion also attenuated Mtb in interferon gamma-deficient mice, pointing to a function of the proteasome beyond defense against the adaptive immune response. Genes that are essential for growth in vitro, in vivo or both account for approximately 20% of Mtb's genome. Conditional gene silencing could therefore facilitate the validation of up to 800 potential Mtb drug targets and improve our understanding of host-pathogen dynamics.	Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10065 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Immunol & Microbial Pathogenesis, New York, NY 10065 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Mol Biol, New York, NY 10065 USA; Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	Cornell University; Cornell University; Cornell University; University of Erlangen Nuremberg	Ehrt, S (corresponding author), Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA.	sae2004@med.cornell.edu	Monteleone, Maria/J-1813-2014; Ehrt, Sabine/AAU-6449-2020	Monteleone, Maria/0000-0003-0777-3965; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063446] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI063446-02, AI63446, R01 AI063446] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Berens C, 2003, EUR J BIOCHEM, V270, P3109, DOI 10.1046/j.1432-1033.2003.03694.x; Chalut C, 2006, P NATL ACAD SCI USA, V103, P8511, DOI 10.1073/pnas.0511129103; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Darwin KH, 2005, MOL MICROBIOL, V55, P561, DOI 10.1111/j.1365-2958.2004.04403.x; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; De Mot R, 1999, TRENDS MICROBIOL, V7, P88, DOI 10.1016/S0966-842X(98)01432-2; De Mot R, 2007, ARCH MICROBIOL, V188, P257, DOI 10.1007/s00203-007-0243-8; DeMartino GN, 2007, CELL, V129, P659, DOI 10.1016/j.cell.2007.05.007; Duncan K, 2004, CURR OPIN MICROBIOL, V7, P460, DOI 10.1016/j.mib.2004.08.011; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; Ehrt S, 2006, FUTURE MICROBIOL, V1, P177, DOI 10.2217/17460913.1.2.177; Festa RA, 2007, J BACTERIOL, V189, P3044, DOI 10.1128/JB.01597-06; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Guo XV, 2007, J BACTERIOL, V189, P4614, DOI 10.1128/JB.00216-07; Hong B, 2005, MICROBIOL-SGM, V151, P3137, DOI 10.1099/mic.0.28034-0; Hu GQ, 2006, MOL MICROBIOL, V59, P1417, DOI 10.1111/j.1365-2958.2005.05036.x; Ji YD, 2001, SCIENCE, V293, P2266, DOI 10.1126/science.1063566; Knipfer N, 1997, MOL MICROBIOL, V25, P375, DOI 10.1046/j.1365-2958.1997.4721837.x; Lamichhane G, 2006, J INFECT DIS, V194, P1233, DOI 10.1086/508288; Lathem WW, 2007, SCIENCE, V315, P509, DOI 10.1126/science.1137195; Lin G, 2006, MOL MICROBIOL, V59, P1405, DOI 10.1111/j.1365-2958.2005.05035.x; Munoz-Elias EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546-551.2005; Nagy I, 2003, J BACTERIOL, V185, P496, DOI 10.1128/JB.185.2.496-503.2003; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x	30	191	208	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1515	1520		10.1038/nm1683	http://dx.doi.org/10.1038/nm1683			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18059281	Green Accepted			2022-12-27	WOS:000251445400028
J	Hunsberger, JG; Newton, SS; Bennett, AH; Duman, CH; Russell, DS; Salton, SR; Duman, RS				Hunsberger, Joshua G.; Newton, Samuel S.; Bennett, Alicia H.; Duman, Catharine H.; Russell, David S.; Salton, Stephen R.; Duman, Ronald S.			Antidepressant actions of the exercise-regulated gene VGF	NATURE MEDICINE			English	Article							GROWTH-FACTOR; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; MESSENGER-RNA; BRAIN; DEPRESSION; EXPRESSION; STRESS; EPIDEMIOLOGY; PROFILE	Exercise has many health benefits, including antidepressant actions in depressed human subjects, but the mechanisms underlying these effects have not been elucidated. We used a custom microarray to identify a previously undescribed profile of exercise-regulated genes in the mouse hippocampus, a brain region implicated in mood and antidepressant response. Pathway analysis of the regulated genes shows that exercise upregulates a neurotrophic factor signaling cascade that has been implicated in the actions of antidepressants. One of the most highly regulated target genes of exercise and of the growth factor pathway is the gene encoding the VGF nerve growth factor, a peptide precursor previously shown to influence synaptic plasticity and metabolism. We show that administration of a synthetic VGF-derived peptide produces a robust antidepressant response in mice and, conversely, that mutation of VGF in mice produces the opposite effects. The results suggest a new role for VGF and identify VGF signaling as a potential therapeutic target for antidepressant drug development.	Yale Univ, Dept Psychiat, New Haven, CT 06508 USA; Mt Sinai Sch Med, Fishberg Dept Neurosci, New York, NY 10029 USA	Yale University; Icahn School of Medicine at Mount Sinai	Duman, RS (corresponding author), Yale Univ, Dept Psychiat, 34 Pk St, New Haven, CT 06508 USA.	ronald.duman@yale.edu	Yan, Shuo/B-8381-2009	Salton, Stephen/0000-0003-4087-8427	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071308, R01DK057702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH025642, R01MH045481, R29MH045481, R37MH045481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-071308, DK57702] Funding Source: Medline; NIMH NIH HHS [MH45481, MH25642] Funding Source: Medline; NINDS NIH HHS [U24 NS05186, NS45305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alder J, 2003, J NEUROSCI, V23, P10800; Alfonso J, 2005, REV NEUROSCIENCE, V16, P43; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Anderson BJ, 2000, PHYSIOL BEHAV, V70, P425, DOI 10.1016/S0031-9384(00)00282-1; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5; Cui XS, 2005, MOL REPROD DEV, V70, P471, DOI 10.1002/mrd.20228; Dimeo F, 2001, BRIT J SPORT MED, V35, P114, DOI 10.1136/bjsm.35.2.114; Dulawa SC, 2005, NEUROSCI BIOBEHAV R, V29, P771, DOI 10.1016/j.neubiorev.2005.03.017; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Duman RS, 2005, NEUROBIOL AGING, V26, pS88, DOI 10.1016/j.neurobiolaging.2005.08.018; Duman RS, 1999, BIOL PSYCHIAT, V46, P1181, DOI 10.1016/S0006-3223(99)00177-8; Eagleson KL, 2001, J NEUROSCI, V21, P9315, DOI 10.1523/JNEUROSCI.21-23-09315.2001; Fava M, 1996, PSYCHIAT CLIN N AM, V19, P179, DOI 10.1016/S0193-953X(05)70283-5; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; Karssen AM, 2006, METHODS, V38, P227, DOI 10.1016/j.ymeth.2005.09.017; Kavanagh T, 1983, Ann Acad Med Singap, V12, P331; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kishi T, 2005, MOL PSYCHIATR, V10, P132, DOI 10.1038/sj.mp.4001638; Koo JW, 2003, FASEB J, V17, P1556, DOI 10.1096/fj.02-1032fje; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; McEwen BS, 2004, EUR NEUROPSYCHOPHARM, V14, pS497, DOI 10.1016/j.euroneuro.2004.09.008; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; Nedivi E, 1998, SCIENCE, V281, P1863, DOI 10.1126/science.281.5384.1863; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/S0006-8993(96)00273-9; Newton SS, 2004, MOL BRAIN RES, V129, P185, DOI 10.1016/j.molbrainres.2004.06.032; Newton SS, 2003, J NEUROSCI, V23, P10841; Newton SS, 2002, BRAIN RES PROTOC, V9, P214, DOI 10.1016/S1385-299X(02)00148-4; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Russo-Neustadt A, 1999, NEUROPSYCHOPHARMACOL, V21, P679, DOI 10.1016/S0893-133X(99)00059-7; Salton SRJ, 2003, MT SINAI J MED, V70, P93; Salton SRJ, 2000, FRONT NEUROENDOCRIN, V21, P199, DOI 10.1006/frne.2000.0199; Tong LQ, 2001, NEUROBIOL DIS, V8, P1046, DOI 10.1006/nbdi.2001.0427; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	42	201	205	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2007	13	12					1476	1482		10.1038/nm1669	http://dx.doi.org/10.1038/nm1669			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	238KB	18059283				2022-12-27	WOS:000251445400022
J	Shepherd, M				Shepherd, Marv			Beef up international cooperation on counterfeits	NATURE MEDICINE			English	Editorial Material								Counterfeit drugs are a menacing and deadly problem worldwide. The proliferation of fake drugs is astounding, with over 100 countries reporting incidents of fake drugs, according to a 2008 report from the Pharmaceutical Security Institute. And incidents of drug counterfeiting show no evidence of declining: some industry insiders suggest that the number of counterfeit medicines on the market has increased as much as 25% each year over the past several years.	[Shepherd, Marv] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA; [Shepherd, Marv] A Vienna, Vienna, Austria	University of Texas System; University of Texas Austin	Shepherd, M (corresponding author), Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.								0	13	13	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					366	366		10.1038/nm0410-366	http://dx.doi.org/10.1038/nm0410-366			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376036				2022-12-27	WOS:000276446800028
J	Liu, FT; Bevins, CL				Liu, Fu-Tong; Bevins, Charles L.			A sweet target for innate immunity	NATURE MEDICINE			English	Editorial Material							ESCHERICHIA-COLI; GALECTINS; EXPRESSION; APOPTOSIS; BINDING; LECTINS	Galectins are carbohydrate-binding proteins with diverse activities, but there is no unifying picture of their primary physiological role. Galectins now emerge as autonomous bacteria-killing agents (pages 295-301), unexpected findings that may point to a principal role of these proteins in innate immunity.	[Liu, Fu-Tong] Univ Calif Davis, Dept Dermatol, Sch Med, Davis, CA 95616 USA; [Bevins, Charles L.] Univ Calif Davis, Dept Microbiol & Immunol, Sch Med, Davis, CA 95616 USA; Univ Calif Davis, Immunol Grad Grp, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Liu, FT (corresponding author), Univ Calif Davis, Dept Dermatol, Sch Med, Davis, CA 95616 USA.	fliu@ucdavis.edu; clbevins@ucdavis.edu	Bevins, Charles L/P-4438-2015; Liu, FU-TONG/A-5749-2019	Bevins, Charles L/0000-0003-2725-2622; Liu, FU-TONG/0000-0002-3354-1001	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032738, R37AI032738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON M, 1989, CARBOHYD RES, V185, P211, DOI 10.1016/0008-6215(89)80036-9; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; Hadari YR, 2000, J CELL SCI, V113, P2385; Hsu DK, 2006, METHOD ENZYMOL, V417, P256, DOI 10.1016/S0076-6879(06)17018-4; Kohatsu L, 2006, J IMMUNOL, V177, P4718, DOI 10.4049/jimmunol.177.7.4718; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Stowell SR, 2010, NAT MED, V16, P295, DOI 10.1038/nm.2103	12	15	15	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2010	16	3					263	264		10.1038/nm0310-263	http://dx.doi.org/10.1038/nm0310-263			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	565KA	20208507				2022-12-27	WOS:000275289500024
J	Oney, S; Lam, RTS; Bompiani, KM; Blake, CM; Quick, G; Heidel, JD; Liu, JYC; Mack, BC; Davis, ME; Leong, KW; Sullenger, BA				Oney, Sabah; Lam, Ruby T. S.; Bompiani, Kristin M.; Blake, Charlene M.; Quick, George; Heidel, Jeremy D.; Liu, Joanna Yi-Ching; Mack, Brendan C.; Davis, Mark E.; Leong, Kam W.; Sullenger, Bruce A.			Development of universal antidotes to control aptamer activity	NATURE MEDICINE			English	Article							VON-WILLEBRAND-FACTOR; ADVERSE DRUG EVENTS; RNA APTAMERS; PROTAMINE; NANOPARTICLES; ANGIOGENESIS; COAGULATION; TECHNOLOGY; GENERATION; DELIVERY	With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to counteract acute side effects of drugs, but, unfortunately, it has been challenging and cost prohibitive to generate antidotes for most therapeutic agents. Here we describe the development of a set of antidote molecules that are capable of counteracting the effects of an entire class of therapeutic agents based upon aptamers. These universal antidotes exploit the fact that, when systemically administered, aptamers are the only free extracellular oligonucleotides found in circulation. We show that protein- and polymer-based molecules that capture oligonucleotides can reverse the activity of several aptamers in vitro and counteract aptamer activity in vivo. The availability of universal antidotes to control the activity of any aptamer suggests that aptamers may be a particularly safe class of therapeutics.	[Oney, Sabah; Bompiani, Kristin M.; Blake, Charlene M.; Quick, George; Sullenger, Bruce A.] Duke Univ, Med Ctr, Duke Translat Res Inst, Durham, NC 27706 USA; [Oney, Sabah; Bompiani, Kristin M.; Blake, Charlene M.; Sullenger, Bruce A.] Duke Univ, Univ Program Genet & Genom, Durham, NC USA; [Oney, Sabah; Bompiani, Kristin M.; Blake, Charlene M.; Sullenger, Bruce A.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Lam, Ruby T. S.; Leong, Kam W.] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Heidel, Jeremy D.; Liu, Joanna Yi-Ching] Calando Pharmaceut, Pasadena, CA USA; [Mack, Brendan C.; Davis, Mark E.] CALTECH, Dept Chem Engn, Pasadena, CA 91125 USA	Duke University; Duke University; Duke University; Duke University; California Institute of Technology	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Duke Translat Res Inst, Durham, NC 27706 USA.	bruce.sullenger@duke.edu	Leong, Kam W/A-7270-2009; Leong, Kam/O-9302-2019	Leong, Kam W/0000-0002-8133-4955; Leong, Kam/0000-0002-8133-4955	US National Institutes of Health [HL065222]; American Heart Association [0615443U]; US National Cancer Institute [CA 119347]; NATIONAL CANCER INSTITUTE [U54CA119347] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065222] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank S.M. Nimjee and J. Layzer for helpful discussions and Calando Pharmaceuticals for providing the CDP and CDP-Im polymers. This work was supported by a grant from the US National Institutes of Health (HL065222 to B.A.S.), a predoctoral fellowship from the American Heart Association (0615443U to S.O.) and a grant from the US National Cancer Institute (CA 119347 to M.E.D).	Anderson J, 2007, MOL THER, V15, P1182, DOI 10.1038/sj.mt.6300157; Becker RC, 2005, THROMB HAEMOSTASIS, V93, P1014, DOI 10.1160/TH04-12-0790; Carr JA, 1999, J CARDIOVASC SURG, V40, P659; Davis ME, 2004, CURR MED CHEM, V11, P179, DOI 10.2174/0929867043456179; Dyke CK, 2006, CIRCULATION, V114, P2490, DOI 10.1161/CIRCULATIONAHA.106.668434; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Fanikos J, 2007, AM J CARDIOL, V100, P1465, DOI 10.1016/j.amjcard.2007.06.041; Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X; Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864; Gonzalez H, 1999, BIOCONJUGATE CHEM, V10, P1068, DOI 10.1021/bc990072j; Harrison P, 2005, BLOOD REV, V19, P111, DOI 10.1016/j.blre.2004.05.002; Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104; HIRD RB, 1995, CIRCULATION, V92, P433, DOI 10.1161/01.CIR.92.9.433; Joachimi A, 2007, J AM CHEM SOC, V129, P3036, DOI 10.1021/ja0677822; Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102; Mao HQ, 2005, ADV GENET, V53, P275, DOI 10.1016/S0065-2660(05)53011-6; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365; Moore TJ, 2007, ARCH INTERN MED, V167, P1752, DOI 10.1001/archinte.167.16.1752; Nimjee SM, 2006, MOL THER, V14, P408, DOI 10.1016/j.ymthe.2006.04.006; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Nirnjee SM, 2005, TRENDS CARDIOVAS MED, V15, P41, DOI 10.1016/j.tcm.2005.01.002; Oney S, 2007, OLIGONUCLEOTIDES, V17, P265, DOI 10.1089/oli.2007.0089; Porsche R, 1999, HEART LUNG, V28, P418, DOI 10.1016/S0147-9563(99)70031-2; Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023; Rusconi CP, 2000, THROMB HAEMOSTASIS, V84, P841; Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Shigeta O, 1999, J THORAC CARDIOV SUR, V118, P354, DOI 10.1016/S0022-5223(99)70227-8; STANKER LH, 1993, MOL IMMUNOL, V30, P1633, DOI 10.1016/0161-5890(93)90436-F; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Welsby IJ, 2005, ANESTHESIOLOGY, V102, P308, DOI 10.1097/00000542-200502000-00011; White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	37	89	95	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2009	15	10					1224	U157		10.1038/nm.1990	http://dx.doi.org/10.1038/nm.1990			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	504EC	19801990	Green Accepted, Green Published			2022-12-27	WOS:000270596400037
J	de Vries, PJ				de Vries, Petrus J.			Genetics and neuropsychiatric disorders: Genome-wide, yet narrow	NATURE MEDICINE			English	Editorial Material							AUTISM; MUTATIONS		[de Vries, Petrus J.] Cambridgeshire & Peterborough NHS Fdn Trust, Neurodev Serv, Cambridge, England; [de Vries, Petrus J.] Univ Cambridge, Dev Psychiat Sect, Cambridge, England	University of Cambridge	de Vries, PJ (corresponding author), Cambridgeshire & Peterborough NHS Fdn Trust, Neurodev Serv, Cambridge, England.	pd215@cam.ac.uk						Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; Bebbington A, 2008, NEUROLOGY, V70, P868, DOI 10.1212/01.wnl.0000304752.50773.ec; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Bolton PF, 2002, BRAIN, V125, P1247, DOI 10.1093/brain/awf124; de Vries PJ, 2007, TRENDS MOL MED, V13, P319, DOI 10.1016/j.molmed.2007.06.003; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Holden C, 2009, SCIENCE, V324, P1628, DOI 10.1126/science.324_1628; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Wang K, 2009, NATURE, V459, P528, DOI 10.1038/nature07999	12	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2009	15	8					850	851		10.1038/nm0809-850	http://dx.doi.org/10.1038/nm0809-850			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19661990				2022-12-27	WOS:000268770400024
J	Ehninger, D; Silva, AJ				Ehninger, Dan; Silva, Alcino J.			Genetics and neuropsychiatric disorders: Treatment during adulthood	NATURE MEDICINE			English	Editorial Material							FRAGILE-X-SYNDROME; NEUROFIBROMATOSIS TYPE-1; MOUSE MODEL; DEFICITS; RESCUE; TRIAL; MICE		[Ehninger, Dan; Silva, Alcino J.] Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; [Ehninger, Dan; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Ehninger, Dan; Silva, Alcino J.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; [Ehninger, Dan; Silva, Alcino J.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Ehninger, D (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA.	silvaa@mednet.ucla.edu	Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Berry-Kravis E, 2009, J MED GENET, V46, P266, DOI 10.1136/jmg.2008.063701; Berry-Kravis E, 2008, J DEV BEHAV PEDIATR, V29, P293, DOI 10.1097/DBP.0b013e31817dc447; Bolduc FV, 2008, NAT NEUROSCI, V11, P1143, DOI 10.1038/nn.2175; de Vrij FMS, 2008, NEUROBIOL DIS, V31, P127, DOI 10.1016/j.nbd.2008.04.002; Dolen G, 2007, NEURON, V56, P955, DOI 10.1016/j.neuron.2007.12.001; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; Ehninger D, 2008, NEURON, V60, P950, DOI 10.1016/j.neuron.2008.12.007; Krab LC, 2008, JAMA-J AM MED ASSOC, V300, P287, DOI 10.1001/jama.300.3.287; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; McBride SMJ, 2005, NEURON, V45, P753, DOI 10.1016/j.neuron.2005.01.038; Yan QJ, 2005, NEUROPHARMACOLOGY, V49, P1053, DOI 10.1016/j.neuropharm.2005.06.004	12	18	18	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2009	15	8					849	850		10.1038/nm0809-849	http://dx.doi.org/10.1038/nm0809-849			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	480XK	19661989				2022-12-27	WOS:000268770400023
J	Galban, CJ; Chenevert, TL; Meyer, CR; Tsien, C; Lawrence, TS; Hamstra, DA; Junck, L; Sundgren, PC; Johnson, TD; Ross, DJ; Rehemtulla, A; Ross, BD				Galban, Craig J.; Chenevert, Thomas L.; Meyer, Charles R.; Tsien, Christina; Lawrence, Theodore S.; Hamstra, Daniel A.; Junck, Larry; Sundgren, Pia C.; Johnson, Timothy D.; Ross, David J.; Rehemtulla, Alnawaz; Ross, Brian D.			The parametric response map is an imaging biomarker for early cancer treatment outcome	NATURE MEDICINE			English	Article							FUNCTIONAL DIFFUSION MAP; CONTRAST-ENHANCED MRI; ADVANCED SOLID TUMORS; HIGH-GRADE GLIOMAS; PHASE-I; ANGIOGENESIS INHIBITOR; HISTOGRAM ANALYSIS; LIVER METASTASES; PROSTATE-CANCER; BREAST-TUMORS	Here we describe the parametric response map (PRM), a voxel-wise approach for image analysis and quantification of hemodynamic alterations during treatment for 44 patients with high-grade glioma. Relative cerebral blood volume (rCBV) and flow (rCBF) maps were acquired before treatment and after 1 and 3 weeks of therapy. We compared the standard approach using region-of-interest analysis for change in rCBV or rCBF to the change in perfusion parameters on the basis of PRM (PRMrCBV and PRMrCBF) for their accuracy in predicting overall survival. Neither the percentage change of rCBV or rCBF predicted survival, whereas the regional response evaluations made on the basis of PRM were highly predictive of survival. Even when accounting for baseline rCBV, which is prognostic, PRMrCBV proved more predictive of overall survival.	[Galban, Craig J.; Chenevert, Thomas L.; Meyer, Charles R.; Sundgren, Pia C.; Rehemtulla, Alnawaz; Ross, Brian D.] Univ Michigan, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Tsien, Christina; Lawrence, Theodore S.; Hamstra, Daniel A.; Ross, David J.; Rehemtulla, Alnawaz] Univ Michigan, Ctr Mol Imaging, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Junck, Larry] Univ Michigan, Ctr Mol Imaging, Dept Neurol, Ann Arbor, MI 48109 USA; [Johnson, Timothy D.] Univ Michigan, Ctr Mol Imaging, Dept Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ross, BD (corresponding author), Univ Michigan, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA.	bdross@umich.edu		Sundgren, Pia/0000-0001-9237-1236; Chenevert, Thomas/0000-0003-1476-4274	US National Institutes of Health [P01CA085878, U24CA083099, P50CA093990]; NATIONAL CANCER INSTITUTE [R24CA083099, P01CA085878, U24CA083099, P50CA093990] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the US National Institutes of Health research grants P01CA085878, U24CA083099 and P50CA093990.	Brix G, 2004, MAGNET RESON MED, V52, P420, DOI 10.1002/mrm.20161; Cao Y, 2006, INT J RADIAT ONCOL, V64, P876, DOI 10.1016/j.ijrobp.2005.09.001; Chan JL, 2002, J CLIN ONCOL, V20, P1635, DOI 10.1200/JCO.20.6.1635; Degani H, 1997, NAT MED, V3, P780, DOI 10.1038/nm0797-780; Eyal E, 2009, NMR BIOMED, V22, P40, DOI 10.1002/nbm.1221; Galbraith SM, 2002, NMR BIOMED, V15, P132, DOI 10.1002/nbm.731; Hamstra DA, 2005, P NATL ACAD SCI USA, V102, P16759, DOI 10.1073/pnas.0508347102; HOFFMANN U, 1995, MAGNET RESON MED, V33, P506, DOI 10.1002/mrm.1910330408; Hylton N, 2006, J CLIN ONCOL, V24, P3293, DOI 10.1200/JCO.2006.06.8080; Kiessling F, 2007, CURR MED CHEM, V14, P77, DOI 10.2174/092986707779313516; Law M, 2007, AM J NEURORADIOL, V28, P761; Law M, 2008, RADIOLOGY, V247, P490, DOI 10.1148/radiol.2472070898; Lee KC, 2007, NEOPLASIA, V9, P1003, DOI 10.1593/neo.07954; Lee KC, 2007, CANCER RES, V67, P3524, DOI 10.1158/0008-5472.CAN-06-4236; Liu G, 2005, J CLIN ONCOL, V23, P5464, DOI 10.1200/JCO.2005.04.143; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; Moffat BA, 2005, P NATL ACAD SCI USA, V102, P5524, DOI 10.1073/pnas.0501532102; Moffat BA, 2006, NEOPLASIA, V8, P259, DOI 10.1593/neo.05844; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Mross K, 2005, EUR J CANCER, V41, P1291, DOI 10.1016/j.ejca.2005.03.005; O'Connor JPB, 2007, BRIT J CANCER, V96, P189, DOI 10.1038/sj.bjc.6603515; O'Donnell A, 2005, BRIT J CANCER, V93, P876, DOI 10.1038/sj.bjc.6602797; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; Rugo HS, 2005, J CLIN ONCOL, V23, P5474, DOI 10.1200/JCO.2005.04.192; Thomas AL, 2005, J CLIN ONCOL, V23, P4162, DOI 10.1200/JCO.2005.09.034; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; Tofts PS, 1997, JMRI-J MAGN RESON IM, V7, P91, DOI 10.1002/jmri.1880070113; Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645; Xiong HQ, 2004, INVEST NEW DRUG, V22, P459, DOI 10.1023/B:DRUG.0000036688.96453.8d; Young R, 2007, J MAGN RESON IMAGING, V26, P1053, DOI 10.1002/jmri.21064; Zahra MA, 2007, LANCET ONCOL, V8, P63, DOI 10.1016/S1470-2045(06)71012-9	32	156	166	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					572	576		10.1038/nm.1919	http://dx.doi.org/10.1038/nm.1919			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19377487	Green Accepted			2022-12-27	WOS:000265889300037
J	Hansen, SG; Vieville, C; Whizin, N; Coyne-Johnson, L; Siess, DC; Drummond, DD; Legasse, AW; Axthelm, MK; Oswald, K; Trubey, CM; Piatak, M; Lifson, JD; Nelson, JA; Jarvis, MA; Picker, LJ				Hansen, Scott G.; Vieville, Cassandra; Whizin, Nathan; Coyne-Johnson, Lia; Siess, Don C.; Drummond, Derek D.; Legasse, Alfred W.; Axthelm, Michael K.; Oswald, Kelli; Trubey, Charles M.; Piatak, Michael, Jr.; Lifson, Jeffrey D.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.			Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge	NATURE MEDICINE			English	Article							CYTOMEGALOVIRUS-SPECIFIC CD4(+); SIV; CMV; INDUCTION; VACCINES; MODEL; AIDS; IMMUNIZATION; REPLICATION; LYMPHOCYTES	The rapid onset of massive, systemic viral replication during primary HIV or simian immunodeficiency virus (SIV) infection and the immune evasion capabilities of these viruses pose fundamental problems for vaccines that depend upon initial viral replication to stimulate effector T cell expansion and differentiation(1-5). We hypothesized that vaccines designed to maintain differentiated effector memory T cell (T-EM cell) responses(5,6) at viral entry sites might improve efficacy by impairing viral replication at its earliest stage(2), and we have therefore developed SIV protein-encoding vectors based on rhesus cytomegalovirus (RhCMV), the prototypical inducer of life-long TEM cell responses(7-9). RhCMV vectors expressing SIV Gag, Rev-Tat-Nef and Env persistently infected rhesus macaques, regardless of preexisting RhCMV immunity, and primed and maintained robust, SIV-specific CD4(+) and CD8(+) TEM cell responses (characterized by coordinate tumor necrosis factor, interferon-c and macrophage inflammatory protein-1 beta expression, cytotoxic degranulation and accumulation at extralymphoid sites) in the absence of neutralizing antibodies. Compared to control rhesus macaques, these vaccinated rhesus macaques showed increased resistance to acquisition of progressive SIVmac239 infection upon repeated limiting-dose intrarectal challenge, including four macaques who controlled rectal mucosal infection without progressive systemic dissemination. These data suggest a new paradigm for AIDS vaccine development-vaccines capable of generating and maintaining HIV-specific TEM cells might decrease the incidence of HIV acquisition after sexual exposure.	[Hansen, Scott G.; Vieville, Cassandra; Whizin, Nathan; Coyne-Johnson, Lia; Siess, Don C.; Drummond, Derek D.; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol, Beaverton, OR 97006 USA; [Hansen, Scott G.; Vieville, Cassandra; Whizin, Nathan; Coyne-Johnson, Lia; Siess, Don C.; Drummond, Derek D.; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Immunol, Beaverton, OR 97006 USA; [Hansen, Scott G.; Vieville, Cassandra; Whizin, Nathan; Coyne-Johnson, Lia; Siess, Don C.; Drummond, Derek D.; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Pathol, Beaverton, OR 97006 USA; [Hansen, Scott G.; Vieville, Cassandra; Whizin, Nathan; Coyne-Johnson, Lia; Siess, Don C.; Drummond, Derek D.; Legasse, Alfred W.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Picker, Louis J.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA; [Oswald, Kelli; Trubey, Charles M.; Piatak, Michael, Jr.; Lifson, Jeffrey D.] Sci Applicat Int Corp, AIDS & Canc Virus Program, Natl Canc Inst Frederick, Frederick, MD 21702 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon National Primate Research Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Picker, LJ (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol, 505 NW 185th Ave, Beaverton, OR 97006 USA.	pickerl@ohsu.edu		Jarvis, Michael A/0000-0002-0124-4061	US National Institute of Allergy and Infectious Diseases; International AIDS Vaccine Initiative; Bill & Melinda Gates Foundation; AIDS Vaccine Discovery; US National Center for Research Resources; US National Cancer Institute; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640, R01AI060392] Funding Source: NIH RePORTER	US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); International AIDS Vaccine Initiative; Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); AIDS Vaccine Discovery; US National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the US National Institute of Allergy and Infectious Diseases, the International AIDS Vaccine Initiative, the Bill & Melinda Gates Foundation-supported Collaboration for AIDS Vaccine Discovery, the US National Center for Research Resources and the US National Cancer Institute. We thank J. Edgar, A. Keech, J. Ford, J. Cook, M. Rohankhedkar, T. Ha, A. Sylwester and J. Dewane for technical assistance; P. Barry (University of California-Davis) for the RhCMV bacterial artificial chromosome, G. Pavlakis (National Cancer Institute) for the SIV Gag and Env constructs, G. Franchini (National Cancer Institute) for the SIV Retanef construct, R. Seder (Vaccine Research Center, National Institutes of Health) for the Gag protein immunogens, C. Miller (University of California-Davis) for the pathogenic SIVmac239 challenge stock, K. Reimann and Centocor for the cM-T807 antibody, M. Mori and J. O'Malley for statistical assistance and K. Frueh and S. Wong for helpful discussion and advice.	Britt W, 2008, CURR TOP MICROBIOL, V325, P417; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; CHACKERIAN B, 1995, VIROLOGY, V213, P386, DOI 10.1006/viro.1995.0011; Chan KS, 2007, J IMMUNOL METHODS, V325, P20, DOI 10.1016/j.jim.2007.05.011; Chang WLW, 2003, J VIROL, V77, P5073, DOI 10.1128/JVI.77.9.5073-5083.2003; Cline AN, 2005, J MED PRIMATOL, V34, P303; DeVico AL, 2004, NAT REV MICROBIOL, V2, P401, DOI 10.1038/nrmicro878; Friedrich TC, 2007, J VIROL, V81, P3465, DOI 10.1128/JVI.02392-06; Gauduin MC, 2006, J EXP MED, V203, P2661, DOI 10.1084/jem.20060134; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Grossman Z, 2008, CURR OPIN HIV AIDS, V3, P380, DOI 10.1097/COH.0b013e3282fbaae6; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Horton H, 2002, J VIROL, V76, P7187, DOI 10.1128/JVI.76.14.7187-7202.2002; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Letvin NL, 2007, J VIROL, V81, P12368, DOI 10.1128/JVI.00822-07; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469; Lu XS, 1998, AIDS, V12, P1, DOI 10.1097/00002030-199801000-00001; Montefiori DC., 2005, CURR PROTOC IMMUNOL, VChapter 12:12.11.11-12.11.15, DOI [10.1002/0471142735.im1211s64, DOI 10.1002/0471142735.IM1211S64]; Passs RF, 2001, FIELDS VIROLOGY, P2675; Petravic J, 2008, J VIROL, V82, P11589, DOI 10.1128/JVI.01596-08; Picker LJ, 2006, J CLIN INVEST, V116, P1514, DOI 10.1172/JCI27564; Pipeling MR, 2008, J IMMUNOL, V181, P546, DOI 10.4049/jimmunol.181.1.546; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Powers C, 2008, MED MICROBIOL IMMUN, V197, P109, DOI 10.1007/s00430-007-0073-y; Price DA, 2008, J IMMUNOL, V180, P269, DOI 10.4049/jimmunol.180.1.269; Robinson HL, 2005, NAT MED, V11, pS25, DOI 10.1038/nm1212; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Rue CA, 2004, J VIROL, V78, P12529, DOI 10.1128/JVI.78.22.12529-12536.2004; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Schmitz JE, 1999, AM J PATHOL, V154, P1923, DOI 10.1016/S0002-9440(10)65450-8; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Venneti S, 2008, AM J PATHOL, V172, P1603, DOI 10.2353/ajpath.2008.070967; Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622; Walker DH, 2004, SER COMPUTERS OPER R, V4, P535; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06	40	549	573	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2009	15	3					293	299		10.1038/nm.1935	http://dx.doi.org/10.1038/nm.1935			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	415DH	19219024	Green Accepted, Green Submitted			2022-12-27	WOS:000263914000029
J	Liu, XJ; Gingrich, JR; Vargas-Caballero, M; Dong, YN; Sengar, A; Beggs, S; Wang, SH; Ding, HK; Frankland, PW; Salter, MW				Liu, Xue Jun; Gingrich, Jeffrey R.; Vargas-Caballero, Mariana; Dong, Yi Na; Sengar, Ameet; Beggs, Simon; Wang, Szu-Han; Ding, Hoi Ki; Frankland, Paul W.; Salter, Michael W.			Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex	NATURE MEDICINE			English	Article							PAW FORMALIN TEST; TYROSINE PHOSPHORYLATION; SYNAPTIC-TRANSMISSION; NR2B SUBUNIT; PROTEIN; KINASE; MECHANISMS; TRANSDUCTION; POTENTIATION; MAINTENANCE	Chronic pain hypersensitivity depends on N-methyl-D-aspartate receptors (NMDARs). However, clinical use of NMDAR blockers is limited by side effects resulting from suppression of the physiological functions of these receptors. Here we report a means to suppress pain hypersensitivity without blocking NMDARs, but rather by inhibiting the binding of a key enhancer of NMDAR function, the protein tyrosine kinase Src. We show that a peptide consisting of amino acids 40-49 of Src fused to the protein transduction domain of the HIV Tat protein (Src40-49Tat) prevented pain behaviors induced by intraplantar formalin and reversed pain hypersensitivity produced by intraplantar injection of complete Freund's adjuvant or by peripheral nerve injury. Src40-49Tat had no effect on basal sensory thresholds, acute nociceptive responses or cardiovascular, respiratory, locomotor or cognitive functions. Thus, through targeting of Src-mediated enhancement of NMDARs, inflammatory and neuropathic pain are suppressed without the deleterious consequences of directly blocking NMDARs, an approach that may be of broad relevance to managing chronic pain.	[Liu, Xue Jun; Gingrich, Jeffrey R.; Vargas-Caballero, Mariana; Dong, Yi Na; Sengar, Ameet; Beggs, Simon; Wang, Szu-Han; Ding, Hoi Ki; Frankland, Paul W.; Salter, Michael W.] Univ Toronto, Program Neurosci & Mental Hlth, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Liu, Xue Jun; Gingrich, Jeffrey R.; Vargas-Caballero, Mariana; Dong, Yi Na; Sengar, Ameet; Beggs, Simon; Wang, Szu-Han; Ding, Hoi Ki; Frankland, Paul W.; Salter, Michael W.] Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; [Liu, Xue Jun; Dong, Yi Na; Beggs, Simon; Salter, Michael W.] Univ Toronto, Univ Toronto Ctr Study Pain, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Salter, MW (corresponding author), Univ Toronto, Program Neurosci & Mental Hlth, Hosp Sick Children, Toronto, ON M5G 1X8, Canada.	Mike.salter@utoronto.ca	Sengar, Ameet/E-6940-2011; Beggs, Simon/AAI-4438-2021; Wang, Szu-Han/AAR-1137-2021	Sengar, Ameet/0000-0002-6328-1108; Beggs, Simon/0000-0002-1582-8391; Vargas-Caballero, Mariana/0000-0003-2326-4001; Wang, Szu-Han/0000-0003-0500-0352	Canadian Institutes of Health Research [MT-12682]; Neuroscience Canada Brain Repair Program; Ontario Neurotrauma Foundation through the Brain Repair Program; Krembil Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Neuroscience Canada Brain Repair Program; Ontario Neurotrauma Foundation through the Brain Repair Program; Krembil Foundation	This work is supported by grants from the Canadian Institutes of Health Research (CIHR; grant number MT-12682), the Neuroscience Canada Brain Repair Program and its partner the Ontario Neurotrauma Foundation through the Brain Repair Program, and the Krembil Foundation (all to M. W. S.). M. W. S. is an International Research Scholar of the Howard Hughes Medical Institute and holds a Canada Research Chair (Tier I) in Neuroplasticity and Pain. X.J.L. is a CIHR & Ronald Melzack Pain Research Award recipient and a fellow of the Canadian Arthritis Network, as well as of the Pain: Molecules to Community Strategic Training Initiative in Health Research of CIHR. M.V.-C. is an International Fellow of the Wellcome Trust UK. Src knockout mice were obtained as gift from B. F. Boyce, University of Rochester Medical Center. We thank S. Singhroy and D. Wong for technical support and T. Trang and J. Hicks for helpful comments on the manuscript.	Abe T, 2005, EUR J NEUROSCI, V22, P1445, DOI 10.1111/j.1460-9568.2005.04340.x; Bast T, 2003, HIPPOCAMPUS, V13, P657, DOI 10.1002/hipo.10115; Berman DE, 2001, SCIENCE, V291, P2417, DOI 10.1126/science.1058165; Bleakman D, 2006, SEMIN CELL DEV BIOL, V17, P592, DOI 10.1016/j.semcdb.2006.10.008; Brown DG, 2006, CURR TOP MED CHEM, V6, P749, DOI 10.2174/156802606777057571; Chong YP, 2005, BBA-PROTEINS PROTEOM, V1754, P210, DOI 10.1016/j.bbapap.2005.07.027; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Dingledine R, 1999, PHARMACOL REV, V51, P7; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Furukawa H, 2005, NATURE, V438, P185, DOI 10.1038/nature04089; Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101; GINGRICH JR, 2004, THESIS U TORONTO; Guo W, 2002, J NEUROSCI, V22, P6208; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Ji Ru-Rong, 2004, Sci STKE, V2004, preE14; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Katsura H, 2006, J NEUROSCI, V26, P8680, DOI 10.1523/JNEUROSCI.1771-06.2006; Liu ST, 2001, ASIAN PAC J ALLERGY, V19, P29; Liu XJ, 2000, EUR J PHARMACOL, V408, P143, DOI 10.1016/S0014-2999(00)00742-1; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Petrenko AB, 2003, ANESTH ANALG, V97, P1108, DOI 10.1213/01.ANE.0000081061.12235.55; Pitcher GM, 1999, J NEUROSCI METH, V87, P185, DOI 10.1016/S0165-0270(99)00004-7; ROSENBLUM K, 1995, P NATL ACAD SCI USA, V92, P1157, DOI 10.1073/pnas.92.4.1157; Saade NE, 2006, PAIN, V126, P280, DOI 10.1016/j.pain.2006.07.010; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sawynok Jana, 2004, Reviews in Analgesia, V7, P145; Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Smith Paul F, 2003, Curr Opin Investig Drugs, V4, P826; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; WHEELERACETO H, 1990, PAIN, V40, P229, DOI 10.1016/0304-3959(90)90073-M; WHEELERACETO H, 1991, PSYCHOPHARMACOLOGY, V104, P35, DOI 10.1007/BF02244551; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xu JD, 2008, J BIOL CHEM, V283, P17503, DOI 10.1074/jbc.M800917200; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	45	156	165	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1325	1332		10.1038/nm.1883	http://dx.doi.org/10.1038/nm.1883			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19011637	Green Accepted			2022-12-27	WOS:000261393600016
J	Kordower, JH; Chu, YP; Hauser, RA; Freeman, TB; Olanow, CW				Kordower, Jeffrey H.; Chu, Yaping; Hauser, Robert A.; Freeman, Thomas B.; Olanow, C. Warren			Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease	NATURE MEDICINE			English	Article							DOPAMINE NEURONS; PATIENT; IMPLANTS	Fourteen years after transplantation into the striatum of an individual with Parkinson's disease, grafted nigral neurons were found to have Lewy body-like inclusions that stained positively for alpha-synuclein and ubiquitin and to have reduced immunostaining for dopamine transporter. These pathological changes suggest that Parkinson's disease is an ongoing process that can affect grafted cells in the striatum in a manner similar to host dopamine neurons in the substantia nigra. These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease.	[Kordower, Jeffrey H.; Chu, Yaping] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Kordower, Jeffrey H.; Chu, Yaping] Rush Univ, Med Ctr, Ctr Brain Repair, Chicago, IL 60612 USA; [Hauser, Robert A.] Univ S Florida, Dept Neurol, Tampa, FL 33606 USA; [Freeman, Thomas B.] Univ S Florida, Dept Neurosurg, Tampa, FL 33606 USA; [Olanow, C. Warren] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Rush University; Rush University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Icahn School of Medicine at Mount Sinai	Kordower, JH (corresponding author), Rush Univ, Med Ctr, Dept Neurol Sci, 1735 W Harrison St, Chicago, IL 60612 USA.	jkordowe@rush.edu	Shahmoradian, Sarah H/C-7465-2015; Hauser, Robert/I-5372-2012	Shahmoradian, Sarah H/0000-0001-9752-7287; 				Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chu YP, 2007, NEUROBIOL DIS, V25, P134, DOI 10.1016/j.nbd.2006.08.021; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Kordower JH, 1997, CELL TRANSPLANT, V6, P213, DOI 10.1016/S0963-6897(97)00019-5; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207	11	1148	1172	2	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					504	506		10.1038/nm1747	http://dx.doi.org/10.1038/nm1747			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18391962				2022-12-27	WOS:000255681800029
J	Sun, K; Metzger, DW				Sun, Keer; Metzger, Dennis W.			Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection	NATURE MEDICINE			English	Article							SCAVENGER RECEPTOR MARCO; STREPTOCOCCUS-PNEUMONIAE; VIRUS-INFECTION; PNEUMOCOCCAL PNEUMONIA; LETHAL SYNERGISM; DENDRITIC CELLS; A VIRUS; CLEARANCE; RESPONSES; LUNG	Secondary bacterial infection often occurs after pulmonary virus infection and is a common cause of severe disease in humans, yet the mechanisms responsible for this viral-bacterial synergy in the lung are only poorly understood. We now report that pulmonary interferon-gamma (IFN-gamma) produced during T cell responses to influenza infection in mice inhibits initial bacterial clearance from the lung by alveolar macrophages. This suppression of phagocytosis correlates with lung IFN-gamma abundance, but not viral burden, and leads to enhanced susceptibility to secondary pneumococcal infection, which can be prevented by IFN-gamma neutralization after influenza infection. Direct inoculation of IFN-gamma can mimic influenza infection and downregulate the expression of the class A scavenger receptor MARCO on alveolar macrophages. Thus, IFN-gamma, although probably facilitating induction of specific anti-influenza adaptive immunity, suppresses innate protection against extracellular bacterial pathogens in the lung.	[Sun, Keer; Metzger, Dennis W.] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Albany Medical College	Metzger, DW (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, 47 New Scotland Ave, Albany, NY 12208 USA.	metzged@mail.amc.edu	Metzger, Dennis W/I-2771-2019	Metzger, Dennis W/0000-0002-8000-9907	NIAID NIH HHS [R01 AI41715, R01 AI041715-11, R01 AI041715] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041715] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON JS, 1981, J INFECT DIS, V143, P836, DOI 10.1093/infdis/143.6.836; Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762; Bot A, 1998, J VIROL, V72, P6637, DOI 10.1128/JVI.72.8.6637-6645.1998; Brown DM, 2006, J IMMUNOL, V177, P2888, DOI 10.4049/jimmunol.177.5.2888; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; Carneiro-Sampaio M, 2007, INFECT IMMUN, V75, P1545, DOI 10.1128/IAI.00787-06; Cleret A, 2006, J INFECT DIS, V194, P86, DOI 10.1086/504686; COUCH RB, 1981, J INFECT DIS, V144, P284, DOI 10.1093/infdis/144.3.284; CRAFT AW, 1976, BRIT MED J, V1, P1570, DOI 10.1136/bmj.1.6025.1570; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Dockrell DH, 2003, J IMMUNOL, V171, P5380, DOI 10.4049/jimmunol.171.10.5380; Hall JN, 1918, J AMER MED ASSOC, V71, P1986, DOI 10.1001/jama.1918.26020500012006c; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; JAKAB GJ, 1982, AM REV RESPIR DIS, V126, P778; Kim KD, 2007, NAT MED, V13, P1248, DOI 10.1038/nm1633; Klugman KP, 2007, SCIENCE, V316, P49; KODIHALLI S, 1994, AVIAN DIS, V38, P93, DOI 10.2307/1591842; La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026; LeVine AM, 2001, J VIROL METHODS, V94, P173, DOI 10.1016/S0166-0934(01)00287-7; Lundborg M, 1999, ENVIRON RES, V81, P309, DOI 10.1006/enrs.1999.3992; McCullers JA, 2003, J INFECT DIS, V187, P1000, DOI 10.1086/368163; McCullers JA, 2002, J INFECT DIS, V186, P341, DOI 10.1086/341462; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; McNamee LA, 2006, INFECT IMMUN, V74, P6707, DOI 10.1128/IAI.00789-06; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; NUGENT KM, 1983, INFECT IMMUN, V42, P1102, DOI 10.1128/IAI.42.3.1102-1108.1983; Palm NW, 2007, NAT MED, V13, P1142, DOI 10.1038/nm1007-1142b; Price GE, 2000, J VIROL, V74, P3996, DOI 10.1128/JVI.74.9.3996-4003.2000; Raju B, 2004, INFECT IMMUN, V72, P1275, DOI 10.1128/IAI.72.3.1275-1283.2004; SPEERT DP, 1991, INFECT IMMUN, V59, P1893, DOI 10.1128/IAI.59.6.1893-1898.1991; Spooner LH, 1919, J AMER MED ASSOC, V72, P155, DOI 10.1001/jama.1919.02610030001001; Stiver H Grant, 2004, Expert Rev Vaccines, V3, P35, DOI 10.1586/14760584.3.1.35; Swain SL, 2004, VIRAL IMMUNOL, V17, P197, DOI 10.1089/0882824041310577; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1992, IMMUNOLOGY, V76, P60; van der Laan LJW, 1999, J IMMUNOL, V162, P939; van der Sluijs KF, 2006, J INFECT DIS, V193, P214, DOI 10.1086/498911; van der Sluijs KF, 2006, AM J PHYSIOL-LUNG C, V290, pL194, DOI 10.1152/ajplung.00050.2005; van der Sluijs KF, 2004, J IMMUNOL, V172, P7603, DOI 10.4049/jimmunol.172.12.7603; Wiley JA, 2001, AM J PATHOL, V158, P119, DOI 10.1016/S0002-9440(10)63950-8	44	436	460	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2008	14	5					558	564		10.1038/nm1765	http://dx.doi.org/10.1038/nm1765			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	18438414				2022-12-27	WOS:000255681800037
J	Piliponsky, AM; Chen, CC; Nishimura, T; Metz, M; Rios, EJ; Dobner, PR; Wada, E; Wada, K; Zacharias, S; Mohanasundaram, UM; Faix, JD; Abrink, M; Pejler, G; Pearl, RG; Tsai, M; Galli, SJ				Piliponsky, Adrian M.; Chen, Ching-Cheng; Nishimura, Toshihiko; Metz, Martin; Rios, Eon J.; Dobner, Paul R.; Wada, Etsuko; Wada, Keiji; Zacharias, Sherma; Mohanasundaram, Uma M.; Faix, James D.; Abrink, Magnus; Pejler, Gunnar; Pearl, Ronald G.; Tsai, Mindy; Galli, Stephen J.			Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS; RECEPTOR ANTAGONIST; CARBOXYPEPTIDASE-A; INNATE IMMUNITY; HIGH-AFFINITY; PEPTIDE; RAT; INHIBITION; MICE; ENDOPEPTIDASE	Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to infection. Neurotensin (NT) is a 13-amino-acid peptide that, among its multiple effects, induces hypotension. We find that intraperitoneal and plasma concentrations of NT are increased in mice after severe cecal ligation and puncture (CLP), a model of sepsis, and that mice treated with a pharmacological antagonist of NT, or NT-deficient mice, show reduced mortality during severe CLP. In mice, mast cells can degrade NT and reduce NT-induced hypotension and CLP-associated mortality, and optimal expression of these effects requires mast cell expression of neurotensin receptor 1 and neurolysin. These findings show that NT contributes to sepsis-related mortality in mice during severe CLP and that mast cells can lower NT concentrations, and suggest that mast cell-dependent reduction in NT levels contributes to the ability of mast cells to enhance survival after CLP.	[Piliponsky, Adrian M.; Chen, Ching-Cheng; Rios, Eon J.; Faix, James D.; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Chen, Ching-Cheng; Nishimura, Toshihiko] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; [Metz, Martin] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; [Metz, Martin] Univ Hosp, Dept Dermatol, D-55131 Mainz, Germany; [Dobner, Paul R.] Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; [Wada, Etsuko; Wada, Keiji] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan; [Wada, Keiji] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3220012, Japan; [Zacharias, Sherma; Mohanasundaram, Uma M.; Pearl, Ronald G.] Stanford Univ, Sch Med, Dept Anesthesiol, Stanford, CA 94305 USA; [Abrink, Magnus] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75105 Uppsala, Sweden; [Pejler, Gunnar] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, S-75007 Uppsala, Sweden; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University Hospital Mainz; University of Massachusetts System; University of Massachusetts Worcester; National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST); Stanford University; Uppsala University; Swedish University of Agricultural Sciences; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	sgalli@stanford.edu	Metz, Martin/B-8799-2009; Wada, Keiji/AAV-1500-2021; Metz, Martin/M-5237-2013; Maurer, Marcus/ABG-2174-2020; Chen, Ching-Cheng/C-1259-2009; Åbrink, Magnus/AAK-8346-2020	Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Chen, Ching-Cheng/0000-0003-4499-0889; Abrink, Magnus/0000-0002-1335-3927; Tsai, Mindy/0000-0002-8421-4721	NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL087936, R00HL087936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI070813] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA072074-15, R01 CA072074] Funding Source: Medline; NHLBI NIH HHS [K99 HL087936, R00 HL087936-05, R00 HL087936-03, K99 HL087936-01, R00 HL087936-04, R00 HL087936, K99 HL087936-02] Funding Source: Medline; NIAID NIH HHS [R01 AI023990-20, R01 AI070813, R01 AI070813-01, R01 AI023990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angus DC, 2001, CRIT CARE MED, V29, pS109, DOI 10.1097/00003246-200107001-00035; BAKER CC, 1983, SURGERY, V94, P331; BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BIENENSTOCK J, 1984, ANN ALLERGY, V53, P535; COCHRANE DE, 1991, PEPTIDES, V12, P1187, DOI 10.1016/0196-9781(91)90193-S; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; Dobner PR, 2001, P NATL ACAD SCI USA, V98, P8048, DOI 10.1073/pnas.141042198; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Feldberg RS, 1998, INFLAMM RES, V47, P245, DOI 10.1007/s000110050325; Feyerabend TB, 2005, MOL CELL BIOL, V25, P6199, DOI 10.1128/MCB.25.14.6199-6210.2005; FOX CC, 1984, J IMMUNOL, V132, P2177; GOLDSTEIN SM, 1991, PEPTIDES, V12, P995, DOI 10.1016/0196-9781(91)90049-U; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Gully D, 1997, J PHARMACOL EXP THER, V280, P802; KUROSE M, 1981, EUR J PHARMACOL, V76, P129, DOI 10.1016/0014-2999(81)90494-5; Maeno H, 2004, BRAIN RES, V998, P122, DOI 10.1016/j.brainres.2003.11.039; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; METCALFE DD, 1984, ANN ALLERGY, V53, P563; Miller LA, 1998, INT ARCH ALLERGY IMM, V116, P147, DOI 10.1159/000023938; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Norman MU, 2003, AM J PHYSIOL-HEART C, V284, pH1978, DOI 10.1152/ajpheart.01116.2002; Patel Gourang P, 2003, Curr Opin Crit Care, V9, P390, DOI 10.1097/00075198-200310000-00009; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; QUIRION R, 1980, LIFE SCI, V27, P1889, DOI 10.1016/0024-3205(80)90435-X; Reinhart K, 2006, CRIT CARE CLIN, V22, P503, DOI 10.1016/j.ccc.2006.03.003; Remaury A, 2002, BRAIN RES, V953, P63, DOI 10.1016/S0006-8993(02)03271-7; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; RIOUX F, 1982, ANN NY ACAD SCI, V400, P56, DOI 10.1111/j.1749-6632.1982.tb31560.x; Schaeffer P, 1997, EUR J PHARMACOL, V323, P215, DOI 10.1016/S0014-2999(97)00041-1; SCHAEFFER P, 1995, J BIOL CHEM, V270, P3409, DOI 10.1074/jbc.270.7.3409; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; Shrimpton CN, 2002, ENDOCR REV, V23, P647, DOI 10.1210/er.2001-0032; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Thakurdas SM, 2007, J BIOL CHEM, V282, P20809, DOI 10.1074/jbc.M611842200; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; Vincent JL, 2002, ANN MED, V34, P606, DOI 10.1080/078538902321117832; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588	47	96	98	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2008	14	4					392	398		10.1038/nm1738	http://dx.doi.org/10.1038/nm1738			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	283ZD	18376408	Green Accepted			2022-12-27	WOS:000254674100025
J	Hilton, MJ; Tu, XL; Wu, XM; Bai, ST; Zhao, HB; Kobayashi, T; Kronenberg, HM; Teitelbaum, SL; Ross, FP; Kopan, R; Long, FX				Hilton, Matthew J.; Tu, Xiaolin; Wu, Ximei; Bai, Shuting; Zhao, Haibo; Kobayashi, Tatsuya; Kronenberg, Henry M.; Teitelbaum, Steven L.; Ross, F. Patrick; Kopan, Raphael; Long, Fanxin			Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation	NATURE MEDICINE			English	Article							EMBRYONIC LETHALITY; MICE LACKING; DEFECTS; EXPRESSION; SKELETAL; PRESENILIN-1; ACTIVATION; REQUIRES; LIMB; WNT	Postnatal bone marrow houses mesenchymal progenitor cells that are osteoblast precursors. These cells have established therapeutic potential, but they are difficult to maintain and expand in vitro, presumably because little is known about the mechanisms controlling their fate decisions. To investigate the potential role of Notch signaling in osteoblastogenesis, we used conditional alleles to genetically remove components of the Notch signaling system during skeletal development. We found that disruption of Notch signaling in the limb skeletogenic mesenchyme markedly increased trabecular bone mass in adolescent mice. Notably, mesenchymal progenitors were undetectable in the bone marrow of mice with high bone mass. As a result, these mice developed severe osteopenia as they aged. Moreover, Notch signaling seemed to inhibit osteoblast differentiation through Hes or Hey proteins, which diminished Runx2 transcriptional activity via physical interaction. These results support a model wherein Notch signaling in bone marrow normally acts to maintain a pool of mesenchymal progenitors by suppressing osteoblast differentiation. Thus, mesenchymal progenitors may be expanded in vitro by activating the Notch pathway, whereas bone formation in vivo may be enhanced by transiently suppressing this pathway.	[Hilton, Matthew J.; Tu, Xiaolin; Wu, Ximei; Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Bai, Shuting; Zhao, Haibo; Teitelbaum, Steven L.; Ross, F. Patrick] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Kobayashi, Tatsuya; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Kopan, Raphael; Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Washington University (WUSTL)	Long, FX (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	flong@wustl.edu	Kopan, Raphael/AAF-1357-2022; Zhao, Haibo/ABG-9729-2021; Kopan, Raphael/AFG-3275-2022	Teitelbaum, Steven/0000-0002-4054-6679; Kobayashi, Tatsuya/0000-0003-4264-5117; Kopan, Raphael/0000-0002-0350-2730; ZHAO, HAIBO/0000-0003-0836-7555; Hilton, Matthew/0000-0003-3165-267X; Wu, Ximei/0000-0002-3316-893X	NIAMS NIH HHS [R37 AR046523, AR046523, 5T32AR07033, T32 AR007033, R01 AR046523, R01 AR046852, AR046852] Funding Source: Medline; NICHD NIH HHS [R01 HD044056, HD044056, R01 HD044056-05] Funding Source: Medline; NIDDK NIH HHS [DK065789, DK11794, R01 DK065789-05, R01 DK065789] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046852, R37AR046523, T32AR007033, R01AR046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, R01DK065789] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Krebs LT, 2000, GENE DEV, V14, P1343; Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181; Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918; Nichols AM, 2004, GENESIS, V40, P40, DOI 10.1002/gene.20061; Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; OWEN M, 1988, CIBA F SYMP, V136, P42; Pan YH, 2005, DEV BIOL, V286, P472, DOI 10.1016/j.ydbio.2005.08.037; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014-4827(03)00349-5; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003; Vooijs M, 2007, DEVELOPMENT, V134, P535, DOI 10.1242/dev.02733; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200	46	434	478	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2008	14	3					306	314		10.1038/nm1716	http://dx.doi.org/10.1038/nm1716			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271VB	18297083	Green Accepted			2022-12-27	WOS:000253815700037
J	Jones, NC; Lynn, ML; Gaudenz, K; Sakai, D; Aoto, K; Rey, JP; Glynn, EF; Ellington, L; Du, C; Dixon, J; Dixon, MJ; Trainor, PA				Jones, Natalie C.; Lynn, Megan L.; Gaudenz, Karin; Sakai, Daisuke; Aoto, Kazushi; Rey, Jean-Phillipe; Glynn, Earl F.; Ellington, Lacey; Du, Chunying; Dixon, Jill; Dixon, Michael J.; Trainor, Paul A.			Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function	NATURE MEDICINE			English	Article							TREACHER-COLLINS-SYNDROME; TERMINATION CODON; CELL-CYCLE; GENE; PROTEIN; MICE; APOPTOSIS; EXPRESSION; DYSOSTOSIS; TRANSCRIPTION	Treacher Collins syndrome (TCS) is a congenital disorder of craniofacial development arising from mutations in TCOF1, which encodes the nucleolar phosphoprotein Treacle. Haploinsufficiency of Tcof1 perturbs mature ribosome biogenesis, resulting in stabilization of p53 and the cyclin G1-mediated cell-cycle arrest that underpins the specificity of neuroepithelial apoptosis and neural crest cell hypoplasia characteristic of TCS. Here we show that inhibition of p53 prevents cyclin G1-driven apoptotic elimination of neural crest cells while rescuing the craniofacial abnormalities associated with mutations in Tcof1 and extending life span. These improvements, however, occur independently of the effects on ribosome biogenesis; thus suggesting that it is p53-dependent neuroepithelial apoptosis that is the primary mechanism underlying the pathogenesis of TCS. Our work further implies that neuroepithelial and neural crest cells are particularly sensitive to cellular stress during embryogenesis and that suppression of p53 function provides an attractive avenue for possible clinical prevention of TCS craniofacial birth defects and possibly those of other neurocristopathies.	[Jones, Natalie C.; Lynn, Megan L.; Gaudenz, Karin; Sakai, Daisuke; Aoto, Kazushi; Rey, Jean-Phillipe; Glynn, Earl F.; Ellington, Lacey; Du, Chunying; Trainor, Paul A.] Stowers Inst Med Res, Kansas City, MO 64110 USA; [Dixon, Michael J.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; [Dixon, Jill; Dixon, Michael J.] Univ Manchester, Sch Dent, Manchester M13 9PT, Lancs, England	Stowers Institute for Medical Research; University of Manchester; University of Manchester	Trainor, PA (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	pat@stowers-institute.org		Trainor, Paul/0000-0003-2774-3624; Jones, Natalie/0000-0002-3300-0571	MRC [G0400264] Funding Source: UKRI; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016215] Funding Source: NIH RePORTER; Medical Research Council [G0400264] Funding Source: Medline; NIDCR NIH HHS [R01 DE016082-01, R01 DE016082-05, R01 DE016082-06, P50 DE016215, R01 DE016082-03, R01 DE016082-04, R01 DE016082-02, R01 DE016082, P50 DE 016215, R01 DE 016082-01] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aleo E, 2006, CANCER RES, V66, P9235, DOI 10.1158/0008-5472.CAN-06-0702; Burstyn-Cohen T, 2002, DEV CELL, V3, P383, DOI 10.1016/S1534-5807(02)00221-6; Dixon J, 2000, HUM MOL GENET, V9, P1473, DOI 10.1093/hmg/9.10.1473; Dixon J, 1996, NAT GENET, V12, P130; Dixon J, 2006, P NATL ACAD SCI USA, V103, P13403, DOI 10.1073/pnas.0603730103; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards SJ, 1997, AM J HUM GENET, V60, P515; FAZEN LE, 1967, AM J DIS CHILD, V113, P405, DOI 10.1001/archpedi.1967.02090190051001; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gladwin AJ, 1996, HUM MOL GENET, V5, P1533, DOI 10.1093/hmg/5.10.1533; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; KAUFMAN MH, 1992, ATLAS MOUSE DEV, V507; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Krull CE, 2004, DEV DYNAM, V229, P433, DOI 10.1002/dvdy.10473; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MEIER UT, 1992, CELL, V70, P127; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Nagy A, 2003, MANIPULATING MOUSE E; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; PHELPS PD, 1981, CLIN OTOLARYNGOL, V6, P15, DOI 10.1111/j.1365-2273.1981.tb01782.x; R Development Core Team, 2006, LANG ENV STAT COMP; Reczek EE, 2003, MOL CANCER RES, V1, P1048; ROVIN S, 1964, J PEDIATR-US, V65, P215, DOI 10.1016/S0022-3476(64)80522-9; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Wise CA, 1997, P NATL ACAD SCI USA, V94, P3110, DOI 10.1073/pnas.94.7.3110; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhao L, 2003, MOL CANCER RES, V1, P195	37	292	299	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2008	14	2					125	133		10.1038/nm1725	http://dx.doi.org/10.1038/nm1725			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	18246078	Green Accepted			2022-12-27	WOS:000252946700020
J	Hu, WG; Ferris, SP; Tweten, RK; Wu, GX; Radaeva, S; Gao, B; Bronson, RT; Halperin, JA; Qin, XB				Hu, Weiguo; Ferris, Sean P.; Tweten, Rodney K.; Wu, Gongxiong; Radaeva, Svetlana; Gao, Bin; Bronson, Roderick T.; Halperin, Jose A.; Qin, Xuebin			Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin	NATURE MEDICINE			English	Article							STREPTOCOCCUS-INTERMEDIUS; PLATELET ACTIVATION; NITRIC-OXIDE; IN-VIVO; RECEPTOR; DISEASE; ENDOTHELIUM; HEMOGLOBIN; THROMBOSIS; HEMOLYSIS	Conditional targeted cell ablation is a powerful approach for investigating the pathogenesis of human diseases and in vivo cellular functions. Intermedilysin (ILY) is a cytolytic poreforming toxin secreted by Streptococcus intermedius that lyses human cells exclusively, owing to its receptor specificity for human CD59. We generated two transgenic mouse strains that express human CD59 either on erythrocytes (strain ThCD59(RBC)) or on endothelia (strain ThCD59(END)). Intravenous injection of ILY in ThCD59(RBC) mice induced acute intravascular hemolysis, leading to reduced nitric oxide bioavailability, increased platelet activation and rapid death. In ThCD59(END) mice, ILY induced rapid endothelial damage, leading to acute death and disseminated intravascular coagulation. Additionally, we show that human serum contains ILY-specific neutralizing antibodies not found in any other animal species. Together, these results suggest that this new rapid conditional targeted ILY-mediated cell ablation technique can be used in combination with any available transgenic expression system to study the physiologic role of specific cell populations.	[Hu, Weiguo; Halperin, Jose A.; Qin, Xuebin] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Hu, Weiguo; Ferris, Sean P.; Wu, Gongxiong; Halperin, Jose A.; Qin, Xuebin] Harvard Univ, Sch Med, Lab Translat Res, Cambridge, MA 02139 USA; [Tweten, Rodney K.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; [Radaeva, Svetlana] NIAAA, Natl Inst Hlth, Lab Physiol Studies, Div Metab & Hlth Effects, Bethesda, MD 20892 USA; [Gao, Bin] NIAAA, Natl Inst Hlth, Sect Liver Biol, Lab Physiol Studies, Bethesda, MD 20892 USA; [Bronson, Roderick T.] Harvard Univ, Ctr Canc, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Harvard University; Dana-Farber Cancer Institute	Qin, XB (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	xuebin_qin@hms.harvard.edu	Hu, Weiguo/AAP-2239-2021	Hu, Weiguo/0000-0002-7397-6800	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061174, R01AI063444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060979] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI063444, R01 AI061174] Funding Source: Medline; NIDDK NIH HHS [R01 DK060979] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brouchet L, 2001, CIRCULATION, V103, P423; Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071; Foteinos G, 2005, CIRCULATION, V112, P1206, DOI 10.1161/CIRCULATIONAHA.105.547414; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; HOMER KA, 1994, J MED MICROBIOL, V41, P414, DOI 10.1099/00222615-41-6-414; Isermann B, 2001, J CLIN INVEST, V108, P537, DOI 10.1172/JCI13077; Jancar S, 2005, TRENDS IMMUNOL, V26, P48, DOI 10.1016/j.it.2004.11.007; Kadl A, 2005, ANTIOXID REDOX SIGN, V7, P1744, DOI 10.1089/ars.2005.7.1744; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Minneci PC, 2005, J CLIN INVEST, V115, P3409, DOI 10.1172/JCI25040; Nagamune H, 1996, INFECT IMMUN, V64, P3093, DOI 10.1128/IAI.64.8.3093-3100.1996; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Polekhina G, 2005, P NATL ACAD SCI USA, V102, P600, DOI 10.1073/pnas.0403229101; Qin XB, 2003, IMMUNITY, V18, P217, DOI 10.1016/S1074-7613(03)00022-0; RAVANAT C, 1995, BLOOD COAGUL FIBRIN, V6, P446, DOI 10.1097/00001721-199507000-00012; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Sierig G, 2003, INFECT IMMUN, V71, P446, DOI 10.1128/IAI.71.1.446-455.2003; Sukeno A, 2005, MICROBIOL IMMUNOL, V49, P681, DOI 10.1111/j.1348-0421.2005.tb03647.x; Van der Zee PM, 2006, CLIN CHEM, V52, P657, DOI 10.1373/clinchem.2005.057414; WHILEY RA, 1992, J CLIN MICROBIOL, V30, P243, DOI 10.1128/JCM.30.1.243-244.1992	29	30	32	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2008	14	1					98	103		10.1038/nm1674	http://dx.doi.org/10.1038/nm1674			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	249IV	18157141				2022-12-27	WOS:000252222400029
